<SEC-DOCUMENT>0001093557-24-000021.txt : 20240208
<SEC-HEADER>0001093557-24-000021.hdr.sgml : 20240208
<ACCEPTANCE-DATETIME>20240208171440
ACCESSION NUMBER:		0001093557-24-000021
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240208
DATE AS OF CHANGE:		20240208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DEXCOM INC
		CENTRAL INDEX KEY:			0001093557
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330857544
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51222
		FILM NUMBER:		24610147

	BUSINESS ADDRESS:	
		STREET 1:		6340 SEQUENCE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8582000200

	MAIL ADDRESS:	
		STREET 1:		6340 SEQUENCE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dxcm-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dxcm="http://www.dexcom.com/20231231" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dxcm-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0001093557</ix:nonNumeric><ix:nonNumeric contextRef="c-8" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-85">366</ix:nonNumeric><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-86">366</ix:nonNumeric><ix:nonNumeric contextRef="c-10" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-87">423</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-88">366</ix:nonNumeric><ix:nonNumeric contextRef="c-14" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-89">366</ix:nonNumeric><ix:nonNumeric contextRef="c-23" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-90">455</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-91">366</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-92">366</ix:nonNumeric><ix:nonNumeric contextRef="c-84" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-509">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-86" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-511">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="c-90" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-519">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-93" name="dxcm:AmortizationPeriodForIncentiveCompensationCosts" id="f-535">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-199" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-1023">0.0243476</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-201" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-1024">0.006662</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-203" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-1025">0.0061571</ix:nonFraction><ix:nonNumeric contextRef="c-24" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1051">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-25" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1058">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1059">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1083">http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-255" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-1286">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dxcm-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:MatthewDolanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:MatthewDolanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:PaulFlynnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:PaulFlynnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:GirishNaganathanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:GirishNaganathanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:StevenRPacelliMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:StevenRPacelliMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:BarryJReganMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:BarryJReganMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:KevinRSayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:KevinRSayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">dxcm:SadieMSternDecember2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">dxcm:SadieMSternDecember2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">dxcm:SadieMStern2023PlanTerminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">dxcm:SadieMStern2023PlanTerminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:JeremeMSylvainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:JeremeMSylvainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dxcm:ComputerSoftwareAndHardwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dxcm:ComputerSoftwareAndHardwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:CollaborativeSalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:CollaborativeSalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:CollaborativeSalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:RestrictedAndPerformanceStockUnitsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:RestrictedAndPerformanceStockUnitsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:RestrictedAndPerformanceStockUnitsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementInitialPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementInitialPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementInitialPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementInitialPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dxcm:ReceiverProductComponentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dxcm:ReceiverProductComponentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dxcm:ReceiverProductComponentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dxcm:ComputerSoftwareAndHardwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dxcm:ComputerSoftwareAndHardwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dxcm:VerilyIntangibleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dxcm:AcquiredTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dxcm:VerilyIntangibleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dxcm:AcquiredTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-02</xbrli:startDate><xbrli:endDate>2023-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trading_day"><xbrli:measure>dxcm:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dxcm:LondonInterbankOfferedRateLIBOR1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dxcm:LondonInterbankOfferedRateLIBOR1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="extensionoption"><xbrli:measure>dxcm:extensionOption</xbrli:measure></xbrli:unit><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ResearchDevelopmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ResearchDevelopmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ForeignTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ForeignTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ResearchDevelopmentTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ResearchDevelopmentTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:AMTTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:AMTTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>dxcm:segment</xbrli:measure></xbrli:unit><xbrli:unit id="primarymarket"><xbrli:measure>dxcm:primaryMarket</xbrli:measure></xbrli:unit><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001093557</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i70f957301cc34339a22f629982cd0734_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C.&#160;20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.768%"><tr><td style="width:1.0%"/><td style="width:1.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.838%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.768%"><tr><td style="width:1.0%"/><td style="width:1.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.838%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">000-51222</ix:nonNumeric></span></div><div style="text-align:center"><img src="dxcm-20231231_g1.jpg" alt="dexcom-logo-green-rgb.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">DEXCOM, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.801%"><tr><td style="width:1.0%"/><td style="width:52.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.410%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">33-0857544</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">6340 Sequence Drive</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">200-0200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.204%"><tr><td style="width:1.0%"/><td style="width:39.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.001 Par Value Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">DXCM</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;&#160;&#160;Yes&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.951%"><tr><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.663%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#160;&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). &#160;&#160;&#160;Yes <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#9746;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="f-29">49.4</ix:nonFraction> billion based on the closing sales price of $128.51 per share as reported on the Nasdaq Global Select Market on that date. Shares held by persons who may be deemed affiliates have been excluded. This determination of affiliate status with respect to the foregoing calculation is not a determination for other purposes.</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the registrant&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.801%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding at February 1, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $0.001 par value per share</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">385,515,421</ix:nonFraction></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement relating to its 2024 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) are incorporated by reference in Part&#160;III, Items 10 through 14 of this Annual Report on Form 10-K, as specified in the responses to those item numbers, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.</span></div></ix:nonNumeric><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">DexCom, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#32ad10;border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Table of Contents</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:14.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.272%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="9" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_16">ITEM&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_19">ITEM&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_19">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_67">ITEM&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_67">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_67">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_3752">I</a><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_3752">TEM 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_3752">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_3752">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_70">ITEM&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_70">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_70">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_73">ITEM&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_73">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_73">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_76">ITEM&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_76">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_76">70</a></span></div></td></tr><tr><td colspan="9" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_82">ITEM&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_82">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_82">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_85">ITEM&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_85">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_85">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_91">ITEM&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_91">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_91">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_121">ITEM&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_121">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_121">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_133">ITEM&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_133">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_133">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_136">ITEM&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_136">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_136">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_139">ITEM&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_139">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_139">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_142">ITEM&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_142">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_142">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_145">ITEM 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_145">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_145">88</a></span></div></td></tr><tr><td colspan="9" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_151">ITEM&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_151">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_151">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_154">ITEM&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_154">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_154">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_157">ITEM&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_157">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_157">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_160">ITEM&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_160">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_160">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_163">ITEM&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_163">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_163">89</a></span></div></td></tr><tr><td colspan="9" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_169">ITEM&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_169">Exhibits</a> and<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_169"> Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_169">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_172">ITEM 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_172">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_172">92</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_175">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_175">93</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i70f957301cc34339a22f629982cd0734_13"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Except for historical financial information contained herein, the matters discussed in this Annual Report on Form 10-K may be considered forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and subject to the safe harbor created by the Securities Litigation Reform Act of 1995. Such statements include declarations regarding our operations, financial condition and prospects, and business strategies, and are based on management&#8217;s current</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">intent, beliefs, expectations, and assumptions. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our control; actual results could differ materially from those indicated or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to: (i)&#160;that the information is of a preliminary nature and may be subject to further adjustment; (ii)&#160;those risks and uncertainties identified under &#8220;Risk Factors&#8221;; and (iii)&#160;the other risks detailed from time-to-time in our reports and registration statements filed with the Securities and Exchange Commission, or the SEC. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.</span></div><div id="i70f957301cc34339a22f629982cd0734_3761"></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate Information</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mailing address of our headquarters is 6340 Sequence Drive, San Diego, California, 92121, and our telephone number at that location is (858) 200-0200. Our website address is located at dexcom.com and our investor relations website is located at investors.dexcom.com. We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make available on our website, free of charge, copies of these reports and other information as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The reports are also available at www.sec.gov.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announce material information to the public about us, our products, and other matters through a variety of means, including filings with the SEC, press releases, public conference calls, presentations, webcasts, and our investor relations website in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We also routinely post important information for investors on our website noted above, and we may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations portion of our website noted above. Also available on our website are printable versions of our Audit Committee charter, Compensation Committee charter, Nominating and Governance Committee charter, Technology Committee charter, Corporate Governance Guidelines and Code of Conduct and Business Ethics. Stockholders may request copies of these documents by mail or telephone, at the address or phone number provided above. Except as expressly set forth in this Annual Report on Form 10-K, the contents of our website is not incorporated by reference into, or otherwise to be regarded as part of, this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our website is intended to be inactive textual references only.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information disclosed by the foregoing channels could be deemed to be material information. As such, we encourage investors, the media, and others to follow the channels listed above and review the information disclosed through such channels.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Dexcom", &#8220;Dexcom Clarity&#8221;, and &#8220;Dexcom One&#8221;, and other trademarks of ours appearing in this report are our property. Other service marks, trademarks and trade names referred to in this Form 10-K are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_3740"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below summary of risk factors provides an overview of many of the risks we are exposed to in the normal course of our business activities. As a result, the below summary risks do not contain all of the information that may be important to you, and you should read the summary risks together with the more detailed discussion of risks set forth following this section under the heading &#8220;Risk Factors,&#8221; as well as elsewhere in this Annual Report on Form 10-K.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional risks, beyond those summarized below or discussed elsewhere in this Annual Report on Form 10-K, may apply to our activities or operations as currently conducted or as we may conduct them in the future or in the markets in which we operate or may in the future operate. Consistent with the foregoing, we are exposed to a variety of risks, including risks associated with the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in revenue.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Although many third-party payors have adopted some form of coverage policy for continuous glucose monitoring devices, our products do not always have such coverage, including simple broad-based contractual coverage with third-party payors, and we frequently experience administrative challenges in obtaining coverage or reimbursement for our products. If we are unable to obtain adequately broad coverage or reimbursement for our products or any future products from third-party payors, our revenue may be negatively impacted.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The research and development efforts we undertake independently, and in some instances in connection with our collaborations with third parties, may not result in the development of commercially viable products, the generation of significant future revenues or adequate profitability.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our products may not achieve or maintain market acceptance.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If our manufacturing capabilities are insufficient to produce an adequate supply of product at appropriate quality levels, our growth could be limited and our business could be harmed.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Manufacturing difficulties and/or any disruption at our facilities may adversely affect our manufacturing operations and related product sales, and increase our expenses.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we are unable to establish and maintain adequate sales, marketing and distribution capabilities or enter into and maintain arrangements with third parties to sell, market and distribute our products, we may have difficulty achieving market awareness and selling our products in the future.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We operate in a highly competitive market and face competition from large, well-established companies with significant resources, and, as a result, we may not be able to compete effectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We are subject to a variety of risks due to our international operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> th</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at could adversely affect our business, our operations or profitability and operating results.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements regarding privacy, data protection, security, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Managed care trends and consolidation in the health care industry could have an adverse effect on our revenues and results of operations.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we are unable to successfully complete the pre-clinical studies or clinical trials necessary to support additional premarket approval, or PMA, de novo, or 510(k) applications or supplements, we may be unable to commercialize our CGM systems under development, which could impair our business, financial condition and operating results.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We are subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief. We may also be subject to other claims or suits.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our inability to adequately protect our intellectual property could allow our competitors and others to produce products based on our technology, which could substantially impair our ability to compete.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We could become the subject of governmental investigations, claims and litigation.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have incurred significant losses in the past and may incur losses in the future.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have indebtedness in the form of convertible senior notes, which could adversely affect our financial health and our ability to respond to changes in our business.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Environmental, social and governance, or ESG, regulations, policies and provisions could expose us to numerous risks.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PART I</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1 - BUSINESS</span></td></tr></table></div><div id="i70f957301cc34339a22f629982cd0734_3645"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> integrated Continuous Glucose Monitoring System, or G6, in 2018 and more recently received marketing clearance from the FDA on the Dexcom G7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or G7,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in December 2022.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;company,&#8221; or &#8220;Dexcom&#8221; refer to DexCom, Inc. and its subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dexcom G6</span><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we obtained marketing authorization from the FDA for the G6 via the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> process. The G6 was the first type of CGM system permitted by the FDA to be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin delivery systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. G6 and substantially equivalent devices of this generic type that may later receive marketing authorization are referred to as integrated continuous glucose monitoring systems, or iCGMs, and have been classified as Class II devices by the FDA. Along with this classification, the FDA established criteria, called special controls, which outline requirements for assuring CGM accuracy, reliability and clinical relevance, and which also describe the type of studies and data required to demonstrate acceptable CGM performance. The G6 is designed to allow our transmitter to run an algorithm to generate a glucose value and to communicate directly to a patient&#8217;s compatible mobile device, including iPhone</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, iPod touch</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, iPad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and certain Android</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mobile devices. A patient&#8217;s glucose data can also be displayed on wearable devices, like the Apple Watch</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Wear OS by Google devices. The G6 transmitter has a labeled useful life of three months. Data from the G6 can be integrated with Dexcom CLARITY</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our cloud-based reporting software, for personalized, easy-to-understand analysis of trends that may improve diabetes management. In the United States, the G6 is covered by Medicare and Medicaid in the majority of states and by commercial insurers, subject to satisfaction of certain eligibility and coverage criteria for individuals with both Type 1 and Type 2 diabetes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we received Conformit&#233; Europ&#233;enne Marking, or CE Mark, approval for the G6, which allows us to market the system in the European Union and the countries in Asia and Latin America that recognize the CE Mark, as well as New Zealand, though certain countries may require compliance with certain local administrative requirements and/or additional marketing authorizations (for example, the inclusion of medical devices on the Australian Register of Therapeutic Goods in Australia).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we also received marketing authorization from the FDA for the Dexcom G6 Pro, or G6 Pro, which allows healthcare professionals to purchase the G6 for use with their patients. The G6 Pro has many of same features as the G6 and is intended for healthcare professionals to use with their patients ages two years and up. The G6 Pro may be used in a blinded or unblinded mode for up to 10 days.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the G6, the sensor is inserted by the user and is intended to be used continuously for up to 10 days, after which it may be replaced with a new disposable sensor. Our transmitter is reusable until it reaches the end of its use life, labeled as three months. Our receiver is also reusable. As we continue to establish an installed base of customers using our products, we expect to generate an increasing portion of our revenues through recurring sales of our disposable sensors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G6 carries forward important features of prior generation Dexcom CGM systems:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Continuous glucose readings.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Automatically sends glucose readings to a Dexcom receiver or compatible display device every five minutes.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Mobile app and sharing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Compatibility with mobile device applications allows for sharing glucose information with up to 10 other people for added support and care coordination.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Integration with the world&#8217;s largest connected CGM ecosystem</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (including Apple Watch, Garmin and other digital health apps).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Customizable alarms and alerts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personalized alert schedule immediately warns the user of pending dangerous high and low blood sugar levels.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G6 also has a number of new or improved features compared to our prior generation devices:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Finger stick elimination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No finger sticks are needed for calibration or diabetes treatment decisions, consistent with the instructions for use, unless symptoms do not match readings.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Easy sensor application.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Complete redesign of the sensor applicator allows for one-touch, simple self-insertion.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Discreet and low profile.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A redesigned transmitter with a 28% lower profile than the previous generation Dexcom CGM system makes the device comfortable and easy to wear under clothing.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Medication blocking.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Allows for more accurate glucose readings without interference from common medications taken at typical indication doses, such as acetaminophen.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Predictive low alert.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Alert feature intended to predict hypoglycemia before it hits to help avoid dangerous low blood sugar events.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Extended 10-day disposable sensor.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Up to 10-day sensor use allows for 43% longer wear than previous generation Dexcom CGM systems.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the foregoing, the features of the G6 are generally consistent with our prior generation CGM systems in its technical capabilities and its indications. Since the G6 is classified by the FDA as a Class II device, it is subject to special controls and modifications of, or revisions to, the device may be made under the 510(k) process.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dexcom G7</span><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we obtained CE Mark approval for G7. In December 2022, we obtained marketing authorization from the FDA for the G7 via the 510(k) review process. Like the G6, the G7 is an iCGM, is classified as a Class II device by the FDA, and is subject to special controls. The glucose value algorithm, ability to communicate with approved display and mobile devices, and compatibility with CLARITY</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are all substantially equivalent in technical performance and capability to the G6. In the United States, the G7 is covered by Medicare and Medicaid in the majority of states and by commercial insurers, subject to satisfaction of certain eligibility and coverage criteria for individuals with both Type 1 and Type 2 diabetes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dexcom G7 is cleared in the United States for all people with diabetes ages two years and older, giving more people than ever access to a powerfully simple diabetes management solution. With an overall Mean Absolute Relative Difference, or MARD, of 8.2%, as well as 94.1% of values within 20% of their comparator, Dexcom G7 is the most accurate CGM cleared by the FDA and is clinically proven to lower A1C (a blood test that provides information about average levels of blood glucose, over the prior three months), reduce hyper- and hypoglycemia, and increase time in range.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G7 carries forward important features of prior generation Dexcom CGM systems:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Finger stick elimination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No finger sticks are needed for calibration or diabetes treatment decisions, consistent with the instructions for use, unless symptoms do not match readings.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Continuous glucose readings.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Automatically sends glucose readings to a Dexcom receiver or compatible display device every five minutes.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Mobile app and sharing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Compatibility with mobile device applications allows for sharing glucose information with up to 10 other people for added support and care coordination.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Designed to integrate with the world&#8217;s largest connected CGM ecosystem</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (including insulin pumps and smart insulin pens, Apple Watch, Garmin and other digital health apps).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Customizable alarms and alerts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personalized alert schedule immediately warns the user of pending dangerous high and low blood sugar levels.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Easy sensor application.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Complete redesign of the sensor applicator allows for one-touch, simple self-insertion.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Medication blocking.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> New feature allows for more accurate glucose readings without interference from common medications taken at typical indication doses, such as acetaminophen.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Predictive low alert.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Alert feature intended to predict hypoglycemia before it hits to help avoid dangerous low blood sugar events.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Extended 10-day disposable sensor.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G7 also has a number of new or improved features compared to our prior generation devices:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">An even more discreet and low profile.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A redesigned transmitter makes for an all-in-one wearable combining our sensor and transmitter that is 60% smaller than the G6, making it even more comfortable and easier to wear under clothing.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Faster warm up.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 30-minute sensor warm up, fastest of any CGM on the market.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Expanded time to replace sensors.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 12-hour grace period to replace finished sensors for a more seamless transition between sessions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">New mobile app.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Redesigned and simplified mobile app with Dexcom Clarity integration.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Improved alert settings for enhanced discretion at the user&#8217;s option</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Redesigned receiver. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The optional receiver is smaller, with a more vibrant, easier to read display.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">New indications for use. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicated in the United States for wear on the back of the upper arm for ages 2 years and older or the upper buttocks for ages 2-6 years old.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Less waste.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Smaller plastic components and packaging, resulting in less waste than the G6.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the foregoing, the G7 is generally consistent with our prior generation CGM systems in its technical capabilities and its indications. Since the G7 is classified by the FDA as a Class II device, it is subject to special controls and modifications of, or revisions to, the device may be made under the 510(k) process.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dexcom Stelo</span><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing regulatory approvals for Dexcom Stelo, our first product designed specifically for people with type 2 diabetes who do not use insulin and are not at risk for hypoglycemia. Stelo was submitted for FDA review in the fourth quarter of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dexcom Share</span><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Dexcom Share remote monitoring system, offered for use with any current Dexcom system, uses an app on the patient&#8217;s compatible iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, or &#8220;followers,&#8221; who can remotely monitor a patient&#8217;s glucose information and receive alert notifications anywhere they have a wireless connection. A patient&#8217;s glucose data can also be displayed on a patient&#8217;s or follower&#8217;s wearable device, such as the Apple Watch and Wear OS by Google devices, when used in conjunction with the patient&#8217;s or follower&#8217;s compatible iPhone or Android mobile device.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dexcom Real-Time API</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we received FDA marketing clearance for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an iCGM system incorporating</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our Real-Time Application Programming Interfaces (API), which is an added software component that expands connectivity and interoperability of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dexcom</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CGM digital ecosystem, enabling communication of iCGM data to client software intended to receive data through the cloud. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dexcom</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Real-Time API enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for specific and permitted use cases including non-medical device application, medical device data analysis, iCGM secondary display alarm, active patient monitoring, and treatment decisions. Real-Time API is not permitted for use in environments not currently cleared for the Dexcom CGM System (e.g., hospital inpatient care), and is not intended to be used by automated insulin delivery systems.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dexcom ONE</span><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we obtained CE Mark approval for our Dexcom ONE CGM system, or Dexcom ONE, which we have launched in several countries in Europe. Dexcom ONE consists of three main components: a sensor, a transmitter, and a display device consisting of either the Dexcom ONE app for users with a compatible mobile device, or a Dexcom ONE receiver. Dexcom ONE carries many of the same features as the G6, and is indicated for persons, including pregnant women, ages 2 years and older. Like our other CGM systems, Dexcom ONE is designed to replace finger stick blood glucose testing for diabetes treatment decisions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we obtained CE Mark approval for Dexcom ONE+. This updated version of our Dexcom ONE system builds upon the software experience of Dexcom ONE with certain additional features, while allowing customers to adopt the all-in-one wearable technology of our G7 CGM system.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data and Insulin Delivery Collaborations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple collaboration agreements that leverage our technology platform to integrate our CGM products with insulin delivery systems. The general purpose of these development and commercial relationships is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to integrate our technology into the insulin pump or pen product offerings of the respective partner, enabling the partner&#8217;s insulin delivery device to receive and display glucose readings from our transmitter and, in some cases, use the glucose readings for semi-automated insulin delivery. We have existing insulin delivery partnerships, and we are also working with other companies that are pursuing varying strategies surrounding semi-automated insulin delivery and data analytics to improve outcomes and ease-of-use in diabetes management.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into collaborations with several organizations that are currently using, or are developing, programs for the treatment of Type 2 diabetes that utilize our current CGM systems. These collaborations align with the strategy to seek broader access to our CGM systems for people with Type 2 diabetes, including those who are not treated with intensive insulin therapy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Verily Collaboration</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Restated Collaboration Agreement with Verily Life Science LLC (an Alphabet Company) and Verily Ireland Limited (collectively, Verily) provides us with an exclusive license to use intellectual property of Verily resulting from the collaboration, and certain Verily patents, in the development, manufacture and commercialization of blood-based or interstitial glucose monitoring products more generally (subject to certain exclusions, which are outside the CGM field as it is commonly understood). It also provides us with non-exclusive license rights under Verily&#8217;s other intellectual property rights to develop, manufacture, and commercialize those kinds of glucose monitoring products and certain CGM product companion software functionalities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of Verily&#8217;s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we have made upfront, incentive, product regulatory approval milestone payments, and a sales-based milestone payment. In the future, we may make a potential additional milestone payment for a future sales-based milestone. At our election, we may make these payments in shares of our common stock or cash. If we elect to make a milestone payment in cash, any such cash payment would be equal to the number of shares that would otherwise be issued for the given milestone payment multiplied by the value of our stock on the date the relevant milestone is achieved, adjusted for stock splits, dividends, and the like. We intend to pay the remaining sales-based contingent milestone in shares of our common stock.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 &#8220;Development and Other Agreements&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report and Exhibit 10.14 of this Annual Report on Form 10-K for a further description of the Restated Collaboration Agreement, including the number of shares of stock for milestone payments.</span></div><div id="i70f957301cc34339a22f629982cd0734_3618"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Market Opportunity</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diabetes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diabetes is a chronic, life-threatening disease for which there is no known cure and which has other significant adverse consequences for human health throughout the world. The disease is caused by the body&#8217;s inability to produce or effectively utilize the hormone insulin. This inability prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit optimal cell function and health. Normally, the pancreas provides control of blood glucose levels by secreting the hormone insulin to decrease blood glucose levels when concentrations are too high. In people with diabetes, the body does not produce sufficient levels of insulin, or fails to utilize insulin effectively, causing blood glucose levels to rise above normal. This condition is called hyperglycemia and often results in acute complications as well as chronic long-term complications such as heart disease, limb amputations, loss of kidney function and blindness. When blood glucose levels are high, people with diabetes often administer insulin in an effort to decrease blood glucose levels. Unfortunately, insulin administration can drive blood glucose levels below the normal range, resulting in hypoglycemia. In cases of severe hypoglycemia, people with diabetes risk acute complications, such as loss of consciousness or death. Due to the drastic nature of acute complications associated with hypoglycemia, many people with diabetes are reluctant to reduce blood glucose levels. Consequently, these individuals often remain in a hyperglycemic state, increasing their odds of developing long-term chronic complications. Diabetes is typically classified into two major groups: Type 1 and Type 2.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International Diabetes Federation, or IDF, estimates that in 2021, 537&#160;million adults (aged 20-79) around the world had diabetes. IDF estimates that by 2045, the worldwide incidence of people suffering from diabetes will reach 783 million. According to the Centers for Disease Control and Prevention, or CDC, in its National Diabetes Statistics Report, 2023, or the 2023 CDC Report, crude estimates for the prevalence of diabetes in the United States as of 2021 include 38.4 million people with diabetes, of which 29.7 million people have diagnosed diabetes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This growing diabetes prevalence and its associated health outcomes also result in sobering economic burdens for global health systems. According to the American Diabetes Association, or ADA, one in every four healthcare dollars </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was spent on treating people with diabetes in 2022, and the direct medical costs and indirect expenditures attributable to diabetes in the United States were an estimated $413 billion, an inflation-adjusted increase of approximately 35% since 2012. Of the $413 billion in overall expenses, the ADA estimated that approximately $307 billion were direct costs associated with diabetes care, chronic complications and excess general medical costs, and $106 billion were indirect costs. The ADA also found that in 2022, average medical expenditures among people with diagnosed diabetes were 2.6 times higher than for people without diabetes. According to the IDF, 2021 expenditures attributable to diabetes were estimated to be $966 billion globally, an increase of 27% from their previous estimate in 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Type 1 Diabetes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the 2023 CDC Report, as of 2021 there were an estimated 2.0 million adults and youth with diagnosed Type 1 diabetes in the United States. Type 1 diabetes is an autoimmune disorder that usually develops during childhood and is characterized by an absence of insulin, resulting from destruction of the insulin producing cells of the pancreas. Individuals with Type&#160;1 diabetes must rely on frequent insulin injections in order to regulate and maintain blood glucose levels.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Type 2 Diabetes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Type 2 diabetes is a metabolic disorder which results when the body is unable to produce sufficient amounts of insulin or becomes insulin resistant. Depending on the severity of Type 2 diabetes, individuals may require diet and nutrition management, exercise, oral medications or insulin injections to regulate blood glucose levels. We estimate that between 5.0 and 6.0&#160;million people with Type 2 diabetes in the United States must use insulin to manage their diabetes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Type 2 diabetes is occurring with increasing frequency in young people, with the increase in prevalence related to an increase in obesity amongst children. According to the CDC, as of 2017-2020, approximately 19.7% of children and adolescents aged 2-19 years, or 14.7 million children, in the United States were obese. In the United States, the percentage of children and adolescents affected by obesity has more than tripled since the 1970s.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Importance of Glucose Monitoring</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Blood glucose levels can be affected by many factors, including the carbohydrate and fat content of meals, exercise, stress, illness or impending illness, hormonal releases, variability in insulin absorption and changes in the effects of insulin in the body. Given the many factors that affect blood glucose levels, maintaining glucose within a normal range is difficult, resulting in frequent and unpredictable excursions above or below normal blood glucose levels. People with diabetes administer insulin or ingest carbohydrates throughout the day in order to maintain blood glucose levels within normal ranges. People with diabetes frequently overcorrect and fluctuate between hyperglycemic and hypoglycemic states, often multiple times during the same day. As a result, many people with diabetes are routinely outside the normal blood glucose range. Failure to maintain blood glucose levels within the normal range leads to numerous and significant health risks. These risks include eye disease, nerve disease, kidney disease, cardiovascular disease and potentially hypoglycemic events.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations of Existing Glucose Monitoring Products</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Single-point finger stick devices are the most prevalent devices for glucose monitoring. These devices require taking a blood sample with a finger stick, placing a drop of blood on a test strip and inserting the strip into a glucose meter that yields a single point in time blood glucose measurement. We believe that these devices suffer from several limitations, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Limited Information.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Even if people with diabetes test several times each day, each measurement represents a single blood glucose value at a single point in time. Given the many factors that can affect blood glucose levels, excursions above and below the normal range often occur between these discrete measurement points in time. Without the ability to determine whether their blood glucose level is rising, falling or holding constant, and the rate at which their blood glucose level is changing, the individual&#8217;s ability to effectively manage and maintain blood glucose levels within normal ranges is severely limited. Further, people with diabetes cannot test themselves during sleep, when the risk of hypoglycemia is significantly increased.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The illustrative graph below shows the limited information provided by four single-point measurements during a single day using a traditional single-point finger stick device, compared to the data provided by our continuous sensor. The continuous data indicates that, even with four finger sticks in one day, the patient&#8217;s blood glucose levels were above the target range of 80-140 milligrams per deciliter (&#8220;mg/dl&#8221;) for a period of 13.5 hours.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Single Day Continuous Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;padding-right:22.5pt;text-align:center"><img src="dxcm-20231231_g2.jpg" alt="Investor Presentation Glucose Chart.jpg" style="height:349px;margin-bottom:5pt;vertical-align:text-bottom;width:556px"/></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Inconvenience.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The process of measuring blood glucose levels with single-point finger stick devices can cause significant disruption in the daily activities of people with diabetes and their families. People with diabetes using single-point finger stick devices must stop whatever they are doing several times per day, self-inflict a painful prick and draw blood to measure blood glucose levels. To do so, people with diabetes must always carry a fully supplied kit that may include a spring-loaded needle, or lancet, disposable test strips, cleansing wipes and the meter, and then safely dispose of the used supplies. This process is inconvenient and may cause uneasiness in social situations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Difficulty of Use.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To obtain a sample with single-point finger stick devices, people with diabetes generally prick one of their fingertips or, occasionally, a forearm with a lancet. They then squeeze the area to produce the blood sample and another prick may be required if a sufficient volume of blood is not obtained the first time. The blood sample is then placed on a disposable test strip that is inserted into a blood glucose meter. This task can be difficult for individuals with decreased tactile sensation and visual acuity, which are common complications of diabetes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Pain.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although the fingertips are rich in blood flow and provide a good site to obtain a blood sample, they are also densely populated with highly sensitive nerve endings. This makes the lancing and subsequent manipulation of the finger to draw blood painful. The pain and discomfort are compounded by the fact that fingers offer limited surface area, so tests are often performed on areas that are sore from prior tests. People with diabetes may also suffer pain when the finger prick site is disturbed during regular activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Dexcom Approach</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe continuous glucose monitoring has the potential to enable more people with diabetes to achieve and sustain tight glycemic control with minimal disruption to their daily lives.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The landmark 1993 Diabetes Control and Complications Trial, or DCCT, demonstrated that improving blood glucose control lowers the risk of developing diabetes-related complications by up to 50%. The study also demonstrated that people with Type 1 diabetes achieved sustained benefits with intensive management.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various clinical studies and real-world evidence also demonstrate the benefits of continuous glucose monitoring in the management of Type 1 diabetes and insulin-requiring Type-2 diabetes, when compared to regimens relying on self-monitoring of blood glucose. Results of several early clinical trials established that CGM usage was associated with improved glycemic outcomes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real-time alerts and multi-device integration further differentiate CGM-based and self-monitoring of blood glucose, or SMBG, based diabetes regimens. Alerts triggered by existing or impending abnormal glucose values are associated with less exposure to hypo- and hyperglycemia in large real-world data sets, and multi-device integration </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allows some CGM systems to communicate with automated insulin delivery systems. One such automated insulin delivery system that uses the G6 was studied in a large clinical trial that associated its use with numerous quality-of-life and glycemic benefits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current target market consists primarily of people with Type 1 and Type 2 diabetes who utilize insulin therapy as well as certain non-insulin using people with diabetes that struggle with hypoglycemia. We also believe that our CGM systems are beginning to have a positive impact on the broader Type 2 population that does not utilize insulin or have hypoglycemia risk, a group that we estimate to be greater than 25 million people in the United States alone. We are extending our commercial efforts for this population through several channels, including through strategic partnerships. In the future, we plan to expand our product offering to people who are pregnant and cleared/approved indications to address people with pre-diabetes, people who are obese, and people in the hospital setting. Although the majority of our revenue has been generated in the United States, we have expanded our operations to include additional markets in North America, Africa, Asia Pacific, Europe, Latin America and the Middle East.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current CGM systems offer the following potential advantages to people with diabetes:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Potential for Improved Outcomes.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Randomized clinical trials and peer reviewed published data have demonstrated that patients with diabetes who used continuous glucose monitoring devices to help manage their disease experienced significant improvements in glucose control, including when compared to patients relying solely on single-point finger stick measurements (i.e., less time in hypoglycemia and hyperglycemia) and reductions in A1c levels when compared to baseline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Access to Real-Time Values, Trend Information and Alerts.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> People with diabetes can view their current glucose value, along with a graphical display of the historical trend information on our receiver or alternate display device. Without continuous monitoring, the individual is often unaware if his or her glucose is rising, declining or remaining constant. Access to continuous real-time glucose measurements provides people with diabetes information that may aid in attaining better glucose control. Additionally, our current CGM systems alert people with diabetes when their glucose levels approach inappropriately high or low levels so that they may intervene.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Intuitive User Interface.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have developed a user interface that we believe is intuitive and easy to use. Our current CGM system receivers are compact with an easy-to-read color display, simple navigation tools, audible alerts and graphical display of trend information. Similar benefits are available via the interfaces we have made available on compatible mobile devices. These devices can serve as substitutes for our receivers or alternate display units in certain geographies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Convenience and Comfort.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our current CGM systems provide people with diabetes with the benefits of continuous monitoring, without having to perform finger stick tests for every measurement. Additionally, the disposable sensor that is inserted under the skin is a very thin wire, minimizing potential discomfort associated with inserting or wearing the disposable sensor. The external portion of the sensor, attached to the transmitter, is small, has a low profile and is designed to be easily worn under clothing. The wireless receiver is the size of a small smart phone and can be carried discreetly in a pocket or purse. We believe that convenience is an important factor in achieving widespread adoption of a CGM system.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Connectivity to Wearables and Others. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients can monitor their glucose levels and trends on compatible wearable devices, such as Apple Watch and Wear OS by Google devices, when used with a compatible mobile device. Also, our Share remote monitoring systems enable users of our current CGM systems to have their sensor glucose information remotely monitored by their family, friends or other designated recipient, or follower, by wirelessly transmitting data from the user&#8217;s smart phone to the cloud and then to the follower&#8217;s mobile device. Several followers can remotely monitor a patient&#8217;s glucose information and receive secondary alert notifications from almost anywhere with an Internet connection via each follower&#8217;s mobile device.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective is to remain a leading provider of CGM systems and related products to enable people with diabetes to more effectively and conveniently manage their condition. We are also developing and commercializing products that integrate our CGM technologies into the insulin delivery systems or data platforms of our respective partners. In addition, we continue to pursue development partnerships with other insulin delivery companies, including automated insulin delivery systems, as well as other players in the disease management sector. We are focusing on the following business strategies as we pursue these objectives:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Establishing and maintaining our technology platform as the leading approach to CGM and leveraging our development expertise to rapidly bring products to market, including for expanded indications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Supporting use of our ambulatory products through a direct sales and marketing effort, as well as key distribution arrangements.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Supporting innovation through technology integration partnerships.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Seeking broad coverage policies and reimbursement for our products from private third-party payors and national health systems.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Providing cloud-based data repository platform that enables people with diabetes to aggregate and analyze data from numerous diabetes devices and share the data with their healthcare providers and other individuals involved in their diabetes management and care.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Pursuing expansion of use of our products to other patient care settings and patient demographics, including use for people with Type 2 diabetes who are not on intensive insulin therapy, population health, patient monitoring including in the hospital setting, and people who are pregnant.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Providing a high level of customer support, service and education.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Pursuing the highest safety and quality levels for our products.</span></div><div id="i70f957301cc34339a22f629982cd0734_3591"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Our Technology Platform</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have a broad technology platform that will support the development of multiple products for continuous glucose monitoring.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sensor Technology</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key enabling technologies for our sensors include biomaterials, membrane systems, electrochemistry and low power microelectronics. Our membrane technology consists of multiple polymer layers configured to selectively allow the appropriate mix of glucose and oxygen to travel through the membrane and react with a glucose specific enzyme to create an extremely low electrical signal, measured in pico-amperes. This electrical signal is then translated into glucose values. We believe that the capability to measure very low levels of an electrical signal and to accurately translate those measurements into glucose values is also a unique and distinguishing feature of our technology. We have also developed technology to allow sensitive electronics to be packaged in a small, fully contained, lightweight sealed unit that minimizes inconvenience and discomfort for the user.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receiver and Transmitter Technology</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current CGM systems wirelessly transmit information from the transmitter to our receiver or to a compatible mobile device. We have developed technology for reliable transmission and reception and have consistently demonstrated a high rate of successful transmissions from transmitter to receiver or compatible mobile device in our clinical trials. Our receiver or the mobile device, via our apps, then displays both real-time and trended glucose values, and provides alerts and alarms. We have used our extensive database of continuous glucose data to create and refine software, algorithms and other technology for the display of data to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compatible Mobile Devices</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our G6 and G7 systems, the functionalities of our proprietary receiver can be obtained through the use of a compatible mobile device, such as an iOS or Android device, and our mobile applications, depending on the patient&#8217;s geographic location. A receiver may be required as the primary display device or a backup to the mobile device in some jurisdictions, including the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products in Development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have gained our technology expertise by developing implants designed to withstand the rigors of functioning within the human body for extended periods of time, and designed to address other considerations such as device sealing, miniaturization, durability and sensor geometry.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging this technology platform with the goal of enhancing the capabilities of our current products (including obtaining expanded indications for use) and to develop additional CGM products. We plan to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration. Over the longer term, we plan to continue to develop and improve networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices. We intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exploring how to extend our offerings to other opportunities, including for people with Type 2 diabetes that are non-insulin using, people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. Eventually, we may apply our technological expertise to products beyond glucose monitoring.</span></div><div id="i70f957301cc34339a22f629982cd0734_3563"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Operations</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built a direct sales organization in North America and certain international markets to call on health care professionals, such as endocrinologists, physicians and diabetes educators, who can educate patients about continuous glucose monitoring. We believe that focusing efforts on these participants is important given the instrumental role they each play in the decision-making process for diabetes therapy, and to ensure that health care professionals and patients are knowledgeable about our products and their functionality. We focus on delivering this important information to participants to drive adoption of our current CGM systems. In addition, our direct sales efforts include the use of e-commerce resources in certain international markets where we have not built a sales force.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complement our direct sales efforts, we have entered into distribution arrangements in North America and several international markets that allow distributors to sell our products. We expect to continue investing in our field sales force and believe our direct, highly specialized and focused sales organization and our domestic and international distribution agreements are sufficient for us to support our sales efforts for at least the next twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a variety of marketing tools to drive adoption, ensure continued use and establish brand loyalty for our CGM systems by:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">creating awareness of the benefits of continuous glucose monitoring and the advantages of our technology with endocrinologists, physicians, diabetes educators and people with diabetes;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">providing strong and simple educational and training programs to healthcare providers and people with diabetes to ensure easy, safe and effective use of our systems; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">maintaining a readily accessible telephone and web-based technical and customer support infrastructure, which includes clinicians, diabetes educators and reimbursement specialists, to help referring physicians, diabetes educators and people with diabetes as necessary.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct-to-consumer (DTC) marketing is one of our key initiatives to increase awareness of our CGM systems and drive new leads for people with diabetes to our website. In jurisdictions where DTC marketing is permitted, we currently focus on reaching people with Type 1 and people with Type 2 diabetes who use insulin. We advertise on television, in print, digital and video media, CRM, offer sponsorships, host or participate in diabetes related events, conduct public relations and maintain a brand ambassador program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically experience seasonality, with lower sales in the first quarter of each year compared to the immediately preceding fourth quarter. This seasonal sales pattern relates to U.S. annual insurance deductible resets and unfunded flexible spending accounts.</span></div><div id="i70f957301cc34339a22f629982cd0734_3537"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competition</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for glucose monitoring devices is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. In selling our current CGM systems, we compete directly with the Diabetes Care division of Abbott Laboratories; Medtronic plc&#8217;s Diabetes Group; Roche Diabetes Care, a division of Roche Diagnostics; privately-held LifeScan, Inc.; and Ascensia Diabetes Care, each of which manufactures and markets products for the single-point finger stick device market. Collectively, these companies currently account for the majority of the worldwide sales of self-monitored glucose testing systems.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several companies are developing or commercializing products for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin that compete directly with our products. We have competed with Abbott and their Libre family of CGM products for many years. Medtronic markets and sells a standalone glucose monitoring product called Guardian Connect, both internationally and in the United States, and a disposable CGM system called Simplera in international markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic and other third parties have developed or are developing, insulin pumps integrated with continuous glucose monitoring systems that provide, among other things, the ability to suspend insulin administration while the user&#8217;s glucose levels are low and to automate basal or bolus insulin dosing. Likewise, Abbott Diabetes Care has </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received FDA clearance to integrate certain versions of their Libre sensors into automated insulin delivery systems and is pursuing such integrations with third-party insulin delivery devices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of companies outside the traditional medical device sector that are attempting to develop competitive products and services, including for the general health and wellness, or population health space. Some of the companies developing or marketing competing devices are large and well-known publicly traded companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the principal competitive factors in our market include:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">safe, reliable and high-quality performance of products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">cost of products and eligibility for reimbursement;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">comfort and ease of use of products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">effective sales, marketing and distribution networks;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">brand awareness and strong acceptance by healthcare professionals and people with diabetes;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">customer service and support and comprehensive education for people with diabetes and diabetes care providers;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">speed of product innovation and time to market;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">regulatory expertise; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">technological leadership and superiority.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on competition, please see our Risk Factor entitled &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We operate in a highly competitive market and face competition from large, well-established companies with significant resources, and, as a result, we may not be able to compete effectively.&#8221;</span></div><div id="i70f957301cc34339a22f629982cd0734_3510"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture our products at our headquarters in San Diego, California and at our manufacturing facilities in Mesa, Arizona and Penang, Malaysia, where we collectively have approximately 65,900 square feet of laboratory space and approximately 155,700 square feet of controlled environment rooms. In 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing. We are also expanding our facility in Mesa, Arizona to scale up manufacturing capacity and plan to begin construction of a new facility in Ireland. We anticipate that the new facilities and the Mesa capacity scale-up will add substantial manufacturing capacity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are technical challenges to increasing manufacturing capacity, finding or enhancing new manufacturing facilities capable of meeting regulatory requirements, government licensure of manufacturing facilities, equipment design and automation, material procurement, problems with production yields, and quality control and assurance. We have focused significant effort on continual improvement programs in our manufacturing operations intended to improve quality, yields and throughput. We have made progress in manufacturing to enable us to supply adequate amounts of product to support our commercialization efforts, however we cannot guarantee that supply will not be constrained going forward. Additionally, the production of our continuous glucose monitoring systems must occur in a highly controlled and clean environment to minimize particles and other yield- and quality-limiting contaminants. Developing and maintaining commercial-scale manufacturing facilities has and will continue to require the investment of substantial additional funds and the hiring and retention of additional management, quality assurance, quality control and technical personnel who have the necessary manufacturing experience.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture our current CGM systems with certain components supplied by outside vendors and other components that we manufacture internally. Key components that we manufacture internally include our wire-based sensors. The remaining components and assemblies are purchased from outside vendors. We then assemble, test, package and ship the finished systems, which may include a reusable transmitter, a receiver and disposable sensors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase certain components and materials used in manufacturing from single sources due to quality considerations, costs or constraints resulting from regulatory or other requirements. As of December&#160;31, 2023, those single sources include suppliers of application-specific integrated circuits used in our transmitters, seals used for the applicator and certain polymers used to synthesize polymeric membranes for our sensors. For additional information, please see our Risk Factor entitled, &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_3483"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third-Party Coverage and Reimbursement</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a medical device company, coverage and reimbursement from Medicare, Medicaid or other governmental healthcare programs or systems, and private third-party healthcare payors is an important element of our success. Medicare covers the CGM system, which includes supplies necessary for the use of the device, under the Durable Medical Equipment, or DME, benefit category. Previously, Medicare coverage for CGM was only available to Medicare patients who take at least three doses of insulin a day, limiting CGM reimbursement for Medicare beneficiaries with intensive Type 1 and 2 diabetes. The Local Coverage Determination, or LCD, that the Centers for Medicare &amp; Medicaid Services released in April 2023 extends Medicare CGM coverage to all patients using insulin. Further, the LCD also allows coverage for patients not taking insulin if the patient has a history of problematic hypoglycemia. We also have coverage under certain international markets and Medicaid coverage in approximately 45 states.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the eight</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">largest private third-party payors, in terms of the number of covered lives, have issued coverage policies for the category of continuous glucose monitoring devices. In addition, we have negotiated contracted rates with all of those third-party payors for the purchase of our current CGM systems by their members. We have personnel with reimbursement expertise to assist customers in obtaining reimbursement from private third-party payors. We also maintain a field-based reimbursement team charged with calling on third-party private payors to obtain coverage decisions and contracts. We have continued our efforts to create and liberalize coverage policies with third-party payors, including obtaining reimbursement for our products under pharmacy benefits and for more people with diabetes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on third-party reimbursement, please see our see Risk Factors in the section entitled &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Pricing and Reimbursement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div id="i70f957301cc34339a22f629982cd0734_3456"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protection of our intellectual property is a strategic priority for our business. We rely on a combination of patents, copyrights, trademarks, trade names, trade secrets, nondisclosure agreements and other measures to establish and protect our proprietary rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio includes numerous issued and pending patent applications in the U.S. and other parts of the world, which in the aggregate, we believe to be of material importance in the operation of our business. U.S. patents, as well as most foreign patents, are generally effective for 20 years from the date the earliest application was filed. In some cases, the patent term may be extended. Our issued patents as of December&#160;31, 2023 are set to expire over a range of years, from 2024 with respect to some of our earlier patents, to 2042, subject to any extensions. We also have various registered U.S. trademarks, registered European Community trademarks, and many other trademark registrations and pending trademark applications around other parts of the world. In addition, we have entered into exclusive and non-exclusive licenses in the ordinary course of business relating to a wide array of technologies or other intellectual property rights or assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patents and patent applications seek to protect aspects of our core membrane and sensor technologies and our product concepts for continuous glucose monitoring. We believe that our patent position provides us with sufficient rights to protect our current and proposed commercial products. However, our patent applications may not result in issued patents, and any patents that have been issued or might be issued may not protect our intellectual property rights. Furthermore, we operate in an industry characterized by extensive patent litigation, and our patents may not be upheld if challenged. Any patents issued to us may be challenged by third parties as being invalid or unenforceable, and patent litigation may result in significant damage awards and injunctions that could prevent the manufacture and sale of affected products or result in significant royalty payments in order to continue selling the products. Third parties may also independently develop similar or competing technology that avoids our patents. The steps we have taken may not prevent the misappropriation of our intellectual property, particularly in international countries where the laws may not protect our proprietary rights as fully as in the United States. We also face risks associated with intellectual property infringement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets, technical know-how and continuing innovation to develop and maintain our competitive position. We seek to protect our proprietary information and other intellectual property by generally requiring our employees, consultants, contractors, suppliers, outside scientific collaborators and other advisors to execute non-disclosure and assignment of invention agreements on commencement of their employment or engagement. Agreements with our employees also forbid them from bringing the proprietary rights of third parties to us. We also generally require confidentiality or material transfer agreements from third parties that receive our confidential data or materials. We cannot guarantee that employees and third parties will abide by the confidentiality </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or assignment terms of these agreements. Despite measures taken to protect our intellectual property, unauthorized parties might copy aspects of our products or obtain and use information that we regard as proprietary.</span></div><div id="i70f957301cc34339a22f629982cd0734_3429"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sustainability</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that taking into account the interests of our various stakeholders &#8211; including patients, caregivers, employees, investors, and our communities &#8211; enables us to operate in a sustainable manner, supports the success of our business and drives long-term value. We do this by holding true to our core values: Listen, Think Big, Be Dependable, and Serve with Integrity. These values are at the heart of our sustainability initiatives.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">Listen</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; We believe in listening to our customers and our employees. We have launched a number of programs to advocate for individuals living with diabetes and we support our employees and their families through a number of benefit programs that are available. In addition, we seek to promote diversity, practice fairness, and treat everyone with respect and dignity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">Think Big </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; We seek to expand global healthcare access for people with diabetes and actively work to increase access to our products. We also have committed to operate our business in a manner that is environmentally sustainable and conserves natural resources and reduces waste.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">Be Dependable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; We are committed to quality and believe that is best achieved through a safe and healthy workplace as well as a Quality Management System that is compliant with all applicable regulatory requirements and which is continuously being improved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">Serve with Integrity &#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While oversight of our ethics and governance structure begins with our Board of Directors and Executive Leadership Team, we expect all employees to foster a culture of accountability in line with our Code of Conduct and Business Ethics. We also maintain a compliance program to help enforce ethical conduct and adherence to applicable laws and regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Governance Committee of the Board of Directors oversees and reviews Dexcom&#8217;s risks, opportunities, strategies, programs, policies, practices, measures, objectives and performance relating to corporate sustainability matters. Our management-level Corporate Sustainability Steering Committee, which is comprised of the functional leads from our Commercial, Operations, Human Capital, Finance and Legal departments, is responsible for, among other things, setting the overall strategy with respect to corporate sustainability matters (subject to direction from the Chief Executive Officer and oversight of the Nominating and Governance Committee), establishing programs, policies and practices relating to corporate sustainability matters (&#8220;Dexcom&#8217;s Corporate Sustainability Program&#8221;) and overseeing and monitoring the implementation of Dexcom&#8217;s Corporate Sustainability Program. The Corporate Sustainability Steering Committee reports to our Chief Executive Officer and provides periodic updates regarding our corporate sustainability programs, policies and practices to the Nominating and Governance Committee of our Board of Directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Sustainability Report is available at https://investors.dexcom.com/governance/governance-documents/, which is provided for reference only and is not incorporated by reference into this Annual Report on Form 10-K.</span></div><div id="i70f957301cc34339a22f629982cd0734_3402"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Regulation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical devices that we manufacture are subject to regulation by numerous regulatory bodies, including the FDA and comparable international regulatory agencies. These agencies require manufacturers of medical devices to comply with applicable laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of medical devices. Devices are generally subject to varying levels of regulatory control, the most comprehensive of which requires that a clinical evaluation program be conducted before a device receives approval for commercial distribution. In addition, healthcare regulatory bodies in the United States and around the world impose a range of requirements related to the payment for medical devices and the procedures in which they are used, including laws intended to prevent fraud, waste, and abuse of healthcare dollars.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Laws and Regulations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the U.S. federal level, our products are medical devices subject to extensive and ongoing regulation by the FDA. The U.S. Federal Food, Drug and Cosmetic Act, referred to as the FDCA, and the FDA&#8217;s implementing regulations govern product design and development, pre-clinical and clinical testing, pre-market clearance, authorization or approval, establishment registration and product listing, product manufacturing, product labeling, product storage, advertising and promotion, product sales, distribution, recalls and field actions, servicing and post-market clinical surveillance. A number of U.S. states also impose licensing and compliance regimes on companies that manufacture or distribute prescription devices in the state.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the delivery of our devices in the U.S market is subject to regulation by various U.S. Department of Health and Human Services divisions including CMS, the DHHS Office of the Inspector General, or OIG, the Department of Veterans Affairs, and comparable state agencies responsible for reimbursement and regulation of payment for health care items and services. U.S. laws and regulations are imposed primarily in connection with the Medicare, Medicaid, and TRICARE programs, as well as the government&#8217;s interest in regulating the quality and cost of health care.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an exemption applies, each medical device we wish to commercially distribute in the United States will require either prior 510(k) clearance, prior </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> down-classification and a related grant of marketing authorization, or prior approval from the FDA through the premarket approval, or PMA process. The FDA classifies medical devices into one of three classes. Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class I devices are subject to general controls such as labeling, pre-market notification, and adherence to the FDA&#8217;s manufacturing requirements, which are contained in the Quality System Regulation, or QSR. Class II devices are subject to special controls such as performance standards, post-market surveillance, FDA guidelines, or particularized labeling, as well as general controls. Some Class I and Class II devices are exempted by regulation from the pre-market notification (i.e., 510(k) clearance) requirement, and/or the requirement of compliance with substantially all of the QSR. As an example, the mobile applications that comprise the Share System were classified by the FDA as Class II exempt. With the mobile applications classified as Class II exempt, we must comply with certain general and special controls required by the FDA but we do not need prior FDA review to commercialize changes to the mobile applications. Some devices are placed in Class III, which requires approval of a PMA application, if they are deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or certain implantable devices, or to be &#8220;not substantially equivalent&#8221; either to a previously 510(k) cleared device or to a &#8220;preamendment&#8221; Class III device in commercial distribution before May&#160;28, 1976 for which PMA applications have not been required.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a previously unclassified new medical device does not qualify for the 510(k) pre-market notification process because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class III. Under FDA law, the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA. If the FDA agrees with the down-classification, the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applicant will then receive authorization to market the device, and a classification regulation will be established for the device type. The device can then be used as a predicate device for future 510(k) submissions by the manufacturer or a competitor.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A PMA application must be supported by valid scientific evidence, which typically requires extensive data, including technical, pre-clinical, clinical, manufacturing and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and efficacy of the device. A PMA application also must include a complete description of the device and its components, a detailed description of the methods, facilities and controls used to manufacture the device, and proposed labeling.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our CGM device, we have a Class I data management service which we market to clinics. This service helps healthcare providers and patients see, understand and use blood glucose meter data to diagnose and manage diabetes. The service also allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The infrastructure of the data management service is considered &#8220;medical device data systems,&#8221; or MDDS. MDDS are hardware or software products that transfer, store, convert formats, and display medical device data. An MDDS does not modify the data or modify the display of the data, and it does not by itself control the functions or parameters of any other medical device. MDDS are not intended to be used for active patient monitoring. The 21st Century Cures Act excluded certain software functions from the definition of &#8220;device&#8221;, thus products meeting the definition of MDDS (which previously might have been regulated as Class I, 510(k)-exempt devices) are no longer considered devices and thus are not subject to FDA regulatory requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional functions of, or intended uses for, our software platform may require us to obtain marketing authorization from the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device is authorized for marketing and placed in commercial distribution, numerous regulatory requirements apply. These include:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">establishment registration and device listing;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">QSR, which requires manufacturers to follow design, testing, control, storage, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">labeling regulations, which prohibit the promotion of products for unapproved or off-label uses or indications and impose other restrictions on labeling, advertising and promotion;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">medical device reporting regulations, which require that manufacturers report to the FDA if a device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">voluntary and mandatory device recalls to address problems when a device is defective and/or could be a risk to health; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">corrections and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the FDA may require us to conduct post-market surveillance studies or order us to establish and maintain a system for tracking our products through the chain of distribution to the patient level. The FDA and the Food and Drug Branch of the California Department of Health Services and other applicable government regulatory agencies enforce regulatory requirements by conducting periodic, unannounced inspections and market surveillance. Inspections may include the manufacturing facilities of our subcontractors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulatory requirements, including those applicable to the conduct of our clinical trials, can result in enforcement action by the FDA, which may lead to any of the following sanctions:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">warning letters or untitled letters that require corrective action;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">fines and civil penalties;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">unanticipated expenditures;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in approving or refusal to approve our future continuous glucose monitoring systems or other products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">FDA refusal to issue certificates to foreign governments needed to export our products for sale in other countries;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">suspension or withdrawal of FDA approval;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">product recall or seizure;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">interruption of production;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">operating restrictions;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">injunctions; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">criminal prosecution.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our contract manufacturers, specification developers, and some suppliers of components or device accessories, are also required to manufacture our products in compliance with current Good Manufacturing Practice requirements set forth in the QSR. The QSR requires a quality system for the design, manufacture, packaging, labeling, storage, installation and servicing of marketed devices, and includes extensive requirements with respect to quality management and organization, device design, buildings, equipment, purchase and handling of components or services, production and process controls, packaging and labeling controls, device evaluation, distribution, installation, complaint handling, servicing, and record keeping. The FDA evaluates compliance with the QSR through periodic unannounced inspections that may include the manufacturing facilities of our subcontractors. If the FDA believes we or any of our contract manufacturers or regulated suppliers are not in compliance with these requirements, it can shut down our manufacturing operations, require recall of our products, refuse to approve new marketing applications, institute legal proceedings to detain or seize products, enjoin future violations, or assess civil and criminal penalties against us or our officers or other employees. Any such action by the FDA would have a material adverse effect on our business. We may be unable to comply with all applicable FDA regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Fraud and Abuse Laws and Other Compliance Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to various U.S. federal and state laws pertaining to healthcare fraud and abuse. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in U.S. federal and state healthcare programs, including Medicare and Medicaid.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-kickback Laws.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or providing remuneration directly or indirectly to induce either (i) the referral of an individual, or (ii) purchasing, ordering, recommending, or arranging for the purchase or order of a good or service, for which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including such items as gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments to consultants, waiver of payments, and providing anything at less than its fair market value. Given the breadth of this prohibition, Congress has issued a number of exceptions and has granted authority to the OIG to issue safe harbor regulations, each of which set forth certain provisions which, if satisfied in their entirety, will exempt an arrangement from being found to violate the federal Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more exceptions or safe harbors is not per se illegal; rather, each arrangement is subject to a facts and circumstances analysis to determine whether the requisite improper intent exists. Therefore, conduct and business arrangements that do not fully satisfy each applicable exception or safe harbor element may result in increased scrutiny by government enforcement authorities or invite litigation by private citizens under federal whistleblower laws. Violation of the Anti-Kickback Statute is a felony and conviction could result in the assessment of fines of up to $100,000 per violation or imprisonment for up to 10 years or both.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Civil False Claims Act.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The federal Civil False Claims Act prohibits, among other things, knowingly presenting, or causing to be presented a false claim or the knowing use of false statements or records to obtain payment from the federal government. When an entity is determined to have violated the False Claims Act, it may be subject to repayment of three times the actual damages sustained by the government, plus significant mandatory civil penalties for each separate false claim. Suits filed under the False Claims Act can be brought by any individual on behalf of the government and such individuals (known as &#8220;relators&#8221; or, more commonly, as &#8220;whistleblowers&#8221;) may share in any amounts paid by the entity to the government in fines or settlement. These whistleblower-initiated False Claims Act cases are commonly referred to as &#8220;qui tam&#8221; actions. False Claims Act cases may also be initiated by the U.S. Department of Justice or any of its local U.S. Attorneys&#8217; Offices. In addition, certain states have enacted laws modeled after the federal False Claims Act. Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend a false claim action, even before the validity of the claim is established and even if the government decides not to intervene in the lawsuit. Healthcare companies may decide to agree to large settlements with the government and/or whistleblowers to avoid the cost and negative publicity associated with litigation. Federal enforcement agencies also have shown increased interest in pharmaceutical and medical device companies&#8217; product promotion, health care professional engagements, and patient assistance programs, including reimbursement and co-pay support services, and a number of investigations into these programs have resulted in significant civil and criminal settlements. In addition, the Affordable Care Act amended federal law to provide that the government may assert that a claim for items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Criminal prosecution is also possible for knowingly making or presenting a false or fictitious or fraudulent claim to the federal government.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Physician Self-Referral Law. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Physician Self-Referral Law, also referred to as the Stark Law, prohibits a physician (or an immediate family member of a physician) who has a financial relationship with an entity from referring patients to that entity for certain designated health services, including durable medical equipment such as the CGM receiver and supplies, payable by Medicare, unless an exception applies. The Stark Law also prohibits such an entity from presenting or causing to be presented a claim to the Medicare program for such designated health services provided pursuant to a prohibited referral, and provides that certain collections related to any such claims must be refunded in a timely manner. Exceptions to the Stark Law include, among other things, exceptions for certain financial relationships, including both ownership and compensation arrangements. The Stark Law is a strict liability statute, therefore, to the extent that the statute is implicated and an exception does not apply, the statute is violated. Violations of the Stark Law must be reported and payment for improper referrals returned to Medicare in order to avoid potential liability under the federal False Claims Act for avoiding a known obligation to return identified overpayments. In the fall of 2020, we transitioned our Medicare business to distributors and we no longer bill Medicare directly for DME and related supplies. In doing so, we have limited our exposure under the Stark Law. In addition to the Stark Law, many states have implemented similar physician self-referral prohibitions that may extend to Medicaid, third party payors, and self-pay patients, and may be applicable to our relationships with physicians and other health care providers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Monetary Penalties Law</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Civil Monetary Penalties Law, or CMPL, authorizes the imposition of substantial civil money penalties against an entity that engages in certain prohibited activities including but not limited to violations of the Stark Law or Anti-Kickback Statute, knowing submission of a false or fraudulent claim, employment of an individual excluded from participation in federal health care programs, and the provision or offer of anything of value to a Medicare or Medicaid beneficiary that the transferring party knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider or supplier from which to receive items or services for which payment may be made in whole or part by a federal health care program, commonly known as the Beneficiary </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inducement CMP. Remuneration is defined under the CMPL as any transfer of items or services for free or for less than fair market value. There are certain exceptions to the definition of remuneration for offerings that meet the Financial Need, Preventative Care, or Promoting Access to Care exceptions. Sanctions for violations of the CMPL include civil monetary penalties and administrative penalties up to and including exclusion from participation in federal health care programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the Stark Law, the Anti-Kickback Statute, the Civil Monetary Penalties Law and/or the federal False Claims Act can also form the basis for exclusion from participation in federal and state healthcare programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State Analogs of Federal Fraud and Abuse Laws</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Many U.S. states have their own laws intended to protect against fraud and abuse in the health</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">care industry and more broadly. In some cases these laws prohibit or regulate additional conduct beyond that covered under federal law. Penalties for violating these laws can range from fines to criminal sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Insurance Portability and Accountability Act of 1996 (HIPAA). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996, as amended by the American Recovery and Reinvestment Act of 2009, and implementing regulations, collectively HIPAA, created two federal crimes: healthcare fraud and false statements relating to healthcare matters. The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government sponsored programs, or integrity oversight and reporting obligations to resolve allegations of non-compliance. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIPAA and Other U.S. Privacy Laws and Regulations. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws, rules and regulations govern the collection, dissemination, use, privacy, security and confidentiality of personal information.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, in addition to the criminal powers above, extensively regulates the use and disclosure of individually identifiable health information, through the Privacy, Security, and Breach Notification Rules. HIPAA requires covered entities, including health plans and most health care providers, to implement administrative, physical and technical safeguards to protect the privacy and security of covered information (known as &#8220;protected health information&#8221;) and sets limits and conditions on the uses and disclosures that may be made of such information without the authorization of the relevant individual. HIPAA&#8217;s Security Rule and certain provisions of the HIPAA Privacy Rule and Breach Notification Rule apply to business associates of covered entities (i.e., entities that provide services to covered entities that may require access and use of protected health information on behalf of covered entities), and business associates are subject to direct liability for violation of these rules. In addition, a covered entity may be subject to criminal and civil penalties as a result of a business associate violating HIPAA, if the business associate is found to be an agent of the covered entity. Covered entities must report breaches of unsecured protected health information to affected individuals without unreasonable delay and notification must also be made to the U.S. Department of Health &amp; Human Services, Office for Civil Rights (OCR) and, in certain situations involving large breaches, to the media. The OCR enforces the HIPAA Rules and performs compliance audits and investigations. In addition to enforcement by OCR, HIPAA authorizes state attorneys general to bring civil actions seeking either injunction or damages in response to HIPAA violations that impact state residents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2022, OCR issued a bulletin on the requirements under HIPAA for online tracking technologies (e.g., cookies, pixels) to protect the privacy and security of health information. This bulletin outlined OCR&#8217;s position on the use of online tracking technology vendors, when certain information received by such vendors constitutes protected health information under HIPAA, and accordingly, when business associate agreements must be executed between covered entities, like us, and such vendors. We are a covered entity under HIPAA because we are a health care provider that engages in certain electronic standard transactions.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we may also be a business associate of another covered entity or of another business associate. We have assessed our responsibilities under the bulletin and undertaken a number of initiatives to support our compliance with HIPAA and other requirements relating to online tracking technologies, including updates to our cookie banners and preference center. These steps are in addition to measures we had taken previously and we continue to evaluate our compliance with applicable laws and adjust our practices to address developments in the field over time. The HIPAA Rules impose and will continue to impose significant costs on us in order to comply with these standards.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous other laws, regulations and legislative and regulatory initiatives at the federal and state levels addressing privacy and security of personal information. We also remain subject to federal and state privacy-related laws that may be more restrictive or contain different requirements than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties. For example, the Federal Trade Commission, or FTC, uses its consumer protection authority to initiate enforcement actions against companies relating to their use and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosure of personally identifiable information. Specifically, FTC has asserted authority and issued enforcement actions in response to actual or perceived unfair or deceptive practices by a company in the handling of consumer information. The FTC has also pursued enforcement actions against companies for violations of its Health Breach Notification Rule and the Children&#8217;s Online Privacy Protection Act. Our use of personal information is also subject to our published privacy policies and notices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, certain states have proposed or enacted legislation that will create new data privacy and security obligations for certain entities. These laws include, for example, the California Consumer Privacy Act, or CCPA, which came into effect January 1, 2020 and was amended and expanded by the California Privacy Rights Act, or CPRA, which came into effect on January 1, 2023; the Virginia Consumer Data Protection Act, effective as of January 1, 2023; the Colorado Privacy Act and the Connecticut Data Privacy Act, both effective as of July 1, 2023; the Utah Consumer Privacy Act, effective as of December 31, 2023; the Washington My Health My Data Act and Nevada Senate Bill 370, both effective as of March 31, 2024; the Oregon Consumer Privacy Act, the Texas Data Privacy and Security Act, and the Florida Digital Bill of Rights, all effective as of July 1, 2024; the Montana Consumer Data Privacy Act, effective as of October 1, 2024; the Delaware Personal Data Privacy Act, effective as of January 1, 2025; the Iowa Act Relating to Consumer Data Protection, effective as of January 1, 2025; the Tennessee Information Protection Act, effective as of July 1, 2025; and the Indiana Consumer Data Protection Act, effective as of January 1, 2026. Several other states have enacted, or are proposing to enact, their own comprehensive privacy laws. Among other things, these state-specific laws create new data privacy obligations for covered companies and provide new privacy rights to state residents, including the right to opt out of certain disclosures of their information. A particular focus of legislatures appears to be consumer health data which is not subject to HIPAA, as evidenced by passage of the Washington My Health My Data Act and Nevada Senate Bill 370. The CCPA also created a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach, and other laws, such as the Telephone Consumer Privacy Act and the Washington My Health My Data Act, also have private rights of action for violations. Regulations implementing the California and Colorado laws have been published (in draft form for California, and final form for Colorado), but many questions remain as to how all of the new statutes will be interpreted and enforced. The effects of state data protection laws are significant and have required us to modify our data processing practices. They may also cause us to incur substantial costs and expenses to ensure ongoing compliance, particularly given our base of operations in California. Various U.S. state laws and regulations may also require us to notify affected individuals and state agencies in the event of a data breach involving individually identifiable information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the laws discussed above, we may see more stringent state and federal privacy legislation passed in 2024 and beyond, as the increased cyber-attacks during recent international conflicts have once again put a spotlight on data privacy and security in the U.S. and other jurisdictions. We cannot predict where new legislation might arise, the scope of such legislation, or the potential impact to our business and operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FCPA and Other Anti-Bribery and Anti-Corruption Laws. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA would include interactions with certain healthcare professionals in many countries, either directly or through our contracted distributors. Our present and future business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physician Payment Sunshine Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Patient Protection and Affordable Care Act that was signed into law in March 2010, the federal government enacted the Physician Payment Sunshine Act. As a manufacturer of U.S. FDA&#8209;regulated devices reimbursable by federal healthcare programs, we are subject to this law, which requires us to track and annually report certain direct or indirect payments and other transfers of value we make to certain U.S.-licensed health care practitioners and U.S. teaching hospitals. We are also required to report certain ownership or investment interests held by physicians and their immediate family members. In 2018, the law was amended to require tracking and reporting of payments and transfers of value provided to health care practitioners besides physicians, including physician assistants, nurse practitioners, and other mid-level practitioners. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These expanded reporting requirements took effect in 2022 for payments and transfers of value made to these additional practitioner-types in 2021.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CMS has the potential to impose penalties of up to $1.36 million per year for violations of the Physician Payment Sunshine Act, depending on the circumstances, and reported payments also have the potential to draw scrutiny to our relationships with health care practitioners and academic medical institutions, which may have implications under the Anti-Kickback Statute and other healthcare laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain states also have laws and regulations related to payments and other transfers of value provided to healthcare professionals and entities. Similar to the federal law, certain states have adopted marketing and/or transparency laws relevant to device manufacturers, some of which are broader in scope. Certain states also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mandate that device manufacturers implement compliance programs. Other states impose restrictions on device manufacturer marketing practices and require tracking and reporting of gifts, compensation, and other remuneration to healthcare professionals and entities. The need to build and maintain a robust compliance program with different compliance and/or reporting requirements increases the possibility that a company may violate one or more of the requirements, resulting in fines and penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales of medical devices are subject to foreign government regulations, which may vary substantially from country to country. The time required to obtain approval in a foreign country may be longer or shorter than that required for FDA approval, and the requirements may differ. There is a trend towards harmonization of quality system standards among the European Union, United States, Canada and various other industrialized countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework governing medical devices is largely harmonized within the European Union, which includes most of the major countries in Europe. Other countries, such as Switzerland, have voluntarily adopted laws and regulations that mirror those of the European Union with respect to medical devices. The European Union has adopted numerous directives and standards regulating the design, manufacture, clinical trials, labeling and adverse event reporting for medical devices. To be placed on the European Union market, devices must undergo a conformity assessment and bear the CE mark, indicating that the device conforms to the essential requirements of the applicable rules. The method of assessing conformity varies depending on the class of the product, but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a &#8220;Notified Body.&#8221; This third-party assessment, which may consist of an audit of the manufacturer&#8217;s quality system and specific testing of the manufacturer&#8217;s product, is always required in order for a manufacturer to commercially distribute the product throughout the European Union, except in case of Class I medical devices (those entailing the lowest level of risk). Outside of the European Union, regulatory approval needs to be sought on a country-by-country basis in order for us to market our products. The European Union Medical Device Regulation, or MDR, went into force in 2017, and replaced the existing Directive. The MDR initially provided three years for transition and compliance, which was subsequently extended to May 2026, December 2027, or December 2028, depending on the device classification. The MDR became applicable in the European Union on May 26, 2021, changing several aspects of the existing regulatory framework. Other countries have adopted medical device regulatory regimes, such as the Classification Rules for Medical Devices published by the Hong Kong Department of Health, the Health Sciences Authority of Singapore regulation of medical devices under the Health Products Act, and Health Canada&#8217;s risk classification system for invasive devices, among others. Each country may have its own processes and requirements for medical device licensing, approval, and regulation, therefore requiring us to seek regulatory approvals on a country-by-country basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States a range of anti-bribery and anti-corruption laws, as well and some industry-specific laws and codes of conduct, apply to the medical device industry and interactions with government officials and entities and healthcare professionals. Laws include the UK Bribery Act of 2010. Further, the EU member countries have emphasized a greater focus on healthcare fraud and abuse and have indicated greater attention to the industry by the European Anti-Fraud Office. MedTech Europe, the medical device industry association, also introduced the Code of Ethical Business Practices, which came into effect on January 1, 2017. Countries in Asia have also become more active in their enforcement of anti-bribery laws and with respect to procurement and supply chain fraud.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, increasingly stringent data protection and privacy rules that have and will continue to have substantial impact on the use of patient data across the healthcare industry became effective in May 2018. The EU General Data Protection Regulation, or GDPR, applies across the European Union and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for non-compliance. The GDPR fine framework can be up to 20 million euros, or up to 4% of the company&#8217;s total global turnover of the preceding fiscal year, whichever is higher. The GDPR also requires companies processing personal data of individuals residing in the European Union to comply with EU privacy and data protection rules, even if the company itself does not have a physical presence in the European Union. Noncompliance could result in the imposition of fines, penalties, or orders to stop noncompliant activities. Due to the strong consumer protection aspects of the GDPR, companies subject to its purview are allocating substantial legal costs to the development of necessary policies and procedures and overall compliance efforts. We expect continued costs associated with maintaining compliance with GDPR into the future. For example, on July 16, 2020, the Court of Justice of the European Union issued a judgment in Case C-311/18 that declared the EU-U.S. Privacy Shield Framework invalid (Data Protection Commissioner v Facebook Ireland Ltd and Maximillian Schrems, also knowns as &#8220;Schrems II&#8221;). In the absence of the new adequacy decision, this judgment still results in additional compliance obligations for companies that rely on mechanisms other than the Privacy Shield, like standard contractual clauses and appropriate supplementary measures to ensure a valid basis for the transfer of personal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data outside of Europe. Though a new adequacy decision (the EU-U.S. Data Privacy Framework) has been adopted, and it may also be subject to challenges similar to those faced by the Privacy Shield. In view of this and other developments, data transfer risk remains a potential issue that requires regular monitoring. We expect continued costs associated with maintaining compliance with the GDPR into the future, and these requirements, as interpreted by EU data protection authorities, could negatively impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and clinical processes involve the handling of potentially harmful biological materials as well as hazardous materials. We are subject to federal, state and local laws and regulations governing the use, handling, storage and disposal of hazardous and biological materials and we incur expenses relating to compliance with these laws and regulations. If violations of environmental, health and safety laws occur, we could be held liable for damages, penalties and costs of remedial actions. These expenses or this liability could have a significant negative impact on our financial condition. We may violate environmental, health and safety laws in the future as a result of human error, equipment failure or other causes. Environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We are subject to potentially conflicting and changing regulatory agendas of political, business and environmental groups. Changes to or restrictions on permitting requirements or processes, hazardous or biological material storage or handling might require an unplanned capital investment or relocation. Failure to comply with new or existing laws or regulations could harm our business, financial condition and results of operations.</span></div><div id="i70f957301cc34339a22f629982cd0734_3375"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advisory Boards and Consultants</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon the advice of experts in the development and commercialization of our products. Since 2005, we have used experts in various disciplines on a consulting basis as needed to solve problems or accelerate development pathways. We may continue to engage advisors from the academic, consultancy, governmental or other areas to assist us as necessary. Relationships between manufacturers and physicians, including in consultancy and advisory board roles, is subject to scrutiny under the federal Anti-Kickback Statute and its state law equivalents. Due to this scrutiny, we incur legal and consulting fees to ensure our relationships with physicians and other health care providers meet regulatory requirements, including that compensation paid to such physicians is within fair market value.</span></div><div id="i70f957301cc34339a22f629982cd0734_3348"></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Human Capital</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to foster a diverse, inclusive and engaging culture that values each person&#8217;s unique skill set and to continue to attract &#8211; and retain &#8211; top talent throughout the organization. 2023 represented a year of growth across Dexcom; our employee population grew both by number and global footprint. With our shift from office to hybrid work, we have access to more &#8211; and more diverse &#8211; talent than ever before. As of December&#160;31, 2023, we have approximately 9,600 employees around the globe, including 9,500 full-time employees. Approximately 64% of our full-time U.S. employees are ethnically diverse.</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:26.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Country</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Female</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Male</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grand Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ethnically Diverse<br/>(US Only)*</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,600&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,200&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,800&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,700&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grand Total**</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,700&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,900&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,600&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,700&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*All diversity data is self-reported. We capture ethnic diversity data in the United States only, comprised of the following categories: Black or African American, Hispanic or Latino, Asian, American Indian/Alaskan Native, Native Hawaiian or Other Pacific Islander, Two or More Races.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Includes full time and part time employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The human capital measures and objectives that we focus on include diversity, equity and inclusion (&#8220;DEI&#8221;); communications and engagement; health, safety and wellness; total rewards and pay equity; and talent growth and development.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity and Inclusion</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our journey to create a more diverse, equitable and inclusive workplace continues. As Dexcom continues to grow and scale, we believe our DEI initiatives have been critical not only for company culture but also for the growing diversity of patients our products will benefit across the globe.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our talent and diversity staff and the DEI Leadership Council, or DLC, are a means for leaders to work closely together to advance the broader DEI strategy across the organization. We are proud to support our global and local employee resource groups, whose employee-led activities and initiatives we believe continue to foster a sense of belonging for our employees. We continue to weave DEI into talent conversations, particularly at senior levels, which we believe has contributed to our improved representation of female leaders at Dexcom.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Communications and Engagement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through strategic communications, we continue to strengthen the connection between our leaders and our business goals, as well as the behaviors needed to drive a positive employee experience. We also believe by listening to our employees, we can create a dynamic workplace that will foster productivity while promoting work-life balance and connection across the organization. We have continued to seek out &#8220;the voice of the employee&#8221; through life cycle surveys. Each year, we offer an engagement survey titled &#8220;We&#8217;re Listening.&#8221; Employee engagement scores consistently remained high based on a six-factor index. Notably, a strong majority of employees indicated they are proud to work for Dexcom and see a clear link between their work and the Dexcom mission.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Safety and Wellness</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are deeply committed to the safety, health and wellness of our employees. The Dexcom Environmental, Health, Safety &amp; Sustainability team develops global safety practices and procedures, trains employees, and monitors compliance. Through these efforts, along with leadership commitment and investment of resources in support of workplace safety initiatives, our total US injury rate has consistently tracked below industry averages.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also provide comprehensive health and well-being programs that support our employees and their families. For example, Inspire, our global wellness program, and our global mental health and employee assistance programs are designed to help employees and their family members develop and achieve their physical, emotional, and financial well-being goals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal to support our employees&#8217; needs remains constant. We continued to provide both COVID and flu vaccination clinics for employees and their families, and continued support of remote work for employees whose roles allow for it. We also continue to evaluate how to maintain a hybrid workplace beyond the pandemic to ensure that we meet our employees&#8217; ever-changing needs outside the workplace.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Rewards and Pay Equity</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards package includes market competitive pay, comprehensive and competitive global benefits and retirement offerings, paid time off and family leave, tuition reimbursement and on-site services. To foster a stronger sense of ownership and align the interests of employees with shareholders, we offer an Employee Stock Purchase Plan, and restricted stock units are provided to eligible employees under our broad-based stock incentive programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we continued our proactive year-end global market adjustment process intended to ensure we maintain pay equity between active employees and potential new external hires. Through this process, employees who meet predefined criteria may be eligible for an additional adjustment in base salary if they have fallen below Dexcom&#8217;s determined minimum. We believe by continuing to ensure equitable pay between existing and new hires, we will be better positioned to retain valued employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we continue to proactively review both gender and ethnicity pay equity for our global employees in the same or similar roles. The goal of these reviews is to identify and close any gaps in average pay, after accounting for legitimate business factors that may explain differences, such as performance, time in role, and tenure with the company. We have incorporated the findings into our compensation assessment cycles, and we recognize the need to regularly review pay equity to maintain our pay equity goals. With the implementation of our global market adjustment process, we conduct the gender and ethnicity review annually. Additionally, in 2023 we identified and engaged a third party consultant to help further evolve our gender and ethnicity pay equity review.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent Growth and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to invest in new learning systems and programming to support employee development. To support the personal and professional growth of our workforce, we have built an extensive library of development offerings to empower employees at all levels to advance their skill sets and knowledge base. Because there is no one-size-fits-all approach to career development, we continue to evolve our curriculum to meet the needs of our diverse workforce. At this time, our employees have completed over 40,000 hours dedicated to this learning.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional details regarding our human capital and other matters can be found in our Sustainability Report. Although not incorporated by reference into this Annual Report on Form 10-K, our Sustainability Report can be accessed on our investors website at investors.dexcom.com, by clicking &#8220;Governance Documents &amp; Sustainability&#8221;.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1A - RISK FACTORS</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our short and long-term success is subject to numerous risks and uncertainties, many of which involve factors that are difficult to predict or beyond our control. Before making a decision to invest in, hold or sell our common stock, stockholders and potential stockholders should carefully consider the risks and uncertainties described below, in addition to the other information contained in or incorporated by reference into this Annual Report on Form 10-K, as well as the other information we file with the SEC, including our subsequent reports on Forms 10-Q and 8-K. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that case, the value of our common stock could decline and stockholders may lose all or part of their investment. Furthermore, additional risks and uncertainties of which we are currently unaware, or which we currently consider to be immaterial, could have a material adverse effect on our business, financial condition or results of operations. Refer to our disclaimer regarding forward-looking statements at the beginning of Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div id="i70f957301cc34339a22f629982cd0734_22"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Business and Operations</span></td></tr></table></div><div id="i70f957301cc34339a22f629982cd0734_25"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Pricing and Reimbursement</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced, and anticipate that we will continue to experience, decreasing prices for our products due to pricing pressure from managed care organizations and other third-party payors, increased market power of payors, and increased competition among suppliers, including manufacturing services providers, as the medical device industry consolidates. If the prices for our products and services decrease and we are unable to reduce our expenses, including the cost of sourcing materials, logistics and the cost to manufacture our products, our business, results of operations, financial condition and cash flows will be adversely affected.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other countries, government and private sector access to health care products continues to be a subject of focus, and efforts to reduce health care costs are being made by third-party payors. Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of our products. We expect that these continuing cost reduction and containment measures may reduce the cost or utilization of our products and could lead to patients being unable to obtain approval for coverage or payment from these third-party payors or to costs being shifted to patients for our products. Additionally, as a result of the economic slowdown, some customers have lost access and others may lose access to their private health insurance plan if they lose their job, and an impact to job status may extend for a prolonged period of time, beyond possible coverage periods through COBRA, or where the cost to maintain coverage may not be affordable to our customers. As most of our customers currently rely on third-party payors, including government programs and private health insurance plans, to cover the cost of our products, our customers may lose coverage or reimbursement for our products, which may harm our business and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced, and anticipate that we will continue to experience, downward pressure on product pricing. To the extent these cost containment efforts are not offset by greater patient access to our products, our revenue may be reduced and our business may be harmed.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although many third-party payors have adopted some form of coverage policy for continuous glucose monitoring devices, our products do not always have such coverage, including simple broad-based contractual coverage with third-party payors, and we frequently experience administrative challenges in obtaining coverage or reimbursement for our products. If we are unable to obtain adequately broad coverage or reimbursement for our products or any future products from third-party payors, our revenue may be negatively impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a medical device company, reimbursement from government and/or commercial third-party healthcare payors, including Medicare and Medicaid, is an important element of our success. The Centers for Medicare &amp; Medicaid Services, or CMS, provides coverage for &#8220;Therapeutic Continuous Glucose Monitors&#8221; as durable medical equipment eligible for coverage under Medicare Part B. Coverage criteria for therapeutic CGMs is determined by CMS under national coverage determinations as well as by local Medicare Administrative Contractors under local coverage determinations. Therefore, Medicare reimbursement for our CGM devices is subject to various coverage conditions </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and often requires a patient-specific coverage analysis. Medicare does not cover any items or services that are not &#8220;reasonable and necessary.&#8221; Medicare covers the CGM system, which includes supplies necessary for the use of the device, under the Durable Medical Equipment, or DME, benefit category. In order to be covered under this benefit, one component of the CGM system must meet the criteria for a durable medical device. To date, the receiver satisfied this criteria. To the extent that a receiver is not used by a Medicare beneficiary or CMS otherwise determines that the items and supplies ordered are not medically necessary, Medicare may not cover that CGM system or any associated supplies</span><span style="color:#008080;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face a number of regulatory and commercial hurdles relating to wide-scale sales where a government or commercial third-party payor provides reimbursement, including sales to Medicare beneficiaries. If we are unable to successfully address these hurdles, reimbursement of our products may be limited to a smaller subset of people with diabetes covered by Medicare or to those people with diabetes covered by other third-party payors that have adopted policies for CGM devices allowing for coverage of these devices if certain conditions are met. Adverse coverage or reimbursement decisions relating to our products, or rescission or limitation of favorable determinations, by CMS, its Medicare Administrative Contractors, other state, federal or international payors, and/or third-party commercial payors could significantly reduce reimbursement, which could have an impact on the acceptance of, and demand for, our products and the prices that our customers are willing to pay for them.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the eight largest private third-party payors, in terms of the number of covered lives, have issued coverage policies for the category of CGM devices. In addition, we have negotiated contracted rates with all of those third-party payors for the purchase of our current CGM systems by their members. Nevertheless, coverage and reimbursement-related barriers remain. Among other things, people with diabetes without insurance that covers our products bear the entire financial cost of using our products. In addition, in the United States, people with diabetes using existing single-point finger stick devices are generally reimbursed all or part of the product cost by Medicare or other third-party payors, which may be perceived as more advantageous for consumers. Further, while many third-party payors have adopted some form of coverage policy on CGM devices, in a sizeable percentage of cases, under durable medical equipment benefits, those coverage policies frequently are restrictive and require significant medical documentation and other requirements in order for policy holders to obtain reimbursement, and as a result, we have difficulty improving the efficiency of our customer service group. Moreover, it is not uncommon for governmental, including federal and/or state, agencies and their contractors to conduct periodic routine billing and compliance reviews that may entail extensive documentation requests, cooperation with which may require significant time and resources, and may result in identification of overpayments that may need to be refunded. The commercial success of our products in both domestic and international markets will substantially depend on whether timely and comprehensive third-party reimbursement is widely available for individuals that use them.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has adopted coverage guidelines for CGMs, which could have a favorable impact on us.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, Medicare coverage for CGM was only available to Medicare patients who take at least three doses of insulin a day, limiting CGM reimbursement for Medicare beneficiaries with intensive Type 1 and 2 diabetes. The Local Coverage Determination, or LCD, that CMS released in April 2023 extends Medicare CGM coverage to patients who use any insulin. Further, the LCD also allows coverage for patients not taking insulin if the patient has a history of problematic hypoglycemia.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nevertheless, third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new and existing medical devices, and, as a result, they may be restrictive, or they may not cover or provide adequate payment for our products. In order to obtain additional reimbursement arrangements, including under pharmacy benefits, we may have to agree to a net sales price lower than the net sales price we might charge in other sales channels. Our revenue may be limited by the continuing efforts of government and third-party payors to contain or reduce the costs of healthcare through various increasingly sophisticated means, such as leveraging increased competition, increasing eligibility requirements such as second opinions and other documentation, purchasing in a bundle, or redesigning benefits. In December 2021, CMS published a final rule expanding the classification of DME under Medicare Parts B &amp; C to include adjunctive CGMs (i.e., CGMs that do not replace standard blood glucose monitors for treatment decisions) and related supplies. This final rule expands coverage of CGMs to include a large competitor&#8217;s competing device, which may negatively impact our sales.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict what effect the current or any future healthcare reform will have on our business, or the effect these matters will have on our customers. Our dependence on the commercial success of our current CGM systems makes us particularly susceptible to any cost containment or reduction efforts. Accordingly, unless government and other third-party payors provide adequate coverage and reimbursement for our current CGM systems or any future products we may develop, people without coverage who have diabetes may not use our products. Furthermore, payors are increasingly basing reimbursement rates on factors such as prior approvals and the effectiveness of the product, clinical outcomes associated with the product, and any factors that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negatively impact the effectiveness or clinical outcomes (or cause a perception of any such negative impact), such as the results of a clinical trial, a product defect, or a product recall, which could negatively impact the reimbursement rate. Also, the trends toward managed healthcare in the United States and legislative efforts intended to reduce the cost of government insurance programs could significantly influence the purchase of healthcare services and products and may result in lower prices for our products or the exclusion of our products from reimbursement programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many foreign markets, pricing and profitability of medical devices are subject to government control. We are susceptible to changes in government-mandated coverage requirements and other controls which could impact access to and affordability of our products. In the United States, we expect that there will continue to be federal and state proposals for similar controls. As we continue to expand internationally, these government controls will have an increasing effect on our business and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above factors may have a material adverse effect on our ability to increase or maintain our revenue or otherwise have a material adverse impact on our business, financial condition, and results of operations.</span></div><div id="i70f957301cc34339a22f629982cd0734_28"></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The research and development efforts we undertake independently, and in some instances in connection with our collaborations with third parties, may not result in the development of commercially viable products, the generation of significant future revenues or adequate profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to address the anticipated needs of our customers, pursue new markets for our existing products and any new products, and to remain competitive, we focus our research and development efforts and strategic third-party collaboration activities on the enhancement of our current CGM products, the development of next-generation products and the development of novel technologies and services.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new products, or novel technologies and services and the enhancement of our current CGM products (including seeking and potentially obtaining new indications for use), requires significant investment in research and development, intellectual property protection, clinical trials, regulatory approvals and in obtaining third party reimbursement. The results of our product development and commercialization efforts may be affected by a range of factors, including our ability to anticipate customer needs, innovate and develop new products (whether independently or with our partners), determine a feasible or timely regulatory pathway or approach, and launch those products cost effectively into multiple markets and geographies. If we are unable to successfully anticipate customer needs, innovate, develop new products and successfully launch them, we may not be able to generate significant future revenues or profits from these efforts. Failing to timely launch our new products and any enhancements to our existing products may cause them to become obsolete and materially and adversely affect our business and financial position.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercial launch timelines for our products depend a great deal on our ability to achieve clinical endpoints and satisfy regulatory requirements and to overcome technology challenges, and may be delayed due to scheduling issues with patients and investigators, requests from institutional review boards, or inquiries from regulators about our independent and collaborative product development activities, product performance and manufacturing supply constraints, among other factors. In addition, support of these clinical trials requires significant resources from employees involved in the production of our products, including research and development, manufacturing, quality assurance, and clinical and regulatory personnel. Even if our development and clinical trial efforts appear successful to us and our regulatory submission appears satisfactory to us, the FDA or comparable international regulator may disagree and may decide not to grant marketing authorization for the products or may require additional product testing or clinical trials or other data to be developed and submitted before approving the products, which would result in product launch delays and additional expense. Even if a product receives marketing authorization from the FDA or comparable international regulator, it may not be accepted in the marketplace by health care professionals and people with diabetes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business we enter into collaborative arrangements with third parties to expand into new markets, including with insulin device manufacturers to integrate our CGM technology into the third parties&#8217; insulin delivery systems. We have also entered into collaborations with several organizations that are currently using, or are developing, programs for the treatment of Type 2 diabetes that utilize our current CGM systems. As a result of these relationships, our operating results depend, to some extent, on the ability of our partners to successfully commercialize their insulin delivery systems or monitoring products. Any factors that may limit our partners&#8217; ability to achieve widespread adoption of their systems, including competitive pressures, technological breakthroughs for the treatment or prevention of diabetes, adverse regulatory or legal actions relating to insulin pump products, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in reimbursement rates or policies of third-party payors relating to insulin pumps or similar products, could have an adverse impact on our operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies that we collaborate with are also competitors or potential competitors who may decide to terminate our collaborative arrangement. In the event of such a termination, we may be required to devote additional resources to product development and commercialization, we may need to cancel some development programs and we may face increased competition. Additionally, collaborations may not result in the development of products that achieve commercial success and could be terminated prior to developing any products. Former collaborators may use the experience and insights they develop in the course of their collaborations with us to initiate or accelerate their development of products that compete with our products, which may create competitive disadvantages for us. Accordingly, we cannot provide assurance that any of our collaborations will result in the successful development of a commercially viable product or result in significant additional future revenues.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may not achieve or maintain market acceptance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that sales of our CGM systems will account for substantially all of our product revenue for the foreseeable future. If and when we receive FDA or other regulators&#8217; marketing authorization for, and begin commercialization of, our next-generation CGM systems, we expect most patients will migrate onto those systems. In the periods leading up to the launch of new or upgraded versions of our CGM systems, however, our customers&#8217; anticipation of the release of those products may cause them to cancel, change or delay current period purchases of our current products, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding our prior experience in marketing and selling our products, we might be unable to successfully expand the commercialization of our existing products or begin commercialization of our next-generation CGM systems on a wide-scale for a number of reasons, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our G6 and G7 systems prompt the user to replace the sensor no later than the tenth day, which might make it expensive for users;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">widespread market acceptance of our products by health care professionals and people with diabetes will largely depend on our ability to demonstrate their relative safety, effectiveness, reliability, cost-effectiveness and ease of use;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the limited size of our sales force;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may not have sufficient financial or other resources to adequately expand the commercialization efforts for our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expanded coverage opportunities for our competitors&#8217; CGM devices and supplies, including coverage for adjunctive CGMs, increasing competition in the marketplace;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our FDA and other regulatory authority marketing application submissions and reviews may be delayed, or cleared or approved with limited product indications and labeling;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may not be able to manufacture our products in commercial quantities commensurate with demand or at an acceptable cost;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the uncertainties associated with establishing and qualifying new manufacturing facilities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">people with diabetes may need to incur the costs of single-point finger stick devices, in addition to our systems;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the relative immaturity of the CGM market internationally, and limited international reimbursement of CGM systems by third-party payors and government healthcare providers outside the United States;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the introduction and market acceptance of competing products and technologies, which may have a lower cost or price, allow for a convenience improvement and/or allow for improved accuracy and reliability;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the introduction and market acceptance of new drug therapies for the treatment and management of diabetes and related conditions, including obesity; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">greater name or brand recognition and more established medical product distribution channels by some of our competitors;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our inability to obtain sufficient quantities of supplies timely and at appropriate quality levels from our single- or sole-source and other key suppliers;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our inability to manufacture products that perform in accordance with expectations of consumers; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">rapid technological change may make our technology and our products obsolete.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the risks outlined above, our G6 and G7 systems are more invasive than many other self-monitored glucose testing systems, including single-point finger stick devices, and people with diabetes may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, people with diabetes may not perceive the benefits of CGM and may be unwilling to change their current treatment regimens. Health care professionals may not recommend or prescribe our products unless and until (i)&#160;there is more long-term clinical evidence to convince them to alter their existing treatment methods, (ii)&#160;there are additional recommendations from prominent physicians that our products are effective in monitoring glucose levels, and (iii)&#160;reimbursement or insurance coverage is more widely available. In addition, market acceptance of our products by physicians and people with diabetes in Europe or other countries will largely depend on our ability to demonstrate their relative safety, effectiveness, reliability, cost-effectiveness and ease of use. If we are unable to do so, we may not be able to generate product revenue from our sales efforts in Europe or other countries. We cannot predict when, if ever, healthcare professionals, including physicians, and people with diabetes may adopt more widespread use of CGM systems, including our systems. We are also aware of the increasing use of GLP-1 products for the treatment of obesity and Type 2 diabetes. While we believe that GLP-1s are a companion product and used in conjunction with our CGM systems, these treatments could potentially compete with our CGM systems and reduce sales of our products. If our CGM systems do not achieve and maintain an adequate level of acceptance by people with diabetes, healthcare professionals, including physicians, and third party payors, our future revenue may be reduced and our business may be harmed.</span></div><div id="i70f957301cc34339a22f629982cd0734_31"></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing, Commercial Operations and Commercialization</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our manufacturing capabilities are insufficient to produce an adequate supply of product at appropriate quality levels, our growth could be limited and our business could be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing manufacturing facilities are designed to manufacture current and next-generation CGM systems, but may not be scaled quickly enough to permit us to manufacture one or more of our CGM systems in quantities sufficient to meet market demand. In the past, we have had difficulty scaling our manufacturing operations to provide a sufficient supply of product to support market demand and our commercialization efforts. From time to time, we have also experienced brief periods of backorder and, at times, have had to limit the efforts of our sales force to introduce our products to new customers. We have focused significant effort on continual improvement programs in our manufacturing operations intended to improve quality, yields and throughput. We have made progress in manufacturing to enable us to supply adequate amounts of product to support our commercialization efforts; however, we cannot guarantee that supply will not be constrained in the future. We may not adequately predict the market demand for our products, in order to produce our products in the quantities we anticipate will be necessary to meet market demand. We will need to adequately predict the market demand for our products and increase our manufacturing capacity by a significant factor over the current level to meet or exceed the anticipated market demand by product. In addition, we may have to modify our manufacturing design, reliability and process for next-generation products that may hereafter be approved, cleared or otherwise authorized by the applicable regulatory body and commercialized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing. We are also expanding our facility in Mesa, Arizona, and plan to begin construction of a new facility in Ireland to scale up manufacturing capacity. There are technical challenges to increasing manufacturing capacity, including equipment design, automation, validation and installation, contractor issues and delays, licensing and permitting delays or rejections, materials procurement, manufacturing site expansion, problems with production yields and quality control and assurance. Continuing to develop commercial-scale manufacturing facilities will require the investment of substantial additional funds and the hiring and retention of additional management, quality assurance, quality control and technical personnel who have the necessary manufacturing experience. Delays in the launch of next-generation products may result in unanticipated continuing increases in demand for current-generation products (to substitute for the unavailability of the next-generation products) which, if not adequately prepared for, may result in deficits in our ability to produce adequate amounts of the prior-generation products to meet demand at appropriate prices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scaling of manufacturing capacity is subject to numerous risks and uncertainties, and may lead to variability in product quality or reliability, increased construction timelines, as well as resources required to design, install and maintain manufacturing equipment, among others, all of which can lead to unexpected delays in manufacturing output. In addition, any changes to our manufacturing processes may trigger the need for submissions or notifications to, and in some cases advance approval from, the FDA or other regulatory authorities because of the potential impact of changes on our previously cleared, approved and/or authorized devices. Our facilities are subject to inspections by the FDA and corresponding state and international agencies on an ongoing basis, and we must comply with Good Manufacturing Practices and the FDA Quality System Regulation, as well as certain state </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements. We may be unable to adequately maintain, develop and expand our manufacturing process and operations or maintain compliance with FDA and state and international agency requirements, and manufacturing issues could impact our cleared and approved products. If we are unable to manufacture a sufficient supply of our current products or any future products for which we may receive approval or clearance, maintain control over expenses or otherwise adapt to anticipated growth, or if we underestimate growth, we may not have the capability to satisfy market demand, contractual obligations, and our business will suffer.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing difficulties and/or any disruption at our facilities may adversely affect our manufacturing operations and related product sales, and increase our expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are manufactured at certain facilities, with limited alternate facilities. If an event occurs at one of our facilities that results in damage to, restrictions on the use of, or closure of, one or more of such facilities, or if our distributions from those facilities are limited or restricted in any way, we may be unable to manufacture the relevant products at the previous levels or at all. Because of the time required to approve, lease, and build out a manufacturing facility, an alternate facility and/or a third-party may not be available on a timely basis to replace production capacity in the event manufacturing capacity is lost.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the majority of our operations are conducted at facilities located in San Diego, California, Mesa, Arizona, and Malaysia. We take precautions to safeguard our facilities, which include manufacturing protocols, insurance, health and safety protocols, and off-site storage of data. However, a natural or man-made disaster, such as fire, flood, earthquake, act of terrorism, cyber-attack or other disruptive event, such as a public health emergency, could cause substantial delays in our operations, damage, destroy or limit our manufacturing equipment, inventory, or records and cause us to incur additional expenses. Earthquakes are of particular significance since our manufacturing facilities in California are located in an earthquake-prone area. Wildfires are also increasingly more common in southern California and present risk to our manufacturing operations. Our Arizona facility may confront water supply issues resulting from the ongoing drought in the Western United States and our Malaysia facility may confront issues related to its construction on a reclaimed wetland and the political stability of the Malaysia government. In the event our existing manufacturing facilities or equipment are affected by man-made or natural disasters, we may be unable to manufacture products for sale or meet customer demands or sales projections. If our manufacturing operations were curtailed or ceased, it would seriously harm our business. The insurance we maintain against fires, floods, earthquakes and other natural disasters and similar events may not be adequate to cover our losses in any particular case.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience manufacturing difficulties or disruptions, it could result in insufficient inventory, increased costs, immediate shortages in product or component supply, and decreased sales, and our business could be harmed. </span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture the majority of our products and procure important third-party services, such as sterilization services, at numerous facilities worldwide. We purchase many of the components, materials and services needed to manufacture these products from numerous suppliers in various countries. We have generally been able to obtain adequate supplies of such materials, components and services. However, we also rely on single and/or sole sources for certain components and materials used in manufacturing, such as for the application-specific integrated circuit that is incorporated into the transmitter and certain polymers used to synthesize the polymeric biointerface membranes for our products. In some cases, our agreements with these and other suppliers can be terminated by either party upon short notice. Our contract manufacturers may also rely on single- or sole-source suppliers to manufacture some of the components used in our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we work with our suppliers to try to ensure continuity of supply while maintaining quality, timeliness and reliability, the supply of these components, materials and services has in some cases been, and may continue to be impacted, interrupted or insufficient. Our manufacturers and suppliers may also encounter problems during manufacturing for a variety of reasons. They may fail to follow specific protocols and procedures, fail to comply with applicable regulations, or be the subject of FDA or other regulatory authority audits or inspections that result in allegations of non-compliance (for example, resulting in Form 483 Observations, Warning Letters, or other FDA enforcement actions). Our manufacturers and suppliers may also experience or be impacted by equipment malfunction, environmental factors, and public health emergencies, any of which could delay or impede their ability to meet our demand.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if our sole- or single-source suppliers shift their manufacturing and assembly sites to other locations, depending on the circumstances and nature of the item supplied, in addition to quality system activities such as verification and validation, there could be a need for FDA or international regulator notifications or submissions, and the new locations could be subject to regulatory inspections. If there are regulatory delays or impediments impacting </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our suppliers or us for any reason, we may not be able to quickly establish additional or replacement suppliers, particularly for our single-source components, in part because of the custom nature of various parts we design. Any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to cancel orders or switch to competitive products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these outside manufacturers and suppliers also subjects us to other risks that could harm our business, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may experience a reduction or interruption in supply, and may not be able to obtain adequate supply in a timely manner or on commercially reasonable terms from additional or replacement sources;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our products are technologically complex and it is difficult to develop alternative supply sources;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we are not a major customer of many of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our suppliers may make errors in manufacturing components that could negatively affect the quality, effectiveness or safety of our products or cause delays in shipment of our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may have difficulty locating and qualifying alternative suppliers for our single-source supplies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">switching components may require product redesign and submission to the FDA or international regulator of new applications (such as new 510(k) submissions or PMA supplements) which could significantly delay production;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our suppliers manufacture products for a range of customers, and fluctuations in demand for the products these suppliers manufacture for others may affect their ability to deliver components to us in a timely manner or at the current pricing;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our suppliers may discontinue the production of components that are critical to our products; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our suppliers may encounter financial and/or other hardships unrelated to our demand for components, including those related to changes in global economic conditions and/or disease outbreaks, which could inhibit their ability to fulfill our orders and meet our requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also outsource certain services to other parties, including inside sales, certain transaction processing, accounting, information technology, manufacturing, and other areas. Outsourcing of services to third parties could expose us to suboptimal quality of service delivery or deliverables and potentially result in repercussions such as missed deadlines or other timeliness issues, erroneous data, supply disruptions, non-compliance (including with applicable legal or regulatory requirements and industry standards) and/or reputational harm, with potential negative effects on our results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also require the suppliers, service providers and business partners of components or services for our products and related services to comply with law and certain of our policies regarding sourcing practices, but we do not control them or their practices. If any supplier, service provider or business partner violates laws or implements unethical practices, there could be disruptions to our supply chain, cancellation of our orders, a termination of the relationship with the partner or damage to our reputation, and the FDA or other regulators could seek to hold us responsible for such violations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain adequate sales, marketing and distribution capabilities or enter into and maintain arrangements with third parties to sell, market and distribute our products, we may have difficulty achieving market awareness and selling our products in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must continue to develop and grow our sales and marketing organization and enter into partnerships or other arrangements to market and sell our products and/or collaborate with third parties, including distributors and others, to market and sell our products to maintain the commercial success of our current systems and to achieve commercial success for any of our future products. If we are unable to establish and maintain adequate sales, marketing and distribution capabilities, independently or with others, our future revenue may be reduced and our business may be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing and managing a direct sales organization is a difficult, expensive and time-consuming process. To continue to develop our sales and marketing organization to successfully achieve market awareness and sell our products, we must:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">recruit and retain adequate numbers of effective and experienced sales and marketing personnel;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">effectively train our sales and marketing personnel in the benefits and risks of our products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">establish and maintain successful sales, marketing, training and education programs that educate health care professionals, including endocrinologists, physicians and diabetes educators, so they can appropriately inform their patients about our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">manage geographically dispersed sales and marketing operations; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">effectively train our sales and marketing personnel on the applicable advertising and promotion, and fraud and abuse laws that govern interactions with healthcare professionals and institutions as well as current and prospective patients and maintain active oversight and auditing measures to ensure continued compliance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently employ sales and marketing personnel for the direct sale and marketing of our products in North America, Asia Pacific, Europe and the Middle East. Our direct sales and marketing team calls on healthcare providers and people with diabetes throughout the applicable country, to the extent permissible, to raise awareness and initiate sales of our products. Our sales and marketing organization competes with the experienced, larger and well-funded marketing and sales operations of our competitors. We may not be able to successfully manage our dispersed sales force or increase our product sales at acceptable rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into distribution arrangements to leverage existing distributors (including wholesalers) already engaged in the distribution of drugs, devices and/or products in the diabetes marketplace. Some of our U.S distributors are focused on accessing underrepresented regions and or third-party payors that contract exclusively with distributors in the United States, while some of our international distributors call directly on healthcare providers and patients to market and sell our products. Because of the competition for their services, we may&#160;be unable to partner with or retain additional qualified distributors. Further, we may&#160;not be able to enter into agreements with distributors on commercially reasonable terms, if at all. Our distributors might not have the resources to continue to support our recent rapid growth.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our distribution agreements generated 10% or more of our total revenue during the twelve months ended December&#160;31, 2023. We cannot guarantee that these relationships will continue or that we will be able to maintain this volume of sales from these relationships in the future. A substantial decrease or loss of these sales could have a material adverse effect on our financial results and operating performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into arrangements with pharmacy organizations in various countries to dispense our products directly to patients. Because of the competition for their services, we may be unable to enter into new partnerships or otherwise expand our pharmacy network on commercially reasonable terms, if at all. In addition, we cannot guarantee that our existing pharmacy relationships will continue, or that we will be able to maintain or increase sales volume from these relationships in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we enter into additional arrangements with third parties to perform sales, marketing, distribution and billing services, our product margins could be lower than if we directly marketed and sold our products. To the extent that we enter into co-promotion or other marketing and sales arrangements with other companies, any revenue received will depend on the skills and efforts of others, and we cannot predict whether these efforts will be successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not adequately predict market demand or otherwise optimize and operate our distribution channel successfully, it could result in excess or insufficient inventory or fulfillment capacity, increased costs, immediate shortages in product or component supply, or harm our business in other ways. </span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive market and face competition from large, well-established companies with significant resources, and, as a result, we may not be able to compete effectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for glucose monitoring devices is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants, including enhanced software capabilities, and related data and IT platforms. Our products are based on our proprietary technology, but a number of companies and medical researchers are pursuing new technologies for the monitoring of glucose levels. FDA or other regulatory approval of a commercially viable continuous glucose monitor or sensor produced by one of our competitors could significantly reduce market acceptance of our systems. In addition, certain development efforts throughout the diabetes industry, including that of the National Institutes of Health and other supporters of diabetes research are continually seeking ways to prevent, cure or improve treatment of diabetes. Therefore, our products may be rendered obsolete by technological breakthroughs in diabetes monitoring, treatment, prevention or cure.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In selling our current CGM systems, we compete directly with the Diabetes Care division of Abbott Laboratories; Medtronic plc&#8217;s Diabetes Group; Roche Diabetes Care, a division of Roche Diagnostics; privately-held LifeScan, Inc.; and Ascensia Diabetes Care, each of which manufactures and markets products for the single-point finger stick </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">device market. Collectively, these companies currently account for the majority of the worldwide sales of self-monitored glucose testing systems.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors manufacturing adjunctive CGMs have also recognized expanded Medicare coverage of their CGM devices and supplies following CMS&#8217; December 2021 final rule expanding the classification of DME under Medicare Parts B &amp; C to include adjunctive CGMs. These devices now directly compete with our CGM products in the Medicare market.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several companies are developing and/or commercializing products for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin that compete directly with our products. We have competed with Abbott for several years and their Libre family of CGM products. Medtronic markets and sells one or more standalone glucose monitoring products both internationally and in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medtronic and other third parties have developed or are developing insulin pumps integrated with CGM systems that provide, among other things, the ability to suspend insulin administration while the user&#8217;s glucose levels are low and to automate basal and bolus insulin dosing. Likewise, Abbott Diabetes Care has received FDA clearance to integrate certain versions of their Libre sensors into automated insulin delivery systems and is pursuing such integrations with third-party insulin delivery devices. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of companies outside the traditional medical device sector that are attempting to develop competitive products and services, including for general health and wellness, or population health. We are also aware of the increasing use of GLP-1 products for the treatment of obesity and Type 2 diabetes. While we believe that GLP-1s are a companion product and used in conjunction with our CGM systems, these treatments could potentially compete with our CGM systems and reduce sales of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the companies developing or marketing competing devices are large and well-known publicly traded companies, and these companies may possess competitive advantages over us, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">greater name recognition;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">established relations with healthcare professionals, customers and third-party payors;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">established distribution networks;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">additional lines of products, and the ability to bundle products to offer higher discounts or incentives to gain a competitive advantage;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">greater experience in conducting research and development, manufacturing, clinical trials, obtaining regulatory approval for products and marketing approved products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">duration of sensor life;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the ability to integrate multiple products to provide additional features beyond CGM systems; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">greater financial and human resources for product development, manufacturing, sales and marketing, and patent litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we may not be able to compete effectively against these companies or their products, which may adversely impact our business.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks associated with public health issues, such as the recent COVID-19 pandemic, and other events beyond our control. Public health issues and crises may adversely impact our operations, supply chain and logistics network if the locations where we operate, manufacture or distribute our products; where our raw materials or products are sourced, manufactured or distributed; or where our third-party distributors, suppliers and other service providers operate, are disrupted, temporarily closed or experience worker shortages for a sustained period of time. In addition, public health issues and crises may adversely impact our customers and/or their businesses due to lockdowns, labor shortages, lost access to private health insurance plans or modified spending priorities, all of which could cause a decline in demand for our products. These disruptions could also cause economic slowdowns or increased economic uncertainty. Any of the forgoing could adversely affect our business, financial condition and results of operations.</span></div><div id="i70f957301cc34339a22f629982cd0734_34"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to our International Operations</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to a variety of risks due to our international operations that could adversely affect our business, our operations or profitability and operating results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in countries outside the United States, which accounted for approximately 28% of our revenue for the twelve months ended December&#160;31, 2023, are accompanied by certain financial and other risks. In addition to our offices with manufacturing and administrative and operations in countries throughout the world, we intend to continue to pursue growth opportunities in sales outside the United States, especially in Asia and Europe. Additionally, we may increase our use of administrative and support functions from locations outside the United States. These business activities could expose us to greater risks associated with our sales and operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we pursue opportunities outside the United States, we may become more exposed to these risks and our ability to scale our operations effectively may be affected. For example, in 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing. We also and plan to begin construction of a new facility in Ireland. Our international expansion efforts, including our new manufacturing facilities in Malaysia and proposed facility in Ireland, may not be successful and we may experience difficulties in scaling these functions from locations outside the United States and may not experience the expected cost efficiencies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our profitability and international operations are, and will continue to be, subject to a number of risks and potential costs, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">local product preferences and product requirements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">longer-term receivables than are typical in the United States;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">fluctuations in foreign currency exchange rates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">less intellectual property protection in some countries outside the United States than exists in the United States;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">trade protection measures and import and export licensing requirements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">workforce instability;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">fluctuations in trade policy and tariff regulations; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">political and economic instability.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the tax laws in which we and our subsidiaries do business could change on a prospective or retroactive basis, and any such changes could adversely affect our business and financial condition. We have a significant presence in the European Union, as well as significant sales in the European Union, such that any changes in tax laws in the European Union will impact our business. The overall impact of such legislation in European Union member states is uncertain, and our business and financial condition could be adversely affected by any laws impacting our tax rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is impossible for us to predict whether these and other proposals will be implemented, or how they will ultimately impact us, they may materially impact our results of operations if, for example, our profits earned abroad are subject to U.S. income tax, or we are otherwise disallowed deductions as a result of these profits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in foreign currency exchange rates may reduce the reported value of our foreign currency denominated revenues, expenses, and cash flows. We cannot predict changes in currency exchange rates, the impact of exchange rate changes, nor the degree to which we will be able to manage the impact of currency exchange rate changes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a 2016 referendum of voters in the United Kingdom, or the U.K, to exit from the European Union, or the E.U., the U.K. left the E.U. on January 31, 2020, which began a transition period that ended on December 31, 2020. In December 2020, the U.K. and E.U. agreed on a trade and cooperation agreement that was ratified by the parties in May 2021. The agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the trade and cooperation agreement or otherwise, could prevent us from marketing our CGM systems in the U.K. and/or the E.U. and restrict our ability to generate revenue and achieve and sustain profitability. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire E.U. single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the E.U. Depending on the application of the terms of the trade and cooperation agreement, we could face new regulatory costs and challenges which could have a material adverse effect on our business, results of operations, or financial condition.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing the export of our products could adversely impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control, and the Bureau of Industry and Security at the U.S. Department of Commerce, administer certain laws and regulations that restrict U.S. persons and, in some </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instances, non-U.S. persons, in conducting activities, and transacting business with or making investments in certain countries, governments, entities and individuals subject to U.S. economic sanctions. Due to our international operations, we are subject to such laws and regulations, which are complex, restrict our business dealings with certain countries and individuals, and are constantly changing. Further restrictions may be enacted, amended, enforced or interpreted in a manner that materially impacts our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of these regulations are punishable by civil penalties, including fines, denial of export privileges, injunctions, asset seizures, debarment from government contracts and revocations or restrictions of licenses, as well as criminal fines and imprisonment. We have established procedures designed to assist with our compliance with such laws and regulations. However, we have only limited experience dealing with these laws and regulations and we cannot guarantee that our procedures will effectively prevent us from violating these regulations in every transaction in which we may engage. Any such violation could adversely affect our reputation, business, financial condition and results of operations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure to comply with U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws in non-U.S. jurisdictions could materially adversely affect our business and result in civil and/or criminal sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act, the UK Bribery Act and similar worldwide anti-bribery laws in non-U.S. jurisdictions generally prohibit companies and their intermediaries from making improper payments to non-U.S. government officials and, in some instances, other persons for the purpose of obtaining or retaining business. Because of the predominance of government-sponsored healthcare systems around the world, most of our customer relationships outside of the United States are with governmental entities and are therefore potentially subject to such anti-bribery laws. Global enforcement of anti-corruption laws has increased substantially in recent years, with more frequent voluntary self-disclosures by companies, aggressive investigations and enforcement proceedings by U.S. and foreign governmental agencies, and assessment of significant fines and penalties against companies and individuals. Our international operations create the risk of unauthorized payments or offers of payments by one of our employees, consultants, sales agents, or distributors, because these parties are not always subject to our direct oversight and control. It is our policy to implement safeguards to educate our employees and agents on these legal requirements and discourage improper practices. However, our existing safeguards and any future improvements may prove to be less than effective, and our employees, consultants, sales agents, or distributors may engage in conduct for which we might be held responsible. In addition, the government agencies may seek to hold us liable for successor liability for anti-corruption law violations committed by any companies in which we invest or that we acquire. Any alleged or actual violations of these regulations may subject us to government scrutiny, severe criminal or civil sanctions and other liabilities, including exclusion from government contracting, and could disrupt our business, and result in a material adverse effect on our business, financial condition, and results of operations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current uncertainty in global economic and political conditions makes it particularly difficult to predict product demand and other related matters and makes it more likely that our actual results could differ materially from expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance depend on worldwide economic and political conditions. These conditions have been adversely impacted by continued global economic uncertainty, political instability and military hostilities in multiple geographies, concerns over continued sovereign debt, potential recessions, a potential U.S. federal government shutdown, monetary and financial uncertainties in Europe and other foreign countries, and global health pandemics. These include potential reductions in the overall stability and suitability of the Euro as a single currency, given the economic and political challenges facing individual Eurozone countries. These conditions have made and may continue to make it difficult for our customers and potential customers to afford our products, and could cause our customers to stop using our products or to use them less frequently. If that were to occur, our revenue may decrease and our performance may be negatively impacted. In addition, the pressure on consumers to absorb more of their own health care costs has resulted in some cases in higher deductibles and limits on durable medical equipment, which may cause seasonality in purchasing patterns. Furthermore, during economic uncertainty, our customers have had job losses and may continue to have issues gaining timely access to sufficient health insurance or credit, which could result in their unwillingness to purchase products or impair their ability to make timely payments to us. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our access to capital on favorable terms or at all, our business and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the reoccurrence of any economic slowdown or the strength or sustainability of the economic recovery, worldwide, in the United States, or in our industry. These and other economic factors could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain any required regulatory authorization in foreign jurisdictions will prevent us from marketing our products abroad.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct limited commercial and marketing efforts in certain international markets in the Asia-Pacific, North America and Europe, Middle East and Africa regions, with respect to our CGM systems and may seek to market our products in other regions in the future. Outside the United States, we can market a product only if we receive a marketing authorization and, in some cases, pricing approval, from the appropriate regulatory authorities. The marketing authorization procedures vary among countries and can involve additional testing, and the time required to obtain any required authorization or approval may differ from that required to obtain FDA marketing authorization(s). Foreign regulatory authorization or approval processes may include all of the risks associated with obtaining FDA marketing authorization(s) in addition to other risks. We may not obtain foreign regulatory authorizations or approvals on a timely basis, if at all. Obtaining a marketing authorization from the FDA does not ensure authorization or approval by regulatory authorities in other countries will follow, and authorization or approval by one foreign regulatory authority does not ensure authorization or approval by regulatory authorities in other foreign countries or by the FDA. In addition, in order to obtain the authorization to market our products in certain foreign jurisdictions, in some cases we may need to obtain a Certificate to Foreign Government from the FDA. The FDA may refuse to issue a Certificate to Foreign Government if significant compliance-related concerns are identified. As a result, there are a range of factors that could preclude or impede our ability to file for regulatory approvals or marketing authorizations or to receive necessary approvals or authorizations to commercialize our products in any market outside the United States on a timely basis, or at all.</span></div><div id="i70f957301cc34339a22f629982cd0734_37"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Privacy and Security</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements regarding privacy, data protection, security, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of foreign, federal and state laws and regulations protecting the use, disclosure, and confidentiality of certain patient and consumer health and personal information, including patient records, and restricting the use and disclosure of that protected information, including state breach notification laws. Some of these laws include the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, the European Union&#8217;s General Data Protection Regulation, or GDPR, the UK Data Protection Act and the UK GDPR, and the California Consumer Privacy Act as amended, or CCPA, and the Washington My Health My Data Act, among others. Various U.S. state laws and regulations may also require us to notify affected individuals and state regulators in the event of a data breach involving personal information. Penalties for failure to adequately protect personal information, notify as required, or provide timely notice vary by jurisdiction. In the U.S., most state data breach notification laws consider violations to be unfair or deceptive trade practices and give the relevant state attorneys general (&#8220;AGs&#8221;) the authority to levy fines or bring enforcement actions. Such AG investigations&#8212;which are often time consuming, expensive, and burdensome&#8212;may lead to a resolution agreement, whereby certain obligations are performed and reports are made to the AG for a period of time, and/or civil penalties. Class action lawsuits against companies which experience a data breach involving personal information are also common. Additionally, the SEC and many jurisdictions have enacted or may enact laws and regulations requiring companies to disclose or otherwise provide notifications regarding data security breaches. For example, the SEC recently adopted cybersecurity risk management and disclosure rules, which require the disclosure of information pertaining to cybersecurity incidents and cybersecurity risk management, strategy, and governance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our customer base grows to include U.S. federal government agencies, Dexcom may also need comply with Federal Risk and Authorization Management Program and Cybersecurity Maturity Model Certification requirements. These frameworks, in addition to similar laws being enacted by other states and other jurisdictions, impose stringent cybersecurity standards and potentially significant non-compliance penalties, and involve the expenditure of significant resources and time and effort to comply. As these laws and regulations continue develop in the United States and internationally, we may be required to expend significant time and resources in order to update existing processes or implement additional mechanisms as necessary to ensure compliance with such laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, foreign data protection, privacy, and other laws and regulations can be more restrictive than those in the United States. For example, data localization laws in some countries generally mandate that certain types of data collected in a particular country be stored and/or processed within that country. We may be subject to inquiries, investigations and audits in Europe and around the world, particularly in the areas of consumer and data protection, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which will arise in the ordinary course of business and may increase in frequency as we continue to grow and expand our operations. Legislators and regulators may make legal and regulatory changes, or interpret and apply existing laws, in ways that make our products less useful to our customers, require us to incur substantial costs, expose us to unanticipated civil or criminal liability, or cause us to change our business practices. These changes or increased costs could negatively impact our business and results of operations in material ways.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, such as our proprietary business information and that of our clients, contractors, vendors and others as well as personally identifiable information of our customers, potential customers, vendors and others, which data may include sensitive information, in our data centers and on our networks. Our employees, contractor and vendors may also have access to and may use personal health information in the ordinary course of our business. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures and business controls, our information technology and infrastructure may be vulnerable to attacks by hackers (including nation states or state-sponsored organizations), viruses, malware, breaches due to employee, contractor or vendor error, or malfeasance or other disruptions or subject to the inadvertent or intentional unauthorized release of information. Any such occurrence could compromise our networks and the information stored thereon could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, and liability under laws that protect the privacy of personal information, including regulatory penalties, disrupt our operations and the services we provide to our clients or damage our reputation, any of which could adversely affect our profitability, revenue and competitive position.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we grow and expand our administrative, customer, or IT support services, we may also utilize the services of personnel and contractors located outside of the United States to perform certain functions. While we make every effort to review our applicable contracts and other payor requirements, a local, state, or federal government agency or one of our customers may find the use of offshore resources to be a violation of a legal or contractual requirement, which could result in termination of the contractual relationship, penalties, or changes in our business operations that could adversely affect our business, financial condition, and results of operations. Additionally, while we have implemented industry standard security measures for offshore access to protected health information and other personal information, unauthorized access or disclosure of such information by offshore personnel could result in legal claims or proceedings, and liability under laws that protect the privacy of personal information and may incur regulatory penalties, disrupt our operations and the services we provide to our clients, damage to our reputation, or result in the termination of contractual relationships, penalties or the loss of coverage, any of which could adversely affect our profitability, revenue and competitive position.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches and other disruptions that compromise our information and expose us to liability could cause our business and reputation to suffer and could subject us to substantial liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA Security Rule requires covered entities, including Dexcom, and business associates to implement administrative, physical, and technical safeguards to protect the integrity, confidentiality and availability of protected health information that is electronically created, received, maintained or transmitted. Covered entities are also required to report any unauthorized use or disclosure of protected health information that meets the definition of a breach under the Breach Notification Rule, to affected individuals, OCR and, depending on the number of affected individuals, the media for the affected market. In addition, HIPAA requires that business associates report breaches to their covered entity customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of HIPAA may result in criminal and civil penalties. The OCR enforces the regulations and performs compliance audits. In addition to enforcement by OCR, HITECH further authorizes state Attorneys General to bring civil actions in response to violations of HIPAA that threaten the privacy of state residents. We have adopted breach notification policies and procedures designed to comply with the applicable requirements set forth in HIPAA. We follow and maintain a HIPAA compliance plan, which we believe complies with the HIPAA privacy and security regulations, but there can be no assurance that OCR or other regulators will agree. The HIPAA Rules have and will continue to impose significant costs on us in order to comply with these standards.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA establishes a federal &#8220;floor&#8221; with respect to privacy, security, and breach notification requirements and does not supersede any state laws insofar as they are broader or more stringent than HIPAA.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state and certain other federal laws protect the confidentiality of health information and other personal information, including but not limited to state medical privacy laws, state laws protecting personal information, state data breach notification laws, state genetic privacy laws, human subjects research laws and federal and state consumer protection laws. These additional federal and state privacy and security-related laws may be more restrictive than HIPAA and could impose additional penalties. For example, the Federal Trade Commission uses its consumer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection authority under Section 5 of the Federal Trade Act to initiate enforcement actions in response to alleged privacy violations and data breaches.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional data protection laws exist at the state level as well.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California enacted the CCPA, which came into effect January 1, 2020, was amended and expanded by the CPRA, which came into effect January 1, 2023. The CCPA and CPRA, among other things, create data privacy obligations for covered companies and provide privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. In addition, other states have, or may, enact similar legislation. It remains unclear what, if any, additional modifications will be made to this legislation or how it will be interpreted. The effects of the CCPA and CPRA and other state privacy laws are significant and have required us to modify our data processing practices, and may cause us to incur substantial costs and expenses to comply, particularly given our base of operations in California. There are also a number of other legislative proposals worldwide, including in the United States at both the federal and state level, that could impose additional and potentially conflicting obligations in areas affecting our business. We expect to incur additional costs to ensure that our data privacy and security policies, procedures, and activities comply with applicable and evolving legal requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may be more onerous than corresponding U.S. laws, including in particular the laws of Europe.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, in the European Union, increasingly stringent data protection and privacy rules that have and will continue to have substantial impact on the use of patient data across the healthcare industry became effective in May 2018. The GDPR applies across the European Union and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for non-compliance. The GDPR fine framework can be up to 20 million euros, or up to 4% of the company&#8217;s total global turnover of the preceding fiscal year, whichever is higher. The GDPR also requires companies processing personal data of individuals residing in the European Union to comply with EU privacy and data protection rules, even if the company itself does not have a physical presence in the European Union. Noncompliance could result in the imposition of fines, penalties, or orders to stop noncompliant activities. Due to the strong consumer protection aspects of the GDPR, companies subject to its purview are allocating substantial legal costs to the development of necessary policies and procedures and overall compliance efforts. Data transfer risk remains a potential issue as certain Data Protection Authorities continue to raise concerns about the transfer of data to the United States. Though a new framework to permit cross-border transfers - the EU-US Data Privacy Framework - came into effect in 2023, it may be challenged as well. We expect continued costs associated with maintaining compliance with GDPR into the future, and these provisions as interpreted by EU agencies and authorities could negatively impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the laws discussed above, we may see more stringent state and federal privacy legislation in the future. We cannot predict where new legislation might arise, the scope of such legislation, or the potential impact to our business and operations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous and evolving risks to our cybersecurity and privacy from cyber threat actors. These cyber threat actors, whether internal of external to the Company, are becoming more frequent, sophisticated and coordinated in their attempts to access data, including third parties with whom the Company conducts business through, without limitation, malicious software; data privacy breaches by employees, insiders or others with authorized access; cyber or phishing-attacks; ransomware; attempts to gain unauthorized access to our data and systems; and other electronic security breaches. In the ordinary course of business, we collect and store sensitive information on our network, including intellectual property, proprietary business information and personally identifiable information of individuals, such as our customers and employees. The secure maintenance of this information and technology is critical to our business operations. We have implemented and deploy multiple layers of security measures to protect the confidentiality, integrity and availability of this data and the systems and devices that store and transmit such data. We utilize current security technologies, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, threats from malicious persons and groups, new vulnerabilities and advanced new attacks against information systems create risk of cybersecurity incidents. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these incidents or techniques, timely discover them, or implement adequate preventative measures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in response to the onset of the COVID-19 pandemic, we modified our business practices and initially implemented telework policies for certain categories of &#8220;non-essential&#8221; employees to the extent possible. We have since adopted a hybrid workplace model for our employees. Our hybrid workplace allows us to work together globally to bring our life-changing products to as many people as possible. This means we have some employees who work primarily onsite, some who work primarily offsite, and others who flex in and out of the office based on the needs of the business and the individual. We recognized the need for flexibility in our physical workplace during the COVID-19 pandemic, but also noted the potential benefits of a hybrid workplace to expand and retain our talent pool and reduce our real estate needs. The hybrid workplace does, however, introduce additional operational risk, including increased cybersecurity risk. These cyber risks include, among other risks, increased phishing, malware, and other cybersecurity attacks, vulnerability to, or disruptions of, our information technology infrastructure and systems to support remote operations, increased risk of unauthorized access, use or dissemination of confidential information, limited ability to restore the systems in the event of a systems failure or interruption, greater risk of a security breach resulting in destruction, alteration or misuse of valuable information, including proprietary business information and personally identifiable information of individuals, all of which could expose us to risks of data or financial loss, litigation and liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These threats can come from a variety of sources, including criminal hackers, state-sponsored intrusions, industrial espionage and malfeasance by employees, contractors, or other insiders. Cyber threats may be generic, or they may be custom-crafted against our information systems or particular personnel. Over the past several years, cyberattacks have become more prevalent and much harder to detect and defend against. These threat actors may be able to penetrate our security measures, breach our information technology systems, misappropriate or compromise confidential and proprietary information of our company and our customers, cause system disruptions and shutdowns, or introduce ransomware, malware, or vulnerabilities into our products, systems, and networks or those of our customers and partners. Our network and storage applications, as well as those of our contractors, may be vulnerable to cyber-attack, malicious intrusion, malfeasance, loss of data privacy or other significant disruption and may be subject to unauthorized access by hackers, employees, consultants or other service providers. In addition, products, hardware, software or applications we develop, or which we procure from third parties, may contain defects in design or manufacture, security flaws, or other problems that could unexpectedly compromise information security or the operation of our products. Our third-party vendors may experience security incidents of varying severity, including but not limited to increased ransomware attacks, network intrusions, and unauthorized data exfiltration. Targeted cyber attacks or those that may result from a security incident directed at a third-party vendor could compromise our services and internal systems, resulting in interruptions, delays, or cessation of service that could disrupt business operations for us and our customers. Our proactive measures and remediation efforts may not be successful or timely. Unauthorized parties may also attempt to gain access to our systems or facilities through fraud, trickery or other forms of deceiving our employees, contractors and temporary staff.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we maintain cybersecurity insurance coverage there is no guarantee that it will be sufficient to cover the financial, legal, business, or reputational losses that may result from an interruption or breach of our systems. Our cybersecurity insurance includes coverage for a breach event covering expenses for notification, credit monitoring, investigation, crisis management, public relations and legal advice. Our cybersecurity insurance also provides coverage in relation to regulatory action defense including oversight, investigations and disclosure obligations as well as fines and penalties, potential payment card industry fines and penalties and costs related to cyber extortion; however, damages and claims arising from such incidents may not be covered and/or may exceed the amount of any coverage and do not cover the time and effort we incur investigating and responding to any incidents, which may be significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and may continue to be subject to cybersecurity incidents that bypass our security measures. Such incidents may impact the integrity, availability or privacy of personal health information or other data subject to privacy laws or disrupt our information systems, devices or business, including our ability to deliver services to our customers. As a result, cybersecurity, physical security and the continued development and enhancement of our controls, processes and practices designed to protect our enterprise, information systems and data from attack, damage or unauthorized access remain a priority for us. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any cybersecurity vulnerabilities. The occurrence of any of these events could result in:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">harm to customers;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">business interruptions and delays;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the loss, misappropriation, corruption or unauthorized access of data, confidential information or intellectual property;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">litigation, including potential class action litigation, and potential liability under privacy, security and consumer protection laws or other applicable laws;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">reputational damage;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">significant remediation costs, including liability for stolen customer or employee information, repairing system damage, or providing benefit to affected customers or employees;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">increase to insurance premiums; and</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">foreign, federal and state governmental inquiries, violations or sanctions, any of which could have a material, adverse effect on our financial position and results of operations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to protect our information technology infrastructure against cyberattacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology and telephone networks and systems, including the Internet, to process and transmit sensitive electronic information and to manage or support a variety of business processes and activities, including sales, billing, customer service, procurement and supply chain, manufacturing, and distribution. We use enterprise information technology systems to record, process, and summarize financial information and results of operations for internal reporting purposes and to comply with regulatory financial reporting, legal, and tax requirements. System failures or outages, including any potential disruptions due to significantly increased global demand on certain cloud-based systems, or failures to adequately scale our data platforms and architectures support patient care could compromise our ability to perform these functions in a timely manner, which could harm our ability to conduct business or delay our financial reporting. Such failures could materially adversely affect our operating results and financial condition. Our information technology systems, some of which are managed by third parties, may be susceptible to damage, disruptions or shutdowns due to computer viruses, denial-of-service attacks, phishing attacks, ransomware or other malware, attacks by computer hackers (including nation states or state-sponsored organizations), failures during the process of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, user errors, natural disasters, terrorist attacks, the outbreak of wars or other armed conflicts, or catastrophic events. Although we have developed systems and processes that are designed to protect customer information and prevent data loss and other security breaches, including systems and processes designed to reduce the impact of a security breach at a third-party vendor, such measures cannot provide absolute security. In addition, certain countries have implemented or may implement legislative and technological actions that either do or can effectively regulate access to the internet, including the ability of internet service providers to limit access to specific websites or content. Other countries have attempted or are attempting to change or limit the legal protections available to businesses that depend on the internet for the delivery of their services. If our systems are breached or suffer severe damage, disruption or shutdown and we are unable to effectively resolve the issues in a timely manner, our business and operating results may significantly suffer and we may be subject to litigation, government enforcement actions and other actions for which we could face financial liability and other adverse consequences which may include:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">additional government oversight of our operations;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">loss of existing customers;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">difficulty in attracting new customers;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">problems in determining product cost estimates and establishing appropriate pricing;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">difficulty in preventing, detecting, and controlling fraud;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">disputes with customers, physicians, and other health care professionals;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">increases in operating expenses, incurrence of expenses, including notification and remediation costs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">regulatory fines or penalties;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">individual actions or class actions for damages;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">loss of revenues (including through loss of coverage or reimbursement);</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">product development delays;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">disruption of key business operations; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">diversion of attention of management and key information technology resources.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyberattacks aimed at accessing our devices, products, and services, or related devices, products, and services, and modifying or using them in a way inconsistent with our FDA clearances and approvals could create risks to users.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices are increasingly connected to the internet, hospital networks, and other medical devices to provide features that improve healthcare and increase the ability of healthcare providers to treat patients and patients to manage their conditions. For example, we are pursuing collaborations to enable the connectivity and interoperability of our current and next-generation sensors and transmitters with third-party patient monitoring products, which may in turn be connected with the internet, hospital networks and in some cases, other medical devices. These same features may also increase cybersecurity risks and the risks of unauthorized access and use by third parties. As such, a cyberattack which intrudes, disrupts, or corrupts our devices, products, and services, or related devices, products, and services could impact the quality-of-care patients receive or the confidentiality of patient information. Additionally, modifying or using any such devices, products, or services in a way inconsistent with our FDA clearances and approvals, which may create risks to users and potential exposure to the company.</span></div><div id="i70f957301cc34339a22f629982cd0734_40"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Non-Compliance with Laws, Regulations and Contractual Requirements and Healthcare Industry Shifts</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry generally, and our business specifically, is subject to extensive foreign, federal, state and local laws and regulations, including those relating to:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">authorizations necessary for the clinical investigation and commercial marketing of products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the pricing of our products and services;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the distribution of our products and services;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the dispensing of our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">billing for or causing the submission of claims for our products and services;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">financial relationships with physicians and other referral sources;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">inducements and courtesies given to physicians and other health care providers and patients;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">labeling, advertising and promoting products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the characteristics and quality of our products and services;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">communications with payors and physicians and other healthcare stakeholders;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">confidentiality, maintenance and security issues associated with medical records and individually identifiable health and other personal information;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">medical device adverse event reporting;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">prohibitions on kickbacks, including the Anti-Kickback Statute and related laws and/or regulations;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">any scheme to defraud any healthcare benefit program;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">physician and other healthcare professional payment disclosure requirements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">use and disclosure of personal health information;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">privacy of health information and personal information;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">data protection and data localization;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">mobile communications;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">patient access and non-discrimination;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">patient consent;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">false claims; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">licensure.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations are extremely complex and, in many cases, still evolving. If our operations are found to violate any of the foreign, federal, state or local laws and regulations which govern our activities, we may be subject to litigation, government enforcement actions, and applicable penalties associated with the violation, potentially including civil and criminal penalties, damages, fines, exclusion from participation in certain payor programs or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">curtailment of our operations. Compliance obligations under these various laws are oftentimes detailed and onerous, further contributing to the risk that we could be found to be out of compliance with particular requirements. The risk of being found in violation of these laws and regulations is further increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, particularly with respect to new and emerging technologies and remote delivery of services, and their provisions are open to a variety of interpretations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, CMS, OIG, OCR, FTC, Department of Justice, states&#8217; attorneys general and other governmental authorities actively enforce the laws and regulations discussed above. In the United States, medical device manufacturers have been the target of numerous government prosecutions and investigations alleging violations of law, including claims asserting impermissible off-label promotion of medical devices, payments intended to influence the referral of federal or state healthcare business, and submission of false claims for government reimbursement. While we make every effort to comply with applicable laws, we cannot rule out the possibility that the government or other third parties could interpret these laws differently and challenge our practices under one or more of these laws. This likelihood of allegations of non-compliance is increased by the fact that under certain federal and state laws applicable to our business, individuals may bring an action on behalf of the government alleging violations of such laws, and potentially be awarded a share of any damages or penalties ultimately awarded to the applicable government body.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the FTC share oversight of medical device promotion. The FDA has broad authority over device marketing (including assessment and oversight of safety and effectiveness) and over FDA-approved &#8220;promotional labeling,&#8221; while the FTC has authority over &#8220;advertising&#8221; for most medical devices (i.e., non-&#8220;restricted&#8221; devices, such as ours).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any action against us alleging a violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s time and attention from the operation of our business, and have a material effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the laws and regulations impacting or affecting our business may change significantly in the future, which may adversely affect our business. A review of our business by courts or regulatory authorities may result in a determination that could adversely affect our operations. Also, the regulatory environment applicable to our business may change in a way that restricts or adversely impacts our operations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our suppliers or distributors fail to comply with ongoing regulatory requirements, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product for which we obtain marketing approval, clearance or authorization (and the activities related to its production, distribution, and promotion, sale, and marketing) will be subject to continual review and periodic inspections by the FDA and other regulatory bodies, which may include inspection of our manufacturing processes, complaint handling and adverse event reporting, post-approval clinical data and promotional activities for such product. The FDA&#8217;s Medical Device Reporting, or MDR, regulations require that we report to the FDA any incident in which our product may have caused or contributed to a death or serious injury, or in which our product malfunctioned and, if the malfunction were to recur, it would likely cause or contribute to a death or serious injury.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that there is a reasonable probability that a device intended for human use would cause serious, adverse health consequences or death, the agency may issue a cease distribution and notification order and a mandatory recall order. We may also decide to recall a product voluntarily if we find a material deficiency, including unacceptable risks to health, manufacturing defects, design errors, component failures, labeling defects, or other issues. Recalls of our products could divert the attention of our management and have an adverse effect on our reputation, financial condition, and operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our suppliers are also required to comply with the FDA&#8217;s Quality System Regulation, or QSR, and other regulations which cover the methods and documentation of the design, testing, production, control, selection and oversight of suppliers or contractors, quality assurance, labeling, packaging, storage, complaint handling, shipping and servicing of our products. The FDA may enforce the QSR through announced (through prior notification) or unannounced inspections.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with ongoing regulatory requirements can be complex, expensive and time-consuming. Failure by us or one of our suppliers or distributors to comply with statutes and regulations administered by the FDA, competent authorities and other regulatory bodies, or failure to take adequate response to any observations, could result in, among other things, any of the following actions:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">warning letters or untitled letters that require corrective action;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in approving, or refusal to approve, our CGM systems;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">fines and civil or criminal penalties;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">unanticipated expenditures;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">FDA refusal to issue certificates to foreign governments needed to export our products for sale in other countries;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">suspension or withdrawal of clearance or approval by the FDA or other regulatory bodies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">product recall or seizure;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">administrative detention;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">interruption of production, partial suspension, or complete shutdown of production;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">interruption of the supply of components from our key component suppliers;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">operating restrictions;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">court consent decrees;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">FDA orders to repair, replace, or refund the cost of devices;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">injunctions; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">criminal prosecution.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential effect of these events can in some cases be difficult to quantify. If any of these actions were to occur, it would harm our reputation and cause our product sales and profitability to suffer. In addition, we believe events that could be classified as reportable events pursuant to MDR regulations are generally underreported by physicians and users, and any underlying problems could be of a larger magnitude than suggested by the number or types of MDRs filed by us. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approval or clearance of a product is granted, the approval or clearance may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for costly post-marketing testing or surveillance to monitor the safety or effectiveness of the product. Later discovery of previously unknown problems with our products, including software bugs, unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as the QSR, MDR reporting, or other post-market requirements may result in restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls (through corrections or removals), fines, suspension of regulatory approvals, product seizures, injunctions, the imposition of civil or criminal penalties, or criminal prosecution. In addition, our distributors have rights to create marketing materials for their sales of our products, and may not adhere to contractual, legal or regulatory limitations that are imposed on their marketing efforts.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quality problems could lead to recalls or safety alerts, reputational harm, and could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality is very important to us and our customers due to the serious and costly consequences of product failure, and our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices. Since the first commercial launch of our products in 2006, we have had periodic field failures related to our products and associated services, including reports of sensor errors, sensor failures, broken sensors, receiver malfunctions, audible alarms and alert failures, as well as server and transmitter failures. To comply with the FDA&#8217;s medical device reporting requirements, for example, we have filed reports of applicable field failures. Although we believe we have taken and are taking appropriate action aimed at reducing and/or eliminating field failures, we may have other product failures in the future. Product or component failures, manufacturing nonconformances, design defects, off-label use, or inadequate disclosure of product-related risks or product-related information with respect to our products, if they were to occur, could result in an unsafe condition or injury to, or death of, a patient. These problems could lead to recalls, corrections or removals of, or issuance of a safety alert relating to, our products, and could result in product liability claims and lawsuits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the production of our products must occur in a highly controlled and clean environment to minimize particles and other yield- and quality-limiting contaminants. Weaknesses in process control or minute impurities in materials may cause a substantial percentage of defective products. If we are not able to maintain stringent quality controls, or if contamination problems arise, our clinical development and commercialization efforts could be delayed, which would harm our business and our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to meet any applicable product quality standards and our products are the subject of recalls or safety alerts, our reputation could be damaged, we could lose customers, our reputation could be harmed and our revenue and results of operations could decline.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential long-term complications from our current or future products or other CGM systems under development may not be revealed by our clinical experience to date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our experience, complications from use of our products may include sensor errors, sensor failures, broken or detached sensor wires, or skin irritation under the adhesive dressing of the sensor. Inflammation or redness, swelling, minor infection, and minor bleeding at the sensor insertion site are also possible risks with an individual&#8217;s use of our products. However, if unanticipated long-term side-effects result from the use of our products or other glucose monitoring systems we have under development, we could be subject to liability and the adoption of our systems may become more limited. With respect to our G6 systems, our clinical trials have been limited to ten days of continuous use. It is possible that the data from our clinical studies and trials may not be indicative of long-term patient outcomes. We cannot assure you that repeated, long-term use would not result in unanticipated adverse effects, potentially even after the sensor is removed.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may never receive approval, marketing authorization or clearance from the U.S. FDA and other governmental agencies to market additional CGM systems, expanded indications for use of current and future generation CGM systems, future software platforms, or any other products under development.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, via the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> process, the FDA classified the G6 and substantially equivalent devices of this generic type (i.e., &#8220;integrated continuous glucose monitoring systems&#8221; or &#8220;iCGMs&#8221;) into Class II, meaning that going forward products of this generic type may utilize the 510(k) pathway. Since then we have received 510(k) clearances for modifications to the G6 and approval for G7.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any subsequent modifications of our cleared products that could significantly affect their safety or effectiveness (for example, a significant change in design or manufacture), or that would constitute a major change in its intended use, will require us to obtain a new 510(k) clearance or could require a new </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> submission or a PMA. The FDA requires each manufacturer to make this determination initially, but the FDA may review any such decision and may disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA may require the manufacturer to cease marketing and/or recall the modified device until appropriate clearance or approval is obtained. Under these circumstances, the FDA may also subject a manufacturer to significant regulatory fines or other penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If future product candidates are not deemed by the FDA to meet the criteria for submission under the 510(k) pathway, or for down-classification under the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> process or otherwise, we would need to pursue a PMA. The PMA process requires us to prove the safety and effectiveness of our systems to the FDA&#8217;s satisfaction. This process can be expensive, prolonged and uncertain, requires detailed and comprehensive scientific and human clinical data, and may never result in the FDA granting a PMA. The FDA&#8217;s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification of our G6 system under the generic name &#8220;integrated continuous glucose monitoring system,&#8221; makes it a predicate device for future 510(k) submissions. Complying with this classification requires ongoing compliance with the general controls required by the federal Food Drug and Cosmetic Act and the special controls specified by the FDA&#8217;s G6 order as a Class II device. Any future system or expanded indications for use of current generation systems will require approval of the applicable regulatory authorities. In addition, we intend to seek either 510(k) clearances or PMA approvals for certain changes and modifications to our existing software platform, but cannot predict when, if ever, those changes and modifications will be approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA can refuse to grant a 510(k) clearance or a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> request for marketing authorization, or delay, limit or deny approval of a PMA application or supplement for many reasons, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the system may not be deemed by the FDA to be substantially equivalent to appropriate predicate devices under the 510(k) pathway;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the system may not satisfy the FDA&#8217;s safety or effectiveness requirements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the data from pre-clinical studies and clinical trials may be insufficient to support clearance or approval;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the manufacturing process or facilities used may not meet applicable requirements; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changes in FDA approval policies or adoption of new regulations may require additional data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if approved or cleared by the FDA or foreign regulatory agencies, future generations of our CGM systems, expanded indications for use of current and future generation CGM systems, our software platforms or any other CGM system under development, may not be cleared or approved for the indications that are necessary or desirable for successful commercialization. We may not obtain the necessary regulatory approvals or clearances to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market these CGM systems in the United States or outside of the United States. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products. The uncertain timing of regulatory approvals for future generations of our products could subject our current inventory to excess or obsolescence charges, which could have an adverse effect on our business, financial condition and operating results.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with laws, regulations and contract requirements relating to reimbursement of health care goods and services may subject us to penalties and adversely impact our reputation, business, financial condition and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws, regulations and contractual requirements regulating the provision of, and reimbursement for, health care goods and services in our capacity as a medical device manufacturer. The laws and regulations of health care goods and services that apply to us, including those described above, are subject to evolving interpretations and enforcement discretion. We have in place a compliance program, through which we seek to reduce common industry risks of noncompliance with U.S. federal and state and applicable foreign laws in areas such as sales contracts, marketing materials, referral source relationships, programmatic offerings, and billing practices (among others), monitor for compliance, and address non-compliance if identified. If a governmental authority were to conclude that we are not in compliance with applicable laws and regulations, we and our officers, directors and employees could be subject to criminal and civil penalties, as well as administrative sanctions such as exclusion from participation in federal healthcare programs, including but not limited to Medicare and Medicaid. Any failure to comply with laws, regulations or contractual requirements relating to reimbursement and health care goods and services could adversely affect our reputation, business, financial condition and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are purchased principally by individual patients, who may be eligible for insurance coverage of their devices from various third-party payors, such as governmental programs (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Medicare, Medicaid, TRICARE, other federal and state health benefit plans, and comparable non-U.S. programs), private insurance plans, and managed care plans. The ability of our customers to obtain appropriate reimbursement for products and services</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from third-party payors is critical because it affects which products customers purchase and the prices they are willing to pay. As a result, our products are subject to regulation regarding quality and cost by the U.S. Department of Health &amp; Human Services, including CMS, as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of health care goods and services. The principal U.S. federal laws relating to reimbursement include those that prohibit (i) the filing of false or improper claims for federal payment, known as the federal civil False Claims Act, (ii) unlawful inducements for the referral of items and services reimbursed by Federal health care programs, known as the federal Anti-Kickback Statute, and (iii) the Civil Monetary Penalties Law, including its prohibitions on Beneficiary Inducement. Many states have similar laws that apply to reimbursement by state Medicaid and other government-funded programs, as well as, in some cases, to all payors, including self-pay patients. Insurance companies can also bring a private cause of action claiming treble damages against a manufacturer for causing a false claim to be filed under the federal Racketeer Influenced and Corrupt Organizations Act, or RICO. Additionally, as a manufacturer of FDA&#8209;approved or -cleared devices reimbursable by federal healthcare programs, we are subject to the federal Physician Payments Sunshine Act, which requires us to annually report certain payments and other transfers of value we make to certain U.S.-licensed health care professionals and U.S. teaching hospitals, and under an expansion of the law to physician assistants, nurse practitioners, and other mid-level practitioners.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the federal Anti-Kickback Statute, Congress and the OIG have established a large number of statutory exceptions and regulatory safe harbors that protect financial relationships with our customers and referral sources. An arrangement that fits squarely into an exception or safe harbor will not be deemed to violate the Anti-Kickback Statute.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We train and educate employees and marketing representatives on the Anti-Kickback Statute and their obligations thereunder, and we endeavor to comply with the applicable safe harbors. However, some of our arrangements, like many other common and non-abusive arrangements, may implicate the Anti-Kickback Statute and are not covered by a safe harbor, but nevertheless we do not believe them to present a significant risk to beneficiaries or federal healthcare programs and, as such, appear unlikely to invite government scrutiny or prosecution, warrant the imposition of sanctions, or be found to violate the statute. However, we cannot offer assurance that the government or a whistleblower would agree with our position that certain arrangements fall within a safe harbor, or that arrangements that do not squarely meet an exception or safe harbor will not be found to violate the Anti-Kickback Statute. Allegations of violations of the Anti-Kickback Statute can also trigger liability under the federal Civil Monetary Penalty Law and federal civil False Claims Act, thereby increasing the penalty structure for these violations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period in which we directly billed Medicare, our financial relationships with referring physicians and their immediate family members were required to comply with the federal Physician Self-Referral law, commonly referred to as the Stark Law, by meeting an applicable exception. Unlike the Anti-Kickback Statute, failure to meet an exception under the Stark Law results in a violation of the Stark Law, even if such violation is unintentional. Violations of the Stark Law create overpayment liability under the federal civil False Claims Act and can also trigger separate penalties under the Civil Monetary Penalties Law. Knowing violations of the Stark Law carry increased civil monetary penalties and would likely be classified as the knowing submission of a false claim or knowingly making a false statement to the government, triggering liability under the federal civil False Claims Act. Certain Stark Law violations can also trigger exclusion from participation in federal healthcare programs. Historical violations of the Stark Law, if any, could continue to give rise to liability during the six year statute of limitations period.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Managed care trends and consolidation in the health care industry could have an adverse effect on our revenues and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private third-party payors and other managed care organizations, such as pharmacy benefit managers, continue to take action to manage utilization and control costs. Consolidation among managed care organizations has increased the negotiating power of managed care organizations and other private third-party payors. Private third-party payors, as well as governments, increasingly employ formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. Failure to obtain or maintain timely adequate pricing or favorable formulary placement for our products, or failure to obtain such formulary placement at favorable pricing, could adversely impact revenue. Private third-party payors, including self-insured employers, often implement formularies with co-payment tiers to encourage utilization of certain products and have also been raising co-payments required from beneficiaries, particularly for higher-cost products. Private third-party payors also use additional measures such as value-based pricing/contracting to improve their cost-containment efforts. Private third-party payors also are increasingly imposing utilization management tools, such as requiring prior authorization or requiring the patient to first fail on a lower-cost product before permitting access to a higher-cost product. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many health care industry companies, including health care systems, distributors, manufacturers, providers, and insurers, are also consolidating or vertically integrating, or have formed strategic alliances. As the health care industry consolidates, competition to provide goods and services to industry participants may become more intense. This consolidation will continue to create larger enterprises with greater negotiating power, which they can try to use to negotiate price concessions or reductions for medical devices and components produced by us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the U.S. payor market consolidates further and we face greater pricing pressure from private third-party payors, who will continue to drive more of their patients to use lower cost alternatives, we may lose customers, our revenues may decrease and our business, financial condition, results of operations and cash flows may suffer.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully complete the pre-clinical studies or clinical trials necessary to support additional PMA, de novo,&#160;or&#160;510(k) applications or supplements, we may be unable to commercialize our CGM systems under development, which could impair our business, financial condition and operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support current and any future additional PMA, 510(k), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications or supplements, we together with our partners, must successfully complete pre-clinical studies, bench-testing, and in some cases clinical trials that will demonstrate that the product is safe and effective. Product development, including pre-clinical studies and clinical trials, is a long, expensive and uncertain process and is subject to delays and failure at any stage. Furthermore, the data obtained from the studies and trials may be inadequate to support approval of an application and the FDA may request additional clinical data in support of those applications, which may result in significant additional clinical expenses and may delay product approvals. While we have in the past obtained, and may in the future obtain, an investigational device exemption, or IDE, prior to commencing clinical trials for our products, FDA approval of an IDE application permitting us to conduct testing does not mean that the FDA will consider the data gathered in the trial to be sufficient to support approval of a PMA, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or 510(k) application or supplement, even if the trial&#8217;s intended safety and effectiveness endpoints are achieved.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to the regulatory landscape may impact our ability to obtain marketing authorization for future product developments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development or changes to the FDA or foreign regulatory approval standards and processes, including both legal and policy changes, could also delay or prevent the approval of our products submitted for review. For example, medical device cybersecurity continues to be an area of focus for and evolving guidance from FDA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, at the end of 2022, Congress passed the Food and Drug Omnibus Reform Act of 2022, or FDORA which (among other things), and similarly to the 2022 FDA Guidance, requires device sponsors to submit clinical trial diversity action plans outlining the goals for increasing representation of participants from racial and ethnic minority populations that have been underrepresented in clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in the laws or regulations that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products. The data contained in our submissions, including data drawn from our clinical trials, may not be sufficient to support clearance or approval of our products or additional or expanded indications. Medical device company stock prices have declined significantly in certain circumstances where companies have failed to meet expectations in regards to the timing of regulatory approval. If the FDA&#8217;s response causes product approval delays, or is not favorable for any of our products, our stock price (and the market price of our senior convertible notes) could decline substantially. It is uncertain how these potential changes may impact our ability to gain clearance or approval from FDA for our products in the future.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commencement or completion of any of our clinical trials may be delayed or halted, or be inadequate to support approval of FDA marketing applications or supplements, for numerous reasons, including, but not limited to, the following:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">patients do not enroll in clinical trials at the rate we expect;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">patients or study site personnel who do not comply with clinical trial protocols;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">patient follow-up does not occur at the rate we expect;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">patients experience adverse side effects;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">patients die during a clinical trial, even though their death may not be related to our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">institutional review boards and third-party clinical investigators may delay or reject our clinical trial protocol;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">third-party clinical investigators decline to participate in a trial or do not perform a trial on our anticipated schedule or consistent with the investigator agreements, clinical trial protocol, good clinical practices or other FDA or institutional review board requirements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we or third-party organizations do not perform data collection, monitoring or analysis in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">third-party clinical investigators have significant financial interests related to us or the study that the FDA deems to make the study results unreliable, or we or clinical investigators fail to disclose such interests;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">regulatory inspections of our clinical trials or manufacturing facilities may results in allegations or findings of noncompliance and, among other things, require us to undertake corrective action or suspend or terminate our clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changes in governmental regulations, policies or administrative actions applicable to our trial protocols;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or efficacy; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the FDA concludes that the results from our trial and/or trial design are inadequate to demonstrate safety and effectiveness of the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, health epidemics could limit or restrict our ability to initiate, conduct or continue our clinical trials. Delays and disruption in our clinical trials could result in delays for expanded FDA clearance or approval of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of pre-clinical studies or other forms of early product testing do not necessarily predict future clinical trial results, and prior clinical trial results might not be repeated in subsequent clinical trials. Additionally, the FDA may disagree with our interpretation of the data from our pre-clinical studies, product testing, and clinical trials, or may find the clinical trial design, conduct or results inadequate to prove safety or effectiveness, and may require us to pursue the development of additional data, which could further delay the approval of our products. If we are unable to demonstrate the safety and effectiveness of our products in our clinical trials to the FDA&#8217;s satisfaction, where clinical data are required, we will be unable to obtain regulatory approval to market our products in the United States. In addition, the data we collect from our current clinical trials, our pre-clinical studies and other clinical trials may not be sufficient to support FDA approval, even if our endpoints are met.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also conduct clinical studies to demonstrate the relative or comparative effectiveness of CGM systems for the treatment of diabetes. These types of studies, which often require substantial investment and effort, may not show adequate, or any, clinical benefit or value for the use of CGM systems.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our CGM systems currently have regulatory marketing authorization limited to individual patient home-use, and have otherwise not received clearance or approval from the FDA or other regulators for use in hospital or other in-patient facility settings, although the FDA has advised us that it will not object to the use of our CGM systems in such settings during the COVID-19 pandemic. Our potential supply of our CGM systems for use in this environment during the COVID-19 pandemic may present risks to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received, and may continue to receive, numerous inquiries from hospitals around the country about the use of our CGM devices to remotely monitor COVID-19 patients admitted into the hospital.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following direct communication with the FDA regarding the potential use of our CGM devices in a hospital or other in-patient setting, the FDA notified us on April 1, 2020 that in an exercise of its enforcement discretion it will not object, in the context of the COVID-19 pandemic, to Dexcom providing CGM devices and support to users to enable real-time remote patient monitoring in hospitals and other healthcare facilities, to support COVID-19 healthcare-related efforts, so long as we provide certain FDA-specified information with respect to the unique challenges that CGM technologies can raise in the hospital environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of its exercise of enforcement discretion, the FDA has advised that we communicate the following information related to implementing the use of CGM systems for remote monitoring of hospitalized patients:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Hospitals should consider whether they have the resources and expertise necessary to adequately implement CGM use and provide appropriate training to healthcare providers.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">CGM glucose results are less accurate than blood glucose results obtained using traditional testing methods (e.g., lab glucose, blood glucose meters). Users should consider all CGM glucose information (e.g., trend) along with individual glucose values, and interpret CGM results in the context of the full clinical picture.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">CGM systems are subject to interferences that may generate falsely high and falsely low glucose readings. Levels of interference depend on drug concentration; substances that may not significantly interfere in non-hospitalized patients may interfere when used in the hospital setting because of higher dose levels. Most drugs used in hospital or critical care settings have not been evaluated and their interference with CGM systems is unknown. Known interferences vary by CGM brand, and can include Acetaminophen, Ascorbic acid, Hydroxyurea, or other reducing drugs/ compounds.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Poor peripheral blood perfusion may cause inaccurate sensor readings.&#160;CGM results should be interpreted considering accompanying patient conditions and medications. Other clinical conditions may also cause inaccurate readings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision of our CGM systems to hospitals and other healthcare facilities for use have and will continue to have the above notice.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we received Breakthrough Device designation for our G6 CGM system in the hospital setting. The FDA&#8217;s Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that hold the potential for more effective treatment or diagnosis of life-threatening or irreversibly debilitating disease or condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not actively promoting for inpatient use, but if we supply them to such facilities as currently permitted by the FDA, this supply could present an increased risk of product liability claims and associated damages should an adverse event occur. Given that our CGM devices have not yet been fully evaluated or tested by either us or the FDA to the extent that would be required in standard circumstances for product development and marketing authorization, there could be unknown or unanticipated risks presented by use in this environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA can also decide, at any time, to change its position regarding its Breakthrough Device Designation and/or enforcement discretion for our devices, and require that we seek marketing authorization for this additional intended use by submitting a 510(k) premarket notification, or that we seek and obtain Emergency Use Authorization. The COVID-19 public health emergency declared by the Department of Health and Human Services expired on May 11, 2023. While the end of the public health emergency does not by itself impact the FDA&#8217;s ability to authorize devices for emergency use, and the FDA has published guidance for transition plans for medical devices that fall within enforcement policies issued during the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to closely monitor regulatory developments that impact our products, business, or financial results, including those relating to FDA enforcement discretion and Breakthrough Device Designation for the provision of our CGM systems in the hospital setting.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on clinical investigators and clinical sites to enroll patients in our clinical trials and other third parties to manage the trials and to perform related data collection and analysis, and, as a result, we may face costs and delays that are outside of our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on clinical investigators and clinical sites to enroll patients in our clinical trials, and other third parties to manage the trial and to perform related data collection and analysis. However, we may not be able to control the amount and timing of resources that clinical sites may devote to our clinical trials. If these clinical investigators and clinical sites fail to enroll a sufficient number of patients in our clinical trials or fail to ensure compliance by patients with clinical protocols or fail to comply with regulatory requirements, we will be unable to complete these trials, which could prevent us from obtaining regulatory approvals for our products. Our agreements with clinical investigators and clinical sites for clinical testing place substantial responsibilities on these parties and, if these parties fail to perform as expected, our trials could be delayed or terminated. If these clinical investigators, clinical sites or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, or the clinical data may be rejected by the FDA, and we may be unable to obtain regulatory approval for, or successfully commercialize, our products.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to perceived increases in health care costs in recent years, there have been and continue to be proposals by the federal government, state governments, regulators, and third-party payors to control these costs and, more generally, to reform the U.S. health care system. Certain of these proposals could limit the prices we are able to charge for our products or the amounts of reimbursement available for our products and could limit the acceptance and availability of our products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the OIG published a Special Fraud Alert addressing manufacturer Speaker Programs, signaling both a more narrow government view of AKS compliance with respect to such programs as well as the potential for increased enforcement in this space by government oversight agencies such as the OIG and DOJ. In March 2022, the Advanced Medical Technology Association, or AdvaMed, announced revisions to its Code of Ethics on Interactions with Health Care Professionals, or Code. The revised Code, effective June 2022, addressed concerns noted in the OIG&#8217;s Special Fraud Alert, addressing things like virtual meetings, speaker programs and alcohol at events. The revised Code also addresses value-based care arrangements. We continue to assess industry responses to the Special Fraud Alert and have and may continue to make modifications to certain aspects of our speaker programs, which may have a detrimental impact on our ability to educate healthcare providers about our products and to promote use of our products, and which may in turn lead to decreased product sales and negatively impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive healthcare legislation, signed into law in the United States in March 2010, titled the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, collectively, the ACA, imposes certain stringent compliance, recordkeeping, and reporting requirements on companies in various sectors of the life sciences industry, and enhanced penalties for non-compliance. Despite the ACA going into effect over a decade ago, there have been numerous legal and Congressional challenges to the law&#8217;s provisions and the effect of certain provisions have made compliance costly. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what additional new legislation, agency priorities, and rulemaking may be on the horizon as the United States continue to reassess how it pays for healthcare. As a result, we cannot quantify or predict what impact any changes might have on our business and results of operations. However, any changes that lower reimbursement for our products could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legal, regulatory and commercial policy influences are subjecting our industry to significant changes, and we cannot predict whether new regulations or policies will emerge from U.S. federal or state governments, foreign governments, or third-party payors. Government and commercial payors may, in the future, consider healthcare policies and proposals intended to curb rising healthcare costs, including those that could significantly affect reimbursement for healthcare products such as our systems. These policies have included, and may in the future include: basing reimbursement policies and rates on clinical outcomes, the comparative effectiveness, and costs, of different treatment technologies and modalities; imposing price controls and taxes on medical device providers; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other measures. Future significant changes in the healthcare systems in the United States or elsewhere could also have a negative impact on the demand for our current and future products. These include changes that may reduce reimbursement rates for our products and changes that may be proposed or implemented by the current or future laws or regulations.</span></div><div id="i70f957301cc34339a22f629982cd0734_43"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property Protection and Use</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief. We may also be subject to other claims or suits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties have asserted, and may assert, infringement or misappropriation claims against us with respect to our current or future products. We are aware of numerous patents issued to third parties that may relate to aspects of our business, including the design and manufacture of CGM sensors and membranes, as well as methods for continuous glucose monitoring. Whether a product infringes a patent involves complex legal and factual issues, the determination of which is often uncertain. Therefore, we cannot be certain that we have not infringed the intellectual property rights of such third parties or others. Our competitors may assert that our CGM systems or the methods we employ in the use of our systems are covered by U.S. or foreign patents held by them. We have in the past settled some such allegations and may need to do so again in the future. This risk is exacerbated by the fact that there are numerous issued patents and pending patent applications relating to self-monitored glucose testing systems in the medical technology field. Because patent applications may take years to issue, there may be applications now pending of which we are unaware that may later result in issued patents that our products infringe. There could also be existing patents of which we are unaware that one or more components of our system may inadvertently infringe. As the number of competitors in the market for CGM systems grows, the possibility of patent infringement by us or a patent infringement claim against us increases. If we are unable to successfully defend any such claims as they may arise or enter into or extend settlement and license agreements on acceptable terms or at all, our business operations may be harmed. We have been involved in various patent infringement actions in the past. For example, in July 2014, we entered into a Settlement and License Agreement with Abbott to settle all pending patent infringement legal proceedings brought by Abbott against us, which expired on March 31, 2021. Since the expiration of that agreement, we and certain Abbott entities have served complaints for patent infringement, validity, and other patent-related actions against each other in multiple jurisdictions, inside and outside the United States. We intend to vigorously pursue our claims and defenses in these cases to protect our intellectual property and to defend against Abbott&#8217;s infringement allegations. See &#8220;Legal Proceedings&#8221; in Part I, Item 3 below for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any infringement or misappropriation claim could cause us to incur significant costs, place significant strain on our financial resources, divert management&#8217;s attention from our business and harm our reputation. In addition, if the relevant patents are upheld as valid and enforceable and we are found to infringe such patents, we could be prohibited from selling any of our products that is found to infringe unless we could obtain licenses to use the technology covered by the patent or are able to design around the patent. We may be unable to obtain a license on terms acceptable to us, if at all, and we may not be able to redesign our products to avoid infringement. We may be unable to maintain or renew licenses on terms acceptable to us, if at all, and we may be prohibited from selling any of our products that required the technology covered by the relevant licensed patents. Even if we are able to redesign our products to avoid an infringement claim, we may not receive FDA approval for such changes in a timely manner or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse determination in litigation or interference proceedings to which we are or may become a party relating to patents or other intellectual property rights could subject us to significant liabilities to third parties or require us to seek licenses from other third parties. If we are found to infringe third-party patents, a court could order us to pay damages to compensate the patent owner for the infringement, such as a reasonable royalty amount and/or profits lost by the patent owners, along with prejudgment and/or post-judgment interest. Furthermore, if we are found to willfully infringe third-party patents, we could, in addition to other penalties, be required to pay treble damages; and if the court finds the case to be exceptional, we may be required to pay attorneys&#8217; fees for the prevailing party. If we are found to infringe third-party copyrights or trademarks or misappropriate third-party trade secrets, based on the intellectual property at issue, a court could order us to pay statutory damages, actual damages, or profits, such as reasonable royalty or lost profits of the owners, unjust enrichment, disgorgement of profits, and/or a reasonable royalty, and the court could potentially award attorneys&#8217; fees or exemplary or enhanced damages. Although patent and intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and would likely include ongoing royalties. We may be unable to obtain necessary intellectual property licenses on satisfactory terms. If we do not obtain any such necessary licenses, we may not be able to redesign our products to avoid infringement and any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redesign may not receive FDA approval or other requisite marketing authorization in a timely manner or at all. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary intellectual property licenses could prevent us from manufacturing and selling our products, which would have a significant adverse impact on our business. If litigation were to be initiated by intellectual property owners, there could significant legal fees and costs incurred in defending litigation (which may include filing administrative actions to attack the intellectual property) as well as a potential monetary settlement payment to the owners, even if the matter is resolved before going to trial. Moreover, the owners may take an overly aggressive approach and/or include multiple allegations in a single litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, from time to time, we are subject to various claims, complaints and legal actions arising out of the ordinary course of business, including commercial insurance, product liability or employment-related matters. Also, from time to time, we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment-related matters. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition or results of operations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our inability to adequately protect our intellectual property could allow our competitors and others to produce products based on our technology, which could substantially impair our ability to compete.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success and our ability to compete depend, in part, upon our ability to maintain the proprietary nature of our technologies. We rely on a combination of patent, copyright and trademark law, and trade secrets and nondisclosure agreements to protect our intellectual property. However, such methods may not be adequate to protect us or permit us to gain or maintain a competitive advantage. Our patent applications may not issue as patents in a form that will be advantageous to us, or at all. Our issued patents, and those that may issue in the future, may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products. In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the U.S. Patent and Trademark Office, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To protect our proprietary rights, we may in the future need to assert claims of infringement against third parties. The outcome of litigation to enforce our intellectual property rights in patents, copyrights, trade secrets or trademarks is highly unpredictable, could result in substantial costs and diversion of resources, and could have a material adverse effect on our business, financial condition and results of operations regardless of the final outcome of such litigation. In the event of an adverse judgment, a court could hold that some or all of our asserted intellectual property rights are not infringed, or are invalid or unenforceable, and could award attorney fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts to safeguard our unpatented and unregistered intellectual property rights, we may not succeed in doing so or the steps taken by us in this regard may not be adequate to detect or deter misappropriation of our technology or to prevent an unauthorized third party from copying or otherwise obtaining and using our products, technology or other information that we regard as proprietary. In addition, third parties may be able to design around our patents. Furthermore, the laws of foreign countries may not protect our proprietary rights to the same extent as the laws of the United States.</span></div><div id="i70f957301cc34339a22f629982cd0734_46"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Litigation Risks</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to the risk of product liability claims that is inherent in the testing, manufacturing and marketing of medical devices, including those which may arise from the misuse (including system hacking or other unauthorized access by third parties to our systems) or malfunction of, or design flaws in, our products. This liability may vary based on the FDA classification associated with our devices. Notably, the classification of our G6 and G7 systems as Class II medical devices is likely to weaken our ability to rely on federal preemption of state law claims that assert liability against us for harms arising from use of those systems. We may be subject to product liability claims if our products cause, or merely appear to have caused, an injury. Claims may be made by customers, healthcare providers or others selling our products. The risk of product liability claims may increase given that G6 and G7 do not require confirmatory finger sticks when making treatment decisions or finger stick tests each day for calibration, although it does require finger stick tests when symptoms do not match readings and when readings are unavailable. The risk of claims may also increase if our products are subject to a product recall or seizure. An example of the difficulty of complying with the regulatory requirements associated with the manufacture of our products, we issued notifications to our customers regarding the audible alarms and alerts associated with our receivers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have insurance at levels that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available, the coverage may not be adequate to protect us against any future product liability claims. Further, if additional products are approved for marketing, we may seek additional insurance coverage. If we are unable to obtain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect against potential product liability claims, we will be exposed to significant liabilities, which may harm our business. A product liability claim, recall or other claims with respect to uninsured liabilities or for amounts in excess of insured liabilities could result in significant costs and significant harm to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims against us even if the apparent injury is due to the actions of others or misuse of the device or a partner device. Our customers, either on their own or following the advice of their physicians, may use our products in a manner not described in the products&#8217; labeling and that differs from the manner in which it was used in clinical studies and approved by the FDA. For example, our current systems are designed to be used by an individual continuously for up to 10 days for our G6 and G7 systems, but the individual might be able to circumvent the safeguards designed into the systems and use the products for longer than 10 days. Off-label use of products by customers is common, and any such off-label use of our products could subject us to additional liability, or require design changes to limit this potential off-label use once discovered. In addition, other regulatory agencies may in the future approve similar diabetes treatment indications. We expect that such diabetes treatment indications could expose us to additional liability. These liabilities could prevent or interfere with our product commercialization efforts. Defending a suit, regardless of merit, could be costly, could divert management attention and might result in adverse publicity, which could result in the withdrawal of, or inability to recruit, clinical trial volunteers or result in reduced acceptance of our products in the market.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could become the subject of governmental investigations, claims and litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare companies are subject to numerous investigations and inquiries by various governmental agencies. Further, under the False Claims Act, private parties have the right to bring&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or &#8220;whistleblower,&#8221; suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Depending upon whether the underlying conduct alleged in such inquiries or investigations could be considered systemic, any resolution of any such investigations could have a material, adverse effect on our financial position and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental agencies and their agents, such as CMS Medicare Administrative Contractors and other CMS contractors, as well as the OIG, state Medicaid programs, and other state and federal agencies may conduct audits of our operations, relating to covered items and services including those furnished to beneficiaries, health care providers and distributors. Commercial and government-funded managed care payors may conduct similar post-payment audits. Depending on the nature of the conduct found in such audits and whether the underlying conduct could be considered systemic, the resolution of these audits could have a material adverse effect on our financial position and results of operations. Our compliance program includes internal audit and monitoring functions designed to identify potential issues and facilitate remediation as appropriate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future investigations of our executives, our managers or us could result in significant liabilities or penalties to us, as well as adverse publicity. Even if we are found to have complied with applicable law, the investigation or litigation may pose a considerable expense and would divert management&#8217;s attention, and have a potentially negative impact on the public&#8217;s perception of us, all of which could negatively impact our financial position and results of operations. Further, should we be found out of compliance with any of these laws, regulations or programs, depending on the nature of the findings, our business, our financial position and our results of operations could be negatively impacted.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to fines, penalties and injunctions if we are determined to be promoting the use of our products for unapproved or improper off-label uses or determined to have made claims that are untruthful or misleading or not adequately substantiated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketing, promotional and educational materials and practices are subject to FDCA, Federal Trade Commission Act, and other applicable laws and regulations, as may be amended from time to time. If the FDA, FTC or other regulatory body with competent jurisdiction over us, our activities or products takes the position that our marketing, promotional or other materials or activities constitute improper promotion or marketing of an unapproved or improper use, or that they contain untruthful, misleading, or inadequately substantiated statements or claims, such regulatory body could request that we modify our materials or practices, or subject us to regulatory enforcement actions, including the issuance, depending on the regulatory body and the nature of the alleged violation, of a warning letter, injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider promotional, marketing or other materials </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or activities to constitute improper promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Recent court decisions have impacted the FDA&#8217;s enforcement activity regarding off-label promotion in light of First Amendment considerations; however, there are still significant risks in this area in part due to the potential False Claims Act exposure and the FDA&#8217;s continued focus on ensuring devices are marketed in a manner consistent with their FDA-required labeling.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not actively promoting nor do we plan to actively promote our G6 or G7 systems for inpatient use, but if we supply them to such facilities as currently permitted by FDA, this supply could present an increased risk of product liability claims and associated damages should an adverse event occur. Given that the G6 and G7 systems have not yet been fully evaluated or tested (by us or by the FDA) to the extent that would be required in standard circumstances for product development and marketing authorization, there could be unknown or unanticipated risks presented by use in this environment.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In some instances in our advertising and promotion, we may make claims regarding our product as compared to competing products, which may subject us to heightened regulatory scrutiny, enforcement risk, and litigation risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA applies a heightened level of scrutiny to comparative claims when applying its statutory standards for advertising and promotion, including with regard to its requirement that promotional labeling be truthful and not misleading. There is potential for differing interpretations of whether certain communications are consistent with a product&#8217;s FDA-required labeling, and FDA will evaluate communications on a fact-specific basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, making comparative claims may draw concerns from our competitors. Where a company makes a claim in advertising or promotion that its product is superior to the product of a competitor (or that the competitor&#8217;s product is inferior), this creates a risk of a lawsuit by the competitor under federal and state false advertising or unfair and deceptive trade practices law, and possibly also state libel law.&#160;Such a suit may seek injunctive relief against further advertising, a court order directing corrective advertising, and compensatory and punitive damages where permitted by law.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct-to-consumer marketing and social media efforts may expose us to additional regulatory scrutiny.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to promote our products via direct-to-consumer marketing and social media initiatives may subject us to additional scrutiny of our practices of effective communication of risk information, benefits or claims, under the oversight of the FDA, FTC, HHS-OCR, or others.</span></div><div id="i70f957301cc34339a22f629982cd0734_49"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Risks Related to Our Business and Financial Condition</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in the past and may incur losses in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses in the past. We have financed our operations primarily through private and public offerings of equity securities and debt and the sales of our products. We have devoted substantial resources to:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">research and development relating to our continuous glucose monitoring systems;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">sales and marketing and manufacturing expenses associated with the commercialization of our CGM systems; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expansion of our workforce.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase in connection with our clinical trials and other development activities related to our products, including our next-generation sensors, transmitters and receivers, as well as other collaborations. We also expect that our general and administrative expenses will continue to increase due, among other things, to the additional operational and regulatory burdens applicable to public healthcare and medical device companies. As a result, it is possible that we could incur operating losses in the future. These losses, among other things, may have an adverse effect on our stockholders&#8217; equity.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success will depend on our ability to attract and retain our personnel and manage our human capital, while controlling labor costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend to a significant degree on our senior management, especially Kevin Sayer, our President and Chief Executive Officer. Our success will depend on our ability to retain our senior management and to attract and retain qualified personnel in the future, including salespersons, scientists, clinicians, engineers and other highly skilled personnel. Competition for senior management personnel, as well as salespersons, scientists, clinicians and engineers, is intense and we may not be able to retain our personnel. The loss of the services of members of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">senior management, scientists, clinicians or engineers could prevent the implementation and completion of our objectives, including the commercialization of our current products and the development and introduction of additional products. The loss of a member of our senior management or our professional staff would require the remaining executive officers to divert immediate and substantial attention to seeking a replacement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our officers may terminate their employment at any time without notice and without cause or good reason. Additionally, volatility or a lack of positive performance in our stock price may adversely affect our ability to retain key employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to expand our operations and grow our research and development, manufacturing, sales and marketing, product development and administrative operations. We expect this expansion to place a significant strain on our management and it will require hiring a significant number of qualified personnel. Accordingly, recruiting and retaining such personnel will be critical to our success. There is intense competition from other companies and research and academic institutions for qualified personnel in the areas of our activities. If we fail to identify, attract, retain and motivate these skilled personnel, we may be unable to continue our development and commercialization activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may undertake reorganizations of our workforce, which may result in a temporary reduction in the number of employees in certain locations. We would undertake a reorganization to reduce operating expenses or achieve other business objectives, though we cannot guarantee any specific amount of long-term cost savings. Further, the turnover in our employee base could result in operational and administrative inefficiencies, which could adversely impact the results of our operations, stock price and customer relationships, and could make recruiting for future management and other positions more difficult.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may conduct additional financings to continue the development or commercialization of our current or future generation CGM systems.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts on commercialization of our products, including growth of our manufacturing capacity, on research and development, and conducting clinical trials for our next-generation CGM sensors and systems. Although we raised substantial net proceeds through the private sale of our convertible notes, we could need funds to continue the commercialization of our current products and to develop and commercialize our next-generation sensors and systems or pursue other strategic initiatives. Additional financing may not be available on a timely basis on terms acceptable to us, or at all. Any additional financing may be dilutive to stockholders or may require us to grant a lender a security interest in our assets. The amount of funding we may need will depend on many factors, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the revenue generated by sales of our products and other future products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the costs, timing and risks of delay of additional regulatory approvals;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the expenses we incur in manufacturing, developing, selling and marketing our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our ability to scale our manufacturing operations to meet demand for our current and any future products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the costs to produce our continuous glucose monitoring systems;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the rate of progress and cost of our clinical trials and other development activities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the success of our research and development efforts;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the emergence of competing or complementary technologies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the terms and timing of any current or collaborative, licensing and other similar arrangements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost of ongoing compliance with legal and regulatory requirements, and third-party payors&#8217; policies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost of obtaining and maintaining regulatory or payor clearance or approval for our current or future products including those integrated with other companies&#8217; products; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the acquisition of business, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available, we may not be able to commercialize our products at the rate we desire and/or we may have to delay the development or commercialization of our products or license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to reduce sales, marketing, customer support or other resources devoted to our products. Any of these factors could harm our business and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncollectible uninsured and patient due accounts could adversely affect our results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary collection risks for our accounts receivable relate to the uninsured patient accounts and patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (exclusions, deductibles and copayments) remain outstanding. In addition, as a result of the economic slowdown, some customers have, and others may, lose access to their private health insurance plan if they lose their job. As most of our customers rely on third-party payors, including private health insurance plans, to cover the cost of our products, there has been, and may continue to be, a shift in financial responsibility to our customers for the amounts previously covered by their primary insurance carrier.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we are unsuccessful in collecting payments owed by patients, and/or experience increases in the amount, or deterioration in the collectability, of uninsured and patient due accounts receivable, this could adversely affect our cash flows and results of operations. We may also be adversely affected by the growth in patient responsibility accounts, as a result of increases in the adoption of plan structures, due to evolving health care policy and insurance landscapes that shift greater responsibility for care to individuals through greater exclusions, prior authorizations, and copayment and deductible amounts.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in our business strategy or restructuring of our businesses may increase our costs or otherwise affect the profitability of our businesses or the value of our assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As changes in our business environment occur we have adjusted, and may further, adjust our business strategies to meet these changes and we may otherwise decide to further restructure our operations or particular businesses or assets. Our new organization and strategies may not produce the anticipated benefits, such as supporting our growth strategies and enhancing shareholder value. Our new organization and strategies could be less successful than our previous organizational structure and strategies. In addition, external events including changing technology, changing consumer patterns, acceptance of our products and changes in macroeconomic conditions may impair the value of our assets. When these changes or events occur, we may incur costs to change our business strategy and may need to write-down the value of assets. For example, current economic conditions, including rising interest rates, inflation and a potential recession, as well as our business decisions, may reduce the value of some of our assets. We also make investments in existing or new businesses, including investments in the international expansion of our sales efforts and the build-out of our manufacturing facility in Malaysia and our planned construction of a new facility in Ireland. Additionally, we also invest in early to late-stage companies for strategic reasons and to support key business initiatives, and we may not realize a return on our equity investments. Many such companies generate net losses and the market for their products, services, or technologies may be slow to develop or never materialize. We are subject to risks associated with our equity investments including partial or complete loss of invested capital, and significant changes in the fair value of this portfolio could adversely impact our financial results. Some of these investments may have returns that are negative or low, the ultimate business prospects of the businesses related to these investments may be uncertain, and these risks may be exacerbated by current macroeconomic conditions. In any of these events, our costs may increase or returns on new investments may be lower than prior to the change in strategy or restructuring.</span></div><div id="i70f957301cc34339a22f629982cd0734_52"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Relating to Our Public Company Status, Tax Laws and Growth Through Acquisition</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face risks associated with acquisitions of companies, products and technologies and our business could be harmed if we are unable to address these risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are presented with appropriate opportunities, we could acquire or make other investments in complementary companies, products or technologies. We may not realize the anticipated benefit of our acquisitions, or the realization of the anticipated benefits may require greater expenditures than anticipated by us. We will likely face risks, uncertainties and disruptions associated with the integration process, including difficulties in the integration of the operations and services of any acquired company, integration of acquired technology with our products, diversion of our management&#8217;s attention from other business concerns, the potential loss of key employees or customers of the acquired businesses and impairment charges if future acquisitions are not as successful as we originally anticipated. If we fail to successfully integrate other companies, products or technologies that we acquire, our business could be harmed. Furthermore, we may have to incur debt or issue equity or equity-linked securities to pay for any future acquisitions or investments, the issuance of which could be dilutive to our existing stockholders. In addition, our operating results may suffer because of acquisition-related costs, amortization expenses or charges relating to acquired intangible assets.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with regulations relating to public company corporate governance matters and reporting may strain our resources and divert management&#8217;s attention.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many laws and regulations, notably those adopted in connection with the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and The Nasdaq Stock Market listing rules, impose obligations on public companies, such as ours, which have increased the scope, complexity and cost of corporate governance, reporting and disclosure practices. Compliance with these laws and regulations, including enhanced new disclosures, has required and will continue to require substantial management time and oversight and the incurrence of significant accounting and legal costs. Additionally, changes to existing accounting rules or standards, such as the potential requirement that U.S. registrants prepare financial statements in accordance with International Financial Reporting Standards, may adversely impact our reported financial results and business, and may require us to incur greater accounting fees. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to continue to invest resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to changes in our tax rates, new U.S. or international tax legislation or additional tax liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxes in the United States and numerous foreign jurisdictions, where a number of our subsidiaries are organized. The tax laws in the United States and in other countries in which we and our subsidiaries do business could change on a prospective or retroactive basis, and any such changes could adversely affect our business and financial condition. Further, due to economic and political conditions, tax rates in various jurisdictions may be subject to change. Our effective tax rates could be affected by numerous factors, including changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, and changes in tax laws or their interpretation, both in and outside the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is growing pressure in many jurisdictions, including the United States, and from multinational organizations such as the OECD and the European Union to amend existing international tax rules in order to render them more responsive to current global business practices. For example, the OECD has published a package of measures for reform of the international tax rules as a product of its BEPS initiative, which was endorsed by the G20 finance ministers. Many of the initiatives in the BEPS package require amendments to the domestic tax legislation of various jurisdictions. Separately, the European Union is asserting that a number of country-specific favorable tax regimes and rulings in certain member states may violate, or have violated, European Union law, and may require rebates of some or all of the associated tax benefits to be paid by benefited taxpayers in particular cases. In 2016, the European Union adopted the &#8220;Anti-Tax Avoidance Directive,&#8221; which requires European Union member states to implement measures to prohibit tax avoidance practices, and Germany published the European Union Anti-Tax Avoidance Directive Implementation Law on June 30, 2021. We have a significant presence in the European Union, as well as significant sales in the European Union, such that any changes in tax laws in the European Union will impact our business. The overall impact of such legislation in European Union member states is uncertain, and our business and financial condition could be adversely affected by any laws impacting our tax rate. The U.S. government has recently enacted comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include, among others, (I) a permanent reduction to the corporate income tax rate, (ii) a partial limitation on the deductibility of business interest expense, (iii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain rules designed to prevent erosion of the U.S. income tax base) and (iv) a one-time tax on accumulated offshore earnings held in cash and illiquid assets, with the latter taxed at a lower rate. The overall impact of this tax reform is uncertain, and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the OECD announced the OECD/G20 Inclusive Framework on BEPS which agreed to a two-pillar solution to address tax challenges arising from digitalization of the economy. On December 20, 2021, the OECD released Pillar Two Model Rules defining the global minimum tax rules, which contemplate a 15% minimum tax rate. The OECD continues to release additional guidance on these rules and the Framework calls for law enactment by OECD and G20 members to take effect in 2024 or 2025. These changes, when enacted by various countries in which we do business, may increase our taxes in these countries. Changes to these and other areas in relation to international tax reform, including future actions taken by foreign governments, could increase uncertainty and may adversely affect our tax rate and cash flow in future years. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tax returns and other tax matters also are subject to examination by the U.S. Internal Revenue Service and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes. We cannot guarantee the outcome of these examinations. If our effective tax rates were to increase, particularly in the United States, or in other countries implementing legislation to reform existing tax legislation, including the European Union and Germany, or if the ultimate determination of our taxes owed is for an amount in excess of amounts previously accrued, our financial condition, operating results and cash flows could be adversely affected.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations which could subject our business to higher tax liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to use our net operating losses, or NOLs, to offset future taxable income may be subject to certain limitations which could subject our business to higher tax liability. We may be limited in the portion of NOL carryforwards that we can use in the future to offset taxable income for U.S. federal and state income tax purposes, and federal tax credits to offset federal tax liabilities. Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state law provisions, limit the use of NOLs and tax credits after a cumulative change in corporate ownership of more than 50% occurs within a three-year period. The statutes place a formula limit on how much NOLs and tax credits a corporation can use in a tax year after a change in ownership. Avoiding an ownership change is generally beyond our control. Although the ownership changes we experienced in the past have not prevented us from using all NOLs and tax credits accumulated before such ownership changes, we could experience another ownership change that might limit our use of NOLs and tax credits in the future. In addition, realization of deferred tax assets, including net operating loss carryforwards, depends upon our future earnings in applicable tax jurisdictions. If we have insufficient future taxable income in the applicable tax jurisdiction for any reason, including any future corporate reorganization or restructuring activities, we may be limited in our ability to utilize some or all of our net operating losses to offset such income and reduce our tax liability in that jurisdiction. We utilized the majority of our remaining NOLs by the end of 2021, with the exception of the NOLs limited by Section 382 of the Internal Revenue Code of 1986. See Note 8 &#8220;Income Taxes&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that due to regulatory changes or changes to federal or state law, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable either in whole or in part to offset future income tax liabilities. For example, under the Coronavirus Aid, Relief, and Economic Security Act of 2020, or CARES Act, which amended certain provisions of the Tax Cuts and Jobs Act of 2017, or TCJA, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. The TCJA, as amended by the CARES Act, also provides that NOLs from tax years that began after December 31, 2017 may offset no more than 80% of current taxable income annually for taxable years beginning after December 31, 2020.</span></div><div id="i70f957301cc34339a22f629982cd0734_55"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the market price of our common stock, like the securities of many other medical products companies, fluctuates and could continue to be volatile in the future, especially as our business continues to grow and our business plan continues to evolve. From January&#160;1, 2023 through December&#160;31, 2023, the closing price of our common stock on the Nasdaq Global Select Market was as high as $137.93 per share and as low as $75.49 per share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is influenced by many factors that are beyond our control, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">securities analyst coverage or lack of coverage of our common stock or changes in their estimates of our financial performance;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">actual or anticipated variations in financial condition and operating results;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">future sales of our common stock by our stockholders;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">investor perception of us and our industry;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">announcements by us or our competitors of significant agreements, acquisitions, or capital commitments or product launches or discontinuations;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changes in market valuation or earnings of our competitors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">material business or financial announcements regarding our partners;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">general economic conditions;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">regulatory actions;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">legislation and political conditions;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">global health pandemics, such as the recent COVID-19 pandemic; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the consummation of, and anticipated benefits of, our share repurchase programs; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">other events or factors, including the ongoing international conflicts, recessions, rising interest rates, inflation, local and national elections, international currency fluctuations, corruption, political instability and acts of war or terrorism</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please also refer to the factors described elsewhere in this &#8220;Risk Factors&#8221; section. In addition, the stock market in general has experienced extreme price and volume fluctuations that have often been unrelated and disproportionate to the operating performance of companies in our industry. These broad market and industry factors may materially reduce the market price of our common stock, regardless of our operating performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities class action litigation has often been brought against public companies that experience periods of volatility in the market prices of their securities. Securities class action litigation could result in substantial costs and a diversion of our management&#8217;s attention and resources, which could seriously harm our business.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of shares by us in the future or sales of shares by our stockholders may cause the market price of our common stock to drop significantly, even if our business is performing well.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This issuance of shares by us in the future, including by conversion of our senior convertible notes in certain circumstances, the issuance of shares of our common stock to partners, including up to 1.5 million additional shares of our common stock that we may issue to Verily pursuant to the Restated Collaboration Agreement, or sales of shares by our stockholders may cause the market price of our common stock to decline, perhaps significantly, even if our business is performing well. The market price of our common stock could also decline if there is a perception that sales of our shares are likely to occur in the future. This might also make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Also, we may issue securities in connection with future financings and acquisitions, and those shares could dilute the holdings of other stockholders.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable future and the terms of our credit agreement restrict our ability to declare or pay any dividends. As a result, stockholders (including holders of our senior convertible notes who receive shares of our common stock, if any, upon conversion of their notes) may only receive a return on their investment in our common stock if the market price of our common stock increases.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover effects of our charter documents and Delaware law could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are provisions in our certificate of incorporation and bylaws, as well as provisions in the Delaware General Corporation Law, that may discourage, delay or prevent a change of control that might otherwise be beneficial to stockholders. For example:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our Board of Directors may, without stockholder approval, issue shares of preferred stock with special voting or economic rights;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our stockholders do not have cumulative voting rights and, therefore, each of our directors can only be elected by holders of a majority of our outstanding common stock;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a special meeting of stockholders may only be called by a majority of our Board of Directors, the Chairman of our Board of Directors, our Chief Executive Officer, our President or our Lead Independent Director;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our stockholders may not take action by written consent; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we require advance notice for nominations for election to the Board of Directors or for proposing matters that can be acted upon by stockholders at stockholder meetings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our bylaws provide that the federal district courts of the United States will, to the fullest extent permitted by law, be the exclusive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal court.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. The exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results, and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, Section 203 of the Delaware General Corporation Law may discourage, delay, or prevent a change of control of our company. Section 203 imposes certain restrictions on mergers, business combinations, and other transactions between us and holders of 15% or more of our common stock.</span></div><div id="i70f957301cc34339a22f629982cd0734_58"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Debt</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing our financial leverage could affect our operations and profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into the First Amendment to our Second Amended and Restated Credit Agreement, or the Amended Credit Agreement, with JPMorgan Chase and other syndicate lenders, which amended and restated the credit agreement, or the Credit Agreement, we had previously entered into in December 2018 and amended in May 2020 and October 2021, respectively. The Amended Credit Agreement is a five-year $200.0 million revolving credit facility, or the Credit Facility. As of December&#160;31, 2023, we had no outstanding borrowings, $7.4 million in outstanding letters of credit, and a total available balance of $192.6 million under the Amended Credit Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leverage ratio may affect the availability to us of additional capital resources as well as our operations in several ways, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the terms on which credit may be available to us could be less attractive, both in the economic terms of the credit and the legal covenants;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the possible lack of availability of additional credit;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the potential for higher levels of interest expense to service or maintain our outstanding debt;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the possibility of additional borrowings in the future to repay our indebtedness when it comes due; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the possible diversion of capital resources from other uses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we will have the ability to service our debt and obtain additional resources in the future if and when needed, that will depend upon our results of operations and financial position at the time, the then-current state of the credit and financial markets, and other factors that may be beyond our control. Therefore, we cannot give assurances that sufficient credit will be available on terms that we consider attractive, or at all, if and when necessary or beneficial to us.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with covenants in the Amended Credit Agreement could result in our inability to borrow additional funds and adversely impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement imposes numerous financial and other restrictive covenants on our operations, including covenants relating to our general profitability and our liquidity. As of December&#160;31, 2023, we were in compliance with the covenants imposed by the Amended Credit Agreement. If we violate these or any other covenants, any outstanding amounts under the Amended Credit Agreement could become due and payable prior to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their stated maturity dates, each lender could proceed against any collateral in our operating accounts and our ability to borrow funds in the future may be restricted or eliminated. These restrictions may also limit our ability to borrow additional funds and pursue other business opportunities or strategies that we would otherwise consider to be in our best interests.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have indebtedness in the form of convertible senior notes, which could adversely affect our financial health and our ability to respond to changes in our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we completed an offering of approximately $1.21 billion aggregate principal amount of 0.25% senior convertible notes due 2025, or 2025 Notes, which offering we refer to as the 2020 Notes Offering. In May 2023, we completed an offering of approximately $1.25 billion aggregate principal amount of 0.375% senior convertible notes due 2028, or 2028 Notes, which offering we refer to as the 2023 Notes Offering. We refer to the 2020 Notes Offering and the 2023 Notes Offering, collectively, as the Notes Offerings, and we refer to the 2025 Notes and the 2028 Notes, collectively, as the Notes. As a result of the Notes Offerings, we incurred $2.46 billion principal amount of indebtedness, the principal amount of which we may be required to pay at maturity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes will have the right to require us to repurchase their notes upon the occurrence of a fundamental change (as defined in the indenture for each of the Notes) at a purchase price equal to 100% of the principal amount of the notes to be purchased, plus accrued and unpaid interest, if any. In addition, each indenture for the Notes provides that we are required to repay amounts due under each indenture in the event that there is an event of default for the Notes that results in the principal, premium, if any, and interest, if any, becoming due prior to the maturity date for the Notes. There can be no assurance that we will be able to repay this indebtedness when due, or that we will be able to refinance this indebtedness on acceptable terms or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our level of increased debt after the completion of the Notes Offerings:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our vulnerability to adverse general economic conditions and competitive pressures will be heightened;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we will be required to dedicate a larger portion of our cash flow from operations to interest payments, limiting the availability of cash for other purposes;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our flexibility in planning for, or reacting to, changes in our business and industry may be more limited; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our ability to obtain additional financing in the future for working capital, capital expenditures, acquisitions, general corporate purposes or other purposes may be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that our leverage resulting from the level of increased debt after the completion of the Notes Offerings will not materially and adversely affect our ability to finance our operations or capital needs or to engage in other business activities. In addition, we cannot be sure that additional financing will be available when required or, if available, will be on terms satisfactory to us. Further, even if we are able to obtain additional financing, we may be required to use such proceeds to repay a portion of our debt.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to repurchase the Notes upon a fundamental change when required by the holders or repay prior to maturity any accelerated amounts due under the notes upon an event of default or redeem the Notes unless specified conditions are met under our Credit Facility, and our future debt may contain additional limitations on our ability to pay cash upon conversion, repurchase or repayment of the Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes will have the right to require us to repurchase their Notes upon the occurrence of a fundamental change at a purchase price equal to 100% of the principal amount of the Notes to be purchased, plus accrued and unpaid interest, if any, to, but not including, the fundamental change purchase date. In addition, each indenture for the Notes provides that we are required to repay amounts due under each indenture in the event that there is an event of default for the Notes that results in the principal, premium, if any, and interest, if any, becoming due prior to the maturity date for the Notes. In addition, upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than cash in lieu of any fractional share), we will be required to make cash payments in respect of the Notes being converted. However, we may not have enough available cash or be able to obtain financing at the time we are required to repurchase Notes surrendered upon a fundamental change or repay prior to maturity any accelerated amounts or pay cash for Notes being converted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to purchase the Notes or repay prior to maturity any accelerated amounts under the Notes upon an event of default or pay cash upon conversions of the Notes may be limited by law, by regulatory authority or by agreements governing our indebtedness outstanding at the time, including our Credit Facility. Under our Credit Facility, we are only permitted to use cash to purchase the Notes or repay prior to maturity any accelerated amounts under the Notes if we meet certain conditions that are defined under the Credit Agreement. We may not meet these conditions in the future. Our failure to repurchase Notes at a time when the repurchase is required by the respective </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indenture (whether upon a fundamental change or otherwise under each indenture) or pay cash payable on future conversions of the Notes as required by the indenture would constitute a default under each indenture. A default under each indenture or the fundamental change itself could also lead to a default under agreements governing our existing or future indebtedness, including our Credit Facility. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness, repurchase the Notes or make cash payments upon conversions thereof.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may still incur substantially more debt or take other actions which would intensify the risks discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur substantial additional debt in the future, subject to the restrictions contained in our debt instruments, some of which may be secured debt. We are not restricted under the terms of the indentures governing the Notes from incurring additional debt, securing existing or future debt, recapitalizing our debt, or taking a number of other actions that are not limited by the terms of the indenture governing the convertible senior notes that could have the effect of diminishing our ability to make payments on the Notes when due.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The capped call transactions we entered into in connection with the pricing of the 2028 Notes may affect the value of our 2028 Notes and common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the pricing of the 2028 Notes, we entered into capped call transactions, or the 2028 Capped Calls, relating to such 2028 Notes with the option counterparties. The 2028 Capped Calls relating to the 2028 Notes cover, subject to customary adjustments, the number of shares of our common stock that initially underlie the 2028 Notes. The 2028 Capped Calls are generally expected to reduce the potential dilution to stockholders upon any conversion of the 2028 Notes, and/or offset any cash payments that we are required to make in excess of the principal amount upon any conversion of the 2028 Notes, with such reduction and/or offset subject to a cap.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock in secondary market transactions following the pricing of the 2028 Notes, as applicable, and prior to the maturity of the 2028 Notes (and are likely to do so during any observation period related to a conversion of such Notes or following any repurchase of such notes by us on any fundamental change repurchase date or otherwise). This activity could also cause or avoid an increase or a decrease in the market price of our 2028 Notes or common stock, which could affect a holder&#8217;s ability to convert its 2028 Notes and, to the extent the activity occurs during any observation period related to a conversion of the 2028 Notes, it could affect the amount and value of the consideration that a holder will receive upon conversion of such 2028 Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential effect, if any, of these transactions and activities on the market price of the 2028 Notes or our common stock will depend in part on market conditions and cannot be ascertained at this time. Any of these activities could adversely affect the value of 2028 Notes or our common stock (and as a result, the amount and value of the consideration that a holder would receive upon the conversion of any 2028 Notes) and, under certain circumstances, a holder&#8217;s ability to convert its notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The warrants related to the 2023 Notes and our common stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of the 2023 Notes, we entered into warrant transactions with the option counterparties pursuant to which we sold warrants for the purchase of our common stock, or the 2023 Warrants. The 2023 Warrant transactions could separately have a dilutive effect to the extent that the market price per share of our common stock exceeds the exercise price of the 2023 Warrants, which is $49.60. We do not make any representation or prediction as to the direction or magnitude of any potential effect that the 2023 Warrants may have on our common stock. In addition, we do not make any representation that the option counterparties will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to counterparty risk with respect to the 2028 Capped Calls.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option counterparties to the 2028 Capped Calls are financial institutions, and we will be subject to the risk that any or all of them may default under the 2028 Capped Calls. Our exposure to the credit risk of these counterparties is not secured by any collateral. Recent global economic conditions have resulted in the actual or perceived failure or financial difficulties of many financial institutions. If a counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings, with a claim equal to our exposure at that time under our transactions with that option counterparty. Our exposure will depend on many factors but, generally, an increase in our exposure will be correlated to an increase in the market price and in the volatility of our common stock. In addition, upon a default by an option counterparty, we may suffer adverse tax consequences and more dilution than we currently anticipate with respect to our common stock. We can provide no assurances as to the financial stability or viability of the counterparties with respect to the 2028 Capped Calls.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the Notes, depends on our future financial condition and operating performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not continue to generate cash flow from operations in the future sufficient to satisfy our obligations under the Notes, our existing indebtedness and any future indebtedness we may incur and to make necessary capital expenditures. We may not maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on (as well as any cash due upon conversion of) our debt, including the Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as reducing or delaying investments or capital expenditures, selling assets, refinancing or obtaining additional equity capital on terms that may be onerous or highly dilutive. These alternative measures may not be successful and may not permit us to meet our scheduled debt servicing obligations. Further, we may need to refinance all or a portion of our debt on or before maturity, and our ability to refinance the Notes, existing indebtedness or future indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities on commercially reasonable terms or at all, which could result in a default on the Notes or our current and future indebtedness.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Credit Facility imposes restrictions on us that may adversely affect our ability to operate our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Credit Facility contains restrictive covenants relating to our capital raising activities and other financial and operational matters which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, our Credit Facility and the agreements governing the Notes each contain cross-default provisions whereby a default under one agreement would likely result in cross defaults under agreements covering other borrowings. For example, the occurrence of a default with respect to any indebtedness or any failure to repay debt when due in an amount in excess of $50.0 million, in the case of the 2025 Notes, and $50.0 million, in the case of the 2028 Notes, that causes such indebtedness to become due prior to its scheduled maturity date would cause a cross-default under the indenture governing the Notes. In addition, the occurrence of a default with respect to any indebtedness or any failure to repay debt when due in an amount in excess of $25.0 million that causes such indebtedness to become due prior to its scheduled maturity date would cause a default under our Credit Facility. The occurrence of a default under any of these borrowing arrangements would permit the holders of the Notes or the lenders under our Credit Facility to declare all amounts outstanding under those borrowing arrangements to be immediately due and payable. If the Note holders or the trustee under the indenture governing the Notes or the lenders under our Credit Facility accelerate the repayment of borrowings, we cannot assure you that we will have sufficient assets to repay those borrowings.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of the Notes will, to the extent we deliver shares upon conversion of such Notes, dilute the ownership interest of existing stockholders, including holders who had previously converted their Notes, or may otherwise depress our stock price.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of some or all of the Notes will dilute the ownership interests of existing stockholders to the extent we deliver shares upon conversion of any of the Notes. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress our stock price.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than cash in lieu of any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders of the Notes do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accounting method for convertible debt securities that may be settled in cash, such as the Notes, may have a material effect on our reported financial results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than by paying cash in lieu of delivering any fractional share), we may settle all or a portion of our conversion obligation in cash, which could adversely affect our liquidity. In addition, the consideration received upon the unwind or termination of the capped call transactions may not completely offset, and may be substantially less than, any cash payments in excess of the principal amount of the Notes we are required to make upon conversion of the Notes. Even if holders do not elect to convert their Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The fundamental change repurchase feature of the Notes may delay or prevent an otherwise beneficial attempt to take over Dexcom.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Notes require us to repurchase the Notes in the event of a fundamental change. A takeover of Dexcom would trigger an option of the holders of the Notes to require us to repurchase the Notes. In addition, if a make-whole fundamental change occurs prior to the maturity date of the Notes, we will in some cases be required to increase the conversion rate for a holder that elects to convert its Notes in connection with such make-whole fundamental change. Furthermore, each indenture for the Notes prohibits us from engaging in certain mergers or acquisitions unless, among other things, the surviving entity assumes our obligations under the notes. These and other provisions of each indenture may have the effect of delaying or preventing a takeover of Dexcom.</span></div><div id="i70f957301cc34339a22f629982cd0734_61"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Environmental, Social and Governance Matters</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental, social and governance, or ESG, regulations, policies and provisions could expose us to numerous risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, regulators, customers, investors, employees and other stakeholders are focusing on ESG matters and related disclosures. These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations and expectations. For example, collecting, measuring and reporting ESG-related data and information is subject to evolving reporting standards, including the SEC&#8217;s proposed climate-related reporting requirements, and similar proposals by other international regulatory bodies. For example, in 2023, California passed three separate climate bills governing disclosure of greenhouse gas emissions data, climate-related financial risks, and details around emissions-related claims and carbon offsets. In addition, a number of our customers who are payors or distributors have adopted, or may adopt, procurement policies that include ESG provisions that their suppliers or manufacturers must comply with, or they may seek to include such provisions in their terms and conditions. An increasing number of participants in the medical device industry are also joining voluntary ESG groups or organizations, such as the Responsible Business Alliance. These ESG provisions and initiatives are subject to change, can be unpredictable, and may be difficult and expensive for us to comply with, given the complexity of our supply chain and the outsourced manufacturing of certain components of our products. If we are unable to comply, or are unable to cause our suppliers to comply, with such policies or provisions, a customer may stop purchasing products from us, and may take legal action against us, which could harm our reputation, revenue and results of operations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by evolving expectations and challenges relating to implementing ESG initiatives, setting ESG-related goals, collecting ESG-related data, and disclosing ESG-related information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may communicate certain initiatives and goals regarding ESG-related matters in our SEC filings or in other public disclosures. These ESG-related initiatives and goals could be difficult and expensive to implement, the technologies needed to implement them may not be cost effective and may not advance at a sufficient pace, and we could be criticized for the accuracy, adequacy or completeness of the disclosure. Further, statements about our ESG-related initiatives and goals, and progress against those goals, may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals, or for any revisions to these goals. If our ESG-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our ESG-related goals on a timely basis, or at all, our reputation, business, financial performance and growth could be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Climate change may have a long-term impact on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we seek to partner with organizations that mitigate their business risks associated with climate change, we recognize that there are inherent risks related to climate change wherever business is conducted. Access to clean water and reliable energy in the communities where we conduct our business, whether for our offices or for our vendors, is a priority. Our manufacturing sites in California, Arizona and Malaysia and our operations in the Philippines are vulnerable to climate change effects. For example, in California and Arizona, increasing intensity of droughts throughout the states and annual periods of wildfire danger increase the probability of planned and unplanned power outages in the communities where we work and live. While this danger has a low-assessed risk of disrupting normal business operations, it has the potential impact on employees&#8217; abilities to commute to work or to work from home and stay connected effectively. Climate-related events, including the increasing frequency of extreme weather events and their impact on the U.S., the Philippines, Malaysia and other major regions&#8217; critical infrastructure, have the potential to disrupt our business, our third-party suppliers, and/or the business of our customers, and may cause us to experience higher attrition, losses, and additional costs to maintain or resume operations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be liable for contamination or other harm caused by materials that we handle, and changes in environmental regulations could cause us to incur additional expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and clinical processes involve the handling of potentially harmful biological materials as well as hazardous materials. We are subject to international and domestic (including federal, state and local) laws, rules and regulations governing the use, handling, storage and disposal of hazardous and biological materials and we incur expenses relating to compliance with these laws and regulations. If violations of environmental, health and safety laws occur, we could be held liable for damages, penalties and costs of remedial actions. These expenses or this liability could have a significant negative impact on our financial condition. We may violate environmental, health and safety laws in the future as a result of human error, equipment failure or other causes. Environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We are subject to potentially conflicting and changing regulatory agendas of political, business and environmental groups. Changes to or restrictions on permitting requirements or processes, hazardous or biological material storage or handling might require unplanned capital investment or relocation. Failure to comply with new or existing laws or regulations could harm our business, financial condition and results of operations.</span></div><div id="i70f957301cc34339a22f629982cd0734_64"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #58a618;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">General Risk Factors</span></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current uncertainty in domestic and global economic and political conditions makes it particularly difficult to predict product demand and other related matters and makes it more likely that our actual results could differ materially from expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance depend on worldwide economic and political conditions. These conditions have been adversely impacted by continued global economic uncertainty, political instability and military hostilities in multiple geographies, monetary and financial uncertainties in Europe and other foreign countries, global health pandemics, rising interest rates, and domestic and global inflationary trends. These include potential reductions in the overall stability and suitability of the Euro as a single currency, given the economic and political challenges facing individual Eurozone countries. These conditions have made and may continue to make it difficult for our customers and potential customers to afford our products, and could cause our customers to stop using our products or to use them less frequently. If that were to occur, our revenue may decrease and our performance may be negatively impacted. In addition, the pressure on consumers to absorb more of their own health care costs has resulted in some cases in higher deductibles and limits on durable medical equipment, which may cause seasonality in purchasing patterns. Furthermore, during economic uncertainty, our customers have had job losses and may continue to have issues gaining timely access to sufficient health insurance or credit, which could result in their unwillingness to purchase products or impair their ability to make timely payments to us. A recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the reoccurrence of any economic slowdown or the strength or sustainability of the economic recovery, worldwide, in the United States, or in our industry. These and other economic factors could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by the effects of inflation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation has the potential to adversely affect our liquidity, business, financial condition and results of operations by increasing our overall cost structure. The existence of inflation in the economy has resulted in, and may continue to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in, higher interest rates and capital costs, supply shortages, increased costs of labor, components, manufacturing and shipping, as well as weakening exchange rates and other similar effects. As a result of inflation, we have experienced and may continue to experience cost increases. Although we may take measures to mitigate the effects of inflation, if these measures are not effective, our business, financial condition, results of operations and liquidity could be materially adversely affected. Even if such measures are effective, there could be a difference between the timing of when these beneficial actions impact our results of operations and when the cost of inflation is incurred.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully maintain effective internal control over financial reporting, investors may lose confidence in our reported financial information and our stock price and our business may be adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal control over financial reporting and our management is required to evaluate the effectiveness of our internal control over financial reporting as of the end of each fiscal year. If we are not successful in maintaining effective internal control over financial reporting, there could be inaccuracies or omissions in the consolidated financial information we are required to file with the SEC. Additionally, even if there are no inaccuracies or omissions, we will be required to publicly disclose the conclusion of our management that our internal control over financial reporting or disclosure controls and procedures are not effective. These events could cause investors to lose confidence in our reported financial information, adversely impact our stock price, result in increased costs to remediate any deficiencies, attract regulatory scrutiny or lawsuits that could be costly to resolve and distract management&#8217;s attention, limit our ability to access the capital markets or cause our stock to be delisted from The Nasdaq Stock Market or any other securities exchange on which it is then listed.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in financial accounting standards or practices or existing taxation rules or practices may cause adverse unexpected revenue and/or expense fluctuations and affect our reported results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in accounting standards or practices or a change in existing taxation rules or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. New accounting pronouncements and taxation rules and varying interpretations of accounting pronouncements and taxation practice have occurred and may occur in the future. The method in which we market and sell our products may have an impact on the manner in which we recognize revenue. In addition, changes to existing rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business. Additionally, changes to existing accounting rules or standards, such as the potential requirement that U.S. registrants prepare financial statements in accordance with International Financial Reporting Standards, may adversely impact our reported financial results and business, and may further require us to incur greater accounting fees.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our financial performance fails to meet the expectations of investors and public market analysts, the market price of our common stock could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues and operating results may fluctuate significantly from quarter to quarter. We believe that period-to-period comparisons of our operating results may not be meaningful and should not be relied on as an indication of our future performance. If quarterly revenues or operating results fall below the expectations of investors or public market analysts, the trading price of our common stock could decline substantially. Factors that might cause quarterly fluctuations in our operating results include:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our inability to manufacture an adequate supply of product at appropriate quality levels and acceptable costs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">possible delays in our research and development programs or in the completion of any clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a lack of acceptance of our products in the marketplace by physicians and people with diabetes;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the inability of customers to receive reimbursements from third-party payors;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the purchasing patterns of our customers, including as a result of seasonality;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">failures to comply with regulatory requirements, which could lead to withdrawal of products from the market;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our failure to continue the commercialization of any of our CGM systems;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">competition;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">inadequate financial and other resources; and</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">global political and economic conditions, political instability and military hostilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1B - UNRESOLVED STAFF COMMENTS</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i70f957301cc34339a22f629982cd0734_3752"></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1C - CYBERSECURITY</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have processes in place for assessing, identifying, and managing material risks from cybersecurity threats, which are integrated into our overall enterprise risk management processes. The processes for assessing, identifying and managing material risks from cybersecurity threats, including threats associated with our use of third-party service providers, include identifying the relevant assets that could be affected, determining possible threat sources and threat events, assessing threats based on their potential likelihood and impact, and identifying controls that are in place or necessary to manage and/or mitigate such risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established cybersecurity and privacy programs to maintain the confidentiality, integrity, availability, and privacy of protected information and ensure compliance with relevant security/privacy regulations, contractual requirements, and industry-standard frameworks. Our cybersecurity program includes annual review and assessment by external, independent third parties, who certify and report on these programs. For example, our Information Security Management System (ISMS) is certified as being in conformity with ISO/IEC 27001 by SRI Quality System Registrar. We maintain cybersecurity and privacy policies and procedures in accordance with industry-standard control frameworks and applicable regulations, laws, and standards. All corporate cybersecurity policies are reviewed and approved by senior leadership at least annually as part of our ISMS.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity controls, which are the mechanisms in place to prevent, detect and mitigate threats in accordance with our policies and procedures, are based on the regulatory requirements to which we are subject and are monitored and tested both internally and externally by third parties at least annually. These controls include regular system updates and patches, employee training on cybersecurity and privacy requirements, incident reporting, and the use of encryption to secure sensitive information. In addition, we also regularly perform phishing tests of our employees and update our training plan at least annually. We maintain business continuity and disaster recovery capabilities to mitigate interruptions to critical information systems and/or the loss of data and services from the effects of natural or man-made disasters to Dexcom locations. We also provide annual privacy and security training for all employees. Our security training incorporates awareness of cyber threats (including but not limited to malware, ransomware and social engineering attacks), password hygiene, incident reporting process, as well as physical security best practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the last three fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from security incidents were immaterial. As a result, we do not believe that risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected us, our results of operations and financial condition. However, as discussed under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report, cybersecurity threats pose multiple risks to us, including potentially to our results of operations and financial condition. See &#8220;Risk Factors &#8212; Risks Related to Privacy and Security.&#8221; As cybersecurity threats become more frequent, sophisticated and coordinated, it is reasonably likely that we will be required to expend greater resources to continue to modify and enhance our protective measures as we pursue our strategy that includes developing and commercializing products that integrate our CGM technologies into insulin delivery systems or data platforms of our partners. The technology integration and cloud-based depository platforms we continue to focus on can make us more vulnerable to cybersecurity threats, thereby making our pursuit of such strategies more costly.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors is responsible for exercising oversight of management&#8217;s identification and management of, and planning for, risks from cybersecurity threats. While the full Board has overall responsibility for risk oversight, the Board has delegated oversight responsibility related to risks from cybersecurity threats to the Board&#8217;s Technology Committee. The Technology Committee reports to the Board as necessary with respect to its activities, including making such reports and recommendations to the Board and its other committees as necessary and appropriate and consistent with its purpose, described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Technology Committee, comprised of independent Board members, is responsible for reviewing cybersecurity, privacy, data protection and other major technology risk exposures of the Company, the steps management has taken to monitor and control such exposures, and the Company&#8217;s compliance with applicable cybersecurity and data privacy laws and industry standards. These reviews are provided at least quarterly. The Technology Committee receives management updates and reports, primarily through the Company&#8217;s Cybersecurity and Privacy Committee, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a multidisciplinary team responsible for the overall governance, decision-making, risk management, awareness and compliance for cybersecurity and privacy activities across the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cybersecurity and Privacy Committee is co-chaired by our Information Security Officer (ISO), Product Security Officer (PSO), and Chief Privacy Officer (CPO), and its members include executive officers of the Company, including our Chief Technology Officer, Chief Financial Officer, Chief Information Officer, and Chief Legal Officer, as well as representatives from the finance, internal audit, quality, regulatory, and legal teams. Management&#8217;s role in assessing and managing the material risks from cybersecurity threats is accomplished primarily through the committee.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of the Cybersecurity and Privacy Committee have broad ranges of expertise and experience in information technology and security. Our ISO, a co-chair of the committee, has over fifteen years of experience in the field of information security management, having previously led security operations and infrastructure and IT functions for a public university campus and a non-profit organization, and holds several licenses and certifications relating to information security, including a Certified Information Systems Security Manager from the Information Systems Audit and Control Association (ISACA), a Certified Information Systems Security Professional (CISSP) from the International Information Security System Security Certification Consortium (ISC2) and several technical cybersecurity certifications from the Global Information Assurance Certification (GIAC). Our PSO, also a co-chair of the committee, has over twenty-five years of previous experience in cyber security architecture and cyber security management for a number of large Fortune 500 technology companies and holds several certifications including CISSP from the International Information Security System Security Certification Consortium , C-CISO from EC-Council, Numerous certifications from Microsoft, CISCO, Juniper, Checkpoint among others and has completed several advanced GIAC security classes from the SANS Institute.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ISO reports directly to our Senior Vice President, Chief Information Officer (CIO), who is a member of the committee. He has held this role at Dexcom since 2021, having previously served as our Senior Vice President, Information Technology since 2018 and Vice President, Information Technology from 2016 to 2018. Our CIO also has a wide range of experience within global organizations in the field of information technology, including having served in various IT leadership roles at CareFusion, a Becton Dickinson Company, from 2012 to 2016, and ResMed in San Diego from 2007 to 2012. He holds a Bachelor of Engineering in Mechanical Engineering and a Master of Industrial Engineering. Our PSO reports directly to our Executive Vice President, Chief Technology Officer (CTO), who is also a member of the committee. Our CTO has held this role since 2022 and has 25 years of experience spanning consumer electronics, data storage, IoT and broadband industries. From 2011 to 2022 he worked at Technicolor (now known as Vantiva), most recently serving as Chief Technology Officer and General Manager of the Broadband Business Division. In addition to an MBA, he holds a Master of Science in Mechanical Engineering and a Bachelor of Mechanical Engineering.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prevention, detection, mitigation and remediation of cybersecurity incidents at Dexcom is accomplished pursuant to various policies, procedures and processes, including incident response plans and the cybersecurity and privacy programs and controls described above under &#8220;Risk Management and Strategy.&#8221; These measures include escalation protocols through which the Cybersecurity and Privacy Committee is informed about cybersecurity and incidents by our ISO and PSO, who are informed through our business units. As described above, members of the Cybersecurity and Privacy Committee provide updates to the Technology Committee of the Board on a regular basis, and the full Board receives updates from the Technology Committee. In addition, there are protocols in place for immediate escalation in the event of any cybersecurity issues or developments that may require consideration between regularly scheduled Technology Committee or Board meetings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2 - PROPERTIES</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease real property to support our business, including manufacturing, research and development, sales, marketing and administration. We believe our facilities are suitable and adequate for our current and near-term needs, and that we will be able to locate additional facilities as needed. The following table sets forth the locations of our manufacturing facilities:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.974%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Lease Expiration Dates</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mesa, Arizona</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2030 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penang, Malaysia</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2082 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Excludes renewals that would be at our option to extend the term of a lease expiring in 2028 for one additional three to five-year term.</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Excludes renewals that would be at our option to extend the term of a lease expiring in 2028 for four additional five-year terms and also excludes renewals that would be at our option to extend the term of a lease expiring in 2030 for two additional five-year terms.</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents 60-year land leases with the state authority expiring at varying dates through 2082.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters, research and development, and certain of our manufacturing operations are located in San Diego, California. We also lease various manufacturing, administrative, warehouse and customer support real properties throughout the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had approximately 65,900 square feet of laboratory space and approximately 155,700 square feet of controlled environment rooms.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we completed the initial phase of construction of our new facility in Malaysia and commenced commercial manufacturing. We are also expanding our facility in Mesa, Arizona to scale up manufacturing capacity.</span></div><div id="i70f957301cc34339a22f629982cd0734_73"></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3 - LEGAL PROCEEDINGS</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since June 2021, we and certain Abbott Diabetes Care, Inc. (&#8220;Abbott&#8221;) entities have served patent infringement complaints against each other in multiple jurisdictions against certain continuous glucose monitoring products of each company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we initiated patent infringement litigation against Abbott in the United States (U.S.D.C., Western District of Texas) and Germany (National Court (&#8220;N.C.&#8221;) in Mannheim). In May 2023, we filed additional patent infringement actions in Germany (N.C. in Munich). In July and August 2023, we initiated patent infringement litigation in the United Patent Court (&#8220;UPC&#8221;) (Paris &amp; Munich) and in Spain (Commercial Courts of Barcelona). In October and November 2023, we initiated patent infringement litigation in Germany (N.C. in Munich) and in the UPC (Paris &amp; Munich). In January 2024, we initiated patent infringement litigation in Germany (N.C. in Hamburg).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, one day after we initiated litigation in the U.S.D.C., Western District of Texas, Abbott initiated patent infringement litigation against Dexcom in the United States (U.S.D.C., Delaware (&#8220;D1&#8221;)). Shortly thereafter, Abbott filed additional patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales) and Germany (N.C. in Mannheim and Dusseldorf).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in the Business and Property Courts of England and Wales. Three trials on liability have already been conducted in the United Kingdom. On October 18, 2023, judgment was handed down in favor of Dexcom in one of these trials. On January 15, 2024, judgment was handed down invalidating both Abbott and Dexcom&#8217;s patents in another one of these trials. The parties are awaiting rulings on the remaining trial. Dexcom and Abbott sought injunctive relief and monetary damages as a result of their respective claims.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Abbott filed a breach of contract lawsuit against Dexcom in the United States (U.S.D.C., District of Delaware) alleging that Dexcom breached the parties' Settlement and License Agreement dated July 2, 2014 (&#8220;SLA&#8221;). The U.S.D.C., District of Delaware consolidated Abbott&#8217;s breach of contract lawsuit with Dexcom&#8217;s patent infringement lawsuit which had been transferred from the U.S.D.C., Western District of Texas (&#8220;D3&#8221;). Dexcom asserted counterclaims that Abbott also breached the SLA. A jury trial on Abbott&#8217;s breach of contract claims commenced on July 10, 2023. On July 14, 2023, the jury verdict determined that Abbott was not licensed to thirteen claims of certain Dexcom patents and that Abbott was licensed to five claims. In April 2022, Abbott initiated the inter partes review (&#8220;IPR&#8221;) process on the asserted claims of Dexcom&#8217;s patents in D3. The U.S. Patent and Trademark Office (the &#8220;PTO&#8221;) denied institution of one of Dexcom&#8217;s patents and instituted IPR on the other four. Ultimately, in November 2023, the PTO issued its Final Written Decision, upholding claims of two Dexcom patents to be patentable, which cover factory calibration and certain alarms and alerts, and two to be unpatentable, which cover certain sensor code and sensor configurations. We will continue to enforce the remaining claims of the patents asserted in Delaware with trial set for February 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Abbott filed patent infringement litigation against us in Germany (N.C. in Hamburg and Munich). In March 2023, Abbott filed a patent infringement litigation in the United States (U.S.D.C., Delaware (&#8220;D4&#8221;)) and we filed counterclaims for patent infringement in that action in June 2023. In June 2023, Abbott filed patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales). In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in that jurisdiction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s patent infringement action, &#8220;D1", against Dexcom is currently scheduled for trial in the U.S.D.C., District of Delaware on March 11, 2024. In the lead up to trial, the U.S.D.C., District of Delaware invalidated one of Abbott&#8217;s patents on factory calibration and Abbott dropped four other patents from the litigation. The claims currently being litigated are isolated to the inserter mechanism and the wearable seal and mount of Dexcom&#8217;s G6.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in January 2024, Abbott has several patent infringement hearings against Dexcom in Germany (N.C. in Hamburg and Munich) wherein Abbott is seeking damages and injunctive relief. On January 31, 2024, the Court in Munich in two such hearings provided Dexcom additional time to brief certain issues Abbott raised late in the proceedings, thus postponing a decision in both proceedings until May 2024.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and April of 2024, Dexcom has several patent infringement hearings in the N.C. in Mannheim and Munich against Abbott, wherein Dexcom is seeking damages and injunctive relief. Dexcom has hearings in May and June 2024 in its first two proceedings in the UPC and in July 2024 in the N.C. in Munich.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainty surrounding patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time. We intend to protect our intellectual property and defend against Abbott&#8217;s claims vigorously in all of these actions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.</span></div><div id="i70f957301cc34339a22f629982cd0734_76"></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4 - MINE SAFETY DISCLOSURES</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PART II</span></div><div><span><br/></span></div><div id="i70f957301cc34339a22f629982cd0734_82"></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 5 - MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div></td></tr></table></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information for Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;DXCM.&#8221;</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately 35 stockholders of record as of February&#160;1, 2024. The number of beneficial owners of our common stock at that date was substantially greater than the number of record holders because a large portion of our common stock is held of record through brokerage firms in &#8220;street name.&#8221;</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable future.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the accelerated share repurchase agreement with Bank of America, N.A., we issued 6,325 shares of our common stock in December 2023 in a private placement exempt from the registration requirements of the Securities Act in reliance on the exemption set forth in Section 4(a)(2) of the Securities Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other unregistered sales of equity securities which have not been previously disclosed in a quarterly report on Form 10-Q or a current report on Form 8-K during the last three fiscal years ended December&#160;31, 2023.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 24, 2023, our Board of Directors authorized and approved a share repurchase program of up to $500.0&#160;million of our outstanding common stock, with a repurchase period ending no later than October 31, 2024 (&#8220;2023 Share Repurchase Program&#8221;). Under the 2023 Share Repurchase Program, on October 31, 2023, we entered into an accelerated share repurchase agreement (&#8220;2023 ASR&#8221;) with Bank of America, N.A. (&#8220;BofA&#8221;) to repurchase shares of our common stock in an aggregate notional amount of up to $500.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9 &#8220;Employee Benefit Plans and Stockholders' Equity&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K for additional information about our share repurchases during the year ended December&#160;31, 2023.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about purchases by us of our shares of common stock during the three months ended December&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total number of shares purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average price paid per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total number of shares purchased as part of publicly announced program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maximum dollar value of shares that may yet be purchased under the program</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(in millions)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10/01/2023 - 10/31/2023</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,710,870&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,710,870&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11/01/2023 - 11/30/2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12/01/2023 - 12/31/2023</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Pursuant to the terms of the 2023 ASR, in October 2023, we paid BofA $500.0 million in cash and received an initial delivery of approximately 4.7 million shares of our common stock based on the closing market price on October 30, 2023 of $84.91. This initial delivery of shares represented approximately 80% of the notional amount of the 2023 ASR. On December 14, 2023, the 2023 ASR was settled. Based on the volume-weighted average price of our common stock, less a discount, of $106.28 during the term of the 2023 ASR, we owed BofA 6,325 shares of common stock. We elected to settle the forward contract by issuing 6,325 treasury shares on December 15, 2023 to BofA.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company Stock Price Performance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 Annual Report on Form 10-K included a comparison of the 5-year cumulative total return of our common stock with the Nasdaq Composite index and the Nasdaq Medical Equipment index. As a result of the discontinuation of the Nasdaq Medical Equipment index in 2022, we believe that the S&amp;P Health Care Equipment Select Industry index is a more appropriate index for comparison of our stock performance. Accordingly, the graph below compares the cumulative total stockholder return on our common stock with the cumulative total returns on the Nasdaq Composite index, the Nasdaq Medical Equipment index, the S&amp;P Health Care Equipment Select Industry index, and the S&amp;P 500 index over the five-year period ended December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph assumes that $100 was invested in Dexcom common stock and in each of the other indices on December&#160;31, 2018 and that all dividends were reinvested. The comparisons in the graph below are based on historical data and are not intended to forecast the possible future performance of Dexcom&#8217;s common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below and related information shall not be deemed &#8220;soliciting material&#8221; or be deemed to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:24.75pt"><img src="dxcm-20231231_g3.jpg" alt="2447" style="height:470px;margin-bottom:5pt;vertical-align:text-bottom;width:618px"/></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* $100 invested on December&#160;31, 2018 in stock or index, including reinvestment of any dividends.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DexCom, Inc.</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">100.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">182.59</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">308.61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">448.21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">378.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">414.32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">S&amp;P 500</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">100.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">131.49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">155.68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">200.37</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">164.08</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">207.21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">S&amp;P Health Care Equipment</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">100.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">122.72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">163.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">169.11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">129.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">122.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Nasdaq Composite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">100.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">136.69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">198.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">242.03</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">163.28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">236.17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Nasdaq Medical Equipment</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">100.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">97.52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">136.07</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">140.62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">94.93</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr></table></div><div id="i70f957301cc34339a22f629982cd0734_85"></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 6 - [RESERVED]</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 7 - MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This document, including the following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements that are not purely historical regarding Dexcom&#8217;s or its management&#8217;s intentions, beliefs, expectations and strategies for the future. These forward-looking statements fall within the meaning of the federal securities laws that relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Forward-looking statements are made as of the date of this report, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that could cause actual results to differ materially are more fully described under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report, elsewhere in this Annual Report, and in our other reports filed with the SEC. We assume no obligation to update any of the forward-looking statements after the date of this report or to conform these forward-looking statements to actual results. You should read the following discussion and analysis together with our consolidated financial statements and related notes in Part II, Item 8 of this Annual Report.</span></div><div id="i70f957301cc34339a22f629982cd0734_94"></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;border-bottom:1pt dotted #58a618;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:0.1%"/><td style="width:1.711%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Who We Are</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> integrated Continuous Glucose Monitoring System, or G6, in 2018 and more recently received marketing clearance from the FDA on the Dexcom G7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or G7,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in December 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;company,&#8221; or &#8220;Dexcom&#8221; refer to DexCom, Inc. and its subsidiaries.</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:0.1%"/><td style="width:1.711%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Global Presence</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built a direct sales organization in North America and certain international markets to call on health care professionals, such as endocrinologists, physicians and diabetes educators, who can educate and influence patient adoption of continuous glucose monitoring. To complement our direct sales efforts, we have entered into distribution arrangements in North America and several international markets that allow distributors to sell our products.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Future Developments</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Development:</span><span style="color:#ff671d;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration. Over the longer term, we plan to continue to develop and improve networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices. We also intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnerships:</span><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continue to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Opportunities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exploring how to extend our offerings to other opportunities, including for people with Type 2 diabetes that are non-insulin using, people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. Eventually, we may apply our technological expertise to products beyond glucose monitoring.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.012%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;border-bottom:1pt dotted #58a618;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as the reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in Note 1 &#8220;Organization and Significant Accounting Policies&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K, we believe that the following accounting estimates are most critical to a full understanding and evaluation of our reported financial results. Members of our senior management have discussed the development and selection of these critical accounting estimates and their disclosure in this Annual Report on Form 10-K with the Audit Committee of our Board of Directors.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacy Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate provisions for pharmacy rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or trends and channel inventory data. Estimates associated with rebates on products sold through our distributors under pharmacy benefits are the most significant component of our variable consideration estimates and most at risk for material adjustment because of the time delay between the recording of the provision and its ultimate settlement, an interval that generally ranges from 30 to 90 days, but can last up to one year. Due to this time lag, in any given period, our adjustments to reflect actual amounts can incorporate changes of estimates related to prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenue. An increase or decrease of 1% in our estimate of products sold subject to rebate during 2023, holding all other assumptions constant, would increase or decrease revenue by approximately $22.9 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 1 &#8220;Organization and Significant Accounting Policies&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Excess and Obsolete Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the value of our inventory on a quarterly basis and write down those inventories based on quality control testing data, obsolescence, or in excess of our forecasted demand to the lower of their cost or net realizable value. Our estimates of forecasted demand are based upon our analysis and assumptions including, but not limited to, expected product lifecycles, product development plans and historical usage by product. If actual market conditions are less favorable than our forecasts, or actual demand from our customers is lower than our estimates, we may be required to record additional inventory write-downs. If actual market conditions are more favorable than anticipated, inventory previously written down may be sold, resulting in lower cost of sales and higher income from operations than expected in that period.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our income taxes based on the various jurisdictions where we conduct business. Significant judgment is required in determining our worldwide income tax provision. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations and the potential for future adjustment of our uncertain tax positions by the Internal Revenue Service or other taxing jurisdictions. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, income taxes payable, and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability approach to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities as described in Note 1 &#8220;Organization and Significant Accounting Policies&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report. Significant judgment is required to evaluate the need for a valuation allowance against deferred tax assets. A valuation allowance is established when it is more likely than not that some or all of the deferred tax assets will not be realized. Realization of deferred tax assets is dependent upon future earnings in applicable tax jurisdictions. We maintain a valuation allowance on our California research and development tax credits and certain foreign intangible assets, as it is more likely than not that those deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize and measure benefits for uncertain tax positions using a two-step approach as described in Note 1 &#8220;Organization and Significant Accounting Policies&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required to evaluate uncertain tax positions and is based upon a number of factors, including changes in facts or circumstances, changes in tax law, correspondence with tax authorities during the course of audits and effective settlement of audit issues. Changes in the recognition or measurement of uncertain tax positions could result in material increases or decreases in our income tax expense in the period in which we make the change, which could have a material impact on our effective tax rate and operating results.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. We review the status of each significant matter quarterly and assess our potential financial exposure</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in the determination of whether a potential loss is probable, reasonably possible, or remote as well as in the determination of whether a potential exposure is reasonably estimable.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our judgments on the best information available at the time. As additional information becomes available, we reassess the potential liability related to our pending claims and litigation and may revise our estimates. Any revision of our estimates of potential liability could have a material impact on our financial position and operating results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:17.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.211%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview of Financial Results</span></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most important financial indicators that we use to assess our business are revenue, gross profit, operating income, net income, and operating cash flow.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Key Highlights for fiscal 2023 include the following:</span></div></td></tr><tr style="height:8pt"><td colspan="39" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gross Profit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#32ad10;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Cash Flow</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$3.62 billion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$2.29 billion</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$597.7 million</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$541.5 million</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$748.5 million</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">up 24% from 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">up 22% from 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">up 53% from 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">up 59% from 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">up 12% from 2022</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ended fiscal 2023 with cash, cash equivalents and short-term marketable securities totaling $2.72 billion.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</span></td></tr><tr><td colspan="3" style="display:none"/></tr></table><img src="dxcm-20231231_g4.jpg" alt="1162" style="height:340px;margin-bottom:5pt;vertical-align:text-bottom;width:405px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Financial Overview</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion related to the results of operations and changes in financial condition for fiscal 2022 compared to fiscal 2021 refer to &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of our 2022 Annual Report on Form 10-K, which was filed with the SEC on February&#160;9, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:36.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.889%"/><td style="width:0.1%"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Twelve Months Ended December&#160;31, 2023 Compared to Twelve Months Ended December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 - 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except per share amounts)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of Revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of Revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,622.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,909.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,333.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,026.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,288.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,883.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">405.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">484.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,185.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,007.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,691.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,491.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">597.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">391.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">710.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">390.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">319.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">341.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income per share</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.30&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.82&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.48&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The sum of the individual percentages may not equal the total due to rounding.</span></div></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">** Not meaningful</span></div></td></tr></table><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the revenue we generate from the sales of our products will fluctuate from quarter to quarter. We typically experience seasonality, with lower sales in the first quarter of each year compared to the immediately preceding fourth quarter. This seasonal sales pattern relates to U.S. annual insurance deductible resets and unfunded flexible spending accounts.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes direct labor and materials costs related to each product sold or produced, including assembly, test labor and scrap, as well as factory overhead supporting our manufacturing operations. Factory overhead includes facilities, material procurement and control, manufacturing engineering, quality assurance, supervision and management. These costs are primarily salary, fringe benefits, share-based compensation, facility expense, supplies and purchased services. All of our manufacturing costs are included in cost of sales. In addition, amortization of certain licensing related intangibles are also included in cost of sales.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses primarily consist of engineering and research expenses related to our sensing technology, clinical trials, regulatory expenses, quality assurance programs, employee compensation, and business process outsourcers.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense primarily relates to acquired technology and intellectual property and other acquired intangible assets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses primarily consist of employee compensation for our executive, financial, sales, marketing, information technology and administrative functions. Other significant expenses include commissions, marketing and advertising, IT software license costs, insurance, professional fees for our outside legal counsel and independent auditors, litigation expenses, patent application expenses and consulting expenses.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from equity investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity investments is comprised of realized gains from the sale of an equity investment.</span></div><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists primarily of interest and dividend income on our cash, cash equivalents and short-term marketable securities portfolio, foreign currency transaction gains and losses due to the effects of foreign currency fluctuations, and interest expense related to our senior convertible notes.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:17.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr style="height:20pt"><td colspan="6" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Twelve Months Ended December&#160;31, 2023 </span></div><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compared to </span></div><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Twelve Months Ended December&#160;31, 2022</span></div></td></tr><tr style="height:20pt"><td colspan="9" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base, partially offset by mix shift and price associated with the evolution of our channel and product strategy.</span></div><div style="padding-left:6pt"><span><br/></span></div><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposable sensor and other revenue comprised approximately 90% of total revenue and Reusable Hardware revenue comprised approximately 10% of total revenue for the twelve months ended December&#160;31, 2023. Disposable sensor and other revenue comprised approximately 87% of total revenue and Reusable Hardware revenue comprised approximately 13% of total revenue for the twelve months ended December&#160;31, 2022.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales &amp; Gross profit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales and gross profit increased primarily due to an increase in sales volume.</span></div><div style="padding-left:6pt"><span><br/></span></div><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in gross profit margin in 2023 compared to 2022 was primarily driven by the increase of the amortization of an intangible asset and price, product, and channel mix changes.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased primarily due to $33.7 million in compensation-related costs most notably due to higher headcount, partially offset by $15.9 million of lower third party and consulting fees primarily related to software development for new products and significant enhancements.</span></div><div style="padding-left:6pt"><span><br/></span></div><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense increased primarily due to $88.8 million in compensation-related costs most notably due to higher headcount, $37.8&#160;million in legal expense primarily related to a patent infringement lawsuit, and $36.6 million in advertising and marketing costs associated with global product launches.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, increased primarily due to $111.2 million in interest and dividend income on our cash, cash equivalents, and marketable securities portfolio. The increase in interest income was related to a change in market interest rates, as well as an increase in the average invested balances during 2023 compared to 2022.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense (benefit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded income tax expense on pre-tax book income for the twelve months ended December&#160;31, 2023 and December&#160;31, 2022. The income tax expense we recorded for 2023 is primarily attributable to income tax expense from normal, recurring operations as well as income taxes related to an intra-entity transfer of certain intellectual property partially offset by excess tax benefits recognized for share-based compensation for employees (net of disallowed executive compensation) and the Verily milestone payment, and generation of research and development tax credits. The income tax expense we recorded for 2022 is primarily attributable to income tax expense from normal, recurring operations partially offset by excess tax benefits recognized for employee share-based compensation (net of disallowed executive compensation) and the Verily milestone.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #58a618;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Overview, Capital Resources, and Capital Requirements</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity are our existing cash, cash equivalents and marketable securities, cash generated from operations, proceeds from our senior convertible notes issuances, and access to our Credit Facility. Our primary uses of cash have been for research and development programs, selling and marketing activities, capital expenditures, acquisitions of businesses, and debt service costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that cash provided by our operations may fluctuate in future periods as a result of a number of factors, including fluctuations in our operating results, working capital requirements and capital deployment decisions. We have historically invested our cash primarily in U.S. dollar-denominated, investment grade, highly liquid obligations of U.S. government agencies, commercial paper, corporate debt, and money market funds. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including but not limited to:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.25pt;text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:0.1%"/><td style="width:1.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.732%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The evolution of the international expansion of our business and the revenue generated by sales of our approved products and other future products;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to efficiently scale our operations to meet demand for our current and any future products;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our research and development efforts;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expenses we incur in manufacturing, developing, selling and marketing our products;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs, timing and risks of delays of additional regulatory approvals;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quality levels of our products and services;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The emergence of competing or complementary technological developments;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and timing of any collaborative, licensing and other arrangements that we may establish; and</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third-party reimbursement of our products for our customers;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate of progress and cost of our clinical trials and other development activities;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of businesses, products and technologies and our ability to integrate and manage any acquired businesses, products and technologies.</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that existing cash and short-term investments and cash flows from our future operations will generally be sufficient to fund our ongoing core business. As current borrowing sources become due, we may be required to access the capital markets for additional funding. As we assess inorganic growth strategies, we may need to supplement our internally generated cash flow with outside sources. In the event that we are required to access the debt market, we believe that we will be able to secure reasonable borrowing rates. As part of our liquidity strategy, we will continue to monitor our current level of earnings and cash flow generation as well as our ability to access the market in light of those earning levels.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our operations are located in the United States, and the majority of our sales since inception have been made in U.S. dollars. <span id="ic6237a5c8e2a4a3e934246be1ae5ee54_11414"></span>We will be exposed to additional foreign currency exchange risk related to our international operations as we expand our manufacturing internationally and as our business continues to increase in international markets. See &#8220;Foreign Currency Exchange Risk&#8221; in Part II, Item 7A of this Annual Report on Form 10-K for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Main Sources of Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and short-term marketable securities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and short-term marketable securities totaled $2.72 billion as of December&#160;31, 2023. None of those funds were restricted and $2.54 billion (approximately 93%) of those funds were located in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flow from Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December&#160;31, 2023, we had positive cash flows of $748.5 million from operating activities. We anticipate that we will continue to generate positive cash flows from operations for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received net proceeds of $1.19 billion in May 2020 from the 2025 Notes offering and net proceeds of $1.23 billion from the 2028 Notes offering. We used $282.6 million of the net proceeds from the offering of the 2025 Notes to repurchase a portion of our senior convertible notes due in 2022. We used $289.9 million of the net proceeds from the offering of the 2028 Notes to purchase capped call transactions and repurchase shares of our common stock in May 2023. We intend to use the remainder of the net proceeds from the 2025 Notes offering and 2028 Notes offering for general corporate purposes and capital expenditures, including working capital needs. We may also use the net proceeds to expand our current business through in-licensing or acquisitions of, or investments in, other businesses, products or technologies; however, we do not have any significant commitments with respect to any such acquisitions or investments at this time.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2028 Notes offering we purchased the 2028 Capped Calls. See Note 5 &#8220;Debt&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K for more information about our senior convertible notes and the 2028 Capped Calls.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had no outstanding borrowings, $7.4 million in outstanding letters of credit, and a total available balance of $192.6 million under the Amended Credit Agreement. We monitor counterparty risk associated with the institutional lenders that are providing the Credit Facility. We currently believe that the Credit Facility will be available to us should we choose to borrow under it. Revolving loans will be available for general corporate purposes, including working capital and capital expenditures. See Note 5 &#8220;Debt&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K for more details on the Revolving Credit Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Liquidity Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our short-term liquidity requirements primarily consist of regular operating costs, interest payments related to our senior convertible notes, capital expenditures for the development of our manufacturing facilities and office spaces, and short-term material cash requirements as described below. As of December&#160;31, 2023, we had a working capital ratio of 2.84 and a quick ratio of 2.38, which indicates that our current assets are more than enough to cover our short-term liabilities. We expect to have significant capital expenditures for the next year to scale-up capacity in Mesa, Arizona and drive our strategic initiatives of building out our manufacturing facilities and/or equipment in Malaysia and Ireland.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and marketable securities balances, projected cash contributions from our commercial operations, and borrowings under our Credit Facility will be sufficient to meet our anticipated seasonal working capital needs, all capital expenditure requirements, material cash requirements as described below, and other liquidity requirements associated with our operations for at least the next 12 months. We may use cash to repurchase Dexcom shares or for other strategic initiatives that strengthen our foundation for long-term growth.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Liquidity Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term liquidity requirements primarily consist of interest and principal payments related to our senior convertible notes, capital expenditures for the development of our manufacturing facilities and office spaces, and long-term material cash requirements as described below. As of December&#160;31, 2023, we had a debt-to-assets ratio of 0.39, which indicates that our total assets are more than enough to cover our short-term and long-term debts. As demand grows for our products, we will continue to expand global operations to meet demand through investments in manufacturing and operations. We expect to meet our long-term liquidity requirements from our main sources of liquidity as described above to support our future operations, capital expenditures, acquisitions, and other liquidity requirements associated with our operations beyond the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we have outstanding senior convertible notes that will mature in November 2025 and May 2028. However, the outstanding principal of our senior convertible notes could be converted into cash and/or shares of our common stock prior to maturity once certain conditions are met. See Note 5 &#8220;Debt&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for information on conversion rights prior to maturity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time in the ordinary course of business, we enter into a variety of purchase arrangements including but not limited to, purchase arrangements related to capital expenditures, components used in manufacturing, and research and development activities. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Commitments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 6 &#8220;Leases and Other Commitments&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued our outstanding senior convertible notes in May 2020 and May 2023. These obligations include both principal and interest for these notes. Although these notes mature in November 2025 and May 2028, respectively, they may be converted into cash and/or shares of our common stock prior to maturity if certain conditions are met. Any conversion prior to maturity can result in repayment of the principal amounts sooner than the scheduled repayment. See Note 5 &#8220;Debt&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for further discussion of the terms of our senior convertible notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to various leasing arrangements, primarily for office, manufacturing and warehouse space that expire at various times through December 2030, excluding any renewal options. We also have land leases in Penang, Malaysia for the build-out of our international manufacturing facility lease that expire through 2082. We anticipate incurring significant expenditures related to our Malaysia manufacturing facility and equipment over the next year and the build-out of the Ireland manufacturing facility and equipment over the next five years. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 6 &#8220;Leases and Other Commitments&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information about our leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5 &#8220;Debt&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information about the terms of the Credit Agreement, our senior convertible notes, and the 2028 Capped Calls.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our cash flows for the periods indicated. See the consolidated financial statements in Part II, Item 8 of this Annual Report for complete consolidated statements of cash flows for these periods.</span></div><div style="text-align:center"><img src="dxcm-20231231_g5.jpg" alt="11044" style="height:393px;margin-bottom:5pt;vertical-align:text-bottom;width:688px"/></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $2.72 billion in cash, cash equivalents and short-term marketable securities, which is an increase of $267.9 million compared to $2.46 billion as of December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary cash flows during the twelve months ended December&#160;31, 2023 and 2022 are described below. See the consolidated financial statements in Part II, Item 8 of this Annual Report for complete consolidated statements of cash flows for these periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"><tr><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:10.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:208.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:10.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:208.00pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Twelve Months Ended</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr style="height:50pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Cash Flows</span></td><td colspan="3" rowspan="2" style="border-right:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#32ad10;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$541.5 million of net income and $203.8 million of net non-cash adjustments, and a net increase of $3.2 million in changes of working capital balances</span></div></td><td colspan="3" rowspan="2" style="border-right:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#32ad10;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$341.2 million of net income and $301.6 million of net non-cash adjustments, and a net increase of $26.7 million in changes of working capital balances</span></div></td></tr><tr style="height:38pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net non-cash adjustments were primarily related to share-based compensation and depreciation and amortization.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net non-cash adjustments were primarily related to share-based compensation and depreciation and amortization.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:26pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Cash Flows</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$253.0 million in net purchases of marketable securities</span></div></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$364.8 million in capital expenditures</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$236.6 million in capital expenditures</span></div></td><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$138.5 million in net purchases of marketable securities</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$19.5&#160;million in purchases of equity investments</span></div></td><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.5 million in purchases of equity investments</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:38pt"><td colspan="3" rowspan="5" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Cash Flows</span></td><td colspan="3" rowspan="5" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#32ad10;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.23&#160;billion</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in proceeds from issuance of senior convertible notes, net of issuance costs</span></div></td><td colspan="3" rowspan="5" style="padding:0 1pt"/><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#32ad10;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$22.5 million in proceeds from issuance of common stock under our employee stock plans</span></div></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#32ad10;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26.6 million in proceeds from issuance of common stock under our employee stock plans</span></div></td><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$557.7 million in purchases of treasury stock</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$787.3&#160;million in payments for conversions of senior convertible notes</span></div></td><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.6 million in payments for financing leases</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$688.7 million in purchases of treasury stock</span></div></td><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:26pt"><td colspan="3" style="border-left:2pt solid #32ad10;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#434141;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$101.3&#160;million in purchases of capped call transactions</span></div></td><td colspan="3" style="border-left:2pt solid #32ad10;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span><br/></span></div><div id="i70f957301cc34339a22f629982cd0734_118"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of recently issued accounting pronouncements and the potential impact on our consolidated financial statements, if any, see Note 1 &#8220;Organization and Significant Accounting Policies&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report.</span></div><div id="i70f957301cc34339a22f629982cd0734_121"></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 7A - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div id="i70f957301cc34339a22f629982cd0734_124"></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is to preserve our capital for the purpose of funding operations while at the same time maximizing the income we receive from our investments without significantly increasing risk. To achieve these objectives, our investment policy allows us to maintain a portfolio of cash equivalents and short-term investments in a variety of securities, including money market funds, U.S. Treasury debt and corporate debt securities. Due to the short-term nature of our investments, we believe that we have no material exposure to interest rate risk. We do not use derivative financial instruments for speculation or trading purposes or for activities other than risk management.</span></div><div id="i70f957301cc34339a22f629982cd0734_127"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Price Sensitive Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Warrants could have a dilutive effect on our earnings per share to the extent that the price of our common stock during a given quarterly or annual measurement period exceeds the strike price of the warrants. The 2028 Capped Calls are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes and/or offset any cash payments that we are required to make in excess of the principal amount of converted 2028 Notes, with such reduction and/or offset subject to a cap. See Note 5 &#8220;Debt&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our operations are located in the United States, and the majority of our sales since inception have been made in U.S. dollars. Historically, our exposure to foreign currency fluctuations is more significant with respect to our revenue than our expenses, as a significant portion of our expenses are denominated in U.S. dollars, such as cost of sales and operating expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to additional foreign currency exchange risk related to our foreign operations as we are now manufacturing internationally and as our business continues to increase in markets outside of the United States. Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies, primarily the Australian Dollar, the British Pound, the Canadian Dollar, the Euro, and the Malaysian Ringgit, could adversely affect our financial results, including income and losses as well as assets and liabilities in addition to risks to our revenues, revenue growth rates, and gross profit margins.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We translate the financial statements of our international subsidiaries with functional currencies other than the U.S. dollar into the U.S. dollar for consolidation using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. We record net gains or losses resulting from the translation of these financial statements and the effect of exchange rate changes on intercompany receivables and payables of a long-term nature as a separate component of stockholders&#8217; equity. These adjustments will affect net income only upon sale or liquidation of the underlying investment in international subsidiaries. We also record exchange rate fluctuations resulting from the translation of the short-term intercompany balances between domestic entities and our international subsidiaries as foreign currency transaction gains or losses and include them in other income (expense), net in our consolidated statements of operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward contracts to hedge monetary assets and liabilities denominated in foreign currencies. These forward contracts are not designated as hedging instruments and generally mature in one month. The derivative gains and losses are included in other income (expense), net in our consolidated statements of operations. See Note 3 &#8220;Fair Value Measurements&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notional principal amounts provide one measure of the transaction volume outstanding as of period end, but they do not represent the amount of our exposure to market loss. Estimates of fair value are based on applicable and commonly used pricing models using prevailing financial market information. The amounts ultimately realized upon settlement of these financial instruments, together with the gains and losses on the underlying exposures, will depend on actual market conditions during the remaining life of the instruments. We monitor and manage our financial exposures due to exchange rate fluctuations as an integral part of our overall risk management program, which recognizes the unpredictability of financial markets and seeks to reduce potentially adverse effects on our financial results.</span></div><div id="i70f957301cc34339a22f629982cd0734_133"></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required is set forth under &#8220;Report of Independent Registered Public Accounting Firm,&#8221; &#8220;Consolidated Balance Sheets,&#8221; &#8220;Consolidated Statements of Operations,&#8221; &#8220; Consolidated Statements of Comprehensive Income,&#8221; &#8220;Consolidated Statements of Stockholders&#8217; Equity,&#8221; &#8220;Consolidated Statements of Cash Flows&#8221; and &#8220;Notes to Consolidated Financial Statements&#8221; on pages </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i70f957301cc34339a22f629982cd0734_199">F-10</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i70f957301cc34339a22f629982cd0734_370">F-4</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i70f957301cc34339a22f629982cd0734_370">3</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report and is incorporated into this Item 8 by reference.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The report of Dexcom&#8217;s independent registered public accounting firm (PCAOB ID:<ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-36">42</ix:nonNumeric>) with respect to the above-referenced financial statements and their report on internal control over financial reporting are included in Item 8 and Item 9A of this Form 10-K. Their consent appears as Exhibit 23.01 of this Form 10-K.</span></div><div id="i70f957301cc34339a22f629982cd0734_136"></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 9 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 9A - CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulations under the Exchange Act, require public companies to maintain &#8220;disclosure controls and procedures,&#8221; which are defined to mean a company&#8217;s controls and other procedures that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Exchange Act, is accumulated and timely communicated to management, including our Chief Executive Officer and Chief Financial Officer, recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation as of the end of the period covered by this report of the effectiveness of our disclosure controls and procedures. Based on their evaluation as of December&#160;31, 2023, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of such date for this purpose.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance to our management and Board of Directors regarding the preparation and fair presentation of published financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of the Chief Executive and Chief Financial Officers, assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2023. In making this assessment, our management used the criteria set forth by the 2013 Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8212;Integrated Framework. Based on this assessment, our management, with the participation of the Chief Executive and Chief Financial Officers, believes that, as of December&#160;31, 2023, our internal control over financial reporting is effective based on those criteria. The effectiveness of our internal control over financial reporting as of December&#160;31, 2023 has been audited by Ernst&#160;&amp; Young LLP, an Independent Registered Public Accounting Firm, as stated in their report which is included herein.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The certifications of our Chief Executive Officer and Chief Financial Officer required under Section&#160;302 of the Sarbanes-Oxley Act have been filed as Exhibits 31.01 and 31.02 to this report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitation on Effectiveness of Controls</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. The design of any control system is based, in part, upon the benefits of the control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these and other inherent limitations of control systems, we cannot guarantee that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div id="i70f957301cc34339a22f629982cd0734_3777"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of DexCom, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited DexCom, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, DexCom, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2023, based on the COSO criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of DexCom, Inc. as of December&#160;31, 2023 and 2022, the related consolidated statements of operations, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes and financial statement schedule listed in the Index at Item 15(a) and our report dated February&#160;8, 2024 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;8, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 9B - OTHER INFORMATION</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trading Plans</span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-37" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2023, the following Section 16 officers and directors adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408 of Regulation S-K of the Exchange Act):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Action</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Action Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Number of Shares to be Sold</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Date</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="ecd:TrdArrIndName" id="f-38">Matthew Dolan</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="ecd:TrdArrIndTitle" id="f-39">Executive Vice President, Strategy, Corporate Development and Dexcom Labs</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-40">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="ecd:TrdArrAdoptionDate" id="f-41">12/15/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-42">15,326</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/15/2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndName" id="f-43">Paul Flynn</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndTitle" id="f-44">Executive Vice President, Global Revenue</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-45">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrAdoptionDate" id="f-46">12/15/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-47">31,253</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/15/2024</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-8" name="ecd:TrdArrIndName" id="f-48">Girish Naganathan</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-8" name="ecd:TrdArrIndTitle" id="f-49">Executive Vice President, Chief Technology Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-8" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-50">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-8" name="ecd:TrdArrAdoptionDate" id="f-51">11/20/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-52">5,137</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/20/2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-10" name="ecd:TrdArrIndName" id="f-53">Steven R. Pacelli</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-10" name="ecd:TrdArrIndTitle" id="f-54">Executive Vice President and Managing Director, Dexcom Ventures</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-10" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-55">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-10" name="ecd:TrdArrAdoptionDate" id="f-56">11/27/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-57">15,000</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/23/2025</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="ecd:TrdArrIndName" id="f-58">Barry J. Regan</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="ecd:TrdArrIndTitle" id="f-59">Executive Vice President, Global Operations</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-60">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="ecd:TrdArrAdoptionDate" id="f-61">12/4/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-62">28,430</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/4/2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-14" name="ecd:TrdArrIndName" id="f-63">Kevin R. Sayer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-14" name="ecd:TrdArrIndTitle" id="f-64">Chairperson,&#160;President and Chief Executive Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-14" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-65">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-14" name="ecd:TrdArrAdoptionDate" id="f-66">12/12/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-67">100,965</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/12/2024</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-16" name="ecd:TrdArrIndName" id="f-68">Sadie M. Stern</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-16" name="ecd:TrdArrIndTitle" id="f-69">Executive Vice President, Chief Human Resources Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><ix:nonNumeric contextRef="c-16" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-70"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></ix:nonNumeric></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-16" name="ecd:TrdArrAdoptionDate" id="f-71">12/12/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-72">12,825</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/11/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrIndName" id="f-73">Sadie M. Stern</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrIndTitle" id="f-74">Executive Vice President, Chief Human Resources Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><ix:nonNumeric contextRef="c-18" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-75"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></ix:nonNumeric></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrTerminationDate" id="f-76">12/12/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-77">4,708</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/8/2024</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrIndName" id="f-78">Jereme M. Sylvain</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrIndTitle" id="f-79">Executive Vice President, Chief Financial Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-20" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-80">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrAdoptionDate" id="f-81">11/21/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-82">6,863</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/21/2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The actual number of shares sold may depend on the net shares vested as a result of tax withholding obligations, the vesting of certain performance-based stock units, the number of shares purchased under employee stock purchase plans, one or more limit orders, as applicable, and therefore, may not be determinable at this time.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the date listed in the table.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 12, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect, under the Exchange Act.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Rule 10b5-1 trading arrangements that were adopted in the above table are in accordance with our insider trading policy and actual sale transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No Section 16 officers or directors <ix:nonNumeric contextRef="c-22" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-83">adopted</ix:nonNumeric>, modified, or <ix:nonNumeric contextRef="c-22" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-84">terminated</ix:nonNumeric> a &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408 of Regulation S-K of the Exchange Act) during the three months ended December&#160;31, 2023.</span></div><div id="i70f957301cc34339a22f629982cd0734_145"></div><div style="margin-bottom:1pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 9C - DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i70f957301cc34339a22f629982cd0734_151"></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 10 - DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information concerning our directors required by this Item is incorporated by reference to the section in the Proxy Statement entitled &#8220;Proposal No.&#160;1 &#8211; Election of Directors.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information concerning our executive officers required by this Item is incorporated by reference to the section in the Proxy Statement entitled &#8220;Executive Officers.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written code of ethics for financial employees that applies to our principal executive officer, principal financial officer, principal accounting officer, controller and other employees of the finance department designated by our Chief Financial Officer. This code of ethics, titled the &#8220;Code of Conduct and Business Ethics,&#8221; is publicly available on our Internet website at https://dexcom.gcs-web.com/corporate-governance. The information contained on our Internet website is not incorporated by reference into this Annual Report on Form 10-K. When required by the rules of Nasdaq, or the SEC, we will disclose any future amendment to, or waiver of, any provision of the code of ethics for our principal executive officer and principal financial officer or any member or members of our board of directors on our website within four business days following the date of such amendment or waiver.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information concerning the Audit Committee of the Board of Directors required by this Item is incorporated by reference to the section of the Proxy Statement entitled &#8220;Committees of the Board and Meetings - Audit Committee.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information concerning material changes to the procedures by which stockholders may recommend nominees to the Board of Directors required by this Item is incorporated by reference to information set forth in the Proxy Statement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information concerning the Company&#8217;s insider trading policies and compliance with Section 16(a) required by this Item is incorporated by reference to the sections of the Proxy Statement entitled &#8220;Insider Trading Policy&#8221; and Delinquent Section 16(a) Reports, respectively.</span></div><div id="i70f957301cc34339a22f629982cd0734_154"></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 11 - EXECUTIVE COMPENSATION</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning executive compensation and our Compensation Committee is incorporated by reference to the sections in the Proxy Statement entitled &#8220;Compensation Discussion and Analysis,&#8221; &#8220;2023 Summary Compensation Table,&#8221; &#8220;Grants of Plan-Based Awards,&#8221; &#8220;Outstanding Equity Awards at December 31, 2023,&#8221; &#8220;2023 Option Awards Exercises and Stock Vested,&#8221; &#8220;Executive Nonqualified Deferred Compensation Plan,&#8221; &#8220;Employment, Severance and Change in Control Arrangements,&#8221; &#8220;2023 Director Compensation,&#8221; &#8220;Risks from Compensation Policies and Practices,&#8221; &#8220;Chief Executive Officer Pay Ratio,&#8221; &#8220;Compensation Committee Interlocks,&#8221; and &#8220;Compensation Committee Report.&#8221;</span></div><div id="i70f957301cc34339a22f629982cd0734_157"></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 12 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the sections in the Proxy Statement entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information.&#8221;</span></div><div id="i70f957301cc34339a22f629982cd0734_160"></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 13 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item with respect to director independence is incorporated by reference to the section in the Proxy Statement entitled &#8220;Corporate Governance - Director Independence&#8221;.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information concerning certain relationships and related transactions required by this Item is incorporated by reference to the section in the Proxy Statement entitled &#8220;Certain Transactions With Related Persons.&#8221;</span></div><div id="i70f957301cc34339a22f629982cd0734_163"></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 14 - PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information concerning principal accountant fees and services required by this Item is incorporated by reference to the section in the Proxy Statement entitled &#8220;Ratification of Independent Registered Public Accounting Firm.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PART IV</span></div><div><span><br/></span></div><div id="i70f957301cc34339a22f629982cd0734_169"></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 15 - EXHIBIT AND FINANCIAL STATEMENT SCHEDULES </span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The following documents are filed as part of this Annual Report:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements listed in Part II, Item&#160;8 of this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Financial Statement Schedules.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i70f957301cc34339a22f629982cd0734_376">Schedule II &#8211; Valuation and Qualifying Accounts</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statement schedules not listed above have been omitted because information required to be set forth therein is not applicable, not required, or the information required by such schedules is shown in the consolidated financial statements or the notes thereto.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Exhibits.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit Description</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporated by Reference</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Provided<br/>Herewith</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date of<br/>First Filing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000119312522171920/d368741dex31.htm">3.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000119312522171920/d368741dex31.htm">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000119312522171920/d368741dex31.htm">Restated Certificate of Incorporation of DexCom, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 10, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm">3.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm">2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000119312521169442/d185301dex33.htm">Amended and Restated Bylaws of DexCom, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 21, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm">4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm">Form of Specimen Certificate for </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm">DexCom, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm"> common stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-122454</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 24, 2005</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.01</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm">4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm">2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm">Indenture, dated November 30, 2018, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 3, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm">4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm">3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm">Indenture, dated May 14, 2020, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.25% Convertible Senior Notes due 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">May 15, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000119312523137248/d300995dex41.htm">4.4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000119312523137248/d300995dex41.htm">Indenture, dated May 5, 2023, between DexCom, Inc. and U.S. Bank Trust Company, National Association (including the form of 0.375% Convertible Senior Notes due 2028).</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">May 5, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex45-securitie.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex45-securitie.htm">Description of Securities Registered Under Section 12 of the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm">10.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm">Offer letter between DexCom, Inc. and Kevin Sayer, dated May&#160;3, 2011.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 3, 2011</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm">Sublease between DexCom, Inc. and Entropic Communications, LLC</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm"> dated February 1, 2016.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 27, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.36</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm">10.3*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm">DexCom, Inc. Executive Deferred Compensation Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 4, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.02</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm">10.4**</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm">Third Amendment to Office Lease between DexCom, Inc. and John Hancock Life Insurance Company, dated January 9, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 13, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm">10.5*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm">Form of Indemnity Agreement between DexCom, Inc. and each of its directors and executive officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 11, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.43</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm">10.6*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm">DexCom, Inc. Incentive Bonus Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 17, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm">10.7</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm">Second Amended and Restated Credit Agreement dated October 13, 2021 by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative Agent.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 14, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1009-officel.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1009-officel.htm">Office Lease Agreement, dated March 31, 2006, between DexCom, Inc. and Kilroy Realty, L.P., as amended on August 18, 2010 and October 1, 2014.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 9, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.09</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm">10.9**</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm">Fourth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated September 9, 2019, as amended on October 21, 2019, May 25, 2021, and December 23, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 9, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000119312523149463/d446905dex101.htm">10.10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1019-2015emp.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000119312523149463/d446905dex101.htm">DexCom, Inc. Amended and Restated Severance and Change in Control Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 19, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355723000174/dxcm6302023ex1006-firstame.htm">10.11</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1093557/000109355723000174/dxcm6302023ex1006-firstame.htm">First Amendment to Second Amended and Restated Credit Agreement, dated June 1, 2023 by and between DexCom, Inc. and JPMorgan Chase Bank National Association.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-51222</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 27, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex1012-2015emp.htm">10.12*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex1012-2015emp.htm">2015 Employee Stock Purchase Plan and forms of subscription agreements.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex1013-amended.htm">10.13*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex1013-amended.htm">Amended and Restated 2015 Equity Incentive Plan and forms of award agreements.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex1014-amended.htm">10.14**</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex1014-amended.htm">Amended and Restated Collaboration and License Agreement, dated November 20, 2018, by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex191-procedur.htm">19.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex191-procedur.htm">Procedures and Guidelines</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex191-procedur.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex191-procedur.htm">Governing</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex191-procedur.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex191-procedur.htm">Securities Trades by Company Personnel</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex191-procedur.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex2101_12312023.htm">21.01</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex2101_12312023.htm">List of Subsidiaries.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex2301_12312023.htm">23.01</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex2301_12312023.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.01</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Power of Attorney (see signature page of this Form 10-K).</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023exhibit3101.htm">31.01</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023exhibit3101.htm">Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023exhibit3102.htm">31.02</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023exhibit3102.htm">Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023exhibit3201.htm">32.01***</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023exhibit3201.htm">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023exhibit3202.htm">32.02***</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023exhibit3202.htm">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex971-compensa.htm">97.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dxcm12312023ex971-compensa.htm">Compensation Recovery Policy.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:4.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Represents a management contract or compensatory plan, contract or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is not deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that Dexcom specifically incorporates it by reference.</span></div></td></tr></table></div><div id="i70f957301cc34339a22f629982cd0734_172"></div><div style="margin-bottom:1pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 16 - FORM 10-K SUMMARY</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i70f957301cc34339a22f629982cd0734_175"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DEXCOM, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: February&#160;8, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ JEREME M. SYLVAIN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Jereme M. Sylvain,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Executive Vice President and Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin R. Sayer and Jereme M. Sylvain, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each of said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitutes, may do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.176%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Date</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;KEVIN R. SAYER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board of Directors, President and Chief&#160;Executive&#160;Officer (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kevin R. Sayer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;JEREME M. SYLVAIN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jereme M. Sylvain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;MARK G. FOLETTA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lead Independent Director<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mark G. Foletta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;STEVEN R. ALTMAN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Steven R. Altman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;NICHOLAS AUGUSTINOS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nicholas Augustinos</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;RICHARD A. COLLINS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Richard A. Collins</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;KAREN DAHUT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Karen Dahut</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;RIMMA DRISCOLL</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rimma Driscoll</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;BRIDGETTE P. HELLER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bridgette P. Heller</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;BARBARA E. KAHN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Barbara E. Kahn</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;KYLE MALADY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kyle Malady</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;ERIC J. TOPOL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 8, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eric J. Topol, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#32ad10;border-top:1pt solid #32ad10;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">DexCom, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#32ad10;border-bottom:1pt solid #32ad10;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_181">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-<a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_181">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_184">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-<a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_184">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_187">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-<a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_187">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_190">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-<a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_190">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_193">Consolidated Statements of Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-<a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_193">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_196">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-<a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_196">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_199">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-<a style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i70f957301cc34339a22f629982cd0734_199">10</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of DexCom, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of DexCom, Inc. (the Company) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;8, 2024 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosures to which it relates.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimation of variable consideration for revenue recognition</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:59pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">As discussed in Note 1 of the consolidated financial statements, the Company includes an estimate of variable consideration in the calculation of the transaction price at the time of sale. The Company estimates reductions for pharmacy rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or trends and channel inventory data.</span></div></td></tr><tr style="height:50pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s determination of variable consideration relating to pharmacy rebates involved a high degree of subjectivity in evaluating management&#8217;s estimates. In estimating pharmacy rebates, management applies contracted rates to estimates of products sold subject to rebate, known market events or trends and channel inventory data.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.357%"/><td style="width:0.1%"/></tr><tr style="height:41pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s processes to determine pharmacy rebates, including the underlying assumptions.</span></div></td></tr><tr style="height:98pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures also included, among others, evaluating the significant assumptions and the accuracy and completeness of the underlying data used in management&#8217;s calculations. This included testing contractual rates, management&#8217;s estimates of products sold subject to rebate, and inventory held by third parties at the end of the period, through a combination of underlying data validation by inspection of source documents, agreement to underlying contracts, and review for consistency against historical data. In addition, we inspected the results of the Company&#8217;s analysis of pharmacy rebates claimed and evaluated the estimates made based on historical experience.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-93">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2000.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-94">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;8, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.368%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DexCom, Inc.</span></div></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.253%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except par value data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-95">566.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-96">642.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:DebtSecuritiesAvailableForSaleAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-97">2,157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:DebtSecuritiesAvailableForSaleAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-98">1,813.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-99">973.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-100">713.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-101">559.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-102">306.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-103">168.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-104">192.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-105">4,425.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-106">3,668.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-107">1,113.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-108">1,055.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-109">71.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-110">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-111">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-112">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-113">134.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-114">173.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Deferred tax assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-115">419.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-116">341.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-117">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-118">47.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-119">6,264.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-120">5,391.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-121">1,345.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="6" id="f-122">901.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-123">171.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-124">134.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current portion of long-term senior convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:ConvertibleNotesPayableCurrent" scale="6" id="f-126">772.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Short-term operating lease liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-127">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-128">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-129">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-130">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-131">1,556.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-132">1,839.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Long-term senior convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-133">2,434.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-134">1,197.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-135">80.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-136">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-137">125.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-138">128.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-139">4,195.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-140">3,259.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-24" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-141"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-25" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-142"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-143"><ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-144">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-145"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-146">5.0</ix:nonFraction></ix:nonFraction> million shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-147"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-148"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-149"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-150">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="f-151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-153"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-154">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-155"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-156">800.0</ix:nonFraction></ix:nonFraction> million shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-157">407.2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-158">385.4</ix:nonFraction> million shares issued and outstanding, respectively, at December&#160;31, 2023; and <ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-159">393.2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-160">386.3</ix:nonFraction> million shares issued and outstanding, respectively, at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:CommonStockValueOutstanding" scale="6" id="f-161">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:CommonStockValueOutstanding" scale="6" id="f-162">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-163">3,514.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-164">2,258.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-165">16.7</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-166">11.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-167">1,021.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-168">479.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-5" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="f-169">21.8</ix:nonFraction> million shares at December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="f-170">6.9</ix:nonFraction> million shares at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-171">2,451.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="f-172">595.0</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-173">2,068.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-174">2,131.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-175">6,264.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-176">5,391.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DexCom, Inc.</span></div></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-177">3,622.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-178">2,909.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-179">2,448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-180">1,333.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-181">1,026.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-182">768.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-183">2,288.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-184">1,883.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-185">1,680.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-186">505.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-187">484.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-188">517.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborative research and development fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:CollaborativeResearchAndDevelopmentFee" format="ixt:fixed-zero" scale="6" id="f-189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:CollaborativeResearchAndDevelopmentFee" format="ixt:fixed-zero" scale="6" id="f-190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:CollaborativeResearchAndDevelopmentFee" scale="6" id="f-191">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-192">1,185.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-193">1,007.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-194">810.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-195">1,691.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-196">1,491.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-197">1,414.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-198">597.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-199">391.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-200">265.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-201">112.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-202">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-203">9.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-204">710.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-205">390.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-206">256.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-207">168.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-208">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-209">39.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-210">541.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-211">341.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-212">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-213">1.40</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-214">0.88</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-215">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used to compute basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-216">386.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-217">389.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-218">386.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income per share</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-219">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-220">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-221">0.53</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used to compute diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-222">425.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-223">427.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-224">428.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DexCom, Inc.</span></div></td></tr><tr><td colspan="3" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-225">541.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-226">341.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-227">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translation adjustments and other</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-228">9.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-229">9.8</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-230">1.0</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain (loss) on marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-231">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-232">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-233">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-234">5.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-235">12.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-236">2.7</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-237">536.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-238">329.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-239">214.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_193"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.140%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DexCom, Inc.</span></div></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.562%"/><td style="width:0.1%"/></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-240">384.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-241">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-242">1,726.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-243">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-244">78.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-245">100.0</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-246">1,551.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="f-247">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:fixed-zero" scale="6" id="f-248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock for Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-249">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-250">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-251">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax benefit related to Senior Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" scale="6" id="f-252">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" scale="6" id="f-253">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversions of 2023 Notes</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="6" id="f-254">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="f-255">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="f-256">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="f-257">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit of note hedge upon conversions of 2023 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-5" name="dxcm:SharesReceivedFromExerciseOfNoteHedge" scale="6" id="f-258">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" sign="-" name="dxcm:SharesReceivedFromBenefitOfNoteHedgeValue" scale="6" id="f-259">130.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="dxcm:SharesReceivedFromBenefitOfNoteHedgeValue" scale="6" id="f-260">130.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:SharesReceivedFromBenefitOfNoteHedgeValue" format="ixt:fixed-zero" scale="6" id="f-261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-262">113.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-263">113.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaborative research and development fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" scale="6" id="f-264">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" scale="6" id="f-265">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-266">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-267">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-268">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-269">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-270">388.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-271">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-272">2,108.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-273">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-274">138.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-275">206.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-276">2,042.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="f-277">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:fixed-zero" scale="6" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock for Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-279">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-280">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-281">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone" scale="6" id="f-282">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" sign="-" name="dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones" scale="6" id="f-283">189.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones" scale="6" id="f-284">189.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones" scale="6" id="f-285">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of treasury stock</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-286">6.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-287">557.7</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-288">557.7</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax benefit related to Senior Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" scale="6" id="f-289">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" scale="6" id="f-290">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversions of 2023 Notes</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="6" id="f-291">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="f-292">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="f-293">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="f-294">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit of note hedge upon conversions of 2023 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="dxcm:SharesReceivedFromExerciseOfNoteHedge" scale="6" id="f-295">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" sign="-" name="dxcm:SharesReceivedFromBenefitOfNoteHedgeValue" scale="6" id="f-296">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="dxcm:SharesReceivedFromBenefitOfNoteHedgeValue" scale="6" id="f-297">33.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:SharesReceivedFromBenefitOfNoteHedgeValue" format="ixt:fixed-zero" scale="6" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-299">126.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-300">126.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Capitalization of sales-based milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" scale="6" id="f-301">152.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" scale="6" id="f-302">152.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-303">341.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-304">341.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-305">12.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-306">12.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-307">386.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-308">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-309">2,258.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-310">11.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-311">479.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-312">595.0</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-313">2,131.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="f-314">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:fixed-zero" scale="6" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock for Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="f-316">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-317">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="f-318">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone" scale="6" id="f-319">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones" scale="6" id="f-320">323.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones" scale="6" id="f-321">323.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones" scale="6" id="f-322">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of treasury stock, including excise tax</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-323">6.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-324">0.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-325">689.0</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-326">689.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax benefit related to Senior Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" scale="6" id="f-327">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" scale="6" id="f-328">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversions of 2023 Notes</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="6" id="f-329">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="f-330">13.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="f-331">13.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Benefit of note hedge upon conversions of 2023 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-5" name="dxcm:SharesReceivedFromExerciseOfNoteHedge" scale="6" id="f-332">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="dxcm:SharesReceivedFromBenefitOfNoteHedgeValue" format="ixt:num-dot-decimal" scale="6" id="f-333">1,496.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="dxcm:SharesReceivedFromBenefitOfNoteHedgeValue" format="ixt:num-dot-decimal" scale="6" id="f-334">1,490.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="dxcm:SharesReceivedFromBenefitOfNoteHedgeValue" scale="6" id="f-335">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of capped call transactions, net of tax</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" scale="6" id="f-336">76.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" scale="6" id="f-337">76.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-338">150.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-339">150.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-340">541.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-341">541.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-342">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-343">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-344">385.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-345">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-346">3,514.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-347">16.7</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-348">1,021.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-349">2,451.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-350">2,068.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_196"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DexCom, Inc.</span></div></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating activities</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-351">541.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-352">341.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-353">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net income to cash provided by operating activities:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-354">186.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-355">155.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-356">102.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-357">150.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-358">126.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-359">113.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Collaborative research and development fee</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:CollaborativeResearchAndDevelopmentFee" format="ixt:fixed-zero" scale="6" id="f-360">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:CollaborativeResearchAndDevelopmentFee" format="ixt:fixed-zero" scale="6" id="f-361">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:CollaborativeResearchAndDevelopmentFee" scale="6" id="f-362">87.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-365">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaidInKindInterest" scale="6" id="f-366">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:PaidInKindInterest" scale="6" id="f-367">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaidInKindInterest" scale="6" id="f-368">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Realized (gain) loss on equity investment</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-369">1.9</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-370">0.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-371">11.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-372">55.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-373">21.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-374">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-cash income and expenses</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-375">83.9</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-376">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-377">43.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-378">260.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-379">199.9</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-380">75.5</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-381">252.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-382">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-383">112.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-384">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-385">131.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-386">21.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" scale="6" id="f-387">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" scale="6" id="f-388">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" scale="6" id="f-389">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-390">466.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-391">295.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-392">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="f-393">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="f-394">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="f-395">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenue and other liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" scale="6" id="f-396">2.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" scale="6" id="f-397">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" scale="6" id="f-398">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-399">748.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-400">669.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-401">442.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investing activities</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-402">3,200.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-403">2,266.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-404">2,473.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from sale and maturity of marketable securities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-405">2,947.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-406">2,127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-407">2,666.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-408">236.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-409">364.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-410">389.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-412">3.9</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-413">30.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-414">17.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-415">14.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-416">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-417">507.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-418">521.5</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-419">216.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-420">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-421">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-422">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-423">688.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-424">557.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from issuance of convertible notes, net of issuance costs</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-426">1,230.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="6" id="f-427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="6" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases of capped call transactions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:PaymentsForPurchasesOfCappedCallTransactions" scale="6" id="f-429">101.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:PaymentsForPurchasesOfCappedCallTransactions" format="ixt:fixed-zero" scale="6" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:PaymentsForPurchasesOfCappedCallTransactions" format="ixt:fixed-zero" scale="6" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments for conversions of senior convertible notes</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="f-432">787.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-435">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-436">17.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-437">9.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-438">318.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-439">552.5</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-440">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-441">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-442">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-443">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-444">75.8</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-445">410.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-446">235.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-447">643.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-448">1,053.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-449">818.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-450">567.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-451">643.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-452">1,053.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Reconciliation of cash, cash equivalents and restricted cash, end of period:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-453">566.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-454">642.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-455">1,052.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-456">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-457">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-458">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-459">567.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-460">643.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-461">1,053.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supplemental disclosure of non-cash investing and financing transactions:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issued for repurchase and conversions of senior convertible notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="f-462">1,501.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="f-463">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="f-464">157.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares received under note hedge upon conversion of 2023 Notes</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:TreasuryStockValueBenefitReceivedFromNoteHedge" format="ixt:num-dot-decimal" scale="6" id="f-465">1,490.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:TreasuryStockValueBenefitReceivedFromNoteHedge" scale="6" id="f-466">33.5</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:TreasuryStockValueBenefitReceivedFromNoteHedge" scale="6" id="f-467">130.8</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition of property and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="6" id="f-468">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="6" id="f-469">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="6" id="f-470">45.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid during the year for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-471">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-472">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="f-473">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid during the year for income taxes</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-474">212.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-475">114.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-476">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DexCom, Inc.</span></div></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr></table></div><div id="i70f957301cc34339a22f629982cd0734_202"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-477" continuedAt="f-477-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;border-bottom:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. Organization and Significant Accounting Policies</span></td></tr></table></div></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_205"></div><ix:continuation id="f-477-1" continuedAt="f-477-2"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DexCom, Inc. is a medical device company that develops and markets continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Unless the context requires otherwise, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;company,&#8221; or &#8220;Dexcom&#8221; refer to DexCom, Inc. and its subsidiaries.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_208"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-479" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-478" escape="true"><ix:continuation id="f-477-2" continuedAt="f-477-3"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of DexCom, Inc. and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. We have reclassified certain amounts previously reported in our financial statements to conform to the current presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash. For international subsidiaries whose functional currencies are the local currencies, we translate the financial statements into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. We include translation-related adjustments in comprehensive income and in accumulated other comprehensive loss in the equity section of our consolidated balance sheets. We record gains and losses resulting from transactions with customers and vendors that are denominated in currencies other than the functional currency and from certain intercompany transactions in other income (expense), net in our consolidated statements of operations.</span></div></ix:continuation></ix:nonNumeric></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_214"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-480" escape="true"><ix:continuation id="f-477-3" continuedAt="f-477-4"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires us to make certain estimates and assumptions that affect the amounts reported in our consolidated financial statements and the disclosures made in the accompanying notes. Areas requiring significant estimates include rebates, excess or obsolete inventories and the valuation of inventory, accruals for litigation contingencies, and the amount of our worldwide tax provision and the realizability of deferred tax assets. Despite our intention to establish accurate estimates and use reasonable assumptions, actual results may differ from our estimates.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_217"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-481" continuedAt="f-481-1" escape="true"><ix:continuation id="f-477-4" continuedAt="f-477-5"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Uses unadjusted quoted prices that are available in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Uses inputs other than quoted prices included in Level&#160;1 that are observable, either directly or indirectly, through correlation with market data. These include quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Uses unobservable inputs that are supported by little or no market activity and that are significant to the determination of fair value. Level 3 assets and liabilities include those whose fair values are determined using pricing models, discounted cash flow methodologies, or similar valuation techniques and significant judgment or estimation.</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-481-1"><ix:continuation id="f-477-5" continuedAt="f-477-6"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of most of our cash equivalents using Level 1 inputs. We estimate the fair value of our marketable equity securities using Level 1 inputs and we estimate the fair value of our marketable debt securities using Level 2 inputs. We carry our marketable securities at fair value. We carry our other financial instruments, such as cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities, at cost, which approximates the related fair values due to the short-term maturities of these instruments. See Note 3 &#8220;Fair Value Measurements&#8221; to the consolidated financial statements for more information.</span></div></ix:continuation></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_220"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-482" escape="true"><ix:continuation id="f-477-6" continuedAt="f-477-7"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments with a maturity of <ix:nonNumeric contextRef="c-1" name="dxcm:MaturityThresholdOfInvestmentsClassifiedToCashEquivalents" format="ixt-sec:durday" id="f-483">90</ix:nonNumeric> days or less at the time of purchase to be cash equivalents.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_223"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-484" escape="true"><ix:continuation id="f-477-7" continuedAt="f-477-8"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have classified our marketable securities with remaining maturity at purchase of more than three months and remaining maturities of one year or less as short-term marketable securities. We have also classified marketable securities with remaining maturities of greater than one year as short-term marketable securities based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate realized gains or losses on our marketable securities using the specific identification method. We carry our marketable debt securities at fair value with unrealized gains and losses reported as a separate component of stockholders&#8217; equity in our consolidated balance sheets and included in comprehensive income. Interest income and realized gains and losses on marketable debt securities are included in other income (expense), net in our consolidated statements of operations. We carry our marketable equity securities at fair value with realized and unrealized gains and losses reported in income (loss) from equity investments in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in various types of debt securities, including debt securities in government-sponsored entities, corporate debt securities, U.S. Treasury securities, supranational securities, and commercial paper. We do not generally intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. See Note 3 &#8220;Fair Value Measurements&#8221; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-Term Marketable Securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 4 &#8220;Balance Sheet Details and Other Financial Information&#8221; to the consolidated financial statements for more information on our marketable securities.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_226"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-485" escape="true"><ix:continuation id="f-477-8" continuedAt="f-477-9"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are generally recorded at the invoiced amount, net of prompt pay discounts, for distributors and at net realizable value for direct customers, which is determined using estimates of claim denials and historical reimbursement experience without regard to aging category. Accounts receivable are not interest bearing. We evaluate the creditworthiness of significant customers based on historical trends, the financial condition of our customers, and external market factors. We generally do not require collateral from our customers. We maintain an allowance for doubtful accounts for potential credit losses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a customer account is uncollectible.&#160;Generally, receivable balances that are more than one year past due are deemed uncollectible.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_229"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-486" escape="true"><ix:continuation id="f-477-9" continuedAt="f-477-10"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Significant Customers</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term marketable securities, and accounts receivable. We limit our exposure to credit risk by placing our cash and investments with a few major financial institutions. We have also established guidelines regarding diversification of our investments and their maturities that are designed to maintain principal and maximize liquidity. We review these guidelines periodically and modify them to take advantage of trends in yields and interest rates and changes in our operations and financial position.</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-487" escape="true"><ix:continuation id="f-477-10" continuedAt="f-477-11"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the percentages of total revenue or gross accounts receivable for customers that represent 10% or more of the respective amounts for the periods shown:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer A</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-488">35</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-489">32</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-67" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-490">28</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-491">20</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-492">19</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-493">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-494">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-495">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer C</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-496">30</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-497">26</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-498">21</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-499">23</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-500">17</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-501">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-502">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-503">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-504">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-505">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer E</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-506">10</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Less than 10%</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">** Total revenue for each customer is net of fees, cash discounts, and rebates directly allocable to that customer. Rebates paid to other entities are excluded; therefore, the combined value may exceed 100%.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_232"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-507" escape="true"><ix:continuation id="f-477-11" continuedAt="f-477-12"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value on a part-by-part basis that approximates first in, first out. We capitalize inventory produced in preparation for commercial launches when it becomes probable that the product will receive regulatory approval and that the related costs will be recoverable through the commercialization of the product. A number of factors are considered, including the status of the regulatory application approval process, management&#8217;s judgment of probable future commercial use, and net realizable value. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record adjustments to inventory for potential excess or obsolete inventory, as well as inventory that does not pass quality control testing, in order to state inventory at net realizable value. Factors influencing these adjustments include inventories on hand and on order compared to estimated future usage and sales for existing and new products, as well as judgments regarding quality control testing data and assumptions about the likelihood of scrap and obsolescence. Once written down the adjustments are considered permanent and are not reversed until the related inventory is disposed of or sold.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products require customized products and components that currently are available from a limited number of sources. We purchase certain components and materials from single sources due to quality considerations, costs or constraints resulting from regulatory requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our inventory reserves have been adequate to cover our actual losses. However, if actual product life cycles, product quality or market conditions differ from our assumptions, additional inventory adjustments that would increase cost of sales could be required.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_235"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-508" continuedAt="f-508-1" escape="true"><ix:continuation id="f-477-12" continuedAt="f-477-13"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization. We capitalize additions and improvements and expense maintenance and repairs as incurred. We also capitalize certain costs incurred for the development of enterprise-level business and finance software that we use internally in our operations. Costs incurred in the application development phase are capitalized while costs related to planning and other preliminary project activities and to post-implementation activities are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate depreciation using the straight-line method over the estimated useful lives of the assets. Estimated useful lives are generally <span style="-sec-ix-hidden:f-509">three</span> to <ix:nonNumeric contextRef="c-85" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-510">five years</ix:nonNumeric> for computer software and hardware, including internal use software, <span style="-sec-ix-hidden:f-511">four</span> to <ix:nonNumeric contextRef="c-87" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-512">fifteen years</ix:nonNumeric> for machinery and equipment, and <ix:nonNumeric contextRef="c-88" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-513">five years</ix:nonNumeric> for furniture and fixtures. Leasehold and land improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Buildings are amortized over the shorter of the ownership of the building or <ix:nonNumeric contextRef="c-89" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-514">forty years</ix:nonNumeric>. We include the amortization of assets that are recorded under finance leases in depreciation expense. On retirement or disposition, the asset cost and related accumulated depreciation are removed from our consolidated balance sheets and any gain or loss is recognized in our consolidated statements of operations.</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-508-1"><ix:continuation id="f-477-13" continuedAt="f-477-14"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the recoverability of the asset by comparing the carrying amount to the future undiscounted cash flows that we expect the asset to generate. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.</span></div></ix:continuation></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_238"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-515" continuedAt="f-515-1" escape="true"><ix:continuation id="f-477-14" continuedAt="f-477-15"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record goodwill when the fair value of consideration transferred in a business combination exceeds the fair value of the identifiable assets acquired and liabilities assumed. Goodwill and other intangible assets that have indefinite useful lives are not amortized, but are tested annually for impairment during the fourth fiscal quarter and whenever events or changes in circumstances indicate that it is more likely than not that the fair value is less than the carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business, and an adverse action or assessment by a regulator.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with Dexcom&#8217;s reporting structure and the availability of discrete financial information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform the first step of our annual impairment analysis by either comparing a reporting unit&#8217;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#8217;s fair value from the last quantitative assessment to determine if there is potential impairment. We may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#8217;s estimated fair value was significantly in excess of the carrying value of its net assets and we do not believe there have been significant changes in the reporting unit&#8217;s operations that would significantly decrease its estimated fair value or significantly increase its net assets.&#160;If a quantitative assessment is performed the evaluation includes management estimates of cash flow projections based on internal future projections&#160;and/or use of a market approach by looking at market values of comparable companies. Key assumptions&#160;for these projections include revenue growth, future gross margin and operating margin growth, and weighted cost of capital and terminal growth rates. The revenue and margin growth are based on increased sales of new and existing products as we maintain investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements&#160;to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including the timing and probability of regulatory approvals for our products to be commercialized. We also consider Dexcom&#8217;s market capitalization as a part of our analysis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the estimated fair value of a reporting unit exceeds the carrying amount of the net assets assigned to that unit, goodwill is not impaired and no further analysis is required. If the carrying value of the net assets assigned to a reporting unit exceeds the estimated fair value of the unit, we perform the second step of the impairment test. In this step we allocate the fair value of the reporting unit calculated in step one to all of the assets and liabilities of that unit, as if we had just acquired the reporting unit in a business combination. The excess of the fair value of the reporting unit over the total amount allocated to the assets and liabilities represents the implied fair value of goodwill. If the carrying amount of a reporting unit&#8217;s goodwill exceeds its implied fair value, we would record an impairment loss equal to the difference. We recorded <ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-516"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-517"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-518">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> significant goodwill impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in goodwill for the twelve months ended December&#160;31, 2023 and 2022 primarily consisted of translation adjustments on our foreign currency denominated goodwill. </span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_241"></div><ix:continuation id="f-515-1" continuedAt="f-515-2"><ix:continuation id="f-477-15" continuedAt="f-477-16"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are included in intangibles and other assets, net in our consolidated balance sheets. We amortize intangible assets with a finite life, such as the customer relationships, acquired technology and intellectual property, trademarks and trade name, and other intangibles, on a straight-line basis over their estimated useful lives, which range from <span style="-sec-ix-hidden:f-519">one</span> to <ix:nonNumeric contextRef="c-91" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-520">seven years</ix:nonNumeric>. We review intangible assets that have finite lives and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-515-2"><ix:continuation id="f-477-16" continuedAt="f-477-17"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For transactions other than a business combination, we also capitalize as intangible assets the cost of certain milestones payable by us to collaborative partners and incurred at or after the product has obtained regulatory approval for marketing. The intangible assets associated with these milestones are amortized over the remaining estimated useful life of the underlying asset.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded <ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-521"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-522"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-523">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> significant intangible asset impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.</span></div></ix:continuation></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_244"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-524" escape="true"><ix:continuation id="f-477-17" continuedAt="f-477-18"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. The effect of a change in tax rate on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under tax law and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal and state income tax returns in the United States and income tax returns in various other foreign jurisdictions with varying statutes of limitations. Due to net operating losses incurred, our income tax returns from inception to date are subject to examination by taxing authorities. We recognize interest expense and penalties related to income tax matters, including unrecognized tax benefits, as a component of income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income tax expense for basis differences related to global intangible low-taxed income ("GILTI") as a period cost if and when incurred. GILTI is a category of income that is earned abroad by U.S.-controlled foreign corporations (CFCs) and is subject to special treatment under the U.S. tax code.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_247"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StandardProductWarrantyPolicy" id="f-525" escape="true"><ix:continuation id="f-477-18" continuedAt="f-477-19"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Warranty Accrual</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated warranty costs associated with a product are recorded at the time revenue is recognized. We estimate future warranty costs by analyzing historical warranty experience for the timing and amount of returned product, and expectations for future warranty activity based on changes and improvements to the product or process that are in place or will be in place in the future. We evaluate these estimates on at least a quarterly basis to determine the continued appropriateness of our assumptions.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_250"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-526" escape="true"><ix:continuation id="f-477-19" continuedAt="f-477-20"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. We review the status of each significant matter quarterly and assess our potential financial exposure. If the potential loss from a claim or legal proceeding is considered probable and the amount can be reasonably estimated, we record a liability and an expense for the estimated loss and disclose it in our financial statements if it is significant. If we determine that a loss is possible and the range of the loss can be reasonably determined, we do not record a liability or an expense but we disclose the range of the possible loss. We base our judgments on the best information available at the time. As additional information becomes available, we reassess the potential liability related to our pending claims and litigation and may revise our estimates. Any revision of our estimates of potential liability could have a material impact on our financial position and operating results.</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-527" escape="true"><ix:continuation id="f-477-20" continuedAt="f-477-21"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income consists of two elements, net income and other comprehensive loss. We report all components of comprehensive income, including net income, in our financial statements in the period in which they are recognized. Total comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net income and the components of other comprehensive loss, including foreign currency translation adjustments and unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive income.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_256"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-528" continuedAt="f-528-1" escape="true"><ix:continuation id="f-477-21" continuedAt="f-477-22"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate our revenue from the sale of disposable sensors and our reusable transmitter and receiver, collectively referred to as Reusable Hardware. We also refer to Reusable Hardware and disposable sensors in this section as Components. We generally recognize revenue when control is transferred to our customers in an amount that reflects the net consideration to which we expect to be entitled.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining how revenue should be recognized, a five-step process is used, which includes identifying performance obligations in the contract, determining whether the performance obligations are separate, allocating the transaction price to each separate performance obligation, estimating the amount of variable consideration to include in the transaction price and determining the timing of revenue recognition for separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contracts and Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider customer purchase orders, which in most cases are governed by agreements with distributors or third-party payors, to be contracts with a customer. For each contract, we consider the obligation to transfer Components to the customer, each of which are distinct, to be separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Price</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for the Components reflects the net consideration to which we expect to be entitled. Transaction price is typically based on the contracted rates less an estimate of claim denials and historical reimbursement experience by payor, which include current and future expectations regarding reimbursement rates and payor mix. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include an estimate of variable consideration in the calculation of the transaction price at the time of sale, when control of the Components transfers to the customer. Variable consideration includes, but is not limited to: rebates, chargebacks, consideration payable to customers such as specialty distributor and wholesaler fees, product returns provision, prompt payment discounts, and various other promotional or incentive arrangements.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our provisions related to variable consideration as a reduction of accounts receivable when we are not required to make a payment or as a liability when we are required to make a payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the adequacy of our estimates for transaction price adjustments and variable consideration at each reporting date. If the actual amounts of consideration we receive differ from our estimates, we would adjust our estimates and that would affect reported revenue in the period that such variances become known. If any of these judgments were to change, it could cause a material increase or decrease in the amount of revenue we report in a particular period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to rebates on pricing programs with managed care organizations, such as pharmacy benefit managers, governmental and third-party commercial payors, primarily in the U.S. We estimate provisions for rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or trends and channel inventory data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in chargeback programs, primarily with government entities in the U.S., under which pricing on products below negotiated list prices is provided to participating entities and equal to the difference between their acquisition cost and the lower negotiated price. We estimate provisions for chargebacks primarily based on historical experience on a product and program basis, current contract prices under the chargeback programs and channel inventory data.</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-528-1" continuedAt="f-528-2"><ix:continuation id="f-477-22" continuedAt="f-477-23"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration Payable to the Customer</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay administrative and service fees to certain of our distributors based on a fixed percentage of the product price. These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price. We accrue for these fees based on actual net sales and contractual fee rates negotiated with the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of their distribution agreements, most distributors do not have rights of return. The distributors typically have a limited time frame to notify us of any missing, damaged, defective or non-conforming products. We generally provide a &#8220;<ix:nonNumeric contextRef="c-1" name="dxcm:RevenueRecognitionSalesReturnsCoveragePeriod" format="ixt-sec:durday" id="f-529">30</ix:nonNumeric>-day money back guarantee&#8221; program whereby first-time end-user customers may return Reusable Hardware. We estimate our product returns provision principally based on historical experience by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Additionally, we consider other specific factors such as estimated shelf life of inventory in the distribution channel and changes to customer terms.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Payment Discounts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. We estimate prompt payment discount accruals based on actual net sales and contractual discount rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Various Other Promotional or Incentive Arrangements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other promotional or incentive arrangements are periodically offered to customers, including but not limited to co-payment assistance we provide to patients with commercial insurance, promotional programs related to the launch of products or other targeted promotions. We record a provision for the incentive earned based on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenue from sales of Components upon transfer of control of the product to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where our free-of-charge software, mobile applications and updates are deemed to be separate performance obligations, revenue is recognized over time on a ratable basis over the estimated life of the related Reusable Hardware component.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales of Components include an assurance-type warranty.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable and deferred revenue. Payment terms vary by contract type and type of customer and generally range from <ix:nonNumeric contextRef="c-92" name="dxcm:ContractPaymentTermsNumberofDays" format="ixt-sec:durday" id="f-530">30</ix:nonNumeric> to <ix:nonNumeric contextRef="c-93" name="dxcm:ContractPaymentTermsNumberofDays" format="ixt-sec:durday" id="f-531">90</ix:nonNumeric> days.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December&#160;31, 2023 included unbilled accounts receivable of $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="f-532">8.0</ix:nonFraction> million. We expect to invoice and collect all unbilled accounts receivable within twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record deferred revenue when we have entered into a contract with a customer and cash payments are received or due prior to transfer of control or satisfaction of the related performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations are generally satisfied within twelve months of the initial contract date. The deferred revenue balances related to performance obligations that will be satisfied after twelve months was $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-533">7.4</ix:nonFraction> million as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-534">19.0</ix:nonFraction> million as of December&#160;31, 2022. These balances are included in other long-term liabilities in our consolidated balance sheets. Revenue recognized in the period from performance obligations satisfied in previous periods was not material for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Cost of Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred cost of sales are associated with transactions for which revenue recognition criteria are not met but product has shipped and released from inventory. Deferred cost of sales are included in prepaid and other current assets in our consolidated balance sheets.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-528-2"><ix:continuation id="f-477-23" continuedAt="f-477-24"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Compensation Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expense incentive compensation associated with our internal sales force when incurred because the amortization period for such costs, if capitalized, would have been <span style="-sec-ix-hidden:f-535">one</span> year or less. We record these costs in selling, general and administrative expense in our consolidated statements of operations.</span></div></ix:continuation></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_262"></div><ix:nonNumeric contextRef="c-1" name="dxcm:ProductShipmentCostsPolicyTextBlock" id="f-536" escape="true"><ix:continuation id="f-477-24" continuedAt="f-477-25"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Product Shipment Costs</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the amounts we charge our customers for the shipping and handling of our products in revenue and we record the related costs as cost of sales in our consolidated statements of operations.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_265"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-537" escape="true"><ix:continuation id="f-477-25" continuedAt="f-477-26"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We expense costs of research and development as we incur them. Our research and development expenses primarily consists of engineering and research expenses related to our sensing technology, clinical trials, regulatory expenses, quality assurance programs, employee compensation, and business process outsourcers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology includes certain software that we develop. We expense software development costs as we incur them until technological feasibility has been established, at which time we capitalize development costs until the product is available for general release to customers. To date, our software has been available for general release concurrent with the establishment of technological feasibility and, accordingly, we have not capitalized any development costs.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_268"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-538" escape="true"><ix:continuation id="f-477-26" continuedAt="f-477-27"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into agreements with collaboration partners for the development and commercialization of our products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we account for these agreements, we consider the unique nature, terms and facts and circumstances of each transaction. Below are some example activities and how we account for them:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Payments to collaboration partners through issuance of common stock as consideration in an asset acquisition are considered share-based payment to non-employees in exchange for goods within the scope of ASC Topic 718, &#8220;Compensation - Stock Compensation.&#8221; The amount and the timing of the cost recognition of such milestones in our financial statements is driven by the accounting for the specific type of equity instrument under ASC 718 that aligns with the terms of the agreement, including any performance conditions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The value associated with in-process research and development (&#8220;IPR&amp;D&#8221;) in an asset acquisition incurred prior to regulatory approval is expensed as it does not have an alternative future use and is recorded as research and development expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The value associated with IPR&amp;D in an asset acquisition incurred at or after regulatory approval is usually capitalized as an intangible asset and amortized over the periods in which the related products are expected to contribute to future cash flows.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_271"></div><ix:continuation id="f-477-27" continuedAt="f-477-28"><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-539" continuedAt="f-539-1" escape="true"><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-539-1">We expense costs to produce advertising as we incur them whereas costs to communicate advertising are expensed when the advertising is first run. Advertising costs are included in selling, general and administrative expenses.</ix:continuation> Advertising expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-540">180.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-541">160.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-542">150.1</ix:nonFraction> million for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_274"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-543" continuedAt="f-543-1" escape="true"><ix:continuation id="f-477-28" continuedAt="f-477-29"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Lease right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Lease right-of-use assets and liabilities with terms of more than 12 months are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to determine the present value is our collateralized incremental borrowing rate unless the interest rate implicit in the lease is readily determinable.</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-543-1"><ix:continuation id="f-477-29" continuedAt="f-477-30"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, lease expense is recognized on a straight-line basis within operating expenses over the lease term. For finance leases, lease expense is recognized as interest and depreciation; interest using the effective interest method and depreciation on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. Short-term leases with lease terms of 12 months or less are not recorded on the balance sheet and are recognized on a straight line basis over the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and lease liabilities are presented separately in our consolidated balance sheets. Finance lease right-of-use assets are included in property and equipment and finance lease liabilities are included in accounts payable and accrued liabilities and in other long-term liabilities in our consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lease agreements may contain lease components and non-lease components. For certain asset classes, we have elected to account for both of those components as a single lease component. We use a portfolio approach to account for the right-of-use assets and liabilities associated with certain machinery and equipment leases. Variable lease payments may include payments associated with non-lease components, payments that do not depend on a rate or index, or other costs. Variable lease payments are recognized in the period in which the obligation for those payments are incurred.</span></div></ix:continuation></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_277"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-544" escape="true"><ix:continuation id="f-477-30" continuedAt="f-477-31"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value time-based restricted stock units or RSUs at the date of grant using the intrinsic value method. Certain RSUs granted to senior management vest based on the achievement of pre-established performance or market goals. We estimate the fair value of these performance/market-based RSUs, or PSUs, at the date of grant using the intrinsic value method and the probability that the specified performance criteria will be met. We update our assessment of the probability that the specified performance criteria will be achieved each quarter and adjust our estimate of the fair value of the PSUs if necessary. The Monte Carlo methodology that we use to estimate the fair value of PSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the PSUs at the date of grant must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the assumptions used change significantly, share-based compensation expense may differ materially from what we have recorded in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for forfeitures as they occur by reversing any share-based compensation expense related to awards that will not vest.</span></div></ix:continuation></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_280"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-545" escape="true"><ix:continuation id="f-477-31" continuedAt="f-477-32"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to common stockholders is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the period and, when dilutive, potential common share equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares consist of shares issuable from RSUs, PSUs, warrants, our senior convertible notes, and collaborative sales-based milestones. Potentially dilutive common shares issuable upon vesting of RSUs, PSUs, and exercise of warrants are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our senior convertible notes are determined using the if-converted method. In periods of net losses, we exclude all potentially dilutive common shares from the computation of the diluted net loss per share for those periods as the effect would be anti-dilutive.</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-477-32" continuedAt="f-477-33"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-546" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per share for the periods shown:</span></div><div style="margin-bottom:10pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-547">541.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-548">341.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-549">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestOnConvertibleDebtNetOfTax" scale="6" id="f-550">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:InterestOnConvertibleDebtNetOfTax" scale="6" id="f-551">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InterestOnConvertibleDebtNetOfTax" scale="6" id="f-552">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income - diluted</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLossAttributableToParentDiluted" scale="6" id="f-553">554.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:NetIncomeLossAttributableToParentDiluted" scale="6" id="f-554">352.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:NetIncomeLossAttributableToParentDiluted" scale="6" id="f-555">228.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per common share</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-556">1.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-557">0.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-558">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-559">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-560">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-561">0.53</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-562">386.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-563">389.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-564">386.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborative sales-based milestones</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-94" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-565">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-95" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-96" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units and performance stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-97" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-568">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-98" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-569">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-570">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior convertible notes</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-571">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-101" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-572">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-573">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-103" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-574">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-104" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-575">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-105" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-576">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-577">425.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-578">427.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-579">428.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-580" escape="true"><div style="margin-bottom:1pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding anti-dilutive securities not included in the diluted net income per share attributable to common stockholders calculations were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units and performance stock units</span></div></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-97" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-98" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-582">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="f-583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_283"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-584" continuedAt="f-584-1" escape="true"><ix:continuation id="f-477-33" continuedAt="f-477-34"><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08,</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This guidance is intended improve the accounting for acquired revenue contracts with customers in a business combination. The new guidance requires that the acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The amendments should be applied prospectively to business combinations occurring on or after the adoption date. We adopted ASU 2021-08 in the first quarter of 2023 and there was no impact to our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements and disclosures.</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-584-1"><ix:continuation id="f-477-34"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity&#8217;s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. The ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The ASU should be applied on a prospective basis although retrospective application is permitted. We are currently evaluating the impact of this standard on our consolidated financial disclosures.</span></div></ix:continuation></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_289"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-585" continuedAt="f-585-1" escape="true"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. Development and Other Agreements</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Verily Life Sciences</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2018, we entered into an Amended and Restated Collaboration and License Agreement with Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited (collectively, &#8220;Verily&#8221;), which we refer to as the Restated Collaboration Agreement. This replaced our original Collaboration and License Agreement with Verily dated August 10, 2015, as amended in October 2016, including the royalty obligations provisions under that original agreement. Pursuant to the Restated Collaboration Agreement, we and Verily have agreed to continue to jointly develop a certain next-generation CGM product, and potentially one or more additional CGM products, for which we will have exclusive commercialization rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Collaboration Agreement also provides us with an exclusive license to use intellectual property of Verily resulting from the collaboration, and certain Verily patents, in the development, manufacture and commercialization of blood-based or interstitial glucose monitoring products more generally (subject to certain exclusions, which are outside of the CGM field as it is commonly understood). It also provides us with non-exclusive license rights under Verily&#8217;s other intellectual property rights to develop, manufacture and commercialize those kinds of glucose monitoring products and certain CGM-product companion software functionalities. The Restated Collaboration Agreement requires us to use commercially reasonable efforts to develop, launch and commercialize the CGM product(s) that are the subject of the collaboration according to certain timing and other objectives, and provides for one executive sponsor from each of Dexcom and Verily to meet periodically and make decisions related to the collaboration (within a limited scope of authority) by consensus.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of Verily&#8217;s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we made upfront, incentive, and the product regulatory approval payments, and will make potential payments for contingent sales-based milestones upon the achievement of certain revenue targets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the contingent milestones payable in shares of our common stock as equity instruments within the scope of ASC Topic 718. The product regulatory approval and sales-based milestones are accounted for as performance-based awards that vest when the performance conditions have been achieved and are recognized when the achievement of the respective contingent milestone is deemed probable. The value of the contingent milestones is based on our closing stock price on December 28, 2018, which was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-586">29.57</ix:nonFraction> per share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront and Incentive payments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the fourth quarter of 2018, we made an initial payment for an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="dxcm:CollaborativeArrangementUpfrontFee" scale="6" id="f-587">250.0</ix:nonFraction> million through the issuance of <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-588">7.4</ix:nonFraction> million shares of our common stock. We recorded a $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="dxcm:CollaborativeResearchAndDevelopmentFee" scale="6" id="f-589">217.7</ix:nonFraction> million charge in our consolidated statements of operations during 2018 relating to the issuance of this common stock because this milestone payment did not meet the capitalization criteria. The value of the charge was based on our closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-590">29.57</ix:nonFraction> per share on December 28, 2018, the date on which we obtained the necessary regulatory approvals and represents the date the performance- based awards were issued. In 2019, we made a cash incentive payment of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="dxcm:CollaborativeResearchAndDevelopmentFee" format="ixt:num-dot-decimal" scale="6" id="f-591">3.2</ix:nonFraction> million due to the completion of certain development obligations and we recorded these payments as research and development expense in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent milestones</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we determined the achievement of the regulatory approval milestone to be probable and recorded an $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="dxcm:CollaborativeResearchAndDevelopmentFee" format="ixt:num-dot-decimal" scale="6" id="f-592">87.1</ix:nonFraction> million research and development charge in our consolidated statements of operations. This charge is associated with IPR&amp;D obtained in an asset acquisition prior to regulatory approval and therefore does not have an alternative future use.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we received regulatory approval and issued <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="dxcm:SharesIssuedInConnectionWithTheRestatedCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-593">2.9</ix:nonFraction> million shares of our common stock in connection with our achievement of the related milestone.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-585-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we received FDA approval and determined the achievement of the sales-based milestones to be probable. As such, we capitalized the full value of the sales-based milestones, $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-594">152.4</ix:nonFraction> million, as an intangible asset. The sales-based milestones are contingent upon the achievement of certain revenue targets. The value of the sales-based milestones is based on: 1) <ix:nonFraction unitRef="shares" contextRef="c-113" decimals="-5" name="dxcm:PotentialFutureCommonStockIssuableSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-595">5.2</ix:nonFraction> million shares of our common stock, as agreed upon in November 2018 and 2) our closing stock price on December 28, 2018 of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-596">29.57</ix:nonFraction> per share. December 28, 2018 is the date on which we obtained the necessary regulatory approvals and represents the date the performance- based awards were issued. The intangible asset will be amortized using the straight-line method over its estimated useful life of <ix:nonNumeric contextRef="c-114" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:durmonth" id="f-597">64</ix:nonNumeric> months through March 2028. The related amortization expense is recognized in cost of sales in our consolidated statements of operations and disclosed in Note 4 &#8220;Intangibles, Net&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we issued <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="-5" name="dxcm:PotentialCommonStockIssuableOrIssuedSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-598">3.7</ix:nonFraction> million shares of our common stock in connection with our achievement of the first sales-based milestone. See the effective tax rate reconciliation in Note 8 &#8220;Income Taxes&#8221; to the consolidated financial statements for more information on the tax benefits related to the collaboration agreement milestone share-based payments for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All milestones may be paid in cash or shares of our common stock, at our election. If we elect to make these milestone payments in cash, any such cash payment would be equal to the number of shares that would otherwise be issued for the given milestone payment multiplied by the value of our stock on the date the relevant milestone is achieved, and adjusted to give effect to any stock splits, dividends, or similar events. We intend to pay the remaining sales-based contingent milestone in shares of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon achievement of the first sales-based milestone event and payment of the corresponding milestone fee by us in December 2023, the term of the Restated Collaboration Agreement was extended from December 31, 2028 to December 31, 2033.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_295"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="f-599" continuedAt="f-599-1" escape="true"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. Fair Value Measurements</span></td></tr></table></div></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_2731"></div><ix:continuation id="f-599-1" continuedAt="f-599-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our Level 1 financial instruments, which are in active markets, using unadjusted quoted market prices for identical instruments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain the fair values for our Level 2 financial instruments, which are not in active markets, from a primary professional pricing source that uses quoted market prices for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Fair values obtained from this professional pricing source can also be based on pricing models whereby all significant observable inputs, including maturity dates, issue dates, settlement dates, benchmark yields, reported trades, broker-dealer quotes, issue spreads, benchmark securities, bids, offers or other market related data, are observable or can be derived from, or corroborated by, observable market data for substantially the full term of the asset. We validate the quoted market prices provided by our primary pricing service by comparing the fair values of our Level 2 marketable securities portfolio balance provided by our primary pricing service against the fair values provided by our investment managers.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-600" continuedAt="f-600-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2023, classified in accordance with the fair value hierarchy:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-601">315.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-602">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-604">315.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-606">1,612.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-608">1,612.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-610">184.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-612">184.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-614">360.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-616">360.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-618">2,157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-620">2,157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="f-621">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="f-624">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-625">331.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-626">2,157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-628">2,488.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-599-2" continuedAt="f-599-3"><ix:continuation id="f-600-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2022, classified in accordance with the fair value hierarchy:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-629">375.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-630">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-632">420.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-634">1,530.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-636">1,530.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-638">119.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-640">119.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-642">163.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-644">163.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-646">1,813.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-648">1,813.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="f-649">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="f-652">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-653">386.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-654">1,858.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-656">2,244.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes assets which are held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="dxcm:FairValueAssetsLevel3TransfersAmount" format="ixt:fixed-zero" scale="0" id="f-657"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="dxcm:FairValueAssetsLevel3TransfersAmount" format="ixt:fixed-zero" scale="0" id="f-658">no</ix:nonFraction></ix:nonFraction> transfers into or out of Level 3 securities during the twelve months ended December&#160;31, 2023 and 2022.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_2758"></div><ix:continuation id="f-599-3" continuedAt="f-599-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Senior Convertible Notes</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" id="f-659" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value, based on trading prices (Level 1 inputs), of our senior convertible notes were as follows as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements Using Level 1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="6" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-661">2,136.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-662">1,262.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-663">1,314.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-664">1,281.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="6" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of outstanding senior convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-666">2,544.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-667">3,451.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on the carrying values of our senior convertible notes, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Convertible Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 5 &#8220;Debt&#8221; to the consolidated financial statements.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_2783"></div><ix:continuation id="f-599-4" continuedAt="f-599-5"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency and Derivative Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward contracts to hedge monetary assets and liabilities denominated in foreign currencies. Our foreign currency forward contracts are not designated as hedging instruments. Therefore, changes in the fair values of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The duration of these contracts is generally <ix:nonNumeric contextRef="c-154" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="f-668">one month</ix:nonNumeric>. The derivative gains and losses are included in other income (expense), net in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2023 and December&#160;31, 2022, the notional amounts of outstanding foreign currency forward contracts were $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-669">71.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-670">62.0</ix:nonFraction> million, respectively. The resulting impact on our consolidated financial statements from currency hedging activities was not significant for the twelve months ended December&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency exposures vary but are primarily concentrated in the Australian Dollar, the British Pound, the Canadian Dollar, the Euro, and the Malaysian Ringgit. We monitor the costs and the impact of foreign currency risks upon our financial results as part of our risk management program. We do not use derivative financial instruments for speculation or trading purposes or for activities other than risk management. We do not require and are not required to pledge collateral for these financial instruments and we do not carry any master netting arrangements to mitigate the credit risk.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_2808"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-599-5"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, we measure certain non-financial assets and liabilities at fair value on a non-recurring basis. These measurements are usually performed using the discounted cash flow method or cost method and Level 3 inputs. These include items such as non-financial assets and liabilities initially measured at fair value in a business combination and non-financial long-lived assets measured at fair value for an impairment assessment. In general, non-financial assets, including goodwill, intangible assets, and property and equipment, are measured at fair value when there are indicators of impairment and are recorded at fair value only when an impairment is recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain other investments that we do not measure at fair value on a recurring basis. The carrying values of these investments are $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="f-671">38.5</ix:nonFraction>&#160;million as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="f-672">19.0</ix:nonFraction> million as of December&#160;31, 2022. We include them in other assets in our consolidated balance sheets. It is impracticable for us to estimate the fair value of these investments on a recurring basis due to the fact that these entities are privately held and limited information is available. We monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant effect on the fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-673">no</ix:nonFraction> significant impairment losses during the twelve months ended December&#160;31, 2023. During the fourth quarter 2022, we vacated a leased building and made it available for sublease, resulting in an impairment of its asset group which consisted primarily of leasehold improvements and right-of-use asset. We recorded $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-674">23.0</ix:nonFraction>&#160;million in impairment losses during the twelve months ended December&#160;31, 2022. See Note 6 &#8220;Leases and Other Commitments&#8221; to the consolidated financial statements for more information. There were <ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-675">no</ix:nonFraction> significant impairment losses during the twelve months ended December&#160;31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_298"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="f-676" continuedAt="f-676-1" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. Balance Sheet Details and Other Financial Information</span></div></td></tr></table></div></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_301"></div><ix:continuation id="f-676-1" continuedAt="f-676-2"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #58a618;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Marketable Securities</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-677" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term marketable securities, consisting of available-for-sale debt securities, were as follows as of the dates indicated:</span></div><div style="margin-bottom:7pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></div></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-678">1,611.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-679">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-680">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-681">1,612.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-682">184.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-684">0.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-685">184.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-686">360.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-687">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-688">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-689">360.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-690">2,157.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-691">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-692">0.9</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-693">2,157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:7pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-694">1,535.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-695">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-696">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-697">1,530.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-698">119.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-700">0.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-701">119.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-702">164.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-704">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-705">163.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-706">1,819.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-707">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-708">5.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-709">1,813.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the estimated market value of our short-term debt securities with contractual maturities up to <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="f-710">12</ix:nonNumeric> months was $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-7" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="9" id="f-711">2.16</ix:nonFraction>&#160;billion. As of December 31, 2022, the estimated market value of our short-term debt securities with contractual maturities up to <ix:nonNumeric contextRef="c-26" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="f-712">12</ix:nonNumeric> months was $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-7" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="9" id="f-713">1.81</ix:nonFraction>&#160;billion. Gross realized gains and losses on sales of our short-term debt securities for the twelve months ended December&#160;31, 2023, 2022 and 2021 were not significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review our portfolio of debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For debt securities where the fair value of the investment is less than the amortized cost basis, we have assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities at December&#160;31, 2023 were primarily due to increases in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, we have not recorded an allowance for credit losses. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_304"></div><ix:continuation id="f-676-2" continuedAt="f-676-3"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended December&#160;31, 2023, 2022 and 2021, we had <ix:nonFraction unitRef="usd" contextRef="c-27" decimals="INF" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-714"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="INF" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-715"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-716">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> unrealized gains or losses recognized during the reporting period on equity investments. Realized gains from the sale of an equity investment were not significant for the twelve months ended December&#160;31, 2023, 2022 and 2021.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_307"></div><ix:continuation id="f-676-3" continuedAt="f-676-4"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-717" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AccountsReceivableGross" scale="6" id="f-718">983.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AccountsReceivableGross" scale="6" id="f-719">720.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: allowance for doubtful accounts</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="f-720">9.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="f-721">7.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts receivable, net</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="6" id="f-722">973.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="6" id="f-723">713.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-676-4" continuedAt="f-676-5"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserve for prompt payment cash discounts recorded against accounts receivable, excluding allowance for doubtful accounts, was $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:AccountsReceivableAllowanceForCreditLossCashDiscount" format="ixt:num-dot-decimal" scale="6" id="f-724">13.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:AccountsReceivableAllowanceForCreditLossCashDiscount" format="ixt:num-dot-decimal" scale="6" id="f-725">8.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="dxcm:AccountsReceivableAllowanceForCreditLossCashDiscount" format="ixt:num-dot-decimal" scale="6" id="f-726">13.7</ix:nonFraction>&#160;million as of December&#160;31, 2023, 2022, and 2021, respectively.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_310"></div><ix:continuation id="f-676-5" continuedAt="f-676-6"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div></td></tr></table><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-727" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-728">319.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-729">159.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-730">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="f-731">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-732">210.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-733">130.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-734">559.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-735">306.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended December&#160;31, 2023, 2022 and 2021, we recorded excess and obsolete inventory charges of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-736">16.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-737">13.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-738">28.1</ix:nonFraction> million respectively, in cost of sales as a result of our ongoing assessment of sales demand, inventory on hand for each product and the continuous improvement and innovation of our products.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_313"></div><ix:continuation id="f-676-6" continuedAt="f-676-7"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></td></tr></table><ix:nonNumeric contextRef="c-1" name="dxcm:PrepaidAndOtherCurrentAssetsTableTextBlock" id="f-739" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="f-740">58.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="f-741">48.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:PrepaidInventoryCurrent" scale="6" id="f-742">31.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:PrepaidInventoryCurrent" scale="6" id="f-743">67.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation plan assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:DeferredCompensationPlanAssetsCurrent" scale="6" id="f-744">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:DeferredCompensationPlanAssetsCurrent" scale="6" id="f-745">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:IncomeTaxesReceivable" scale="6" id="f-746">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:IncomeTaxesReceivable" scale="6" id="f-747">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-748">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-749">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-750">168.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-751">192.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_316"></div><ix:continuation id="f-676-7" continuedAt="f-676-8"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></td></tr></table><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-752" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land and land improvements</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-753">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-754">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-755">190.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-756">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-757">36.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-758">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software and hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-759">65.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-760">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-761">683.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-762">449.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-763">283.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-764">264.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-765">328.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-766">542.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-767">1,622.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-768">1,418.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="f-769">509.4</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="f-770">363.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-771">1,113.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-772">1,055.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment for the twelve months ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-773">147.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-774">144.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-775">96.3</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on disposal of property and equipment during the twelve months ended December&#160;31, 2023, 2022 and 2021 recorded in operating expenses was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-776">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-777">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="6" id="f-778">24.5</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_319"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-676-8" continuedAt="f-676-9"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;Intangibles, Net</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-779" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of gross intangible assets, accumulated amortization, and net intangible asset balances as of December&#160;31, 2023 and December&#160;31, 2022</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verily intangible asset</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-173" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-780">4.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-781">152.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-782">31.0</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-783">121.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-174" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-784">2.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-785">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-786">15.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-787">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired technology and intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-175" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-788">0.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-789">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-790">12.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-791">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-176" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-792">2.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-793">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-794">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-795">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, other</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-177" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-796">0.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-797">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-798">0.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="f-799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-24" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-800">4.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-801">195.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-802">61.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-803">134.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Useful Life<br/>(in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verily intangible</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-178" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-804">5.3</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-805">152.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-806">2.4</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-807">150.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-179" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-808">3.3</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-809">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-810">8.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-811">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired technology and intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-180" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-812">1.7</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-813">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-814">9.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-815">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-181" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-816">3.5</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-817">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-818">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-819">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, other</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-182" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-820">0.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-821">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-822">0.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="f-823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-25" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-824">4.9</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-825">195.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-826">22.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-827">173.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 2 &#8220;Development and Other Agreements&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Excludes Verily intangible asset.</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="f-828" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total amortization expense of finite-lived intangible assets for the twelve months ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense included in cost of sales</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales" scale="6" id="f-829">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales" scale="6" id="f-830">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales" scale="6" id="f-831">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense included in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-832">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-833">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-834">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" scale="6" id="f-835">38.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" scale="6" id="f-836">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" scale="6" id="f-837">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-838" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents estimated future amortization of the Company&#8217;s finite-lived intangible assets as of December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.035%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-839">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-840">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-841">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-842">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-843">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:fixed-zero" scale="6" id="f-844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-845">134.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_322"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-676-9" continuedAt="f-676-10"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div></td></tr></table><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="f-846" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term investments</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LongTermInvestments" scale="6" id="f-847">38.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:LongTermInvestments" scale="6" id="f-848">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:LongTermDeposits" scale="6" id="f-849">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:LongTermDeposits" scale="6" id="f-850">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:OtherLongTermAssets" scale="6" id="f-851">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:OtherLongTermAssets" scale="6" id="f-852">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-853">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-854">47.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_325"></div><ix:continuation id="f-676-10" continuedAt="f-676-11"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Accrued Liabilities</span></div></td></tr></table><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-855" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable trade</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AccountsPayableTradeCurrent" scale="6" id="f-856">276.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AccountsPayableTradeCurrent" scale="6" id="f-857">237.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued tax, audit, and legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:AccruedTaxAuditAndLegalFeesCurrent" scale="6" id="f-858">42.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:AccruedTaxAuditAndLegalFeesCurrent" scale="6" id="f-859">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued rebates </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:PharmacyRebatesCurrent" scale="6" id="f-860">950.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:PharmacyRebatesCurrent" scale="6" id="f-861">556.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" scale="6" id="f-862">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" scale="6" id="f-863">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax payable</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-864">7.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-865">12.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation plan liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="6" id="f-866">15.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="6" id="f-867">10.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-868">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-869">39.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-870">1,345.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="6" id="f-871">901.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_328"></div><ix:continuation id="f-676-11" continuedAt="f-676-12"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accrued Payroll and Related Expenses</span></div></td></tr></table><ix:nonNumeric contextRef="c-1" name="dxcm:ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock" id="f-872" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued wages, bonus and taxes</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:AccruedWagesBonusesAndTaxesCurrent" scale="6" id="f-873">139.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:AccruedWagesBonusesAndTaxesCurrent" scale="6" id="f-874">96.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="f-875">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="f-876">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued payroll and related expenses</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-877">171.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-878">134.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_3826"></div><ix:continuation id="f-676-12" continuedAt="f-676-13"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accrued Warranty</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="f-879" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty costs are reflected in our statements of operations as cost of sales. Reconciliations of our accrued warranty costs for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" scale="6" id="f-880">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" scale="6" id="f-881">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" scale="6" id="f-882">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses" scale="6" id="f-883">51.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses" scale="6" id="f-884">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses" scale="6" id="f-885">41.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProductWarrantyAccrualPayments" scale="6" id="f-886">51.7</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ProductWarrantyAccrualPayments" scale="6" id="f-887">43.1</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProductWarrantyAccrualPayments" scale="6" id="f-888">40.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" scale="6" id="f-889">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" scale="6" id="f-890">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:StandardProductWarrantyAccrual" scale="6" id="f-891">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_331"></div><ix:continuation id="f-676-13" continuedAt="f-676-14"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Long-Term Liabilities</span></div></td></tr></table><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" id="f-892" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease obligations</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-893">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-894">59.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-895">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-896">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset retirement obligation</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AssetRetirementObligation" scale="6" id="f-897">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AssetRetirementObligation" scale="6" id="f-898">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:OtherTaxLiabilitiesNoncurrent" scale="6" id="f-899">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:OtherTaxLiabilitiesNoncurrent" scale="6" id="f-900">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="f-901">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="f-902">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-903">125.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-904">128.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_3285"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-676-14"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div></td></tr></table><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="f-905" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income</span></div></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-906">135.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-907">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-908">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-909">20.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-910">18.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-911">18.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity investments</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DebtAndEquitySecuritiesGainLoss" scale="6" id="f-912">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:DebtAndEquitySecuritiesGainLoss" scale="6" id="f-913">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DebtAndEquitySecuritiesGainLoss" scale="6" id="f-914">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-915">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-917">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherNonoperatingExpense" scale="6" id="f-918">3.9</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:OtherNonoperatingExpense" scale="6" id="f-919">5.8</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OtherNonoperatingExpense" scale="6" id="f-920">3.4</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-921">112.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-922">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-923">9.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_337"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-924" continuedAt="f-924-1" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. Debt</span></td></tr></table></div></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_3095"></div><ix:continuation id="f-924-1" continuedAt="f-924-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Senior Convertible Notes</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-925" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of our senior convertible notes were as follows as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amount:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="6" id="f-926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-927">774.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-928">1,207.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-929">1,207.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-930">1,250.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="6" id="f-931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total principal amount</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-932">2,457.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-933">1,982.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="f-934">23.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="f-935">12.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount of senior convertible notes</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-936">2,434.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-937">1,970.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConvertibleDebtTableTextBlock" id="f-938" continuedAt="f-938-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our senior convertible notes for which the if-converted value exceeded the principal amount, the amount in excess of principal was as follows as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" format="ixt:fixed-zero" scale="6" id="f-939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" format="ixt:num-dot-decimal" scale="6" id="f-940">1,361.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="f-941">56.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="f-942">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="f-943">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" format="ixt:fixed-zero" scale="6" id="f-944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total by which the notes&#8217; if-converted value exceeds their principal amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" scale="6" id="f-945">89.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" format="ixt:num-dot-decimal" scale="6" id="f-946">1,395.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="f-947" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our senior convertible notes for the periods shown:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash interest expense:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon interest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="6" id="f-948">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="6" id="f-949">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="6" id="f-950">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-951">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-952">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-953">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense recognized on senior notes</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-954">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-955">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-956">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective interest rate:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-191" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-957">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-192" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-958">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-193" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-959">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-960">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-195" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-961">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-196" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-962">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-963">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest on the 2023 Notes began accruing upon issuance and is payable semi-annually on June 1 and December 1 of each year. Interest on the 2025 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year. Interest on the 2028 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effective interest rate presented represents the rate applicable for the period outstanding. The Senior Convertible Notes due 2023 matured on December 1, 2023 and all outstanding principal was settled as described below.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Not applicable as no notes were outstanding at this date.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_343"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-924-2" continuedAt="f-924-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt Summary</span></div><ix:continuation id="f-938-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key details for our unsecured senior convertible notes due 2023 (the &#8220;2023 Notes&#8221;), unsecured senior convertible notes due 2025 (the &#8220;2025 Notes&#8221;), and unsecured senior convertible notes due 2028 (the &#8220;2028 Notes&#8221;):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Senior Convertible Notes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Offering Completion Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stated Interest Rate</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Principal Amount</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Proceeds</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Initial Conversion Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(per $1,000 principal amount)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Conversion Price</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(per share)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Settlement Methods</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November 2018</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;1, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-198" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-964">0.75</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-965">850.0</ix:nonFraction> million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-966">836.6</ix:nonFraction> million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.3476&#160;shares </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-967">41.07</ix:nonFraction></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and/or shares</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November&#160;15, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-200" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-968">0.25</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-969">1.21</ix:nonFraction> billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-7" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="9" id="f-970">1.19</ix:nonFraction> billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6620 shares </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-971">150.11</ix:nonFraction></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and/or shares</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028 Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May&#160;15, 2028</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-972">0.375</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-973">1.25</ix:nonFraction>&#160;billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-7" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="9" id="f-974">1.23</ix:nonFraction>&#160;billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.1571 shares</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-202" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-975">162.41</ix:nonFraction></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and/or shares</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Net proceeds is calculated by deducting the aggregate principal amount from the initial purchasers&#8217; discounts and estimated costs directly related to the offering.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Subject to adjustments as defined in the indentures.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The senior convertible notes may be settled in cash, stock, or a combination thereof, solely at our discretion. </span></div></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the if-converted method for assumed conversion of our senior convertible notes to compute the weighted average shares of common stock outstanding for diluted earnings per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No principal payments are due on the senior convertible notes prior to maturity. Other than restrictions relating to certain fundamental changes and consolidations, mergers or asset sales and customary anti-dilution adjustments, the indenture relating to our senior convertible notes include customary terms and covenants, including certain events of default after which the senior convertible notes may be due and payable immediately.</span></div><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Note Hedge</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the 2023 Notes, in November 2018 we entered into convertible note hedge transactions with two of the initial purchasers of the 2023 Notes (the &#8220;2023 Counterparties&#8221;) entitling us to purchase up to&#160;<ix:nonFraction unitRef="shares" contextRef="c-204" decimals="-5" name="dxcm:DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="f-976">20.7</ix:nonFraction> million&#160;shares of our common stock at an initial price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-977">41.07</ix:nonFraction>&#160;per share, each of which is subject to adjustment. The cost of the 2023 Note Hedge was&#160;$<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-978">218.9</ix:nonFraction> million and we accounted for it as an equity instrument by recognizing $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-979">218.9</ix:nonFraction> million in&#160;additional paid-in capital&#160;during 2018. The 2023 Note Hedge expired on December&#160;1, 2023. The 2023 Note Hedge is expected to reduce the potential equity dilution upon any conversion of the 2023 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2023 Notes if the daily volume-weighted average price per share of our common stock exceeds the strike price of the 2023 Note Hedge.&#160;The strike price of the 2023 Note Hedge initially corresponds to the conversion price of the 2023 Notes and is subject to certain adjustments under the terms of the 2023 Note Hedge. An assumed exercise of the 2023 Note Hedge by us is considered anti-dilutive since the effect of the inclusion would always be anti-dilutive with respect to the calculation of diluted earnings per share. See below for a description of conversion activity related to the 2023 Notes and shares received as the result of exercising the remaining portion of the 2023 Note Hedge.</span></div><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we also sold warrants to the 2023 Counterparties to acquire up to&#160;<ix:nonFraction unitRef="shares" contextRef="c-199" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="6" id="f-980">20.7</ix:nonFraction> million shares of our common stock. The 2023 Warrants require net share settlement and a pro rated number of warrants will expire on each of the <ix:nonFraction unitRef="d" contextRef="c-199" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-981">60</ix:nonFraction> scheduled trading days starting on March&#160;1, 2024. We received&#160;$<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-982">183.8</ix:nonFraction> million&#160;in cash proceeds from the sale of the 2023 Warrants, which we recorded in&#160;additional paid-in capital during 2018. The 2023 Warrants could have a dilutive effect on our earnings per share to the extent that the price of our common stock during a given measurement period exceeds the strike price of the 2023 Warrants. The strike price of the 2023 Warrants is initially $<ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-983">49.60</ix:nonFraction> per share and is subject to certain adjustments under the terms of the warrant agreements. We use the treasury share method for assumed conversion of the 2023 Warrants when computing the weighted average common shares outstanding for diluted earnings per share.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-924-3" continuedAt="f-924-4"><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 Capped Call Transactions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, in connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions (the &#8220;2028 Capped Calls&#8221;) with certain financial institutions. The 2028 Capped Calls will cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2028 Notes, the number of shares of our common stock that will initially underlie the 2028 Notes. The 2028 Capped Calls are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes and/or offset any cash payments that we are required to make in excess of the principal amount of converted 2028 Notes, as the case may be, with such reduction and/or offset subject to a cap. The 2028 Capped Calls have an initial cap price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="INF" name="dxcm:DebtInstrumentCapCallTransactionCapPricePerShare" scale="0" id="f-984">212.62</ix:nonFraction> per share, subject to adjustments, which represents a premium of <ix:nonFraction unitRef="number" contextRef="c-206" decimals="INF" name="dxcm:DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage" scale="-2" id="f-985">80</ix:nonFraction>% over the closing price of our common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-207" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-986">118.12</ix:nonFraction> per share on the Nasdaq Global Select Market on May&#160;2, 2023. The cost to purchase the 2028 Capped Calls of $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="dxcm:PaymentsForPurchasesOfCappedCallTransactions" format="ixt:num-dot-decimal" scale="6" id="f-987">101.3</ix:nonFraction> million was recorded as a reduction to additional paid-in capital in our consolidated balance sheets as the 2028 Capped Calls met the criteria for classification in stockholders&#8217; equity.</span></div><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion Activity for Senior Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2023 Notes, Circumstance 1 as listed below occurred during the quarters ended December&#160;31, 2022, March&#160;31, 2023, and June&#160;30, 2023. <ix:nonNumeric contextRef="c-1" name="dxcm:ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock" id="f-988" continuedAt="f-988-1" escape="true">As a result, the 2023 Notes were convertible at the option of the holders from January&#160;1, 2023 through August 31, 2023. Circumstance 5 was applicable to the 2023 Notes beginning September 1, 2023. The 2023 Notes matured on December 1, 2023 and were completely settled. See the following table for the details on the conversion activity:</ix:nonNumeric></span></div><ix:continuation id="f-988-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Period</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Converted Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Principal Amount Converted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Issued for Settlement</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Received from Exercise of 2023 Note Hedge</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/1/2022 - 12/31/2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 Notes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="dxcm:DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" format="ixt:num-dot-decimal" scale="6" id="f-989">17.5</ix:nonFraction> million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-208" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-990">0.4</ix:nonFraction> million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="dxcm:SharesReceivedFromBenefitOfNoteHedge" format="ixt:num-dot-decimal" scale="6" id="f-991">0.3</ix:nonFraction> million</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/1/2023 - 12/31/2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 Notes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="dxcm:DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" format="ixt:num-dot-decimal" scale="6" id="f-992">774.8</ix:nonFraction>&#160;million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-209" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-993">12.2</ix:nonFraction> million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="dxcm:SharesReceivedFromBenefitOfNoteHedge" format="ixt:num-dot-decimal" scale="6" id="f-994">12.2</ix:nonFraction> million</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-924-4" continuedAt="f-924-5"><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion Rights for Senior Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our senior convertible notes have the right to require us to repurchase for cash all or a portion of their notes at <ix:nonFraction unitRef="number" contextRef="c-146" decimals="INF" name="dxcm:DebtInstrumentCovenantRepurchasePricePercentage" scale="-2" id="f-995">100</ix:nonFraction>% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the notes). We will also be required to increase the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or following the delivery by Dexcom of a notice of redemption.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the conversion options related for each of our senior convertible notes:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:16.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.760%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Conversions Rights at the Option of the Holders for the 2023, 2025, and 2028 Notes (&#8220;Notes&#8221;)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion Rights at the Option of the Holders</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes have the ability to convert all or a portion of their notes in multiples of $1,000 principal amount, at their option prior to 5:00 p.m., New York City time, on the business day immediately preceding September&#160;1, 2023, August&#160;15, 2025, and February&#160;15, 2028 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively, only under the following circumstances:</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During any calendar quarter commencing after the applicable period (and only during such calendar quarter), if the last reported sale price of Dexcom&#8217;s common stock for at least <ix:nonFraction unitRef="d" contextRef="c-210" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-996">20</ix:nonFraction> trading days (whether or not consecutive) during the period of <ix:nonFraction unitRef="d" contextRef="c-211" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-997">30</ix:nonFraction> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="c-210" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-998">130</ix:nonFraction>% of the applicable conversion price for the Notes on each applicable trading day</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the <ix:nonFraction unitRef="trading_day" contextRef="c-212" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-999">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="trading_day" contextRef="c-213" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-1000">five</ix:nonFraction> consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each trading day of that <ix:nonFraction unitRef="trading_day" contextRef="c-213" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-1001">five</ix:nonFraction> consecutive trading day period was less than <ix:nonFraction unitRef="number" contextRef="c-213" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-1002">98</ix:nonFraction>% of the product of the last reported sale price of Dexcom&#8217;s common stock and the applicable conversion rate of the Notes on each such trading day</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we call any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date (only with respect to the notes called or deemed called for redemption)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of specified corporate events</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2023 Notes and 2028 Notes, until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding the maturity date (for the 2025 Notes, it is until the business day immediately preceding the maturity date), holders of the Notes may convert all or a portion of their notes regardless of the foregoing circumstances</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Circumstance 1 is available after the calendar quarter ending March&#160;31, 2019, September&#160;30, 2020, and September&#160;30, 2023 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively.</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Circumstance 5 is available on or after September&#160;1, 2023, August&#160;15, 2025, and February&#160;15, 2028 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.919%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Conversion Right at Option of the Company for the 2023, 2025, and 2028 Notes</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conversion Right at Our Option</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dexcom may redeem for cash all or part of the Notes, at its option, if the last reported sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-185" decimals="INF" name="dxcm:DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock" scale="-2" id="f-1003">130</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="trading_day" contextRef="c-214" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-1004">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="trading_day" contextRef="c-215" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-1005">30</ix:nonFraction> consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Dexcom provides notice of redemption. The redemption price will be equal to <ix:nonFraction unitRef="number" contextRef="c-185" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-1006">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Dexcom does not have the right to redeem the Notes prior to December&#160;1, 2021, May&#160;20, 2023, and May&#160;20, 2026 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively. Dexcom has the right to redeem the notes on or after December&#160;1, 2021 and prior to September&#160;1, 2023 for the 2023 Notes, on or after May&#160;20, 2023 and prior to August&#160;15, 2025 for the 2025 Notes, and on or after May&#160;20, 2026 and prior to February&#160;15, 2028 for the 2028 Notes.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/></tr></table></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_3120"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-924-5"><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Agreement</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Terms of the Revolving Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into the First Amendment to the Second Amended and Restated Credit Agreement (the "Amended Credit Agreement"), which we had previously entered into in October 2021. The Amended Credit Agreement is a <ix:nonNumeric contextRef="c-216" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1007">five-year</ix:nonNumeric> revolving credit facility, that provides for an available principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1008">200.0</ix:nonFraction> million which can be increased up to $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="INF" name="dxcm:LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount" format="ixt:num-dot-decimal" scale="6" id="f-1009">500.0</ix:nonFraction> million at our option subject to customary conditions and approval of our lenders (the &#8220;Credit Facility&#8221;). The Amended Credit Agreement will mature on October&#160;13, 2026. Borrowings under the Amended Credit Agreement are available for general corporate purposes, including working capital and capital expenditures.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="f-1010" continuedAt="f-1010-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to availability and outstanding borrowings on our Amended Credit Agreement is as follows as of the date indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available principal amount </span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1011">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Letters of credit sub-facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1012">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding borrowings </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="f-1013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding letters of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="f-1014">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total available balance</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="f-1015">192.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving loans under the Amended Credit Agreement bear interest at our choice of one of three base rates plus a range of applicable rates that are based on our leverage ratio. <ix:continuation id="f-1010-1" continuedAt="f-1010-2">The minimum and maximum range of applicable rates per annum with respect to any ABR Loan or, Term Benchmark Revolving Loan, RFR Revolving Loan (as defined in the Amended Credit Agreement) under the captions &#8220;ABR Spread&#8221;, &#8220;Term Benchmark/CDOR Spread&#8221;, &#8220;RFR Spread&#8221;, or &#8220;Unused Commitment Fee Rate&#8221;, respectively, are outlined in the following table:</ix:continuation></span></div><ix:continuation id="f-1010-2"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:17.961%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ABR Spread</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term Benchmark/CDOR Spread and RFR Spread</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unused Commitment Fee Rate</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1016">0.375</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-221" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1017">1.375</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-222" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-1018">0.175</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximum</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1019">1.000</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1020">2.000</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-225" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-1021">0.250</ix:nonFraction>%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Amended Credit Agreement are guaranteed by our existing and future wholly-owned domestic subsidiaries, and are secured by a first-priority security interest in substantially all of the assets of Dexcom and the guarantors, including all or a portion of the equity interests of our domestic subsidiaries and first-tier foreign subsidiaries but excluding real property and intellectual property (which is subject to a negative pledge). The Amended Credit Agreement contains covenants that limit certain indebtedness, liens, investments, transactions with affiliates, dividends and other restricted payments, subordinated indebtedness and amendments to subordinated indebtedness documents, and sale and leaseback transactions of Dexcom or any of its domestic subsidiaries. The Amended Credit Agreement also requires us to maintain a maximum leverage ratio and a minimum fixed charge coverage ratio. We were in compliance with these covenants as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we also have a guarantee facility related to our international operations which is collateralized by a $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DepositAssets" format="ixt:num-dot-decimal" scale="6" id="f-1022">5.5</ix:nonFraction>&#160;million term deposit that is included in non-current &#8220;Other assets&#8221; on our consolidated balance sheets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_349"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1027" continuedAt="f-1027-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-1026" continuedAt="f-1026-1" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. Leases and Other Commitments</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_352"></div><ix:continuation id="f-1027-1" continuedAt="f-1027-2"><ix:continuation id="f-1026-1" continuedAt="f-1026-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have leases for certain machinery and facilities, including office, manufacturing and warehouse space facilities under various domestic and international operating and finance lease arrangements. We also have land leases in Penang, Malaysia that expire through 2082 for the build-out of our international manufacturing facility. Our leases, excluding our land leases in Malaysia, have remaining lease terms of up to <ix:nonNumeric contextRef="c-91" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-1028">seventeen years</ix:nonNumeric>.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the leases include &#160;&#160;&#160;&#160;<ix:nonFraction unitRef="extensionoption" contextRef="c-90" decimals="INF" name="dxcm:LesseeOperatingLeaseNumberOfOptionsToExtend" format="ixt-sec:numwordsen" scale="0" id="f-1029">one</ix:nonFraction> or more options to extend the leases for up to <ix:nonNumeric contextRef="c-91" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1030">five years</ix:nonNumeric> per option. Our lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1032" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-1031" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of our operating and finance lease liabilities were as shown in the table below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-1033">26.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-1034">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-1035">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-1036">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-1037">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-1038">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-1039">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-1040">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-1041">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-1042">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="f-1043">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="f-1044">60.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="f-1045">117.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="f-1046">91.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-1047">16.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-1048">28.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of future payments</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1049">101.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="f-1050">63.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1051">Less: Current portion</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-1052">21.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-1053">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-1054">80.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-1055">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain lease agreements require us to return designated areas of leased space to its original condition upon termination of the lease agreement, for which we record an asset retirement obligation and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, the asset retirement obligation is accreted for the change in its present value and the capitalized asset is depreciated, both over the term of the associated lease agreement. Asset retirement obligations of $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AssetRetirementObligation" format="ixt:num-dot-decimal" scale="6" id="f-1056">15.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AssetRetirementObligation" format="ixt:num-dot-decimal" scale="6" id="f-1057">11.1</ix:nonFraction>&#160;million as of December&#160;31, 2023 and 2022, respectively, are included in <span style="-sec-ix-hidden:f-1058"><span style="-sec-ix-hidden:f-1059">other long-term liabilities</span></span> in our consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1060" continuedAt="f-1060-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-1061">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-1062">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-1063">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1064">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1065">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1066">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1067">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1068">22.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1069">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset impairment</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-1070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="f-1071">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:fixed-zero" scale="6" id="f-1072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-1073">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-1074">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-1075">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="f-1076">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="f-1077">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="f-1078">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1079">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1080">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-1081">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the result of the Company&#8217;s transition to a flexible working environment, we vacated a building in San Diego during the fourth quarter of 2022 and made it available for sublease. This resulted in an impairment indicator. We tested the asset group as of November 30, 2022 consisting primarily of the leasehold improvements and right-of-use asset for recoverability by comparing its carrying value to an estimate of future undiscounted cash flows. Based on the results of the recoverability test, we determined that the undiscounted cash flows of the asset group were below its carrying value. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1027-2" continuedAt="f-1027-3"><ix:continuation id="f-1026-2" continuedAt="f-1026-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the asset group by discounting the estimated future cash flows using level 3 fair value inputs under ASC 820 as described in Note 1. As a result of the impairment test, we recorded a non-cash charge of $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-1082">23.0</ix:nonFraction>&#160;million for the twelve months ended December 31, 2022 in the &#8220;<span style="-sec-ix-hidden:f-1083">Selling, general and administrative</span>&#8221; caption of our consolidated statements of operations. The fair value of the asset group immediately subsequent to the impairment was $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:ImpairedLongLivedAssetsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1084">2.5</ix:nonFraction>&#160;million and was categorized as Level 3 within the ASC 820, &#8220;Fair Value Measurements&#8221; fair value hierarchy.</span></div><ix:continuation id="f-1060-1"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to our leases is as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-1085">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-1086">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-1087">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="f-1088">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="f-1089">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="f-1090">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="f-1091">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="f-1092">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="f-1093">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-1094">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-1095">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-1096">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="f-1097">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="f-1098">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="f-1099">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-24" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1100">5.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-25" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1101">5.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-44" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1102">5.5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-24" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1103">14.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-25" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1104">15.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-44" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1105">15.9</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-24" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1106">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1107">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-44" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1108">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-24" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1109">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1110">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-44" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1111">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of operating lease right-of-use asset included in cash flows from operating activities in our consolidated statements of cash flows was </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:LesseeOperatingLeasesLeaseCostAmortization" scale="6" id="f-1112">16.5</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:LesseeOperatingLeasesLeaseCostAmortization" scale="6" id="f-1113">16.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:LesseeOperatingLeasesLeaseCostAmortization" scale="6" id="f-1114">18.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div></ix:continuation></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_355"></div><ix:continuation id="f-1027-3" continuedAt="f-1027-4"><ix:continuation id="f-1026-3" continuedAt="f-1026-4"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1027-4"><ix:continuation id="f-1026-4">We are party to various purchase arrangements related to our operational, manufacturing, and research and development activities. We had approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" format="ixt:num-dot-decimal" scale="6" id="f-1115">793.0</ix:nonFraction> million as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" format="ixt:num-dot-decimal" scale="6" id="f-1116">442.7</ix:nonFraction> million as of December&#160;31, 2022 of open purchase orders and contractual obligations in the ordinary course of business, the majority of which are due within <ix:nonNumeric contextRef="c-1" name="dxcm:RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm" format="ixt-sec:durwordsen" id="f-1117">one year</ix:nonNumeric></ix:continuation></ix:continuation>.</span></div><div id="i70f957301cc34339a22f629982cd0734_358"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-1118" escape="true"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. Contingencies</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between June 2021 through the year ended December 31, 2023, we and certain Abbott Diabetes Care, Inc. (&#8220;Abbott&#8221;) entities have served patent infringement complaints against each other in multiple jurisdictions against certain continuous glucose monitoring products of each company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainty surrounding patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time. We intend to protect our intellectual property and defend against Abbott&#8217;s claims vigorously in all of these actions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_361"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1119" continuedAt="f-1119-1" escape="true"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. Income Taxes</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1120" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes subject to taxes in the following jurisdictions is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1121">732.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1122">463.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="f-1123">318.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1124">22.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1125">72.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="f-1126">61.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1127">710.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1128">390.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1129">256.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1130" escape="true"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1131">149.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1132">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1133">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1134">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1135">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1136">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1137">56.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1138">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-1139">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income taxes</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1140">223.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1141">71.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1142">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1143">93.7</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1144">4.3</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-1145">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-1146">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-1147">17.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-1148">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1149">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1150">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-1151">7.0</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1152">55.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1153">21.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1154">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1155">168.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1156">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1157">39.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock" id="f-1159" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="f-1158" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant loss and tax credit carryforwards and years of expiration are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year of Expiration</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1160">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1161">28.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1162">167.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1163">185.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other states</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1164">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1165">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UK</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="6" id="f-1166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1167">90.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1168">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1169">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:fixed-zero" scale="6" id="f-1170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:fixed-zero" scale="6" id="f-1171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credits</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1172">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:fixed-zero" scale="6" id="f-1173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1174">111.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1175">96.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California AMT Credits</span></div></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1176">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:fixed-zero" scale="6" id="f-1177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of net operating losses and credit carryforwards is subject to an annual limitation due to ownership change limitations provided by Section&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. An ownership change limitation occurred as a result of the stock offering completed in February 2009. The limitation will result in approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:UnusedExpiredFederalIncomeTaxCredits" format="ixt:num-dot-decimal" scale="6" id="f-1178">1.5</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of U.S. research and development tax credits that will expire unused, and is therefore, not reflected in the tax credit carryforwards above. In addition, the related deferred tax assets have been removed from the components of our deferred tax assets as summarized in the table below. The tax benefits related to the remaining federal and state net operating losses and tax credit carryforwards may be further limited or lost if future cumulative changes in ownership exceed 50% within any three-year period.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1119-1" continuedAt="f-1119-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below. Significant judgment is required to evaluate the need for a valuation allowance against deferred tax assets. We review all available positive and negative evidence, including projections of pre-tax book income, earnings history, reliability of forecasting, and reversal of temporary differences. A valuation allowance is established when it is more likely than not that some or all of the deferred tax assets will not be realized. Realization of deferred tax assets is dependent upon future earnings in applicable tax jurisdictions.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1179" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-1180">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-1181">46.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="f-1182">233.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="f-1183">211.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="f-1184">71.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="f-1185">61.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1186">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-1187">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed and intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:DeferredTaxAssetsFixedAssetsAndIntangibleAssets" scale="6" id="f-1188">279.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:DeferredTaxAssetsFixedAssetsAndIntangibleAssets" scale="6" id="f-1189">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities and reserves</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="f-1190">91.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="f-1191">105.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" sign="-" name="dxcm:DeferredTaxAssetsConvertibleDebt" scale="6" id="f-1192">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" sign="-" name="dxcm:DeferredTaxAssetsConvertibleDebt" scale="6" id="f-1193">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-1194">741.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-1195">485.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1196">264.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1197">78.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net deferred tax assets</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="f-1198">477.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="f-1199">406.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets and acquired intangibles assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="6" id="f-1200">60.4</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="dxcm:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="6" id="f-1201">69.9</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="6" id="f-1202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1203">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-1204">60.4</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-1205">70.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="f-1206">416.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="f-1207">336.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we completed an intra-entity asset transfer of certain intellectual property between two of our wholly owned foreign subsidiaries to align our structure with the expansion of international business operations. We recorded a $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" format="ixt:num-dot-decimal" scale="6" id="f-1208">193.2</ix:nonFraction>&#160;million deferred tax asset, which represents the difference between the basis of the intellectual property for financial statement and tax purposes, applying the appropriate enacted statutory tax rate. Based on available evidence, management believes it is not more-likely-than-not that the additional foreign deferred tax asset will be realizable, and is therefore, fully offset by a valuation allowance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1209">264.3</ix:nonFraction> million against our California research and development tax credits, foreign tax credits, and certain foreign intangible assets. During the year ended December&#160;31, 2023, the valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-1210">185.5</ix:nonFraction> million primarily due to generation of California research and development tax credits, and establishing a valuation allowance against the fair value of certain intellectual property located in Ireland in connection with the intra-entity transfer of this property.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1119-2" continuedAt="f-1119-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1211" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between our effective tax rate on income (loss) from continuing operations and the statutory rate is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal statutory tax rate</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1212">149.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1213">82.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1214">53.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1215">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1216">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1217">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent items</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="dxcm:EffectiveIncomeTaxReconciliationPermanentItems" scale="6" id="f-1218">2.7</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:EffectiveIncomeTaxReconciliationPermanentItems" scale="6" id="f-1219">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:EffectiveIncomeTaxReconciliationPermanentItems" scale="6" id="f-1220">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="f-1221">28.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="f-1222">23.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="f-1223">28.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credit</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:fixed-zero" scale="6" id="f-1224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:fixed-zero" scale="6" id="f-1225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="6" id="f-1226">3.7</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="f-1227">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="f-1228">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="f-1229">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock and officers compensation</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1230">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1231">1.2</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1232">20.4</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreement milestone share-based payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="dxcm:EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" scale="6" id="f-1233">72.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" sign="-" name="dxcm:EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" scale="6" id="f-1234">52.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" format="ixt:fixed-zero" scale="6" id="f-1235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in statutory tax rates</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="f-1236">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="f-1237">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="f-1238">10.0</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property transfer</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" scale="6" id="f-1239">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" format="ixt:fixed-zero" scale="6" id="f-1240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" format="ixt:fixed-zero" scale="6" id="f-1241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="f-1242">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="f-1243">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="f-1244">0.4</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-1245">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-1246">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-1247">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes at effective rates</span></div></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1248">168.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1249">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1250">39.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="f-1251" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our gross unrecognized tax benefits:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.035%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at January&#160;1, 2021</span></div></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1252">36.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to prior year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1253">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1254">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1255">46.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreases related to prior year tax positions </span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1256">0.9</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1257">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1258">52.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to prior year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-1259">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-1260">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-1261">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total unrecognized tax benefits at December 31, 2023, 2022, and 2021, $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1262">37.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1263">32.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1264">29.5</ix:nonFraction>&#160;million, respectively, would affect our annual effective tax rate if recognized. Also included in the balance of unrecognized tax benefits at December&#160;31, 2023 is $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="dxcm:UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-1265">0.2</ix:nonFraction>&#160;million of tax benefits that, if recognized, would result in adjustments to other tax accounts, primarily deferred tax assets. Interest and penalties are classified as a component of income tax expense and were not material for any period presented. Although the timing and outcome of audit settlements are uncertain, it is unlikely there will be a significant reduction of the uncertain tax benefits in the next twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our global business activities, we file income tax returns and are subject to routine compliance audits in numerous jurisdictions, including those material jurisdictions listed in the following table. The U.S. net operating losses generated since 1999 and utilized in recent years are open for examination. <ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfIncomeTaxExaminationsTextBlock" id="f-1266" continuedAt="f-1266-1" escape="true">The years remaining subject to audit, by major jurisdiction, are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1266-1"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.035%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States (Federal and state)</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1999 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 - 2023</span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1119-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate under a tax holiday in the Philippines, which is effective through April 30, 2023, and may be extended for another <ix:nonNumeric contextRef="c-1" name="dxcm:PossibleExtensionPeriodofTaxHoliday" format="ixt-sec:durwordsen" id="f-1267">three years</ix:nonNumeric> if certain additional requirements are satisfied. The tax holiday is conditional upon remaining in good standing, committing no violation of Philippine Economic Zone Authority Rules and Regulations, pertinent circulars and directives. After the expiration of the tax holiday we are still entitled to a preferential rate for a period of <ix:nonNumeric contextRef="c-1" name="dxcm:PreferentialTaxRatePeriod" format="ixt-sec:duryear" id="f-1268">10</ix:nonNumeric> years. Therefore from April 30, 2023 through December 31, 2023 we are still subject to a reduced rate of tax. The impact of this tax holiday and preferential rate was immaterial in in 2023, 2022, and 2021. We have been granted an investment tax allowance incentive by the Malaysian Investment Development Authority (MIDA) in Malaysia, which will not be triggered until we meet certain milestones related to the commencement of operations. The tax incentive had no effect on foreign taxes during 2023, 2022, or 2021. As of December 31, 2023 the tax holiday in Malaysia has not yet been triggered, therefore we are subject to the statutory rate and the related tax expense has been included in total tax expense for 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have approximately $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-1269">36.5</ix:nonFraction>&#160;million of undistributed earnings attributable to operations in our controlled foreign corporations as of December 31, 2023. We assert that any foreign earnings will be indefinitely reinvested. Accordingly, we have not recorded a liability for taxes associated with these undistributed earnings. If we determine that all or a portion of such foreign earnings are no longer indefinitely reinvested, we may be subject to additional foreign withholding taxes and U.S. state income taxes. Determination of the amount of unrecognized deferred tax liability on these unremitted earnings is not practicable.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_364"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-1270" continuedAt="f-1270-1" escape="true"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. Employee Benefit Plans and Stockholders&#8217; Equity</span></td></tr></table></div></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_2977"></div><ix:continuation id="f-1270-1" continuedAt="f-1270-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer various defined contribution plans for U.S. and international employees. The largest defined contribution plan is the 401(k) retirement plan (the 401(k) Plan) covering substantially all employees in the United States that meet certain age requirements. Employees who participate in the 401(k) Plan may contribute up to <ix:nonFraction unitRef="number" contextRef="c-246" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-1271">90</ix:nonFraction>% of their compensation each year, subject to Internal Revenue Service limitations and the terms and conditions of the plan. Under the terms of the 401(k) Plan, we may elect to match a discretionary percentage of contributions. We match <ix:nonFraction unitRef="number" contextRef="c-246" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1272">50</ix:nonFraction>% of contributions up to <ix:nonFraction unitRef="number" contextRef="c-246" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1273">6</ix:nonFraction>% of eligible compensation. Total matching contributions under the 401(k) Plan were $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1274">14.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1275">11.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1276">9.9</ix:nonFraction>&#160;million for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively. Our contributions for other defined contribution plans are not significant for the twelve months ended December&#160;31, 2023, 2022 and 2021.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_2953"></div><ix:continuation id="f-1270-2" continuedAt="f-1270-3"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2015 Employee Stock Purchase Plan (the 2015 ESPP), amended in December 2019, eligible employees may purchase shares of our common stock at semi-annual intervals through periodic payroll deductions during defined Offering Periods. Payroll deductions may not exceed <ix:nonFraction unitRef="number" contextRef="c-24" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-1277">10</ix:nonFraction>% of the participant&#8217;s cash compensation subject to certain limitations, and the purchase price will be <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="dxcm:EmployeePurchasePriceFloorPercentage" scale="-2" id="f-1278">85</ix:nonFraction>% of the lower of the fair market value of the common stock at either the beginning of the applicable Offering Period or the Purchase Date. A total of <ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="dxcm:EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized" scale="6" id="f-1279">6.0</ix:nonFraction> million shares of common stock are reserved for issuance under the 2015 ESPP. The 2015 ESPP shall continue until the earlier to occur of (a) termination of the 2015 ESPP by our Board of Directors, (b) issuance of all of the shares of common stock reserved for issuance under the plan, or (c) May&#160;28, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued approximately <ix:nonFraction unitRef="shares" contextRef="c-249" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="f-1280">0.3</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="f-1281">0.3</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="f-1282">0.3</ix:nonFraction> million shares of common stock under the 2015 ESPP during the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively. As of December&#160;31, 2023, approximately <ix:nonFraction unitRef="shares" contextRef="c-252" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1283">2.5</ix:nonFraction> million shares remained available for future issuance under the 2015 ESPP.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_2929"></div><ix:continuation id="f-1270-3" continuedAt="f-1270-4"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2015, we adopted the Amended and Restated 2015 Equity Incentive Plan (the 2015 Plan), which replaced our 2005 Equity Incentive Plan and provides for the grant of incentive and nonstatutory stock options, restricted stock, stock bonuses, stock appreciation rights, RSUs, and PSUs to employees, directors or consultants of the Company. On May 30, 2019, our stockholders approved an increase to the maximum number of shares that may be issued under the 2015 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue up to&#160;<ix:nonFraction unitRef="shares" contextRef="c-253" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1284">39.2</ix:nonFraction> million&#160;shares of our common stock under the 2015 Plan. As of December&#160;31, 2023, approximately <ix:nonFraction unitRef="shares" contextRef="c-254" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1285">13.9</ix:nonFraction> million shares remained available for future issuance under the 2015 Plan. We issue new shares of common stock to satisfy RSU and PSU vesting under our employee equity incentive plans.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1270-4" continuedAt="f-1270-5">RSU awards typically vest in annual installments over <span style="-sec-ix-hidden:f-1286">three</span> or <ix:nonNumeric contextRef="c-256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1287">four years</ix:nonNumeric> and vesting is subject to continued service. PSUs are granted to a group of senior officers and the number of shares of our common stock to be received at vesting will range from <ix:nonFraction unitRef="number" contextRef="c-257" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1288">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-258" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1289">200</ix:nonFraction>% of the target award based on the achievement of pre-established performance and market goals. PSUs vest approximately <ix:nonNumeric contextRef="c-259" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1290">three years</ix:nonNumeric> from the date of grant, subject to continued employment through that date and certification by the Compensation Committee</ix:continuation>.</span></div><div id="i70f957301cc34339a22f629982cd0734_2905"></div><ix:continuation id="f-1270-5" continuedAt="f-1270-6"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program and Treasury Shares</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchased shares of our common stock are held as treasury shares until they are reissued or retired. When we reissue treasury stock, if the proceeds from the sale are more than the average price we paid to acquire the shares we record an increase in additional paid-in capital. Conversely, if the proceeds from the sale are less than the average price we paid to acquire the shares, we record a decrease in additional paid-in capital to the extent of increases previously recorded for similar transactions and a decrease in retained earnings for any remaining amount.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1270-6" continuedAt="f-1270-7"><ix:nonNumeric contextRef="c-1" name="dxcm:ScheduleOfTreasuryShareActivityTableTextBlock" id="f-1291" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our treasury share activity for the periods shown.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued in connection with 2023 Notes conversions</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="6" id="f-1292">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="6" id="f-1293">0.4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="6" id="f-1294">0.8</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares received from Note Hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="dxcm:SharesReceivedFromExerciseOfNoteHedge" scale="6" id="f-1295">12.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="dxcm:SharesReceivedFromExerciseOfNoteHedge" scale="6" id="f-1296">0.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="dxcm:SharesReceivedFromExerciseOfNoteHedge" scale="6" id="f-1297">1.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued in connection with the Restated Collaboration Agreement</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone" scale="6" id="f-1298">3.7</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone" scale="6" id="f-1299">2.9</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone" format="ixt:fixed-zero" scale="6" id="f-1300">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares repurchased under the 2022 Share Repurchase Program</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-260" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1301">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-261" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-1302">6.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1303">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares repurchased under the 2023 Share Repurchase Program</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-263" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-1304">4.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-264" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1305">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-265" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1306">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares repurchased with 2028 Notes proceeds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-1307">1.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-267" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1308">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1309">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2022, a duly authorized committee of our Board of Directors authorized and approved a share repurchase program of up to $<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1310">700.0</ix:nonFraction>&#160;million of our outstanding common stock, with a repurchase period that ended on June 30, 2023 (the &#8220;2022 Share Repurchase Program&#8221;). Shares of common stock repurchased under the 2022 Share Repurchase Program became treasury shares. We repurchased approximately $<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1311">557.7</ix:nonFraction> million of our outstanding common stock throughout the duration of the 2022 Share Repurchase Program. The 2022 Share Repurchase Program and the remaining authorization of approximately $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1312">142.3</ix:nonFraction>&#160;million expired on June 30, 2023. There were <ix:nonFraction unitRef="usd" contextRef="c-272" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="0" id="f-1313">no</ix:nonFraction> share repurchases under the 2022 Share Repurchase Program in 2023. On August 1, 2022, we entered into an accelerated share repurchase agreement (&#8220;2022 ASR&#8221;) with JPMorgan Chase Bank, National Association (&#8220;JP Morgan&#8221;) to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-273" decimals="INF" name="dxcm:AcceleratedShareRepurchaseAgreementAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-1314">700.0</ix:nonFraction>&#160;million of our common stock on an accelerated basis through September 29, 2022. On August 3, 2022, we paid $<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-1315">700.0</ix:nonFraction>&#160;million to JP Morgan and received an initial delivery of approximately <ix:nonFraction unitRef="shares" contextRef="c-274" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1316">3.0</ix:nonFraction> million shares of common stock. The final notional amount under the 2022 ASR was $<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1317">557.7</ix:nonFraction>&#160;million or approximately <ix:nonFraction unitRef="shares" contextRef="c-270" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1318">6.6</ix:nonFraction>&#160;million shares of our common stock based on the daily average volume-weighted average price of our common stock during the term of the 2022 ASR for the period from August 1, 2022 to August 31, 2022, less a discount. The 2022 ASR concluded on September 1, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 24, 2023, our Board of Directors authorized and approved a share repurchase program of up to $<ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1319">500.0</ix:nonFraction>&#160;million of our outstanding common stock, with a repurchase period ending no later than October 31, 2024 (the &#8220;2023 Share Repurchase Program&#8221;). On October 31, 2023, we entered into an accelerated share repurchase agreement (&#8220;2023 ASR&#8221;) with Bank of America, N.A. (&#8220;BofA&#8221;) to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-276" decimals="INF" name="dxcm:AcceleratedShareRepurchaseAgreementAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-1320">500.0</ix:nonFraction> million of our common stock on an accelerated basis through December 14, 2023. On October 31, 2023, we paid $<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-1321">500.0</ix:nonFraction> million to BofA and received an initial delivery of approximately <ix:nonFraction unitRef="shares" contextRef="c-277" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1322">4.7</ix:nonFraction> million shares of common stock. The final notional amount under the 2023 ASR was $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1323">500.0</ix:nonFraction> million or approximately <ix:nonFraction unitRef="shares" contextRef="c-278" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1324">4.7</ix:nonFraction> million shares of our common stock based on the daily average volume-weighted average price of our common stock during the term of the 2023 ASR for the period from November 1, 2023 to December 14, 2023, less a discount. The 2023 ASR concluded on December 14, 2023. After completion of the repurchases under the 2023 ASR, no shares remained available for additional repurchases under our 2023 Share Repurchase Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 ASR and 2023 ASR were forward contracts indexed to our own common stock. The forward contracts met all of the applicable criteria for equity classification, so we did not account for them as a derivative instrument. We have reflected the shares delivered to us by the financial institution as treasury shares as of the dates they were delivered to us in computing weighted average shares outstanding for both basic and diluted net income per share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we used a portion of the proceeds of the 2028 Notes to repurchase <ix:nonFraction unitRef="shares" contextRef="c-279" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1325">1.6</ix:nonFraction> million shares of our common stock for $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1326">188.7</ix:nonFraction> million, excluding excise tax due under the Inflation Reduction Act of 2022, for an average per share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-279" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1327">118.12</ix:nonFraction>, via privately negotiated transactions, independent of the 2022 Share Repurchase Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchased shares of our common stock are held as treasury shares until they are reissued or retired. We have not yet determined the ultimate disposition of repurchased shares and consequently we continue to hold them as treasury shares rather than retiring them. Authorization of future stock repurchase programs is subject to the final determination of our Board of Directors.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_2857"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1270-7" continuedAt="f-1270-8"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Award Activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-1328" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU and PSU activity under the 2015 Plan for the twelve months ended December&#160;31, 2023, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:22.5pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nonvested RSU and PSU Activity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except weighted average grant date fair value)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Available for Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted&#160;<br/>Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-1329">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-1330">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-281" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1331">45.88</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-282" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="6" id="f-1332">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-1333">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1334">87.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="-5" name="dxcm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" format="ixt:fixed-zero" scale="6" id="f-1335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-283" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="f-1336">2.9</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1337">34.47</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="6" id="f-1338">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-283" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="f-1339">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1340">69.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-284" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-1341">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-285" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-1342">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-285" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1343">76.88</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="f-1344">403.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-286" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="6" id="f-1345">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-287" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-1346">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-287" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1347">96.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-286" decimals="-5" name="dxcm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" format="ixt:fixed-zero" scale="6" id="f-1348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-287" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="f-1349">1.6</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-287" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1350">63.90</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-286" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="6" id="f-1351">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-287" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="f-1352">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-287" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1353">92.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-288" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-1354">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-289" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-1355">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-289" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1356">94.08</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="f-1357">325.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-290" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="6" id="f-1358">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-291" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="f-1359">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-291" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1360">112.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-290" decimals="-5" name="dxcm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" format="ixt:fixed-zero" scale="6" id="f-1361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-291" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="f-1362">1.4</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-291" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1363">88.57</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-290" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="6" id="f-1364">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-291" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="f-1365">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-291" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1366">106.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-292" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-1367">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-254" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="f-1368">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-254" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1369">105.98</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="f-1370">361.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vest-date fair value of RSUs and PSUs that vested during the twelve months ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1371">157.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1372">160.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-1373">284.5</ix:nonFraction> million, respectively. As of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-296" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="f-1374">2.6</ix:nonFraction> million unvested RSUs and <ix:nonFraction unitRef="shares" contextRef="c-297" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="f-1375">0.3</ix:nonFraction> million unvested PSUs were outstanding under the 2015 Plan.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_2833"></div><ix:continuation id="f-1270-8"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share-based compensation expense is associated with RSUs, PSUs, and ESPP. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1376" continuedAt="f-1376-1" escape="true">The following table summarizes the share-based compensation expense included in our consolidated statements of operations for the periods shown.</ix:nonNumeric></span></div><ix:continuation id="f-1376-1"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1377">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1378">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1379">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1380">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1381">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1382">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1383">90.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1384">72.7</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1385">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1386">150.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1387">126.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1388">113.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total tax benefit related to share-based compensation expense</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1389">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1390">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1391">71.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, unrecognized estimated compensation costs related to RSUs and PSUs totaled $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-1392">199.5</ix:nonFraction> million and are expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-291" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1393">1.7</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value RSUs at the date of grant using the intrinsic value method. We estimate the fair value of PSUs at the date of grant using the intrinsic value method and the probability that the specified performance criteria will be met. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="f-1394" continuedAt="f-1394-1" escape="true">We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.</ix:nonNumeric></span></div><ix:continuation id="f-1394-1"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-307" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1395">5.20</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-308" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1396">5.47</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-309" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1397">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-310" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1398">3.34</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-311" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1399">0.06</ix:nonFraction>%&#160;- <ix:nonFraction unitRef="number" contextRef="c-312" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1400">0.07</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-313" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-314" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-315" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility of Dexcom common stock</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-307" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1404">34</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-308" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1405">48</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-309" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1406">45</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-310" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1407">55</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-311" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1408">36</ix:nonFraction>%&#160;- <ix:nonFraction unitRef="number" contextRef="c-312" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1409">45</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-313" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1410">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-314" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1411">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-315" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1412">0.5</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_370"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1413" continuedAt="f-1413-1" escape="true"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. Business Segment and Geographic Information</span></td></tr></table></div></ix:nonNumeric><div id="i70f957301cc34339a22f629982cd0734_3002"></div><ix:continuation id="f-1413-1" continuedAt="f-1413-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An operating segment is identified as a component of a business that has discrete financial information available and for which the chief operating decision maker must decide the level of resource allocation. In addition, the guidance for segment reporting indicates certain quantitative materiality thresholds. None of the components of our business meet the definition of an operating segment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently consider our operations to be, and manage our business globally within, <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1414">one</ix:nonFraction> reportable segment, which is consistent with how our President and Chief Executive Officer, who is our chief operating decision maker, reviews our business, makes investment and resource allocation decisions, and assesses operating performance.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_3072"></div><ix:continuation id="f-1413-2" continuedAt="f-1413-3"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We disaggregate revenue by geographic region and by major sales channel. We have determined that disaggregating revenue into these categories achieves the ASC Topic 606 disclosure objectives of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</span></div></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_3026"></div><ix:continuation id="f-1413-3" continuedAt="f-1413-4"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by geographic region</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended December&#160;31, 2023, 2022 and 2021, no individual country outside the United States generated revenue that represented more than 10% of our total revenue. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1415" continuedAt="f-1415-1" escape="true">The following table sets forth revenue by our <ix:nonFraction unitRef="primarymarket" contextRef="c-1" decimals="INF" name="dxcm:NumberOfPrimaryGeographicMarkets" format="ixt-sec:numwordsen" scale="0" id="f-1416">two</ix:nonFraction> primary geographical markets, the United States and International, based on the geographic location to which we deliver the components, for the periods shown:</ix:nonNumeric></span></div><ix:continuation id="f-1415-1" continuedAt="f-1415-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1417">2,625.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-316" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1418">72</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1419">2,142.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-317" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1420">74</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1421">1,849.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-318" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1422">76</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1423">997.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-319" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1424">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1425">767.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-320" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1426">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1427">599.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-321" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1428">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1429">3,622.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1430">100</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1431">2,909.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1432">100</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1433">2,448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1434">100</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_3049"></div><ix:continuation id="f-1413-4" continuedAt="f-1413-5"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by customer sales channel</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our CGM systems through a direct sales organization and through distribution arrangements that allow distributors to sell our products. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-1435" continuedAt="f-1435-1" escape="true">The following table sets forth revenue by major sales channel for the twelve months ended December&#160;31, 2023, 2022 and 2021:</ix:nonNumeric></span></div><ix:continuation id="f-1435-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.446%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributor</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1436">3,095.6</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-322" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1437">85</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1438">2,470.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-323" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1439">85</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1440">2,024.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-324" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1441">83</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1442">526.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-325" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1443">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1444">439.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-326" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1445">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1446">424.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-327" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1447">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1448">3,622.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1449">100</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1450">2,909.8</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1451">100</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1452">2,448.5</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="2" name="dxcm:RevenuePercentage" scale="-2" id="f-1453">100</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div id="i70f957301cc34339a22f629982cd0734_3313"></div><ix:continuation id="f-1413-5"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Information</span></div><ix:continuation id="f-1415-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our long-lived assets, which consists of property and equipment, net, and operating lease right-of-use assets by geographic region:</span></div><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1454">544.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1455">686.1</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1456">515.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1457">346.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other countries</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1458">125.0</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="f-1459">103.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-lived assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1460">1,184.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1461">1,135.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><div id="i70f957301cc34339a22f629982cd0734_376"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="f-1462" escape="true"><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DexCom, Inc.</span></div></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE II</span><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8211; </span><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for doubtful accounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning Balance</span></div></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1463">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1464">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1465">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-1466">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-1467">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-1468">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-offs and adjustments</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="dxcm:SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" format="ixt:fixed-zero" scale="6" id="f-1469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="dxcm:SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" scale="6" id="f-1470">0.5</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="dxcm:SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" scale="6" id="f-1471">0.5</ix:nonFraction>)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesRecoveries" format="ixt:fixed-zero" scale="6" id="f-1472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesRecoveries" format="ixt:fixed-zero" scale="6" id="f-1473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesRecoveries" scale="6" id="f-1474">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending Balance</span></div></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1475">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1476">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"/><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1477">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>dxcm12312023ex45-securitie.htm
<DESCRIPTION>EX-4.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8000feda8e144bb9a15b6da3db8344fc_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.5</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As of December 31, 2023, DexCom, Inc. (the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;our&#8221;) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934&#58; our common stock.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Capital Stock</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary of the terms of our capital stock is based upon our restated certificate of incorporation and our restated bylaws. The summary is not complete, and is qualified by reference to our restated certificate of incorporation and our restated bylaws, each of which are incorporated by reference as exhibits to the Annual Report on Form 10-K to which this Exhibit 4.5 is attached and are incorporated by reference herein. We encourage you to read our restated certificate of incorporation, our restated bylaws, and the applicable provisions of the Delaware General Corporation Law, or DGCL, for additional information.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized Shares</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have authorized capital stock consisting of 800,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of undesignated preferred stock, $0.001 par value per share.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend rights</font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting rights</font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">No preemptive or similar rights</font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right to receive liquidation distributions</font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors is authorized, subject to limitations prescribed by the DGCL, to issue from time to time up to 5,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors is also able to increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may be able to authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exclusive Forum</font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our restated certificate of incorporation, or our amended and restated bylaws, any action to interpret, apply, enforce or determine the validity of  our restated certificate of incorporation, or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complain asserting a cause of action arising under the Securities Act.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Takeover Provisions</font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of the DGCL, our restated certificate of incorporation, and our restated bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware Law</font></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, DGCL Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation&#8217;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that DGCL Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restated Certificate of Incorporation and Restated Bylaws Provisions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation and our restated bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following&#58;</font></div><div style="margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board of directors vacancies.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Our restated certificate of incorporation and restated bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholder action&#59; special meetings of stockholders.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Our restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws and restated certificate of incorporation provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairperson of our board of directors, our chief executive officer, our president or our lead independent director, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advance notice requirements for stockholder proposals and director nominations.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Our restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No cumulative voting.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our restated certificate of incorporation does not provide for cumulative voting.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance of undesignated preferred stock.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Our board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Listing </font></div><div style="margin-top:4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;DXCM.&#8221;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="margin-top:4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for our Common Stock is Equiniti Trust Company, LLC. Its address is PO Box 500 Newark, NJ 07101 and its telephone number is (718) 921-8200.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>3
<FILENAME>dxcm12312023ex1012-2015emp.htm
<DESCRIPTION>EX-10.12
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i344e9ea2d36f47fc8658d75fe24587b5_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 EMPLOYEE STOCK PURCHASE PLAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective On May 28, 2015, As Amended On December 13, 2019</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">PURPOSE. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company through payroll deductions, to enhance such employees&#8217; sense of participation in the affairs of the Company. Capitalized terms not defined elsewhere in the text are defined in Section 28.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">ESTABLISHMENT OF PLAN. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company proposes to grant rights to purchase shares of Common Stock to eligible employees of the Company and its Participating Corporations pursuant to this Plan. The Company intends this Plan to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Code (including any amendments to or replacements of such Section), and this Plan shall be so construed. Any term not expressly defined in this Plan but defined for purposes of Section 423 of the Code shall have the same definition herein. In addition, with regard to offers of options to purchase shares of the Common Stock under the Plan to employees working for a Subsidiary or an Affiliate outside the United States, the Board or Committee (as defined herein) may offer a subplan or an option that is not intended to meet the Code Section 423 requirements, provided, if necessary under Code Section 423, that the other terms and conditions of the Plan are met.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to Section 14, a total of 6,000,000 Shares are reserved for issuance under this Plan. The number of shares initially reserved for issuance under this Plan and the maximum number of shares that may be issued under this Plan shall be subject to adjustments effected in accordance with Section 14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">ADMINISTRATION.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Plan will be administered by the Committee. Subject to the provisions of this Plan and the limitations of Section 423 of the Code or any successor provision in the Code, all questions of interpretation or application of this Plan shall be determined by the Committee and its decisions shall be final and binding upon all Participants. The Committee will have full and exclusive discretionary authority to construe, interpret and apply the terms of the Plan, to determine eligibility, to designate the Participating Corporations, to determine when to grant options that are not intended to meet the Code Section 423 requirements and to decide upon any and all claims filed under the Plan. Every finding, decision and determination made by the Committee will, to the full extent permitted by law, be final and binding upon all parties. Notwithstanding any provision to the contrary in this Plan, the Committee may adopt rules, sub-plans, and&#47;or procedures relating to the operation and administration of the Plan designed to comply with local laws, regulations or customs or to achieve tax, securities law or other objectives for eligible employees outside of the United States. The Committee will have the authority to determine the Fair Market Value of the Common Stock (which determination shall be final, binding and conclusive for all purposes) in accordance with Section 8 below and to interpret Section 8 of the Plan in connection with circumstances that impact the Fair Market Value. Members of the Committee shall receive no compensation for their services in connection with the administration of this Plan, other than standard fees as established from time to time by the Board for services rendered by Board members serving on Board committees. All expenses incurred in connection with the administration of this Plan shall be paid by the Company. For purposes of this Plan, the Committee may designate separate offerings under the Plan (the terms of which need not be identical) in which eligible employees of one or more Participating Corporations will participate, even if the dates of the applicable Offering Periods of each such offering are identical.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">ELIGIBILITY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Any employee of the Company or the Participating Corporations is eligible to participate in an Offering Period under this Plan, except that one or more of the following categories of employees may be excluded from coverage under the Plan by the Committee (other than where prohibited by applicable law)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">Employees who are not employed by the Company or a Participating Corporation prior to the beginning of such Offering Period or prior to such other time period as specified by the Committee&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">employees who are customarily employed for twenty (20) hours or less per week&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">employees who are customarily employed for five (5) months or less in a calendar year&#59; and</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Reflects June 10, 2022 four-for-one forward stock split.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">employees who have been an employee of the Company for less than thirty (30) days prior to the first day of an Offering Period (or such longer period of time, not to exceed two (2) years, as determined by the Committee)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">employees who do not meet any other eligibility requirements that the Committee may choose to impose (within the limits permitted by the Code).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The foregoing notwithstanding, an individual shall not be eligible if his or her participation in the Plan is prohibited by the law of any country that has jurisdiction over him or her, if complying with the laws of the applicable country would cause the Plan to violate Section 423 of the Code, or if he or she is subject to a collective bargaining agreement that does not provide for participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">No employee who, together with any other person whose stock would be attributed to such employee pursuant to Section 424(d) of the Code, owns stock or holds options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or its Parent or Subsidiary or who, as a result of being granted an option under this Plan with respect to such Offering Period, would own stock or hold options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or its Parent or Subsidiary shall be granted an option to purchase Common Stock under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">OFFERING DATES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The offering periods of this Plan (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Offering Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) are described below. Each Offering Period shall consist of one or more purchase periods (individually, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Purchase Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) during which payroll deductions of the Participants are accumulated under this Plan. The first business day of each Offering Period is referred to as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Offering Date.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; The last business day of each Purchase Period is referred to as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Purchase Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; The Committee shall have the power to change the Offering Dates, the Purchase Dates, the duration of Offering Periods (provided that an Offering Period will in no event be longer than twenty-seven (27) months), and the Purchase Periods, in each case without stockholder approval if such change is announced prior to the relevant Offering Period or prior to such other time period as specified by the Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">All Offering Periods that commence following the Amendment Date shall be of six (6) months duration commencing on March 1 and September 1 of each year and respectively ending on August 31</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and February 28</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (or the 29</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> if February has 29 days) of each year. Each such Offering Period shall consist of one six (6)-month Purchase Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Offering Periods that commenced on March 1, 2019 and September 1, 2019 shall continue in accordance with the terms of the Plan prior to the Amendment Date and shall respectively end on February 29</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or August 31</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">PARTICIPATION IN THIS PLAN.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Any employee who is an eligible employee determined in accordance with Section&#160;4 immediately prior to an Offering Period will be eligible to participate in this Plan, subject to the requirement of Section 6(b) hereof and the other terms and provisions of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">With respect to each Offering Period, a Participant may elect to participate in this Plan by submitting an enrollment agreement (or any electronic or online enrollment form provided by the Company) prior to the commencement of the Offering Period (or such earlier date as the Committee may determine) to which such agreement (or any electronic or online enrollment form provided by the Company) relates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Once an employee becomes a Participant in an Offering Period, then such Participant will automatically participate in each subsequent Offering Period commencing immediately following the last day of the prior Offering Period unless the Participant withdraws or is deemed to withdraw from this Plan or terminates further participation in an Offering Period as set forth in Section 11 below. A Participant who is continuing participation pursuant to the preceding sentence is not required to file any additional enrollment agreement in order to continue participation in this Plan&#59; a Participant who is not continuing participation pursuant to the preceding sentence is required to file an enrollment agreement (or any electronic or online enrollment form provided by the Company) prior to the commencement of the Offering Period (or such earlier date as the Committee may determine) to which such agreement (or any electronic or online enrollment form provided by the Company) relates.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">GRANT OF OPTION ON ENROLLMENT.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Becoming a Participant with respect to an Offering Period will constitute the grant (as of the Offering Date) by the Company to such Participant of an option to purchase on the Purchase Date up to that number of shares of Common Stock of the Company determined by a fraction, the numerator of which is the amount accumulated in such Participant&#8217;s payroll deduction account during such Purchase Period and the denominator of which is the lower of (i) eighty-five percent (85%) of the Fair Market Value of a share of Common Stock on the Offering Date (but in no event less than the par value of a share of the Common Stock), or (ii) eighty-five percent (85%) of the Fair Market Value of a share of the Common Stock on the Purchase Date, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that the number of shares of Common Stock subject to any option granted pursuant to this Plan shall not exceed the lesser of (x) the maximum number of shares set by the Committee pursuant to Section 10(b) below with respect to the applicable Purchase Date, or (y) the maximum number of shares which may be purchased pursuant to Section 10(a) below with respect to the applicable Purchase Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">PURCHASE PRICE.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Purchase Price per share at which a share of Common Stock will be sold in any Offering Period shall be eighty-five percent (85%) of the lesser of&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The Fair Market Value on the Offering Date&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The Fair Market Value on the Purchase Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">PAYMENT OF PURCHASE PRICE&#59; PAYROLL DEDUCTION CHANGES&#59; SHARE ISSUANCES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The Purchase Price shall be accumulated by regular payroll deductions made during each Offering Period, unless the Committee determines with respect to categories of Participants outside the United States that contributions may be made in another form due to local legal requirements. The deductions are made as a percentage of the Participant&#8217;s compensation in one percent (1%) increments not less than one percent (1%), nor greater than ten percent (10%) after taking into account any such lower limit set by the Committee. Compensation shall mean base salary or regular hourly wages (or in foreign jurisdictions, equivalent cash compensation)&#59; however, the Committee may at any time prior to the beginning of an Offering Period determine that for that and future Offering Periods, Compensation shall mean solely base salary or all W-2 cash compensation, including without limitation base salary or regular hourly wages, bonuses, incentive compensation, commissions, overtime, shift premiums, plus draws against commissions (or in foreign jurisdictions, equivalent cash compensation) but excluding any W-2 non-cash compensation which includes a disqualifying dispositions, equity grants, equity exercises or settlements. For purposes of determining a Participant&#8217;s Compensation, any election by such Participant to reduce his or her regular cash remuneration under Sections 125 (i.e. pre-tax cafeteria plan contributions) or 401(k) (i.e. pre-tax retirement contributions) of the Code (or in foreign jurisdictions, equivalent salary deductions) shall be treated as if the Participant did not make such election and as if such reductions were not made. Payroll deductions shall commence on the first payday following the last Purchase Date and shall continue to the end of the Offering Period unless sooner altered or terminated as provided in this Plan. Notwithstanding the foregoing, the terms of any sub-plan may permit matching shares without the payment of any purchase price.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">A Participant may decrease (but not increase) the rate of payroll deductions during an Offering Period by filing with the Company a new authorization (or any electronic or online authorization form provided by the Company) for payroll deductions , with the new rate to become effective no later than the second payroll period commencing after the Company&#8217;s receipt of the authorization or once any trading restrictions are lifted and continuing for the remainder of the Offering Period unless changed as described below. A decrease in the rate of payroll deductions may be made once during a Purchase Period or more frequently under rules determined by the Committee. A Participant may increase or decrease the rate of payroll deductions for any subsequent Purchase Period by filing with the Company a new authorization for payroll deductions prior to the beginning of the Offering Period for such applicable Purchase Period, or such other time period as specified by the Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">A Participant may reduce his or her payroll deduction percentage to zero during an Offering Period by filing with the Company a request (or any electronic or online request form provided by the Company) for cessation of payroll deductions. Such reduction shall be effective beginning no later than the second payroll period after the Company&#8217;s receipt of the request or once any trading restrictions are lifted and no further payroll deductions will be made for the duration of the Offering Period. Payroll deductions credited to the Participant&#8217;s account prior to the effective date of the request shall be used to purchase shares of Common Stock in accordance with Subsection (e) below. A reduction of the payroll deduction percentage to zero shall be treated as such Participant&#8217;s withdrawal from such Offering Period and the Plan, effective as of the day after the next Purchase Date following the filing date of such request with the Company.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">All payroll deductions made for a Participant are credited to his or her account under this Plan and are deposited with the general funds of the Company, except to the extent local legal restrictions outside the United States require segregation of such payroll deductions. No interest accrues on the payroll deductions, except to the extent required due to local legal requirements. All payroll deductions received or held by the Company may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions, except to the extent necessary to comply with local legal requirements outside the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">On each Purchase Date, so long as this Plan remains in effect and provided that the Participant has not submitted a signed and completed withdrawal form before that date which notifies the Company that the Participant wishes to withdraw from that Offering Period under this Plan and have all payroll deductions accumulated in the account maintained on behalf of the Participant as of that date returned to the Participant, the Company shall apply the funds then in the Participant&#8217;s account to the purchase of whole shares of Common Stock reserved under the option granted to such Participant with respect to the Offering Period to the extent that such option is exercisable on the Purchase Date. The Purchase Price per share shall be as specified in Section&#160;8 of this Plan. Any fractional share, as calculated under this Subsection (e), shall be rounded down to the next lower whole share, unless the Committee determines with respect to all Participants that any fractional share shall be credited as a fractional share. Any amount remaining in a Participant&#8217;s account on a Purchase Date which is less than the amount necessary to purchase a full share of Common Stock shall be returned to the Participant, without interest (except to the extent necessary to comply with local legal requirements outside of the United States), unless the Committee determines that such amount shall be applied to the Participant&#8217;s account, without interest (except to the extent necessary to comply with local legal requirements outside the United States). In the event that this Plan has been oversubscribed, all funds not used to purchase shares on the Purchase Date shall be returned to the Participant, without interest (except to the extent required due to local legal requirements outside the United States). No Common Stock shall be purchased on a Purchase Date on behalf of any employee whose participation in this Plan has terminated prior to such Purchase Date, except to the extent required due to local legal requirements outside the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">As promptly as practicable after the Purchase Date, the Company shall issue shares for the Participant&#8217;s benefit representing the shares purchased upon exercise of his or her option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Unless determined otherwise by the Committee, the shares issued pursuant to Section 9(f) above shall be deposited into an account established in the Participant&#8217;s name at the ESPP Broker. Subject to any applicable insider trading policy, a Participant shall be free to undertake a disposition (as that term is defined in Section 424(c) of the Code) of the shares in his or her ESPP Broker account at any time, whether by sale, exchange, gift or other transfer of legal title but in the absence of such a disposition of the shares, the shares must remain in the Participant&#8217;s ESPP Broker account until the holding period set forth in Section&#160;423(a) of the Code has been satisfied. With respect to shares for which the Section&#160;423(a) holding period has been satisfied, the Participant may move those shares to another brokerage account of Participant&#8217;s choosing. Notwithstanding the above, a Participant who is not subject to income taxation under the Code may move his or her shares to another brokerage account of his or her choosing at any time, without regard to the satisfaction of the Section&#160;423(a) holding period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">During a Participant&#8217;s lifetime, his or her option to purchase shares hereunder is exercisable only by him or her. The Participant will have no interest or voting right in shares covered by his or her option until such option has been exercised.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">To the extent required by applicable federal, state, local or foreign law, a Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise in connection with the Plan. The Company or any Subsidiary or Affiliate, as applicable, may withhold, by any method permissible under the applicable law, the amount necessary for the Company or Subsidiary or Affiliate, as applicable, to meet applicable withholding obligations, including any withholding required to make available to the Company or Subsidiary or Affiliate, as applicable, any tax deductions or benefits attributable to the sale or early disposition of shares of Common Stock by a Participant. The Company shall not be required to issue any shares of Common Stock under the Plan until such obligations are satisfied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">LIMITATIONS ON SHARES TO BE PURCHASED.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Any other provision of the Plan notwithstanding, no Participant shall purchase Common Stock with a Fair Market Value in excess of the following limit&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">In the case of Common Stock purchased during an Offering Period that commenced in the current calendar year, the limit shall be equal to (A) $25,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased in the current calendar year (under this Plan and all other employee stock purchase plans of the Company or any parent or Subsidiary of the Company).</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">In the case of Common Stock purchased during an Offering Period that commenced in the immediately preceding calendar year, the limit shall be equal to (A) $50,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased (under this Plan and all other employee stock purchase plans of the Company or any parent or Subsidiary of the Company) in the current calendar year and in the immediately preceding calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">In the case of Common Stock purchased during an Offering Period that commenced two calendar years prior, the limit shall be equal to (A) $75,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased (under this Plan and all other employee stock purchase plans of the Company or any parent or Subsidiary of the Company) in the current calendar year and in the two immediately preceding calendar years.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Initially, a Participant shall not be permitted to purchase more than 20,000 shares on any one Purchase Date. The Committee may, in its sole discretion, set a new maximum number of shares which may be purchased by any employee at any single Purchase Date, which shall then be the Maximum Share Amount for subsequent Offering Periods. If a lower limit is set under this Subsection (b), then all Participants will be notified of such limit prior to the commencement of the next Offering Period for which it is to be effective. If a new Maximum Share Amount is set, then all participants must be notified of such Maximum Share Amount prior to the commencement of the next Offering Period for which it is to be effective. The Maximum Share Amount shall continue to apply with respect to all succeeding Purchase Dates and Offering Periods unless revised by the Committee as set forth above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">If the number of shares to be purchased on a Purchase Date by all employees participating in this Plan exceeds the number of shares then available for issuance under this Plan, then the Company will make a pro rata allocation of the remaining shares in as uniform a manner as shall be reasonably practicable and as the Committee shall determine to be equitable. In such event, the Company shall give written notice of such reduction of the number of shares to be purchased under a participant&#8217;s option to each participant affected.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Any payroll deductions accumulated in a participant&#8217;s account which are not used to purchase stock due to the limitations in this Section 10 shall be returned to the participant as soon as practicable after the end of the applicable Purchase Period, without interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If a Participant is precluded by this Subsection (a) from purchasing additional Common Stock under the Plan, then his or her employee contributions may be automatically discontinued by the Company and shall automatically resume at the beginning of the earliest Purchase Period that will end in the next calendar year (if he or she then is an eligible employee), provided that when the Company automatically resumes such payroll deductions, the Company must apply the rate in effect immediately prior to such suspension.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">If the number of shares to be purchased on a Purchase Date by all Participants exceeds the number of shares then available for issuance under this Plan, then the Company will make a pro rata allocation of the remaining shares in as uniform a manner as shall be reasonably practicable and as the Committee shall determine to be equitable. In such event, the Company will give notice of such reduction of the number of shares to be purchased under a Participant&#8217;s option to each Participant affected.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Any payroll deductions accumulated in a Participant&#8217;s account which are not used to purchase stock due to the limitations in this Section 10, and not covered by Section 9(e), shall be returned to the Participant as soon as practicable after the end of the applicable Purchase Period, without interest (except to the extent required due to local legal requirements outside the United States).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">WITHDRAWAL.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Each Participant may withdraw from an Offering Period under this Plan pursuant to a method specified for such purpose by the Company. Such withdrawal may be elected at any time prior to the end of an Offering Period, or such other time period as specified by the Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Upon withdrawal from this Plan, the accumulated payroll deductions shall be returned to the withdrawn Participant, without interest (except to the extent required due to local legal requirements outside the United States), and his or her interest in this Plan shall terminate. In the event a Participant voluntarily elects to withdraw from this Plan, he or she may not resume his or her participation in this Plan during the same Offering Period, but he or she may participate in any Offering Period under this Plan which commences on a date subsequent to such withdrawal by filing a new authorization for payroll deductions in the same manner as set forth in Section 6 above for initial participation in this Plan.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">TERMINATION OF EMPLOYMENT.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Termination of a Participant&#8217;s employment for any reason, including retirement, death, disability, or the failure of a Participant to remain an eligible employee of the Company or of a Participating Corporation, immediately terminates his or her participation in this Plan. In such event, accumulated payroll deductions credited to the Participant&#8217;s account will be returned to him or her or, in the case of his or her death, to his or her legal representative, without interest (except to the extent required due to local legal requirements outside the United States). For purposes of this Section 12, an employee will not be deemed to have terminated employment or failed to remain in the continuous employ of the Company or of a Participating Corporation in the case of sick leave, military leave, or any other leave of absence approved by the Company&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that such leave is for a period of not more than ninety (90) days or reemployment upon the expiration of such leave is guaranteed by contract or statute. The Company will have sole discretion to determine whether a Participant has terminated employment and the effective date on which the Participant terminated employment, regardless of any notice period or garden leave required under local law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">RETURN OF PAYROLL DEDUCTIONS.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In the event a Participant&#8217;s interest in this Plan is terminated by withdrawal, termination of employment or otherwise, or in the event this Plan is terminated by the Board, the Company shall deliver to the Participant all accumulated payroll deductions credited to such Participant&#8217;s account. No interest shall accrue on the payroll deductions of a Participant in this Plan (except to the extent required due to local legal requirements outside the United States).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">CAPITAL CHANGES.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If the number of outstanding shares is changed by a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then the Committee shall adjust the number and class of Common Stock that may be delivered under the Plan, the Purchase Price per share and the number of shares of Common Stock covered by each option under the Plan which has not yet been exercised, and the numerical limits of Sections 2 and 10 shall be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company and in compliance with the applicable securities laws&#59; provided that fractions of a share will not be issued.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">NONASSIGNABILITY.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Neither payroll deductions credited to a Participant&#8217;s account nor any rights with regard to the exercise of an option or to receive shares under this Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in Section 22 below) by the Participant. Any such attempt at assignment, transfer, pledge or other disposition shall be void and without effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">USE OF PARTICIPANT FUNDS AND REPORTS.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company may use all payroll deductions received or held by it under the Plan for any corporate purpose, and the Company will not be required to segregate Participant payroll deductions (except to the extent required due to local legal requirements outside the United States). Until shares are issued, a Participant will only have the rights of an unsecured creditor unless otherwise required under local law. Each Participant shall receive promptly after the end of each Purchase Period a report of his or her account setting forth the total payroll deductions accumulated, the number of shares purchased, the per share price thereof and the remaining cash balance, if any, carried forward to the next Purchase Period or Offering Period, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">NOTICE OF DISPOSITION.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Each U.S. taxpayer Participant shall notify the Company in writing if the Participant disposes of any of the shares purchased in any Offering Period pursuant to this Plan if such disposition occurs within the Notice Period. The Company may, at any time during the Notice Period, place a legend or legends on any certificate representing shares acquired pursuant to this Plan requesting the Company&#8217;s transfer agent to notify the Company of any transfer of the shares. The obligation of the Participant to provide such notice shall continue notwithstanding the placement of any such legend on the certificates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">NO RIGHTS TO CONTINUED EMPLOYMENT.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Neither this Plan nor the grant of any option hereunder shall confer any right on any employee to remain in the employ of the Company or any Participating Corporation, or restrict the right of the Company or any Participating Corporation to terminate such employee&#8217;s employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">EQUAL RIGHTS AND PRIVILEGES.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All eligible employees granted an option under this Plan that is intended to meet the Code Section 423 requirements shall have equal rights and privileges with respect to this Plan or within any separate offering under the Plan so that this Plan qualifies as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 or any successor provision of the Code and the related regulations. Any provision of this Plan which is inconsistent with Section 423 or any successor provision of the Code, without further act or amendment by the Company, the Committee or the Board, shall be reformed to comply with the requirements of Section 423. This Section 19 shall take precedence over all other provisions in this Plan.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">NOTICES.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">TERM&#59; STOCKHOLDER APPROVAL.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Plan will become effective on the Effective Date. This Plan shall be approved by the stockholders of the Company, in any manner permitted by applicable corporate law, within twelve (12) months before or after the date this Plan is adopted by the Board. No purchase of shares that are subject to such stockholder approval before becoming available under this Plan shall occur prior to stockholder approval of such shares and the Board or Committee may delay any Purchase Date and postpone the commencement of any Offering Period subsequent to such Purchase Date as deemed necessary or desirable to obtain such approval (provided that if a Purchase Date would occur more than twelve (12) months after commencement of the Offering Period to which it relates, then such Purchase Date shall not occur and instead such Offering Period shall terminate without the purchase of such shares and Participants in such Offering Period shall be refunded their contributions without interest). This Plan shall continue until the earlier to occur of (a) termination of this Plan by the Board (which termination may be effected by the Board at any time pursuant to Section 25 below), (b) issuance of all of the shares of Common Stock reserved for issuance under this Plan, or (c) the tenth anniversary of the Effective Date under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">DESIGNATION OF BENEFICIARY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Unless otherwise determined by the Committee, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant&#8217;s account under this Plan in the event of such Participant&#8217;s death prior to a Purchase Date. Such form shall be valid only if it was filed with the Company at the prescribed location before the Participant&#8217;s death.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Such designation of beneficiary may be changed by the Participant at any time by written notice filed with the Company at the prescribed location before the Participant&#8217;s death. In the event of the death of a Participant and in the absence of a beneficiary validly designated under this Plan who is living at the time of such Participant&#8217;s death, the Company shall deliver such cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such cash to the spouse or, if no spouse is known to the Company, then to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">CONDITIONS UPON ISSUANCE OF SHARES&#59; LIMITATION ON SALE OF SHARES.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Shares shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock exchange or automated quotation system upon which the shares may then be listed, exchange control restrictions and&#47;or securities law restrictions outside the United States, and shall be further subject to the approval of counsel for the Company with respect to such compliance. Shares may be held in trust or subject to further restrictions as permitted by any subplan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">APPLICABLE LAW.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Plan shall be governed by the substantive laws (excluding the conflict of laws rules) of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">AMENDMENT OR TERMINATION.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Committee, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason. If the Plan is terminated, the Committee, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the next Purchase Date (which may be sooner than originally scheduled, if determined by the Committee in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to Section 14). If an Offering Period is terminated prior to its previously-scheduled expiration, all amounts then credited to Participants&#8217; accounts for such Offering Period, which have not been used to purchase shares of Common Stock, shall be returned to those Participants (without interest thereon, except as otherwise required under local laws) as soon as administratively practicable. Further, the Committee will be entitled to change the Purchase Periods and Offering Periods, limit the frequency and&#47;or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld or contributed in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the administration of the Plan, establish reasonable waiting and adjustment periods and&#47;or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant&#8217;s base salary and other eligible compensation, and establish such other limitations or procedures as the Committee determines in its sole discretion advisable which are consistent with the Plan. Such actions will not require stockholder approval or the consent of any Participants. However, no amendment shall be made without approval of the stockholders of the Company (obtained in accordance with Section 21 above) within twelve (12) months of the adoption of such </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">amendment (or earlier if required by Section 21) if such amendment would&#58; (a) increase the number of shares that may be issued under this Plan&#59; or (b) change the designation of the employees (or class of employees) eligible for participation in this Plan. In addition, in the event the Board or Committee determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Board or Committee may, in its discretion and, to the extent necessary or desirable, modify, amend or terminate the Plan to reduce or eliminate such accounting consequences including, but not limited to&#58; (i) amending the definition of compensation, including with respect to an Offering Period underway at the time&#59; (ii) altering the Purchase Price for any Offering Period including an Offering Period underway at the time of the change in Purchase Price&#59; (iii) shortening any Offering Period by setting a Purchase Date, including an Offering Period underway at the time of the Committee&#8217;s action&#59; (iv) reducing the maximum percentage of compensation a participant may elect to set aside as payroll deductions&#59; and (v) reducing the maximum number of shares a Participant may purchase during any Offering Period. Such modifications or amendments will not require approval of the stockholders of the Company or the consent of any Participants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">CORPORATE TRANSACTIONS.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In the event of a Corporate Transaction, the Offering Period for each outstanding right to purchase Common Stock will be shortened by setting a new Purchase Date and will end on the new Purchase Date (unless otherwise specified in the agreement effecting the applicable Corporate Transaction). The new Purchase Date shall occur on or prior to the consummation of the Corporate Transaction, as determined by the Board or Committee, and the Plan shall terminate on the consummation of the Corporate Transaction (unless otherwise specified in the agreement effecting the applicable Corporate Transaction).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">CODE SECTION 409A&#59; TAX QUALIFICATION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Options granted under the Plan generally are exempt from the application of Section 409A of the Code. However, options granted to U.S. taxpayers which are not intended to meet the Code Section 423 requirements are intended to be exempt from the application of Section&#160;409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. Subject to Subsection (b), options granted to U.S. taxpayers outside of the Code Section 423 requirements shall be subject to such terms and conditions that will permit such options to satisfy the requirements of the short-term deferral exception available under Section 409A of the Code, including the requirement that the shares of Common Stock subject to an option be delivered within the short-term deferral period. Subject to Subsection (b), in the case of a Participant who would otherwise be subject to Section 409A of the Code, to the extent the Committee determines that an option or the exercise, payment, settlement or deferral thereof is subject to Section 409A of the Code, the option shall be granted, exercised, paid, settled or deferred in a manner that will comply with Section 409A of the Code, including Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date. Notwithstanding the foregoing, the Company shall have no liability to a Participant or any other party if the option that is intended to be exempt from or compliant with Section 409A of the Code is not so exempt or compliant or for any action taken by the Committee with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Although the Company may endeavor to (i) qualify an option for favorable tax treatment under the laws of the United States or jurisdictions outside of the United States or (ii)&#160;avoid adverse tax treatment (e.g., under Section 409A of the Code), the Company makes no representation to that effect and expressly disavows any covenant to maintain favorable or avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan, including Subsection (a). The Company shall be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">DEFINITIONS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (i) any entity that, directly or indirectly, is controlled by, controls or is under common control with, the Company and (ii) any entity in which the Company has a significant equity interest, in either case as determined by the Committee, whether now or hereafter existing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Amendment Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means December 13, 2019.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the Compensation Committee of the Board that consists exclusively of one or more members of the Board appointed by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the common stock of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean Dexcom, Inc.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Corporate Transaction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following events&#58; (i)&#160;any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company&#8217;s then outstanding voting securities&#59; or (ii) the consummation of the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; or (iii) the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean May 28, 2015, the date on which the Company obtained the stockholder approval pursuant to Section 21.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ESPP Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean a stock brokerage or other entity designated by the Company to establish account for stock purchased under the Plan by Participants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Fair Market Value</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean, as of any date, the value of a share of Common Stock determined as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if such Common Stock is then quoted on the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Nasdaq Market</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), its closing price on the Nasdaq Market on the date of determination, or if there are no sales for such date, then the last preceding business day on which there were sales, as reported in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Wall Street Journal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or such other source as the Board or the Committee deems reliable&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Wall Street Journal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or such other source as the Board or the Committee deems reliable&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if such Common Stock is publicly traded but is neither quoted on the Nasdaq Market nor listed or admitted to trading on a national securities exchange, the average of the closing bid and asked prices on the date of determination as reported in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Wall Street Journal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or such other source as the Board or the Committee deems reliable&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if none of the foregoing is applicable, by the Board or the Committee in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean within two (2) years from the Offering Date or within one (1) year from the Purchase Date on which such shares were purchased.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.01pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Offering Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the first business day of each Offering Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Offering Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean a period with respect to which the right to purchase Common Stock may be granted under the Plan, as determined by the Committee pursuant to Section 5(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Parent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the same meaning as &#8220;parent corporation&#8221; in Sections 424(e) and 424(f) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean an eligible employee who meets the eligibility requirements set forth in Section 4 and who is either automatically enrolled in the initial Offer Period or who elects to participate in this Plan pursuant to Section 6(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participating Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean any Parent, Subsidiary or Affiliate that the Committee designates from time to time as eligible to participate in this Plan, provided, however, that employees of Affiliates that are designated for participation may be granted only options that do not intend to comply with the Code Section 423 requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean this Dexcom, Inc. 2015 Employee Stock Purchase Plan, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Purchase Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the last business day of each Purchase Period.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Purchase Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean a period during which contributions may be made toward the purchase of Common Stock under the Plan, as determined by the Committee pursuant to Section 5(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Purchase Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the price at which Participants may purchase shares of Common Stock under the Plan, as determined pursuant to Section 8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the same meaning as &#8220;subsidiary corporation&#8221; in Sections&#160;424(e) and 424(f) of the Code.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><div id="i344e9ea2d36f47fc8658d75fe24587b5_4"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enrollment&#47;Change Form</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Employee Stock Purchase Plan (&#8220;ESPP&#8221;)<br></font><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br><br><br></font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actions</font></div></td><td colspan="6" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Check Desired Action&#58;&#160;&#160;&#160;&#160;and Complete Sections&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#9744;  Enroll in the ESPP&#160;&#160;&#160;&#160;&#160;&#160;2 + 3 + 4 + 17</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#9744;  Elect &#47; Change Contribution Percentage&#160;&#160;&#160;&#160;2 + 4 + 17</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#9744;  Withdraw from Plan&#47;Discontinue Contributions 2 + 5 + 17</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Personal Data</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name_____________________</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Address&#58;_____________________</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">__________________________________</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Social Security No&#58;___________________</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Department</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enroll</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744; I hereby elect to participate in the ESPP, effective at the beginning of the next Offering Period. I elect to purchase shares of the Common Stock of Dexcom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) pursuant to the ESPP. I understand that the shares purchased on my behalf will be issued in street name and deposited directly into my brokerage account at the Company&#8217;s captive broker (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ESPP Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). I hereby agree to take all steps, and sign all forms, required to establish an account with the Company&#8217;s ESPP Broker for this purpose. I understand and agree that I will be required to utilize the ESPP Broker with respect to the shares purchased under this ESPP until the end of the time period described in Section 6 below.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">My participation will continue as long as I remain eligible, unless I withdraw from the ESPP by filing a new Enrollment&#47;Change Form with the Company. I understand that if I am subject to U.S. taxation, I must notify the Company of any disposition of shares purchased under the ESPP.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4&#58;</font></div><div style="margin-bottom:12pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Elect&#47;Change Contribution Percentage</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I hereby authorize the Company or the Parent, Subsidiary or Affiliate employing me (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) to withhold a percentage of my bi-weekly payroll that will total ___% of my compensation (as defined in the ESPP) for the Purchase Period. That amount will be applied to the purchase of shares of the Company&#8217;s Common Stock pursuant to the ESPP. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The percentage compensation to purchase common stock must be a whole number (from 1%, up to a maximum of 10%).</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You may decrease your contribution percentage once within a six-month Purchase Period. Each change will become effective as soon as reasonably practicable after the form is received by the Company.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 5&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discontinue Contributions</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744; I hereby elect to stop my contributions under the ESPP, effective as soon as reasonably practicable after this form is received by the Company. The contributions that I have made to date during this Offering Period should be applied as follows&#58;</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744; Purchase shares of the Company&#8217;s Common Stock at the end of the Purchase Period.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744; Refund all contributions to me in cash, without interest.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I understand that I cannot resume participation until the start of the next Offering Period.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP Broker</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I hereby agree the shares issued to me under the ESPP shall be deposited into an account established in my name at the ESPP Broker. Subject to any applicable insider trading policy, I shall be free to undertake a disposition (as that term is defined in Section&#160;424(c) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) of the shares in my ESPP Broker account at any time, whether by sale, exchange, gift, or other transfer of legal title, but in the absence of such a disposition of the shares, the shares must remain in my ESPP Broker account until the holding period set forth in Section&#160;423(a) of the Code has been satisfied. With respect to shares for which the Section&#160;423(a) holding period has been satisfied, I may move those shares to another brokerage account of my choosing. Notwithstanding the above, if I am not subject to income taxation under the Code, I may move my shares to another brokerage account of my choosing at any time, without regard to the satisfaction of the Section&#160;423(a) holding period.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature of Grant</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By enrolling in the ESPP, I understand, acknowledge and agree that (a) the ESPP is established voluntarily by the Company, it is discretionary in nature and it may be amended, terminated or modified at any time, to the extent permitted by the ESPP&#59; (b) the grant of the right to purchase shares of Common Stock under the ESPP is voluntary and does not create any contractual or other right to receive future rights to purchase shares of Common Stock, or benefits in lieu of rights to purchase shares, even if rights to purchase shares have been granted in the past&#59; (c) all decisions with respect to future grants of rights to purchase shares of Common Stock under the ESPP, if any, will be at the sole discretion of the Company&#59; (d) the grant of rights to purchase shares of Common Stock under the ESPP and my participation in the ESPP will not create a right to employment or be interpreted as forming an employment or service agreement with the Company&#59; (e) the grant of rights to purchase shares of Common Stock under the ESPP and my participation in the ESPP will not interfere with the ability of the Employer to terminate my employment relationship at any time with or without cause&#59; (f) I am voluntarily participating in the ESPP&#59; (g) the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not intended to replace any pension rights or compensation&#59; (h) the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not part of normal or expected compensation for purposes of, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments&#59; (i) unless otherwise agreed with the Company, the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not granted as consideration for, or in connection with, any service I may provide as a director of the Subsidiary or Affiliate&#59; (j) the future value of the underlying shares purchased or to be purchased under the ESPP is unknown, indeterminable and cannot be predicted with certainty, and the value of the shares of Common Stock purchased under the ESPP may increase or decrease in the future, even below the Purchase Price&#59; (k) no claim or entitlement to compensation or damages will arise from termination of the right to purchase shares of Common Stock under the ESPP resulting from termination of my employment (for any reason whatsoever and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where I am employed or the terms of my employment agreement, if any) and in consideration of the grant of rights to purchase shares of Common Stock under the ESPP, I irrevocably agree never to institute any claim against the Company, the Parent, the Employer or any other Subsidiary or Affiliate, I hereby waive my ability, if any, to bring any such claim, and I release the Company, the Parent, the Employer or any other Subsidiary or Affiliate from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by enrolling in the ESPP, I will be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claims&#59; (l) in the event of termination of my employment (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where I am employed or the terms of my employment agreement, if any), my right to participate in the ESPP and my right to purchase shares of Common Stock, if any, will terminate effective as of the date I cease to actively provide services and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, employment would not include any contractual notice or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where I am employed or the terms of my employment agreement, if any)&#59; the Committee will have exclusive discretion to determine when I am no longer actively employed for purposes of my participation in the ESPP (including whether I may still be considered to be providing services while on a leave of absence)&#59; (m) unless otherwise provided in the ESPP or by the Company in its discretion, the right to purchase shares of Common Stock and the benefits evidenced by this Enrollment&#47;Change Form do not create any entitlement to have the ESPP or any such benefits granted thereunder transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any Corporate Transaction affecting the Common Stock&#59; and (n) if I am providing services outside the United States&#58; (1) the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not part of normal or expected compensation or salary for any purpose, and (2) neither the Company, the Parent, the Employer nor any other Subsidiary or Affiliate will be liable for any foreign exchange rate fluctuation between my local currency and the United States Dollar that may affect the value of the rights to purchase shares of Common Stock, the shares purchased under the ESPP or any amounts due to me pursuant to the sale of any shares of Common Stock acquired under the ESPP.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Privacy</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">I hereby explicitly, voluntarily and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this Enrollment&#47;Change Form and any other ESPP grant materials by and among, as applicable, the Company, the Parent and any of their respective Subsidiaries or Affiliates or any third parties assisting in the implementation, administration and management of my participation in the ESPP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">I understand that the Company may hold certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Company, the fact and conditions of my participation in the ESPP, details of all rights to purchase shares or any other entitlement to shares of Common Stock awarded, cancelled, exercised, vested, unvested or outstanding in my favor (&#8220;Data&#8221;), for the exclusive purpose of implementing, administering and managing the ESPP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">I also authorize any transfer of Data, as may be required, to the stock plan service provider that may be designated by the Company from time to time, which is assisting the Company with the implementation, administration and management of the ESPP and&#47;or with whom any shares of Common Stock acquired under the ESPP are deposited. I acknowledge that these recipients may be located in my country or elsewhere, and that the recipient&#8217;s country (e.g., the United States) may have different data privacy laws and protections to my country, which may not give the same level of protection to Data. I understand that, if I reside outside the United States, I may request a list with the names and addresses of any potential recipients of Data by contacting my local human resources representative. I authorize the Company, the designated broker and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing my participation in the ESPP to receive, possess, use, retain and transfer Data, in electronic or other form, for the sole purpose of implementing, administering and managing my participation in the ESPP. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the ESPP. I understand that, if I reside outside the United States, I may at any time view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case, without cost, by contacting in writing my local human resources representative. Further, I understand that I am providing the consents herein on a purely voluntary basis. If I do not consent, or if I later seek to revoke my consent, my employment status or service and career with the Company will not be adversely affected&#59; the only adverse consequence of refusing or withdrawing my consent is that the Company would not be able to grant future rights to purchase shares of Common Stock or other equity awards to me or administer or maintain such awards. Therefore, I understand that refusing or withdrawing my consent may affect my ability to participate in the ESPP. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Responsibility for Taxes</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that, regardless of any action taken by the Company or the Employer, the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to my participation in the ESPP and legally applicable to me (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Tax-Related Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is and remains my responsibility and may exceed the amount actually withheld by the Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or the Employer. I further acknowledge that the Company and&#47;or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the ESPP, including, but not limited to, my enrollment in the ESPP, the grant of rights to purchase shares of Common Stock, the purchase of shares of Common Stock, the issuance of Common Stock purchased, the sale of shares of Common Stock purchased under the ESPP or the receipt of any dividends&#59; and (2) do not commit to and are under no obligation to structure the terms of the ESPP to reduce or eliminate my liability for Tax-Related Items or achieve any particular tax result. Further, if I am subject to Tax-Related Items in more than one jurisdiction, I acknowledge that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, as applicable, I agree to make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Tax-Related Items. In this regard, I authorize the Company and&#47;or the Employer to satisfy their withholding obligations with regard to all Tax-Related Items by one or a combination of the following&#58; (a) withholding from my wages or other cash compensation payable to me by the Company and&#47;or the Employer, (b) withholding from proceeds of the sale of shares of Common Stock purchased under the ESPP, either through a voluntary sale or through a mandatory sale arranged by the Company (on my behalf pursuant to this authorization without further consent), and (c) withholding in shares to be issued upon purchase under the ESPP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable statutory withholding amounts or other applicable withholding rates, including up to the maximum applicable rates, in which case I will receive a refund of any over-withheld amount in cash and will have no entitlement to the Common Stock equivalent. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, I am deemed to have been issued the full number of shares of Common Stock, notwithstanding that a number of the shares of Common Stock are held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, I agree to pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of my participation in the ESPP that cannot be satisfied by the means previously described. The Company may refuse to purchase or deliver the shares or the proceeds from the sale of shares of Common Stock, if I fail to comply with my obligations in connection with the Tax-Related Items.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governing Law &#38; Language</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rights to purchase shares and the provisions of this Enrollment&#47;Change Form are governed by, and subject to, the laws of the State of Delaware, without regard to any conflict of law provisions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If I have received this or any other document related to the ESPP translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 11&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Appendix &#38; Imposition of Other Requirements</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any provision herein, my participation in the ESPP will be subject to any special terms and conditions as set forth in the Appendix for my country, if any. Moreover, if I relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to me, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of this Enrollment&#47;Change Form.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company reserves the right to impose other requirements on my participation in the ESPP or on any shares of Common Stock purchased under the ESPP, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require me to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 12&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Electronic Delivery and Acceptance</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the ESPP by electronic means. I hereby consent to receive such documents by electronic delivery and agree to participate in the ESPP through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 13&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severability &#38; Waiver</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of this Enrollment&#47;Change Form are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions will nevertheless be binding and enforceable. I acknowledge that a waiver by the Company of breach of any provision of this Enrollment&#47;Change Form will not operate or be construed as a waiver of any other provision herein, or of any subsequent breach by me or any other Participant.</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insider Trading Restrictions &#47;Market Abuse Laws</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that I may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect my ability to acquire or sell shares of Common Stock or my rights to purchase shares under the ESPP during such times as I am considered to have &#8220;inside information&#8221; regarding the Company (as defined by or determined under the laws in my country).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable the Company insider trading policy.  I acknowledge that it is my responsibility to comply with any applicable restrictions, and that I am advised to speak to my personal advisor on this matter.</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No Advice Regarding Grant</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding my participation in the ESPP, or my purchase or sale of the shares of Common Stock. I am hereby advised to consult with my own personal tax, legal and financial advisors regarding my participation in the ESPP before taking any action related to the ESPP.</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compliance With Law</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless there is an available exemption from any registration, qualification or other legal requirement applicable to the shares of Common Stock, the Company will not be required to deliver any shares under the ESPP prior to the completion of any registration or qualification of the shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company will, in its absolute discretion, deem necessary or advisable. I understand that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the shares. Further, I agree that the Company will have unilateral authority to amend the ESPP and the Enrollment&#47;Change Form without my consent to the extent necessary to comply with securities or other laws applicable to issuance of shares.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17&#58;</font></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acknowledgment and Signature</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that I have received a copy of the Prospectus summarizing the major features of the ESPP. I have read the Prospectus and this form and hereby agree to be bound by the terms of the ESPP.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature&#58;&#160;___________&#160;&#160;&#160;&#160;Date&#58; ________</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><div id="i344e9ea2d36f47fc8658d75fe24587b5_91"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right;text-indent:-0.1pt"><font><br></font></div><div style="text-align:right;text-indent:-0.1pt"><font><br></font></div></div><div style="padding-left:16.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.416%"><tr><td style="width:1.0%"></td><td style="width:62.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DEXCOM, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2015 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Enrollment&#47;Change Form</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(CANADA)</font></div></td></tr></table></div><div style="text-indent:-0.1pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 1&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Actions</font></div></td><td colspan="6" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Check Desired Action</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                and Complete Sections</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;&#160;&#160;&#160;&#160;Enroll in the ESPP&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                 2 + 3 + 4 + 17<br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;&#160;&#160;&#160;&#160;Elect &#47; Change Contribution Percentage&#160;&#160;&#160;&#160;   2 + 4 + 17</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;&#160;&#160;&#160;&#160;Withdraw from Plan&#47;Discontinue Contributions    2 + 5 + 17<br></font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.11pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 2&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.11pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Personal Data</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Home Address&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Social Security No&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Department</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 3&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Enroll</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;&#160;&#160;&#160;&#160;I hereby elect to participate in the ESPP, effective at the beginning of the next Offering Period. I elect to purchase shares of the Common Stock of Dexcom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) pursuant to the ESPP.  I understand that the shares purchased on my behalf will be issued in street name and deposited directly into my brokerage account at the Company&#8217;s captive broker (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">ESPP Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;).  I hereby agree to take all steps, and sign all forms, required to establish an account with the Company&#8217;s ESPP Broker for this purpose.  I understand and agree that I will be required to utilize the ESPP Broker with respect to the shares purchased under this ESPP until the end of the time period described in Section 6 below.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">My participation will continue as long as I remain eligible, unless I withdraw from the ESPP by filing a new Enrollment&#47;Change Form with the Company. I understand that if I am subject to U.S. taxation, I must notify the Company of any disposition of shares purchased under the ESPP.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Elect&#47;Change Contribution Percentage</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I hereby authorize the Company or the Parent, Subsidiary or Affiliate employing me (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) to withhold a percentage of my bi-weekly payroll that will total ___% of my compensation (as defined in the ESPP) for the Purchase Period. That amount will be applied to the purchase of shares of the Company&#8217;s Common Stock pursuant to the ESPP.&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The percentage compensation to purchase common stock must be a whole number (from 1%, up to a maximum of 10%).</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">You may decrease your contribution percentage once within a six-month Purchase Period. Each change will become effective as soon as reasonably practicable after the form is received by the Company.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-indent:-0.1pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 5&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Discontinue Contributions</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#9744;&#160;&#160;&#160;&#160;I hereby elect to stop my contributions under the ESPP, effective as soon as reasonably practicable after this form is received by the Company. The contributions that I have made to date during this Offering Period should be applied as follows&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#9744;&#160; Purchase shares of the Company&#8217;s Common Stock at the end of the Purchase Period.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#9744;  Refund all contributions to me in cash, without interest.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">I understand that I cannot resume participation until the start of the next Offering Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 6&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ESPP Broker</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I hereby agree the shares issued to me under the ESPP shall be deposited into an account established in my name at the ESPP Broker.  Subject to any applicable insider trading policy, I shall be free to undertake a disposition (as that term is defined in Section&#160;424(c) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) of the shares in my ESPP Broker account at any time, whether by sale, exchange, gift, or other transfer of legal title, but in the absence of such a disposition of the shares, the shares must remain in my ESPP Broker account until the holding period set forth in Section&#160;423(a) of the Code has been satisfied.  With respect to shares for which the Section&#160;423(a) holding period has been satisfied, I may move those shares to another brokerage account of my choosing.  Notwithstanding the above, if I am not subject to income taxation under the Code, I may move my shares to another brokerage account of my choosing at any time, without regard to the satisfaction of the Section&#160;423(a) holding period.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-indent:-0.1pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 7&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Nature of Grant</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By enrolling in the ESPP, I understand, acknowledge and agree that (a) the ESPP is established voluntarily by the Company, it is discretionary in nature and it may be amended, terminated or modified at any time, to the extent permitted by the ESPP&#59; (b) the grant of the right to purchase shares of Common Stock under the ESPP is voluntary and does not create any contractual or other right to receive future rights to purchase shares of Common Stock, or benefits in lieu of rights to purchase shares, even if rights to purchase shares have been granted in the past&#59; (c) all decisions with respect to future grants of rights to purchase shares of Common Stock under the ESPP, if any, will be at the sole discretion of the Company&#59; (d) the grant of rights to purchase shares of Common Stock under the ESPP and my participation in the ESPP will not create a right to employment or be interpreted as forming an employment or service agreement with the Company&#59; (e) the grant of rights to purchase shares of Common Stock under the ESPP and my participation in the ESPP will not interfere with the ability of the Employer to terminate my employment relationship at any time with or without cause&#59; (f) I am voluntarily participating in the ESPP&#59; (g) the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not intended to replace any pension rights or compensation&#59; (h) the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not part of normal or expected compensation for purposes of, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments except as may be required under applicable employment or labour standards legislation&#59; (i) unless otherwise agreed with the Company, the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not granted as consideration for, or in connection with, any service I may provide as a director of the Subsidiary or Affiliate&#59; (j) the future value of the underlying shares purchased or to be purchased under the ESPP is unknown, indeterminable and cannot be predicted with certainty, and the value of the shares of Common Stock purchased under the ESPP may increase or decrease in the future, even below the Purchase Price&#59; (k) no claim or entitlement to compensation or damages will arise from termination of the right to purchase shares of Common Stock under the ESPP resulting from termination of my employment (for any reason whatsoever and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where I am employed or the terms of my employment agreement, if any), except to the extent that such entitlement to compensation or damages is included in an entitlement I have under applicable employment or labour standards legislation and in consideration of the grant of rights to purchase shares of Common Stock under the ESPP, except for a proceeding made under applicable employment or labour standards regulation to the applicable tribunal, ministry or regulatory authority, I irrevocably agree never to institute any claim against the Company, the Parent, the Employer or any other Subsidiary or Affiliate, I hereby waive my ability, if any, to bring any such claim, and I release the Company, the Parent, the Employer or any other Subsidiary or Affiliate from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by enrolling in the ESPP, I will be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claims&#59; (l) in the event of termination of my employment (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where I am employed or the terms of my employment agreement, if any), except to the extent required under applicable employment or labour standards legislation, my right to participate in the ESPP and my right to purchase shares of Common Stock, if any, will terminate effective as of the date I cease to be Actively Employed&#59; (m) unless otherwise provided in the ESPP or by the Company in its discretion, the right to purchase shares of Common Stock and the benefits evidenced by this Enrollment&#47;Change Form do not create any entitlement to have the ESPP or any such benefits granted thereunder transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any Corporate Transaction affecting the Common Stock&#59; and (n) if I am providing services outside the United States&#58; (1) the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not part of normal or expected compensation or salary for any purpose, except to the extent required under applicable employment or labour standards legislation and (2) neither the Company, the Parent, the Employer nor any other Subsidiary or Affiliate will be liable for any foreign exchange rate fluctuation between my local currency and the United States Dollar that may affect the value of the rights to purchase shares of Common Stock, the shares purchased under the ESPP or any amounts due to me pursuant to the sale of any shares of Common Stock acquired under the ESPP.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The last day on which I am &#8220;Actively Employed&#8221; will be the later of&#58; (i) the last day I actually perform my duties prior to the termination of my employment with the Employer for any reason&#59; or (ii) the end of the period of statutory notice of termination prescribed by applicable employment or labour standards legislation. For clarity, except to the extent required by applicable employment or labour standards legislation&#58; (i) the last day I am Actively Employed shall not be extended by any contractual or common law notice of termination period in respect of which I receive or may receive pay in lieu of notice of termination or damages in lieu of such notice of termination&#59; and (ii) entitlement to any rights or benefits under the ESPP shall not be included in any entitlement which I may have to pay in lieu of notice or damages in lieu of notice of termination.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-indent:-0.1pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 8&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Data Privacy</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I hereby explicitly, voluntarily and unambiguously consent to the collection, use and transfer, in electronic or other form, of my personal data as described in this Enrollment&#47;Change Form and any other ESPP grant materials by and among, as applicable, the Company, the Parent and any of their respective Subsidiaries or Affiliates or any third parties assisting in the implementation, administration and management of my participation in the ESPP.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I understand that the Company may hold certain personal information about me, including, but not limited to, my name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Company, the fact and conditions of my participation in the ESPP, details of all rights to purchase shares or any other entitlement to shares of Common Stock awarded, cancelled, exercised, vested, unvested or outstanding in my favor (&#8220;Data&#8221;), for the exclusive purpose of implementing, administering and managing the ESPP.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I also authorize any transfer of Data, as may be required, to the stock plan service provider that may be designated by the Company from time to time, which is assisting the Company with the implementation, administration and management of the ESPP and&#47;or with whom any shares of Common Stock acquired under the ESPP are deposited.  I acknowledge that these recipients may be located in my country or elsewhere, and that the recipient&#8217;s country (e.g., the United States) may have different data privacy laws and protections to my country, which may not give the same level of protection to Data.  I understand that, if I reside outside the United States, I may request a list with the names and addresses of any potential recipients of Data by contacting my local human resources representative. I authorize the Company, the designated broker and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing my participation in the ESPP to receive, possess, use, retain and transfer Data, in electronic or other form, for the sole purpose of implementing, administering and managing my participation in the ESPP.  I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the ESPP. I understand that, if I reside outside the United States, I may at any time view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case, without cost, by contacting in writing my local human resources representative.  Further, I understand that I am providing the consents herein on a purely voluntary basis.  If I do not consent, or if I later seek to revoke my consent, my employment status or service and career with the Company will not be adversely affected&#59; the only adverse consequence of refusing or withdrawing my consent is that the Company would not be able to grant future rights to purchase shares of Common Stock or other equity awards to me or administer or maintain such awards.  Therefore, I understand that refusing or withdrawing my consent may affect my ability to participate in the ESPP.  For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.  </font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 9&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Responsibility for Taxes</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that, regardless of any action taken by the Company or the Employer, the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to my participation in the ESPP and legally applicable to me (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Tax-Related Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is and remains my responsibility and may exceed the amount actually withheld by the Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or the Employer.  I further acknowledge that the Company and&#47;or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the ESPP, including, but not limited to, my enrollment in the ESPP, the grant of rights to purchase shares of Common Stock, the purchase of shares of Common Stock, the issuance of Common Stock purchased, the sale of shares of Common Stock purchased under the ESPP or the receipt of any dividends&#59; and (2) do not commit to and are under no obligation to structure the terms of the ESPP to reduce or eliminate my liability for Tax-Related Items or achieve any particular tax result.  Further, if I am subject to Tax-Related Items in more than one jurisdiction, I acknowledge that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, as applicable, I agree to make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Tax-Related Items.  In this regard, I authorize the Company and&#47;or the Employer to satisfy their withholding obligations with regard to all Tax-Related Items by one or a combination of the following&#58; (a) withholding from my wages or other cash compensation payable to me by the Company and&#47;or the Employer, (b) withholding from proceeds of the sale of shares of Common Stock purchased under the ESPP, either through a voluntary sale or through a mandatory sale arranged by the Company (on my behalf pursuant to this authorization without further consent), and (c) withholding in shares to be issued upon purchase under the ESPP.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable statutory withholding amounts or other applicable withholding rates, including up to the maximum applicable rates, in which case I will receive a refund of any over-withheld amount in cash and will have no entitlement to the Common Stock equivalent.  If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, I am deemed to have been issued the full number of shares of Common Stock, notwithstanding that a number of the shares of Common Stock are held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, I agree to pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of my participation in the ESPP that cannot be satisfied by the means previously described.  The Company may refuse to purchase or deliver the shares or the proceeds from the sale of shares of Common Stock, if I fail to comply with my obligations in connection with the Tax-Related Items.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-indent:-0.1pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 10&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Governing Law &#38; Language</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rights to purchase shares and the provisions of this Enrollment&#47;Change Form are governed by, and subject to, the laws of the State of Delaware, without regard to any conflict of law provisions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If I have received this or any other document related to the ESPP translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 11&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Appendix &#38; Imposition of Other Requirements</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any provision herein, my participation in the ESPP will be subject to any special terms and conditions as set forth in the Appendix for my country, if any.  Moreover, if I relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to me, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Enrollment&#47;Change Form.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company reserves the right to impose other requirements on my participation in the ESPP or on any shares of Common Stock purchased under the ESPP, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require me to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 12&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Electronic Delivery and Acceptance</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the ESPP by electronic means.  I hereby consent to receive such documents by electronic delivery and agree to participate in the ESPP through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 13&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Severability &#38; Waiver</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of this Enrollment&#47;Change Form are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions will nevertheless be binding and enforceable.  I acknowledge that a waiver by the Company of breach of any provision of this Enrollment&#47;Change Form will not operate or be construed as a waiver of any other provision herein, or of any subsequent breach by me or any other Participant.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-indent:-0.1pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 14&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Insider Trading Restrictions&#47;Market Abuse Laws</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that I may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect my ability to acquire or sell shares of Common Stock or my rights to purchase shares under the ESPP during such times as I am considered to have &#8220;inside information&#8221; regarding the Company (as defined by or determined under the laws in my country).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable the Company insider trading policy.&#160; I acknowledge that it is my responsibility to comply with any applicable restrictions, and that I am advised to speak to my personal advisor on this matter.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 15&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">No Advice Regarding Grant</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding my participation in the ESPP, or my purchase or sale of the shares of Common Stock.  I am hereby advised to consult with my own personal tax, legal and financial advisors regarding my participation in the ESPP before taking any action related to the ESPP.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 16&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Compliance With Law</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless there is an available exemption from any registration, qualification or other legal requirement applicable to the shares of Common Stock, the Company will not be required to deliver any shares under the ESPP prior to the completion of any registration or qualification of the shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company will, in its absolute discretion, deem necessary or advisable.  I understand that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the shares.  Further, I agree that the Company will have unilateral authority to amend the ESPP and the Enrollment&#47;Change Form without my consent to the extent necessary to comply with securities or other laws applicable to issuance of shares.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 17&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acknowledgment and Signature</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that I have received a copy of the Prospectus summarizing the major features of the ESPP. I have read the Prospectus and this form and hereby agree to be bound by the terms of the ESPP.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signature&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><div id="i344e9ea2d36f47fc8658d75fe24587b5_94"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right;text-indent:-0.1pt"><font><br></font></div><div style="text-align:right;text-indent:-0.1pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Appendix - CANADA</font></div><div style="text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FOR THE DEXCOM, INC.</font></div><div style="text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 EMPLOYEE STOCK PURCHASE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This appendix (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Appendix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) is provided by the Committee designated to administer the Dexcom, Inc. (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dexcom</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) 2015 Employee Stock Purchase Plan (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) pursuant to Section 3 of the Plan.  Terms used herein without definition have the meanings given to them in the Plan.  This Appendix shall apply only to the Participants in the Plan who are employees of</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> DexCom Canada Co. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) who are resident in Canada (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Canadian Participants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  The purpose of this Appendix is to establish certain terms and conditions applicable to the grants made to Canadian Participants under the Plan, from time to time, in compliance with Canadian securities and other applicable laws which are currently in force.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Except as otherwise provided by this Appendix, all grants made to Canadian Participants pursuant to the Plan and this Appendix shall be governed by the terms of the Plan as interpreted under the laws of the State of Delaware, U.S.A., being the governing law thereof.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Plan and this Appendix shall be read together. This Appendix may be amended or rescinded from time to time by the Administrator.</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.77pt">Acceptance, Consent, Authorization and Acknowledgement</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.21pt">The Canadian Participant to whom this Appendix has been delivered hereby accepts and consents to the terms of the Plan and this Appendix, and hereby authorizes the Employer to do all such further acts and things and execute and deliver all such other instruments and documents as are required to implement, carry out and give effect to such Canadian Participant&#8217;s participation in the Plan.  The Canadian Participant hereby acknowledges and agrees that he or she is responsible for obtaining his or her own tax, financial and legal advice relating to the Plan and the Awards.</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.77pt">Canadian Employment Law Matters</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.21pt">For purposes of Section 12, a Canadian Participant will be deemed to have been terminated on the last day they are &#8220;Actively Employed&#8221;.  The last day on a Canadian Participant is &#8220;Actively Employed&#8221; will be the later of&#58; (i) the last day the Canadian Participant actually perform their duties prior to the termination of their employment with the Employer for any reason&#59; or (ii) the end of the period of statutory notice of termination prescribed by applicable employment or labour standards legislation. For clarity, except to the extent required by applicable employment or labour standards legislation&#58; (i) the last day a Canadian Participant is Actively Employed shall not be extended by any contractual or common law notice of termination period in respect of which the Canadian Participant receives or may receive pay in lieu of notice of termination or damages in lieu of such notice of termination&#59; and (ii) entitlement to any rights or benefits under the Plan shall not be included in any entitlement which a Canadian Participant may have to pay in lieu of notice or damages in lieu of notice of termination. The Committee shall have the exclusive discretion to determine when a Canadian Participant is no longer actively providing Service (including whether he may still be considered to be providing services while on an approved leave of absence).</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.77pt">Canadian Securities Law Matters</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.21pt">The grant of options to purchase shares will be granted to Canadian Participants pursuant to exemptions from the prospectus requirements of applicable Canadian provincial securities laws, on the basis that&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">such Canadian Participant is either an employee of the Employer (as such terms are interpreted under Canadian securities laws)&#59;</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.88pt">the Employer is a wholly-owned Subsidiary of Dexcom&#59; and</font></div><div style="text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.44pt">such Canadian Participant&#8217;s participation in the Plan is &#8220;voluntary&#8221;, in the sense that Canadian Participants are not required to purchase or participate in the Plan as a condition of employment or continued employment with the Company.</font></div><div style="text-indent:-0.1pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.21pt">You acknowledge and agree that you will only sell shares of Common Stock acquired through participation in the Plan outside of Canada through E*TRADE or such other broker designated under the Plan, provided that such sale takes place outside of Canada through the facilities of a stock exchange on which the shares of Common Stock are listed.  Currently, the shares of Common Stock are listed on Nasdaq Global Select Market.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-indent:-0.1pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The issuance of the shares of Common Stock in accordance with the terms and conditions of the grants of options to purchase shares will also be exempt from the above-noted Canadian securities laws prospectus requirements.</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.77pt">Foreign Asset&#47;Account Reporting Information</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You may be required to report foreign specified property (including shares) on Form T1135 (Foreign Income Verification Statement) if the total cost of your foreign specified property exceeds C$100,000 at any time in the year.  If applicable, the form must be filed by April 30 of the following year.  When shares of Common Stock are acquired, their cost generally is the adjusted cost base (&#8220;ACB&#8221;) of the Common Stock.  The ACB ordinarily would equal the fair market value of the Common Stock at the time of acquisition, but if you own other shares of Stock of the same Company, this ACB may have to be leveraged with the ACB of the other Stock.  Please refer to form T1135 (Foreign Income Verification Statement) and consult your tax advisor for further details.</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.77pt">Language Acknowledgment (Quebec only)</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The parties acknowledge that it is their express wish that this agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be provided to them in English.</font></div><div style="margin-bottom:12pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Les parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224;, la pr&#233;sente convention.</font></div><div style="text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">     </font></div><div style="margin-bottom:6pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">***************************</font></div><div style="text-align:justify;text-indent:-0.1pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-indent:-0.1pt"><font><br></font></div></div><div style="text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I hereby confirm that&#58;</font></div><div style="text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.88pt">I have read, understand and accept the terms of the Plan and this Appendix.</font></div><div style="text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.88pt">I am voluntarily participating in the Plan&#59; and</font></div><div style="text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.44pt">I have requested that the Plan and this Appendix and all documentation issued pursuant or related to the Plan be prepared in the English language only. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">J'ai demand&#233; que le plan et la pr&#233;sente annexe ainsi que tous les documents &#233;mis en vertu du plan ou li&#233;s &#224; celui-ci soient pr&#233;par&#233;s en anglais seulement.</font></div><div style="text-align:justify;text-indent:-0.1pt"><font><br></font></div><div style="text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DATED this ____ day of ________________, 20____.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________________________________</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(signature of Canadian Participant)</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________________________________</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Please print name)</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________________________________</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Employee Number, if applicable)</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:-0.1pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><div id="i344e9ea2d36f47fc8658d75fe24587b5_97"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right;text-indent:-0.1pt"><font><br></font></div><div style="text-align:right;text-indent:-0.1pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Employee Stock Purchase Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subplan for Employees in the United Kingdom and Ireland</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective February 6, 2023</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">General. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The Board of Directors of DexCom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) has established the Dexcom, Inc. 2015 Employee Stock Purchase Plan, as amended on December 13, 2019, and as may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for the benefit of eligible employees of the Company and its Participating Corporations. Capitalized terms used but not defined herein shall have the meanings ascribed to them in Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">Paragraph 3 of the Plan specifically authorizes the Committee to designate (i) Participating Corporations under the Plan and (ii) separate offerings under the Plan in which one or more Participating Corporations will participate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Paragraphs 2 and 3 of the Plan provide that the Board or Committee may offer a subplan that is not intended to meet Code Section 423 requirements and separate offerings pursuant to such subplan that are not intended to meet Code Section 423 requirements (subject to the terms of the Plan) (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-423 Component</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">The Committee has established this subplan of the Plan for certain employees in the United Kingdom and Ireland pursuant to Paragraph 3 and Paragraph 2 of the Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UK and Ireland Subplan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subplan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  The UK and Ireland Subplan is a Non-423 Component of the Plan and the offerings pursuant to the UK and Ireland Subplan are separate from the offerings under the Plan and are not intended to meet Code Section 423 requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Paragraph 4(a)(v) of the Plan provides that the Committee may impose additional eligibility requirements on participation in the Plan (or any subplans) within the limits prescribed by the Code.  The UK and Ireland Subplan is a Non-423 Component and therefore the Committee may impose additional eligibility requirements on participation beyond those enumerated in Section 423 of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">The terms of the Plan, except as specifically modified or superseded by this UK and Ireland Subplan, are hereby incorporated into the terms of this UK and Ireland Subplan by reference as if set forth herein in their entirety.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Participating Corporations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The following subsidiaries of the Company will be Participating Corporations under this UK and Ireland Subplan and the Committee may add additional Participating Corporations from time to time&#58; DexCom (UK) Limited, DexCom Intermediate Holdings Limited, DexCom UK Operating Limited, DexCom UK Distribution Limited, and DexCom International Limited (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subplan Participating Corporations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Eligible Employees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Section 4 (Eligibility) of the Plan is replaced in its entirety with the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">An employee of a Subplan Participating Corporation who is on the payroll in the United Kingdom or Ireland (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subplan Eligible Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is eligible to participate in an Offering Period under this UK and Ireland Subplan except that one or more of the following categories of employees may be excluded from coverage under this UK and Ireland Subplan by the Committee (other than where prohibited by applicable law)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Subplan Eligible Employees who are customarily employed for twenty (20) hours or less per week&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Subplan Eligible Employees who are customarily employed for five (5) months or less in a calendar year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.03pt">Subplan Eligible Employees who have been an employee of a Subplan Participating Corporation for less than thirty (30) days prior to the first day of an Offering Period (or such longer period of time, not to exceed two (2) years, as determined by the Committee)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.01pt">Subplan Eligible Employees who do not meet any other eligibility requirements that the Committee may choose to impose.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-indent:-0.1pt"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The foregoing notwithstanding, an individual shall not be eligible if his or her participation in the UK and Ireland Subplan is prohibited by the law of any country that has jurisdiction over him or her, if complying with the laws of the applicable country would cause the Plan to violate Section 423 of the Code, or if he or she is subject to a collective bargaining agreement that does not provide for participation in the UK and Ireland Subplan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any employee of a Subplan Participating Corporation who is not on, or ceases to be on, the payroll in the United Kingdom or Ireland will not be eligible to participate in the UK and Ireland Subplan or the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">If an eligible employee under subsection (a) above either (i) ceases to be an employee of a Subplan Participating Corporation, including, but not limited to, as a result of a transfer of employment to the Company or a different subsidiary of the Company, or (ii) ceases to be on the payroll in the United Kingdom or Ireland, such employee&#8217;s participation in the UK and Ireland Subplan will termination on the date of either such cessation and such employee will be treated as having their employment terminated on such date for purposes of the UK and Ireland Subplan and Section 12 of the Plan.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The Committee will have discretion to set and determine rules regarding transfers among Subplan Participating Corporations and whether employees remain or become eligible to participate in the UK and Ireland Subplan.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><div id="i344e9ea2d36f47fc8658d75fe24587b5_100"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:16.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.416%"><tr><td style="width:1.0%"></td><td style="width:62.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UK and Ireland Subplan (the &#8220;UK and Ireland ESPP Subplan&#8221;) under the 2015 Employee Stock Purchase Plan (collectively with the UK and Ireland ESPP Subplan, the &#8220;ESPP&#8221;) </font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UK and Ireland Subplan Enrollment&#47;Change Form</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:15.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.812%"><tr><td style="width:1.0%"></td><td style="width:19.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actions</font></div></td><td colspan="6" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Check Desired Action</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                and Complete Sections</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Enroll in the UK and Ireland ESPP Subplan&#160;&#160;&#160;&#160;                2 + 3 + 4 + 17 + 18</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Elect &#47; Change Contribution Percentage&#160;&#160;&#160;&#160;                2 + 4 + 17 + 18</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Withdraw from Plan&#47;Discontinue Contributions                  2 + 5 + 17 + 18</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Personal Data</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Address&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax ID No&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Department</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enroll</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;I hereby elect to participate in the UK and Ireland ESPP Subplan, effective at the beginning of the next Offering Period. I elect to purchase shares of the Common Stock of Dexcom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) pursuant to the UK and Ireland ESPP Subplan.  I understand that the shares purchased on my behalf will be issued in street name and deposited directly into my brokerage account at the Company&#8217;s captive broker (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ESPP Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  I hereby agree to take all steps, and sign all forms, required to establish an account with the Company&#8217;s ESPP Broker for this purpose.  I understand and agree that I will be required to utilize the ESPP Broker with respect to the shares purchased under this ESPP until the end of the time period described in Section 6 below.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">My participation will continue as long as I remain eligible under the UK and Ireland ESPP Subplan, unless I withdraw from the UK and Ireland ESPP Subplan by filing a new UK and Ireland Enrollment&#47;Change Form with the Company. I understand that if I am subject to U.S. taxation, I must notify the Company of any disposition of shares purchased under the UK and Ireland ESPP Subplan.  If I cease to be employed by one of the Subplan Participating Corporations (as defined in the UK and Ireland ESPP Subplan) or if I cease to be on the UK or Ireland payroll, I will be withdrawn from the UK and Ireland ESPP Subplan on the date of such cessation and I will be treated as if my employment was terminated on such date for purposes of the UK and Ireland ESPP Subplan and Section 12 of the ESPP.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:15.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.812%"><tr><td style="width:1.0%"></td><td style="width:19.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Elect&#47;Change Contribution Percentage</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I hereby authorize the Company or the Participating Corporation employing me (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) to withhold a percentage of my bi-weekly, semi-monthly, or monthly payroll (as applicable based on payroll cadence) that will total ___% of my compensation (as defined in the ESPP) for the Purchase Period. That amount will be applied to the purchase of shares of the Company&#8217;s Common Stock pursuant to the ESPP.&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The percentage compensation to purchase common stock must be a whole number (from 1%, up to a maximum of 10%).</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You may decrease your contribution percentage once within a six-month Purchase Period. Each change will become effective as soon as reasonably practicable after the form is received by the Company.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 5&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discontinue Contributions</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#9744;&#160;&#160;&#160;&#160;I hereby elect to stop my contributions under the ESPP, effective as soon as reasonably practicable after this form is received by the Company. The contributions that I have made to date during this Offering Period should be applied as follows&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#9744;&#160; Purchase shares of the Company&#8217;s Common Stock at the end of the Purchase Period.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#9744;  Refund all contributions to me in cash, without interest.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I understand that I cannot resume participation until the start of the next Offering Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ESPP Broker</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I hereby agree the shares issued to me under the ESPP shall be deposited into an account established in my name at the ESPP Broker.  Subject to any applicable insider trading policy, I shall be free to dispose of the shares in my ESPP Broker account at any time, whether by sale, exchange, gift, or other transfer of legal title and I may move my shares to another brokerage account of my choosing at any time.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:15.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.812%"><tr><td style="width:1.0%"></td><td style="width:19.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature of Grant</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By enrolling in the ESPP, I understand, acknowledge and agree that (a) the ESPP is established voluntarily by the Company, it is discretionary in nature and it may be amended, terminated or modified at any time, to the extent permitted by the ESPP&#59; (b) the grant of the right to purchase shares of Common Stock under the ESPP is voluntary and does not create any contractual or other right to receive future rights to purchase shares of Common Stock, or benefits in lieu of rights to purchase shares, even if rights to purchase shares have been granted in the past&#59; (c) all decisions with respect to future grants of rights to purchase shares of Common Stock under the ESPP, if any, will be at the sole discretion of the Company&#59; (d) the grant of rights to purchase shares of Common Stock under the ESPP and my participation in the ESPP will not create a right to employment or be interpreted as forming an employment or service agreement with the Company or the Employer&#59; (e) the grant of rights to purchase shares of Common Stock under the ESPP and my participation in the ESPP will not interfere with the ability of the Employer to terminate my employment relationship at any time with or without cause, subject to applicable law&#59; (f) I am voluntarily participating in the ESPP&#59; (g) the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not intended to replace any pension rights or compensation&#59; (h) the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not part of normal or expected compensation for purposes of, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments&#59; (i) unless otherwise agreed with the Company, the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not granted as consideration for, or in connection with, any service I may provide as a director of the Subsidiary or Affiliate&#59; (j) the future value of the underlying shares purchased or to be purchased under the ESPP is unknown, indeterminable and cannot be predicted with certainty, and the value of the shares of Common Stock purchased under the ESPP may increase or decrease in the future, even below the Purchase Price&#59; (k) no claim or entitlement to compensation or damages will arise from termination of the right to purchase shares of Common Stock under the ESPP resulting from termination of my employment (for any reason whatsoever and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where I am employed or the terms of my employment agreement, if any) and in consideration of the grant of rights to purchase shares of Common Stock under the ESPP, I irrevocably agree never to institute any claim against the Company, the Parent, the Employer or any other Subsidiary or Affiliate, I hereby waive my ability, if any, to bring any such claim, and I release the Company, the Parent, the Employer or any other Subsidiary or Affiliate from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by enrolling in the ESPP, I will be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claims&#59; (l) in the event of termination of my employment (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where I am employed or the terms of my employment agreement, if any), my right to participate in the ESPP and my right to purchase shares of Common Stock, if any, will terminate effective as of the date I cease to actively provide services and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, employment would not include any contractual notice or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where I am employed or the terms of my employment agreement, if any)&#59; the Committee will have exclusive discretion to determine when I am no longer actively employed for purposes of my participation in the ESPP (including whether I may still be considered to be providing services while on a leave of absence)&#59; (m) unless otherwise provided in the ESPP or by the Company in its discretion, the right to purchase shares of Common Stock and the benefits evidenced by this Enrollment&#47;Change Form do not create any entitlement to have the ESPP or any such benefits granted thereunder transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any Corporate Transaction affecting the Common Stock&#59; and (n) if I am providing services outside the United States&#58; (1) the rights to purchase shares of Common Stock and the shares purchased under the ESPP, and the income and value of same, are not part of normal or expected compensation or salary for any purpose, and (2) neither the Company, the Parent, the Employer nor any other Subsidiary or Affiliate will be liable for any foreign exchange rate fluctuation between my local currency and the United States Dollar that may affect the value of the rights to purchase shares of Common Stock, the shares purchased under the ESPP or any amounts due to me pursuant to the sale of any shares of Common Stock acquired under the ESPP.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:15.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.812%"><tr><td style="width:1.0%"></td><td style="width:19.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Privacy</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Collected and Purposes of Collection.  I understand that the Company, acting as controller, as well as the employing Parent or Subsidiary or any other Parent or Subsidiary, will process, to the extent permissible under applicable law, certain personal information about me, including name, home address and telephone number, information necessary to process the right to purchase shares of Common Stock (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, mailing address for a check payment or bank account wire transfer information), date of birth, social insurance number or other identification number, salary, nationality, job title, employment location, details of all right to purchase shares of Common Stocks granted, canceled, vested, unvested or outstanding in my favor, and where applicable service termination date and reason for termination, any capital shares or directorships held in the Company (where needed for legal or tax compliance), and any other information necessary to process mandatory tax withholding and reporting (all such personal information is referred to as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  The Data is collected from me, and from the Company and any Parent or Subsidiary, for the purpose of implementing, administering, and managing the ESPP pursuant to its terms.  The legal basis (that is, the legal justification) for processing the Data is that it is necessary to perform, administer and manage the ESPP and in Company&#8217;s legitimate interests, which means the Company is using the relevant Data to conduct and develop its business activities, subject to my interest and fundamental rights. The Data must be provided in order for me to participate in the ESPP and for the parties to this Enrollment&#47;Change Form to perform their respective obligations hereunder.  If I do not provide Data, I will not be able to participate in the ESPP and become a party to this Enrollment&#47;Change Form.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers and Retention of Data.  I understand that the Data will be transferred to and among the Company and any Parent or Subsidiary, as well as service providers (such as stock administration providers, brokers, transfer agents, accounting firms, payroll processing firms, or tax firms), for the purposes explained above.  I understand that the recipients of the Data may be located in the United States and in other jurisdictions outside of the European Economic Area where we or our service providers have operations.  The United States and some of these other jurisdictions have not been found by the European Commission and the Federal Data Protection to have adequate data protection safeguards. If the Company and any Parent or Subsidiary transfer Data outside of the European Economic Area, we will take steps as required and recognized by the European Commission to provide adequate safeguards for the transferred Data. I have a right to obtain details of the mechanism(s) under which my Data is transferred outside of the European Economic Area, or the United Kingdom, which I may exercise by contacting the appropriate human resource representative.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">My Rights in Respect of Data.  I have the right to access my Data being processed by the Company or any Parent or Subsidiary as well as understand why Company or any Parent or Subsidiary is processing such Data.  Additionally, subject to applicable law, I am entitled to have any inadequate, incomplete, or incorrect Data corrected (that is, rectified).  Further, subject to applicable law, I may be entitled to the following rights in regard to my Data&#58;  (i) to object to the processing of Data&#59; (ii) to have my Data erased, under certain circumstances, such as where it is no longer necessary in relation to the purposes for which it was processed&#59; (iii) to restrict the processing of my Data so that it is stored but not actively processed (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, while the Company assesses whether I am entitled to have Data erased) under certain circumstances&#59; (iv) to port a copy of the Data provided pursuant to this Enrollment&#47;Change Form or generated by me, in a common machine-readable format&#59; and (v) to obtain a copy of the appropriate safeguards under which Data is transferred to a third country or international organization.&#160;To exercise my rights, I may contact the applicable human resources representative.&#160;I may also contact the relevant data protection supervisory authority, as I have the right to lodge a complaint.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">  </font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Responsibility for Taxes</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that, regardless of any action taken by the Company or the Employer, the ultimate liability for all income tax, social insurance or National Insurance Contributions, payroll tax, fringe benefits tax, payment on account or other tax-related items related to my participation in the ESPP and legally applicable to me (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Tax-Related Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is and remains my responsibility and may exceed the amount actually withheld by the Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or the Employer.  I further acknowledge that the Company and&#47;or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the ESPP, including, but not limited to, my enrollment in the ESPP, the grant of rights to purchase shares of Common Stock, the purchase of shares of Common Stock, the issuance of Common Stock purchased, the sale of shares of Common Stock purchased under the ESPP or the receipt of any dividends&#59; and (2) do not commit to and are under no obligation to structure the terms of the ESPP to reduce or eliminate my liability for Tax-Related Items or achieve any particular tax result.  Further, if I am subject to Tax-Related Items in more than one jurisdiction, I acknowledge that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, as applicable, I agree to make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Tax-Related Items.  In this regard, I authorize the Company and&#47;or the Employer to satisfy their withholding obligations with regard to all Tax-Related Items by one or a combination of the following&#58; (a) withholding from my wages or other cash compensation payable to me by the Company and&#47;or the Employer, (b) withholding from proceeds of the sale of shares of Common Stock purchased under the ESPP, either through a voluntary sale or through a mandatory sale arranged by the Company (on my behalf pursuant to this authorization without further consent), and (c) withholding in shares to be issued upon purchase under the ESPP.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable statutory withholding amounts or other applicable withholding rates, including up to the maximum applicable rates, in which case I will receive a refund of any over-withheld amount in cash and will have no entitlement to the Common Stock equivalent.  If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, I am deemed to have been issued the full number of shares of Common Stock, notwithstanding that a number of the shares of Common Stock are held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, I agree to pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of my participation in the ESPP that cannot be satisfied by the means previously described and I agree to fully indemnify and hold harmless the Company and the Employer from any Tax-Related Items and all costs, expenses, liabilities and losses (including, without limitation, reasonable attorneys&#8217;fees, judgments, fines, excise taxes, or penalties, interest, and the amounts paid or to be paid in settlement) incurred or suggered by the Company related to any Tax-Related Items.  The Company may refuse to purchase or deliver the shares or the proceeds from the sale of shares of Common Stock, if I fail to comply with my obligations in connection with the Tax-Related Items.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:15.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.812%"><tr><td style="width:1.0%"></td><td style="width:19.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governing Law &#38; Language</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rights to purchase shares and the provisions of this Enrollment&#47;Change Form are governed by, and subject to, the laws of the State of Delaware, without regard to any conflict of law provisions.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If I have received this or any other document related to the ESPP translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 11&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Appendix &#38; Imposition of Other Requirements</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any provision herein, my participation in the ESPP will be subject to any special terms and conditions as set forth in the Appendix for my country, if any.  Moreover, if I relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to me, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Enrollment&#47;Change Form.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company reserves the right to impose other requirements on my participation in the ESPP or on any shares of Common Stock purchased under the ESPP, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require me to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 12&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Electronic Delivery and Acceptance</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the ESPP by electronic means.  I hereby consent to receive such documents by electronic delivery and agree to participate in the ESPP through an on-line or electronic system established and maintained by the Company or a third party designated by the Company. I agree that the foregoing online or electronic participation in the ESPP shall have the same force and effect as documentation executed in hardcopy written form.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 3.75pt 0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.75pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 13&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severability &#38; Waiver</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of this Enrollment&#47;Change Form are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions will nevertheless be binding and enforceable.  I acknowledge that a waiver by the Company of breach of any provision of this Enrollment&#47;Change Form will not operate or be construed as a waiver of any other provision herein, or of any subsequent breach by me or any other Participant.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 3.75pt 0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:15.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.812%"><tr><td style="width:1.0%"></td><td style="width:19.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insider Trading Restrictions&#47;Market Abuse Laws</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.5pt solid #000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that I may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect my ability to acquire or sell shares of Common Stock or my rights to purchase shares under the ESPP during such times as I am considered to have &#8220;inside information&#8221; regarding the Company (as defined by or determined under the laws in my country).&#160; Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.&#160; I acknowledge that it is my responsibility to comply with any applicable restrictions, and that I am advised to speak to my personal advisor on this matter.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No Advice Regarding Grant</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding my participation in the ESPP, or my purchase or sale of the shares of Common Stock.  I am hereby advised to consult with my own personal tax, legal and financial advisors regarding my participation in the ESPP before taking any action related to the ESPP.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compliance With Law</font></div></td><td colspan="6" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless there is an available exemption from any registration, qualification or other legal requirements applicable to the shares of Common Stock, the Company will not be required to deliver any shares under the ESPP prior to the completion of any registration or qualification of the shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company will, in its absolute discretion, deem necessary or advisable.  I understand that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the shares.  Further, I agree that the Company will have unilateral authority to amend the ESPP and the Enrollment&#47;Change Form without my consent to the extent necessary to comply with securities or other laws applicable to the issuance of shares.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion on Payroll Deduction</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I understand that, if my payroll deductions or contributions under the ESPP are made in any currency other than U.S. dollars, such payroll deductions or contributions will be converted to U.S. dollars on or prior to the Purchase Date using a prevailing exchange rate in effect at the time such conversion is performed, as determined by the administrator.   I understand and agree that neither the Company, the Employer nor any Parent or Subsidiary shall be liable for any foreign exchange rate fluctuation between my local currency and the U.S. Dollar that may affect the value of the right to purchase shares of Common Stock granted to me under the ESPP, or of any amounts due to me under the ESPP or as a result of the subsequent sale of any shares of Common Stock acquired under the ESPP.</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 18&#58;</font></div><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acknowledgment and Signature</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.75pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:18pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that I have received a copy of the Prospectus summarizing the major features of the ESPP. I have read the Prospectus and this form and hereby agree to be bound by the terms of the ESPP.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><div id="i344e9ea2d36f47fc8658d75fe24587b5_103"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Appendix</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dexcom, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 Employee Stock Purchase Plan </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UK and Ireland ESPP Subplan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COUNTRY-SPECIFIC PROVISIONS FOR EMPLOYEES OUTSIDE THE U.S.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms used but not defined herein shall have the meanings ascribed to them in the ESPP, the UK and Ireland Subplan or UK and Ireland Subplan Enrollment&#47;Change Form, as applicable.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Appendix includes additional terms and conditions that govern my participation in the ESPP and the UK and Ireland Subplan if I reside and&#47;or work in one of the countries listed below.  If I am a citizen or resident (or are considered as such for local law purposes) of a country other than the country in which I am currently residing and&#47;or working, or if I transfer to another country after enrolling in the ESPP and the UK and Ireland Subplan, the Company shall, in its discretion, determine to what extent the special terms and conditions contained herein shall be applicable to me under these circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Appendix also includes information regarding securities, exchange controls, foreign asset&#47;account reporting and other issues of which I should be aware with respect to my participation in the ESPP and the UK and Ireland Subplan.  The information is based on the securities, exchange control, foreign asset&#47;account reporting and other laws in effect in my country as of January 2023.  Such laws are often complex and change frequently.  As a result, I should not rely on the information in this Appendix as the only source of information relating to the consequences of my participation in the ESPP and the UK and Ireland Subplan because the information may be out of date at the time I exercise my right to purchase shares, sell shares of Common Stock purchased under the ESPP and the UK and Ireland Subplan or take any other action in connection with the ESPP and the UK and Ireland Subplan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the information contained herein is general in nature and may not apply to my particular situation, and the Company is not in a position to assure me of any particular result.  Accordingly, I should seek appropriate professional advice as to how the relevant laws in my country may apply to my situation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, if I am a citizen or resident of a country, or am considered a resident of a country, other than the one in which I am currently residing and&#47;or working, or if I transfer employment and&#47;or residency after I enroll in the ESPP and the UK and Ireland Subplan, the information contained herein may not be applicable to me in the same manner.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Ireland</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The grant of the right to purchase shares of Common Stock under the ESPP is exempt or excluded from the requirement to publish a prospectus under the EU Prospectus Regulation as implemented in Ireland.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Director Notification Requirement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If I am a director, shadow director or secretary of a Parent or Subsidiary in Ireland, I am required to notify such Parent or Subsidiary in writing within five business days of (i) receiving or disposing of an interest in the Company (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, right to purchase shares of Common Stocks, shares of Common Stock, etc.), (ii) becoming aware of the event giving rise to the notification requirement, or (iii) becoming a director, shadow director or secretary of a Parent or Subsidiary in Ireland if such an interest exists at the time.&#160; This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director, or secretary, as the case may be).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">United Kingdom</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that, regardless of any action taken by the Company or the Employer, the ultimate liability for all Tax-Related Items is and remains the responsibility of mine and may exceed the amount actually withheld by the Company or the Employer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Neither this Enrollment&#47;Change Form nor the Appendix is an approved prospectus for the purposes of section 85(1) of the Financial Services and Markets Act 2000 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">FSMA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and no offer of transferable securities to the public (for the purposes of section 102B of FSMA) is being made in connection with this Enrollment&#47;Change Form.  This Enrollment&#47;Change Form and the right to purchase shares of Common Stock is exclusively available in the UK to bona fide employees and former employees of the Company or its Parent or Subsidiary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Qualified Grants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The right to purchase shares of Common Stock is not intended to be tax-qualified or tax-preferred under current tax rules and regulations in the United Kingdom.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Consultation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I understand that I may suffer adverse tax consequences as a result of his or her acquisition, holding, or disposition of the shares of Common Stock. I represent that I will consult with any tax advisors that I deem appropriate in connection with the acquisition, holding, or disposition of the shares of Common Stock and that I am not relying on the Company and any Parent or Subsidiary for any tax advice.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibition Against Insider Dealing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I should be aware of the UK's insider dealing rules under the Criminal Justice Act 1993, which may affect transactions under the ESPP such as the acquisition or sale of shares of Common Stock acquired under the ESPP, if I have inside information regarding the Company.  If I am uncertain whether the insider dealing rules apply, the Company recommends that I consult with a legal advisor.  The Company cannot be held liable if I violate the UK's insider dealing rules.  I am responsible for ensuring his or her compliance with these rules.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>4
<FILENAME>dxcm12312023ex1013-amended.htm
<DESCRIPTION>EX-10.13
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i25370b9402e34802bc5629f9ffd2c742_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.13</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Adopted by the Board on April 18, 2019)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">PURPOSE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by offering them an opportunity to participate in the Company&#8217;s future performance through the grant of Awards. Capitalized terms not defined elsewhere in the text are defined in Section&#160;28.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SHARES SUBJECT TO THE PLAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Number of Shares Available</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to Sections&#160;2.5, and 21 and any other applicable provisions hereof, the total number of Shares reserved and available for grant and issuance pursuant to this Plan as of the date of adoption of this Plan by the Board, is 39,200,000 Shares, plus (i) Shares that are subject to stock options or other awards granted under the Company&#8217;s 2005 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Prior Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) on the Effective Date (as defined below), that cease to be subject to such stock options or other awards by forfeiture or otherwise after the Effective Date for any reason other than the exercise of a stock option or SAR, (ii) Shares issued under the Prior Plan that are repurchased by the Company at the original issue price&#59; or (iii)&#160;Shares that are subject to stock options or other awards granted under the Prior Plan that otherwise terminate without Shares being issued.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Lapsed, Returned Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Shares subject to Awards, and Shares issued under this Plan under any Award, will again be available for grant and issuance in connection with subsequent Awards under this Plan to the extent such Shares&#58; (a)&#160;are subject to issuance upon exercise of an Option or SAR granted under this Plan but which cease to be subject to the Option or SAR for any reason other than exercise of the Option or SAR&#59; (b)&#160;are subject to Awards granted under this Plan that are forfeited or are repurchased by the Company at the original issue price&#59; (c)&#160;are subject to Awards granted under this Plan that otherwise terminate without such Shares being issued&#59; or (d)&#160;are surrendered pursuant to an Exchange Program. To the extent an Award under this Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under this Plan. Shares used to pay the exercise price of an Award, Shares withheld to satisfy the tax withholding obligations related to an Award or Shares repurchased by the Company for any reason other than Shares repurchased at their original issue price, in each case will not become available for future grant or sale under this Plan. Except as set forth above, any Awards granted including but not limited to Awards granted as SARs shall reduce the number of shares granted on a one-for-one Share for Share basis and any Shares withheld shall not again be made available for Awards under the Plan. To the extent that any Award is forfeited, repurchased or terminates without Shares being issued, Shares may again be available for issuance under this Plan. For the avoidance of doubt, Shares that otherwise become available for grant and issuance because of the provisions of this Section&#160;2.2 shall not include Shares subject to Awards that initially became available because of the substitution clause in Section&#160;21.2 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Minimum Share Reserve</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. At all times the Company shall reserve and keep available a sufficient number of Shares as shall be required to satisfy the requirements of all outstanding Awards granted under this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. No more than 39,200,000 Shares shall be issued pursuant to the exercise of ISOs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Adjustment of Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the number of outstanding Shares is changed by an extraordinary cash dividend, a stock dividend, recapitalization, spin-off, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then (a)&#160;the number of Shares reserved for issuance and future grant under this Plan set forth in Sections&#160;2.1 and 2.2, (b)&#160;the Exercise Prices of and number of Shares subject to outstanding Options and SARs, (c)&#160;the number of Shares subject to other outstanding Awards, (d)&#160;the maximum number of Shares that may be issued as ISOs set forth in Section&#160;2.4, and (e)&#160;the maximum number of Shares that may be issued to an individual or to a new Employee in any one calendar year set forth in Section&#160;3 or to a Non-Employee Director in Section&#160;12 shall be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company and in compliance with applicable securities laws&#59; provided that fractions of a Share will not be issued but will either be replaced by a cash payment equal to the Fair Market Value of such fraction of a Share or will be rounded up (down in the case of ISOs) to the nearest whole Share, as determined by the Committee&#59; and provided further that the Exercise Price of any Option may not be decreased to below the par value of the Shares.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Reflects June 10, 2022 four-for-one forward stock split.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting &#47; Acceleration Restriction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Awards shall not provide for any vesting prior to at least twelve (12) months from grant. In addition, the Committee will not permit the discretionary acceleration of vesting of Awards. Notwithstanding the foregoing, the Committee may permit (i) acceleration of vesting of Awards in the event of the Participant&#8217;s death or Disability, or Change of Control and (ii) the vesting of Awards on any basis prior to twelve (12) months from grant or any acceleration of vesting of Awards representing up to an aggregate of five percent (5%) of the Shares reserved and available for grant under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ELIGIBILITY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> ISOs may be granted only to an eligible Employee. All other Awards may be granted to an eligible Employee, Consultant, Director or Non-Employee Director&#59; provided such Consultant, Director or Non-Employee Director renders bona fide services not in connection with the offer and sale of securities in a capital-raising transaction. No Participant will be eligible to be granted more than 4,000,000 Shares in any calendar year under this Plan pursuant to the grant of Awards except that a new Employee (including a new Employee who is also an officer or director of the Company or any Parent, Subsidiary or Affiliate) is eligible to be granted up to a maximum of 8,000,000 Shares in the calendar year in which such Employee commences employment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ADMINISTRATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Committee Composition&#59; Authority</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Plan will be administered by the Committee or by the Board acting as the Committee. Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board, the Committee will have full power to implement and carry out this Plan, except, however, the Board shall establish the terms for the grant of an Award to Non-Employee Directors. The Committee will have the authority to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">construe and interpret this Plan, any Award Agreement and any other agreement or document executed pursuant to this Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">prescribe, amend and rescind rules and regulations relating to this Plan or any Award&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">select persons to receive Awards&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">determine the form and terms and conditions, not inconsistent with the terms of this Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the exercise price, subject to Section 2.6, the time or times when Awards may vest and be exercised (which may be based on performance criteria) or settled, subject to Section 2.6, any vesting acceleration or waiver of forfeiture restrictions, the method to satisfy tax withholding obligations or any other tax liability legally due, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Committee will determine&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">determine the number of Shares or other consideration subject to Awards&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">determine the Fair Market Value and interpret the applicable provisions of this Plan and the definition of Fair Market Value in connection with circumstances that impact the Fair Market Value, if necessary&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">determine whether Awards will be granted singly, in combination with, in tandem with, in replacement of, or as alternatives to, other Awards under this Plan or any other incentive or compensation plan of the Company or any Parent or Subsidiary of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">grant waivers of Plan or Award conditions&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">determine the vesting, exercisability and payment of Awards&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">correct any defect, supply any omission or reconcile any inconsistency in this Plan, any Award or any Award Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">determine whether an Award has been earned&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">determine the terms and conditions of any, and to institute any Exchange Program approved by stockholders&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reduce or waive any criteria with respect to Performance Factors&#59;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">adjust Performance Factors to take into account changes in law and accounting or tax rules as the Committee deems necessary or appropriate to reflect the impact of extraordinary or unusual items, events or circumstances to avoid windfalls or hardships, including without limitation (i) restructurings, discontinued operations, extraordinary items, and other unusual or non-recurring charges, (ii) an event either not directly related to the operations of the Company or not within the reasonable control of the Company&#8217;s management, or (iii) a change in accounting standards required by generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">adopt terms and conditions, rules and&#47;or procedures (including the adoption of any subplan under this Plan and any country addenda to the Award Agreements) relating to the operation and administration of this Plan to accommodate grants to participants residing outside of the United States and comply with the requirements of local law and procedures&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(p)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">make all other determinations necessary or advisable for the administration of this Plan&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(q)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">delegate any of the foregoing to a subcommittee consisting of one or more executive officers pursuant to a specific delegation as permitted by applicable law, including Section&#160;157(c) of the Delaware General Corporation Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Committee&#160;Interpretation and Discretion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Any determination made by the Committee with respect to any Award shall be made in its sole discretion at the time of grant of the Award or, unless in contravention of any express term of this Plan or Award, at any later time, and such determination shall be final and binding on the Company and all persons having an interest in any Award under this Plan. Any dispute regarding the interpretation of this Plan or any Award Agreement shall be submitted by the Participant or Company to the Committee for review. The resolution of such a dispute by the Committee shall be final and binding on the Company and the Participant. The Committee may delegate to one or more executive officers the authority to review and resolve disputes with respect to Awards held by Participants who are not Insiders, and such resolution shall be final and binding on the Company and the Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;16 of the Exchange Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Awards granted to Participants who are subject to Section&#160;16 of the Exchange Act must be approved by two or more &#8220;non-employee directors&#8221; (as defined in the regulations promulgated under Section&#160;16 of the Exchange Act).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Documentation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Award Agreement for a given Award, this Plan and any other documents may be delivered to, and accepted by, a Participant or any other person in any manner (including electronic distribution or posting) that meets applicable legal requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Foreign Award Recipients</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision of this Plan to the contrary, in order to comply with the laws and practices in countries other than the United States in which the Company and its Subsidiaries and Affiliates operate or have employees or other individuals eligible for Awards, the Committee, in its sole discretion, shall have the power and authority to&#58; (i)&#160;determine which Subsidiaries and Affiliates shall be covered by this Plan&#59; (ii)&#160;determine which individuals outside the United States are eligible to participate in this Plan, which may include individuals who provide services to the Company, Subsidiary or Affiliate under an agreement with a foreign nation or agency&#59; (iii)&#160;modify the terms and conditions of any Award granted to individuals who are located outside the United States or who are foreign nationals to comply with applicable foreign laws, policies, customs and practices&#59; (iv)&#160;establish subplans and modify exercise procedures and other terms and procedures, to the extent determined necessary or advisable by the Committee and provided that (a) no such subplans and&#47;or modifications shall increase the share limitations contained in Section&#160;2.1 hereof and (b) in such instance, such subplans and&#47;or modifications shall be attached to this Plan as appendices&#59; and (v)&#160;take any action, before or after an Award is made, that the Committee determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no Award shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code or any other applicable United States governing statute or law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">OPTIONS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> An Option is the right but not the obligation to purchase a Share, subject to certain conditions, if applicable, granted to an eligible Employee, Consultant or Director. All Options shall be granted pursuant to an Award Agreement.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Terms of Options</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Option granted under this Plan will be identified as an Incentive Stock Options within the meaning of the Code (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ISO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or a Nonqualified Stock Option (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">NSO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Applicable conditions may be based on completion of a specified number of years of service with the Company or upon satisfaction of performance goals based on Performance Factors during a Performance Period as set out in advance in the Award Agreement. Prior to the grant of an Option that is being earned upon satisfaction of performance goals based on Performance Factors, the Committee shall&#58; (a)&#160;determine the nature, length and starting date of any Performance Period for the Option&#59; (b)&#160;select from among the Performance Factors to be used to measure performance goals, if any&#59; and (c)&#160;determine the number of Shares that may be earned by the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Options that are subject to different Performance Periods and having performance goals based on different Performance Factors and other criteria.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Date of Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. An Option&#8217;s date of grant will be that date on which the Committee makes the determination to grant such Option, or any such future date specified by the Committee. The Award Agreement will be delivered to the Participant within a reasonable time after the date of grant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to Section 2.6, Options will vest and be exercisable within the times or upon the conditions as set forth in the Award Agreement&#59;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that no Option will be exercisable after the expiration of ten (10) years from the date of grant&#59; and&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;that no ISO granted to a person who, at the time the ISO is granted, directly or by attribution owns more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any Parent or Subsidiary of the Company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Ten Percent Stockholder</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) will be exercisable after the expiration of five (5) years from the date the ISO is granted. The Committee also may provide for Options to vest and be exercisable at one time or from time to time, periodically or otherwise (including, without limitation, upon the attainment during a Performance Period of performance goals based on Performance Factors), in such number of Shares or percentage of Shares as the Committee determines.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Exercise Price of an Option will be determined by the Committee when the Option is granted&#59; provided that&#58; (i)&#160;the Exercise Price of an Option will be not less than one hundred percent (100%) of the Fair Market Value of the Shares on the date of grant and (ii)&#160;the Exercise Price of any ISO granted to a Ten Percent Stockholder will be not less than one hundred ten percent (110%) of the Fair Market Value of the Shares on the date of grant. Payment for the Shares purchased must be made in accordance with Section&#160;11 of this Plan, the Award Agreement and any procedures established by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Method of Exercise</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Any Option granted hereunder will vest and be exercisable at such times and under such conditions as determined by the Committee and set forth in the Award Agreement, subject to the terms and conditions of this Plan. An Option may not be exercised for a fraction of a Share. An Option will be deemed exercised when the Company receives&#58; (i)&#160;notice of exercise (in such form as the Committee may specify from time to time) from the person entitled to exercise the Option, and (ii)&#160;full payment for the Shares with respect to which the Option is exercised plus payment or provision for applicable withholding taxes. Shares issued upon exercise of an Option will be issued in the name of the Participant. Notwithstanding the exercise of the Option, until such time as the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section&#160;2.5 of this Plan. Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of this Plan and for sale under the Option, by the number of Shares as to which the Option is exercised.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the Participant&#8217;s Service terminates for any reason except a termination by the Company for Cause or because of the Participant&#8217;s death or Disability, then the Participant may exercise such Participant&#8217;s Options only to the extent that such Options would have been exercisable by the Participant on the&#160;date Participant&#8217;s Service terminates, no later than three (3) months after the date Participant&#8217;s Service terminates (or such shorter or longer time period as may be determined by the Committee, with any exercise beyond three (3) months after the date Participant&#8217;s Service terminates deemed to be the exercise of an NSO), but in any event no later than the expiration date of the Options.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the Participant&#8217;s Service terminates because of the Participant&#8217;s death (or the Participant dies within three (3) months after Participant&#8217;s Service terminates for any reason except a termination by the Company for Cause or because of the Participant&#8217;s Disability), then the Participant&#8217;s Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the date Participant&#8217;s Service terminates and must be exercised by the Participant&#8217;s legal representative, or authorized assignee, no later than twelve (12) months after the date Participant&#8217;s Service terminates (or such shorter or longer time period as may be determined by the Committee), but in any event no later than the expiration date of the Options.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the Participant&#8217;s Service terminates because of the Participant&#8217;s Disability, then the Participant&#8217;s Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the date Participant&#8217;s Service terminates and must be exercised by the Participant (or the Participant&#8217;s legal representative or authorized assignee) no later than twelve (12) months after the date Participant&#8217;s Service terminates (with any exercise beyond (a)&#160; three (3) months after the date Participant&#8217;s employment terminates when the termination of Service is for a Disability that is not a &#8220;permanent and total disability&#8221; as defined in Section&#160;22(e)(3) of the Code, or (b)&#160;twelve (12) months after the date Participant&#8217;s employment terminates when the termination of Service is for a Disability that is a &#8220;permanent and total disability&#8221; as defined in Section&#160;22(e)(3) of the Code, deemed to be exercise of an NSO), but in any event no later than the expiration date of the Options.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the Participant is terminated by the Company for Cause, then Participant&#8217;s Options shall expire on the date Service terminates, or at such later time and on such conditions as are determined by the Committee, but in any event no later than the expiration date of the Options. Unless otherwise provided in the Award Agreement, Cause shall have the meaning set forth in this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on Exercise</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Committee may specify a minimum number of Shares that may be purchased on any exercise of an Option, provided that such minimum number will not prevent a Participant from exercising the Option for the full number of Shares for which it is then exercisable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations on ISOs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. With respect to Awards granted as ISOs, to the extent that the aggregate Fair Market Value of the Shares with respect to which such ISOs are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated as NSOs. For purposes of this Section&#160;5.7, ISOs will be so evaluated in the order in which they were granted, beginning with the grant first in time. The Fair Market Value of the Shares will be determined as of the Option&#8217;s date of grant. In the event that the Code or the regulations promulgated thereunder are amended after the Effective Date to provide for a different limit on the Fair Market Value of Shares permitted to be subject to ISOs, such different limit will be automatically incorporated herein and will apply to any Options granted after the effective date of such amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Modification, Extension or Renewal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Committee may modify, extend or renew outstanding Options and authorize the grant of new Options in substitution therefor, provided that any such action may not, without the written consent of a Participant, impair any of such Participant&#8217;s rights under any Option previously granted. Subject to Section&#160;18, the Committee may (a)&#160;reduce the Exercise Price of outstanding Options or (b)&#160;grant Options in substitution for cancelled options or other Awards authorized under the Plan. Any outstanding ISO that is modified, extended, renewed or otherwise altered will be treated in accordance with Section&#160;424(h) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Disqualifying Dispositions of Shares Acquired on Exercise of an ISO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If a Participant sells or otherwise disposes of any Shares acquired pursuant to the exercise of an ISO on or before the later of (a) the date two years after the Date of Grant, and (b) the date one year after the exercise of the ISO (in either case, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Disqualifying Disposition</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Company may require the Participant to immediately notify the Company in writing of such Disqualifying Disposition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No Disqualification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any other provision in this Plan, no term of this Plan relating to ISOs will be interpreted, amended or altered, nor will any discretion or authority granted under this Plan be exercised, so as to disqualify this Plan under Section&#160;422 of the Code or, without the consent of the Participant affected, to disqualify any ISO under Section&#160;422 of the Code</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as otherwise set forth in the Award Agreement or as otherwise determined by the Committee, vesting ceases on the date Participant&#8217;s Service terminates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">RESTRICTED STOCK AWARDS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A Restricted Stock Award is an offer by the Company to sell Shares subject to restrictions (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) to an eligible Employee, Consultant, or Director. The Committee will determine to whom an offer will be made, the number of Shares the Participant may purchase, the Purchase&#160;Price, the restrictions applicable to the Shares and all other terms and conditions of the Restricted Stock Award, subject to this Plan.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Stock Purchase Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. All purchases under a Restricted Stock Award will be evidenced by an Award Agreement. Except as may otherwise be provided in an Award Agreement, a Participant accepts a Restricted Stock Award by signing and delivering to the Company an Award Agreement with full payment of the Purchase Price plus payment or provision for applicable withholding taxes, within thirty (30) days from the date the Award Agreement was delivered to the Participant. If the Participant does not accept such Award within thirty (30) days, then such Restricted Stock Award will terminate, unless the Committee determines otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Purchase Price for a Restricted Stock Award will be determined by the Committee and may be less than Fair Market Value but not less than the par value of the Shares on the date the Restricted Stock Award is granted. Payment of the Purchase Price must be made in accordance with Section&#160;11 of this Plan, and the Award Agreement and in accordance with any procedures established by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Terms of Restricted Stock Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to Section 2.6, Restricted Stock Awards will be subject to such restrictions as the Committee may impose or are required by law. Applicable restrictions may be based on completion of a specified number of years of service with the Company or upon satisfaction of performance goals based on Performance Factors during a Performance Period as set out in advance in the Award Agreement. Prior to the grant of a Restricted Stock Award that is being earned upon satisfaction of performance goals based on Performance Factors, the Committee shall&#58; (a)&#160;determine the nature, length and starting date of any Performance Period for the Restricted Stock Award&#59; (b)&#160;select from among the Performance Factors to be used to measure performance goals, if any&#59; and (c)&#160;determine the number of Shares that may be earned by the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Restricted Stock Awards that are subject to different Performance Periods and having performance goals based on different Performance Factors and other criteria.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as otherwise set forth in the Award Agreement or as otherwise determined by the Committee, vesting ceases on the date Participant&#8217;s Service terminates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">STOCK BONUS AWARDS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A Stock Bonus Award is an award of Shares made to an eligible Employee, Consultant, or Director in consideration for Services to be rendered or for past Services already rendered to the Company or any Parent or Subsidiary, as permitted by law. All Stock Bonus Awards shall be made pursuant to an Award Agreement. No payment from the Participant will be required for Shares awarded pursuant to a Stock Bonus Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Terms of Stock Bonus Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to Section 2.6, the Committee will determine to whom a Stock Bonus Award will be made, the number of Shares under the Stock Bonus Award, the restrictions, if any, applicable to such Shares and all other terms and conditions of the Stock Bonus Award, subject to this Plan. Applicable restrictions may be based upon completion of a specified number of years of service with the Company or upon satisfaction of performance goals based on Performance Factors during a Performance Period as set out in advance in the Award Agreement. Prior to the grant of any Stock Bonus Award that is being earned upon satisfaction of performance goals, the Committee shall&#58; (a)&#160;determine the nature, length and starting date of any Performance Period for the Stock Bonus Award&#59; (b)&#160;select from among the Performance Factors to be used to measure performance goals&#59; and (c)&#160;determine the number of Shares that may be awarded to the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Stock Bonus Awards that are subject to different Performance Periods and performance goals based on different Performance Factors and other criteria.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Payment to Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. As determined in the sole discretion of the Committee, a Stock Bonus Award may be paid in the form of cash, whole Shares, or a combination thereof, based on the Fair Market Value (as of the date of payment) of the Shares earned under such Stock Bonus Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as otherwise set forth in the Award Agreement or as otherwise determined by the Committee, vesting ceases on the date Participant&#8217;s Service terminates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">STOCK APPRECIATION RIGHTS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A Stock Appreciation Right (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">SAR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is an award to an eligible Employee, Consultant, or Director that may be settled in cash, or Shares (which may consist of Restricted Stock), having a value equal to (a)&#160;the difference between the Fair Market Value on the date of exercise over the Exercise Price multiplied by (b)&#160;the number of Shares with respect to which the SAR is being settled (subject to any maximum number of Shares that may be issuable as specified in an Award Agreement). All SARs shall be made pursuant to an Award Agreement.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Terms of SARs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Committee will determine the terms of each SAR including, without limitation&#58; (a)&#160;the number of Shares subject to the SAR&#59; (b)&#160;the Exercise Price and the time or times during which the SAR may be settled&#59; (c)&#160;the consideration to be distributed on settlement of the SAR&#59; and (d)&#160;the effect of the Participant&#8217;s termination of Service on each SAR. The Exercise Price of the SAR will be determined by the Committee when the SAR is granted, and may be not less than Fair Market Value or the par value of the Shares. A SAR may be awarded upon satisfaction of Performance Factors, if any, during any Performance Period as are set out in advance in the Award Agreement. Prior to the grant of any SAR that is being earned upon satisfaction of performance goals, then the Committee will&#58; (x)&#160;determine the nature, length and starting date of any Performance Period for each SAR&#59; and (y)&#160;select from among the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap and Participants may participate simultaneously with respect to SARs that are subject to different Performance Periods and performance goals based on different Performance Factors and other criteria.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise Period and Expiration Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to Section 2.6, a SAR will be exercisable within the times or upon the occurrence of events determined by the Committee and set forth in the Award Agreement. The SAR Agreement shall set forth the expiration date&#59; provided that no SAR will be exercisable after the expiration of ten (10) years from the date the SAR is granted. The Committee may also provide for SARs to become exercisable at one time or from time to time, periodically or otherwise (including, without limitation, upon the attainment during a Performance Period of performance goals based on Performance Factors), in such number of Shares or percentage of the Shares subject to the SAR as the Committee determines. Notwithstanding the foregoing, the rules of Section&#160;5.6 also will apply to SARs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Upon exercise of a SAR, a Participant will be entitled to receive payment from the Company in an amount determined by multiplying (i)&#160;the difference between the Fair Market Value of a Share on the date of exercise over the Exercise Price&#59; times (ii)&#160;the number of Shares with respect to which the SAR is exercised (subject to any maximum number of Shares that may be issuable as specified in an Award Agreement). At the discretion of the Committee, the payment from the Company for the SAR exercise may be in cash, in Shares of equivalent value, or in some combination thereof. The portion of a SAR being settled may be paid currently or on a deferred basis with such interest or dividend equivalent, if any, as the Committee determines, provided that the terms of the SAR and any deferral satisfy the requirements of Section&#160;409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as otherwise set forth in the Award Agreement or as otherwise determined by the Committee, vesting ceases on the date Participant&#8217;s Service terminates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">RESTRICTED STOCK UNITS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A Restricted Stock Unit (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSU</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is an award to an eligible Employee, Consultant, or Director covering a number of Shares that may be settled in cash, or by issuance of those Shares (which may consist of Restricted Stock). All RSUs shall be made pursuant to an Award Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Terms of RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to Section 2.6, the Committee will determine the terms of an RSU including, without limitation&#58; (a)&#160;the number of Shares subject to the RSU&#59; (b)&#160;the time or times during which the RSU may be settled&#59; (c)&#160;the consideration to be distributed on settlement&#59; and (d)&#160;the effect of the Participant&#8217;s termination of Service on each RSU. An RSU may be awarded upon satisfaction of such performance goals based on Performance Factors during any Performance Period as are set out in advance in the Award Agreement. Prior to the grant of any RSU that is being earned upon satisfaction of performance goals, the Committee will&#58; (x)&#160;determine the nature, length and starting date of any Performance Period for the RSU&#59; (y)&#160;select from among the Performance Factors to be used to measure the performance, if any&#59; and (z)&#160;determine the number of Shares deemed subject to the RSU. Performance Periods may overlap and participants may participate simultaneously with respect to RSUs that are subject to different Performance Periods and performance goals based on different Performance Factors and other criteria.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form and Timing of Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Payment of earned RSUs shall be made as soon as practicable after the date(s) determined by the Committee and set forth in the Award Agreement. The Committee, in its sole discretion, may settle earned RSUs in cash, Shares, or a combination of both. The Committee may also permit a Participant to defer payment under a RSU to a date or dates after the RSU is earned provided that the terms of the RSU and any deferral satisfy the requirements of Section&#160;409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as otherwise set forth in the Award Agreement or as otherwise determined by the Committee, vesting ceases on the date Participant&#8217;s Service terminates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">PERFORMANCE AWARDS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A Performance Award is an award to an eligible Employee, Consultant, or Director of Performance Shares or a cash bonus denominated in Shares that may be settled in cash, or by issuance of those Shares (which may consist of Restricted Stock). Grants of Performance Awards shall be made pursuant to an Award Agreement.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Terms of Performance Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to Section 2.6, the Committee will determine the terms of a Performance Award including, without limitation&#58; (a) the number of Shares or amount of cash subject to the Performance Award&#59; (b) the time or times during which the Performance Award may be settled&#59; and (c) the consideration to be distributed on settlement, and the effect of the Participant&#8217;s termination of Service on each Performance Award. A Performance Award may be awarded upon satisfaction of performance goals based on Performance Factors during any Performance Period as set out in advance in the Award Agreement. Prior to the grant of any Performance Award that is being earned upon satisfaction of performance goals, the Committee will&#58; (x) determine the nature, length and starting date of any Performance Period for the Performance Award&#59; (y) select from among the Performance Factors to be used to measure such performance goals, if any&#59; and (z) determine the number of Shares deemed subject to the Performance Award. Performance Periods may overlap and participants may participate simultaneously with respect to Performance Awards that are subject to different Performance Periods and performance goals based on different Performance Factors and other criteria.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as otherwise set forth in the Award Agreement or as otherwise determined by the Committee, vesting ceases on the date Participant&#8217;s Service terminates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">PAYMENT FOR SHARE PURCHASES</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Payment from a Participant for Shares purchased pursuant to this Plan may be made in cash or by check or, where approved for the Participant by the Committee and where permitted by law (and to the extent not otherwise set forth or prohibited in the applicable Award Agreement)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by cancellation of indebtedness of the Company to the Participant&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by surrender of Shares held by the Participant that have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which said Award will be exercised or settled&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by waiver of compensation due or accrued to the Participant for services rendered or to be rendered to the Company or a Parent or Subsidiary of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by consideration received by the Company pursuant to a broker-assisted or other form of cashless exercise program implemented by the Company in connection with this Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by any combination of the foregoing&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by any other method of payment as is permitted by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless determined otherwise by the Committee, all payments under any of the methods indicated above shall be made in United States dollars.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">GRANTS TO NON-EMPLOYEE DIRECTORS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Non-Employee Directors are eligible to receive any type of Award offered under this Plan except ISOs. Awards pursuant to this Section&#160;12 may be automatically made pursuant to policy adopted by the Board, or made from time to time as determined in the discretion of the Board. The aggregate number of Shares subject to Awards granted under this Section 12 to a Non-Employee Director in any calendar year shall not exceed 120,000 Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Awards pursuant to this Section&#160;12 shall be granted only to Non-Employee Directors. A Non-Employee Director who is elected or re-elected as a member of the Board will be eligible to receive an Award under this Section&#160;12.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting, Exercisability and Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as set forth in Section&#160;6 and 21, Awards shall vest, be exercisable and be settled as determined by the Board. With respect to Options and SARs, the exercise price granted to Non-Employee Directors shall be not less than the Fair Market Value of the Shares at the time that such Option or SAR is granted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Election to receive Awards in Lieu of Cash</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. A Non-Employee Director may elect to receive his or her annual retainer payments and&#47;or meeting fees from the Company in the form of cash or Awards or in a combination thereof, as determined by the Board. Such Awards shall be issued under this Plan. An election under this Section&#160;12.3 shall be filed with the Company on the form prescribed by the Company.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">WITHHOLDING TAXES</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Withholding Generally</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Whenever Shares are to be issued in satisfaction of Awards granted under this Plan or the applicable tax event occurs, the Company may require the Participant to remit to the Company, or to the Parent, Subsidiary or Affiliate employing the Participant, an amount sufficient to satisfy applicable U.S.&#160;federal, state, local and international withholding tax requirements or any other tax or social insurance liability legally due from the Participant prior to the delivery of Shares pursuant to exercise or settlement of any Award. Whenever payments in satisfaction of Awards granted under this Plan are to be made in cash, such payment will be net of an amount sufficient to satisfy applicable U.S.&#160;federal, state, local and international withholding tax and social insurance requirements or any other tax liability legally due from the Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Withholding</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Committee, or its delegate(s), as permitted by applicable law, in its sole discretion and pursuant to such procedures as it may specify from time to time and to limitations of local law, may require or permit a Participant to satisfy such tax withholding obligation or any other tax liability legally due from the Participant, in whole or in part by (without limitation) (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable cash or Shares having a Fair Market Value equal to up to the maximum statutory amount permitted to be withheld, (iii) delivering to the Company Shares having a Fair Market Value equal to up to the maximum amount permitted to be withheld or (iv) withholding from the proceeds of the sale of otherwise deliverable Shares acquired pursuant to an Award either through a voluntary sale or through a mandatory sale arranged by the Company. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">TRANSFERABILITY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Generally</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Unless determined otherwise by the Committee or pursuant to Section&#160;14.2, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent and distribution. If the Committee makes an Award transferable, including, without limitation, by instrument to an inter vivos or testamentary trust in which the Awards are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift or by domestic relations order to a Permitted Transferee, such Award will contain such additional terms and conditions as the Committee deems appropriate. All Awards shall be exercisable&#58; (i)&#160;during the Participant&#8217;s lifetime only by (A)&#160;the Participant, or (B)&#160;the Participant&#8217;s guardian or legal representative&#59; (ii)&#160;after the Participant&#8217;s death, by the legal representative of the Participant&#8217;s heirs or legatees&#59; and (iii)&#160;in the case of all awards except ISOs, by a Permitted Transferee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Beneficiaries</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Participant under this Plan may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom any benefit under this Plan is to be paid in case of such Participant&#8217;s death before he or she receives any or all of such benefit. Each such designation shall&#160;revoke all prior designations by the same Participant, shall be in a form prescribed by the Committee, and will be effective only when filed by such Participant in writing with the Company during such Participant&#8217;s lifetime. In the absence of any such beneficiary designation, benefits remaining unpaid or rights remaining unexercised at such Participant&#8217;s death shall be paid to or exercised by such Participant&#8217;s executor, administrator, or legal representative.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">PRIVILEGES OF STOCK OWNERSHIP&#59; RESTRICTIONS ON SHARES</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Voting and Dividends</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. No Participant will have any of the rights of a stockholder with respect to any Shares until the Shares are issued to the Participant, except for any Dividend Equivalent Rights permitted by an applicable Award Agreement. After Shares are issued to the Participant, the Participant will be a stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends or other distributions made or paid with respect to such Shares&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that if such Shares are Restricted Stock, then any new, additional or different securities the Participant may become entitled to receive with respect to such Shares by virtue of a stock dividend, stock split or any other change in the corporate or capital structure of the Company will be subject to the same restrictions as the Restricted Stock&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that the Participant will have no right to such stock dividends or stock distributions with respect to Unvested Shares, and any such dividends or stock distributions shall be accrued and paid only at such time if any, as such Unvested Shares become vested Shares. The Committee, in its discretion, may provide in the Award Agreement evidencing any Award that the Participant shall be entitled to Dividend Equivalent Rights with respect to the payment of cash dividends on Shares subject to such Award during the period beginning on the date the Award is granted and ending, with respect to each Share subject to the Award, on the earlier of the date on which the Award is exercised or settled or the date on which they are forfeited&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that under no circumstances may Dividend Equivalent Rights be granted for any Option or SAR and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that no Dividend Equivalent Right shall be paid with respect to Unvested Shares, and any such dividends or stock distributions shall be accrued and paid only at such time, if any, as such Unvested Shares become vested Shares. Such Dividend Equivalent Rights, if any, shall be credited to the Participant in the form of additional whole Shares as of the date of payment of such cash dividends on Shares.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictions on Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. At the discretion of the Committee, the Company may reserve to itself and&#47;or its assignee(s) a right to repurchase (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Right of Repurchase</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) a portion of any or all Unvested Shares held by a Participant following such Participant&#8217;s termination of Service at any time within ninety (90) days after the later of the date Participant&#8217;s Service terminates and the date the Participant purchases Shares under this Plan, for cash and&#47;or cancellation of purchase money indebtedness, at the Participant&#8217;s Purchase Price or Exercise Price, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CERTIFICATES</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All Shares or other securities whether or not certificated, delivered under this Plan will be subject to such stock transfer orders, legends and other restrictions as the Committee may deem necessary or advisable, including restrictions under any applicable U.S. federal, state or foreign securities law, or any rules, regulations and other requirements of the SEC or any stock exchange or automated quotation system upon which the Shares may be listed or quoted and any non-U.S. exchange controls or securities law restrictions to which the Shares are subject.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ESCROW&#59; PLEDGE OF SHARES</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To enforce any restrictions on a Participant&#8217;s Shares, the Committee may require the Participant to deposit all certificates representing Shares, together with stock powers or other instruments of transfer approved by the Committee, appropriately endorsed in blank, with the Company or an agent designated by the Company to hold in escrow until such restrictions have lapsed or terminated, and the Committee may cause a legend or legends referencing such restrictions to be placed on the certificates. Any Participant who is permitted to execute a promissory note as partial or full consideration for the purchase of Shares under this Plan will be required to pledge and deposit with the Company all or part of the Shares so purchased as collateral to secure the payment of the Participant&#8217;s obligation to the Company under the promissory note&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that the Committee may require or accept other or additional forms of collateral to secure the payment of such obligation and, in any event, the Company will have full recourse against the Participant under the promissory note notwithstanding any pledge of the Participant&#8217;s Shares or other collateral. In connection with any pledge of the Shares, the Participant will be required to execute and deliver a written pledge agreement in such form as the Committee will from time to time approve. The Shares purchased with the promissory note may be released from the pledge on a pro rata basis as the promissory note is paid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EXCHANGE AND BUYOUT OF AWARDS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. An Exchange Program, including but not limited to any repricing of Options or SARs is not permitted without prior stockholder approval.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SECURITIES LAW AND OTHER REGULATORY COMPLIANCE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> An Award will not be effective unless such Award is in compliance with all applicable U.S. and foreign federal and state securities and exchange control laws, rules and regulations of any governmental body, and the requirements of any stock exchange or automated quotation system upon which the Shares may then be listed or quoted, as they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no obligation to issue or deliver certificates for Shares under this Plan prior to&#58; (a)&#160;obtaining any approvals from governmental agencies that the Company determines are necessary or advisable&#59; and&#47;or (b)&#160;completion of any registration or other qualification of such Shares under any state or federal or foreign law or ruling of any governmental body that the Company determines to be necessary or advisable. The Company will be under no obligation to register the Shares with the SEC or to effect compliance with the registration, qualification or listing requirements of any foreign or state securities laws, exchange control laws, stock exchange or automated quotation system, and the Company will have no liability for any inability or failure to do so.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NO OBLIGATION TO EMPLOY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Nothing in this Plan or any Award granted under this Plan will confer or be deemed to confer on any Participant any right to continue in the employ of, or to continue any other relationship with, the Company or any Parent, Subsidiary or Affiliate or limit in any way the right of the Company or any Parent, Subsidiary or Affiliate to terminate Participant&#8217;s employment or other relationship at any time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CORPORATE TRANSACTIONS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assumption or Replacement of Awards by Successor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In the event that the Company is subject to a Corporate Transaction, outstanding Awards acquired under this Plan shall be subject to the documentation evidencing the Corporate Transaction, which need not treat all outstanding Awards in an identical manner. Such agreement, without the Participant&#8217;s consent, shall provide for one or more of the following with respect to all outstanding Awards as of the effective date of such Corporate Transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The continuation of an outstanding Award by the Company (if the Company is the successor entity).</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The assumption of an outstanding Award by the successor or acquiring entity (if any) of such Corporate Transaction (or by its parents, if any), which assumption, will be binding on all selected Participants&#59; provided that the exercise price and the number and nature of shares issuable upon exercise of any such option or stock appreciation right, or any award that is subject to Section&#160;409A of the Code, will be adjusted appropriately pursuant to Section&#160;424(a) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The substitution by the successor or acquiring entity in such Corporate Transaction (or by its parents, if any) of an equivalent award with substantially the same terms for such outstanding Award (except that the exercise price and the number and nature of shares issuable upon exercise of any such option or stock appreciation right, or any award that is subject to Section&#160;409A of the Code, will be adjusted appropriately pursuant to Section&#160;424(a) of the Code).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A payment to the Participant equal to the excess of (i)&#160;the Fair Market Value of the Shares subject to the Award as of the effective date of such Corporate Transaction over (ii)&#160;the Exercise Price or Purchase Price of Shares, as the case may be, subject to the Award in connection with the cancellation of the Award. Such payment will be made in the form of cash, cash equivalents, or securities of the surviving corporation or its parent with a Fair Market Value equal to the required amount. The successor corporation may provide substantially similar consideration to Participants as was provided to stockholders (after taking into account the existing provisions of the Awards). Subject to Section&#160;409A of the Code, such payment may be made in installments, may be deferred until the date or dates when the Award would have become exercisable or such Shares would have vested, and such payment may be subject to vesting based on the Participant&#8217;s continuing such payment initially will be calculated without regard to whether or not the Award is then exercisable or such Shares are then vested. In addition, any escrow, holdback, earnout or similar provisions in the agreement for such Corporate Transaction may apply to such payment to the same extent and in the same manner as such provisions apply to the holders of Shares. If the Exercise Price of the Shares subject to an Option exceeds the Fair Market Value of such Shares, then the Option may be cancelled without making a payment to the Participant. For purposes of this subsection, the Fair Market Value of any security will be determined without regard to any vesting conditions that may apply to such security.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board shall have full power and authority to assign the Company&#8217;s right to repurchase or re-acquire or forfeiture rights to such successor or acquiring corporation. Notwithstanding the foregoing, solely upon a Corporate Transaction in which the successor or acquiring corporation refuses to assume, convert, replace or substitute Awards, as provided above, pursuant to a Corporate Transaction notwithstanding any other provision in this Plan to the contrary, and unless otherwise determined by the Committee, all Awards granted under this Plan shall accelerate in full as of the time of consummation of the Corporate Transaction. In such event, the Committee will notify the Participant in writing or electronically that such Award will be exercisable for a period of time determined by the Committee in its sole discretion, and such Award will terminate upon the expiration of such period. Awards need not be treated similarly in a Corporate Transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assumption of Awards by the Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Company, from time to time, also may substitute or assume outstanding awards granted by another company, whether in connection with an acquisition of such other company or otherwise, by either&#59; (a)&#160;granting an Award under this Plan in substitution of such other company&#8217;s award&#59; or (b)&#160;assuming such award as if it had been granted under this Plan if the terms of such assumed award could be applied to an Award granted under this Plan. Such substitution or assumption will be permissible if the holder of the substituted or assumed award would have been eligible to be granted an Award under this Plan if the other company had applied the rules of this Plan to such grant. In the event the Company assumes an award granted by another company, the terms and conditions of such award will remain unchanged (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;that the Purchase Price or the Exercise Price, as the case may be, and the number and nature of Shares issuable upon exercise or settlement of any such Award will be adjusted appropriately pursuant to Section&#160;424(a) of the Code). In the event the Company elects to grant a new Option in substitution rather than assuming an existing option, such new Option may be granted with a similarly adjusted Exercise Price. Substitute Awards shall not reduce the number of Shares authorized for grant under this Plan or authorized for grant to a Participant in a calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Employee Directors&#8217; Awards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary herein, in the event of a Corporate Transaction, the vesting of all Awards granted to Non-Employee Directors shall accelerate and such Awards shall become exercisable (as applicable) in full prior to the consummation of such event at such times and on such conditions as the Committee determines.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ADOPTION AND STOCKHOLDER APPROVAL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Plan shall be submitted for the approval of the Company&#8217;s stockholders, consistent with applicable laws, within twelve (12) months before or after the date this Plan is adopted by the Board.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">TERM OF PLAN&#47;GOVERNING LAW</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Unless earlier terminated as provided herein, this Plan will become effective on the Effective Date and will terminate ten (10) years from the date this Plan is adopted by the Board. After this Plan is terminated or expires, no Awards may be granted but Awards previously granted shall remain outstanding in accordance with their applicable terms and conditions and this Plan&#8217;s terms and conditions. This Plan and all Awards granted hereunder shall be governed by and construed in accordance with the laws of the State of Delaware (excluding its conflict of laws rules).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">AMENDMENT OR TERMINATION OF PLAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Board may at any time terminate or amend this Plan in any respect, including, without limitation, amendment of any form of Award Agreement or instrument to be executed pursuant to this Plan&#59;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that the Board will not, without the approval of the stockholders of the Company, amend this Plan in any manner that requires such stockholder approval&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that a Participant&#8217;s Award shall be governed by the version of this Plan then in effect at the time such Award was granted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NONEXCLUSIVITY OF THE PLAN&#59; UNFUNDED PLAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Neither the adoption of this Plan by the Board, the submission of this Plan to the stockholders of the Company for approval, nor any provision of this Plan will be construed as creating any limitations on the power of the Board to adopt such additional compensation arrangements as it may deem desirable, including, without limitation, the granting of stock awards and bonuses otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">INSIDER TRADING POLICY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Each Participant who receives an Award shall comply with any policy adopted by the Company from time to time covering transactions in the Company&#8217;s securities by Employees, officers and&#47;or directors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ALL AWARDS SUBJECT TO COMPANY CLAWBACK OR RECOUPMENT POLICY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All Awards held by an executive officer shall be subject to clawback, recoupment or forfeiture (i) to the extent that such executive officer is determined to have engaged in fraud or intentional illegal conduct materially contributing to a financial restatement, as determined by the Board in its sole discretion, (ii) as provided under any clawback, recoupment or forfeiture policy adopted by the Board or (iii) required by law. Such clawback, recoupment or forfeiture policy, in addition to any other remedies available under applicable law, may require the cancellation of outstanding Awards and the recoupment of any gains realized with respect to Awards.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DEFINITIONS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> As used in this Plan, and except as elsewhere defined herein, the following terms will have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (i)&#160;any entity that, directly or indirectly, is controlled by, controls or is under common control with, the Company and (ii)&#160;any entity in which the Company has a significant equity interest, in either case as determined by the Committee, whether now or hereafter existing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any award under this Plan, including any Option, Restricted Stock, Stock Bonus, Stock Appreciation Right, Restricted Stock Unit or award of Performance Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to each Award, the written or electronic agreement between the Company and the Participant setting forth the terms and conditions of the Award and country-specific appendix thereto for grants to non-U.S. Participants, which shall be in substantially a form (which need not be the same for each Participant) that the Committee (or in the case of Award agreements that are not used for Insiders, the Committee&#8217;s delegate(s)) has from time to time approved, and will comply with and be subject to the terms and conditions of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of the Participant&#8217;s Service on the basis of the Participant&#8217;s conviction (or a plea of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of fraud, misappropriation, embezzlement or any other act or acts of dishonesty constituting a felony and resulting or intended to result directly or indirectly in a substantial gain or personal enrichment to the Participant at the expense of the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Compensation Committee of the Board or those persons to whom administration of this Plan, or part of this Plan, has been delegated as permitted by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the common stock of the Company.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Dexcom, Inc., or any successor corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any person, including an advisor or independent contractor, engaged by the Company or a Parent, Subsidiary or Affiliate to render services to such entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Corporate Transaction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following events&#58; (i)&#160;any &#8220;person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Exchange Act) becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company&#8217;s then-outstanding voting securities&#59; provided, however, that for purposes of this subclause (i)&#160;the acquisition of additional securities by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the securities of the Company will not be considered a Corporate Transaction&#59; (ii)&#160;the consummation of the sale, transfer or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; (iii)&#160;the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation&#59; (iv)&#160;any other transaction which qualifies as a &#8220;corporate transaction&#8221; under Section&#160;424(a) of the Code wherein the stockholders of the Company give up all of their equity interest in the Company (except for the acquisition, sale or transfer of all or substantially all of the outstanding shares of the Company) or (v)&#160;a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by members of the Board whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purpose of this subclause (v), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Corporate Transaction. For purposes of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. Notwithstanding the foregoing, to the extent that any amount constituting deferred compensation (as defined in Section&#160;409A of the Code) would become payable under this Plan by reason of a Corporate Transaction, such amount shall become payable only if the event constituting a Corporate Transaction would also qualify as a change in ownership or effective control of the Company or a change in the ownership of a substantial portion of the assets of the Company, each as defined within the meaning of Code Section&#160;409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and IRS guidance that has been promulgated or may be promulgated thereunder from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, a Corporate Transaction shall not be deemed to result from any transaction precipitated by the Company&#8217;s insolvency, appointment of a conservator, or determination by a regulatory agency that the Company is insolvent, nor from any transaction the sole purpose of which is to change the state of the Company&#8217;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a member of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means in the case of ISOs, total and permanent disability as defined in Section&#160;22(e)(3) of the Code and in the case of other Awards, that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Dividend Equivalent Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the right of a Participant, granted at the discretion of the Committee or as otherwise provided by the Plan, to receive a credit for the account of such Participant in an amount equal to the cash dividends paid on one Share for each Share represented by an Award held by such Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date the Plan is approved by the stockholders of the Company which shall be within twelve (12) months of the approval of the Plan by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any person, including officers and Directors, providing services as an employee to the Company or any Parent, Subsidiary or Affiliate. Neither service as a Director nor payment of a director&#8217;s fee by the Company will be sufficient to constitute &#8220;employment&#8221; by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Securities Exchange Act of 1934, as amended.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Exchange Program</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a program pursuant to which (i)&#160;outstanding Awards are surrendered, cancelled or exchanged for cash, the same type of Award or a different Award (or combination thereof) or (ii)&#160;the exercise price of an outstanding Award is increased or reduced.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Exercise Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to an Option, the price at which a holder may purchase the Shares issuable upon exercise of an Option and with respect to a SAR, the price at which the SAR is granted to the holder thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Fair Market Value</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, as of any date, the value of a Share determined as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Wall Street </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Journal or such other source as the Committee deems reliable&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if such Common Stock is publicly traded but is neither listed nor admitted to trading on a national securities exchange, the average of the closing bid and asked prices on the date of determination as reported in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Wall Street Journal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or such other source as the Committee deems reliable&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if none of the foregoing is applicable, by the Board or the Committee in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an officer or director of the Company or any other person whose transactions in the Company&#8217;s Common Stock are subject to Section&#160;16 of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">IRS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Internal Revenue Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Non-Employee Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a Director who is not an Employee of the Company or any Parent or Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an award of an option to purchase Shares pursuant to Section&#160;5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Parent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any corporation (other than the Company) in an unbroken chain of corporations ending with the Company if each of such corporations other than the Company owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a person who holds an Award under this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Performance Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means cash or stock granted pursuant to Section&#160;10 or Section&#160;12 of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Performance Factors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any of the factors selected by the Committee and specified in an Award Agreement, from among the following objective measures, either individually, alternatively or in any combination, applied to the Company as a whole or any business unit or Subsidiary, either individually, alternatively, or in any combination, on a GAAP or non-GAAP basis, and measured, to the extent applicable on an absolute basis or relative to a pre-established target, to determine whether the performance goals established by the Committee with respect to applicable Awards have been satisfied&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit Before Tax&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billings&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (which may include earnings before interest and taxes, earnings before taxes, and net earnings, or as otherwise adjusted)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating margin&#59;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controllable operating profit, or net operating profit&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Profit&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses or operating expenses as a percentage of revenue&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholder return&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(p)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market share&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(q)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return on assets or net assets&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(r)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s stock price&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(s)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Growth in stockholder value relative to a pre-determined index&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(t)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return on equity&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(u)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return on invested capital&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow (including free cash flow or operating cash flows)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(w)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash conversion cycle&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(x)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Economic value added&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(y)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual confidential business objectives&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(z)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract awards or backlog&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(aa)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Overhead or other expense reduction&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(bb)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit rating&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(cc)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic plan development and implementation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dd)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Succession plan development and implementation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(ee)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Improvement in workforce diversity&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(ff)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer indicators&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(gg)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New product invention or innovation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(hh)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attainment of research and development milestones&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Improvements in productivity&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(jj)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bookings&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(kk)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attainment of objective operating goals and employee metrics&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(ll)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any other metric that is capable of measurement as determined by the Committee.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Performance Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the period of service determined by the Committee, not to exceed five (5) years, during which years of service or performance is to be measured for the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.30.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Performance Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an Award granted pursuant to Section&#160;10 or Section&#160;12 of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.31.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Permitted Transferee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law (including adoptive relationships) of the Employee, any person sharing the Employee&#8217;s household (other than a tenant or employee), a trust in which these persons (or the Employee) have more than 50% of the beneficial interest, a foundation in which these persons (or the Employee) control the management of assets, and any other entity in which these persons (or the Employee) own more than 50% of the voting interests.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.32.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning as such term is used in Sections&#160;13(d) and 14(d) of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.33.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means this DexCom, Inc. 2015 Equity Incentive Plan, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.34.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Purchase Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the price to be paid for Shares acquired under this Plan, other than Shares acquired upon exercise of an Option or SAR.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.35.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an award of Shares pursuant to Section&#160;6 or Section&#160;12 of this Plan, or issued pursuant to the early exercise of an Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.36.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Unit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an Award granted pursuant to Section&#160;9 or Section&#160;12 of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.37.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.38.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Securities Act of 1933, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.39.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean service as an Employee, Consultant, Director or Non-Employee Director, to the Company or a Parent, Subsidiary or Affiliate of the Company, subject to such further limitations as may be set forth in this Plan or the applicable Award Agreement. An Employee will not be deemed to have ceased to provide Service in the case of (i) medical leave, (ii) military leave, or (iii) any other leave of absence approved by the Company. In the case of any Employee on an approved leave of absence, Awards shall not vest during such leave of absence, except as (A) may be required by applicable Law, or (B) as otherwise provided by the Committee or the Company in writing. At such time as such Employee returns to regular and continuous service with the Company following the leave of absence, the vesting schedule applicable to the Awards shall recommence, and, if applicable, the total period of the vesting schedule will be extended by a number of days equal to the total number of days of Employee&#8217;s leave of absence, except that in no event may an Award be exercised after the expiration term set forth in the Award Agreement. Similarly, if Employee&#8217;s schedule reduces to a less than a full-time service arrangement, except as otherwise provided by the Committee or the Company in writing, Awards shall vest on a proportionately and commensurately slower schedule, except that in no event may an Award be exercised after the expiration term set forth in the Award Agreement. No fractional shares may be issued. In the event of military leave, if required by applicable laws, vesting shall continue for not less than the longest period that vesting continues under any other statutory or Company approved leave of absence and, upon a Participant&#8217;s returning from military leave (under conditions that would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment Rights Act), he or she shall be given vesting credit with respect to Awards to the same extent as would have applied had the Participant continued to provide services to the Company throughout the leave on the same terms as he or she was providing services immediately prior to such leave. Except as set forth in this Section 28.39, an employee shall have terminated employment as of the date he or she ceases to provide Services (regardless of whether the termination is in breach of local employment laws or is later found to be invalid) and employment shall not be extended by any notice period or garden leave mandated by local law, provided however, that a change in status from an employee to a consultant or advisor shall not terminate the service provider&#8217;s Service, unless determined by the Committee, in its discretion. The Committee will have sole discretion to determine whether a Participant has ceased to provide Services and the effective date on which the Participant ceased to provide Services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.40.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means shares of the Company&#8217;s Common Stock and the common stock of any successor security.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.41.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Stock Appreciation Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an Award granted pursuant to Section&#160;8 or Section&#160;12 of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.42.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Stock Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an Award granted pursuant to Section&#160;7 or Section&#160;12 of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.43.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.44.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Treasury Regulations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means regulations promulgated by the United States Treasury Department.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.45.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Unvested Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Shares that have not yet vested or are subject to a right of repurchase in favor of the Company (or any successor thereto).</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_13"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global &#8211; Form of Employee RSU Grant Agreement &#8211; General</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTICE OF RESTRICTED STOCK UNIT AWARD</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GRANT NUMBER&#58;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) Amended and Restated 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same meanings in this Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.579%"><tr><td style="width:1.0%"></td><td style="width:55.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_________________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Address&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Address 2&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">City, State Zip&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">__________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) have been granted an award of Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Award Agreement (Restricted Stock Units) (hereinafter &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSU Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.579%"><tr><td style="width:1.0%"></td><td style="width:36.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Commencement Date&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The date on which settlement of all RSUs granted hereunder occurs, with earlier expiration upon the Termination Date.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the limitations set forth in this Notice, the Plan and the RSU Agreement, the RSUs will vest in accordance with the following schedule&#58;</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.579%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Shares</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Vest Date&#47;Performance Conditions</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that your employment or consulting relationship or service with the Company or the relevant Subsidiary is for an unspecified duration, can be terminated at any time (i.e., is &#8220;at-will&#8221;) other than as required by applicable local law, and that nothing in this Notice, the RSU Agreement or the Plan changes the nature of that relationship nor shall create an employment or consulting relationship with the Company by virtue of this Notice or your participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You acknowledge that the vesting of the RSUs pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company&#160;or the relevant Subsidiary (as applicable). You also understand that this Notice is subject to the terms and conditions of both the RSU Agreement and the Plan, both of which are incorporated herein by reference.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Privacy Statement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By signing below you confirm that you have read this Notice, the RSU Agreement and the Plan, you agree to be bound by them and you freely and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Notice, the RSU Agreement and any other Restricted Stock Unit Award grant materials by the Company, its affiliates and Subsidiaries (including your employer), and any third parties assisting in the implementation, administration and management of the Plan, for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that the Company, its Subsidiaries (including your employer) may collect, hold, process, disclose and transfer certain personal data about you. For the purposes of this Notice and the RSU Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means certain personal and&#47;or sensitive information about you, including, but not limited to, your name, home address and telephone&#47;fax number, date of birth, social insurance number or other identification number, family size, marital status, gender, beneficiary information, emergency contacts, passport&#47;visa information, salary and benefit information, personal bank account number, tax related information, tax identification number, nationality, job title, any Shares or directorships held in the Company, details of all RSUs or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in your favor and any other information required by providers for the purpose of implementing, administering and managing the Plan .</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that Data will be transferred to E*TRADE Financial (&#8220;E*TRADE&#8221;) or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of Data may be located in the United States or elsewhere, where you may not have the same rights under applicable data protection and privacy law as in your home jurisdiction. You authorize the Company, E*TRADE and any other possible recipients that may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the plan.</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_549755814335"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AWARD AGREEMENT (RESTRICTED STOCK UNITS) TO THE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) Amended and Restated 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same defined meanings in this Award Agreement (Restricted Stock Units) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) have been granted Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) subject to the terms, restrictions and conditions of the Plan, the Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Settlement of RSUs shall be made within the earlier of (i) 90 days following the applicable date of vesting under the vesting schedule or (ii) March 15 of the year following the year of vesting as set forth in the Notice.  Settlement of RSUs shall be in Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Regardless of any action the Company and&#47;or Participant&#8217;s employer(s) (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) take with respect to any foreign, federal, state, or local income tax, social insurance (including if permissible under local law, any statutory employer&#8217;s contribution to social insurance), national insurance contributions, payroll tax, payment on account, or other tax-related withholding with respect to this Agreement, as a result of Participant&#8217;s participation in the Plan and&#47;or any aspect of the RSUs (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Tax-Related Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;), Participant agrees and acknowledges that the ultimate liability for all Tax-Related Items is the responsibility of Participant and that the Company and&#47;or the Employer&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are not making any representations and are not committing to take any actions regarding any Tax-Related Items, including, but not limited to, the grant of the RSUs, the vesting of the RSUs, the delivery of Shares upon vesting of the RSUs, the subsequent sale of Shares acquired upon vesting of the RSUs, and the receipt of any dividends&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">do not commit to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Before any Tax-Related Items become due, Participant will pay or make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy those Tax-Related Items.  If permissible under local law, Participant authorizes the Company and&#47;or the Employer to withhold all applicable Tax-Related Items legally payable by or due with respect to and&#47;or on behalf of Participant by one or a combination of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;withholding from the Shares to be issued, the number of Shares having a fair market value (determined on the date that the amount of tax to be withheld is determined) equal to the amount required to be withheld for Tax-Related Items, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;arranging to have sold on Participant&#8217;s behalf through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) a sufficient number of Shares that is equal to the amount required to be withheld for Tax-Related Items.  The Company shall arrange to sell or withhold a whole number of shares to satisfy the minimum tax withholding obligation, and to the extent that any tax obligation balance remains, such amount shall be withheld from your following payroll cycle.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the obligation for Tax-Related Items is satisfied by withholding a number of Shares as described herein, Participant will be deemed to have been issued the full number of Shares to which Participant is entitled pursuant to the vesting of the RSUs even though a portion of those Shares will be withheld for the purpose of satisfying the Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, if Participant has relocated to a different jurisdiction between the date of grant and the date of any taxable event, Participant acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, Participant will pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of Participant&#8217;s participation in the Plan or any aspect of the RSUs that cannot be satisfied by any of the means described in the preceding paragraph.  The Company may refuse to deliver Shares to Participant if Participant fails to meet his&#47;her obligations for the Tax-Related Items, as described herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless and until such time as Shares are issued in settlement of vested RSUs, Participant shall have no ownership of the Shares allocated to the RSUs and shall have no right to dividends or to vote from such Shares.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If dividends are declared and paid on Shares, dividend equivalent payments, if any (whether in cash or Shares), shall be credited to Participant at such time as Shares as issued in settlement of vested RSUs.  Such dividend equivalent payments shall have the same vesting requirements as the underlying RSUs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The RSUs and any interest therein shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to the terms of the Notice, if Participant&#8217;s service terminates for any reason, all unvested RSUs shall be forfeited to the Company forthwith, and all rights of Participant to such RSUs shall immediately terminate.  For the avoidance of doubt, Participant shall not be entitled to any compensation for the loss of any rights or opportunities under the Plan other than as provided for herein.  In case of any dispute as to whether Termination has occurred, the Committee shall have sole discretion to determine whether such Termination has occurred and the effective date of such Termination.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Tax Consequences</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Participant acknowledges that there will be tax consequences upon settlement of the RSUs or disposition of the Shares, if any, received in connection therewith, and Participant should consult a tax adviser regarding Participant&#8217;s tax obligations prior to such settlement or disposition.  You should consult your personal tax advisor for information on the actual and potential tax consequences of this RSU.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Company and Participant agree that the RSUs are granted under and governed by the Notice, this Agreement and the provisions of the Plan.  Participant&#58; (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Country-Specific Terms and Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant&#8217;s participation in the Plan will be subject to any special terms and conditions set forth in Appendix A to this Agreement (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Appendix A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for Participant&#8217;s country of residence, if any.  Appendix A constitutes part of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, if Participant relocates to another country, any special terms and conditions applicable to RSUs granted in such country may apply to Participant to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the Company reserves the right to impose other requirements on the RSUs and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Entire Agreement&#59; Enforcement of Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them.  Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded.  No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement.  The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company&#8217;s Shares may be listed or quoted at the time of such issuance or transfer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Governing Law Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If one or more provisions of this Agreement (including the Appendix) are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith.  In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms.  This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, U.S.A, without giving effect to principles of conflicts of law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">No Rights as Employee, Director or Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8217;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s service, for any reason, with or without cause, subject to compliance with applicable local laws.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Recipient Data Privacy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Through Participant&#8217;s acceptance of this grant, Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of his or her personal and&#47;or sensitive data as described in this document by and among, as applicable, the Company, its affiliates and its subsidiaries for the exclusive purpose of implementing, administering and managing Participant&#8217;s participation in the Plan.  Participant understands that the Company holds certain personal and&#47;or sensitive information about him or her, including, but not limited to, his or her name, home address and telephone&#47;fax number, date of birth, social insurance number or other identification number, family size, marital status, gender, beneficiary information, emergency contacts, passport&#47;visa information, salary and benefit information, personal bank account number, tax related information, tax identification number, nationality, job title, any Shares or directorships held in the Company, details of all RSUs or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#8217;s favor and any other information required by providers for the purpose of implementing, administering and managing the Plan (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Participant also understands and unambiguously consents to the fact that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in Participant&#8217;s country or elsewhere, and that Participant&#8217;s country may have different data privacy laws and protections than the laws in the recipient's country.  Participant understands that he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative.  Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom Participant may elect to deposit any Shares acquired.  Participant understands that Data will be held only as long as is necessary to implement, administer and manage his or her participation in the Plan.  Participant understands that he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local human resources representative.  Participant understands, however, that refusing or withdrawing his or her consent may affect his or her ability to participate in the Plan.  For more information on the consequences of Participant&#8217;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">By acknowledging and accepting this RSU grant, Participant agrees that the granting of this RSU is completely at the discretion of the Committee pursuant to the Plan, that Participant does not expect that future awards will be granted under the Plan, or any other plan, and that Participant waives any claim for losses under the Agreement of the Plan in connection with termination of employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The RSU grant is non-transferrable and non-assignable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Board at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The grant of this award is voluntary and occasional and does not create any contractual or other right to receive future grants of awards, or benefits in lieu of awards, even if awards have been granted repeatedly in the past.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Participant is voluntarily participating in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">This RSU grant is an extraordinary item that does not constitute compensation of any kind for services of any kind rendered to the Company or its affiliates (including, as applicable, Participant&#8217;s employer) and which is outside the scope of Participant&#8217;s employment contract, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">This RSU grant is not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The future value of the underlying Shares is unknown and cannot be predicted with certainty.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">For the purposes of this Agreement, termination of service shall be the last day of active service provided by Participant to the Company or one of its affiliates and such period shall not be extended by any notice of termination or similar period including any period of garden leave.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Translations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If Participant receives this Agreement or any other document or communication related to the Plan or this grant in a language other than English and the meaning in the translation is different than in the English version, the terms expressed in the English version will govern.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the RSUs and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with any applicable law or facilitate the administration of the Plan.  Participant agrees to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.  Furthermore, Participant acknowledges that the laws of the country in which Participant is working at the time of grant, vesting or the sale of Shares received pursuant to this RSU grant (including any rules or regulations governing securities, foreign exchange, tax, labor, or other matters) may subject Participant to additional procedural or regulatory requirements that Participant is and will be solely responsible for and must fulfill.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By your signature and the signature of the Company&#8217;s representative on the Notice, Participant and the Company agree that this RSU is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement.  Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and this Agreement.  Participant further agrees to notify the Company upon any change in Participant&#8217;s residence address.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_19"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX A</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADDITIONAL COUNTRY-SPECIFIC TERMS AND CONDITIONS OF THE DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN (RESTRICTED STOCK UNITS)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Appendix A includes additional terms and conditions that govern the RSUs granted to you under the Plan if you reside in one of the countries listed below.  Capitalized terms used but not defined in this Appendix A are defined in the Plan and&#47;or the Agreement, and have the meanings set forth therein.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Appendix A also includes information regarding exchange controls and certain other issues of which you should be aware with respect to your participation in the Plan.  The information is based on the securities, exchange control and other laws in effect in the respective countries as of August 2017.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you not rely on the information noted in this Appendix A as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the RSUs or sell Shares acquired under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the information contained herein is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of a particular result.  Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transfer employment after the grant date, or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you, and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CANADA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Settled in Shares Only</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any discretion contained in the Plan, or any provision in the Agreement to the contrary, RSUs shall be paid in Shares only and do not provide any right for Participant to receive a cash payment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The following provisions shall apply if Participant is a resident of Quebec&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Language Consent</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Les Parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224; la pr&#233;sente convention.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Privacy Notice and Consent</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This provision supplements the Data Privacy section of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant hereby authorizes the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.  Participant further authorizes the Company and the Employer to disclose and discuss his or her participation in the Plan with their advisors.  Finally, Participant authorizes the Company and the Employer to record such information and to keep such information in his or her employee file.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Control Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank.  If Participant uses a German bank to transfer a cross-border payment in excess of &#8364;12,500 in connection with the sale of Shares acquired under the Plan, the bank will make the report for him or her.  In addition, Participant must report any receivables, payables, or debts in foreign currency exceeding an amount of &#8364;5,000,000 on a monthly basis.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insider-Trading Notification</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant should be aware of the Dutch insider-trading rules, which may impact the sale of Shares issued to Participant at vesting and settlement of the RSUs.  In particular, Participant may be prohibited from effectuating certain transactions involving Shares if Participant has inside information about the Company.  If Participant is uncertain whether the insider-trading rules apply to Participant, Participant should consult his or her personal legal advisor.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED KINGDOM</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Withholding Taxes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This provision supplements the Withholding Taxes section of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If payment or withholding of the Tax-Related Items (including the Employer's Liability, as defined below) is not made within 90 days of the end of the UK tax year in which vesting occurs (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Due Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003, the amount of any uncollected Tax-Related Items will constitute a loan owed by Participant to the Employer, effective on the Due Date.  Participant agrees that the loan will bear interest at the then-current Official Rate of Her Majesty's Revenue and Customs (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">HMRC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;), it will be immediately due and repayable, and the Company or the Employer may recover it at any time thereafter by any of the means referred to in the Withholding Taxes section of the Agreement.  Participant also authorizes the Company to delay the issuance of Shares to Participant unless and until the loan is repaid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if Participant is a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), Participant will not be eligible for such a loan to cover the Tax-Related Items.  In the event that Participant is a director or executive officer and the Tax-Related Items are not collected from or paid by Participant by the Due Date, the amount of any uncollected Tax-Related Items will constitute a benefit to Participant on which additional income tax and national insurance contributions (including the Employer's Liability, as defined below) will be payable.  Participant will be responsible for reporting and paying any income tax and national insurance contributions (including the Employer's Liability, as defined below) due on this additional benefit directly to HMRC under the self-assessment regime.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joint Election&#47;recoverability of employer national insurance contributions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a condition of Participant&#8217;s participation in the Plan and the vesting of the RSUs (, Participant agrees to accept any liability for secondary Class 1 national insurance contributions (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Employer's Liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) which may be payable by the Company and&#47;or the Employer in connection with the RSUs and any event giving rise to Tax-Related Items.  To accomplish the foregoing, Participant agrees to execute a joint election with the Company and&#47;or the Employer (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Election</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;), the form of such Election being formally approved by HMRC, and&#47;or any other agreements, consents or elections required to accomplish the transfer of the Employer's Liability to Participant.  Participant further agrees to execute such other joint elections, other agreements, consents or elections (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other Agreement(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) as may be required by the Company and&#47;or the Employer between Participant and the Company, any successor to the Company and&#47;or the Employer in order to transfer the Employer&#8217;s Liability to Participant or in order to provide for the reimbursement of the Employer&#8217;s Liability by Participant to the Company and&#47;or the Employer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If Participant does not enter into the Election when Participant accepts the Agreement, if the Election is revoked and&#47;or abolished at any time by HMRC or if Participant fails to enter into any Other Agreement as required by the Company, any successor to the Company and&#47;or the Employer, the Company may choose, in its sole discretion, not to allow Participant to vest in the RSUs and they will cease to vest, become null and void, and no Shares will be acquired under the Plan, without any liability to the Company, the Employer and&#47;or any Affiliate.  Participant further agrees that the Company and&#47;or the Employer may collect the Employer's Liability by any of the means set forth in the Withholding Taxes section of the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the avoidance of doubt, this requirement will apply to all Participants that work in the U.K. during any period from grant through the vesting date of the RSUs regardless of whether Participant was in the U.K. at the time of grant.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED STATES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This provision supplements the Tax Consequences provision of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon vesting of the RSU, Participant will include in income the fair market value of the Shares subject to the RSU.  The included amount will be treated as ordinary income by Participant and will be subject to withholding by the Company when required by applicable law.  Upon disposition of the Shares, any subsequent increase or decrease in value will be treated as short-term or long-term capital gain or loss, depending on whether the Shares are held for more than one year from the date of settlement.  Further, an RSU may be considered a deferral of compensation that may be subject to Section 409A of the Code.  Section 409A of the Code imposes special rules to the timing of making and effecting certain amendments of this RSU with respect to distribution of any deferred compensation.  You should consult your personal tax advisor for information on the actual and potential tax consequences of this RSU.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_31"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global &#8211; Form of Employee RSU Grant Agreement &#8211; Director and Senior Director</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.<br>AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN<br>NOTICE OF RESTRICTED STOCK UNIT AWARD<br>GRANT NUMBER&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> _____________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) Amended and Restated 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same meanings in this Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.579%"><tr><td style="width:1.0%"></td><td style="width:55.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_________________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Address&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Address 2&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">City, State Zip&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">__________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) have been granted an award of Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Award Agreement (Restricted Stock Units) (hereinafter &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSU Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.579%"><tr><td style="width:1.0%"></td><td style="width:36.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Commencement Date&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The date on which settlement of all RSUs granted hereunder occurs, with earlier expiration upon the Termination Date.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the limitations set forth in this Notice, the Plan and the RSU Agreement, the RSUs will vest in accordance with the following schedule&#58;</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.579%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Shares</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Vest Date&#47;Performance Conditions</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Acceleration&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing Vesting Schedule, if the Participant is subject to a Qualifying Termination (as defined below) during a Change in Control Period (as defined below), then, subject to Participant&#8217;s delivery to the Company of a general release (in a form prescribed by the Company) of all known and unknown claims that Participant may then have against the Company or persons affiliated with the Company (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and satisfaction of all conditions to make the Release effective, within sixty (60) days following Participant&#8217;s Qualifying Termination (such sixty (60) day period, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Release Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the then-unvested RSUs shall accelerate and become vested and settled with respect to 100% of the shares subject thereto.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The accelerated vesting described above shall be effective as of the Qualifying Termination, subject to delivery of the effective Release&#59; provided, that, if the Qualified Termination occurs prior to the Change in Control (as defined below), then any unvested portion of Participant&#8217;s RSUs will remain outstanding for three (3) months following the Qualifying Termination (provided that in no event will the RSUs remain outstanding beyond the tenth anniversary of the Date of Grant). In the event that the proposed Change in Control is terminated without having been completed, any unvested portion of Participant&#8217;s RSUs automatically will be forfeited.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any other provision in the Plan, the Notice or this Agreement to the contrary, if the successor or acquiring corporation (if any) of the Company refuses to assume, convert, replace or substitute the unvested RSUs in connection with a Corporate Transaction (as defined in the Plan) as provided in Section 21.1 of the Plan, then such RSUs shall accelerate and become vested and settled with respect to 100% of the shares subject thereto effective immediately prior to the Change in Control.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (i) the Participant has been convicted of, or has pleaded guilty or nolo contendere to, any felony or crime involving moral turpitude, (ii) the Participant has (X) engaged in willful misconduct which is injurious to the Company or materially failed or refused to perform the material duties lawfully and reasonably assigned to the Participant or has performed such material duties with gross negligence or (Y) breached any material term or condition of this Plan, the Participant&#8217;s Employee Proprietary Information and Inventions Agreement with the Company, any written Company policy or the Company&#8217;s written code of conduct that has been made available to Participant prior to such breach or any other material agreement with the Company, in any case after written notice by the Company of such misconduct, performance issue, gross negligence or breach of terms or conditions and an opportunity to cure within thirty (30) days of such written notice thereof from the Company, unless such misconduct, performance issue, gross negligence or breach is, by its nature, not curable, or (iii) the Participant has committed any act of fraud, theft, embezzlement, misappropriation of funds, breach of fiduciary duty or other willful act of material dishonesty against the Company that results in material harm to the Company.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following events&#58; (i) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company&#8217;s then outstanding voting securities&#59; or (ii) the consummation of the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; or (iii) the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation, provided that the transaction or series of transactions pursuant to subsections (i), (ii) or (iii) also qualifies as a &#8220;change in control event&#8221; under U.S. Treasury Regulation 1.409A-3(i)(5).</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Change in Control Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the period commencing three (3) months prior to a Change in Control (only if after a Potential Change in Control) and ending twelve (12) months following a Change in Control.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 22(e)(3) of the Code.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following events or conditions, without Participant&#8217;s express written consent&#58;</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">a material reduction in Participant&#8217;s base salary as an employee of the Company&#59;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">a material reduction in the Participant&#8217;s duties, responsibilities or authority at the Company&#59; or</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">a change in the geographic location at which Participant must perform services that results in an increase in the one-way commute of Participant by more than 50 miles.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to each of subsection (i), (ii), and (iii) above, Participant must provide notice to the Company of the condition giving rise to &#8220;Good Reason&#8221; within one hundred twenty (120) days of Participant&#8217;s knowledge of the existence of such condition, and the Company will have thirty (30) days following such notice to remedy such condition. Participant must resign Participant&#8217;s employment no later than thirty (30) days following expiration of the Company&#8217;s thirty (30) day cure period.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Potential Change in Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date of execution of a definitive agreement providing for a Change in Control if such transaction is consummated.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Qualifying Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a termination of employment resulting from (i) a termination by the Company of the Participant&#8217;s employment for any reason other than Cause, death or Disability, and (ii) if upon or within (12) months following a Change in Control, a voluntary resignation by the Participant of his or her employment for Good Reason. Termination due to Participant&#8217;s death or Participant&#8217;s Disability will in no event constitute a Qualifying Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that your employment or consulting relationship or service with the Company or the relevant Subsidiary is for an unspecified duration, can be terminated at any time (i.e., is &#8220;at-will&#8221;) other than as required by applicable local law, and that nothing in this Notice, the RSU Agreement or the Plan changes the nature of that relationship nor shall create an employment or consulting relationship with the Company by virtue of this Notice or your participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You acknowledge that the vesting of the RSUs pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company or the relevant Subsidiary (as applicable). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You also understand that this Notice is subject to the terms and conditions of both the RSU Agreement and the Plan, both of which are incorporated herein by reference.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Privacy Statement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By signing below you confirm that you have read this Notice, the RSU Agreement and the Plan, you agree to be bound by them</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and you freely and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Notice, the RSU Agreement and any other Restricted Stock Unit Award grant materials by the Company, its affiliates and Subsidiaries (including your employer), and any third parties assisting in the implementation, administration and management of the Plan, for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that the Company, its Subsidiaries (including your employer) may collect, hold, process, disclose and transfer certain personal data about you. For the purposes of this Notice and the RSU Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means certain personal and&#47;or sensitive information about you, including, but not limited to, your name, home address and telephone&#47;fax number, date of birth, social insurance number or other identification number, family size, marital status, gender, beneficiary information, emergency contacts, passport&#47;visa information, salary and benefit information, personal bank account number, tax related information, tax identification number, nationality, job title, any Shares or directorships held in the Company, details of all RSUs or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in your favor and any other information required by providers for the purpose of implementing, administering and managing the Plan.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that Data will be transferred to E*TRADE Financial (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">E*TRADE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of Data may be located in the United States or elsewhere, where you may not have the same rights under applicable data protection and privacy law as in your home jurisdiction. You authorize the Company, E*TRADE and any other possible recipients that may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the plan.</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_34"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.<br>AWARD AGREEMENT (RESTRICTED STOCK UNITS) TO THE<br>DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) Amended and Restated 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same defined meanings in this Award Agreement (Restricted Stock Units) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) have been granted Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) subject to the terms, restrictions and conditions of the Plan, the Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Settlement of RSUs shall be made within the earlier of (i) 90 days following the applicable date of vesting under the vesting schedule or (ii) March 15 of the year following the year of vesting as set forth in the Notice. Settlement of RSUs shall be in Shares.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Regardless of any action the Company and&#47;or Participant&#8217;s employer(s) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) take with respect to any foreign, federal, state, or local income tax, social insurance (including if permissible under local law, any statutory employer&#8217;s contribution to social insurance), national insurance contributions, payroll tax, payment on account, or other tax-related withholding with respect to this Agreement, as a result of Participant&#8217;s participation in the Plan and&#47;or any aspect of the RSUs (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Tax-Related Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), Participant agrees and acknowledges that the ultimate liability for all Tax-Related Items is the responsibility of Participant and that the Company and&#47;or the Employer&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are not making any representations and are not committing to take any actions regarding any Tax- Related Items, including, but not limited to, the grant of the RSUs, the vesting of the RSUs, the delivery of Shares upon vesting of the RSUs, the subsequent sale of Shares acquired upon vesting of the RSUs, and the receipt of any dividends&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">do not commit to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Before any Tax-Related Items become due, Participant will pay or make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy those Tax-Related Items. If permissible under local law, Participant authorizes the Company and&#47;or the Employer to withhold all applicable Tax-Related Items legally payable by or due with respect to and&#47;or on behalf of Participant by one or a combination of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">withholding from the Shares to be issued, the number of Shares having a fair market value (determined on the date that the amount of tax to be withheld is determined) equal to the amount required to be withheld for Tax-Related Items, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">arranging to have sold on Participant&#8217;s behalf through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) a sufficient number of Shares that is equal to the amount required to be withheld for Tax-Related Items.  The Company shall arrange to sell or withhold a whole number of shares to satisfy the minimum tax withholding obligation, and to the extent that any tax obligation balance remains, such amount shall be withheld from your following payroll cycle.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the obligation for Tax-Related Items is satisfied by withholding a number of Shares as described herein, Participant will be deemed to have been issued the full number of Shares to which Participant is entitled pursuant to the vesting of the RSUs even though a portion of those Shares will be withheld for the purpose of satisfying the Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, if Participant has relocated to a different jurisdiction between the date of grant and the date of any taxable event, Participant acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, Participant will pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of Participant&#8217;s participation in the Plan or any aspect of the RSUs that cannot be satisfied by any of the means described in the preceding paragraph. The Company may refuse to deliver Shares to Participant if Participant fails to meet his&#47;her obligations for the Tax-Related Items, as described herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Unless and until such time as Shares are issued in settlement of vested RSUs, Participant shall have no ownership of the Shares allocated to the RSUs and shall have no right to dividends or to vote from such Shares.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If dividends are declared and paid on Shares, dividend equivalent payments, if any (whether in cash or Shares), shall be credited to Participant at such time as Shares as issued in settlement of vested RSUs. Such dividend equivalent payments shall have the same vesting requirements as the underlying RSUs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The RSUs and any interest therein shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to the terms of the Notice, if Participant&#8217;s service terminates for any reason, all unvested RSUs shall be forfeited to the Company forthwith, and all rights of Participant to such RSUs shall immediately terminate. For the avoidance of doubt, Participant shall not be entitled to any compensation for the loss of any rights or opportunities under the Plan other than as provided for herein. In case of any dispute as to whether Termination has occurred, the Committee shall have sole discretion to determine whether such Termination has occurred and the effective date of such Termination.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Tax Consequences</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Participant acknowledges that there will be tax consequences upon settlement of the RSUs or disposition of the Shares, if any, received in connection therewith, and Participant should consult a tax adviser regarding Participant&#8217;s tax obligations prior to such settlement or disposition. You should consult your personal tax advisor for information on the actual and potential tax consequences of this RSU.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Company and Participant agree that the RSUs are granted under and governed by the Notice, this Agreement and the provisions of the Plan. Participant&#58; (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Country-Specific Terms and Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Participant&#8217;s participation in the Plan will be subject to any special terms and conditions set forth in Appendix A to this Agreement (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Appendix A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for Participant&#8217;s country of residence, if any. Appendix A constitutes part of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, if Participant relocates to another country, any special terms and conditions applicable to RSUs granted in such country may apply to Participant to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the Company reserves the right to impose other requirements on the RSUs and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Entire Agreement&#59; Enforcement of Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company&#8217;s Shares may be listed or quoted at the time of such issuance or transfer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Governing Law Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If one or more provisions of this Agreement (including the Appendix) are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, U.S.A, without giving effect to principles of conflicts of law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">No Rights as Employee, Director or Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Participant&#8217;s service, for any reason, with or without cause, subject to compliance with applicable local laws.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Recipient Data Privacy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Through Participant&#8217;s acceptance of this grant, Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of his or her personal and&#47;or sensitive data as described in this document by and among, as applicable, the Company, its affiliates and its subsidiaries for the exclusive purpose of implementing, administering and managing Participant&#8217;s participation in the Plan. Participant understands that the Company holds certain personal and&#47;or sensitive information about him or her, including, but not limited to, his or her name, home address and telephone&#47;fax number, date of birth, social insurance number or other identification number, family size, marital status, gender, beneficiary information, emergency contacts, passport&#47;visa information, salary and benefit information, personal bank account number, tax related information, tax identification number, nationality, job title, any Shares or directorships held in the Company, details of all RSUs or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#8217;s favor and any other information required by providers for the purpose of implementing, administering and managing the Plan (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Participant also understands and unambiguously consents to the fact that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in Participant&#8217;s country or elsewhere, and that Participant&#8217;s country may have different data privacy laws and protections than the laws in the recipient&#8217;s country. Participant understands that he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative. Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom Participant may elect to deposit any Shares acquired. Participant understands that Data will be held only as long as is necessary to implement, administer and manage his or her participation in the Plan. Participant understands that he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local human resources representative. Participant understands, however, that refusing or withdrawing his or her consent may affect his or her ability to participate in the Plan. For more information on the consequences of Participant&#8217;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources representative.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">By acknowledging and accepting this RSU grant, Participant agrees that the granting of this RSU is completely at the discretion of the Committee pursuant to the Plan, that Participant does not expect that future awards will be granted under the Plan, or any other plan, and that Participant waives any claim for losses under the Agreement of the Plan in connection with termination of employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The RSU grant is non-transferrable and non-assignable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Board at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The grant of this award is voluntary and occasional and does not create any contractual or other right to receive future grants of awards, or benefits in lieu of awards, even if awards have been granted repeatedly in the past.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Participant is voluntarily participating in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">This RSU grant is an extraordinary item that does not constitute compensation of any kind for services of any kind rendered to the Company or its affiliates (including, as applicable, Participant&#8217;s employer) and which is outside the scope of Participant&#8217;s employment contract, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">This RSU grant is not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The future value of the underlying Shares is unknown and cannot be predicted with certainty.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">For the purposes of this Agreement, termination of service shall be the last day of active service provided by Participant to the Company or one of its affiliates and such period shall not be extended by any notice of termination or similar period including any period of garden leave.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Translations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If Participant receives this Agreement or any other document or communication related to the Plan or this grant in a language other than English and the meaning in the translation is different than in the English version, the terms expressed in the English version will govern.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the RSUs and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with any applicable law or facilitate the administration of the Plan. Participant agrees to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. Furthermore, Participant acknowledges that the laws of the country in which Participant is working at the time of grant, vesting or the sale of Shares received pursuant to this RSU grant (including any rules or regulations governing securities, foreign exchange, tax, labor, or other matters) may subject Participant to additional procedural or regulatory requirements that Participant is and will be solely responsible for and must fulfill.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By your signature and the signature of the Company&#8217;s representative on the Notice, Participant and the Company agree that this RSU is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement. Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and this Agreement. Participant further agrees to notify the Company upon any change in Participant&#8217;s residence address.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. For purposes of this Agreement, a termination of employment will be determined consistent with the rules relating to a &#8220;separation from service&#8221; as defined in Section 409A of the Internal Revenue Code and the regulations thereunder (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding anything else provided herein, to the extent any payments provided under this RSU Agreement in connection with Participant&#8217;s termination of employment constitute deferred compensation subject to Section 409A, and Participant is deemed at the time of such termination of employment to be a &#8220;specified employee&#8221; under Section 409A, then such payment shall not be made or commence until the earlier of (i) the expiration of the six-month period measured from Participant&#8217;s separation from service from the Company or (ii) the date of Participant&#8217;s death following such a separation from service&#59; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to Participant including, without limitation, the additional tax for which Participant would otherwise be liable under Section 409A(a)(1)(B) in the absence of such a deferral. To the extent any payment under this RSU Agreement may be classified as a &#8220;short-term deferral&#8221; within the meaning of Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A. Payments pursuant to this section are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_37"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX A</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADDITIONAL COUNTRY-SPECIFIC TERMS AND CONDITIONS OF THE DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN (RESTRICTED STOCK UNITS)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Appendix A includes additional terms and conditions that govern the RSUs granted to you under the Plan if you reside in one of the countries listed below. Capitalized terms used but not defined in this Appendix A are defined in the Plan and&#47;or the Agreement, and have the meanings set forth therein.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Appendix A also includes information regarding exchange controls and certain other issues of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of August 2017. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information noted in this Appendix A as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the RSUs or sell Shares acquired under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the information contained herein is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of a particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transfer employment after the grant date, or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you, and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Settled in Shares Only</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any discretion contained in the Plan, or any provision in the Agreement to the contrary, RSUs shall be paid in Shares only and do not provide any right for Participant to receive a cash payment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The following provisions shall apply if Participant is a resident of Quebec&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Language Consent</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Les Parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224; la pr&#233;sente convention.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Privacy Notice and Consent</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This provision supplements the Data Privacy section of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant hereby authorizes the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. Participant further authorizes the Company and the Employer to disclose and discuss his or her participation in the Plan with their advisors. Finally, Participant authorizes the Company and the Employer to record such information and to keep such information in his or her employee file.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Control Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank. If Participant uses a German bank to transfer a cross-border payment in excess of &#8364;12,500 in connection with the sale of Shares acquired under the Plan, the bank will make the report for him or her. In addition, Participant must report any receivables, payables, or debts in foreign currency exceeding an amount of &#8364;5,000,000 on a monthly basis.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insider-Trading Notification</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant should be aware of the Dutch insider-trading rules, which may impact the sale of Shares issued to Participant at vesting and settlement of the RSUs. In particular, Participant may be prohibited from effectuating certain transactions involving Shares if Participant has inside information about the Company. If Participant is uncertain whether the insider-trading rules apply to Participant, Participant should consult his or her personal legal advisor.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED KINGDOM</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Withholding Taxes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This provision supplements the Withholding Taxes section of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If payment or withholding of the Tax-Related Items (including the Employer&#8217;s Liability, as defined below) is not made within 90 days of the end of the UK tax year in which vesting occurs (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Due Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003, the amount of any uncollected Tax-Related Items will constitute a loan owed by Participant to the Employer, effective on the Due Date. Participant agrees that the loan will bear interest at the then-current Official Rate of Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">HMRC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), it will be immediately due and repayable, and the Company or the Employer may recover it at any time thereafter by any of the means referred to in the Withholding Taxes section of the Agreement. Participant also authorizes the Company to delay the issuance of Shares to Participant unless and until the loan is repaid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if Participant is a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), Participant will not be eligible for such a loan to cover the Tax-Related Items. In the event that Participant is a director or executive officer and the Tax-Related Items are not collected from or paid by Participant by the Due Date, the amount of any uncollected Tax-Related Items will constitute a benefit to Participant on which additional income tax and national insurance contributions (including the Employer&#8217;s Liability, as defined below) will be payable. Participant will be responsible for reporting and paying any income tax and national insurance contributions (including the Employer&#8217;s Liability, as defined below) due on this additional benefit directly to HMRC under the self-assessment regime.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joint Election&#47;recoverability of employer national insurance contributions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a condition of Participant&#8217;s participation in the Plan and the vesting of the RSUs (, Participant agrees to accept any liability for secondary Class 1 national insurance contributions (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Employer&#8217;s Liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) which may be payable by the Company and&#47;or the Employer in connection with the RSUs and any event giving rise to Tax- Related Items. To accomplish the foregoing, Participant agrees to execute a joint election with the Company and&#47;or the Employer (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Election</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the form of such Election being formally approved by HMRC, and&#47;or any other agreements, consents or elections required to accomplish the transfer of the Employer&#8217;s Liability to Participant. Participant further agrees to execute such other joint elections, other agreements, consents or elections (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other Agreement(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) as may be required by the Company and&#47;or the Employer between Participant and the Company, any successor to the Company and&#47;or the Employer in order to transfer the Employer&#8217;s Liability to Participant or in order to provide for the reimbursement of the Employer&#8217;s Liability by Participant to the Company and&#47;or the Employer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If Participant does not enter into the Election when Participant accepts the Agreement, if the Election is revoked and&#47;or abolished at any time by HMRC or if Participant fails to enter into any Other Agreement as required by the Company, any successor to the Company and&#47;or the Employer, the Company may choose, in its sole discretion, not to allow Participant to vest in the RSUs and they will cease to vest, become null and void, and no Shares will be acquired under the Plan, without any liability to the Company, the Employer and&#47;or any Affiliate. Participant further agrees that the Company and&#47;or the Employer may collect the Employer&#8217;s Liability by any of the means set forth in the Withholding Taxes section of the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the avoidance of doubt, this requirement will apply to all Participants that work in the U.K. during any period from grant through the vesting date of the RSUs regardless of whether Participant was in the U.K. at the time of grant.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED STATES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This provision supplements the Tax Consequences provision of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon vesting of the RSU, Participant will include in income the fair market value of the Shares subject to the RSU. The included amount will be treated as ordinary income by Participant and will be subject to withholding by the Company when required by applicable law. Upon disposition of the Shares, any subsequent increase or decrease in value will be treated as short-term or long-term capital gain or loss, depending on whether the Shares are held for more than one year from the date of settlement. Further, an RSU may be considered a deferral of compensation that may be subject to Section 409A of the Code. Section 409A of the Code imposes special rules to the timing of making and effecting certain amendments of this RSU with respect to distribution of any deferred compensation. You should consult your personal tax advisor for information on the actual and potential tax consequences of this RSU.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_22"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global &#8211; Form of Employee RSU Grant Agreement &#8211; VP+</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.<br>AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN<br>NOTICE OF RESTRICTED STOCK UNIT AWARD<br>GRANT NUMBER&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) Amended and Restated 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same meanings in this Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.579%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_________________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Address&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Address 2&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">City, State Zip&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">__________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) have been granted an award of Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Award Agreement (Restricted Stock Units) (hereinafter &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSU Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.579%"><tr><td style="width:1.0%"></td><td style="width:36.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Commencement Date&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The date on which settlement of all RSUs granted hereunder occurs, with earlier expiration upon the Termination Date.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the limitations set forth in this Notice, the Plan and the RSU Agreement, the RSUs will vest in accordance with the following schedule&#58;</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.579%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Shares</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Vest Date&#47;Performance Conditions</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Acceleration&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing Vesting Schedule, the RSUs are eligible for vesting acceleration under the Company&#8217;s Severance and Change in Control Plan, subject to the terms and conditions thereof.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that your employment or consulting relationship or service with the Company or the relevant Subsidiary is for an unspecified duration, can be terminated at any time (i.e., is &#8220;at-will&#8221;) other than as required by applicable local law, and that nothing in this Notice, the RSU Agreement or the Plan changes the nature of that relationship nor shall create an employment or consulting relationship with the Company by virtue of this Notice or your participation in the Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You acknowledge that the vesting of the RSUs pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company or the relevant Subsidiary (as applicable). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You also understand that this Notice is subject to the terms and conditions of both the RSU Agreement and the Plan, both of which are incorporated herein by reference. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Privacy Statement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By signing below you confirm that you have read this Notice, the RSU Agreement and the Plan, you agree to be bound by them and you freely and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Notice, the RSU Agreement and any other Restricted Stock Unit Award grant materials by the Company, its affiliates and Subsidiaries (including your employer), and any third parties assisting in the implementation, administration and management of the Plan, for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that the Company, its Subsidiaries (including your employer) may collect, hold, process, disclose and transfer certain personal data about you. For the purposes of this Notice and the RSU Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means certain personal and&#47;or sensitive information about you, including, but not limited to, your name, home address and telephone&#47;fax number, date of birth, social insurance number or other identification number, family size, marital status, gender, beneficiary information, emergency contacts, passport&#47;visa information, salary and benefit information, personal bank account number, tax related information, tax identification number, nationality, job title, any Shares or directorships held in the Company, details of all RSUs or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in your favor and any other information required by providers for the purpose of implementing, administering and managing the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that Data will be transferred to E*TRADE Financial (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">E*TRADE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of Data may be located in the United States or elsewhere, where you may not have the same rights under applicable data protection and privacy law as in your home jurisdiction. You authorize the Company, E*TRADE and any other possible recipients that may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the plan.</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_25"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.<br>AWARD AGREEMENT (RESTRICTED STOCK UNITS) TO THE<br>DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) Amended and Restated 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same defined meanings in this Award Agreement (Restricted Stock Units) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) have been granted Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) subject to the terms, restrictions and conditions of the Plan, the Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Settlement of RSUs shall be made within the earlier of (i) 90 days following the applicable date of vesting under the vesting schedule or (ii) March 15 of the year following the year of vesting as set forth in the Notice. Settlement of RSUs shall be in Shares.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Regardless of any action the Company and&#47;or Participant&#8217;s employer(s) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) take with respect to any foreign, federal, state, or local income tax, social insurance (including if permissible under local law, any statutory employer&#8217;s contribution to social insurance), national insurance contributions, payroll tax, payment on account, or other tax-related withholding with respect to this Agreement, as a result of Participant&#8217;s participation in the Plan and&#47;or any aspect of the RSUs (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Tax-Related Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), Participant agrees and acknowledges that the ultimate liability for all Tax-Related Items is the responsibility of Participant and that the Company and&#47;or the Employer&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">are not making any representations and are not committing to take any actions regarding any Tax- Related Items, including, but not limited to, the grant of the RSUs, the vesting of the RSUs, the delivery of Shares upon vesting of the RSUs, the subsequent sale of Shares acquired upon vesting of the RSUs, and the receipt of any dividends&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">do not commit to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate your liability for Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Before any Tax-Related Items become due, Participant will pay or make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy those Tax-Related Items. If permissible under local law, Participant authorizes the Company and&#47;or the Employer to withhold all applicable Tax-Related Items legally payable by or due with respect to and&#47;or on behalf of Participant by one or a combination of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">withholding from the Shares to be issued, the number of Shares having a fair market value (determined on the date that the amount of tax to be withheld is determined) equal to the amount required to be withheld for Tax-Related Items, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">arranging to have sold on Participant&#8217;s behalf through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) a sufficient number of Shares that is equal to the amount required to be withheld for Tax-Related Items.  The Company shall arrange to sell or withhold a whole number of shares to satisfy the minimum tax withholding obligation, and to the extent that any tax obligation balance remains, such amount shall be withheld from your following payroll cycle.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the obligation for Tax-Related Items is satisfied by withholding a number of Shares as described herein, Participant will be deemed to have been issued the full number of Shares to which Participant is entitled pursuant to the vesting of the RSUs even though a portion of those Shares will be withheld for the purpose of satisfying the Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, if Participant has relocated to a different jurisdiction between the date of grant and the date of any taxable event, Participant acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, Participant will pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of Participant&#8217;s participation in the Plan or any aspect of the RSUs that cannot be satisfied by any of the means described in the preceding paragraph. The Company may refuse to deliver Shares to Participant if Participant fails to meet his&#47;her obligations for the Tax-Related Items, as described herein.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Unless and until such time as Shares are issued in settlement of vested RSUs, Participant shall have no ownership of the Shares allocated to the RSUs and shall have no right to dividends or to vote from such Shares.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If dividends are declared and paid on Shares, dividend equivalent payments, if any (whether in cash or Shares), shall be credited to Participant at such time as Shares as issued in settlement of vested RSUs. Such dividend equivalent payments shall have the same vesting requirements as the underlying RSUs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The RSUs and any interest therein shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to the terms of the Notice, if Participant&#8217;s service terminates for any reason, all unvested RSUs shall be forfeited to the Company forthwith, and all rights of Participant to such RSUs shall immediately terminate. For the avoidance of doubt, Participant shall not be entitled to any compensation for the loss of any rights or opportunities under the Plan other than as provided for herein.  In case of any dispute as to whether Termination has occurred, the Committee shall have sole discretion to determine whether such Termination has occurred and the effective date of such Termination.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Tax Consequences</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Participant acknowledges that there will be tax consequences upon settlement of the RSUs or disposition of the Shares, if any, received in connection therewith, and Participant should consult a tax adviser regarding Participant&#8217;s tax obligations prior to such settlement or disposition. You should consult your personal tax advisor for information on the actual and potential tax consequences of this RSU.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Company and Participant agree that the RSUs are granted under and governed by the Notice, this Agreement and the provisions of the Plan. Participant&#58; (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Country-Specific Terms and Conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Participant&#8217;s participation in the Plan will be subject to any special terms and conditions set forth in Appendix A to this Agreement (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Appendix A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for Participant&#8217;s country of residence, if any. Appendix A constitutes part of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moreover, if Participant relocates to another country, any special terms and conditions applicable to RSUs granted in such country may apply to Participant to the extent the Company determines that the application of such terms and conditions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the Company reserves the right to impose other requirements on the RSUs and any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Entire Agreement&#59; Enforcement of Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company&#8217;s Shares may be listed or quoted at the time of such issuance or transfer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Governing Law Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If one or more provisions of this Agreement (including the Appendix) are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, U.S.A, without giving effect to principles of conflicts of law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">No Rights as Employee, Director or Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Participant&#8217;s service, for any reason, with or without cause, subject to compliance with applicable local laws.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Recipient Data Privacy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Through Participant&#8217;s acceptance of this grant, Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of his or her personal and&#47;or sensitive data as described in this document by and among, as applicable, the Company, its affiliates and its subsidiaries for the exclusive purpose of implementing, administering and managing Participant&#8217;s participation in the Plan. Participant understands that the Company holds certain personal and&#47;or sensitive information about him or her, including, but not limited to, his or her name, home address and telephone&#47;fax number, date of birth, social insurance number or other identification number, family size, marital status, gender, beneficiary information, emergency contacts, passport&#47;visa information, salary and benefit information, personal bank account number, tax related information, tax identification number, nationality, job title, any Shares or directorships held in the Company, details of all RSUs or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#8217;s favor and any other information required by providers for the purpose of implementing, administering and managing the Plan (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Participant also understands and unambiguously consents to the fact that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in Participant&#8217;s country or elsewhere, and that Participant&#8217;s country may have different data privacy laws and protections than the laws in the recipient&#8217;s country. Participant understands that he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative. Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing my participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom Participant may elect to deposit any Shares acquired. Participant understands that Data will be held only as long as is necessary to implement, administer and manage his or her participation in the Plan. Participant understands that he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local human resources representative. Participant understands, however, that refusing or withdrawing his or her consent may affect his or her ability to participate in the Plan. For more information on the consequences of Participant&#8217;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources representative.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">By acknowledging and accepting this RSU grant, Participant agrees that the granting of this RSU is completely at the discretion of the Committee pursuant to the Plan, that Participant does not expect that future awards will be granted under the Plan, or any other plan, and that Participant waives any claim for losses under the Agreement of the Plan in connection with termination of employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The RSU grant is non-transferrable and non-assignable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Board at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The grant of this award is voluntary and occasional and does not create any contractual or other right to receive future grants of awards, or benefits in lieu of awards, even if awards have been granted repeatedly in the past.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Participant is voluntarily participating in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">This RSU grant is an extraordinary item that does not constitute compensation of any kind for services of any kind rendered to the Company or its affiliates (including, as applicable, Participant&#8217;s employer) and which is outside the scope of Participant&#8217;s employment contract, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">This RSU grant is not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The future value of the underlying Shares is unknown and cannot be predicted with certainty.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">For the purposes of this Agreement, termination of service shall be the last day of active service provided by Participant to the Company or one of its affiliates and such period shall not be extended by any notice of termination or similar period including any period of garden leave.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Translations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If Participant receives this Agreement or any other document or communication related to the Plan or this grant in a language other than English and the meaning in the translation is different than in the English version, the terms expressed in the English version will govern.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the RSUs and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with any applicable law or facilitate the administration of the Plan. Participant agrees to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. Furthermore, Participant acknowledges that the laws of the country in which Participant is working at the time of grant, vesting or the sale of Shares received pursuant to this RSU grant (including any rules or regulations governing securities, foreign exchange, tax, labor, or other matters) may subject Participant to additional procedural or regulatory requirements that Participant is and will be solely responsible for and must fulfill.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By your signature and the signature of the Company&#8217;s representative on the Notice, Participant and the Company agree that this RSU is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement. Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and this Agreement. Participant further agrees to notify the Company upon any change in Participant&#8217;s residence address.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. For purposes of this Agreement, a termination of employment will be determined consistent with the rules relating to a &#8220;separation from service&#8221; as defined in Section 409A of the Internal Revenue Code and the regulations thereunder (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Section 409A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding anything else provided herein, to the extent any payments provided under this RSU Agreement in connection with Participant&#8217;s termination of employment constitute deferred compensation subject to Section 409A, and Participant is deemed at the time of such termination of employment to be a &#8220;specified employee&#8221; under Section 409A, then such payment shall not be made or commence until the earlier of (i) the expiration of the six-month period measured from Participant&#8217;s separation from service from the Company or (ii) the date of Participant&#8217;s death following such a separation from service&#59; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to Participant including, without limitation, the additional tax for which Participant would otherwise be liable under Section 409A(a)(1)(B) in the absence of such a deferral. To the extent any payment under this RSU Agreement may be classified as a &#8220;short-term deferral&#8221; within the meaning of Section 409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section 409A under another provision of Section 409A. Payments pursuant to this section are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_28"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPENDIX A</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADDITIONAL COUNTRY-SPECIFIC TERMS AND CONDITIONS OF THE DEXCOM, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN (RESTRICTED STOCK UNITS)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Appendix A includes additional terms and conditions that govern the RSUs granted to you under the Plan if you reside in one of the countries listed below. Capitalized terms used but not defined in this Appendix A are defined in the Plan and&#47;or the Agreement, and have the meanings set forth therein.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Appendix A also includes information regarding exchange controls and certain other issues of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of August 2017. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information noted in this Appendix A as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the RSUs or sell Shares acquired under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the information contained herein is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of a particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, if you are a citizen or resident of a country other than the one in which you are currently working, transfer employment after the grant date, or are considered a resident of another country for local law purposes, the information contained herein may not be applicable to you, and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CANADA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Settled in Shares Only</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any discretion contained in the Plan, or any provision in the Agreement to the contrary, RSUs shall be paid in Shares only and do not provide any right for Participant to receive a cash payment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The following provisions shall apply if Participant is a resident of Quebec&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Language Consent</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Les Parties reconnaissent avoir exig&#233; la r&#233;daction en anglais de cette convention, ainsi que de tous documents, avis et proc&#233;dures judiciaires, ex&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224; la pr&#233;sente convention.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Privacy Notice and Consent</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This provision supplements the Data Privacy section of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant hereby authorizes the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. Participant further authorizes the Company and the Employer to disclose and discuss his or her participation in the Plan with their advisors. Finally, Participant authorizes the Company and the Employer to record such information and to keep such information in his or her employee file.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">GERMANY</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Control Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-border payments in excess of &#8364;12,500 must be reported monthly to the German Federal Bank. If Participant uses a German bank to transfer a cross-border payment in excess of &#8364;12,500 in connection with the sale of Shares acquired under the Plan, the bank will make the report for him or her. In addition, Participant must report any receivables, payables, or debts in foreign currency exceeding an amount of &#8364;5,000,000 on a monthly basis.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NETHERLANDS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insider-Trading Notification</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant should be aware of the Dutch insider-trading rules, which may impact the sale of Shares issued to Participant at vesting and settlement of the RSUs. In particular, Participant may be prohibited from effectuating certain transactions involving Shares if Participant has inside information about the Company. If Participant is uncertain whether the insider-trading rules apply to Participant, Participant should consult his or her personal legal advisor.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SWEDEN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SWITZERLAND</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED KINGDOM</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Withholding Taxes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This provision supplements the Withholding Taxes section of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If payment or withholding of the Tax-Related Items (including the Employer&#8217;s Liability, as defined below) is not made within 90 days of the end of the UK tax year in which vesting occurs (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Due Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003, the amount of any uncollected Tax-Related Items will constitute a loan owed by Participant to the Employer, effective on the Due Date. Participant agrees that the loan will bear interest at the then-current Official Rate of Her Majesty&#8217;s Revenue and Customs (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">HMRC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), it will be immediately due and repayable, and the Company or the Employer may recover it at any time thereafter by any of the means referred to in the Withholding Taxes section of the Agreement. Participant also authorizes the Company to delay the issuance of Shares to Participant unless and until the loan is repaid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if Participant is a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), Participant will not be eligible for such a loan to cover the Tax-Related Items. In the event that Participant is a director or executive officer and the Tax-Related Items are not collected from or paid by Participant by the Due Date, the amount of any uncollected Tax-Related Items will constitute a benefit to Participant on which additional income tax and national insurance contributions (including the Employer&#8217;s Liability, as defined below) will be payable. Participant will be responsible for reporting and paying any income tax and national insurance contributions (including the Employer&#8217;s Liability, as defined below) due on this additional benefit directly to HMRC under the self-assessment regime.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joint Election&#47;recoverability of employer national insurance contributions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a condition of Participant&#8217;s participation in the Plan and the vesting of the RSUs (, Participant agrees to accept any liability for secondary Class 1 national insurance contributions (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Employer&#8217;s Liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) which may be payable by the Company and&#47;or the Employer in connection with the RSUs and any event giving rise to Tax- Related Items. To accomplish the foregoing, Participant agrees to execute a joint election with the Company and&#47;or the Employer (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Election</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the form of such Election being formally approved by HMRC, and&#47;or any other agreements, consents or elections required to accomplish the transfer of the Employer&#8217;s Liability to Participant. Participant further agrees to execute such other joint elections, other agreements, consents or elections (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other Agreement(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) as may be required by the Company and&#47;or the Employer between Participant and the Company, any successor to the Company and&#47;or the Employer in order to transfer the Employer&#8217;s Liability to Participant or in order to provide for the reimbursement of the Employer&#8217;s Liability by Participant to the Company and&#47;or the Employer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If Participant does not enter into the Election when Participant accepts the Agreement, if the Election is revoked and&#47;or abolished at any time by HMRC or if Participant fails to enter into any Other Agreement as required by the Company, any successor to the Company and&#47;or the Employer, the Company may choose, in its sole discretion, not to allow Participant to vest in the RSUs and they will cease to vest, become null and void, and no Shares will be acquired under the Plan, without any liability to the Company, the Employer and&#47;or any Affiliate. Participant further agrees that the Company and&#47;or the Employer may collect the Employer&#8217;s Liability by any of the means set forth in the Withholding Taxes section of the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the avoidance of doubt, this requirement will apply to all Participants that work in the U.K. during any period from grant through the vesting date of the RSUs regardless of whether Participant was in the U.K. at the time of grant.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">UNITED STATES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This provision supplements the Tax Consequences provision of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon vesting of the RSU, Participant will include in income the fair market value of the Shares subject to the RSU. The included amount will be treated as ordinary income by Participant and will be subject to withholding by the Company when required by applicable law. Upon disposition of the Shares, any subsequent increase or decrease in value will be treated as short-term or long-term capital gain or loss, depending on whether the Shares are held for more than one year from the date of settlement. Further, an RSU may be considered a deferral of compensation that may be subject to Section 409A of the Code. Section 409A of the Code imposes special rules to the timing of making and effecting certain amendments of this RSU with respect to distribution of any deferred compensation. You should consult your personal tax advisor for information on the actual and potential tax consequences of this RSU.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_40"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of RSU Grant Agreement &#8211; Board Members &#8211; Annual Grant</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.<br>AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN<br>NOTICE OF RESTRICTED STOCK UNIT AWARD<br>GRANT NUMBER&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) Amended and Restated 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same meanings in this Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; ________________________</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; _______________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) have been granted an award of Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Award Agreement (Restricted Stock Units) (hereinafter &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSU Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; _______________________</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; _______________________</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; _______________________</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The date on which settlement of all RSUs granted hereunder occurs, with earlier expiration upon the Termination Date</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Subject to the limitations set forth in this Notice, the Plan and the RSU Agreement, the RSUs will vest in accordance with the following schedule&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">in one annual installment (i.e., 100% of the RSUs subject to this Notice will vest upon the earlier of the first anniversary of the Date of Grant or the date of the next annual meeting of stockholders).</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate Transaction&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If a Corporate Transaction occurs then the vesting and (if applicable) exercisability of the RSUs shall be accelerated in full and any reacquisition or repurchase rights held by the Company with respect to the shares of Common Stock subject to such acceleration shall lapse in full, as appropriate.</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Corporate Transaction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following events&#58; (i) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company&#8217;s then-outstanding voting securities&#59; provided, however, that for purposes of this subclause (i) the acquisition of additional securities by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the securities of the Company will not be considered a Corporate Transaction&#59; (ii) the consummation of the sale, transfer or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; (iii) the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation&#59; (iv) any other transaction which qualifies as a &#8220;corporate transaction&#8221; under Section 424(a) of the Code wherein the stockholders of the Company give up all of their equity interest in the Company (except for the acquisition, </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">sale or transfer of all or substantially all of the outstanding shares of the Company) or (v) a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by members of the Board whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purpose of this subclause (v), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Corporate Transaction. For purposes of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. Notwithstanding the foregoing, to the extent that any amount constituting deferred compensation (as defined in Section 409A of the Code) would become payable under this Plan by reason of a Corporate Transaction, such amount shall become payable only if the event constituting a Corporate Transaction would also qualify as a change in ownership or effective control of the Company or a change in the ownership of a substantial portion of the assets of the Company, each as defined within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and IRS guidance that has been promulgated or may be promulgated thereunder from time to time.</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, a Corporate Transaction shall not be deemed to result from any transaction precipitated by the Company&#8217;s insolvency, appointment of a conservator, or determination by a regulatory agency that the Company is insolvent, nor from any transaction the sole purpose of which is to change the state of the Company&#8217;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that your relationship or service with the Company is for an unspecified duration, and that nothing in this Notice, the RSU Agreement or the Plan changes the at-will nature of that relationship. You acknowledge that the vesting of the RSUs pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company. You also understand that this Notice is subject to the terms and conditions of both the RSU Agreement and the Plan, both of which are incorporated herein by reference. Participant has read both the RSU Agreement and the Plan.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.202%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PARTICIPANT</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature&#58; ___________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58; __________________________</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; ________________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58; _________________________________</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_1099511628281"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AWARD AGREEMENT (RESTRICTED STOCK UNITS) TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) Amended and Restated 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same defined meanings in this Award Agreement (Restricted Stock Units) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You have been granted Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) subject to the terms, restrictions and conditions of the Plan, the Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Settlement of RSUs shall be made within the earlier of (i) 90 days following the applicable date of vesting under the vesting schedule or (ii) March 15 of the year following the year of vesting as set forth in the Notice.  Settlement of RSUs shall be in Shares.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Withholding and Net Issuance of the Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  When, under applicable tax laws, Participant incurs tax liability in connection with the vesting or settlement of any RSUs or issuance of Shares in connection therewith that is subject to tax withholding by the Company, the Company may, at the Compensation Committee&#8217;s election, satisfy the minimum tax withholding obligation on behalf of the Participant by either (a) withholding from the Shares to be issued, the number of Shares having a fair market value (determined on the date that the amount of tax to be withheld is determined) equal to the amount required to be withheld for income and employment taxes, or (b) arranging to have sold on Participant&#8217;s behalf through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) a sufficient number of Shares that is equal to the amount required to be withheld.  The Company shall arrange to sell or withhold a whole number of shares to satisfy the minimum tax withholding obligation, and to the extent that any tax obligation balance remains, such amount shall be withheld from your following payroll cycle, if applicable.    </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Unless and until such time as Shares are issued in settlement of vested RSUs, Participant shall have no ownership of the Shares allocated to the RSUs and shall have no right to dividends or to vote such Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Dividends, if any (whether in cash or Shares), shall not be credited to Participant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The RSUs and any interest therein shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  If Participant&#8217;s service Terminates for any reason, all unvested RSUs shall be forfeited to the Company forthwith, and all rights of Participant to such RSUs shall immediately terminate.  In case of any dispute as to whether Termination has occurred, the Committee shall have sole discretion to determine whether such Termination has occurred and the effective date of such Termination.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">U.S. Tax Consequences</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Participant acknowledges that there will be tax consequences upon settlement of the RSUs or disposition of the Shares, if any, received in connection therewith, and Participant should consult a tax adviser regarding Participant&#8217;s tax obligations prior to such settlement or disposition.  Upon vesting of the RSU, Participant will include in income the fair market value of the Shares subject to the RSU.  The included amount will be treated as ordinary income by Participant and will be subject to withholding by the Company when required by applicable law.  Upon disposition of the Shares, any subsequent increase or decrease in value will be treated as short-term or long-term capital gain or loss, depending on whether the Shares are held for more than one year from the date of settlement.  Further, an RSU may be considered a deferral of compensation that may be subject to Section 409A of the Code.  Section 409A of the Code imposes special rules to the timing of making and effecting certain amendments of this RSU with respect to distribution of any deferred compensation.  You should consult your personal tax advisor for more information on the actual and potential tax consequences of this RSU.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The Company and Participant agree that the RSUs are granted under and governed by the Notice, this Agreement and the provisions of the Plan.  Participant&#58; (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice.  </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Entire Agreement&#59; Enforcement of Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company&#8217;s Common Stock may be listed or quoted at the time of such issuance or transfer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Governing Law&#59; Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms.  This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">No Rights as Employee, Director or Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8217;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s service, for any reason, with or without cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By your signature and the signature of the Company&#8217;s representative on the Notice, Participant and the Company agree that this RSU is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement.  Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and this Agreement.  Participant further agrees to notify the Company upon any change in Participant&#8217;s residence address.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_43"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of RSU Grant Agreement &#8211; Board Members &#8211; Incoming Grant</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOTICE OF RESTRICTED STOCK UNIT AWARD</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GRANT NUMBER&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same meanings in this Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; ________________________</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Address</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; _______________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) have been granted an award of Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Award Agreement (Restricted Stock Units) (hereinafter &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSU Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; _______________________</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; _______________________</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; _______________________</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The date on which settlement of all RSUs granted hereunder occurs, with earlier expiration upon the Termination Date</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Subject to the limitations set forth in this Notice, the Plan and the RSU Agreement, the RSUs will vest in accordance with the following schedule&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">in three annual installments (i.e., 33.3% of the RSUs subject to this Notice will vest upon the first anniversary of the Date of Grant&#59; 33.3% of the RSUs subject to this Notice will vest upon the second anniversary of the Date of Grant&#59; and 33.3% of the RSUs subject to this Notice will vest upon the third anniversary of the Date of Grant)</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify;text-indent:-144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate Transaction&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If a Corporate Transaction occurs then the vesting and (if applicable) exercisability of the RSUs shall be accelerated in full and any reacquisition or repurchase rights held by the Company with respect to the shares of Common Stock subject to such acceleration shall lapse in full, as appropriate.</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Corporate Transaction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following events&#58; (i) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company&#8217;s then-outstanding voting securities&#59; provided, however, that for purposes of this subclause (i) the acquisition of additional securities by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the securities of the Company will not be considered a Corporate Transaction&#59; (ii) the consummation of the sale, transfer or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; (iii) the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation&#59; (iv) any other transaction which qualifies as a &#8220;corporate transaction&#8221; under Section 424(a) of the Code wherein the stockholders of the Company give up </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all of their equity interest in the Company (except for the acquisition, sale or transfer of all or substantially all of the outstanding shares of the Company) or (v) a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by members of the Board whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purpose of this subclause (v), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Corporate Transaction. For purposes of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. Notwithstanding the foregoing, to the extent that any amount constituting deferred compensation (as defined in Section 409A of the Code) would become payable under this Plan by reason of a Corporate Transaction, such amount shall become payable only if the event constituting a Corporate Transaction would also qualify as a change in ownership or effective control of the Company or a change in the ownership of a substantial portion of the assets of the Company, each as defined within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and IRS guidance that has been promulgated or may be promulgated thereunder from time to time.</font></div><div style="margin-bottom:12pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, a Corporate Transaction shall not be deemed to result from any transaction precipitated by the Company&#8217;s insolvency, appointment of a conservator, or determination by a regulatory agency that the Company is insolvent, nor from any transaction the sole purpose of which is to change the state of the Company&#8217;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You understand that your relationship or service with the Company is for an unspecified duration, and that nothing in this Notice, the RSU Agreement or the Plan changes the at-will nature of that relationship. You acknowledge that the vesting of the RSUs pursuant to this Notice is earned only by continuing service as an Employee, Director or Consultant of the Company. You also understand that this Notice is subject to the terms and conditions of both the RSU Agreement and the Plan, both of which are incorporated herein by reference. Participant has read both the RSU Agreement and the Plan.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.202%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PARTICIPANT</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature&#58; ___________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name&#58; __________________________</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; ________________________________</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58; _________________________________</font></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i25370b9402e34802bc5629f9ffd2c742_495"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AWARD AGREEMENT (RESTRICTED STOCK UNITS) TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unless otherwise defined herein, the terms defined in the DexCom, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) Amended and Restated 2015 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall have the same defined meanings in this Award Agreement (Restricted Stock Units) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You have been granted Restricted Stock Units (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) subject to the terms, restrictions and conditions of the Plan, the Notice of Restricted Stock Unit Award (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Settlement of RSUs shall be made within the earlier of (i) 90 days following the applicable date of vesting under the vesting schedule or (ii) March 15 of the year following the year of vesting as set forth in the Notice.  Settlement of RSUs shall be in Shares.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Withholding and Net Issuance of the Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  When, under applicable tax laws, Participant incurs tax liability in connection with the vesting or settlement of any RSUs or issuance of Shares in connection therewith that is subject to tax withholding by the Company, the Company may, at the Compensation Committee&#8217;s election, satisfy the minimum tax withholding obligation on behalf of the Participant by either (a) withholding from the Shares to be issued, the number of Shares having a fair market value (determined on the date that the amount of tax to be withheld is determined) equal to the amount required to be withheld for income and employment taxes, or (b) arranging to have sold on Participant&#8217;s behalf through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) a sufficient number of Shares that is equal to the amount required to be withheld.  The Company shall arrange to sell or withhold a whole number of shares to satisfy the minimum tax withholding obligation, and to the extent that any tax obligation balance remains, such amount shall be withheld from your following payroll cycle, if applicable.    </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Unless and until such time as Shares are issued in settlement of vested RSUs, Participant shall have no ownership of the Shares allocated to the RSUs and shall have no right to dividends or to vote such Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Dividends, if any (whether in cash or Shares), shall not be credited to Participant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">No Transfer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The RSUs and any interest therein shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  If Participant&#8217;s service Terminates for any reason, all unvested RSUs shall be forfeited to the Company forthwith, and all rights of Participant to such RSUs shall immediately terminate.  In case of any dispute as to whether Termination has occurred, the Committee shall have sole discretion to determine whether such Termination has occurred and the effective date of such Termination.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">U.S. Tax Consequences</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Participant acknowledges that there will be tax consequences upon settlement of the RSUs or disposition of the Shares, if any, received in connection therewith, and Participant should consult a tax adviser regarding Participant&#8217;s tax obligations prior to such settlement or disposition.  Upon vesting of the RSU, Participant will include in income the fair market value of the Shares subject to the RSU.  The included amount will be treated as ordinary income by Participant and will be subject to withholding by the Company when required by applicable law.  Upon disposition of the Shares, any subsequent increase or decrease in value will be treated as short-term or long-term capital gain or loss, depending on whether the Shares are held for more than one year from the date of settlement.  Further, an RSU may be considered a deferral of compensation that may be subject to Section 409A of the Code.  Section 409A of the Code imposes special rules to the timing of making and effecting certain amendments of this RSU with respect to distribution of any deferred compensation.  You should consult your personal tax advisor for more information on the actual and potential tax consequences of this RSU.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The Company and Participant agree that the RSUs are granted under and governed by the Notice, this Agreement and the provisions of the Plan.  Participant&#58; (i) acknowledges receipt of a copy of the Plan and the Plan prospectus, (ii) represents that Participant has carefully read and is familiar with their provisions, and (iii) hereby accepts the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice.  </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt;text-decoration:underline">Entire Agreement&#59; Enforcement of Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  This Agreement, the Plan and the Notice constitute the entire agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing and signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The issuance of Shares will be subject to and conditioned upon compliance by the Company and Participant with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company&#8217;s Common Stock may be listed or quoted at the time of such issuance or transfer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">Governing Law&#59; Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of this Agreement shall be enforceable in accordance with its terms.  This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt;text-decoration:underline">No Rights as Employee, Director or Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company, or a Parent or Subsidiary of the Company, to terminate Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8217;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s service, for any reason, with or without cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By your signature and the signature of the Company&#8217;s representative on the Notice, Participant and the Company agree that this RSU is granted under and governed by the terms and conditions of the Plan, the Notice and this Agreement.  Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and this Agreement.  Participant further agrees to notify the Company upon any change in Participant&#8217;s residence address.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>5
<FILENAME>dxcm12312023ex1014-amended.htm
<DESCRIPTION>EX-10.14
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i144f451e526b49a3802aac32b5158b97_7"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.14</font></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is executed on November 20, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) (as defined below) by and between DexCom, Inc., (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) having its principal place of business at 6340 Sequence Drive, San Diego, California 92121, Verily Ireland Limited (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) having its principal place of business at 70 Sir John Rogerson&#8217;s Quay, Dublin 2, Ireland and Verily Life Sciences LLC (formerly Google Life Sciences LLC) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VLS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and together with VIL, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), having its principal place of business at 1600 Amphitheatre Parkway, Mountain View, California 94043, and amends and restates in its entirety that certain Collaboration and License Agreement dated as of August 10, 2015 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) by and between DexCom and Verily (as amended by Amendment No. 1 thereto effective as of October 25, 2016, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  DexCom and Verily are each referred to herein by name or, individually, as a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or, collectively, as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BACKGROUND</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Verily has rights to certain proprietary technologies related to electronic devices and assemblies for glucose monitoring, including receiving and transmitting electronic signals in connection therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;DexCom develops, manufactures and distributes continuous glucose monitoring systems and components of such systems, and has rights to certain proprietary technologies relating to such systems.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Verily and DexCom wish to collaboratively develop Future Products (as defined below) and for DexCom to commercialize such Future Products, all on the terms and conditions set forth&#160;herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;In order to better align the goals and interests of the parties, Verily and DexCom wish to amend certain terms of the Original Agreement, and to restate the Original Agreement, as so amended, in its entirety in this Agreement, all on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants and agreements provided herein below and other consideration, the receipt and sufficiency of which is hereby acknowledged, DexCom and Verily hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 1.<br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following capitalized terms shall have the meanings given in this Article 1 when used in this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">510(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a pre-market notification submitted to the FDA for clearance under Section 510(k) of the FD&#38;C Act, 21 U.S.C.  &#167; 360(k), and 21 C.F.R.  Part 807, Subpart&#160;E.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acceptance Submission Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquirer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a Third Party with whom DexCom enters into a definitive agreement pursuant to which a Change of Control is effected.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any &#91;***&#93; that the Parties agree to &#91;***&#93; hereunder in accordance with Section 4.3, as such &#91;***&#93; may be updated or upgraded pursuant to the Final Additional Product Supplement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adverse Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product, any reportable event, as defined in the United States under 21 C.F.R.  &#167; 803.3 (or other applicable Law in the Territory) or pursuant to Good Clinical Practice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to Verily, the subsidiaries of Verily, and (b) with respect to DexCom, any Person directly or indirectly controlling, controlled by or under common control with DexCom.  For purposes of this Section 1.5 only, &#8220;control&#8221; means (a) direct or indirect ownership of more than fifty percent (50%) (or, if less than fifty percent (50%), the maximum ownership interest permitted by applicable Law) of the stock or shares having the right to vote for the election of directors of such corporate entity or (b) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such entity, whether through the ownership of voting securities, by contract or otherwise.  For the avoidance of doubt, the following shall not be Affiliates of Verily for purposes of this Agreement&#58; (i) Alphabet Inc.  or any subsidiaries of Alphabet Inc.  other than Verily and its subsidiaries&#59; (ii) Google LLC or any subsidiaries of Google LLC&#59; (iii) Calico LLC, (iv) all portfolio companies of GV Management Company, L.L.C., CapitalG Management </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company LLC or any other investment arm of Verily or Google Inc.&#59; (v) all portfolio companies of Verily or Google Inc.  or its subsidiaries in which such entity or entities hold securities primarily for investment purposes, and (vi) any joint venture entity formed by Verily or its subsidiaries together with one or more Third Parties unless Verily possesses the power to wholly-control such joint venture entity, whether through the ownership of voting securities, by contract, or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the individual appointed by a Party to act as alliance manager for that Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Alphabet</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Alphabet Inc.  having its principal place of business at 1600 Amphitheatre Parkway, Mountain View, CA 94043.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Alternative Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (a) any &#91;***&#93;, or (b) if &#91;***&#93; elects not to submit &#91;***&#93; with respect to the applicable &#91;***&#93;, then any &#91;***&#93;, provided, however, that if &#91;***&#93;, it being understood that in no event shall &#91;***&#93;.  &#91;***&#93; shall be deemed to have occurred if either of the following occurs&#58; &#91;***&#93;&#59; or (ii)&#160;&#91;***&#93;.  Notwithstanding the foregoing, with respect to any &#91;***&#93;.  A &#91;***&#93; shall be subject to this Section 1.9 only if &#91;***&#93;.  For purposes of this definition&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a &#91;***&#93; that (in each case as compared to the &#91;***&#93; (1) comprises or utilizes (a) &#91;***&#93;, (b) &#91;***&#93;, (c) &#91;***&#93;, (d) &#91;***&#93;, (e) &#91;***&#93;, (f) &#91;***&#93;, and&#47;or (g) &#91;***&#93;, and (2) &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a Third Party that has &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#8220;&#91;***&#93;&#8221; means that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.11&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Antitrust Clearance Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Stock Purchase Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Antitrust Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Stock Purchase Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assigned Software</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any &#91;***&#93; which (a) is &#91;***&#93; and&#47;or (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bankruptcy Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 14.12.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.1.2(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any day other than a Saturday, Sunday or any other day on which commercial banks in the State of California, U.S.A.  are authorized or required by Law to remain closed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any of the following &#91;***&#93;&#58; (a) &#91;***&#93;&#59; and&#47;or (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all &#91;***&#93;, (i) whether on a standalone basis or as integrated into, or connected with, other products, systems (&#91;***&#93;), or components (including but not limited to the Products), whether or not such products, systems, or components &#91;***&#93;, and (ii) whether or not such &#91;***&#93;.  &#91;***&#93; may include the following to the extent used or incorporated in such &#91;***&#93;&#58; (a) &#91;***&#93;.  &#91;***&#93; exclude &#91;***&#93;.  If there is another method for &#91;***&#93; and the Parties agree in writing &#91;***&#93;, then this definition will be expanded to include that method.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any merger, consolidation, sale of substantially all of the assets to which this Agreement relates, or similar transaction or series of transactions in which DexCom is the entity being acquired or selling such assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Chief Executive Officer of DexCom and&#47;or the Chief Executive Officer of Verily, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collaboration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all activities performed by or on behalf of each Party under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all IP in subject matter conceived, developed or (in the case of IP in Software) authored by or on behalf of a Party and&#47;or its Affiliates, and&#47;or any Third Party acting on such Party&#8217;s behalf (or employees of the foregoing), in each case in the course of performing activities under the &#91;***&#93;, and&#47;or activities that have been or will be conducted under this Agreement, &#91;***&#93;, at any time during the period </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">from the Original Effective Date through the end of the Term of this Agreement (including, for the sake of clarity, the period beginning as of the Original Effective Date and ended on the Effective Date).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collaboration Patent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any Patent that claims Collaboration IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a &#91;***&#93; in connection with or support of any of the foregoing.  Commercialization also includes activities with respect to &#91;***&#93;.  &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercializing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; have their correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercialization Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, the efforts and resources normally applied by such Party to its other programs and products of similar commercial potential at a similar stage in its product life, but no less than a sustained, continued and active commitment of efforts and resources (financial and otherwise) consistent with those normally applied in the medical device industry for novel, high-priority programs and products of similar commercial potential, provided that the determination of efforts and resources applied (or to be applied) by DexCom shall not take into consideration any of the payments made or to be made (including the possibility thereof) by DexCom to Verily under this Agreement.  Without limiting the foregoing, Commercially Reasonable Efforts shall require the applicable Party to&#58; (a) promptly assign responsibilities for activities for which it is responsible to specific employee(s) who are held accountable for the progress, monitoring and completion of such activities, (b) set and consistently seek to achieve meaningful objectives for carrying out such activities, and (c) consistently make and implement decisions and allocate the full complement of resources necessary or appropriate to advance progress with respect to and complete such objectives in an expeditious manner.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.27&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Communication IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Collaboration IP in subject matter consisting of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Competing Program</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Completed Deliverables</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.31&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any item of IP, the possession (whether by ownership or license, other than a license granted by one Party to the other pursuant to this Agreement), by a Party (or its Affiliates) of the ability to grant to the other Party an assignment, exclusivity, access, a license or a sublicense (as applicable), or a covenant, or to extend other rights as provided in this Agreement, to such IP, without violating the terms of any agreement or other arrangements with any Affiliate or Third Party existing at the time such Party (or its Affiliates) would be first required to grant any such assignment, exclusivity, access, license, sublicense, covenant, or any other right under this Agreement.  For clarity, in the event an item of IP is &#8220;Controlled&#8221; by a Party as of the Original Effective Date or thereafter during the term of the Original Agreement and&#47;or the Term, and is subsequently transferred to an Affiliate of such Party or a Third Party, such item shall continue to be covered by the licenses granted under this Agreement following such transfer (to the same extent, if any, that it was covered prior to such transfer).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.32&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defending Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.4.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.35&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product, any and all development activities, including, to the extent applicable, use, electrical and mechanical design, chemistry and materials development, software and firmware development, &#91;***&#93; development and scale-up, design and process verification and validation, test method development, biocompatibility and toxicology, quality assurance&#47;quality control development, statistical analysis, primary packaging development, &#91;***&#93; in support of Regulatory Approvals, &#91;***&#93; for the purposes of obtaining Regulatory Approvals, and development and implementation of (a) &#91;***&#93;, (b) &#91;***&#93; and (c) &#91;***&#93;.  &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; have their correlative&#160;meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.36&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Development Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a &#91;***&#93; completion of its obligations &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.1.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Deliverable</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.4.3.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (a) &#91;***&#93; and (b) &#91;***&#93;, the terms of which are incorporated by reference herein, as such plans may be amended or updated as provided in this Agreement (including any amendments &#91;***&#93;).  The Parties acknowledge and agree that the &#91;***&#93;, in effect as of the Effective Date, have been exchanged between the Parties in (or as one or more attachments to) a signed letter on the date hereof&#59; provided, however, that the &#91;***&#93; is, as of the Effective Date, tentative and will be effective only upon mutual agreement of the Parties within ninety (90) days after the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Background IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all IP (other than Collaboration IP) Controlled by DexCom and its Affiliates as of the Effective Date and&#47;or at any time between the Effective Date and the end of the Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any present or future (a) &#91;***&#93;, or (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Collaboration Patents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any Collaboration Patents solely owned by DexCom and&#47;or its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Common Stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means shares of common stock of DexCom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Delay</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means DexCom Collaboration IP and DexCom Background IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Other Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Collaboration IP in subject matter consisting of (i) &#91;***&#93; and&#47;or (ii) &#91;***&#93;, in each case (i) and (ii) where such Collaboration IP is conceived, developed, and&#47;or authored solely by or on behalf of DexCom, and&#47;or its Affiliates, and&#47;or a Third Party acting on DexCom&#8217;s behalf (or employees of the foregoing).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Programs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means DexCom&#8217;s programs &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.51&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 13.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enforcement Action</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.5.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enforcing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.5.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Sponsor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Existing Distribution Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means that certain &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Food and Drug Administration, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Final Additional Product Supplement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 14.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Products</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Products other than the First Product.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Good Clinical Practice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means generally accepted standards for design, conduct, performance, monitoring, auditing, analysis and reporting of clinical trials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HSR Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incentive Milestone Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indemnify</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.4.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial VWAP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (i) if the Agreement is announced by press release prior to the open of trading on the Nasdaq Stock Market on the Effective Date, the VWAP of DexCom Common Stock on the day prior to the Effective Date, or (ii) if the Agreement is announced by press release after the close of trading on the Nasdaq Stock Market on the Effective Date, the VWAP of DexCom Common Stock on the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.6.1(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.6.3(e).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infringing Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.5.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all intellectual property rights of every kind throughout the world, including any and all&#58; (a) Patents, (b) rights in Software, (c) rights in Know-How, (d) copyrights, and registrations and applications for copyrights, and (e) rights and remedies against past, present and future infringement, misappropriation, or other violation thereof with respect to any of the foregoing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joint Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all Collaboration IP (other than the DexCom Collaboration IP and the Verily Collaboration IP).  For clarity, Joint Collaboration IP shall include any and all Communication IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joint Collaboration Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joint Collaboration Patent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; any Collaboration Patent jointly owned by Verily and DexCom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any proprietary data, results, material(s), technology, and nonpublic information of any type whatsoever, in any tangible or intangible form, including information, techniques, technology, prototypes, practices, commercial models (including product pricing and&#47;or reimbursement models or strategies), trade secrets, software, algorithms, discoveries, developments, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, chemical, pharmacological, toxicological and clinical test data and results, protocols and process for the conduct of pre-clinical and clinical studies, analytical and quality control results or descriptions, software and algorithms, reports and study reports.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Launch</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the first bona fide, arm&#8217;s length commercial sale of a Product that makes such Product generally commercially available in any country following receipt of Marketing Approval for such Product in such country.  &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Launched</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has its correlative meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, individually and collectively, any and all laws, ordinances, orders, rules, rulings, directives and regulations of any kind whatsoever of any governmental authority or Regulatory Authority within the applicable jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.4.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means all activities involved in manufacturing, preparing, quality control, testing, packaging and storing any of the products.  &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has its correlative meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.82&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marketing Approval</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product in a particular jurisdiction, all clearances, approvals, licenses, registrations or authorizations necessary for the Commercialization of such Product in such jurisdiction in the indication(s) specified in the Specifications, including, only where mandatory for Commercialization of such Product, approval of labeling, price or reimbursement.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Milestone Date VWAP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Milestone Event, the VWAP of DexCom Common Stock as determined on the date that such Milestone Event is first achieved, as equitably adjusted to reflect any stock split, stock dividend, combination, reclassification, recapitalization or other similar event involving DexCom Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Milestone Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Milestone Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.86&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Onduo</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Onduo, LLC, having its principal place of business at 55 Chapel Street Suite 10, Newton, Massachusetts 02458.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93; as defined under the Original Agreement as in effect at any relevant time during the term of the Original Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outside Software</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.3.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any of the following, whether existing now or in the future anywhere in the world&#58; (a) any issued patent, including inventor's certificates, substitutions, extensions, confirmations, reissues, reexamination, renewal or any like governmental grant for protection of inventions&#59; and (b) any pending application for any of the foregoing, including any continuation, divisional, substitution, continuations-in-part, provisional and converted provisional applications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Permitted Encumbrances</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the agreements between Verily and&#47;or its Affiliates, Alphabet, or Alphabet Affiliates and a Third Party with respect to the Verily IP in the &#91;***&#93;, as set out at&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1.92</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any individual, corporation, partnership, association, joint-stock company, trust, unincorporated organization or government or political subdivision thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase Gate IV</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date of completion of the design validation, clinical pivotal trial (if applicable), and process validation for the applicable Product, in accordance with DexCom&#8217;s standard operating procedures &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PMA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a pre-market approval application submitted to the FDA for approval in accordance with 21 U.S.C.  &#167; 360(e) and 21 C.F.R.  Part 814.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pricing Assumptions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means that (a) &#91;***&#93;&#59; (b) &#91;***&#93;&#59; (c) &#91;***&#93;&#59; (d) &#91;***&#93;, (e) &#91;***&#93;, and (f) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pricing Expectations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.6.5(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a &#91;***&#93;.  For clarity, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prior Agreements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.100&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the First Product, Second Product, the Third Product (if agreed by DexCom pursuant to Section 3.1.1), and&#47;or any Additional Product (if agreed by the Parties pursuant to Section 4.3).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.101&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product Deadlines</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the deadlines for the completion of Development, Regulatory Filing in the U.S. and EU and Launch in the U.S. and EU for the &#91;***&#93;.  The Product Deadlines for such Development, Regulatory Filing(s) &#91;***&#93; are also referred to as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product Development Deadlines</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#8221; The Product Deadlines for such Launch in the U.S. and EU are also referred to as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product Launch Deadlines</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.102&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product Development Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the development, clinical and regulatory obligations of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.103&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Proposed Additional Product Supplement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.104&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Proposed Third Product Supplement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.1.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.105&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prosecution and Maintenance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Patent, the preparing, filing, prosecuting and maintenance of such Patent, as well as reexaminations, reissues, requests for Patent term extensions and the like with respect to such Patent, together with the conduct of interferences, the defense of post-grant reviews,&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter partes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;reviews, oppositions and other similar proceedings with respect to the particular Patent&#59; and &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prosecute and Maintain</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.106&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product in a particular jurisdiction, any Marketing Approval and all clearances, approvals, licenses, registrations or authorizations necessary for the Development or Manufacture of such Product in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.107&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity, agency or other organization (e.g., notified bodies) with authority over the Development, Manufacture, Commercialization or other use or exploitation (including the granting of Marketing Approvals) of any Product in any jurisdiction, including the&#160;FDA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.108&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Filing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any filing, application or submission for Regulatory Approval, and any notification and other correspondence made to or with a Regulatory Authority in connection with a Regulatory Approval, in each case that are necessary or reasonably desirable in Development, Manufacture or Commercialization in a particular country, whether submitted before or after a Marketing Approval in the country, including a PMA, a 510(k), or any other pre-market notification of intent, including any Regulatory Approvals, in each case with respect to a Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.109&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Required Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.110&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.111&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; in subject matter consisting of&#58; (a) &#91;***&#93;, (b) &#91;***&#93;, (c) &#91;***&#93;, (d) &#91;***&#93;, (e) &#91;***&#93;, or (f) any combination thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.112&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Software</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means software source code, object code, and any associated technical documentation, including, if applicable, the associated graphical interface, images, design materials, and schema design.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.113&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Specifications</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product or component, written functional, performance, form and configuration specifications, cost objectives and technical designs, and proposed indications for use, of or for such Product or component that are consistent with the technological capabilities of such Product or component and are intended to support the market requirements for such Product, together with the acceptance criteria for such Product or component, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.114&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standalone Product Limitation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.1.2(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.115&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Work</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a writing executed by the Parties that sets forth the services to be rendered by Verily and any terms and conditions related to such services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.116&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Purchase Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.117&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Suppliers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.6.1(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.118&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supply Agreements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.6.1(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.119&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technical Lead</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.1.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.120&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 12.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.121&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.122&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any Person other than DexCom, Verily or their respective Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.123&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third Party Claim</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.4.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.124&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93;, if any, developed pursuant to Section 3.1.1, as such &#91;***&#93; may be updated or upgraded.  For the avoidance of doubt, all references to Third Product in this Agreement, except </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for the restrictive covenant set forth in Section 3.1.1, shall apply if and only if DexCom elects to proceed with Third Product development as set forth in Section 3.1.1 and shall otherwise have no effect in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.125&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third Product Negotiation Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.126&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third Product Supplement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.127&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Product Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means total net revenue attributable to the sale by DexCom and&#47;or its Affiliates of the First Product, Second Product, Third Product, and&#47;or any Alternative Product, as calculated in accordance with GAAP, consistent with DexCom&#8217;s revenue disclosed in DexCom&#8217;s financial statements filed with the SEC in its periodic (quarterly and annual) reports.  If a Product (or Alternative Product) is Commercialized, directly or indirectly, in a manner that is combined or integrated with any product or service that is not a Product (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the portion of the total net revenue attributable to the Product (or Alternative Product) shall be calculated by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.128&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trademark</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership, including registrations and applications therefor and the goodwill and activities associated with each of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.129&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Upfront Payment Amount</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.130&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Upfront Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.131&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.132&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Background IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all IP (other than Collaboration IP) Controlled by Verily and&#47;or its Affiliates as of the Effective Date and&#47;or at any time during the Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.133&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.134&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Verily Software IP and Verily Retained Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.135&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Delay</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.136&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Deliverable</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.4.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.137&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Development Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; to support the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.138&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.139&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Infrastructure Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.140&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, collectively, (i) Verily Collaboration IP, (ii) Verily Licensed Patents, and (iii) Verily Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.141&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How (a) incorporated by Verily into the First Product, Second Product, Third Product and&#47;or any Additional Product or (b) otherwise used by Verily for its performance of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.142&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Licensed Patents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (a) (i) the &#91;***&#93;, (ii) any Patents that are entitled to claim priority to the foregoing Patents, and (iii) any Patents hereafter issuing on any of the Patents described in clause (i) or (ii) above, (b) &#91;***&#93;, and&#47;or (c) any other Patents that are Controlled by Verily (and&#47;or its Affiliates) as of the Effective Date and&#47;or at any time between the Effective Date and the end of the Term (excluding any Patents that are Verily Software IP), which Patents under (c) claim or cover the First Product, Second Product, Third Product and&#47;or any Additional Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.143&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Patents listed in&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1.143</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.144&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Patents listed in&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1.144</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.145&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Milestone Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2.1.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.146&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Platform</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93; platform developed by or on behalf of &#91;***&#93;, which platform (a) &#91;***&#93; and (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.147&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Programs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Verily&#8217;s programs for &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.148&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Program Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.149&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Program &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Retained Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.1.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.151&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, collectively, the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.152&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Software IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.153&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Trademarks</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Trademarks set forth on&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1.153</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;or such replacements therefor as may be designated by Verily from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.154&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Upfront Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.155&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VWAP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a publicly traded stock and a specified end date, the volume weighted average trading price of such stock during a period of fifteen (15) consecutive trading days ending on the specified end date, calculated utilizing &#8220;VWAP&#8221; in the Bloomberg function VAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.156&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.  Unless specified to the contrary, references to Articles, Sections or Exhibits mean the particular Articles, Sections or Exhibits to this Agreement and references to this Agreement include all Exhibits hereto.  Unless context otherwise clearly requires, whenever used in this Agreement&#58; (a) the words &#8220;include&#8221; or &#8220;including&#8221; shall be construed as incorporating, also, &#8220;but not limited to&#8221; or &#8220;without limitation&#59;&#8221; (b) the word &#8220;day&#8221; or &#8220;year&#8221; means a calendar day or year unless otherwise specified&#59; (c) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other communications contemplated under this Agreement&#59; (d) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement (including any Exhibits)&#59; (e) the word &#8220;or&#8221; shall be construed as the inclusive meaning identified with the phrase &#8220;and&#47;or&#59;&#8221; (f) provisions that require that a Party, the Parties or the Executive Sponsors &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise&#59; (g) words of any gender include the other gender&#59; (h) words using the singular or plural number also include the plural or singular number, respectively&#59; (i) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement law, rule or regulation thereof&#59; and (j) neither Party nor its Affiliates shall be deemed to be acting &#8220;on behalf of&#8221; or &#8220;under authority of&#8221; the other Party hereunder.  This Agreement has been prepared jointly and shall not be strictly construed against either Party.  Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 2.<br>GOVERNANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Executive Sponsors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Parties will each appoint an individual to act as executive sponsor for that Party (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Sponsor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  The Executive Sponsors shall provide oversight with respect to the Development of the Products and the Parties&#8217; respective activities to be conducted under this Agreement.  The initial Executive Sponsor for DexCom shall be &#91;***&#93; and for Verily shall be &#91;***&#93;.  The name and contact information for any replacement Executive Sponsor(s) chosen by a Party in its sole discretion from time to time, shall be promptly provided to the other Party in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Executive Sponsors will meet &#91;***&#93;, and more or less frequently as the Parties mutually deem appropriate, on such dates, and at such places and times, as provided herein or as the Parties shall agree.  Meetings of the Executive Sponsors may occur &#91;***&#93;&#59; provided, that at least &#91;***&#93; of the Executive Sponsor meetings per calendar year shall be held in person.  &#91;***&#93;.  As appropriate, other employee representatives of the Parties may attend meetings of the Executive Sponsors as nonvoting observers, but no personnel of a Party&#8217;s Affiliates or of a Third Party may attend unless otherwise mutually agreed to by the Parties.  Each Party may also call for special meetings to resolve particular matters requested by such Party.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Decision Making</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Decisions of the Executive Sponsors shall be made &#91;***&#93;.  Each Party shall work in good faith to &#91;***&#93; and act in the general spirit of cooperation (taking into consideration the scope of the Executive Sponsors&#8217; authority and the principles set forth in Sections 2.2.1 and 2.2.2) and in no event shall either Party unreasonably withhold, condition or delay any approval or other decision of the Executive Sponsors.  Except as set forth in Section 3.3, in the event that the Executive Sponsors fail &#91;***&#93; with respect to a particular matter within its authority, then either Party may, by notice to the other Party, have such matter referred to &#91;***&#93; for resolution by good faith discussions for a period of at least fifteen (15) Business Days.  In the event that &#91;***&#93; are unable to reach agreement with respect to such matter within such fifteen (15) Business Days, then the dispute shall be resolved pursuant to Article 13, provided that each Party shall retain final decision-making authority with respect to &#91;***&#93; (so long as in compliance with this Agreement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Alliance Managers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Party shall appoint an Alliance Manager, who will serve as a primary point of contact between the Parties, and who shall be responsible for communicating the status of activities under this Agreement to its Executive Sponsor and to the other Party&#8217;s Alliance Manager.  The initial Alliance Manager for DexCom shall be &#91;***&#93; and for Verily shall be &#91;***&#93;.  The Alliance Managers shall be the primary point of contact for the Parties with respect to the activities to be conducted under this Agreement.  The name and contact information for the Alliance Managers, as well as any replacement(s) chosen by either Party in their sole discretion from time to time, shall be promptly provided to the other Party in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Technical Leads</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Parties will each appoint an individual to act as a technical lead for that Party (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technical Lead</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  The initial Technical Lead for DexCom shall be &#91;***&#93;, and for Verily shall be &#91;***&#93; and &#91;***&#93;.  The name and contact information for the Technical Leads, as well as any replacement(s) chosen by either Party in their sole discretion from time to time, shall be promptly provided to the other Party in writing.  The Technical Leads shall be responsible for (i) communicating on day-to-day implementation &#91;***&#93; with the other Technical Lead, and (ii) proposing updates or amendments &#91;***&#93; to the Executive Sponsors in accordance with Section 3.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding the appointment of the Executive Sponsors, each Party shall retain the rights, powers and discretion granted to it hereunder, and the Executive Sponsors shall not be delegated or vested with rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing.  The Executive Sponsors shall not have the power to (i) amend, modify or waive compliance with this Agreement, (ii) to determine whether or not a Party has met its diligence or other obligations under the Agreement, or (iii) to determine whether or not a breach of this Agreement has occurred, and no decision of the Executive Sponsors shall be in contravention of any terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Guiding Principles</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Executive Sponsors shall perform their responsibilities under this Agreement based on the principles of prompt and diligent Development and Commercialization of Future Products in &#91;***&#93; throughout the Territory, consistent with Commercially Reasonable Efforts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Day-to-Day Responsibilities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3.1&#160;&#160;&#160;&#160;Each Party shall&#58; (a) be responsible for its day-to-day activities hereunder, provided that such activities are consistent with the express terms of this Agreement or the decisions of the Executive Sponsors within the scope of their authority specified herein&#59; and (b) keep the other Party informed as to the progress of such activities as reasonably requested by the other Party and as otherwise determined by the Executive Sponsors.  Without limiting the foregoing, (i) the Executive Sponsor of each Party shall promptly notify the Executive Sponsor of the other Party after becoming aware of circumstances that are reasonably likely to result in a delay in achieving a Product Deadline, achieving Phase Gate IV, or providing a Verily Service (as the case may be)&#59; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3.2&#160;&#160;&#160;&#160;The Parties&#8217; Technical Leads shall discuss use of Third Party Software or Software developed &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outside Software</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) as proposed to be incorporated into or relied on by any Assigned Software, in advance of delivery of such Assigned Software.  If such use of Outside Software adversely impacts DexCom&#8217;s IP rights in such Assigned Software or the licensing terms for such Outside Software would impose restrictions or obligations on DexCom as a result of such use, then Verily will not use such Outside Software in or with the Assigned Software without first obtaining approval from DexCom, such approval not to be unreasonably withheld.  For clarity, DexCom&#8217;s approval of a whitelisted open source license constitutes an approval of the use of any Outside Software under such whitelisted open source license for purposes of the foregoing.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 3.<br>DEVELOPMENT&#59; DILIGENCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to oversight and review of the Executive Sponsors, Verily and DexCom shall conduct a program to Develop the Second Product and, at DexCom&#8217;s option in accordance with Section 3.1.1, the Third Product, in each case, on a collaborative basis and in accordance with the &#91;***&#93; (the &#8220;&#91;***&#93;&#8221;).  Each Party shall use &#91;***&#93;.  In addition, Verily shall, at its own cost, use &#91;***&#93;, until Verily&#8217;s Development Completion of such Verily Services or the end date specified for such Verily Services &#91;***&#93;, whichever is earlier.  In accordance with Section 8.11, each Party will bear its own costs in performing its obligations &#91;***&#93; except as otherwise expressly provided herein or otherwise agreed by the&#160;Parties.  Notwithstanding anything to the contrary in this Agreement, as of the Effective Date, neither Party shall have any Development, Commercialization, support, manufacturing, or other performance obligations with respect to the First Product or otherwise &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Third Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Commencing on the Effective Date, DexCom shall cooperate with Verily in good faith, and shall make its personnel available for discussion with Verily upon Verily&#8217;s reasonable request, for purposes of evaluating and drafting Third Product requirements.  &#91;***&#93;.  The Parties shall &#91;***&#93;.  Product deadlines in the Third Product Supplement shall be deemed Product Deadlines under this Agreement.  Notwithstanding the foregoing, the Parties acknowledge and agree that (i) &#91;***&#93;, (ii) &#91;***&#93;.  In the event the Parties &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Development of the Future Products shall be carried out in accordance &#91;***&#93;, which may be updated or amended as set forth in Section 3.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Content &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The &#91;***&#93; will set forth the Development activities to be undertaken by each Party with respect to the Future Products, including&#58; (1) up to date Specifications for the Second Product and, if applicable, Third Product or any Additional Product, (2) each Party&#8217;s Product Development Obligations, (3) the Verily Services, (4) the acceptance criteria for the deliverables contemplated in the &#91;***&#93; and the Verily Services, and (5) the party responsible for performing each obligation and the deadline for such performance, consistent with the Product Development Deadlines.  &#91;***&#93; will include the &#91;***&#93;.  &#91;***&#93; will at all times contain terms that reflect the use of Commercially Reasonable Efforts to Develop the Second Product and, if applicable, Third Product or any Additional Product, provide the Verily Services and obtain Marketing Approval for the Second Product and, if applicable, Third Product or any Additional Product, in a timely manner&#59; provided that no action shall be required to be taken with respect to the Third Product or any Additional Product unless the Parties agree on a final Third Product Supplement in accordance with Section 3.1.1, or such Additional Product in accordance with Section 4.4, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Updates or Amendments &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;shall be reviewed by the Executive Sponsors on a quarterly basis (or more frequently if appropriate).  The Technical Leads shall be responsible for proposing updates and&#47;or amendments &#91;***&#93; for approval.  The Executive Sponsors shall propose that their respective Party approve &#91;***&#93;, which will become effective and supersede &#91;***&#93; as of the date of such written approval signed by authorized signatories of the Parties.  In the event of a disagreement regarding a proposed update or amendment &#91;***&#93; that (a) cannot be resolved by the Executive Sponsors, and (b) will result in a delay (or is reasonably likely to result in a delay) of &#91;***&#93; or more in any material aspect &#91;***&#93;, the matter will be escalated to the Chief Executives.  If the Chief Executives are unable to reach an agreement to amend or update &#91;***&#93; within thirty (30) days, &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Verily Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Verily will provide to DexCom the &#91;***&#93;, in each case &#91;***&#93;, in accordance with this Agreement &#91;***&#93;.  As part of the Verily Services, Verily will provide to DexCom &#91;***&#93;, provided however, that, except for &#91;***&#93;, Verily shall not be obligated to provide such assistance with respect to &#91;***&#93; Competing Programs.  For the avoidance of doubt, &#91;***&#93; Verily Services do not include services in connection with &#91;***&#93;&#59; if the Parties wish to contract for such services, the Parties will do so, subject to mutual agreement, in a separate agreement or Statement of Work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Verily Additional Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Upon DexCom&#8217;s request in each case, the Parties will discuss in good faith entering into one or more Statement(s) of Work for the provision by Verily of services (other than the Verily Services) &#91;***&#93;.  Each such Statement of Work shall describe, among other things, Verily&#8217;s responsibilities, deliverables, and timelines, rights and obligations with respect to the services, as well as commercially reasonable fees payable by DexCom.  Neither Party shall have any obligation to enter into such Statement of Work, and the terms discussed by the Parties shall not be binding unless set forth in a writing signed by both Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DexCom Cooperation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  At Verily&#8217;s request, DexCom will promptly provide Verily with access and any licenses to any DexCom Software as reasonably necessary (a) to provide the Verily Services, (b) to facilitate interoperation of the Products with the Verily Platform, and (c) to fulfill Verily obligations &#91;***&#93;,&#160;provided that Verily agrees not to use, copy or distribute DexCom Software, or disclose DexCom Software or related DexCom IP to Third Parties except as approved by DexCom in writing.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Resource Commitments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In conducting the activities assigned to it under the &#91;***&#93;, each Party agrees to use scientific, technical and other personnel who are sufficiently qualified and have the requisite skills to perform such activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product Deadlines</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DexCom Diligence Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Without limiting DexCom&#8217;s obligations under this Agreement, DexCom shall use Commercially Reasonable Efforts to achieve the Product Deadlines and perform its obligations &#91;***&#93; and &#91;***&#93;&#59; provided that if DexCom fails to achieve a Product Deadline within the timeframe specified due to any causes such as unforeseen technical delays, regulatory or clinical process or delays, or delays caused by Verily&#8217;s failure to perform the Verily Services or Verily&#8217;s failure to perform its obligations &#91;***&#93; or the Commercialization Plan, in each case to the extent beyond the reasonable control of DexCom, and despite DexCom&#8217;s Commercially Reasonable Efforts to achieve such Product Deadline, then DexCom shall not be deemed in default or breach of this Section 3.8.1 on account of such failure to achieve the Product Deadline, and the timeframe for achieving such Product Deadline will be extended by the time of the delay reasonably attributable to the causes that were beyond the reasonable control of DexCom.  Subject to this Section 3.8.1, if there is a delay in achieving a Product Deadline for which DexCom is responsible under this Section 3.8.1 and such delay exceeds &#91;***&#93; beyond the later of (a) the applicable Product Deadline and (b) the deadline mutually agreed upon by the Executive Sponsors in a modification to &#91;***&#93; as set forth in Section 3.3 (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Delay</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), DexCom will pay to Verily &#91;***&#93;, which payment shall be made on a quarterly basis, within thirty (30) days of the end of the applicable calendar quarter.  The Parties acknowledge and agree that the remedy set out in this Section 3.8.1 shall be Verily&#8217;s sole and exclusive remedy for a DexCom Delay and is a reasonable estimate of the damages suffered by Verily in the event of DexCom&#8217;s failure to meet a Product Deadline, and is not intended to be, nor will be construed as, a penalty.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Verily Diligence Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Without limiting Verily&#8217;s obligations under this Agreement, Verily shall use Commercially Reasonable Efforts to achieve the Product Deadlines and perform its obligations under the &#91;***&#93;, including the Verily Services, and Commercialization Plan&#59; provided that if Verily fails to achieve a Product Deadline within the timeframe specified due to any causes such as unforeseen technical delays, regulatory or clinical process or delays, or delays caused by DexCom&#8217;s failure to perform its obligations under the &#91;***&#93; or the Commercialization Plan, in each case to the extent beyond the reasonable control of Verily, and despite Verily&#8217;s Commercially Reasonable Efforts to achieve such Product Deadline, then Verily shall not be deemed in default or breach of this Section 3.8.2 on account of such failure to achieve the Product Deadline and the timeframe for achieving such Product Deadline will be extended by the time of the delay reasonably attributable to the causes that were beyond the reasonable control of Verily.  Subject to this Section 3.8.2, if there is a delay in achieving a Product Deadline for which Verily is responsible under this Section 3.8.2 and such delay exceeds &#91;***&#93; (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Delay</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), Verily will pay to DexCom &#91;***&#93;, which payment shall be made on a quarterly basis, within thirty (30) days of the end of the applicable calendar quarter.  The Parties acknowledge and agree that the remedies set out in this Section 3.8.2 (in addition to the adjustments to the &#91;***&#93; in Section 1.9) are DexCom&#8217;s sole and exclusive remedies for a Verily Delay, are a reasonable estimate of the damages suffered by DexCom in the event of Verily&#8217;s failure to meet a Product Deadline, and are not intended to be, nor will be construed as, a penalty.  In addition, with respect to the Second Product, in the event Verily fails to meet a Product Deadline by &#91;***&#93; or more but less than &#91;***&#93;, the Parties agree that if a Milestone Payment for the First Marketing Approval becomes due, such Milestone Payment for the first Marketing Approval of the Second Product shall be reduced by one divided by three hundred sixty five (1&#47;365</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of the total of such Milestone Payment for each day after the &#91;***&#93; period following the expiration of such timeframe specified in the &#91;***&#93; for such Verily Service.  In the event Verily fails to meet a Product Deadline by &#91;***&#93; or more, the Parties agree that DexCom shall not be obligated to (i) pay Verily any Milestone Payment for the first Marketing Approval of the Second Product, or (ii) Launch the Second Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Excused Delays</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In order for a Party to be excused from its payment obligations under Section 3.8.1 or 3.8.2 (as applicable) for a delay in achieving a Product Deadline, such Party (after becoming aware of circumstances likely to result in a delay in the performance of its obligations) must notify the other Party&#8217;s Executive Sponsor and (i) propose, timely implement, and adhere to a mitigation plan approved by the other Party in the exercise of its reasonable discretion or (ii) provide reasonable substantiating evidence that such delay was caused by the other Party or by a Force Majeure Event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Acceptance Process</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9.1&#160;&#160;&#160;&#160;Verily may, at any time, request DexCom&#8217;s acceptance that it has achieved Development Completion with respect to any deliverable, Product, or Verily Service, or any component thereof that is subject to a Product Development Deadline (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Completed Deliverables</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) by providing written or email notification to DexCom&#8217;s Technical Lead of such request (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acceptance Submission Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Verily shall provide DexCom&#8217;s Technical Lead with access to review and evaluate the Completed Deliverables.  The Technical Leads shall promptly review the Completed Deliverables and confer on whether the Completed Deliverables meet the applicable Specifications &#91;***&#93;, and shall, no later than ten (10) calendar days after the </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">date of the Acceptance Submission Notice, make a single (unanimous) or separate (split) recommendation(s) to the Executive Sponsors as to whether the Completed Deliverables should be accepted and be deemed to have achieved Development Completion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9.2&#160;&#160;&#160;&#160;If the Technical Leads unanimously agree to reject the Completed Deliverables, then the Presenting Party may rescind such Acceptance Submission Notice and resubmit such Completed Deliverable using the process set forth in Section 3.9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9.3&#160;&#160;&#160;&#160;If the Technical Leads make a single (unanimous) recommendation that a Party has achieved such Development Completion with respect to such Completed Deliverable, then, no later than twenty (20) calendar days after the date of the Acceptance Submission Notice, the Executive Sponsors shall review the recommendation(s) of the Technical Leads and determine whether to accept the Completed Deliverables as meeting the Specifications or reject the Completed Deliverables as not meeting the Specifications, which acceptance or rejection shall be made by a unanimous decision of the Executive Sponsors.  If the Executive Sponsors unanimously agree to accept a Completed Deliverable, then Verily will be deemed to have achieved Development Completion with respect to such Completed Deliverable.  If the Executive Sponsors unanimously agree to reject a Completed Deliverable, then the Completed Deliverable shall be referred back to the Technical Leads for review and remediation, and Verily may resubmit such Completed Deliverable using the process set forth in Section 3.9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9.4&#160;&#160;&#160;&#160;If the Technical Leads make a separate (split) recommendation regarding whether Verily has achieved Development Completion with respect to such Completed Deliverable, then, no later than twenty (20) calendar days after the date of the Acceptance Submission Notice, the Executive Sponsors shall review the recommendation(s) of the Technical Leads and attempt to resolve the differences in the recommendations.  If the Executive Sponsors are unable to reach a unanimous decision in such time, then the matter shall be referred to the Chief Executives of DexCom and Verily for resolution by good faith discussions for a period of at least fifteen (15) Business Days.  In the event that the Chief Executives are unable to reach agreement with respect to such matter within such fifteen (15) Business Days, then the dispute shall be resolved pursuant to Article 13, provided that each Party shall retain final decision-making authority with respect to the implementation of its own responsibilities under the &#91;***&#93; (so long as in compliance with this Agreement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reporting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Without limiting any other provisions of this Agreement, each Party shall keep the other reasonably informed through the Executive Sponsors as to the progress of its activities &#91;***&#93; or otherwise under this Article 3 and provide such reports and information with respect thereto as designated by the Executive Sponsors or as may be reasonably requested by the other Party.  Also, each Party shall promptly notify the other Party if it anticipates, or there are, material deviations from the &#91;***&#93; and shall discuss in good faith, and keep such other Party reasonably informed, as to any corrective actions that it intends to take, or is taking, to address such deviations.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 4.<br>SUPPLY&#59; ADDITIONAL PRODUCTS&#59; PROGRAMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amended and Restated Supply Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In order to enable DexCom to become the preferred provider of &#91;***&#93; to Onduo, the Existing Distribution Agreement will be amended and restated in its entirety by DexCom and Onduo concurrently with the execution of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Supply ROFN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Parties acknowledge and agree that Verily, whether by itself or in collaboration with others, is, or may be, working to develop one or more Verily Programs.  During the Term, if Verily, whether by itself or in collaboration with others, Develops a Verily Program &#91;***&#93;, Verily shall provide notice to DexCom of such Verily Program (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Program Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and DexCom shall have a first right of negotiation, as set forth in this Section 4.2, to be the preferred supplier &#91;***&#93;.  Such right of first negotiation shall be exercisable by DexCom by notice given to Verily within &#91;***&#93; of the date of the Verily Program Notice.  In the event that DexCom exercises its right of first negotiation pursuant to this Section 4.2, the Parties shall promptly begin to negotiate in good faith on an exclusive basis with respect to the foregoing.  If the Parties are unable to reach such agreement within &#91;***&#93; following DexCom&#8217;s receipt of the Verily Program Notice, Verily shall not be prevented by this Section 4.2 or Section 7.5 from purchasing the applicable &#91;***&#93; from a Third Party, provided that in no event shall Verily, for &#91;***&#93; from the earlier of DexCom&#8217;s decision to pass on the preferred supplier opportunity and the expiration of such &#91;***&#93;, enter into any agreement with such Third Party on terms that are more favorable to the Third Party than those last offered to DexCom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Products ROFN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  During the Term, if Verily desires to Develop any &#91;***&#93; other than the First Product, Second Product, and Third Product), then, before commencing &#91;***&#93;, Verily shall notify DexCom in writing and shall include with such notice &#91;***&#93; which shall set forth the Parties&#8217; respective roles and responsibilities with respect to the Development of such &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Proposed Additional Product Supplement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Thereafter, the Parties shall have &#91;***&#93; following the receipt of the Proposed Additional Product Supplement to negotiate, in good faith, a final Additional Product Supplement for the development of such &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Final </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Product Supplement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and, upon the Parties&#8217; mutual written agreement on the Final Additional Product Supplement, the &#91;***&#93; subject to the Final Additional Product Supplement shall become an Additional Product &#91;***&#93;.  Notwithstanding the foregoing, the Parties acknowledge and agree that (i) neither Party shall be obligated to assume any of the costs and expenses of the Development and Commercialization of any Additional Product, and (ii) the Development and Commercialization of the Second Product and, if applicable, Third Product, shall be the initial priority of the Collaboration, and the Development and Commercialization of any Additional Product shall not materially impact the Product Deadlines for the Second Product and, if applicable, Third Product, unless revised Product Deadlines for such Products are mutually agreed upon by the Parties.  If the Parties are unable to reach written agreement on the Final Additional Product Supplement within &#91;***&#93; following DexCom&#8217;s receipt of the Proposed Additional Product Supplement, Verily shall not be prevented by this Section 4.3 or Section 7.5 from independently developing the &#91;***&#93; that was the subject of the Final Additional Product Supplement (&#8220;&#91;***&#93;&#8221;),&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided, however,&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that (a) as between the Products and &#91;***&#93;, the Development and Commercialization of the Products shall continue to be Verily&#8217;s priority, and the development and commercialization, if any, of the &#91;***&#93; shall in no event impact the Product Deadlines for the Products, and (b) in no event shall Verily be granted or otherwise have any right to exploit any IP owned or Controlled by DexCom or its Affiliates or exclusively licensed to DexCom hereunder (other than the Verily Licensed Patents), or use any of DexCom&#8217;s Confidential Information, whether to develop, manufacture and&#47;or commercialize the &#91;***&#93; or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Preferred Provider &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Verily will use &#91;***&#93; to facilitate discussions with Alphabet to enable DexCom to become the preferred provider of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 5.<br>COMMERCIALIZATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement and the oversight of the Executive Sponsors, as between the Parties, DexCom shall have the exclusive right to Commercialize the Products in &#91;***&#93; in the Territory.  DexCom shall, &#91;***&#93; be responsible for all Commercialization efforts for the Products in the Exclusive CGM Field in the Territory, including the &#91;***&#93; to support such Commercialization, in accordance with the Commercialization Plan.  Verily shall, &#91;***&#93; use Commercially Reasonable Efforts to assist with DexCom&#8217;s &#91;***&#93;&#59; provided that Verily shall have the right to approve or reject in writing any such assistance that exceeds a&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">de minimis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;effort or contribution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Commercialization of each Future Product will be carried out in accordance with a Commercialization Plan.  Each such Commercialization Plan will set forth&#58; (1) the timing for Launch of the applicable Products consistent with the Product Launch Deadlines, (2) the obligations required for the Commercialization of the applicable Products, and (3) the Party responsible for performing each obligation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Second Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom shall propose and submit to the Executive Sponsors an initial Commercialization Plan for the Second Product at least nine (9) months prior to the Product Deadline for Launch of such Product in the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Third Product and Additional Products</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  At least nine (9) months in advance of the Launch of the Third Product and each Additional Product, DexCom shall propose and submit to the Executive Sponsors an initial Commercialization Plan for such Product in the Territory.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Updates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Until such time as DexCom has paid to Verily all of the Milestone Payments set forth in Section 8.2.1, each Commercialization Plan will be updated at least annually.  DexCom shall provide each Commercialization Plan and any material modification or addition thereto to the Executive Sponsors for its review and comment.  The Parties acknowledge that the comments of the Executive Sponsors with respect to any Commercialization Plan and any material modification or addition thereto are &#91;***&#93; with respect thereto.  For the avoidance of doubt, the Commercialization Plan and any updates thereto shall not amend or modify the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Diligence Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom shall use Commercially Reasonable Efforts to&#58; (a) Launch each Product by the applicable Product Launch Deadlines and (b) Commercialize Products so as to achieve each of the Milestone Events set forth in Section 8.2.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership of Marks</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom will be responsible for the selection, registration, maintenance and defense of, and will solely own all right, title and interest in, all Trademarks (except the Verily Trademarks) for use in connection with the Commercialization of the Products, as well as all expenses associated therewith.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Branding of Products</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom will have the right to implement a branding strategy for the Products, as outlined in the Commercialization Plan&#59; provided, however, that if requested by Verily, and to the extent allowed by the applicable Regulatory Authority, DexCom will include on all labels, packaging, inserts and promotional materials for each Product a designation that each Product incorporates Verily technology, provided that such designation may be subordinate to any Trademark selected by DexCom for a Product and any Trademark used by DexCom&#59; provided that size and placement of the designation shall be consistent with DexCom&#8217;s practices with respect to other Third Party Trademarks.  Such designation will include at least one of the Verily Trademarks as agreed by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Verily Trademarks</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In advance of each separate use of a Verily Trademark for a Product, DexCom shall notify Verily in writing and obtain Verily&#8217; prior written approval on the final selection, placement, look and feel of the Verily Trademark.  DexCom recognizes the reputation of Verily as a provider of high quality products and services and agrees to continue to maintain, and to require its sublicensees to continue to maintain, the same high standard of quality for the Commercialization of the Products.  DexCom will not, without Verily&#8217;s prior written consent, use any other Trademarks of Verily, or Trademarks confusingly similar thereto, in connection with its marketing or promotion of the Products.  DexCom acknowledges that it obtains no ownership interest in, or to, the Verily Trademarks under this Agreement.  DexCom will at any time, whether during or after the Term, execute any documents that are reasonably required by Verily to confirm Verily&#8217;s ownership of the Verily Trademarks.  DexCom agrees that it will do nothing inconsistent with Verily&#8217;s ownership of the Verily Trademarks.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reporting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Without limiting any other provisions of this Agreement, until such time as DexCom has paid to Verily all of the Milestone Payments set forth in Section 8.2.1, DexCom shall keep Verily reasonably informed through the Executive Sponsors as to the progress of its activities with respect to the Commercialization of Products or otherwise under this Article 5 and provide Product sales forecasts, Total Product Revenue estimates, and such other reports and information with respect to Commercialization of Products as designated by the Executive Sponsors or as may be reasonably requested by Verily, except as prohibited by Law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 6.<br>REGULATORY MATTERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  As between the Parties, &#91;***&#93; shall, &#91;***&#93;, be the manufacturer of record with respect thereto and take the lead and be responsible for (in each case with respect to Products)&#58; (a) conducting any clinical trials or clinical studies required for any Regulatory Filings and&#47;or Regulatory Approvals&#59; (b) filing, obtaining and maintaining Regulatory Filings and Regulatory Approvals for Development, Manufacture and Commercialization of the Products in the Territory&#59; (c) communicating with Regulatory Authorities&#59; (d) preparing and submitting supplements, communications, annual reports, Adverse Event reports, manufacturing changes, supplier designations and all other Regulatory Filings&#59; and (e) all costs and expenses associated with the foregoing, except to the extent otherwise provided herein, and provided that &#91;***&#93; shall, at its own cost, provide to &#91;***&#93; any documentation or other assistance reasonably required to support the foregoing activities &#91;***&#93;.  &#91;***&#93; will keep &#91;***&#93; or its designee reasonably informed regarding the status and progress of such activity, including (i) providing &#91;***&#93; or its designee with advance notice of all meetings scheduled with a Regulatory Authority involving a Regulatory Filing&#59; and (ii) providing &#91;***&#93; a copy of each Regulatory Approval for each Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Safety Reporting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  With</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">respect to any Adverse Event, any safety monitoring and any obligation to report to any Regulatory Authority relating to any safety issue with respect to Products or any component thereof, &#91;***&#93; shall be responsible for, and shall establish (subject to the oversight and comment of the Executive Sponsors as described below) operating procedures to report to the appropriate Regulatory Authority(ies), all such matters in accordance with applicable Law.  Such activities and operating procedures by &#91;***&#93; shall include any measures necessary for &#91;***&#93; to fully comply with such Laws and, if necessary, allow &#91;***&#93; to comply with its requirements for Adverse Event reporting under applicable Laws.  Such activities and operating procedures, and any material revisions to them, shall be provided to the Executive Sponsors for review and comment.  To the extent requested by &#91;***&#93;, &#91;***&#93; shall provide &#91;***&#93; any information or regular updates on Adverse Events, safety monitoring and&#47;or any interaction with Regulatory Authorities relating to safety issues with respect to the Products or any component thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Quality Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Parties will enter into a mutually agreed-upon Quality Agreement in connection with the Commercialization Plan.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 7.<br>LICENSES AND EXCLUSIVITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Licenses to DexCom</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">License to Verily Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;As of the Original Effective Date, Verily hereby grants to DexCom, &#91;***&#93; under any Verily Collaboration IP and Verily&#8217;s interest in any Joint Collaboration IP (in each case other than Verily Software IP) to (either by itself or in collaboration with a Third Party) Develop, Manufacture and Commercialize &#91;***&#93;.  The Parties acknowledge and agree that the &#91;***&#93; nature of the license granted under this Section 7.1.1(a) shall not be construed to limit Verily&#8217;s or its Affiliates&#8217; ability to develop, manufacture or commercialize Software that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;As of the Original Effective Date, Verily hereby grants to DexCom, a &#91;***&#93; license under any Verily Software IP to (either by itself or in collaboration with a Third Party) Develop, Manufacture and Commercialize &#91;***&#93;&#59; provided that DexCom may not use any Software covered by Verily Software IP, which Software was delivered to DexCom by Verily &#91;***&#93; (or which constitutes a derivative work of the foregoing Software), to co-develop, co-brand or white-label with a Third Party a Competing Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Verily hereby grants to DexCom, a &#91;***&#93; license under any Verily Software IP covering or claiming the Assigned Software to use, reproduce, modify, distribute, publicly display and publicly perform and otherwise exploit such Assigned Software for any purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Licenses to Verily Background IP and for &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;As of the Original Effective Date, Verily hereby grants to DexCom, a &#91;***&#93; license, under any Verily Background IP (other than the Verily Licensed Patents) &#91;***&#93;.  For the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">avoidance of doubt, any Verily Background IP that covers, claims, is used in, or is used to make a &#91;***&#93; shall be deemed to be &#8220;necessary&#8221; for purposes of the foregoing license.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;As of the Original Effective Date, Verily hereby grants to DexCom, a &#91;***&#93; license, under any Verily Licensed Patents and other Verily Background IP and Verily Collaboration IP (including Verily Software IP) as necessary to Develop, Manufacture, or Commercialize &#91;***&#93; for purposes of Developing, Manufacturing and Commercializing &#91;***&#93;, to the extent that such &#91;***&#93; is commercialized (or, if not yet commercialized, designed) as part of a standalone &#91;***&#93;, regardless of whether (i) reimbursement is for the standalone &#91;***&#93; or for a bundle of products or services offered by a Third Party that includes the &#91;***&#93;, or (ii) DexCom re-sells &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standalone Product Limitation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  For the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">avoidance of doubt, any Verily Background IP that covers, claims, is used in, or is used to make &#91;***&#93; that is commercialized by DexCom as part of a standalone &#91;***&#93; shall be deemed to be &#8220;necessary&#8221; for purposes of the foregoing license.  A &#8220;&#91;***&#93;&#8221; means a medical device, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;As of the Original Effective Date, Verily hereby grants to DexCom, a &#91;***&#93; license, under any Verily Licensed Patents and other Verily Background IP covering or claiming the Assigned Software, in each case to use, reproduce, modify, distribute, publicly display and publicly perform and otherwise exploit the Assigned Software for any purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The licenses contained in Sections 7.1.1(b) and (c) and 7.1.2(a), (b) and (c) shall be sublicensable (through multiple tiers) in connection with the Development, Manufacturing and&#47;or Commercialization of any &#91;***&#93; (subject to the Standalone Product Limitation), and Assigned Software, as applicable, provided that (i) material DexCom Background IP and&#47;or &#91;***&#93; is included in such sublicense, and (ii) DexCom retains a material involvement in the Development, Manufacturing and&#47;or Commercialization of such &#91;***&#93;, as applicable, which sublicense shall not be effective until DexCom delivers to Verily an executed copy of any such sublicense agreement, provided that DexCom may reasonably redact from any such sublicense agreement any confidential information of DexCom or the applicable sublicensee, and further provided that upon such delivery to Verily, the sublicense will be deemed effective as of the date specified in the applicable sublicense agreement.  Delivery to Verily of a standard sublicense template used by DexCom with multiple customers, resellers, or distributors in the ordinary course of its business will be sufficient for purposes of the delivery condition set forth in the preceding sentence.  Without limiting the foregoing, the Parties will use good faith efforts to implement shared procedures to limit the administrative burdens associated with complying with the foregoing delivery obligation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">License to Verily Licensed Patents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  As of the Original Effective Date, Verily hereby grants to DexCom, an &#91;***&#93; license under the Verily Licensed Patents to (either by itself or in collaboration with a Third Party) Develop, Manufacture and Commercialize &#91;***&#93;.  The Parties acknowledge and agree that the &#91;***&#93; nature of the license granted under this Section 7.1.4 shall not be construed to limit Verily&#8217;s or its Affiliates&#8217; ability to develop, manufacture or commercialize Software &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Covenant Not to Sue for DexCom &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  For a period of &#91;***&#93; from the Effective Date, Verily on behalf of itself and its Affiliates, covenants that Verily and its Affiliates will not initiate or continue any </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">judicial or administrative proceeding (e.g., before the U.S.  International Trade Commission) anywhere in the world against DexCom, its Affiliates, or any of its or their customers or direct distributors, based upon any claim that the manufacture, use, sale, license, distribution, offer for sale, offer for license, import, export, or other exploitation of a DexCom&#160;&#91;***&#93; constitutes infringement or misappropriation (including direct, contributory or inducement of infringement) of any &#91;***&#93; Controlled by Verily as necessary to manufacture, use, distribute, sell, license, offer for sale, offer for license, import, export, or otherwise exploit such DexCom &#91;***&#93;.  For the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">avoidance of doubt, any such Patent rights or Verily Know-How that covers, claims, or is used in or to make a DexCom&#160;&#91;***&#93;&#160;shall be deemed to be &#8220;necessary&#8221; for purposes of the foregoing covenant.  &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; Commercialized by DexCom or (subject to Section 7.1.7) any of its Affiliates &#91;***&#93;.  This covenant is personal to DexCom, not transferable or assignable to a Third Party.  If DexCom or its Affiliates, customers, or direct distributors commences or participates in a legal proceeding in the same or similar technical subject matter covered under this covenant not to sue against Verily, its Affiliates, or Onduo LLC or its Affiliates, then Verily may, at its sole discretion, suspend or terminate the covenant not to sue provided under this Agreement upon providing written notice to DexCom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">License to Verily Trademarks</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to Section 5.4.3, Verily hereby grants to DexCom a &#91;***&#93; license to use the Verily Trademarks solely as provided for under Section 5.4 in connection with the Commercialization of Products.  The ownership and all goodwill accruing to the Verily Trademarks arising directly from use of the Verily Trademarks will vest in and inure to the benefit of Verily.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DexCom Affiliates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom shall have the right to exercise the licenses granted under Sections 7.1.1, 7.1.2, and 7.1.4 through its Affiliates as of the Effective Date, solely for as long as such entity remains an Affiliate of DexCom, and DexCom shall remain responsible for the compliance of such Affiliate with all terms of this Agreement.  Furthermore, DexCom shall have the right to exercise the licenses granted under Sections 7.1.1, 7.1.2 and 7.1.4 through its future Affiliates in connection with restructuring or tax matters, subject to Verily&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed.  For clarity, DexCom&#8217;s ability to grant sublicenses to future Affiliates under the licenses granted under Sections 7.1.1, 7.1.2 and 7.1.4 shall be subject to the terms set forth therein and in Section 7.1.3 with respect to Third Parties, excluding the condition set forth therein regarding delivery of an executed copy of the sublicense agreement to Verily.  Notwithstanding anything to the contrary in this Agreement, the non-transferable licenses in Section 7.1.2 and Section 7.1.4 may not be transferred to a Third Party or Affiliate in connection with a permitted assignment of this Agreement under Section 14.2 (unless such transfer is otherwise expressly authorized under the preceding provisions of this Section 7.1.7).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Licenses to Verily</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">License to Perform Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, DexCom hereby grants to Verily a &#91;***&#93; license under any DexCom IP, during the Term, solely to perform Verily&#8217;s service and development and commercialization obligations to DexCom under the &#91;***&#93;, Commercialization Plan, and&#47;or otherwise under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">License to &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom hereby grants to Verily a &#91;***&#93; license under (i) any &#91;***&#93; jointly developed by the Parties or solely developed by Verily, solely for use outside of the &#91;***&#93; and (ii) any &#91;***&#93; solely developed by DexCom in subject matter consisting of &#91;***&#93;, in each case under (i) and (ii) solely for use &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No Other Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Party acknowledges that the rights and licenses granted under this Article 7 and elsewhere in this Agreement are limited to the scope expressly granted.  Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party.  All rights with respect to Know-How, Patent, Trademarks or other IP rights that are not specifically granted herein are reserved to the owner thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Other Licenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  No license to Collaboration IP owned by Verily shall be granted by Verily or its Affiliates to &#91;***&#93; of the foregoing unless Verily (a) &#91;***&#93;, and (b) &#91;***&#93;.  Notwithstanding the foregoing, any license granted by &#91;***&#93;, or any subsidiary of the foregoing under the Collaboration IP shall be subject to the exclusive and non-exclusive rights granted by Verily to DexCom pursuant to this Agreement and the foregoing shall not be construed to allow or authorize any grant of a license under the Collaboration IP that is in conflict with any such exclusive or non-exclusive license granted to DexCom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  During the Term, Verily and DexCom will collaborate on &#91;***&#93; on the Development of the Products, and DexCom will have the &#91;***&#93;, in each case subject to Section 4.3 of this Agreement, and in accordance with the terms and conditions of this Agreement.  Subject to Section 4.3 of this Agreement, Verily and its Affiliates shall not, during the Term, Develop, Manufacture or Commercialize &#91;***&#93;, except as necessary to fulfill its obligations under this Agreement or to allow any &#91;***&#93;.  Subject to Section 4.3, during the Term, Verily and its Affiliates shall not &#91;***&#93; except (i) solely to the extent necessary to &#91;***&#93;, and&#47;or (ii) in an open source license accompanying distributable source code (for each case (i) and (ii), solely with respect to communication </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">software and&#47;or other similar software)&#160;hosted by or on behalf of Verily.  For clarity, &#91;***&#93; granted under this Section 7.5 shall not be construed &#91;***&#93;, provided that in no event shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; Supply</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Support for &#91;***&#93; Supply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Verily will use Commercially Reasonable Efforts to enter into an agreement with &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Suppliers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) (the two principal suppliers for &#91;***&#93;) on terms that would (a) allow DexCom, or a vendor identified by DexCom and reasonably acceptable to Verily, to have &#91;***&#93; and (b) specify &#91;***&#93;.  For clarity, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;To facilitate manufacturing of &#91;***&#93;, Verily will provide to DexCom &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; Application Engineer Support Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  During development of the &#91;***&#93;, Verily will use Commercially Reasonable Efforts to provide reasonable and customary application engineer support services relating to use of &#91;***&#93; in a Future Product.  This support will include providing updates to &#91;***&#93; as necessary and in response inquiries from the DexCom technical team.  This support obligation does not include design changes, new features, or integrations &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Support for &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;If DexCom reasonably believes that a Future Product unit has failed or has been returned due to a defect in &#91;***&#93;, then, upon DexCom&#8217;s reasonable request and delivery of the defective &#91;***&#93; to Verily, Verily will use Commercially Reasonable Efforts to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Verily&#8217;s Technical Lead will notify DexCom&#8217;s Technical Lead of the determination of any design or manufacturing defect in &#91;***&#93; pursuant to the foregoing section (which notice may be provided by email).  DexCom&#8217;s technical lead shall notify Verily if DexCom wishes for Verily to present a Defect Notification Plan (the date of such notice, the &#8220;Defect Notification Date&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;If such failure is determined to be due to a design defect, and DexCom demonstrates with reasonably detailed, objective evidence that such design defect is caused primarily by &#91;***&#93;, then, notwithstanding DexCom&#8217;s prior acceptance of such Deliverable pursuant to Section 3.9 of the Agreement, &#91;***&#93;.  All other services, and any services &#91;***&#93;, and any related capital expenditures, will be subject to a separate Statement of Work negotiated between the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;If, (a) by &#91;***&#93; Business Days after the Defect Notification Date, Verily does not deliver to DexCom a plan for addressing a design defect, or (b) by &#91;***&#93; days after the Defect Notification Date, the Parties are unable to reach terms on which Verily will provide design modifications to address a design defect in &#91;***&#93;, then such matter shall be referred to the Executive Sponsors for resolution.  If the Executive Sponsors are unable to reach resolution on commercially reasonable terms within &#91;***&#93; Business Days of such referral, then Verily will, at DexCom&#8217;s request, provide the &#91;***&#93; to DexCom for purposes of addressing design defects in &#91;***&#93;&#59; provided, however, that the foregoing obligation shall not apply if Verily offers commercially reasonable terms in good faith and DexCom does not accept such terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;On and after the third anniversary of Launch, Verily may, in lieu of providing any support for design defects in &#91;***&#93; for a Future Product, provide to DexCom (i) the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Services After Completion of Verily&#8217;s Deliverables</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  After completion of Verily&#8217;s Deliverables, any additional design or test changes requested by DexCom will be negotiated under a Statement of Work on terms to be mutually agreed upon by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; Pricing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Verily anticipates that if the Pricing Assumptions set forth below are satisfied, then the &#91;***&#93; for the Second Product will be available under the Supply Agreements at the following purchase prices (which prices reflect the cost per unit excluding taxes, duties, shipping, and other fees) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pricing Expectations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;For volume commitments greater than &#91;***&#93; units per year, the purchase price under the Supply Agreements is expected to be &#91;***&#93; per unit&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;For volume commitments greater than &#91;***&#93; units per year and less than &#91;***&#93; units per year, the purchase price under the Supply Agreements is expected to be &#91;***&#93; per unit&#59;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;No pricing commitment is provided for volume commitments below &#91;***&#93; units per year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;If, notwithstanding satisfaction of the Pricing Assumptions, the actual &#91;***&#93; cost upon completion of Phase Gate IV is higher than the Pricing Expectations (based on &#91;***&#93; through the Phase Gate IV completion date and a complete set of quoted supplier costs for a volume of &#91;***&#93;), then Verily shall pay to DexCom a fee of &#91;***&#93;, such fee not to exceed &#91;***&#93; in total.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;If the actual &#91;***&#93; cost upon completion of Phase Gate IV is lower than the Pricing Expectations (based on &#91;***&#93; through the Phase Gate IV completion date and a complete set of quoted supplier costs for a volume of &#91;***&#93; units purchased per year), then DexCom shall pay to Verily a fee of &#91;***&#93;, such fee not to exceed &#91;***&#93; in total.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;The fees set forth in this Section 7.6.5 are the Parties sole and exclusive remedies for any deviations from the Pricing Expectations.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 8.<br>PAYMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Second Upfront Fee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Parties acknowledge and agree that DexCom has paid to Verily the upfront fee set forth in Section 8.1 of the Original Agreement.  Within ten (10) Business Days following the Antitrust Clearance Date, in consideration of (a) Verily&#8217;s performance of its obligations under the Development Plan, (b) the licenses granted to DexCom under Section 7.1, and (c) the Parties&#8217; agreement to amend and restate the Original Agreement, DexCom shall pay a second upfront payment of $250 million (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Upfront Payment Amount</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), or, at DexCom&#8217;s election, an equivalent number of shares of DexCom Common Stock as determined by dividing the Upfront Payment Amount by the Initial VWAP (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Upfront Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  The Upfront Payment Amount shall be paid as follows, at the direction of Verily&#58; (1) $15 million (or six percent (6%) of Upfront Shares, which shall be &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Upfront Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), to Verily and (2) $235 million (or ninety four percent (94%) of Upfront Shares) to Onduo and shall be issued pursuant to the Stock Purchase Agreement (as defined below)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Upfront Payment Amount (or the Upfront Shares in lieu of the Upfront Payment Amount, if applicable) shall be non-refundable and shall not be creditable.  The Parties acknowledge and agree that the $15 million paid to Verily or Verily Upfront Shares issued directly to Verily under this Section 8.1 are attributable to a buyout of the First Product milestone described in Section 8.2.1 of the Original Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Milestones</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to DexCom&#8217;s right to pay in cash pursuant to and subject to the calculation methodology set forth in Section 8.2.2, DexCom shall pay the DexCom Common Stock as set forth in the following table (each such payment, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Milestone Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) upon the first achievement of the corresponding milestone event for the applicable Product (each such event, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Milestone Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), it being understood that, at Verily&#8217;s direction, part of such Milestone Payment shall be paid to Onduo, as set forth below&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.202%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Milestone Event</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Milestone Payment</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The earlier of (i) &#91;***&#93; or (ii) &#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Common Stock equal to $100 million divided by the Initial VWAP (half issued to Verily (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Milestone Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) half issued to Onduo)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First time Total Product Revenue exceeds &#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Common Stock equal to $125 million divided by the Initial VWAP, issued to Onduo</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First time Total Product Revenue exceeds &#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Common Stock equal to $50 million divided by the Initial VWAP, issued to Onduo</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties acknowledge and agree that the Verily Milestone Shares issued directly to Verily, or the equivalent amount in cash upon DexCom&#8217;s election to pay in cash subject to the calculation methodology set forth in </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.2.2, under this Section 8.2.1 are attributable to a milestone buyout of the Second Product milestone described in Section 8.2.1 of the Original Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2.2&#160;&#160;&#160;&#160;For clarity, it is understood that each Milestone Payment shall be payable only once upon the first achievement of the applicable Milestone Event and, if paid in DexCom Common Stock, shall be issued pursuant to the Stock Purchase Agreement.  At DexCom&#8217;s option, DexCom may pay cash to Verily and Onduo in lieu of delivering any DexCom Common Stock required to be paid pursuant to Section 8.2.1, which cash payment amount shall be the applicable number of shares of DexCom Common Stock set forth in Section 8.2.1 multiplied by Milestone Date VWAP for such Milestone Event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Incentive Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  With respect to the Second Product, if Verily completes its Product Development Obligations, as determined by the Parties in accordance with Section 3.9 at least &#91;***&#93; prior to Verily&#8217;s Product Development Deadline (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incentive Milestone Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), then Verily shall be entitled to receive an incentive payment of &#91;***&#93;.  The date on which Verily will be deemed to have completed its Product Development Obligations will be the date on which Verily last submitted for acceptance or approval (pursuant to Section 3.9) the Product Development Obligations that were ultimately approved or accepted pursuant to Section 3.9 without an intervening notice of rejection from DexCom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Terms</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Milestone Payments set forth in this Section 8.2 shall each be payable in, at DexCom&#8217;s sole election, cash or in shares of DexCom Common Stock, and due to Verily or Onduo, as applicable, within thirty (30) days of the achievement of the corresponding Milestone Event or completion of the Product Development Obligations, as applicable, except to the extent set forth in the Stock Purchase Agreement (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom agrees to promptly notify Verily of its achievement of each Milestone Event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No Royalties, Milestones or Other Amounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except for the amounts payable to Verily by DexCom under Sections 8.1 and 8.2 above, no other amounts shall be payable to Verily in connection with the First Product, Second Product, Third Product, any Additional Product, or the Verily Services.  For clarity, the foregoing payments replace in their entirety any and all payment obligations of DexCom under the Original Agreement, including any and all royalty and&#47;or milestone payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">First Product Purchase</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Verily agrees to purchase &#91;***&#93; units of First Product &#91;***&#93;, and prepay for that Product within 14 days after &#91;***&#93;, where the prices shall be no higher than &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Terms</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All cash payments due under this Agreement shall be made by bank wire transfer in immediately available funds to an account designated by the receiving Party.  All payments hereunder shall be made in the legal currency of the United States of America, and all references to &#8220;$&#8221; or &#8220;Dollars&#8221; shall refer to United States dollars.  Except as otherwise provided herein, all payments due to a Party hereunder shall be due and payable within thirty (30) days of achievement of the applicable milestone event as set forth herein, subject to receipt of a proper invoice from the other Party.  If any withholding taxes, levies or similar taxes is due with respect to such a payment, such amounts shall be payable by the paying Party to the applicable taxing authority, including any tax or withholding levied by a foreign taxing authority in respect of the payment or accrual of any product fee.  Each Party agrees to assist the other Party as reasonably requested by the other Party in claiming exemption from or otherwise reducing such deductions or withholdings under any taxation or similar agreement or treaty from time to time in force.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Purchase Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom shall issue any DexCom Common Stock to be issued to Verily or Onduo as described in this Agreement pursuant to the stock purchase agreement attached hereto as&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 8.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Purchase Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;that if DexCom is unable to deliver the shares under the Stock Purchase Agreement in accordance with the terms of the Stock Purchase Agreement, DexCom shall make the applicable payment in cash at the scheduled time for such Closing (as defined in the Stock Purchase Agreement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Until such time as DexCom has paid all of the Milestone Payments set forth in Section 8.2.1, DexCom shall provide to Verily, within forty-five (45) days of the end of each calendar quarter, a reasonably detailed report setting forth worldwide Total Product Revenue broken down by Product and territory, together with such substantiating information reasonably requested by Verily for purposes of confirming the accuracy of the Total Product Revenue calculation (which information may be redacted with respect to information unrelated to the calculation of Total Product Revenue).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Inspection of Records</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Section 8.8 shall be in effect until such time as DexCom has paid to Verily all of the Milestone Payments set forth in Section 8.2.1.  DexCom shall, and shall cause its Affiliates and Third Parties acting on their behalf or under their authority, to keep full and accurate books and records </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">regarding the sales of the First Product, Second Product, Third Product and any Additional Products and&#47;or Alternative Product.  DexCom shall permit Verily, by independent qualified public accountants engaged by Verily and reasonably acceptable to DexCom, to examine such books and records for the sole purposes of verifying the accuracy of the reports provided pursuant to Section 8.7.  Such examination may be conducted at any reasonable time, but not later than three (3) years following the rendering of any corresponding reports, accountings and payments pursuant to Section 8.7.  Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable prior written notice.  The records for any particular calendar quarter shall be subject to no more than one inspection.  The accountant shall be obligated to execute a reasonable confidentiality agreement prior to commencing any such inspection.  Any inspection conducted under this Section 8.8 shall be at the expense of Verily, unless such inspection reveals that a Milestone Event had been achieved and DexCom did not provide the applicable notice to Verily pursuant to Section 8.2.5 in which case such inspection shall be at the expense of DexCom.  Any underpayment shall be paid within fifteen (15) Business Days with interest on the underpayment at the rate specified in Section 8.9 from the date such payment was originally due&#59; and any overpayment may be credited against future payments hereunder without interest or if there will be no future payments by DexCom, then reimbursed within fifteen (15) Business Days.  Any disputes arising under this Section 8.8 regarding any discrepancy identified by the accountant shall be subject to resolution under Article 13.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Late Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any payments or portions thereof due hereunder which are not paid when due shall bear interest at the rate of one and a half percent (1.5%) per month from the payment due date until paid in full.  This Section 8.9 shall in no way limit any other remedies available to either Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Currency Conversion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  With respect to sales invoiced and received in a currency other than U.S. Dollars, such sales shall be converted into the U.S. Dollar equivalent in accordance with DexCom&#8217;s standard practices used in preparing its audited financial statements for the applicable calendar quarter and DexCom shall provide Verily the basis for such conversion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Collaboration Costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except as otherwise expressly provided herein or otherwise agreed by the Parties, each Party shall bear all of its own costs and costs of any Third Party acting on its behalf in carrying out those activities assigned to it under the Collaboration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Splits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The number of shares of DexCom Common Stock issuable hereunder shall be adjusted for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event with respect to DexCom Common Stock after the date of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 9.<br>INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DexCom Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  As between the Parties, DexCom shall solely own all right, title and interest to any and all&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Collaboration IP that is &#91;***&#93;, whether developed solely by a Party or jointly by the Parties.  For purposes of clarity, DexCom shall own any &#91;***&#93; in the First Product, Second Product, Third Product and&#47;or any Additional Product (in each case, whether such Products are Launched or not)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Collaboration IP that is copyright in or that is Assigned Software.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Collaboration IP that is DexCom Other Collaboration IP.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The foregoing under (a), (b) and (c), collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to Section 9.1.4, to the extent Verily and&#47;or its Affiliates has or acquires any right, title or interest (including any IP) in or to any DexCom Collaboration IP, Verily shall assign, and does hereby assign to DexCom (and shall cause its Affiliates to assign), any such right, title and&#47;or interest (including any IP).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Verily Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  As between the Parties, Verily shall solely own all right, title and interest to any and all Verily Collaboration IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Collaboration IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All right, title and interest to any and all Joint Collaboration IP shall be jointly owned by DexCom and Verily.  Each Party shall assign, and does hereby assign to the other Party an undivided joint interest in the Joint Collaboration IP.  Subject to the licenses and other rights or exclusivities granted to the other Party herein (including in Article 7), (i) each Party reserves the right to use, </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">practice or otherwise exploit its solely owned Collaboration IP (DexCom Collaboration IP with respect to DexCom and Verily Collaboration IP with respect to Verily) and the Joint Collaboration IP&#59; and (ii) neither Party shall have any obligation to account to the other Party for profits, or to obtain any approval of the other Party to license, assign, enforce (subject to Section 9.5) or otherwise exploit any Joint Collaboration IP or intellectual property with respect thereto, by reason of joint ownership thereof, and each Party hereby waives any right it may have under the applicable Law of any jurisdiction to require any such approval or accounting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Retained Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding Section 9.1.1, Verily shall have no obligation to assign to DexCom any Know-How developed by Verily and included in DexCom Collaboration IP, except to the extent such Know-How (i) consists of subject matter that is patentable, copyrightable or otherwise registrable, or is otherwise claimed or included in a Patent, copyright registration or other statutory registration owned by DexCom under Section 9.1.1 (it being understood that the IP assigned to DexCom under Section 9.1.1 includes the right to seek patent, copyright or any other available statutory protection) or (ii) is expressly identified as DexCom-owned Know-How in &#91;***&#93;.  Any Know-How developed by Verily and included in DexCom Collaboration IP, which Know-How is not assigned to DexCom under this Section 9.1.4 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Retained Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall be deemed part of Verily Collaboration IP and, without limiting the foregoing, shall be licensed to DexCom under Section 7.1.1(a) and 7.1.2(b) and subject to use and disclosure restrictions in Section 11.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1.5&#160;&#160;&#160;&#160;Each Party shall disclose under the coordination of the Executive Sponsors to the other Party all Collaboration IP first conceived in the course of its performance of the &#91;***&#93; (or in the course of the Parties&#8217; activities &#91;***&#93;, to the extent not disclosed previously) or required for the other Party to perform the activities assigned to it &#91;***&#93;, and the Parties shall work in good faith, together with their respective counsel, to jointly identify respective lists of &#91;***&#93;, Verily Software IP, or other Collaboration IP.  Notwithstanding anything to the contrary, DexCom will have no obligation to share information with Verily regarding &#91;***&#93; and Verily will have no obligation to share information with DexCom regarding patenting Verily Software IP.  The Parties will form a Patent Review Committee with equal representation.  The composition, rules, and roles of the Patent Review Committee shall be defined under the Patent Committee Rules, which have been exchanged between the Parties in as of the Effective Date can be amended by consensus of the Patent Review Committee from time to time without amending this Agreement.  If there is a conflict between the Patent Committee Rules and the Agreement, the Agreement shall govern.  The representative(s) of each Party in the Patent Review Committee will consult with each other on patent claiming strategy for the Collaboration Patents in furtherance of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1.6&#160;&#160;&#160;&#160;The Parties acknowledge and agree that (i) DexCom has developed and will continue to develop &#91;***&#93; other than the Products outside the scope of the Collaboration, and (ii) to the extent DexCom uses in the Collaboration components or other technology from such &#91;***&#93;, in no event shall such components or technology be deemed part of Joint Collaboration IP or licensed to Verily other than as expressly set forth in Section 7.2.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Research Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties hereby acknowledge that this Agreement qualifies as a &#8220;joint research agreement&#8221; as defined in 35 U.S.C.  &#167; 100(h) and agree that the Parties will cooperate to take advantage of the &#8220;joint research agreement&#8221; provisions of 35 U.S.C.  &#167; 102(c), including by the filing of a terminal disclaimer as provided for in Manual of Patent Examining Procedure Section 717.02(c), if reasonably prudent or necessary during the filing and&#47;or prosecution of a patent application that is subject to a license grant or assignment under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Prosecution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Verily Patents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  As between the Parties, Verily shall have the right to control the Prosecution and Maintenance of the Verily Licensed Patents and Joint Collaboration Patents with at least one Verily inventor using counsel of its choice.  Verily agrees to&#58; (a) keep DexCom reasonably informed with respect to such activities&#59; and (b) consult in good faith with DexCom regarding such matters, including notice prior to the abandonment of any claims thereof covering the Products and in the &#91;***&#93;.  If Verily does not want to Prosecute and Maintain any of the Joint Collaboration Patents, then Verily shall give DexCom sufficient notice (i.e. in order to avoid any adverse events such as missing a filing deadline) and DexCom shall have the right to control the Prosecution and Maintenance of such Joint Collaboration Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DexCom Patents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  As between the Parties, DexCom shall have the right to control the Prosecution and Maintenance of the DexCom Collaboration Patents and Joint Collaboration Patents without any Verily inventors using counsel of its choice.  DexCom agrees to&#58; (i) keep Verily reasonably informed with respect to such activities&#59; and (ii) consult in good faith with Verily regarding such matters, including notice prior the abandonment of any claims thereof covering the Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Filing Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Party agrees to give notice to the other Party at least four weeks prior to filing of any new patent application that constitutes Collaboration IP and highlight any proposed inclusion of the other Party&#8217;s Confidential Information in such new patent application.  Such Party will consult with the </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other Party in good faith to resolve any objections to inventorship (under applicable law) and&#47;or content of the patent application.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Defense of Third Party Infringement Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  During the Term, if any Product that is Commercialized by DexCom or its Affiliates becomes the subject of a Third Party&#8217;s claim or assertion of infringement of a Patent relating to the manufacture, use, sale, offer for sale or importation of such Product, the Party first having notice of the claim or assertion shall promptly notify the other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action.  Except as provided in Section 11.4, or by separate written agreement of the Parties, each Party shall have the right to defend itself against a suit that names it as a defendant (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defending Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Except as provided in Section 11.4, neither Party shall enter into any settlement of any claim described in this Section 9.4 that adversely affects the other Party&#8217;s rights or interests without such other Party&#8217;s written consent, which consent shall not be unreasonably conditioned, withheld or delayed.  In any event, the other Party shall reasonably assist the Defending Party and cooperate in any such litigation at the Defending Party&#8217;s request and expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to the provisions of this Section 9.5 and during the Term, in the event that either Party reasonably believes that any Verily Licensed Patent (a) is being infringed by a Third Party or (b) is or will become subject to a declaratory judgment action arising from such infringement, in each case, (a) and (b), which infringement arises from the manufacture, sale, use or import of a &#91;***&#93; in the Territory (an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infringing Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) such Party shall promptly notify the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcement in the &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  During the Term, DexCom shall have the initial right (but not the obligation), at its expense, to enforce the Verily Licensed Patents in the &#91;***&#93; or to defend any declaratory judgment action with respect thereto in the Territory (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enforcement Action</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Prior to the commencement of any activity by DexCom with respect to an Enforcement Action, (a) DexCom shall provide thirty (30) days advance written notice to Verily and (b) if requested by Verily, DexCom shall consult in good faith with respect to such Enforcement Action and consider in good faith Verily&#8217;s input, including to prevent any Verily Licensed Patent to be subject to undue risk of invalidation.  DexCom agrees not to settle any Enforcement Action, or intentionally make any admissions or assert any position in such Enforcement Action, in a manner that would materially adversely affect the validity, enforceability or scope of any Verily Licensed Patent in or outside the Territory, without the prior written consent of Verily, which shall not be unreasonably withheld, conditioned or delayed.  In the event that DexCom or its designee fails to commence or defend an Enforcement Action with respect to Infringing Products in the Territory within &#91;***&#93; of a request by Verily to do so (or such shorter period as is necessary to bring and maintain such action), Verily or its designee may commence an Enforcement Action with respect to such Infringing Products at its own expense.  In such case, Verily agrees not to settle any Enforcement Action, or intentionally make any admissions or assert any position in such Enforcement Action, in a manner that would materially adversely affect DexCom&#8217;s rights or interests in &#91;***&#93; in the Territory, without the prior written consent of DexCom, which shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcement Outside of the &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  As between the Parties, Verily shall have the sole right (but not the obligation), at its expense, to enforce the Verily Licensed Patents outside of the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Party commencing, controlling or defending any action under Section 9.5.2 (such Party, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enforcing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall keep the other Party reasonably informed of the progress of any such Enforcement Action, and such other Party shall have the right to participate with counsel of its own choice at its own expense.  The non-Enforcing Party hereby gives the Enforcing Party the right to name the non- Enforcing Party in any Enforcement Action if required for standing.  In any event, the other Party shall reasonably cooperate with the Enforcing Party, including providing information and materials, at the Enforcing Party&#8217;s request and expense.  The Enforcing Party shall also have the right to control settlement of such Enforcement Action&#59;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, no settlement shall be entered into without the consent of the other Party, which consent not to be unreasonably withheld, conditioned or delayed, if such settlement would materially and adversely affect the interests of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Recoveries</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any recovery received as a result of any Enforcement Action to enforce a Patent pursuant to Section 9.5.2 shall be used first to reimburse the Parties for the costs and expenses (including attorneys&#8217; and professional fees) incurred in connection with such Enforcement Action (and not previously reimbursed), and the remainder of the recovery shall be shared (a) for any Enforcement Action in the &#91;***&#93; and (b) for any Enforcement Action &#91;***&#93;.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 10.<br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality&#59; Exceptions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except to the extent expressly authorized by this Agreement or otherwise agreed by the Parties in writing, the Parties agree that the receiving Party shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any confidential or proprietary information or materials or Know-How furnished to it by the other Party pursuant to this Agreement and the terms and conditions of this Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding the foregoing, Confidential Information shall not be deemed to include information or materials to the extent that it can be established by the receiving Party that such information or material&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.1&#160;&#160;&#160;&#160;was already known to or possessed by the receiving Party, other than under an obligation of confidentiality (except to the extent such obligation has expired or an exception is applicable under the relevant agreement pursuant to which such obligation established), at the time of disclosure&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.2&#160;&#160;&#160;&#160;was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.3&#160;&#160;&#160;&#160;became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.4&#160;&#160;&#160;&#160;was independently developed by the receiving Party without use of or reference to the disclosing Party&#8217;s Confidential Information as demonstrated by documented evidence prepared contemporaneously with such independent development&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.5&#160;&#160;&#160;&#160;was disclosed to the receiving Party on a non-confidential basis by a Third Party having the right to make such non-confidential disclosure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Authorized Use and Disclosure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Party may use and disclose Confidential Information of the other Party as follows&#58; (a) under appropriate confidentiality provisions substantially equivalent to those in this Agreement in connection with the performance of its obligations or exercise of rights granted to such Party in this Agreement&#59; (b) to the extent such disclosure is reasonably necessary for the Prosecution and Maintenance of Patents (including applications therefor) in accordance with Section 9.3, prosecuting or defending litigation, filing for and conducting preclinical or clinical trials, obtaining and maintaining Regulatory Approvals for Products&#59; (c) in communication with existing and potential acquirers, investors, strategic partners, licensees, distributors, consultants, advisors (including financial advisors, lawyers and accountants) and others on a need to know basis, in each case, under appropriate confidentiality provisions substantially equivalent to those of this Agreement&#59; (d) for the purposes of the performance of this Agreement and exercising any rights of a Party pursuant to this Agreement and in connection with the grant of any license pursuant to Article 7 of this Agreement&#59; or (e) to the extent mutually agreed to by the Parties.  Notwithstanding the foregoing, and without limiting Section 9.1.4, to the extent any Verily Retained Know-How is Confidential Information, (i) such Verily Retained Know-How shall not be used by Verily or its Affiliates in the &#91;***&#93; except to perform the activities contemplated in the Agreement, (ii) Verily and its Affiliates shall not disclose to any Third Party in the &#91;***&#93; any such Verily Retained Know-How without DexCom&#8217;s prior written consent except where such disclosure is for purposes of performing activities under this Agreement, and (iii) without limiting the foregoing, any disclosure of Verily Retained Know-How to any Third Party shall be under a use restriction limiting such use of such Verily Retained Know-How to be outside of &#91;***&#93;.  In addition, to the extent any Know-How is assigned to DexCom under this Agreement, such Know-How shall be protected as DexCom&#8217;s Confidential Information under this Article 7.  Furthermore, during the Term, to the extent any proprietary, non-public Know-How is included in Joint Collaboration IP (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joint Collaboration Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), then (i) such Joint Collaboration Know-How shall not be used by Verily or its Affiliates in &#91;***&#93; except to perform the activities contemplated in the Agreement, (ii) Verily and its Affiliates shall not disclose to any Third Party for use in &#91;***&#93; any such Joint Collaboration Know-How without DexCom&#8217;s prior written consent, and (iii) without limiting the foregoing, any disclosure of Joint Collaboration Know-How to any Third Party shall be under a use restriction limiting such use of such Joint Collaboration Know-How to be outside of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Methods Marking Requirement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any non-public algorithm or other method shared by a Party under this Agreement that is outside of the scope of &#91;***&#93; and is not marked or identified by such Party as confidential or proprietary will not be considered Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Required Disclosures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in this Agreement, each Party may make any disclosures required of it by applicable Law or the rules of a stock exchange upon which a Party&#8217;s capital stock is listed, provided that (a) the Party required to make such disclosure (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Required Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall notify the other Party in writing of the proposed content of the required disclosures at least five (5) Business Days prior to the date on which the disclosure is to be made, except with respect to the current report </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">on Form 8-K to be filed by DexCom immediately following the execution of this Agreement regarding its entry into this Agreement, and the non-Required Party shall be entitled to reasonably comment with respect to the form and content of such required disclosure, which the Required Party shall consider in good faith&#59; (b) if so requested by the non-Required Party in the case of disclosures required by applicable Law, the Required Party shall use reasonable efforts to obtain an order protecting to the maximum extent possible the confidentiality of the provisions of this Agreement and the non-Required Party&#8217;s Confidential Information as reasonably requested by the non-Required Party&#59; and (c) if the Parties are unable to agree on the form or content of any required disclosure, such disclosure shall be limited to the minimum required as determined by the Required Party in consultation with its legal counsel.  Without limiting the foregoing, the Required Party shall provide the non-Required Party with a draft of the proposed redactions to the provisions of this Agreement, together with exhibits or other attachments hereto, to be filed by Verily or DexCom with the Securities and Exchange Commission (or other applicable regulatory body) or as otherwise required by Law, and the non-Required Party shall be entitled to reasonably comment with respect to the content of the redactions, which the Required Party shall consider in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Agreements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Agreement supersedes (a) the Non-binding Term Sheet between DexCom and Verily exchanged by the Parties in August and September, 2018, (b) the Collaboration and License Agreement between DexCom and Google Life Sciences LLC, dated August 10, 2015, as amended, (c) the and Non-binding Term Sheet for Collaboration and License Agreement between DexCom and Google Inc.  dated June 29, 2015, and, (d) solely with regard to the subject matter of this Agreement and the information disclosed pursuant hereto, the Non-Disclosure Agreement dated April 6, 2015 between DexCom and Google Inc., acting on its behalf and on behalf of its affiliates (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prior Agreements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  All Confidential Information disclosed by a Party under the Prior Agreements shall be deemed Confidential Information of such disclosing Party under this Agreement and shall be subject to the terms of this Article 10.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Publications</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Party shall submit to the other Party any proposed publication or public disclosure containing clinical or scientific results for the Products at least thirty (30) days in advance to allow that Party to review such proposed publication or disclosure.  The reviewing Party will promptly review such proposed publication or disclosure and make any objections or comments that it may have thereto, and the Parties shall discuss the advantages and disadvantages of publishing or disclosing such results.  If the Parties are unable to agree on whether to publish or disclose the same, the matter shall be referred to the Executive Sponsors for review and comment.  In resolving whether to publish or disclose the same, DexCom shall consider the good faith comments of Verily with respect thereto.  This Section 10.6 shall not be deemed to limit the Parties&#8217; obligations under Section 10.1 above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Press Release</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither Party shall issue any press release or other public statement, whether oral or written, disclosing the existence of this Agreement, the terms hereof or any information relating to this Agreement without the prior written consent of the other Party.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 11.<br>REPRESENTATIONS, WARRANTIES AND COVENANTS&#59; INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General Representations and Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Party represents and warrants to the other that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1.1&#160;&#160;&#160;&#160;it is duly organized and validly existing under the Laws of the jurisdiction of its incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1.2&#160;&#160;&#160;&#160;it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1.3&#160;&#160;&#160;&#160;this Agreement is legally binding upon it and enforceable in accordance with its terms.  The execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material applicable Law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1.4&#160;&#160;&#160;&#160;except for the Permitted Encumbrances, it has not granted, and shall not grant during the Term, any right to any Third Party which would conflict with the IP rights granted to the other Party hereunder&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1.5&#160;&#160;&#160;&#160;it is not aware of any action, suit or inquiry or investigation instituted by any Person which questions or threatens the validity of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1.6&#160;&#160;&#160;&#160;with respect to Verily only,</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Verily, together with its Affiliates, is the sole owner of the &#91;***&#93; and the &#91;***&#93; and has the exclusive right to such Patents to grant the licenses granted to DexCom hereunder&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Verily will not assign or transfer any rights in the Verily Licensed Patents in a manner that would cause a license to be granted to a Third Party pursuant to &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;none of the agreements identified in&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1.63</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;grant any Third Party (i)&#160;any exclusive rights with respect to any of the Verily Licensed Patents in &#91;***&#93;, (ii) any right to Verily Know-How in &#91;***&#93;, (iii) any right to file applications for, prosecute, maintain, enforce or defend any of the Verily Licensed Patents in &#91;***&#93;, or (iv) rights necessary to Develop, Manufacture and Commercialize &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;without limiting the foregoing, Verily has not, prior to the Effective Date, and will not have, as of the Effective Date, (i) assigned to any Third Party any Verily IP for which Verily granted any license or other rights to DexCom under the Original Agreement, or (ii) otherwise granted to any Third Party any rights to such Verily IP that, in each case (i) and (ii), adversely affect Verily&#8217;s ability to grant rights to or in such Verily IP to the same extent that Verily granted such rights in the Original Agreement&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;it will conduct its obligations under &#91;***&#93; and Commercialization Plan, including the Development of Products thereunder, using its employees or contractors that are obligated to assign to Verily and&#47;or its Affiliates all rights in and to any Collaboration IP and associated intellectual property rights and to maintain in confidence all of the other Party&#8217;s Confidential Information, and will not use any employee of an Affiliate in the conduct of such &#91;***&#93; and Commercialization Plan unless such employee is under such obligations of assignment and confidentiality.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DexCom Antitrust Representation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom represents and warrants to Verily that DexCom, or if different its ultimate parent entity under the HSR Act, has determined that the value of the non-exempt assets it will acquire from Verily under this Agreement (including U.S.  patent rights), as determined under the HSR Act (including 16 C.F.R.  Section 801.10), is less than $84.4 million and has therefore concluded, taking into account the aggregation rules under the HSR Act, that the HSR Act&#8217;s size of transaction test will not be satisfied, with respect to the non-exempt assets DexCom will acquire under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Verily Service Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Verily covenants that the Verily Services provided by it hereunder will be provided by qualified professionals conforming to Verily&#8217;s standard practices (in no event less than industry standard practices) governing the design and development of application software of the same general nature and complexity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Disclaimer of Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  EXCEPT AS SET FORTH IN THIS ARTICLE 11, VERILY AND DEXCOM EXPRESSLY DISCLAIM ANY WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT (INCLUDING THE VERILY IP, VERILY BACKGROUND IP, JOINT COLLABORATION IP, OR COLLABORATION IP ASSIGNED TO DEXCOM FROM VERILY), INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  WITHOUT LIMITING EITHER PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER SECTION 11.4 BELOW, NEITHER PARTY SHALL BE LIABLE TO THE OTHER UNDER THIS AGREEMENT FOR ANY LOSS OF PROFITS, LOSS OF BUSINESS, INTERRUPTION OF BUSINESS, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND SUFFERED BY SUCH OTHER PARTY FOR BREACH HEREOF, WHETHER BASED ON CONTRACT OR TORT CLAIMS OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS&#59; PROVIDED, HOWEVER, THAT THE FOREGOING SHALL NOT APPLY TO ANY MATERIAL WILLFUL BREACH OF THIS AGREEMENT BY A PARTY OR A BREACH OF A PARTY&#8217;S CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 10.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by Verily</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Verily hereby agrees to defend, hold harmless and indemnify (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indemnify</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) DexCom and its Affiliates, and its and their agents, directors, officers and employees (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) from and against any liability or expense (including reasonable legal expenses and attorneys&#8217; fees) (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), resulting from suits, claims, actions and demands, in each case brought by a Third Party (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third-Party Claim</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) arising out of (a) a breach of any of Verily&#8217;s covenants, representations or warranties hereunder, (b) the gross negligence or willful misconduct or omission of Verily or its Affiliates under this Agreement, (c) actual or alleged infringement of the intellectual property rights of a Third Party by a Verily Service or deliverable of Verily under the Development Plan (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Deliverable</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), except to the extent that such infringement results from a modification, enhancement or improvement made or </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">implemented by DexCom to the Verily Deliverable, or combination of the Verily Deliverable with materials not furnished by Verily.  Verily&#8217;s obligation to Indemnify the DexCom Indemnitees pursuant to this Section 11.4.1 shall not apply to the extent that any such Losses arise from the gross negligence or intentional misconduct of any DexCom Indemnitee, arise from any material breach by DexCom of this Agreement&#59; or are Losses for which DexCom is obligated to Indemnify the Verily Indemnitees pursuant to Section 11.4.3.  Verily may, at Verily&#8217;s option, (i) obtain, at its expense, a license from such Third Party for the benefit of DexCom and its customers, and&#47;or (ii) replace or modify the deliverable in question so that it is no longer infringing but provides comparable functionality.  Verily&#8217;s obligation to indemnify under this Section 11.4.1 shall not extend to use of its deliverable or Verily Service after Verily has offered or implemented a technically reasonable non-infringing alternative design with comparable functionality.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by Verily for &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Verily hereby agrees to Indemnify the DexCom Indemnitees from and against any and all Losses resulting&#160;from a claim by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by DexCom</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  DexCom hereby agrees to Indemnify Verily and its Affiliates, and its and their agents, directors, officers and employees (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) from and against any and all Losses resulting from Third-Party Claims arising out of&#58; (a) a breach of any of DexCom&#8217;s covenants, representations or warranties hereunder, (b) the gross negligence or willful misconduct or omission of DexCom or its Affiliates under this Agreement, (c) actual or alleged infringement of the intellectual property rights of a Third Party by a deliverable of DexCom under the Development Plan (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DexCom Deliverable</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), except to the extent that such infringement results from a modification, enhancement or improvement made or implemented by Verily to the DexCom Deliverable, or combination of the DexCom Deliverable with materials not furnished by DexCom.  DexCom&#8217;s obligation to Indemnify the Verily Indemnitees pursuant to this Section 11.4.3 shall not apply to the extent that any such Losses arise from the gross negligence or intentional misconduct of any Verily Indemnitee, arise from any material breach by Verily of this Agreement or are Losses for which Verily is obligated to Indemnify the DexCom Indemnitees pursuant to Section 11.4.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Procedure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The indemnified Party shall provide the indemnifying Party with prompt notice of the Third-Party Claim or &#91;***&#93; giving rise to the indemnification obligation pursuant to this Section 11.4 and, to be eligible to be Indemnified hereunder, the exclusive ability to defend (with the reasonable cooperation of the indemnified Party) or settle any such claim&#59; provided, however, that the indemnifying Party shall not enter into any settlement that admits fault, wrongdoing or damages without the indemnified Party&#8217;s written consent, such consent not to be unreasonably withheld or delayed.  The indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Party shall obtain and maintain, during the term of this Agreement and for six (6) years thereafter, comprehensive general liability insurance, including products liability insurance and coverage for clinical trials.  Such insurance shall be with reputable and financially secure insurance carriers, or self-insurance in a form and at levels consistent with industry standards based upon such Party&#8217;s activities hereunder and indemnification obligations hereunder, and shall name the other Party as an additional insured.  Such liability insurance or self-insurance shall be maintained on an occurrence basis to provide such protection after expiration or termination of the policy itself or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 12.<br>TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Agreement shall become effective as of the Effective Date and continue in full force and effect, unless earlier terminated pursuant to the other provisions of this Article&#160;12, until December 31, 2028,&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;that upon achievement of the first revenue-related Milestone Event and the payment of the Milestone Payment related thereto (or corresponding cash amount calculated pursuant to Section 8.2.2) the term shall be extended until December 31, 2033 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination for Breach</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Either Party may terminate this Agreement in the event the other Party materially breaches this Agreement, and such material breach shall have continued for &#91;***&#93; days after written notice thereof was provided to the breaching Party by the other Party.  Any such termination shall become effective at the end of such &#91;***&#93; day period unless the breaching Party has cured any such material breach prior to the expiration of the &#91;***&#93; day period,&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, in the event that, following the Launch of the first Product, a good faith dispute arises with respect to the existence of any material breach of a Party&#8217;s obligations to use Commercially Reasonable Efforts to Develop, Manufacture, Launch, or Commercialize (which material breach, if existing, would give the other Party the right to terminate this Agreement as set forth herein), such termination right shall be tolled commencing on the date of receipt of written notice of such good faith dispute until such time as the dispute is resolved pursuant to Article 13.  If this Agreement is terminated following a tolling period as described in this Section 12.2, then, for purposes of determining what constitutes Verily Background IP, the &#8220;Term&#8221; shall be deemed to end on the date on which such termination would otherwise have been effective in the absence of such tolling.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General Effects of Expiration or Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Expiration or termination of this Agreement for any reason shall not release either Party of any obligation or liability which, at the time of such expiration or termination, has already accrued to the other Party or which is attributable to a period prior to such expiration or termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Exclusive Remedy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, termination of this Agreement by a Party shall be without prejudice to other remedies such Party may have at Law or equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Licenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Section 7.1 (Licenses to DexCom) (except for Section 7.1.6 (License to Verily Trademarks))</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and Section 7.2.2 (License to &#91;***&#93;) shall survive any expiration or termination of Agreement,&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided however,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;that&#58; (i) each of the licenses granted to DexCom pursuant to Section 7.1.1(a) and Section 7.1.4 shall (upon such expiration or termination) become non-exclusive (but shall otherwise be subject to the terms set forth therein)&#59; and (ii) for clarity, Section 7.1.5 (Covenant Not to Sue for DexCom &#91;***&#93;) will not apply beyond the limited period specified therein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General Survival</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In addition to the surviving provisions identified in Section 12.3.3.  above, Article 1 (Definitions), Section 5.5 (Reporting), Section 7.3 (No Other Rights), Section 7.4 (Other Licenses), Article 8 (Payments) (except for Section 8.1 (Second Upfront Fee) unless such payment is due prior such termination or expiration and Section 8.2.3 (Incentive Payment) unless such payment is due before such termination or expiration, and provided that Section 8.7 (Reports) and Section 8.8 (Inspection of Records) survive only as long as DexCom or its Affiliates are Commercializing any Products), Section 9.1 (Ownership) (except for Section 9.1.5), Section 9.3 (Patent Prosecution), Section 9.5.3 (Enforcement Outside of &#91;***&#93;), Article 10 (Confidentiality) (except for the last sentence of 10.2 with respect to Joint Collaboration Know-How), Section 11.2 (Disclaimer of Warranties), Section 11.3 (Limitation of Liability), Section 11.4 (Indemnification), Section 11.5 (Insurance), Section 12.3 (General Effects of Expiration or Termination), Article 13 (Dispute Resolution), and Article 14 (Miscellaneous) shall survive expiration or termination of this Agreement for any reason,&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that&#58; (i) if this Agreement terminates for Verily&#8217;s breach or bankruptcy, then in addition to the foregoing, Section 7.6 (&#91;***&#93; Supply) shall survive for 2 years after such termination&#59; and (ii) for clarity, Section 11.5 (Insurance) will not apply beyond the limited period specified therein.  Except as otherwise provided in this Section 12.3.4, all rights and obligations of the Parties under this Agreement shall terminate upon expiration or termination of this Agreement for any reason.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 13.<br>DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Parties agree that any dispute, controversy or claim arising from or in connection with (a) the interpretation, enforcement, termination or invalidity of this Agreement, (b) the failure of the Executive Sponsors to reach unanimous agreement on any issue within their authority under this Agreement, (c) any alleged failure to perform, or breach of, this Agreement, (d) or claim relating to the ownership, scope, validity, enforceability or infringement of any Patent rights covering the manufacture, use or sale of any Product or of any Trademark rights relating to any Product, or (e) any issue relating to the interpretation or application of this Agreement (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), shall be first referred to the Chief Executives of DexCom and Verily for resolution in accordance with Section 2.1.2.  In the event that the Chief Executives are unable to reach agreement with respect to such Dispute in accordance with Section 2.1.2, such Dispute shall be resolved through the procedures set forth in this Article 13.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Jurisdiction&#59; Venue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Other than those Disputes resolved as described in Section 13.3 all Disputes shall be subject to the exclusive jurisdiction and venue of the federal courts within the State of California.  Each Party hereto waives and covenants not to assert or plead any objection that such Party might otherwise have to such jurisdiction and venue.  Except as set forth herein, each Party hereto hereby agrees not to commence any legal proceedings relating to or arising out of this Agreement or the transactions contemplated hereby in any jurisdiction or courts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Executive Sponsor Disputes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Disputes as to matters within the authority of the Executive Sponsors will be resolved as set forth in Section 2.1.2 and shall not otherwise be subject to the provisions of this Article 13&#59; provided that any Dispute as to the application of such Section 2.1.2 shall be subject to the provisions of this Article 13.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Article 14.<br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Agreement and any dispute arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the Law of the State of California, without reference to conflicts of laws principles.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Agreement shall not be assignable by either Party to any Third Party without the written consent of the other Party and any such attempted assignment shall be void.  Notwithstanding the foregoing, either Party may assign this Agreement, without the written consent of the other Party, to an Affiliate or to an entity that acquires all or substantially all of the business or assets of such Party to which this Agreement pertains (whether by merger, reorganization, acquisition, sale or otherwise), and agrees in writing to be bound by the terms and conditions of this Agreement.  No assignment or transfer of this Agreement shall be valid and effective unless and until the assignee&#47;transferee agrees in writing to be bound by the provisions of this Agreement.  The terms and conditions of this Agreement shall be binding on and inure to the benefit of the permitted successors and assigns of the Parties.  Notwithstanding Section 8.5, in the event any withholding or similar tax is levied by or due to an assignment of this Agreement or any obligation by a Party to an Affiliate or any Third Party, then such Party (itself or its successor) shall bear the full cost of such tax.  Except as expressly provided in this Section 14.2, any attempted assignment or transfer of this Agreement shall be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any notice, request, delivery, approval or consent required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted via electronic mail or by express courier service (signature required) or five (5) days after it was sent by registered letter, return receipt requested (or its equivalent), provided that no postal strike or other disruption is then in effect or comes into effect within two (2) days after such mailing, to the Party to which it is directed at its physical or email address shown below or such other address.  Notices sent by electronic means shall be effective upon confirmation of receipt, notices sent by mail or overnight delivery service shall be effective upon receipt, and notices given personally shall be effective when delivered.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to Verily, addressed to&#58;&#160;&#160;&#160;&#160;Verily Life Sciences LLC</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 East Grand Avenue</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South San Francisco, CA 94080</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attention&#58; Andy Conrad</font></div><div style="margin-bottom:12pt;padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a copy to (which shall<br>not constitute notice)&#58; &#160;&#160;&#160;&#160;Verily Life Sciences LLC</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 East Grand Avenue</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South San Francisco, CA 94080</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attention&#58; General Counsel</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with a copy to &#91;***&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to DexCom, addressed to&#58;&#160;&#160;&#160;&#160;DexCom, Inc.</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6340 Sequence Drive</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, CA 92121</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attention&#58; Kevin Sayer,<br>President and Chief Executive Officer</font></div><div style="margin-bottom:12pt;padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a copy (which shall</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">not constitute notice) to&#58;&#160;&#160;&#160;&#160;Fenwick &#38; West LLP</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801 California Street</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mountain View, CA 94041</font></div><div style="padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attention&#58; Stefano Quintini and Michael Brown</font></div><div style="margin-bottom:12pt;padding-left:220.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither Party may waive or release any of its rights or interests in this Agreement except in writing.  The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition.  No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties as nearly as may be possible.  Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.  If a Party seeks to avoid a provision of this Agreement by asserting that such provision is invalid, illegal or otherwise unenforceable, such action shall be deemed to be a material breach of this Agreement.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except for the rights to indemnification provided for certain Third Parties as specified in Section 11.4 and as otherwise specified in this Section 14.6, all rights, benefits and remedies under this Agreement are solely intended for the benefit of DexCom and its Affiliates and Verily and its Affiliates, and except for such rights to indemnification expressly provided pursuant to Section 11.4, no Third Party shall have any rights whatsoever to (a) enforce any obligation contained in this Agreement (b) seek a benefit or remedy for any breach of this Agreement, or (c) take any other action relating to this Agreement under any legal theory, including, actions in contract, tort (including but not limited to, negligence, gross negligence and strict liability), or as a defense, setoff or counterclaim to any action or claim brought or made by either Party.  Notwithstanding the foregoing, Onduo shall be a Third Party beneficiary with respect to the obligations to make payments or transfer shares to Onduo under this Agreement, which payments shall be &#8220;Product Fee Payments&#8221; as referenced in the Contribution Agreement between Verily Life Sciences LLC and Onduo LLC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement&#47;Modification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Agreement, including its Exhibits, sets forth all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties and supersedes and terminates all prior agreements and understandings between the Parties including the Original Agreement and the Prior Agreements.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties.  All references to the Original Agreement in any other agreement or other document between the Parties that pre-dates the Effective Date shall, on and after the Effective Date, be deemed to refer to this Agreement (except to the extent, if any, that such interpretation would conflict with the terms of this Agreement as they refer or pertain to the Original Agreement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Relationship of the Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Parties agree that the relationship of Verily and DexCom established by this Agreement is that of independent contractors.  Furthermore, the Parties agree that this Agreement does not, is not intended to, and shall not be construed to, establish an employment, agency or any other relationship.  Except as may be specifically provided herein, neither Party shall have any right, power or authority, nor shall they represent themselves as having any authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other Party for any&#160;purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except with respect to payment of money, neither Party shall be liable to the other for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by earthquake, riot, civil commotion, war, terrorist acts, strike, flood, or governmental acts or restriction or other cause, in each case to the extent beyond the reasonable control of the respective Party (any of the foregoing, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  The Party affected by such force majeure will provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable.  If the performance of any such obligation under this Agreement is delayed owing to such a force majeure for any continuous period of more than &#91;***&#93; days, the Parties will consult with respect to an equitable solution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Laws&#47;Other</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary contained herein, all rights and obligations of Verily and DexCom are subject to prior compliance with, and each Party shall comply with, all applicable Laws, including obtaining all necessary approvals required by the applicable agencies of the governments of the United States and foreign jurisdictions.  In addition, each Party shall conduct its activities under the Collaboration in accordance with good scientific and business practices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together, shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy Matters</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bankruptcy Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined in Section 101 of the Bankruptcy Code.  The Parties agree that each Party may fully exercise all of its rights and elections under the Bankruptcy&#160;Code.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;The remainder of this page intentionally left blank&#59; the signature page follows.&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the Parties have executed this Agreement in duplicate originals by their duly authorized representatives as of the Effective Date, with effect as of Effective Date.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:394.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:106.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:106.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:106.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VERILY LIFE SCIENCES LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VERILY IRELAND LIMITED</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Andrew Conrad</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kristian Marthinsen</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew Conrad</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristian Marthinsen</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#47;19&#47;2018</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:139.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEXCOM, INC. </font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Quentin Blackford</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quentin Blackford</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#47;20&#47;2018</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">List of Exhibits</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 1.92 &#8211; Permitted Encumbrances</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 1.143 &#8211; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 1.144 &#8211; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 1.153 &#8211; &#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 1.92<br>PERMITTED ENCUMBRANCES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 1.143</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.202%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.202%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.202%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 1.144</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.202%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.202%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 1.153</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.202%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:38.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 8.6</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STOCK PURCHASE AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Previously Filed&#93;</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>6
<FILENAME>dxcm12312023ex191-procedur.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2bdf62ee734a4535b5add9feaaaee673_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEXCOM, INC.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Procedures and Guidelines Governing</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Trades by Company Personnel</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted by the Board of Directors</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">on March 11, 2005 and amended through February 27, 2023</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURPOSE</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is illegal for any employee, officer or director of DexCom, Inc. (collectively, with its subsidiaries, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to trade in the securities of the Company while in the possession of material nonpublic information about the Company.  It is also illegal for any employee, officer or director of the Company to give material nonpublic information to others who may trade on the basis of that information.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to comply with federal and state securities laws governing (i) trading in Company securities while in the possession of material nonpublic information concerning the Company and (ii) tipping or disclosing material nonpublic information to any outside persons, and in order to prevent the appearance of improper trading or tipping, the Company has adopted this policy for all of its employees, officers and directors, members of their immediate families and others living in their households, and venture capital funds and other entities (such as trusts and corporations) over which such employees, officers or directors have or share voting or investment control.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;SCOPE</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;This policy covers all employees, officers and directors of the Company, members of their immediate families and others living in their households and venture capital funds and other entities (such as trusts and corporations) over which such employees, officers or directors have or share voting or investment control (collectively referred to herein as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">employees, officers or directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees, officers and directors are responsible for ensuring compliance by their immediate families and other members of their households and entities over which they exercise voting or investment control.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This policy applies to any and all transactions in the Company&#8217;s securities, including shares of its Common Stock and options to purchase Common Stock or other rights to acquire Common Stock, such as restricted stock units (as described in more detail in Section VI.E below), however acquired, and any other type of securities that the Company may issue, such as shares of preferred stock, convertible debentures, warrants and exchange-traded options or other derivative securities.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;This policy will be communicated to all employees, officers and directors upon its adoption by the Company, and to all new employees, officers and directors at the start of their employment or relationship with the Company. Upon first receiving a copy of this policy or any revised versions, each employee, officer or director must sign a certification that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he or she has received a copy and agrees to comply with the terms of this policy. This certification and agreement will constitute consent for the Company to impose sanctions for violation of this policy and to issue any necessary stop-transfer orders to the Company&#8217;s transfer agent to enforce compliance with this policy. As discussed in Section VII.B, sanctions for individuals may include demotion or other disciplinary actions, up to and including termination of employment, if the Company has a reasonable basis to conclude that this policy has been violated.  Section 16 Parties, as defined below, may be required to certify compliance with this policy on an annual basis.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.&#160;&#160;&#160;&#160;This policy allows for trades by employees, officers and directors made in compliance with Rule 10b5-1 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 10b5-1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) promulgated by the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) under the Securities Exchange Act of 1934, as amended (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), subject to the approval of the Compliance Officer (as defined in Section IV below).</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.&#160;&#160;&#160;&#160;The Company may change</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these procedures or adopt such other procedures in the future as the Company considers appropriate in order to carry out the</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purposes of this policy.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">III.&#160;&#160;&#160;&#160;SECTION 16 PARTIES&#59; ACCESS PERSONS</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 16 Parties.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has designated those persons listed on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached hereto as the officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors who are subject to the reporting provisions and trading restrictions of Section 16 of the Exchange Act,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the underlying rules and regulations promulgated by the SEC.  Each such person, and</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each entity affiliated or associated with any such officer or director, is referred herein as a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 16 Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; and collectively the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 16 Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16 Parties must obtain prior approval of all trades in Company securities from the Chief Financial Officer and Compliance Officer in accordance with the procedures set forth in Section VI below. The Company will amend </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from time to time as necessary to reflect the addition and the resignation, departure or change of status of Section 16 Parties.  Each Section 16 Party must notify the Compliance Officer in writing when such Section 16 Party believes that he or she is no longer subject to Section 16 of the Exchange Act.  If the Company agrees that such Section 16 Party is no longer so subject, or if the Company determines independently that such Section 16 Party is no longer so subject, then such Section 16 Party automatically will be deemed to be removed from </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective when it is determined that such Section 16 Party is no longer subject to Section 16 of the Exchange Act.  The Company will notify any Section 16 Party in writing if the Company independently determines that such Section 16 Party is no longer legally subject to Section 16 of the Exchange Act.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Access Persons.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has designated those persons listed on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attached hereto as the persons who have regular access to material nonpublic information in the normal course of their duties for the Company (other than Section 16 Parties)&#59; each person listed on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is referred to herein as an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Access Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; The executive leadership team, which is comprised of the Section 16 Parties (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Leadership Team</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), with input from departmental team leaders, shall determine the list of Access Persons for each fiscal year before the start of such fiscal year. Access Persons must obtain prior approval of all trades in Company securities from the Chief Financial Officer and Compliance Officer in accordance with the procedures set forth in Section VI below. The Company will amend </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from time to time as necessary to reflect the addition and the resignation, departure or change of status of Access Persons.  If the Company determines that such Access Person is no longer subject to the requirements of this Section III.B., then such Access Person will be deemed to be removed from Exhibit B effective when it was so determined. The Company will notify any Access Person in writing if the Company independently determines that such Access Person no longer has access to material nonpublic information about the Company.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director-Level Employees. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each employee at a &#8220;director&#8221; level or above who is not a Section 16 Party or an Access Person (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director-Level Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) must obtain prior approval of all trades in Company securities from the Chief Financial Officer and Compliance Officer in accordance with the procedures set forth in Section VI below.  </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IV.&#160;&#160;&#160;&#160;INSIDER TRADING COMPLIANCE OFFICER</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has designated the Company&#8217;s Chief Legal Officer, as its</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insider trading compliance officer (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and in the event of the Chief Legal Officer&#8217;s unavailability, the Company&#8217;s Chief Financial Officer or Chief Executive Officer, shall be authorized to serve as Compliance Officer in the interim.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Financial Officer and Compliance Officer (or his or her designee) will review and either approve or prohibit all proposed trades by Section 16 Parties or Access Persons in accordance with the procedures set forth in Section VI.D below, except that with respect to the Chief Financial Officer or Compliance Officer, any proposed trades must be approved by the other officer, or Chief Executive Officer.  The Compliance Officer, Chief Financial Officer and Chief Executive Officer may consult with the Company&#8217;s outside legal counsel.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the trading approval duties described in Section VI.D below, the duties of the Compliance Officer will include the following&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A. &#160;&#160;&#160;&#160;Administering and interpreting this policy and monitoring and enforcing compliance with all provisions and procedures of this policy.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;Responding to all inquiries relating to this policy and its procedures.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Designating and announcing special trading blackout periods (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Blackout Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) during which no designated employees, officers or directors may trade in Company securities.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.&#160;&#160;&#160;&#160;Providing copies of this policy and other appropriate materials to all current and new employees, officers and directors, and such other persons who the Compliance Officer determines may have access to material nonpublic information concerning the Company.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.&#160;&#160;&#160;&#160;Administering, monitoring and enforcing compliance with all federal and state insider trading laws and regulations, including, without limitation, Sections 10(b), 16, 20A and 21A of the Exchange Act and the rules and regulations promulgated thereunder, and Rule 144 under the Securities Act of 1933, as amended (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and assisting in the preparation and filing of all required SEC reports relating to insider trading in Company securities, including without limitation Forms 3, 4, 5 and 144 and Schedules 13D and 13G.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F.&#160;&#160;&#160;&#160;Revising the policy as necessary to reflect changes in federal or state insider trading laws and regulations.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.&#160;&#160;&#160;&#160;Maintaining as Company records originals or copies of all documents required by the provisions of this policy or the procedures set forth herein, and copies of all required SEC reports relating to insider trading, including without limitation Forms 3, 4, 5 and 144 and Schedules 13D and 13G.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.&#160;&#160;&#160;&#160;Maintaining the accuracy of the list of Section 16 Parties as attached on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the list of Access Persons as attached on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and updating such lists periodically as necessary to reflect additions or deletions.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Financial Officer and Compliance Officer may designate one or more individuals who may perform that officer&#8217;s duties in the event that one or both of them is unable or unavailable to perform such duties.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">V.&#160;&#160;&#160;&#160;DEFINITION OF &#8220;MATERIAL NONPUBLIC INFORMATION&#8221;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;&#8220;MATERIAL&#8221; INFORMATION</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company is &#8220;material&#8221; if it would be expected to affect the investment or voting decisions of a reasonable stockholder or investor, or if the disclosure of the information would be expected to alter significantly the total mix of the information in the marketplace about the Company.  In simple terms, material information is any type of information that could reasonably be expected to affect the market price of the Company&#8217;s securities. Both positive and negative information may be material.  While it is not possible to identify all information that would be deemed &#8220;material,&#8221; the following types of information ordinarily would be considered material&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Financial performance, especially quarterly and year-end earnings, and significant changes in financial performance or liquidity.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Financial and operational forecasts.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Results or material data of clinical or pre-clinical testing or trials, or other significant development milestones.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Significant communications to or from, or receipt of information from, United States or foreign regulatory authorities regarding products and&#47;or product candidates. </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Operational metrics of the Company or its partners, such as customer counts and associated retention or attrition rates, performance or other metrics, employee counts and distribution by geography or function and any changes in such metrics. </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Potential material mergers and acquisitions or material sales of Company assets or subsidiaries.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Stock splits, public or private securities&#47;debt offerings, or changes in Company dividend policies or amounts.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Significant changes in senior management.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Regulatory approvals of products and the achievement of key product development milestones.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Customer, product, pricing, geography and market strategies and shifts.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Developments regarding customers, suppliers or partners, such as the potential acquisition or loss of a significant contract, development agreement or strategic relationship.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Initiation of a significant lawsuit.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Introduction of key new products.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Changes in the Company&#8217;s auditor or notification that the Company may no longer rely on an auditor&#8217;s report.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Significant cybersecurity incident experienced by the Company.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;&#8220;NONPUBLIC&#8221; INFORMATION</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Material information is &#8220;nonpublic&#8221; if it has not been widely disseminated to the public, for example, through major newswire services, national news services, webcasts or financial news services.  For the purposes of this policy, information will be considered public, i.e., no longer &#8220;nonpublic,&#8221; at the open of trading on the third full trading day following the Company&#8217;s widespread public release of the information.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;CONSULT THE COMPLIANCE OFFICER FOR GUIDANCE</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees, officers or directors who are unsure whether the information that they possess is material or nonpublic must consult the Compliance Officer for guidance before trading in any Company securities.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VI.&#160;&#160;&#160;&#160;STATEMENT OF COMPANY POLICY AND PROCEDURES</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;PROHIBITED ACTIVITIES</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;No employee, officer or director may trade in Company securities while possessing material nonpublic information concerning the Company (except as permitted by Section VI.C).  It does not matter that there may exist a justifiable reason for a purchase or sale apart from the nonpublic information&#59; if the employee, officer or director has material nonpublic information, the prohibition still applies. For clarity, as used in this policy, a &#8220;trade&#8221; excludes the exercise of an option in order to hold shares of stock, and not accompanied by a sale. </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;No employee, officer or director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may trade in Company securities outside of the applicable &#8220;trading windows&#8221; described in Section VI.B below and no employee, officer or director may trade in the Company securities during any Blackout Periods designated by the Compliance Officer that are applicable to such employee, officer or director (except as permitted by Section VI.C and Section VI.D.3).</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;No Section 16 Party or Access Person may trade in Company securities unless the trade has been approved by the Chief Financial Officer and Compliance Officer in accordance with the procedures set forth in Section VI.D below (except as permitted by Section VI.C and Section VI.D.3).</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Compliance Officer may not trade in Company securities unless the trade has been approved by the Company&#8217;s Chief Financial Officer or Chief Executive Officer in accordance with the procedures set forth in Section VI.D below (except as permitted by Section VI.C and Section VI.D.3).</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;No employee, officer or director may disclose material nonpublic information concerning the Company to any outside person (including family members, analysts, individual investors and members of the investment community and news media), unless required as part of the regular duties of such employee, director or officer for the Company or authorized by the Compliance Officer.  In any instance in which such information is disclosed to outsiders, the Company will take such steps as are necessary to preserve the confidentiality of the information, including requiring the outsider to agree in writing to comply with the terms of this policy and&#47;or to sign a confidentiality agreement. All inquiries from outsiders regarding material nonpublic information about the Company must be forwarded to the Compliance Officer.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;No employee, officer or director may give trading advice of any kind about the Company to anyone while possessing material nonpublic information about the Company, except that employees, officers or directors should advise others not to trade if doing so might violate the law or this policy.  The Company strongly discourages all employees, officers and directors from giving trading advice concerning the Company to third parties even when the employees, officers and directors do not possess material nonpublic information about the Company.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;No employee, officer or director may acquire, sell, or trade in any interest or position relating to the future price of Company securities, such as a put option, a call option or a short sale (including a short sale &#8220;against the box&#8221;).</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;No employee, officer or director may (a) trade in the securities of any other public company while possessing material nonpublic information concerning that company obtained in the course of service as an employee, officer or director, (b) &#8220;tip&#8221; or disclose such material nonpublic information concerning any other public company to anyone, or (c) give trading advice of any kind to anyone concerning any other public company while possessing such material nonpublic information about that company.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;Except as permitted by Section VI.B(1), Section VI.C and Section VI.D.3, no employee, officer or director may make a gift or other transfer without consideration of Company securities during a period when that employee, officer or director is not permitted to trade.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;No employee, officer or director may participate, in any manner other than passive observation, in any of the investment or stock-related Internet &#8220;chat&#8221; rooms, blogs, social media sites or message boards relating to the Company.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;No entity over which an employee, officer or director has or shares voting or investment control may distribute securities of the Company to its limited partners, general partners or stockholders during a period when the employee, officer or director is not permitted to trade, unless the limited partners, general partners or stockholders of that entity have agreed in writing to hold the securities until the next open trading window described in VI.B below.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;It is the Company&#8217;s policy to disclose material information concerning the Company to the public only in accordance with its communications and disclosure guidelines and policies, in order to avoid inappropriate publicity and to ensure that all such information is communicated in a way that is reasonably designed to provide broad, non-exclusionary distribution of information to the public. All inquiries or calls from the press, investors and financial analysts should be referred to the Executive Vice President of Strategy and Corporate Development or, in his absence, the Chief Executive Officer (or their designees). The Company has designated its Chief Executive Officer and Executive Vice President of Strategy and Corporate Development as its official spokespersons for financial matters and for marketing, technical and other related information.  These persons are the only ones who are authorized to communicate with the press, investors or financial analysts on behalf of the Company, unless specifically authorized to do so by the Chief Executive Officer or the Executive Vice President of Strategy and Corporate Development.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;TRADING WINDOWS AND BLACKOUT PERIODS</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.67pt">Trading Windows for Section 16 Parties, Access Persons and all Employees with a Title of Senior Vice President or Higher</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Section 16 Parties, all Access Persons and all employees with a title of Senior Vice President or higher (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) may only sell or dispose of shares pursuant to Sections VI.C and VI.D.3&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, any employee of the Company that is promoted to Senior Vice President in an open trading window shall be entitled to sell or dispose of shares other than pursuant to Section VI.C and VI.D.3 (but with approval from the Chief Financial Officer and Compliance Officer) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">only</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during such first open trading window and such employee shall remain subject to all other provisions hereof including the prohibition against trading in securities of the Company while in possession of material non-public information&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, after obtaining trading approval from the Chief Financial Officer and Compliance Officer in accordance with the procedures set forth in Section VI.D below, a (a) purchase of shares on the open market, (b) gift or transfer without consideration may be made by a Restricted Person to (i) any member of such Restricted Person&#8217;s immediate family, (ii) any trust for the direct or indirect benefit of such Restricted Person or the immediate family of such Restricted Person, or (iii) any charitable foundation established by such Restricted Person over which such Restricted Person has dispositive power, or (c) gift or transfer may be made by a Restricted Person to any donor advised fund or similar entity without complying with Section VI.C and VI.D.3 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-10b5 Trades</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that in the case of each transfer pursuant to the clause (b) of the foregoing proviso, the transferee shall be restricted by the terms of this policy and may not trade in Company securities or dispose of any of the gifted or transferred securities, other than pursuant to Section VI.C and VI.D.3.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.67pt">Trading Windows for Director-Level Employees.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After obtaining trading approval from the Chief Financial Officer and Compliance Officer in accordance with the procedures set forth in Section VI.D below, Director-Level Employees may trade in Company securities only during the period </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">beginning</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> at the opening of trading on the third business day following the Company&#8217;s widespread public release of quarterly or year-end operating results, and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ending</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> at the close of trading on the fifteen (15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">) day of the last month of the then-current quarter (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quarterly Close Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;), as long as they are not in possession of material nonpublic information or subject to any Blackout Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.67pt">Trading Windows for Employees.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All employees who are not Restricted Persons or Director-Level Employees may trade in Company securities only during the period </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">beginning</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> at the opening of trading on the third business day following the Company&#8217;s widespread public release of quarterly or year-end operating results, and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ending</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> at the close of trading on the Quarterly Close Date, as long as they are not in possession of material nonpublic information or subject to any Blackout Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Employees who are not Restricted Persons or Director-Level Employees need not obtain approval from the Chief Financial Officer or Compliance Officer prior to trading.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.67pt">No Trading During Trading Windows While in the Possession of Material Nonpublic Information.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No employee, officer or director possessing material nonpublic information concerning the Company may trade in Company securities even during applicable trading windows.  Persons possessing such information may trade during a trading window only after the opening of trading on the third full trading day following the Company&#8217;s widespread public release of the information.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.67pt">No Trading During Blackout Periods</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Compliance Officer may designate Blackout Periods that apply to particular individuals or groups of persons, for such time as is determined by the Compliance Officer.  No director, officer or employee subject to a Blackout Period may trade in Company securities outside of the applicable trading windows or during a Blackout Period.  No director, officer or employee is permitted to anyone, either internally or externally, not subject to a Blackout Period that a Blackout Period has been designated or that one was previously in place. </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;EXCEPTION FOR TRANSFERS PURSUANT TO RULE 10b5-1</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restrictions outlined in Sections VI.A.1, 2, 3, 4 and 9 and VI.B shall not prohibit transfers of Company securities made pursuant to a written contract, letter of instruction or plan that is established by a Section 16 Party, an Access Person or any other employee, and&#58; (a) complies with the requirements of Rule 10b5-1 and the Rule 10b5-1 Guidelines of the Company, as amended or modified from time to time (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 10b5-1 Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), including the requirement that such Rule 10b5-1 Plan be established when such person is not in possession of material information or subject to Blackout Period, (b) has been approved by the Compliance Officer at least ninety (90) days in advance of the first trade thereunder and (c) with respect to which the Company&#8217;s Compliance Officer has received the certification referred to in Section VI.D.3.d. See the Company&#8217;s Rule 10b5-1 Plan Guidelines for additional restrictions regarding Rule 10b5-1 Plans. No such approval by the Compliance Officer and&#47;or acknowledgement of the Rule 10b5-1 Plan by the Company shall be considered the Compliance Officer&#8217;s or the Company&#8217;s determination that the Rule 10b5-1 Plan satisfies the requirements of Rule 10b5-1.  It shall be the sole responsibility of the person establishing the Rule 10b5-1 Plan to ensure that such plan complies with the requirements of Rule 10b5-1. The Company reserves the right to prevent any transactions in Company securities, even those pursuant to a Rule 10b5-1 Plan, if the Compliance Officer determines that prevention of such transaction is necessary to comply with securities law or contractual obligations.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.&#160;&#160;&#160;&#160;PROCEDURES FOR APPROVING TRADES</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trades by</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Persons.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other than the Non-10b5 Trades, a Restricted Person may only trade pursuant to Section VI.D.3.  With respect to Non-10b5 Trades, a Restricted Employee may not make such Non-10b5 Trades other than in compliance with Section VI.D.2 below.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trades by Director-Level Employees Not Made Pursuant to a Rule 10b5-1 Plan and Restricted Persons with respect to Non-10b5 Trades.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Director-Level Employee that is not otherwise a Restricted Person and a Restricted Person with respect to Non-10b5 Trades may not trade in Company securities, until&#58;</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The person trading has notified the Compliance Officer in writing of the amount and nature of the proposed trade(s) (see form attached hereto) no later than two business days prior to the Quarterly Close Date&#59;</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;The person trading has certified to the Compliance Officer in writing (see form attached hereto) no earlier than two business days prior to the proposed trade(s) that&#58;</font></div><div style="margin-top:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Such person is not in possession of material nonpublic information concerning the Company and, to such person&#8217;s knowledge, he or she will have no material nonpublic information as of the proposed trade date&#59; and</font></div><div style="margin-top:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the proposed trade(s) do not violate the trading restrictions of Section 16 of the Exchange Act, Rule 144 of the Securities Act (if applicable) or any other securities laws&#59; </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The Executive Leadership Team member with oversight of such Director-Level Employee or Restricted Person (unless such Restricted Person is a member of the Executive Leadership Team, in which case, this provision shall not be applicable) has certified to the Chief Financial Officer and Compliance Officer in writing (see form attached hereto) no earlier than two business days prior to the proposed trade(s) that such Director-Level Employee or Restricted Person is not in possession of material nonpublic information concerning the Company&#59; and</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;The Chief Financial Officer and the Compliance Officer have each approved the trade(s), in each case, at his or her discretion, and has certified such approval in writing.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of this Section VI.D, notification or certification in writing shall include such notification or certification via e-mail. The person may satisfy the requirements of Section VI.D.2(b) and (c) by emailing the required information and certification to the Compliance Officer and must notify the Compliance Officer promptly via email of any changes to the certification in Section VI.D.2(b) prior to the proposed trade. </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 10b5-1 Plans.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No trades shall be treated as having been made pursuant to a Rule 10b5-1 Plan under this policy unless&#58;</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;The Rule 10b5-1 Plan complies with the requirements of Rule 10b5-1&#59;</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;The Rule 10b5-1 Plan complies with the terms of the Company&#8217;s Rule 10b-1 Plan Guidelines&#59;</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;The Compliance Officer has approved the Rule 10b5-1 Plan, and has certified such approval in writing at least one month in advance of the first trade thereunder&#59; and</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;The person establishing the Rule 10b5-1 Plan has certified to the Compliance Officer in writing of the terms of the proposed Rule 10b5-1 Plan no later than two business days prior to the Quarterly Close Date. </font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;The person establishing Rule 10b5-1 Plan has certified to the Compliance Officer in writing (and shall not have withdrawn such certification prior to such adoption) no earlier than two business days prior to the date that the Rule 10b5-1 Plan is formally established, that as of such date and as of the adoption date of the Rule 10b5-1 Plan&#58;</font></div><div style="margin-top:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;such person is not and to such person&#8217;s knowledge, will not be, aware of material nonpublic information concerning the Company&#59; </font></div><div style="margin-top:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;all such trades to be made pursuant to Rule 10b5-1 Plan will be made in accordance with the applicable SEC rules&#59; </font></div><div style="margin-top:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;such person is adopting the Rule 10b5-1 Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) of the Exchange Act and Rule&#160;10b-5&#59;</font></div><div style="margin-top:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;such person will act in good faith with respect to the Rule 10b5-1 Plan throughout its duration&#59;</font></div><div style="margin-top:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;the Rule 10b5-1 Plan complies with the requirements of Rule 10b5-1&#59; and</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:180pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (vi)&#160;&#160;&#160;&#160;the Rule 10b5-1 Plan complies with the terms of the Rule 10b5-1 Guidelines of the Company.</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification may be made in an email to the Compliance Officer.  The person establishing the Rule 10b5-1 Plan must notify the Compliance Officer promptly via email and withdraw the certification if any changes of circumstances prior to the adoption date of the Rule 10b5-1 Plan have or will render such certification to be inaccurate as of that time.</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;The first trade under the Rule 10b5-1 Plan does not occur until the later of (A) ninety days after the adoption of the Rule 10b5-1 Plan and (B) two business days following the disclosure of the Company&#8217;s financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the Rule 10b5-1 Plan was adopted that discloses the Company&#8217;s financial results (but not to exceed 120 days following the adoption of the Rule 10b5-1 Plan), following the Compliance Officer&#8217;s approval of the Rule 10b5-1 Plan. This waiting period is referred to as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cooling-Off Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.&#160;&#160;&#160;&#160;In order to effect an amendment to an existing Rule 10b5-1 Plan, the person amending such plan must satisfy all of the conditions set forth in Section VI.D.3.a-e with respect to such amendment. Any Rule 10b5-1 Plan amendment will need approval from the Compliance Officer. Modifying or changing the amount, price, or timing of the purchase or sale of the Company&#8217;s securities underlying the Rule 10b5-1 Plan (or a modification or change to a written formula or algorithm, or computer program that affects the amount, price, or timing of the purchase or sale of such securities) (any such modification or change, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan Modification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) will be deemed to be the same as terminating such person&#8217;s existing Rule 10b5-1 Plan and entering into a new Rule 10b5-1 Plan and must satisfy all of the conditions set forth in Section VI.D.3.a-f with respect to such amendment. As a result, the approval process for a Plan Modification is the same as the approval process for initially adopting a Rule 10b5-1 Plan, including being subject to a new Cooling-Off Period. The Company discourages such person from making multiple Plan Modifications, as that may give the appearance that such person is trading on material nonpublic information under the guise of that plan. Plan Modifications can only be made during a trading window and not during any Blackout Period and only when such person is not in possession of material nonpublic information. For other modifications to a Rule 10b5-1 Plan, such must notify the Compliance Officer of such modification in writing at least two business days prior to the modification and such modification must be approved by the Compliance Officer.</font></div><div style="margin-top:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.&#160;&#160;&#160;&#160;In order to terminate an existing Rule 10b5-1 Plan, the person terminating such plan must receive approval from the Compliance Officer to terminate it. </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">No Obligation to Approve Trades.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existence of the foregoing approval procedures does not in any way obligate the Compliance Officer to approve any trades requested by Restricted Persons or Access Persons or to approve any Rule 10b5-1 Plan.  The Compliance Officer may reject any trading requests or Rule 10b5-1 Plans at his or her sole reasonable discretion.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Single-Trade Plans.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No person may adopt a single-trade Rule 10b5-1 Plan during the 12-month period immediately following the person&#8217;s adoption of another single-trade Rule 10b5-1 Plan, subject to the exceptions noted in Rule 10b5-1.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  A person may have no more than one Rule 10b5-1 Plan adopted at any point in time (i.e., multiple concurrent or overlapping plans are prohibited), subject </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the express approval by the Compliance Officer and the exceptions noted in Rule 10b5-1. One of these exceptions is for plans authorizing certain &#8220;sell-to-cover&#8221; transactions.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Trading Arrangements. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees, officers or directors are not allowed to enter into &#8220;non-Rule 10b5-1 trading arrangements&#8221; (as defined in Regulation S-K Item 408(c)) unless otherwise approved in advance by the Compliance Officer.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;E.&#160;&#160;&#160;&#160;EMPLOYEE BENEFIT PLANS</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading prohibitions and restrictions set forth in this policy do not apply to periodic wage withholding contributions by the Company or employees to any of the Company&#8217;s Employee Stock Purchase Plan that are used to purchase Company securities pursuant to the employees&#8217; advance instructions.  However, no officers or employees may alter their instructions regarding the level of withholding or purchase by the employee of Company securities under such plan while in the possession of material nonpublic information.  Any sale of securities acquired under such plan is subject to the prohibitions and restrictions of this policy.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading prohibitions and restrictions of this policy do not apply to the exercise of a stock option or settlement of a restricted stock unit or other form of equity award, or to the exercise of a tax withholding right pursuant to which an election has been made to have the Company withhold shares subject to such awards to satisfy tax withholding requirements, provided that such sales are arranged pursuant to advanced instructions from the compensation committee of the board of directors. The policy does apply, however, to any sales of stock, including as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option or satisfy tax withholding requirements.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;F.&#160;&#160;&#160;&#160;PRIORITY OF STATUTORY OR REGULATORY TRADING RESTRICTIONS</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading prohibitions and restrictions set forth in this policy will be superseded by any greater prohibitions or restrictions prescribed by federal or state securities laws and regulations, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, contractual restrictions on the sale of securities, short-swing trading by Section 16 Parties or restrictions on the sale of securities subject to Rule 144 under the Securities Act.  Any employee, officer or director who is uncertain whether other prohibitions or restrictions apply should ask the Compliance Officer.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VII.&#160;&#160;&#160;&#160;POTENTIAL CIVIL, CRIMINAL AND DISCIPLINARY SANCTIONS</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;CIVIL AND CRIMINAL PENALTIES</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consequences of prohibited insider trading or tipping can be severe.  Persons violating insider trading or tipping rules may be required to disgorge the profit made or the loss avoided by trading, pay the loss suffered by the persons who purchased securities from or sold securities to the insider tippee, pay civil penalties up to three times the profit made or loss avoided, pay a criminal penalty of up to $1 million and serve a jail term of up to 10 years.  The Company and&#47;or the supervisors of the person violating the rules may also be required to pay major civil or criminal penalties and could under certain circumstances be subject to private lawsuits by contemporaneous traders for damages suffered as a result of illegal insider trading or tipping by persons under the Company&#8217;s control.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;COMPANY DISCIPLINE</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violation of this policy or federal or state insider trading or tipping laws by any employee, officer or director may subject a director to dismissal proceedings and an officer or employee to disciplinary action by the Company up to and including termination for cause. A violation of this policy is not necessarily the same as a violation of law.  In fact, for the reasons indicated above, this policy is intended to be broader than the law.  The Company reserves the right to determine, in its own discretion and on the basis of the information available to it, whether this policy has been violated.  The Company may determine that specific conduct violates this policy, whether or not the conduct also violates the law.  It is not necessary for the Company to await the filing or conclusion of a civil or criminal action against the alleged violator before taking disciplinary action.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;REPORTING OF VIOLATIONS</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any employee, officer or director who violates this policy or any federal or state laws governing insider trading or tipping, or knows of any such violation by any other employee, officer or director, must report the violation immediately to the Compliance Officer or the Chief Financial Officer. Alternatively, an employee, officer or director may report such violation anonymously through the procedures set forth in the Company&#8217;s Code of Conduct and Ethics for Employees and Directors.  Upon learning of any such violation, the Compliance Officer or the Chief Financial Officer, in consultation with the Company&#8217;s legal counsel, will determine whether the Company should release any material nonpublic information, or whether the Company should report the violation to the SEC or other appropriate governmental authority.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;D&#160;&#160;&#160;&#160;WAIVER  </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Financial Officer and the Chief Legal Officer, acting together, may approve such waivers of this policy as they may deem appropriate provided that such waivers shall be immaterial and consistent with the spirit of this policy. Our board of directors reserves the right in its sole discretion to modify or grant waivers to this Policy. Any amendment or waiver may be publicly disclosed if required by applicable laws, rules and regulations. For the avoidance of doubt, unless explicitly stated by the board of directors, any waiver, amendment or modification of this Policy by the Board shall not be considered a waiver of the Company&#8217;s Code of Business Conduct and Ethics.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIII.&#160;&#160;&#160;&#160;INQUIRIES</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please direct all inquiries regarding any of the provisions or procedures of this policy to the Compliance Officer.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IX.&#160;&#160;&#160;&#160;EFFECTIVE DATE</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective date of this policy is February 27, 2023. The amendments to this policy would not apply to any existing Rule 10b5-1 Plan that was entered into prior to the effective date of this policy, except to the extent that a Plan Modification is made to such plan after the effective date of this policy.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i2bdf62ee734a4535b5add9feaaaee673_4"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEXCOM, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Section 16 Parties</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As of January 1, 2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">DIRECTORS&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin Sayer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Steven R. Altman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nicholas Augustinos</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard Collins</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Karen Dahut</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rimma Driscoll</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark Foletta</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bridgette Heller</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barbara E. Kahn</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kyle Malady</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eric Topol, M.D.</font></div><div style="margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">OFFICERS&#58;</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.826%"><tr><td style="width:1.0%"></td><td style="width:21.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Position</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Brown</font></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Legal Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Dolan</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Strategy, Corporate Development &#38; Dexcom Labs</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teri Lawver</font></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Commercial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacob Leach</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Operating Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin Sayer</font></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sadie Stern</font></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Human Resources Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jereme Sylvain</font></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2bdf62ee734a4535b5add9feaaaee673_67"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEXCOM, INC.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Access Persons</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(As of January 1, 2024)</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All DexCom Vice Presidents and above and all directors and above in the Legal, Finance and Corporate Development departments.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEXCOM, INC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPLICATION AND APPROVAL FORM FOR TRADING<br>BY RESTRICTED PERSONS AND DIRECTOR-LEVEL EMPLOYEES</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proposed Trade Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Type of Security to be Traded&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Type of Trade (Purchase&#47;Sale)&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of Shares or Other Securities to be Traded&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXAMPLES OF MATERIAL NONPUBLIC INFORMATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible to identify all information that would be deemed &#8220;material nonpublic information,&#8221; the following types of information ordinarily would be included in the definition if not yet publicly released by the Company&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Financial performance, especially quarterly and year-end earnings, and significant changes in financial performance or liquidity.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Financial and operational forecasts.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Results or material data of clinical or pre-clinical testing or trials, or other significant development milestones.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Significant communications to or from, or receipt of information from, United States or foreign regulatory authorities regarding products and&#47;or product candidates. </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Operational metrics of the Company or its partners, such as customer counts and associated retention or attrition rates, performance or other metrics, employee counts and distribution by geography or function and any changes in such metrics. </font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Potential material mergers and acquisitions or material sales of Company assets or subsidiaries.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Stock splits, public or private securities&#47;debt offerings, or changes in Company dividend policies or amounts.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Significant changes in senior management.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Regulatory approvals of products and the achievement of key product development milestones.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Customer, product, pricing, geography and market strategies and shifts.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Developments regarding customers, suppliers or partners, such as the potential acquisition or loss of a significant contract, development agreement or strategic relationship.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Initiation of a significant lawsuit.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Introduction of key new products.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Changes in the Company&#8217;s auditor or notification that the Company may no longer rely on an auditor&#8217;s report.</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Significant cybersecurity incident experienced by the Company.</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2bdf62ee734a4535b5add9feaaaee673_110"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEXCOM, INC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(please print name)_________________________________________________</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hereby certify that (i) I am not currently in possession, and to my knowledge will not be in possession of any &#8220;material nonpublic information&#8221; concerning DexCom, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as defined in the Company&#8217;s &#8220;Procedures and Guidelines Governing Securities Trades by Company Personnel&#8221; as of the proposed trade date, and (ii) to the best of my knowledge, the proposed trade(s) listed above do not violate the trading restrictions of Section 16 of the Securities Exchange Act of 1934, as amended or Rule 144 under the Securities Act of 1933, as amended.  I understand that, if I trade while possessing such information or in violation of such trading restrictions, I may be subject to severe civil and&#47;or criminal penalties, and may be subject to discipline by the Company up to and including termination for cause.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Signature)</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date signed&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">REVIEW AND DECISION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned hereby certifies that the following persons of the Company has reviewed the foregoing application and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(to initial one of the following)&#58; _________ </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPROVES _________ PROHIBITS the proposed trade(s).</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Legal Officer</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Date&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Leadership Team Member</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2bdf62ee734a4535b5add9feaaaee673_96"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEXCOM, INC.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULE 10b5-1 PLAN CERTIFICATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(please print name)_________________________________________________</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hereby certify that (i) I am not currently in possession, and to my knowledge will not be in possession of any &#8220;material nonpublic information&#8221; concerning DexCom, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as defined in the Company&#8217;s &#8220;Procedures and Guidelines Governing Securities Trades by Company Personnel&#8221; as of the proposed trade date, (ii)  the proposed trade(s) to be made pursuant to the Rule 10b5-1 Plan listed above will be made in accordance with the trading restrictions of Section 16 of the Securities Exchange Act of 1934, as amended, and Rule 144 under the Securities Act of 1933, as amended, and (iii) the Rule 10b5-1 Plan complies with the requirements of Rule 10b5-1 of the Securities and Exchange Act of 1934, as amended.  I understand that, if I implement a Rule 10b5-1 Plan while possessing such material nonpublic information or in violation of such trading restrictions, I may be subject to severe civil and&#47;or criminal penalties, and may be subject to discipline by the Company up to and including termination for cause.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Signature)</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date signed&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INSIDER TRADING COMPLIANCE OFFICER REVIEW AND DECISION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned hereby certifies that the Insider Trading Compliance Officer of the Company has reviewed the foregoing Rule 10b5-1 Plan and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Insider Trading Compliance Officer to initial one of the following)&#58; _________ </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APPROVES _________ PROHIBITS the plan.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Signature)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Insider Trading Compliance Officer (or Designee)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date signed&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2bdf62ee734a4535b5add9feaaaee673_82"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEXCOM, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Insider Trading Compliance Program - Preclearance Checklist</font></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:31.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Individual Proposing to Trade&#58; </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compliance Officer&#58; </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Proposed Trade&#58; </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date&#58; </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trading Window</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Confirm that the trade will be made during the Company&#8217;s &#8220;trading window.&#8221;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16 Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Confirm, if the individual is an officer or director subject to Section 16, that the proposed trade will not give rise to any potential liability under Section 16 as a result of matched past (or intended future) transactions.  Ensure that no matching purchase or sale has occurred in the past six (6) months (or is likely to occur in the next six (6) months).  </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, ensure that a Form 4 has been or will be completed and will be timely filed.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prohibited Trades</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Confirm that the proposed transaction is not a &#8220;short sale,&#8221; put, call or other prohibited transaction.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rule 144 Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Confirm that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Current public information requirement has been met.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Shares are not restricted or, if restricted, the one or two year holding period has been met.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Volume limitations are not exceeded (confirm the individual is not part of an aggregated group).</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The manner of sale requirements will be met.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Notice on Form 144 has been completed and filed.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rule 10b-5 Concerns</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Confirm that (i) the individual has been reminded that trading is prohibited when in possession of any material information regarding the Company that has not been adequately disclosed to the public, and (ii) the Compliance Officer has discussed with the insider any information known to the individual or the Compliance Officer which might be considered material, so that the individual has made an informed judgment as to the inside information.</font></div><div style="margin-top:24pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.676%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature of Compliance Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature of Chief Financial Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEXCOM, INC.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Re&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Procedures And Guidelines Governing Securities Trades By Company Personnel</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Enclosed is a copy of the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Procedures and Guidelines Governing Securities Trades by Company Personnel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as adopted by the Board of Directors of DexCom, Inc. (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on ___________.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLEASE READ IT VERY CAREFULLY.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As it indicates, the consequences of insider trading can be drastic to both you and the Company.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To show that you have read the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Procedures and Guidelines Governing Securities Trades by Company Personnel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and agree to be bound by them, please sign and return the attached copy of this letter to the Company&#8217;s Compliance Officer, as soon as possible.</font></div><div style="margin-top:12pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="margin-top:12pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________ </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Brown</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Legal Officer and <br>Compliance Officer</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned certifies that the undersigned has read, understands and agrees to comply with the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Procedures and Guidelines Governing Securities Trades by Company Personnel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of DexCom, Inc. (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The undersigned agrees that the undersigned will be subject to sanctions, including, as to employees of the Company, termination of employment, that may be imposed by the Company, in its discretion, for violation of the Company&#8217;s policy, and that the Company may give stop-transfer and other instructions to the Company&#8217;s transfer agent against the transfer of Company securities by the undersigned in a transaction that the Company considers to be in contravention of its policy.</font></div><div style="margin-top:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">INDIVIDUAL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-top:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Signature)</font></div><div style="padding-left:252pt;text-align:justify"><font><br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Printed name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date signed&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.01
<SEQUENCE>7
<FILENAME>dxcm12312023ex2101_12312023.htm
<DESCRIPTION>EX-21.01
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5ae702be16694441b0e4dea99efc0f2d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.01</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEXCOM, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.373%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARY</font></div><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(Name under which subsidiary does business)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">JURISDICTION&#160;OF INCORPORATION</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SweetSpot Diabetes Care, Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TypeZero Technologies, Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCapital, LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Glucose Program, LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nintamed Handels GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Canada, Co.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom International Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyprus</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Deutschland GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Lithuania UAB</font></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lithuania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom (Malaysia) Sdn. Bhd.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Philippines Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Asia Pacific Operations PTE Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Suisse GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom (UK) Limited</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom (UK) Intermediate Holdings Ltd</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom Operating Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:36pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DexCom (UK) Distribution Limited</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-left:9pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr></table></div><div style="margin-top:4pt"><font><br></font></div><div style="margin-top:9pt;text-align:right"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.01
<SEQUENCE>8
<FILENAME>dxcm12312023ex2301_12312023.htm
<DESCRIPTION>EX-23.01
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i628cf17019e24871aa1d8a7dc8d77651_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.01</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Registration Statement (Form S-3 Nos. 333-206619, 333-211101, and 333-261265) of DexCom, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Registration Statement (Form S-8 No. 333-204699) pertaining to the 2015 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan of DexCom, Inc., and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Registration Statement (Form S-8 Nos. 333-218562 and 333-234682) pertaining to the Amended and Restated 2015 Equity Incentive Plan of DexCom, Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;8, 2024 with respect to the consolidated financial statements and schedule of DexCom, Inc., and the effectiveness of internal control over financial reporting of DexCom, Inc., included in this Annual Report (Form 10-K) of DexCom, Inc. for the year ended December&#160;31, 2023.</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;8, 2024</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.01
<SEQUENCE>9
<FILENAME>dxcm12312023exhibit3101.htm
<DESCRIPTION>EX-31.01
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ifd937d710ecf409aa74b145e2a0e880e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.01</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kevin R. Sayer, certify that&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form 10-K of DexCom, Inc.&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.364%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; KEVIN R. SAYER</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin R. Sayer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors, President and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.02
<SEQUENCE>10
<FILENAME>dxcm12312023exhibit3102.htm
<DESCRIPTION>EX-31.02
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9f54c7d5e19f41778c18c770d0f73089_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.02</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jereme M. Sylvain, certify that&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form 10-K of DexCom, Inc.&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.364%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JEREME M. SYLVAIN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jereme M. Sylvain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.01
<SEQUENCE>11
<FILENAME>dxcm12312023exhibit3201.htm
<DESCRIPTION>EX-32.01
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6194293a7e6246e2aa502f01c514079a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.01</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Kevin R. Sayer, President and Chief Executive Officer of DexCom, Inc. (the &#8220;Company&#8221;), pursuant to 18 U.S.C. &#167;1350, hereby certifies that&#58;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) the annual Report on Form 10-K for the year ended December&#160;31, 2023 of the Company (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;8, 2024</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; KEVIN R. SAYER</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin R. Sayer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors, President and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.02
<SEQUENCE>12
<FILENAME>dxcm12312023exhibit3202.htm
<DESCRIPTION>EX-32.02
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3be8a9b38e5844129551add78e4a08fd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.02</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Jereme M. Sylvain, Executive Vice President and Chief Financial Officer of DexCom, Inc. (the &#8220;Company&#8221;), pursuant to 18 U.S.C. &#167;1350, hereby certifies that&#58;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) the annual Report on Form 10-K for the year ended December&#160;31, 2023 of the Company (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;8, 2024</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.637%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JEREME M. SYLVAIN</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jereme M. Sylvain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>13
<FILENAME>dxcm12312023ex971-compensa.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2228d292c85d4705a550b033d44bdcea_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 97.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DexCom, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Recovery Policy</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Adopted August 21, 2023)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement due to the Company&#8217;s material noncompliance with any financial reporting requirements under the federal securities laws,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.  Capitalized terms are defined in Section 13.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Policy </font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is designed to comply with Rule 10D-1 of the Exchange Act and </font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall become effective on the Adoption Date and supersede the Company&#8217;s prior clawback policy, adopted on April 8, 2015 (the &#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prior Policy</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and shall apply to </font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incentive-Based Compensation Received by Covered Persons on or after the Listing Rule Effective Date</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Prior Policy will apply to Incentive-Based Compensation Received before the Listing Rule Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Administration</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Policy shall be administered by the Administrator.  The Administrator is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy.  The Administrator may retain, at the Company&#8217;s expense, outside legal counsel and such compensation, tax or other consultants as it may determine are advisable for purposes of administering this Policy.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Covered Persons and Applicable Compensation </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Policy applies to any Incentive-Based Compensation Received by a person (a) after beginning service as a Covered Person&#59; (b) who served as a Covered Person at any time during the performance period for that Incentive-Based Compensation&#59; and (c) was a Covered Person during the Clawback Period.  </font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, recovery is not required with respect to&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">Incentive</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-Based Compensation Received prior to an individual becoming a Covered Person, even if the individual served as a Covered Person during the Clawback Period.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">Incentive-Based Compensation Received prior to the Listing Rule Effective Date. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Incentive</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-Based Compensation Received prior to the Clawback Period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">Incentive-Based Compensation Received while the Company did not have a class of listed securities on a national securities exchange or a national securities association, including the Exchange. </font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administrator will not consider the Covered Person&#8217;s responsibility or fault or lack thereof in enforcing this Policy with respect to recoupment under the Rules.  </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Triggering Event</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to and in accordance with the provisions of this Policy, if there is a Triggering Event, the Administrator shall take steps to recover the Recoupment Amount applicable to such Covered Person.  The</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Company&#8217;s obligation to recover the Recoupment Amount is not dependent on if or when the restated financial statements are filed. </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Calculation of Recoupment Amount </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Recoupment Amount will be calculated in accordance with the Rules.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Method of Recoupment</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to compliance with the Rules and applicable law, the Administrator will determine, in its sole discretion, the method for recouping the Recoupment Amount hereunder which may include, without limitation&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">Requiring reimbursement or forfeiture of the pre-tax amount of cash Incentive-Based Compensation previously paid&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">Offsetting the Recoupment Amount from any compensation otherwise owed by the Company to the Covered Person, including without limitation, any prior cash incentive payments, executive retirement benefits or deferred compensation, wages, equity grants or other amounts payable by the Company to the Covered Person in the future&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Seeking recovery of any gain realized on the vesting, exercise, settlement, cash sale, transfer, or other disposition of any equity-based awards&#59; and&#47;or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">Taking any other remedial and recovery action permitted by law, as determined by the Administrator.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the Covered Person fails to timely repay the Recoupment Amount in a manner determined by the Administrator, the Covered Person shall further be required to reimburse the Company for any and all expenses (including legal fees) reasonably incurred by the Company in recovery of such Recoupment Amount.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Recovery Process&#59; Impracticability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actions by the Administrator to recover the Recoupment Amount will be reasonably prompt. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administrator must cause the Company to recover the Recoupment Amount unless the Administrator shall have previously determined that recovery is impracticable and one of the following conditions is met&#58;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.01pt">The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered&#59; before concluding that it would be impracticable to recover any Recoupment Amount based on expense of enforcement, the Company must make a reasonable attempt to recover such Recoupment Amount, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.79pt">Recovery would violate home country law where that law was adopted prior to November 28, 2022&#59; before concluding that it would be impracticable to recover any Recoupment Amount based on violation of home country law, the Company must obtain an opinion of home country counsel, acceptable to the Exchange, that recovery would result in such a violation, and must provide such opinion to the Exchange&#59; or </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.  </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Non-Exclusivity</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administrator intends that this Policy will be applied to the fullest extent of the law.  Without limitation to any broader or alternate clawback authorized in any written document with a Covered Person, (i) the Administrator may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the Adoption Date shall, as a condition to the grant of any benefit thereunder, require a Covered Person to agree to abide by the terms of this Policy, and (ii) this Policy will nonetheless apply to Incentive-Based Compensation as required by the Rules, whether or not specifically referenced in those arrangements.  Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar&#160;policy&#160;in any employment agreement, equity award agreement, or similar agreement and any other legal remedies or regulations available or applicable to the Company (including SOX 304).  If recovery is required under both SOX 304 and this Policy, any amounts recovered pursuant to SOX 304 may be credited toward the amount recovered under this Policy, or vice versa. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">No Indemnification</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall not indemnify any Covered Persons against (i) the loss of the Recoupment Amount </font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any adverse tax consequences associated with any Recoupment Amount or any recoupment hereunder, or (ii) any claims relating to the Company enforcement of its rights under this Policy.  For the avoidance of doubt, this prohibition on indemnification will also prohibit the Company from reimbursing or paying any premium or payment of any third-party insurance policy to fund potential recovery obligations obtained by the Covered Person directly.  No Covered Person will seek or retain any such prohibited indemnification or reimbursement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Company shall not enter into any agreement that exempts any Incentive-Based Compensation from the application of this Policy or that waives the Company&#8217;s right to recovery of any Recoupment Amount and this Policy shall supersede any such agreement (whether entered into before, on or after the Adoption Date).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt">Covered Person Acknowledgement and Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Covered Persons subject to this Policy must acknowledge their understanding of, and agreement to comply with, the Policy by executing an acknowledgement in the form attached hereto as </font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Notwithstanding the foregoing, this Policy will apply to Covered Persons whether or not such person executes such acknowledgment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Successors</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Policy shall be binding and enforceable against all Covered Persons and, to the extent required by law, their beneficiaries, heirs, executors, administrators or other legal representatives and shall inure to the benefit of any successor to the Company.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Interpretation of Policy</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent there is any ambiguity between this Policy and the Rules, this Policy shall be interpreted so that it complies with the Rules.  If any provision of this Policy, or the application of such provision to any Covered Person or circumstance, shall be held invalid, the remainder of this Policy, or the application of such provision to Covered Persons or circumstances other than those as to which it is held invalid, shall not be affected thereby. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event any provision of this Policy is inconsistent with any requirement of any Rules, the Administrator, in its sole discretion, shall amend and administer this Policy and bring it into compliance with such rules.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any determination under this Policy by the Administrator shall be conclusive and binding on all parties, including the applicable Covered Person.  Determinations of the Administrator need not be uniform with respect to Covered Persons or from one payment or grant to another.  </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Amendments&#59; Termination </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administrator may make any amendments to this Policy as required under applicable law, the Rules, or as otherwise determined by the Administrator in its sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Administrator may terminate this Policy at any time.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:22.11pt">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Administrator</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Compensation Committee of the Board, or in the absence of a committee of independent directors responsible for executive compensation decisions, a majority of the independent directors serving on the Board. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clawback Measurement Date</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is the earlier to occur of&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.01pt">The date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an accounting restatement as described in this Policy&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.79pt">The date a court, regulator, or other legally authorized body directs the Company to prepare an accounting restatement as described in this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clawback Period</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s three (3) completed fiscal years immediately prior to the Clawback Measurement Date and any transition period between the last day of the Company&#8217;s previous fiscal year end and the first day of its new fiscal year  (that results from a change in the Company&#8217;s fiscal year) within or immediately following such three (3)-year period&#59; provided that any transition period between the last day of the Company&#8217;s previous fiscal year end and the first day of its new fiscal year that comprises a period of 9 to 12 months will be deemed a completed fiscal year. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means DexCom, Inc., a Delaware corporation, or any successor corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covered Person</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Executive Officer (as defined in the Rules), including, but not limited to, (i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those persons who are or have been determined to be &#8220;officers&#8221; of the Company within the meaning of Section&#160;16 of Rule&#160;16a-1(f) of the rules promulgated under the Exchange Act&#59; (ii) &#8220;executive officers&#8221; of the Company within the meaning of Item&#160;401(b) of Regulation&#160;S-K, Rule&#160;3b-7 promulgated under the Exchange Act, and Rule&#160;405 promulgated under the Securities Act of 1933, as amended&#59; and (iii) &#8220;executive officers&#8221; of the Company&#8217;s subsidiaries if they perform policy-making functions for the Company</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; provided that the Administrator may identify additional employees who shall be treated as Covered Persons for the purposes of this Policy with prospective effect, in accordance with the Rules</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption Date</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means August 21, 2023, the date the Policy was adopted by the Compensation Committee of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Nasdaq Global Select Market or any other national securities exchange or national securities association in the United States on which the Company has listed its securities for trading.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rules</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the&#160; rules promulgated by the SEC under Section&#160;954 of the Dodd-Frank Act, Rule&#160;10D-1 and </font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange listing standards, as may be amended from time to time</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Reporting Measure</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; are measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and TSR are also financial reporting measures. A financial </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting measure need not be presented within the financial statements or included in a filing with the SEC.  Financial reporting measures may include &#8220;non-GAAP financial measures&#8221; as well as other measures, metrics and ratios that are not GAAP measures.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means compensation that is granted, earned or vested based wholly or in part on the attainment of any Financial Reporting Measure. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Listing Rule Effective Date</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means October 2, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means this Compensation Recovery Policy. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incentive-Based Compensation is deemed &#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Received</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in the Company&#8217;s fiscal period during which the relevant Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, irrespective of whether the payment or grant occurs on a later date or if there are additional vesting or payment requirements, such as time-based vesting or certification or approval by the Compensation Committee or Board, that have not yet been satisfied.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recoupment Amount</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the amount of Incentive-Based Compensation received by the Covered Person based on the financial statements prior to the restatement that exceeds the amount such Covered Person would have received had the Incentive-Based Compensation been determined based on the financial restatement, computed without regard to any taxes paid (</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., gross of taxes withheld).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SARs</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means stock appreciation rights.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SOX 304</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Section 304 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Triggering Event</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any event in which the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TSR</font><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means total stockholder return.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i2228d292c85d4705a550b033d44bdcea_57"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#171717;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acknowledgement and Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have read and understand the Company&#8217;s Compensation Recovery Policy (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  I understand that the Company is available to answer any questions I have regarding the Policy.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I understand that the Policy applies to all of my existing and future compensation-related agreements with the Company Received after the Listing Rule Effective Date, whether or not explicitly stated therein. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I agree that notwithstanding the Company&#8217;s certificate of incorporation, bylaws, and any agreement I have with the Company, including any indemnity agreement I have with the Company, I will not be entitled to, and will not seek indemnification from the Company for, any amounts recovered or recoverable by the Company in accordance with the Policy.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I understand and agree that in the event of a conflict between the Policy and the foregoing agreements and understandings on the one hand, and any prior, existing or future agreement, arrangement or understanding, whether oral or written, with respect to the subject matter of the Policy and this Certification, on the other hand, the terms of the Policy and this Certification shall control, and the terms of this Certification shall supersede any provision of such an agreement, arrangement or understanding to the extent of such conflict with respect to the subject matter of the Policy and this Certification.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I agree to abide by the terms of the Policy, including, without limitation, by returning any Recoupment Amount to the Company to the extent required by, and in a manner permitted by, the Policy.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I agree to abide by the terms of the following arbitration provisions.</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">To the fullest extent permitted by law, any disputes under this Policy shall be submitted to mandatory binding arbitration (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Arbitrable Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), governed by the Federal Arbitration Act (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FAA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Further, to the fullest extent permitted by law, no class or collective actions can be asserted in arbitration or otherwise.  All claims, whether in arbitration or otherwise, must be brought solely in Covered Person&#8217;s individual capacity, and not as a plaintiff or class member in any purported class or collective proceeding.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">SUBJECT TO THE ABOVE PROVISO, ANY RIGHTS THAT COVERED PERSON MAY HAVE TO TRIAL BY JURY IN REGARD TO ARBITRABLE CLAIMS ARE WAIVED. ANY RIGHTS THAT COVERED PERSON MAY HAVE TO PURSUE OR PARTICIPATE IN A CLASS OR COLLECTIVE ACTION PERTAINING TO ANY CLAIMS BETWEEN COVERED PERSON AND THE COMPANY ARE WAIVED.</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.23pt">Covered Person is not restricted from filing administrative claims that may be brought before any government agency where, as a matter of law, Covered Person&#8217;s ability to file such claims may not be restricted.  However, to the fullest extent permitted by law, arbitration shall be the exclusive remedy for the subject matter of such administrative claims.  The arbitration shall be conducted in San Diego, CA through JAMS before a single neutral arbitrator, in accordance with the JAMS </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive Arbitration Rules and Procedures </font><font style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">then in effect, provided however, that the FAA, including its procedural provisions for compelling arbitration, shall govern and apply to this arbitration provision.  The arbitrator shall issue a written decision that contains the essential findings and conclusions on which the decision is based.  If, for any reason, any term of this arbitration provision is held to be invalid or unenforceable, all other valid terms and conditions herein shall be severable in nature and remain fully enforceable.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signature&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>dxcm-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5fb5fd4-e534-47c9-8b16-9bac89e1806a,g:3346d81c-3328-4944-8257-c9afd724cc18-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dxcm="http://www.dexcom.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dexcom.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dxcm-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dxcm-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dxcm-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dxcm-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.dexcom.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.dexcom.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.dexcom.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DevelopmentandOtherAgreements" roleURI="http://www.dexcom.com/role/DevelopmentandOtherAgreements">
        <link:definition>0000010 - Disclosure - Development and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.dexcom.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformation" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformation">
        <link:definition>0000012 - Disclosure - Balance Sheet Details and Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.dexcom.com/role/Debt">
        <link:definition>0000013 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesandOtherCommitments" roleURI="http://www.dexcom.com/role/LeasesandOtherCommitments">
        <link:definition>0000014 - Disclosure - Leases and Other Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.dexcom.com/role/Contingencies">
        <link:definition>0000015 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.dexcom.com/role/IncomeTaxes">
        <link:definition>0000016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansandStockholdersEquity" roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquity">
        <link:definition>0000017 - Disclosure - Employee Benefit Plans and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentandGeographicInformation" roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformation">
        <link:definition>0000018 - Disclosure - Business Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" roleURI="http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS">
        <link:definition>0000019 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesTables" roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.dexcom.com/role/FairValueMeasurementsTables">
        <link:definition>9954473 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationTables" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables">
        <link:definition>9954474 - Disclosure - Balance Sheet Details and Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.dexcom.com/role/DebtTables">
        <link:definition>9954475 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesandOtherCommitmentsTables" roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsTables">
        <link:definition>9954476 - Disclosure - Leases and Other Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.dexcom.com/role/IncomeTaxesTables">
        <link:definition>9954477 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansandStockholdersEquityTables" roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityTables">
        <link:definition>9954478 - Disclosure - Employee Benefit Plans and Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentandGeographicInformationTables" roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationTables">
        <link:definition>9954479 - Disclosure - Business Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954480 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails" roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails">
        <link:definition>9954481 - Disclosure - Organization and Significant Accounting Policies - Schedule of Percentage of Total Revenues and Accounts Receivable by Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails" roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails">
        <link:definition>9954482 - Disclosure - Organization and Significant Accounting Policies - Schedule of Basic and Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails" roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails">
        <link:definition>9954483 - Disclosure - Organization and Significant Accounting Policies - Schedule of Outstanding Anti-Dilutive Securities Excluded in Diluted Net Income (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DevelopmentandOtherAgreementsNarrativeDetails" roleURI="http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails">
        <link:definition>9954484 - Disclosure - Development and Other Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails" roleURI="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails">
        <link:definition>9954485 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954486 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails" roleURI="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails">
        <link:definition>9954487 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Senior Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails">
        <link:definition>9954488 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Short-Term Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails">
        <link:definition>9954489 - Disclosure - Balance Sheet Details and Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails">
        <link:definition>9954490 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails">
        <link:definition>9954491 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails">
        <link:definition>9954492 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails">
        <link:definition>9954493 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails">
        <link:definition>9954494 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Intangible Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails">
        <link:definition>9954495 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Amortization Expenses of Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>9954496 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails">
        <link:definition>9954497 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>9954498 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails">
        <link:definition>9954499 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accrued Payroll and Related Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails">
        <link:definition>9954500 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accrued Warranty (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails">
        <link:definition>9954501 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Other Long-Term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails" roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails">
        <link:definition>9954502 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Other Income (Expense), Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails" roleURI="http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails">
        <link:definition>9954503 - Disclosure - Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofConvertedValueofNotesDetails" roleURI="http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails">
        <link:definition>9954504 - Disclosure - Debt - Schedule of Converted Value of Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails" roleURI="http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails">
        <link:definition>9954505 - Disclosure - Debt - Schedule of Components of Interest Expense and Effective Interest Rates of Senior Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofKeyDetailsofConvertibleNotesDetails" roleURI="http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails">
        <link:definition>9954506 - Disclosure - Debt - Schedule of Key Details of Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt2023NoteHedgeDetails" roleURI="http://www.dexcom.com/role/Debt2023NoteHedgeDetails">
        <link:definition>9954507 - Disclosure - Debt - 2023 Note Hedge (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt2023WarrantsDetails" roleURI="http://www.dexcom.com/role/Debt2023WarrantsDetails">
        <link:definition>9954508 - Disclosure - Debt - 2023 Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt2028CappedCallTransactionsDetails" roleURI="http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails">
        <link:definition>9954509 - Disclosure - Debt - 2028 Capped Call Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConversionActivityforSeniorConvertibleNotesDetails" roleURI="http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails">
        <link:definition>9954510 - Disclosure - Debt - Conversion Activity for Senior Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConversionRightsforSeniorsConvertibleNotesDetails" roleURI="http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails">
        <link:definition>9954511 - Disclosure - Debt - Conversion Rights for Seniors Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails" roleURI="http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails">
        <link:definition>9954512 - Disclosure - Debt - Availability and Outstanding Borrowings under Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtRevolvingCreditAgreementDetails" roleURI="http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails">
        <link:definition>9954513 - Disclosure - Debt - Revolving Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesandOtherCommitmentsNarrativeDetails" roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails">
        <link:definition>9954514 - Disclosure - Leases and Other Commitments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails" roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails">
        <link:definition>9954515 - Disclosure - Leases and Other Commitments - Schedule of Maturity of Lease and Finance Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1" roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1">
        <link:definition>9954515 - Disclosure - Leases and Other Commitments - Schedule of Maturity of Lease and Finance Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails" roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails">
        <link:definition>9954516 - Disclosure - Leases and Other Commitments - Schedule of Components of Lease Expense and Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesandOtherCommitmentsOtherInformationDetails" roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails">
        <link:definition>9954517 - Disclosure - Leases and Other Commitments - Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails" roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails">
        <link:definition>9954518 - Disclosure - Income Taxes - Schedule of Income (Loss) before Income Taxes Subject to Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9954519 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails" roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails">
        <link:definition>9954520 - Disclosure - Income Taxes - Schedule of Tax Credits and Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.dexcom.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954521 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954522 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails" roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails">
        <link:definition>9954523 - Disclosure - Income Taxes - Schedule of Reconciliation between Effective Tax Rate and Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>9954524 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansandStockholdersEquityNarrativeDetails" roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails">
        <link:definition>9954525 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails" roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails">
        <link:definition>9954526 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of Treasure Share Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails" roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails">
        <link:definition>9954527 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of RSU and PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails" roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails">
        <link:definition>9954528 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of Share-Based Compensation Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails" roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails">
        <link:definition>9954529 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of Valuation Assumptions for Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentandGeographicInformationNarrativeDetails" roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationNarrativeDetails">
        <link:definition>9954530 - Disclosure - Business Segment and Geographic Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentandGeographicInformationSummaryDetails" roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails">
        <link:definition>9954531 - Disclosure - Business Segment and Geographic Information - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentandGeographicInformationGeographicInformationDetails" roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails">
        <link:definition>9954532 - Disclosure - Business Segment and Geographic Information - Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" roleURI="http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails">
        <link:definition>9954533 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dxcm_ComputerSoftwareAndHardwareMember" abstract="true" name="ComputerSoftwareAndHardwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_OtherForeignMember" abstract="true" name="OtherForeignMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_CollaborativeArrangementInitialPaymentMember" abstract="true" name="CollaborativeArrangementInitialPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_CustomerDMember" abstract="true" name="CustomerDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_CustomerEMember" abstract="true" name="CustomerEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" abstract="false" name="DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses" abstract="false" name="StandardProductWarrantyAccrualChargesToCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_PaymentsForPurchasesOfCappedCallTransactions" abstract="false" name="PaymentsForPurchasesOfCappedCallTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" abstract="false" name="AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_AcquiredTechnologyAndIntellectualPropertyMember" abstract="true" name="AcquiredTechnologyAndIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_AcceleratedShareRepurchaseASRMember" abstract="true" name="AcceleratedShareRepurchaseASRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_LondonInterbankOfferedRateLIBOR1Member" abstract="true" name="LondonInterbankOfferedRateLIBOR1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_IncreaseDecreaseInTreasuryStockRollForward" abstract="true" name="IncreaseDecreaseInTreasuryStockRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_JeremeMSylvainMember" abstract="true" name="JeremeMSylvainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_CollaborativeSalesBasedMilestoneMember" abstract="true" name="CollaborativeSalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_ScheduleOfTreasuryShareActivityTableTextBlock" abstract="false" name="ScheduleOfTreasuryShareActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dxcm_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_SadieMSternMember" abstract="true" name="SadieMSternMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized" abstract="false" name="EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dxcm_RevenuePercentage" abstract="false" name="RevenuePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dxcm_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement" abstract="false" name="SharesIssuedInConnectionWithTheRestatedCollaborationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dxcm_CashInterestExpenseAbstract" abstract="true" name="CashInterestExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ForeignTaxCreditsMember" abstract="true" name="ForeignTaxCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount" abstract="false" name="AcceleratedShareRepurchaseAgreementAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_A2028NotesMember" abstract="true" name="A2028NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_SadieMSternDecember2023PlanMember" abstract="true" name="SadieMSternDecember2023PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_SadieMStern2023PlanTerminationMember" abstract="true" name="SadieMStern2023PlanTerminationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets" abstract="false" name="UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_PotentialFutureCommonStockIssuableSharesNewIssues" abstract="false" name="PotentialFutureCommonStockIssuableSharesNewIssues" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dxcm_DeferredCompensationPlanAssetsCurrent" abstract="false" name="DeferredCompensationPlanAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_EmployeePurchasePriceFloorPercentage" abstract="false" name="EmployeePurchasePriceFloorPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dxcm_CollaborativeArrangementMilestonePaymentsMember" abstract="true" name="CollaborativeArrangementMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone" abstract="false" name="StockIssuedDuringPeriodSharesAchievementOfMilestone" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues" abstract="false" name="PotentialCommonStockIssuableOrIssuedSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dxcm_DevelopmentAgreementsLineItems" abstract="true" name="DevelopmentAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_AccruedTaxAuditAndLegalFeesCurrent" abstract="false" name="AccruedTaxAuditAndLegalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones" abstract="false" name="StockIssuedDuringPeriodValueAchievementOfMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember" abstract="true" name="RestrictedStockUnitsRSUsAndPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_PrepaidInventoryCurrent" abstract="false" name="PrepaidInventoryCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_LongTermDeposits" abstract="false" name="LongTermDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_NumberOfPrimaryGeographicMarkets" abstract="false" name="NumberOfPrimaryGeographicMarkets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dxcm_OtherTaxLiabilitiesNoncurrent" abstract="false" name="OtherTaxLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_DebtInstrumentConversionTermOneMember" abstract="true" name="DebtInstrumentConversionTermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_PaymentsUnderCollaborationAgreementsDomain" abstract="true" name="PaymentsUnderCollaborationAgreementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_UnusedExpiredFederalIncomeTaxCredits" abstract="false" name="UnusedExpiredFederalIncomeTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ShareRepurchaseProgramMember" abstract="true" name="ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_ContractPaymentTermsNumberofDays" abstract="false" name="ContractPaymentTermsNumberofDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" abstract="false" name="DeferredTaxAssetsFixedAssetsAndIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_A2022ShareRepurchaseProgramMember" abstract="true" name="A2022ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock" abstract="false" name="ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dxcm_PaymentsUnderCollaborationAgreementsAxis" abstract="true" name="PaymentsUnderCollaborationAgreementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_DeferredTaxAssetsConvertibleDebt" abstract="false" name="DeferredTaxAssetsConvertibleDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_CollaborativeResearchAndDevelopmentFee" abstract="false" name="CollaborativeResearchAndDevelopmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_CollaborativeArrangementUpfrontFee" abstract="false" name="CollaborativeArrangementUpfrontFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_DebtInstrumentConversionTermAxis" abstract="true" name="DebtInstrumentConversionTermAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_SharesReceivedFromBenefitOfNoteHedge" abstract="false" name="SharesReceivedFromBenefitOfNoteHedge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dxcm_LesseeOperatingLeasesLeaseCostAmortization" abstract="false" name="LesseeOperatingLeasesLeaseCostAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock" abstract="false" name="ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dxcm_EffectiveIncomeTaxReconciliationPermanentItems" abstract="false" name="EffectiveIncomeTaxReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities" abstract="false" name="DebtSecuritiesAvailableForSaleAndEquitySecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ConvertibleNotesDue2028Member" abstract="true" name="ConvertibleNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_StevenRPacelliMember" abstract="true" name="StevenRPacelliMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_OtherLongTermAssets" abstract="false" name="OtherLongTermAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ConvertibleNotesDue2025Member" abstract="true" name="ConvertibleNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_SharesReceivedFromExerciseOfNoteHedge" abstract="false" name="SharesReceivedFromExerciseOfNoteHedge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" abstract="false" name="EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_RevenueRecognitionSalesReturnsCoveragePeriod" abstract="false" name="RevenueRecognitionSalesReturnsCoveragePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dxcm_MatthewDolanMember" abstract="true" name="MatthewDolanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock" abstract="false" name="PrepaidAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dxcm_BarryJReganMember" abstract="true" name="BarryJReganMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_DebtInstrumentCapCallTransactionCapPricePerShare" abstract="false" name="DebtInstrumentCapCallTransactionCapPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm" abstract="false" name="RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dxcm_GirishNaganathanMember" abstract="true" name="GirishNaganathanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_AccruedWagesBonusesAndTaxesCurrent" abstract="false" name="AccruedWagesBonusesAndTaxesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ConvertibleNotesDue2023Member" abstract="true" name="ConvertibleNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_PossibleExtensionPeriodofTaxHoliday" abstract="false" name="PossibleExtensionPeriodofTaxHoliday" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dxcm_FairValueAssetsLevel3TransfersAmount" abstract="false" name="FairValueAssetsLevel3TransfersAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents" abstract="false" name="MaturityThresholdOfInvestmentsClassifiedToCashEquivalents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend" abstract="false" name="LesseeOperatingLeaseNumberOfOptionsToExtend" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dxcm_EquityIncentivePlan2015Member" abstract="true" name="EquityIncentivePlan2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_PaulFlynnMember" abstract="true" name="PaulFlynnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_DebtInstrumentConversionTermDomain" abstract="true" name="DebtInstrumentConversionTermDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_AMTTaxCreditsMember" abstract="true" name="AMTTaxCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_PreferentialTaxRatePeriod" abstract="false" name="PreferentialTaxRatePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" abstract="false" name="IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ProductShipmentCostsPolicyTextBlock" abstract="false" name="ProductShipmentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares" abstract="false" name="DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge" abstract="false" name="TreasuryStockValueBenefitReceivedFromNoteHedge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_NonCashInterestExpenseAbstract" abstract="true" name="NonCashInterestExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_PharmacyRebatesCurrent" abstract="false" name="PharmacyRebatesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales" abstract="false" name="AmortizationOfIntangibleAssetsIncludedInCostOfSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_DebtInstrumentConversionTermTwoMember" abstract="true" name="DebtInstrumentConversionTermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock" abstract="false" name="DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dxcm_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_KevinRSayerMember" abstract="true" name="KevinRSayerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_A2023ShareRepurchaseProgramMember" abstract="true" name="A2023ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_VerilyIntangibleMember" abstract="true" name="VerilyIntangibleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_ResearchDevelopmentTaxCreditsMember" abstract="true" name="ResearchDevelopmentTaxCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage" abstract="false" name="DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dxcm_SharesReceivedFromBenefitOfNoteHedgeValue" abstract="false" name="SharesReceivedFromBenefitOfNoteHedgeValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_VerilyLifeSciencesMember" abstract="true" name="VerilyLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_ReceiverProductComponentMember" abstract="true" name="ReceiverProductComponentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_DevelopmentAgreementsTable" abstract="true" name="DevelopmentAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" abstract="false" name="SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_ImpairedLongLivedAssetsFairValue" abstract="false" name="ImpairedLongLivedAssetsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_AmortizationPeriodForIncentiveCompensationCosts" abstract="false" name="AmortizationPeriodForIncentiveCompensationCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dxcm_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dxcm_RestrictedAndPerformanceStockUnitsMemberMember" abstract="true" name="RestrictedAndPerformanceStockUnitsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_A401kPlanMember" abstract="true" name="A401kPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_OtherStatesMember" abstract="true" name="OtherStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_EmployeeStockPurchasePlan2015Member" abstract="true" name="EmployeeStockPurchasePlan2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" abstract="false" name="EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount" abstract="false" name="AccountsReceivableAllowanceForCreditLossCashDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dxcm_DebtInstrumentCovenantRepurchasePricePercentage" abstract="false" name="DebtInstrumentCovenantRepurchasePricePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>dxcm-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5fb5fd4-e534-47c9-8b16-9bac89e1806a,g:3346d81c-3328-4944-8257-c9afd724cc18-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ac404d38-7199-4dc5-80a1-0939371d5545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa7d4dcd-f372-460c-bd2f-598db3475035" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac404d38-7199-4dc5-80a1-0939371d5545" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fa7d4dcd-f372-460c-bd2f-598db3475035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities_9d857a62-6b5e-415b-b287-ff5f4ef23932" xlink:href="dxcm-20231231.xsd#dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac404d38-7199-4dc5-80a1-0939371d5545" xlink:to="loc_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities_9d857a62-6b5e-415b-b287-ff5f4ef23932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6c933234-44fa-4fba-b1fb-bba31cedf2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac404d38-7199-4dc5-80a1-0939371d5545" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6c933234-44fa-4fba-b1fb-bba31cedf2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e3f4ffcf-5d75-4bd2-a531-73e31d045dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac404d38-7199-4dc5-80a1-0939371d5545" xlink:to="loc_us-gaap_InventoryNet_e3f4ffcf-5d75-4bd2-a531-73e31d045dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5c0a3f2c-0e6d-472a-a047-0ec2e64965dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ac404d38-7199-4dc5-80a1-0939371d5545" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5c0a3f2c-0e6d-472a-a047-0ec2e64965dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c36bf002-78fd-4748-bf32-fb8ec20b8182" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_00516bcc-abc5-4df9-a23a-f8bb62ba3727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c36bf002-78fd-4748-bf32-fb8ec20b8182" xlink:to="loc_us-gaap_LiabilitiesCurrent_00516bcc-abc5-4df9-a23a-f8bb62ba3727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_8d6794a1-c2d4-4794-b56c-de5f0e4ad43b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c36bf002-78fd-4748-bf32-fb8ec20b8182" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_8d6794a1-c2d4-4794-b56c-de5f0e4ad43b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_037d3ef8-4b37-48b3-b9db-d4a649bdee67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c36bf002-78fd-4748-bf32-fb8ec20b8182" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_037d3ef8-4b37-48b3-b9db-d4a649bdee67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cd874541-b3e1-4915-a466-fed917b6fdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c36bf002-78fd-4748-bf32-fb8ec20b8182" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_cd874541-b3e1-4915-a466-fed917b6fdbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d20a0d69-6b8f-41df-a957-1b58f633c42c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_de070422-85a7-4509-aacd-934f66ced999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d20a0d69-6b8f-41df-a957-1b58f633c42c" xlink:to="loc_us-gaap_Liabilities_de070422-85a7-4509-aacd-934f66ced999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bea08ac5-2c0d-4bc7-9c54-3f991658fa86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d20a0d69-6b8f-41df-a957-1b58f633c42c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bea08ac5-2c0d-4bc7-9c54-3f991658fa86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b269813-037e-41c4-a18c-35a8b25f4c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d20a0d69-6b8f-41df-a957-1b58f633c42c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b269813-037e-41c4-a18c-35a8b25f4c47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_212bd7a2-415b-40e5-b20b-7ef0bc1ba8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3bfa7793-c209-460e-b2f9-786b9951a604" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_212bd7a2-415b-40e5-b20b-7ef0bc1ba8b3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3bfa7793-c209-460e-b2f9-786b9951a604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_4aa93956-b5d6-421b-a686-22cfa084f527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_212bd7a2-415b-40e5-b20b-7ef0bc1ba8b3" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_4aa93956-b5d6-421b-a686-22cfa084f527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_dbda6fa4-9b6d-49a9-a26d-fc9bf49c4d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_212bd7a2-415b-40e5-b20b-7ef0bc1ba8b3" xlink:to="loc_us-gaap_CommonStockValueOutstanding_dbda6fa4-9b6d-49a9-a26d-fc9bf49c4d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_76efeb3d-a6b7-43d1-b63d-e6d6aea49bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_212bd7a2-415b-40e5-b20b-7ef0bc1ba8b3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_76efeb3d-a6b7-43d1-b63d-e6d6aea49bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fef2b2a2-5175-40bd-ab99-18b2f11b9ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_212bd7a2-415b-40e5-b20b-7ef0bc1ba8b3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fef2b2a2-5175-40bd-ab99-18b2f11b9ffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9f6d081c-93fc-421c-ba0d-00ac45acec06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_212bd7a2-415b-40e5-b20b-7ef0bc1ba8b3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9f6d081c-93fc-421c-ba0d-00ac45acec06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_9d3080fe-8910-4f6c-a456-3c6e373feb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_212bd7a2-415b-40e5-b20b-7ef0bc1ba8b3" xlink:to="loc_us-gaap_TreasuryStockCommonValue_9d3080fe-8910-4f6c-a456-3c6e373feb9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5f87e4c9-483c-4bfa-b46f-4b601e4af0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0b17980c-e382-48c2-82a5-032ac91b9a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5f87e4c9-483c-4bfa-b46f-4b601e4af0e3" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0b17980c-e382-48c2-82a5-032ac91b9a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0aa27bb6-6009-40dd-ad5d-619b672adb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5f87e4c9-483c-4bfa-b46f-4b601e4af0e3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0aa27bb6-6009-40dd-ad5d-619b672adb4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a15c3c64-16cd-4646-a463-c792b1faaeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5f87e4c9-483c-4bfa-b46f-4b601e4af0e3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a15c3c64-16cd-4646-a463-c792b1faaeb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d3e801b2-eabe-4d55-8678-0f53c701b693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5f87e4c9-483c-4bfa-b46f-4b601e4af0e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d3e801b2-eabe-4d55-8678-0f53c701b693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_9d33d7ca-911d-4ed2-97b0-7346b7771ded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5f87e4c9-483c-4bfa-b46f-4b601e4af0e3" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_9d33d7ca-911d-4ed2-97b0-7346b7771ded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b51db265-6216-4b6d-821d-cb6198ed0853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_5073d6a9-5c1c-40ca-a9c1-a9d472745c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b51db265-6216-4b6d-821d-cb6198ed0853" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_5073d6a9-5c1c-40ca-a9c1-a9d472745c79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_63636873-3687-463d-b78d-059f8c167745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b51db265-6216-4b6d-821d-cb6198ed0853" xlink:to="loc_us-gaap_Goodwill_63636873-3687-463d-b78d-059f8c167745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d84a2c9e-6a65-49bf-a20b-d3731d9d9b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b51db265-6216-4b6d-821d-cb6198ed0853" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d84a2c9e-6a65-49bf-a20b-d3731d9d9b3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a4bbb113-005d-4814-810d-0a3775729eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b51db265-6216-4b6d-821d-cb6198ed0853" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a4bbb113-005d-4814-810d-0a3775729eb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ba90b3cb-a657-46ec-805f-7cc8407fb35e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b51db265-6216-4b6d-821d-cb6198ed0853" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ba90b3cb-a657-46ec-805f-7cc8407fb35e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8eb236af-32c3-4c9a-ad82-1c5928fa4f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b51db265-6216-4b6d-821d-cb6198ed0853" xlink:to="loc_us-gaap_AssetsCurrent_8eb236af-32c3-4c9a-ad82-1c5928fa4f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_bd9d80d3-18a5-4e0c-8f0f-aec571c94044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b51db265-6216-4b6d-821d-cb6198ed0853" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_bd9d80d3-18a5-4e0c-8f0f-aec571c94044" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8815b858-a846-407d-a612-5784a305f796" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_713e2fff-395b-4537-b7c4-b49e920f5ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8815b858-a846-407d-a612-5784a305f796" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_713e2fff-395b-4537-b7c4-b49e920f5ac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8ce2df4-1043-412c-a663-091d211d3ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8815b858-a846-407d-a612-5784a305f796" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8ce2df4-1043-412c-a663-091d211d3ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeResearchAndDevelopmentFee_e999f2fc-1ec5-4c03-b05c-4b4395e3df8a" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeResearchAndDevelopmentFee"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8815b858-a846-407d-a612-5784a305f796" xlink:to="loc_dxcm_CollaborativeResearchAndDevelopmentFee_e999f2fc-1ec5-4c03-b05c-4b4395e3df8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9df36b71-97da-4e34-a2ff-9e6a413682f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a5bb5352-c0d6-4b6a-ae79-d880b8d880ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9df36b71-97da-4e34-a2ff-9e6a413682f6" xlink:to="loc_us-gaap_OperatingIncomeLoss_a5bb5352-c0d6-4b6a-ae79-d880b8d880ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cf692233-2060-496c-8e82-1070fc0a8209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9df36b71-97da-4e34-a2ff-9e6a413682f6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cf692233-2060-496c-8e82-1070fc0a8209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a3b3ebdb-5ab5-4af0-a208-ad0e7d4fa566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81bbeaa8-09b6-4aa1-b143-3e817085c17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a3b3ebdb-5ab5-4af0-a208-ad0e7d4fa566" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81bbeaa8-09b6-4aa1-b143-3e817085c17c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0f2ea0a3-82ae-4748-bb13-dd44c31333cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a3b3ebdb-5ab5-4af0-a208-ad0e7d4fa566" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0f2ea0a3-82ae-4748-bb13-dd44c31333cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71108f2d-f1d1-4309-8b19-efd95721f5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d36afbb8-345d-4b34-9388-038ad3616c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_71108f2d-f1d1-4309-8b19-efd95721f5fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d36afbb8-345d-4b34-9388-038ad3616c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_776343e8-0189-4f15-b568-7bc31f50afb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_71108f2d-f1d1-4309-8b19-efd95721f5fd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_776343e8-0189-4f15-b568-7bc31f50afb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fffdea45-fd6a-4213-81d5-6202a2d2fe45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_99037677-8ff0-4477-bc3d-c058acc41407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fffdea45-fd6a-4213-81d5-6202a2d2fe45" xlink:to="loc_us-gaap_GrossProfit_99037677-8ff0-4477-bc3d-c058acc41407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_21700ced-245e-4e76-a6d9-3622483193d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fffdea45-fd6a-4213-81d5-6202a2d2fe45" xlink:to="loc_us-gaap_OperatingExpenses_21700ced-245e-4e76-a6d9-3622483193d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0d22bf8a-c0d8-4249-8b72-8591252081a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_abd7c74b-0c7d-40bc-8b14-a928473b8d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0d22bf8a-c0d8-4249-8b72-8591252081a9" xlink:to="loc_us-gaap_NetIncomeLoss_abd7c74b-0c7d-40bc-8b14-a928473b8d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_757c513d-f3f5-4780-bc80-e309b63b1fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0d22bf8a-c0d8-4249-8b72-8591252081a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_757c513d-f3f5-4780-bc80-e309b63b1fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0469d104-a025-498c-93d2-97e210a5afa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_763d27fd-5b74-4140-a8f2-3f4ca2613e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0469d104-a025-498c-93d2-97e210a5afa8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_763d27fd-5b74-4140-a8f2-3f4ca2613e21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_22930a51-38c2-46e7-bfc0-fd70a5f5358b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0469d104-a025-498c-93d2-97e210a5afa8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_22930a51-38c2-46e7-bfc0-fd70a5f5358b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef1720c6-2599-4ab6-a574-9049770b761e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_abdba2dd-b466-42e0-9b51-b3f0b2f30afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef1720c6-2599-4ab6-a574-9049770b761e" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_abdba2dd-b466-42e0-9b51-b3f0b2f30afa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8cd0cbe9-db2e-4f10-b7b9-90fa752964f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef1720c6-2599-4ab6-a574-9049770b761e" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8cd0cbe9-db2e-4f10-b7b9-90fa752964f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f478c8b7-e28d-471f-849d-809c02f9e9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef1720c6-2599-4ab6-a574-9049770b761e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f478c8b7-e28d-471f-849d-809c02f9e9ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7f21ef4-5e14-4874-992a-a31bb2e36dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef1720c6-2599-4ab6-a574-9049770b761e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7f21ef4-5e14-4874-992a-a31bb2e36dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions_224a1fc9-01b3-4937-937c-7a49ac343375" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsForPurchasesOfCappedCallTransactions"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef1720c6-2599-4ab6-a574-9049770b761e" xlink:to="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions_224a1fc9-01b3-4937-937c-7a49ac343375" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_f2cd5d71-1b5d-4f33-af27-b467c78c62a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef1720c6-2599-4ab6-a574-9049770b761e" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_f2cd5d71-1b5d-4f33-af27-b467c78c62a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_173146cd-471c-4a6c-9462-15263afccc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_NetIncomeLoss_173146cd-471c-4a6c-9462-15263afccc7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a57af8da-9c3f-43f8-b855-9c8215afd11e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a57af8da-9c3f-43f8-b855-9c8215afd11e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_60e95714-e2be-4266-929f-3153ed674b96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_ShareBasedCompensation_60e95714-e2be-4266-929f-3153ed674b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeResearchAndDevelopmentFee_1e910bbe-7283-4e95-98d9-d0c4104e96e6" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeResearchAndDevelopmentFee"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_dxcm_CollaborativeResearchAndDevelopmentFee_1e910bbe-7283-4e95-98d9-d0c4104e96e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f032f060-3fe7-4093-9a8e-a8b266907971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f032f060-3fe7-4093-9a8e-a8b266907971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_b9e8f650-9669-431f-b224-e64c99fb7e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_PaidInKindInterest_b9e8f650-9669-431f-b224-e64c99fb7e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_48104aeb-3535-4725-a19c-7b344c3b4bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_48104aeb-3535-4725-a19c-7b344c3b4bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_35b345b2-04b1-4ad8-9135-315db6530547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_35b345b2-04b1-4ad8-9135-315db6530547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_319ff687-1e4c-4757-bf5f-eab47c3974d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_319ff687-1e4c-4757-bf5f-eab47c3974d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_af0d2746-3c21-4510-b7f4-f1b3f99b0397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_af0d2746-3c21-4510-b7f4-f1b3f99b0397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d62cf699-2e38-47ef-8741-1819c7764c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d62cf699-2e38-47ef-8741-1819c7764c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a6982374-bd6e-49bf-b6a5-d0e1bc63bf97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a6982374-bd6e-49bf-b6a5-d0e1bc63bf97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet_d6372591-ee01-448e-aa07-c799cdfde296" xlink:href="dxcm-20231231.xsd#dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet_d6372591-ee01-448e-aa07-c799cdfde296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7aaac698-a1e7-4865-b153-dfd6b54c317e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7aaac698-a1e7-4865-b153-dfd6b54c317e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2abeec1e-f991-4918-8e6e-21d708a19183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2abeec1e-f991-4918-8e6e-21d708a19183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability_eeb0bb38-b082-42fe-9c31-77a9c7538e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd3afeac-c29b-4402-9c6b-6ed1dcd8d8dd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability_eeb0bb38-b082-42fe-9c31-77a9c7538e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c31941ab-cc66-44ef-9307-58b791752e12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_441096fd-0ac8-47a0-aeae-27db123f83cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c31941ab-cc66-44ef-9307-58b791752e12" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_441096fd-0ac8-47a0-aeae-27db123f83cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c8bc1fc3-de01-4763-b226-ae41b1293282" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c31941ab-cc66-44ef-9307-58b791752e12" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c8bc1fc3-de01-4763-b226-ae41b1293282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b89c44f-9516-44ad-8bff-59931f80c421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c31941ab-cc66-44ef-9307-58b791752e12" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b89c44f-9516-44ad-8bff-59931f80c421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b58efd0f-e974-4983-910a-6d5a1dc3213d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c31941ab-cc66-44ef-9307-58b791752e12" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b58efd0f-e974-4983-910a-6d5a1dc3213d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_621a5b38-8007-438e-8071-0ad8b9a1c2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c31941ab-cc66-44ef-9307-58b791752e12" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_621a5b38-8007-438e-8071-0ad8b9a1c2ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dfa15c6-c591-44ab-9e39-9f7a9cde58b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1197db1d-0ae4-4364-ad65-4ef89c2f06b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dfa15c6-c591-44ab-9e39-9f7a9cde58b5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1197db1d-0ae4-4364-ad65-4ef89c2f06b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f83974fd-fdd6-4e78-a151-77d43c4777bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dfa15c6-c591-44ab-9e39-9f7a9cde58b5" xlink:to="loc_us-gaap_RestrictedCash_f83974fd-fdd6-4e78-a151-77d43c4777bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a5840a6-8034-4e27-b122-102f27be4af6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86b80ce0-d14d-4e8f-b116-5e403762e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a5840a6-8034-4e27-b122-102f27be4af6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86b80ce0-d14d-4e8f-b116-5e403762e1aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7af2a67-6217-4a67-93ae-a95b476334bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a5840a6-8034-4e27-b122-102f27be4af6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7af2a67-6217-4a67-93ae-a95b476334bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2eebdfe0-a1af-4667-910d-7c1946c65d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a5840a6-8034-4e27-b122-102f27be4af6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2eebdfe0-a1af-4667-910d-7c1946c65d85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a024c282-de32-4656-9944-b7019623b4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a5840a6-8034-4e27-b122-102f27be4af6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a024c282-de32-4656-9944-b7019623b4ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebfeb3ef-b962-4250-b03b-78fd6f986a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_074e9b26-a583-4a75-b674-36addee7a642" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebfeb3ef-b962-4250-b03b-78fd6f986a5b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_074e9b26-a583-4a75-b674-36addee7a642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6876a2c3-86b1-4b07-a4f2-0124820b607e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebfeb3ef-b962-4250-b03b-78fd6f986a5b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6876a2c3-86b1-4b07-a4f2-0124820b607e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_f8b4a1d6-15f4-4b44-b4a0-64060ba9a189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_3f898215-7fad-41fb-89d9-327557434af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_f8b4a1d6-15f4-4b44-b4a0-64060ba9a189" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_3f898215-7fad-41fb-89d9-327557434af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d9a3c244-47e8-4440-9031-06970b0caf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_f8b4a1d6-15f4-4b44-b4a0-64060ba9a189" xlink:to="loc_us-gaap_NetIncomeLoss_d9a3c244-47e8-4440-9031-06970b0caf4b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1994c91b-2a33-4249-90d4-f2a0d7616d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_cff09a33-5f2f-47fe-a680-73c86c43f53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1994c91b-2a33-4249-90d4-f2a0d7616d20" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_cff09a33-5f2f-47fe-a680-73c86c43f53b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_712d286c-5dff-4190-a27b-b5a3f2638b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1994c91b-2a33-4249-90d4-f2a0d7616d20" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_712d286c-5dff-4190-a27b-b5a3f2638b3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_cc4642c7-7e53-4f32-bea2-e535a4d2b57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1994c91b-2a33-4249-90d4-f2a0d7616d20" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_cc4642c7-7e53-4f32-bea2-e535a4d2b57e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5233d2a3-cc74-41b7-9cf3-f65a662fd576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_15066129-4866-4ebf-96b5-afd0e7fa8bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5233d2a3-cc74-41b7-9cf3-f65a662fd576" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_15066129-4866-4ebf-96b5-afd0e7fa8bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aac01c52-a48d-4bb5-99e0-4bc6d59d3dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5233d2a3-cc74-41b7-9cf3-f65a662fd576" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aac01c52-a48d-4bb5-99e0-4bc6d59d3dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0399ea61-56e8-4bb8-92c3-7f26594902cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5233d2a3-cc74-41b7-9cf3-f65a662fd576" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0399ea61-56e8-4bb8-92c3-7f26594902cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_c7dc344a-0261-4541-bdd3-b510c187d1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_0ecf82a9-91ea-4f87-b82a-1ffdb603980a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNet_c7dc344a-0261-4541-bdd3-b510c187d1d9" xlink:to="loc_us-gaap_AccountsReceivableGross_0ecf82a9-91ea-4f87-b82a-1ffdb603980a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0099e0c1-ed69-40f9-ba58-98f165556984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNet_c7dc344a-0261-4541-bdd3-b510c187d1d9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0099e0c1-ed69-40f9-ba58-98f165556984" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_05eb667e-5e9e-4a67-8290-f2241db3cdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d70d5114-f4af-483e-be44-28db5e6c8360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_05eb667e-5e9e-4a67-8290-f2241db3cdd1" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d70d5114-f4af-483e-be44-28db5e6c8360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_df9b7ff8-0cf0-49a5-bead-dc38aa127258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_05eb667e-5e9e-4a67-8290-f2241db3cdd1" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_df9b7ff8-0cf0-49a5-bead-dc38aa127258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b3fec665-7eee-4f4e-b1e5-65f809789e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_05eb667e-5e9e-4a67-8290-f2241db3cdd1" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b3fec665-7eee-4f4e-b1e5-65f809789e25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf6281c5-a830-492e-bceb-fadbaa65da8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_aaa03924-86d3-4a7c-ba6d-713281ce1733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf6281c5-a830-492e-bceb-fadbaa65da8f" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_aaa03924-86d3-4a7c-ba6d-713281ce1733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9819ebb3-d7a9-4f61-b4e0-8887af69a200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf6281c5-a830-492e-bceb-fadbaa65da8f" xlink:to="loc_us-gaap_OtherAssetsCurrent_9819ebb3-d7a9-4f61-b4e0-8887af69a200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_24dc62f4-f6ac-425f-9552-23b87b07ff34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf6281c5-a830-492e-bceb-fadbaa65da8f" xlink:to="loc_us-gaap_IncomeTaxesReceivable_24dc62f4-f6ac-425f-9552-23b87b07ff34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PrepaidInventoryCurrent_32b66a3a-2b66-480e-be5a-ea8fd77f87cb" xlink:href="dxcm-20231231.xsd#dxcm_PrepaidInventoryCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf6281c5-a830-492e-bceb-fadbaa65da8f" xlink:to="loc_dxcm_PrepaidInventoryCurrent_32b66a3a-2b66-480e-be5a-ea8fd77f87cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredCompensationPlanAssetsCurrent_f297a7e0-de5a-4c47-bdd8-63ad5ee9342a" xlink:href="dxcm-20231231.xsd#dxcm_DeferredCompensationPlanAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf6281c5-a830-492e-bceb-fadbaa65da8f" xlink:to="loc_dxcm_DeferredCompensationPlanAssetsCurrent_f297a7e0-de5a-4c47-bdd8-63ad5ee9342a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b8bf6eb6-7ce9-4771-9f6b-9e3751139f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ce10da86-ab7f-42c9-8ede-b79b5c615f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b8bf6eb6-7ce9-4771-9f6b-9e3751139f51" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ce10da86-ab7f-42c9-8ede-b79b5c615f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_727962b2-aa03-46d2-9d30-3abb6edd263f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_6d9e2c23-b526-4735-b04d-f1079624be4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_727962b2-aa03-46d2-9d30-3abb6edd263f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_6d9e2c23-b526-4735-b04d-f1079624be4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1c46167c-9bae-449c-8e81-8563173c2f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_727962b2-aa03-46d2-9d30-3abb6edd263f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1c46167c-9bae-449c-8e81-8563173c2f16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_add8fb84-d590-45dd-992c-7f52df98a30f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_164caa91-15db-4246-bc4d-75d91ffb881a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_add8fb84-d590-45dd-992c-7f52df98a30f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_164caa91-15db-4246-bc4d-75d91ffb881a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9d20aecc-127d-4f04-aaba-adf47e3ba2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_add8fb84-d590-45dd-992c-7f52df98a30f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9d20aecc-127d-4f04-aaba-adf47e3ba2ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses_0669c6a2-b62e-4ef4-85d1-ac88cd2886c5" xlink:href="dxcm-20231231.xsd#dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_91d3d9fc-348c-4ec7-8434-79de1e419e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses_0669c6a2-b62e-4ef4-85d1-ac88cd2886c5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_91d3d9fc-348c-4ec7-8434-79de1e419e39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales_b1158939-9bef-4cba-85fe-11cdb090601c" xlink:href="dxcm-20231231.xsd#dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses_0669c6a2-b62e-4ef4-85d1-ac88cd2886c5" xlink:to="loc_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales_b1158939-9bef-4cba-85fe-11cdb090601c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67dc5ea8-cf2a-4306-994b-d0248b2d1d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7f866031-8bf8-4b48-8491-510b703baaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67dc5ea8-cf2a-4306-994b-d0248b2d1d29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7f866031-8bf8-4b48-8491-510b703baaf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fdfa30fe-5f3f-4d24-8cde-d06de21ee187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67dc5ea8-cf2a-4306-994b-d0248b2d1d29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fdfa30fe-5f3f-4d24-8cde-d06de21ee187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1dadb65d-ac03-482b-b6c7-cd2be35340f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67dc5ea8-cf2a-4306-994b-d0248b2d1d29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1dadb65d-ac03-482b-b6c7-cd2be35340f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4240669a-d659-4e86-b86b-2bcfadc25c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67dc5ea8-cf2a-4306-994b-d0248b2d1d29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4240669a-d659-4e86-b86b-2bcfadc25c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a0e82247-bed8-475c-9374-d10cf90fa825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67dc5ea8-cf2a-4306-994b-d0248b2d1d29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a0e82247-bed8-475c-9374-d10cf90fa825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fdcf053d-dbb4-48e4-aad7-c20812a5e8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_67dc5ea8-cf2a-4306-994b-d0248b2d1d29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fdcf053d-dbb4-48e4-aad7-c20812a5e8dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_02494e03-e392-4fc5-8a33-eb66aa5aad5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_9aced25c-1419-44ad-9c6a-e1ae094733a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_02494e03-e392-4fc5-8a33-eb66aa5aad5a" xlink:to="loc_us-gaap_LongTermInvestments_9aced25c-1419-44ad-9c6a-e1ae094733a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LongTermDeposits_e57693c7-e138-435b-aef5-4b975194eb9f" xlink:href="dxcm-20231231.xsd#dxcm_LongTermDeposits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_02494e03-e392-4fc5-8a33-eb66aa5aad5a" xlink:to="loc_dxcm_LongTermDeposits_e57693c7-e138-435b-aef5-4b975194eb9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherLongTermAssets_1d4838bb-ee3a-4dcb-9a44-2f3a405898ce" xlink:href="dxcm-20231231.xsd#dxcm_OtherLongTermAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_02494e03-e392-4fc5-8a33-eb66aa5aad5a" xlink:to="loc_dxcm_OtherLongTermAssets_1d4838bb-ee3a-4dcb-9a44-2f3a405898ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_34f719b9-3db6-4410-b5c5-2f1984d7e843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_3c7c2496-f0ff-4402-b35f-e7a984ec9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_34f719b9-3db6-4410-b5c5-2f1984d7e843" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_3c7c2496-f0ff-4402-b35f-e7a984ec9e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AccruedTaxAuditAndLegalFeesCurrent_401034ef-1f99-4d74-bb56-e920c785c5f2" xlink:href="dxcm-20231231.xsd#dxcm_AccruedTaxAuditAndLegalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_34f719b9-3db6-4410-b5c5-2f1984d7e843" xlink:to="loc_dxcm_AccruedTaxAuditAndLegalFeesCurrent_401034ef-1f99-4d74-bb56-e920c785c5f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PharmacyRebatesCurrent_2ad8d420-972c-421e-ad35-e21a850086af" xlink:href="dxcm-20231231.xsd#dxcm_PharmacyRebatesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_34f719b9-3db6-4410-b5c5-2f1984d7e843" xlink:to="loc_dxcm_PharmacyRebatesCurrent_2ad8d420-972c-421e-ad35-e21a850086af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_335b10cc-7cac-4f70-be9f-ed9dfe9172cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_34f719b9-3db6-4410-b5c5-2f1984d7e843" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_335b10cc-7cac-4f70-be9f-ed9dfe9172cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b8e7f893-2e66-4654-bbe8-66f7460b5101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_34f719b9-3db6-4410-b5c5-2f1984d7e843" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b8e7f893-2e66-4654-bbe8-66f7460b5101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_8b230f83-5217-49cc-83a5-1803ea15a79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_34f719b9-3db6-4410-b5c5-2f1984d7e843" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_8b230f83-5217-49cc-83a5-1803ea15a79f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_716fccca-0405-4ed5-9680-62e67fea2df2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_34f719b9-3db6-4410-b5c5-2f1984d7e843" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_716fccca-0405-4ed5-9680-62e67fea2df2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_630d102a-03d3-4b1a-90be-5421e6d602ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AccruedWagesBonusesAndTaxesCurrent_095f9b44-538b-4c26-ace3-0195d2c03fe8" xlink:href="dxcm-20231231.xsd#dxcm_AccruedWagesBonusesAndTaxesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_630d102a-03d3-4b1a-90be-5421e6d602ec" xlink:to="loc_dxcm_AccruedWagesBonusesAndTaxesCurrent_095f9b44-538b-4c26-ace3-0195d2c03fe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_9c44e3c9-7261-4d43-93cd-91a66f5238cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_630d102a-03d3-4b1a-90be-5421e6d602ec" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_9c44e3c9-7261-4d43-93cd-91a66f5238cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f6983143-7049-459d-b344-378dae474b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherTaxLiabilitiesNoncurrent_49ef0c10-1ff2-4f2a-890a-2746f649b1ec" xlink:href="dxcm-20231231.xsd#dxcm_OtherTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f6983143-7049-459d-b344-378dae474b21" xlink:to="loc_dxcm_OtherTaxLiabilitiesNoncurrent_49ef0c10-1ff2-4f2a-890a-2746f649b1ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_7f671238-e8ab-4a31-9960-f5ab6680bb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f6983143-7049-459d-b344-378dae474b21" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_7f671238-e8ab-4a31-9960-f5ab6680bb6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3bf908e1-a663-4d5e-aa83-0f983c5aea63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f6983143-7049-459d-b344-378dae474b21" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3bf908e1-a663-4d5e-aa83-0f983c5aea63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3f47f070-dc33-4472-93ef-d892cd8ed876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f6983143-7049-459d-b344-378dae474b21" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3f47f070-dc33-4472-93ef-d892cd8ed876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation_025c3f97-4a37-4244-9159-f8810441d5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetRetirementObligation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_f6983143-7049-459d-b344-378dae474b21" xlink:to="loc_us-gaap_AssetRetirementObligation_025c3f97-4a37-4244-9159-f8810441d5ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fbc5940b-3d24-4cd8-8524-ac7ad6524c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b9c902b7-b927-48e0-af5e-87a605551ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_fbc5940b-3d24-4cd8-8524-ac7ad6524c47" xlink:to="loc_us-gaap_InterestExpense_b9c902b7-b927-48e0-af5e-87a605551ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_ac5e79f3-e0e7-4c1d-811a-b169b24dcc70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_fbc5940b-3d24-4cd8-8524-ac7ad6524c47" xlink:to="loc_us-gaap_OtherNonoperatingExpense_ac5e79f3-e0e7-4c1d-811a-b169b24dcc70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_286713d5-a588-47c6-8c5c-24327792035a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_fbc5940b-3d24-4cd8-8524-ac7ad6524c47" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_286713d5-a588-47c6-8c5c-24327792035a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_972c7a91-ee80-4b4d-9163-00ab2ef644b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_fbc5940b-3d24-4cd8-8524-ac7ad6524c47" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_972c7a91-ee80-4b4d-9163-00ab2ef644b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_40543827-8b0f-4fa2-a191-8e955b47ec4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_fbc5940b-3d24-4cd8-8524-ac7ad6524c47" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_40543827-8b0f-4fa2-a191-8e955b47ec4b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_3d6b96e0-4370-435b-9205-e40db7a94212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e1cd187a-693c-4ca3-aab6-689e7a08d751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayable_3d6b96e0-4370-435b-9205-e40db7a94212" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e1cd187a-693c-4ca3-aab6-689e7a08d751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_826ec6ef-82a8-4e15-bb6f-8084f5ea22d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayable_3d6b96e0-4370-435b-9205-e40db7a94212" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_826ec6ef-82a8-4e15-bb6f-8084f5ea22d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_32012528-cec5-4392-bd08-3f665862d31e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7e15be48-53e3-4e81-9435-6de6eceed235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_32012528-cec5-4392-bd08-3f665862d31e" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7e15be48-53e3-4e81-9435-6de6eceed235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_3f401052-fe46-4e97-b2e4-4672af17ba08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_32012528-cec5-4392-bd08-3f665862d31e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_3f401052-fe46-4e97-b2e4-4672af17ba08" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1c886660-296d-402e-827d-db28d7bc1ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_9d5429ce-8c67-4941-a669-ff4618b8fc60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1c886660-296d-402e-827d-db28d7bc1ede" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_9d5429ce-8c67-4941-a669-ff4618b8fc60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_7858e126-6699-4867-ba18-73aabec6c6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1c886660-296d-402e-827d-db28d7bc1ede" xlink:to="loc_us-gaap_FinanceLeaseLiability_7858e126-6699-4867-ba18-73aabec6c6dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d365ac3-6acc-43b3-b39d-a5bc69a0a037" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b63e7a1a-b801-4b6c-aeec-8a9b22b07ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d365ac3-6acc-43b3-b39d-a5bc69a0a037" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b63e7a1a-b801-4b6c-aeec-8a9b22b07ec4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_826adcfb-6e14-4b9d-bde4-a539f3ae59dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d365ac3-6acc-43b3-b39d-a5bc69a0a037" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_826adcfb-6e14-4b9d-bde4-a539f3ae59dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0cadb6e6-6db7-42e5-956d-2afafec58b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d365ac3-6acc-43b3-b39d-a5bc69a0a037" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0cadb6e6-6db7-42e5-956d-2afafec58b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1af1a39b-559d-49fc-9ab0-4c385d454305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d365ac3-6acc-43b3-b39d-a5bc69a0a037" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1af1a39b-559d-49fc-9ab0-4c385d454305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1bb85251-d02b-4dfe-9e74-36c640f7a079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d365ac3-6acc-43b3-b39d-a5bc69a0a037" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1bb85251-d02b-4dfe-9e74-36c640f7a079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_48dc2826-3718-4292-8c67-7f99038b5abc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3d365ac3-6acc-43b3-b39d-a5bc69a0a037" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_48dc2826-3718-4292-8c67-7f99038b5abc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_dfbbade5-714b-4277-af55-3e034aaaa015" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f0eeadf2-b43f-48f4-a124-d312650dfee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_dfbbade5-714b-4277-af55-3e034aaaa015" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f0eeadf2-b43f-48f4-a124-d312650dfee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_04d13899-10d7-4558-9dc6-02574635c254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_dfbbade5-714b-4277-af55-3e034aaaa015" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_04d13899-10d7-4558-9dc6-02574635c254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_67ed9889-1e4c-4eae-b4f4-64dcc27e8f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_92df3665-1798-4d13-8cfe-5db23c328924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_67ed9889-1e4c-4eae-b4f4-64dcc27e8f0e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_92df3665-1798-4d13-8cfe-5db23c328924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fe3bd736-903d-417f-8f99-e37e89fb0429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_67ed9889-1e4c-4eae-b4f4-64dcc27e8f0e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fe3bd736-903d-417f-8f99-e37e89fb0429" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_34f0922c-b22f-4b58-beb7-864592257d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7f49aa99-6628-4b52-9852-b7e919daaf54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_34f0922c-b22f-4b58-beb7-864592257d20" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7f49aa99-6628-4b52-9852-b7e919daaf54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1b021693-faf7-43df-927f-0d27a3f5442a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_34f0922c-b22f-4b58-beb7-864592257d20" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1b021693-faf7-43df-927f-0d27a3f5442a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d4dc6883-036e-483e-bb37-5baa44aa6b69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_34f0922c-b22f-4b58-beb7-864592257d20" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d4dc6883-036e-483e-bb37-5baa44aa6b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b3b3b8f1-2ebf-4018-89d3-9149f9a2f332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_34f0922c-b22f-4b58-beb7-864592257d20" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b3b3b8f1-2ebf-4018-89d3-9149f9a2f332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_98b6f733-4187-42c6-b32a-76694c9bce24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_34f0922c-b22f-4b58-beb7-864592257d20" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_98b6f733-4187-42c6-b32a-76694c9bce24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f5e6473e-d629-497b-8fce-7ef334f76fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_34f0922c-b22f-4b58-beb7-864592257d20" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f5e6473e-d629-497b-8fce-7ef334f76fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e27e33f-a916-4a98-836b-61aa65909a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4536ea5d-d890-439c-9be9-90e9b9b57582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e27e33f-a916-4a98-836b-61aa65909a34" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4536ea5d-d890-439c-9be9-90e9b9b57582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a07ee0e1-4c7a-4921-85eb-fb016bc7430c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8e27e33f-a916-4a98-836b-61aa65909a34" xlink:to="loc_us-gaap_OperatingLeaseLiability_a07ee0e1-4c7a-4921-85eb-fb016bc7430c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b5df88be-59f7-417d-b003-f705f776c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d2ae74ee-0f0a-4bfa-9b34-41194ee8c00c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b5df88be-59f7-417d-b003-f705f776c6ec" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d2ae74ee-0f0a-4bfa-9b34-41194ee8c00c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_3c7affcd-82a9-4d1c-9c30-dca9a05fa549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b5df88be-59f7-417d-b003-f705f776c6ec" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_3c7affcd-82a9-4d1c-9c30-dca9a05fa549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_772be4ef-7219-4fe9-a22d-1cdfeb676edc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b5df88be-59f7-417d-b003-f705f776c6ec" xlink:to="loc_us-gaap_OperatingLeaseCost_772be4ef-7219-4fe9-a22d-1cdfeb676edc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_b3a682ad-b9ed-4cec-b6fd-6fef78367b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b5df88be-59f7-417d-b003-f705f776c6ec" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_b3a682ad-b9ed-4cec-b6fd-6fef78367b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c02923ed-d90a-45a8-a439-f33221b7e67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b5df88be-59f7-417d-b003-f705f776c6ec" xlink:to="loc_us-gaap_ShortTermLeaseCost_c02923ed-d90a-45a8-a439-f33221b7e67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e818b86c-f846-4d63-8a5d-c4cd3a47c3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b5df88be-59f7-417d-b003-f705f776c6ec" xlink:to="loc_us-gaap_VariableLeaseCost_e818b86c-f846-4d63-8a5d-c4cd3a47c3f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17956ca5-0ee7-4321-9f31-4966b01e2604" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1cb2489d-8a0e-41e9-a584-7e1285ba625b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17956ca5-0ee7-4321-9f31-4966b01e2604" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1cb2489d-8a0e-41e9-a584-7e1285ba625b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5b876f67-a7e4-479b-9916-770ce52d7bed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17956ca5-0ee7-4321-9f31-4966b01e2604" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5b876f67-a7e4-479b-9916-770ce52d7bed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31fa465f-4b0d-45f6-bd82-fbe999268dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b4ecbcac-dfb1-48b9-90bd-a8033f7c48f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31fa465f-4b0d-45f6-bd82-fbe999268dbb" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b4ecbcac-dfb1-48b9-90bd-a8033f7c48f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_24341fd4-b3d2-4b83-a069-2d38c2780c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31fa465f-4b0d-45f6-bd82-fbe999268dbb" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_24341fd4-b3d2-4b83-a069-2d38c2780c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5fe478b8-320b-47ec-81af-b4b696028e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_31fa465f-4b0d-45f6-bd82-fbe999268dbb" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5fe478b8-320b-47ec-81af-b4b696028e8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_fadce29c-9050-4204-90d8-50886f80bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d64425e0-c22b-4cf6-9315-6cb9bf5ee8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_fadce29c-9050-4204-90d8-50886f80bc6e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d64425e0-c22b-4cf6-9315-6cb9bf5ee8c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ca0fe182-a7e4-4c0c-b5ad-90f707c1e6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_fadce29c-9050-4204-90d8-50886f80bc6e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ca0fe182-a7e4-4c0c-b5ad-90f707c1e6e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fc4fdfb3-b285-488f-bb6b-634dc3af191b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_fadce29c-9050-4204-90d8-50886f80bc6e" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_fc4fdfb3-b285-488f-bb6b-634dc3af191b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c38af590-e2df-4dd2-832c-645546524ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_43d71510-1e00-432e-a930-3a8fe0f526ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c38af590-e2df-4dd2-832c-645546524ca1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_43d71510-1e00-432e-a930-3a8fe0f526ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_378f4760-9990-4c4d-bb8e-44bbc2cd5d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c38af590-e2df-4dd2-832c-645546524ca1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_378f4760-9990-4c4d-bb8e-44bbc2cd5d34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f18f74ec-a332-4ff8-9685-6e6a17ccfd37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a1111683-9767-4078-9c13-3d78359613fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f18f74ec-a332-4ff8-9685-6e6a17ccfd37" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a1111683-9767-4078-9c13-3d78359613fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5bfede15-4ae9-4a3b-a102-4d44d5be3e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f18f74ec-a332-4ff8-9685-6e6a17ccfd37" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5bfede15-4ae9-4a3b-a102-4d44d5be3e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_99a96f2e-6a16-4749-ae14-269982eceaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9fcafa59-952f-490f-b2bf-e5f7a4117827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_99a96f2e-6a16-4749-ae14-269982eceaf2" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9fcafa59-952f-490f-b2bf-e5f7a4117827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0467ac6e-a9f2-43a5-8a94-2ef0d91a13fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_99a96f2e-6a16-4749-ae14-269982eceaf2" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0467ac6e-a9f2-43a5-8a94-2ef0d91a13fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5db6afea-2ab5-468e-9855-a87ac0041834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_1b708465-dcec-4ca7-a8f7-21c535a9b643" xlink:href="dxcm-20231231.xsd#dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5db6afea-2ab5-468e-9855-a87ac0041834" xlink:to="loc_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_1b708465-dcec-4ca7-a8f7-21c535a9b643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_91c49a4c-10f8-4379-9eee-7231d7d38455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5db6afea-2ab5-468e-9855-a87ac0041834" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_91c49a4c-10f8-4379-9eee-7231d7d38455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0af2c862-29da-45b2-ac5d-4678cbaa87b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_13c339ac-328f-4995-be06-ab57d790e873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0af2c862-29da-45b2-ac5d-4678cbaa87b4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_13c339ac-328f-4995-be06-ab57d790e873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_70220378-0232-4995-9a24-fa05823fdfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0af2c862-29da-45b2-ac5d-4678cbaa87b4" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_70220378-0232-4995-9a24-fa05823fdfd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b302c938-8f1d-4656-bbc3-a61d8b9c5964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0af2c862-29da-45b2-ac5d-4678cbaa87b4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b302c938-8f1d-4656-bbc3-a61d8b9c5964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0ef0a94e-25cb-4ad3-8954-070d9c3e04c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0af2c862-29da-45b2-ac5d-4678cbaa87b4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0ef0a94e-25cb-4ad3-8954-070d9c3e04c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_96faab98-ff11-4cc1-8291-8baa53194581" xlink:href="dxcm-20231231.xsd#dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0af2c862-29da-45b2-ac5d-4678cbaa87b4" xlink:to="loc_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_96faab98-ff11-4cc1-8291-8baa53194581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_37d31e1e-375c-479c-8a99-7797e02fa592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0af2c862-29da-45b2-ac5d-4678cbaa87b4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_37d31e1e-375c-479c-8a99-7797e02fa592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredTaxAssetsConvertibleDebt_1a5bbffe-d719-45c8-ba6e-90daba1c7bc4" xlink:href="dxcm-20231231.xsd#dxcm_DeferredTaxAssetsConvertibleDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0af2c862-29da-45b2-ac5d-4678cbaa87b4" xlink:to="loc_dxcm_DeferredTaxAssetsConvertibleDebt_1a5bbffe-d719-45c8-ba6e-90daba1c7bc4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0bd6f6cb-115e-4d67-82f6-4bfff033fed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0bd6f6cb-115e-4d67-82f6-4bfff033fed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f67261fb-244e-450f-afab-ed27fc325f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f67261fb-244e-450f-afab-ed27fc325f75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EffectiveIncomeTaxReconciliationPermanentItems_4d60d490-b690-4fe2-acd7-8329521a71bd" xlink:href="dxcm-20231231.xsd#dxcm_EffectiveIncomeTaxReconciliationPermanentItems"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_dxcm_EffectiveIncomeTaxReconciliationPermanentItems_4d60d490-b690-4fe2-acd7-8329521a71bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_622bf4a4-9532-4f7a-a846-e209e8e4d930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_622bf4a4-9532-4f7a-a846-e209e8e4d930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2734c481-b615-4631-bd57-8f77908a3e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2734c481-b615-4631-bd57-8f77908a3e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e8175858-a615-4d41-b961-904681a92294" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e8175858-a615-4d41-b961-904681a92294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_bf5d153a-6e13-4221-8a80-fbb89489ffee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_bf5d153a-6e13-4221-8a80-fbb89489ffee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c084f717-e30b-4b97-999d-30d6c2194e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_c084f717-e30b-4b97-999d-30d6c2194e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7f44f9f4-a521-4abb-9408-3f13f48dfb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7f44f9f4-a521-4abb-9408-3f13f48dfb4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment_0ddd9229-3b89-423a-957f-aab43d08f1b7" xlink:href="dxcm-20231231.xsd#dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment_0ddd9229-3b89-423a-957f-aab43d08f1b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_4f408743-b85b-475c-b541-be76a4d9099a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_4f408743-b85b-475c-b541-be76a4d9099a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_d7611fb1-dbb0-4872-a3d1-e6f46a4e2c60" xlink:href="dxcm-20231231.xsd#dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e6c81f0f-01f1-4e58-83f5-f5e01ecb5f45" xlink:to="loc_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_d7611fb1-dbb0-4872-a3d1-e6f46a4e2c60" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>dxcm-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5fb5fd4-e534-47c9-8b16-9bac89e1806a,g:3346d81c-3328-4944-8257-c9afd724cc18-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5e39018f-087e-4455-b1c0-104741c029b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dbf6c501-e9da-4dec-b60e-0ea58593cf19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5e39018f-087e-4455-b1c0-104741c029b6" xlink:to="loc_us-gaap_StatementTable_dbf6c501-e9da-4dec-b60e-0ea58593cf19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33409dab-680a-40b6-9ce5-73f293e4d685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dbf6c501-e9da-4dec-b60e-0ea58593cf19" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33409dab-680a-40b6-9ce5-73f293e4d685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33409dab-680a-40b6-9ce5-73f293e4d685_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33409dab-680a-40b6-9ce5-73f293e4d685" xlink:to="loc_us-gaap_EquityComponentDomain_33409dab-680a-40b6-9ce5-73f293e4d685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33409dab-680a-40b6-9ce5-73f293e4d685" xlink:to="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bb76eb41-f8f5-422e-8df7-8f2f64073579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_CommonStockMember_bb76eb41-f8f5-422e-8df7-8f2f64073579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_888ba15c-38de-41a6-8cc9-9c07d726d195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_888ba15c-38de-41a6-8cc9-9c07d726d195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c3f77dc8-da72-4df3-a6cc-9ec354b94958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c3f77dc8-da72-4df3-a6cc-9ec354b94958" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5226fcbc-b411-4955-8e8f-a1ce1220709c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_RetainedEarningsMember_5226fcbc-b411-4955-8e8f-a1ce1220709c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_3f3c94ac-73a4-426d-bacf-70a7e6ee10f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_TreasuryStockCommonMember_3f3c94ac-73a4-426d-bacf-70a7e6ee10f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5e39018f-087e-4455-b1c0-104741c029b6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d8176583-395b-4957-bd16-0d5f4164a7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d8176583-395b-4957-bd16-0d5f4164a7c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a5957da0-11f2-4ee5-a966-9ae446a12646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockholdersEquity_a5957da0-11f2-4ee5-a966-9ae446a12646" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_10c4bd71-47c9-48f7-a179-3d324140076b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_10c4bd71-47c9-48f7-a179-3d324140076b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_af19c07c-7d87-4df7-8657-913d2fc6bfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_af19c07c-7d87-4df7-8657-913d2fc6bfd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e9843359-f81f-471c-b54f-8dd091ed4346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e9843359-f81f-471c-b54f-8dd091ed4346" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ff078534-1787-485b-93ff-78d4660ecdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ff078534-1787-485b-93ff-78d4660ecdd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_29c791ca-a602-41c4-8d58-79fd0a3fb7e5" xlink:href="dxcm-20231231.xsd#dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_29c791ca-a602-41c4-8d58-79fd0a3fb7e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones_30058a06-379d-47f2-b6ce-762aa094d5c7" xlink:href="dxcm-20231231.xsd#dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones_30058a06-379d-47f2-b6ce-762aa094d5c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt_a603c1f8-fde8-4985-834e-3cb0f68b2c6b" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt_a603c1f8-fde8-4985-834e-3cb0f68b2c6b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_42c4bd80-167a-43a8-9652-a01a69598a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_42c4bd80-167a-43a8-9652-a01a69598a7a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ea7681a7-769e-40fd-8df0-f007ec99058a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ea7681a7-769e-40fd-8df0-f007ec99058a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge_7ad2e43a-2a95-4505-ae85-617bb11ced8a" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromExerciseOfNoteHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge_7ad2e43a-2a95-4505-ae85-617bb11ced8a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue_30f37d1d-bc25-45e4-8757-9952185073c2" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromBenefitOfNoteHedgeValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue_30f37d1d-bc25-45e4-8757-9952185073c2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_04cf3bc2-23fb-474a-bd1a-539b416f3fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_04cf3bc2-23fb-474a-bd1a-539b416f3fb6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4641b267-57ef-4739-af23-ad247fbbe364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4641b267-57ef-4739-af23-ad247fbbe364" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax_e291bc1b-b909-451c-a023-fa76a2d8f984" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax_e291bc1b-b909-451c-a023-fa76a2d8f984" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ae09cf5a-197e-4e54-895e-f7447fd30eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ae09cf5a-197e-4e54-895e-f7447fd30eb1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee_76232e4c-5a33-433f-819f-82b1a8617657" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee_76232e4c-5a33-433f-819f-82b1a8617657" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones_cebbd568-385d-4bdd-a531-7d9ce7dc08b0" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones_cebbd568-385d-4bdd-a531-7d9ce7dc08b0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb5038c0-fb1d-4aaa-b5b0-0b7c1429d749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_NetIncomeLoss_eb5038c0-fb1d-4aaa-b5b0-0b7c1429d749" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3ccd463-8d85-4a70-a29b-122253dc9437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3ccd463-8d85-4a70-a29b-122253dc9437" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d8f2c5e7-3415-4f65-ae93-5982c55462c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bbba3e33-70ed-4f95-863d-2f3d4b2f2f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:href="dxcm-20231231.xsd#dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8cc6d6eb-112e-4332-9afa-f5d4e4b49f52" xlink:href="dxcm-20231231.xsd#dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8cc6d6eb-112e-4332-9afa-f5d4e4b49f52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16a8fa9c-c066-46d4-b4f6-53fa96912615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8cc6d6eb-112e-4332-9afa-f5d4e4b49f52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16a8fa9c-c066-46d4-b4f6-53fa96912615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16a8fa9c-c066-46d4-b4f6-53fa96912615_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16a8fa9c-c066-46d4-b4f6-53fa96912615" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16a8fa9c-c066-46d4-b4f6-53fa96912615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16a8fa9c-c066-46d4-b4f6-53fa96912615" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ComputerSoftwareAndHardwareMember_e6cf58ff-c30e-4baa-878d-1efe9075b81a" xlink:href="dxcm-20231231.xsd#dxcm_ComputerSoftwareAndHardwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:to="loc_dxcm_ComputerSoftwareAndHardwareMember_e6cf58ff-c30e-4baa-878d-1efe9075b81a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_a6bda176-453a-49b5-bde4-a4d1769d508c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_a6bda176-453a-49b5-bde4-a4d1769d508c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ec154641-aa10-498b-b5e9-a24b555b65e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ec154641-aa10-498b-b5e9-a24b555b65e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_c84c382e-a2a5-404a-a199-eb1801637cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:to="loc_us-gaap_BuildingMember_c84c382e-a2a5-404a-a199-eb1801637cec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81254af1-b053-4439-b262-7d441870e4c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8cc6d6eb-112e-4332-9afa-f5d4e4b49f52" xlink:to="loc_srt_RangeAxis_81254af1-b053-4439-b262-7d441870e4c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81254af1-b053-4439-b262-7d441870e4c9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_81254af1-b053-4439-b262-7d441870e4c9" xlink:to="loc_srt_RangeMember_81254af1-b053-4439-b262-7d441870e4c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_421eef59-4bfb-4dd3-be0d-bb94f7677f27" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_81254af1-b053-4439-b262-7d441870e4c9" xlink:to="loc_srt_RangeMember_421eef59-4bfb-4dd3-be0d-bb94f7677f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f009b31c-f260-42fb-9c4f-28994652ceb8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_421eef59-4bfb-4dd3-be0d-bb94f7677f27" xlink:to="loc_srt_MinimumMember_f009b31c-f260-42fb-9c4f-28994652ceb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_18c3aed8-b6d1-4abe-921f-855fa29c060d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_421eef59-4bfb-4dd3-be0d-bb94f7677f27" xlink:to="loc_srt_MaximumMember_18c3aed8-b6d1-4abe-921f-855fa29c060d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents_f0a6a80e-1aa8-4827-af74-2025a1c459c1" xlink:href="dxcm-20231231.xsd#dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents_f0a6a80e-1aa8-4827-af74-2025a1c459c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e5bfe582-30a0-48b2-b1df-aa30b18ace13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e5bfe582-30a0-48b2-b1df-aa30b18ace13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_394981b8-8aed-41c5-9615-292498cafd45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_394981b8-8aed-41c5-9615-292498cafd45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d324a5a9-6566-4c5d-8d5b-83621cec1c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d324a5a9-6566-4c5d-8d5b-83621cec1c85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ed21309f-7e86-48cb-b649-12cd5e34fab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ed21309f-7e86-48cb-b649-12cd5e34fab0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod_35e597fc-590e-45b4-a339-84688170a57f" xlink:href="dxcm-20231231.xsd#dxcm_RevenueRecognitionSalesReturnsCoveragePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod_35e597fc-590e-45b4-a339-84688170a57f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ContractPaymentTermsNumberofDays_b2eaa1df-b98a-42df-b02f-2af7d1c7e6a0" xlink:href="dxcm-20231231.xsd#dxcm_ContractPaymentTermsNumberofDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_dxcm_ContractPaymentTermsNumberofDays_b2eaa1df-b98a-42df-b02f-2af7d1c7e6a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_a5790885-223b-4f4d-9670-4fdc634932ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_UnbilledContractsReceivable_a5790885-223b-4f4d-9670-4fdc634932ed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fee4c48-4a19-4cfd-b8af-069a5f446d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fee4c48-4a19-4cfd-b8af-069a5f446d83" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AmortizationPeriodForIncentiveCompensationCosts_657c97cf-0a0a-4a95-9440-a413592a805c" xlink:href="dxcm-20231231.xsd#dxcm_AmortizationPeriodForIncentiveCompensationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_dxcm_AmortizationPeriodForIncentiveCompensationCosts_657c97cf-0a0a-4a95-9440-a413592a805c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_5447a352-e699-49b1-b6f2-896736c4b556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_AdvertisingExpense_5447a352-e699-49b1-b6f2-896736c4b556" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_69307eab-2e75-4a7c-9def-6f4239ef0542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_69307eab-2e75-4a7c-9def-6f4239ef0542" xlink:to="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_067fc678-3c8b-4a48-9b2e-36b639a91a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_067fc678-3c8b-4a48-9b2e-36b639a91a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_067fc678-3c8b-4a48-9b2e-36b639a91a1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_067fc678-3c8b-4a48-9b2e-36b639a91a1b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_067fc678-3c8b-4a48-9b2e-36b639a91a1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_50e34603-f513-49f1-843a-49d986e05978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_067fc678-3c8b-4a48-9b2e-36b639a91a1b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_50e34603-f513-49f1-843a-49d986e05978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_702cef41-6ae7-406a-a63e-f436927f2e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_50e34603-f513-49f1-843a-49d986e05978" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_702cef41-6ae7-406a-a63e-f436927f2e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4b23568e-8cf7-4364-9197-8a56754ee70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4b23568e-8cf7-4364-9197-8a56754ee70f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4b23568e-8cf7-4364-9197-8a56754ee70f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4b23568e-8cf7-4364-9197-8a56754ee70f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4b23568e-8cf7-4364-9197-8a56754ee70f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf6bd593-caab-4c36-b07e-ca91623453b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4b23568e-8cf7-4364-9197-8a56754ee70f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf6bd593-caab-4c36-b07e-ca91623453b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7d7fead2-190b-4ed7-9190-a66b46e4fa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf6bd593-caab-4c36-b07e-ca91623453b3" xlink:to="loc_us-gaap_SalesRevenueNetMember_7d7fead2-190b-4ed7-9190-a66b46e4fa0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_eb4ae31b-a76e-47ed-bb03-4bafd13eb41c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf6bd593-caab-4c36-b07e-ca91623453b3" xlink:to="loc_us-gaap_AccountsReceivableMember_eb4ae31b-a76e-47ed-bb03-4bafd13eb41c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_20a5ee09-5c12-4818-8b40-25341729c42c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:to="loc_srt_MajorCustomersAxis_20a5ee09-5c12-4818-8b40-25341729c42c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_20a5ee09-5c12-4818-8b40-25341729c42c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_20a5ee09-5c12-4818-8b40-25341729c42c" xlink:to="loc_srt_NameOfMajorCustomerDomain_20a5ee09-5c12-4818-8b40-25341729c42c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_20a5ee09-5c12-4818-8b40-25341729c42c" xlink:to="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerAMember_b4fb250a-d741-472d-80f3-1aed039b16c9" xlink:href="dxcm-20231231.xsd#dxcm_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerAMember_b4fb250a-d741-472d-80f3-1aed039b16c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerBMember_6f81227f-abf1-4799-9eb4-d48b89e324a3" xlink:href="dxcm-20231231.xsd#dxcm_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerBMember_6f81227f-abf1-4799-9eb4-d48b89e324a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerCMember_5942f5ba-14f3-416a-9c3b-a705007d38df" xlink:href="dxcm-20231231.xsd#dxcm_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerCMember_5942f5ba-14f3-416a-9c3b-a705007d38df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerDMember_3a4d5288-47e4-450e-aa53-efb159e2a6a0" xlink:href="dxcm-20231231.xsd#dxcm_CustomerDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerDMember_3a4d5288-47e4-450e-aa53-efb159e2a6a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerEMember_b3f8d62f-466a-4df7-8295-d82c3070841e" xlink:href="dxcm-20231231.xsd#dxcm_CustomerEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerEMember_b3f8d62f-466a-4df7-8295-d82c3070841e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_78c9027e-47c2-4c69-9e7c-cc620644fa21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_69307eab-2e75-4a7c-9def-6f4239ef0542" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_78c9027e-47c2-4c69-9e7c-cc620644fa21" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_132aa8f9-fc74-43dd-b16c-9d4700bf0b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_132aa8f9-fc74-43dd-b16c-9d4700bf0b3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6ac64225-12ac-4e2b-881e-1fe2c05198f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_132aa8f9-fc74-43dd-b16c-9d4700bf0b3f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6ac64225-12ac-4e2b-881e-1fe2c05198f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6ac64225-12ac-4e2b-881e-1fe2c05198f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6ac64225-12ac-4e2b-881e-1fe2c05198f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6ac64225-12ac-4e2b-881e-1fe2c05198f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6ac64225-12ac-4e2b-881e-1fe2c05198f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeSalesBasedMilestoneMember_2ffe8a75-a095-4bb7-8791-69b28409a3e6" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeSalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:to="loc_dxcm_CollaborativeSalesBasedMilestoneMember_2ffe8a75-a095-4bb7-8791-69b28409a3e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_b48aee6c-0aaa-4666-a9db-73a428d76e86" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedAndPerformanceStockUnitsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:to="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_b48aee6c-0aaa-4666-a9db-73a428d76e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1a366399-1f34-493e-8873-013a71d2b341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1a366399-1f34-493e-8873-013a71d2b341" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_99f77ae5-e5d7-44cb-bc16-2573bc7a284b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:to="loc_us-gaap_WarrantMember_99f77ae5-e5d7-44cb-bc16-2573bc7a284b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9011cb7c-9ee9-456a-a5fb-1c66000f6952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_NetIncomeLoss_9011cb7c-9ee9-456a-a5fb-1c66000f6952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_5c6e0713-1b54-4093-97b6-4585d5aed6de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_5c6e0713-1b54-4093-97b6-4585d5aed6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_ea85e848-b664-49fa-bd54-df041cb12696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_ea85e848-b664-49fa-bd54-df041cb12696" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ad998e83-5d7c-434c-9489-b482787a347f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_EarningsPerShareBasic_ad998e83-5d7c-434c-9489-b482787a347f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fae08e56-ce95-43b1-85e9-9c70244de114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fae08e56-ce95-43b1-85e9-9c70244de114" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c118a8c7-e2c1-4dc0-9111-9dd0852ebbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c118a8c7-e2c1-4dc0-9111-9dd0852ebbad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8d7bc6f7-5117-4ee8-bea7-e0bb1850fbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8d7bc6f7-5117-4ee8-bea7-e0bb1850fbb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b83728e9-345c-4893-89f4-4c967d897f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b83728e9-345c-4893-89f4-4c967d897f32" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_367b8a2c-d896-4fb7-912b-58a7c4f5b644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9df9e339-def4-440d-b4fa-f448f3366302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_367b8a2c-d896-4fb7-912b-58a7c4f5b644" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9df9e339-def4-440d-b4fa-f448f3366302" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_18f0e8a5-67a3-4c04-a876-52ef7cbda9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9df9e339-def4-440d-b4fa-f448f3366302" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_18f0e8a5-67a3-4c04-a876-52ef7cbda9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_18f0e8a5-67a3-4c04-a876-52ef7cbda9b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_18f0e8a5-67a3-4c04-a876-52ef7cbda9b3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_18f0e8a5-67a3-4c04-a876-52ef7cbda9b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2958c225-857d-4f12-a3b3-cc528fa0e1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_18f0e8a5-67a3-4c04-a876-52ef7cbda9b3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2958c225-857d-4f12-a3b3-cc528fa0e1ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_d4ae29c0-867a-4342-8515-d6e3dec803b3" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedAndPerformanceStockUnitsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2958c225-857d-4f12-a3b3-cc528fa0e1ee" xlink:to="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_d4ae29c0-867a-4342-8515-d6e3dec803b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d13290cb-6dc7-4ccf-8ae9-cc597e15e760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_367b8a2c-d896-4fb7-912b-58a7c4f5b644" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d13290cb-6dc7-4ccf-8ae9-cc597e15e760" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DevelopmentandOtherAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:href="dxcm-20231231.xsd#dxcm_DevelopmentAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:href="dxcm-20231231.xsd#dxcm_DevelopmentAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsUnderCollaborationAgreementsAxis_2971d074-aa19-4aa9-a51f-fe13972e2aec" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsUnderCollaborationAgreementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:to="loc_dxcm_PaymentsUnderCollaborationAgreementsAxis_2971d074-aa19-4aa9-a51f-fe13972e2aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_2971d074-aa19-4aa9-a51f-fe13972e2aec_default" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsUnderCollaborationAgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dxcm_PaymentsUnderCollaborationAgreementsAxis_2971d074-aa19-4aa9-a51f-fe13972e2aec" xlink:to="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_2971d074-aa19-4aa9-a51f-fe13972e2aec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_01dbf6b3-b862-443f-b3e6-0cf67efafadb" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsUnderCollaborationAgreementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dxcm_PaymentsUnderCollaborationAgreementsAxis_2971d074-aa19-4aa9-a51f-fe13972e2aec" xlink:to="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_01dbf6b3-b862-443f-b3e6-0cf67efafadb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeArrangementInitialPaymentMember_db0cac93-e197-465c-8ed2-a3e8a40a0273" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeArrangementInitialPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_01dbf6b3-b862-443f-b3e6-0cf67efafadb" xlink:to="loc_dxcm_CollaborativeArrangementInitialPaymentMember_db0cac93-e197-465c-8ed2-a3e8a40a0273" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeArrangementMilestonePaymentsMember_7636ae86-fb22-4e15-8a8b-fa629877e7b9" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeArrangementMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_01dbf6b3-b862-443f-b3e6-0cf67efafadb" xlink:to="loc_dxcm_CollaborativeArrangementMilestonePaymentsMember_7636ae86-fb22-4e15-8a8b-fa629877e7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9566a06e-0e53-41b2-a8a3-ddda981bb0bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:to="loc_srt_CounterpartyNameAxis_9566a06e-0e53-41b2-a8a3-ddda981bb0bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9566a06e-0e53-41b2-a8a3-ddda981bb0bb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9566a06e-0e53-41b2-a8a3-ddda981bb0bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9566a06e-0e53-41b2-a8a3-ddda981bb0bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fac64d7-0a08-4d8f-86de-2e62a840ed90" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9566a06e-0e53-41b2-a8a3-ddda981bb0bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fac64d7-0a08-4d8f-86de-2e62a840ed90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_VerilyLifeSciencesMember_51528fbb-c102-4d7b-97f6-777a63179d2d" xlink:href="dxcm-20231231.xsd#dxcm_VerilyLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fac64d7-0a08-4d8f-86de-2e62a840ed90" xlink:to="loc_dxcm_VerilyLifeSciencesMember_51528fbb-c102-4d7b-97f6-777a63179d2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ceb853e6-0165-48b2-9976-e54bc1086923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ceb853e6-0165-48b2-9976-e54bc1086923" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb853e6-0165-48b2-9976-e54bc1086923_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ceb853e6-0165-48b2-9976-e54bc1086923" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb853e6-0165-48b2-9976-e54bc1086923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_074d2989-219a-4d5b-9f7b-1a09fa73df45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ceb853e6-0165-48b2-9976-e54bc1086923" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_074d2989-219a-4d5b-9f7b-1a09fa73df45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_bf6a1099-bee3-4624-a05a-50acf97d08ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_074d2989-219a-4d5b-9f7b-1a09fa73df45" xlink:to="loc_us-gaap_CollaborativeArrangementMember_bf6a1099-bee3-4624-a05a-50acf97d08ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d9d2a5c1-aca6-449b-b676-4ed985d85a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_us-gaap_SharePrice_d9d2a5c1-aca6-449b-b676-4ed985d85a55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeArrangementUpfrontFee_e6e4048a-9952-4ddc-be04-7d46c5ddfecf" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeArrangementUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_CollaborativeArrangementUpfrontFee_e6e4048a-9952-4ddc-be04-7d46c5ddfecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07539f4d-e2fd-44b0-9cca-129b366fa763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07539f4d-e2fd-44b0-9cca-129b366fa763" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeResearchAndDevelopmentFee_05c18c1b-8e93-406a-83d9-4ae89f302769" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeResearchAndDevelopmentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_CollaborativeResearchAndDevelopmentFee_05c18c1b-8e93-406a-83d9-4ae89f302769" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement_6209517c-cc78-4109-80e0-236a66c096c7" xlink:href="dxcm-20231231.xsd#dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement_6209517c-cc78-4109-80e0-236a66c096c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_adab636e-40ac-4b1d-b38a-3d9d922a02f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_adab636e-40ac-4b1d-b38a-3d9d922a02f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues_7962dc38-9226-4c84-bd8b-55537c1d0dcf" xlink:href="dxcm-20231231.xsd#dxcm_PotentialFutureCommonStockIssuableSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues_7962dc38-9226-4c84-bd8b-55537c1d0dcf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a863cfe5-a077-4592-9f9c-9018cfbef091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a863cfe5-a077-4592-9f9c-9018cfbef091" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues_b2f9b74d-82a6-4ba1-b0a1-de07325dba31" xlink:href="dxcm-20231231.xsd#dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues_b2f9b74d-82a6-4ba1-b0a1-de07325dba31" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e447d82-cd3d-41ee-8139-f3ae1aca891f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e447d82-cd3d-41ee-8139-f3ae1aca891f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_349797b9-a448-4c62-a42e-fe67d1ec50aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e447d82-cd3d-41ee-8139-f3ae1aca891f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_349797b9-a448-4c62-a42e-fe67d1ec50aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_349797b9-a448-4c62-a42e-fe67d1ec50aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_349797b9-a448-4c62-a42e-fe67d1ec50aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_349797b9-a448-4c62-a42e-fe67d1ec50aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_349797b9-a448-4c62-a42e-fe67d1ec50aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6b777418-704f-47bb-bfbd-c0d36172ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6b777418-704f-47bb-bfbd-c0d36172ec5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1959995b-0260-44ca-9cc6-2830a6fd36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:to="loc_us-gaap_CommercialPaperMember_1959995b-0260-44ca-9cc6-2830a6fd36d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_01b1ab28-7181-47be-8f52-73f39790d0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_01b1ab28-7181-47be-8f52-73f39790d0c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a589f0b2-b708-4294-bdea-221f736c4cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e447d82-cd3d-41ee-8139-f3ae1aca891f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a589f0b2-b708-4294-bdea-221f736c4cea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a589f0b2-b708-4294-bdea-221f736c4cea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a589f0b2-b708-4294-bdea-221f736c4cea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a589f0b2-b708-4294-bdea-221f736c4cea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a589f0b2-b708-4294-bdea-221f736c4cea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_835c6a4c-5b38-4a0e-b6a3-a41358618cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_835c6a4c-5b38-4a0e-b6a3-a41358618cab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0162453b-2910-44e0-8278-d18aa7dd3ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0162453b-2910-44e0-8278-d18aa7dd3ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d89b6d55-21f9-4d9a-8155-c148dce2aa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d89b6d55-21f9-4d9a-8155-c148dce2aa0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c417d8df-b712-44b6-b535-617e45e81504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_c417d8df-b712-44b6-b535-617e45e81504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd5c49b7-4694-4a22-b858-796101395700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd5c49b7-4694-4a22-b858-796101395700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_e9d87139-e3a0-46dc-bf86-5bc749db99b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_e9d87139-e3a0-46dc-bf86-5bc749db99b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3d21a70e-702d-419a-9f32-05ba87f760fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3d21a70e-702d-419a-9f32-05ba87f760fa" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e42687-8675-40a2-9e9e-903f866a0db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e42687-8675-40a2-9e9e-903f866a0db3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f7e1635b-80ad-4df9-9b16-662ea1ec3b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e42687-8675-40a2-9e9e-903f866a0db3" xlink:to="loc_us-gaap_HedgingDesignationAxis_f7e1635b-80ad-4df9-9b16-662ea1ec3b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f7e1635b-80ad-4df9-9b16-662ea1ec3b4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_f7e1635b-80ad-4df9-9b16-662ea1ec3b4a" xlink:to="loc_us-gaap_HedgingDesignationDomain_f7e1635b-80ad-4df9-9b16-662ea1ec3b4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1d9ffd7e-e356-4ec5-ad69-9cdff325d53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_f7e1635b-80ad-4df9-9b16-662ea1ec3b4a" xlink:to="loc_us-gaap_HedgingDesignationDomain_1d9ffd7e-e356-4ec5-ad69-9cdff325d53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_816085cc-8f8b-42d4-876c-c4fd84f6f60e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1d9ffd7e-e356-4ec5-ad69-9cdff325d53a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_816085cc-8f8b-42d4-876c-c4fd84f6f60e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_46466c6f-797e-4642-93a5-cd4033d0acd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e42687-8675-40a2-9e9e-903f866a0db3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_46466c6f-797e-4642-93a5-cd4033d0acd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_46466c6f-797e-4642-93a5-cd4033d0acd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_46466c6f-797e-4642-93a5-cd4033d0acd2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_46466c6f-797e-4642-93a5-cd4033d0acd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5418bf66-d8ee-4be4-a33c-6b05090c8bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_46466c6f-797e-4642-93a5-cd4033d0acd2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5418bf66-d8ee-4be4-a33c-6b05090c8bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_c0e59e19-78cc-4518-817f-1678929ad118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5418bf66-d8ee-4be4-a33c-6b05090c8bab" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_c0e59e19-78cc-4518-817f-1678929ad118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_FairValueAssetsLevel3TransfersAmount_bf368de7-02ac-467a-91b8-1ffe797364af" xlink:href="dxcm-20231231.xsd#dxcm_FairValueAssetsLevel3TransfersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_dxcm_FairValueAssetsLevel3TransfersAmount_bf368de7-02ac-467a-91b8-1ffe797364af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_1fd6c39e-0a81-4d9c-a1c5-3a68ff45fb47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_us-gaap_DerivativeTermOfContract_1fd6c39e-0a81-4d9c-a1c5-3a68ff45fb47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_984d05e4-cfc6-47bc-bf46-4ace39aef39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_984d05e4-cfc6-47bc-bf46-4ace39aef39e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c2f9e73d-4c30-4593-a854-1985b9e3f946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c2f9e73d-4c30-4593-a854-1985b9e3f946" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_29dc7076-003d-4794-b582-eefd260113cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_29dc7076-003d-4794-b582-eefd260113cc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11c6cf99-57cb-4e01-8ca6-d7faa8e39706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17331bf3-dd3d-4a18-bc3e-836adfa4c694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11c6cf99-57cb-4e01-8ca6-d7faa8e39706" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17331bf3-dd3d-4a18-bc3e-836adfa4c694" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5612436-e4af-4324-97ce-55b6d2113c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17331bf3-dd3d-4a18-bc3e-836adfa4c694" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5612436-e4af-4324-97ce-55b6d2113c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b5612436-e4af-4324-97ce-55b6d2113c1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5612436-e4af-4324-97ce-55b6d2113c1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b5612436-e4af-4324-97ce-55b6d2113c1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5612436-e4af-4324-97ce-55b6d2113c1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_9c0c4c2d-a3a3-448c-a788-3acfc9500ae3" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_9c0c4c2d-a3a3-448c-a788-3acfc9500ae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_6c7dc19f-6812-48b1-b833-7c9ff8717492" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_6c7dc19f-6812-48b1-b833-7c9ff8717492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_8046f563-a486-4c67-b365-4ba3535e7958" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_8046f563-a486-4c67-b365-4ba3535e7958" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e5421793-cdb8-4fd3-817a-e641670941a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17331bf3-dd3d-4a18-bc3e-836adfa4c694" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e5421793-cdb8-4fd3-817a-e641670941a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e5421793-cdb8-4fd3-817a-e641670941a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e5421793-cdb8-4fd3-817a-e641670941a4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e5421793-cdb8-4fd3-817a-e641670941a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_603f666e-aff1-4bbd-b99e-7a414a9d9bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e5421793-cdb8-4fd3-817a-e641670941a4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_603f666e-aff1-4bbd-b99e-7a414a9d9bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e5b261d9-cdf9-42d1-bd16-d18a202979a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_603f666e-aff1-4bbd-b99e-7a414a9d9bc7" xlink:to="loc_us-gaap_SeniorNotesMember_e5b261d9-cdf9-42d1-bd16-d18a202979a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_81a8f780-01a7-4973-b1cc-be5fafc3af61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11c6cf99-57cb-4e01-8ca6-d7faa8e39706" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_81a8f780-01a7-4973-b1cc-be5fafc3af61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969e164e-4ba1-423e-af2e-7f20ee0bba7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969e164e-4ba1-423e-af2e-7f20ee0bba7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_14949caa-a63b-4c0f-b448-26e38f9b4f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969e164e-4ba1-423e-af2e-7f20ee0bba7f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_14949caa-a63b-4c0f-b448-26e38f9b4f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14949caa-a63b-4c0f-b448-26e38f9b4f0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_14949caa-a63b-4c0f-b448-26e38f9b4f0d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14949caa-a63b-4c0f-b448-26e38f9b4f0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_14949caa-a63b-4c0f-b448-26e38f9b4f0d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_062a30b6-07a5-40b2-9d6d-824f9f6f9e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_062a30b6-07a5-40b2-9d6d-824f9f6f9e8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a89154a4-7dde-4a41-a405-b8f819611429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:to="loc_us-gaap_CommercialPaperMember_a89154a4-7dde-4a41-a405-b8f819611429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_060d6604-be14-4807-bed2-a5d99e673091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_060d6604-be14-4807-bed2-a5d99e673091" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_630efa6f-be8e-4004-ace2-5d7ed7b7719e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_630efa6f-be8e-4004-ace2-5d7ed7b7719e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1b60a385-ff3b-4286-8401-6f0cb56c6595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1b60a385-ff3b-4286-8401-6f0cb56c6595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fec78eb-6195-41bb-9f47-2e9f08382d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fec78eb-6195-41bb-9f47-2e9f08382d30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf6cf34b-d3ac-4e41-9127-7420b489dca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf6cf34b-d3ac-4e41-9127-7420b489dca6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e8e0c0c7-6d94-4ef1-919b-11850cb28079" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e8e0c0c7-6d94-4ef1-919b-11850cb28079" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_682e2949-1452-4e9e-a337-b34724d861e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e8e0c0c7-6d94-4ef1-919b-11850cb28079" xlink:to="loc_srt_ProductOrServiceAxis_682e2949-1452-4e9e-a337-b34724d861e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_682e2949-1452-4e9e-a337-b34724d861e0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_682e2949-1452-4e9e-a337-b34724d861e0" xlink:to="loc_srt_ProductsAndServicesDomain_682e2949-1452-4e9e-a337-b34724d861e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_76e3b106-5597-426d-8a97-348f7692c2a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_682e2949-1452-4e9e-a337-b34724d861e0" xlink:to="loc_srt_ProductsAndServicesDomain_76e3b106-5597-426d-8a97-348f7692c2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ReceiverProductComponentMember_781ed31e-619b-43d9-a6e7-b58261fb3230" xlink:href="dxcm-20231231.xsd#dxcm_ReceiverProductComponentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_76e3b106-5597-426d-8a97-348f7692c2a7" xlink:to="loc_dxcm_ReceiverProductComponentMember_781ed31e-619b-43d9-a6e7-b58261fb3230" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_b75a5398-ac23-43a6-8c67-30c45a150284" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_DebtInstrumentTerm_b75a5398-ac23-43a6-8c67-30c45a150284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3f10284-a0ed-4512-a4a1-18063badeb71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3f10284-a0ed-4512-a4a1-18063badeb71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_076c8c60-c6ed-4d0c-9bbf-fe3dfe3e20a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_076c8c60-c6ed-4d0c-9bbf-fe3dfe3e20a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount_8d575cad-5d43-4108-a7d6-78e83ca2bd7f" xlink:href="dxcm-20231231.xsd#dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount_8d575cad-5d43-4108-a7d6-78e83ca2bd7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f495f4f2-5ae0-4b50-8132-1fe78384eacd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_InventoryWriteDown_f495f4f2-5ae0-4b50-8132-1fe78384eacd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_16a6bb3e-2f8e-47c1-b780-6507e51190de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_Depreciation_16a6bb3e-2f8e-47c1-b780-6507e51190de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cdc5bb21-500c-456e-85a9-db048ae459f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cdc5bb21-500c-456e-85a9-db048ae459f2" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ca12ab2f-8f26-4fb6-9e2a-11b95b8535b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ca12ab2f-8f26-4fb6-9e2a-11b95b8535b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60c6ceb2-3b0c-4564-9acb-b3cd281a2e82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ca12ab2f-8f26-4fb6-9e2a-11b95b8535b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60c6ceb2-3b0c-4564-9acb-b3cd281a2e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60c6ceb2-3b0c-4564-9acb-b3cd281a2e82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60c6ceb2-3b0c-4564-9acb-b3cd281a2e82" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60c6ceb2-3b0c-4564-9acb-b3cd281a2e82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60c6ceb2-3b0c-4564-9acb-b3cd281a2e82" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_bae3d0c0-ac68-4edf-8f8f-44105768c8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_LandMember_bae3d0c0-ac68-4edf-8f8f-44105768c8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_00c1f901-78c2-4b5f-bd11-a22f6be76751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_BuildingMember_00c1f901-78c2-4b5f-bd11-a22f6be76751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4632c97c-fda9-4945-98b6-3cb85f7add8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4632c97c-fda9-4945-98b6-3cb85f7add8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ComputerSoftwareAndHardwareMember_cd5198d3-e0d1-4ddd-979b-e4ccad56e358" xlink:href="dxcm-20231231.xsd#dxcm_ComputerSoftwareAndHardwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_dxcm_ComputerSoftwareAndHardwareMember_cd5198d3-e0d1-4ddd-979b-e4ccad56e358" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aa6c0763-2cb0-4429-a04b-3fc07873da6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_EquipmentMember_aa6c0763-2cb0-4429-a04b-3fc07873da6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b45b4c2c-d2ac-4c82-bdaf-7a4aeb700b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b45b4c2c-d2ac-4c82-bdaf-7a4aeb700b36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_9de74d1c-f154-4304-9342-7874ae0db5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_ConstructionInProgressMember_9de74d1c-f154-4304-9342-7874ae0db5e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6b08bb74-54f1-4de0-938e-64e8930a4c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6b08bb74-54f1-4de0-938e-64e8930a4c9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2dd27e22-9d9d-42db-9d73-b383c673ee89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2dd27e22-9d9d-42db-9d73-b383c673ee89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0c3f532a-b8be-4b86-b36c-23c306662e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0c3f532a-b8be-4b86-b36c-23c306662e05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_89e62c34-2502-4a96-b3b4-bf60ad28cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_89e62c34-2502-4a96-b3b4-bf60ad28cbbb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d44e1cc-b279-42ea-becc-da7c0465de86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d44e1cc-b279-42ea-becc-da7c0465de86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00bb677c-f398-464d-86b3-4eb8ee837f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d44e1cc-b279-42ea-becc-da7c0465de86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00bb677c-f398-464d-86b3-4eb8ee837f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_00bb677c-f398-464d-86b3-4eb8ee837f94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00bb677c-f398-464d-86b3-4eb8ee837f94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_00bb677c-f398-464d-86b3-4eb8ee837f94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00bb677c-f398-464d-86b3-4eb8ee837f94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_VerilyIntangibleMember_fe63756c-4ce7-4dd0-b9bf-80b41afef35f" xlink:href="dxcm-20231231.xsd#dxcm_VerilyIntangibleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_dxcm_VerilyIntangibleMember_fe63756c-4ce7-4dd0-b9bf-80b41afef35f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3b3fbc60-c9e4-4bdf-8bfa-3e4e43e6f6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3b3fbc60-c9e4-4bdf-8bfa-3e4e43e6f6a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AcquiredTechnologyAndIntellectualPropertyMember_829c739c-33fc-45fa-bc6e-e0c5094c299d" xlink:href="dxcm-20231231.xsd#dxcm_AcquiredTechnologyAndIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_dxcm_AcquiredTechnologyAndIntellectualPropertyMember_829c739c-33fc-45fa-bc6e-e0c5094c299d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_c4d6accb-7db3-4dcc-8cb4-a77f29d24e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_c4d6accb-7db3-4dcc-8cb4-a77f29d24e92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_5cf5d24f-ad69-4772-b043-8cdb5862255d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_5cf5d24f-ad69-4772-b043-8cdb5862255d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e98b87da-a795-4f35-8692-6b96c1e9ec07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e98b87da-a795-4f35-8692-6b96c1e9ec07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38c9d01b-6207-40e4-bec9-353ff67334c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38c9d01b-6207-40e4-bec9-353ff67334c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_312b9b4c-7a57-4b10-8e14-63936ae7a6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_312b9b4c-7a57-4b10-8e14-63936ae7a6cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_001d40cc-02b9-498c-84c6-c23a3a925b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_001d40cc-02b9-498c-84c6-c23a3a925b17" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a84d7dea-14a0-42e3-bfbd-2c162d90c779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2b304c02-f400-44d0-aef0-37ff9329b890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a84d7dea-14a0-42e3-bfbd-2c162d90c779" xlink:to="loc_us-gaap_DebtInstrumentTable_2b304c02-f400-44d0-aef0-37ff9329b890" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7b4cc7b7-afb4-4456-86e5-1e0cc35e5b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2b304c02-f400-44d0-aef0-37ff9329b890" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7b4cc7b7-afb4-4456-86e5-1e0cc35e5b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7b4cc7b7-afb4-4456-86e5-1e0cc35e5b4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7b4cc7b7-afb4-4456-86e5-1e0cc35e5b4e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7b4cc7b7-afb4-4456-86e5-1e0cc35e5b4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_562991ba-8179-46bc-8ce7-cc09a61fa815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7b4cc7b7-afb4-4456-86e5-1e0cc35e5b4e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_562991ba-8179-46bc-8ce7-cc09a61fa815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3e278fd3-f140-41ba-bf78-e334fe1329ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_562991ba-8179-46bc-8ce7-cc09a61fa815" xlink:to="loc_us-gaap_SeniorNotesMember_3e278fd3-f140-41ba-bf78-e334fe1329ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2b2259de-96e7-42ee-a524-3272128cc635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2b304c02-f400-44d0-aef0-37ff9329b890" xlink:to="loc_us-gaap_DebtInstrumentAxis_2b2259de-96e7-42ee-a524-3272128cc635" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2b2259de-96e7-42ee-a524-3272128cc635_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2b2259de-96e7-42ee-a524-3272128cc635" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2b2259de-96e7-42ee-a524-3272128cc635_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2b2259de-96e7-42ee-a524-3272128cc635" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_1dfa31d2-428e-4acb-ab61-e39191e24a54" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_1dfa31d2-428e-4acb-ab61-e39191e24a54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_3c4b9bdf-0c42-4a94-9963-c0dd73d9d4a8" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_3c4b9bdf-0c42-4a94-9963-c0dd73d9d4a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_a322d52d-d390-46f6-b261-7447c8644da8" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_a322d52d-d390-46f6-b261-7447c8644da8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a84d7dea-14a0-42e3-bfbd-2c162d90c779" xlink:to="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_47501cdf-ebd6-4f07-b08a-365280c2f624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_47501cdf-ebd6-4f07-b08a-365280c2f624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_6d9b7537-3709-4a3b-b749-39723cfe6505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_6d9b7537-3709-4a3b-b749-39723cfe6505" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_cc41dd16-0a6c-48ac-b4da-5ce034d6d22f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:to="loc_us-gaap_ConvertibleNotesPayable_cc41dd16-0a6c-48ac-b4da-5ce034d6d22f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofConvertedValueofNotesDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_46ccd49e-6b3f-44d5-b524-64f892bbe03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_27a5c579-c971-4953-bab5-7c9fb4258672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46ccd49e-6b3f-44d5-b524-64f892bbe03d" xlink:to="loc_us-gaap_DebtInstrumentTable_27a5c579-c971-4953-bab5-7c9fb4258672" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a5f10e42-ead9-458f-b443-bc8453137646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_27a5c579-c971-4953-bab5-7c9fb4258672" xlink:to="loc_us-gaap_DebtInstrumentAxis_a5f10e42-ead9-458f-b443-bc8453137646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a5f10e42-ead9-458f-b443-bc8453137646_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a5f10e42-ead9-458f-b443-bc8453137646" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a5f10e42-ead9-458f-b443-bc8453137646_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a5f10e42-ead9-458f-b443-bc8453137646" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_0fafbab1-433e-4765-bb97-502e67089fc2" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_0fafbab1-433e-4765-bb97-502e67089fc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_38b0256e-02ad-4a0b-9add-41b915c07560" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_38b0256e-02ad-4a0b-9add-41b915c07560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_bb678a46-4736-4865-b04b-54451aab9f6b" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_bb678a46-4736-4865-b04b-54451aab9f6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c0c0572c-9f4c-4d95-b832-b7a14f341efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_27a5c579-c971-4953-bab5-7c9fb4258672" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c0c0572c-9f4c-4d95-b832-b7a14f341efb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c0c0572c-9f4c-4d95-b832-b7a14f341efb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c0c0572c-9f4c-4d95-b832-b7a14f341efb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c0c0572c-9f4c-4d95-b832-b7a14f341efb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0f0457d1-4f19-49c8-b18c-6a6be82d72cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c0c0572c-9f4c-4d95-b832-b7a14f341efb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0f0457d1-4f19-49c8-b18c-6a6be82d72cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f83dbef1-1c85-4f74-97b2-2e341a98cca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0f0457d1-4f19-49c8-b18c-6a6be82d72cd" xlink:to="loc_us-gaap_SeniorNotesMember_f83dbef1-1c85-4f74-97b2-2e341a98cca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_1d586e90-8c88-4b00-b453-b6f5105652b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46ccd49e-6b3f-44d5-b524-64f892bbe03d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_1d586e90-8c88-4b00-b453-b6f5105652b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ec5cca9b-8dac-4db9-bbee-17ac03b7ed31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:to="loc_us-gaap_DebtInstrumentTable_ec5cca9b-8dac-4db9-bbee-17ac03b7ed31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d42ce324-7425-40e6-b4dc-0800c15857b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ec5cca9b-8dac-4db9-bbee-17ac03b7ed31" xlink:to="loc_us-gaap_DebtInstrumentAxis_d42ce324-7425-40e6-b4dc-0800c15857b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d42ce324-7425-40e6-b4dc-0800c15857b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d42ce324-7425-40e6-b4dc-0800c15857b2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d42ce324-7425-40e6-b4dc-0800c15857b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d42ce324-7425-40e6-b4dc-0800c15857b2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_e749487c-52a9-4043-88b3-1ba8ef314894" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_e749487c-52a9-4043-88b3-1ba8ef314894" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_1e0dc387-431a-4412-9734-9bed1db67588" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_1e0dc387-431a-4412-9734-9bed1db67588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_1fbe2e47-05bc-48b0-8bca-6eb5e3e34fcb" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_1fbe2e47-05bc-48b0-8bca-6eb5e3e34fcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CashInterestExpenseAbstract_a78c92ed-8d79-4642-b48c-d272161f3108" xlink:href="dxcm-20231231.xsd#dxcm_CashInterestExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:to="loc_dxcm_CashInterestExpenseAbstract_a78c92ed-8d79-4642-b48c-d272161f3108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_b60a6406-5ebb-455a-8ead-fc2c0b27edc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_CashInterestExpenseAbstract_a78c92ed-8d79-4642-b48c-d272161f3108" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_b60a6406-5ebb-455a-8ead-fc2c0b27edc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_NonCashInterestExpenseAbstract_47a5aef7-fcbd-4074-b1a1-70a9864e5e2d" xlink:href="dxcm-20231231.xsd#dxcm_NonCashInterestExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:to="loc_dxcm_NonCashInterestExpenseAbstract_47a5aef7-fcbd-4074-b1a1-70a9864e5e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ebc58a5a-ed41-4400-888f-f98b3faf1c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_NonCashInterestExpenseAbstract_47a5aef7-fcbd-4074-b1a1-70a9864e5e2d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ebc58a5a-ed41-4400-888f-f98b3faf1c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_69d0488d-a853-4899-b18c-1fc5f5ad46ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_NonCashInterestExpenseAbstract_47a5aef7-fcbd-4074-b1a1-70a9864e5e2d" xlink:to="loc_us-gaap_InterestExpenseDebt_69d0488d-a853-4899-b18c-1fc5f5ad46ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a0d89fa9-b550-4478-aac0-c9da09e97831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a0d89fa9-b550-4478-aac0-c9da09e97831" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofKeyDetailsofConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6de4d4ec-c23d-4df0-9e1f-385a017c1d44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_DebtInstrumentTable_6de4d4ec-c23d-4df0-9e1f-385a017c1d44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_67437e9d-5088-49b1-af20-914ea06ecf44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6de4d4ec-c23d-4df0-9e1f-385a017c1d44" xlink:to="loc_us-gaap_DebtInstrumentAxis_67437e9d-5088-49b1-af20-914ea06ecf44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_67437e9d-5088-49b1-af20-914ea06ecf44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_67437e9d-5088-49b1-af20-914ea06ecf44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_67437e9d-5088-49b1-af20-914ea06ecf44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_67437e9d-5088-49b1-af20-914ea06ecf44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_f138ad2a-971d-45c1-877d-366830ef2652" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_f138ad2a-971d-45c1-877d-366830ef2652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_63013022-c66c-48aa-b68b-720ad07d9d8a" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_63013022-c66c-48aa-b68b-720ad07d9d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_dd5ae44d-e16f-43b3-9165-7cc9af8a433b" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_dd5ae44d-e16f-43b3-9165-7cc9af8a433b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_21b8fd13-5537-4e44-8679-45d4c4da4414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6de4d4ec-c23d-4df0-9e1f-385a017c1d44" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_21b8fd13-5537-4e44-8679-45d4c4da4414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_21b8fd13-5537-4e44-8679-45d4c4da4414_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_21b8fd13-5537-4e44-8679-45d4c4da4414" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_21b8fd13-5537-4e44-8679-45d4c4da4414_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c54cad5a-3dd2-4443-99bd-3e4848128ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_21b8fd13-5537-4e44-8679-45d4c4da4414" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c54cad5a-3dd2-4443-99bd-3e4848128ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_011663bb-700e-47e4-ab37-ef1247617b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c54cad5a-3dd2-4443-99bd-3e4848128ba2" xlink:to="loc_us-gaap_SeniorNotesMember_011663bb-700e-47e4-ab37-ef1247617b1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68577bfa-88e7-4a43-b96f-a8f5e7c4a1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68577bfa-88e7-4a43-b96f-a8f5e7c4a1ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fb722fed-f60c-4bbc-94d3-f69a24c3e793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fb722fed-f60c-4bbc-94d3-f69a24c3e793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_cdcb500d-27ea-4802-b8b3-84ce0a60322a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_cdcb500d-27ea-4802-b8b3-84ce0a60322a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5b66024c-6470-4020-94fa-9e40548865b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5b66024c-6470-4020-94fa-9e40548865b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_140d0b94-109b-45cb-a67f-eb9caf7820bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_140d0b94-109b-45cb-a67f-eb9caf7820bb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/Debt2023NoteHedgeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#Debt2023NoteHedgeDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/Debt2023NoteHedgeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:to="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_40f8aec5-aac8-4c31-96a4-cd02824ad443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:to="loc_us-gaap_DebtInstrumentAxis_40f8aec5-aac8-4c31-96a4-cd02824ad443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_40f8aec5-aac8-4c31-96a4-cd02824ad443_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_40f8aec5-aac8-4c31-96a4-cd02824ad443" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_40f8aec5-aac8-4c31-96a4-cd02824ad443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7be2ed3-a891-466f-9419-e937e0d99121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_40f8aec5-aac8-4c31-96a4-cd02824ad443" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7be2ed3-a891-466f-9419-e937e0d99121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_4e8e0340-51be-496a-bd24-f5412489f827" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7be2ed3-a891-466f-9419-e937e0d99121" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_4e8e0340-51be-496a-bd24-f5412489f827" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8f128f02-2fcf-4d18-adbf-842968626e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:to="loc_us-gaap_HedgingDesignationAxis_8f128f02-2fcf-4d18-adbf-842968626e0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8f128f02-2fcf-4d18-adbf-842968626e0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_8f128f02-2fcf-4d18-adbf-842968626e0d" xlink:to="loc_us-gaap_HedgingDesignationDomain_8f128f02-2fcf-4d18-adbf-842968626e0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_391df25b-38c3-4daf-86d8-6ffb994c0884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_8f128f02-2fcf-4d18-adbf-842968626e0d" xlink:to="loc_us-gaap_HedgingDesignationDomain_391df25b-38c3-4daf-86d8-6ffb994c0884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5cdbf547-15da-4e60-8152-4de636ef8152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_391df25b-38c3-4daf-86d8-6ffb994c0884" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5cdbf547-15da-4e60-8152-4de636ef8152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_384588e9-8544-4e58-a20c-6b540de5e4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_384588e9-8544-4e58-a20c-6b540de5e4e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_384588e9-8544-4e58-a20c-6b540de5e4e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_384588e9-8544-4e58-a20c-6b540de5e4e2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_384588e9-8544-4e58-a20c-6b540de5e4e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_70b2c24f-9180-4f31-81d1-d6d3745afdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_384588e9-8544-4e58-a20c-6b540de5e4e2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_70b2c24f-9180-4f31-81d1-d6d3745afdd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3bb84932-a4cc-425b-9413-7734736c1d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_70b2c24f-9180-4f31-81d1-d6d3745afdd6" xlink:to="loc_us-gaap_SeniorNotesMember_3bb84932-a4cc-425b-9413-7734736c1d29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares_2754df30-5a57-4489-a04a-0a31bc7a6393" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:to="loc_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares_2754df30-5a57-4489-a04a-0a31bc7a6393" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3eb3f691-81bb-4a8c-b09a-72e9bee44ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3eb3f691-81bb-4a8c-b09a-72e9bee44ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_c08a1733-2932-48d0-ac7d-d156f9070401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_c08a1733-2932-48d0-ac7d-d156f9070401" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/Debt2023WarrantsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#Debt2023WarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/Debt2023WarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1bf0364d-99d9-4a56-8c0f-fb8c1bf57d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:to="loc_us-gaap_DebtInstrumentTable_1bf0364d-99d9-4a56-8c0f-fb8c1bf57d24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4d7a6a5f-35b2-419b-8ac4-8b157cefe694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1bf0364d-99d9-4a56-8c0f-fb8c1bf57d24" xlink:to="loc_us-gaap_DebtInstrumentAxis_4d7a6a5f-35b2-419b-8ac4-8b157cefe694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4d7a6a5f-35b2-419b-8ac4-8b157cefe694_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4d7a6a5f-35b2-419b-8ac4-8b157cefe694" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4d7a6a5f-35b2-419b-8ac4-8b157cefe694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0fd5863-ba54-4fed-b0d5-bd08cf396151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4d7a6a5f-35b2-419b-8ac4-8b157cefe694" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0fd5863-ba54-4fed-b0d5-bd08cf396151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_b6190eb9-bd1d-4ab8-944b-067807768ab7" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fd5863-ba54-4fed-b0d5-bd08cf396151" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_b6190eb9-bd1d-4ab8-944b-067807768ab7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aa4f3702-86d1-4af0-b6d6-f84950abfdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1bf0364d-99d9-4a56-8c0f-fb8c1bf57d24" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aa4f3702-86d1-4af0-b6d6-f84950abfdbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aa4f3702-86d1-4af0-b6d6-f84950abfdbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa4f3702-86d1-4af0-b6d6-f84950abfdbc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aa4f3702-86d1-4af0-b6d6-f84950abfdbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6bc2f1da-d89b-4976-baa1-a9de60b05a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa4f3702-86d1-4af0-b6d6-f84950abfdbc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6bc2f1da-d89b-4976-baa1-a9de60b05a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ce941d7b-01e5-44dd-b5bb-3f55d1c1be61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6bc2f1da-d89b-4976-baa1-a9de60b05a6e" xlink:to="loc_us-gaap_SeniorNotesMember_ce941d7b-01e5-44dd-b5bb-3f55d1c1be61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_653bd752-acc1-430e-92af-c2975c824095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_653bd752-acc1-430e-92af-c2975c824095" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_7f68ef69-62fb-4db8-a1b8-47f30c030395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_7f68ef69-62fb-4db8-a1b8-47f30c030395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_2e29a2ad-5403-4068-9bbf-d18ffd6394ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_2e29a2ad-5403-4068-9bbf-d18ffd6394ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aa1aac10-8c41-4f98-ae7a-eb9f0b158fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aa1aac10-8c41-4f98-ae7a-eb9f0b158fcb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#Debt2028CappedCallTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bb293843-5467-4c1b-9850-faf44d2b77fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:to="loc_us-gaap_DebtInstrumentTable_bb293843-5467-4c1b-9850-faf44d2b77fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf32a4b3-d048-4edb-bb1e-b08a7915a32d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bb293843-5467-4c1b-9850-faf44d2b77fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf32a4b3-d048-4edb-bb1e-b08a7915a32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cf32a4b3-d048-4edb-bb1e-b08a7915a32d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf32a4b3-d048-4edb-bb1e-b08a7915a32d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cf32a4b3-d048-4edb-bb1e-b08a7915a32d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98548308-35a0-4c3b-b583-5fdef346e271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf32a4b3-d048-4edb-bb1e-b08a7915a32d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98548308-35a0-4c3b-b583-5fdef346e271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_bfe65050-3cce-4cfa-b645-95991d446247" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98548308-35a0-4c3b-b583-5fdef346e271" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_bfe65050-3cce-4cfa-b645-95991d446247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b3292c10-9940-4185-b46d-1468ade7e2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bb293843-5467-4c1b-9850-faf44d2b77fe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b3292c10-9940-4185-b46d-1468ade7e2ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b3292c10-9940-4185-b46d-1468ade7e2ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b3292c10-9940-4185-b46d-1468ade7e2ee" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b3292c10-9940-4185-b46d-1468ade7e2ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3795ed29-37a9-4519-aec0-f9be8aa628c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b3292c10-9940-4185-b46d-1468ade7e2ee" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3795ed29-37a9-4519-aec0-f9be8aa628c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f65ca643-751d-453a-8192-47974728b748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3795ed29-37a9-4519-aec0-f9be8aa628c5" xlink:to="loc_us-gaap_SeniorNotesMember_f65ca643-751d-453a-8192-47974728b748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare_69313157-26c4-47bd-a5ed-c7f551286367" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:to="loc_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare_69313157-26c4-47bd-a5ed-c7f551286367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage_fbe8ed95-be0b-43ab-b9bd-20f505beb064" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:to="loc_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage_fbe8ed95-be0b-43ab-b9bd-20f505beb064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_98ff5efd-f8e1-4243-8d84-18baad483034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:to="loc_us-gaap_SharePrice_98ff5efd-f8e1-4243-8d84-18baad483034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions_f28d4dbd-1a2f-4ddc-bd3f-feeb7fc682fb" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsForPurchasesOfCappedCallTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:to="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions_f28d4dbd-1a2f-4ddc-bd3f-feeb7fc682fb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtConversionActivityforSeniorConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:to="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a94165a-11c5-4107-b7da-f82070079118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a94165a-11c5-4107-b7da-f82070079118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a94165a-11c5-4107-b7da-f82070079118_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a94165a-11c5-4107-b7da-f82070079118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a94165a-11c5-4107-b7da-f82070079118_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0a835c7-08b7-4d76-839d-2a48b1ffe8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a94165a-11c5-4107-b7da-f82070079118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0a835c7-08b7-4d76-839d-2a48b1ffe8c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_dba6600e-7896-4666-9608-1b71b67cc8dd" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0a835c7-08b7-4d76-839d-2a48b1ffe8c5" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_dba6600e-7896-4666-9608-1b71b67cc8dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a6255ca8-d7d1-48a4-ae9d-02c4acb28bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a6255ca8-d7d1-48a4-ae9d-02c4acb28bcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a6255ca8-d7d1-48a4-ae9d-02c4acb28bcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a6255ca8-d7d1-48a4-ae9d-02c4acb28bcd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a6255ca8-d7d1-48a4-ae9d-02c4acb28bcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df9f297f-297c-4d1f-a029-d9e4e8401e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a6255ca8-d7d1-48a4-ae9d-02c4acb28bcd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df9f297f-297c-4d1f-a029-d9e4e8401e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_12105073-acd5-4f28-9ef9-c0df1e07686c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df9f297f-297c-4d1f-a029-d9e4e8401e2e" xlink:to="loc_us-gaap_SeniorNotesMember_12105073-acd5-4f28-9ef9-c0df1e07686c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb3a2796-652e-43f9-85bc-fa8388ecade1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb3a2796-652e-43f9-85bc-fa8388ecade1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb3a2796-652e-43f9-85bc-fa8388ecade1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb3a2796-652e-43f9-85bc-fa8388ecade1" xlink:to="loc_us-gaap_EquityComponentDomain_eb3a2796-652e-43f9-85bc-fa8388ecade1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45c1d82f-19b2-4de9-91dc-1f65d3436f46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb3a2796-652e-43f9-85bc-fa8388ecade1" xlink:to="loc_us-gaap_EquityComponentDomain_45c1d82f-19b2-4de9-91dc-1f65d3436f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3303a111-b0fc-4c89-b56a-7e28a4c527ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45c1d82f-19b2-4de9-91dc-1f65d3436f46" xlink:to="loc_us-gaap_CommonStockMember_3303a111-b0fc-4c89-b56a-7e28a4c527ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled_e1d9e259-6fc9-49b6-9a25-8e35c04c1de0" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:to="loc_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled_e1d9e259-6fc9-49b6-9a25-8e35c04c1de0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_191ab2f6-410a-473b-b776-05426807852b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_191ab2f6-410a-473b-b776-05426807852b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromBenefitOfNoteHedge_5a0e5cb7-39c1-4ea7-be30-f9289bd5e17c" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromBenefitOfNoteHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:to="loc_dxcm_SharesReceivedFromBenefitOfNoteHedge_5a0e5cb7-39c1-4ea7-be30-f9289bd5e17c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtConversionRightsforSeniorsConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_12af25a3-0fc9-4571-948b-b09c7596f3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:to="loc_us-gaap_DebtInstrumentAxis_12af25a3-0fc9-4571-948b-b09c7596f3f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_12af25a3-0fc9-4571-948b-b09c7596f3f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_12af25a3-0fc9-4571-948b-b09c7596f3f4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_12af25a3-0fc9-4571-948b-b09c7596f3f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_357d3cca-3268-419f-be1d-0f087c8f4f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_12af25a3-0fc9-4571-948b-b09c7596f3f4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_357d3cca-3268-419f-be1d-0f087c8f4f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_b8fd1833-7a91-4c30-b7c5-2ea07de2a114" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_357d3cca-3268-419f-be1d-0f087c8f4f5c" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_b8fd1833-7a91-4c30-b7c5-2ea07de2a114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_638ec0ba-07e9-45ea-85f9-6a3cb3c6c14a" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_357d3cca-3268-419f-be1d-0f087c8f4f5c" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_638ec0ba-07e9-45ea-85f9-6a3cb3c6c14a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_88302c2c-ba16-4dee-9ef5-5a705b3852dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_88302c2c-ba16-4dee-9ef5-5a705b3852dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_88302c2c-ba16-4dee-9ef5-5a705b3852dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_88302c2c-ba16-4dee-9ef5-5a705b3852dd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_88302c2c-ba16-4dee-9ef5-5a705b3852dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_82382679-1df3-4288-80cf-b33890ffc970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_88302c2c-ba16-4dee-9ef5-5a705b3852dd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_82382679-1df3-4288-80cf-b33890ffc970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1e0114a8-dce9-4cf3-9c41-757c6e8fd641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_82382679-1df3-4288-80cf-b33890ffc970" xlink:to="loc_us-gaap_SeniorNotesMember_1e0114a8-dce9-4cf3-9c41-757c6e8fd641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermAxis_16deee48-9dd8-439c-beef-80a15f71b708" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:to="loc_dxcm_DebtInstrumentConversionTermAxis_16deee48-9dd8-439c-beef-80a15f71b708" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermDomain_16deee48-9dd8-439c-beef-80a15f71b708_default" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dxcm_DebtInstrumentConversionTermAxis_16deee48-9dd8-439c-beef-80a15f71b708" xlink:to="loc_dxcm_DebtInstrumentConversionTermDomain_16deee48-9dd8-439c-beef-80a15f71b708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermDomain_a13b5f56-7b85-4f56-bb62-08fa95211899" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dxcm_DebtInstrumentConversionTermAxis_16deee48-9dd8-439c-beef-80a15f71b708" xlink:to="loc_dxcm_DebtInstrumentConversionTermDomain_a13b5f56-7b85-4f56-bb62-08fa95211899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermOneMember_7f555d70-fa38-4fc5-9a86-23b0cd1bd079" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DebtInstrumentConversionTermDomain_a13b5f56-7b85-4f56-bb62-08fa95211899" xlink:to="loc_dxcm_DebtInstrumentConversionTermOneMember_7f555d70-fa38-4fc5-9a86-23b0cd1bd079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermTwoMember_3cddea3b-9270-446d-befe-197d17fc0f42" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_DebtInstrumentConversionTermDomain_a13b5f56-7b85-4f56-bb62-08fa95211899" xlink:to="loc_dxcm_DebtInstrumentConversionTermTwoMember_3cddea3b-9270-446d-befe-197d17fc0f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_debebe0a-0576-46b7-9b5c-833693beb168" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:to="loc_srt_RangeAxis_debebe0a-0576-46b7-9b5c-833693beb168" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_debebe0a-0576-46b7-9b5c-833693beb168_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_debebe0a-0576-46b7-9b5c-833693beb168" xlink:to="loc_srt_RangeMember_debebe0a-0576-46b7-9b5c-833693beb168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68ae1bd1-6eea-4b99-93cc-6aebc3e4cecf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_debebe0a-0576-46b7-9b5c-833693beb168" xlink:to="loc_srt_RangeMember_68ae1bd1-6eea-4b99-93cc-6aebc3e4cecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2205bfe1-db84-4832-b9cd-052ac0cff866" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68ae1bd1-6eea-4b99-93cc-6aebc3e4cecf" xlink:to="loc_srt_MinimumMember_2205bfe1-db84-4832-b9cd-052ac0cff866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb43483e-5b88-4889-be4e-5a972dae7532" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68ae1bd1-6eea-4b99-93cc-6aebc3e4cecf" xlink:to="loc_srt_MaximumMember_fb43483e-5b88-4889-be4e-5a972dae7532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentCovenantRepurchasePricePercentage_95aada60-7d78-499c-b07f-6a743ab34b53" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentCovenantRepurchasePricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_dxcm_DebtInstrumentCovenantRepurchasePricePercentage_95aada60-7d78-499c-b07f-6a743ab34b53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_8c96df24-b196-4566-980a-e1f2e99642d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_8c96df24-b196-4566-980a-e1f2e99642d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_54745c74-e664-4231-872d-85481e8ec423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_54745c74-e664-4231-872d-85481e8ec423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock_8971fe68-fc87-42c2-8f13-f05b550c2adb" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock_8971fe68-fc87-42c2-8f13-f05b550c2adb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d70248d5-e432-486f-8d1a-f991d709941f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d70248d5-e432-486f-8d1a-f991d709941f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_507c7368-2066-4454-acbc-c264f99e73a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_507c7368-2066-4454-acbc-c264f99e73a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_507c7368-2066-4454-acbc-c264f99e73a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_507c7368-2066-4454-acbc-c264f99e73a7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_507c7368-2066-4454-acbc-c264f99e73a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f93cb64e-c9a7-4466-9867-575718e9d8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_507c7368-2066-4454-acbc-c264f99e73a7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f93cb64e-c9a7-4466-9867-575718e9d8ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_eb2daeb2-98a1-40e9-b12e-63a8da2cb0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f93cb64e-c9a7-4466-9867-575718e9d8ad" xlink:to="loc_us-gaap_LineOfCreditMember_eb2daeb2-98a1-40e9-b12e-63a8da2cb0c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_292d459c-1960-48a1-bb06-d75fdf88e6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:to="loc_us-gaap_CreditFacilityAxis_292d459c-1960-48a1-bb06-d75fdf88e6e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_292d459c-1960-48a1-bb06-d75fdf88e6e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_292d459c-1960-48a1-bb06-d75fdf88e6e7" xlink:to="loc_us-gaap_CreditFacilityDomain_292d459c-1960-48a1-bb06-d75fdf88e6e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1cf23003-3123-4d68-98a8-04a5e9f6dbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_292d459c-1960-48a1-bb06-d75fdf88e6e7" xlink:to="loc_us-gaap_CreditFacilityDomain_1cf23003-3123-4d68-98a8-04a5e9f6dbb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_86a2c9b8-172f-48e2-a955-2f0c5567dfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1cf23003-3123-4d68-98a8-04a5e9f6dbb0" xlink:to="loc_us-gaap_LetterOfCreditMember_86a2c9b8-172f-48e2-a955-2f0c5567dfa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da2bb1d5-e485-4396-8c4d-a4d504507091" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:to="loc_srt_RangeAxis_da2bb1d5-e485-4396-8c4d-a4d504507091" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da2bb1d5-e485-4396-8c4d-a4d504507091_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_da2bb1d5-e485-4396-8c4d-a4d504507091" xlink:to="loc_srt_RangeMember_da2bb1d5-e485-4396-8c4d-a4d504507091_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94353d3c-5507-4d2d-ac1f-c7b263a09c71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_da2bb1d5-e485-4396-8c4d-a4d504507091" xlink:to="loc_srt_RangeMember_94353d3c-5507-4d2d-ac1f-c7b263a09c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0c18eab8-d3d9-4261-881c-9b88f9857800" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_94353d3c-5507-4d2d-ac1f-c7b263a09c71" xlink:to="loc_srt_MinimumMember_0c18eab8-d3d9-4261-881c-9b88f9857800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5d9dca5-9051-4bc2-831b-3823e5ef1b8f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_94353d3c-5507-4d2d-ac1f-c7b263a09c71" xlink:to="loc_srt_MaximumMember_d5d9dca5-9051-4bc2-831b-3823e5ef1b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e0787b82-545f-4c7f-8da8-29f90b41e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:to="loc_us-gaap_VariableRateAxis_e0787b82-545f-4c7f-8da8-29f90b41e4bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e0787b82-545f-4c7f-8da8-29f90b41e4bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_e0787b82-545f-4c7f-8da8-29f90b41e4bb" xlink:to="loc_us-gaap_VariableRateDomain_e0787b82-545f-4c7f-8da8-29f90b41e4bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_342a73b9-6f8a-45de-9a8a-7800f34b5e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_e0787b82-545f-4c7f-8da8-29f90b41e4bb" xlink:to="loc_us-gaap_VariableRateDomain_342a73b9-6f8a-45de-9a8a-7800f34b5e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_5386fa59-0c13-48db-9ddb-24b6cd4aa4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_342a73b9-6f8a-45de-9a8a-7800f34b5e08" xlink:to="loc_us-gaap_BaseRateMember_5386fa59-0c13-48db-9ddb-24b6cd4aa4f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LondonInterbankOfferedRateLIBOR1Member_09497315-6c00-4bfc-a5b5-4f810041739f" xlink:href="dxcm-20231231.xsd#dxcm_LondonInterbankOfferedRateLIBOR1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_342a73b9-6f8a-45de-9a8a-7800f34b5e08" xlink:to="loc_dxcm_LondonInterbankOfferedRateLIBOR1Member_09497315-6c00-4bfc-a5b5-4f810041739f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4eb05e52-90de-4e28-853c-1605cb679f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4eb05e52-90de-4e28-853c-1605cb679f4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_06d26d66-29da-4a60-8a84-1fa7b0d78cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LineOfCredit_06d26d66-29da-4a60-8a84-1fa7b0d78cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_1cce002c-70a1-44d9-872f-ee52727be5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_1cce002c-70a1-44d9-872f-ee52727be5fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_43b0f87a-2c94-4aa1-84e9-a12949b932ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_43b0f87a-2c94-4aa1-84e9-a12949b932ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_167aaf69-2248-40f5-8a8e-5105956bace6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_167aaf69-2248-40f5-8a8e-5105956bace6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2b7f90cb-ded1-497a-a9b5-825982e8e52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2b7f90cb-ded1-497a-a9b5-825982e8e52d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtRevolvingCreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_0f049b3c-9163-420a-bfbc-f4004d3f6d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_0f049b3c-9163-420a-bfbc-f4004d3f6d33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9d9c02a2-ed9d-40e4-830f-9473a417b226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0f049b3c-9163-420a-bfbc-f4004d3f6d33" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9d9c02a2-ed9d-40e4-830f-9473a417b226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9d9c02a2-ed9d-40e4-830f-9473a417b226_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9d9c02a2-ed9d-40e4-830f-9473a417b226" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9d9c02a2-ed9d-40e4-830f-9473a417b226_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d60dd216-e61d-4fef-9422-ed2d346aa07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9d9c02a2-ed9d-40e4-830f-9473a417b226" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d60dd216-e61d-4fef-9422-ed2d346aa07b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_607cd4cf-87d9-4e14-b5bf-a32fed7980ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d60dd216-e61d-4fef-9422-ed2d346aa07b" xlink:to="loc_us-gaap_LineOfCreditMember_607cd4cf-87d9-4e14-b5bf-a32fed7980ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_ad95b200-d80c-4bca-8acd-7360971bdaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:to="loc_us-gaap_DebtInstrumentTerm_ad95b200-d80c-4bca-8acd-7360971bdaf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6d6723e0-c698-4ead-b880-4ca1f9817c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6d6723e0-c698-4ead-b880-4ca1f9817c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount_9a81fcb3-89c7-420f-9e06-eaec4a252b58" xlink:href="dxcm-20231231.xsd#dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:to="loc_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount_9a81fcb3-89c7-420f-9e06-eaec4a252b58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets_433e72e8-6503-4d23-820f-0a66ced1c95a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:to="loc_us-gaap_DepositAssets_433e72e8-6503-4d23-820f-0a66ced1c95a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_71dfdd60-b80a-4de4-997a-deb3c9b81a84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_71dfdd60-b80a-4de4-997a-deb3c9b81a84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00cacbb9-d35b-48d8-8f9e-b0cbf4c6fec0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_71dfdd60-b80a-4de4-997a-deb3c9b81a84" xlink:to="loc_srt_RangeAxis_00cacbb9-d35b-48d8-8f9e-b0cbf4c6fec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00cacbb9-d35b-48d8-8f9e-b0cbf4c6fec0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_00cacbb9-d35b-48d8-8f9e-b0cbf4c6fec0" xlink:to="loc_srt_RangeMember_00cacbb9-d35b-48d8-8f9e-b0cbf4c6fec0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37828310-e7d2-4187-82f9-74f50d5b6725" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_00cacbb9-d35b-48d8-8f9e-b0cbf4c6fec0" xlink:to="loc_srt_RangeMember_37828310-e7d2-4187-82f9-74f50d5b6725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f0d7bb8f-6b10-4f79-bf25-dd906be85e44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37828310-e7d2-4187-82f9-74f50d5b6725" xlink:to="loc_srt_MaximumMember_f0d7bb8f-6b10-4f79-bf25-dd906be85e44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5a8805f-30c9-4270-91c8-bc4ebb6c3682" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37828310-e7d2-4187-82f9-74f50d5b6725" xlink:to="loc_srt_MinimumMember_e5a8805f-30c9-4270-91c8-bc4ebb6c3682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_61fa068c-8c2c-4c1b-9f56-6fd42cd70d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_61fa068c-8c2c-4c1b-9f56-6fd42cd70d38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend_6c736b30-5635-4136-831f-945f213c8947" xlink:href="dxcm-20231231.xsd#dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend_6c736b30-5635-4136-831f-945f213c8947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_60b61059-5a0c-4aba-a577-d95bc79477e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_60b61059-5a0c-4aba-a577-d95bc79477e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_29bd88ff-25ce-4246-b78d-1e03c0cf7c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_29bd88ff-25ce-4246-b78d-1e03c0cf7c16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation_78398542-89b9-4c15-9437-6b8a25f7394e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetRetirementObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_AssetRetirementObligation_78398542-89b9-4c15-9437-6b8a25f7394e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e35a3641-0d38-4aaa-b63f-38865737ab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e35a3641-0d38-4aaa-b63f-38865737ab9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_30e7b1ee-4d08-4b94-9710-599928473745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_30e7b1ee-4d08-4b94-9710-599928473745" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ImpairedLongLivedAssetsFairValue_fd80648e-24d0-480d-963c-5daa5ff91191" xlink:href="dxcm-20231231.xsd#dxcm_ImpairedLongLivedAssetsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_dxcm_ImpairedLongLivedAssetsFairValue_fd80648e-24d0-480d-963c-5daa5ff91191" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LesseeOperatingLeasesLeaseCostAmortization_3a5c858c-d965-4401-a06b-5f1ad16fe277" xlink:href="dxcm-20231231.xsd#dxcm_LesseeOperatingLeasesLeaseCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_dxcm_LesseeOperatingLeasesLeaseCostAmortization_3a5c858c-d965-4401-a06b-5f1ad16fe277" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_5ad6f569-ec8b-4fe8-8d54-283b51d5fa16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_5ad6f569-ec8b-4fe8-8d54-283b51d5fa16" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm_7e24595e-584a-483f-a417-dd4a9b19563b" xlink:href="dxcm-20231231.xsd#dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm_7e24595e-584a-483f-a417-dd4a9b19563b" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_125f242e-bccc-4119-8e3a-7487fdc62995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_125f242e-bccc-4119-8e3a-7487fdc62995" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_267e92e7-fec9-44e7-a737-c8a873c180e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_267e92e7-fec9-44e7-a737-c8a873c180e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_267e92e7-fec9-44e7-a737-c8a873c180e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_267e92e7-fec9-44e7-a737-c8a873c180e9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_267e92e7-fec9-44e7-a737-c8a873c180e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_267e92e7-fec9-44e7-a737-c8a873c180e9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4cf9ebff-ee05-4bc5-8b60-08326ff34965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:to="loc_us-gaap_DomesticCountryMember_4cf9ebff-ee05-4bc5-8b60-08326ff34965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_dd25d71b-48d7-460a-afb2-2522070d2555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_dd25d71b-48d7-460a-afb2-2522070d2555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_53e9468c-5bc3-442b-ae2a-83d4d0671d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:to="loc_us-gaap_ForeignCountryMember_53e9468c-5bc3-442b-ae2a-83d4d0671d43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_08a27bf9-4a61-49ec-9070-dd0bea2f6947" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:to="loc_srt_StatementGeographicalAxis_08a27bf9-4a61-49ec-9070-dd0bea2f6947" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_08a27bf9-4a61-49ec-9070-dd0bea2f6947_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_08a27bf9-4a61-49ec-9070-dd0bea2f6947" xlink:to="loc_srt_SegmentGeographicalDomain_08a27bf9-4a61-49ec-9070-dd0bea2f6947_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_08a27bf9-4a61-49ec-9070-dd0bea2f6947" xlink:to="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_aaf4b395-c9e1-4c08-8922-0f597a8a0353" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:to="loc_stpr_CA_aaf4b395-c9e1-4c08-8922-0f597a8a0353" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherStatesMember_d10df970-8b07-4ef2-bbab-4bb219841194" xlink:href="dxcm-20231231.xsd#dxcm_OtherStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:to="loc_dxcm_OtherStatesMember_d10df970-8b07-4ef2-bbab-4bb219841194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_36cde68b-d946-41e2-94b2-29b8058fd2f6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:to="loc_country_GB_36cde68b-d946-41e2-94b2-29b8058fd2f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherForeignMember_d123b5c7-5c39-4950-a4d7-516679d16a31" xlink:href="dxcm-20231231.xsd#dxcm_OtherForeignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:to="loc_dxcm_OtherForeignMember_d123b5c7-5c39-4950-a4d7-516679d16a31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_d3dfd9ff-e4f5-45d6-8336-27e57e407c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_d3dfd9ff-e4f5-45d6-8336-27e57e407c5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d3dfd9ff-e4f5-45d6-8336-27e57e407c5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d3dfd9ff-e4f5-45d6-8336-27e57e407c5a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d3dfd9ff-e4f5-45d6-8336-27e57e407c5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d3dfd9ff-e4f5-45d6-8336-27e57e407c5a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ResearchDevelopmentTaxCreditsMember_908cb467-4eff-4996-b5f1-5992519dc6f2" xlink:href="dxcm-20231231.xsd#dxcm_ResearchDevelopmentTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:to="loc_dxcm_ResearchDevelopmentTaxCreditsMember_908cb467-4eff-4996-b5f1-5992519dc6f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ForeignTaxCreditsMember_ec3084de-4c72-4367-9b2b-418a63616096" xlink:href="dxcm-20231231.xsd#dxcm_ForeignTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:to="loc_dxcm_ForeignTaxCreditsMember_ec3084de-4c72-4367-9b2b-418a63616096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AMTTaxCreditsMember_a077c29a-d7d1-40d7-b64d-774f941e7e18" xlink:href="dxcm-20231231.xsd#dxcm_AMTTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:to="loc_dxcm_AMTTaxCreditsMember_a077c29a-d7d1-40d7-b64d-774f941e7e18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_87ed697f-6c0c-468c-b376-bb77c8ebed53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_125f242e-bccc-4119-8e3a-7487fdc62995" xlink:to="loc_us-gaap_OperatingLossCarryforwards_87ed697f-6c0c-468c-b376-bb77c8ebed53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_463e9059-ac0e-4f1b-a3dc-78ed098b45a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_125f242e-bccc-4119-8e3a-7487fdc62995" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_463e9059-ac0e-4f1b-a3dc-78ed098b45a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_518ef6bb-c823-4dc3-b6f3-3320d5d0025f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_518ef6bb-c823-4dc3-b6f3-3320d5d0025f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d8d4375c-f620-4e9a-bd86-912906058d07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_518ef6bb-c823-4dc3-b6f3-3320d5d0025f" xlink:to="loc_srt_StatementGeographicalAxis_d8d4375c-f620-4e9a-bd86-912906058d07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d8d4375c-f620-4e9a-bd86-912906058d07_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d8d4375c-f620-4e9a-bd86-912906058d07" xlink:to="loc_srt_SegmentGeographicalDomain_d8d4375c-f620-4e9a-bd86-912906058d07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e1946713-79b5-4875-941d-b72d625954c4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d8d4375c-f620-4e9a-bd86-912906058d07" xlink:to="loc_srt_SegmentGeographicalDomain_e1946713-79b5-4875-941d-b72d625954c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_0ac0f9b2-173c-4445-bd5d-0fc5c61ec8ba" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e1946713-79b5-4875-941d-b72d625954c4" xlink:to="loc_stpr_CA_0ac0f9b2-173c-4445-bd5d-0fc5c61ec8ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_UnusedExpiredFederalIncomeTaxCredits_29155b97-2c3f-4b55-9a00-09592561b599" xlink:href="dxcm-20231231.xsd#dxcm_UnusedExpiredFederalIncomeTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_dxcm_UnusedExpiredFederalIncomeTaxCredits_29155b97-2c3f-4b55-9a00-09592561b599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_24a876d9-3128-4ead-87e0-e637fd8e6717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_24a876d9-3128-4ead-87e0-e637fd8e6717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_87b0f2df-39db-4b78-94e5-b2bd7fdfd3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_87b0f2df-39db-4b78-94e5-b2bd7fdfd3c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_21a439d3-1d97-4d41-819b-a12c255d7a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_21a439d3-1d97-4d41-819b-a12c255d7a5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5ccaf641-9ba4-47ce-9c9c-5f6bba18faaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5ccaf641-9ba4-47ce-9c9c-5f6bba18faaa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets_47332410-75be-4b1d-905c-add192f865e2" xlink:href="dxcm-20231231.xsd#dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets_47332410-75be-4b1d-905c-add192f865e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PossibleExtensionPeriodofTaxHoliday_d234a927-89a9-424c-9072-a5bf9e3a90c8" xlink:href="dxcm-20231231.xsd#dxcm_PossibleExtensionPeriodofTaxHoliday"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_dxcm_PossibleExtensionPeriodofTaxHoliday_d234a927-89a9-424c-9072-a5bf9e3a90c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PreferentialTaxRatePeriod_4638e497-fa90-496a-bdb7-853786d3a675" xlink:href="dxcm-20231231.xsd#dxcm_PreferentialTaxRatePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_dxcm_PreferentialTaxRatePeriod_4638e497-fa90-496a-bdb7-853786d3a675" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_7a1b4a88-82f0-4478-9d58-7808844f67d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_7a1b4a88-82f0-4478-9d58-7808844f67d0" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0af3ed74-92ee-45d0-b20e-99b8d258a397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:to="loc_us-gaap_AwardTypeAxis_0af3ed74-92ee-45d0-b20e-99b8d258a397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0af3ed74-92ee-45d0-b20e-99b8d258a397_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0af3ed74-92ee-45d0-b20e-99b8d258a397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0af3ed74-92ee-45d0-b20e-99b8d258a397_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86da479e-eaa9-4a2f-8778-d006827a8e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0af3ed74-92ee-45d0-b20e-99b8d258a397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86da479e-eaa9-4a2f-8778-d006827a8e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_ac4f24a3-8c20-452c-be56-975ca13d1b21" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86da479e-eaa9-4a2f-8778-d006827a8e2d" xlink:to="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_ac4f24a3-8c20-452c-be56-975ca13d1b21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f9eb01bd-fc59-41d7-a148-7588e1fa84c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_ac4f24a3-8c20-452c-be56-975ca13d1b21" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f9eb01bd-fc59-41d7-a148-7588e1fa84c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5de0b061-f8d2-4e12-a294-1a155ac3a647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_ac4f24a3-8c20-452c-be56-975ca13d1b21" xlink:to="loc_us-gaap_PerformanceSharesMember_5de0b061-f8d2-4e12-a294-1a155ac3a647" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1dfa5d47-93f2-4d74-8b94-0a2a8f3e44e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:to="loc_us-gaap_PlanNameAxis_1dfa5d47-93f2-4d74-8b94-0a2a8f3e44e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1dfa5d47-93f2-4d74-8b94-0a2a8f3e44e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1dfa5d47-93f2-4d74-8b94-0a2a8f3e44e2" xlink:to="loc_us-gaap_PlanNameDomain_1dfa5d47-93f2-4d74-8b94-0a2a8f3e44e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1dfa5d47-93f2-4d74-8b94-0a2a8f3e44e2" xlink:to="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A401kPlanMember_0f3ab942-2635-4915-b766-3b15c9f68b21" xlink:href="dxcm-20231231.xsd#dxcm_A401kPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:to="loc_dxcm_A401kPlanMember_0f3ab942-2635-4915-b766-3b15c9f68b21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeeStockPurchasePlan2015Member_95620265-c81b-443a-8430-e0972659cd10" xlink:href="dxcm-20231231.xsd#dxcm_EmployeeStockPurchasePlan2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:to="loc_dxcm_EmployeeStockPurchasePlan2015Member_95620265-c81b-443a-8430-e0972659cd10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EquityIncentivePlan2015Member_da7a25fe-ec5c-4a5a-9477-6c6dc97348e1" xlink:href="dxcm-20231231.xsd#dxcm_EquityIncentivePlan2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:to="loc_dxcm_EquityIncentivePlan2015Member_da7a25fe-ec5c-4a5a-9477-6c6dc97348e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5cc3b6a7-6b03-43ea-9617-9a5ab4a0adb1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:to="loc_srt_RangeAxis_5cc3b6a7-6b03-43ea-9617-9a5ab4a0adb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5cc3b6a7-6b03-43ea-9617-9a5ab4a0adb1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5cc3b6a7-6b03-43ea-9617-9a5ab4a0adb1" xlink:to="loc_srt_RangeMember_5cc3b6a7-6b03-43ea-9617-9a5ab4a0adb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07c4427e-152b-48ec-b121-cd21212a66c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5cc3b6a7-6b03-43ea-9617-9a5ab4a0adb1" xlink:to="loc_srt_RangeMember_07c4427e-152b-48ec-b121-cd21212a66c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_68205224-3946-44d9-b4bc-df88b83734bf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07c4427e-152b-48ec-b121-cd21212a66c8" xlink:to="loc_srt_MinimumMember_68205224-3946-44d9-b4bc-df88b83734bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_283b28ab-e355-4851-bd8c-ace0cc508290" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07c4427e-152b-48ec-b121-cd21212a66c8" xlink:to="loc_srt_MaximumMember_283b28ab-e355-4851-bd8c-ace0cc508290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_3489b6f0-67f0-45c1-8f6b-be79b2f1c5af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_3489b6f0-67f0-45c1-8f6b-be79b2f1c5af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_3489b6f0-67f0-45c1-8f6b-be79b2f1c5af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3489b6f0-67f0-45c1-8f6b-be79b2f1c5af" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_3489b6f0-67f0-45c1-8f6b-be79b2f1c5af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_c25673f9-0db2-4abd-bac7-5b9fad61bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3489b6f0-67f0-45c1-8f6b-be79b2f1c5af" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_c25673f9-0db2-4abd-bac7-5b9fad61bb09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ShareRepurchaseProgramMember_e86f4e4b-cc5e-4148-89b9-01f742980414" xlink:href="dxcm-20231231.xsd#dxcm_ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_c25673f9-0db2-4abd-bac7-5b9fad61bb09" xlink:to="loc_dxcm_ShareRepurchaseProgramMember_e86f4e4b-cc5e-4148-89b9-01f742980414" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AcceleratedShareRepurchaseASRMember_d5bcad0b-4d0e-4d61-8c30-b7bbc3190f9a" xlink:href="dxcm-20231231.xsd#dxcm_AcceleratedShareRepurchaseASRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_c25673f9-0db2-4abd-bac7-5b9fad61bb09" xlink:to="loc_dxcm_AcceleratedShareRepurchaseASRMember_d5bcad0b-4d0e-4d61-8c30-b7bbc3190f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0264d527-6f3c-438d-9869-c4433a6ee290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0264d527-6f3c-438d-9869-c4433a6ee290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_67e5be6b-0304-47b5-a28f-ee75e2d385b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_67e5be6b-0304-47b5-a28f-ee75e2d385b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6a04bba0-a193-454b-a3ed-588243014205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6a04bba0-a193-454b-a3ed-588243014205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_c98a2384-43d9-4550-87de-6efc92679c20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_c98a2384-43d9-4550-87de-6efc92679c20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_79167e50-9de0-4c65-bf2b-90fb6b61649f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_79167e50-9de0-4c65-bf2b-90fb6b61649f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeePurchasePriceFloorPercentage_91e790de-31da-4961-a801-e5fefa5b013a" xlink:href="dxcm-20231231.xsd#dxcm_EmployeePurchasePriceFloorPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_dxcm_EmployeePurchasePriceFloorPercentage_91e790de-31da-4961-a801-e5fefa5b013a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized_c8f51fb7-9833-40a6-a1fa-01e81b61b14a" xlink:href="dxcm-20231231.xsd#dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized_c8f51fb7-9833-40a6-a1fa-01e81b61b14a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_160213f6-4d37-488f-8833-c9b28232e1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_160213f6-4d37-488f-8833-c9b28232e1a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_813a896c-9ce6-4c1f-8aea-539498088df2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_813a896c-9ce6-4c1f-8aea-539498088df2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_85fe4ea9-7684-4e66-add9-04b5e2f90dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_85fe4ea9-7684-4e66-add9-04b5e2f90dd5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e8acc8a-5429-4aee-84c1-4a8356254309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e8acc8a-5429-4aee-84c1-4a8356254309" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_25ff8bf3-d63f-4609-83a8-0b7ca6cbbe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_25ff8bf3-d63f-4609-83a8-0b7ca6cbbe4f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_52922732-b1f0-44ad-9b4c-bf0947c5f0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_52922732-b1f0-44ad-9b4c-bf0947c5f0a7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount_67a6a2e5-e8f5-4b47-a2db-6b82e06e4727" xlink:href="dxcm-20231231.xsd#dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount_67a6a2e5-e8f5-4b47-a2db-6b82e06e4727" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_810d8671-d87c-4b93-95b9-5425bb63bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_810d8671-d87c-4b93-95b9-5425bb63bf3b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_81d5c914-4db8-4bfb-824b-59bb31ab4fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_81d5c914-4db8-4bfb-824b-59bb31ab4fd7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6de78c79-66a1-4a9c-b8b6-446a84e3b0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6de78c79-66a1-4a9c-b8b6-446a84e3b0b7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_e586b226-a519-4d6a-b101-11c8fe119905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_e586b226-a519-4d6a-b101-11c8fe119905" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_736d9038-70a4-40cc-aba1-9f3a313c4ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_736d9038-70a4-40cc-aba1-9f3a313c4ce0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c1ba3d43-e2be-45b7-9ac9-34a4ecd02eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c1ba3d43-e2be-45b7-9ac9-34a4ecd02eb7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0abdb48a-16b1-4cd2-bca9-7f73918fcb91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0abdb48a-16b1-4cd2-bca9-7f73918fcb91" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_76a5a4b7-24e4-4a29-a2b0-11280d138544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_76a5a4b7-24e4-4a29-a2b0-11280d138544" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6916be7-d26f-46f5-b4e8-26dc21a70615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41fd38e9-10e8-4155-9c74-350bc1b59bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6916be7-d26f-46f5-b4e8-26dc21a70615" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41fd38e9-10e8-4155-9c74-350bc1b59bde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d58c4648-759b-4ad6-9ec3-85e0c0c8e095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41fd38e9-10e8-4155-9c74-350bc1b59bde" xlink:to="loc_us-gaap_PlanNameAxis_d58c4648-759b-4ad6-9ec3-85e0c0c8e095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d58c4648-759b-4ad6-9ec3-85e0c0c8e095_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d58c4648-759b-4ad6-9ec3-85e0c0c8e095" xlink:to="loc_us-gaap_PlanNameDomain_d58c4648-759b-4ad6-9ec3-85e0c0c8e095_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d58c4648-759b-4ad6-9ec3-85e0c0c8e095" xlink:to="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A2022ShareRepurchaseProgramMember_61628bd3-dda2-4188-9882-3340b1391fa8" xlink:href="dxcm-20231231.xsd#dxcm_A2022ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:to="loc_dxcm_A2022ShareRepurchaseProgramMember_61628bd3-dda2-4188-9882-3340b1391fa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A2023ShareRepurchaseProgramMember_dc2f3ce8-3340-4d8f-aabb-0410b6a4d7cd" xlink:href="dxcm-20231231.xsd#dxcm_A2023ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:to="loc_dxcm_A2023ShareRepurchaseProgramMember_dc2f3ce8-3340-4d8f-aabb-0410b6a4d7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A2028NotesMember_e6310de4-9578-4f19-bace-8997388beb63" xlink:href="dxcm-20231231.xsd#dxcm_A2028NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:to="loc_dxcm_A2028NotesMember_e6310de4-9578-4f19-bace-8997388beb63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:href="dxcm-20231231.xsd#dxcm_IncreaseDecreaseInTreasuryStockRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6916be7-d26f-46f5-b4e8-26dc21a70615" xlink:to="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a8fe8d50-5d05-487e-8c0c-60235813a007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a8fe8d50-5d05-487e-8c0c-60235813a007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge_04e906eb-6f73-40c5-9fd0-da9541745f53" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromExerciseOfNoteHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:to="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge_04e906eb-6f73-40c5-9fd0-da9541745f53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_7654162b-a717-4758-829f-98f62e46a46d" xlink:href="dxcm-20231231.xsd#dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:to="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_7654162b-a717-4758-829f-98f62e46a46d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_75ddcb8c-10a6-4449-9c8d-819720d2b346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_75ddcb8c-10a6-4449-9c8d-819720d2b346" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44972f10-3598-4b7c-9451-e680c83484da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44972f10-3598-4b7c-9451-e680c83484da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_438b45a6-4d0c-4d0d-adde-5bf4156633b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44972f10-3598-4b7c-9451-e680c83484da" xlink:to="loc_us-gaap_PlanNameAxis_438b45a6-4d0c-4d0d-adde-5bf4156633b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_438b45a6-4d0c-4d0d-adde-5bf4156633b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_438b45a6-4d0c-4d0d-adde-5bf4156633b8" xlink:to="loc_us-gaap_PlanNameDomain_438b45a6-4d0c-4d0d-adde-5bf4156633b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_66b35b54-5a8d-4b8a-940e-231d231718d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_438b45a6-4d0c-4d0d-adde-5bf4156633b8" xlink:to="loc_us-gaap_PlanNameDomain_66b35b54-5a8d-4b8a-940e-231d231718d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EquityIncentivePlan2015Member_2b2b3b3f-6f66-4ef5-bcab-83b71f939188" xlink:href="dxcm-20231231.xsd#dxcm_EquityIncentivePlan2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_66b35b54-5a8d-4b8a-940e-231d231718d8" xlink:to="loc_dxcm_EquityIncentivePlan2015Member_2b2b3b3f-6f66-4ef5-bcab-83b71f939188" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5ab63c0-1d4a-4738-b3ac-b473f30ed185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44972f10-3598-4b7c-9451-e680c83484da" xlink:to="loc_us-gaap_AwardTypeAxis_f5ab63c0-1d4a-4738-b3ac-b473f30ed185" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5ab63c0-1d4a-4738-b3ac-b473f30ed185_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f5ab63c0-1d4a-4738-b3ac-b473f30ed185" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5ab63c0-1d4a-4738-b3ac-b473f30ed185_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a65e9731-3280-4863-9116-631b00054cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f5ab63c0-1d4a-4738-b3ac-b473f30ed185" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a65e9731-3280-4863-9116-631b00054cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_accb257d-fb07-448a-bec2-9f71a74647e4" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a65e9731-3280-4863-9116-631b00054cea" xlink:to="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_accb257d-fb07-448a-bec2-9f71a74647e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:href="dxcm-20231231.xsd#dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:to="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c96ab736-525f-4065-992f-e61e6dd9baef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c96ab736-525f-4065-992f-e61e6dd9baef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_588c58e0-d412-4fb4-be57-7b23cb685c20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_588c58e0-d412-4fb4-be57-7b23cb685c20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_76da28d3-e4db-4fcc-867a-11d6d262ef72" xlink:href="dxcm-20231231.xsd#dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:to="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_76da28d3-e4db-4fcc-867a-11d6d262ef72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_7092b6d3-ae6a-457e-ae3b-324786af6ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_7092b6d3-ae6a-457e-ae3b-324786af6ab5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_284c0c76-6d69-4f99-b6ab-c34c4d3224bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b2f2cc1-5af1-4507-b970-90ff184c5747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b2f2cc1-5af1-4507-b970-90ff184c5747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7288c38c-651e-4e2f-830c-12bb207efb64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7288c38c-651e-4e2f-830c-12bb207efb64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7f688b4a-9cb5-4e97-a25a-9381f40348d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7f688b4a-9cb5-4e97-a25a-9381f40348d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_175a4777-ee97-4a87-8e76-970f40effda8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_175a4777-ee97-4a87-8e76-970f40effda8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_640fcee9-130f-41a2-add1-ec90fce14dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6de5391e-4dfb-4152-8746-3953d19bb7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6de5391e-4dfb-4152-8746-3953d19bb7a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536d2cc8-3e2f-4db9-910b-dd6199bf6cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536d2cc8-3e2f-4db9-910b-dd6199bf6cf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_95a229ec-01b3-40af-845f-a57405b39194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_95a229ec-01b3-40af-845f-a57405b39194" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_21b08a28-dc83-43fa-ad59-32d2cb0e8956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_21b08a28-dc83-43fa-ad59-32d2cb0e8956" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ec2eb48-fd69-4e03-b26d-865f40e98342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_d27a8ed5-86b8-41c2-95a9-2769365795ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_d27a8ed5-86b8-41c2-95a9-2769365795ce" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3b9fe833-0f5a-4e72-a465-ab20e8852dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ecff9e27-97ec-42e0-a740-e34bdd0fd40d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3b9fe833-0f5a-4e72-a465-ab20e8852dc0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ecff9e27-97ec-42e0-a740-e34bdd0fd40d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f1f85fc7-4133-42ed-9ddb-f8283b288ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ecff9e27-97ec-42e0-a740-e34bdd0fd40d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f1f85fc7-4133-42ed-9ddb-f8283b288ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f1f85fc7-4133-42ed-9ddb-f8283b288ec2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1f85fc7-4133-42ed-9ddb-f8283b288ec2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f1f85fc7-4133-42ed-9ddb-f8283b288ec2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1f85fc7-4133-42ed-9ddb-f8283b288ec2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_0f7a12b8-e7a8-4da4-97f0-32c9a0c97e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:to="loc_us-gaap_CostOfSalesMember_0f7a12b8-e7a8-4da4-97f0-32c9a0c97e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0d395329-a24f-4edb-9f61-86ad4f9c4a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0d395329-a24f-4edb-9f61-86ad4f9c4a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_59849fd9-6dea-4894-84c8-8dd6d6e8e03a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_59849fd9-6dea-4894-84c8-8dd6d6e8e03a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b90cf16b-a7c3-41c2-be47-51a294f5fe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3b9fe833-0f5a-4e72-a465-ab20e8852dc0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b90cf16b-a7c3-41c2-be47-51a294f5fe3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_083dae34-18c9-46bb-b684-feabfcf0d963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3b9fe833-0f5a-4e72-a465-ab20e8852dc0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_083dae34-18c9-46bb-b684-feabfcf0d963" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f5e6d3a-91bf-4745-ae14-0a87c6c17ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f5e6d3a-91bf-4745-ae14-0a87c6c17ed1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5df16250-c99b-41f3-83c8-23f0bd20bd29" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f5e6d3a-91bf-4745-ae14-0a87c6c17ed1" xlink:to="loc_srt_RangeAxis_5df16250-c99b-41f3-83c8-23f0bd20bd29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5df16250-c99b-41f3-83c8-23f0bd20bd29_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5df16250-c99b-41f3-83c8-23f0bd20bd29" xlink:to="loc_srt_RangeMember_5df16250-c99b-41f3-83c8-23f0bd20bd29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c924bae9-a591-4d29-b580-f378ba66f783" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5df16250-c99b-41f3-83c8-23f0bd20bd29" xlink:to="loc_srt_RangeMember_c924bae9-a591-4d29-b580-f378ba66f783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_35a93170-ca05-45fd-b840-30ffca965698" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c924bae9-a591-4d29-b580-f378ba66f783" xlink:to="loc_srt_MinimumMember_35a93170-ca05-45fd-b840-30ffca965698" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a09a289-6a7e-4274-be6c-206005097f49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c924bae9-a591-4d29-b580-f378ba66f783" xlink:to="loc_srt_MaximumMember_6a09a289-6a7e-4274-be6c-206005097f49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6aa1fd1f-d27e-4a35-9eb1-8fee5f80ea68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f5e6d3a-91bf-4745-ae14-0a87c6c17ed1" xlink:to="loc_us-gaap_PlanNameAxis_6aa1fd1f-d27e-4a35-9eb1-8fee5f80ea68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6aa1fd1f-d27e-4a35-9eb1-8fee5f80ea68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6aa1fd1f-d27e-4a35-9eb1-8fee5f80ea68" xlink:to="loc_us-gaap_PlanNameDomain_6aa1fd1f-d27e-4a35-9eb1-8fee5f80ea68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c0676b47-cba1-4c79-8e87-0a42d14cf591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6aa1fd1f-d27e-4a35-9eb1-8fee5f80ea68" xlink:to="loc_us-gaap_PlanNameDomain_c0676b47-cba1-4c79-8e87-0a42d14cf591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeeStockPurchasePlanMember_b9e31b9e-fdf9-4710-867d-323382c6c3f4" xlink:href="dxcm-20231231.xsd#dxcm_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c0676b47-cba1-4c79-8e87-0a42d14cf591" xlink:to="loc_dxcm_EmployeeStockPurchasePlanMember_b9e31b9e-fdf9-4710-867d-323382c6c3f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1f701d5-82ac-4de9-ad8c-e8a721268584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1f701d5-82ac-4de9-ad8c-e8a721268584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_652abc51-5e6a-44f8-9515-a448cc88d35a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_652abc51-5e6a-44f8-9515-a448cc88d35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40653317-34a9-422f-b96d-80a5ab71dd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40653317-34a9-422f-b96d-80a5ab71dd7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4e22e29e-6ccb-463d-82c7-8b7cc99535c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4e22e29e-6ccb-463d-82c7-8b7cc99535c4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BusinessSegmentandGeographicInformationSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_52cf5e86-c336-4102-a5ff-1ceab68a2484" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a17b288d-79c6-4a41-937d-9325e4b1709f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52cf5e86-c336-4102-a5ff-1ceab68a2484" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a17b288d-79c6-4a41-937d-9325e4b1709f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0151ad83-d61c-40f9-a740-d0dcd3805b50" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a17b288d-79c6-4a41-937d-9325e4b1709f" xlink:to="loc_srt_StatementGeographicalAxis_0151ad83-d61c-40f9-a740-d0dcd3805b50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0151ad83-d61c-40f9-a740-d0dcd3805b50_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0151ad83-d61c-40f9-a740-d0dcd3805b50" xlink:to="loc_srt_SegmentGeographicalDomain_0151ad83-d61c-40f9-a740-d0dcd3805b50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_848dffbc-98a5-48d7-8c28-18effe622aa5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0151ad83-d61c-40f9-a740-d0dcd3805b50" xlink:to="loc_srt_SegmentGeographicalDomain_848dffbc-98a5-48d7-8c28-18effe622aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7cf9daf8-01e8-49a7-ab0d-0e4028ef5eb1" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_848dffbc-98a5-48d7-8c28-18effe622aa5" xlink:to="loc_country_US_7cf9daf8-01e8-49a7-ab0d-0e4028ef5eb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_94bcccba-7963-425e-968b-6f6a50c3317e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_848dffbc-98a5-48d7-8c28-18effe622aa5" xlink:to="loc_us-gaap_NonUsMember_94bcccba-7963-425e-968b-6f6a50c3317e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_3e670702-b2ee-44a5-a5a9-d5249f90e448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a17b288d-79c6-4a41-937d-9325e4b1709f" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_3e670702-b2ee-44a5-a5a9-d5249f90e448" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_3e670702-b2ee-44a5-a5a9-d5249f90e448_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_3e670702-b2ee-44a5-a5a9-d5249f90e448" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_3e670702-b2ee-44a5-a5a9-d5249f90e448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6e66f903-dc64-41ce-a9e9-7f9b28e389e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_3e670702-b2ee-44a5-a5a9-d5249f90e448" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6e66f903-dc64-41ce-a9e9-7f9b28e389e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_4ece497d-5f58-4702-a071-8045cd1428dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6e66f903-dc64-41ce-a9e9-7f9b28e389e8" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_4ece497d-5f58-4702-a071-8045cd1428dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_54394c10-1fe1-47af-9518-2d78f6182aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6e66f903-dc64-41ce-a9e9-7f9b28e389e8" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_54394c10-1fe1-47af-9518-2d78f6182aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d85cd77-0297-4d54-abf6-a11df68b2ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52cf5e86-c336-4102-a5ff-1ceab68a2484" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d85cd77-0297-4d54-abf6-a11df68b2ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RevenuePercentage_70ea1799-e6d6-49dc-a640-ba864ddede85" xlink:href="dxcm-20231231.xsd#dxcm_RevenuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52cf5e86-c336-4102-a5ff-1ceab68a2484" xlink:to="loc_dxcm_RevenuePercentage_70ea1799-e6d6-49dc-a640-ba864ddede85" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BusinessSegmentandGeographicInformationGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2117784a-1f0b-4df5-b055-602140858523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_14d093bd-7e76-478f-8341-4a5d33e47f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2117784a-1f0b-4df5-b055-602140858523" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_14d093bd-7e76-478f-8341-4a5d33e47f29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e6a90631-1fc3-4fed-a143-9b8ed2e23552" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_14d093bd-7e76-478f-8341-4a5d33e47f29" xlink:to="loc_srt_StatementGeographicalAxis_e6a90631-1fc3-4fed-a143-9b8ed2e23552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e6a90631-1fc3-4fed-a143-9b8ed2e23552_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e6a90631-1fc3-4fed-a143-9b8ed2e23552" xlink:to="loc_srt_SegmentGeographicalDomain_e6a90631-1fc3-4fed-a143-9b8ed2e23552_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e6a90631-1fc3-4fed-a143-9b8ed2e23552" xlink:to="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_69800877-9882-4c42-a7e2-4aa00b004ac7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:to="loc_country_US_69800877-9882-4c42-a7e2-4aa00b004ac7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MY_d6d4ece3-bd04-40a7-aa00-5200e8fb4f03" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:to="loc_country_MY_d6d4ece3-bd04-40a7-aa00-5200e8fb4f03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherCountriesMember_fbf5900f-7ee2-4ff2-91a4-adac97d7a79e" xlink:href="dxcm-20231231.xsd#dxcm_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:to="loc_dxcm_OtherCountriesMember_fbf5900f-7ee2-4ff2-91a4-adac97d7a79e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_afabc4e4-0c8f-41fd-b1a2-a85562e98957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2117784a-1f0b-4df5-b055-602140858523" xlink:to="loc_us-gaap_NoncurrentAssets_afabc4e4-0c8f-41fd-b1a2-a85562e98957" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SadieMSternDecember2023PlanMember_49ba8383-dc40-491e-8f41-ae34a52a1ad8" xlink:href="dxcm-20231231.xsd#dxcm_SadieMSternDecember2023PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_dxcm_SadieMSternDecember2023PlanMember_49ba8383-dc40-491e-8f41-ae34a52a1ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SadieMStern2023PlanTerminationMember_fce64f14-1859-413e-935b-2aaff44f140d" xlink:href="dxcm-20231231.xsd#dxcm_SadieMStern2023PlanTerminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_dxcm_SadieMStern2023PlanTerminationMember_fce64f14-1859-413e-935b-2aaff44f140d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_1e970d08-4bc0-4da0-99fd-809362e8bb46" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_1e970d08-4bc0-4da0-99fd-809362e8bb46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_MatthewDolanMember_f20b00af-baca-4071-a5d2-9f18029496bb" xlink:href="dxcm-20231231.xsd#dxcm_MatthewDolanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_MatthewDolanMember_f20b00af-baca-4071-a5d2-9f18029496bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaulFlynnMember_540cfe02-89cb-4d47-8380-9b2b15abf438" xlink:href="dxcm-20231231.xsd#dxcm_PaulFlynnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_PaulFlynnMember_540cfe02-89cb-4d47-8380-9b2b15abf438" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_GirishNaganathanMember_31133fd8-6a33-4139-af24-92c03ff416d4" xlink:href="dxcm-20231231.xsd#dxcm_GirishNaganathanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_GirishNaganathanMember_31133fd8-6a33-4139-af24-92c03ff416d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StevenRPacelliMember_b1c0b70c-7f83-4b4e-81a5-5786df0aa116" xlink:href="dxcm-20231231.xsd#dxcm_StevenRPacelliMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_StevenRPacelliMember_b1c0b70c-7f83-4b4e-81a5-5786df0aa116" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_BarryJReganMember_b58318cb-86ee-4203-ba5e-e8b1bd84e1e4" xlink:href="dxcm-20231231.xsd#dxcm_BarryJReganMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_BarryJReganMember_b58318cb-86ee-4203-ba5e-e8b1bd84e1e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_KevinRSayerMember_9ce46918-0687-4caa-ba51-2e93856ec9d5" xlink:href="dxcm-20231231.xsd#dxcm_KevinRSayerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_KevinRSayerMember_9ce46918-0687-4caa-ba51-2e93856ec9d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SadieMSternMember_46429901-b1bf-4ddf-be17-7e86f5749178" xlink:href="dxcm-20231231.xsd#dxcm_SadieMSternMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_SadieMSternMember_46429901-b1bf-4ddf-be17-7e86f5749178" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_JeremeMSylvainMember_5908cb13-5a66-4eed-8b8b-5b72a22ee29b" xlink:href="dxcm-20231231.xsd#dxcm_JeremeMSylvainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_JeremeMSylvainMember_5908cb13-5a66-4eed-8b8b-5b72a22ee29b" xlink:type="arc" order="9"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>dxcm-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5fb5fd4-e534-47c9-8b16-9bac89e1806a,g:3346d81c-3328-4944-8257-c9afd724cc18-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dda435f2-b3e3-4703-8d7d-9add432c3b0a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit available</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4993f133-df41-4981-9b9a-9e908ee8d38a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ecfab370-7b33-421f-92d1-5ab191864820_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a743a300-97f1-4977-a60b-7d5f207259a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_f788929b-46a4-467b-9733-8b0f5d53711a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_f1bda017-1be1-4d75-a880-3a8457bdc896_verboseLabel_en-US" xlink:label="lab_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares)</link:label>
    <link:label id="lab_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_7eaba194-a1a4-47a1-8b67-9ad61d941cd7_negatedTerseLabel_en-US" xlink:label="lab_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Restated Collaboration Agreement (in shares)</link:label>
    <link:label id="lab_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_label_en-US" xlink:label="lab_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Achievement Of Milestone</link:label>
    <link:label id="lab_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_documentation_en-US" xlink:label="lab_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Achievement Of Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:href="dxcm-20231231.xsd#dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:to="lab_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a5610309-e7ce-45a0-a7a5-0c039b9d0974_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_457455ed-fffd-4e56-b540-f8f627011ade_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_c96a9c51-890d-4e7a-af63-aa604310b1c5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_1a3c067b-e004-4688-8acd-d71e430f1758_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_b65bd9da-e686-4d75-93f5-cff4982bdbb1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_64ae68ed-668e-47f0-953c-0056abb3068c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2402f44d-10b3-44de-92fe-b251b03459e0_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c6ef13ec-0149-4310-b204-19a32067461b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8a75e5dd-1e77-432f-80e3-b6cb57818353_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue_67f59c98-62c6-42cc-8c9e-6b1b94139e3a_negatedTerseLabel_en-US" xlink:label="lab_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit of note hedge upon conversions of 2023 Notes</link:label>
    <link:label id="lab_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue_label_en-US" xlink:label="lab_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received From Benefit Of Note Hedge, Value</link:label>
    <link:label id="lab_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue_documentation_en-US" xlink:label="lab_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received From Benefit Of Note Hedge, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromBenefitOfNoteHedgeValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue" xlink:to="lab_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_c5fbac4d-396f-4e82-b2c3-925d44f2f2e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in statutory tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7bf34fcf-f609-4a8e-afc1-691485eb842d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8797ba64-fbf4-462d-894d-3b9d36276d08_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ce11193d-5875-45b1-a0e3-d0de15ea39fc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_70a54a08-ab90-4e22-ad4c-1efaeada0ba1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_658dbe85-5d9b-4a35-86a7-65234bd81aec_terseLabel_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligations</link:label>
    <link:label id="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_label_en-US" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded Unconditional Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermTwoMember_5747ccc1-1f93-49d6-a1c9-c1d2eb109fb2_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term Two</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermTwoMember_label_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term Two [Member]</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermTwoMember_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermTwoMember" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentConversionTermTwoMember" xlink:to="lab_dxcm_DebtInstrumentConversionTermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_87947dce-1264-49a5-998e-e15f016f62d1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f116f8d6-e73e-4b36-8f96-1bd02a6248cb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_5fe44a4c-eb2b-4556-8d5e-ec6b98a0d8bb_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_3912d6e8-83fa-4123-ab19-5aa085d4f749_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e7915511-4dbe-451d-8188-876adba9d191_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled_4998fbec-129b-4f0b-a0b1-32d2a7f9ac4e_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible principal amount settled</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled_label_en-US" xlink:label="lab_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Principal Amount Exercised And Settled</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Principal Amount Exercised And Settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" xlink:to="lab_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_b1d9be30-9cb7-455b-aeec-df120859b572_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AccruedWagesBonusesAndTaxesCurrent_f092a89f-bf68-4278-b171-f7f371ae74ac_verboseLabel_en-US" xlink:label="lab_dxcm_AccruedWagesBonusesAndTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued wages, bonus and taxes</link:label>
    <link:label id="lab_dxcm_AccruedWagesBonusesAndTaxesCurrent_label_en-US" xlink:label="lab_dxcm_AccruedWagesBonusesAndTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Wages, Bonuses and Taxes, Current</link:label>
    <link:label id="lab_dxcm_AccruedWagesBonusesAndTaxesCurrent_documentation_en-US" xlink:label="lab_dxcm_AccruedWagesBonusesAndTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Wages, Bonuses and Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AccruedWagesBonusesAndTaxesCurrent" xlink:href="dxcm-20231231.xsd#dxcm_AccruedWagesBonusesAndTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AccruedWagesBonusesAndTaxesCurrent" xlink:to="lab_dxcm_AccruedWagesBonusesAndTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermAxis_d92c21a9-4af5-4858-9154-7548add023f6_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermAxis_label_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermAxis_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermAxis" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentConversionTermAxis" xlink:to="lab_dxcm_DebtInstrumentConversionTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a125f5b0-ba87-4ce3-9f5c-c5b377d58b26_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_8b4a25f3-da74-4f02-b3e6-6a7334e6a42e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_836f806b-a252-4c5c-b9d0-b27dc0ce5301_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_507a2b6a-4678-4d97-8b0e-352d7ca527e4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet_65f0f756-0781-4891-bc3c-cd570e62bf39_negatedLabel_en-US" xlink:label="lab_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet_label_en-US" xlink:label="lab_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Assets and Liabilities, Net</link:label>
    <link:label id="lab_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet_documentation_en-US" xlink:label="lab_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" xlink:href="dxcm-20231231.xsd#dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" xlink:to="lab_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ResearchDevelopmentTaxCreditsMember_9ed47f88-f3d4-43fb-a48d-794b650a843d_terseLabel_en-US" xlink:label="lab_dxcm_ResearchDevelopmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D credits</link:label>
    <link:label id="lab_dxcm_ResearchDevelopmentTaxCreditsMember_label_en-US" xlink:label="lab_dxcm_ResearchDevelopmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research &amp; Development Tax Credits [Member]</link:label>
    <link:label id="lab_dxcm_ResearchDevelopmentTaxCreditsMember_documentation_en-US" xlink:label="lab_dxcm_ResearchDevelopmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research &amp; Development Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ResearchDevelopmentTaxCreditsMember" xlink:href="dxcm-20231231.xsd#dxcm_ResearchDevelopmentTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ResearchDevelopmentTaxCreditsMember" xlink:to="lab_dxcm_ResearchDevelopmentTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d425be1b-5601-423c-b482-0b280f80c787_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_fb87a13c-af41-40e1-af82-e994b3a89032_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_49b53c00-1189-4969-a658-b880b3eff8f1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_de21f421-0901-4ce5-b6fd-f533a10cbbb5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_285b0bf1-6e3f-4727-9d09-d98f7c1a3f75_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca47260d-02ba-4597-963a-622c2ee532f2_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9b5261aa-9ce3-40d6-883e-05840c12bb9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock available for issuance for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b5b695c6-c4d7-4a16-b820-7a7c09300834_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a9adfe46-909b-4600-945a-4addcdc4933f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_MatthewDolanMember_label_en-US" xlink:label="lab_dxcm_MatthewDolanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matthew Dolan [Member]</link:label>
    <link:label id="lab_dxcm_MatthewDolanMember_documentation_en-US" xlink:label="lab_dxcm_MatthewDolanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matthew Dolan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_MatthewDolanMember" xlink:href="dxcm-20231231.xsd#dxcm_MatthewDolanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_MatthewDolanMember" xlink:to="lab_dxcm_MatthewDolanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AuditInformationAbstract_label_en-US" xlink:label="lab_dxcm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_dxcm_AuditInformationAbstract_documentation_en-US" xlink:label="lab_dxcm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AuditInformationAbstract" xlink:href="dxcm-20231231.xsd#dxcm_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AuditInformationAbstract" xlink:to="lab_dxcm_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7c667a9a-0025-4c75-823d-b7489017c9a9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2078a045-09d7-422e-a542-8149259acb2b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_441f7b7d-a5e1-465f-abc0-c5d5574155a8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_9bdbaa3f-4762-41f0-860a-ec0766fd20be_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_a489dda0-3402-44b9-b0a9-c0ffb994ae72_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CustomerEMember_1ac66b74-d1ae-4378-86ce-378e115c4a61_terseLabel_en-US" xlink:label="lab_dxcm_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer E</link:label>
    <link:label id="lab_dxcm_CustomerEMember_label_en-US" xlink:label="lab_dxcm_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer E [Member]</link:label>
    <link:label id="lab_dxcm_CustomerEMember_documentation_en-US" xlink:label="lab_dxcm_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerEMember" xlink:href="dxcm-20231231.xsd#dxcm_CustomerEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CustomerEMember" xlink:to="lab_dxcm_CustomerEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_0ff68f91-3fab-40b6-befd-91e961173c13_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount of outstanding hedge to currency risk</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1bc7e163-34fd-4b9f-8a8e-0502042556de_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToParentDiluted_5cb507c8-4c7f-4bf9-9cb4-d2318a0ebb0d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Diluted, Total</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToParentDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:to="lab_us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3da9d4d0-1333-4d01-8e2e-ca5f44206977_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6251b2ab-a9dc-41ad-b5c4-35d1c94f20b4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1844fb3e-99e4-4cb5-8194-8dd27ea413d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock and officers compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_GirishNaganathanMember_label_en-US" xlink:label="lab_dxcm_GirishNaganathanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Girish Naganathan [Member]</link:label>
    <link:label id="lab_dxcm_GirishNaganathanMember_documentation_en-US" xlink:label="lab_dxcm_GirishNaganathanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Girish Naganathan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_GirishNaganathanMember" xlink:href="dxcm-20231231.xsd#dxcm_GirishNaganathanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_GirishNaganathanMember" xlink:to="lab_dxcm_GirishNaganathanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_393dfaf3-9fed-40b8-89ef-89af6937ec55_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_475ceb61-298d-4668-bb4f-6a210dec6b87_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_53ce333f-97da-471d-953c-00ebf9ef22d3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AMTTaxCreditsMember_68090a39-05ce-439b-831c-6ef97171a697_terseLabel_en-US" xlink:label="lab_dxcm_AMTTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMT Tax Credits</link:label>
    <link:label id="lab_dxcm_AMTTaxCreditsMember_label_en-US" xlink:label="lab_dxcm_AMTTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMT Tax Credits [Member]</link:label>
    <link:label id="lab_dxcm_AMTTaxCreditsMember_documentation_en-US" xlink:label="lab_dxcm_AMTTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMT Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AMTTaxCreditsMember" xlink:href="dxcm-20231231.xsd#dxcm_AMTTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AMTTaxCreditsMember" xlink:to="lab_dxcm_AMTTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock_8e420df9-dc09-470d-9b48-6eb2e2ff4201_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of conversion price (as a percent)</link:label>
    <link:label id="lab_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock_label_en-US" xlink:label="lab_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Covenant, Percent Of Conversion Price, Last Reported Sale Price Of Common Stock</link:label>
    <link:label id="lab_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Covenant, Percent Of Conversion Price, Last Reported Sale Price Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock" xlink:to="lab_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_793d9442-4852-4aa6-8c5d-a88ac4887f90_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ae69a10d-0495-4da3-8421-d9c112c5b4f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ddca2f6e-dbee-49b2-a925-9f9ce12bb261_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Anti-Dilutive Securities Excluded in Diluted Net Income per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_be794aec-7aa9-4c55-a230-73e05823a47d_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense recognized on senior notes</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3a3093f1-262f-4be3-8da1-74e8b1b2dee4_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_439e4c3d-7c56-43f7-b7be-75a79a123aef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6b382333-35e3-43cd-9897-f0a1e9925870_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_71eb28d3-efa2-4045-be35-ee96586e1a36_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad9e96c5-4db2-4896-979b-322234529447_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b3651e31-fc56-484b-b38b-5bc13e4bfaec_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_f5acecf9-2a63-415e-bacf-ae378b2f6d32_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_035f07d0-dccc-4a11-b122-ab8c70e70fb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_794c5f6b-7448-41a4-a9a5-bf8410d55528_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_294b00c3-6870-481e-9c02-c575cc7c93bd_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2deab89a-1489-4c7c-bf1f-70e63c9fa859_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod_4fcf1f6b-1e18-4008-954a-428b4e2504ee_terseLabel_en-US" xlink:label="lab_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return period (in days)</link:label>
    <link:label id="lab_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod_label_en-US" xlink:label="lab_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Sales Returns, Coverage Period</link:label>
    <link:label id="lab_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod_documentation_en-US" xlink:label="lab_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Sales Returns, Coverage Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod" xlink:href="dxcm-20231231.xsd#dxcm_RevenueRecognitionSalesReturnsCoveragePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod" xlink:to="lab_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cedfa96c-6bc9-49ff-a162-6126d9faf334_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_39255122-c664-4cdf-8b71-6531857b032d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5ae916c5-e75b-4855-8330-cd46febd63f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_f5b01f75-73e6-486f-8381-9cfd71992bb4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases and Other Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_14d613a5-61b6-41dc-a885-d79750310f36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_ba2b288d-093f-4775-b7f4-831521bbaae1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6384ad45-e4e4-451b-8d72-33a59d9346fd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of 2025 Notes issuance, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_24151836-7635-4489-a920-b11192bb7d7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock_e41f916a-b439-4434-bc61-790116a5b0c9_terseLabel_en-US" xlink:label="lab_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Conversion Activity for Senior Convertible Notes</link:label>
    <link:label id="lab_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock_label_en-US" xlink:label="lab_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Conversion Activity For Senior Convertible Notes [Table Text Block]</link:label>
    <link:label id="lab_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock_documentation_en-US" xlink:label="lab_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Conversion Activity For Senior Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock" xlink:href="dxcm-20231231.xsd#dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock" xlink:to="lab_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_ecc922dc-154e-41c4-ad6f-63d62867a020_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_OtherLongTermAssets_29a822ac-9104-4783-98fe-885b95f5d8ed_terseLabel_en-US" xlink:label="lab_dxcm_OtherLongTermAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_dxcm_OtherLongTermAssets_label_en-US" xlink:label="lab_dxcm_OtherLongTermAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long -Term Assets</link:label>
    <link:label id="lab_dxcm_OtherLongTermAssets_documentation_en-US" xlink:label="lab_dxcm_OtherLongTermAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long -Term Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherLongTermAssets" xlink:href="dxcm-20231231.xsd#dxcm_OtherLongTermAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_OtherLongTermAssets" xlink:to="lab_dxcm_OtherLongTermAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_bed9fea9-9e1a-4ba8-8139-5747dfe0929a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee_33a8a413-e710-4fbd-b0c6-5f539f49cbeb_terseLabel_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative research and development fee</link:label>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee_label_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Collaborative Research And Development Fee</link:label>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee_documentation_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Collaborative Research And Development Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" xlink:to="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f608f4bf-31aa-4156-8dae-90c0b3bc40ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9d628914-c0c8-4ffa-bf95-d2ec29cb0024_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_75c5fbb5-ef8a-4625-82d9-a22c5396b8c3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_9e57f66b-24a5-4743-8088-42de656b4304_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3af7e437-e03e-4f3d-96b5-b71c2b83ca2f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_28f57f4d-1853-4efd-93e5-e8ef623f883c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_750690ae-d423-4d43-bed1-3df080e8d930_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_239fdf0a-74e1-4d63-bce3-088857ddffaa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AcceleratedShareRepurchaseASRMember_bfcb3945-573c-4099-a3eb-6a90e2ab4708_terseLabel_en-US" xlink:label="lab_dxcm_AcceleratedShareRepurchaseASRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase (ASR)</link:label>
    <link:label id="lab_dxcm_AcceleratedShareRepurchaseASRMember_label_en-US" xlink:label="lab_dxcm_AcceleratedShareRepurchaseASRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase (ASR) [Member]</link:label>
    <link:label id="lab_dxcm_AcceleratedShareRepurchaseASRMember_documentation_en-US" xlink:label="lab_dxcm_AcceleratedShareRepurchaseASRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase (ASR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AcceleratedShareRepurchaseASRMember" xlink:href="dxcm-20231231.xsd#dxcm_AcceleratedShareRepurchaseASRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AcceleratedShareRepurchaseASRMember" xlink:to="lab_dxcm_AcceleratedShareRepurchaseASRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5a8db1c1-6d78-4c6c-a099-e20e319a3611_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_4979fe94-e6df-47a2-a460-392868ae3025_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8dce2d99-4b32-4f4e-afe1-ba63b89283b3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_9933734b-5f70-4eea-99a8-2cfa07514552_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3b42863d-11be-4969-910d-34d83338428d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2e87cdf7-6f9d-4d20-b097-8c7f5374147d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a1e1f593-fa6f-4552-803e-1ee212e257e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGross_8eefbd73-d103-4efe-a0b1-ab504c622b74_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGross" xlink:to="lab_us-gaap_AccountsReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d97bfb4c-afbd-43b4-b243-309713c6d54d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income (Loss) before Income Taxes Subject to Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_265d351c-74e6-414f-80e4-4a79d31a5b71_terseLabel_en-US" xlink:label="lab_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed and intangible assets</link:label>
    <link:label id="lab_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_label_en-US" xlink:label="lab_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Fixed Assets and Intangible Assets</link:label>
    <link:label id="lab_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_documentation_en-US" xlink:label="lab_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Fixed Assets and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:href="dxcm-20231231.xsd#dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:to="lab_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_069fdc55-449d-4aba-931f-7feb3623b282_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of the United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_8998b079-8cdb-42d1-8015-2ead9bea18a3_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_39a8adb9-5a38-41f3-ad7a-3ef6bd8ed8be_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_742ed8e7-e6e1-4052-a339-16ce330b3aeb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e04a625e-5374-44d9-8f0c-b26a74326577_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AmortizationPeriodForIncentiveCompensationCosts_e58ecd3b-b531-4251-ae11-caac722cf553_terseLabel_en-US" xlink:label="lab_dxcm_AmortizationPeriodForIncentiveCompensationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period for incentive compensation costs (in years)</link:label>
    <link:label id="lab_dxcm_AmortizationPeriodForIncentiveCompensationCosts_label_en-US" xlink:label="lab_dxcm_AmortizationPeriodForIncentiveCompensationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Period For Incentive Compensation Costs</link:label>
    <link:label id="lab_dxcm_AmortizationPeriodForIncentiveCompensationCosts_documentation_en-US" xlink:label="lab_dxcm_AmortizationPeriodForIncentiveCompensationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Period For Incentive Compensation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AmortizationPeriodForIncentiveCompensationCosts" xlink:href="dxcm-20231231.xsd#dxcm_AmortizationPeriodForIncentiveCompensationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AmortizationPeriodForIncentiveCompensationCosts" xlink:to="lab_dxcm_AmortizationPeriodForIncentiveCompensationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_aff6359c-2b04-433f-962d-5e4a9e006a88_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1319056c-2cb6-4db4-869e-1a92e61c46cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b1fcd30f-0210-401f-80e0-b425d7c7173c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common received vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6faf1bd5-d570-49cd-8f21-50e97235e800_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Other Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses_33bf585c-cf49-4923-8e1d-54bbd0dc8cad_verboseLabel_en-US" xlink:label="lab_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges to costs and expenses</link:label>
    <link:label id="lab_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses_label_en-US" xlink:label="lab_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual Charges To Costs And Expenses</link:label>
    <link:label id="lab_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses_documentation_en-US" xlink:label="lab_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual Charges To Costs And Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses" xlink:href="dxcm-20231231.xsd#dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses" xlink:to="lab_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d8575d1f-bff5-4a7f-94e7-f8c08f7ea4bb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_2936bf72-16bf-4a6f-815e-41c2123c50fb_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_be70aa25-a353-4fa7-bde9-86ceb63a78f3_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_IncreaseDecreaseInTreasuryStockRollForward_99dcfd7c-ae3f-4e60-8b32-06380b31faa7_terseLabel_en-US" xlink:label="lab_dxcm_IncreaseDecreaseInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_dxcm_IncreaseDecreaseInTreasuryStockRollForward_label_en-US" xlink:label="lab_dxcm_IncreaseDecreaseInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_dxcm_IncreaseDecreaseInTreasuryStockRollForward_documentation_en-US" xlink:label="lab_dxcm_IncreaseDecreaseInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward" xlink:href="dxcm-20231231.xsd#dxcm_IncreaseDecreaseInTreasuryStockRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward" xlink:to="lab_dxcm_IncreaseDecreaseInTreasuryStockRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_1a859b3f-19cc-4835-a30d-344160d9ddaa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_5a7db297-b707-467f-b6a6-5681cba8bcac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_9a9d118d-85f5-463c-ba65-3cb75501e191_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4631f4c4-c179-4ed2-8602-e521aaee52d5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_84b6bda7-3c4b-40ac-9664-a4a6c8ce02b2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_c0dab801-3696-4db4-9f1f-05fb388f3884_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from equity investments</link:label>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:to="lab_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_8cbee5c5-6d9c-4f8b-ba26-f2ce4097741e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1fe1e14f-93ff-4cb6-9865-5ea4f0952c19_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_37d3fb0b-7a50-4bf3-b86b-90d4836afb3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash income and expenses</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c1a68ee1-eb1f-4efa-a7fa-ecdeed5feb24_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8488b5fa-b6aa-4473-856d-9d4d0431d27c_terseLabel_en-US" xlink:label="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="dxcm-20231231.xsd#dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_a31961eb-949a-4118-8fd0-c856d0c03b48_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and trade name</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_f818776a-3516-4bc0-ad3e-ffc0a56e3d0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Availability and Outstanding Borrowings on Credit Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_3df90228-d022-425c-a84a-33ecd883641e_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_fbe20424-746e-4086-89e9-ceda50ea90fe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_b53b702e-1a9c-4f72-abc4-c08b02b00a8c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3350f5b4-eaa5-4f02-b583-c9847f6bea7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_114891a8-fff5-486c-acc7-5a2347061bc2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d63f3cb9-f806-4c0f-97bc-9a8d5fd521da_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_071f3f68-8850-48fe-88a6-b07d04a5f8da_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc0cd1f6-63ee-424a-8937-2d78c4e366ab_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d9697927-b2aa-4fac-9dda-8da8386c55c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues_624a247b-7845-4600-8067-b9f8cc641668_terseLabel_en-US" xlink:label="lab_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future common stock issuable (in shares)</link:label>
    <link:label id="lab_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues_label_en-US" xlink:label="lab_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Common Stock Issuable, Shares, New Issues</link:label>
    <link:label id="lab_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues_documentation_en-US" xlink:label="lab_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Common Stock Issuable, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues" xlink:href="dxcm-20231231.xsd#dxcm_PotentialFutureCommonStockIssuableSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues" xlink:to="lab_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_5a57a4bc-3f83-4f64-8bba-6480cd2c97c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CollaborativeResearchAndDevelopmentFee_255599d2-b441-4f65-97fd-ebe72e04d057_terseLabel_en-US" xlink:label="lab_dxcm_CollaborativeResearchAndDevelopmentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative research and development fee</link:label>
    <link:label id="lab_dxcm_CollaborativeResearchAndDevelopmentFee_label_en-US" xlink:label="lab_dxcm_CollaborativeResearchAndDevelopmentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Research And Development Fee</link:label>
    <link:label id="lab_dxcm_CollaborativeResearchAndDevelopmentFee_documentation_en-US" xlink:label="lab_dxcm_CollaborativeResearchAndDevelopmentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Research and Development Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeResearchAndDevelopmentFee" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeResearchAndDevelopmentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CollaborativeResearchAndDevelopmentFee" xlink:to="lab_dxcm_CollaborativeResearchAndDevelopmentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0152d69d-ef3b-47d5-97e7-b53404436b18_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3c87823f-4633-43bc-be20-71b72a5b616a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_190372d8-6af9-4a5a-907c-3d38ad76e393_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a9339db8-93f4-4a1b-bd48-7d67eb08978b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock counterparties to acquire with warrants purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_NumberOfPrimaryGeographicMarkets_0958268a-20b5-418e-8402-347c11e97c0f_terseLabel_en-US" xlink:label="lab_dxcm_NumberOfPrimaryGeographicMarkets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of primary geographic markets</link:label>
    <link:label id="lab_dxcm_NumberOfPrimaryGeographicMarkets_label_en-US" xlink:label="lab_dxcm_NumberOfPrimaryGeographicMarkets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Primary Geographic Markets</link:label>
    <link:label id="lab_dxcm_NumberOfPrimaryGeographicMarkets_documentation_en-US" xlink:label="lab_dxcm_NumberOfPrimaryGeographicMarkets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Primary Geographic Markets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_NumberOfPrimaryGeographicMarkets" xlink:href="dxcm-20231231.xsd#dxcm_NumberOfPrimaryGeographicMarkets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_NumberOfPrimaryGeographicMarkets" xlink:to="lab_dxcm_NumberOfPrimaryGeographicMarkets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ac89906e-b092-467a-94b3-ebde313929a6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_363b0111-72dd-42ae-84be-97728f81b170_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual coupon interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_LesseeOperatingLeasesLeaseCostAmortization_018cbe3d-e1fc-4af4-9237-e800f7b77de8_terseLabel_en-US" xlink:label="lab_dxcm_LesseeOperatingLeasesLeaseCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use asset</link:label>
    <link:label id="lab_dxcm_LesseeOperatingLeasesLeaseCostAmortization_label_en-US" xlink:label="lab_dxcm_LesseeOperatingLeasesLeaseCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Lease Cost, Amortization</link:label>
    <link:label id="lab_dxcm_LesseeOperatingLeasesLeaseCostAmortization_documentation_en-US" xlink:label="lab_dxcm_LesseeOperatingLeasesLeaseCostAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Lease Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LesseeOperatingLeasesLeaseCostAmortization" xlink:href="dxcm-20231231.xsd#dxcm_LesseeOperatingLeasesLeaseCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_LesseeOperatingLeasesLeaseCostAmortization" xlink:to="lab_dxcm_LesseeOperatingLeasesLeaseCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CashInterestExpenseAbstract_169db7a9-afb8-47d1-9219-9dee8a3b44d5_terseLabel_en-US" xlink:label="lab_dxcm_CashInterestExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash interest expense:</link:label>
    <link:label id="lab_dxcm_CashInterestExpenseAbstract_label_en-US" xlink:label="lab_dxcm_CashInterestExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Interest Expense [Abstract]</link:label>
    <link:label id="lab_dxcm_CashInterestExpenseAbstract_documentation_en-US" xlink:label="lab_dxcm_CashInterestExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CashInterestExpenseAbstract" xlink:href="dxcm-20231231.xsd#dxcm_CashInterestExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CashInterestExpenseAbstract" xlink:to="lab_dxcm_CashInterestExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a94faf8c-d30b-4518-a111-c2f67c202d66_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligation_6dfcb389-d466-4899-aff2-12a0087da119_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset retirement obligation</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligation_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetRetirementObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligation" xlink:to="lab_us-gaap_AssetRetirementObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_1b8ea9f6-bd3b-4744-a1dd-41e2e74b7bc4_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of senior convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_5e34da8e-4bfa-472a-b24d-fc43aad4058d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7ec71249-6e91-4367-96b0-2ad751cc500d_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b95340e-4432-4a8d-b800-8a7fbcb099b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd2c999f-3536-43c2-8509-310ff8fe860b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_46a3e312-42ac-4597-baef-e35b7265ce94_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8f115467-1142-430b-99f5-c00d9aa2dcfc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_6d4051b2-05ee-49eb-aa9d-c687742ba6ac_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_07377fe0-7f29-413c-8906-1fa6520b5436_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f63f0aa8-c823-4f1a-8d59-662cf860d731_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ContractPaymentTermsNumberofDays_6d6726a6-8eea-4234-b294-0e8d91e76b7d_terseLabel_en-US" xlink:label="lab_dxcm_ContractPaymentTermsNumberofDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contract payment terms (in days)</link:label>
    <link:label id="lab_dxcm_ContractPaymentTermsNumberofDays_label_en-US" xlink:label="lab_dxcm_ContractPaymentTermsNumberofDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Payment Terms, Number of Days</link:label>
    <link:label id="lab_dxcm_ContractPaymentTermsNumberofDays_documentation_en-US" xlink:label="lab_dxcm_ContractPaymentTermsNumberofDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Payment Terms, Number of Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ContractPaymentTermsNumberofDays" xlink:href="dxcm-20231231.xsd#dxcm_ContractPaymentTermsNumberofDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ContractPaymentTermsNumberofDays" xlink:to="lab_dxcm_ContractPaymentTermsNumberofDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_36d5957e-007b-4b3f-8df1-34477e0db6f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5858c1fd-17f7-4d9b-824d-797c6a6027f1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_27877756-d903-4843-a047-90521c4646cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aa1a5db7-722e-4d63-b1a1-18d3fb251f3c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_acc0b4c2-cded-4b76-b509-59c57b7447a6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1b46ec98-c1a5-4ffa-9da8-b5e1c7f9ced8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_284bd10a-8890-46ac-bda5-870264db85a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2265e0a1-7e41-48b7-a6b9-2e3cd16f2773_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period ( in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_88834f47-d8b3-49e1-a041-0df4ebe26d95_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt_3e4cc7bf-423e-4ed8-9a60-69527778101c_negatedTerseLabel_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to Senior Convertible Notes</link:label>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Tax Benefit from Equity Component of Convertible Debt</link:label>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt_documentation_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Tax Benefit from Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" xlink:to="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_7e960b04-12a4-4710-abae-a200fdc32562_terseLabel_en-US" xlink:label="lab_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property transfer</link:label>
    <link:label id="lab_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_label_en-US" xlink:label="lab_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Transfer</link:label>
    <link:label id="lab_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_documentation_en-US" xlink:label="lab_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:href="dxcm-20231231.xsd#dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:to="lab_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_335d4ecb-69ca-4057-aa61-eaadadc09d57_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset impairment</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_EquityIncentivePlan2015Member_406d7659-72b7-477a-8947-027fdee24724_terseLabel_en-US" xlink:label="lab_dxcm_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EIP 2015</link:label>
    <link:label id="lab_dxcm_EquityIncentivePlan2015Member_label_en-US" xlink:label="lab_dxcm_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:label id="lab_dxcm_EquityIncentivePlan2015Member_documentation_en-US" xlink:label="lab_dxcm_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2015</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EquityIncentivePlan2015Member" xlink:href="dxcm-20231231.xsd#dxcm_EquityIncentivePlan2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_EquityIncentivePlan2015Member" xlink:to="lab_dxcm_EquityIncentivePlan2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ba13a0c7-5093-4f9e-a8a9-1ba32b224b30_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Significant Customers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_78a8888d-3225-41c9-af6c-82f3bdd0a8e6_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_0beccdf6-a0f6-4ed7-ac51-25b598bc5884_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term senior convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_a9146a5a-6e98-4f8f-a094-c1cd2b6de45a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of applicable conversion price (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_4034384c-d93e-41ec-9a15-8c7f1358771e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7771212e-0b12-4581-8dd2-e348add84236_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_0bf1feb7-08dd-4bfa-b65e-9d3d203f1ade_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost:</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3c17a8f0-1628-47a3-a567-709f8bfda82f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DeferredCompensationPlanAssetsCurrent_fad053e4-3b76-48ac-bda7-d9b4b2927c74_terseLabel_en-US" xlink:label="lab_dxcm_DeferredCompensationPlanAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan assets</link:label>
    <link:label id="lab_dxcm_DeferredCompensationPlanAssetsCurrent_label_en-US" xlink:label="lab_dxcm_DeferredCompensationPlanAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Assets, Current</link:label>
    <link:label id="lab_dxcm_DeferredCompensationPlanAssetsCurrent_documentation_en-US" xlink:label="lab_dxcm_DeferredCompensationPlanAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredCompensationPlanAssetsCurrent" xlink:href="dxcm-20231231.xsd#dxcm_DeferredCompensationPlanAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DeferredCompensationPlanAssetsCurrent" xlink:to="lab_dxcm_DeferredCompensationPlanAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_81cc811f-40a8-4dc5-8ee6-ffd830e14326_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_2a3c5278-69bd-4cc1-b956-a1d3e82f58c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_652a6d27-4774-4764-a312-50d51647d6c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains recognized during the reporting period on equity investments still held at the reporting date</link:label>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_afe48b1f-e455-4799-80a4-8708e3b681f0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents_bb5e96bb-cfa5-4ae0-a937-4ed0132af20f_terseLabel_en-US" xlink:label="lab_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity threshold of investments classified to cash equivalents</link:label>
    <link:label id="lab_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents_label_en-US" xlink:label="lab_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Threshold Of Investments Classified To Cash Equivalents</link:label>
    <link:label id="lab_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents_documentation_en-US" xlink:label="lab_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Threshold Of Investments Classified To Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents" xlink:href="dxcm-20231231.xsd#dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents" xlink:to="lab_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6c976e2c-94aa-4a91-af09-9d4767fde89c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_c6e49ea5-11f9-4736-bdfe-7685c3602529_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a9938176-1e3b-4697-b7b8-8a2f15cda5b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility of common stock (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ProductShipmentCostsPolicyTextBlock_22fe0e67-253f-4dff-858d-aec31103fe53_terseLabel_en-US" xlink:label="lab_dxcm_ProductShipmentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Shipment Costs</link:label>
    <link:label id="lab_dxcm_ProductShipmentCostsPolicyTextBlock_label_en-US" xlink:label="lab_dxcm_ProductShipmentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Shipment Costs [Policy Text Block]</link:label>
    <link:label id="lab_dxcm_ProductShipmentCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_dxcm_ProductShipmentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Shipment Costs [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ProductShipmentCostsPolicyTextBlock" xlink:href="dxcm-20231231.xsd#dxcm_ProductShipmentCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ProductShipmentCostsPolicyTextBlock" xlink:to="lab_dxcm_ProductShipmentCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_20817649-10c7-41e0-ba7c-a07429faa6ed_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_69f0ed59-f41b-4041-82aa-42d3bf197449_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_BarryJReganMember_label_en-US" xlink:label="lab_dxcm_BarryJReganMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Barry J. Regan [Member]</link:label>
    <link:label id="lab_dxcm_BarryJReganMember_documentation_en-US" xlink:label="lab_dxcm_BarryJReganMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Barry J. Regan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_BarryJReganMember" xlink:href="dxcm-20231231.xsd#dxcm_BarryJReganMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_BarryJReganMember" xlink:to="lab_dxcm_BarryJReganMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_1956c75b-01de-4066-a1dc-dba5ab6f9aa5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a7e1e30f-33b2-4ab3-9d38-009f4c74a632_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_VerilyIntangibleMember_8a70f53b-9fb3-4f7b-aaf2-912d59c9289d_terseLabel_en-US" xlink:label="lab_dxcm_VerilyIntangibleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verily intangible asset</link:label>
    <link:label id="lab_dxcm_VerilyIntangibleMember_label_en-US" xlink:label="lab_dxcm_VerilyIntangibleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verily Intangible [Member]</link:label>
    <link:label id="lab_dxcm_VerilyIntangibleMember_documentation_en-US" xlink:label="lab_dxcm_VerilyIntangibleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verily Intangible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_VerilyIntangibleMember" xlink:href="dxcm-20231231.xsd#dxcm_VerilyIntangibleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_VerilyIntangibleMember" xlink:to="lab_dxcm_VerilyIntangibleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermOneMember_c46aa518-fba1-4b44-8a73-1496c4d8e267_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term One</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermOneMember_label_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term One [Member]</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermOneMember_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermOneMember" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentConversionTermOneMember" xlink:to="lab_dxcm_DebtInstrumentConversionTermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1ec8ac64-2f82-4493-8936-e2b7a07f0fd1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0f629f31-d979-488c-9133-69efba36f0b7_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Percentage of Total Revenues and Accounts Receivable by Customer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e40558c4-51b2-4b74-8e2e-0eafc3109892_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PossibleExtensionPeriodofTaxHoliday_13db294d-3a3d-4408-9d2e-1f172d9bf281_terseLabel_en-US" xlink:label="lab_dxcm_PossibleExtensionPeriodofTaxHoliday" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible extension period of tax holiday (in years)</link:label>
    <link:label id="lab_dxcm_PossibleExtensionPeriodofTaxHoliday_label_en-US" xlink:label="lab_dxcm_PossibleExtensionPeriodofTaxHoliday" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible Extension Period of Tax Holiday</link:label>
    <link:label id="lab_dxcm_PossibleExtensionPeriodofTaxHoliday_documentation_en-US" xlink:label="lab_dxcm_PossibleExtensionPeriodofTaxHoliday" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible Extension Period of Tax Holiday</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PossibleExtensionPeriodofTaxHoliday" xlink:href="dxcm-20231231.xsd#dxcm_PossibleExtensionPeriodofTaxHoliday"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PossibleExtensionPeriodofTaxHoliday" xlink:to="lab_dxcm_PossibleExtensionPeriodofTaxHoliday" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm_14b6cc01-d8b2-4ffd-90e6-89e483073555_terseLabel_en-US" xlink:label="lab_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of purchase obligations (in years)</link:label>
    <link:label id="lab_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm_label_en-US" xlink:label="lab_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term</link:label>
    <link:label id="lab_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm_documentation_en-US" xlink:label="lab_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded Unconditional Purchase Obligation Due Within One Year, Maximum Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm" xlink:href="dxcm-20231231.xsd#dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm" xlink:to="lab_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_LondonInterbankOfferedRateLIBOR1Member_c91c08b3-61c8-412c-9ee6-56d440c28e25_terseLabel_en-US" xlink:label="lab_dxcm_LondonInterbankOfferedRateLIBOR1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_dxcm_LondonInterbankOfferedRateLIBOR1Member_label_en-US" xlink:label="lab_dxcm_LondonInterbankOfferedRateLIBOR1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) 1 [Member]</link:label>
    <link:label id="lab_dxcm_LondonInterbankOfferedRateLIBOR1Member_documentation_en-US" xlink:label="lab_dxcm_LondonInterbankOfferedRateLIBOR1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LondonInterbankOfferedRateLIBOR1Member" xlink:href="dxcm-20231231.xsd#dxcm_LondonInterbankOfferedRateLIBOR1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_LondonInterbankOfferedRateLIBOR1Member" xlink:to="lab_dxcm_LondonInterbankOfferedRateLIBOR1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_14e56f40-6449-4d2b-920e-b54e62278228_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock_2008b0e2-366e-488f-b98b-95efe57d6f1f_terseLabel_en-US" xlink:label="lab_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Treasury Share Activity Table Text Block</link:label>
    <link:label id="lab_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock_label_en-US" xlink:label="lab_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Treasury Share Activity [Table Text Block]</link:label>
    <link:label id="lab_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock_documentation_en-US" xlink:label="lab_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Treasury Share Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock" xlink:href="dxcm-20231231.xsd#dxcm_ScheduleOfTreasuryShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock" xlink:to="lab_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_7a53bc98-602e-414e-a093-180a7ea62b1a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_A2022ShareRepurchaseProgramMember_019a51ae-e64b-47a8-8998-c6acc02db534_terseLabel_en-US" xlink:label="lab_dxcm_A2022ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Share Repurchase Program</link:label>
    <link:label id="lab_dxcm_A2022ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_dxcm_A2022ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_dxcm_A2022ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_dxcm_A2022ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A2022ShareRepurchaseProgramMember" xlink:href="dxcm-20231231.xsd#dxcm_A2022ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_A2022ShareRepurchaseProgramMember" xlink:to="lab_dxcm_A2022ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_59ac96d9-a0a0-49d5-9d23-41071a85528d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_14fe2a3b-c110-4a41-b28b-ac939d975ad7_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tax Credit Carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Tax Credit Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1aa06dd0-fb12-44d6-beda-0f7678379f13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5f0d6e22-c363-4ee0-8c33-558e2a2b02bd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_c2ada631-2909-40ab-b808-b12695f8ff47_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_3520baa5-1fb8-445d-8bfd-86bd53a77cd5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_OtherTaxLiabilitiesNoncurrent_36179b02-030e-4350-9a12-333285fcb5f5_terseLabel_en-US" xlink:label="lab_dxcm_OtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax liabilities</link:label>
    <link:label id="lab_dxcm_OtherTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_dxcm_OtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Liabilities, Noncurrent</link:label>
    <link:label id="lab_dxcm_OtherTaxLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_dxcm_OtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherTaxLiabilitiesNoncurrent" xlink:href="dxcm-20231231.xsd#dxcm_OtherTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_OtherTaxLiabilitiesNoncurrent" xlink:to="lab_dxcm_OtherTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_111b5af8-4b9d-42f9-a82b-ead5af520111_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_123e421e-6f9e-4969-9b4f-e85c79af4156_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_NonCashInterestExpenseAbstract_b9167caf-087c-4377-9f74-7c686c4ff7b4_terseLabel_en-US" xlink:label="lab_dxcm_NonCashInterestExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense:</link:label>
    <link:label id="lab_dxcm_NonCashInterestExpenseAbstract_label_en-US" xlink:label="lab_dxcm_NonCashInterestExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense [Abstract]</link:label>
    <link:label id="lab_dxcm_NonCashInterestExpenseAbstract_documentation_en-US" xlink:label="lab_dxcm_NonCashInterestExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_NonCashInterestExpenseAbstract" xlink:href="dxcm-20231231.xsd#dxcm_NonCashInterestExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_NonCashInterestExpenseAbstract" xlink:to="lab_dxcm_NonCashInterestExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_OtherForeignMember_6bf67c8f-9866-45c1-9951-37fdcd1e46c5_terseLabel_en-US" xlink:label="lab_dxcm_OtherForeignMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign</link:label>
    <link:label id="lab_dxcm_OtherForeignMember_label_en-US" xlink:label="lab_dxcm_OtherForeignMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign [Member]</link:label>
    <link:label id="lab_dxcm_OtherForeignMember_documentation_en-US" xlink:label="lab_dxcm_OtherForeignMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherForeignMember" xlink:href="dxcm-20231231.xsd#dxcm_OtherForeignMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_OtherForeignMember" xlink:to="lab_dxcm_OtherForeignMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9bd785c8-eb6d-42c6-a858-bd041ca7228b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_d7f3915c-87cd-4a46-a4f0-2bdada369a96_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_d89fafbc-79c6-4822-8516-fca713c341fc_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_EmployeePurchasePriceFloorPercentage_5195f850-dcf8-4d82-ac81-09d858315f80_terseLabel_en-US" xlink:label="lab_dxcm_EmployeePurchasePriceFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee purchase price floor (as a percent)</link:label>
    <link:label id="lab_dxcm_EmployeePurchasePriceFloorPercentage_label_en-US" xlink:label="lab_dxcm_EmployeePurchasePriceFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Purchase Price Floor Percentage</link:label>
    <link:label id="lab_dxcm_EmployeePurchasePriceFloorPercentage_documentation_en-US" xlink:label="lab_dxcm_EmployeePurchasePriceFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee purchase price floor, percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeePurchasePriceFloorPercentage" xlink:href="dxcm-20231231.xsd#dxcm_EmployeePurchasePriceFloorPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_EmployeePurchasePriceFloorPercentage" xlink:to="lab_dxcm_EmployeePurchasePriceFloorPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CustomerDMember_c49ee546-3b04-48d8-bebc-0f47712bddf2_terseLabel_en-US" xlink:label="lab_dxcm_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_dxcm_CustomerDMember_label_en-US" xlink:label="lab_dxcm_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_dxcm_CustomerDMember_documentation_en-US" xlink:label="lab_dxcm_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerDMember" xlink:href="dxcm-20231231.xsd#dxcm_CustomerDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CustomerDMember" xlink:to="lab_dxcm_CustomerDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_613d6bb1-5bda-47f1-8e22-5357f90152d2_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_4ba1d60e-6907-4568-b1b2-89e0e60d4744_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_eddf1a46-064b-4d56-92e0-5e08db143d24_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b41f7f83-e742-472f-ab50-ef547fe469d9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance amount</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d5fe8b5c-832e-4450-8409-043c07f33684_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2eb8ace-f6b3-43ea-b39e-faa7185ea3cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_02cf2ac6-87ef-417a-aa5f-d67ac1aca445_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4572b48f-125e-4909-8eb1-9fb87fe8a016_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying values of investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a38b7c00-f6eb-4ee7-a49b-10fe10e287e1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6cded4da-183e-4bff-896d-23ae2802ebed_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PaymentsUnderCollaborationAgreementsAxis_34363ffd-83c3-4f11-bc43-9d32e4516e9d_terseLabel_en-US" xlink:label="lab_dxcm_PaymentsUnderCollaborationAgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Under Collaboration Agreements [Axis]</link:label>
    <link:label id="lab_dxcm_PaymentsUnderCollaborationAgreementsAxis_label_en-US" xlink:label="lab_dxcm_PaymentsUnderCollaborationAgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Under Collaboration Agreements [Axis]</link:label>
    <link:label id="lab_dxcm_PaymentsUnderCollaborationAgreementsAxis_documentation_en-US" xlink:label="lab_dxcm_PaymentsUnderCollaborationAgreementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Under Collaboration Agreements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsUnderCollaborationAgreementsAxis" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsUnderCollaborationAgreementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PaymentsUnderCollaborationAgreementsAxis" xlink:to="lab_dxcm_PaymentsUnderCollaborationAgreementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_642c3d8c-3d8e-46d6-9a3d-7f866c3b107e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_cba7537d-3b0f-465b-abd7-c33bd70c6d80_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UK</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones_6eb2d2b3-f8f5-49ea-8660-06550753e196_terseLabel_en-US" xlink:label="lab_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs</link:label>
    <link:label id="lab_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones_label_en-US" xlink:label="lab_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Achievement Of Milestones</link:label>
    <link:label id="lab_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones_documentation_en-US" xlink:label="lab_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Achievement Of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones" xlink:href="dxcm-20231231.xsd#dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones" xlink:to="lab_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_be23603c-ae48-444a-a27d-114252ef49ae_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_91ca053a-9d2d-4390-8bf0-3d1884f0d94b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_b1e10702-5eb7-4a1f-8536-40b1200e78cd_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty Accrual</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MY_80954774-42a1-4c85-8076-c08c001f75aa_terseLabel_en-US" xlink:label="lab_country_MY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Malaysia</link:label>
    <link:label id="lab_country_MY_label_en-US" xlink:label="lab_country_MY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MALAYSIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MY" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MY" xlink:to="lab_country_MY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1324c858-dd75-4a1f-b418-27f578de95a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_032f5f79-91c7-4e05-a10e-58ff19f60e36_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_c60ac3d9-b7d5-4bb5-9f64-bdf671a30b22_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_61c30d8a-44aa-408a-8334-3596c1d58ad6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_dfc1cab7-b12c-4f2e-b8c3-9d6a992b6060_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f75927ea-cceb-4fd9-9131-d4e04e1b2ae5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0a114384-4373-4307-82b0-38b56ed6dc2a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a7a7c68a-6f84-4957-93b9-70da20285d34_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_b1016c1a-bf33-44fe-8aa8-50bccdb0b751_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct</link:label>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Directly to Consumer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:to="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments_04575da0-1763-4125-96d7-e1ea57574552_negatedTerseLabel_en-US" xlink:label="lab_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction, Write-offs and Adjustments</link:label>
    <link:label id="lab_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments_label_en-US" xlink:label="lab_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction, Write-offs and Adjustments</link:label>
    <link:label id="lab_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments_documentation_en-US" xlink:label="lab_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of the write-offs and adjustments in a given period to allowances and reserves for doubtful accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" xlink:href="dxcm-20231231.xsd#dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" xlink:to="lab_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_7d86766e-a0d7-4be7-88f9-a6e44cf21e57_verboseLabel_en-US" xlink:label="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grant</link:label>
    <link:label id="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_label_en-US" xlink:label="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_documentation_en-US" xlink:label="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:href="dxcm-20231231.xsd#dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1b2a148a-3ca1-4c13-ad86-f8f0321a2410_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_fc084eb9-8ecb-4bec-8bbf-16cc61ea35c3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c147ac3c-75dc-4988-867d-b854d2a712e1_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bd40a642-6734-4f5e-a6ff-7def1513e3d4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_d2405f62-79c7-447f-97e3-b07d8a6ab2a0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_27a6b9e1-9385-4bd6-b827-73e026aac247_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a4998f12-0f23-4585-b1cf-9b7d5a7756d7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_26a89cca-a5dc-4733-9310-a71214c1b04e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_StevenRPacelliMember_label_en-US" xlink:label="lab_dxcm_StevenRPacelliMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Steven R. Pacelli [Member]</link:label>
    <link:label id="lab_dxcm_StevenRPacelliMember_documentation_en-US" xlink:label="lab_dxcm_StevenRPacelliMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Steven R. Pacelli</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StevenRPacelliMember" xlink:href="dxcm-20231231.xsd#dxcm_StevenRPacelliMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_StevenRPacelliMember" xlink:to="lab_dxcm_StevenRPacelliMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e7401b1d-8cc3-49c3-84dc-aad6e36cca0e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_SadieMSternDecember2023PlanMember_label_en-US" xlink:label="lab_dxcm_SadieMSternDecember2023PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sadie M Stern December 2023 Plan [Member]</link:label>
    <link:label id="lab_dxcm_SadieMSternDecember2023PlanMember_documentation_en-US" xlink:label="lab_dxcm_SadieMSternDecember2023PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sadie M Stern December 2023 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SadieMSternDecember2023PlanMember" xlink:href="dxcm-20231231.xsd#dxcm_SadieMSternDecember2023PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_SadieMSternDecember2023PlanMember" xlink:to="lab_dxcm_SadieMSternDecember2023PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_42863de9-a33d-4268-8810-1ddc17002665_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f7ef8351-3e89-4200-8dfe-7bc75a89bdb3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment_bd126dbf-2263-4a15-8ec7-3cf392229b40_terseLabel_en-US" xlink:label="lab_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement milestone share-based payment</link:label>
    <link:label id="lab_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment_label_en-US" xlink:label="lab_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Collaboration Agreement Milestone, Share-based Payment</link:label>
    <link:label id="lab_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment_documentation_en-US" xlink:label="lab_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Collaboration Agreement Milestone, Share-based Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" xlink:href="dxcm-20231231.xsd#dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" xlink:to="lab_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_e67173c4-51e9-4cd9-8928-f059134a6e05_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_d144a9b1-2b89-4c4f-95dd-fb9a0dd2761d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Converted Value of Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CollaborativeSalesBasedMilestoneMember_f61b6ea6-1d18-4064-94ac-db771154a473_terseLabel_en-US" xlink:label="lab_dxcm_CollaborativeSalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative sales-based milestones</link:label>
    <link:label id="lab_dxcm_CollaborativeSalesBasedMilestoneMember_label_en-US" xlink:label="lab_dxcm_CollaborativeSalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Sales-based Milestone [Member]</link:label>
    <link:label id="lab_dxcm_CollaborativeSalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_dxcm_CollaborativeSalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Sales-based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeSalesBasedMilestoneMember" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeSalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CollaborativeSalesBasedMilestoneMember" xlink:to="lab_dxcm_CollaborativeSalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_94de68cf-f023-46d9-9d37-f585e2b52f90_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_98746ac2-712c-44fa-ab5c-d4c832454819_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ce39c219-8b08-4583-b714-41e7048b22b9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_bdb39ac1-b227-4a6b-ad5a-a073a6fce639_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor</link:label>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Through Intermediary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:to="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_0a946409-9a08-4287-ac7a-0635ad97526e_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of outstanding senior convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_54e1609f-3ac4-4e6e-9f1a-fda9f0ce4544_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ForeignTaxCreditsMember_4dba4752-d4fd-40bb-8cfd-082aeda19c12_terseLabel_en-US" xlink:label="lab_dxcm_ForeignTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax credits</link:label>
    <link:label id="lab_dxcm_ForeignTaxCreditsMember_label_en-US" xlink:label="lab_dxcm_ForeignTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Credits [Member]</link:label>
    <link:label id="lab_dxcm_ForeignTaxCreditsMember_documentation_en-US" xlink:label="lab_dxcm_ForeignTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ForeignTaxCreditsMember" xlink:href="dxcm-20231231.xsd#dxcm_ForeignTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ForeignTaxCreditsMember" xlink:to="lab_dxcm_ForeignTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_1c78a531-4fe3-46ed-b16d-9326fea8ea15_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f22ab0c9-e8b2-40fc-abeb-ce26646b4251_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_a3c5789f-4d0b-458c-8b91-0787f9d96f31_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3745ffda-985d-40c6-9c0a-b74934b144e4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, deferred tax asset, increase (decrease), amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_7a53306b-a554-487d-b2e2-b8ccb70ffd1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_LongTermDeposits_ace13459-bc0c-42c4-aacb-b0cdc779a546_terseLabel_en-US" xlink:label="lab_dxcm_LongTermDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deposits</link:label>
    <link:label id="lab_dxcm_LongTermDeposits_label_en-US" xlink:label="lab_dxcm_LongTermDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long -Term Deposits</link:label>
    <link:label id="lab_dxcm_LongTermDeposits_documentation_en-US" xlink:label="lab_dxcm_LongTermDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long -Term Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LongTermDeposits" xlink:href="dxcm-20231231.xsd#dxcm_LongTermDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_LongTermDeposits" xlink:to="lab_dxcm_LongTermDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_43c09463-88b3-4c41-bc6c-434181c6d408_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 800.0 million shares authorized; 407.2 million and 385.4 million shares issued and outstanding, respectively, at December&#160;31, 2023; and 393.2 million and 386.3 million shares issued and outstanding, respectively, at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_A2023ShareRepurchaseProgramMember_86392bb3-f32a-4c93-87f3-56194cc9c133_terseLabel_en-US" xlink:label="lab_dxcm_A2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Program</link:label>
    <link:label id="lab_dxcm_A2023ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_dxcm_A2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_dxcm_A2023ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_dxcm_A2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A2023ShareRepurchaseProgramMember" xlink:href="dxcm-20231231.xsd#dxcm_A2023ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_A2023ShareRepurchaseProgramMember" xlink:to="lab_dxcm_A2023ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5cb1c503-6bf3-4c65-bb7b-023178dda179_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3c35de4c-8d60-4215-9984-1a17f6560518_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7dea45a2-124f-4249-a806-f2fa6916e7a0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_80610f4b-8250-408b-9bba-fd6e40f7b206_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_1dbbc5b7-4098-487a-aeaf-a9ab68c0e782_negatedTerseLabel_en-US" xlink:label="lab_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets and acquired intangibles assets</link:label>
    <link:label id="lab_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_label_en-US" xlink:label="lab_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</link:label>
    <link:label id="lab_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_documentation_en-US" xlink:label="lab_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:href="dxcm-20231231.xsd#dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:to="lab_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_edf253e8-4c91-4005-bce2-11248dde8a5e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_7af52b56-17f2-411e-8dc2-428ecd2d1416_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_c2cf6934-ca8c-46d5-b1f6-785c0feffdda_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_807c33c0-7b98-4902-920a-1aaeef240f1a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_b3030789-7e79-49ee-a87d-63866895a122_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contribution (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_226dcc74-9bf8-4238-8e00-f7a8363912b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_11896712-108c-459b-9af0-9ad03e35aa4c_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing stock price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f96f6084-28e6-4912-bde0-a583233674ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PreferentialTaxRatePeriod_d050163f-e1df-47bf-8c0e-20010f8122fc_terseLabel_en-US" xlink:label="lab_dxcm_PreferentialTaxRatePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferential tax rate period (in years)</link:label>
    <link:label id="lab_dxcm_PreferentialTaxRatePeriod_label_en-US" xlink:label="lab_dxcm_PreferentialTaxRatePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferential Tax Rate Period</link:label>
    <link:label id="lab_dxcm_PreferentialTaxRatePeriod_documentation_en-US" xlink:label="lab_dxcm_PreferentialTaxRatePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferential Tax Rate Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PreferentialTaxRatePeriod" xlink:href="dxcm-20231231.xsd#dxcm_PreferentialTaxRatePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PreferentialTaxRatePeriod" xlink:to="lab_dxcm_PreferentialTaxRatePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_8004e2c9-c7b1-44c6-86cb-74624dd0593a_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard Product Warranty Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard Product Warranty Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInStandardProductWarrantyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:to="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_UnusedExpiredFederalIncomeTaxCredits_06572acb-1fc6-41eb-9515-e508d5b4f0a5_terseLabel_en-US" xlink:label="lab_dxcm_UnusedExpiredFederalIncomeTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards subject to expiration</link:label>
    <link:label id="lab_dxcm_UnusedExpiredFederalIncomeTaxCredits_label_en-US" xlink:label="lab_dxcm_UnusedExpiredFederalIncomeTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Expired Federal Income Tax Credits</link:label>
    <link:label id="lab_dxcm_UnusedExpiredFederalIncomeTaxCredits_documentation_en-US" xlink:label="lab_dxcm_UnusedExpiredFederalIncomeTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax credits likely to expire unused as a result of limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_UnusedExpiredFederalIncomeTaxCredits" xlink:href="dxcm-20231231.xsd#dxcm_UnusedExpiredFederalIncomeTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_UnusedExpiredFederalIncomeTaxCredits" xlink:to="lab_dxcm_UnusedExpiredFederalIncomeTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1e6d5f2f-6bf6-44dc-9a97-f85474217f82_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CollaborativeArrangementUpfrontFee_902872ea-f78b-4e4a-b473-bd947363a12e_terseLabel_en-US" xlink:label="lab_dxcm_CollaborativeArrangementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial payment on collaborative agreement</link:label>
    <link:label id="lab_dxcm_CollaborativeArrangementUpfrontFee_label_en-US" xlink:label="lab_dxcm_CollaborativeArrangementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Fee</link:label>
    <link:label id="lab_dxcm_CollaborativeArrangementUpfrontFee_documentation_en-US" xlink:label="lab_dxcm_CollaborativeArrangementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeArrangementUpfrontFee" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeArrangementUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CollaborativeArrangementUpfrontFee" xlink:to="lab_dxcm_CollaborativeArrangementUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_5328c821-0471-4646-86b2-19556d3996a2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_7ac0048a-b0f5-4204-b21e-f59a736058a2_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents incorporated by reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0b86401c-db7d-43fb-af83-f8c668a57711_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_SadieMSternMember_label_en-US" xlink:label="lab_dxcm_SadieMSternMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sadie M. Stern [Member]</link:label>
    <link:label id="lab_dxcm_SadieMSternMember_documentation_en-US" xlink:label="lab_dxcm_SadieMSternMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sadie M. Stern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SadieMSternMember" xlink:href="dxcm-20231231.xsd#dxcm_SadieMSternMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_SadieMSternMember" xlink:to="lab_dxcm_SadieMSternMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_32671028-7e6b-4973-bbcd-aa38f3d4c890_terseLabel_en-US" xlink:label="lab_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_label_en-US" xlink:label="lab_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) and Performance Shares [Member]</link:label>
    <link:label id="lab_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_documentation_en-US" xlink:label="lab_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) and Performance Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember" xlink:to="lab_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount_327d3860-afe7-4c08-b7f3-49a23b96130d_terseLabel_en-US" xlink:label="lab_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash discounts reserve</link:label>
    <link:label id="lab_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount_label_en-US" xlink:label="lab_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Cash Discount</link:label>
    <link:label id="lab_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount_documentation_en-US" xlink:label="lab_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Cash Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount" xlink:href="dxcm-20231231.xsd#dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount" xlink:to="lab_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_d2de6fd5-d9e6-4a8d-9b40-14596c263f09_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate of finance leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_65084018-5582-449b-8b23-b821339a1fad_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_a637d6fb-82dc-44c5-9095-151dd6cc961a_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_3bd9b45c-8676-4e3b-bb61-dd9ee401ed61_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_661fb971-f2bf-4cc4-89b5-22d0380c2d55_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount_a22fd66a-6624-4a03-b833-0b59c3be1ba7_terseLabel_en-US" xlink:label="lab_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to increase revolving line of credit</link:label>
    <link:label id="lab_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount_label_en-US" xlink:label="lab_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity, Option To Increase, Amount</link:label>
    <link:label id="lab_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount_documentation_en-US" xlink:label="lab_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Option to Increase, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount" xlink:href="dxcm-20231231.xsd#dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount" xlink:to="lab_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9ebd03a1-7c4c-4f6b-9f18-6228d75ac7aa_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of machinery and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d50b8349-876c-4718-97ef-bdffa6464602_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ff1a5bc4-f0c7-48ff-931b-ebd84105c14c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes at effective rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_bf32513d-4e44-4d9d-b740-4feefe8c1834_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized_08eea49f-195c-4051-b651-25074ec7d981_terseLabel_en-US" xlink:label="lab_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock authorized in ESPP (in shares)</link:label>
    <link:label id="lab_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized_label_en-US" xlink:label="lab_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP), Number of Shares Authorized</link:label>
    <link:label id="lab_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized_documentation_en-US" xlink:label="lab_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP), Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized" xlink:href="dxcm-20231231.xsd#dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized" xlink:to="lab_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_6da76aaf-7026-4643-bb7c-7bf9c8986ff9_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_RevenuePercentage_d0d5bd90-9af9-4645-b5e5-cf851ae26c22_terseLabel_en-US" xlink:label="lab_dxcm_RevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of revenue (as a percent)</link:label>
    <link:label id="lab_dxcm_RevenuePercentage_label_en-US" xlink:label="lab_dxcm_RevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Percentage</link:label>
    <link:label id="lab_dxcm_RevenuePercentage_documentation_en-US" xlink:label="lab_dxcm_RevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RevenuePercentage" xlink:href="dxcm-20231231.xsd#dxcm_RevenuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_RevenuePercentage" xlink:to="lab_dxcm_RevenuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_777957a7-402f-4325-b16d-13ba271c2fd5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term of operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_082c9438-2ea0-4a76-bce6-69e143d55a1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_78893dbb-b6e2-4351-9811-d61cfc788a4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions for Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_df1b47dd-ce00-492d-b2c4-9468e4ccfdb4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e56c4a94-8399-45a1-a89f-4248f8dff003_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea25d09e-c215-49e9-ab41-551828ee1691_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0b67615d-6d5b-4e77-ad42-53c0a817b14d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones_2406c378-0a80-45b1-920f-8296afd8812a_terseLabel_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization of sales-based milestones</link:label>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones_label_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Capitalization Of Sales-based Milestones</link:label>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones_documentation_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Capitalization Of Sales-based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" xlink:to="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d5fd476c-7d75-458d-a874-397a095457de_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_528ace05-b120-46ce-978c-0d4ad76e28fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_bb09a551-34c2-45b5-80f3-ba40ae6c47d0_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased under the Share Repurchase Program (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_473aeeea-e177-4313-9ab0-d80bd6b48a65_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased under the Share Repurchase Program (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d6c4e5d9-a4e8-4c3f-bcde-da37c044ca18_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_643f7f4d-0c20-4e44-96f4-38c65c1d8a02_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PaulFlynnMember_label_en-US" xlink:label="lab_dxcm_PaulFlynnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paul Flynn [Member]</link:label>
    <link:label id="lab_dxcm_PaulFlynnMember_documentation_en-US" xlink:label="lab_dxcm_PaulFlynnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paul Flynn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaulFlynnMember" xlink:href="dxcm-20231231.xsd#dxcm_PaulFlynnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PaulFlynnMember" xlink:to="lab_dxcm_PaulFlynnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9a393adf-1252-49f2-846e-4bac9cad03d7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_0932b829-234f-4816-89de-b64254b8c05e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8c484a11-11df-4b07-9679-c7c056020f96_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a374371b-2099-48e6-a861-d22ea3f477a9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_fe687c4e-1f50-473c-b8c3-3fa60335f930_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_VerilyLifeSciencesMember_c258d3ec-c26d-4b12-91a3-05d2548391f5_terseLabel_en-US" xlink:label="lab_dxcm_VerilyLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verily Life Sciences</link:label>
    <link:label id="lab_dxcm_VerilyLifeSciencesMember_label_en-US" xlink:label="lab_dxcm_VerilyLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verily Life Sciences [Member]</link:label>
    <link:label id="lab_dxcm_VerilyLifeSciencesMember_documentation_en-US" xlink:label="lab_dxcm_VerilyLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verily Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_VerilyLifeSciencesMember" xlink:href="dxcm-20231231.xsd#dxcm_VerilyLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_VerilyLifeSciencesMember" xlink:to="lab_dxcm_VerilyLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ef54f3df-e6da-4ab3-8d36-5c22cbdf6335_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized (gain) loss on equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8594701d-34dd-47c4-b217-a1f2f368f01f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_820a92aa-3436-4890-957d-0f929dd2c22c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_9aaad882-38a7-44a3-a280-415383cc5c9f_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_d2760ceb-d8e1-486b-97ca-e2b555feefb8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_49f580de-f197-4cd9-9ae4-43025cc7e9be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_347d7aff-63cd-4d83-95ef-4af09986628c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_46a07466-416d-40e9-ac1c-ca0ae9d9cab0_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a1c4e629-5172-4ffa-ac67-9b61c03d1335_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease cost</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CustomerBMember_aa3e849c-6fdd-47d2-bc06-7fd1880ba9ea_terseLabel_en-US" xlink:label="lab_dxcm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_dxcm_CustomerBMember_label_en-US" xlink:label="lab_dxcm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_dxcm_CustomerBMember_documentation_en-US" xlink:label="lab_dxcm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerBMember" xlink:href="dxcm-20231231.xsd#dxcm_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CustomerBMember" xlink:to="lab_dxcm_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_55e04984-1ff2-40c6-af45-eb3eaecf9e9b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8598529c-3ed6-456e-8e53-1b55ab022f5b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_cb88df6e-ffe8-47f5-af20-d5ff8020e92f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_959e73e1-cd3a-42dd-85fd-64a38e508a86_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_602f535c-f255-4726-b07f-d86ab915f6d4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_625b6a49-f91f-4ca8-89e1-aaab0c234c8a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b6fd6324-f75c-4ec1-98a2-2b799d435eec_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_acb2cba3-4bd0-417b-9932-3616259c64f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_0a4cb617-fe09-4718-a0d4-c9bf6d423304_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_f6bcbcff-4efc-411a-bb72-684b299974cc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_719a34f6-1fc7-438c-a598-7775e204703d_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_149e0f55-8b51-41a4-9975-3fa2cd11dd84_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_f4a8d7dd-7850-428d-a2fa-d4a33117fe41_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_57d090c9-38b5-4772-91fa-cff4ca954286_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CustomerAMember_d0ecc7c0-7a81-43ec-a2cc-74e6198ab1a9_terseLabel_en-US" xlink:label="lab_dxcm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_dxcm_CustomerAMember_label_en-US" xlink:label="lab_dxcm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_dxcm_CustomerAMember_documentation_en-US" xlink:label="lab_dxcm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerAMember" xlink:href="dxcm-20231231.xsd#dxcm_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CustomerAMember" xlink:to="lab_dxcm_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_5f58373b-a662-4871-9aba-8c57260bb479_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare_c772b356-3af7-436c-af83-14c04d2c37bd_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped call, cap price (in usd per share)</link:label>
    <link:label id="lab_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare_label_en-US" xlink:label="lab_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Cap Call Transaction, Cap Price Per Share</link:label>
    <link:label id="lab_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Cap Call Transaction, Cap Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:to="lab_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7f960232-c5ee-40ae-9a02-42df4ed88d3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_19fbf795-30ec-4c7b-9896-f031f1961c8c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_05d4fbf1-2f40-4825-8592-6c37f2ac6f4d_terseLabel_en-US" xlink:label="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="dxcm-20231231.xsd#dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_f7ab5305-27c0-4827-8636-5014e70f3e9a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_5ecb1038-b731-4afb-a086-11cc26a4e3c7_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_SharesReceivedFromExerciseOfNoteHedge_03ac169f-79f2-409c-a35c-d25cc8467607_negatedTerseLabel_en-US" xlink:label="lab_dxcm_SharesReceivedFromExerciseOfNoteHedge" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit of note hedge upon conversions of 2023 Notes (in shares)</link:label>
    <link:label id="lab_dxcm_SharesReceivedFromExerciseOfNoteHedge_9c3119cf-3a0b-459a-992c-19442fc8fe02_verboseLabel_en-US" xlink:label="lab_dxcm_SharesReceivedFromExerciseOfNoteHedge" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received from note hedge (in shares)</link:label>
    <link:label id="lab_dxcm_SharesReceivedFromExerciseOfNoteHedge_label_en-US" xlink:label="lab_dxcm_SharesReceivedFromExerciseOfNoteHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received From Exercise Of Note Hedge</link:label>
    <link:label id="lab_dxcm_SharesReceivedFromExerciseOfNoteHedge_documentation_en-US" xlink:label="lab_dxcm_SharesReceivedFromExerciseOfNoteHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received From Exercise Of Note Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromExerciseOfNoteHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge" xlink:to="lab_dxcm_SharesReceivedFromExerciseOfNoteHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_EmployeeStockPurchasePlanMember_2f633170-3841-454b-9531-ac26e50c914f_terseLabel_en-US" xlink:label="lab_dxcm_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_dxcm_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_dxcm_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dxcm_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_dxcm_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeeStockPurchasePlanMember" xlink:href="dxcm-20231231.xsd#dxcm_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_EmployeeStockPurchasePlanMember" xlink:to="lab_dxcm_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge_7bb86021-7764-452f-8edb-90fc83c0f370_negatedTerseLabel_en-US" xlink:label="lab_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received under note hedge upon conversion of 2023 Notes</link:label>
    <link:label id="lab_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge_label_en-US" xlink:label="lab_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Benefit Received From Note Hedge</link:label>
    <link:label id="lab_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge_documentation_en-US" xlink:label="lab_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Benefit Received From Note Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge" xlink:href="dxcm-20231231.xsd#dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge" xlink:to="lab_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PaymentsForPurchasesOfCappedCallTransactions_d5937126-d2b0-4cbd-90bb-402027863ea1_negatedTerseLabel_en-US" xlink:label="lab_dxcm_PaymentsForPurchasesOfCappedCallTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capped call transactions</link:label>
    <link:label id="lab_dxcm_PaymentsForPurchasesOfCappedCallTransactions_21c69b99-e948-40a8-a40b-53391acc1c16_terseLabel_en-US" xlink:label="lab_dxcm_PaymentsForPurchasesOfCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capped call transactions</link:label>
    <link:label id="lab_dxcm_PaymentsForPurchasesOfCappedCallTransactions_label_en-US" xlink:label="lab_dxcm_PaymentsForPurchasesOfCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Purchases Of Capped Call Transactions</link:label>
    <link:label id="lab_dxcm_PaymentsForPurchasesOfCappedCallTransactions_documentation_en-US" xlink:label="lab_dxcm_PaymentsForPurchasesOfCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Purchases Of Capped Call Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsForPurchasesOfCappedCallTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions" xlink:to="lab_dxcm_PaymentsForPurchasesOfCappedCallTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_75e295b5-ac37-4c83-b649-918eddd7be04_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_00d7ceb2-0ec0-4d62-a5ad-6ef2ce6c12ae_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5a31f5a1-ef27-4224-a32c-a5837f7a1b9b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_84e8c9ad-696f-4015-bf56-1593f5f4bf5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Senior Convertible Notes</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_8b1bd44a-c5e5-41cd-bff0-9f341ab784bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CustomerCMember_2c845ef7-cdb1-4106-ad2e-1c4f2d8d61ec_terseLabel_en-US" xlink:label="lab_dxcm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_dxcm_CustomerCMember_label_en-US" xlink:label="lab_dxcm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_dxcm_CustomerCMember_documentation_en-US" xlink:label="lab_dxcm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerCMember" xlink:href="dxcm-20231231.xsd#dxcm_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CustomerCMember" xlink:to="lab_dxcm_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_a6f50371-4c2e-449d-b826-4f720d5638db_terseLabel_en-US" xlink:label="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_label_en-US" xlink:label="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested</link:label>
    <link:label id="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_documentation_en-US" xlink:label="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" xlink:href="dxcm-20231231.xsd#dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" xlink:to="lab_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7139866c-81dd-47b2-8868-8c16af54b96c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_897f6119-6fc5-41a5-a019-4af8dbe3268a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2680e617-ca8a-4e0a-a213-0aaed3a657fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4a5f9340-258f-4683-b736-5dc8b7dc1d12_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6b0cb481-a48f-497e-99a0-9b6abdeeb118_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_16ed7684-098d-46b2-b2ff-b62cb7a25040_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9f548d55-ce6c-46ee-9f22-abfe867c9b80_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7662f291-02b3-452c-8059-4e4029bb5faa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_f517d3f5-0b3a-42c1-9e6c-9d6b0880f9f5_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_93454fb9-1be3-42bc-8e12-f3e956bda9d6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_KevinRSayerMember_label_en-US" xlink:label="lab_dxcm_KevinRSayerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kevin R. Sayer [Member]</link:label>
    <link:label id="lab_dxcm_KevinRSayerMember_documentation_en-US" xlink:label="lab_dxcm_KevinRSayerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kevin R. Sayer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_KevinRSayerMember" xlink:href="dxcm-20231231.xsd#dxcm_KevinRSayerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_KevinRSayerMember" xlink:to="lab_dxcm_KevinRSayerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_880c6e97-1299-448c-a859-26410b958293_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_fdc29c6f-4c98-4775-a5fb-d2d81181bf09_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4dc8be55-034d-47bd-85a6-625b6d2c3ce7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2dd4af71-1d9c-45da-8944-bf6fce035e3a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_907b9602-e47e-40d3-bf33-2a7900496500_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_d30176a2-73e6-4e5b-9b03-77bc8eb4fab4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5b41061b-7211-469f-a624-a8874ebcdd3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses_9f5b0290-6fa1-4fcb-a222-552d6195f0fc_totalLabel_en-US" xlink:label="lab_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amortization of intangible assets</link:label>
    <link:label id="lab_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses_label_en-US" xlink:label="lab_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Intangibles Included In Cost Of Sales And Operating Expenses</link:label>
    <link:label id="lab_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses_documentation_en-US" xlink:label="lab_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Intangibles Included In Cost Of Sales And Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" xlink:href="dxcm-20231231.xsd#dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" xlink:to="lab_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares_254b7399-9d82-44ca-8e4b-ef1eb528addf_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued upon conversion of senior notes (in shares)</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares_label_en-US" xlink:label="lab_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Associated Derivative Transactions, Number Of Shares</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Associated Derivative Transactions, Number Of Shares1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares" xlink:to="lab_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_407a2b18-374f-4d2c-9846-25ddc2393d9d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_d5ee39c0-d6cf-4275-91d9-d0bfaf524145_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a27deb7e-4bfa-44a7-b920-73df113c5841_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5cf0713e-9015-4c32-92a0-af23b2db5eca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6558181a-811a-40bc-b22a-a60bd3dee900_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2af1c3d8-e381-465c-9095-acca308cc719_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Grant&#160;Date Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24cefc3e-acfb-4309-8e00-5ca6f94e578f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_55140b7b-be24-42f2-88dd-3127a055e872_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fd600943-2cf5-4e46-8342-e481658ebc56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_7a7e2ae1-8565-49b9-828f-3f3afcb6e53b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_52dd4338-240e-43a5-bbd6-f12378a683ec_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_ae39f924-85d0-49b5-bdb8-778327d44735_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4e236b87-5774-4646-bc58-a24932b6e9bd_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a1095a2e-436c-4617-9568-676e57fc7e5a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c0199ecc-75c1-4554-b05e-3e446406a3c8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_8d757c28-fdfd-4da2-9aaf-d7b9d5a64017_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_27c0cca1-2705-4f43-8c36-cbc3d207256f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ffa68b46-c77b-479e-b0a1-ee7bc54ecc78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases and Other Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1aacba94-ffc1-4165-ac03-029a57bcddf2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_fbae9281-45fa-4d8c-b85e-c2afc4b12a8f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b11cf9c0-0e6e-4d20-b9cf-3fa4f5873be0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_42499932-f59f-4747-bf60-547868693d6f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_5db92d18-9d0f-4953-9508-0c38effa1250_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for conversions of senior convertible notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bab29ee3-4ee0-4edd-8e56-b3319775ec27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_f6e271da-6883-43e8-8c16-b475c2b3dc3c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_cec79a66-cdc0-4a20-b108-44c1111a1966_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term senior convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1d51d27f-67ec-42c0-941e-24946977cd36_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_1b9bec12-684e-4cf3-91a3-359cbc9004d1_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivables and Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_54d0d4af-5d37-4c16-adf5-b1a599843e26_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_f5b284ce-4059-4a90-a9e4-72e5fe60b93d_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Years Remaining Subject to Audit by Major Jurisdiction</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Examinations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxExaminationsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ecf8999b-77a7-4c40-93de-55e7896ddc24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_4fe4a954-fe67-4344-863f-b4971c368366_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales_241880ab-c029-47cc-89e4-ebc32dd80ec1_verboseLabel_en-US" xlink:label="lab_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense included in cost of sales</link:label>
    <link:label id="lab_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales_label_en-US" xlink:label="lab_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Intangible Assets Included In Cost Of Sales</link:label>
    <link:label id="lab_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales_documentation_en-US" xlink:label="lab_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Intangible Assets Included In Cost Of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales" xlink:href="dxcm-20231231.xsd#dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales" xlink:to="lab_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_1ec2dcf8-0e9e-4a89-8b42-edf8f470ed8b_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes</link:label>
    <link:label id="lab_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_cd1c01a0-dc34-441a-b278-f05badc9eee4_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0aaf343a-f758-4731-ac2d-465e10b2f450_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_483e034d-c4fe-44a6-8d60-af2f081c6dfb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d144aefd-9b4a-47f6-bf4c-d15d45040666_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock_92872a35-a025-4f42-8a8f-e2947896caf9_terseLabel_en-US" xlink:label="lab_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Payroll and Related Expenses</link:label>
    <link:label id="lab_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock_label_en-US" xlink:label="lab_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Payroll and Related Expenses [Table Text Block]</link:label>
    <link:label id="lab_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock_documentation_en-US" xlink:label="lab_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Payroll and Related Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock" xlink:href="dxcm-20231231.xsd#dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock" xlink:to="lab_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9e568a2c-a4b3-4ae5-bdd9-8538a1a23587_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86b968c9-3ab7-447e-adf4-4120d1e565b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_95001810-b2d8-4eca-962e-a388383debd5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_31d7780c-e894-4c24-8233-1c21dcf03b1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_33c3c730-fa50-4f57-b84d-f776bd3bdc5d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_a32ec4ac-e622-4fbe-9cf7-5939b9755d76_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of debt instrument (in months)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_73dc5d4a-602e-42bb-b3ac-c6c314a1ce7f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of debt instrument (in years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_149076ed-57d7-482a-9ec8-f9e9f94e47c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bca43082-1a99-4b86-a16c-4c1413a26b87_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_3bd3cccd-489d-49c1-90b9-74ae0d62c083_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_031e3740-20ea-4119-a73d-7eee2597ff3a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_b3753cc4-1cee-4426-a0a0-a486afad599d_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c7eab6f2-bb9c-4ca7-9aa5-d62304806edf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_ad42ad00-2185-42e7-bc05-65dc16deffb9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c07667d6-87ce-44b7-994e-7e1f0b4e667d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_a5566c22-4ae4-4ba4-980d-3b4eb81efefc_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed foreign earnings</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9a7e7c16-4d2e-4ce7-9fc9-6d2eeedcf7aa_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_021d8055-4a5f-4358-9c71-17cd989145de_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense and Other Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_da4e5abd-6a6f-4a4f-b606-1dea5617f261_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_OtherCountriesMember_d1beaca5-3ab7-40b0-be34-2c3daf08f88d_terseLabel_en-US" xlink:label="lab_dxcm_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other countries</link:label>
    <link:label id="lab_dxcm_OtherCountriesMember_label_en-US" xlink:label="lab_dxcm_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_dxcm_OtherCountriesMember_documentation_en-US" xlink:label="lab_dxcm_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherCountriesMember" xlink:href="dxcm-20231231.xsd#dxcm_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_OtherCountriesMember" xlink:to="lab_dxcm_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_695e9fe3-ce46-40ec-9d05-24c0f326b44f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_a90e81a3-63cb-49ea-a25d-dde716eaf24d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_2cce0129-6e95-4908-b5a8-2735e3da5cf2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_b2b0e332-2298-40df-ae28-b6c2b7a14a54_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c8b8c6a2-98fa-44a4-acff-4ae2ea2ded17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a5aee8d7-eb88-42ee-933f-f572fb65aa0b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs related to unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_56937f8d-771a-4b98-b9a3-0922a202341c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Details and Other Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ef20aab8-2da3-452a-9780-64ab3363a4c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_23960767-2cf7-4094-be8f-505c7c628190_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f5a9ac1c-9ba6-4006-88b5-cf035fa373f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_7b0086d9-c3ac-4d6e-a213-7ebc1fa43321_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_c0cbacc6-9746-41a1-ae9e-2e78d7ecd897_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_5a260940-9ecb-4220-a6d7-a29265bfcfad_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Interest Expense and Effective Interest Rates of Senior Convertible Notes</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_7098901e-e759-4457-a2b5-9004836953bc_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues_5626c5b6-fdd1-4d27-98a8-2878dc4910f7_terseLabel_en-US" xlink:label="lab_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential common stock issued shares (in shares)</link:label>
    <link:label id="lab_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues_label_en-US" xlink:label="lab_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Common Stock Issuable Or Issued, Shares, New Issues</link:label>
    <link:label id="lab_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues_documentation_en-US" xlink:label="lab_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Common Stock Issuable Or Issued, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues" xlink:href="dxcm-20231231.xsd#dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues" xlink:to="lab_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e4363da4-2239-487c-931c-bcaf06e56ce5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_a798fc27-446b-407b-b1fa-fd4e3f1ed995_terseLabel_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes</link:label>
    <link:label id="lab_us-gaap_InterestOnConvertibleDebtNetOfTax_label_en-US" xlink:label="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on Convertible Debt, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="lab_us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d2db531c-73dc-4fe9-9975-9429f39ccfd2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_83719c0b-b527-4b84-bc8c-43e0805181c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_f6914c5f-dfb3-4c95-a17d-e108bf8d35e9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of derivative contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PharmacyRebatesCurrent_f912b225-b558-4d37-9977-27ae92297674_verboseLabel_en-US" xlink:label="lab_dxcm_PharmacyRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_dxcm_PharmacyRebatesCurrent_label_en-US" xlink:label="lab_dxcm_PharmacyRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebates, Current</link:label>
    <link:label id="lab_dxcm_PharmacyRebatesCurrent_documentation_en-US" xlink:label="lab_dxcm_PharmacyRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebates, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PharmacyRebatesCurrent" xlink:href="dxcm-20231231.xsd#dxcm_PharmacyRebatesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PharmacyRebatesCurrent" xlink:to="lab_dxcm_PharmacyRebatesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_9fdac179-686a-4ea3-a7cc-c83ac7217eec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_75d12d63-5573-4457-8c0a-b918acd541c0_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_6b5c00a2-f61f-45a7-87f5-c9ccc617806e_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense included in operating expenses</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9249238d-4089-4fca-95bc-04d202c6f6f3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_25ab4cd6-2bbf-4a05-8d27-2bff2418f8fd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PaymentsUnderCollaborationAgreementsDomain_49f764da-46e3-48d8-8488-7d06ac89ee33_terseLabel_en-US" xlink:label="lab_dxcm_PaymentsUnderCollaborationAgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Under Collaboration Agreements [Domain]</link:label>
    <link:label id="lab_dxcm_PaymentsUnderCollaborationAgreementsDomain_label_en-US" xlink:label="lab_dxcm_PaymentsUnderCollaborationAgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Under Collaboration Agreements [Domain]</link:label>
    <link:label id="lab_dxcm_PaymentsUnderCollaborationAgreementsDomain_documentation_en-US" xlink:label="lab_dxcm_PaymentsUnderCollaborationAgreementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payments Under Collaboration Agreements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsUnderCollaborationAgreementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain" xlink:to="lab_dxcm_PaymentsUnderCollaborationAgreementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0ac7183b-a9a6-412c-82b3-b062fd98bb8d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2818cf6f-9816-41b0-b985-05ee166905f5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d3a73e3-ac8b-4ebb-ae43-23933bd34933_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8afa1733-1171-439e-bd70-db1d94610c31_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_A2028NotesMember_8da28b94-d679-41d4-83c4-d2bd9de6e36b_terseLabel_en-US" xlink:label="lab_dxcm_A2028NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 Notes</link:label>
    <link:label id="lab_dxcm_A2028NotesMember_label_en-US" xlink:label="lab_dxcm_A2028NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 Notes [Member]</link:label>
    <link:label id="lab_dxcm_A2028NotesMember_documentation_en-US" xlink:label="lab_dxcm_A2028NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A2028NotesMember" xlink:href="dxcm-20231231.xsd#dxcm_A2028NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_A2028NotesMember" xlink:to="lab_dxcm_A2028NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_385e785e-c07f-4c5a-9de1-585b2d84ecc0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e45ee0f8-99ae-4b74-a56a-d572ae69a949_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_13c6e800-9b99-4972-af9a-afc1d5ea1df5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ef857ce0-fdb8-483e-a005-0bad8b324954_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_7f61958d-e4fc-4d66-89a4-b70581c2cf5e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 21.8 million shares at December&#160;31, 2023 and 6.9 million shares at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1f81d5f5-f973-4f7d-895b-d2db469dd3f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_2bd0b0cb-5714-434b-a764-63cb5a7218bb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_56db58d1-9023-40fc-ad36-e2cd3a7de342_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_e8312d8c-5690-4845-90da-994a7fccdec9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_810f99ba-82d4-4363-91b1-feafbbe0354e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_013c99f0-2dae-45f4-ac06-627bf0e86a13_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b47f31ed-4fc7-466a-8c53-9b1e60e4c27c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs recognized weighted average period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ReceiverProductComponentMember_fe7730d8-7c65-4cdb-baab-4e56b395dd26_terseLabel_en-US" xlink:label="lab_dxcm_ReceiverProductComponentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receiver Product Component</link:label>
    <link:label id="lab_dxcm_ReceiverProductComponentMember_label_en-US" xlink:label="lab_dxcm_ReceiverProductComponentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receiver Product Component [Member]</link:label>
    <link:label id="lab_dxcm_ReceiverProductComponentMember_documentation_en-US" xlink:label="lab_dxcm_ReceiverProductComponentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receiver Product Component [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ReceiverProductComponentMember" xlink:href="dxcm-20231231.xsd#dxcm_ReceiverProductComponentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ReceiverProductComponentMember" xlink:to="lab_dxcm_ReceiverProductComponentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_88f78a15-8e19-4789-8411-fd74faedf18c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2fad59ca-66f8-49c8-a220-300f2fe142a4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_OtherStatesMember_05e9d936-688f-4bac-aece-f8d9b138e819_terseLabel_en-US" xlink:label="lab_dxcm_OtherStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other states</link:label>
    <link:label id="lab_dxcm_OtherStatesMember_label_en-US" xlink:label="lab_dxcm_OtherStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other States [Member]</link:label>
    <link:label id="lab_dxcm_OtherStatesMember_documentation_en-US" xlink:label="lab_dxcm_OtherStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherStatesMember" xlink:href="dxcm-20231231.xsd#dxcm_OtherStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_OtherStatesMember" xlink:to="lab_dxcm_OtherStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5cd5c2f5-a7f1-453e-aa42-d95a0b5d69cf_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_e03d1d50-7297-4f92-8877-55e102ca9cfd_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1ae01dca-af86-4f77-a10e-4e373e17fa8f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c7659fe7-6fcd-45b1-9458-d330787a7ccc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f0f84af9-3c23-432d-b9cb-29d04a34bd6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payroll deductions (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_15758993-2138-4476-b6b7-bd49835ad8a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f812ef6e-c9e6-48d9-8a47-2b0264bdadae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Weighted Average Amortization Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_80f97872-2374-49a2-ad48-f98a8900b24e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fdb93db4-a556-46ec-9f8a-697e5702dfc0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with acquisition, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_SadieMStern2023PlanTerminationMember_label_en-US" xlink:label="lab_dxcm_SadieMStern2023PlanTerminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sadie M Stern 2023 Plan Termination [Member]</link:label>
    <link:label id="lab_dxcm_SadieMStern2023PlanTerminationMember_documentation_en-US" xlink:label="lab_dxcm_SadieMStern2023PlanTerminationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sadie M Stern 2023 Plan Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SadieMStern2023PlanTerminationMember" xlink:href="dxcm-20231231.xsd#dxcm_SadieMStern2023PlanTerminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_SadieMStern2023PlanTerminationMember" xlink:to="lab_dxcm_SadieMStern2023PlanTerminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_9b16adb7-87e6-4f29-b512-994e5823cb4c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_017da0ca-f39f-42ab-83a6-f7f6fe71863f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5cd47a65-15b2-488d-bf1e-d5f23b989b64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositAssets_4d95866b-a01a-4424-8595-3851b47fe6b1_terseLabel_en-US" xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit assets</link:label>
    <link:label id="lab_us-gaap_DepositAssets_label_en-US" xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets" xlink:to="lab_us-gaap_DepositAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_20b025e5-693b-4f5d-8934-fd8099755ee1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for repurchase and conversions of senior convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f3d2df80-af3a-486f-afc6-822ca5eac4ec_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5b84a658-2072-4557-b816-e4621d58526a_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_a50ef4c2-739f-4839-b935-c63a3b3e1e40_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a2f79a13-28c9-4011-9fa7-dd37986d1e10_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_9d8e5b7a-5a27-431a-8187-b86b6d33c1a2_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_a7cc022c-11e9-441d-972b-2df2414ff149_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash, end of period:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1ab78817-a95e-4348-8112-a3961193be3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1b6d3c36-5c3d-479b-977b-f2f0b10d36c0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_44b85f6c-82e7-4221-937e-f738b01e48b2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2436a7e9-286d-4293-bad6-eb888e8d6cac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_adf4ff4c-9bf1-406b-a3f8-fc69ccaf0a60_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_feac454d-ed42-4356-a418-8cf1ed76fefa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_870f99e6-6094-4d29-b458-526955cb1bdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_714e2881-6a67-4bf6-aba0-168d16986fa8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_14537bd9-fff5-417f-a3dc-2ba7beb4a9c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9fd96017-bc06-4ac7-9f52-f5233088674b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_91bf14a2-2d5e-4691-99fa-897e7e8e384c_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e6241cf2-7355-49c3-8f99-9d84a5c3d33c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2a107bad-bb80-4fcd-8668-ad34475ec1d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_389ae61d-fd10-404e-83fa-cd91044ee0fb_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease cost</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_490eff86-552d-4422-a611-f037728aafe8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_SharesReceivedFromBenefitOfNoteHedge_35588bfa-631f-4d9e-8b4a-da5afbf1159e_verboseLabel_en-US" xlink:label="lab_dxcm_SharesReceivedFromBenefitOfNoteHedge" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received from Note Hedge</link:label>
    <link:label id="lab_dxcm_SharesReceivedFromBenefitOfNoteHedge_label_en-US" xlink:label="lab_dxcm_SharesReceivedFromBenefitOfNoteHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received From Benefit Of Note Hedge</link:label>
    <link:label id="lab_dxcm_SharesReceivedFromBenefitOfNoteHedge_documentation_en-US" xlink:label="lab_dxcm_SharesReceivedFromBenefitOfNoteHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Received From Benefit Of Note Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromBenefitOfNoteHedge" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromBenefitOfNoteHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_SharesReceivedFromBenefitOfNoteHedge" xlink:to="lab_dxcm_SharesReceivedFromBenefitOfNoteHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_a03531a6-819e-47a5-ae3a-1340a8f6f849_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price of convertible notes (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_65ebc54d-6751-4379-8511-137be43aa1e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_6a4e9f99-e65d-41eb-8c96-24c77ad59bdc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing transactions:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_6c963129-f818-495f-a513-27d6695bcfe0_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_369f700e-0429-48ea-a344-1ec03a3c065f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee contribution (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9708859a-ceda-40b6-894c-20577c50c3e6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_b10bc9dd-4c0f-4a01-bca2-342cc946111e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AccruedTaxAuditAndLegalFeesCurrent_fea2ff6f-11bd-445b-a3ab-65b8014e8f13_verboseLabel_en-US" xlink:label="lab_dxcm_AccruedTaxAuditAndLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued tax, audit, and legal fees</link:label>
    <link:label id="lab_dxcm_AccruedTaxAuditAndLegalFeesCurrent_label_en-US" xlink:label="lab_dxcm_AccruedTaxAuditAndLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Tax Audit And Legal Fees, Current</link:label>
    <link:label id="lab_dxcm_AccruedTaxAuditAndLegalFeesCurrent_documentation_en-US" xlink:label="lab_dxcm_AccruedTaxAuditAndLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of accrued current tax, audit and legal fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AccruedTaxAuditAndLegalFeesCurrent" xlink:href="dxcm-20231231.xsd#dxcm_AccruedTaxAuditAndLegalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AccruedTaxAuditAndLegalFeesCurrent" xlink:to="lab_dxcm_AccruedTaxAuditAndLegalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5bf113de-5b17-45b2-bbd7-679d5bc4dfb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CollaborativeArrangementInitialPaymentMember_12cf644f-c813-4829-90ab-e8b13a08fc59_terseLabel_en-US" xlink:label="lab_dxcm_CollaborativeArrangementInitialPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Initial Payment</link:label>
    <link:label id="lab_dxcm_CollaborativeArrangementInitialPaymentMember_label_en-US" xlink:label="lab_dxcm_CollaborativeArrangementInitialPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Initial Payment [Member]</link:label>
    <link:label id="lab_dxcm_CollaborativeArrangementInitialPaymentMember_documentation_en-US" xlink:label="lab_dxcm_CollaborativeArrangementInitialPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Initial Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeArrangementInitialPaymentMember" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeArrangementInitialPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CollaborativeArrangementInitialPaymentMember" xlink:to="lab_dxcm_CollaborativeArrangementInitialPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_c5307a2a-1864-4bce-ad7f-1c5ce494bd26_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_cd136c62-84be-4422-afdf-0be4ecb0cee2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_70659025-bc1e-4727-9d38-c4253228499f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU and PSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8cc599e1-89c7-4aaf-8d30-e946ec912987_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_76404826-80c9-4fcd-97ba-0cf02246f345_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1ce67d26-7108-4de0-84ed-609d2fb11f07_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b495dd33-411e-433b-8bc7-6b4c308741a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_9d1688ea-4682-4bb7-a13d-a4926e09a7c3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_ee35b09c-2806-4d55-8a05-3594a34904d3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_4818890e-8a79-408e-bd9e-8eabb9ea02ed_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, long-term</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_232f6c26-379c-42fb-91d3-d96fec8f6cac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_a95813a9-e377-4bb7-a0aa-104abe2ef4ed_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_793985ad-7643-42d8-b131-e428a30d95b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_56f03412-a0bb-4927-a0ea-44e93a720758_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax benefit related to share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b60c2b36-56c1-4233-8fcc-2b2399175a82_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_dc4b3965-72bb-4b9b-b8df-8cd21e06b7e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_e2f052d6-8331-48c2-bb80-120fce3b9bf7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6e7c76f3-ca85-4d74-9039-3da760b3b253_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability_bdcd5a68-f26e-4829-9631-224afc4bdedd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Deferred Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_8a904525-be7b-47f0-96b7-61c1f631b7e1_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount_9e620337-f5e3-4f2b-80fa-86bdbe9f8bd6_terseLabel_en-US" xlink:label="lab_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchase agreement, authorized amount</link:label>
    <link:label id="lab_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount_label_en-US" xlink:label="lab_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement, Authorized Amount</link:label>
    <link:label id="lab_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount_documentation_en-US" xlink:label="lab_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase Agreement, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount" xlink:href="dxcm-20231231.xsd#dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount" xlink:to="lab_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax_be65a5e8-f3c3-437a-a8e6-34b141c401f4_negatedTerseLabel_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of capped call transactions, net of tax</link:label>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax_label_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid-In Capital, Purchase Of Capped Call Transactions, Net Of Tax</link:label>
    <link:label id="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax_documentation_en-US" xlink:label="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid-In Capital, Purchase Of Capped Call Transactions, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" xlink:to="lab_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_eb101f3d-1ff9-4250-b88b-907f243cd49a_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_54095608-1a15-4da4-9f06-a3f8044092b1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_7918b8ce-de6e-4b3a-b85f-06251287b7a3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentCovenantRepurchasePricePercentage_8f7533b5-5c83-40dd-8a97-1673f0d5a23e_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentCovenantRepurchasePricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holder's repurchase price percentage in event of fundamental change (as a percent)</link:label>
    <link:label id="lab_dxcm_DebtInstrumentCovenantRepurchasePricePercentage_label_en-US" xlink:label="lab_dxcm_DebtInstrumentCovenantRepurchasePricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Repurchase Price, Percentage</link:label>
    <link:label id="lab_dxcm_DebtInstrumentCovenantRepurchasePricePercentage_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentCovenantRepurchasePricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Repurchase Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentCovenantRepurchasePricePercentage" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentCovenantRepurchasePricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentCovenantRepurchasePricePercentage" xlink:to="lab_dxcm_DebtInstrumentCovenantRepurchasePricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_7fbbfda7-6bfa-4cd7-b441-480d7102ea14_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_19e250a0-32ce-4d29-a415-4e1c44b042e6_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_d83cd269-01d1-44d6-9960-bf37d4a069eb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities_e3b9e02e-b294-4b26-a479-bc140d234fc2_terseLabel_en-US" xlink:label="lab_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities_label_en-US" xlink:label="lab_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale And Equity Securities</link:label>
    <link:label id="lab_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities_documentation_en-US" xlink:label="lab_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale And Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities" xlink:href="dxcm-20231231.xsd#dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities" xlink:to="lab_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3c48ac10-9294-49e8-834d-6a84b93d097f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_bf1a0ac3-cdf9-45af-9823-663cea3ccce8_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6616cc4b-5e41-4a1a-9fb3-14a1e52ea220_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_df390051-aa2f-4e4d-8ae7-ffcb07905060_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0238b6aa-d30e-4987-ad16-6ff0e42d470a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a2864306-8a07-442c-8d62-742c965383f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_5ab764a5-8f4d-45fd-a9c7-f9faede91d78_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable trade</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_377b6166-7f2b-4148-806c-03319076b3dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation between Effective Tax Rate and Statutory Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fd8c236d-8687-4114-9326-e542c971f5a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0ea56877-cf79-4716-9956-e462379742e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_cf4041d0-3af6-49b1-b474-108104ee06c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage_7c06de16-c5f9-47b6-8711-e6ac39134769_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock premium (as percent)</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage_label_en-US" xlink:label="lab_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Capped Calls Initial Cap Price, Premium Percentage</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Capped Calls Initial Cap Price, Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage" xlink:to="lab_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c5062f71-b1ac-427a-9030-7cc453794c48_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_54014ce7-a586-4588-af2e-3ef3015c7f04_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_b3851cbe-75a3-4ff7-9c45-6ca3662beff0_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DevelopmentAgreementsTable_0e90ab28-4fb4-479b-9364-023ad7b36c9f_terseLabel_en-US" xlink:label="lab_dxcm_DevelopmentAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreements [Table]</link:label>
    <link:label id="lab_dxcm_DevelopmentAgreementsTable_label_en-US" xlink:label="lab_dxcm_DevelopmentAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreements [Table]</link:label>
    <link:label id="lab_dxcm_DevelopmentAgreementsTable_documentation_en-US" xlink:label="lab_dxcm_DevelopmentAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DevelopmentAgreementsTable" xlink:href="dxcm-20231231.xsd#dxcm_DevelopmentAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DevelopmentAgreementsTable" xlink:to="lab_dxcm_DevelopmentAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7773a3b4-2410-4d00-bd0f-a5439755bcf4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_d7b6464d-ad2d-4bef-979c-c3dbe8179939_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3e3cca83-db79-494e-bff6-984671218eee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_da44b324-b323-486f-816b-2854df595bdc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_e08ae884-05b6-4aff-b2f1-9170229ffb1f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ConvertibleNotesDue2025Member_22df8f34-9458-4b6d-8557-37650046eb52_terseLabel_en-US" xlink:label="lab_dxcm_ConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes due 2025</link:label>
    <link:label id="lab_dxcm_ConvertibleNotesDue2025Member_label_en-US" xlink:label="lab_dxcm_ConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Due 2025 [Member]</link:label>
    <link:label id="lab_dxcm_ConvertibleNotesDue2025Member_documentation_en-US" xlink:label="lab_dxcm_ConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ConvertibleNotesDue2025Member" xlink:to="lab_dxcm_ConvertibleNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_fbd1cea2-22a3-4f5c-89fc-9e436fba9f34_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on convertible notes (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_83304d58-df33-4743-8075-b7f8f6e2b99f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ec474cbb-0f2f-4e35-bed1-dd84cd5c3986_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DevelopmentAgreementsLineItems_3a04f234-034b-4714-9af3-7245c79841d7_terseLabel_en-US" xlink:label="lab_dxcm_DevelopmentAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreements [Line Items]</link:label>
    <link:label id="lab_dxcm_DevelopmentAgreementsLineItems_label_en-US" xlink:label="lab_dxcm_DevelopmentAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreements [Line Items]</link:label>
    <link:label id="lab_dxcm_DevelopmentAgreementsLineItems_documentation_en-US" xlink:label="lab_dxcm_DevelopmentAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DevelopmentAgreementsLineItems" xlink:href="dxcm-20231231.xsd#dxcm_DevelopmentAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems" xlink:to="lab_dxcm_DevelopmentAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c9793971-4514-44ed-a17b-bd7427e8c827_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c7d0e50c-3ab9-431b-b2e0-4550e77f9083_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e4e323fc-6b46-450a-8cd4-ddd75e4f6990_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_497e8a00-f5cf-4089-b1cd-02b76c39c36a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_FairValueAssetsLevel3TransfersAmount_78c6db9f-8908-4bfc-9f62-b67a039d8c05_terseLabel_en-US" xlink:label="lab_dxcm_FairValueAssetsLevel3TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers in or out of Level 3 securities</link:label>
    <link:label id="lab_dxcm_FairValueAssetsLevel3TransfersAmount_label_en-US" xlink:label="lab_dxcm_FairValueAssetsLevel3TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets, Level 3 Transfers, Amount</link:label>
    <link:label id="lab_dxcm_FairValueAssetsLevel3TransfersAmount_documentation_en-US" xlink:label="lab_dxcm_FairValueAssetsLevel3TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets, Level 3 Transfers, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_FairValueAssetsLevel3TransfersAmount" xlink:href="dxcm-20231231.xsd#dxcm_FairValueAssetsLevel3TransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_FairValueAssetsLevel3TransfersAmount" xlink:to="lab_dxcm_FairValueAssetsLevel3TransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_CollaborativeArrangementMilestonePaymentsMember_2928f19b-ec03-4604-a810-db1ecc374831_terseLabel_en-US" xlink:label="lab_dxcm_CollaborativeArrangementMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payments</link:label>
    <link:label id="lab_dxcm_CollaborativeArrangementMilestonePaymentsMember_label_en-US" xlink:label="lab_dxcm_CollaborativeArrangementMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payments [Member]</link:label>
    <link:label id="lab_dxcm_CollaborativeArrangementMilestonePaymentsMember_documentation_en-US" xlink:label="lab_dxcm_CollaborativeArrangementMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeArrangementMilestonePaymentsMember" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeArrangementMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_CollaborativeArrangementMilestonePaymentsMember" xlink:to="lab_dxcm_CollaborativeArrangementMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b08a67e8-69c3-476e-8f6f-a0c44068ba65_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d674c5d1-47f8-4124-9c61-34799cbdb242_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_25796f1b-213c-4c02-a671-7e828ddfb5f0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eae74a5e-558c-48b1-a01d-97fab4ff4524_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_3a936dc9-6471-47c6-acb1-840c3ca6b2fd_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled accounts receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8f6c7aec-0808-4e99-ac68-15019be784e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_bbcc1131-ddac-4a6b-942a-0e9799a24431_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8a0a55fe-7c7f-4032-ab91-58030f89a997_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversions of 2023 Notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e6c82031-3b68-4a83-9ab3-750c4b15451e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and conversions of notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a020d611-534f-4c40-b545-5f71ed9205d8_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with 2023 Notes conversions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d37a8b9b-ee36-4fec-b856-1f21970e134f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_f168cc5a-c3ad-44c7-bd7d-733e33b5a18a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Warranty</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_93d7b2ce-74b6-4fcd-96a5-aa6aa6c9c7d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PrepaidInventoryCurrent_e4c4b10d-4962-414d-a653-3a4f98ae0f64_terseLabel_en-US" xlink:label="lab_dxcm_PrepaidInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid inventory</link:label>
    <link:label id="lab_dxcm_PrepaidInventoryCurrent_label_en-US" xlink:label="lab_dxcm_PrepaidInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Inventory, Current</link:label>
    <link:label id="lab_dxcm_PrepaidInventoryCurrent_documentation_en-US" xlink:label="lab_dxcm_PrepaidInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PrepaidInventoryCurrent" xlink:href="dxcm-20231231.xsd#dxcm_PrepaidInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PrepaidInventoryCurrent" xlink:to="lab_dxcm_PrepaidInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f945dcf-b2fd-4a47-be1d-e0e3e5d1f758_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DeferredTaxAssetsConvertibleDebt_4f960f88-0721-47a7-9e96-306a1ddce977_negatedTerseLabel_en-US" xlink:label="lab_dxcm_DeferredTaxAssetsConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_dxcm_DeferredTaxAssetsConvertibleDebt_label_en-US" xlink:label="lab_dxcm_DeferredTaxAssetsConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Convertible Debt</link:label>
    <link:label id="lab_dxcm_DeferredTaxAssetsConvertibleDebt_documentation_en-US" xlink:label="lab_dxcm_DeferredTaxAssetsConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredTaxAssetsConvertibleDebt" xlink:href="dxcm-20231231.xsd#dxcm_DeferredTaxAssetsConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DeferredTaxAssetsConvertibleDebt" xlink:to="lab_dxcm_DeferredTaxAssetsConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_dfaed4d0-ee8f-46f0-a8b0-39b3d5f2ad2a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_296d0892-9905-459d-9c1f-ce28c2b0553a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_922183d7-eefd-490f-875e-b048cd4fa8cc_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Useful Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c9df4287-edc9-418a-ba4c-1883cbf24b73_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available balance</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_3bee3d50-0cc5-41e7-844c-04b80aa9903f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b881d58e-e2f0-4a2b-953b-84225f7c66c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_65abac01-986a-4dcd-a6f7-775c6e896007_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_4f5c6770-62eb-4d55-9f37-1b85178b32db_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_d097ee9e-ecfd-400d-8c2c-dbbe7e588f13_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d4bc3ce6-5939-42b5-8536-1246ac91e31a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_8c25c73c-852f-4f04-a139-6d5d2213d20f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_59a9e39a-8621-45c2-8658-b4c38b31842e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_40c2a390-aa24-49aa-a479-eebebb4d94ba_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_2f6ae770-7682-43f1-97a2-b465086e8612_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_314dd9bb-b7e8-49ae-9c64-51773de82353_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_20cdd25b-e369-4aa8-ab10-a8794baa845f_verboseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued warranty</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_7f2d9a96-fdb9-46b5-a328-22b5e61ff4ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_b3d87493-4e4b-435c-8ada-31d0b61e536f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrual" xlink:to="lab_us-gaap_StandardProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_33eef16a-8219-43a9-ac11-c09053c4fbc0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hierarchy for Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesRecoveries_f6e9cc97-6dbd-4537-831c-cae75a9ec678_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesRecoveries_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesRecoveries" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_72316fee-7690-43ce-a65c-2f972835aa26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_29f6ca80-302b-44c8-9dc2-6dccf6e8d281_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9f4d5db2-f05c-4e5c-bc75-803fd5ede8da_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0e7cf09e-d0e0-4311-aed8-ba28dfe3ad61_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_cc4d1cb4-fcf1-4d77-84a0-9768c17f6538_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_784ceec2-3959-4d95-af84-a3da21266026_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_5342b70d-5bb2-4725-8606-7b4652bc2651_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period (in months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9272cc36-0196-4533-bdf0-b6d2c688f811_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1ed98e01-597b-47ea-8d2b-1c498faaf89f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_5281e36c-87c2-4126-9acd-5e9a04ab6b85_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ImpairedLongLivedAssetsFairValue_2742fb56-2c5c-466b-89ce-4603932eeb0b_terseLabel_en-US" xlink:label="lab_dxcm_ImpairedLongLivedAssetsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of impaired long-lived asset</link:label>
    <link:label id="lab_dxcm_ImpairedLongLivedAssetsFairValue_label_en-US" xlink:label="lab_dxcm_ImpairedLongLivedAssetsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Long-Lived Assets, Fair Value</link:label>
    <link:label id="lab_dxcm_ImpairedLongLivedAssetsFairValue_documentation_en-US" xlink:label="lab_dxcm_ImpairedLongLivedAssetsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Long-Lived Assets, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ImpairedLongLivedAssetsFairValue" xlink:href="dxcm-20231231.xsd#dxcm_ImpairedLongLivedAssetsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ImpairedLongLivedAssetsFairValue" xlink:to="lab_dxcm_ImpairedLongLivedAssetsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets_6d0aa77e-6bca-43ad-9da4-3549b8c7e711_terseLabel_en-US" xlink:label="lab_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential adjustment to other tax accounts, including deferred tax assets</link:label>
    <link:label id="lab_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets_label_en-US" xlink:label="lab_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Potential Adjustment To Deferred Tax Assets</link:label>
    <link:label id="lab_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets_documentation_en-US" xlink:label="lab_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Potential Adjustment To Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets" xlink:href="dxcm-20231231.xsd#dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets" xlink:to="lab_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_962899fc-baab-426c-8997-dc97c5fdac7c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5656a4ff-5064-47c6-964d-9b8c2bb41d47_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f071d26e-abaa-42c4-9bea-523974f105a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ac4cd268-d7a0-46d6-bf93-7660bc109828_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94e0f6aa-8bc3-4732-9705-f34e5e50b3ae_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_412b586e-6c98-439e-bafe-e5cd3c7715da_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfEquity_5cb54a5b-684b-4fe8-8d59-84683a3b75e5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of equity</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfEquity_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsFairValueDisclosure_59d58e38-4cdd-468f-89e3-f1f4aa463b47_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsFairValueDisclosure" xlink:to="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_EmployeeStockPurchasePlan2015Member_fff6c1e0-ff0c-41b4-9041-b6c0f5a79d13_terseLabel_en-US" xlink:label="lab_dxcm_EmployeeStockPurchasePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP 2015</link:label>
    <link:label id="lab_dxcm_EmployeeStockPurchasePlan2015Member_label_en-US" xlink:label="lab_dxcm_EmployeeStockPurchasePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2015 [Member]</link:label>
    <link:label id="lab_dxcm_EmployeeStockPurchasePlan2015Member_documentation_en-US" xlink:label="lab_dxcm_EmployeeStockPurchasePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2015</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeeStockPurchasePlan2015Member" xlink:href="dxcm-20231231.xsd#dxcm_EmployeeStockPurchasePlan2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_EmployeeStockPurchasePlan2015Member" xlink:to="lab_dxcm_EmployeeStockPurchasePlan2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ShareRepurchaseProgramMember_aa26ee9a-11c6-498d-b1aa-e2873197141c_terseLabel_en-US" xlink:label="lab_dxcm_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:label id="lab_dxcm_ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_dxcm_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Member]</link:label>
    <link:label id="lab_dxcm_ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_dxcm_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ShareRepurchaseProgramMember" xlink:href="dxcm-20231231.xsd#dxcm_ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ShareRepurchaseProgramMember" xlink:to="lab_dxcm_ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_726c8e32-8a32-442f-9b25-c2558ac1880d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ConvertibleNotesDue2023Member_31a4e1c0-3840-4a75-ab9c-654d8da1fe5c_terseLabel_en-US" xlink:label="lab_dxcm_ConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes due 2023</link:label>
    <link:label id="lab_dxcm_ConvertibleNotesDue2023Member_label_en-US" xlink:label="lab_dxcm_ConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Due 2023 [Member]</link:label>
    <link:label id="lab_dxcm_ConvertibleNotesDue2023Member_documentation_en-US" xlink:label="lab_dxcm_ConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ConvertibleNotesDue2023Member" xlink:to="lab_dxcm_ConvertibleNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_JeremeMSylvainMember_label_en-US" xlink:label="lab_dxcm_JeremeMSylvainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jereme M. Sylvain [Member]</link:label>
    <link:label id="lab_dxcm_JeremeMSylvainMember_documentation_en-US" xlink:label="lab_dxcm_JeremeMSylvainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jereme M. Sylvain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_JeremeMSylvainMember" xlink:href="dxcm-20231231.xsd#dxcm_JeremeMSylvainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_JeremeMSylvainMember" xlink:to="lab_dxcm_JeremeMSylvainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_a8976799-f15c-4eac-894c-2eca2f08a9a6_terseLabel_en-US" xlink:label="lab_dxcm_RestrictedAndPerformanceStockUnitsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units and performance stock units</link:label>
    <link:label id="lab_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_label_en-US" xlink:label="lab_dxcm_RestrictedAndPerformanceStockUnitsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted And Performance Stock Units Member [Member]</link:label>
    <link:label id="lab_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_documentation_en-US" xlink:label="lab_dxcm_RestrictedAndPerformanceStockUnitsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted And Performance Stock Units Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedAndPerformanceStockUnitsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember" xlink:to="lab_dxcm_RestrictedAndPerformanceStockUnitsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1580f2bc-02c8-4032-9992-e6468bb806d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_72549420-71f2-4de5-a55c-0d0617635ec9_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3750eed7-f746-4e69-8a77-e4803207032b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_d9a1221a-704a-4dcf-ab33-8fee86fe939d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3f6b7089-c1d9-4ca0-86a0-8cf434f3f166_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18d92cae-0903-4923-8758-95d971bad2ed_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fc42cc05-ca77-4287-92d7-3f6fa124c0c6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b5ec538f-7143-4815-bedc-077dd51f0d22_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_EffectiveIncomeTaxReconciliationPermanentItems_bb736dca-01de-4c92-8ca0-de6b1ebdec34_terseLabel_en-US" xlink:label="lab_dxcm_EffectiveIncomeTaxReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_dxcm_EffectiveIncomeTaxReconciliationPermanentItems_label_en-US" xlink:label="lab_dxcm_EffectiveIncomeTaxReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Permanent Items</link:label>
    <link:label id="lab_dxcm_EffectiveIncomeTaxReconciliationPermanentItems_documentation_en-US" xlink:label="lab_dxcm_EffectiveIncomeTaxReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Permanent Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EffectiveIncomeTaxReconciliationPermanentItems" xlink:href="dxcm-20231231.xsd#dxcm_EffectiveIncomeTaxReconciliationPermanentItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_EffectiveIncomeTaxReconciliationPermanentItems" xlink:to="lab_dxcm_EffectiveIncomeTaxReconciliationPermanentItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f62f94de-fda8-4369-b640-87906c09a1ba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_397fbb99-9e6d-4ed5-bf8c-22edc6942573_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend_3e650cc2-e0d8-4ed1-9408-c1211b9132f8_terseLabel_en-US" xlink:label="lab_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend (in extension options)</link:label>
    <link:label id="lab_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend_label_en-US" xlink:label="lab_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Options To Extend</link:label>
    <link:label id="lab_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend_documentation_en-US" xlink:label="lab_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Options To Extend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:href="dxcm-20231231.xsd#dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:to="lab_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_1440b086-d420-47a0-a7cf-e9c500c9419d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6ffd716f-155e-4433-af00-8252df8c40a2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8931bd43-5fce-4864-a414-7feef9a665ab_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_8ec106c7-82e6-4e16-8a8b-4edfde2855ec_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_df0656a6-c4d8-4e63-9343-dcf68f61464d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2f3ceed8-1067-4f0f-8a40-31f4a1ed9a12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_6a12309b-1e05-4dd3-8e4f-d8ecdf030324_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0357c204-b128-4373-b079-86d43cdc6c2b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_d2f0b296-94fa-4976-998f-d0f639a02bfe_totalLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_35e20c86-2af6-48d2-af2d-5161b9599a9d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fde7037d-ca70-47e2-addf-a4583b309b9b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d6d61e9-2405-4362-9206-2ecc5f45ded1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_A401kPlanMember_89398d02-857e-41fb-92cf-a5e0a7bbb988_terseLabel_en-US" xlink:label="lab_dxcm_A401kPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_dxcm_A401kPlanMember_label_en-US" xlink:label="lab_dxcm_A401kPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan [Member]</link:label>
    <link:label id="lab_dxcm_A401kPlanMember_documentation_en-US" xlink:label="lab_dxcm_A401kPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A401kPlanMember" xlink:href="dxcm-20231231.xsd#dxcm_A401kPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_A401kPlanMember" xlink:to="lab_dxcm_A401kPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_f90a81bd-78e3-4567-b551-1c55e0d4b131_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_aa8880b0-16ca-42a0-8cc1-72695d45ac64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_942215fc-3db0-4ff6-94a0-59fce1437164_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ad09334-020c-46e8-855e-cc9566470908_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c1dcab6c-218d-42c8-80aa-ea2cb55a67ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5295defa-060a-40f5-8c77-1f98f1f8877e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ComputerSoftwareAndHardwareMember_8f575376-b188-44f2-9706-6ebdbe0dde76_terseLabel_en-US" xlink:label="lab_dxcm_ComputerSoftwareAndHardwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_dxcm_ComputerSoftwareAndHardwareMember_label_en-US" xlink:label="lab_dxcm_ComputerSoftwareAndHardwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software And Hardware [Member]</link:label>
    <link:label id="lab_dxcm_ComputerSoftwareAndHardwareMember_documentation_en-US" xlink:label="lab_dxcm_ComputerSoftwareAndHardwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software And Hardware</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ComputerSoftwareAndHardwareMember" xlink:href="dxcm-20231231.xsd#dxcm_ComputerSoftwareAndHardwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ComputerSoftwareAndHardwareMember" xlink:to="lab_dxcm_ComputerSoftwareAndHardwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_bab2de51-1dd8-468e-98c0-d949917c55f3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total by which the notes&#8217; if-converted value exceeds their principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="lab_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3745ffaa-2f35-4598-b1af-b90d76f344aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate of operating leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_378cf466-fdb4-4b6a-82eb-9a048d9b4715_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock_23854a00-17d7-4fec-94a3-690d99f3612a_terseLabel_en-US" xlink:label="lab_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid and Other Current Assets</link:label>
    <link:label id="lab_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock" xlink:href="dxcm-20231231.xsd#dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_91161b53-aca6-493b-b2bb-304c2b6f33f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_dd9c6474-cd59-45c0-a1eb-80682327192c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term of finance leases (in years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_82fc4a04-712d-4ed5-b633-e74fb69b4d11_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_b0ed390c-101d-49f7-a015-dab46f52035f_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7d0ecc9-0fa5-49e5-af4c-6c131c0039d6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3eefbc2f-28db-4bfa-9a08-6cd629473162_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_539fc85d-3244-474f-a9cc-1d220d352abb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22470bb2-c00c-41de-b047-7ebb23c641b6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_AcquiredTechnologyAndIntellectualPropertyMember_22d7d9b6-6df4-41c8-8555-fc69e5360d70_terseLabel_en-US" xlink:label="lab_dxcm_AcquiredTechnologyAndIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired technology and intellectual property</link:label>
    <link:label id="lab_dxcm_AcquiredTechnologyAndIntellectualPropertyMember_label_en-US" xlink:label="lab_dxcm_AcquiredTechnologyAndIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Technology And Intellectual Property [Member]</link:label>
    <link:label id="lab_dxcm_AcquiredTechnologyAndIntellectualPropertyMember_documentation_en-US" xlink:label="lab_dxcm_AcquiredTechnologyAndIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Technology And Intellectual Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AcquiredTechnologyAndIntellectualPropertyMember" xlink:href="dxcm-20231231.xsd#dxcm_AcquiredTechnologyAndIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_AcquiredTechnologyAndIntellectualPropertyMember" xlink:to="lab_dxcm_AcquiredTechnologyAndIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cc37519d-995c-4367-bdb4-2b326849ac24_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_13b63de3-a226-4018-a653-dfba754a8db5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_905aa6f2-7500-437b-ab90-9e86bb3587e7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_8a21cc69-dbff-4dbd-bd1e-af77840b02de_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_c022c262-72ee-412f-b5ca-c31f4063d837_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_e3d0a438-103b-4368-9196-17a815e3ad97_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_da8f79ad-c17e-43b5-8e96-7324ac695095_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement_8e0e117c-8f5f-4196-8ea8-0b0d37e82ae2_verboseLabel_en-US" xlink:label="lab_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued In Connection With The Restated Collaboration Agreement</link:label>
    <link:label id="lab_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement_label_en-US" xlink:label="lab_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued In Connection With The Restated Collaboration Agreement</link:label>
    <link:label id="lab_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement_documentation_en-US" xlink:label="lab_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued In Connection With The Restated Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement" xlink:href="dxcm-20231231.xsd#dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement" xlink:to="lab_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_22d14692-ca31-4945-9881-2fefb47843c8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_248f2465-c7a4-42a5-8f34-6409e955e407_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_2b244892-4b39-4fcb-b155-ae6f642d083c_verboseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3976db56-4310-4378-a92c-346ae9e8e925_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermDomain_94dce9d3-eeab-4a20-b263-3c3205e6b04f_terseLabel_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermDomain_label_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_dxcm_DebtInstrumentConversionTermDomain_documentation_en-US" xlink:label="lab_dxcm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermDomain" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_DebtInstrumentConversionTermDomain" xlink:to="lab_dxcm_DebtInstrumentConversionTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_722471d5-3afe-4d3b-a1c6-98289e02383c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_41390dbf-36f8-485f-8b33-d1740884d3f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ba427ed7-c190-40bb-9de7-b5823ba56df7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81c54a10-5415-4bc1-a177-a7a5cca06582_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_44f1a486-87dc-46be-8ff7-d4561b10d0f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_335de092-c2ee-4186-9eaf-f0fd04beb2b5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_5ff70c0e-4f54-4530-990e-24197d011213_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic&#160;Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9512e537-f754-4ba0-9b4d-8ced43d12085_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused capacity fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ec002438-8d29-4ee3-8a90-4e823724c5d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_304b5587-e8f1-4d2c-a4f1-d0ccbe778304_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversions of 2023 Notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_3e607845-d360-4b65-9b3f-4d680843056e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dxcm_ConvertibleNotesDue2028Member_1f926004-ef2b-4ef7-b8d8-d0a9d34c349b_terseLabel_en-US" xlink:label="lab_dxcm_ConvertibleNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes due 2028</link:label>
    <link:label id="lab_dxcm_ConvertibleNotesDue2028Member_label_en-US" xlink:label="lab_dxcm_ConvertibleNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Due 2028 [Member]</link:label>
    <link:label id="lab_dxcm_ConvertibleNotesDue2028Member_documentation_en-US" xlink:label="lab_dxcm_ConvertibleNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dxcm_ConvertibleNotesDue2028Member" xlink:to="lab_dxcm_ConvertibleNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_7e421715-0c7c-442c-a6fd-019ecf4c7cd6_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ed28d68f-a50f-4352-9809-1723b6a36bdd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-Term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_f1aa43b6-7a80-48e3-8f7b-06539e5c2620_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_879fb7a6-2cc9-4b2a-ae42-401f11f6a1f9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>dxcm-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:a5fb5fd4-e534-47c9-8b16-9bac89e1806a,g:3346d81c-3328-4944-8257-c9afd724cc18-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dexcom.com/role/CoverPage" xlink:type="simple" xlink:href="dxcm-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f2634b4d-9193-4697-9e43-a91b244d5968" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_DocumentType_f2634b4d-9193-4697-9e43-a91b244d5968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_921f0cff-ddbb-4a4a-8b67-1fd9d81fc74c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_DocumentAnnualReport_921f0cff-ddbb-4a4a-8b67-1fd9d81fc74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a39a4b21-9fed-41b2-ace3-861ef3a3a675" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_DocumentPeriodEndDate_a39a4b21-9fed-41b2-ace3-861ef3a3a675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_048533e2-fe0c-408a-aaef-3237b806b73c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_CurrentFiscalYearEndDate_048533e2-fe0c-408a-aaef-3237b806b73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7e21c6a4-67c9-4ca6-b53e-32bc030f44cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_DocumentTransitionReport_7e21c6a4-67c9-4ca6-b53e-32bc030f44cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f04f4734-b7f7-460d-a0be-c086cd408f81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityFileNumber_f04f4734-b7f7-460d-a0be-c086cd408f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fba6cbba-43bf-4637-8f7e-4c1792b45bfd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityRegistrantName_fba6cbba-43bf-4637-8f7e-4c1792b45bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1023f742-a3d7-4740-bac6-b2d20e868e9a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1023f742-a3d7-4740-bac6-b2d20e868e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8a99c68f-438c-4d7f-a70d-8395a8800fac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityTaxIdentificationNumber_8a99c68f-438c-4d7f-a70d-8395a8800fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_363b11e2-2791-4ff9-a309-6785ae71c6bc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityAddressAddressLine1_363b11e2-2791-4ff9-a309-6785ae71c6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1f91d058-722b-403f-94ef-095e5302f20b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityAddressCityOrTown_1f91d058-722b-403f-94ef-095e5302f20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a88a5460-5749-4331-9536-efd1208d9876" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityAddressStateOrProvince_a88a5460-5749-4331-9536-efd1208d9876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_84711700-1eb7-42df-9073-6ab3ef5f531a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityAddressPostalZipCode_84711700-1eb7-42df-9073-6ab3ef5f531a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_194a7ca2-5595-47fd-9e11-830424cb903e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_CityAreaCode_194a7ca2-5595-47fd-9e11-830424cb903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0841d087-b97c-4663-be58-9fb5da711dfa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_LocalPhoneNumber_0841d087-b97c-4663-be58-9fb5da711dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b5aa7a52-9c59-46ec-b53d-ea39b870b2da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_Security12bTitle_b5aa7a52-9c59-46ec-b53d-ea39b870b2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9f3fceb0-b6b2-4e41-80f4-05b22f5fe020" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_TradingSymbol_9f3fceb0-b6b2-4e41-80f4-05b22f5fe020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e283a7a4-918f-4478-9575-6951ea00ddcb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_SecurityExchangeName_e283a7a4-918f-4478-9575-6951ea00ddcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9988e34b-f52b-4347-ab54-40411fe55833" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9988e34b-f52b-4347-ab54-40411fe55833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_e95175f5-8903-4b39-a273-fbfa931e581c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityVoluntaryFilers_e95175f5-8903-4b39-a273-fbfa931e581c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d083f9f7-7b77-49cf-9929-4c77e910f069" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityCurrentReportingStatus_d083f9f7-7b77-49cf-9929-4c77e910f069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c07b1f59-87dd-4f19-aab5-d3a012ca18f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityInteractiveDataCurrent_c07b1f59-87dd-4f19-aab5-d3a012ca18f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0c94d5cb-fbd6-46b4-afec-c6f8d02e9d0f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityFilerCategory_0c94d5cb-fbd6-46b4-afec-c6f8d02e9d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_60a35253-c41e-4593-bfda-331758577322" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntitySmallBusiness_60a35253-c41e-4593-bfda-331758577322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0e4eae49-868d-43bf-a7cb-55c11bf68712" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityEmergingGrowthCompany_0e4eae49-868d-43bf-a7cb-55c11bf68712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_faf1093d-d21c-4ff8-8a11-078b53222f7e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_IcfrAuditorAttestationFlag_faf1093d-d21c-4ff8-8a11-078b53222f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_0a893eb3-ee16-41fd-b92c-1f5754493ebb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_0a893eb3-ee16-41fd-b92c-1f5754493ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1e152799-e11f-48e6-9b24-8c98b90d8732" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityShellCompany_1e152799-e11f-48e6-9b24-8c98b90d8732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_2b8084a7-4271-4c80-a8c8-cdc3c5597c8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityPublicFloat_2b8084a7-4271-4c80-a8c8-cdc3c5597c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cad6ac43-ee78-4793-a64f-6405433d5ef7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cad6ac43-ee78-4793-a64f-6405433d5ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_57c474f8-df2a-4c26-bf8a-9626e2e8adae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_57c474f8-df2a-4c26-bf8a-9626e2e8adae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9a7aff54-47af-4123-9f4d-0e29af147200" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_AmendmentFlag_9a7aff54-47af-4123-9f4d-0e29af147200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3e161791-8e46-4a43-b694-be5b78cd867c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_DocumentFiscalYearFocus_3e161791-8e46-4a43-b694-be5b78cd867c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_17c04095-2b59-4036-b16a-32e5c1d8fdf5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_17c04095-2b59-4036-b16a-32e5c1d8fdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5c85f132-ebd5-4d7a-b9ba-102da9249096" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9ac7d3b6-4989-4899-8eb4-8e6795b1f9c9" xlink:to="loc_dei_EntityCentralIndexKey_5c85f132-ebd5-4d7a-b9ba-102da9249096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/AuditInformation" xlink:type="simple" xlink:href="dxcm-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AuditInformationAbstract_57bb41b1-230b-4853-8423-ef83d8fdadce" xlink:href="dxcm-20231231.xsd#dxcm_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_bf8514a6-806b-4814-bce8-2a961bfed3bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_AuditInformationAbstract_57bb41b1-230b-4853-8423-ef83d8fdadce" xlink:to="loc_dei_AuditorName_bf8514a6-806b-4814-bce8-2a961bfed3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_bc6ea7cb-09cf-48cf-8026-7c759988eb57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_AuditInformationAbstract_57bb41b1-230b-4853-8423-ef83d8fdadce" xlink:to="loc_dei_AuditorLocation_bc6ea7cb-09cf-48cf-8026-7c759988eb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_dabbffc6-6e53-4c44-9fc3-9e90bf09bab4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_AuditInformationAbstract_57bb41b1-230b-4853-8423-ef83d8fdadce" xlink:to="loc_dei_AuditorFirmId_dabbffc6-6e53-4c44-9fc3-9e90bf09bab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a6f2396b-9753-467d-8bb1-26ab4eaa9e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6f2396b-9753-467d-8bb1-26ab4eaa9e5c" xlink:to="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2054b8e7-d035-4db1-a0f6-3f9b694b21c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2054b8e7-d035-4db1-a0f6-3f9b694b21c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a84e2b9-76fa-4a50-999d-dd359afb9564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2054b8e7-d035-4db1-a0f6-3f9b694b21c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a84e2b9-76fa-4a50-999d-dd359afb9564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities_3008842d-79d9-4238-b7c3-0916d031c6f3" xlink:href="dxcm-20231231.xsd#dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2054b8e7-d035-4db1-a0f6-3f9b694b21c0" xlink:to="loc_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities_3008842d-79d9-4238-b7c3-0916d031c6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4c73a01b-a3b3-4201-af3d-0ee18cb97eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2054b8e7-d035-4db1-a0f6-3f9b694b21c0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4c73a01b-a3b3-4201-af3d-0ee18cb97eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_48c4a0d0-c84d-4348-bcbd-3bab49dfcc23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2054b8e7-d035-4db1-a0f6-3f9b694b21c0" xlink:to="loc_us-gaap_InventoryNet_48c4a0d0-c84d-4348-bcbd-3bab49dfcc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_508d4d04-8103-44ae-9513-b362c3510bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2054b8e7-d035-4db1-a0f6-3f9b694b21c0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_508d4d04-8103-44ae-9513-b362c3510bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7fc6b4c9-c565-4973-9449-a8ea7dd902b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2054b8e7-d035-4db1-a0f6-3f9b694b21c0" xlink:to="loc_us-gaap_AssetsCurrent_7fc6b4c9-c565-4973-9449-a8ea7dd902b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_030cbbc6-9eec-494e-9013-51e414377b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_030cbbc6-9eec-494e-9013-51e414377b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_624da693-1db4-40bf-b9a0-5331d7ead0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_624da693-1db4-40bf-b9a0-5331d7ead0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_67f0ae5d-2189-48e6-81fa-752a3c6880cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:to="loc_us-gaap_Goodwill_67f0ae5d-2189-48e6-81fa-752a3c6880cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dbd0c17e-3296-4a09-a8b0-763b0e197b05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dbd0c17e-3296-4a09-a8b0-763b0e197b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_742622a9-b86a-4751-a2d5-be0ac4b4fd85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_742622a9-b86a-4751-a2d5-be0ac4b4fd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f39b491d-9161-4527-a855-93e4fbdb73d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f39b491d-9161-4527-a855-93e4fbdb73d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_db35e75e-fa3f-400f-a876-355f18757d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82e40758-7fa4-4450-aa2b-d6a2f41120a0" xlink:to="loc_us-gaap_Assets_db35e75e-fa3f-400f-a876-355f18757d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6f2396b-9753-467d-8bb1-26ab4eaa9e5c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a288e09b-d844-4854-a6e3-2e5701a2fc40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a288e09b-d844-4854-a6e3-2e5701a2fc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_5f48faee-bc1b-43b5-acdc-4ce89bae45c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a288e09b-d844-4854-a6e3-2e5701a2fc40" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_5f48faee-bc1b-43b5-acdc-4ce89bae45c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba45a506-b1ad-4662-97b2-b9d7b3595c90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a288e09b-d844-4854-a6e3-2e5701a2fc40" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ba45a506-b1ad-4662-97b2-b9d7b3595c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_788481cd-51e4-4b86-ad45-275061e6f2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a288e09b-d844-4854-a6e3-2e5701a2fc40" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_788481cd-51e4-4b86-ad45-275061e6f2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b27df539-da72-4851-944c-f28a371c3ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a288e09b-d844-4854-a6e3-2e5701a2fc40" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b27df539-da72-4851-944c-f28a371c3ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_552d1241-ba8e-439d-9667-d28300eecedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a288e09b-d844-4854-a6e3-2e5701a2fc40" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_552d1241-ba8e-439d-9667-d28300eecedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_13f09a4f-0870-4216-b550-f9917ff9937f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a288e09b-d844-4854-a6e3-2e5701a2fc40" xlink:to="loc_us-gaap_LiabilitiesCurrent_13f09a4f-0870-4216-b550-f9917ff9937f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_ca8dd34b-64ad-46e5-822a-2eac51800810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_ca8dd34b-64ad-46e5-822a-2eac51800810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d24cab04-6e3c-4adc-8686-a55c8ed47019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d24cab04-6e3c-4adc-8686-a55c8ed47019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a7e1b935-23a4-4b2e-80c7-aec5cf4232e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a7e1b935-23a4-4b2e-80c7-aec5cf4232e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fcafe6be-f21d-4bd2-8cee-60f660ff783d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:to="loc_us-gaap_Liabilities_fcafe6be-f21d-4bd2-8cee-60f660ff783d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ba5777c4-af53-4aab-ac4c-0b2d3d348609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ba5777c4-af53-4aab-ac4c-0b2d3d348609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_20410f11-a6a3-4baf-aa58-5ba392a0e453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_20410f11-a6a3-4baf-aa58-5ba392a0e453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_9d0fec68-23b9-495b-8505-170c454838e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20410f11-a6a3-4baf-aa58-5ba392a0e453" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_9d0fec68-23b9-495b-8505-170c454838e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_8957b428-2688-473e-9a5f-b1609eb08566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20410f11-a6a3-4baf-aa58-5ba392a0e453" xlink:to="loc_us-gaap_CommonStockValueOutstanding_8957b428-2688-473e-9a5f-b1609eb08566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b9664c3f-c5eb-4689-bb64-4ff1eeba8e25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20410f11-a6a3-4baf-aa58-5ba392a0e453" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b9664c3f-c5eb-4689-bb64-4ff1eeba8e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d206a1ee-f04e-44a2-96f6-e64eaf4b62a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20410f11-a6a3-4baf-aa58-5ba392a0e453" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d206a1ee-f04e-44a2-96f6-e64eaf4b62a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d360b070-6228-4a81-b245-0003d1dbab63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20410f11-a6a3-4baf-aa58-5ba392a0e453" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d360b070-6228-4a81-b245-0003d1dbab63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_ef5898a7-df5b-4924-bb46-4f6c9d90d820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20410f11-a6a3-4baf-aa58-5ba392a0e453" xlink:to="loc_us-gaap_TreasuryStockCommonValue_ef5898a7-df5b-4924-bb46-4f6c9d90d820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41ebb986-6a25-4b56-9c89-89639a61671e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20410f11-a6a3-4baf-aa58-5ba392a0e453" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41ebb986-6a25-4b56-9c89-89639a61671e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e8dd77eb-06ee-45e7-b40b-371d00a73569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9b3693b4-e032-4b5a-802f-be758af0292b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e8dd77eb-06ee-45e7-b40b-371d00a73569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b560734-03e6-4372-881c-74fed709765f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b560734-03e6-4372-881c-74fed709765f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_406637ff-1e8c-4bb5-8563-7207acd4dbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_406637ff-1e8c-4bb5-8563-7207acd4dbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_bc0a1e39-c97c-478c-9fda-861498666d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_bc0a1e39-c97c-478c-9fda-861498666d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_613f4a92-f7e0-415f-a66f-82ec63075b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_613f4a92-f7e0-415f-a66f-82ec63075b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e3064256-33c7-4aad-a197-7416163ddaba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e3064256-33c7-4aad-a197-7416163ddaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_495e4783-92d8-45c3-8adb-c89103441a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_495e4783-92d8-45c3-8adb-c89103441a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0096349a-d92c-4939-a09b-0d857080c15f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:to="loc_us-gaap_CommonStockSharesIssued_0096349a-d92c-4939-a09b-0d857080c15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f91bd3cb-7fd6-4a6d-a36e-b56cd6adc806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f91bd3cb-7fd6-4a6d-a36e-b56cd6adc806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_8746c91a-82e9-4628-ab6b-185facd485e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4463ff3f-8388-4677-b71b-91c4bc2e191b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_8746c91a-82e9-4628-ab6b-185facd485e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94ed3e80-c0cc-443a-b5bd-a757620fd9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94ed3e80-c0cc-443a-b5bd-a757620fd9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c57a87b0-464c-4fb2-8577-8136249c6702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c57a87b0-464c-4fb2-8577-8136249c6702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e1367956-e38b-4873-8c3a-9080765f9f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_GrossProfit_e1367956-e38b-4873-8c3a-9080765f9f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7cca6cc1-4685-4618-87c5-c31bcf92c068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7cca6cc1-4685-4618-87c5-c31bcf92c068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_73b19c11-3320-4fec-9e10-27730f19ba21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7cca6cc1-4685-4618-87c5-c31bcf92c068" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_73b19c11-3320-4fec-9e10-27730f19ba21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeResearchAndDevelopmentFee_d14f4c9d-b60d-451f-b3df-12310d891bc7" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeResearchAndDevelopmentFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7cca6cc1-4685-4618-87c5-c31bcf92c068" xlink:to="loc_dxcm_CollaborativeResearchAndDevelopmentFee_d14f4c9d-b60d-451f-b3df-12310d891bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_085514df-fdc9-4590-94d5-dfa10ae8be2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7cca6cc1-4685-4618-87c5-c31bcf92c068" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_085514df-fdc9-4590-94d5-dfa10ae8be2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d576d0fb-0bee-4047-a872-3f390028c9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7cca6cc1-4685-4618-87c5-c31bcf92c068" xlink:to="loc_us-gaap_OperatingExpenses_d576d0fb-0bee-4047-a872-3f390028c9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ae2b421f-2b08-439e-8d60-30e086a7e4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_ae2b421f-2b08-439e-8d60-30e086a7e4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2252e99d-722f-450c-967e-e16ab7bb93ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2252e99d-722f-450c-967e-e16ab7bb93ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f0b69ac0-cccb-4043-9cf1-b4eecc23a71c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f0b69ac0-cccb-4043-9cf1-b4eecc23a71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7682eea1-87db-4f06-8d6b-ead411c6305a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7682eea1-87db-4f06-8d6b-ead411c6305a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce18308e-1465-49ff-b1a4-9bedeca53e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_NetIncomeLoss_ce18308e-1465-49ff-b1a4-9bedeca53e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a9e5be82-86c5-488f-b946-9ebb03a246e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_EarningsPerShareBasic_a9e5be82-86c5-488f-b946-9ebb03a246e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2c17dea1-25c0-4831-8c8d-e4afa92c6cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2c17dea1-25c0-4831-8c8d-e4afa92c6cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3eee6b36-fba6-4442-924c-7ffd33b2f643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3eee6b36-fba6-4442-924c-7ffd33b2f643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47c2d588-eb8c-4385-8154-7fc50b84cc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a54cb90f-6a9d-4c39-b4a4-1bb6c49cf8e5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_47c2d588-eb8c-4385-8154-7fc50b84cc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c677fbfd-89a3-4ff0-ab7d-4d0a80b52e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c159cf5-bfb8-4a00-9f05-a38e8a161415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c677fbfd-89a3-4ff0-ab7d-4d0a80b52e65" xlink:to="loc_us-gaap_NetIncomeLoss_5c159cf5-bfb8-4a00-9f05-a38e8a161415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b22c698f-ebd9-4b94-a900-37cd4be7d1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c677fbfd-89a3-4ff0-ab7d-4d0a80b52e65" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b22c698f-ebd9-4b94-a900-37cd4be7d1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a08b403e-9b21-4a2a-abe5-974cc068e45f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b22c698f-ebd9-4b94-a900-37cd4be7d1d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a08b403e-9b21-4a2a-abe5-974cc068e45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_28848d97-a67b-4cad-aeb3-5f2ac1bfdd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b22c698f-ebd9-4b94-a900-37cd4be7d1d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_28848d97-a67b-4cad-aeb3-5f2ac1bfdd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_47b44211-a23e-4067-8585-561f5a8f4ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b22c698f-ebd9-4b94-a900-37cd4be7d1d1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_47b44211-a23e-4067-8585-561f5a8f4ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_83d5a430-45f3-492a-8216-4f06f0765ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c677fbfd-89a3-4ff0-ab7d-4d0a80b52e65" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_83d5a430-45f3-492a-8216-4f06f0765ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6191418f-7577-4223-9906-9b4d68e584f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dbf6c501-e9da-4dec-b60e-0ea58593cf19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6191418f-7577-4223-9906-9b4d68e584f5" xlink:to="loc_us-gaap_StatementTable_dbf6c501-e9da-4dec-b60e-0ea58593cf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33409dab-680a-40b6-9ce5-73f293e4d685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dbf6c501-e9da-4dec-b60e-0ea58593cf19" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33409dab-680a-40b6-9ce5-73f293e4d685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33409dab-680a-40b6-9ce5-73f293e4d685" xlink:to="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bb76eb41-f8f5-422e-8df7-8f2f64073579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_CommonStockMember_bb76eb41-f8f5-422e-8df7-8f2f64073579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_888ba15c-38de-41a6-8cc9-9c07d726d195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_888ba15c-38de-41a6-8cc9-9c07d726d195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c3f77dc8-da72-4df3-a6cc-9ec354b94958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c3f77dc8-da72-4df3-a6cc-9ec354b94958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5226fcbc-b411-4955-8e8f-a1ce1220709c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_RetainedEarningsMember_5226fcbc-b411-4955-8e8f-a1ce1220709c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_3f3c94ac-73a4-426d-bacf-70a7e6ee10f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5e100c8-0996-4b58-bc41-7fd96d064dd8" xlink:to="loc_us-gaap_TreasuryStockCommonMember_3f3c94ac-73a4-426d-bacf-70a7e6ee10f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5e39018f-087e-4455-b1c0-104741c029b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dbf6c501-e9da-4dec-b60e-0ea58593cf19" xlink:to="loc_us-gaap_StatementLineItems_5e39018f-087e-4455-b1c0-104741c029b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5e39018f-087e-4455-b1c0-104741c029b6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d8176583-395b-4957-bd16-0d5f4164a7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d8176583-395b-4957-bd16-0d5f4164a7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a5957da0-11f2-4ee5-a966-9ae446a12646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockholdersEquity_a5957da0-11f2-4ee5-a966-9ae446a12646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_10c4bd71-47c9-48f7-a179-3d324140076b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_10c4bd71-47c9-48f7-a179-3d324140076b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_af19c07c-7d87-4df7-8657-913d2fc6bfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_af19c07c-7d87-4df7-8657-913d2fc6bfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e9843359-f81f-471c-b54f-8dd091ed4346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e9843359-f81f-471c-b54f-8dd091ed4346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ff078534-1787-485b-93ff-78d4660ecdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ff078534-1787-485b-93ff-78d4660ecdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_29c791ca-a602-41c4-8d58-79fd0a3fb7e5" xlink:href="dxcm-20231231.xsd#dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_29c791ca-a602-41c4-8d58-79fd0a3fb7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones_30058a06-379d-47f2-b6ce-762aa094d5c7" xlink:href="dxcm-20231231.xsd#dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones_30058a06-379d-47f2-b6ce-762aa094d5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt_a603c1f8-fde8-4985-834e-3cb0f68b2c6b" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt_a603c1f8-fde8-4985-834e-3cb0f68b2c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_42c4bd80-167a-43a8-9652-a01a69598a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_42c4bd80-167a-43a8-9652-a01a69598a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ea7681a7-769e-40fd-8df0-f007ec99058a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_ea7681a7-769e-40fd-8df0-f007ec99058a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge_7ad2e43a-2a95-4505-ae85-617bb11ced8a" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromExerciseOfNoteHedge"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge_7ad2e43a-2a95-4505-ae85-617bb11ced8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue_30f37d1d-bc25-45e4-8757-9952185073c2" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromBenefitOfNoteHedgeValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue_30f37d1d-bc25-45e4-8757-9952185073c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_04cf3bc2-23fb-474a-bd1a-539b416f3fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_04cf3bc2-23fb-474a-bd1a-539b416f3fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4641b267-57ef-4739-af23-ad247fbbe364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4641b267-57ef-4739-af23-ad247fbbe364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax_e291bc1b-b909-451c-a023-fa76a2d8f984" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax_e291bc1b-b909-451c-a023-fa76a2d8f984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ae09cf5a-197e-4e54-895e-f7447fd30eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ae09cf5a-197e-4e54-895e-f7447fd30eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee_76232e4c-5a33-433f-819f-82b1a8617657" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee_76232e4c-5a33-433f-819f-82b1a8617657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones_cebbd568-385d-4bdd-a531-7d9ce7dc08b0" xlink:href="dxcm-20231231.xsd#dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones_cebbd568-385d-4bdd-a531-7d9ce7dc08b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb5038c0-fb1d-4aaa-b5b0-0b7c1429d749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_NetIncomeLoss_eb5038c0-fb1d-4aaa-b5b0-0b7c1429d749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3ccd463-8d85-4a70-a29b-122253dc9437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3ccd463-8d85-4a70-a29b-122253dc9437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d8f2c5e7-3415-4f65-ae93-5982c55462c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d8f2c5e7-3415-4f65-ae93-5982c55462c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bbba3e33-70ed-4f95-863d-2f3d4b2f2f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c215a0ef-e017-4ceb-8eed-80e2e8bd3a27" xlink:to="loc_us-gaap_StockholdersEquity_bbba3e33-70ed-4f95-863d-2f3d4b2f2f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="dxcm-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58d23ce5-c9d8-4917-ac54-a969b23002a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58d23ce5-c9d8-4917-ac54-a969b23002a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dfeef083-ae6a-4f92-997d-15f75655e401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58d23ce5-c9d8-4917-ac54-a969b23002a9" xlink:to="loc_us-gaap_NetIncomeLoss_dfeef083-ae6a-4f92-997d-15f75655e401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58d23ce5-c9d8-4917-ac54-a969b23002a9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_97aee550-a16b-4de4-8b54-7ffcad51044c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_97aee550-a16b-4de4-8b54-7ffcad51044c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6542e1dd-cef5-43eb-b3fe-a276f01dba71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:to="loc_us-gaap_ShareBasedCompensation_6542e1dd-cef5-43eb-b3fe-a276f01dba71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeResearchAndDevelopmentFee_e3f66c42-9359-47f9-b0e6-4b787854b3b2" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeResearchAndDevelopmentFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:to="loc_dxcm_CollaborativeResearchAndDevelopmentFee_e3f66c42-9359-47f9-b0e6-4b787854b3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_272fd6fa-7182-40ed-89be-f48f77ce6a22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_272fd6fa-7182-40ed-89be-f48f77ce6a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_0303cd06-4087-431e-9eb5-ae5a120a8ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:to="loc_us-gaap_PaidInKindInterest_0303cd06-4087-431e-9eb5-ae5a120a8ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_7164b467-38b2-4cb8-a0b4-3ff82bc0e82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_7164b467-38b2-4cb8-a0b4-3ff82bc0e82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a299ef3a-85ad-4ab8-88af-4d30b7b31e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a299ef3a-85ad-4ab8-88af-4d30b7b31e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0bb0bff4-ac67-41f3-bd1c-4b1ebde94429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0bb0bff4-ac67-41f3-bd1c-4b1ebde94429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59247633-f35a-46ff-87ed-301bf3350ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40ff3c55-5a1b-491d-b63a-f08085da0fff" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59247633-f35a-46ff-87ed-301bf3350ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_219d43ec-4fab-4d0c-b2e0-b98b2a8ff585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59247633-f35a-46ff-87ed-301bf3350ad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_219d43ec-4fab-4d0c-b2e0-b98b2a8ff585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3163606e-89f5-49c3-b98d-9582c0edcd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59247633-f35a-46ff-87ed-301bf3350ad0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3163606e-89f5-49c3-b98d-9582c0edcd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_331d3359-8020-476c-b618-32b80e865ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59247633-f35a-46ff-87ed-301bf3350ad0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_331d3359-8020-476c-b618-32b80e865ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet_9135aa3e-5167-4b17-85fe-b02cd7f8a63b" xlink:href="dxcm-20231231.xsd#dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59247633-f35a-46ff-87ed-301bf3350ad0" xlink:to="loc_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet_9135aa3e-5167-4b17-85fe-b02cd7f8a63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d365ff6f-9443-4e53-909a-5de37fc5045a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59247633-f35a-46ff-87ed-301bf3350ad0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d365ff6f-9443-4e53-909a-5de37fc5045a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8bee295e-e547-4329-8cc2-15df4d6cf04e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59247633-f35a-46ff-87ed-301bf3350ad0" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8bee295e-e547-4329-8cc2-15df4d6cf04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability_401d53a5-8dff-4afd-bba8-2465c93c02c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59247633-f35a-46ff-87ed-301bf3350ad0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability_401d53a5-8dff-4afd-bba8-2465c93c02c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b39e3cf-5e7b-42e2-8617-e71cc60e603e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58d23ce5-c9d8-4917-ac54-a969b23002a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b39e3cf-5e7b-42e2-8617-e71cc60e603e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a7f6bce-1288-4341-ac40-b9595e262eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a7f6bce-1288-4341-ac40-b9595e262eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1e42f51c-f5a5-4e96-85a4-2173529f55ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a7f6bce-1288-4341-ac40-b9595e262eb0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1e42f51c-f5a5-4e96-85a4-2173529f55ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bd3e8c86-3bcb-4c30-821f-852afea7b0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a7f6bce-1288-4341-ac40-b9595e262eb0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bd3e8c86-3bcb-4c30-821f-852afea7b0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c48b22d9-cccc-4df6-b027-c005f9e59f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a7f6bce-1288-4341-ac40-b9595e262eb0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c48b22d9-cccc-4df6-b027-c005f9e59f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_43a5c0b0-08fd-42f0-9467-5965cf5c764a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a7f6bce-1288-4341-ac40-b9595e262eb0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_43a5c0b0-08fd-42f0-9467-5965cf5c764a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93ed29a2-b7e9-49d2-bb40-c17b6a6c29fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a7f6bce-1288-4341-ac40-b9595e262eb0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93ed29a2-b7e9-49d2-bb40-c17b6a6c29fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10f637d6-fbe4-4e41-ab4f-99c63039fb35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a7f6bce-1288-4341-ac40-b9595e262eb0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10f637d6-fbe4-4e41-ab4f-99c63039fb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a4ea006-e50b-4c64-b53e-f9b2babe5d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a4ea006-e50b-4c64-b53e-f9b2babe5d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5008f87e-8f6d-4c67-8682-8db4acd941c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a4ea006-e50b-4c64-b53e-f9b2babe5d33" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5008f87e-8f6d-4c67-8682-8db4acd941c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1c74c5ca-c08d-498b-9519-567cf53a9ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a4ea006-e50b-4c64-b53e-f9b2babe5d33" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1c74c5ca-c08d-498b-9519-567cf53a9ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_edbbabb1-49d1-48db-86ce-fdae523d5657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a4ea006-e50b-4c64-b53e-f9b2babe5d33" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_edbbabb1-49d1-48db-86ce-fdae523d5657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions_3facda4e-662a-4df9-9c22-3c01822c89c3" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsForPurchasesOfCappedCallTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a4ea006-e50b-4c64-b53e-f9b2babe5d33" xlink:to="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions_3facda4e-662a-4df9-9c22-3c01822c89c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_25f6431d-8297-4d48-a3b5-4789124bbd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a4ea006-e50b-4c64-b53e-f9b2babe5d33" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_25f6431d-8297-4d48-a3b5-4789124bbd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30a1be30-c7db-4adb-b7c5-52828e04cddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a4ea006-e50b-4c64-b53e-f9b2babe5d33" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30a1be30-c7db-4adb-b7c5-52828e04cddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_73c1e19f-e0ab-4206-ad4b-73cd1734abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5a4ea006-e50b-4c64-b53e-f9b2babe5d33" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_73c1e19f-e0ab-4206-ad4b-73cd1734abd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99912824-55b7-4799-8bbd-e2659edbcae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99912824-55b7-4799-8bbd-e2659edbcae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa4f737a-ecd3-40a9-8c7f-0ea003907914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa4f737a-ecd3-40a9-8c7f-0ea003907914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_de284da8-fdc7-4536-b69c-b137a54d885f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_de284da8-fdc7-4536-b69c-b137a54d885f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22cc31f8-09b2-4316-8028-2dfedd5e0829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22cc31f8-09b2-4316-8028-2dfedd5e0829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9ac86856-8849-4e89-a3c7-14096372839d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9ac86856-8849-4e89-a3c7-14096372839d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c176d729-b35e-4d4e-b457-ae85b3dfd118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9ac86856-8849-4e89-a3c7-14096372839d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c176d729-b35e-4d4e-b457-ae85b3dfd118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bc855b00-79c2-499f-9ddb-2d55ea6a6e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9ac86856-8849-4e89-a3c7-14096372839d" xlink:to="loc_us-gaap_RestrictedCash_bc855b00-79c2-499f-9ddb-2d55ea6a6e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0579754-19cd-4cc8-b277-db7699ba4698" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9ac86856-8849-4e89-a3c7-14096372839d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0579754-19cd-4cc8-b277-db7699ba4698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_2d1a117f-257c-4cbb-8363-5786d685886f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_2d1a117f-257c-4cbb-8363-5786d685886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15986e11-b93a-4ced-bcd5-ccb68b4ba3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_2d1a117f-257c-4cbb-8363-5786d685886f" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_15986e11-b93a-4ced-bcd5-ccb68b4ba3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge_fae8f9f2-985d-4bb9-bac6-ec917e500425" xlink:href="dxcm-20231231.xsd#dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_2d1a117f-257c-4cbb-8363-5786d685886f" xlink:to="loc_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge_fae8f9f2-985d-4bb9-bac6-ec917e500425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_3d41a4a9-0900-4f83-8223-33f586ed125f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_2d1a117f-257c-4cbb-8363-5786d685886f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_3d41a4a9-0900-4f83-8223-33f586ed125f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e350f35-41f3-45bc-8790-d9ad58cc09a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_10ef18b5-5bb7-4982-a9e4-5804bec5b9d5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e350f35-41f3-45bc-8790-d9ad58cc09a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_6a6b1809-e99f-43a5-9269-238d79187593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e350f35-41f3-45bc-8790-d9ad58cc09a1" xlink:to="loc_us-gaap_InterestPaidNet_6a6b1809-e99f-43a5-9269-238d79187593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_d8837d26-6a3f-445c-a606-5e7a6113cbba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4e350f35-41f3-45bc-8790-d9ad58cc09a1" xlink:to="loc_us-gaap_IncomeTaxesPaid_d8837d26-6a3f-445c-a606-5e7a6113cbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f14566ad-87d5-4656-ba3a-2aaf92cbd98d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1816bb9c-0b0b-41b6-8965-16bcd2b1c6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f14566ad-87d5-4656-ba3a-2aaf92cbd98d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1816bb9c-0b0b-41b6-8965-16bcd2b1c6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DevelopmentandOtherAgreements" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DevelopmentandOtherAgreements"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DevelopmentandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d892722d-a321-49b5-9169-ab91df082a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_267d9b52-c8ff-4372-bf48-ffe1bc2f90f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d892722d-a321-49b5-9169-ab91df082a08" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_267d9b52-c8ff-4372-bf48-ffe1bc2f90f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="dxcm-20231231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9de97cad-5b6b-49a4-8d6c-a6dd6aa10d23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_dfffa35d-655a-45d9-b247-b014cdd27513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9de97cad-5b6b-49a4-8d6c-a6dd6aa10d23" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_dfffa35d-655a-45d9-b247-b014cdd27513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformation" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d28acebf-a9d0-4422-b1b2-841a9adeb7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_596af24d-6cd3-439c-bd86-936eb9497f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d28acebf-a9d0-4422-b1b2-841a9adeb7c0" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_596af24d-6cd3-439c-bd86-936eb9497f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/Debt" xlink:type="simple" xlink:href="dxcm-20231231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e0bcf57b-b91a-4528-8a73-c4fc91c70013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3e478de5-c618-41c7-8878-ab32f85f0775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0bcf57b-b91a-4528-8a73-c4fc91c70013" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3e478de5-c618-41c7-8878-ab32f85f0775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitments" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitments"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b8418536-c2d2-45a4-ac92-05003cc88ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_d4d64628-e21e-4564-a247-1f8ce7063b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b8418536-c2d2-45a4-ac92-05003cc88ea8" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_d4d64628-e21e-4564-a247-1f8ce7063b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6e44d046-09ba-4e6a-a4fc-b875460b8a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b8418536-c2d2-45a4-ac92-05003cc88ea8" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6e44d046-09ba-4e6a-a4fc-b875460b8a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/Contingencies" xlink:type="simple" xlink:href="dxcm-20231231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_915012cd-a5a7-4432-b9d5-13a37985dd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_67ad4931-b727-4368-8152-1b083b20a430" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_915012cd-a5a7-4432-b9d5-13a37985dd48" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_67ad4931-b727-4368-8152-1b083b20a430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxes" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ed96aaf2-1ee4-423b-b857-af8a7e5d2cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1717972f-8f8d-4e26-a7d9-e3add2af5f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ed96aaf2-1ee4-423b-b857-af8a7e5d2cf6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1717972f-8f8d-4e26-a7d9-e3add2af5f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquity" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_361a290c-39de-458e-ae9f-0ac794f2e9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_d5cd20e2-05c1-4be3-a67e-8f5b2274bb61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_361a290c-39de-458e-ae9f-0ac794f2e9e0" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_d5cd20e2-05c1-4be3-a67e-8f5b2274bb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformation" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BusinessSegmentandGeographicInformation"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BusinessSegmentandGeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e0f11f2b-1f4c-4af1-bcfd-0dae096114ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_463b8665-1be4-43f6-85ea-5c15799cfbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e0f11f2b-1f4c-4af1-bcfd-0dae096114ae" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_463b8665-1be4-43f6-85ea-5c15799cfbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="dxcm-20231231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_542b9e55-491c-49a1-b02f-98800e950b7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_21b681a9-8d38-4221-8c02-7ea0aea17885" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_542b9e55-491c-49a1-b02f-98800e950b7c" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_21b681a9-8d38-4221-8c02-7ea0aea17885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45dbd9f8-dcf2-4d44-9608-44789e513c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45dbd9f8-dcf2-4d44-9608-44789e513c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_393b9476-537e-4462-9b87-56b28ccd6be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_393b9476-537e-4462-9b87-56b28ccd6be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_851971ae-b3d1-4dfc-be86-83db2900a2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_UseOfEstimates_851971ae-b3d1-4dfc-be86-83db2900a2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3854cd19-e903-403c-8d9a-dba268c6d99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3854cd19-e903-403c-8d9a-dba268c6d99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fafb023b-17e8-4890-bfba-2074c041d033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fafb023b-17e8-4890-bfba-2074c041d033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_8c3c89ec-beca-46fb-9c11-6ea627e56e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_8c3c89ec-beca-46fb-9c11-6ea627e56e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_054f72c9-a293-42cf-ab3a-e13db1aa6363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_054f72c9-a293-42cf-ab3a-e13db1aa6363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_3fba05fd-ac90-4d6a-8d33-b10432c652a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_3fba05fd-ac90-4d6a-8d33-b10432c652a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_243a634b-6c0b-4a7b-9735-8d17820627be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_243a634b-6c0b-4a7b-9735-8d17820627be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ba507240-6e87-4050-bd52-ec2307a75da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ba507240-6e87-4050-bd52-ec2307a75da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_cf674e94-7dcd-4daa-8ac4-326eaad9f42d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_cf674e94-7dcd-4daa-8ac4-326eaad9f42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5a0a60b7-8126-4cf5-9558-b127302552a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5a0a60b7-8126-4cf5-9558-b127302552a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_b3b4389e-e3a7-453d-9f9d-0d061c90aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_b3b4389e-e3a7-453d-9f9d-0d061c90aec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_afa1679c-440e-4150-aa45-da1f7da73443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_afa1679c-440e-4150-aa45-da1f7da73443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c48a47bb-0b94-4a7a-9378-866aab62856f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c48a47bb-0b94-4a7a-9378-866aab62856f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6a35315e-9a27-4e4b-821c-fc953c178eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6a35315e-9a27-4e4b-821c-fc953c178eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ProductShipmentCostsPolicyTextBlock_bbebbc19-3cab-46f1-a193-97c443145741" xlink:href="dxcm-20231231.xsd#dxcm_ProductShipmentCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_dxcm_ProductShipmentCostsPolicyTextBlock_bbebbc19-3cab-46f1-a193-97c443145741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_54395f9c-9663-4c33-8d63-b5476ef1dae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_54395f9c-9663-4c33-8d63-b5476ef1dae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_d222cfeb-9168-487f-8349-c5daf6cdc03a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_d222cfeb-9168-487f-8349-c5daf6cdc03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1a23d041-da36-4047-bec8-b1f07738c548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1a23d041-da36-4047-bec8-b1f07738c548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f4707ec6-f5cc-422f-822f-be9741bc9448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f4707ec6-f5cc-422f-822f-be9741bc9448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_bec8a058-c364-4a2c-8013-0cd84d697b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_bec8a058-c364-4a2c-8013-0cd84d697b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_e185dd6d-ff74-47b8-a267-e123e5848a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_e185dd6d-ff74-47b8-a267-e123e5848a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c836c230-7c09-4915-9e9b-a0c1553ef91c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18662048-8db4-4c5d-9b5d-0509a694da3d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c836c230-7c09-4915-9e9b-a0c1553ef91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6546dd7-2e6b-4108-b4ef-6a352516cc36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_9e3e073c-ad05-46f0-8884-e7459f6395e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6546dd7-2e6b-4108-b4ef-6a352516cc36" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_9e3e073c-ad05-46f0-8884-e7459f6395e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_41fc26a1-adb5-44db-9efd-dc8c8a9e9b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6546dd7-2e6b-4108-b4ef-6a352516cc36" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_41fc26a1-adb5-44db-9efd-dc8c8a9e9b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_350bc525-c032-47dd-96e2-95ce4dc38d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6546dd7-2e6b-4108-b4ef-6a352516cc36" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_350bc525-c032-47dd-96e2-95ce4dc38d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="dxcm-20231231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_546de301-b2bd-4604-b211-adb8b7686813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5c40967b-851d-419d-a64f-31e699715fad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_546de301-b2bd-4604-b211-adb8b7686813" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5c40967b-851d-419d-a64f-31e699715fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_fb1f824a-8973-4be2-b92d-dee929e3c5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_546de301-b2bd-4604-b211-adb8b7686813" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_fb1f824a-8973-4be2-b92d-dee929e3c5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c30228fc-fcbf-44cf-9bce-886c1b8c5789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c30228fc-fcbf-44cf-9bce-886c1b8c5789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a5c7d803-495f-4f05-b3cb-b032c262be0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a5c7d803-495f-4f05-b3cb-b032c262be0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d72ea5f0-0656-488a-90ff-eb7a02985b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d72ea5f0-0656-488a-90ff-eb7a02985b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock_bd221214-1022-41dc-83f7-851206f8fcb7" xlink:href="dxcm-20231231.xsd#dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock_bd221214-1022-41dc-83f7-851206f8fcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ff54baca-d443-46a5-9beb-d420d28aeeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ff54baca-d443-46a5-9beb-d420d28aeeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_26ba2ceb-07d2-4e45-8615-862bffee2deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_26ba2ceb-07d2-4e45-8615-862bffee2deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_0e965aa7-98ed-4bb8-9f2e-f18d85ea1590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_0e965aa7-98ed-4bb8-9f2e-f18d85ea1590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_473cf471-da40-44a2-ae2b-ad14f2a12cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_473cf471-da40-44a2-ae2b-ad14f2a12cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_83bda1cc-412b-4d70-8b77-f40c742ec287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_83bda1cc-412b-4d70-8b77-f40c742ec287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_123acd6d-7fb3-40ca-8e0a-f9a3afdb1b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_123acd6d-7fb3-40ca-8e0a-f9a3afdb1b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock_0c925140-b434-474b-8bd0-1a10ba061aaa" xlink:href="dxcm-20231231.xsd#dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock_0c925140-b434-474b-8bd0-1a10ba061aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_227402dc-47d9-4836-be79-99d91fe02f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_227402dc-47d9-4836-be79-99d91fe02f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_90b2ab45-4a55-4a20-9325-7e1f72f79091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_90b2ab45-4a55-4a20-9325-7e1f72f79091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3481285b-435d-496d-a0f8-a6f9dd3cf5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64b762d6-0007-4284-9ca3-cf3d6ae3e456" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3481285b-435d-496d-a0f8-a6f9dd3cf5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtTables" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0db3016a-6bc9-4867-bb7c-6463b6adcb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_3e494584-e3d5-43fb-8666-145ad6209349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0db3016a-6bc9-4867-bb7c-6463b6adcb2a" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_3e494584-e3d5-43fb-8666-145ad6209349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_ce0ed231-b61f-4869-8d8c-95eb454c8c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0db3016a-6bc9-4867-bb7c-6463b6adcb2a" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_ce0ed231-b61f-4869-8d8c-95eb454c8c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_37a1837c-4c91-4dc5-bb6e-8cade8daaeac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0db3016a-6bc9-4867-bb7c-6463b6adcb2a" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_37a1837c-4c91-4dc5-bb6e-8cade8daaeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock_18dd1672-1cdf-48b2-808e-57ef62dcecac" xlink:href="dxcm-20231231.xsd#dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0db3016a-6bc9-4867-bb7c-6463b6adcb2a" xlink:to="loc_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock_18dd1672-1cdf-48b2-808e-57ef62dcecac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_611c3116-72b1-4ac1-8d83-5b1ddc08ec2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0db3016a-6bc9-4867-bb7c-6463b6adcb2a" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_611c3116-72b1-4ac1-8d83-5b1ddc08ec2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsTables" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsTables"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0c5ffbf5-782e-4f47-94bc-0473a1c889a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ce758fd0-c772-4ac9-a38b-4496df6c53ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c5ffbf5-782e-4f47-94bc-0473a1c889a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ce758fd0-c772-4ac9-a38b-4496df6c53ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_fda5245a-ee52-4ac0-a585-c3a5e03b40cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c5ffbf5-782e-4f47-94bc-0473a1c889a7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_fda5245a-ee52-4ac0-a585-c3a5e03b40cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f9912d49-9017-4132-bbff-5b64d7fdf2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0c5ffbf5-782e-4f47-94bc-0473a1c889a7" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f9912d49-9017-4132-bbff-5b64d7fdf2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_05c32a33-e565-4920-9421-0610a16a2a43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9146a7f9-9ca3-4472-8654-bde2aba698dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05c32a33-e565-4920-9421-0610a16a2a43" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9146a7f9-9ca3-4472-8654-bde2aba698dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8f5f6b7b-d135-45b8-9e29-8f6893169cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05c32a33-e565-4920-9421-0610a16a2a43" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8f5f6b7b-d135-45b8-9e29-8f6893169cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_589e9030-4dcd-4475-8dcd-c7619b06ae2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05c32a33-e565-4920-9421-0610a16a2a43" xlink:to="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_589e9030-4dcd-4475-8dcd-c7619b06ae2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_22705601-6d2f-4d85-a1a8-15a6d3b8460e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05c32a33-e565-4920-9421-0610a16a2a43" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_22705601-6d2f-4d85-a1a8-15a6d3b8460e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_902eba5f-8615-4f7d-8b0e-1d40ce98aef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05c32a33-e565-4920-9421-0610a16a2a43" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_902eba5f-8615-4f7d-8b0e-1d40ce98aef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_75833781-d3de-415c-8939-a1277a3d3c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05c32a33-e565-4920-9421-0610a16a2a43" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_75833781-d3de-415c-8939-a1277a3d3c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_57e0920d-1bc9-45fa-a9c9-dbfacbbe0c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05c32a33-e565-4920-9421-0610a16a2a43" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_57e0920d-1bc9-45fa-a9c9-dbfacbbe0c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_8ac4ab6a-c9cc-4f62-adb1-2e6913c3a02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxExaminationsTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_05c32a33-e565-4920-9421-0610a16a2a43" xlink:to="loc_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_8ac4ab6a-c9cc-4f62-adb1-2e6913c3a02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityTables" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffc3ac5e-d79b-48a1-bc37-4eca918d7b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock_2d7d954b-ed00-4888-b9ef-8ccb3610374a" xlink:href="dxcm-20231231.xsd#dxcm_ScheduleOfTreasuryShareActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffc3ac5e-d79b-48a1-bc37-4eca918d7b3c" xlink:to="loc_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock_2d7d954b-ed00-4888-b9ef-8ccb3610374a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_451359c7-43ff-4d7c-a896-af91fb0d89af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffc3ac5e-d79b-48a1-bc37-4eca918d7b3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_451359c7-43ff-4d7c-a896-af91fb0d89af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9dcbb410-edf6-4ff8-8ff0-9984face25f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffc3ac5e-d79b-48a1-bc37-4eca918d7b3c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9dcbb410-edf6-4ff8-8ff0-9984face25f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_01953a61-6fbe-4b14-ad97-c61d86bf8a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffc3ac5e-d79b-48a1-bc37-4eca918d7b3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_01953a61-6fbe-4b14-ad97-c61d86bf8a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationTables" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BusinessSegmentandGeographicInformationTables"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3216d53f-cb4f-42b6-8e0c-9128f8d133c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_dff6fcd0-55f9-4357-87f4-2beace26c2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3216d53f-cb4f-42b6-8e0c-9128f8d133c9" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_dff6fcd0-55f9-4357-87f4-2beace26c2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e2ec9b39-1471-43b8-a31d-99020cb88de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3216d53f-cb4f-42b6-8e0c-9128f8d133c9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e2ec9b39-1471-43b8-a31d-99020cb88de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7a3847e-0a8f-4461-a072-d9aec3845207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8cc6d6eb-112e-4332-9afa-f5d4e4b49f52" xlink:href="dxcm-20231231.xsd#dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7a3847e-0a8f-4461-a072-d9aec3845207" xlink:to="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8cc6d6eb-112e-4332-9afa-f5d4e4b49f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16a8fa9c-c066-46d4-b4f6-53fa96912615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8cc6d6eb-112e-4332-9afa-f5d4e4b49f52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16a8fa9c-c066-46d4-b4f6-53fa96912615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16a8fa9c-c066-46d4-b4f6-53fa96912615" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ComputerSoftwareAndHardwareMember_e6cf58ff-c30e-4baa-878d-1efe9075b81a" xlink:href="dxcm-20231231.xsd#dxcm_ComputerSoftwareAndHardwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:to="loc_dxcm_ComputerSoftwareAndHardwareMember_e6cf58ff-c30e-4baa-878d-1efe9075b81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_a6bda176-453a-49b5-bde4-a4d1769d508c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_a6bda176-453a-49b5-bde4-a4d1769d508c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ec154641-aa10-498b-b5e9-a24b555b65e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ec154641-aa10-498b-b5e9-a24b555b65e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_c84c382e-a2a5-404a-a199-eb1801637cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f252214a-137d-421c-a97f-c8e901870980" xlink:to="loc_us-gaap_BuildingMember_c84c382e-a2a5-404a-a199-eb1801637cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81254af1-b053-4439-b262-7d441870e4c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8cc6d6eb-112e-4332-9afa-f5d4e4b49f52" xlink:to="loc_srt_RangeAxis_81254af1-b053-4439-b262-7d441870e4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_421eef59-4bfb-4dd3-be0d-bb94f7677f27" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_81254af1-b053-4439-b262-7d441870e4c9" xlink:to="loc_srt_RangeMember_421eef59-4bfb-4dd3-be0d-bb94f7677f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f009b31c-f260-42fb-9c4f-28994652ceb8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_421eef59-4bfb-4dd3-be0d-bb94f7677f27" xlink:to="loc_srt_MinimumMember_f009b31c-f260-42fb-9c4f-28994652ceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_18c3aed8-b6d1-4abe-921f-855fa29c060d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_421eef59-4bfb-4dd3-be0d-bb94f7677f27" xlink:to="loc_srt_MaximumMember_18c3aed8-b6d1-4abe-921f-855fa29c060d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:href="dxcm-20231231.xsd#dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8cc6d6eb-112e-4332-9afa-f5d4e4b49f52" xlink:to="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents_f0a6a80e-1aa8-4827-af74-2025a1c459c1" xlink:href="dxcm-20231231.xsd#dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents_f0a6a80e-1aa8-4827-af74-2025a1c459c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e5bfe582-30a0-48b2-b1df-aa30b18ace13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e5bfe582-30a0-48b2-b1df-aa30b18ace13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_394981b8-8aed-41c5-9615-292498cafd45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_394981b8-8aed-41c5-9615-292498cafd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d324a5a9-6566-4c5d-8d5b-83621cec1c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d324a5a9-6566-4c5d-8d5b-83621cec1c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ed21309f-7e86-48cb-b649-12cd5e34fab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ed21309f-7e86-48cb-b649-12cd5e34fab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod_35e597fc-590e-45b4-a339-84688170a57f" xlink:href="dxcm-20231231.xsd#dxcm_RevenueRecognitionSalesReturnsCoveragePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod_35e597fc-590e-45b4-a339-84688170a57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ContractPaymentTermsNumberofDays_b2eaa1df-b98a-42df-b02f-2af7d1c7e6a0" xlink:href="dxcm-20231231.xsd#dxcm_ContractPaymentTermsNumberofDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_dxcm_ContractPaymentTermsNumberofDays_b2eaa1df-b98a-42df-b02f-2af7d1c7e6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_a5790885-223b-4f4d-9670-4fdc634932ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_UnbilledContractsReceivable_a5790885-223b-4f4d-9670-4fdc634932ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fee4c48-4a19-4cfd-b8af-069a5f446d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fee4c48-4a19-4cfd-b8af-069a5f446d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AmortizationPeriodForIncentiveCompensationCosts_657c97cf-0a0a-4a95-9440-a413592a805c" xlink:href="dxcm-20231231.xsd#dxcm_AmortizationPeriodForIncentiveCompensationCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_dxcm_AmortizationPeriodForIncentiveCompensationCosts_657c97cf-0a0a-4a95-9440-a413592a805c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_5447a352-e699-49b1-b6f2-896736c4b556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_f5f0f45a-112d-45ec-8da2-ce3162190fd3" xlink:to="loc_us-gaap_AdvertisingExpense_5447a352-e699-49b1-b6f2-896736c4b556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a28ef73-9dc5-43a4-9a48-a70b2a2df2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a28ef73-9dc5-43a4-9a48-a70b2a2df2e3" xlink:to="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_067fc678-3c8b-4a48-9b2e-36b639a91a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_067fc678-3c8b-4a48-9b2e-36b639a91a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_50e34603-f513-49f1-843a-49d986e05978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_067fc678-3c8b-4a48-9b2e-36b639a91a1b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_50e34603-f513-49f1-843a-49d986e05978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_702cef41-6ae7-406a-a63e-f436927f2e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_50e34603-f513-49f1-843a-49d986e05978" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_702cef41-6ae7-406a-a63e-f436927f2e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4b23568e-8cf7-4364-9197-8a56754ee70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4b23568e-8cf7-4364-9197-8a56754ee70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf6bd593-caab-4c36-b07e-ca91623453b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4b23568e-8cf7-4364-9197-8a56754ee70f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf6bd593-caab-4c36-b07e-ca91623453b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7d7fead2-190b-4ed7-9190-a66b46e4fa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf6bd593-caab-4c36-b07e-ca91623453b3" xlink:to="loc_us-gaap_SalesRevenueNetMember_7d7fead2-190b-4ed7-9190-a66b46e4fa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_eb4ae31b-a76e-47ed-bb03-4bafd13eb41c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cf6bd593-caab-4c36-b07e-ca91623453b3" xlink:to="loc_us-gaap_AccountsReceivableMember_eb4ae31b-a76e-47ed-bb03-4bafd13eb41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_20a5ee09-5c12-4818-8b40-25341729c42c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:to="loc_srt_MajorCustomersAxis_20a5ee09-5c12-4818-8b40-25341729c42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_20a5ee09-5c12-4818-8b40-25341729c42c" xlink:to="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerAMember_b4fb250a-d741-472d-80f3-1aed039b16c9" xlink:href="dxcm-20231231.xsd#dxcm_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerAMember_b4fb250a-d741-472d-80f3-1aed039b16c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerBMember_6f81227f-abf1-4799-9eb4-d48b89e324a3" xlink:href="dxcm-20231231.xsd#dxcm_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerBMember_6f81227f-abf1-4799-9eb4-d48b89e324a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerCMember_5942f5ba-14f3-416a-9c3b-a705007d38df" xlink:href="dxcm-20231231.xsd#dxcm_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerCMember_5942f5ba-14f3-416a-9c3b-a705007d38df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerDMember_3a4d5288-47e4-450e-aa53-efb159e2a6a0" xlink:href="dxcm-20231231.xsd#dxcm_CustomerDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerDMember_3a4d5288-47e4-450e-aa53-efb159e2a6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CustomerEMember_b3f8d62f-466a-4df7-8295-d82c3070841e" xlink:href="dxcm-20231231.xsd#dxcm_CustomerEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_60127917-0b0e-4ed5-9104-ebd1721875e3" xlink:to="loc_dxcm_CustomerEMember_b3f8d62f-466a-4df7-8295-d82c3070841e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_69307eab-2e75-4a7c-9def-6f4239ef0542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_127d16de-b027-4aaf-99c4-1ed78c74d47f" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_69307eab-2e75-4a7c-9def-6f4239ef0542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_78c9027e-47c2-4c69-9e7c-cc620644fa21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_69307eab-2e75-4a7c-9def-6f4239ef0542" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_78c9027e-47c2-4c69-9e7c-cc620644fa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f17a65d5-108e-4ac0-bbf5-2e539c6f3359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_132aa8f9-fc74-43dd-b16c-9d4700bf0b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f17a65d5-108e-4ac0-bbf5-2e539c6f3359" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_132aa8f9-fc74-43dd-b16c-9d4700bf0b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6ac64225-12ac-4e2b-881e-1fe2c05198f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_132aa8f9-fc74-43dd-b16c-9d4700bf0b3f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6ac64225-12ac-4e2b-881e-1fe2c05198f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6ac64225-12ac-4e2b-881e-1fe2c05198f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeSalesBasedMilestoneMember_2ffe8a75-a095-4bb7-8791-69b28409a3e6" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeSalesBasedMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:to="loc_dxcm_CollaborativeSalesBasedMilestoneMember_2ffe8a75-a095-4bb7-8791-69b28409a3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_b48aee6c-0aaa-4666-a9db-73a428d76e86" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedAndPerformanceStockUnitsMemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:to="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_b48aee6c-0aaa-4666-a9db-73a428d76e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1a366399-1f34-493e-8873-013a71d2b341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1a366399-1f34-493e-8873-013a71d2b341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_99f77ae5-e5d7-44cb-bc16-2573bc7a284b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d79fb9a6-26d8-4928-bd0f-77ffe0763672" xlink:to="loc_us-gaap_WarrantMember_99f77ae5-e5d7-44cb-bc16-2573bc7a284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_132aa8f9-fc74-43dd-b16c-9d4700bf0b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9011cb7c-9ee9-456a-a5fb-1c66000f6952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_NetIncomeLoss_9011cb7c-9ee9-456a-a5fb-1c66000f6952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_5c6e0713-1b54-4093-97b6-4585d5aed6de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_InterestOnConvertibleDebtNetOfTax_5c6e0713-1b54-4093-97b6-4585d5aed6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_ea85e848-b664-49fa-bd54-df041cb12696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToParentDiluted_ea85e848-b664-49fa-bd54-df041cb12696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ad998e83-5d7c-434c-9489-b482787a347f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_EarningsPerShareBasic_ad998e83-5d7c-434c-9489-b482787a347f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fae08e56-ce95-43b1-85e9-9c70244de114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fae08e56-ce95-43b1-85e9-9c70244de114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c118a8c7-e2c1-4dc0-9111-9dd0852ebbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c118a8c7-e2c1-4dc0-9111-9dd0852ebbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8d7bc6f7-5117-4ee8-bea7-e0bb1850fbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8d7bc6f7-5117-4ee8-bea7-e0bb1850fbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b83728e9-345c-4893-89f4-4c967d897f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c3b6d35-1e00-4dc1-9945-9f666e02d17c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b83728e9-345c-4893-89f4-4c967d897f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_673d35db-85dd-455f-91a1-d950cc45e7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6b37a1a8-6ee6-483b-937c-ffb5c669b96d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_673d35db-85dd-455f-91a1-d950cc45e7e5" xlink:to="loc_us-gaap_AccountingPoliciesAbstract_6b37a1a8-6ee6-483b-937c-ffb5c669b96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9df9e339-def4-440d-b4fa-f448f3366302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6b37a1a8-6ee6-483b-937c-ffb5c669b96d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9df9e339-def4-440d-b4fa-f448f3366302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_18f0e8a5-67a3-4c04-a876-52ef7cbda9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9df9e339-def4-440d-b4fa-f448f3366302" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_18f0e8a5-67a3-4c04-a876-52ef7cbda9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2958c225-857d-4f12-a3b3-cc528fa0e1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_18f0e8a5-67a3-4c04-a876-52ef7cbda9b3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2958c225-857d-4f12-a3b3-cc528fa0e1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_d4ae29c0-867a-4342-8515-d6e3dec803b3" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedAndPerformanceStockUnitsMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2958c225-857d-4f12-a3b3-cc528fa0e1ee" xlink:to="loc_dxcm_RestrictedAndPerformanceStockUnitsMemberMember_d4ae29c0-867a-4342-8515-d6e3dec803b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_367b8a2c-d896-4fb7-912b-58a7c4f5b644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9df9e339-def4-440d-b4fa-f448f3366302" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_367b8a2c-d896-4fb7-912b-58a7c4f5b644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d13290cb-6dc7-4ccf-8ae9-cc597e15e760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_367b8a2c-d896-4fb7-912b-58a7c4f5b644" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d13290cb-6dc7-4ccf-8ae9-cc597e15e760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DevelopmentandOtherAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_304c04b7-f4f8-49f2-8243-14633cfea0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:href="dxcm-20231231.xsd#dxcm_DevelopmentAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_304c04b7-f4f8-49f2-8243-14633cfea0c6" xlink:to="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsUnderCollaborationAgreementsAxis_2971d074-aa19-4aa9-a51f-fe13972e2aec" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsUnderCollaborationAgreementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:to="loc_dxcm_PaymentsUnderCollaborationAgreementsAxis_2971d074-aa19-4aa9-a51f-fe13972e2aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_01dbf6b3-b862-443f-b3e6-0cf67efafadb" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsUnderCollaborationAgreementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_PaymentsUnderCollaborationAgreementsAxis_2971d074-aa19-4aa9-a51f-fe13972e2aec" xlink:to="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_01dbf6b3-b862-443f-b3e6-0cf67efafadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeArrangementInitialPaymentMember_db0cac93-e197-465c-8ed2-a3e8a40a0273" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeArrangementInitialPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_01dbf6b3-b862-443f-b3e6-0cf67efafadb" xlink:to="loc_dxcm_CollaborativeArrangementInitialPaymentMember_db0cac93-e197-465c-8ed2-a3e8a40a0273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeArrangementMilestonePaymentsMember_7636ae86-fb22-4e15-8a8b-fa629877e7b9" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeArrangementMilestonePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_PaymentsUnderCollaborationAgreementsDomain_01dbf6b3-b862-443f-b3e6-0cf67efafadb" xlink:to="loc_dxcm_CollaborativeArrangementMilestonePaymentsMember_7636ae86-fb22-4e15-8a8b-fa629877e7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9566a06e-0e53-41b2-a8a3-ddda981bb0bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:to="loc_srt_CounterpartyNameAxis_9566a06e-0e53-41b2-a8a3-ddda981bb0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fac64d7-0a08-4d8f-86de-2e62a840ed90" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9566a06e-0e53-41b2-a8a3-ddda981bb0bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fac64d7-0a08-4d8f-86de-2e62a840ed90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_VerilyLifeSciencesMember_51528fbb-c102-4d7b-97f6-777a63179d2d" xlink:href="dxcm-20231231.xsd#dxcm_VerilyLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fac64d7-0a08-4d8f-86de-2e62a840ed90" xlink:to="loc_dxcm_VerilyLifeSciencesMember_51528fbb-c102-4d7b-97f6-777a63179d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ceb853e6-0165-48b2-9976-e54bc1086923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ceb853e6-0165-48b2-9976-e54bc1086923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_074d2989-219a-4d5b-9f7b-1a09fa73df45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ceb853e6-0165-48b2-9976-e54bc1086923" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_074d2989-219a-4d5b-9f7b-1a09fa73df45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_bf6a1099-bee3-4624-a05a-50acf97d08ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_074d2989-219a-4d5b-9f7b-1a09fa73df45" xlink:to="loc_us-gaap_CollaborativeArrangementMember_bf6a1099-bee3-4624-a05a-50acf97d08ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:href="dxcm-20231231.xsd#dxcm_DevelopmentAgreementsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsTable_5e6de26a-1035-43f3-90a9-dc34d65b0557" xlink:to="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d9d2a5c1-aca6-449b-b676-4ed985d85a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_us-gaap_SharePrice_d9d2a5c1-aca6-449b-b676-4ed985d85a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeArrangementUpfrontFee_e6e4048a-9952-4ddc-be04-7d46c5ddfecf" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeArrangementUpfrontFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_CollaborativeArrangementUpfrontFee_e6e4048a-9952-4ddc-be04-7d46c5ddfecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07539f4d-e2fd-44b0-9cca-129b366fa763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07539f4d-e2fd-44b0-9cca-129b366fa763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CollaborativeResearchAndDevelopmentFee_05c18c1b-8e93-406a-83d9-4ae89f302769" xlink:href="dxcm-20231231.xsd#dxcm_CollaborativeResearchAndDevelopmentFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_CollaborativeResearchAndDevelopmentFee_05c18c1b-8e93-406a-83d9-4ae89f302769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement_6209517c-cc78-4109-80e0-236a66c096c7" xlink:href="dxcm-20231231.xsd#dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement_6209517c-cc78-4109-80e0-236a66c096c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_adab636e-40ac-4b1d-b38a-3d9d922a02f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_adab636e-40ac-4b1d-b38a-3d9d922a02f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues_7962dc38-9226-4c84-bd8b-55537c1d0dcf" xlink:href="dxcm-20231231.xsd#dxcm_PotentialFutureCommonStockIssuableSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues_7962dc38-9226-4c84-bd8b-55537c1d0dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a863cfe5-a077-4592-9f9c-9018cfbef091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a863cfe5-a077-4592-9f9c-9018cfbef091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues_b2f9b74d-82a6-4ba1-b0a1-de07325dba31" xlink:href="dxcm-20231231.xsd#dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DevelopmentAgreementsLineItems_47a20a25-252c-4e77-918c-7f8470dfb2ba" xlink:to="loc_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues_b2f9b74d-82a6-4ba1-b0a1-de07325dba31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_257aee17-3f8e-4000-9701-50196e564695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e447d82-cd3d-41ee-8139-f3ae1aca891f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_257aee17-3f8e-4000-9701-50196e564695" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e447d82-cd3d-41ee-8139-f3ae1aca891f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_349797b9-a448-4c62-a42e-fe67d1ec50aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e447d82-cd3d-41ee-8139-f3ae1aca891f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_349797b9-a448-4c62-a42e-fe67d1ec50aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_349797b9-a448-4c62-a42e-fe67d1ec50aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6b777418-704f-47bb-bfbd-c0d36172ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_6b777418-704f-47bb-bfbd-c0d36172ec5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1959995b-0260-44ca-9cc6-2830a6fd36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:to="loc_us-gaap_CommercialPaperMember_1959995b-0260-44ca-9cc6-2830a6fd36d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_01b1ab28-7181-47be-8f52-73f39790d0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_acee868b-99ec-4a50-bf5e-d26109373793" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_01b1ab28-7181-47be-8f52-73f39790d0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a589f0b2-b708-4294-bdea-221f736c4cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e447d82-cd3d-41ee-8139-f3ae1aca891f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a589f0b2-b708-4294-bdea-221f736c4cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a589f0b2-b708-4294-bdea-221f736c4cea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_835c6a4c-5b38-4a0e-b6a3-a41358618cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_835c6a4c-5b38-4a0e-b6a3-a41358618cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0162453b-2910-44e0-8278-d18aa7dd3ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0162453b-2910-44e0-8278-d18aa7dd3ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d89b6d55-21f9-4d9a-8155-c148dce2aa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b97ad3e8-4e47-4893-bbbd-57b4de4d295c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d89b6d55-21f9-4d9a-8155-c148dce2aa0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e447d82-cd3d-41ee-8139-f3ae1aca891f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_c417d8df-b712-44b6-b535-617e45e81504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_c417d8df-b712-44b6-b535-617e45e81504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd5c49b7-4694-4a22-b858-796101395700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dd5c49b7-4694-4a22-b858-796101395700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_e9d87139-e3a0-46dc-bf86-5bc749db99b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_e9d87139-e3a0-46dc-bf86-5bc749db99b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3d21a70e-702d-419a-9f32-05ba87f760fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5c183669-d49c-4de2-8527-350e270d4bfa" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3d21a70e-702d-419a-9f32-05ba87f760fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_47ad6c53-c0a1-4343-85ac-abcd636094b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e42687-8675-40a2-9e9e-903f866a0db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_47ad6c53-c0a1-4343-85ac-abcd636094b7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e42687-8675-40a2-9e9e-903f866a0db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f7e1635b-80ad-4df9-9b16-662ea1ec3b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e42687-8675-40a2-9e9e-903f866a0db3" xlink:to="loc_us-gaap_HedgingDesignationAxis_f7e1635b-80ad-4df9-9b16-662ea1ec3b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1d9ffd7e-e356-4ec5-ad69-9cdff325d53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_f7e1635b-80ad-4df9-9b16-662ea1ec3b4a" xlink:to="loc_us-gaap_HedgingDesignationDomain_1d9ffd7e-e356-4ec5-ad69-9cdff325d53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_816085cc-8f8b-42d4-876c-c4fd84f6f60e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1d9ffd7e-e356-4ec5-ad69-9cdff325d53a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_816085cc-8f8b-42d4-876c-c4fd84f6f60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_46466c6f-797e-4642-93a5-cd4033d0acd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e42687-8675-40a2-9e9e-903f866a0db3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_46466c6f-797e-4642-93a5-cd4033d0acd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5418bf66-d8ee-4be4-a33c-6b05090c8bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_46466c6f-797e-4642-93a5-cd4033d0acd2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5418bf66-d8ee-4be4-a33c-6b05090c8bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_c0e59e19-78cc-4518-817f-1678929ad118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5418bf66-d8ee-4be4-a33c-6b05090c8bab" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_c0e59e19-78cc-4518-817f-1678929ad118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e42687-8675-40a2-9e9e-903f866a0db3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_FairValueAssetsLevel3TransfersAmount_bf368de7-02ac-467a-91b8-1ffe797364af" xlink:href="dxcm-20231231.xsd#dxcm_FairValueAssetsLevel3TransfersAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_dxcm_FairValueAssetsLevel3TransfersAmount_bf368de7-02ac-467a-91b8-1ffe797364af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_1fd6c39e-0a81-4d9c-a1c5-3a68ff45fb47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_us-gaap_DerivativeTermOfContract_1fd6c39e-0a81-4d9c-a1c5-3a68ff45fb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_984d05e4-cfc6-47bc-bf46-4ace39aef39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_984d05e4-cfc6-47bc-bf46-4ace39aef39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c2f9e73d-4c30-4593-a854-1985b9e3f946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_c2f9e73d-4c30-4593-a854-1985b9e3f946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_29dc7076-003d-4794-b582-eefd260113cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9e75c286-0c30-425c-8252-e01a0827f3a0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_29dc7076-003d-4794-b582-eefd260113cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_92509f89-1dac-4caa-a848-2cc27bc7e767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17331bf3-dd3d-4a18-bc3e-836adfa4c694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_92509f89-1dac-4caa-a848-2cc27bc7e767" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17331bf3-dd3d-4a18-bc3e-836adfa4c694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5612436-e4af-4324-97ce-55b6d2113c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17331bf3-dd3d-4a18-bc3e-836adfa4c694" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5612436-e4af-4324-97ce-55b6d2113c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5612436-e4af-4324-97ce-55b6d2113c1d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_9c0c4c2d-a3a3-448c-a788-3acfc9500ae3" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_9c0c4c2d-a3a3-448c-a788-3acfc9500ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_6c7dc19f-6812-48b1-b833-7c9ff8717492" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_6c7dc19f-6812-48b1-b833-7c9ff8717492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_8046f563-a486-4c67-b365-4ba3535e7958" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09bd7306-bf2d-4657-a257-bf9c0c4cfe67" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_8046f563-a486-4c67-b365-4ba3535e7958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e5421793-cdb8-4fd3-817a-e641670941a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17331bf3-dd3d-4a18-bc3e-836adfa4c694" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e5421793-cdb8-4fd3-817a-e641670941a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_603f666e-aff1-4bbd-b99e-7a414a9d9bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e5421793-cdb8-4fd3-817a-e641670941a4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_603f666e-aff1-4bbd-b99e-7a414a9d9bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e5b261d9-cdf9-42d1-bd16-d18a202979a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_603f666e-aff1-4bbd-b99e-7a414a9d9bc7" xlink:to="loc_us-gaap_SeniorNotesMember_e5b261d9-cdf9-42d1-bd16-d18a202979a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11c6cf99-57cb-4e01-8ca6-d7faa8e39706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17331bf3-dd3d-4a18-bc3e-836adfa4c694" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11c6cf99-57cb-4e01-8ca6-d7faa8e39706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_81a8f780-01a7-4973-b1cc-be5fafc3af61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11c6cf99-57cb-4e01-8ca6-d7faa8e39706" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_81a8f780-01a7-4973-b1cc-be5fafc3af61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19952580-4d65-46d7-b2ed-931f3aee5280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969e164e-4ba1-423e-af2e-7f20ee0bba7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19952580-4d65-46d7-b2ed-931f3aee5280" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969e164e-4ba1-423e-af2e-7f20ee0bba7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_14949caa-a63b-4c0f-b448-26e38f9b4f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969e164e-4ba1-423e-af2e-7f20ee0bba7f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_14949caa-a63b-4c0f-b448-26e38f9b4f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_14949caa-a63b-4c0f-b448-26e38f9b4f0d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_062a30b6-07a5-40b2-9d6d-824f9f6f9e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_062a30b6-07a5-40b2-9d6d-824f9f6f9e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a89154a4-7dde-4a41-a405-b8f819611429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:to="loc_us-gaap_CommercialPaperMember_a89154a4-7dde-4a41-a405-b8f819611429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_060d6604-be14-4807-bed2-a5d99e673091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18dd6acf-8bb8-4856-946d-316e74b7acc2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_060d6604-be14-4807-bed2-a5d99e673091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969e164e-4ba1-423e-af2e-7f20ee0bba7f" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_630efa6f-be8e-4004-ace2-5d7ed7b7719e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_630efa6f-be8e-4004-ace2-5d7ed7b7719e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1b60a385-ff3b-4286-8401-6f0cb56c6595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1b60a385-ff3b-4286-8401-6f0cb56c6595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fec78eb-6195-41bb-9f47-2e9f08382d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fec78eb-6195-41bb-9f47-2e9f08382d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf6cf34b-d3ac-4e41-9127-7420b489dca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9016e043-2094-407a-a161-8609c640def6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bf6cf34b-d3ac-4e41-9127-7420b489dca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a8e3ac9-57d8-4f4d-9113-16f2cd85179f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e8e0c0c7-6d94-4ef1-919b-11850cb28079" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a8e3ac9-57d8-4f4d-9113-16f2cd85179f" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e8e0c0c7-6d94-4ef1-919b-11850cb28079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_682e2949-1452-4e9e-a337-b34724d861e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e8e0c0c7-6d94-4ef1-919b-11850cb28079" xlink:to="loc_srt_ProductOrServiceAxis_682e2949-1452-4e9e-a337-b34724d861e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_76e3b106-5597-426d-8a97-348f7692c2a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_682e2949-1452-4e9e-a337-b34724d861e0" xlink:to="loc_srt_ProductsAndServicesDomain_76e3b106-5597-426d-8a97-348f7692c2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ReceiverProductComponentMember_781ed31e-619b-43d9-a6e7-b58261fb3230" xlink:href="dxcm-20231231.xsd#dxcm_ReceiverProductComponentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_76e3b106-5597-426d-8a97-348f7692c2a7" xlink:to="loc_dxcm_ReceiverProductComponentMember_781ed31e-619b-43d9-a6e7-b58261fb3230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e8e0c0c7-6d94-4ef1-919b-11850cb28079" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_b75a5398-ac23-43a6-8c67-30c45a150284" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_DebtInstrumentTerm_b75a5398-ac23-43a6-8c67-30c45a150284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3f10284-a0ed-4512-a4a1-18063badeb71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3f10284-a0ed-4512-a4a1-18063badeb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_076c8c60-c6ed-4d0c-9bbf-fe3dfe3e20a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_076c8c60-c6ed-4d0c-9bbf-fe3dfe3e20a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount_8d575cad-5d43-4108-a7d6-78e83ca2bd7f" xlink:href="dxcm-20231231.xsd#dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount_8d575cad-5d43-4108-a7d6-78e83ca2bd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f495f4f2-5ae0-4b50-8132-1fe78384eacd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_InventoryWriteDown_f495f4f2-5ae0-4b50-8132-1fe78384eacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_16a6bb3e-2f8e-47c1-b780-6507e51190de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_Depreciation_16a6bb3e-2f8e-47c1-b780-6507e51190de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cdc5bb21-500c-456e-85a9-db048ae459f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_31e59637-8457-4cf7-9e4a-4708b68e6215" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cdc5bb21-500c-456e-85a9-db048ae459f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54fa00dc-c762-421f-9266-4e34e8a480de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_1a3c65c6-4021-4712-bee1-976cdec08d19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54fa00dc-c762-421f-9266-4e34e8a480de" xlink:to="loc_us-gaap_AccountsReceivableGross_1a3c65c6-4021-4712-bee1-976cdec08d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2954b253-00f3-481f-935c-1066f4d7746a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54fa00dc-c762-421f-9266-4e34e8a480de" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2954b253-00f3-481f-935c-1066f4d7746a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_27cfc98d-1aff-4a7e-b8e4-85de568911f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54fa00dc-c762-421f-9266-4e34e8a480de" xlink:to="loc_us-gaap_AccountsReceivableNet_27cfc98d-1aff-4a7e-b8e4-85de568911f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_44efe3da-7ce6-475c-852f-4ae08b1a13c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d7846dd1-3518-4360-8cfa-f00d36c1590d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_44efe3da-7ce6-475c-852f-4ae08b1a13c4" xlink:to="loc_us-gaap_InventoryDisclosureAbstract_d7846dd1-3518-4360-8cfa-f00d36c1590d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9882a4a1-a1cb-4150-8d11-ec2218d43111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d7846dd1-3518-4360-8cfa-f00d36c1590d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9882a4a1-a1cb-4150-8d11-ec2218d43111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5ee77530-a8bc-47b2-9262-5a417c167ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d7846dd1-3518-4360-8cfa-f00d36c1590d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5ee77530-a8bc-47b2-9262-5a417c167ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d967fa8c-5d45-4ad5-9b53-4c13136e67f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d7846dd1-3518-4360-8cfa-f00d36c1590d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d967fa8c-5d45-4ad5-9b53-4c13136e67f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a2abb2b3-47df-4fe9-a34b-d386568bea5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d7846dd1-3518-4360-8cfa-f00d36c1590d" xlink:to="loc_us-gaap_InventoryNet_a2abb2b3-47df-4fe9-a34b-d386568bea5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29bb8b73-526e-4e84-849e-52dda30e15b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_0032aaa6-393a-4277-b7aa-0aff8395330c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29bb8b73-526e-4e84-849e-52dda30e15b2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_0032aaa6-393a-4277-b7aa-0aff8395330c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PrepaidInventoryCurrent_c28836bc-fbfc-4f11-a07a-5f0fbb475180" xlink:href="dxcm-20231231.xsd#dxcm_PrepaidInventoryCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29bb8b73-526e-4e84-849e-52dda30e15b2" xlink:to="loc_dxcm_PrepaidInventoryCurrent_c28836bc-fbfc-4f11-a07a-5f0fbb475180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredCompensationPlanAssetsCurrent_6ea4bd25-5601-45fc-aa0f-fd8efb9646db" xlink:href="dxcm-20231231.xsd#dxcm_DeferredCompensationPlanAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29bb8b73-526e-4e84-849e-52dda30e15b2" xlink:to="loc_dxcm_DeferredCompensationPlanAssetsCurrent_6ea4bd25-5601-45fc-aa0f-fd8efb9646db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_eccd6214-6fa6-4955-b4e6-ecf24504c47e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29bb8b73-526e-4e84-849e-52dda30e15b2" xlink:to="loc_us-gaap_IncomeTaxesReceivable_eccd6214-6fa6-4955-b4e6-ecf24504c47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_546fa4fb-85ec-40ab-99a0-b0ed06d62156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29bb8b73-526e-4e84-849e-52dda30e15b2" xlink:to="loc_us-gaap_OtherAssetsCurrent_546fa4fb-85ec-40ab-99a0-b0ed06d62156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_066507b6-8d35-4b61-937f-af1cfabd4dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29bb8b73-526e-4e84-849e-52dda30e15b2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_066507b6-8d35-4b61-937f-af1cfabd4dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1168b5bb-a432-4b06-ae55-d2735c89bfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ca12ab2f-8f26-4fb6-9e2a-11b95b8535b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1168b5bb-a432-4b06-ae55-d2735c89bfd8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ca12ab2f-8f26-4fb6-9e2a-11b95b8535b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60c6ceb2-3b0c-4564-9acb-b3cd281a2e82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ca12ab2f-8f26-4fb6-9e2a-11b95b8535b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60c6ceb2-3b0c-4564-9acb-b3cd281a2e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60c6ceb2-3b0c-4564-9acb-b3cd281a2e82" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_bae3d0c0-ac68-4edf-8f8f-44105768c8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_LandMember_bae3d0c0-ac68-4edf-8f8f-44105768c8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_00c1f901-78c2-4b5f-bd11-a22f6be76751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_BuildingMember_00c1f901-78c2-4b5f-bd11-a22f6be76751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4632c97c-fda9-4945-98b6-3cb85f7add8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4632c97c-fda9-4945-98b6-3cb85f7add8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ComputerSoftwareAndHardwareMember_cd5198d3-e0d1-4ddd-979b-e4ccad56e358" xlink:href="dxcm-20231231.xsd#dxcm_ComputerSoftwareAndHardwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_dxcm_ComputerSoftwareAndHardwareMember_cd5198d3-e0d1-4ddd-979b-e4ccad56e358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_aa6c0763-2cb0-4429-a04b-3fc07873da6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_EquipmentMember_aa6c0763-2cb0-4429-a04b-3fc07873da6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b45b4c2c-d2ac-4c82-bdaf-7a4aeb700b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b45b4c2c-d2ac-4c82-bdaf-7a4aeb700b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_9de74d1c-f154-4304-9342-7874ae0db5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d4d6fc3-30de-41b4-93cc-23d6854bf35a" xlink:to="loc_us-gaap_ConstructionInProgressMember_9de74d1c-f154-4304-9342-7874ae0db5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ca12ab2f-8f26-4fb6-9e2a-11b95b8535b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6b08bb74-54f1-4de0-938e-64e8930a4c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6b08bb74-54f1-4de0-938e-64e8930a4c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2dd27e22-9d9d-42db-9d73-b383c673ee89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2dd27e22-9d9d-42db-9d73-b383c673ee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0c3f532a-b8be-4b86-b36c-23c306662e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0c3f532a-b8be-4b86-b36c-23c306662e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_89e62c34-2502-4a96-b3b4-bf60ad28cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6a713639-fe25-4576-89f8-f4a74c7ffe2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_89e62c34-2502-4a96-b3b4-bf60ad28cbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6740e14a-c798-480f-a9fb-bc558fc40695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d44e1cc-b279-42ea-becc-da7c0465de86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6740e14a-c798-480f-a9fb-bc558fc40695" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d44e1cc-b279-42ea-becc-da7c0465de86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00bb677c-f398-464d-86b3-4eb8ee837f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d44e1cc-b279-42ea-becc-da7c0465de86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00bb677c-f398-464d-86b3-4eb8ee837f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_00bb677c-f398-464d-86b3-4eb8ee837f94" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_VerilyIntangibleMember_fe63756c-4ce7-4dd0-b9bf-80b41afef35f" xlink:href="dxcm-20231231.xsd#dxcm_VerilyIntangibleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_dxcm_VerilyIntangibleMember_fe63756c-4ce7-4dd0-b9bf-80b41afef35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3b3fbc60-c9e4-4bdf-8bfa-3e4e43e6f6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3b3fbc60-c9e4-4bdf-8bfa-3e4e43e6f6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AcquiredTechnologyAndIntellectualPropertyMember_829c739c-33fc-45fa-bc6e-e0c5094c299d" xlink:href="dxcm-20231231.xsd#dxcm_AcquiredTechnologyAndIntellectualPropertyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_dxcm_AcquiredTechnologyAndIntellectualPropertyMember_829c739c-33fc-45fa-bc6e-e0c5094c299d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_c4d6accb-7db3-4dcc-8cb4-a77f29d24e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_c4d6accb-7db3-4dcc-8cb4-a77f29d24e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_5cf5d24f-ad69-4772-b043-8cdb5862255d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_be30e105-b7d7-402d-87a5-dfd6d0df4743" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_5cf5d24f-ad69-4772-b043-8cdb5862255d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2d44e1cc-b279-42ea-becc-da7c0465de86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e98b87da-a795-4f35-8692-6b96c1e9ec07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e98b87da-a795-4f35-8692-6b96c1e9ec07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38c9d01b-6207-40e4-bec9-353ff67334c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38c9d01b-6207-40e4-bec9-353ff67334c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_312b9b4c-7a57-4b10-8e14-63936ae7a6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_312b9b4c-7a57-4b10-8e14-63936ae7a6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_001d40cc-02b9-498c-84c6-c23a3a925b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fd55fb94-ff00-425b-a065-15182d1baf50" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_001d40cc-02b9-498c-84c6-c23a3a925b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a77f17a-b2ea-4f8c-98b9-a0ed3ad58c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales_3c32ed5b-6257-465d-bee2-ad28dab4b8fe" xlink:href="dxcm-20231231.xsd#dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a77f17a-b2ea-4f8c-98b9-a0ed3ad58c7a" xlink:to="loc_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales_3c32ed5b-6257-465d-bee2-ad28dab4b8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2303eabe-b6d2-4a11-b9f5-a2d149c488ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a77f17a-b2ea-4f8c-98b9-a0ed3ad58c7a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2303eabe-b6d2-4a11-b9f5-a2d149c488ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses_5c2e8edc-8140-4c45-b540-cdc7943b6362" xlink:href="dxcm-20231231.xsd#dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a77f17a-b2ea-4f8c-98b9-a0ed3ad58c7a" xlink:to="loc_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses_5c2e8edc-8140-4c45-b540-cdc7943b6362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a6ff32-ed74-47a9-b36b-24538c36ec51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0163e402-7ee8-442d-b713-3c52e1418fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a6ff32-ed74-47a9-b36b-24538c36ec51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0163e402-7ee8-442d-b713-3c52e1418fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_51e8c132-c6de-458b-9d4f-68c1bac0a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a6ff32-ed74-47a9-b36b-24538c36ec51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_51e8c132-c6de-458b-9d4f-68c1bac0a65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_916c9592-c311-4d2a-a580-31fdf6b4bf46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a6ff32-ed74-47a9-b36b-24538c36ec51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_916c9592-c311-4d2a-a580-31fdf6b4bf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_78cf0749-3269-4210-9e2a-0e0443ec37e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a6ff32-ed74-47a9-b36b-24538c36ec51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_78cf0749-3269-4210-9e2a-0e0443ec37e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c4c5b2f9-a193-417a-a170-7cabb8417690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a6ff32-ed74-47a9-b36b-24538c36ec51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c4c5b2f9-a193-417a-a170-7cabb8417690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_19b59ac8-cabd-40bb-96e9-26731439ca00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a6ff32-ed74-47a9-b36b-24538c36ec51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_19b59ac8-cabd-40bb-96e9-26731439ca00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3a4fbb8b-6b22-4c86-9b0c-ab5df42b278f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a6ff32-ed74-47a9-b36b-24538c36ec51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3a4fbb8b-6b22-4c86-9b0c-ab5df42b278f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ea95b41-2a24-4fec-bb4e-3fe47e4054de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3a63fd56-ee28-4eeb-9acf-6156dfb1a6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ea95b41-2a24-4fec-bb4e-3fe47e4054de" xlink:to="loc_us-gaap_LongTermInvestments_3a63fd56-ee28-4eeb-9acf-6156dfb1a6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LongTermDeposits_1942db8d-ec96-4d7e-aaa3-81f606628b90" xlink:href="dxcm-20231231.xsd#dxcm_LongTermDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ea95b41-2a24-4fec-bb4e-3fe47e4054de" xlink:to="loc_dxcm_LongTermDeposits_1942db8d-ec96-4d7e-aaa3-81f606628b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherLongTermAssets_ef52caa5-9170-45da-99d0-4bc4f1d52973" xlink:href="dxcm-20231231.xsd#dxcm_OtherLongTermAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ea95b41-2a24-4fec-bb4e-3fe47e4054de" xlink:to="loc_dxcm_OtherLongTermAssets_ef52caa5-9170-45da-99d0-4bc4f1d52973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c51ce3d6-4b5f-4d1b-aaca-6f4926e6e227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ea95b41-2a24-4fec-bb4e-3fe47e4054de" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c51ce3d6-4b5f-4d1b-aaca-6f4926e6e227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad02441-8081-4552-818e-c8f81a8fead1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_ca7d41fe-9329-415c-85b5-c14b9f9426a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad02441-8081-4552-818e-c8f81a8fead1" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_ca7d41fe-9329-415c-85b5-c14b9f9426a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AccruedTaxAuditAndLegalFeesCurrent_24417d91-517a-478c-bc57-a3ba8b0671eb" xlink:href="dxcm-20231231.xsd#dxcm_AccruedTaxAuditAndLegalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad02441-8081-4552-818e-c8f81a8fead1" xlink:to="loc_dxcm_AccruedTaxAuditAndLegalFeesCurrent_24417d91-517a-478c-bc57-a3ba8b0671eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PharmacyRebatesCurrent_53458455-d34b-421e-be2c-0a14454504d0" xlink:href="dxcm-20231231.xsd#dxcm_PharmacyRebatesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad02441-8081-4552-818e-c8f81a8fead1" xlink:to="loc_dxcm_PharmacyRebatesCurrent_53458455-d34b-421e-be2c-0a14454504d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_b56c39bf-6d0f-4a80-9427-702deb859e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad02441-8081-4552-818e-c8f81a8fead1" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_b56c39bf-6d0f-4a80-9427-702deb859e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_ad9bc93d-41f7-451e-b18c-5cf8ab315c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad02441-8081-4552-818e-c8f81a8fead1" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_ad9bc93d-41f7-451e-b18c-5cf8ab315c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_6c1bc424-9ff6-4498-bec9-a14609addbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad02441-8081-4552-818e-c8f81a8fead1" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_6c1bc424-9ff6-4498-bec9-a14609addbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_aabad49c-e979-4d77-b4f3-6a2891c3eefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad02441-8081-4552-818e-c8f81a8fead1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_aabad49c-e979-4d77-b4f3-6a2891c3eefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ab07dc7f-8a57-4360-9030-7d5709ef42a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad02441-8081-4552-818e-c8f81a8fead1" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ab07dc7f-8a57-4360-9030-7d5709ef42a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b82f1c9e-c0ba-4e67-b8b3-39673f722f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AccruedWagesBonusesAndTaxesCurrent_64121c65-86e8-473a-af88-b37f4282845b" xlink:href="dxcm-20231231.xsd#dxcm_AccruedWagesBonusesAndTaxesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b82f1c9e-c0ba-4e67-b8b3-39673f722f91" xlink:to="loc_dxcm_AccruedWagesBonusesAndTaxesCurrent_64121c65-86e8-473a-af88-b37f4282845b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_73cddf9f-6407-44e0-b97d-41405dd09c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b82f1c9e-c0ba-4e67-b8b3-39673f722f91" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_73cddf9f-6407-44e0-b97d-41405dd09c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_716a326f-a1d6-45c4-815d-146617dc051b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b82f1c9e-c0ba-4e67-b8b3-39673f722f91" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_716a326f-a1d6-45c4-815d-146617dc051b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e670e163-885b-44cd-9739-1132dbf47f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_1c086590-e4ea-4171-95c8-ac2ab48d1ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInStandardProductWarrantyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e670e163-885b-44cd-9739-1132dbf47f51" xlink:to="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_1c086590-e4ea-4171-95c8-ac2ab48d1ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_2535c545-97d8-4f87-99ef-07cf6b943b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_1c086590-e4ea-4171-95c8-ac2ab48d1ff6" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_2535c545-97d8-4f87-99ef-07cf6b943b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses_68837cb7-1087-4a98-b41f-3e5570f1e05f" xlink:href="dxcm-20231231.xsd#dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_1c086590-e4ea-4171-95c8-ac2ab48d1ff6" xlink:to="loc_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses_68837cb7-1087-4a98-b41f-3e5570f1e05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments_f09edbaa-a159-4808-a96b-72bd897fa7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_1c086590-e4ea-4171-95c8-ac2ab48d1ff6" xlink:to="loc_us-gaap_ProductWarrantyAccrualPayments_f09edbaa-a159-4808-a96b-72bd897fa7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_1dfb90e6-6d05-4989-851e-57552aac6923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_1c086590-e4ea-4171-95c8-ac2ab48d1ff6" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_1dfb90e6-6d05-4989-851e-57552aac6923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f912ba8a-27e7-42f0-85e7-7a412f59d7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6b015832-69e5-40f4-aa45-979665fab9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f912ba8a-27e7-42f0-85e7-7a412f59d7bf" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6b015832-69e5-40f4-aa45-979665fab9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bd708edd-4434-4a1d-9d3f-f5aba5881ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f912ba8a-27e7-42f0-85e7-7a412f59d7bf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bd708edd-4434-4a1d-9d3f-f5aba5881ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation_d2d31a21-6d09-491c-a575-62e5829cf0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetRetirementObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f912ba8a-27e7-42f0-85e7-7a412f59d7bf" xlink:to="loc_us-gaap_AssetRetirementObligation_d2d31a21-6d09-491c-a575-62e5829cf0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherTaxLiabilitiesNoncurrent_37510c64-48d9-457b-8b4a-876aebe4ca1f" xlink:href="dxcm-20231231.xsd#dxcm_OtherTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f912ba8a-27e7-42f0-85e7-7a412f59d7bf" xlink:to="loc_dxcm_OtherTaxLiabilitiesNoncurrent_37510c64-48d9-457b-8b4a-876aebe4ca1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_aa7fef1f-71d2-4227-a1fd-a7c8fabc902c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f912ba8a-27e7-42f0-85e7-7a412f59d7bf" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_aa7fef1f-71d2-4227-a1fd-a7c8fabc902c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_075bfb62-4db3-4020-af1c-02e0920b514b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f912ba8a-27e7-42f0-85e7-7a412f59d7bf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_075bfb62-4db3-4020-af1c-02e0920b514b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4252dddc-6574-411a-914a-2fb17f42cf00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_6ba2c9e0-948c-4c4e-b1bc-32c9762a381e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4252dddc-6574-411a-914a-2fb17f42cf00" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_6ba2c9e0-948c-4c4e-b1bc-32c9762a381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_978c3e08-ca2d-40c8-9ae9-697b9a27ab00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4252dddc-6574-411a-914a-2fb17f42cf00" xlink:to="loc_us-gaap_InterestExpense_978c3e08-ca2d-40c8-9ae9-697b9a27ab00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_13025e14-e70b-4116-86df-9210d5e1cf41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4252dddc-6574-411a-914a-2fb17f42cf00" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_13025e14-e70b-4116-86df-9210d5e1cf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0588ab0d-c325-4cb6-ac45-5748b2203902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4252dddc-6574-411a-914a-2fb17f42cf00" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0588ab0d-c325-4cb6-ac45-5748b2203902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_c7e6bcb9-3fe3-4d15-9222-a54ecf5898c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4252dddc-6574-411a-914a-2fb17f42cf00" xlink:to="loc_us-gaap_OtherNonoperatingExpense_c7e6bcb9-3fe3-4d15-9222-a54ecf5898c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8b123e27-1cac-4f3e-bac3-84849d685973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4252dddc-6574-411a-914a-2fb17f42cf00" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8b123e27-1cac-4f3e-bac3-84849d685973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_94df975d-3a34-4cdd-b424-aaac52cadfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2b304c02-f400-44d0-aef0-37ff9329b890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94df975d-3a34-4cdd-b424-aaac52cadfe9" xlink:to="loc_us-gaap_DebtInstrumentTable_2b304c02-f400-44d0-aef0-37ff9329b890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7b4cc7b7-afb4-4456-86e5-1e0cc35e5b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2b304c02-f400-44d0-aef0-37ff9329b890" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7b4cc7b7-afb4-4456-86e5-1e0cc35e5b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_562991ba-8179-46bc-8ce7-cc09a61fa815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7b4cc7b7-afb4-4456-86e5-1e0cc35e5b4e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_562991ba-8179-46bc-8ce7-cc09a61fa815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3e278fd3-f140-41ba-bf78-e334fe1329ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_562991ba-8179-46bc-8ce7-cc09a61fa815" xlink:to="loc_us-gaap_SeniorNotesMember_3e278fd3-f140-41ba-bf78-e334fe1329ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2b2259de-96e7-42ee-a524-3272128cc635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2b304c02-f400-44d0-aef0-37ff9329b890" xlink:to="loc_us-gaap_DebtInstrumentAxis_2b2259de-96e7-42ee-a524-3272128cc635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2b2259de-96e7-42ee-a524-3272128cc635" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_1dfa31d2-428e-4acb-ab61-e39191e24a54" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_1dfa31d2-428e-4acb-ab61-e39191e24a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_3c4b9bdf-0c42-4a94-9963-c0dd73d9d4a8" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_3c4b9bdf-0c42-4a94-9963-c0dd73d9d4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_a322d52d-d390-46f6-b261-7447c8644da8" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44d4e78f-5fca-41e7-b695-3720eddd5dff" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_a322d52d-d390-46f6-b261-7447c8644da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a84d7dea-14a0-42e3-bfbd-2c162d90c779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2b304c02-f400-44d0-aef0-37ff9329b890" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a84d7dea-14a0-42e3-bfbd-2c162d90c779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a84d7dea-14a0-42e3-bfbd-2c162d90c779" xlink:to="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_47501cdf-ebd6-4f07-b08a-365280c2f624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_47501cdf-ebd6-4f07-b08a-365280c2f624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_6d9b7537-3709-4a3b-b749-39723cfe6505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_6d9b7537-3709-4a3b-b749-39723cfe6505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_cc41dd16-0a6c-48ac-b4da-5ce034d6d22f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract_e5f4f59e-ef88-42c3-a569-dff8cff3aec7" xlink:to="loc_us-gaap_ConvertibleNotesPayable_cc41dd16-0a6c-48ac-b4da-5ce034d6d22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofConvertedValueofNotesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_26ae0004-b7dc-4076-8404-ceaedf51fba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_27a5c579-c971-4953-bab5-7c9fb4258672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_26ae0004-b7dc-4076-8404-ceaedf51fba0" xlink:to="loc_us-gaap_DebtInstrumentTable_27a5c579-c971-4953-bab5-7c9fb4258672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a5f10e42-ead9-458f-b443-bc8453137646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_27a5c579-c971-4953-bab5-7c9fb4258672" xlink:to="loc_us-gaap_DebtInstrumentAxis_a5f10e42-ead9-458f-b443-bc8453137646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a5f10e42-ead9-458f-b443-bc8453137646" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_0fafbab1-433e-4765-bb97-502e67089fc2" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_0fafbab1-433e-4765-bb97-502e67089fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_38b0256e-02ad-4a0b-9add-41b915c07560" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_38b0256e-02ad-4a0b-9add-41b915c07560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_bb678a46-4736-4865-b04b-54451aab9f6b" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_852485af-0211-416d-b5a3-f48161736792" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_bb678a46-4736-4865-b04b-54451aab9f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c0c0572c-9f4c-4d95-b832-b7a14f341efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_27a5c579-c971-4953-bab5-7c9fb4258672" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c0c0572c-9f4c-4d95-b832-b7a14f341efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0f0457d1-4f19-49c8-b18c-6a6be82d72cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c0c0572c-9f4c-4d95-b832-b7a14f341efb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0f0457d1-4f19-49c8-b18c-6a6be82d72cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f83dbef1-1c85-4f74-97b2-2e341a98cca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0f0457d1-4f19-49c8-b18c-6a6be82d72cd" xlink:to="loc_us-gaap_SeniorNotesMember_f83dbef1-1c85-4f74-97b2-2e341a98cca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_46ccd49e-6b3f-44d5-b524-64f892bbe03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_27a5c579-c971-4953-bab5-7c9fb4258672" xlink:to="loc_us-gaap_DebtInstrumentLineItems_46ccd49e-6b3f-44d5-b524-64f892bbe03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_1d586e90-8c88-4b00-b453-b6f5105652b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46ccd49e-6b3f-44d5-b524-64f892bbe03d" xlink:to="loc_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_1d586e90-8c88-4b00-b453-b6f5105652b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6a222677-0138-40c4-b1c6-dd3a24807cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ec5cca9b-8dac-4db9-bbee-17ac03b7ed31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6a222677-0138-40c4-b1c6-dd3a24807cb5" xlink:to="loc_us-gaap_DebtInstrumentTable_ec5cca9b-8dac-4db9-bbee-17ac03b7ed31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d42ce324-7425-40e6-b4dc-0800c15857b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ec5cca9b-8dac-4db9-bbee-17ac03b7ed31" xlink:to="loc_us-gaap_DebtInstrumentAxis_d42ce324-7425-40e6-b4dc-0800c15857b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d42ce324-7425-40e6-b4dc-0800c15857b2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_e749487c-52a9-4043-88b3-1ba8ef314894" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_e749487c-52a9-4043-88b3-1ba8ef314894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_1e0dc387-431a-4412-9734-9bed1db67588" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_1e0dc387-431a-4412-9734-9bed1db67588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_1fbe2e47-05bc-48b0-8bca-6eb5e3e34fcb" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e0c9a1b3-a9a9-41ad-b54f-292dfff5d239" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_1fbe2e47-05bc-48b0-8bca-6eb5e3e34fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ec5cca9b-8dac-4db9-bbee-17ac03b7ed31" xlink:to="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_CashInterestExpenseAbstract_a78c92ed-8d79-4642-b48c-d272161f3108" xlink:href="dxcm-20231231.xsd#dxcm_CashInterestExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:to="loc_dxcm_CashInterestExpenseAbstract_a78c92ed-8d79-4642-b48c-d272161f3108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_b60a6406-5ebb-455a-8ead-fc2c0b27edc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_CashInterestExpenseAbstract_a78c92ed-8d79-4642-b48c-d272161f3108" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_b60a6406-5ebb-455a-8ead-fc2c0b27edc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_NonCashInterestExpenseAbstract_47a5aef7-fcbd-4074-b1a1-70a9864e5e2d" xlink:href="dxcm-20231231.xsd#dxcm_NonCashInterestExpenseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:to="loc_dxcm_NonCashInterestExpenseAbstract_47a5aef7-fcbd-4074-b1a1-70a9864e5e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ebc58a5a-ed41-4400-888f-f98b3faf1c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_NonCashInterestExpenseAbstract_47a5aef7-fcbd-4074-b1a1-70a9864e5e2d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ebc58a5a-ed41-4400-888f-f98b3faf1c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_69d0488d-a853-4899-b18c-1fc5f5ad46ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_NonCashInterestExpenseAbstract_47a5aef7-fcbd-4074-b1a1-70a9864e5e2d" xlink:to="loc_us-gaap_InterestExpenseDebt_69d0488d-a853-4899-b18c-1fc5f5ad46ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a0d89fa9-b550-4478-aac0-c9da09e97831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_48a6dbcd-d8d0-4a48-849b-400de753877e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a0d89fa9-b550-4478-aac0-c9da09e97831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtScheduleofKeyDetailsofConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_aa7c17fe-851f-4a6a-bbdb-36d607eac030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6de4d4ec-c23d-4df0-9e1f-385a017c1d44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aa7c17fe-851f-4a6a-bbdb-36d607eac030" xlink:to="loc_us-gaap_DebtInstrumentTable_6de4d4ec-c23d-4df0-9e1f-385a017c1d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_67437e9d-5088-49b1-af20-914ea06ecf44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6de4d4ec-c23d-4df0-9e1f-385a017c1d44" xlink:to="loc_us-gaap_DebtInstrumentAxis_67437e9d-5088-49b1-af20-914ea06ecf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_67437e9d-5088-49b1-af20-914ea06ecf44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_f138ad2a-971d-45c1-877d-366830ef2652" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_f138ad2a-971d-45c1-877d-366830ef2652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_63013022-c66c-48aa-b68b-720ad07d9d8a" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_63013022-c66c-48aa-b68b-720ad07d9d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_dd5ae44d-e16f-43b3-9165-7cc9af8a433b" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26e0a31a-6cf8-427d-b0fc-d9577e2798eb" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_dd5ae44d-e16f-43b3-9165-7cc9af8a433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_21b8fd13-5537-4e44-8679-45d4c4da4414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6de4d4ec-c23d-4df0-9e1f-385a017c1d44" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_21b8fd13-5537-4e44-8679-45d4c4da4414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c54cad5a-3dd2-4443-99bd-3e4848128ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_21b8fd13-5537-4e44-8679-45d4c4da4414" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c54cad5a-3dd2-4443-99bd-3e4848128ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_011663bb-700e-47e4-ab37-ef1247617b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c54cad5a-3dd2-4443-99bd-3e4848128ba2" xlink:to="loc_us-gaap_SeniorNotesMember_011663bb-700e-47e4-ab37-ef1247617b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6de4d4ec-c23d-4df0-9e1f-385a017c1d44" xlink:to="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68577bfa-88e7-4a43-b96f-a8f5e7c4a1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68577bfa-88e7-4a43-b96f-a8f5e7c4a1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fb722fed-f60c-4bbc-94d3-f69a24c3e793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fb722fed-f60c-4bbc-94d3-f69a24c3e793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_cdcb500d-27ea-4802-b8b3-84ce0a60322a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_cdcb500d-27ea-4802-b8b3-84ce0a60322a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5b66024c-6470-4020-94fa-9e40548865b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_5b66024c-6470-4020-94fa-9e40548865b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_140d0b94-109b-45cb-a67f-eb9caf7820bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37736be0-5204-47c8-afe1-6925eae5801a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_140d0b94-109b-45cb-a67f-eb9caf7820bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/Debt2023NoteHedgeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#Debt2023NoteHedgeDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/Debt2023NoteHedgeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_eddeddc2-6e8d-4ea4-9009-ef4a11fc9437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_eddeddc2-6e8d-4ea4-9009-ef4a11fc9437" xlink:to="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_40f8aec5-aac8-4c31-96a4-cd02824ad443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:to="loc_us-gaap_DebtInstrumentAxis_40f8aec5-aac8-4c31-96a4-cd02824ad443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7be2ed3-a891-466f-9419-e937e0d99121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_40f8aec5-aac8-4c31-96a4-cd02824ad443" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7be2ed3-a891-466f-9419-e937e0d99121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_4e8e0340-51be-496a-bd24-f5412489f827" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7be2ed3-a891-466f-9419-e937e0d99121" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_4e8e0340-51be-496a-bd24-f5412489f827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8f128f02-2fcf-4d18-adbf-842968626e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:to="loc_us-gaap_HedgingDesignationAxis_8f128f02-2fcf-4d18-adbf-842968626e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_391df25b-38c3-4daf-86d8-6ffb994c0884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_8f128f02-2fcf-4d18-adbf-842968626e0d" xlink:to="loc_us-gaap_HedgingDesignationDomain_391df25b-38c3-4daf-86d8-6ffb994c0884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5cdbf547-15da-4e60-8152-4de636ef8152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_391df25b-38c3-4daf-86d8-6ffb994c0884" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5cdbf547-15da-4e60-8152-4de636ef8152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_384588e9-8544-4e58-a20c-6b540de5e4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_384588e9-8544-4e58-a20c-6b540de5e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_70b2c24f-9180-4f31-81d1-d6d3745afdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_384588e9-8544-4e58-a20c-6b540de5e4e2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_70b2c24f-9180-4f31-81d1-d6d3745afdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3bb84932-a4cc-425b-9413-7734736c1d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_70b2c24f-9180-4f31-81d1-d6d3745afdd6" xlink:to="loc_us-gaap_SeniorNotesMember_3bb84932-a4cc-425b-9413-7734736c1d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_09c5b618-12c3-42e1-84f3-69c0decb0926" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares_2754df30-5a57-4489-a04a-0a31bc7a6393" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:to="loc_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares_2754df30-5a57-4489-a04a-0a31bc7a6393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3eb3f691-81bb-4a8c-b09a-72e9bee44ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3eb3f691-81bb-4a8c-b09a-72e9bee44ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_c08a1733-2932-48d0-ac7d-d156f9070401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ebfc559-03be-4acd-b18b-1843d3548abe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_c08a1733-2932-48d0-ac7d-d156f9070401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/Debt2023WarrantsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#Debt2023WarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/Debt2023WarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9e14c1b8-6587-4bc0-8487-c6795d5ac8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1bf0364d-99d9-4a56-8c0f-fb8c1bf57d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9e14c1b8-6587-4bc0-8487-c6795d5ac8f3" xlink:to="loc_us-gaap_DebtInstrumentTable_1bf0364d-99d9-4a56-8c0f-fb8c1bf57d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4d7a6a5f-35b2-419b-8ac4-8b157cefe694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1bf0364d-99d9-4a56-8c0f-fb8c1bf57d24" xlink:to="loc_us-gaap_DebtInstrumentAxis_4d7a6a5f-35b2-419b-8ac4-8b157cefe694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0fd5863-ba54-4fed-b0d5-bd08cf396151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4d7a6a5f-35b2-419b-8ac4-8b157cefe694" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0fd5863-ba54-4fed-b0d5-bd08cf396151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_b6190eb9-bd1d-4ab8-944b-067807768ab7" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fd5863-ba54-4fed-b0d5-bd08cf396151" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_b6190eb9-bd1d-4ab8-944b-067807768ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aa4f3702-86d1-4af0-b6d6-f84950abfdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1bf0364d-99d9-4a56-8c0f-fb8c1bf57d24" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aa4f3702-86d1-4af0-b6d6-f84950abfdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6bc2f1da-d89b-4976-baa1-a9de60b05a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa4f3702-86d1-4af0-b6d6-f84950abfdbc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6bc2f1da-d89b-4976-baa1-a9de60b05a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ce941d7b-01e5-44dd-b5bb-3f55d1c1be61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6bc2f1da-d89b-4976-baa1-a9de60b05a6e" xlink:to="loc_us-gaap_SeniorNotesMember_ce941d7b-01e5-44dd-b5bb-3f55d1c1be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1bf0364d-99d9-4a56-8c0f-fb8c1bf57d24" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_653bd752-acc1-430e-92af-c2975c824095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_653bd752-acc1-430e-92af-c2975c824095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_7f68ef69-62fb-4db8-a1b8-47f30c030395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_7f68ef69-62fb-4db8-a1b8-47f30c030395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_2e29a2ad-5403-4068-9bbf-d18ffd6394ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_2e29a2ad-5403-4068-9bbf-d18ffd6394ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aa1aac10-8c41-4f98-ae7a-eb9f0b158fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e7dabd2-1377-44a6-b44e-5a4b6614c0ec" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aa1aac10-8c41-4f98-ae7a-eb9f0b158fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#Debt2028CappedCallTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9365feb4-3b51-4341-aa50-abd91deff7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bb293843-5467-4c1b-9850-faf44d2b77fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9365feb4-3b51-4341-aa50-abd91deff7c6" xlink:to="loc_us-gaap_DebtInstrumentTable_bb293843-5467-4c1b-9850-faf44d2b77fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cf32a4b3-d048-4edb-bb1e-b08a7915a32d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bb293843-5467-4c1b-9850-faf44d2b77fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_cf32a4b3-d048-4edb-bb1e-b08a7915a32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98548308-35a0-4c3b-b583-5fdef346e271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cf32a4b3-d048-4edb-bb1e-b08a7915a32d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98548308-35a0-4c3b-b583-5fdef346e271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2028Member_bfe65050-3cce-4cfa-b645-95991d446247" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98548308-35a0-4c3b-b583-5fdef346e271" xlink:to="loc_dxcm_ConvertibleNotesDue2028Member_bfe65050-3cce-4cfa-b645-95991d446247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b3292c10-9940-4185-b46d-1468ade7e2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bb293843-5467-4c1b-9850-faf44d2b77fe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b3292c10-9940-4185-b46d-1468ade7e2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3795ed29-37a9-4519-aec0-f9be8aa628c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b3292c10-9940-4185-b46d-1468ade7e2ee" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3795ed29-37a9-4519-aec0-f9be8aa628c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f65ca643-751d-453a-8192-47974728b748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3795ed29-37a9-4519-aec0-f9be8aa628c5" xlink:to="loc_us-gaap_SeniorNotesMember_f65ca643-751d-453a-8192-47974728b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bb293843-5467-4c1b-9850-faf44d2b77fe" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare_69313157-26c4-47bd-a5ed-c7f551286367" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentCapCallTransactionCapPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:to="loc_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare_69313157-26c4-47bd-a5ed-c7f551286367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage_fbe8ed95-be0b-43ab-b9bd-20f505beb064" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:to="loc_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage_fbe8ed95-be0b-43ab-b9bd-20f505beb064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_98ff5efd-f8e1-4243-8d84-18baad483034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:to="loc_us-gaap_SharePrice_98ff5efd-f8e1-4243-8d84-18baad483034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions_f28d4dbd-1a2f-4ddc-bd3f-feeb7fc682fb" xlink:href="dxcm-20231231.xsd#dxcm_PaymentsForPurchasesOfCappedCallTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b876fb38-ecf8-4710-8bc5-aa2983f79dcd" xlink:to="loc_dxcm_PaymentsForPurchasesOfCappedCallTransactions_f28d4dbd-1a2f-4ddc-bd3f-feeb7fc682fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtConversionActivityforSeniorConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cf75aaab-75b3-4733-9e4a-643ad8ee1620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cf75aaab-75b3-4733-9e4a-643ad8ee1620" xlink:to="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a94165a-11c5-4107-b7da-f82070079118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a94165a-11c5-4107-b7da-f82070079118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0a835c7-08b7-4d76-839d-2a48b1ffe8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a94165a-11c5-4107-b7da-f82070079118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0a835c7-08b7-4d76-839d-2a48b1ffe8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_dba6600e-7896-4666-9608-1b71b67cc8dd" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0a835c7-08b7-4d76-839d-2a48b1ffe8c5" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_dba6600e-7896-4666-9608-1b71b67cc8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a6255ca8-d7d1-48a4-ae9d-02c4acb28bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a6255ca8-d7d1-48a4-ae9d-02c4acb28bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df9f297f-297c-4d1f-a029-d9e4e8401e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a6255ca8-d7d1-48a4-ae9d-02c4acb28bcd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df9f297f-297c-4d1f-a029-d9e4e8401e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_12105073-acd5-4f28-9ef9-c0df1e07686c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df9f297f-297c-4d1f-a029-d9e4e8401e2e" xlink:to="loc_us-gaap_SeniorNotesMember_12105073-acd5-4f28-9ef9-c0df1e07686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb3a2796-652e-43f9-85bc-fa8388ecade1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb3a2796-652e-43f9-85bc-fa8388ecade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45c1d82f-19b2-4de9-91dc-1f65d3436f46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb3a2796-652e-43f9-85bc-fa8388ecade1" xlink:to="loc_us-gaap_EquityComponentDomain_45c1d82f-19b2-4de9-91dc-1f65d3436f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3303a111-b0fc-4c89-b56a-7e28a4c527ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45c1d82f-19b2-4de9-91dc-1f65d3436f46" xlink:to="loc_us-gaap_CommonStockMember_3303a111-b0fc-4c89-b56a-7e28a4c527ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_148eb966-c2be-4397-9d37-71f8d0c98256" xlink:to="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled_e1d9e259-6fc9-49b6-9a25-8e35c04c1de0" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:to="loc_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled_e1d9e259-6fc9-49b6-9a25-8e35c04c1de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_191ab2f6-410a-473b-b776-05426807852b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_191ab2f6-410a-473b-b776-05426807852b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromBenefitOfNoteHedge_5a0e5cb7-39c1-4ea7-be30-f9289bd5e17c" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromBenefitOfNoteHedge"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_491faeb4-ae60-48bf-bbca-5b0c16fa128c" xlink:to="loc_dxcm_SharesReceivedFromBenefitOfNoteHedge_5a0e5cb7-39c1-4ea7-be30-f9289bd5e17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtConversionRightsforSeniorsConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4e1b1883-0c2d-482f-8178-a25c713953b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4e1b1883-0c2d-482f-8178-a25c713953b5" xlink:to="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_12af25a3-0fc9-4571-948b-b09c7596f3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:to="loc_us-gaap_DebtInstrumentAxis_12af25a3-0fc9-4571-948b-b09c7596f3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_357d3cca-3268-419f-be1d-0f087c8f4f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_12af25a3-0fc9-4571-948b-b09c7596f3f4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_357d3cca-3268-419f-be1d-0f087c8f4f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2023Member_b8fd1833-7a91-4c30-b7c5-2ea07de2a114" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_357d3cca-3268-419f-be1d-0f087c8f4f5c" xlink:to="loc_dxcm_ConvertibleNotesDue2023Member_b8fd1833-7a91-4c30-b7c5-2ea07de2a114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ConvertibleNotesDue2025Member_638ec0ba-07e9-45ea-85f9-6a3cb3c6c14a" xlink:href="dxcm-20231231.xsd#dxcm_ConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_357d3cca-3268-419f-be1d-0f087c8f4f5c" xlink:to="loc_dxcm_ConvertibleNotesDue2025Member_638ec0ba-07e9-45ea-85f9-6a3cb3c6c14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_88302c2c-ba16-4dee-9ef5-5a705b3852dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_88302c2c-ba16-4dee-9ef5-5a705b3852dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_82382679-1df3-4288-80cf-b33890ffc970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_88302c2c-ba16-4dee-9ef5-5a705b3852dd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_82382679-1df3-4288-80cf-b33890ffc970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1e0114a8-dce9-4cf3-9c41-757c6e8fd641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_82382679-1df3-4288-80cf-b33890ffc970" xlink:to="loc_us-gaap_SeniorNotesMember_1e0114a8-dce9-4cf3-9c41-757c6e8fd641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermAxis_16deee48-9dd8-439c-beef-80a15f71b708" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:to="loc_dxcm_DebtInstrumentConversionTermAxis_16deee48-9dd8-439c-beef-80a15f71b708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermDomain_a13b5f56-7b85-4f56-bb62-08fa95211899" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DebtInstrumentConversionTermAxis_16deee48-9dd8-439c-beef-80a15f71b708" xlink:to="loc_dxcm_DebtInstrumentConversionTermDomain_a13b5f56-7b85-4f56-bb62-08fa95211899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermOneMember_7f555d70-fa38-4fc5-9a86-23b0cd1bd079" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DebtInstrumentConversionTermDomain_a13b5f56-7b85-4f56-bb62-08fa95211899" xlink:to="loc_dxcm_DebtInstrumentConversionTermOneMember_7f555d70-fa38-4fc5-9a86-23b0cd1bd079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentConversionTermTwoMember_3cddea3b-9270-446d-befe-197d17fc0f42" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentConversionTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_DebtInstrumentConversionTermDomain_a13b5f56-7b85-4f56-bb62-08fa95211899" xlink:to="loc_dxcm_DebtInstrumentConversionTermTwoMember_3cddea3b-9270-446d-befe-197d17fc0f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_debebe0a-0576-46b7-9b5c-833693beb168" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:to="loc_srt_RangeAxis_debebe0a-0576-46b7-9b5c-833693beb168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68ae1bd1-6eea-4b99-93cc-6aebc3e4cecf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_debebe0a-0576-46b7-9b5c-833693beb168" xlink:to="loc_srt_RangeMember_68ae1bd1-6eea-4b99-93cc-6aebc3e4cecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2205bfe1-db84-4832-b9cd-052ac0cff866" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_68ae1bd1-6eea-4b99-93cc-6aebc3e4cecf" xlink:to="loc_srt_MinimumMember_2205bfe1-db84-4832-b9cd-052ac0cff866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb43483e-5b88-4889-be4e-5a972dae7532" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_68ae1bd1-6eea-4b99-93cc-6aebc3e4cecf" xlink:to="loc_srt_MaximumMember_fb43483e-5b88-4889-be4e-5a972dae7532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2663493b-ef27-48ae-a585-bfd237ff760d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentCovenantRepurchasePricePercentage_95aada60-7d78-499c-b07f-6a743ab34b53" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentCovenantRepurchasePricePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_dxcm_DebtInstrumentCovenantRepurchasePricePercentage_95aada60-7d78-499c-b07f-6a743ab34b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_8c96df24-b196-4566-980a-e1f2e99642d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_8c96df24-b196-4566-980a-e1f2e99642d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_54745c74-e664-4231-872d-85481e8ec423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_54745c74-e664-4231-872d-85481e8ec423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock_8971fe68-fc87-42c2-8f13-f05b550c2adb" xlink:href="dxcm-20231231.xsd#dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock_8971fe68-fc87-42c2-8f13-f05b550c2adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d70248d5-e432-486f-8d1a-f991d709941f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6d2f2f7-12c2-4ba1-a17b-4ee2ddbcc971" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d70248d5-e432-486f-8d1a-f991d709941f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1328165b-257f-45b9-b36f-aa8299cc5737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1328165b-257f-45b9-b36f-aa8299cc5737" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_507c7368-2066-4454-acbc-c264f99e73a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_507c7368-2066-4454-acbc-c264f99e73a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f93cb64e-c9a7-4466-9867-575718e9d8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_507c7368-2066-4454-acbc-c264f99e73a7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f93cb64e-c9a7-4466-9867-575718e9d8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_eb2daeb2-98a1-40e9-b12e-63a8da2cb0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f93cb64e-c9a7-4466-9867-575718e9d8ad" xlink:to="loc_us-gaap_LineOfCreditMember_eb2daeb2-98a1-40e9-b12e-63a8da2cb0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_292d459c-1960-48a1-bb06-d75fdf88e6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:to="loc_us-gaap_CreditFacilityAxis_292d459c-1960-48a1-bb06-d75fdf88e6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1cf23003-3123-4d68-98a8-04a5e9f6dbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_292d459c-1960-48a1-bb06-d75fdf88e6e7" xlink:to="loc_us-gaap_CreditFacilityDomain_1cf23003-3123-4d68-98a8-04a5e9f6dbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_86a2c9b8-172f-48e2-a955-2f0c5567dfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1cf23003-3123-4d68-98a8-04a5e9f6dbb0" xlink:to="loc_us-gaap_LetterOfCreditMember_86a2c9b8-172f-48e2-a955-2f0c5567dfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da2bb1d5-e485-4396-8c4d-a4d504507091" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:to="loc_srt_RangeAxis_da2bb1d5-e485-4396-8c4d-a4d504507091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94353d3c-5507-4d2d-ac1f-c7b263a09c71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_da2bb1d5-e485-4396-8c4d-a4d504507091" xlink:to="loc_srt_RangeMember_94353d3c-5507-4d2d-ac1f-c7b263a09c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0c18eab8-d3d9-4261-881c-9b88f9857800" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_94353d3c-5507-4d2d-ac1f-c7b263a09c71" xlink:to="loc_srt_MinimumMember_0c18eab8-d3d9-4261-881c-9b88f9857800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5d9dca5-9051-4bc2-831b-3823e5ef1b8f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_94353d3c-5507-4d2d-ac1f-c7b263a09c71" xlink:to="loc_srt_MaximumMember_d5d9dca5-9051-4bc2-831b-3823e5ef1b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e0787b82-545f-4c7f-8da8-29f90b41e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:to="loc_us-gaap_VariableRateAxis_e0787b82-545f-4c7f-8da8-29f90b41e4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_342a73b9-6f8a-45de-9a8a-7800f34b5e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_e0787b82-545f-4c7f-8da8-29f90b41e4bb" xlink:to="loc_us-gaap_VariableRateDomain_342a73b9-6f8a-45de-9a8a-7800f34b5e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_5386fa59-0c13-48db-9ddb-24b6cd4aa4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_342a73b9-6f8a-45de-9a8a-7800f34b5e08" xlink:to="loc_us-gaap_BaseRateMember_5386fa59-0c13-48db-9ddb-24b6cd4aa4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LondonInterbankOfferedRateLIBOR1Member_09497315-6c00-4bfc-a5b5-4f810041739f" xlink:href="dxcm-20231231.xsd#dxcm_LondonInterbankOfferedRateLIBOR1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_342a73b9-6f8a-45de-9a8a-7800f34b5e08" xlink:to="loc_dxcm_LondonInterbankOfferedRateLIBOR1Member_09497315-6c00-4bfc-a5b5-4f810041739f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7374cba1-02b5-41d9-8b45-6c95dad51c80" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4eb05e52-90de-4e28-853c-1605cb679f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4eb05e52-90de-4e28-853c-1605cb679f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_06d26d66-29da-4a60-8a84-1fa7b0d78cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LineOfCredit_06d26d66-29da-4a60-8a84-1fa7b0d78cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_1cce002c-70a1-44d9-872f-ee52727be5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_1cce002c-70a1-44d9-872f-ee52727be5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_43b0f87a-2c94-4aa1-84e9-a12949b932ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_43b0f87a-2c94-4aa1-84e9-a12949b932ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_167aaf69-2248-40f5-8a8e-5105956bace6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_167aaf69-2248-40f5-8a8e-5105956bace6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2b7f90cb-ded1-497a-a9b5-825982e8e52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_657e9e40-507a-4385-8392-a5f9a3472e10" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2b7f90cb-ded1-497a-a9b5-825982e8e52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#DebtRevolvingCreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7decdf07-5fac-450a-9e69-765163f78de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_0f049b3c-9163-420a-bfbc-f4004d3f6d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7decdf07-5fac-450a-9e69-765163f78de4" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_0f049b3c-9163-420a-bfbc-f4004d3f6d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9d9c02a2-ed9d-40e4-830f-9473a417b226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0f049b3c-9163-420a-bfbc-f4004d3f6d33" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9d9c02a2-ed9d-40e4-830f-9473a417b226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d60dd216-e61d-4fef-9422-ed2d346aa07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9d9c02a2-ed9d-40e4-830f-9473a417b226" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d60dd216-e61d-4fef-9422-ed2d346aa07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_607cd4cf-87d9-4e14-b5bf-a32fed7980ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d60dd216-e61d-4fef-9422-ed2d346aa07b" xlink:to="loc_us-gaap_LineOfCreditMember_607cd4cf-87d9-4e14-b5bf-a32fed7980ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_0f049b3c-9163-420a-bfbc-f4004d3f6d33" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_ad95b200-d80c-4bca-8acd-7360971bdaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:to="loc_us-gaap_DebtInstrumentTerm_ad95b200-d80c-4bca-8acd-7360971bdaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6d6723e0-c698-4ead-b880-4ca1f9817c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6d6723e0-c698-4ead-b880-4ca1f9817c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount_9a81fcb3-89c7-420f-9e06-eaec4a252b58" xlink:href="dxcm-20231231.xsd#dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:to="loc_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount_9a81fcb3-89c7-420f-9e06-eaec4a252b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositAssets_433e72e8-6503-4d23-820f-0a66ced1c95a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_c455b3b1-8b7c-4b91-82c5-e3595f95ff8b" xlink:to="loc_us-gaap_DepositAssets_433e72e8-6503-4d23-820f-0a66ced1c95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_636d3ede-6fc6-41e1-9c2c-eed23ff6981b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_71dfdd60-b80a-4de4-997a-deb3c9b81a84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_636d3ede-6fc6-41e1-9c2c-eed23ff6981b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_71dfdd60-b80a-4de4-997a-deb3c9b81a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00cacbb9-d35b-48d8-8f9e-b0cbf4c6fec0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_71dfdd60-b80a-4de4-997a-deb3c9b81a84" xlink:to="loc_srt_RangeAxis_00cacbb9-d35b-48d8-8f9e-b0cbf4c6fec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37828310-e7d2-4187-82f9-74f50d5b6725" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_00cacbb9-d35b-48d8-8f9e-b0cbf4c6fec0" xlink:to="loc_srt_RangeMember_37828310-e7d2-4187-82f9-74f50d5b6725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f0d7bb8f-6b10-4f79-bf25-dd906be85e44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37828310-e7d2-4187-82f9-74f50d5b6725" xlink:to="loc_srt_MaximumMember_f0d7bb8f-6b10-4f79-bf25-dd906be85e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5a8805f-30c9-4270-91c8-bc4ebb6c3682" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37828310-e7d2-4187-82f9-74f50d5b6725" xlink:to="loc_srt_MinimumMember_e5a8805f-30c9-4270-91c8-bc4ebb6c3682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_71dfdd60-b80a-4de4-997a-deb3c9b81a84" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_61fa068c-8c2c-4c1b-9f56-6fd42cd70d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_61fa068c-8c2c-4c1b-9f56-6fd42cd70d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend_6c736b30-5635-4136-831f-945f213c8947" xlink:href="dxcm-20231231.xsd#dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend_6c736b30-5635-4136-831f-945f213c8947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_60b61059-5a0c-4aba-a577-d95bc79477e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_60b61059-5a0c-4aba-a577-d95bc79477e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_29bd88ff-25ce-4246-b78d-1e03c0cf7c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_29bd88ff-25ce-4246-b78d-1e03c0cf7c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation_78398542-89b9-4c15-9437-6b8a25f7394e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetRetirementObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_AssetRetirementObligation_78398542-89b9-4c15-9437-6b8a25f7394e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e35a3641-0d38-4aaa-b63f-38865737ab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e35a3641-0d38-4aaa-b63f-38865737ab9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_30e7b1ee-4d08-4b94-9710-599928473745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_30e7b1ee-4d08-4b94-9710-599928473745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ImpairedLongLivedAssetsFairValue_fd80648e-24d0-480d-963c-5daa5ff91191" xlink:href="dxcm-20231231.xsd#dxcm_ImpairedLongLivedAssetsFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_dxcm_ImpairedLongLivedAssetsFairValue_fd80648e-24d0-480d-963c-5daa5ff91191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_LesseeOperatingLeasesLeaseCostAmortization_3a5c858c-d965-4401-a06b-5f1ad16fe277" xlink:href="dxcm-20231231.xsd#dxcm_LesseeOperatingLeasesLeaseCostAmortization"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_dxcm_LesseeOperatingLeasesLeaseCostAmortization_3a5c858c-d965-4401-a06b-5f1ad16fe277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_5ad6f569-ec8b-4fe8-8d54-283b51d5fa16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_5ad6f569-ec8b-4fe8-8d54-283b51d5fa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm_7e24595e-584a-483f-a417-dd4a9b19563b" xlink:href="dxcm-20231231.xsd#dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b3b15d0f-1c4e-41bf-9c64-52cf82dc4b46" xlink:to="loc_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm_7e24595e-584a-483f-a417-dd4a9b19563b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1fd3233a-fe3a-4fb4-bf45-fae9eec42f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1fd3233a-fe3a-4fb4-bf45-fae9eec42f5e" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ec0bd1f9-0461-4e55-92b1-5469864aa0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ec0bd1f9-0461-4e55-92b1-5469864aa0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5b6cda06-392e-4a6c-85c4-1d25abb5c4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5b6cda06-392e-4a6c-85c4-1d25abb5c4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4d542292-5517-48fa-817a-d03c8655a97e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4d542292-5517-48fa-817a-d03c8655a97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2024ae9c-07f2-4a21-bf30-bbd9dadf5230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2024ae9c-07f2-4a21-bf30-bbd9dadf5230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_182b565f-394b-4bd8-b49a-6ba5dce4526a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_182b565f-394b-4bd8-b49a-6ba5dce4526a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e37c1caa-e012-4846-b58f-0deede53f1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e37c1caa-e012-4846-b58f-0deede53f1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dba172ef-4fb0-410f-b5a1-80328fa61fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dba172ef-4fb0-410f-b5a1-80328fa61fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cdf2e18f-45cd-41d3-b4db-24df25184836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cdf2e18f-45cd-41d3-b4db-24df25184836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_daa5d989-dda7-4caf-acce-a883762752e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_OperatingLeaseLiability_daa5d989-dda7-4caf-acce-a883762752e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_12212fea-4771-4554-b82f-6760c2a26afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_12212fea-4771-4554-b82f-6760c2a26afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_09a7afa8-30ac-41cd-b413-9b84594d69d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0b34cd7-2bbe-489e-a0c5-1eab896ff8a3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_09a7afa8-30ac-41cd-b413-9b84594d69d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1fd3233a-fe3a-4fb4-bf45-fae9eec42f5e" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d6cf6518-3f15-4280-808b-002acbce4d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d6cf6518-3f15-4280-808b-002acbce4d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1b06fb6b-a608-4b18-a393-ab5c5327c169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1b06fb6b-a608-4b18-a393-ab5c5327c169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9355dcec-09f3-45e7-8414-5edb5b0c85b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_9355dcec-09f3-45e7-8414-5edb5b0c85b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a538e847-2876-4779-95ae-9c1b64f99cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a538e847-2876-4779-95ae-9c1b64f99cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_017aadea-9757-4967-b998-c2feed202e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_017aadea-9757-4967-b998-c2feed202e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_25121cf4-489a-4d78-9b9f-f5ad3338cd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_25121cf4-489a-4d78-9b9f-f5ad3338cd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b4424250-d3b1-4173-9033-c79dd38afde1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b4424250-d3b1-4173-9033-c79dd38afde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f59eaa12-1f5d-4509-9ea7-3eba6ea73d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f59eaa12-1f5d-4509-9ea7-3eba6ea73d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_a62f4c12-1605-43bd-9c0e-c838b1c1c040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiability_a62f4c12-1605-43bd-9c0e-c838b1c1c040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_7010a297-4549-45b3-9e38-fff7e6f2af1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_7010a297-4549-45b3-9e38-fff7e6f2af1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_75bd1c98-6e71-4da5-9007-ee216fec762d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_650a2cce-9382-4925-9586-455780b44b4d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_75bd1c98-6e71-4da5-9007-ee216fec762d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2593f839-702e-472b-a35c-0e572fe49f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1fd3233a-fe3a-4fb4-bf45-fae9eec42f5e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2593f839-702e-472b-a35c-0e572fe49f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4c1f8021-abdc-4810-86c3-0c13ccc68ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_a9a6e484-5744-4abc-9232-34d9f576da5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4c1f8021-abdc-4810-86c3-0c13ccc68ab8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_a9a6e484-5744-4abc-9232-34d9f576da5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9f378a32-6e04-4908-b88d-7da26193cc93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_a9a6e484-5744-4abc-9232-34d9f576da5a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9f378a32-6e04-4908-b88d-7da26193cc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_bc71e16e-1d8c-419a-8921-afd6dc5611ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_a9a6e484-5744-4abc-9232-34d9f576da5a" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_bc71e16e-1d8c-419a-8921-afd6dc5611ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_78397f2b-4a9d-4b07-9d32-c2688eb4e2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4c1f8021-abdc-4810-86c3-0c13ccc68ab8" xlink:to="loc_us-gaap_OperatingLeaseCost_78397f2b-4a9d-4b07-9d32-c2688eb4e2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_8fde5721-6e6b-43d4-98fd-38a4a804a104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4c1f8021-abdc-4810-86c3-0c13ccc68ab8" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_8fde5721-6e6b-43d4-98fd-38a4a804a104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_0441fa75-cba8-4839-b8b4-ca0b1455da34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4c1f8021-abdc-4810-86c3-0c13ccc68ab8" xlink:to="loc_us-gaap_ShortTermLeaseCost_0441fa75-cba8-4839-b8b4-ca0b1455da34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_7d9e1ab1-0136-4e3b-88e1-1900675efaee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4c1f8021-abdc-4810-86c3-0c13ccc68ab8" xlink:to="loc_us-gaap_VariableLeaseCost_7d9e1ab1-0136-4e3b-88e1-1900675efaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_e9f033d0-fdc2-4ad4-b9de-edc3c2ac5ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4c1f8021-abdc-4810-86c3-0c13ccc68ab8" xlink:to="loc_us-gaap_LeaseCost_e9f033d0-fdc2-4ad4-b9de-edc3c2ac5ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#LeasesandOtherCommitmentsOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5daa19b9-b15a-4fdc-82b3-32bc79198255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:to="loc_us-gaap_OperatingLeasePayments_5daa19b9-b15a-4fdc-82b3-32bc79198255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_a618ae76-9703-48e8-92d0-52d9123cfdef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_a618ae76-9703-48e8-92d0-52d9123cfdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_70caa1e6-272d-4496-ab4d-6a0a0cc73d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_70caa1e6-272d-4496-ab4d-6a0a0cc73d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5c85f854-a5fc-4387-a3da-cafd52eed56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5c85f854-a5fc-4387-a3da-cafd52eed56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e67fc664-7a2f-466c-94bb-3c6494bb112a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e67fc664-7a2f-466c-94bb-3c6494bb112a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_99380ea2-4c8d-4d83-81e3-8c8ed0f3a496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_99380ea2-4c8d-4d83-81e3-8c8ed0f3a496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c0642cab-bbb9-4f9d-b42f-a9d694b47e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c0642cab-bbb9-4f9d-b42f-a9d694b47e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fdff2768-44b9-4504-8bb6-0d909b0faffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fdff2768-44b9-4504-8bb6-0d909b0faffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_64a20f5d-93f4-49bd-8a5b-34ae34f867ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08dbda5b-831b-42ca-90c4-e511edfff4a7" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_64a20f5d-93f4-49bd-8a5b-34ae34f867ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5d28c-fbdb-43e6-a06c-25a07ee3b50e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1c8935d3-29f1-47d6-ba98-c85984fc02a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5d28c-fbdb-43e6-a06c-25a07ee3b50e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1c8935d3-29f1-47d6-ba98-c85984fc02a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_19a0c950-3eff-45ed-bfee-73e61f3d0646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5d28c-fbdb-43e6-a06c-25a07ee3b50e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_19a0c950-3eff-45ed-bfee-73e61f3d0646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_93a4833b-8b00-46b2-bf8c-cb110bd9845c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c8b5d28c-fbdb-43e6-a06c-25a07ee3b50e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_93a4833b-8b00-46b2-bf8c-cb110bd9845c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_62d7e7c1-e34d-4a8f-b752-03040ad647e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7bac1c44-50f3-4a8e-8550-31ce94fea3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62d7e7c1-e34d-4a8f-b752-03040ad647e9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7bac1c44-50f3-4a8e-8550-31ce94fea3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d1581d6c-462c-46bc-837a-1a21bdd418a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7bac1c44-50f3-4a8e-8550-31ce94fea3bb" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d1581d6c-462c-46bc-837a-1a21bdd418a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8de5ce12-9f06-40e4-a3c8-8e7f1d73bed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7bac1c44-50f3-4a8e-8550-31ce94fea3bb" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8de5ce12-9f06-40e4-a3c8-8e7f1d73bed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_701fed32-3746-41d1-b459-f47dc45dc0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7bac1c44-50f3-4a8e-8550-31ce94fea3bb" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_701fed32-3746-41d1-b459-f47dc45dc0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_516aedae-fd6c-49ea-a9d0-1c1012441aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7bac1c44-50f3-4a8e-8550-31ce94fea3bb" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_516aedae-fd6c-49ea-a9d0-1c1012441aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c0dc78f-527a-46a4-a35e-72a3fecfd054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62d7e7c1-e34d-4a8f-b752-03040ad647e9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c0dc78f-527a-46a4-a35e-72a3fecfd054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_af2973f0-bf41-41ad-b3a6-cbe2013eb2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c0dc78f-527a-46a4-a35e-72a3fecfd054" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_af2973f0-bf41-41ad-b3a6-cbe2013eb2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10f53d76-c416-4eb1-8052-db78b2c67966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c0dc78f-527a-46a4-a35e-72a3fecfd054" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10f53d76-c416-4eb1-8052-db78b2c67966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_744195a4-09fe-4b1f-8da9-fb5344a87622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c0dc78f-527a-46a4-a35e-72a3fecfd054" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_744195a4-09fe-4b1f-8da9-fb5344a87622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_beec2413-2c49-4ded-b1be-db8a4dc6cfee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6c0dc78f-527a-46a4-a35e-72a3fecfd054" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_beec2413-2c49-4ded-b1be-db8a4dc6cfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01131759-1f7f-4d45-88c3-3e9bc1c79f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62d7e7c1-e34d-4a8f-b752-03040ad647e9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_01131759-1f7f-4d45-88c3-3e9bc1c79f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5724b32d-3eaf-4025-906b-a999266f7ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5724b32d-3eaf-4025-906b-a999266f7ba7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_267e92e7-fec9-44e7-a737-c8a873c180e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_267e92e7-fec9-44e7-a737-c8a873c180e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_267e92e7-fec9-44e7-a737-c8a873c180e9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4cf9ebff-ee05-4bc5-8b60-08326ff34965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:to="loc_us-gaap_DomesticCountryMember_4cf9ebff-ee05-4bc5-8b60-08326ff34965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_dd25d71b-48d7-460a-afb2-2522070d2555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_dd25d71b-48d7-460a-afb2-2522070d2555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_53e9468c-5bc3-442b-ae2a-83d4d0671d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_dfc3a329-573d-47d3-b540-6ee8b5916640" xlink:to="loc_us-gaap_ForeignCountryMember_53e9468c-5bc3-442b-ae2a-83d4d0671d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_08a27bf9-4a61-49ec-9070-dd0bea2f6947" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:to="loc_srt_StatementGeographicalAxis_08a27bf9-4a61-49ec-9070-dd0bea2f6947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_08a27bf9-4a61-49ec-9070-dd0bea2f6947" xlink:to="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_aaf4b395-c9e1-4c08-8922-0f597a8a0353" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:to="loc_stpr_CA_aaf4b395-c9e1-4c08-8922-0f597a8a0353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherStatesMember_d10df970-8b07-4ef2-bbab-4bb219841194" xlink:href="dxcm-20231231.xsd#dxcm_OtherStatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:to="loc_dxcm_OtherStatesMember_d10df970-8b07-4ef2-bbab-4bb219841194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_36cde68b-d946-41e2-94b2-29b8058fd2f6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:to="loc_country_GB_36cde68b-d946-41e2-94b2-29b8058fd2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherForeignMember_d123b5c7-5c39-4950-a4d7-516679d16a31" xlink:href="dxcm-20231231.xsd#dxcm_OtherForeignMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_54595b0b-b2ee-4064-9165-148c6736752d" xlink:to="loc_dxcm_OtherForeignMember_d123b5c7-5c39-4950-a4d7-516679d16a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_d3dfd9ff-e4f5-45d6-8336-27e57e407c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_d3dfd9ff-e4f5-45d6-8336-27e57e407c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d3dfd9ff-e4f5-45d6-8336-27e57e407c5a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ResearchDevelopmentTaxCreditsMember_908cb467-4eff-4996-b5f1-5992519dc6f2" xlink:href="dxcm-20231231.xsd#dxcm_ResearchDevelopmentTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:to="loc_dxcm_ResearchDevelopmentTaxCreditsMember_908cb467-4eff-4996-b5f1-5992519dc6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ForeignTaxCreditsMember_ec3084de-4c72-4367-9b2b-418a63616096" xlink:href="dxcm-20231231.xsd#dxcm_ForeignTaxCreditsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:to="loc_dxcm_ForeignTaxCreditsMember_ec3084de-4c72-4367-9b2b-418a63616096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AMTTaxCreditsMember_a077c29a-d7d1-40d7-b64d-774f941e7e18" xlink:href="dxcm-20231231.xsd#dxcm_AMTTaxCreditsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_d651aa8b-87d9-455f-b916-26a240bbc32a" xlink:to="loc_dxcm_AMTTaxCreditsMember_a077c29a-d7d1-40d7-b64d-774f941e7e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_125f242e-bccc-4119-8e3a-7487fdc62995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_56169fd9-08a8-4164-ba1e-0d7d6a89a2c0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_125f242e-bccc-4119-8e3a-7487fdc62995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_87ed697f-6c0c-468c-b376-bb77c8ebed53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_125f242e-bccc-4119-8e3a-7487fdc62995" xlink:to="loc_us-gaap_OperatingLossCarryforwards_87ed697f-6c0c-468c-b376-bb77c8ebed53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_463e9059-ac0e-4f1b-a3dc-78ed098b45a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_125f242e-bccc-4119-8e3a-7487fdc62995" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_463e9059-ac0e-4f1b-a3dc-78ed098b45a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3e3dc146-3eb7-491f-a350-6e450111284d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_518ef6bb-c823-4dc3-b6f3-3320d5d0025f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e3dc146-3eb7-491f-a350-6e450111284d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_518ef6bb-c823-4dc3-b6f3-3320d5d0025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d8d4375c-f620-4e9a-bd86-912906058d07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_518ef6bb-c823-4dc3-b6f3-3320d5d0025f" xlink:to="loc_srt_StatementGeographicalAxis_d8d4375c-f620-4e9a-bd86-912906058d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e1946713-79b5-4875-941d-b72d625954c4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d8d4375c-f620-4e9a-bd86-912906058d07" xlink:to="loc_srt_SegmentGeographicalDomain_e1946713-79b5-4875-941d-b72d625954c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_0ac0f9b2-173c-4445-bd5d-0fc5c61ec8ba" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e1946713-79b5-4875-941d-b72d625954c4" xlink:to="loc_stpr_CA_0ac0f9b2-173c-4445-bd5d-0fc5c61ec8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_518ef6bb-c823-4dc3-b6f3-3320d5d0025f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_UnusedExpiredFederalIncomeTaxCredits_29155b97-2c3f-4b55-9a00-09592561b599" xlink:href="dxcm-20231231.xsd#dxcm_UnusedExpiredFederalIncomeTaxCredits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_dxcm_UnusedExpiredFederalIncomeTaxCredits_29155b97-2c3f-4b55-9a00-09592561b599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_24a876d9-3128-4ead-87e0-e637fd8e6717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_24a876d9-3128-4ead-87e0-e637fd8e6717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_87b0f2df-39db-4b78-94e5-b2bd7fdfd3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_87b0f2df-39db-4b78-94e5-b2bd7fdfd3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_21a439d3-1d97-4d41-819b-a12c255d7a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_21a439d3-1d97-4d41-819b-a12c255d7a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5ccaf641-9ba4-47ce-9c9c-5f6bba18faaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5ccaf641-9ba4-47ce-9c9c-5f6bba18faaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets_47332410-75be-4b1d-905c-add192f865e2" xlink:href="dxcm-20231231.xsd#dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets_47332410-75be-4b1d-905c-add192f865e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PossibleExtensionPeriodofTaxHoliday_d234a927-89a9-424c-9072-a5bf9e3a90c8" xlink:href="dxcm-20231231.xsd#dxcm_PossibleExtensionPeriodofTaxHoliday"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_dxcm_PossibleExtensionPeriodofTaxHoliday_d234a927-89a9-424c-9072-a5bf9e3a90c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PreferentialTaxRatePeriod_4638e497-fa90-496a-bdb7-853786d3a675" xlink:href="dxcm-20231231.xsd#dxcm_PreferentialTaxRatePeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_dxcm_PreferentialTaxRatePeriod_4638e497-fa90-496a-bdb7-853786d3a675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_7a1b4a88-82f0-4478-9d58-7808844f67d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12afdc9d-b88b-4884-bb87-2660dfc96e67" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_7a1b4a88-82f0-4478-9d58-7808844f67d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_673c5aee-c3a1-4654-a9b8-99791cf69526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_673c5aee-c3a1-4654-a9b8-99791cf69526" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_31d651e3-c548-4edd-a58e-922c00c3ac23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_31d651e3-c548-4edd-a58e-922c00c3ac23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6320f454-0ba4-402c-821e-85d5ea9532b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6320f454-0ba4-402c-821e-85d5ea9532b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c50861c8-a14f-45ac-967f-9000a7002a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c50861c8-a14f-45ac-967f-9000a7002a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5d6ff334-c986-48ca-918e-0c0446c74b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5d6ff334-c986-48ca-918e-0c0446c74b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_cdf6b904-6e0a-47c2-be7f-b5a65eb1804b" xlink:href="dxcm-20231231.xsd#dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_cdf6b904-6e0a-47c2-be7f-b5a65eb1804b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_5c6442fc-9067-4578-b2f4-13c30a0c0439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_5c6442fc-9067-4578-b2f4-13c30a0c0439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredTaxAssetsConvertibleDebt_4e9eb1ea-0d45-43af-8827-bbfe33fddf0e" xlink:href="dxcm-20231231.xsd#dxcm_DeferredTaxAssetsConvertibleDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_dxcm_DeferredTaxAssetsConvertibleDebt_4e9eb1ea-0d45-43af-8827-bbfe33fddf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0aa0f41a-e70c-4bfa-9265-e4dcd44352db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0aa0f41a-e70c-4bfa-9265-e4dcd44352db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4a9adcb8-a8b8-4703-a888-cb0e41003b90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4a9adcb8-a8b8-4703-a888-cb0e41003b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_29947626-137d-4d9b-9b92-405cdf8747d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ea1cf013-1b29-416a-b856-18ff532206fb" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_29947626-137d-4d9b-9b92-405cdf8747d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_508d7ee4-493c-4e3b-87f0-1916e4085da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_673c5aee-c3a1-4654-a9b8-99791cf69526" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_508d7ee4-493c-4e3b-87f0-1916e4085da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_4aee415f-77fc-4521-a47e-591fea5a7f3b" xlink:href="dxcm-20231231.xsd#dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_508d7ee4-493c-4e3b-87f0-1916e4085da3" xlink:to="loc_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_4aee415f-77fc-4521-a47e-591fea5a7f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3e469c6b-723b-48b7-9b23-f2982a768843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_508d7ee4-493c-4e3b-87f0-1916e4085da3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3e469c6b-723b-48b7-9b23-f2982a768843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2a077a1e-a873-4659-995c-e1a489ac36e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_508d7ee4-493c-4e3b-87f0-1916e4085da3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2a077a1e-a873-4659-995c-e1a489ac36e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d2b8308c-6330-4864-b977-6d68186f8d13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_673c5aee-c3a1-4654-a9b8-99791cf69526" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d2b8308c-6330-4864-b977-6d68186f8d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_30ea08c2-407a-47d1-b3ba-24424341691d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30ea08c2-407a-47d1-b3ba-24424341691d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f4a648b8-d6ad-431a-9bcd-33d0cb24489d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_f4a648b8-d6ad-431a-9bcd-33d0cb24489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_b8f9f2ac-c9e9-403e-beef-941cf5c3ca45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_b8f9f2ac-c9e9-403e-beef-941cf5c3ca45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EffectiveIncomeTaxReconciliationPermanentItems_e6285c36-4d36-4515-abb6-1d43135217b2" xlink:href="dxcm-20231231.xsd#dxcm_EffectiveIncomeTaxReconciliationPermanentItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_dxcm_EffectiveIncomeTaxReconciliationPermanentItems_e6285c36-4d36-4515-abb6-1d43135217b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_db07f269-27b8-45d4-b72d-30451c2f2cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_db07f269-27b8-45d4-b72d-30451c2f2cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_1c938757-1685-42f1-9585-8f15e20fe30c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_1c938757-1685-42f1-9585-8f15e20fe30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_a6e7f6fa-ce9f-4e50-9ec0-2d9e15ca3180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_a6e7f6fa-ce9f-4e50-9ec0-2d9e15ca3180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_89c1b2cd-1d8e-4078-8dd9-8808bcf58b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_89c1b2cd-1d8e-4078-8dd9-8808bcf58b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment_d0c732c3-1ef5-4e94-ab08-3be7ee9d22af" xlink:href="dxcm-20231231.xsd#dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment_d0c732c3-1ef5-4e94-ab08-3be7ee9d22af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_c970ab29-491d-4adf-8d54-a24c1a0d9b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_c970ab29-491d-4adf-8d54-a24c1a0d9b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_913e2d8f-2329-4f67-baa2-d6f24930d8d9" xlink:href="dxcm-20231231.xsd#dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_913e2d8f-2329-4f67-baa2-d6f24930d8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_78c595f4-b477-40af-9472-16ad6443f857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_78c595f4-b477-40af-9472-16ad6443f857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0d24a00-3715-44e0-a526-6d89b7c57549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0d24a00-3715-44e0-a526-6d89b7c57549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f494302f-ff2a-492f-b21b-095bdb4a23a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54d48f98-060d-484e-bdd9-d84e46cbf878" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f494302f-ff2a-492f-b21b-095bdb4a23a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e24174c9-4ded-414d-a82b-2c6fcf260efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_760436b2-1382-4e46-bacf-21fec6666a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e24174c9-4ded-414d-a82b-2c6fcf260efc" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_760436b2-1382-4e46-bacf-21fec6666a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2a4b8b5d-fd39-4092-9671-4dc6bc764de5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_760436b2-1382-4e46-bacf-21fec6666a07" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2a4b8b5d-fd39-4092-9671-4dc6bc764de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5e22eec8-9c0a-426e-8436-e6552619b7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_760436b2-1382-4e46-bacf-21fec6666a07" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5e22eec8-9c0a-426e-8436-e6552619b7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_61fa970c-ff8c-4be0-bb0b-fe746a69f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_760436b2-1382-4e46-bacf-21fec6666a07" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_61fa970c-ff8c-4be0-bb0b-fe746a69f2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_82d4515f-2280-411e-b8b9-edc5852d64fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_760436b2-1382-4e46-bacf-21fec6666a07" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_82d4515f-2280-411e-b8b9-edc5852d64fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3d3a8b20-bf53-4034-aa80-ba73326e21fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_760436b2-1382-4e46-bacf-21fec6666a07" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3d3a8b20-bf53-4034-aa80-ba73326e21fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87d6aa50-3883-4301-a0d8-89ec8d470c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87d6aa50-3883-4301-a0d8-89ec8d470c52" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0af3ed74-92ee-45d0-b20e-99b8d258a397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:to="loc_us-gaap_AwardTypeAxis_0af3ed74-92ee-45d0-b20e-99b8d258a397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86da479e-eaa9-4a2f-8778-d006827a8e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0af3ed74-92ee-45d0-b20e-99b8d258a397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86da479e-eaa9-4a2f-8778-d006827a8e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_ac4f24a3-8c20-452c-be56-975ca13d1b21" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86da479e-eaa9-4a2f-8778-d006827a8e2d" xlink:to="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_ac4f24a3-8c20-452c-be56-975ca13d1b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f9eb01bd-fc59-41d7-a148-7588e1fa84c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_ac4f24a3-8c20-452c-be56-975ca13d1b21" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f9eb01bd-fc59-41d7-a148-7588e1fa84c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5de0b061-f8d2-4e12-a294-1a155ac3a647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_ac4f24a3-8c20-452c-be56-975ca13d1b21" xlink:to="loc_us-gaap_PerformanceSharesMember_5de0b061-f8d2-4e12-a294-1a155ac3a647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1dfa5d47-93f2-4d74-8b94-0a2a8f3e44e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:to="loc_us-gaap_PlanNameAxis_1dfa5d47-93f2-4d74-8b94-0a2a8f3e44e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1dfa5d47-93f2-4d74-8b94-0a2a8f3e44e2" xlink:to="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A401kPlanMember_0f3ab942-2635-4915-b766-3b15c9f68b21" xlink:href="dxcm-20231231.xsd#dxcm_A401kPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:to="loc_dxcm_A401kPlanMember_0f3ab942-2635-4915-b766-3b15c9f68b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeeStockPurchasePlan2015Member_95620265-c81b-443a-8430-e0972659cd10" xlink:href="dxcm-20231231.xsd#dxcm_EmployeeStockPurchasePlan2015Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:to="loc_dxcm_EmployeeStockPurchasePlan2015Member_95620265-c81b-443a-8430-e0972659cd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EquityIncentivePlan2015Member_da7a25fe-ec5c-4a5a-9477-6c6dc97348e1" xlink:href="dxcm-20231231.xsd#dxcm_EquityIncentivePlan2015Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97fdeb46-69fc-47fa-9b4a-a7f6913ef138" xlink:to="loc_dxcm_EquityIncentivePlan2015Member_da7a25fe-ec5c-4a5a-9477-6c6dc97348e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5cc3b6a7-6b03-43ea-9617-9a5ab4a0adb1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:to="loc_srt_RangeAxis_5cc3b6a7-6b03-43ea-9617-9a5ab4a0adb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07c4427e-152b-48ec-b121-cd21212a66c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5cc3b6a7-6b03-43ea-9617-9a5ab4a0adb1" xlink:to="loc_srt_RangeMember_07c4427e-152b-48ec-b121-cd21212a66c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_68205224-3946-44d9-b4bc-df88b83734bf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07c4427e-152b-48ec-b121-cd21212a66c8" xlink:to="loc_srt_MinimumMember_68205224-3946-44d9-b4bc-df88b83734bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_283b28ab-e355-4851-bd8c-ace0cc508290" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07c4427e-152b-48ec-b121-cd21212a66c8" xlink:to="loc_srt_MaximumMember_283b28ab-e355-4851-bd8c-ace0cc508290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_3489b6f0-67f0-45c1-8f6b-be79b2f1c5af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_3489b6f0-67f0-45c1-8f6b-be79b2f1c5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_c25673f9-0db2-4abd-bac7-5b9fad61bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3489b6f0-67f0-45c1-8f6b-be79b2f1c5af" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_c25673f9-0db2-4abd-bac7-5b9fad61bb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ShareRepurchaseProgramMember_e86f4e4b-cc5e-4148-89b9-01f742980414" xlink:href="dxcm-20231231.xsd#dxcm_ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_c25673f9-0db2-4abd-bac7-5b9fad61bb09" xlink:to="loc_dxcm_ShareRepurchaseProgramMember_e86f4e4b-cc5e-4148-89b9-01f742980414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AcceleratedShareRepurchaseASRMember_d5bcad0b-4d0e-4d61-8c30-b7bbc3190f9a" xlink:href="dxcm-20231231.xsd#dxcm_AcceleratedShareRepurchaseASRMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_c25673f9-0db2-4abd-bac7-5b9fad61bb09" xlink:to="loc_dxcm_AcceleratedShareRepurchaseASRMember_d5bcad0b-4d0e-4d61-8c30-b7bbc3190f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b822515-c308-4a8b-9055-48c0cf2f215e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0264d527-6f3c-438d-9869-c4433a6ee290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_0264d527-6f3c-438d-9869-c4433a6ee290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_67e5be6b-0304-47b5-a28f-ee75e2d385b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_67e5be6b-0304-47b5-a28f-ee75e2d385b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6a04bba0-a193-454b-a3ed-588243014205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6a04bba0-a193-454b-a3ed-588243014205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_c98a2384-43d9-4550-87de-6efc92679c20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_c98a2384-43d9-4550-87de-6efc92679c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_79167e50-9de0-4c65-bf2b-90fb6b61649f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_79167e50-9de0-4c65-bf2b-90fb6b61649f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeePurchasePriceFloorPercentage_91e790de-31da-4961-a801-e5fefa5b013a" xlink:href="dxcm-20231231.xsd#dxcm_EmployeePurchasePriceFloorPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_dxcm_EmployeePurchasePriceFloorPercentage_91e790de-31da-4961-a801-e5fefa5b013a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized_c8f51fb7-9833-40a6-a1fa-01e81b61b14a" xlink:href="dxcm-20231231.xsd#dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized_c8f51fb7-9833-40a6-a1fa-01e81b61b14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_160213f6-4d37-488f-8833-c9b28232e1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_160213f6-4d37-488f-8833-c9b28232e1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_813a896c-9ce6-4c1f-8aea-539498088df2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_813a896c-9ce6-4c1f-8aea-539498088df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_85fe4ea9-7684-4e66-add9-04b5e2f90dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_85fe4ea9-7684-4e66-add9-04b5e2f90dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e8acc8a-5429-4aee-84c1-4a8356254309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e8acc8a-5429-4aee-84c1-4a8356254309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_25ff8bf3-d63f-4609-83a8-0b7ca6cbbe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_25ff8bf3-d63f-4609-83a8-0b7ca6cbbe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_52922732-b1f0-44ad-9b4c-bf0947c5f0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_52922732-b1f0-44ad-9b4c-bf0947c5f0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount_67a6a2e5-e8f5-4b47-a2db-6b82e06e4727" xlink:href="dxcm-20231231.xsd#dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount_67a6a2e5-e8f5-4b47-a2db-6b82e06e4727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_810d8671-d87c-4b93-95b9-5425bb63bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_810d8671-d87c-4b93-95b9-5425bb63bf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_81d5c914-4db8-4bfb-824b-59bb31ab4fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_81d5c914-4db8-4bfb-824b-59bb31ab4fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6de78c79-66a1-4a9c-b8b6-446a84e3b0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6de78c79-66a1-4a9c-b8b6-446a84e3b0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_e586b226-a519-4d6a-b101-11c8fe119905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_e586b226-a519-4d6a-b101-11c8fe119905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_736d9038-70a4-40cc-aba1-9f3a313c4ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_736d9038-70a4-40cc-aba1-9f3a313c4ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c1ba3d43-e2be-45b7-9ac9-34a4ecd02eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c1ba3d43-e2be-45b7-9ac9-34a4ecd02eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0abdb48a-16b1-4cd2-bca9-7f73918fcb91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0abdb48a-16b1-4cd2-bca9-7f73918fcb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_76a5a4b7-24e4-4a29-a2b0-11280d138544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5a78b1d-b42b-4b91-b5ff-0b24faeeeb68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_76a5a4b7-24e4-4a29-a2b0-11280d138544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_654116a3-d88e-4616-b172-ebcc0889b8be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41fd38e9-10e8-4155-9c74-350bc1b59bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_654116a3-d88e-4616-b172-ebcc0889b8be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41fd38e9-10e8-4155-9c74-350bc1b59bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d58c4648-759b-4ad6-9ec3-85e0c0c8e095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41fd38e9-10e8-4155-9c74-350bc1b59bde" xlink:to="loc_us-gaap_PlanNameAxis_d58c4648-759b-4ad6-9ec3-85e0c0c8e095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d58c4648-759b-4ad6-9ec3-85e0c0c8e095" xlink:to="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A2022ShareRepurchaseProgramMember_61628bd3-dda2-4188-9882-3340b1391fa8" xlink:href="dxcm-20231231.xsd#dxcm_A2022ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:to="loc_dxcm_A2022ShareRepurchaseProgramMember_61628bd3-dda2-4188-9882-3340b1391fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A2023ShareRepurchaseProgramMember_dc2f3ce8-3340-4d8f-aabb-0410b6a4d7cd" xlink:href="dxcm-20231231.xsd#dxcm_A2023ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:to="loc_dxcm_A2023ShareRepurchaseProgramMember_dc2f3ce8-3340-4d8f-aabb-0410b6a4d7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_A2028NotesMember_e6310de4-9578-4f19-bace-8997388beb63" xlink:href="dxcm-20231231.xsd#dxcm_A2028NotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_97544111-98da-4aa9-b11e-e7fc383f211a" xlink:to="loc_dxcm_A2028NotesMember_e6310de4-9578-4f19-bace-8997388beb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6916be7-d26f-46f5-b4e8-26dc21a70615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_41fd38e9-10e8-4155-9c74-350bc1b59bde" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6916be7-d26f-46f5-b4e8-26dc21a70615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:href="dxcm-20231231.xsd#dxcm_IncreaseDecreaseInTreasuryStockRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6916be7-d26f-46f5-b4e8-26dc21a70615" xlink:to="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a8fe8d50-5d05-487e-8c0c-60235813a007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a8fe8d50-5d05-487e-8c0c-60235813a007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge_04e906eb-6f73-40c5-9fd0-da9541745f53" xlink:href="dxcm-20231231.xsd#dxcm_SharesReceivedFromExerciseOfNoteHedge"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:to="loc_dxcm_SharesReceivedFromExerciseOfNoteHedge_04e906eb-6f73-40c5-9fd0-da9541745f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_7654162b-a717-4758-829f-98f62e46a46d" xlink:href="dxcm-20231231.xsd#dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:to="loc_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone_7654162b-a717-4758-829f-98f62e46a46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_75ddcb8c-10a6-4449-9c8d-819720d2b346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_IncreaseDecreaseInTreasuryStockRollForward_db1bd14e-4fe3-47aa-a91a-2349501f0f59" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_75ddcb8c-10a6-4449-9c8d-819720d2b346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e978e501-8664-4a68-bc9a-a36975c49aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44972f10-3598-4b7c-9451-e680c83484da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e978e501-8664-4a68-bc9a-a36975c49aba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44972f10-3598-4b7c-9451-e680c83484da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_438b45a6-4d0c-4d0d-adde-5bf4156633b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44972f10-3598-4b7c-9451-e680c83484da" xlink:to="loc_us-gaap_PlanNameAxis_438b45a6-4d0c-4d0d-adde-5bf4156633b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_66b35b54-5a8d-4b8a-940e-231d231718d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_438b45a6-4d0c-4d0d-adde-5bf4156633b8" xlink:to="loc_us-gaap_PlanNameDomain_66b35b54-5a8d-4b8a-940e-231d231718d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EquityIncentivePlan2015Member_2b2b3b3f-6f66-4ef5-bcab-83b71f939188" xlink:href="dxcm-20231231.xsd#dxcm_EquityIncentivePlan2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_66b35b54-5a8d-4b8a-940e-231d231718d8" xlink:to="loc_dxcm_EquityIncentivePlan2015Member_2b2b3b3f-6f66-4ef5-bcab-83b71f939188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5ab63c0-1d4a-4738-b3ac-b473f30ed185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44972f10-3598-4b7c-9451-e680c83484da" xlink:to="loc_us-gaap_AwardTypeAxis_f5ab63c0-1d4a-4738-b3ac-b473f30ed185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a65e9731-3280-4863-9116-631b00054cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f5ab63c0-1d4a-4738-b3ac-b473f30ed185" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a65e9731-3280-4863-9116-631b00054cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_accb257d-fb07-448a-bec2-9f71a74647e4" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a65e9731-3280-4863-9116-631b00054cea" xlink:to="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember_accb257d-fb07-448a-bec2-9f71a74647e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44972f10-3598-4b7c-9451-e680c83484da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:href="dxcm-20231231.xsd#dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:to="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c96ab736-525f-4065-992f-e61e6dd9baef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c96ab736-525f-4065-992f-e61e6dd9baef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_588c58e0-d412-4fb4-be57-7b23cb685c20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_588c58e0-d412-4fb4-be57-7b23cb685c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_76da28d3-e4db-4fcc-867a-11d6d262ef72" xlink:href="dxcm-20231231.xsd#dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:to="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested_76da28d3-e4db-4fcc-867a-11d6d262ef72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_7092b6d3-ae6a-457e-ae3b-324786af6ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_7092b6d3-ae6a-457e-ae3b-324786af6ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_284c0c76-6d69-4f99-b6ab-c34c4d3224bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_5f1efff3-eb8d-4b3e-9886-26f8d9e53206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_284c0c76-6d69-4f99-b6ab-c34c4d3224bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b2f2cc1-5af1-4507-b970-90ff184c5747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4b2f2cc1-5af1-4507-b970-90ff184c5747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7288c38c-651e-4e2f-830c-12bb207efb64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7288c38c-651e-4e2f-830c-12bb207efb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7f688b4a-9cb5-4e97-a25a-9381f40348d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7f688b4a-9cb5-4e97-a25a-9381f40348d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_175a4777-ee97-4a87-8e76-970f40effda8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_175a4777-ee97-4a87-8e76-970f40effda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_640fcee9-130f-41a2-add1-ec90fce14dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e19d3cca-7d42-44d6-a2f2-a0d510f16679" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_640fcee9-130f-41a2-add1-ec90fce14dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6de5391e-4dfb-4152-8746-3953d19bb7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6de5391e-4dfb-4152-8746-3953d19bb7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536d2cc8-3e2f-4db9-910b-dd6199bf6cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536d2cc8-3e2f-4db9-910b-dd6199bf6cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_95a229ec-01b3-40af-845f-a57405b39194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_95a229ec-01b3-40af-845f-a57405b39194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_21b08a28-dc83-43fa-ad59-32d2cb0e8956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_21b08a28-dc83-43fa-ad59-32d2cb0e8956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ec2eb48-fd69-4e03-b26d-865f40e98342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_04975e95-cc42-45a3-8366-a17b1d871659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ec2eb48-fd69-4e03-b26d-865f40e98342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_d27a8ed5-86b8-41c2-95a9-2769365795ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab0eed7f-25c2-442b-903d-ab97ae24f79c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_d27a8ed5-86b8-41c2-95a9-2769365795ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f12d18ac-9768-42d4-8e26-f99f2956c4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ecff9e27-97ec-42e0-a740-e34bdd0fd40d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f12d18ac-9768-42d4-8e26-f99f2956c4ec" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ecff9e27-97ec-42e0-a740-e34bdd0fd40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f1f85fc7-4133-42ed-9ddb-f8283b288ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ecff9e27-97ec-42e0-a740-e34bdd0fd40d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f1f85fc7-4133-42ed-9ddb-f8283b288ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1f85fc7-4133-42ed-9ddb-f8283b288ec2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_0f7a12b8-e7a8-4da4-97f0-32c9a0c97e10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:to="loc_us-gaap_CostOfSalesMember_0f7a12b8-e7a8-4da4-97f0-32c9a0c97e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0d395329-a24f-4edb-9f61-86ad4f9c4a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0d395329-a24f-4edb-9f61-86ad4f9c4a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_59849fd9-6dea-4894-84c8-8dd6d6e8e03a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ebb42fc4-114c-456e-a5ba-16ae4e56addb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_59849fd9-6dea-4894-84c8-8dd6d6e8e03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3b9fe833-0f5a-4e72-a465-ab20e8852dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ecff9e27-97ec-42e0-a740-e34bdd0fd40d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3b9fe833-0f5a-4e72-a465-ab20e8852dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b90cf16b-a7c3-41c2-be47-51a294f5fe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3b9fe833-0f5a-4e72-a465-ab20e8852dc0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b90cf16b-a7c3-41c2-be47-51a294f5fe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_083dae34-18c9-46bb-b684-feabfcf0d963" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3b9fe833-0f5a-4e72-a465-ab20e8852dc0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_083dae34-18c9-46bb-b684-feabfcf0d963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8eacf846-4348-47e4-8c56-5acfe3750c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f5e6d3a-91bf-4745-ae14-0a87c6c17ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8eacf846-4348-47e4-8c56-5acfe3750c72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f5e6d3a-91bf-4745-ae14-0a87c6c17ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5df16250-c99b-41f3-83c8-23f0bd20bd29" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f5e6d3a-91bf-4745-ae14-0a87c6c17ed1" xlink:to="loc_srt_RangeAxis_5df16250-c99b-41f3-83c8-23f0bd20bd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c924bae9-a591-4d29-b580-f378ba66f783" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5df16250-c99b-41f3-83c8-23f0bd20bd29" xlink:to="loc_srt_RangeMember_c924bae9-a591-4d29-b580-f378ba66f783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_35a93170-ca05-45fd-b840-30ffca965698" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c924bae9-a591-4d29-b580-f378ba66f783" xlink:to="loc_srt_MinimumMember_35a93170-ca05-45fd-b840-30ffca965698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a09a289-6a7e-4274-be6c-206005097f49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c924bae9-a591-4d29-b580-f378ba66f783" xlink:to="loc_srt_MaximumMember_6a09a289-6a7e-4274-be6c-206005097f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6aa1fd1f-d27e-4a35-9eb1-8fee5f80ea68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f5e6d3a-91bf-4745-ae14-0a87c6c17ed1" xlink:to="loc_us-gaap_PlanNameAxis_6aa1fd1f-d27e-4a35-9eb1-8fee5f80ea68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c0676b47-cba1-4c79-8e87-0a42d14cf591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6aa1fd1f-d27e-4a35-9eb1-8fee5f80ea68" xlink:to="loc_us-gaap_PlanNameDomain_c0676b47-cba1-4c79-8e87-0a42d14cf591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_EmployeeStockPurchasePlanMember_b9e31b9e-fdf9-4710-867d-323382c6c3f4" xlink:href="dxcm-20231231.xsd#dxcm_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c0676b47-cba1-4c79-8e87-0a42d14cf591" xlink:to="loc_dxcm_EmployeeStockPurchasePlanMember_b9e31b9e-fdf9-4710-867d-323382c6c3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6f5e6d3a-91bf-4745-ae14-0a87c6c17ed1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1f701d5-82ac-4de9-ad8c-e8a721268584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a1f701d5-82ac-4de9-ad8c-e8a721268584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_652abc51-5e6a-44f8-9515-a448cc88d35a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_652abc51-5e6a-44f8-9515-a448cc88d35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40653317-34a9-422f-b96d-80a5ab71dd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40653317-34a9-422f-b96d-80a5ab71dd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4e22e29e-6ccb-463d-82c7-8b7cc99535c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00db2583-b695-4d69-a394-32a6baa10312" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4e22e29e-6ccb-463d-82c7-8b7cc99535c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationNarrativeDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BusinessSegmentandGeographicInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_29c89579-7fab-47f5-b456-29c559ae63d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_41f90dc8-c01b-48a3-9449-00b92a0df5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_29c89579-7fab-47f5-b456-29c559ae63d2" xlink:to="loc_us-gaap_NumberOfReportableSegments_41f90dc8-c01b-48a3-9449-00b92a0df5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_NumberOfPrimaryGeographicMarkets_191f0d26-b98d-4087-878c-aeec20004324" xlink:href="dxcm-20231231.xsd#dxcm_NumberOfPrimaryGeographicMarkets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_29c89579-7fab-47f5-b456-29c559ae63d2" xlink:to="loc_dxcm_NumberOfPrimaryGeographicMarkets_191f0d26-b98d-4087-878c-aeec20004324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BusinessSegmentandGeographicInformationSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ebcd23e6-1a14-45ce-aa20-72f757962bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a17b288d-79c6-4a41-937d-9325e4b1709f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ebcd23e6-1a14-45ce-aa20-72f757962bb9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a17b288d-79c6-4a41-937d-9325e4b1709f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0151ad83-d61c-40f9-a740-d0dcd3805b50" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a17b288d-79c6-4a41-937d-9325e4b1709f" xlink:to="loc_srt_StatementGeographicalAxis_0151ad83-d61c-40f9-a740-d0dcd3805b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_848dffbc-98a5-48d7-8c28-18effe622aa5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0151ad83-d61c-40f9-a740-d0dcd3805b50" xlink:to="loc_srt_SegmentGeographicalDomain_848dffbc-98a5-48d7-8c28-18effe622aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7cf9daf8-01e8-49a7-ab0d-0e4028ef5eb1" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_848dffbc-98a5-48d7-8c28-18effe622aa5" xlink:to="loc_country_US_7cf9daf8-01e8-49a7-ab0d-0e4028ef5eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_94bcccba-7963-425e-968b-6f6a50c3317e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_848dffbc-98a5-48d7-8c28-18effe622aa5" xlink:to="loc_us-gaap_NonUsMember_94bcccba-7963-425e-968b-6f6a50c3317e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_3e670702-b2ee-44a5-a5a9-d5249f90e448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a17b288d-79c6-4a41-937d-9325e4b1709f" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_3e670702-b2ee-44a5-a5a9-d5249f90e448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6e66f903-dc64-41ce-a9e9-7f9b28e389e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_3e670702-b2ee-44a5-a5a9-d5249f90e448" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6e66f903-dc64-41ce-a9e9-7f9b28e389e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_4ece497d-5f58-4702-a071-8045cd1428dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6e66f903-dc64-41ce-a9e9-7f9b28e389e8" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_4ece497d-5f58-4702-a071-8045cd1428dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_54394c10-1fe1-47af-9518-2d78f6182aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6e66f903-dc64-41ce-a9e9-7f9b28e389e8" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_54394c10-1fe1-47af-9518-2d78f6182aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_52cf5e86-c336-4102-a5ff-1ceab68a2484" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a17b288d-79c6-4a41-937d-9325e4b1709f" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_52cf5e86-c336-4102-a5ff-1ceab68a2484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d85cd77-0297-4d54-abf6-a11df68b2ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52cf5e86-c336-4102-a5ff-1ceab68a2484" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d85cd77-0297-4d54-abf6-a11df68b2ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RevenuePercentage_70ea1799-e6d6-49dc-a640-ba864ddede85" xlink:href="dxcm-20231231.xsd#dxcm_RevenuePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52cf5e86-c336-4102-a5ff-1ceab68a2484" xlink:to="loc_dxcm_RevenuePercentage_70ea1799-e6d6-49dc-a640-ba864ddede85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#BusinessSegmentandGeographicInformationGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8042c66e-7824-4268-822b-1a4dc3aa04fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_14d093bd-7e76-478f-8341-4a5d33e47f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8042c66e-7824-4268-822b-1a4dc3aa04fb" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_14d093bd-7e76-478f-8341-4a5d33e47f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e6a90631-1fc3-4fed-a143-9b8ed2e23552" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_14d093bd-7e76-478f-8341-4a5d33e47f29" xlink:to="loc_srt_StatementGeographicalAxis_e6a90631-1fc3-4fed-a143-9b8ed2e23552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e6a90631-1fc3-4fed-a143-9b8ed2e23552" xlink:to="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_69800877-9882-4c42-a7e2-4aa00b004ac7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:to="loc_country_US_69800877-9882-4c42-a7e2-4aa00b004ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MY_d6d4ece3-bd04-40a7-aa00-5200e8fb4f03" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MY"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:to="loc_country_MY_d6d4ece3-bd04-40a7-aa00-5200e8fb4f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_OtherCountriesMember_fbf5900f-7ee2-4ff2-91a4-adac97d7a79e" xlink:href="dxcm-20231231.xsd#dxcm_OtherCountriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ff7789b1-e766-4804-8ae7-61255a344aa8" xlink:to="loc_dxcm_OtherCountriesMember_fbf5900f-7ee2-4ff2-91a4-adac97d7a79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2117784a-1f0b-4df5-b055-602140858523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_14d093bd-7e76-478f-8341-4a5d33e47f29" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2117784a-1f0b-4df5-b055-602140858523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_afabc4e4-0c8f-41fd-b1a2-a85562e98957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2117784a-1f0b-4df5-b055-602140858523" xlink:to="loc_us-gaap_NoncurrentAssets_afabc4e4-0c8f-41fd-b1a2-a85562e98957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="simple" xlink:href="dxcm-20231231.xsd#SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"/>
  <link:presentationLink xlink:role="http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_c31cbf0c-9ac0-4a99-b255-b7a47468c769" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7752bb9e-f1c0-4f76-9de3-4e3864e18563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_c31cbf0c-9ac0-4a99-b255-b7a47468c769" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7752bb9e-f1c0-4f76-9de3-4e3864e18563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_94af0b59-bbc1-4805-81e9-be3b6dad4bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7752bb9e-f1c0-4f76-9de3-4e3864e18563" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_94af0b59-bbc1-4805-81e9-be3b6dad4bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_8f72a25a-72ee-4fcf-a57b-ad01f44cf10d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7752bb9e-f1c0-4f76-9de3-4e3864e18563" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_8f72a25a-72ee-4fcf-a57b-ad01f44cf10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments_5e1146d5-2e38-4051-b97f-b3ed98a6a2a1" xlink:href="dxcm-20231231.xsd#dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7752bb9e-f1c0-4f76-9de3-4e3864e18563" xlink:to="loc_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments_5e1146d5-2e38-4051-b97f-b3ed98a6a2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesRecoveries_3b583048-fade-4ef1-a2be-d9c2c54caf41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7752bb9e-f1c0-4f76-9de3-4e3864e18563" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesRecoveries_3b583048-fade-4ef1-a2be-d9c2c54caf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0c7a3a79-409b-49e3-ad31-3b26acfd8041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7752bb9e-f1c0-4f76-9de3-4e3864e18563" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0c7a3a79-409b-49e3-ad31-3b26acfd8041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember" xlink:href="dxcm-20231231.xsd#dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SadieMSternDecember2023PlanMember" xlink:href="dxcm-20231231.xsd#dxcm_SadieMSternDecember2023PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_dxcm_SadieMSternDecember2023PlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SadieMStern2023PlanTerminationMember" xlink:href="dxcm-20231231.xsd#dxcm_SadieMStern2023PlanTerminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_dxcm_SadieMStern2023PlanTerminationMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_MatthewDolanMember" xlink:href="dxcm-20231231.xsd#dxcm_MatthewDolanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_MatthewDolanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_PaulFlynnMember" xlink:href="dxcm-20231231.xsd#dxcm_PaulFlynnMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_PaulFlynnMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_GirishNaganathanMember" xlink:href="dxcm-20231231.xsd#dxcm_GirishNaganathanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_GirishNaganathanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_StevenRPacelliMember" xlink:href="dxcm-20231231.xsd#dxcm_StevenRPacelliMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_StevenRPacelliMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_BarryJReganMember" xlink:href="dxcm-20231231.xsd#dxcm_BarryJReganMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_BarryJReganMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_KevinRSayerMember" xlink:href="dxcm-20231231.xsd#dxcm_KevinRSayerMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_KevinRSayerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_SadieMSternMember" xlink:href="dxcm-20231231.xsd#dxcm_SadieMSternMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_SadieMSternMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dxcm_JeremeMSylvainMember" xlink:href="dxcm-20231231.xsd#dxcm_JeremeMSylvainMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_dxcm_JeremeMSylvainMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>dxcm-20231231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dxcm-20231231_g1.jpg
M_]C_X  02D9)1@ ! @$$L 2P  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE
M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N W 7<BMT0W9;>'-ZB
MWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M_?R@",T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M[R<E]TKK\#KO^&GO%W_00_\ )>V_^-5O_:57^;\(_P"1V_ZP8G^?_P DA_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5?YOPC_D'^L&)_G_ /)(?_(A_P -/>+O^@A_Y+VW_P :H_M*K_-^$?\ (/\
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M()[Z>+IU-I+7I>S^YZGMT<SHUK<LXZNR3:3O>VSL_334]&KK/3"@ H * "@
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M ,DA_P#(A_PT]XN_Z"'_ )+VW_QJC^TJO\WX1_R#_6#$_P __DD/_D30TO\
M:K\5:?,LDEU'<(N<Q201!&R".3$L;\9R-K#D#.1D&HYI53O>_DTOT29I3XCQ
M,'=R4O)QC;_R51?XG7?\-G^(/^?:P_[]S?\ Q^NC^V*G:/W/_P"2.S_6JO\
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ME0RDCC<.HX7G7:/_ )-_P$>-+BUVTIZVTO.ZOZ<JO]Z]3B?^&S_$'_/M8?\
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M_P#DD/\ Y$X'_A:WB#_H*W__ (%S?_%US?6JG\TO_ G_ )GG?VC7_P"?D_\
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M^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\
M_/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X
M_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\
MD'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_
M^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\
M_/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X
M_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\
MD'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_
M^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\
M_/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X
M_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\
MD'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_
M^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\
M_/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X
M_1_;%/M+[E_\D'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\
MD'^M5#^6?W1_^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_
M^3#_ (;/\/\ _/M?_P#?N'_X_1_;%/M+[E_\D'^M5#^6?W1_^3.NTO\ :K\*
MZA"LDEU);NV<Q202EUP2.3$LB<XR-K'@C.#D#>.:4FKWMY-/]$T=E/B/#35W
M)Q\G&5__ "527XGJN@?$G1?%#1)97]K-),NZ.)9D\TC;N/[HG>"!DLI4,N#D
M#!KMIXB%3:2=^EU?[MSUZ./I5[*$XMM:)25]K[;^JMIU.VKH.\* "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M18BKLU%-6M%6^=W=I^C7EJ>!ZIJMQK<S7%U+)/,^-TDCL[M@ #+,23@  9/
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 5[N[CL(WFF=8XXU+.[$*JJHR68G@
M#DD\ <TF[:LF4E%7>B2NV]%8^9?'?[66A>%U9+$MJ%P&9=L>4B!5@#F9EP01
MN*-$LJMMZJ&#5X]?-(4_A]Y^6B^__*Y\KC.)*-#2'ON[VT6C[M?<TG?\3Y-\
M8_M8>(?$VZ.V>.QA;S%Q"N9"C\ -*^XAU'1XA$<DM@';M\2MFE2>WNK7;?[W
M^:L?'XKB2O6TC:"U^%:V?F[ZKNK=^UOG35-5N-;F:XNI9)YGQNDD=G=L  99
MB2<  #)X  Z"O*E)S=V[ON]3YFI4E4?-)MM]6VWVW9GU!F% !0 4 % !0 4
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MLX)4-M8=4<!@2C ,N>0#7MTZL:BO%W1]A0Q$,1'F@U)=T_*]GV>NSU1OUJ=
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!P/Q,^(-O\ #'3)=2N!
MOV86.(,JM+(QPJ*3^+,0&*HKL%;;@\N)KJA%R?R7=_U^!YV/QL<%3=26MME=
M*[>RU^][Z)NSL?G#K7[6/BG5) \,\-JH4 QPP(5)R3N)F$K9.<<,%P!\N<D_
M*3S2K+9I>B7ZW/S*KQ)B)NZ:CIM&*MZ^]S/\3(_X:>\7?]!#_P E[;_XU6?]
MI5?YOPC_ )&/^L&)_G_\DA_\B'_#3WB[_H(?^2]M_P#&J/[2J_S?A'_(/]8,
M3_/_ .20_P#D0_X:>\7?]!#_ ,E[;_XU1_:57^;\(_Y!_K!B?Y__ "2'_P B
M'_#3WB[_ *"'_DO;?_&J/[2J_P WX1_R#_6#$_S_ /DD/_D0_P"&GO%W_00_
M\E[;_P"-4?VE5_F_"/\ D'^L&)_G_P#)(?\ R(?\-/>+O^@A_P"2]M_\:H_M
M*K_-^$?\@_U@Q/\ /_Y)#_Y$/^&GO%W_ $$/_)>V_P#C5']I5?YOPC_D'^L&
M)_G_ /)(?_(GT'X!_;-6XD\K7;98U9N)[8,50$J!OB=F; ^9F=&9L841$\UZ
ME#.+Z37S7^3_ *\CZ/!<57=JT;:_%&]EMNFV^[;3?9(^V= U^U\46L5[92K-
M;S+NCD7H1T/!Y!!R&4@,K J0""*^AIU%45UJF?=T:T:\5.#NFM&OZ^]=-F:]
M:&P4 % !0!P/C3XHZ-\/=HU.[C@=\;8_F>0@[L-Y<89]GRL-^-N1MSD@5RUL
M3"C\3M^+^Y7?0\[%YA2PG\225^FK?76R3=M-[6/D;QI^VG]U=$L_0M)=_P#
MLJ(XG_W2',G]Y?+Z-7AULX_D7SE_DG^OR/C<7Q7_ ,^H^KG\]+1?IK?Y=3Y<
M\3_&_P 1^,(_)O-0F,>UU9(]L*NK@!E<0J@<$#&'W  D#&XY\:IC:E31R?RT
MW]+7/D\1F]?$*TINUFK*T4T][\J5_F>55Q'D!0 4 % !0 4 % !0 4 % !0
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M?7=[O?79=;'SW7EGS84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MB]0>AX/!!&0RD%64E2""16E.HZ;NM&C:C6E0DIP=FGHU_7WKKLS]UZ_2#^@
MH * "@ H * "@ H * "@ H * "@ H X'X@_$S3/AC;BXU*79OW"*-06DE95R
M511^ +,512RAG7<,\M?$QH*\GZ+J_P"ON/.QN/IX*/-4=KWLMV[*^B_5V6JN
MU<^%_''[8^IZHTD>D0QVD)X260"6?AR=V#^Z7<N 4*R;<MB0G:5^<K9O*6D%
M9=WJ]_N_/U/@<7Q14G=4DHKHW[TM]^RNNEG;74^3M:\07GB2037UQ-<R!0H>
M:1I&"@DA07).,DG'3))[UXDZCGK)M^KO^9\=5KRK.\VY.UKR;;M\S'K,Q"@
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M^V?_ ,B_;?\ 7_'_ .B9Z\/./X:_Q+\I'QO%7\"/_7Q?^DS/S)KX\_*PH *
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M3K6C5]R7?>+V6^ZUOOHEO(^N:]P^R"@ H * "@ H * "@ H * "@ H * "@
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MYI-MOJVV^V[,^H,PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_3YVN[NW4\YKD/,"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MN]3\IJ5)5'S2;;?5MM]MV9]09A0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M+%8Y&0%B !G YP ,]A7YS6AR2<5T;7W.Q^"8NDJ-24%M&<DK[V3:.8K$Y H
M* "@ H * "@ H * +%I=R6$B30NT<D;!D=25964Y#*1R"#R".0>::=M45&3B
M[K1IW36CN%W=R7\CS3.TDDC%G=B69F8Y+,3R23R2>2>:&[ZL)2<G=ZMN[;U=
MRO2)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#8T#7[KPO
M=17ME*T-Q"VZ.1>H/0\'@@C(92"K*2I!!(K2G4=-W6C1M1K2H24X.S3T:_K[
MUUV9^R/PM^)5K\5=-74+96C.XQS1-R8Y5 ++NP PPP*L.JD9"MN1?O<-B%B(
M\R]&O,_;<NQ\<=3YXZ:V:?1Z:>>^C_)Z'HU=9Z8Y: '4 % 'GWQ6_P"1?U7_
M *\+O_T2]<N*_AR_PR_)GG9C_ J?]>Y_^DL_$VOST_"@H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^NOA
M)^U;?>$MMKK/F7MH-Y\W.^Z4GD#<[@2)G(PY# -P^U%C/NX3-)4])^\M==Y?
MB]?ZUZ'V66<1SH>[5O..NN\_O;U7KKKO9)'Z/:!K]KXHM8KVRE6:WF7='(O0
MCH>#R"#D,I 96!4@$$5]73J*HKK5,_3J-:->*G!W36C7]?>NFS->M#8* "@
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MK?@[;/M=(^BZ]4^F"@ H * "@ H * "@ H * /@C]L?X;?ZGQ!;)Z07>U?\
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M]Y^/XW'U,;+FJ.]KV6R5W?1?J[O17;L<#7*><% !0 4 % !0 4 % !0 4 %
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M_$#Q*=.EI&]G+K)>G1?BU:]M4?'M>"?%A0 4 % !0 4 % !0 4 % !0 4 %
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MJWX77FGSX4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5C.6,:*W;YGJUHKI+SN]=].7;8_/"OE3\V"@ H * "@ H * "@ H * "@ H
M^F_V5OAW_P )GK@O)1FVT[;,W/68D^0O#*PPRF3(#+^[V,,.*]C+,/[6=WM'
M7Y].OS^1]5P[@?K%;F?PT[2_[>^SU3W5^JTL]S]5*^T/UP* "@ H * "@ H
M* "@ H \Y^*7Q*M?A5IK:A<JTAW".&)>#)*P)5=V"%&%)9CT4' 9MJ-R8G$+
M#QYGZ)>9YF8X^.!I\\M=;)+J]=/+;5_F]#\A?''CB^^(E])?W\F^5^%4<)&@
MSMCC7)VH,G Y))+,6=F8_"UJTJTN:6_]:'XSB\7/%S<YN[?W)=EY?\.]3D*P
M.(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#8T#0+KQ1=165E$TUQ,VV.->I/4\G@ #)9B0JJ"Q( )K2G3=1V6
MK9M1HRKR4(*[;T2_K[WTW9^W'A30_P#A&-/M;#?YGV:WBAWXV[O+0)NVY.,X
MSC)QTR:_0Z4/9Q4>R2^Y6/WC#4?8PC"]^6,8WVV27GV-^M3H"@ H * "@ H
M* "@ H KW=W'81O-,ZQQQJ6=V(5551DLQ/  '))X YI-VU9,I**N]$E=MZ*Q
M^7?[07[04GQ)D;3]/9H]+C;D\JURRGAW'41@\QQGG.)'&_:L7QN/Q_M_=C\/
MY_\  [+YOR_)\ZSIXQ\D-*:?HY/N_+LOF];)?+E>,?)A0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'UU^S'\
M<?\ A"[@:3J<^W39<^2S\K!,S \MD;(GRV_@JKD/\@,KGW<MQOLGR2?NO;R?
MZ+]>VI]EP_F_U>7LZC]Q[7Z2OWZ)]>B>NFK/TUKZ\_5 H * "@ H * "@ H
M* "@ H * "@ H _.']M719(-4L;XE?+FM6A49.X-#(SL2,8P1,NW!)R&R!@9
M^3SF%I*7=6^YW_4_,N*Z352$^CA;SO%MO_TI?B?%U?/GPP4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % '[L>']:C\26=O?0AA'<PQS(& #!9%#@, 2,X/."1GN:_2*<^=*2ZI/[]3
M^@*%55HJ:VE%-7WLU<V5K0V'4 % 'GWQ6_Y%_5?^O"[_ /1+URXK^'+_  R_
M)GG9C_ J?]>Y_P#I+/Q-K\]/PH* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]=^"_Q4F^%&II=9D>
MTD^6ZA0C]XF#@@-P70G>GW2>4WJKL:[L'BGAY7Z/=?UV_P"!U/9RK,7@:BEJ
MXO2275?/JMUMVNDV?KWH&OVOBBUBO;*59K>9=T<B]".AX/((.0RD!E8%2 01
M7W5.HJBNM4S]GHUHUXJ<'=-:-?U]ZZ;,UZT-@H * "@ H * "@ H * "@ H
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MA6,Q3Q5251_:>W9;);+9)*_4Y"L#B"@ H * "@ H * "@ H * "@ H _7O\
M9]^%K?"[1UBN%47UPWFW)!5L'HD>\ 9"+U&642-(58JP-?=8##>PA9[O5_Y?
MUUN?L^2Y=]2I6E\4G>6S]%=+HO75NSLSW2O2/?"@ H * "@ H * "@ H KW=
MW'81O-,ZQQQJ6=V(5551DLQ/  '))X YI-VU9,I**N]$E=MZ*Q^.OQH^*DWQ
M7U-[K,B6D?RVL+D?NTP,DA> [D;W^\1PF]E137P6,Q3Q$K]%LOZ[_P# Z'XI
MFN8O'5'+516D4^B^75[O?M=I(\BKA/&"@ H * "@ H * "@ H * "@ H * "
M@#M_"/PWUCQVP&FV<TZEF7S N(@RKN*M*V(U.,'#,"<J!RP!Z*6'G5^%-^?3
M[]COPV JXK^'%O6U[:72ON[)?-GT'X7_ &.-<U7RWOYK>SC;=O7)FF3&0ORI
MB-LD \2\*<_>&RO5I91.7Q-+\7^&GXGT>'X7K3LYN,5K?[4EOT6G_DVWGH>N
MZ'^Q/I]OO^WZA<39QL\F-(-O7=NW^=NSQC&W&#][/'=#)HKXI-^B2_.Y[-'A
M."OSSD^W*E'\^>_X&_\ \,8>'_\ GYO_ /OY#_\ &*U_L>GWE]Z_^1.G_56A
M_-/[X_\ R ?\,8>'_P#GYO\ _OY#_P#&*/['I]Y?>O\ Y$/]5:'\T_OC_P#(
M%>[_ &+M#>-Q#=7RR%3L9FB=0V."RB)2P!Y*AE)'&X=1+R>'1R_#_)$RX5HV
MTE.]M+N+5_3E5_O7J<#=_L0R)&YAU56D"G8K6I12V. S"9BH)X+!6('.T]#S
M/)>TO_)?^"SSI<).VE36VEX65_7F=ON?H>-^)?V5_$_A[<R01W<:QEV>WD#8
MQG*A)/+D9\#("(V[( RV0//J994ATOIT?^=G^!XE?AW$4MDI)*]XN_RL[-OT
M3\M3P/5-*N-$F:WNHI()DQNCD1D=<@$95@",@@C(Y!!Z&O-E%P=FK/L]#YVI
M3E3?+)--=&FGWV9GU!F% !0 4 % !0 4 6+2TDOY$AA1I))&"HB@LS,QP%4#
MDDG@ <D\4TKZ(J,7)V6K;LDM7<_47]GW]GV/X;1KJ&H*LFJ2+P.&6V5A@HAZ
M&0CB20<8S&AV;FE^RP& ]A[TOB_+_@]W\EY_K&2Y*L&N>>M1KU45V7GW?R6E
MV_J*O9/K H * "@ H * "@ H * "@#\ROVG/CC_PFEP=)TR?=IL6/.9.%GF5
MB>&R=\2879P%9P7^<")Q\AF6-]J^2+]U;^;_ %7Z]]#\KX@S?ZQ+V=-^XM[=
M97[]4NG1O771GR+7A'QH4 % !0 4 % !0 4 % !0 4 % !0!ZKX$^"FN_$55
MEL;5OLY91]HD(CBP6*E@S8,@4JV_R@[+C&W) /;0P<ZVL5IW>B_X/RN>O@\I
MK8O6$=+KWGHM[7UWM;6U['T9HO[$MY/&3?:C##)N.%AA:92N!@EG:$@YR-NT
MC !W'.!ZT,F;^*27HK_G8^FI<)R:]^:3O]F+DK>K<?R^9Z;:?L7:&D:":ZOF
MD"C>RM$BEL<E5,3%03R%+,0.-QZGK63PZN7X?Y,]6/"M&VLIWMK9Q2OZ<KM]
M[]2Q_P ,8>'_ /GYO_\ OY#_ /&*K^QZ?>7WK_Y$K_56A_-/[X__ "!@:Y^Q
M/I]QL^P:A<0XSO\ .C2?=TV[=GD[<<YSNSD?=QSE/)HOX9->J3_*QS5N$X.W
M).2[\R4ORY+?B>)>)?V0/$.D;FM#;WJ>8554D\N39SAV64(B]!E5=R"<#< 6
M'G5,IJ1VL]>]G^-E^)X5?ABO3^'EGKI9V=N[YK+Y7?S/FW6O#]YX;D$-];S6
MTA4,$FC:-BI) 8!P#C((STR".U>3.FX:237JK?F?+U:$J+M-.+M>TDT[?,QZ
MS,0H * "@ H * "@ H * "@ H * "@#[_P#V6/CG&8T\/ZI*WF;MME+(P*E2
M %M\XR"#GRMQ(8'R@5VQHWT^68W_ )=R?^%O\O\ +[NQ^B\.YNK*A4>M_<;V
MM_+_ )7WVTLD_O"OI3]!"@ H * "@ H * "@ H * "@ H * /@C]N#_F$_\
M;Y_[0KYG.OL_]O?^VGYYQ;_R[_[B?^V'P/7S)^>!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 =O:?#37+^-)H=-OI(Y%#(ZVTK*RL,AE(7!!'((X(Y
MKH6&F]5&7_@+_P COC@*TE=0FTU=-0DU;[CT7_AF'Q=_T#__ "8MO_CM=?\
M9M7^7\8_YGI_ZOXG^3_R>'_R10U3]G/Q5I$+3R:=(R+C(C>*5^2!Q'$[NW7G
M:IP,DX )$RR^K%7Y?N:?X)MF53(\335W!Z=G&3^Z+;_ \QUSPIJ'AC9]OM;B
MV\S.SSHGCW;<;MN\#.,C..F1ZUQSI2I_$FK]TU^9Y=;#3HVYXRC?;FBUMZI=
MS K(Y@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]M\-?L[>)_
M$^UDL)(8S($9[@B#;TRQ20B0H <DHC9P0-S BO1IY?4J?9MKUT_/7\#W:&1X
MBMM!I7M>7N_.SL[:]$_+4]DT7]BK5)Y"+Z^M88]IPT*R3,6R, JZP@#&3NW$
MY &TYR.^&32?Q-+TN_SL>Y2X4J-^_.*5OLWD[^C4?S^1T_\ PP__ -1;_P D
M_P#[?6W]B_WO_)?_ +8ZO]4?^GG_ )3_ /MSD/$O[&&K:?N;3[NWND6,MM<-
M!(SC/R*O[Q.<##,Z#)P=H&XX5,GFOA:>GH_U7XG'7X5J0^"49:=;Q=^R^)?-
MM?(^7?%W@V_\"71L]2@:"<*K;2005;HRLI*L.HRI(#!E/S*0/&JT94G:2LSY
M/$X6>%ER5%9VOTV?FKI_+T.8K$Y H * "@ H * "@ H * "@ H * "@#]L?A
M3_R+^E?]>%I_Z)2OT+"_PX_X8_DC]UR[^!3_ .O</_24>@+74>B.H * //OB
MM_R+^J_]>%W_ .B7KEQ7\.7^&7Y,\[,?X%3_ *]S_P#26?B;7YZ?A04 % !0
M 4 % !0 4 % !0 4 % !0!U_@OP)J/Q"N&M=,A\^9(S(R[T3"!E4G,C*.K*,
M9SSTP#6]&A*L[15W:^Z7YV[G;A,'/%RY::NTKVNEI=+JUW/3?^&8?%W_ $#_
M /R8MO\ X[79_9M7^7\8_P"9ZO\ J_B?Y/\ R>'_ ,D'_#,/B[_H'_\ DQ;?
M_':/[-J_R_C'_,/]7\3_ "?^3P_^2#_AF'Q=_P! _P#\F+;_ ..T?V;5_E_&
M/^8?ZOXG^3_R>'_R0?\ #,/B[_H'_P#DQ;?_ !VC^S:O\OXQ_P P_P!7\3_)
M_P"3P_\ D@_X9A\7?] __P F+;_X[1_9M7^7\8_YA_J_B?Y/_)X?_)!_PS#X
MN_Z!_P#Y,6W_ ,=H_LVK_+^,?\P_U?Q/\G_D\/\ Y(X'Q1\+=<\&>8;^QN(H
MXMN^786A&[&W]\FZ,Y+ <,?F.W[W%<U7#3I?%%JW6VGWK0\[$9=6P]^>$DE:
M[M>.MNJNNO??3<X&N4\X* "@ H * "@ H * "@ H * "@ H * /I/]G7XW+\
M*[I[:]W-IUTRF0@L3 XX$JH."","4 ;RJH024"/Z^7XWZN[/X7^#[_Y]?NL?
M49'FWU&3C/X)-7WT?>WY]=%;:S_52TNX[^-)H762.10R.I#*RL,AE(X((Y!'
M!'-?:)WU1^N1DI*ZU35TUJK%BF4% !0 4 % !0 4 % !0 4 % !0 4 % 'Q]
M^UM\4E\.6 T2W9A=WBAI2 PVVV6!^<%>9&785^8&,2!@NY"?!S7$\D>1;RW]
M/^#;[KGQ?$N8^QA[&/Q36N_P7?6ZW:M;72]]T?FC7R)^6A0 4 % !0 4 % !
M0 4 % !0 4 % 'W_ / S]EB,1Q:IX@1O,W+)%9-@*% ./M"D9))PWE<!0 LF
M[<\:_3X++-I5/E'_ #_R^_L?HN4<.JRJ5UK>ZATM_>_.W3K>[2^Z+2TCL(TA
MA18XXU"HB@*JJHP%4#@ #@ < <5](E;1'W\8J*LM$E9):*Q8IE!0 4 % !0
M4 % 'RK\>?V<K?Q["U]I4<<&IIN9E4*B7.268/T E))*RG[Q.V0[2KQ^+CLO
M59<T=)?=?_@^?W^7R.<Y%'%+GII*:N^B4NNOGV?79]U^85W:26$CPS(T<D;%
M71@5964X*L#R"#P0>0>*^.:MHS\IE%Q=GHT[-/1W*](D* "@ H * "@ H *
M"@ H _2[]D'XAMX@TV72KF9I+BS8&$.5S]F8 *J<[V$; @Y&$5XD#8VJOUV4
MXCGBXMZQV]/^!^&A^I<,8[VM-TY.[@]+V^#1675V?W72\C[!KWC[0* "@ H
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M[M:^2_X/Y>J9\3Q%FOL8^Q@US23YNMHM;=KM/U2Z:IGYLU\D?EX4 % !0 4
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M * "@ H * "@ H * /T7_9R_9R_L#R]:UJ/_ $KA[:V<?ZGN)) ?^6O=$/\
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M7P]0Q%[+DD^L=%M;X=K=7:S?<^3?%W['VNZ*Q;3WAOX]RA0&$,N"N2S)(=@
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M=QW\:30NLD<BAD=2&5E89#*1P01R".".:_0$[ZH_<8R4E=:IJZ:U5BQ3*"@
MH * "@ H * "@ H * "@#X(_;@_YA/\ V^?^T*^9SK[/_;W_ +:?GG%O_+O_
M +B?^V'P/7S)^>!0 4 % !0 4 % !0 4 % !0 4 % '7^!_ ]]\1+Z.PL(]\
MK\LQX2-!C=)(V#M09&3R22%4,[*IWHT95I<L=_ZU.W"82>+FH05V_N2[OR_X
M9:GZ/?#']EC1_!\<<VI(M_>[1O\ ,^:W1B&!"1D ,,,!NE#$E0ZK&3M'UF&R
MR%/67O/SV^[_ #]=#]-R_AVEATG47/*VM]8IZ[+KOUOM=)'U%7LGU@4 % !0
M 4 % !0 4 ?C[^T+X'7P%XAN8(8_+MIMMQ OR8V2?>"J@ 5%D$B(I (51U&&
M/PF/H^QJ-+9ZK;KZ>=T?BV=X3ZK7DDK1?O1VV?ILD[I+LCQ*O./""@ H * "
M@ H * "@ H * "@ H * .O\  _@>^^(E]'86$>^5^68\)&@QNDD;!VH,C)Y)
M)"J&=E4[T:,JTN6._P#6IVX3"3Q<U""NW]R7=^7_  RU/U4^%?P&TGX5J)(E
M^T7AP6NI54NIV;6$0Q^Z0Y;@$L0VUG<!<?:87 PP^VK[OTZ=OZU/US+LFIX'
M5>]+^9I7VMIV6_GK9MGME>B>Z% !0 4 % !0 4 % 'R;^V#X176M"34%"^98
M3*2Q9@?*F(C=5 ^4DOY1^;&%5L,,D-XF;4N:'-_*_P 'I^=CX_B?#>THJ?6$
MEWVE[K7W\OW??^85?''Y2% !0 4 % !0 4 % !0 4 % !0!^V/PI_P"1?TK_
M *\+3_T2E?H6%_AQ_P ,?R1^ZY=_ I_]>X?^DH] 6NH]$=0 4 >??%;_ )%_
M5?\ KPN__1+URXK^'+_#+\F>=F/\"I_U[G_Z2S\3:_/3\*"@ H * "@ H *
M"@ H * "@ H * /KK]C#_D8+G_KPD_\ 1T%>[D_\1_X7^<3[+A7^/+_KV_\
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MT7AW*8N*KSU=WRKHK-J[\[K3MOO:WWA7TI^@A0 4 % !0 4 % !0 4 % !0
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M<&OL<JK^TARO[/Y/;\ONL?JW#.-=>DX/>FTK_P!UWMU>UFNB2L?65>V?8!0
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MR6_^7S/D^),9["CR+>H[:-K16;_1-=;^I^65?&'Y*% !0 4 % !0 4 % !0
M4 % !0 4 ?L'\!OA6OPKTE8I!F\N-LMTQ"95RHQ$&7.4CY ^9@6+N,!]H^[P
M.%^KPMU>KV^[Y?YG[3DV7?4:=G\4K.6V]MM.B]7K=K<]LKT3W0H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#PO]H+XI
M-\+M':6W91?7#>5; A6P>KR;"1D(O0X91(T892K$5YN/Q/L(76[T7^?]=;'@
M9UF/U*E>/Q2=H[/U=F^B]=6KJS/R$KX4_& H * "@ H * "@ H * "@ H *
M/KK]D?X;?\)+J;:M<)FVL,>7N7*O<,/EQE2I\M<N<%71S"PX->[E6'YY<[VC
MMZ_=TW\G8^RX:P'MJGM9+W8;><GMNK:+7>Z?*S]-:^O/U0* "@ H * "@ H
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M,?R1^ZY=_ I_]>X?^DH] 6NH]$=0 4 >??%;_D7]5_Z\+O\ ]$O7+BOX<O\
M#+\F>=F/\"I_U[G_ .DL_$VOST_"@H * "@ H * "@ H * "@ H * "@#ZZ_
M8P_Y&"Y_Z\)/_1T%>[D_\1_X7^<3[+A7^/+_ *]O_P!*@?IK7UY^J!0 4 %
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M5+?RI+[];_C^!^2\38AU*_+TA%+?2[7,W;INE\D?+E>,?)A0 4 % !0 4 %
M!0 4 % !0 4 ?3?[*WP[_P"$SUP7DHS;:=MF;GK,2?(7AE8893)D!E_=[&&'
M%>QEF']K.[VCK\^G7Y_(^JX=P/UBMS/X:=I?]O?9ZI[J_5:6>Y^JE?:'ZX%
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MHKYON_Z_ _<\!@HX*FJ<=;;NR5V]WI]RWT25W8[ZNH]$* "@ H * "@ H *
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M*^9SK[/_ &]_[:?GG%O_ "[_ .XG_MA\#U\R?G@4 % !0 4 % !0 4 % !0
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MXZ?+'1+XI=$O\^RZ^EVOUS\#^!['X=V,=A81[(DY9CR\CG&Z21L#<YP,G@
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MW_EW_P!Q/_;#X'KYD_/ H * "@ H * "@ H * "@ H * /VQ^%/_ "+^E?\
M7A:?^B4K]"PO\./^&/Y(_=<N_@4_^O</_24=]74>B% !0 4 % !0 4 % !0
M4 % 'X(5^9G\\A0 4 % !0 4 % !0 4 % !0 4 ?MC\*?^1?TK_KPM/_ $2E
M?H6%_AQ_PQ_)'[KEW\"G_P!>X?\ I*/0%KJ/1'4 % 'GWQ6_Y%_5?^O"[_\
M1+URXK^'+_#+\F>=F/\  J?]>Y_^DL_$VOST_"@H * "@ H * "@ H * "@
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MQ^%/_(OZ5_UX6G_HE*_0L+_#C_AC^2/W7+OX%/\ Z]P_])1WU=1Z(4 % !0
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MDK:(_>XQ459:)*R2T5BQ3*"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /DW]L77VTSP_':I*JM=72*\?R[GBC5I#@'G
M"N(BS+C!*J3AL'Q,WJ<M.W=K3R6OYV/C^**W)144_BFKK2[23?X-+5>7<_,*
MOCC\I"@ H * "@ H * "@ H * "@ H ^V?V)]#^T:AJ%_OQY-O'#LQ][SWW[
MMV>-ODXQ@YW9R-O/T.30O*4NR2^]W_0^[X3HWG.=]HJ-O\3O_P"V?B?HM7U9
M^EA0 4 % !0 4 % !0 4 % !0 4 % !0!Y5\<=%CU[PUJ<,I8*MK),"I .Z
M><@Y!X+( W<KD @X(XL;#GIR3[-_=K^AY&;TE5P]1/\ D;T[Q]Y?BM3\9:^
M/Q * "@ H * "@ H * "@ H * "@"Q:7<EA(DT+M')&P9'4E65E.0RD<@@\@
MCD'FFG;5%1DXNZT:=TUH[G[D>%-<_P"$GT^UO]GE_:;>*;9G=M\Q ^W=@9QG
M&<#/7 K]&I3]I%2[I/[U<_?,-6]M",[6YHQE;?=)^7<WZU.@* "@ H * "@
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M "@ H * "@ H * "@#\$*_,S^>0H * "@ H * "@ H * "@ H * /VQ^%/\
MR+^E?]>%I_Z)2OT+"_PX_P"&/Y(_=<N_@4_^O</_ $E'H"UU'HCJ "@#S[XK
M?\B_JO\ UX7?_HEZY<5_#E_AE^3/.S'^!4_Z]S_])9^)M?GI^%!0 4 % !0
M4 % !0 4 % !0 4 % 'UU^QA_P C!<_]>$G_ *.@KW<G_B/_  O\XGV7"O\
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M%G=B69F8Y+,3R23R2>2>:_-F[ZL_G^4G)W>K;NV]7<KTB0H * "@ H * "@
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M?:T:,:,>6.W]:GZ]A,)#"04(*R7WM]WY_P##+0ZZMSM"@ H * "@ H * "@
MH * "@ H _/C]MCQ+YEQI^F*T@V1R7$BY_=MYC>7&<9Y=?+EY(^4/P3N8#Y?
M.:FL8^3?EKHOR9^<<65[RA3UT3D^VKLOFK/[_-GPO7S9\ % !0 4 % !0 4
M% !0 4 % !0!])_LG:+)JGBF"9"H6UAGFD!)R5*&$!< Y.Z53S@;0QSG /KY
M7#FJI]DW^%OU/J.&Z3GB$U]F,F_2W+^<D?JY7VI^O!0 4 % !0 4 % !0 4
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M\,?R1^ZY=_ I_P#7N'_I*.^KJ/1"@ H * "@ H * "@ H * /@C]N#_F$_\
M;Y_[0KYG.OL_]O?^VGYYQ;_R[_[B?^V'P/7S)^>!0 4 % !0 4 % !0 4 %
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M9)?>[_H?=\)T;SG.^T5&W^)W_P#;/Q/T6KZL_2PH * "@ H * "@ H * "@
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MP:K_ -?]W_Z.>OSW%?Q)?XI?FS\*S'^/4_Z^3_\ 2F<#7*><% !0 4 % !0
M4 % !0 4 % !0!^@_P"Q'JDTMOJ=JS9ACDMY$7 X>59%<YQDY$2#!) V\ $G
M/U&32;4ET33^^_\ DC]'X2J-QJ1Z)Q:7FU)/_P!)1]T5](??A0 4 % !0 4
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MC\*?^1?TK_KPM/\ T2E?H6%_AQ_PQ_)'[KEW\"G_ ->X?^DH] 6NH]$=0 4
M>??%;_D7]5_Z\+O_ -$O7+BOX<O\,OR9YV8_P*G_ %[G_P"DL_$VOST_"@H
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MT+"_PX_X8_DC]UR[^!3_ .O</_24=]74>B% !0 4 % !0 4 % !0 4 % !0
M4 % !0!D:_H%KXHM9;*]B6:WF7;)&W0CJ.1R"#@JP(96 8$$ UG4IJHK/5,Q
MK48UXN$U=-:I_P!?<^FZ/R;^-WP1NOA'=;EW3:=,Q$$Y'(/7RI<<"0#.#PLB
M@LH!#HGQ.-P3P[[Q>S_1^?Y_E^/YME,L!+O!OW9?H_/\]UU2\+KS3Y\* "@
MH * "@ H * "@ H [[P7\4=9^'NX:9=R0(^=T?RO&2=N6\N0,F_Y5&_&[ VY
MP2*ZJ.)G1^%V_%?<[KH>CA,PJX3^')J_31KIK9IJ^F]KF!XE\4WWC"X:ZU">
M2XF;/S.V< L6VJ.B("Q(10%7/  K*I5E4=Y.[.>OB)XB7--N3[M^=[+LM=EH
MC K(Y@H * "@ H * "@ H * "@#W3X(_!&Z^+EUN;=#IT+ 3S@<D]?*BSP9"
M,9/*QJ0S DHC^E@L$\0^T5N_T7G^7Y_093E,L?+M!/WI?HO/\MWT3_630- M
M?"]K%9642PV\*[8XUZ =3R>22<EF)+,Q+$DDFOMJ=-4U9:)'[!1HQH14(*R2
MT2_K[WUW9KUH;!0 4 % !0 4 % !0 4 % !0 4 % !0!^%'B#6I/$EY<7TP4
M27,TDSA00H:1BY"@DG&3QDDX[FOS>I/G;D^K;^_4_G^O5=:3F]Y2;=MKMW,>
MLS$* "@ H * "@ H * "@ H * "@#[X_8?\ ^8M_VY_^UZ^FR7[7_;O_ +<?
MH?"/_+S_ +A_^WGWO7TQ^AA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!^%_BO7/^$GU"ZO\ 9Y?VFXEFV9W;?,<O
MMW8&<9QG SUP*_.*L_:2<N[;^]W/P+$UO;3E.UN:4I6WW;?EW,"LCF"@ H *
M "@ H * "@ H * "@ H _;'X4_\ (OZ5_P!>%I_Z)2OT+"_PX_X8_DC]UR[^
M!3_Z]P_])1WU=1Z(4 % !0 4 % !0 4 % !0 4 % !0 4 % 'XG?%;_D8-5_
MZ_[O_P!'/7Y[BOXDO\4OS9^%9C_'J?\ 7R?_ *4S@:Y3S@H * "@ H * "@
MH * "@ H * /JK]CS5(=/\2-'(VU[BSECB&"=SAHY2. 0/DC=LG XQG) /M9
M3)*IKUBTOO3_ "1]=PO44*]G]J$DO6\9?E%GZBU]D?K 4 % !0 4 % !0 4
M% 'P1^W!_P PG_M\_P#:%?,YU]G_ +>_]M/SSBW_ )=_]Q/_ &P^!Z^9/SP*
M "@ H * "@ H * "@ H * "@#]L?A3_R+^E?]>%I_P"B4K]"PO\ #C_AC^2/
MW7+OX%/_ *]P_P#24=]74>B% !0 4 % !0 4 % !0 4 ?!'[<'_,)_[?/_:%
M?,YU]G_M[_VT_/.+?^7?_<3_ -L/@>OF3\\"@ H * "@ H * "@ H * "@ H
M _;'X4_\B_I7_7A:?^B4K]"PO\./^&/Y(_=<N_@4_P#KW#_TE'?5U'HA0 4
M% !0 4 % !0 4 % !0!^"%?F9_/(4 % !0 4 % !0 4 % !0 4 % '[8_"G_
M )%_2O\ KPM/_1*5^A87^''_  Q_)'[KEW\"G_U[A_Z2CT!:ZCT1U !0!Y]\
M5O\ D7]5_P"O"[_]$O7+BOX<O\,OR9YV8_P*G_7N?_I+/Q-K\]/PH* "@ H
M* "@ H * "@ H * "@ H ^NOV,/^1@N?^O"3_P!'05[N3_Q'_A?YQ/LN%?X\
MO^O;_P#2H'Z:U]>?J@4 % !0 4 % !0 4 % !0 4 % 'YL_MIZ7-%K%G=,N(
M9+/RT;(Y>*5V<8SD8$J') !W<$D''R6<1:FGT<;?<W_FC\PXKIM58RZ.%D_-
M2;?_ *4CXVKP#X@* "@ H * "@ H * "@ H * "@#U7X':U)H/B73)H@I9KJ
M.$A@2-LY\ESP1R%<E>P;!((R#VX*?)4BUW2^_3]3U\HJNEB*;7\Z6O:7NO\
M!Z'[-5]^?MX4 % !0 4 % !0 4 ?!'[<'_,)_P"WS_VA7S.=?9_[>_\ ;3\\
MXM_Y=_\ <3_VP^!Z^9/SP* "@ H * "@ H * "@ H * "@ H _>^OTP_H8*
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MQD\K&I#,"2B/Z6"P3Q#[16[_ $7G^7Y_093E,L?+M!/WI?HO/\MWT3_630-
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M/Q/.S&I[.C.5[6A*SO;6S2U[WM;S/Q.K\]/PH* "@ H * "@ H * "@ H *
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MN'_I*.^KJ/1"@ H * "@ H * "@ H * "@#\$*_,S^>0H * "@ H * "@ H
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M)_[?/_:%?,YU]G_M[_VT_/.+?^7?_<3_ -L/@>OF3\\"@ H * "@ H * "@
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MGAWWB]G^C\_S_+\?S;*98"7>#?NR_1^?Y[KJEX77FGSX4 % !0 4 % !0 4
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M;_Q/\HGZIPK_  )?]?'_ .DP/KFO</L@H * "@ H * "@ H * "@ H * "@
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M 4 % !0!^]]?IA_0P4 % !0 4 % !0 4 ?!'[<'_ #"?^WS_ -H5\SG7V?\
MM[_VT_/.+?\ EW_W$_\ ;#X'KYD_/ H * "@ H * "@ H * "@ H * "@#]%
M_"W[9>F0V,":E!>->+&JS/&D+([KP7'[R/&[&XJ% 4DJ,@!C]72S>*BN9.]M
M;)?YH_2\/Q334$JBGS)*[2BTWWWCOO:VFQO_ /#9_A__ )]K_P#[]P__ !^M
M?[8I]I?<O_DCI_UJH?RS^Z/_ ,F'_#9_A_\ Y]K_ /[]P_\ Q^C^V*?:7W+_
M .2#_6JA_+/[H_\ R8?\-G^'_P#GVO\ _OW#_P#'Z/[8I]I?<O\ Y(/]:J'\
ML_NC_P#)A_PV?X?_ .?:_P#^_</_ ,?H_MBGVE]R_P#D@_UJH?RS^Z/_ ,F8
M^M?MJZ7!&#8V-U-)N&5F:.%0N#DAD:8DYP-NT#!)W#&#G/.8KX4WZV7Y7,:O
M%=-+W(2;O]JT5;U3E^7S/&_%'[8^N:KYB6$-O9QMMV-@S3)C!;YGQ&V2".8N
M%./O#?7!5S><OA27XO\ '3\#P\1Q16G=048K2WVI+;J]/_)=O/4^?/%WQ(UC
MQVQ.I7DTZEE;RRV(@RKM#+$N(U.,C*J"<L3RQ)\JKB)U?B;?ET^[8^<Q./JX
MK^))O6]KZ72MLK)?)'$5SG % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 :&
MEZ5<:W,MO:Q23S/G;'&C.[8!)PJ@DX ).!P 3T%7&+F[)7?9:FE.G*H^6*;;
MZ)-OOLC]#OV??V:6\*2+JNN1J;Q&S;V^5=82#Q*Y4E6D[Q@$K&,/DR8\KZG
M9=[/WI[]%O;S]>W;UV_2LER'V#]I67O)^['1I>;M=-]NV^^WVC7T!]P% !0
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MJJC 50.  . !P!Q7V25M$?K$8J*LM$E9):*Q8IE!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!^"%?F9_/(4 % !0 4 % !0 4 % !0 4 % !0!^FW[&'
M_(OW/_7_ "?^B8*^PR?^&_\ $_RB?JG"O\"7_7Q_^DP/KFO</L@H * "@ H
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M]$I7Z%A?X<?\,?R1^ZY=_ I_]>X?^DH[ZNH]$* "@ H * "@ H * "@ H *
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M_P#2F?LO#_\ NT/^W_\ TN1[Y7IGT(4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!\C?MG_\B_;?]?\ '_Z)GKP\X_AK
M_$ORD?&\5?P(_P#7Q?\ I,S\R:^//RL* "@ H * "@ H * "@ H * "@ H _
M;'X4_P#(OZ5_UX6G_HE*_0L+_#C_ (8_DC]UR[^!3_Z]P_\ 24=]74>B% !0
M 4 % !0 4 % !0 4 % !0 4 % !0!^5?[6^A_P!D^)Y)M^[[7;PS8QC9M!@V
MYR=W^JW9X^]C'&3\7FL.6I?ND_T_0_(^):/L\0W?XXQEZ?9_]MO\SYDKQSY4
M* "@ H * "@ H * "@ H * "@ H _;'X4_\ (OZ5_P!>%I_Z)2OT+"_PX_X8
M_DC]UR[^!3_Z]P_])1WU=1Z(4 % !0 4 % !0 4 ?!'[<'_,)_[?/_:%?,YU
M]G_M[_VT_/.+?^7?_<3_ -L/@>OF3\\"@ H * "@ H * "@ H * "@ H _;'
MX4_\B_I7_7A:?^B4K]"PO\./^&/Y(_=<N_@4_P#KW#_TE'?5U'HA0 4 % !0
M 4 % !0 4 % 'P1^W!_S"?\ M\_]H5\SG7V?^WO_ &T_/.+?^7?_ '$_]L/@
M>OF3\\"@ H * "@ H * "@ H * "@ H _;'X4_\ (OZ5_P!>%I_Z)2OT+"_P
MX_X8_DC]UR[^!3_Z]P_])1WU=1Z(4 % !0 4 % !0 4 % !0 4 ?@A7YF?SR
M% !0 4 % !0 4 % !0 4 % !0!^V/PI_Y%_2O^O"T_\ 1*5^A87^''_#'\D?
MNN7?P*?_ %[A_P"DH] 6NH]$=0 4 >??%;_D7]5_Z\+O_P!$O7+BOX<O\,OR
M9YV8_P "I_U[G_Z2S\3:_/3\*"@ H * "@ H * "@ H * "@ H * /KK]C#_
M )&"Y_Z\)/\ T=!7NY/_ !'_ (7^<3[+A7^/+_KV_P#TJ!^FM?7GZH% !0 4
M % !0 4 % !0 4 % !0!\$?MP?\ ,)_[?/\ VA7S.=?9_P"WO_;3\\XM_P"7
M?_<3_P!L/@>OF3\\"@ H * "@ H * "@ H * "@ H * /WOK],/Z&"@ H *
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M_7_'_P"B9Z\/./X:_P 2_*1\;Q5_ C_U\7_I,S\R:^//RL* "@ H * "@ H
M* "@ H * "@ H _;'X4_\B_I7_7A:?\ HE*_0L+_  X_X8_DC]UR[^!3_P"O
M</\ TE'?5U'HA0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?F5^V?_ ,C!;?\
M7A'_ .CIZ^0SC^(O\*_.1^5\5?QX_P#7M?\ I4SY%KPCXT* "@ H * "@ H
M* "@ H * "@ H _;'X4_\B_I7_7A:?\ HE*_0L+_  X_X8_DC]UR[^!3_P"O
M</\ TE'?5U'HA0 4 % !0 4 % !0!\$?MP?\PG_M\_\ :%?,YU]G_M[_ -M/
MSSBW_EW_ -Q/_;#X'KYD_/ H * "@ H * "@ H * "@ H * /VQ^%/\ R+^E
M?]>%I_Z)2OT+"_PX_P"&/Y(_=<N_@4_^O</_ $E'?5U'HA0 4 % !0 4 % !
M0 4 % 'P1^W!_P PG_M\_P#:%?,YU]G_ +>_]M/SSBW_ )=_]Q/_ &P^!Z^9
M/SP* "@ H * "@ H * "@ H * "@#]L?A3_R+^E?]>%I_P"B4K]"PO\ #C_A
MC^2/W7+OX%/_ *]P_P#24=]74>B% !0 4 % !0 4 % !0 4 % 'X(5^9G\\A
M0 4 % !0 4 % !0 4 % !0 4 ?MC\*?^1?TK_KPM/_1*5^A87^''_#'\D?NN
M7?P*?_7N'_I*/0%KJ/1'4 % 'GWQ6_Y%_5?^O"[_ /1+URXK^'+_  R_)GG9
MC_ J?]>Y_P#I+/Q-K\]/PH* "@ H * "@ H * "@ H * "@ H ^NOV,/^1@N
M?^O"3_T=!7NY/_$?^%_G$^RX5_CR_P"O;_\ 2H'Z:U]>?J@4 % !0 4 % !0
M 4 % !0 4 % 'P1^W!_S"?\ M\_]H5\SG7V?^WO_ &T_/.+?^7?_ '$_]L/@
M>OF3\\"@ H * "@ H * "@ H * "@ H * /WOK],/Z&"@ H * "@ H * "@#
MX(_;@_YA/_;Y_P"T*^9SK[/_ &]_[:?GG%O_ "[_ .XG_MA\#U\R?G@4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M\*?^1?TK_KPM/_1*5^A87^''_#'\D?NN7?P*?_7N'_I*.^KJ/1"@ H * "@
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M "@ H * "@ H * "@#\$*_,S^>0H * "@ H * "@ H * "@ H * /VQ^%/\
MR+^E?]>%I_Z)2OT+"_PX_P"&/Y(_=<N_@4_^O</_ $E'H"UU'HCJ "@#S[XK
M?\B_JO\ UX7?_HEZY<5_#E_AE^3/.S'^!4_Z]S_])9^)M?GI^%!0 4 % !0
M4 % !0 4 % !0 4 % 'UU^QA_P C!<_]>$G_ *.@KW<G_B/_  O\XGV7"O\
M'E_U[?\ Z5 _36OKS]4"@ H * "@ H * "@ H * "@ H ^"/VX/^83_V^?\
MM"OF<Z^S_P!O?^VGYYQ;_P N_P#N)_[8? ]?,GYX% !0 4 % !0 4 % !0 4
M % !0 4 ?O?7Z8?T,% !0 4 % !0 4 % 'P1^W!_S"?^WS_VA7S.=?9_[>_]
MM/SSBW_EW_W$_P#;#X'KYD_/ H * "@ H * "@ H * "@ H * "@ H * "@
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M 4 % !0 4 % !0 4 % !0!R/CCQQ8_#NQDO[^39$G"J.7D<YVQQKD;G.#@<
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M,OX4OE_Z4CY[B#_=I_\ ;G_I<3\C*^&/QH* "@ H * "@ H * "@ H * "@
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M -H5\SG7V?\ M[_VT_/.+?\ EW_W$_\ ;#X'KYD_/ H * "@ H * "@ H *
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M'P/7S)^>!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M[<;N,YP,>A# TX;17SU_.Y[=')L/2O:$=?YO?_\ 2KV^1Z[7<>R% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M <CXX\<6/P[L9+^_DV1)PJCEY'.=L<:Y&YS@X'  !9BJ*S#"M6C1CS2V_K0X
ML7BX82#G-V2^]OLO/_AWH?D9\5/BI??%B^-U='9$F5M[=3E(D/8=-SG +N0"
MQ X5%1%^&Q6*EB)7>W1=OZZL_&\QS&>.GS2T2^&/1+_/N^OI9+S&N,\H* "@
M H * "@ H * "@ H * "@ H L6EW)82)-"[1R1L&1U)5E93D,I'((/((Y!YI
MIVU149.+NM&G=-:.Y^CWP&_:<_X3.9=+UHQQW;[5MYU&U)FP!L<9PLK'E2NU
M')V*J,$63ZS YE[5\L]'T??_ (/X/;U_3LFX@^L/V=6RD[<LMD_)]F^G1[))
MVO\ 9->^?;!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'X(5^9G\
M\A0 4 % !0 4 % !0 4 % !0 4 % 'ZY_LP_\BCI_P#V\?\ I3+7W.6_PH_/
M_P!*9^R\/_[M#_M__P!+D>^5Z9]"% !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 >!_M/?\BCJ'_;O_Z4Q5YF9?PI?+_T
MI'SW$'^[3_[<_P#2XGY&5\,?C04 % !0 4 % !0 4 % !0 4 % !0!^V/PI_
MY%_2O^O"T_\ 1*5^A87^''_#'\D?NN7?P*?_ %[A_P"DH[ZNH]$* "@ H *
M"@ H * "@ H * "@ H * "@#X(_;@_YA/_;Y_P"T*^9SK[/_ &]_[:?GG%O_
M "[_ .XG_MA\#U\R?G@4 % !0 4 % !0 4 % !0 4 % !0!^V/PI_P"1?TK_
M *\+3_T2E?H6%_AQ_P ,?R1^ZY=_ I_]>X?^DH[ZNH]$* "@ H * "@ H *
M/@C]N#_F$_\ ;Y_[0KYG.OL_]O?^VGYYQ;_R[_[B?^V'P/7S)^>!0 4 % !0
M 4 % !0 4 % !0 4 ?MC\*?^1?TK_KPM/_1*5^A87^''_#'\D?NN7?P*?_7N
M'_I*.^KJ/1"@ H * "@ H * "@ H * /@C]N#_F$_P#;Y_[0KYG.OL_]O?\
MMI^><6_\N_\ N)_[8? ]?,GYX% !0 4 % !0 4 % !0 4 % !0!^V/PI_P"1
M?TK_ *\+3_T2E?H6%_AQ_P ,?R1^ZY=_ I_]>X?^DH[ZNH]$* "@ H * "@
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MZT-@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#D?''CBQ^'=C)?W\FR).%4<O(YSMCC7(W.<' X
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M/#I+[,I)^M^;\I(^DZ]<^H"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /,OC1I<.K^&]4CG7<BV<T@&2/GB4RQG@@\.
MBMCH<8(()!X\9%2IRO\ RM_<KK\4>5FM-5*%1/\ DD_G%<R_%(_%VOS\_#@H
M * "@ H * "@ H * "@ H * "@#]L?A3_P B_I7_ %X6G_HE*_0L+_#C_AC^
M2/W7+OX%/_KW#_TE'?5U'HA0 4 % !0 4 % !0 4 % !0 4 % !0 4 ? '[;
MUW&\FE0AU,BK=,R9&X*YA"L1U 8JP4G@E6 Z''S&=/X5_B_3_(_.N+9*]-=4
MINW6SY;?D_N9\'U\T?GP4 % !0 4 % !0 4 % !0 4 % !0!^\]I:1V$:0PH
ML<<:A410%5548"J!P !P . .*_2TK:(_H2,5%66B2LDM%8L4R@H * "@ H *
M "@ H ^"/VX/^83_ -OG_M"OF<Z^S_V]_P"VGYYQ;_R[_P"XG_MA\#U\R?G@
M4 % !0 4 % !0 4 % !0 4 % '[8_"G_ )%_2O\ KPM/_1*5^A87^''_  Q_
M)'[KEW\"G_U[A_Z2COJZCT0H * "@ H * "@ H * "@#X(_;@_YA/_;Y_P"T
M*^9SK[/_ &]_[:?GG%O_ "[_ .XG_MA\#U\R?G@4 % !0 4 % !0 4 % !0
M4 % '[8_"G_D7]*_Z\+3_P!$I7Z%A?X<?\,?R1^ZY=_ I_\ 7N'_ *2COJZC
MT0H * "@ H * "@ H * "@ H _!"OS,_GD* "@ H * "@ H * "@ H * "@#
M]L?A3_R+^E?]>%I_Z)2OT+"_PX_X8_DC]UR[^!3_ .O</_24>@+74>B.H *
M//OBM_R+^J_]>%W_ .B7KEQ7\.7^&7Y,\[,?X%3_ *]S_P#26?B;7YZ?A04
M% !0 4 % !0 4 % !0 4 % !0!]=?L8?\C!<_P#7A)_Z.@KW<G_B/_"_SB?9
M<*_QY?\ 7M_^E0/TUKZ\_5 H * "@ H * "@ H * "@ H * /@C]N#_F$_\
M;Y_[0KYG.OL_]O?^VGYYQ;_R[_[B?^V'P/7S)^>!0 4 % !0 4 % !0 4 %
M!0 4 =O\-+2._P!<TV&9%DCDOK971@&5E:5058'@@C@@\$<5T897G%/^:/YH
M[\!%2K03U3J033U5N9'[<5^B'[N% !0 4 % !0 4 % 'P1^W!_S"?^WS_P!H
M5\SG7V?^WO\ VT_/.+?^7?\ W$_]L/@>OF3\\"@ H * "@ H * "@ H * "@
M H * /VB^#GA:'PAH-C;QP?9Y&MXI)T*E7,[HIE,F[YM^[@AON@!  JA1^@8
M2DJ<$K6T3?JUJ?N.5X=8>C"*7*W&+DK6?,TKWOK>_P!VVR/3:[#U0H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#D?''CBQ^'=C)?W\FR).%4<O(YSMCC
M7(W.<' X  +,516885JT:,>:6W]:'%B\7#"0<YNR7WM]EY_\.]#\C/BI\5+[
MXL7QNKH[(DRMO;J<I$A[#IN<X!=R 6('"HJ(OPV*Q4L1*[VZ+M_75GXWF.8S
MQT^:6B7PQZ)?Y]WU]+)>8UQGE!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 ?HO^SE^T;_;_EZ+K4G^E<);7+G_ %W81R$_\M>R.?\ 6_=/[W!E^KR_
M,.?W)[]'W\GY_GZ[_I>19[[6U*J_>VC)]?)^?9]?7?[8KZ$^["@ H * "@ H
M * "@ H * "@ H * "@ H * "@#\$*_,S^>0H * "@ H * "@ H * "@ H *
M "@#]%_V)]<^T:?J%ALQY-Q'-OS][STV;=N.-ODYSDYW8P-O/U>33O&4>S3^
M]6_0_2^$ZUX3A;:2E?\ Q*W_ +9^)]L5]"?=A0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ' _%;_D7]5_Z\+O\ ]$O7
M+BOX<O\ #+\F>=F/\"I_U[G_ .DL_$ZOST_"@H * "@ H * "@ H * "@ H
M* "@#]L?A3_R+^E?]>%I_P"B4K]"PO\ #C_AC^2/W7+OX%/_ *]P_P#24=]7
M4>B% !0 4 % !0 4 % !0 4 % !0 4 % !0!^87[9-W'<>(H51U9H[&)9 ""
M48R2N%8#H=K*V#SM93T(KX[-W>HO**_-L_*>*9)UU;I3BGY/FD_R:9\FUXA\
M>% !0 4 % !0 4 % !0 4 % !0!ZK\#M%DU[Q+ID,14,MU',2Q(&V ^<XX!Y
M*H0O8M@$@9([<%#GJ12[I_=K^AZ^44G5Q%-+^=/7M'WG^"T/V:K[\_;PH *
M"@ H * "@ H * /@C]N#_F$_]OG_ +0KYG.OL_\ ;W_MI^><6_\ +O\ [B?^
MV'P/7S)^>!0 4 % !0 4 % !0 4 % !0 4 ?MC\*?^1?TK_KPM/_ $2E?H6%
M_AQ_PQ_)'[KEW\"G_P!>X?\ I*.^KJ/1"@ H * "@ H * "@ H * /@C]N#_
M )A/_;Y_[0KYG.OL_P#;W_MI^><6_P#+O_N)_P"V'P/7S)^>!0 4 % !0 4
M% !0 4 % !0 4 ?MC\*?^1?TK_KPM/\ T2E?H6%_AQ_PQ_)'[KEW\"G_ ->X
M?^DH[ZNH]$* "@ H * "@ H * "@ H * /P0K\S/YY"@ H * "@ H * "@ H
M * "@ H _;'X4_\ (OZ5_P!>%I_Z)2OT+"_PX_X8_DC]UR[^!3_Z]P_])1Z
MM=1Z(Z@ H \^^*W_ "+^J_\ 7A=_^B7KEQ7\.7^&7Y,\[,?X%3_KW/\ ])9^
M)M?GI^%!0 4 % !0 4 % !0 4 % !0 4 % 'UU^QA_R,%S_UX2?^CH*]W)_X
MC_PO\XGV7"O\>7_7M_\ I4#]-:^O/U0* "@ H * "@ H * "@ H * "@#X(_
M;@_YA/\ V^?^T*^9SK[/_;W_ +:?GG%O_+O_ +B?^V'P/7S)^>!0 4 % !0
M4 % !0 4 % !0 4 ?3?[)&A_VMXGCFW[?LEO--C&=^X"#;G(V_ZW=GG[N,<Y
M'L95#FJ7[)O]/U/JN&J/M,0G?X(REZ_9_P#;K_(_52OM#]<"@ H * "@ H *
M "@#XG_;8T/[1I^GW^_'DW$D.S'WO/3?NW9XV^3C&#G=G(V\_/9S"\8R[-K[
MU?\ 0^$XLHWA"=]I.-O\2O\ ^V?B?G17RA^:!0 4 % !0 4 % !0 4 % !0
M4 % '[WU^F']#!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M3_ _1ZOK#]-"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * ,#Q7H?_"3Z?=6&_P O[3;RP[\;MOF(4W;<C.,YQD9Z9%95
M8>TBX]TU]ZL<^)H^VA*%[<T91OONFO+N?A?7YP?@(4 % !0 4 % !0 4 % !
M0 4 % !0!^V/PI_Y%_2O^O"T_P#1*5^A87^''_#'\D?NN7?P*?\ U[A_Z2CO
MJZCT0H * "@ H * "@ H * "@ H * "@ H * /R,_:>_Y&[4/^W?_P!)HJ^&
MS+^++Y?^DH_&^(/]YG_VY_Z1$\#KS#YT* "@ H * "@ H * "@ H * "@#ZC
M_9"T6/5/$HF<L&M;6::, C!8E82&R#D;96/&#N"G.,@^SE,.:I?LF_R7ZGUG
M#-)3Q%W]F$FO72/Y29^IE?9GZT% !0 4 % !0 4 % !0!\$?MP?\PG_M\_\
M:%?,YU]G_M[_ -M/SSBW_EW_ -Q/_;#X'KYD_/ H * "@ H * "@ H * "@
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MR2268L[,Q^&K5I5I<TM_ZT/QO%XN>+FYS=V_N2[+R_X=ZG(5@<04 % !0 4
M% !0 4 % !0![I\-?V>=:^*%JU[:^3#;AMJ27#.@E(R&\L*CDA2,%B N[*@D
MJX7TL/@)UU=62\[Z_<F?08#)*N-CSQLE?1R;5^]K)[=_ET=N)^(/PSU/X8W
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M\K'[GEDE*A3MK^[@M.ZBD_N:LST:NL],* "@ H * "@ H * "@ H * "@ H
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MA'[J% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'YI?MD^$5TC6+?4D"A;Z$A_F8L98-JEB#P!L:)5VGDJQ*@\M\CF
M]+EFI?S+\5_P+'Y;Q3AO9U547VXZ[WO&RO\ <TM.S^?Q[7@GQ84 % !0 4 %
M !0 4 % !0 4 % 'Z+_L3ZY]HT_4+#9CR;B.;?G[WGILV[<<;?)SG)SNQ@;>
M?J\FG>,H]FG]ZM^A^E\)UKPG"VTE*_\ B5O_ &S\3[8KZ$^["@ H * "@ H
M* "@ H * "@ H * "@ H _"CQ!K4GB2\N+Z8*)+F:29PH(4-(Q<A023C)XR2
M<=S7YO4GSMR?5M_?J?S_ %ZKK2<WO*3;MM=NYCUF8A0 4 % !0 4 % !0 4
M% !0 4 ?JY^R=HL>E^%H)D+%KJ:>:0$C 8.80%P!@;8E/.3N+'., ?:Y7#EI
M)]VW^-OT/U[ANDH8=-?:E)OUOR_E%'TG7KGU 4 % !0 4 % !0 4 % 'P1^W
M!_S"?^WS_P!H5\SG7V?^WO\ VT_/.+?^7?\ W$_]L/@>OF3\\"@ H * "@ H
M * "@ H * "@ H _;'X4_P#(OZ5_UX6G_HE*_0L+_#C_ (8_DC]UR[^!3_Z]
MP_\ 24=]74>B% !0 4 % !0 4 % !0 4 ?!'[<'_ #"?^WS_ -H5\SG7V?\
MM[_VT_/.+?\ EW_W$_\ ;#X'KYD_/ H * "@ H * "@ H * "@ H * /VQ^%
M/_(OZ5_UX6G_ *)2OT+"_P ./^&/Y(_=<N_@4_\ KW#_ -)1WU=1Z(4 % !0
M 4 % !0 4 % !0 4 ?@A7YF?SR% !0 4 % !0 4 % !0 4 % !0!^V/PI_Y%
M_2O^O"T_]$I7Z%A?X<?\,?R1^ZY=_ I_]>X?^DH] 6NH]$=0 4 >??%;_D7]
M5_Z\+O\ ]$O7+BOX<O\ #+\F>=F/\"I_U[G_ .DL_$VOST_"@H * "@ H *
M"@ H * "@ H * "@#ZZ_8P_Y&"Y_Z\)/_1T%>[D_\1_X7^<3[+A7^/+_ *]O
M_P!*@?IK7UY^J!0 4 % !0 4 % !0 4 % !0!@>*]<_X1C3[J_V>9]FMY9MF
M=N[RT+[=V#C.,9P<=<&LJL_9Q<NR;^Y7.?$UO8PE.U^6,I6VV3?GV/POK\X/
MP$* "@ H * "@ H * "@ H * "@ H _=#PIH?_",:?:V&_S/LUO%#OQMW>6@
M3=MR<9QG&3CIDU^CTH>SBH]DE]RL?OV&H^QA&%[\L8QOMLDO/L;]:G0% !0
M4 % !0 4 % !0!^*WQ=T!O#/B#4;4Q+"JW4K1QKM"K%(WF1;0O &QE(48VCY
M2 00/S[%T_9U)+;5Z>3U7X'X9F='V-:<;6]]V2M:S=UMY-:=#SFN0\P* "@
MH * "@ H * "@ H * "@#]5/V2-<_M;PQ'#LV_9+B:'.<[]Q$^[&!M_UNW'/
MW<YYP/M,JGS4[=FU^OZGZYPU6]IATK?!*4?7[7_MUOD?3=>P?5!0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M5Z1(4 % !0 4 % !0 4 % !0!]L_LY?M&_V!Y>BZU)_HO"6URY_U/81R$_\
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M%&$[W;BKNUO>6CZ+JGY=M#OJZCT0H * "@ H * "@ H * "@ H * "@ H *
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M_(OZ5_UX6G_HE*_0L+_#C_AC^2/W7+OX%/\ Z]P_])1WU=1Z(4 % !0 4 %
M!0 4 % !0!\$?MP?\PG_ +?/_:%?,YU]G_M[_P!M/SSBW_EW_P!Q/_;#X'KY
MD_/ H * "@ H * "@ H * "@ H * /VQ^%/_ "+^E?\ 7A:?^B4K]"PO\./^
M&/Y(_=<N_@4_^O</_24=]74>B% !0 4 % !0 4 % !0 4 % 'X(5^9G\\A0
M4 % !0 4 % !0 4 % !0 4 ?MC\*?^1?TK_KPM/_ $2E?H6%_AQ_PQ_)'[KE
MW\"G_P!>X?\ I*/0%KJ/1'4 % 'GWQ6_Y%_5?^O"[_\ 1+URXK^'+_#+\F>=
MF/\  J?]>Y_^DL_$VOST_"@H * "@ H * "@ H * "@ H * "@#ZZ_8P_P"1
M@N?^O"3_ -'05[N3_P 1_P"%_G$^RX5_CR_Z]O\ ]*@?IK7UY^J!0 4 % !0
M 4 % !0 4 % !0!^=/[9_C'[;?6FD1ME+>,S2A9,CS)>$5XQP'1%W*6R=LW
M .6^4SBM>2AV5WKU?EZ?F?FG%6*YIQI+[*YGKU>UUW25UY2^_P")J^>/A H
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M)_[?/_:%?,YU]G_M[_VT_/.+?^7?_<3_ -L/@>OF3\\"@ H * "@ H * "@
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MP2-V<8&!7Y]B:WMIN7=_@M%WZ(_#,PQ?UNK*IMS/3T2275ZV2OYG URGG!0
M4 % !0 4 % !0 4 % !0!8M+22_D2&%&DDD8*B*"S,S' 50.22> !R3Q32OH
MBHQ<G9:MNR2U=S]H?A1X!C^&FCV^G+M,BKNG=<?/,_+MG:I8 _*A8;A&J*>E
M?H&%H>P@H_?Z]>WR\C]QRW!+!THPZI7D^\GOT5^ROK9(]&KK/3"@ H * "@
MH * "@ H * *]W:1W\;PS(LD<BE71@&5E88*L#P01P0>".*35]&3**DK/5-6
M:>JL?B?\2/"+>!-8O--(8+!,PCW,K,8C\T3,5XRR%6. ,$X*J<@?GF(I>RFX
M]G^'3\#\*Q^&^JU94_Y9.U[-VW3T[IIG$5SG % !0 4 % !0 4 % !0 4 %
M!0!^JG[)_C'_ (2;P\EM(VZ:QD:$[I-[F,_/$Q!Y1 &,2#D8B.#@;5^TRNMS
MT[=8NV]]-U_DO0_7.&\5[:ARO>#<=[NVZ]%K9>FG9?3=>P?5!0 4 % !0 4
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MKS3L]C/J#,* "@ H * "@ H * "@ H * /JK]G+X\S> KB/2KYM^F3R!59F
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MA7S.=?9_[>_]M/SSBW_EW_W$_P#;#X'KYD_/ H * "@ H * "@ H * "@ H
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M!!%?=4ZBJ*ZU3/V>C6C7BIP=TUHU_7WKILS7K0V"@ H * "@ H * "@ H *
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MN9^B7D?B&8X^6.J<\M-+)+HM=//?5_DM#SFN0\P* "@ H * "@ H * "@ H
M* /5?@S\-6^*FL1V!9D@"M+<2+MW+$F =H8]68J@(#;2V\JRJ17;@\/]8GR]
M-WZ?UH>OE6 ^O55#96;DU:]EZ]VTNMKWL['[)6EI'81I#"BQQQJ%1% 5551@
M*H'  '  X XK[Y*VB/VV,5%66B2LDM%8L4R@H * "@ H * "@ H ^+OVLOA
MNMVIU^R11<6R_P"EA48O-%\H5_ER,Q#)8D#]UDEP(E4_/YIA.9>T6ZW\U_P/
MRZZ'P_$F6>TC[:"UBO>LG=K17T[=?+=Z)'YPU\F?F(4 % !0 4 % !0 4 %
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MW!_S"?\ M\_]H5\SG7V?^WO_ &T_/.+?^7?_ '$_]L/@>OF3\\"@ H * "@
MH * "@ H * "@ H _;'X4_\ (OZ5_P!>%I_Z)2OT+"_PX_X8_DC]UR[^!3_Z
M]P_])1WU=1Z(4 % !0 4 % !0 4 % !0 4 ?@A7YF?SR% !0 4 % !0 4 %
M!0 4 % !0!^V/PI_Y%_2O^O"T_\ 1*5^A87^''_#'\D?NN7?P*?_ %[A_P"D
MH] 6NH]$=0 4 >??%;_D7]5_Z\+O_P!$O7+BOX<O\,OR9YV8_P "I_U[G_Z2
MS\3:_/3\*"@ H * "@ H * "@ H * "@ H * /KK]C#_ )&"Y_Z\)/\ T=!7
MNY/_ !'_ (7^<3[+A7^/+_KV_P#TJ!^FM?7GZH% !0 4 % !0 4 % !0!\3_
M +1O[1O]@>9HNBR?Z5RES<H?]3V,<9'_ "U[.X_U7W1^]R8OGLPS#D]R&_5]
MO)>?Y>NWPF>Y[[*]*D_>VE)=/)>?=]/7;\Z*^4/S0* "@ H * "@ H * "@
MH * "@#8T#0+KQ1=165E$TUQ,VV.->I/4\G@ #)9B0JJ"Q( )K2G3=1V6K9M
M1HRKR4(*[;T2_K[WTW9^U/@+P?#X!TRVTR [DMXPI;D;W)+2/@LQ&YRS;<D+
MG:. *_0:%)48J*Z+_A_Q/W/!X586G&FOLK?N]V]WNVW;H==6YVA0 4 % !0
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MGH^OW[=#]2P.;T<9I%VE_++277Y/17T;LM['KM=Q[(4 % !0 4 % !0 4 %
M!0 4 % '(^)?'^D^#]PU"\M[=UC,GEO(HD*#/*QYWOG:0 H)8C: 3Q6%2O"G
M\32TOOK]VYQ5\;3P_P <HQTO9M7MY+=[=%J?+GCO]LFPTMFAT:W:\;:V)Y"8
MH@Q4%"$*^8X!)#JWDGY<*Q#!AXU?-XQT@K^;T7^;_ ^4QG%,(:4ES:/WG>*O
M;32UWY_#MH^I\(>./'%]\1+Z2_OY-\K\*HX2-!G;'&N3M09.!R2268L[,Q^:
MK5I5I<TM_P"M#\^Q>+GBYN<W=O[DNR\O^'>IR%8'$>J_"WXOZE\*KI9;9VDM
M=Q,UHSD12!L!CCD+)A1MD W# !W)N1NW#8N6'=UMU73_ (?S/7R[,ZF!E>+O
M&^L6]'M]STT?YK0_4WX5_%2Q^+%B+JU.R5,+<6['+Q.>QZ;D."4< !@#PKJZ
M+]GA<5'$1NM^J[?UT9^M9=F,,=#FCHU\4>J?^79]?6Z7IM=AZH4 % !0 4 %
M !0 4 % !0 4 % !0 4 ?GC^UM\7UU20>'[%U:*)@]W(CMS*I8" @84A.'<?
M/^\VCY'B8'Y;-<7S?NX[+?U[?UU]#\VXES/G?L(/1.\FF]U?W>VF[WUMLTSX
M>KYP^""@ H * "@ H * "@ H * "@ H _6S]G#X6K\.-'66966^O526Y#%OE
M W&*/8P7:45OG!&[S"XW%0@'W&7X;V$+O>5F_P!%^.OF?L619=]3I7?Q32<M
M_.RLTK63U\[ZVL?0=>H?2!0 4 % !0 4 % !0 4 % 'Y.?M$?!?_ (5;?":S
M20Z9<\QLW(BDY)@+9). -R%\%E)&7:-W/Q&88/ZO*Z^%[>3[?Y?K8_'\\RKZ
ME.\4^26WD]?=O^*ONN]FSYSKRCYD* "@ H * "@ H * "@ H * +%I=R6$B3
M0NT<D;!D=25964Y#*1R"#R".0>::=M45&3B[K1IW36CN?L'\#/B='\3]'BG:
M16O856.[3(W"09 <@*H E WKM&P$L@)*-C[S!8GV\$^JT?KWZ;[_ (=#]IRC
M,%C:2=_>2M)=;]]EO:^FFZZ,]DKO/;"@ H * "@ H * "@ H * /.?BOX!C^
M)>CW&G-M$C+N@=L?),G*-G:Q4$_*Y4;C&SJ.M<F*H>W@X_=Z]._S\CS,RP2Q
ME*4.K5XOM);=';L[:V;/Q>N[22PD>&9&CDC8JZ,"K*RG!5@>00>"#R#Q7Y^U
M;1GX=*+B[/1IV:>CN5Z1(4 % !0 4 % !0 4 % !0 4 % 'HWPU^*6I?"JZ:
MYT]EQ(NV6&0%HI ,[=R@J<J3E6!##D9VLZMUX?$RP[O'YI['IX#,:F!ES0ZK
M5/5/UU6W1_HV?JY\*_BI8_%BQ%U:G9*F%N+=CEXG/8]-R'!*.  P!X5U=%^U
MPN*CB(W6_5=OZZ,_7LNS&&.AS1T:^*/5/_+L^OK=+TVNP]4* "@ H * "@ H
M * "@ H * "@#(UKQ!9^&XQ-?7$-M&6"AYI%C4L02%!<@9P"<=< GM6<ZBAK
M)I>KM^9C5KQHJ\VHJ]KR:2O\SY%^(/[8MAIT;Q:'&US<!DVS3(4M]I&6(7<L
MK$?<VD1C.6W$* _AXC-XQTAJ^[6GZ/\ (^-QO%$()JBN9W6LDU&W7JI/MLN]
M^_QMK7QQ\2Z]()9M3NE8*% AD,"X!)Y2'8I//WB-Q&!G  '@3QM2>KD_D[?E
M8^(JYOB*KNZDMOLOE7W1LOF;_A']H_Q+X188O&NH]S,8[K,P8E=O+D^: .&"
MJZKN&<'+!M:685*?6_E+7_@_B=.&SW$4/M<ROM/WNEMW[WR37YGZ#_"+X]Z;
M\5H]GRVM\&(-H\@+,,%@T387S!M!+84,A!W+MVLWU&$QT<1Y/M?\MK_H?H^6
M9S3QRM\,K_"WKU=UM?1:Z:==+-^Z5Z1[X4 % !0 4 % !0 4 % !0!X7^T%\
M+6^*.CM%;JIOK=O-MB2JY/1X]Y!P'7H,JID6,LP52:\W'X;V\++=:K_+^NMC
MP,ZR[Z[2M'XHN\=EZJ[75>FJ5W9'Y"5\*?C 4 % !0 4 % !0 4 % !0 4 %
M 'OGP(^-DWPFNRLYDDTR;<9X4 9@^T[)(PS(%?(57.<,G4%E0KZ>!QCP[U^%
M[K]5JO\ AOD?19/FSP,M;N#O=+76VC5VM=D^Z]%;]7- U^U\46L5[92K-;S+
MNCD7H1T/!Y!!R&4@,K J0""*^UIU%45UJF?KU&M&O%3@[IK1K^OO739FO6AL
M% !0 4 % !0 4 % !0!\3_M<?%G^R;=="L9L3S9-YL;YDA*_+$WR\>;NW$!E
M;8N&4QR\_/9KBN5<D7J]_3M\_P O)GPG$N9>SC[&#U?QV>T;;/3K>^][+721
M^=%?*'YH% !0 4 % !0 4 % !0 4 % !0!]=?LC_  V_X274VU:X3-M88\O<
MN5>X8?+C*E3Y:Y<X*NCF%AP:]W*L/SRYWM';U^[IOY.Q]EPU@/;5/:R7NPV\
MY/;=6T6N]T^5GZ:U]>?J@4 % !0 4 % !0 4 % !0 4 % 'P1^W!_P PG_M\
M_P#:%?,YU]G_ +>_]M/SSBW_ )=_]Q/_ &P^!Z^9/SP* "@ H * "@ H * "
M@ H * "@#]L?A3_R+^E?]>%I_P"B4K]"PO\ #C_AC^2/W7+OX%/_ *]P_P#2
M4=]74>B% !0 4 % !0 4 % !0 4 ?!'[<'_,)_[?/_:%?,YU]G_M[_VT_/.+
M?^7?_<3_ -L/@>OF3\\"@ H * "@ H * "@ H * "@ H _;'X4_\B_I7_7A:
M?^B4K]"PO\./^&/Y(_=<N_@4_P#KW#_TE'?5U'HA0 4 % !0 4 % !0 4 %
M!0!^"%?F9_/(4 % !0 4 % !0 4 % !0 4 % '[8_"G_ )%_2O\ KPM/_1*5
M^A87^''_  Q_)'[KEW\"G_U[A_Z2CT!:ZCT1U !0!Y]\5O\ D7]5_P"O"[_]
M$O7+BOX<O\,OR9YV8_P*G_7N?_I+/Q-K\]/PH* "@ H * "@ H * "@ H *
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M# '#*K9 ^!K4G2DXO='XGBL-+"S=.6\7TU6UT_FG?\SF*Q.0* "@ H * "@
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MU=RO2)"@ H * "@ H * "@ H * "@#8T#0+KQ1=165E$TUQ,VV.->I/4\G@
M#)9B0JJ"Q( )K2G3=1V6K9M1HRKR4(*[;T2_K[WTW9^U/@+P?#X!TRVTR [D
MMXPI;D;W)+2/@LQ&YRS;<D+G:. *_0:%)48J*Z+_ (?\3]SP>%6%IQIK[*W[
MO=O=[MMVZ'75N=H4 % !0 4 % !0 4 % !0 4 % 'P1^W!_S"?\ M\_]H5\S
MG7V?^WO_ &T_/.+?^7?_ '$_]L/@>OF3\\"@ H * "@ H * "@ H * "@ H
M_;'X4_\ (OZ5_P!>%I_Z)2OT+"_PX_X8_DC]UR[^!3_Z]P_])1WU=1Z(4 %
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MO_\ P+F_^+H^M5/YI?\ @3_S#^T:_P#S\G_X'+_,/^%K>(/^@K?_ /@7-_\
M%T?6JG\TO_ G_F']HU_^?D__  .7^8?\+6\0?]!6_P#_  +F_P#BZ/K53^:7
M_@3_ ,P_M&O_ ,_)_P#@<O\ ,X&N4\X* "@ H * "@ H * "@ H * "@ H *
M "@#ZC_9]_9]D^),BZAJ"M'I<;<#E6N64X*(>HC!XDD'.<QH=^YHO9P& ]O[
MTOA_/_@=W\EY?69+DKQCYYZ4T_1R?9>7=_):W:_4ROLS]:"@ H * "@ H *
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M/B#+/K4.>"O."V25VKZKOINOFDKL_+*OC#\E"@ H * "@ H * "@ H * "@
MH _3W]E#XI-XPTUM+NF7[58*BQ\*I>V "IP#EC&1L=@H 4Q9+.S$_8Y7B?:1
MY7O&UO3_ ('^1^K<.9C]8I^SE\5-*VRO#9==;;-V[;MGUE7MGV 4 % !0 4
M% !0 4 % !0!0U72X=;MY;6X7?#/&\<BY(W(ZE6&001D$C((([$&IE%333V:
ML_F9U*:J1<9:J2::\FK/8_)/XW?!&Z^$=UN7=-ITS$03D<@]?*EQP) ,X/"R
M*"R@$.B?#XW!/#OO%[/]'Y_G^7X[FV4RP$N\&_=E^C\_SW75+PNO-/GPH *
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MY%_2O^O"T_\ 1*5^A87^''_#'\D?NN7?P*?_ %[A_P"DH[ZNH]$* "@ H *
M"@ H * "@ H * /P0K\S/YY"@ H * "@ H * "@ H * "@ H _;'X4_\B_I7
M_7A:?^B4K]"PO\./^&/Y(_=<N_@4_P#KW#_TE'H"UU'HCJ "@#S[XK?\B_JO
M_7A=_P#HEZY<5_#E_AE^3/.S'^!4_P"O<_\ TEGXFU^>GX4% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 ?77P._9CN/&GD:GJP\K36^=8<LLTZC&T\ ;(GR?GR'91\H =)1[N"RUU
M;2GI'MU?^2_'[[GV64</RQ%JE32#UMJI/MZ)]]VMMTS]+;2TCL(TAA18XXU"
MHB@*JJHP%4#@ #@ < <5]<E;1'ZE&*BK+1)626BL6*904 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!R/CCP/8_$2QDL+^/?$_*L.'C<9VR1M@[7&3@\@@E6
M#(S*<*U&-:/++;^M3BQ>$ABX.$U=/[T^Z\_^&>A^-OCCP/??#N^DL+^/9*G*
ML.4D0YVR1M@;D.#@\$$%6"NK*/@:U&5&7++?^M3\3Q>$GA)N$U9K[FNZ\O\
MAGJ<A6!Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M'Y#GF5?4IWBGR2V\GK[M_P 5?==[-GSG7E'S(4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^B_[.7[.7]@>7
MK6M1_P"E</;6SC_4]Q)(#_RU[HA_U7WC^]P(OJ\OR_D]^>_1=O-^?Y>NWZ7D
M61>RM5JKWMXQ?3S?GV73UV^V*^A/NPH * "@ H * "@ H * "@ H * "@ H
M^"/VX/\ F$_]OG_M"OF<Z^S_ -O?^VGYYQ;_ ,N_^XG_ +8? ]?,GYX% !0
M4 % !0 4 % !0 4 % !0!^V/PI_Y%_2O^O"T_P#1*5^A87^''_#'\D?NN7?P
M*?\ U[A_Z2COJZCT0H * "@ H * "@ H * "@#X(_;@_YA/_ &^?^T*^9SK[
M/_;W_MI^><6_\N_^XG_MA\#U\R?G@4 % !0 4 % !0 4 % !0 4 % '[8_"G
M_D7]*_Z\+3_T2E?H6%_AQ_PQ_)'[KEW\"G_U[A_Z2COJZCT0H * "@ H * "
M@ H * "@ H _!"OS,_GD* "@ H * "@ H * "@ H * "@#]L?A3_ ,B_I7_7
MA:?^B4K]"PO\./\ AC^2/W7+OX%/_KW#_P!)1Z M=1Z(Z@ H \^^*W_(OZK_
M ->%W_Z)>N7%?PY?X9?DSSLQ_@5/^O<__26?B;7YZ?A04 % !0 4 % !0 4
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M5G:_39^:NG\O0YBL3D"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MMT??^NJ/Q3,<NG@9\LM4_AET:_S[KIZ6;\QKC/*"@ H * "@ H * "@ H *
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M,OR9YV8_P*G_ %[G_P"DL_$VOST_"@H * "@ H * "@ H * "@ H * "@ H
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M0PPP&&4@J>#C<J,O)B,-'$*TODUN>9C\NIXZ/+/H]&M&O31[]5^J1^8?Q4^
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M^AAHT%:*]7U?]?<?J>"P%/!1Y::M>UWNW96U?Z*RU=DKG?5U'HA0 4 % !0
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MO%27S79_U^!^XX#&QQM-5(Z7W5T[-;K3[UMHT[*YWU=1Z(4 % !0 4 % !0
M4 % !0 4 <CXX\#V/Q$L9+"_CWQ/RK#AXW&=LD;8.UQDX/(()5@R,RG"M1C6
MCRRV_K4XL7A(8N#A-73^]/NO/_AGH?E'\6O@CJ7PCD4W&V:TE9EBN(P=I()P
MK@_<D*C=MRRD9VN^Q]OQ6*P4L/OJGLU_6C/R',LIJ8!^]K%MVDMO1]G;6WW-
MV9XU7GGB!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MP/URLHOX5[TO\*^:>KLM-5>_0_8JTM(["-(846..-0J(H"JJJ,!5 X  X '
M'%?>I6T1^UQBHJRT25DEHK%BF4% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M 4-5TN'6[>6UN%WPSQO'(N2-R.I5AD$$9!(R"".Q!J914TT]FK/YF=2FJD7&
M6JDFFO)JSV/Q&\:>&)/!FI76G2[BUM,\89D*%U!^1]I)P'7#KR058$$C!/YW
M6I^RDXOHVNWS/PC%X=X>I*#^S)K56NNCMYK5',5B<@4 % !0 4 % !0 4 %
M!0 4 ?9/[''CAM+U.;2)),0W<9DB0[S^_B&3MP=J[H]Y<D#=Y<8W9 5O?RBM
MRR<'M)76^Z_X'Y(^WX7Q?)4=)O2:NEK\2_!75[][+4_2:OK3]/"@ H * "@
MH * "@ H * "@ H KW=I'?QO#,BR1R*5=& 965A@JP/!!'!!X(XI-7T9,HJ2
ML]4U9IZJQ\(?%O\ 9$^]=^&_]@&Q=OP9HYI'_P!UBDA_OD2?<CKYK%Y3UI^7
MN_\ !;_/[^A^?9GPS]JAY>XW][4I/\'YZ[(^%]4TJXT29K>ZBD@F3&Z.1&1U
MR 1E6 (R"",CD$'H:^<E%P=FK/L]#X"I3E3?+)--=&FGWV9GU!F% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '3^$?!M_X[NA9Z; T\
MY5FV@@ *O5F9B%4=!EB 6*J/F8 [4J,JKM%79UX;"SQ4N2FKNU^FR\W9+Y^A
M^A_PD_92L?"6VZUGR[V[&\>5C?:J#P#M= 9'QDY<!06X3<BR'ZK"97&GK/WG
MKIO'\5K_ %IU/TG+.'(4/>JVG+73>'W-:OUTUVNDSZYKW#[(* "@ H * "@
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M?^B4K]"PO\./^&/Y(_=<N_@4_P#KW#_TE'?5U'HA0 4 % !0 4 % !0 4 %
M!0!^"%?F9_/(4 % !0 4 % !0 4 % !0 4 % '[8_"G_ )%_2O\ KPM/_1*5
M^A87^''_  Q_)'[KEW\"G_U[A_Z2CT!:ZCT1U !0!Y]\5O\ D7]5_P"O"[_]
M$O7+BOX<O\,OR9YV8_P*G_7N?_I+/Q-K\]/PH* "@ H * "@ H * "@ H *
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MVOV5EOH>FUV'JA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5?\  _(_,N*<'R355?;5I:.UTE;7S733X6^Y\75\^?#!0 4 % !0 4 % !0
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MP_\ 24=]74>B% !0 4 % !0 4 % !0 4 ?!'[<'_ #"?^WS_ -H5\SG7V?\
MM[_VT_/.+?\ EW_W$_\ ;#X'KYD_/ H * "@ H * "@ H * "@ H * /VQ^%
M/_(OZ5_UX6G_ *)2OT+"_P ./^&/Y(_=<N_@4_\ KW#_ -)1WU=1Z(4 % !0
M 4 % !0 4 % !0 4 ?@A7YF?SR% !0 4 % !0 4 % !0 4 % !0!^V/PI_Y%
M_2O^O"T_]$I7Z%A?X<?\,?R1^ZY=_ I_]>X?^DH] 6NH]$=0 4 >??%;_D7]
M5_Z\+O\ ]$O7+BOX<O\ #+\F>=F/\"I_U[G_ .DL_$VOST_"@H * "@ H *
M"@ H * "@ H * -_0_"FH>)]_P!@M;BY\O&_R8GDV[L[=VP'&<'&>N#Z5K"E
M*I\*;MV3?Y'31PTZU^2,I6WY8M[^B?8W_P#A5/B#_H%7_P#X"3?_ !%:_5:G
M\LO_  %_Y'1_9U?_ )]S_P# )?Y!_P *I\0?] J__P# 2;_XBCZK4_EE_P"
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M_P"&8?%W_0/_ /)BV_\ CM5_9M7^7\8_YFO^K^)_D_\ )X?_ "0?\,P^+O\
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MG;'&BHBY))PJ@ 9)).!R23U->G&*@K)679:'T5.G&FN6*22Z))+OLB_5&@4
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M(8UC4L0 6(0 9P ,]< #M7K0IJ&D4EZ*WY'U%*A&BK02BKWM%)*_R->M#8*
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M_P#_  $F_P#B*/JM3^67_@+_ ,@_LZO_ ,^Y_P#@$O\ (/\ A5/B#_H%7_\
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M7_\ X"3?_$4?5:G\LO\ P%_Y!_9U?_GW/_P"7^0?\*I\0?\ 0*O_ /P$F_\
MB*/JM3^67_@+_P @_LZO_P ^Y_\ @$O\@_X53X@_Z!5__P" DW_Q%'U6I_++
M_P !?^0?V=7_ .?<_P#P"7^0?\*I\0?] J__ / 2;_XBCZK4_EE_X"_\@_LZ
MO_S[G_X!+_(/^%4^(/\ H%7_ /X"3?\ Q%'U6I_++_P%_P"0?V=7_P"?<_\
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MZMSM"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M!_PQAX?_ .?F_P#^_D/_ ,8H_L>GWE]Z_P#D0_U5H?S3^^/_ ,@'_#&'A_\
MY^;_ /[^0_\ QBC^QZ?>7WK_ .1#_56A_-/[X_\ R ?\,8>'_P#GYO\ _OY#
M_P#&*/['I]Y?>O\ Y$/]5:'\T_OC_P#(!_PQAX?_ .?F_P#^_D/_ ,8H_L>G
MWE]Z_P#D0_U5H?S3^^/_ ,@'_#&'A_\ Y^;_ /[^0_\ QBC^QZ?>7WK_ .1#
M_56A_-/[X_\ R!O:'^R1X8TG?YT=Q=[L8\Z8KLQG.WR!%USSNW=!C'.=(953
MCO=^K_RL=%'AK#T[W4I7_FE:W_@/+^-ST[2_@OX;TB%8(]+LV1<X,D*ROR2>
M9)0[MUXW,<# &  !V1P=.*MRKYI/\7=GJT\JH4U94X:=XJ3^^5W^)Z;78>J%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M'_\ GYO_ /OY#_\ &*/['I]Y?>O_ )$/]5:'\T_OC_\ (!_PQAX?_P"?F_\
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M  QAX?\ ^?F__P"_D/\ \8H_L>GWE]Z_^1#_ %5H?S3^^/\ \@'_  QAX?\
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M=]74>B% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 .6
M@!U !0 F* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H
M ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4
M &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &*
M #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #%
M !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B
M@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q
M0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8
MH ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,
M4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &
M* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #
M% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !
MB@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@
MQ0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0
M8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H
M,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4
M&* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &*
*#% !C% "T ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>dxcm-20231231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dxcm-20231231_g2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#(UO7;+P[;&\U"011 X'!+,Q!(5%&2S'!X'09)( )
M!YY;?&?09Y1$RW4*DX\R2)-@YQD[)7?'?[F<=J .PUSQC9: ;03"28:BX2%H
M0C+SLPS%I$^4^8I!7=D9XZ9 .JH * "@ H * "@ H * .?\ $/B6U\-1127(
MDD:XE6&**%5:1W;H%#,@P.Y+#J!R2 0#H* "@ H * ,2;7[>'5(M%*R-<30M
M< J%\M8U)7+DL&!9@0N%89ZD4 2Z[K,/A^QEU&Y5WB@ +",*7.YE0;0S*O5A
MU8<9^E '/R^/;"%=-9H[C&ML%M\+'\A+1)^^_>_*,RK]SS. WH 0#8T[Q%;:
MC?76F()([FQ*^8L@5=RN,K)'AFW1D$<D*1E<@9% &]0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M'&0KKMY'*@4 >A4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M<^A0'H] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 1SP1W$;
M0S*LD;J596 *LI&""#P01P0: .5T_P !Z'I<Z75M:JLL1)CW22R+&3WCCDD>
M.,YY!15(/3% '2WEI%?P26EPN^&>-XI%R1N1U*LN5(894D94@CJ"#0!7&D6@
MLETLQ*UFD2P")\NOE(H15)8DG"@#));C.<\T 96C^#=(T&;[38VXCFV[ [22
MRLJ?W4,KOL7V3:.W2@#IJ "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * ,NTUS3[Z4V]K=6\\R_>CCFC=QCU56+#\10 M]K>GZ6P2]NK>V9O
MNK--'&3] [*3^% %]9HW3S593&1N#@@KMQG=NZ8QSG.,4 4;'6;#5"RV5S;W
M+1_>$,L<A7M\P1FQ^- &E0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 >$>)KVZ^(FLGPQIDIBTVS^:_G3G>RG!C!Z':WR*IX,@=R&6,4]
M@'7WP72R@>71+Z\CNT4M$'D4*S#D*6C2,KNZ!LX4G)!% '8?#;Q9-XFL'BO@
M5O[!_(N01@L1G:Y7^%FVLKC &]&( ! " ]%H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!ROC?5FT31+R]C81R1PL(VS@B1\1H1_M!F!7WQ0!Y7\*?%.IO
M?-HVLS23_:+9+NV>8EGPRJY4.WS,K(Q(#$A?+;;@'E@>_4@"@#R/QQXSNVNA
MX8\-CS=4GXEE7I;(1D_-T5]IW,YXB7&,R$;6!U?@GPA#X-L?LJ-YL\I\RXF/
M623&.,\A%Z*#[L?F8T@.QH \2\)'^R/&^L:<>%O$%TN.A.5D_/\ ?O\ D?49
M8'MM( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M2F-<A(U!"KCWBDEVCJ0F.PH ]PMKB*\B2>!EDBE4.CJ<JRL,@@CJ"#D4@)J
M/$_A2@NM3UW4& +RWI16/4+YD[E0>P.4R/\ 97T%,#VRD 4 >*G]U\1A_P!-
M;#^2'_XBF![52 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .0\<^)_^$2T
MF74% >8%8X5;H9'.!GN0JAG(&"0I&1G( .=^&GA2XTB*;6-482:CJI663@9C
M5B7"9_O,6W2!<*"%0 A 2 >@:OI5OK=I+87BAX9U*L#U&>C*>S*<,I'((!%
M'C?PMUN;01?>&];81/I(:=2QR%@',N#WC7*2H0.5E)Z "F!'<>*-9^(]T++P
MP9=.TZ(GS[]AM9O0+@@CU5$;S#D,YC4$4 >B>"/!B>"[:6 3O=R7,OFR2.H3
M)V@<+N<^I)+$DFD!VM !0!XKJO[CXC6!Z>=8O^B7G_Q I@>U4@"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % 'B'Q%'_"0^(M(\-]82QNYQV9 6X/H1'#*!_OBF![?2 *
M/F3XVV4NF:E!J-J2AU"VDM90O\6S (/^^DBK_P  %,#W_P -:0-!TNUTX=;>
M%$8^KXS(?H7+'\:0&Y0 4 % 'B'Q/<:'K6C>(&XBAF,$[8/RH6#=LYS&\QQW
MV^],#VV.195#H0RL 592""",@@C@@CD$<$4@'4 % !0 4 % !0 4 % !0 4
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M?^$BO_\ GK_XY'_\17'_ &SCO^?W_E.E_P#(&WU##_R?^33_ /D@_P"$BO\
M_GK_ ..1_P#Q%']LX[_G]_Y3I?\ R ?4,/\ R?\ DT__ )(/^$BO_P#GK_XY
M'_\ $4?VSCO^?W_E.E_\@'U##_R?^33_ /D@_P"$BO\ _GK_ ..1_P#Q%']L
MX[_G]_Y3I?\ R ?4,/\ R?\ DT__ )(/^$BO_P#GK_XY'_\ $4?VSCO^?W_E
M.E_\@'U##_R?^33_ /D@_P"$BO\ _GK_ ..1_P#Q%']LX[_G]_Y3I?\ R ?4
M,/\ R?\ DT__ )(/^$BO_P#GK_XY'_\ $4?VSCO^?W_E.E_\@'U##_R?^33_
M /D@_P"$BO\ _GK_ ..1_P#Q%']LX[_G]_Y3I?\ R ?4,/\ R?\ DT__ )(/
M^$BO_P#GK_XY'_\ $4?VSCO^?W_E.E_\@'U##_R?^33_ /D@_P"$BO\ _GK_
M ..1_P#Q%']LX[_G]_Y3I?\ R ?4,/\ R?\ DT__ )(/^$BO_P#GK_XY'_\
M$4?VSCO^?W_E.E_\@'U##_R?^33_ /D@_P"$BO\ _GK_ ..1_P#Q%']LX[_G
M]_Y3I?\ R ?4,/\ R?\ DT__ )(/^$BO_P#GK_XY'_\ $4?VSCO^?W_E.E_\
M@'U##_R?^33_ /D@_P"$BO\ _GK_ ..1_P#Q%']LX[_G]_Y3I?\ R ?4,/\
MR?\ DT__ )(/^$BO_P#GK_XY'_\ $4?VSCO^?W_E.E_\@'U##_R?^33_ /D@
M_P"$BO\ _GK_ ..1_P#Q%']LX[_G]_Y3I?\ R ?4,/\ R?\ DT__ )(/^$BO
M_P#GK_XY'_\ $4?VSCO^?W_E.E_\@'U##_R?^33_ /D@_P"$BO\ _GK_ ..1
M_P#Q%']LX[_G]_Y3I?\ R ?4,/\ R?\ DT__ )(/^$BO_P#GK_XY'_\ $4?V
MSCO^?W_E.E_\@'U##_R?^33_ /D@_P"$BO\ _GK_ ..1_P#Q%']LX[_G]_Y3
MI?\ R ?4,/\ R?\ DT__ )(/^$BO_P#GK_XY'_\ $4?VSCO^?W_E.E_\@'U#
M#_R?^33_ /D@_P"$BO\ _GK_ ..1_P#Q%']LX[_G]_Y3I?\ R ?4,/\ R?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 (S!06/  R3Z
M4 >*_!L&^&JZR1_Q_7S8)ZX7=+_[7_,8[4P/:Z0!0 4 % !0 4 % !0!A>)/
M#MIXHL7T^]7*/RK#[T<@!VR(>S+D^S E6!5B" 8/@CP#:>"$E^SR/<2W.S?)
M(%& F[:J*H^498ELL<\?W10!QFKM_P (]X^M+Q_EAU:W^SEO60#RU7W^9+<?
M\"'I3 ]NI % !0 4 % 'D6I?\?<__7:3_P!#-?B.._WK$?\ 7ZK_ .ER/O\
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MD/FLT_Y=?]O_ /MAVM??GS84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %  3CD\ 4 9
M-MK^FWDWV:WN[::<=8XYXGD&.OR*Q;CZ4 27VLV&ELJ7MS;VS/\ =$TT<9;M
M\H=E)YXXH OB5"GFAALQNW9&W;C.[/3&.<],<T 4+'6;#5"RV5S;W+1_>$,L
M<A7M\P1FQ^- &E0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MVLGF?(F\_-B)F? .Z,L,  SX$:3PA8:>DP:/4=2AM950M^YBFN&9K8E@'!C
M"L"!U(&4P2 =?XKTVT\/WNCZAI\4=K(=0AL6\E%0/#<HZE'"[0P4H"N0=I)*
MX/4 ]3I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >)?%H?VI>Z-H?5+N[W2#_
M &0T<>?^^9)/RI@>V*HC 50%50  .  .  .P%(!: "@ H * "@ H * "@ H
M* *&JV(U.SGLB=@N8982W7 D1DSCVSF@#Y\MKWQ=\+]/6.XM[6;2[24@N&#,
M1+(3\I$BN 78[2T606&X$4P/HFSNDOH([F+F.>-)$_W74,OZ$4@+- !0 4 >
M1:E_Q]S_ /7:3_T,U^(X[_>L1_U^J_\ I<C[_#_P:?\ @A_Z2BE7 =1CQ^'M
M,AN?M\=G:I=EF<SK!$)MSY#-Y@3?N8$ACNR<G/4UU/$5G#V+JU'3LER.<N6R
MV7+>UE965M+&*I4U+G4(J6_-RJ]WOK:Y:O\ 3+358Q#?00W408,$FC25 P!
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M_P Q'_<+_P!R'S6:?\NO^W__ &P[6OOSYL* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#&\0S7]OI\SZ1$+B^"@0QLR*"S,%W$NR+A%)?!8;MNWJ0* /,_"\.M^'E9
MVT26XO;DAKJ\DU"S,DK'KW.V-3]R)3A1CDGDL#9MK+6/"E[?&QLQJEIJ-R]V
MK+/%!)%+( 'CD\X_-'E1L*%MH_AR<! 9Z^![]]$FC=HX]4FU%M610288[C>K
M+$&Z[=J[=PX#-GD#)8&B;/6?%%]8R:G:#3;339?M3C[1',T]PJE8P@B)"HA9
MF)?YB#@ <Y0'I= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MI:6ZZO,.L* "@ H [7P?_P M_P#MG_[4K[[AS_F(_P"X7_N0^:S3_EU_V_\
M^V':U]^?-A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M',C%)"A8!U"ISP#C+  TIM>U;5K^YLM!2T6+3V$4T]WYK*\Y4,8HDB*D>6"
M[L3@GA2,$@#)O&=S8:'_ &G>V<D-]YOV9;5MR"2<OY:>6S $Q/\ ?#X^Z" 6
MP"0!(M?UG2+ZUM->2S,.HL8HI;3SAY4X7<L<@E9MP<9"NNWD<J!0!Z%0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MX3?]^W_PH^HXK_H'K?\ @J?_ ,B'UBC_ ,_(?^!Q_P P_LR[_P">$W_?M_\
M"CZCBO\ H'K?^"I__(A]8H_\_(?^!Q_S#^S+O_GA-_W[?_"CZCBO^@>M_P""
MI_\ R(?6*/\ S\A_X''_ ##^S+O_ )X3?]^W_P */J.*_P"@>M_X*G_\B'UB
MC_S\A_X''_,/[,N_^>$W_?M_\*/J.*_Z!ZW_ (*G_P#(A]8H_P#/R'_@<?\
M,/[,N_\ GA-_W[?_  H^HXK_ *!ZW_@J?_R(?6*/_/R'_@<?\P_LR[_YX3?]
M^W_PH^HXK_H'K?\ @J?_ ,B'UBC_ ,_(?^!Q_P P_LR[_P">$W_?M_\ "CZC
MBO\ H'K?^"I__(A]8H_\_(?^!Q_S#^S+O_GA-_W[?_"CZCBO^@>M_P""I_\
MR(?6*/\ S\A_X''_ ##^S+O_ )X3?]^W_P */J.*_P"@>M_X*G_\B'UBC_S\
MA_X''_,/[,N_^>$W_?M_\*/J.*_Z!ZW_ (*G_P#(A]8H_P#/R'_@<?\ ,/[,
MN_\ GA-_W[?_  H^HXK_ *!ZW_@J?_R(?6*/_/R'_@<?\P_LR[_YX3?]^W_P
MH^HXK_H'K?\ @J?_ ,B'UBC_ ,_(?^!Q_P P_LR[_P">$W_?M_\ "CZCBO\
MH'K?^"I__(A]8H_\_(?^!Q_S#^S+O_GA-_W[?_"CZCBO^@>M_P""I_\ R(?6
M*/\ S\A_X''_ ##^S+O_ )X3?]^W_P */J.*_P"@>M_X*G_\B'UBC_S\A_X'
M'_,/[,N_^>$W_?M_\*/J.*_Z!ZW_ (*G_P#(A]8H_P#/R'_@<?\ ,/[,N_\
MGA-_W[?_  H^HXK_ *!ZW_@J?_R(?6*/_/R'_@<?\P_LR[_YX3?]^W_PH^HX
MK_H'K?\ @J?_ ,B'UBC_ ,_(?^!Q_P P_LR[_P">$W_?M_\ "CZCBO\ H'K?
M^"I__(A]8H_\_(?^!Q_S#^S+O_GA-_W[?_"CZCBO^@>M_P""I_\ R(?6*/\
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MMC+'.I'W@-WEO@^@5]Y_W >H% '=^&]4&M:9:WX.3<01NWLY4;Q_P%PP/N*
M-J@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@#.U?4H]'LI[^;[EM$\I'3.Q2=H]V(P/<B@#RWX/Z;-):W
M/B&].ZYU>9GR0!\B,_( Z!I"_  &U4QQBF!['2 * "@ H * "@ H * "@ H
M* "@ H * "@#F_%%S$ME):2J'^UH\14_W&4JQ/T!X]\>E?*YWFJRFBO9I2KU
M+JFGLK;SDNRNDEU;71,]+!X7ZU/WM(1^)]^R7K^1YWIC/HT"6EBSPP19V1J[
M%1DECP2>K$DYZDD]:_&Y9QF$I^U>)JWO>RDU'_P!6A;RY;'UJPE!+E5.-O2[
M^_?\3T30-:;4 89\>:HR".-P[\#@$=\<$=!P:_4\@SJ69*6%Q=OK$%S*222J
M1V;LK)2BVKI633NDK,^:QV#6'M4I? W:V_*_7L_/[SI*^[/%"@ H * "@ H
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M5S=>-+[3HDLKNRM;"Y6^N'NX?)'F1*PBBB#<R'<S;F7Y0,-DG& #U2D 4 %
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MON_T70];KZT\L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#!O?$-O83-!(LA9,9*A2.0&&,N#T/I7SF
M)SC#X.K+#58U7*%KN*BUK%25KS3V:Z;GJ4L#4KP56#@D[VNW?1M=(OMW*O\
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M 4 >A>$O^/1_^NS?^@)7Z=P]_NL_^OTO_2*9\CF?\:/^!?\ I4CJ*^O/$"@
MH * "@ H * "@ H * "@ H S-9U:'0K*;4+G/E6Z%VVC+''  ''+$@#) R>2
M!0!Q;>.+ZP2&[U736L]/N7C3SQ<QRM%YI C::%44HIR-Q5G*]"-Q"D N3>+K
MVYN[FST;3S?BP<1SR/<QVR^;C<8X]R.78#J3L4'J0,$@#T\>61T9];=)$$3F
M![<@&87 <)Y '0L6(P0<;3N.,$  2R\6W:7L%AK-B=.-Z&%M(+A+A&=!N,3E
M43RY-O*CY@QX5B: .YH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /!=%M?MGQ'OYST
MM8-V?<PV\('Y.WY&F![U2 * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@#QGXX0'^Q8+I.)+:\C8-W *2#_T+8?PI@>PV\PN(DE7I(JL/HP!_K2 EH *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M![9" ]%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MH/(H \R^"^H--HKZ?*"LVG7$D3*>H5SY@]OOF1<9.-ON*8'KU( H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M ^VP'^[P_P"WO_2Y&+7@'IA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 >A>$O^/1_^NS?^@)7Z=P]_NL_^OTO_ $BF?(YG_&C_ (%_Z5(ZBOKSQ H
M* "@ H * "@ H * "@ H * ,;Q#J4VD:?->6L$EY/$H\N")6=W=F"J-J L5!
M;<^ 2$#'M0!Y/X8U3[!,=3U33]9N]6N0%DG.GR".%2<^3;@M^[B7.-V S]6Q
MG:&!O6UU=^#-1U".6SO+VTO[@WMO):0F;$DB*LL4@7_5G<HVLQ"D<Y% &5_P
MBFI_V ;@1@:JVI_VSY&5!\WS0_D[AA=_ECZ;_E[4 :EU<W7C2^TZ)+*[LK6P
MN5OKA[N'R1YD2L(HH@W,AW,VYE^4##9)Q@ ]4I % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 >*>)O]+\?:1;'E8K9Y?H0+EO_ &DOZ4P/:Z0!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!#<V\=W$]O,H>*5&1U/1E8%6!]B"10!X?X-NI
M_ &M/X2OR6LKMC+I\Q'=NB9Z?/C:P_AF7(&),TP/=J0!0 4 % !0 4 % !0
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M "8?7L1_/_Y+#_Y$/^$=L/\ GE_X_)_\71_8V!_Y\_\ E2K_ /)A]>Q'\_\
MY+#_ .1#_A';#_GE_P"/R?\ Q=']C8'_ )\_^5*O_P F'U[$?S_^2P_^1#_A
M';#_ )Y?^/R?_%T?V-@?^?/_ )4J_P#R8?7L1_/_ .2P_P#D0_X1VP_YY?\
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M']C8'_GS_P"5*O\ \F'U[$?S_P#DL/\ Y$T+2RAL$,<"[%)W$9)Y( SEB3T
MKT\/AJ6#@Z6&CRQ<N9J\I:M)7O)M[)>1R5:LZ[YZKNTK;)::OHEW9:KL, H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M /%+K][\1K?_ *96!_5)O_BZ8'M=( H * "@ H * "@ H * "@ H * "@ H
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M1[&D!MRSQP &1E0$X&XA<GT&<<T .1U<;E(8>H.1^E #J "@ H * "@ H *
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M- 'D7P1U+SM)GTYV#/87+  =HY?F4CV:19B*8'M%( H * "@ H * "@ H *
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M: .QH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H \4^''^F^)-?OCR4N!"I_V1+,/Y1)3
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MD 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!%<3I:Q/-(<)$K.Q]%4$D_D*
M/'?@I"TFFW>I2##WMX[?4*JG.?\ ?=Q^%,#V>D 4 % !0 4 % !0 4 % !0
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MR"#R""."".AI +0 4 % 'B/B<_\ "0>-],TQ?FBTQ#=2^BO_ *T9'OY=N/\
M@8[4P/;J0'D&N_"2WU[6)-3EN7BMK@QO-;(F/,=  ?WF_ #8R3L+!BQ!&<A@
M>N11) BQ1@(B *JC@!5&  .P &!2 ?0 4 % $4\$=U&\$RAXY59'4\AE8$,I
M]B"0: / =+U&3X1:E+I>I>8^B7C-+:S@%_*;NI R20,+(HRV0DBKASE@>S:1
MXHTK7@#I]U#.3_ K@2#ZQMB0?BHI ;,TT=NAEE98T499F(50/4DX 'UH KPZ
ME:W'$,T4G^[(C?R)H N4 % !0 4 % !0!Q?C[Q1_PB6D2WL93[2Q6.W5^0TC
M'KC(SL3<Y'3Y<'K0!G_#'PT_AO1D$YW7%XWVJ7@Y4R(FV,D\DJH&[H-Y;&1R
M0#T2@ H \1\._P#%.>.=0TT\0ZK%]ICQQEQF0\>Q-P/P'K3 ]NI % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $4[.D;M$OF
M2*K%$R%W, =JY/ R<#)X'6@#R;0(M43Q;YFLR(T\VDR2+#%GRK=#=P*(E)Y=
MAMR[_P 3' RH!I@8$M_8^(=5U%M5M;W5S97#VL-K:QNZ6\4("M,1YD2>9-('
MP=S2'8VQ=N* +TEXZ>%[:TTR^EN5U"_BL8YV4QSP133$-"^7=Q)$ 8]Q(.T@
MJ NTT :>J:':>!K_ $N\T=3;)=WL=A<QAY&69;A6V,X9FRZ,F0_!R?F)'0 ]
M<I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0!YI\6M9_LCP_,B'$MZ5M4QUQ)DR<=<&)77ZL
M/H0#IO!^C?\ "/Z/::>1AXHE,G_75_GD_P#'V;\,4 =+0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Q7Q&L(]0\.WT<HXC@:93W#P_O
M5Q^*X/L2.E '&>&/B1I6B^'K'^U;@?:1#L\J,-)+MC=XX]P7(4E$4YD9<]>]
M,#3A^,WAN3[TLT7^] Y_] WT@'R?&/PVA4)-+*68+\D$@VY_B.]4X'?;N;T4
MT >I4 0W-PEG$]Q*=L<2,[GT5 68_@ : /#O"5K<_$+6AXMOT$5A9DQV,)PQ
M+(3AS[QL2Y;C][M"<1T]@/=Z0!0!D:[H=KXCLI-/O5WQ2C_@2,/NNA[,IY![
M\@Y4D$ \M^&FJW.B7=QX-U5LS61+6CG/[R'J57/\(4B2,<D*77@1XI@>TT@"
M@ H \1^&)_MS6M8\1?>26;[/ WK&#NQGVC2W_.F![=2 * "@ H * "@ H KW
M5G!?1F&ZCCGB;JDB*ZGZJP(/Y4 >:ZQ\(- U(^9;H]A-G(>W<@ CH?+?<@ _
MV A]Q0!@R?"34KM/LM[KMW/9Y ,++(0RJ00I#7+)Q@8)1@" 0.,4P-*;X)>'
MI?N_:HO]V8'_ -#1Z ,R7X37^C*7\.:M=6Q4';#*QVL?1FC** 3ZPL* -[P!
MXYEU9VT/6U-OK%IE75@%\X+U90.-X'S,%^5E_>1_(2%0'J= !0 4 % '@=G$
MGQ)\5R7<@:72-& 2($_NY)@W!QC#!V#.?6-(P_RL%I[ >^4@"@ H \3\;?\
M$N\9:'?]//W6V?JS)C_R9_6F![92 * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#B&M)O^$M6Z\M_LXTAXO-VMY?F&[C81
M[\;=^T%MN=VT$XQ0!SUB]QX)U+4?-LKN[M=1N#=PRV<)G.]P3)%(JD%"&SM9
ML*<\D9H S%\*ZH="EN5BV:@^K'6HK3<,H?,5EM\_=#[ 3CLQ"G!SA@:]U<W7
MC2^TZ)+*[LK6PN5OKA[N'R1YD2L(HH@W,AW,VYE^4##9)Q@ ]4I % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!XAXP_XJ;QAINACYH+ ?:YQVS_K-K>Q6.-1_P!=3[FF![?2
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * (IX([J-X
M)E#QRJR.IY#*P(92/0@D'VH XK1?AMH&A2--;VJO(QX:<F;8/1!)N"_[P&_L
M6QQ0!TDN@:;-_K+2V?\ WH(C_-: . ^(G@>QO=%G>P@@M+BT!ND:&)(V;RE8
MLA**I(9-V!G&\*>U '3^ ]=?Q'HEK?S8,SJR2X_OQNT9/L6VA\?[5 %?XCWG
MV'PY?R XW0&+_O\ ,L6/Q#T +\.;/[!X<L(L8W0"7_O\3+G_ ,?H [6@ H *
M /%OBKITNF367BVQ4F;39$6<#/S0%LKN]%!9XV/7$WHO# ]8TG5;?6[2*_LV
M\R&=0RGN/56'9E.58=0P(I :- 'GWQ.\1MX;T.62$XN+D_9X><$-(#N<=\H@
M8@]FVYH O> /#9\+:-#9/S,V9IO:63!*_P#  %3)Z[<\9P #LZ "@ H * "@
M H * "@ H * "@ H \O^(7@VYU<PZSHI$6K6!#(1A3,BG(C).!N4YV[OE8,R
M-PP( #PM\3K/5 UIK)32M1@;9+%.WEHS#J4:3&#D<QL=RG !<'- 'I<$\=U&
MLT#K+&XRKHP96!Z%64D$>X.* ): .+^(FKOHF@7EU$=LIC$2$=0TS+%D>ZAR
MP_W: *_PTT1=#T"UC  DN$%S*>Y:8!AG@<K'L3VV]3U(!WE !0 4 >-?&FW:
M+3K358>)M/NT93C( ?G)]/WD<?7CMU(I@>L:9?)JEI#>Q9$=S%',H/4+(@<
M^^#S2 NT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!XEX /\ ;?BC6=<',2,+
M6-C_ ! ,J\?\ MT/T84P/;:0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 R2-95,;@,K@JP/0@C!!]B* /$?AE<-X9U._\
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M* .%^#VKG4-"6TE/[_3Y'MW4_>"YWQY'8 ,8Q_US([&@#U6@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H P(O$ME/JK:'$Q
MDNHH#<2;<%(U#HFQFW9$A,BL%VG"\L0< @%C7=<M?#EE)J-ZQ6&$9(7!9B3A
M40$@%V.  2!W) !( ('\264&E)KD[&&T>".X!<?.%E5612JELN=RKM4M\QP"
M1S0!FZ7XTMM1NDL)K>\L)YT9X%O(1$)@@RPC*NX+*OS%&VL!SB@#L* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@#$\2:L-!TRYU$XS;0NZ@]"^,1K_P "<JOXT <-\'-*;3O#
MZ32@B2^EDN#GKM.(TS[%8]X_WZ /5* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H \2^+EHVER6'BBU7]]87")*1P6C)W
M*&/]T,K)_P!MB/HP&>!-+O/%FJOXQU=&2, II\+?PQ_, X&!\JJQ",1\[LT@
MZ*2 >X4@"@ H * "@#DO%_@VR\8VRP7>Z.2(EH9DP'C)QG&>"K8&Y3UP""&
M( /+I-4\3?##<-0#:UHX9=MR6/FQ!B%PQ)=D[ +)NCSM5)%R13 L?#>^CU[Q
M/K&KVN3;2+&J,P*D[B,<'D<1$X[<9H ]VI % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!RWC/PRGBS2Y=.8JDC8>&1AD1RH<JW<@$91B.=C-@&@#S2TTKXA10
M1Z?'/96\4,:Q+*=K-L10@))BD8G Z[ V>>#3 Z7PM\./[+O/[9UFY;5-2(^6
M1P=D7;*!B26 X5CM"#[J*>:0'I] !0 4 % !0!X!XA$_PS\0OXAMX?,TK4@(
MIT1MH25B&9MN#\Q*-(AQ@[Y$!3-,#W>TO(+Z,3VLB3Q-G#QLKJ<'!PRDC@\'
MG@\&D!8H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@"*>$3QO$2R!U9=RG##<",J>S#.0>QYH \NT;0K/P]XK2TL4\M/[&D=B26>
M1S>Q;I)'.2[MCDGV    # YGQ1KNG>*!J,EQ=6Z6VFVUW#96SS1K)<7A@=6N
M/*9@[!"?+MAM.YBSK@\$ N7MW:W_ (9T&-)8Y85N](@N=CJP0K&GF12;2=K+
MQN1L,O&1TH ZOQ_\LVBNF/.&LVRCG!\MEE$N.1Q@#/X#O@H#T6@#R#XKZG=Z
M=]B^QSS6^_[1N\J1X]VWR,;MA&<9.,],G'4U\OF]6I2]E[*<H7Y[\LG&]N2U
M[-;79\[F=2=/V7LY2C?GORMJ]N6U[,\ML_&VMV&[RKR9M^,^:1/C&<;?.$FW
MKSMQGC.<#'SD,=B:=^6K)W_FM/;MSJ5OE:_4\*&,Q%._+4D[_P WO;=N:]OD
M59?%6L3.TC7MT"Y+$+-(BY)S\JHRJH]%4!0.  *S>+Q$FY.K4NW?2<DODDTD
MO)*RZ&;Q-=MMU9ZZZ2:7R2:2]%H7;OQWKEZGER7<B@'.8@D+9&1]Z%48CG[I
M.#P2,@8VGC\547+*K)+?W;0?WQ2?RO8UEC<1-6=1K_#:+^^*3^6PRS\;:W8;
MO*O)FWXSYI$^,9QM\X2;>ISMQNXSG Q,,=B:=^6K)W_F]_;MSJ5OE:_79"AC
M,13ORU)._P#-[VW;FO;Y;]2K+XKUB9VD:]N@6))"S2(N3Z(C*JCT"@ = !6;
MQ>(DW)U:EWKI.27R2:2]$K&;Q->3;=6>O:32^2327HD7KKQWKEXGER7<BJ"#
MF,)"W'^W$J/CGD;L'N.!6T\PQ51<LJLDO[MHO[XI/Y7-98W$37*ZC2\K1?WQ
M2?XD5GXUUNPW>5>3-OQGS2)^F<;?.$FWKSMQGC.<#$PQV)IWY:LG?^9\^W;G
MYK?+?J3#&8BG?EJ2=_YO>^[FO;Y%:;Q7K$[M(U[<AF.2$F=%Y]$1E11[*H [
M"LY8O$2;DZM2[[2:7R2:2]$B'BJ\FVZL]>TFE\DFDODB]<^.]<NX_*DNY%4$
M',82)N/]N)4?'J-V#WS6T\PQ4URRJR2_NI1?WQ2?XFLL;B)KE=1I>5HO[XI/
M\2*S\:ZW8%C%>3-NQGS2)NGH)A(%Z\[<9[YP*F&.Q-._+5D[_P SY_NY^:WR
M)AC,13ORU):_S/F_]*O;Y%>;Q9K$[F1KVY#,<D),\:_@B%44>RJ![5G+%XB3
M<G5J7?:3BODDTE\D0\57DW)U9W?:32^Y-)?)%VY\=ZY=1^2]W(%&.8PD3\=/
MWD:H_P!?FY[YK:688J:Y75DEY)1>G]Z*3_'7J:RQN(DN5U';RM%_?%)_B0V?
MC36[$DQ7DS;@ ?-83#CT$PD"^Y4 GO40QV)IW<:LG?\ F?/]W/S6^1,,9B*>
ML:DM?YGS?^E7M\B"?Q9K%PYE>]N0S')"3/&OX(A5%'LJ@>U1+&8B3<G5J7?:
M3BODDTE\D3+%5Y-R=6=WVDTON5DODBY<>.M<N8O)>[D"C'*!(WXZ?O(U63Z_
M-\W?-;2Q^*E'D=65O*T7I_>BE+\=>II+&XB2Y74=O*T7IYI)_CJ16?C36K$E
MHKR9BPP?-;SA^ F$@4^Z@'MFHACL33NXU9._\SY_PGS6^1,,9B*>L:DG?^9\
MW_I5[?(@G\6:Q<2&5[VY#,<D)*\:_@D95%^BJ!42QF(DW)U:EWVDXKY*+27R
M1,L57D^9U9W?:32^Y62^2+L_CO7+B+R'NY O'*!(WXZ?O(U63Z_-\W\6:VEF
M&*E'D=65M-DHO3^]%*7KKKU-)8W$27*ZCMY63T_O))_CKU(;/QIK5BQ:*\F8
ML,'S6\X?@)A( ?< 'MG%1#'8FF[QJS=_YGS_ (3YDOD3#&5Z>L:DG_B?-_Z5
M>WR(;CQ;K%S(97O;D,W4)*\:],<)&51>G\*CGGJ34RQF(DW)U9W?:3BODHV2
M^2)EBJ\GS.K.[[2<5]RLE\D7)O'>N3P_9VNY F ,H$1_EQC]ZBK)GCD[\MSN
MSDUK+,,5*/(ZLK:;))Z?WDE+UUUZFCQN(E'D=1V\K)Z?WDE+\=>I!9^,]:L6
M+17D[%A@^:WG#UX682*#[@ ]LXJ(8[$TW>-6;O\ S/G7W2YDO5$PQ=>F[QJ2
M_P"WGS?A*Z(KCQ;K-U(97O;D,V,A)6C7@ <)&51>G.U1DY)Y)-3+&8B;<G5F
MF^TG%?)1LE\D3+%5Y/F=2=WVDXK[E9+Y(N2^.]<FA^SM=R!,*,J$23Y<8_>H
MJRYX^8[\MR&)R<ZO,,5*/(ZLK:;64M/[R2EZN^O4T>-Q#CR.H[:;63T_O)*7
MKKKU(+/QGK5BQ>*\G8D8_>MYPQD'A9MZ@\=0 <9&<$U$,;B:;O&K-]/>?.ON
ME=?/<F&+KTW>-27_ &\^9?=*Z^9'<^+M9NI#*][<!FQD1RM$O  X2,HB\#G:
MHR<DY)),RQF(FW)U9IOM)Q7;:-DODO/<F6*KR?,ZD[OM)Q7W1LE\D6I?'>N2
MP_9FNY F%7*A%DPN,?O542YX&YM^6Y#$Y.=7C\5*/LW5E;1:64M/[R2ETU=[
MOK>[-'C<0X\CJ.VBTLGI_>24O5WN^I!9^,M:L7+Q7D[$C;B5_.7&0>%FWJ#Q
M]X -C(S@D&(8W$TW>-6;TM[SYU]TKJ_G:Y$,77IN\:DNWO/F7W2NOGN,N?%V
MLW4AE>]N S8R(Y6B7@ <)&40=.<*,G).22:F6,Q$WS.K--]I.*^Z-DODO,4L
M57D^9U)W\I.*^Z-E^!:?QWKDD'V8W<@0*JY 19,+C'[Y5$N>/F;?N;G<3DYU
M>/Q3C[-U96LEI92T_O)<U^[O=];W-'C<0X\GM':R71/3^\ES7[N]WU(+/QEK
M5DYDBO)V)&W$KF9<$@\+-O4'C[P&X#(!P2#G#&XFF^:-6;TM[SYU]TKJ_G:_
MWD0Q=>F[QJ2[>\^9?=*Z^>XRY\7ZS=R&5[RX#''$<C1+P,<)$40>^%&3R<DY
MI2QF(F^9U9I_W9.*^Z-E^ I8JO)\SJ3OY2<5]T;+\"V_CO7'@^S&[D"!0N0$
M63"XQ^^"B7=QRV_<W.XG)SJ\PQ3C[/VLK62Z*6G]Y+FOW=[OJS1XW$./)[1V
MM;HGI_>MS7\[W?4Y+7_$6I75J;.:ZN)DN"JM')*\BD*RN.'8@$.J$$8/;."0
M?6RNK5G4G.K4FZ<(-OFDY+?31M]$W??3S/2R^K4G.<ZDY.$(-OFDVO+1M]$]
M39C\2:I%''"EW<1I#&D2)%(T2*D:A% 2,JO  R<9)Y8D\UXU3&XBI)S]K-7Z
M1DXI+II&R_SZGESQ=><G+VDU?HI.*2]%9&HWCO7&@^S&[DV;0N0$$F!_TV"B
M7=QRV_<>Y.35_P!H8IQ]G[65K6V7-_X%;FOYWOYE?7<1R\GM':UNE_\ P*W-
M?SO<K6GC'6K)_,CO)V.",2N9EP?]B7>N>.#C(['DUG#&XFF^:-6;>WO/F7W2
MNOG:Y$<77@[QJ2^;YE]TKK\!+KQAK-X_FR7EPK$ 8CD:)>/]B+8F?4[<GO1/
M&XF;YI59I_W9.*^Z-E^ 2Q=>;YG4FGY-Q7W1LOP+1\=ZX8/LWVN39MVYPGF8
M'_3;;YN[_:W[O>M/[0Q7+[/VLK6MLN;_ ,"MS7\[W\R_KN(Y>3VCM:W2_P#X
M%;FOYWN5K3QAK-D_F1WEPS8(Q(YF7G_8EWIGT.W([&LX8W$TWS1JS;_O-R7W
M2NOP(CBZ\'S*I/YOF7W2NOP$NO&&LWC^;)>7"M@#$<AB7C_8BV)GU.W)[FB>
M-Q,WS2JS3_NR<5]T;+\ EBZ\WS.I._DW%?=&R_ L_P#"=:YY'V;[7)LV[<X3
MS,?]=MOFY_VM^[WK3Z_BN7V?M96M;IS?^!6YK^=[E_7<1R\GM':UNE__  *W
M-?SO<K6OC#6;-_-CO+@L 1B20RKS_L2[TSZ';D=C6<,;B:;YHU9W_O2<E]TK
MK\"(XNO!\RJ3OYMR7W2NOP%NO&&LWC^9)>7"M@#$;F%>/]B+8F?4[<GN:)XW
M$U'S2JS3_NMQ7W1LOP"6+KS?,ZDUZ/E7W1LOP+(\=ZX(/LWVN39MVYPGF8_Z
M[;?-W?[6_=[UI_:&*4?9^UE:UMES?^!6YK^=[^9?UW$*/)[1VM;I?_P*W-?S
MO<JVOC#6;-_-CO+@L 1B21I5Y_V)=Z9]#MR.U9PQN)IOFC5G?^])R7W2NOP(
MCBZ\'S*I._FW)?=*Z_ 6[\8ZU>/YDEY.IP!B-S"N!_L1;%SSR<9/<\"B>-Q-
M1\TJLT]O=?*ONC9?.UPEBZ\W=U)+T?*ONC9?@65\=ZXL'V87<FS:5R0ADP?^
MFQ4R[N>&W[AV(P*T688I1]G[65K6V7-_X%;FOYWOYE_7<0H\GM':UNE__ K<
MU_.]RK:^+]9LY!+'>7!89&))&E7GCE)2Z'V)7(ZC!K*&,Q%-\T:L[_WI.2^Z
M5U^!$<57@^95)W\VY+[I77X#KOQCK5Z_F27DZD#;B)S"N!D_<AV*3S]XC)X!
M. ,.>-Q-1\TJLT]O=?(ONC9?.UPEBZ\W=U)+I[KY5]T;+YVN6$\=ZXD'V87<
MFS:5R0ADP<Y_?%3+NYX;?N7C:1@8T688I1]FJLK6:Z.6O]YKFOV=[KHRUC<0
MH\BJ.UK=&]?[UN:_G>ZZ%2V\7ZS:2"6.\N"PS@22-*O(QRDI=#[94X/(P1FL
MHXS$4WS1JSNOYI.2^Z5U^!G'%5X/F52=UWDY+[I77X#[OQEK5ZXDDO)U(&W$
M3F%< D\K#L4GG[Q&XC )P  YXW$U'S2JS6EO=?(ONC97\[7^X<\77F[RJ273
MW7RK[HV7SW)X_'>N1P?9A=R;"K+DA&DPV<_OF4RYY^5M^Y>-I&!C18_%*/LU
M5E:S6MG+7^\US7[.]UTM8M8W$*/(JCM9KHWK_>:YK]G>ZZ%6V\7:S:2"5+VX
M++G DE:5>01RDA=#UXRIP<$8(!K*.,Q$&I*K.Z[R<E]TKI_->9G'%5X/F52=
MUWDY+[I77X#[SQEK5ZX>2\G4@;<1/Y*XR3RL.Q2>?O$%L8&<  5/&XFH[RJS
M6EO=?(ONC97\[7'/%UYN\JDET]U\J^Z-E\]R>+QWKD,/V9;N0IAERP1I,-G/
M[UE,N>3M;?E> I&!BUC\5&/LU5E;5:V<M?[S3EZ.]UTM9%K&XB,>15';5:V;
MU_O-<WH[W70JVWB[6;602I>W!9<X$DK2KR".4D+HW!XW*<'!&" 1E'&8B#4E
M5G==Y.2[;2NG\UY[F<<57@^95)W7>3DONE=/YHDO/&>M7K!Y+R=2!@>4WDC&
M2>5A\M2>>I!.,#. *J>-Q-1WE5FK:>Z^1?=&R^>Y4\77F[RJ27^%\J^Z-E\R
M>+QWKD$/V=;N0IAAE@CR?-G/[UU:7//RG?E> I&!BUF&*C'D565M=[.6O]YI
MR]'?3H4L;B(QY%4=M=[-Z_WFG+TUTZ%.W\6ZS:R"5+VY++G >5I%Y!'*2%D;
MKQN4X.".0#64<9B(-256=UWDY+YJ5T_FC..*KP?,JD[KO)R7W.Z?S1+>>,]:
MO6#27DZE1@>4WDCUY6$1J3[D$]LXJIX[$U'>56:M_*^1?='E3]65/%UYN\JD
ME;^5\OX1L@;QEJ\EJUC+<&>!P0RS)%,2"<\O*CN<'E26RN!MQ@8N.88J,>15
M96UWLWK_ 'FG+TUTZ%+&XB,>15';SLWK_>:<OQTZ$%KXKU>R97BO+C]WPJM*
MSH!C !C<LA '0%2!P1R!64<9B(-256=UWDY+YJ5T_FC..*KQ:DJL[KO)M?<[
MI_-%B\\::U?,&EO)E*C \IO)'XB$1@GW()[9Q53QV)J-.56:M_*^3\(<J?S*
MGC*\]95)*W\KY?\ TFQ-!X[URWB\A+N0KSRX21^>O[R16D^GS?+_  XQ5QS#
M%0CR*K*WFE)Z_P!Z2<OQTZ%1QN(BN55';SLWK_>:;_'3H4H/%FL6T@E2]N2R
MG(#RO(OXI(61OHRD5C'&8B#4E5J77>3DOFI-I_-&<<57BU)59W7>3:^YW3^:
M)[SQIK5\0TMY,I48'E-Y(_$0B,,?<@GMFKGCL34LY59*W\KY/PARW^94\9B)
MZRJ25OY7R_\ I-K_ #);?QUKEM%Y*7<A7GEPDC\]?WDBM)]/F^7MBKCC\5"/
M(JLK>=I/7^]).7XZ="HXW$17*JCMYV;^]IO\=.A3@\6:Q;N)4O;DLIR \SR+
M^*.61A[,I'M6,<9B(M256I==Y.2^:;:?S1G'%5XM256=UWDVON=T_FA=4\6:
MMK*>5>7,CQE2K(NV-&!ZATC"*_\ P,'':KGCL34LY59*W\KY/OY.6_S*GC,1
M.W-4DK?ROE_])M?YB:3XIU+0H#:Z?*((F)8A8H222,9W-&6S@8'S<=L5<<PQ
M4%RJK*WG:3_\"DF_QTZ%1QN(@N55';SM)_?)-_B$'BS6+=UD2]N2R'(#S.Z_
MBCED8>S*1[5C'%XB+4E5J77>3:^:;:?S1DL57BU)59W7>3:^YMI_-%B\\:ZW
M?%3+>3+LSCRB(.OJ(1&&Z<;LX[8R:TGCL34MS59*W\KY/OY.6_S+GC,14MS5
M)*W\KY?_ $FU_F2VOCO7+./RH[N0KDG,@25N?]N57?'H-V!VQ50S#%4URQJR
MM_>2D_ODF_Q*CC<1!<JJ.WG:3^^2;_$HP^*]8@=9%O;DLAR \SNO'JCLR,/9
ME(/<5C'%XB+4E5J77>3:^:;:?HT9+%5XM-59Z=Y-KYIMI_-%F\\:ZW?;?-O)
MEV9QY1$'7'WO)$>[IQNSCG&,G.D\=B:EN:K)6_E?)]_)RW^>W0N>,Q%2W-4D
MK?R^[]_+:_S);3QWKEDGEQW<C+DG,@29N?\ ;E5WQQP-V!V')JH9ABJ:Y8U9
M-?WK2?WR3?RN5'&XB"Y8U';SM)_?)-_B48?%>L0.LBWMT2A! ::1UR/5'9E8
M>H8$'H0:Q6+Q$6I*K4NM=9R:^:;:?HU8R6)KQ::JST[R;7S3;3]&BU>>-M;O
MMOFWDR[,X\HB#KC.[R1'NZ#&[.WG&,G.D\=B:EN:K)6_E]S?OR*-_G>W3=FD
M\9B*EN:I)6_E]W[^6U_GMT'VGCO7+)/+CNY&!.<RA)FR<#[TRNP''W0<#D@9
M)S4,?BJ:Y8U9-;^]:;^^2;^5[#AC<135HU'_ -O6D_ODF_EL4HO%6L0NLBWM
MT2A# --(ZY!R-RNS*P]58%2.""*Q6+Q$6I*K4NG?6<FM.Z;::\FK,R6)KQ::
MJSTUUDVOFFVGZ/0M7GC;6[[;YMY,NS./*(@ZXSN\D1[NG&[..<8R<Z3QV)J6
MYJLE;^6T-^_(HW^=[=#2>,Q%2W-4DK?R^[]_+:_SV'V?CK7+)#'%=R,"=V90
MDS9( X:978#C[H.T') R22X8_%4URQJR:O?WK3?WR3=O*]OO'#&XBFK1J/O[
MUI/[Y)OY;%*/Q5K$3B1;VZ)5@P#32,N0<C*,Q1AZJRE2."".*R6+Q$6I*K4N
MG?6<FM.Z;::\FK,R6)KIIJK/1WUDVON;LUY-6+5YXWUN^"B6\E79G'E$0=<=
M?)$>[IQNSCG&,FM)X[$U+<U62M_+:'W\BC?Y[&D\9B*EN:I)6_EM'[^6U_F/
ML_'6N6*&.*[D8$[OWH29LX X:978#C[H(7.3C))+AC\337+&K)ZW]ZTW]\DW
M;RO8<,;B*:M&H^_O6D_ODF_EL4D\5:Q&XD%[=95@P!FD9<@YY0L4(]5*E2."
M,<5DL7B$^95:ET[_ !R:^YNS7DU8R6)KIW56>CO\3:^YNUO*UBW>>-];O@!+
M>2KMR1Y6V$\^IA6,M[!L@=NM:3Q^)J64JLE;^6T/OY%&_P S2>,Q$[*522M_
M+:/_ *2E?YBV?CG7+%2D5W*P)S^]V3'. .&F5V XZ @9R<9)IPQ^)IJT:LGU
M]ZTW]\DW\MAPQN(IJT:C_P"WK2?WR3?R*:^*M85Q(+VZR&W8,TA7(.>4+%"/
M]DKM(XQCBLEB\0GS>UJ7O?XY6^Z]K>5K&7UFNG?VL][_ !.WW7M;RM8MWGCC
M6[X!9;R50IR/*VPGGU,*QEA[,2!VK6>/Q-2RE5DK?RVA]_(HW^9I/&8B>DJD
ME;^6T?\ TE*_S%L_'.N6*E(KR5@QR?-VS'TX:99& ]@0.^,T0Q^)IJT:LG?^
M:TW]\E)KT00QN(IJT:DO^WK2_&2;*8\5:P'\S[;=9W;L>=)MSG/W-VS'^SMV
MXXQCBLOK>(OS>UJ7O?XY6^Z]K>5K&?UFO>_M9[W^)V^Z]K>5K%N\\<:Y? ++
M>2J%.1Y6V$_B85C+#V)(]JUGC\34LI59*W\MH?\ I"C?YFD\9B)Z2J25OY;1
M_P#24K_,Q]1UO4-5LWT^[N99H)&5R)6\Q@R'*E7DW.ON%8 Y.16E',<10=^=
MSCUC-\U].[]Y=]&BZ6.KTG?F<UU4GS7^;U7R9C:!KFH:)(]C:W,\,:-YB(DK
MJA/&24!"DD;<@@@X.<BO8QE>K4H4<;1G*%_=FHR:C?TO;=-:[II,]3%5JDZ-
M+%TI2C?22BVE?TVW36N^B.RO/'&N7JA9;R50IR/*VPGTY,*QDCV)([XS7ASQ
M^)J*TJLE;^6T/Q@HM_,\B>-Q$U:522M_+:/XQ2$L_'&N6(*Q7DK!CD^;MF/X
M&99"H]E('M1#'XFG=1JR=_YK3_\ 2U*WR"&,Q%/2-23O_-:7_I2=OD5#XJU@
MOYGVVZR6W8\Z0+G.?N!MF/\ 9V[<<8QQ67UO$7YO:U+WO\<K?=>UO*UC/ZS7
MO?VL][_$[?=>UO*UBY>>.=<O5"27<JA3D>5MA.<8Y:%8V(]B2,\XR!6L\?B:
MBM*K)6_EM!_?%)_+8UGC<1-6E4DK?RVC^,4F)9^-];L01%>2L&()\W;,>/0S
M+(5]PI />E#'XFG=1JR=_P":T_NYU*WR%#&8BGI&I+7^:TO_ $I.WR*C>*M8
M9S(;VZR6W8$T@7).>$#! /10H4#@#'%9O%XAOF]K4O>_QR2^Y.UO*UC-XFNW
M?VL][_$TONO:WE:Q=O/'.N7JA)+N10#G]T$A;.".6A5&(Y^Z21G!QD#&L\?B
M:BM*K)6U]VT']\4G\MC6>-Q$U:51K_#:+^^*3^6PRS\;ZW8!A%>2MNQGS2LW
M3T,PD*]>=N,]\X%*&/Q-.ZC5D[_S6G]W.I6^0H8S$4[\M26O\UI?^E)V^15?
MQ5K$CF0WMT&9BQ FD5<DYX16"*/10H4#@ #BLWB\0VY.K4NW?2<DON3LEY)6
M,WB:[=_:SU=_B:7W)V2\DK%V[\=:Y>H(Y+N10#NS$$A;(!'+0JC$<_=)VDX)
M&0"-9X_%5%RRJR2O?W;0?WQ2=O*]ON-9XW$35I5&NONVB_OBD_EL,L_&VMV&
MX17DK;\9\TB?IG&WSA)MZ\[<9XSG PH8[$T[\M63O_-:>W;G4K?+?J*&,Q%.
M_+4D[_S>]]W->WR*LGBK6)7:1KVZ!9BQ"S2*N2<G"*P51Z*H"@<  <5F\7B&
MW)U:EV[Z3DE\DFDEY)670S>)KMMNK/5WTDTODD[)>25B[=^.M<O4$<EW(H!W
M9B"0MD CEH51B.?ND[2<$C(&-9X_%5%RRJR2O?W;0?WQ2=O*]C6>-Q$U:51K
MK[MHO[XI/Y;#+/QMK=AN\J\F;?C/FD3XQG&WSA)MZG.W&[C.<#"ACL33ORU9
M._\ -[^W;G4K?*U^NR%#&8BG?EJ2=_YO>V[<U[?+?J59?%6L3.TC7MT"Y)(6
M:1%R>>$1E51Z*H '0 "LWB\1)N3JU+O72<DODDTEZ)6,WB:[;;JSU[2:7R2:
M2]$K%Z[\=ZY>IY<EW(H!!S$$A;(S_'$J-CGIG!X)' K:>88JHN65626_NV@_
MOBD_E>QK+&XB:Y74:_PVB_OBD_E<BL_&VMV&[RKR9M^,^:1/C&<;?.$FWKSM
MQGC.<#$PQV)IWY:LG?\ F]_;MS\UOE:_44,9B*=^6I)W_F][;MS7M\BM-XKU
MB=VD:]N@6))"S2(N3Z(C*JCT"@ =A6;Q>(DW)U:EWVFTODDTEZ)6,WBJ\FVZ
ML]>TFE\DFDODB]=>.]<O(_*DNY%4$',82)N/]N)4?'J-V#W!K:>88J:Y959)
M?W;1?WQ2?XFLL;B)KE=1I>5HO[XI/\3U[X6SW-]93W=W<3W#M/Y0$LC2!!&B
MME-Q)!8RG=S@A5XXKZ?*93J4IU:LYS?/R^])R244GI>]K\VOHCZ++93G3G4J
M3E)\W+[TFTDDGI?OS:^B/3Z^B/<"@ H * "@# .A9UH:WYGW;)K/R=G]Z=9O
M,W[NVW;LV=\[NU #-6\,6.IV=Q:+#!"]S#+$)1 A9&D1E$@&%)*D[OO*21]X
M=: *#^"[270TT&0[5CBA7SHE$;^="J!;@ 9PY9 QR6)'REB.: *UCX1NVO(+
M[6;]M2-B&^S1B!($5V&TRR;7<RR;> 3M"GD &@#NJ /)/B]-$MC;0MCSGG+I
MQSL2-A)\V.!N>+(S\W!P=O'S&<RBJ5.#^)SNM.BBU+7U<=.OR/GLU<53A%_$
MY77HD[Z^KCZ_(\ KXH^2"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H QK[Y[J!.P.[]<_P#LM?1X/W,'
MBJBW:4?P:_\ ;CW<+[F%Q$UU7+^#7_MQLU\X>$% !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MOELY@W"E5Z1E*-O\237_ *0_O1\YFL&X4ZG12<?_  ))K_TEG@]?&'R@4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % &-<<W\0]$/_L_^%?1T-,NKO_IXE^-/_,]VCI@:S_OI?C3_ ,S9
MKYP\(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * &2()%*'HP(/XU<)NE*-2.\6FO5.Y<).G)
M3CO%IKY.YEZ.Y\MHFZQL1^?_ -?->[FL5[6%>.U2"?S6GY<I[&917M(UH[5(
M)_-?\"QKU\^>(% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0![Y\(+P/
M9W-I@@Q3+*6[$2H$ QZCR23_ +P]*^TR:=Z=2E;6,E*_^)6M\N3\3ZS*IWIS
MI]I*5_\ $K?AR_B>O5]0?1!0 4 % $4\I@C>0*SE%9MJC+-M!.U1W8XP!W-
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M%T_Y+B>/IEMP'MD_XBOH\=[^%PM5;*/*WY\L?_D6>[C/>P^&J+I'E;\[1_\
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M_P# DFO_ $E_@>#U\:?*!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M< Y)QS7"TZ"A6HQ4;MQ:6BVNFETV=[?\/CF.&A1Y:M)*-VTTMMKII=.M[?\
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M<=0I/#PG1Y==^9M)[I7C:W7;JSZ.GA\71I^QA*ERZ[\S:ONE[MK?+JR#X/\
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M*M7@ISE;1I/5JZBKW2LKW?D_)&SX0M]!\2)+>PV,,4@*I+"Z)(B$ E6C!7:
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M.K>OEI'%Y8^@R^VD!YSM0V#P-@6G_"7^6 #E3;^<#C.2-N<^W /N6!Z)X_\
MEFT5TQYPUFV4<X/ELLHEQR., 9_ =\% >BT >1_%Z6%;&VC;'GM.63Y>?+6-
MA+AL8 W-%E<C<=IP=I(^8SEQ5*G%_&YW6FO*HOFUZ:N-U?73MI\]FKBJ<(OX
MG*ZTULD^;7U<=.NG8\!KXH^2"@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * ,K4YF 6WBX>4X^@Z?KG\@:]W+J
M,&YXNM\%%<UN\MU]UMN[1[.!I1;GB:OP4E>W>6Z^ZVW=HNVMN+6,1KSCOZD]
M37F8BO+%595I:7V79+1+_/S//KUGB*CJRTOLNR6B7]=2Q7*<P4 % !0 4 6[
M/4+K3F+6DTMNS#!,4C1DCK@E2"1GL:TA4G2=Z4I0;WY6XW^YHTA4G3UIRE%O
M^5M?D033R7+F69FDD<Y9W)9F/J6)))]R:F4G)N4FVWNV[M^K9+;DW*3;;W;=
MV_F7Y-;U"6(P/=7#1$8,;32%"/3:6VX]L5LZ]5QY'4FX[6<I6MZ7L:NM5:Y'
M.;CVYG;[KV(Y=5O)X5M99YG@0*%B:5VC4*,* A8J HX7 X'2I=6I**IRG)P5
MK1<FXJVUE>VG3L2ZLY14)3DXJUHN3:5MM+VTZ!=:K>WR"*YN)IXT(*I)*[J"
M!@$*S$ @$@$#H<43K5*B4:DYR2V4I-I>B;"56I-*,YRDELG)M+Y-F_X..D&Y
M:+6=R*P4PS*[IY4BGN4/&[((9@0I4= 2:[<%]7YW'%W2=N62;7+)/R[]WM8[
M,)[#F<<3=)VY9)M<K7IW[O:QZ9'IFF+=QW4^O?:+:WD26.WEN4D(9&#*"QE(
M(!'($0..,CK7T"I454C4GC>>G&2DH2J)ZQ::NW)W5_[J=CVE3I*:J2Q?-"+4
ME"4T]4[K5R_]MN<#\0?$</B&_4VA+6]NFQ6((WL22S 'D+]T#(!.W/0BO%S'
M$QQ55>RUA!63VN[W;7ELOD>5CL1'$5%[/6,59/N[ZOTV7R.4M=8OK!?+M;F>
M!/[L<LB#GKPK 5YL*U6FN6G4G%=HRDE]R9Y\:M2FK0G**[*32_!E6YNYKU_-
MN9'F?&-TC,[8';+$G'-9RG*H^:I)R?=MM_>R)2E-\TVV^[;;_$LVNKWU@ACM
M;B>!"<E8Y712?4A6 S6D*U6FN6G.<5VC)I?<F7&K4IKEA.45V4FE^#*,DC2L
M7<EG8EF9B222<DDGDDGDD\DUBVVVV[MZMO=LR;;=WJWJVQM(1IVVMZA9H([>
MYN(4'18YI$4?0*P%=$:]6FN6%2<5V4I)?<F;QK5(+EA.<5V4FE^#*ES=SWC>
M9<2/,_3=(S.<>F6)-92G*H^:<G)]VVW^)G*4IN\VV^[;;_$GL]5O-.!6TGFM
MPQRPBE>,$CH2$89(]ZN%:I2NJ4Y03WY9.-_N:*A5J4]*<Y1OORR:_)E*.1HF
M#QDHRG(92001T((Y!'J*R3<7>+LULUHT9IM.ZT:V:Z&C/K>H7( FNKB0(0RA
MYI& *G*D98X((R".0>16\J]6=E.I-VLU>4G9K9J[Z=#9UJLM)3F[:J\F[-;=
M2"\U&ZU$@W<TMP4R%,LCR%0>N-Y.,X&<5$ZLZMG5G*5MN:3E;TNV1.I.I;VD
MI2MMS-NWWDEIJ]]8+LM;B>!2<[8I709]<*P&:J%:K25J<YQ7:,FE^#14:M2F
MK4YRBNT9-?DRK<7,UV_FW#O*YZL[%F..G+$FLI3E-\TVY/NVV_O9G*4IOFFV
MWW;;?WLEM-0NK DVLTL!/4Q2,A./7:1FJA4G2UIRE'_"VOR:*A4G3UIRE'_"
MVOR"[U"YOR&NII9V7.#*[.1GK@L3C..:)U)U=:DI2:VYFW;[VPE4G4UJ2E*W
M\S;_ #([:[FLG\RVD>%\8W1LR-@]LJ0<<=*49RIOFIR<7W3:?WH492@^:#<7
MW3:?X%RYUO4+Q#%<75Q,AZK)-(ZGZAF(K65>K47+.I.2[.4FON;-)5JLURSG
M-KLY-K[FS,!*G(X(Z'TKGVV,-C8/B'5"NPWEUMZ;?/EQCZ;\5U?6:]K>UJ6[
M<\K?F=/MZUK>TG;MSR_S,<G/)KE.8D@GDMG66%FCD0Y5T)5E/J&!!!]P:J,G
M!J4&TULT[->C12;BU*+::V:=FOF37=]<:@XDNY9)W VAI79V"@DA06)( ))Q
MTR2>]5.I.J^:I*4G:UY-MV[7=]-2ISE4?-4DY/:\FV[=M0L[^YT]C):2R6[D
M;2T3M&Q&0<$J0<9 ..F0*(5)TGS4I2B]KQ;B[=M+!"<J;O3DXO:\6T[?(>^I
MW<LPNGGF:=>!*9',@ &.')W#@D=>AINK4<O:.<G-?:<GS??>XW4FY>T<I.2^
MU=W^^]R6;6K^X=));FXD>([D9II&9&]5)8E3[C!JW7JR:E*I-N+NFY2;3[IW
MT?H4ZU233E.;:U3<FVGW6N@U]7OI)ENGN)VGC&$E,KF11SPKEMRCYCP".I]3
M2=:JY*HYS<UHI.3YDO)WNMW]XG5J.2FYR<EM+F=UZ.]UNR"[O;B_?S;J62>3
M &Z1V=L#H-S$G R<#-9SG.H^:I)R>UY-MV]61*<JCYIR<GW;;?WLGN-7OKJ(
M6\]Q/+"N,1O*[(-O"X5F*C Z<<=JTE6JSCR3G-Q7V7)M:;:-VT+E5J27)*<G
M'LY-K3;1NQZAX?AT*[L%^S7TFC7X15F87#QAI%&"Y5W575N6 1UV[L?+TKZ'
M#QPLZ2]G6EAZUDI/G<4Y+K9M)I[V35K]#W*"P\Z:Y*KH5;)2?.XIM=;-I-/>
MR:M?H=%8ZKI7@NTGF;4%U6[G(8E75W=E4A%.UY"JC)RSN0!TYP#WTZM#+Z<Y
MNNJ]26NC3;:5DM'*R\V_3L=L*M'!0G)UE5J2UT:;;2T6CE9>;9X"LSJ_FAF$
M@.[<"0V[.<[NN<\YSG-?$W:?,F[WO>^M^]^Y\C=I\R;OO?K?O<TI-?U.9#')
M=W+H1@JT\I4CI@@MC&*Z'B*TERRJU&NSG)K[KF[KU6N5U)M=G*5OS,FN8YPH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,.Q=8)YU<A1NR,G
M'&6_Q%?38V$JV'PLZ<7)\G*[)O6T>WFF?08N,JM##3@FWR\KLF];1[>:99EU
M:WBX!+G_ &1_4X'Y5QT\KQ-35Q4%_>=OP5VOFD<M/+J]35I17]Y_HKO[TC01
MUD4,IR#T(KR)PE3DX334EHT]#S)1E3;A---;ICZ@@* "@ H * .,\1Z@X?[+
M&<* "^.Y/(!]L8/OGVKV,)25O:R6M]/*W7U/5PU-6]H]^GE;J<G7JGI'<>'-
M0>X5K>4EFC&5)Z[>A!^AQCV..PKQ,524&JD=$]&O/_@GD8FFHM3CHGH_4Z>O
M-//"@ H * "@ H ]Q^#N_9>YSLS!MZ[=V)MV.V<;-V.<;<]J^OR6]JV]KPMV
MO[U_GM?Y'U&4WM5WM[ENU_>O^E_D>TU]:?3!0 4 % !0!@'0LZT-;\S[MDUG
MY.S^].LWF;]W;;MV;.^=W:@#$O?"-VE]/J&C7[:<UZ%^T1F!+A'=!M$J!G3R
MY-O!/S GDB@";_A!K+^Q?[!W2;/O^?D>=Y^_S//W?W_,Y_W?EZ4 0V/A&[:\
M@OM9OVU(V(;[-&($@178;3+)M=S+)MX!.T*>0 : .ZH \<^,%F[VUI=@C9%)
M)$1SN+2JK*1QC $+9R0<E< \X^5SF#<*572T92B^]Y)-?+W'?Y'SF:P;C3J=
M$W'SO))K_P!)=_D>$5\:?*!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!%+,D W2,%'O_ $'4_A6U.E4KODI1<GY+
M;U>R^9K3I3JOEIQ<GY?J]E\S+&L(SJJHVQCMW'C].?YU[CRF<:<IRJ1YXQ<N
M1:Z+7>ZM]S5^I[#RV<82E*<>>,7+D6NWG=6^YJXV(_;+TR#E(1@'MGD?S)_*
MM*B^IX!49:5*TN9KJEH_R44UW;151?5<&J4M)U7S-=4M'^2BGYMFW7S)X 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M7VF30M3J5;ZRFHV_PJ__ +?^!]9E4+4YU.KDHV_PJ_\ [=^!Z]7U!]$% !0
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M>+?WMDRRN@VVG-+LFK+[XM_>V7)_ACH<L7E)%)"W'[U)7+\=>)"\?S=_W?\
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M89;0B[RYI>4I6_\ 25%_B1W'PIT:>0NC7,"G&(XY%*K@ <&2.1^<9.YSR3C
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M ($I?A8FM_ACH<$?EO%),W/[QY7#\].(S''QV^3ZYJXY5A8QY7&4G_,Y._\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#E]7\66^E7(L(X;F^NRGF-!:1B5XX\X#R%G1$#'A07W'L.1D A3QOIC:8V
MKEG6&.0PM&T;"=9P0OD&+KYN2/E'KG.WF@!VD>+[?5+K^SY(+JPNC'YJ17D0
MB:1!PS1E7=6V_P 0R&'IP< '64 % %:]LH-1A>UNHTFAE&UXW 96'7D'T(!!
MZ@@$8(!H \9@^#$%KJD5S'<;]-BF,_V*1&8 X&%#%R&!*J&9E#%5"G=3 ]O
MQP*0",H<%6 *D$$$9!!X(([@]Q0!R4_@'P]<'<^GVH)_NQ*GZ)M% ',ZU\(]
M(O5633-VDW41RDT!8X/;<A<=#R"C1M_M$<4 8_\ PJ">_P#^0SK%]>K_ '02
MO'I^]DG'_COX4P-ZP^$/AVP5U\EYFDC>/?,^]E#J5+(NT1B0 Y5]A*-@K@T@
M.9^&"2>%]:U+PI*YD2+;<P%AC(P@)QG&7CDA) [H?0X8'NE( H * "@ H *
M"@ H * "@ H * &22)"C22,$1 69F("JH&223P !R2> .30!X/K/B._^)-ZV
M@^&Y#!IT8_TR]P0'4Y!1>AV-RJJ,-,<Y(B!)>P'JOA?PEI_A*V%M8H-^/WDS
M >;*>I+L #C/W4'RJ.@SDE =-0 4 % !0 4 % 'P[_PENM?]!"]_\"I__BZ^
M)]O5_P"?D_\ P*7^9_4/]EX#_H$PW_@BE_\ (A_PENM?]!"]_P# J?\ ^+H]
MO5_Y^3_\"E_F']EX#_H$PW_@BE_\B'_"6ZU_T$+W_P "I_\ XNCV]7_GY/\
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M_P# J?\ ^+H]O5_Y^3_\"E_F']EX#_H$PW_@BE_\B'_"6ZU_T$+W_P "I_\
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M-_X(I?\ R(?\);K7_00O?_ J?_XNCV]7_GY/_P "E_F']EX#_H$PW_@BE_\
M(A_PENM?]!"]_P# J?\ ^+H]O5_Y^3_\"E_F']EX#_H$PW_@BE_\B'_"6ZU_
MT$+W_P "I_\ XNCV]7_GY/\ \"E_F']EX#_H$PW_ ((I?_(A_P );K7_ $$+
MW_P*G_\ BZ/;U?\ GY/_ ,"E_F']EX#_ *!,-_X(I?\ R(?\);K7_00O?_ J
M?_XNCV]7_GY/_P "E_F']EX#_H$PW_@BE_\ (A_PENM?]!"]_P# J?\ ^+H]
MO5_Y^3_\"E_F']EX#_H$PW_@BE_\B'_"6ZU_T$+W_P "I_\ XNCV]7_GY/\
M\"E_F']EX#_H$PW_ ((I?_(A_P );K7_ $$+W_P*G_\ BZ/;U?\ GY/_ ,"E
M_F']EX#_ *!,-_X(I?\ R)ZK\(-<U#4M7FBO;JXN8ULY&"3322*&$T #!78@
M, 2 <9P2.YKU,#4G.HU.4FN1NS;?6/=GP?%6#PV%P5.IAJ%&E)XB$7*G3A!M
M>SJNS<8IVND[;72['T;7T1^-!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M>H% !0 4 >P_!/\ Y#4__7E)_P"C[>O7R_\ BR_P/_TJ)^=<8?[A2_["8?\
MIJL?4-?3GX8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M:-P&1P58'H01@@^Q'% 'B'PGN$T"75M N76,6-T9%=V"@J?W18DD<8BC//\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MR3*BM@@[8R 1DFF![=9V4&GQ+;VL:00I]V.-0BCZ*H &3R>.3R:0%F@ H *
M"@ H * "@ H * /S]KX$_K@]6^#_ !J\^6*?Z#-\PSE?GA^88YXZ\<UZN!_B
M2Z>Y+\T?!<5_[E2LN;_::7N]_=J::Z:[:FCIZ6>I:G8V<FM7&N0RW(\RVGCN
MHX\(CNK-Y\CH_P ZJNS&2&(Z9K2/+.I"#K2JIRUC)22T3:^)M/72QQUW7PN$
MQ6(AEE+ 5(47R5J4Z$YWE*,9)>RA&4?=;ES7LK=[ /%NMGQ>;<33&,WWV?[-
MEC%Y D\O_5?=!\H;_,QG.9,XS1[>K]9Y;NW/R\NMN6]MMMM;_,/[+P"R3VWL
MZ:FL-[7VWNJI[7DY_P")\7Q^[R7M]BUSM]2L[6PTV6TM]0;0X1K$B)-$)"-S
M1L3 ?*>/RXPQ8EG81H(@&QP1VSC&%-PC4=)>U:35^J^'1JR]796/F,/6K5\5
M#$5<'''U/[/A*5.HX7M&:2JKVD9\\VDE:,7.7.[7U3\^^*,[6:V6AW#375S8
MQL[7DX ,ZS8(*8=V*J5*,7.[='C+'+MY^,?+R4)7E*";<Y?:OVU>FEM>W7<^
MNX;@JSQ.:453I4:\HQCAZ3;5)T[WYKQBE)IJ245:T]HZ16C\)M6B\U]-BMXT
MD^S7$LUR<M+)@H(T&<".-0?F49#L%;Y2&W:8*:NZ:BD^63<NKVLO)+MUW./B
MC"SY(8V=:<H>VHPIT=%3A=2YY/\ GG)K23MRIN.JM;RWPS_R%['_ *^[?_T<
ME>91_B0_QQ_-'W68_P"Y8K_L'K?^FY'N_P#9>E?\)G]J_M'_ $[SL_8_LLOW
MO(QM^T;O+^[\V<8_AZU[G)3^M<WM/?O\'*_Y?YMMM3\K^LXS^PO8?4_]F]G;
MZQ[>GM[6]_96Y]_=M>_78R/%E[<:#HCS:8[6TE[J]]]HFB8K(2EQ<!%WC#*"
ML:\*02%(Z,P;*O*5*DW2;BY59\S6CTE*RONMOZNST,KHT\?CXT\;&-6%#+\+
M[*G-*4%S4:+E+E?NRUF]T]6GO&+6GX6NI=9L=&U#4B7NHM1DMXIGYDDA-O-D
M%NK?,H!8Y),?)+,2=*,G4A1J5-9*HXIO=KEEU]5OY=SAS*E#!8C,L'@ERT)X
M2%6=..D(5%5I6:CLO=E=15DE/1**2.>\$<>,-1SQC[?GV_?USX?_ 'FI_P!Q
M/_2CU\X_Y$>#_P"Y3_TT=#%:'4-)T.SBU6;1YIX'6-(EEQ<-^[.&:.6)%*=$
M#G+&3:G/!Z%'GIT(*JZ;<79*_O;=4TM.E][Z'D2JK#8S-,1/ 4\;3IU8.<IN
MG>BO?5U&<*DFI;R<5[JA>6FJ\V^*&HB]U?R-DBR6,*6LCS!5>9D9V\W"DKMD
M5PR'@E2"0 0H\[&3YJG+9W@E%M[MJ^NG1WNC[3AN@Z&"]KS0<:]25:$:;;C3
MC)17L[R2?-!Q<9+5)JUV[M^<UYQ]D% !0 4 % !0 4 % !0 4 >P_!/_ )#4
M_P#UY2?^C[>O7R_^++_ _P#TJ)^=<8?[A2_["8?^FJQ]0U].?A@4 % !0 4
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M;UZ^7_Q9?X'_ .E1/SKC#_<*7_83#_TU6/J&OIS\,"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /C[_A5GB7_GS_ /(]M_\
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M_P"4J_\ \J#_ (59XE_Y\_\ R/;?_'J/J=?^3_R:/_R0?ZRY5_T$_P#E*O\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .:U?Q?I
M.A3"VO9PDQ7?Y:1RS.%[,R0I(R@]BP /:@"U'XDTR6P.K+<Q&R ),V[Y1@X(
M.>0V>-A&[.!C)% $&C>+-+\02-#83B26-0S1LDD3[3T8)*B,R]/F4%>1SR*
M.BH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .6U&32?
M"/VG6[C$,ESL\U]S/),T:[8HXT9C\V.%2,*.,MPI8 'DBZ5<1K8F_C^S1ZSK
MXO#:=HT\LM&CCIN8J&D7O\H8 @@,#O/%Q^RZ[H=S$/WK7$]NQ'5HI(OF5N#E
M5/S@'A3DC!.:0'I% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!Y/JWAGQ%=ZVVK)_9MS# -ME%=27.(!@;I/+CBV&9SR7+/MXVXPN&!
MK:AH&L^(;$+J+V=MJ%I<QW-G+:^<\:O$./-$JJV&RRL%R,$'!(Q2 EL] U74
M=3M]4UY[0#3TD%M!:>:R^9,H5Y9&F53D*,(@!"]<Y!+ '>T % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '*>,]=FT#3_-LU5[NXFBMK
M=7SM\V9MJE@.2%&6QW( Z&@# :[UGPO?V4>I7@U*TU&7[*Q-O' T,[*6B*&+
M 9'*LI5\LH&030!Z50 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M/5_^_DG_ ,50 ?9D]7_[^2?_ !5 !]F3U?\ [^2?_%4 'V9/5_\ OY)_\50
M?9D]7_[^2?\ Q5 !]F3U?_OY)_\ %4 'V9/5_P#OY)_\50 ?9D]7_P"_DG_Q
M5 !]F3U?_OY)_P#%4 'V9/5_^_DG_P 50 ?9D]7_ ._DG_Q5 !]F3U?_ +^2
M?_%4 'V9/5_^_DG_ ,50 ?9D]7_[^2?_ !5 !]F3U?\ [^2?_%4 'V9/5_\
MOY)_\50 ?9D]7_[^2?\ Q5 !]F3U?_OY)_\ %4 'V9/5_P#OY)_\50 ?9D]7
M_P"_DG_Q5 !]F3U?_OY)_P#%4 'V9/5_^_DG_P 50 ?9D]7_ ._DG_Q5 !]F
M3U?_ +^2?_%4 'V9/5_^_DG_ ,50 ?9D]7_[^2?_ !5 !]F3U?\ [^2?_%4
M'V9/5_\ OY)_\50 ?9D]7_[^2?\ Q5 !]F3U?_OY)_\ %4 'V9/5_P#OY)_\
M50 ?9D]7_P"_DG_Q5 !]F3U?_OY)_P#%4 'V9/5_^_DG_P 50 ?9D]7_ ._D
MG_Q5 !]F3U?_ +^2?_%4 'V9/5_^_DG_ ,50 ?9D]7_[^2?_ !5 !]F3U?\
M[^2?_%4 'V9/5_\ OY)_\50 ?9D]7_[^2?\ Q5 !]F3U?_OY)_\ %4 'V9/5
M_P#OY)_\50!*B",8&?Q8M^K$G\* '4 % !0 4 % !0 4 (RAP58 J0001D$'
M@@CN#W% &=8Z-8:66:RMK>V9_O&&*.,M_O%%7/XT :5 !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MQP01$I/(:F!ZQ8,7MHF8DDQH23R22HR2?6D!:H * "@ H * "@ H * "@ H
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M NTKYA$WF;L<==V 6![7H5K+8Z=:VUP=TT%M#'(<YRZ1JKG/?+ \T@-2@ H
M* "@ H * "@#S'Q\BQ7NF7FH1M/H]M+,;M0C2(DC1@6\LT:YWQHX/\)"<YW;
M@M &=H\UGJGB>*\\.*!91VLBWTL,9C@E<G]PGW55Y4/.0"0H(SP0&!Z_2 *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#D/%EGK]VL(\/7,%HRE_.,RAMP(79
MMS!/T(;/"]1U[ 'D?A[4O&_B62ZAM=0MT:QD\J3S8H0"Q+C*;;-\CY#]X*>G
M'7 !Z-X?\210Q7]S?ZH+^.R=1+BS: 6O+J4&V,-."1C>%)^3.!NH OQ?$?P[
M-(D*WL>^7;MRLJK\W3<[($C//(=E([@4 7-,\;Z+J]U]@LKI);CG"!7 ; ).
MQF0(^ "?D9N 3TH CU+QYH>D7)LKR[2.=3AE"R/M/H[(C*AYY#,".] '50S)
M<1K+"P>-P&5E(*LI&001P01R"* //]0\0WESXHMM"L7\J"")KB](1&+#&4CR
MP)0<IEEVM^\Z\8H YS0_B*EGJ.KPZ_=JD%K=^5:*8QN"B6Y5@HAC\QP%2,%F
MW8XR<L<@'J5IKEA>V?\ :4$\;6@4L9<[54+][=NP5*]PP!'<4 8FF^/M!U:X
M%G:7:/.YPJE9$W'T5I$56)[!6)/09H UO^$BL/[1_L;S?].V>9Y6R3[N-V=^
MSR^G.-^?;- %>/Q9I<KW<239;3%=[H>7*/*6/=N.2F'QL;B/>3CC.10!0L?'
M^@ZC(D-M=J[R))( 4E4!(@[.SL\:K'M6-F_>%25 (!#*2 1VOQ%\/7DXM8;Q
M#*[!5!25%+$X $CQK'R>!\W/:@"G<^(;K2O%$>EW3[['48 UN-JKY4R9#+N"
MAF#[<_.QPSJ%P 00#T&@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M,D1ZC+,<$C"L": /0/'CFYUSPZ44I,;CS'0C#JADM6(;CL%D&.Q!Z9H ]GH
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H "0HR> .I]* ,R'6;*XADN(IDDBMPS2,IW!54$ECC)VX4E2 0P&5)% %
MRUN8KR)+B!M\<BAE;D9!]C@@]B" 0<@@$$4 3T % !0 4 % !0 4 4XM0@F2
M65&RENSI(<,-K1_?&",G'JN0>Q- $]O.EU$D\1W1RJKH<$95@&4X(!&00<$
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MS0L'C<!E8="#_GD'D'@\T 4I]8M+9WBE?:\1A##:YP9V*1<A2#O92.,[<9;
MYH LV=Y%?Q">W;?&VX X(SM8J>& /# CIVR.* +- %>SNXK^%+FW;?%*H9&P
M1D'OA@"/Q - "7EY%81&>X;9&NT$X)QN8*.%!/+$#I[GB@"6*59=VT,-C%3N
M5EY'7&X#<OHRY4]B: )* "@ H * "@ H K6=Y%?PK<6[;XGR5;!&<$@\, 1R
M#U% %F@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MCY<8X(P #FGT]_LL:O;3.?[.CCLU6"0&"\!_>LPVKY#F7RY#,^Q71"0[ $,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !)YP ,\4 24 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
' % !0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>dxcm-20231231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dxcm-20231231_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@#
MK 34 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _%?_@X#_;W_ &Q_CS_P4#^'7_!#7]@#
MXF77@O5O&26;^/?%6FWDEM<C[4'E%L9HOWL-O#9QM=3>6=\JR*G165_-OVD?
M^#3[]H+]D?X03?M+?\$XOVY_B/KOQL\/&&\DL4==,EUV0.HD^RSPS!X) "75
M97E5PI4L,[JQOVY_$ND_L-?\'BGP^_:C^/E_'H_@OQC;:;-8ZYJ#".T@AN?#
MTOA\RO(WRHD=TA9V) 1?F; YK]G_ -OW]N_X*?\ !.[]E#Q%^UI\9M06;2=%
MMX_[.TRTNHUN=:NY6"PVEMO.'D<G/&0J*[G"JQ !\K?%[_@I%^VO_P $[?\
M@A:W[6'_  4 ^%6G:=\?='TU-#CT8W]I<6^J:O-.8+.\E^Q2-$,Q$7,T4;*,
MQ2JNP%0/SX_8(_X( _M%_P#!;3X&V?\ P40_X*;_ +>/CW[9X_EFOO".BV02
MXEAM!*Z)<-YY,-M$Y5C';01*JQ;"&&[8OOO_  7?_:#T'_@K;_P;II^VA^S7
MX#\66'AK3/'EAKEQI_B73(X+PVEM/<:=<2[(9)5>))KC)=6(VQ.QP%./KO\
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MEAI>H:RL@95OI+$2W<$Z!T*22A8YMQ3S&!9#7S-\'_AS^T5_P;Q_\%V_@_\
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M2T2;P[XQO-&8VWFZA!-9R+>1!"#$)H)X7(7"B0RJN%4"OF3_ ((X?\$")O\
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MXN:E/#XC\./J,UQ;Z>)W5M1T](V8JC1MMO;4#;D(81\L3D[/_!:#]L[XH_\
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MUZ]X(M=8O[&^C\4>$Y%-TBP2K*JH=P!5\8)ST-?SJ?\ !4?_ ()<>)_V O\
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M2;0?!/C&UN+>ZTC4;?S;K3XV^TQ1.P>T>YA$FQ#,_DG'04 ?0WBSXK?%&/\
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MYKW[-GBFS@A\43A1ISQ:9=3+/"R.2LF0!D8(KYQ_X+L?\K3?[%7_ %[^!?\
MU+]2K]=_^"H.@:CXK_X)I?M#^%]'MGFO-1^!OBVVM(8URSRR:-=*B@=R6(%
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M'^O7VE>./$-_HB:UJ>F2-9RW<L&I3VC7/[K;L\\0"8JN%_>\ # JS_P:1?\
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M$VE_\)'=ZQ_:>OQ0I/YEPL2LF(55=H\H8XSR:^CZ* /SV^'G_!N7^R-\(?\
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ME_KOB.]UR[LO"]]!;+I^CRZG,9)3 40281'EB0,3\DASG%=K^P!_P1U^$/\
MP3Z_:M^,_P"UCX!^+/B37=5^-6K3W^LZ7K$%NMOI[RWT]X5A,:AB T[*-Q/"
MCO7V#10!^8/_  4+_P"#6K]D7]M/]HG4OVL/A-\9_%GP<\<Z[>O>Z_<^%X8[
MBRO+U\^9>+"6C>&>0DF1HY0KDEBNYF9KW_!-O_@V&_9*_8,_:$L_VLOB'\7_
M !7\7OB%I$QGT'4_%,4<%II]R5*_:Q I=Y9U!(1Y)65#AE4.JNOZ844 ?"G_
M  5T_P""$'P2_P""O7C_ ,$_$+XJ?'/Q=X0N_ ^EW-EIZ>&8;9A,)I4E+L9D
M8A@4&,8KY<_X@Z/@%_TD2^.'_@7:_P#Q%?L=10!^>7AW_@W=^!$/[9GP9_;'
M^(W[17C?Q=>_ [PCX=T#PAX<UB&U-H8]&L1!:S2,$\PR&Y#7K8(!F<XPO%?H
M/J&GV&K6$^E:I9Q7-K<PM%<V\\8=)8V!#*RG@@@D$'J#4U% 'Q+_ ,$I_P#@
MB-\(O^"2'Q'^(7BOX"_';Q?J^@_$)(?MGA'7H[<VMD\$TCV\D3QH'+1QS2Q9
M8G<K@GD"K?[>O_!%?X-?M]?MK_"/]MOQY\8/$^AZU\(;C3I=)T;2(+=K6^-I
MJ7V]!,9$+C<_R':1\O3FOL^B@#DOC]\(M)_:!^!/C7X#:_JMQ86/C?PEJ6@7
MM]9JIFMX;RUDMWD0,"I95D)&1C(&:\*_X)+_ /!+3X8?\$COV=-;_9Q^$_Q+
MU[Q5IVM^-;CQ)/J'B**!)HYIK2SM3$HA55V!;-&&1G+M[5]144 ?GA_P54_X
M-QOV5?\ @JS^T?IG[3/Q)^+'BSPAK=IX<M]'U&'PQ#:F/4HH997CED,T;$2A
M93'N'\*(,?+7W]X0\)^'? 7A/2_ WA#28K#2=%TZ"PTNQ@&$M[:&-8XXU'8*
MBJ!["M&B@#\=_$?_  9S_LP:UX_U_P"(6E?MO_%O1[GQ%JUQ?WD6EK91*&EE
M>4ID1@E07(&:Z_\ 9N_X-4?@E^S=^T+X%_:%TC]N[XPZS=^!O%^G:_;:1JES
M;&VO9+.YCN%AE"IDQN8PK8YP37ZLT4 %>&?\%'_V%/ __!2;]D#Q/^QY\1O&
MNJ^'M(\3SV$MSJVB1Q-<PFUO8;M0HE!7YFA53D="<<U[G10!Y%^P?^R%X2_8
M)_9(\%?LB>!?%>HZYI/@FPFM;+5=62-;BX62YEG)<1@*"#*1P.@%>-?\%4?^
M"(O[%G_!6G2-.O\ X\:5JFA>,=#M3;:'X]\*S1PZA#;EB_V:82(\=S!O)8(Z
MY4L_EM&7<M]A44 ?C-\/?^#-']F[_A,=,U']H_\ ;D^)WQ"\.:.X^P^&5MXK
M!1$"/W!F:2=DC( #"(1L1]UE."/UV^$'PA^&7P"^&.A_!CX,^";#PYX6\-Z=
M'8Z'HFF0[(;2!!PH'4D\DLQ+,Q+,222>CHH ^,/VHO\ @BO\&OVI?^"F?PU_
MX*=>)_C!XGTSQ+\,[?2XM-\.6$%N;&[%C=W%RAE9T,@W-<,IVD<*,5Z9_P %
M./\ @G_H7_!37]E2^_9*\8?&'Q!X,T+5]8L[S6[OPW#"\]]#;.94MF\Y641F
M9893QG,*CH37T'10!Y3^P_\ LA_#7]@S]E+P5^R1\(YKF?0O!6D_9(+R]5!/
M>3/(\T]S($ 7?+-))(<# +X%?.O_  4(_P""&WP4_;V_;%^'/[=)^-/BKX?_
M !!^&\=FNF:EX7M[9UNVL[PW=J\HE0DM'(SC(/S*P4\**^X** /S._X*'_\
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M,_X>_P#!,GXK?M9>/=2\/?#3Q;#K'ASQ5):69U(6\-K>6T%A)E"C11)>NJ'
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MC_X.<OVJ/C;\<O\ @JC\3]-^$?Q'URP\+? _PGH^AWK:3K$]O 9GEB:;Y8V
M,OVK47B.>2ML>R"OT4_;5_X*S?$G_@FE_P &ZW[-?C'X3ZMYGQ2^)OPG\,:1
MX;UG4 +AM/\ ^))!->:DPDR)9$78JA\CS9T9@P5E/Y97WA+Q%\:O^",W[6?_
M  4R^(-BW]L_%_\ :8T:VAEFY:-8Y[B_N0A[HTNI1IZ9M@!C::^CO^"_/P?\
M9>)?^"!G[ 'QOTC3YIM%\)_#O2-,UF2)"P@DU#0-/>!WQ]U<V,B;CQN=1U8
M@'K/[,__  :?_$O]LWX&Z)^U3_P4#_;^^(:_%7QII46M1P1#[>^C&X02Q1W,
M]W(TD\P5E+JAB"-E%9@H<[?_  1V_;,_;>_X)J?\%;=3_P""&'[=_P 9+SXA
M>'-2WQ_#WQ1JMU+/):2FS-[:/#+,S2"VN(%,9MV9Q#.%5" )-_Z\?L+_ +5?
MP@_;,_9,\$?M%_!CQ58ZCHNN>'K62=;2X5CIUT(5\^SF /[N6%]R.AP05]""
M?Q"\?_$'PQ_P41_X/!_ VL_LT:K#X@T#X;3V2:QXDTF02VCII-G-/=RB1<AH
MQ<2"T#_=9]H4D,I(!\X?\%*O^"@_[3?[!G_!QI\3OVAOA-XOUV^LO WCJTN=
M1\,R:G.=/N].>QM(;BUECR42.59C&'V_))(C+\X6OT=_X.:?VNO"_P"T)_P0
MF^'O[5O[,7Q%OXM"\:?$70KW2M3TR]>WG$4EEJ.^WD,;922.16CDCS\LD;*>
M5KP?X.?LZ?"O]KC_ (.FOVOOV:_C9H"ZEX7\9?##5M-U:VX#JKPZ(5EC8@[)
M8W"21OC*O&K#D5^=?[=>O_M.?\$Z_@S\3_\ @A;^T'#/J>B:#\6+#QAX%UI@
M5C$(@N8S/ &)_P!'NX;B&;8"?*FBE4C<\A !^X'_  41_P""KGCG_@F)_P $
M%/@9\2/A?>QS_$[X@_#;POHGA*_U%!<?897T6&:ZU)TDR)FB1<*&R#+-$6#J
M&4_-'[,O_!JQ\5OV[_@?HG[6W_!1[]O_ .(DOQ+\<Z5#K=M90XOGT9+A!+"E
MQ-=NS22!&4M'&(EC/R*2%W'G/^#D/X'^-?&7_!"S]B[X[Z#837&D^"/".A66
MO&%2PMDU'0;(0S/C[J>9:B/<>-TZ#JPK],[[7_%/_!8#_@D'X<U'_@GM^V!)
M\,_$7B?1=%=?&?AZ^F6ZT"ZMV@>]T^7[+(DD4HV20,NX<'/S*P) /GS_ ((8
M_LG?\%K/^"?'[5OCC]E7]J34KWX@_LY6L,\?@_Q[J_BBVE:WN4V/;RV=M+<2
M7<,$L9:.6W*F..7!1OE=I/UAK^='_@G7\:?V^_@+_P '(O@3_@GY\7_^"I?C
M;XX>&-,N=2BUV9?'=]=Z1J$W_",WEWY$D$EQ*A>"?:K*Q)66'H"N!_1=0!_,
M9^S#^PEXO_X*R?\ !<K]KG]G+Q=^U]\0O NF>$_'7C/6=.G\.ZG)+S'XF-JD
M'EO(%6,+.3A<8V # KN?VTO@?_P43_X-<OC+\-_VH/@U^W!XI^+'PE\4:^=.
M\0^%_$\T\5O/,B^:]E<6[SS1%I8%F:&ZCVR1M&XP /WGI_\ P;Y_\K*G[</_
M &$_''_J8PUVW_!ZS\=?AW+^RA\*/V4M/UZUN_&VJ_$Z/Q%'H=K*)+J*QM]/
MO;7S'C7+());Z-4R!O,;[<[&P <?_P 'BG[0.K>(?V:OV6_BY\$_'^L:;I/C
M ZQJME<Z9J$MJUS:SV>FS0E_+89^20'!SC)KL=-_X-;?@+>Z=!>2?\%F/B@C
M2PJ[+_;UKP2 <?Z^OG__ (.HOAAXF^"7_!-/]A+X,>-(&BUGPCX)?1=6C<\I
M<VNC:/!*#[AXVKZNTK_@RS_X);7VEVU[+\>_C\'FMT=@OBG1, E03C_B3T ?
M0>K_ /!$?PMK7_!(/4O^"=O@[]J7Q-XBU6&\O-<\"?%#4=39+NTU9I'D@+R0
M.=T&6>!U!.8I'P P4C\O?V+?^#BKXW?\$UO^">OQC_8-_:KTS6'^/GPKO[C1
M/A4=<C>Y<2S3/%+%=R-N#"PDWSH6)$T;1Q*0JAC^Z/P/^%'[.O\ P2;_ &#+
M'X;_ /"PM2MOAM\(?#%W<7'B+Q;=PRW4=FCRW,CS-!%$COEV"JD8+?*H!8\_
MRW?MBG]K[_@K?\8/CQ_P6Q^%?P#LX/A[\/?$VF&\AETR*3RK.()%;"6(HRW\
MD4$4$EV6W!$F!.(MH4 _:G_@W"_8L^('[&?[%'B/_@H[^W'X^\1WWC/XAZ!-
MX@G7Q)JD]Q)H/AJ-&NP625CB>X"_:9.X00*=K*X/Q/\ LG? ?]L;_@[!^._Q
M)_: _:7_ &I/$OP[^!'A#6ET[PYX%\./YD2O(#)':Q0LPA,L<'EO/=RJ[NTJ
M*JA"!%^J/[-7[:'AC_@MC_P1F\;>,/@O%;67B[Q=\+]=\)^(O#5O-SHWB&73
M)8&MQDY$;-+'+$QZQ2H3AMP'Q'_P94?'KP!8?LZ_%[]CW6]6@T_QUI/Q$;Q(
MVA7K"*ZFLYK*ULW9(VPS>3+9%9,#Y#-'NQO&0"#]G7_@DO\ \%@/^"-7_!1W
MP/I?[ /Q"\1_&+]GK7Y('\=:/K^N6MA:V-D9A'<QRP7%PL?VJ.,B:">W4.Q!
M0IL#J_2_\'&/_!1O]L/Q?^V%\-_^"*W_  3T\:W?ACQ9\0ULF\7^)],O7M;E
M1>RO'!9+<1_O+:%(D:YN)(_G:-D4':)$?[1_;._X+F?LE?L3_MP?#W]@OQGX
M>\3^*?&7CXV\(B\$V]O>-HUS=7"064-U$TR,IF+,P"[G5 C;"LBFOR^_X*M^
M+]+_ &"_^#K_ .$7[8WQX=M/\!^(+31KH:[<(?LUI;-93:/<2LW0"!_WS@?,
MJ,K8^89 /0?%'_!G%XD\"?#:?XG? +_@H_XV3XX65F;NTUNXMOL5E>WZKN$8
MEAE^TVP9AM$QDD*Y#%3TKU+_ (-Z_P#@K1\?_P!MW]DOXT?LK?M@:S=7WQ3^
M#6@W"?V_?86]U/3WBN(<7)7[]S;30F-Y>"XEB+;G#NWZI_$'XY_!WX5?!_4/
MV@/B#\2]&TOP3I>CG5;WQ/<7Z?8UL]F\3+("0ZL"-NW)<LH7)(!_ K_@V*TC
MQ#\=/VE_VV_VX](T&YLO">N^'=6M[0SQ[5-QJ5[<:@L(QP7BBA&X#.WS4S]X
M9 /B?_@A=^UM\>/V=/\ @I!\ _CO\1?BCXAO?!'C'XBWG@>^35-<GFMY'GMK
M:WD,BNQ4")M4LYL]MF>@K[:_X.]_VE_BYX__ &U?A_\ LC_ [QQJVG)\//A=
MJGBWQ*='U.6V57G629UF,;#)2VTZ-DW<9N@!RYKX>^#WP"U+QW_P;M>.OVD?
M"BR0ZU\'_P!J6QU1=1@XDMK.[TNRLWVD<J?M,EBV?^F=>T?"WX@>)O\ @IW'
M_P %$?\ @K!X^T)H!8_ VVT/2;:8#;:S77V6!/+QP&6VTN0$#I]I.>6S0!^R
MW_!KUXC\0^+/^")OPEU[Q5KU[J=]-?>(Q->ZA=/-*X77K]1EW))P  ,G@ "O
MT!K\Z/\ @UOUC2-!_P""%7PDU37-4MK*VCU#Q&)+B[G6.-<^(+\#+,0!DD"O
MT1T_4=/U:RCU'2KZ&YMYEW13V\H=''J&'!'TH _&C_@])\<^-? O[('P>O?!
M/C#5-'FG^)-RDTVE:A);M(O]GRG:QC8$C/.#7BG_  =C^/OB;X;_ &3OV+O^
M$#\::]87FJ>'=36X_LC4IHI;N3[!HFT-Y; R-ECC.3ECZUZO_P 'N7_)F_P9
M_P"RFW/_ *;I:\N_X.DO^2,?\$_O^N<__I-H% 'V=_P0@_X*PS?\%'_^"97B
M/PM\3O$3/\7?A3X8GT?QKY\I%QJ,(M9!9ZKZEI5C9)#U\^&0X4.@KYX_X--_
MVF9OAA_P2L_:'_:-^.?C+5]6TOP'XOO]:U*XU"_DN)DL[31+>XD2,R,>2$;"
MYY)]Z\E_X+)?!/XD_P#!!G_@J+8_\%1OV7_#4S_"7XUI?Z3\0_#EE^[MX[V[
MC8WUF<?*@GP+ZWSP)X)1@(@4U_\ @WA^$GC#X\?\&]O[9_P?^'UC+=Z]K\^M
MVNC64"DO=71\/P&*!0.ID<!!_O4 9'[$/[%_[8G_  =0>+/'W[97[;O[6_B7
MP;\)]'\3R:/X5\#>%F\RVBN!&DS6]M#(1#$D,,UN&N'CDEG=^2"I-?0G[$'_
M  3#_P""Q?\ P1[_ ."G?AOX9?LN>.=?^,/[+NO?9Y/%[Z_KEK:6NE6<TCQ3
M-]FN;CY;ZV*K,&M5_?IM5@ S*F__ ,&8'[0_PS\2_L"^,OV98O$5I#XS\*?$
M6\U6[T-YE6XETZ[MK4172H>63S8IHF(!VE$SC>N?L']H'_@N9^R5^SU_P4B\
M&_\ !,G4_#WB?Q-XV\8&PMQ>^#[>WO+?1K^\G,<-K>J9D>$^6%F=E#[(Y$9E
M .0 ?:%%4)O%'AFWUJ/PW<>(K"/491F*P>[03N,$Y"$[CP">G8T1^*?#,VMO
MX9B\16#:E&,R:>MXAG48!R8\[AP0>G0T 4/BGX&3XG_#'Q'\-9=9N-.7Q#H-
MYIC:A9_ZVU$\+Q>:G^TN_</<"OYO?^"[/_!%'4_^"2/['VA_M*_#K]O_ .+/
MBZ^U;XAV?AR33-:U%H(HXIK*^N#*&BDR6!M%4#IASZ"OZ8*_(G_@])_Y14^#
M?^R[Z3_Z:-9H S/^"1?_  ;\6'AK2_V??^"B^H_M]_%75M1NO#.@>-+GP=J%
MP'T^6:ZL(KEK5B9"S1@S%02,D**\M_X(;_%'Q9>_\'+W[:/ASQA\1=1FTBRN
M/'"V%AJ6KR-;0%?%]HJ"-';:N$R!@# R!Q7ZS?\ !+G_ )1F?LZ_]D)\(_\
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MO^"9?A,^!_%?B/6T.I^$M"U*>1)O+U"TMHCY<DCL$NX[BYMG0'9(L3?+DN2
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M]M#I^G7*R,+BTF;S"]Y("0P&%7@')-WX:?\ !.[X1_\ !+W_ (.E/@7^RO\
M!+Q?XCUS0[:XLM32_P#%4]O)=F6XT^\+J3;PQ)M&T8^7/J30!VO_  5_^%?B
M']K;_@YZTS]C?6_VDO%/@#POXMT'2HKS5=%UEX18[-%EN=ZHSK'EGB53G^]Z
MU]#K_P &L7P$=@B?\%FOBB23@ :[:Y)_[_U\V?\ !6K]D+X:_MZ_\'6^A_LC
M_&#7-<TWPWXST+2[?5+WPU<PPWT2Q:%-<*8GGBEC4[X5!W1MP3T."/LO1?\
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MT\0_&_Q[\<O@3J&N06GC&PO]8DL+W3[@-N2&23,\:).JL([CRSLD78RY:,N
M?;?_  3+_;S_ &GOVQ/^#8[]IKQ;^T!XZU?6O$GP\\(^,- T?QK>73F^OK:/
M08[J%I9\[Y)XFN2GFD[BJQEB6RQ^3O\ @BM_P1U\+_\ !3K]CJX_:1^,7_!3
M;XB^!-7A\8WVCKHEEX@1D,,$5NZR_OY@V6,S#T^6OT].H?L-ZQ_P;)_$[7?^
M"=WA2'0_AE??L^^*IK+2C(9+NUO3IUR+N*]=F9WNUF#K(S,V2H*DILK\T?\
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MB=5#QRJRD\'G'0X /F[X+_$#QY/_ ,'HOCGP-/XVU=]$CTVX,>COJ4IM5/\
MPB5L_$6[8/F);IU.:/V-_B!X\OO^#Q#XQ>";WQMJ\VC0:;JQATB74I6M8R-,
MLB-L1;8,$D\#O7/?LDZWHWQ9_P"#T7XG^,_ &IPZKINDV&IQWEY92"2.-[;0
M+73Y@67(^6YS$?1ABK7[%O\ RN;?&?\ [!FK_P#IKLJ / /@U^Q'XN_X*M_\
M'!?[5O[*WBS]K7X@^!='\-^(/%_B"PN?#>IR2$-;^(;:T2W$;R!5CVWC'CIY
M:@<5=_:D^'G[8O\ P;2_\%(_@M_PJ;]O/Q7\3/"/CZ>&?5_"VN74R"\M%O(K
M>ZM;FT:>6)]Z29AN %=7#8 ,9+<K\$?V,/VG/VZ/^#B?]K;X2_LH?MK^)/@/
MXBT[Q#XRU>]\7^%[N]AN+RRC\16L+V+-9W-O(4>2XAE(+E<VZY4D C]%OV/?
M^#5S3/A_^UGH'[8_[?G[>'BS]H'Q%X8N[:]T>PUW3IHXWNK=M\#75Q=7EU-<
MQ1O\ZPCRU+*-VY2R$ ^&?^#M+6/CIJO_  5S\/\ P_\ A#X^U^P8_ 6WU/\
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MGG2?4[Z-3N6 %$1(( WS"*-5R0I<NRAA]844 ?'WP5_X(Z_"'X)?\%3O'O\
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M%H(+<Z?,(K.6U!9BGF<K*6.&Z@5]GT4 %%%% 'R!_P %8O\ @BW^RU_P5O\
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M65E]C\,Q6@BA6V@$*LCR(7!91SSW->,?\0='P"_Z2)?'#_P+M?\ XBOV.HH
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MJ\K&;PY:P+J$4$;$DV\4WFPRF(9^596E8#JS=:_8^B@#XM_X)*_\$,?V1O\
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MX=^,]5\0:/X2?4&M-7UJ.-;F?[7?W%Z^\1 *-KW#*,#HHSS7M]% 'QA\2/\
M@BQ\&OB3_P %9/#?_!6S4?C!XFM_%?AJW@AMO"T$%N=.F$5E+: LQ3S.5E+<
M-U [5WG_  6 ^&_PP^+O_!-?XL_#KXR3>,$\.:EH$2WZ^ -"?4]9F9+N"2*&
MTMD1S)))*D<?*[5#EF*JI8?2=% 'R5_P0H_9H^*?[(/_  2:^#/P ^-?AZ72
M/%.DZ%>7>L:3<8\VQ>]U&ZOU@D ^[(B7*HZ_PLK#M7UK110!\8? +_@BQ\&O
MV?\ _@J/X[_X*G:#\8/$U]XH\>6]_#?>&;R"W%A;"Z,!8QLJ"0[?(7&2?O&O
M1O\ @J%_P3F^'G_!4K]EF?\ 95^)WQ UKPUI<^O6>J-J>@Q0O<"2W+E4Q*K+
MM.\YXSQ7T310!YS^R)^SAX=_9 _9A\"?LN^$O$%[JVF> _#-KHMCJ6HJBSW,
M4"!%>0( H8@<X %?.W[!O_!%?X-?L#_MM_%S]N#P)\8/$^N:W\7[C49=6T;5
MX+=;6Q-YJ7V]Q"8T#G:_R#<3\O7FOL^B@#\A/B9_P: _LR?$/XS^+_C9:?MK
M?%?0]0\9>([[5[^WT=;*)(WNKEYVC4B/<45G(&23@"M7X(_\&FWP.^"7QH\(
M?&?3OV]_C+J=QX1\4:?K4&FW]U;&"[>UN8YUBDPF=C&,*V.<$U^LU% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?RG_MQ_P#!1G]I;]@'_@XL^*G[1'PV\5Z]JFE>"_B4[ZUX6?4Y
MFL;S29$AAN+9XR3'&KK+M1RN$E:-A\P6OT:_X.G?VJ_#WQL_X(E?"7]IW]F3
MXEWRZ#XT^+&B7VD:OI-\]M+);2Z/K#&*3RV!5U9=KQDY5XRI&5KPG]F+]F+X
M4?MF_P#!R_\ MQ?LO_&[1?MWAGQE\,?$%AJ"*!YD!.H:"T5Q$2"%EBE5)8VP
M=KQJ><5^='[=?C']I_\ 84^ /CG_ ((4_M'VDU]9>!?C79^+_!>KG*Q);?8;
M^&1X Q)-O=I>6URB@_NW$X8;W; !_61^R/XLTW0/V$?ACXY\::ZMO:67PDT6
M_P!6U.^F^6.--+ADEFD<]@ S%CZ$U_+/\6_V_OV[_B!^V!XE_P""ZG@/6/$:
M?#O0_P!H2QL-)L)-7G2T*K%)/::7)"IV;#IUHD4QP 3,.,O7Z[_\%P_VXO\
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MK<S./]'MI8!,RR8^ZT8)5QU5D8'D5_,E^SU\:OVP_AW_ ,$;O%G_  2ZL_\
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MH%I)8VDUVUJK9(F>:\CAA<@D+YCKAU5ADZ7_ ,&E'Q:^.?Q,T'QC_P %(?\
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M1N-4CL;!_LE^UI#;H]T?LD,S1*)GDD4O.SX4X"A?KK]A?_@E!_P4\_X)9_\
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MKUKK<EQJD\EG>6IFBCU9U@+%%2$W^^%?[]H0,!,U^I7_  >._MD:UX1_9C\
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M[-_C?4[SQ%/J5Z\TUIIC02R2*6D)8A+BPU Y)QR!QBOR#_X)[_'C]J+XK?\
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M/5?'7@#2-?U+1H=?MREC/=V<4\D"[YPV$:0J-W/'-??'[+O[//PH_P""!O\
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MV@/&E_X]UJ?6;;Q5J2V^K3:K,US$!<Z2 %E+;U')Z'N?6M?_ ((RZ%J.D_\
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M;ZQ\*:]I<%BBVNHW%K&8TN--FD!*1*6S(<L21@8  /T__P""0_\ P2#\ _\
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MC_MS3Q!:3J>1+:F"6W]/+CB')#$_UN?M!_\ )!/&_P#V*&I?^DLE '\TW_!
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MF/A[:^)/"FN1K]ILIV9)()5.8[B"5"'AF0\K(A!'(Y!(/H]% 'XK:Y_P9?\
MP(AU6\T/X<?\%"/BCHG@F_N?,N_"MQIUM</*O&%>5'BB<C &YH#T'%?HU_P3
M8_X)6?LB?\$K/A-=?"[]EWPE=K<:O+'-XF\5Z[<+<:KK4L8(C,\JHBA$#-LB
MC5(UW,0NYW9OH^B@#\R?^"A'_!KQ^R+^VC^T1J'[6GPD^,GB_P"#/Q UJ\:]
MUS4/"*QRV=Y>M]^\$!,;PSN22[1RJKDEBN]F9C_@GK_P:]?LE?L6_M%:=^UO
M\6OC1XP^,OQ T2\6\T+4/%JQPV=G>+]R\,(,DDTZ8!1I)65" P7>JLOZ;44
M?&'QW_X(K_!KX\_\%2O _P#P52UWXP>)['Q1X&M[&*Q\,VD%N;"Y%L)]I=F0
MR#/GMG!_A%>^?MM?LJ^%_P!M_P#93\;_ +)_C7Q-?Z-I7CC1SIU[JFEHC7%L
MAD1]R"0%2<H!R,<UZG10!X'_ ,$TOV ? ?\ P3+_ &2M%_9&^&WCG5_$>DZ+
MJ%]=PZKKD<27$C7-P\[*PB4+@%R!@=!7RM_P4F_X-K?V?_\ @I-^UW>_MB^-
M?VF_'_A#7KS2;*P%GX9BM!%"MO%Y2NKR(7#,,YY[U^DM% 'XX_\ $'1\ O\
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M6!:.".(;<;%#%<%C7VM10!%8V-EIEE#ING6D=O;V\2Q000H%2-%&%50.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M('D,<C$*=J$E0<=3UH ]>HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL2X\6ZA:PM<7/A6[2-!EG9U
M_.G)XHU61 Z>$;PAAD$.O(_.@#9HK'_X275_^A0O?^^EH_X275_^A0O?^^EH
M V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^E
MH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8H
MK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275
M_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7
M_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?
M^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O
M?^^EJ.;Q??6\D<4_A:Z1I6VQJTB@L?0<T ;E%8__  DNK_\ 0H7O_?2T?\)+
MJ_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__
M  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\
M)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_
M /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+
MJ_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__
M  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\
M)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45AK
MXOOGN6LU\+71E10S1B1<@'H<9J3_ (275_\ H4+W_OI: -BBL?\ X275_P#H
M4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z
M6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI
M:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -
MBBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6
MC_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_
M .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7
M_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:C7Q??/<M9KX6NC*BAFC$BY /0
MXS0!N45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7
MO_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_
M -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A
M>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]
M]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7
MO_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_
M -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A
M>_\ ?2T?\)+J_P#T*%[_ -]+0!L45AVWB^^O(S+:^%KJ10Q4LDBD9'4=:D_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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M% !1110 4444 %%%% !1110!CV7_ ".][_UY1?S-;%8]E_R.][_UY1?S-;%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5CV7_(
M[WO_ %Y1?S-;%8]E_P CO>_]>47\S0!L4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &/X'_Y!$O_ %^S?^A5L5C^!_\ D$2_
M]?LW_H5;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!F^,?^18O?^N!JYIW_(/@_P"N*_R%4_&/_(L7O_7 U<T[_D'P?]<5_D*
M)J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KPOP#_RD$\?_ /8B:5_Z,:O=*\+\ _\ *03Q_P#]B)I7
M_HQJ /=**** "BBB@ HHHH **** "BBB@#-\8_\ (L7O_7 U<T[_ )!\'_7%
M?Y"J?C'_ )%B]_ZX&KFG?\@^#_KBO\A0!-1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5C^)?^0OH_P#U^G_T$UL5C^)?^0OH_P#U
M^G_T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!CV7_([WO_ %Y1?S-;%8]E_P CO>_]>47\S6Q0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %8]E_R.][_ ->47\S6Q6/9
M?\CO>_\ 7E%_,T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!C^!_^01+_ -?LW_H5;%8_@?\ Y!$O_7[-_P"A5L4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;XQ_Y%B]_Z
MX&KFG?\ (/@_ZXK_ "%4_&/_ "+%[_UP-7-._P"0?!_UQ7^0H FHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!&?PW\9/!FHZXFG:EHJVFG-;IJMG))\DJ1P1JS1#<['S%"'<KIZ)_P $8_\
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MQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\
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M#_\ ((E_Z_9O_0JV*YGPEXET&QTR2&[U2*-C=2L%8]BW!K4_X3'PQ_T&H/\
MOJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_
MX3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[
MZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC
M_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$
MQ\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
MOJ@ \8_\BQ>_]<#5S3O^0?!_UQ7^0K#\4>*/#]YX?N[6UU6)Y'B(1%/)-6['
MQ=X:CLH8WUF$,L2@@GH<4 :]%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I
M45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8
M_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H
M-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5% &E1110 4444 %%%%
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M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
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M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MPO!=E9RZ5(TMI$Q^V2C+1@\;JU_[.T__ )\8?^_0K-\#_P#((E_Z_9O_ $*M
MB@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y
M\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*
M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@
M"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8
M?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@#(\76-E'X:O'CLXE80
MG!6, BK>GZ?8-80$V4))A7),8]!4/C'_ )%B]_ZX&KFG?\@^#_KBO\A0 ?V=
MI_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%
M344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^
MA14U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%^ ?^4@GC
M_P#[$32O_1C5[I7A?@'_ )2">/\ _L1-*_\ 1C4 >Z4444 %%%% !1110 44
M44 %%%% &;XQ_P"18O?^N!JYIW_(/@_ZXK_(53\8_P#(L7O_ %P-7-._Y!\'
M_7%?Y"@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z": -BBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q[+_D=[W_ *\HOYFMBL>R
M_P"1WO?^O*+^9K8H **** "BBB@ HHHH **** "BBB@ HHHH **.G6OSC_X*
M9_\ !3U]2>__ &=OV:_$96V4M;^)O%5C-@S'HUK;./X.H>4?>Y53MR6\'B+B
M++^&LO>*Q3\HQ6\GV7ZO9(\;/<]P.08)XC$/_#%;R?9?J^AU_P#P4,_X*MVO
MPWGO?@I^S'JUO=Z\A:'6?%,8$D.G-T,5OU628=W.53H-S9V?.'[%_P#P3G^+
M_P"V7K__  M;XI:IJ.D^$KJZ:>]UZ]8O>ZPY;+^1YF2V3G,S94'.-Y! ]%_X
M)R?\$LIOB/%I_P >?VD](>'P^X6XT+PO.I634QU6:X'58#U5.L@Y.$QO_3.S
ML[33K2+3]/M8X+>"-8X((4"I&BC"JJC@    #I7YWE7#F:\;XN.;<07C1WIT
M5=*W=]4G_P"!2\HV3^%R[(<RXNQ,<RSN\:6].DM%;N^R?_@4O)61R_P:^!_P
MM_9_\%P> /A+X/M=(TZ'!=85S)</C!DED.6E<_WF)/;@ "NLHHK]=HT:.&I1
MI4HJ,8JR25DEV21^GTJ5*A35.G%1BM$DK)+R04445J:!6/9?\CO>_P#7E%_,
MUL5CV7_([WO_ %Y1?S- &Q1110 4444 %?/W[6?_  3@_9^_:IM[C7+S25\.
M>*G!,?B71X%5Y7_Z>(^%N!TY.'XP' XKZ!HKAS#+<!FN&>'QE-3@^C7XKJGY
MJS1QX[ 8+,L.Z&*IJ<7T?Z=GYK4_%OXK_L_?M=_\$WOB;;^,[#4+W3D28II7
MB_079K.[7.?*DR, G',,HYP<!@,U]L_L2?\ !6WP!\;6M/AQ\?C9^%_%4FV*
MVU(-LT[4WZ !F/\ H\A_NL=I/W6R0E?7GB?POX;\:^'[OPIXOT*TU/3+Z$Q7
MEA?6ZRQ3(>JLK @BOS?_ &X_^"/VL>#TO/BC^RC:7.IZ8NZ6^\'LYDNK4=2;
M5CS.@_YYG,@QP7S@?E6*X=XBX%K2QF0R=;#[SHRU:75KOZKWEI=25S\WQ&19
M[P=5>*R:3JT-Y4GJUZ=_5>]W4E<_2^BORD_87_X*I^._V?KJU^$_[0#WVN>$
M8G%O!>2 O?Z, <8&>98EZ&,_,H'RG "']1? _CKP?\2_"EEXX\ ^([35M)U&
M$2V=_92AXY%^O8@Y!4X((((!!%?><,\697Q1AN?#NTU\4'\4?\UV:^=GH?9\
M/\2Y;Q%A^>@[37Q0?Q+_ #7FOG9Z&M1117TY]"%%%% !1110 4444 %%%% !
M1110!C^!_P#D$2_]?LW_ *%6Q6/X'_Y!$O\ U^S?^A5L4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &;XQ_Y%B]_P"N!JYIW_(/
M@_ZXK_(5Y-\?_P!LC]E_X-VU[X5^(GQIT:RU01E9-,AD:YN8FZX>*!7>,_[P
M%6O@Q^VA^RU\;;FV\.?#3XV:-?ZD\:K%ILTCVMS*V.0D4ZH[G_=!KSO[8RGZ
MS]6^L0]IMR\\>:_I>_X'#_:F6?6/8>WAS[<O-'F^Z]SU6BBBO1.X**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O"_ /_ "D$\?\ _8B:5_Z,:O=*\+\ _P#*03Q__P!B)I7_ *,:@#W2BBB@
M HHHH **** "BBB@ HHHH S?&/\ R+%[_P!<#5S3O^0?!_UQ7^0JGXQ_Y%B]
M_P"N!JYIW_(/@_ZXK_(4 34444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?_030!L4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/9?\CO>
M_P#7E%_,UL5CV7_([WO_ %Y1?S-;% !1110 4444 %%%% !1110 4444 %%%
M?&G_  5+_P""@J_ ;P]-\!?A!K0'C35K7&IW]N_S:+:N.H(^[.ZGY>Z*=_!*
M$^5G><X'(,NGC,5*T8].K?2*[M_\%Z)GFYMFN#R7 SQ6)=HQ^]OHEYO_ (+T
M//\ _@JE_P %'C8C4/V7O@)KW[XAK?QAK]G+_JQT:RA8?Q=1(PZ<H.=V,'_@
MF!_P30A\8QZ?^TE^T-H.[2MRS^%_#5W%Q?8Y6ZG4]8NZ1G[_ -X_)@/RW_!+
MK_@GD?CQK,7[0/QKTAF\'V%T3I.FW*\:W<HW+,#]ZW1A@]G8;>0KBOU1CCCA
MC6*) JJ %51@ #H *_-.&\CQO%^8KB#.X^Y_RYI/9+HVNW57^)^\]+)_ 9!D
M^+XGQZSO-U[G_+JGT2Z-KMV_F>KTM=0 H"J, = ****_8#]1"BBB@ HHHH *
MQ[+_ )'>]_Z\HOYFMBL>R_Y'>]_Z\HOYF@#8HHHH **** "BBB@ HHHH ^4O
MV\/^"87@']IV&Z^(WPR%KX=\=[2\DX3;::N0/NW 4?+)Z3 $]F##!7X+^!?[
M2'[3O_!-OXO7G@S7-$NX+>.Z'_"0^#-78B"Y7IYL3#(1RH^69,A@!G>O%?M#
M7DW[6?[&_P (OVOO!7_".^/]/^S:I:QM_8OB*TC'VJP<]@?^6D9/WHVX/4;6
M 8?F_$_ SQ.)_M3)I^QQ<==-(S?GT3??:6TEK=?!<0\'O$8C^T<IE[+$QUTT
M4O7HF^^S^TM;FI^S3^U'\)/VJ_ 2>.OA9KHD,85=3TJX(6ZT^4C_ %<J9..A
MPPRK8."<''HM?BMXX^'G[57_  3&^.]OK%GJ$VG7"LW]EZY9J7L-9M@1NC8'
MAP>-\3_,IP?[K5^DG[#_ /P4+^&/[8&B)H=P8=#\:VL&[4?#TLW$X ^::V8\
MR1]ROWTZ'(PS;<*\;QS.N\MS2'L<7'1Q>BD_[M]G_=Z[Q;6VO#G%\<PK?4,Q
MC[+%1T:>BEZ>?EUW5UM]"T445^A'W 4444 %%%% !1110 4444 8_@?_ )!$
MO_7[-_Z%6Q6/X'_Y!$O_ %^S?^A5L4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?%?_  5P_;B\3_ ?0;'X#_"367L/$?B&R-UJNJV[
MXEL+$L458B/NR2LKC<.45"1@LK#[4K\:?^"L.OV_B+]N7Q9<6.M6U]:P6VGP
M6TEK<K*L86SAWIE20")#)D=CUK\^\3,XQ63\,MX:7+.I)0NMTFFVU\E:_2_<
M^(\0,TQ.5\/MT)<LJDE"ZW2:;=ONM\SYSEEEGE:>>1G=V+.[MDL3U)/<T12R
MP2K/!(R.C!D=&P5(Z$'L:;17\L7=S^<KNY^J'_!(_P#;B\3_ !XT&^^ _P 6
MM9DO_$?AZR%UI6JW#[I;^Q#!&64G[TD3,@W'EU<$Y*LQ^U*_'3_@D-_:W_#=
M?AC^SMWD_P!GZE]OVYQY7V.7&?;S/+Z]\5^Q=?U1X:9MC,WX8C+$MRE3DX7>
M[22:OWLG:_EKJ?T=X?YGBLSX>4L0[RA)PN]VDDU?TO;Y!1117Z ?;!1110 4
M444 %%%% !1110 4444 %%%% !1110!\W_\ !03_ (*O?L3?\$TO#\$_[3'Q
M7BM/$.JZ=/=>&O!>EV<UYJFK^6&QLA@1S%&S*4$TNR($$;LJ12_\$]?^"K7[
M%?\ P4T\)3ZO^S'\58KS7-*L+>X\3^#M1MI;35-&:51\LD,R(9$#'9YT6^(G
M@-DXK\V?^"GOCS1_^"?W_!5C]H7]I[]L;X::W/X$^-W[-S^$O@[\3;;0I=0L
MO#FIC3?L\VER/&K&U:XG61\@9Q,IQL>1D^LO^"5'P7_X)U?M)77PD_X*'?L^
M_%32M<^*G@[X#Z'X'\7IX0\30F.-5L8U:'5+2/YS.K+M5IL'%O%C(C7 !]_W
MEY::?:2W]_=1P001M)--,X5(T49+,3P  "23TKAOV</VH/@#^UY\-E^,/[-7
MQ1TWQAX8?4)[&/6M)+F!YX6VRHI91NVGN.#V)KX\_P""F7Q2\>_MT_M#:?\
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M/:.":*%?]F): /T%HHHH *\+\ _\I!/'_P#V(FE?^C&KW2O"_ /_ "D$\?\
M_8B:5_Z,:@#W2BBB@ HHHH **** "BBB@ HHHH S?&/_ "+%[_UP-7-._P"0
M?!_UQ7^0JGXQ_P"18O?^N!JYIW_(/@_ZXK_(4 34444 %%%% !1110 4444
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M4QA1110 4444 %8]E_R.][_UY1?S-;%8]E_R.][_ ->47\S0!L4444 %%%%
M!1110 4444 %%%% ',_%WX/?#CX[>!;SX<?%/PO;ZMI-XOSPS##1.,[9(W'S
M1NN>&4@CZ$U^3_[9/[ OQD_8;\81?%'X<ZQJ-_X6@O5ETCQ18,8[K2Y=WR)<
M%,>6X. )1A&X^Z3L'[#56U?1])\0:5<:%KVF6][97D+0W=I=PK)%-&PPR.K
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MWKYB^%?_  3&_;=_:.U7_A+/&>@W&A0WK![C6_'-Y(EQ+ZDQ'=.S8Z;E /\
M>KZ^^!?_  16_9T\ >3JOQ?U[4O&U^F&:V<FRL0>O^KC8R-@_P!Z3![KVKP/
M[;\1.)M,NPJPM)_;J?%;NKK\H/U/%_M?CGB#3 8=8>F_M3W_ !7Y0?J?%7CG
M]KC]O']MW79/!6DZSKVHQ7/!\,>"[&2&W"'M(L.6=/>9F ]>*V-7_P""1W[8
MF@_".]^*.I>&-/-U9HLI\*VE[]HU*2+^-E6,&-F48.P.6(R ,@ _K?X'^'O@
M/X9Z%'X8^'?@W3-#T^/[EGI5BD$>?4J@ )]2>36Q6E+PMHXU2JYOBZE:LUO>
MRB_*]V[=-EY&E/PZI8M2JYIBIU:K6][)>E[MVZ;+R/YW98I8)6@GC9'1BKHZ
MX*D=01V-$44MQ*L$$3.[L%1$7)8GH .YK]P_C_\ L;_LO_&2VO?%7Q$^"VC7
MNJ&,M)J<,;6US*W3+RP,CR'_ 'B:M?!C]B_]EKX)7-MXC^&GP3T:PU)(U:+4
MIHWNKF)L<E)9V=T/^Z17R7_$&\V^M<OUF'L^]I<UO\-K?^3'S/\ Q"K,OK%O
MK$/9][2YK?X;6_\ )CP#_@D?^P[XG^ V@W_QW^+6C/8>(_$-D+72M*N$VRV%
MB6#LTH/W9)65#M/**@!P691]J445^WY'DV#R#+*>"PWPQZO=M[M^;?W;+1'Z
M[D^587)<OAA,/\,>KW;>[?F_^ %%%%>L>F%%%% !1110 4444 %%%% !1110
M 4444 %%%% 'YV?M<?\ !4_PAJWQJ_:H_P""7O[0/PZTWP->Z-\"[W5_AGKF
MLZ\KQ^.[>?29WG,$<D,:H\3D((E>5F,$Y_Y9D#X^_93\#? GX>_\%?\ ]BZT
M_P""<UEHFF>+-9_9MENOVE=/\'%1IPM6T.)K2;4HH/W<=P]V4=\@.TGV5W!+
MAF_5G]OO_@G#^RM_P44^$U_X!_:!^#_AO6=7CT:\M?"GBC5-*\V\T&YFB94G
MAE1DE"K)LD,0D57,8#>S?^"?O_!-_P#9:_X)S?!_3_AY\ ?A)X=TC6)-&LK;
MQ=XITS2_*N_$%U#"JO<32.TDNUI-\BQ%V2,R,%ZDD ^"?V/_ /@F]_P<5?L5
MVOC.Y^&GQ\_9+UC7OB)XMN/$GCCQ?XKLO$%WJFLWTIX,LJ6\:B*-25CB152,
M%MH!9B>._P"#6[X:_ML_$?\ 8'\5>#?''B_X<CX$^(5\6:386%C:7G_"21:]
M/<11232.P\@V?EM<84'?DQ^]?M)7&? ?]G?X'?LO^ A\+?V>_A?I'A#PZM]-
M>+H^B6HA@%Q,VZ63:/XF/)/>@#\^/^#;O]J+X1?";_@F6O[(WQZ^).@>#O'W
M[/?B7Q#H7Q&T+Q)K$-E-IH&J7=VMRXF9<0;)RGF_<S"XSD&OG7]G7]GGQC_P
M40_82_X*7_M._"30;R]TO]H+QOJ)^$Z_9G63Q!:Z%YTMK+"A&2)Y&\E?^FBN
MI^Z:_3G]I?\ X)(_\$VOVP_B5'\8_P!I+]CSP=XH\4JL8FUVXM'@N+H1@*@N
M&@=/M(50% EWX4!>@ KW;P/X%\%?#+P?IOP]^''A+3=!T'1K-+32=&T>R2VM
M;.!!A(HHHP%1 . H  H ^*/^"=O_  5/_8XL_P#@C=\/OVF/&_QT\.Z=9_#_
M .%>GZ=XWL+C5HDO+'5-.L8[>>S,#,)/.>6(B*/;NE$L94'>,XO_  ;&?!;Q
MY\)O^"37A?Q7\2=%ETW5?B5XGU?QH;"="KQV][<8MW(/:2"&*9?595->T^._
M^",'_!*SXF_&R3]HCQY^PK\/]2\6W%\;V\OYM)Q#=W);<TT]JK"WG=F^9FDC
M8L222237TU;V\%I EK:P)%%$@2..-0JHH&  !P !VH ?1110!XEJG[!'P:U?
M4[G5KGQ5XW62ZG>:18O%]RJAF8L0 #P,G@=JX;X!? [PC\-_VV?''@[0M3UF
M:UMO!>GRQR:AJTD\I,DI+9=N2/E&!VYKZFKPOP#_ ,I!/'__ &(FE?\ HQJ
M/7/^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X
M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
MX0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_
M )^;W_P+:MBB@#F?$OA+3+'0;J[AN+HM'$2 ]RQ'XBK-EX+TJ6SBE:YO,M$I
M.+IL=*M^,?\ D6+W_K@:N:=_R#X/^N*_R% &;_P@^D?\_-[_ .!;4?\ "#Z1
M_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'
M_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[
M_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/
MS>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X
M%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@
M6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L4
M4 8__"#Z1_S\WO\ X%M69KGA73K74=-ACGN2)[DJY:X8D#;V]*ZNL?Q+_P A
M?1_^OT_^@F@ _P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W
M_P "VK8HH Y2U\*Z=)XINK!I[G9';1LI%PV[))ZFM/\ X0?2/^?F]_\  MJ+
M+_D=[W_KRB_F:V* ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0
M?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB@#'_ .$'TC_GYO?_  +:C_A!](_Y
M^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q+CP?H-I
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M .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U%;%% !1110 4444
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MCO>_]>47\S0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S?\
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MI^RG\,MC^"_V?_"UM-'CR[N?28[B=?I+,'?_ ,>KTJ&&&VB6"WB6.-%PB(N
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M7_D+Z/\ ]?I_]!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8]E_R.][_P!>47\S6Q6/9?\ ([WO_7E%_,UL4 %%%% !
M1110 445\O?\%//VVXOV6_A5_P (5X&U-5\;^*+=X],\MOGTVVY62\([-U6/
M/5\MR(R*\[-LTPF2Y?4QF)=H05_-]DO-O1'#F>8X7*<#/%8AVC%7]>R7FWHC
MYB_X*_\ [;A^(OBI_P!EWX9ZONT+0[H-XHNK=_EOKY#Q;Y'6.$]1T,G;]V"?
MH;_@E/\ L1?\,[_#;_A;_P 1-(\OQGXIM%*PSIA]+L#AD@P>5D?"O)W&$7 *
MG/S%_P $E_V)9?CA\0/^&B/B?IC3>&/#E[NTV"Z7*ZKJ*D,"<_>CB.&;LS[5
MY <5^JM?F_!65XO/\SGQ/F:]Z6E&+VC':Z^6D>^LNJ9\%PEEV*SK,)<0Y@M9
M:4H](QVNOR7?675,****_63]+"BBB@ HHHH **** "BBB@ HHHH *Q[+_D=[
MW_KRB_F:V*Q[+_D=[W_KRB_F: -BBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#QW]N?\ 9;M/VM_@!J'PUAN(K;6+:9;_ ,.WDV=D
M5Y&& 5R.=CHSQD\XW[L$J!7XK?$'X>>-_A3XOO? 7Q$\,W>D:OI\ICN[&\CV
MNA[$=F4CD,"58$$$@YK^@NN/^+7[/_P4^.VGQZ=\7OAEH^OI"I6WEO[0&: '
MJ(Y1AX\]]K#-?G'&W %+BFI'%4)JG72MJO=DNE[:IKNKZ:-;6^#XNX*I<136
M(HS4*R5M=I+I>VJ:[ZZ:6VM^!=?9/_!*;]ACQ9\6/BCI7[0OC_0IK3P?X<NU
MO-+:ZC*_VM>QG,0C!^]%&X#L_P!TE @SEMOVU\)_^"=W[%GAJ4^(K#]G[1Y[
MJ*\D\LZG-/>QC#<?N[B1TX_W:]^M[>WM+=+6U@2**) D<<:A510,  #@ #M7
MS?#/A/4P&80Q69U8S4'=0A=IM;<S:6B[6UZNVC\'A_PUG@L='$YA4C)0=U&-
MVFUM=M+1=K:][:-]%%%?M9^M!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &;XQ_P"18O?^N!JYIW_(/@_ZXK_(53\8_P#(L7O_ %P-7-._
MY!\'_7%?Y"@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/F__ (*"?\%7OV)O^":7A^"?]ICXKQ6GB'5=.GNO#7@O2[.:\U35_+#8V0P(
MYBC9E*":79$""-V5(I?^">O_  5:_8K_ ."FGA*?5_V8_BK%>:YI5A;W'B?P
M=J-M+::IHS2J/EDAF1#(@8[/.BWQ$\!LG%?FS_P4]\>:/_P3^_X*L?M"_M/?
MMC?#36Y_ GQN_9N?PE\'?B;;:%+J%EX<U,:;]GFTN1XU8VK7$ZR/D#.)E.-C
MR,GUE_P2H^"__!.K]I*Z^$G_  4._9]^*FE:Y\5/!WP'T/P/XO3PAXFA,<:K
M8QJT.J6D?SF=67:K38.+>+&1&N #Z+_:S_X*>_L _L+:[8>%?VL/VJ/"W@W5
M]3A$UGHU[<O->M"6*B9K>!7E2(D$"1E"$JV#P<>E? [X^_!/]ICX;V/Q?_9\
M^*FA>,O#&H[A9ZWX=U*.ZMW9>&0LA.UU/#(V&4\$ U\D:]^S;_P3Y_X)5?$?
MXU_\%.?VT_B_#J5[\5_%<+7GBWQWH0OI-#MF1EM]&L5@ADD\@(NP*J[F2&,.
M6\L&O&/^#<JWT#XD?&7]K+]K[]G#PW'X9_9]^)GQ+L9/A9X83RX MQ:PSIJ%
M\MFC?Z$D[R0LL;*I*A1M C6@#[ ^+?\ P5U_X)E? ;XCZM\(?C'^V[\/O#GB
M?0;G[/K.B:GKJ1W%G+M#;'7^%L,#CWKT;]FK]KO]F7]L;PE?>//V6_C=X?\
M'6C:9J)L-0U+P[?">*"Y$:2&)B.C;)$;'HPK\+?^"=G[9O[&7B:__:*_:4^,
M/_!)WXB?M0>(/'7[0GB'7[C7/"?P*M?$]GX9T$E#:6S7=X J/M,K^5&2-FPL
M5Q7WA\0/V_OV(;'_ ((5?'']L[_@E'X;\.>"[*U\,7]O+8>&/"MOH=WH>OS1
MQ6:M=6UNBA+N+SX7#?,&"QE69,&@#Z*\<?\ !:'_ ()5_#7XW3?LZ^.?VZO
M&F^+K:^-G>V$^JDP6ER&VM#-=!3;PR*WRLCR*5((8 @U]-V]Q;W=NEU:SI+%
M*@>.2-@RNI&001P01WKX7_X)U_\ !+;]CZ]_X(V?#S]F7QY\#_#NI67C_P"%
M=AJ/C:]N=)B>[O=4U&R2XN+PSLID\Y)9CY4F[=&(H@I&Q<8O_!L;\:_'OQ;_
M ."3GACPI\2M9EU'5?AIXGU?P4;^=RSRV]C/FW4D]HX)HH5_V8EH _06BBB@
M KPOP#_RD$\?_P#8B:5_Z,:O=*\+\ _\I!/'_P#V(FE?^C&H ]THHHH ****
M "BBB@ HHHH **** ,WQC_R+%[_UP-7-._Y!\'_7%?Y"J?C'_D6+W_K@:N:=
M_P @^#_KBO\ (4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %8_B7_D+Z/_ -?I_P#036Q6/XE_Y"^C_P#7Z?\ T$T ;%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CV7_ ".]
M[_UY1?S-;%8]E_R.][_UY1?S-;% !1110 445%>WMGIMG+J.H74<%O!$TD\\
MSA4C11EF8G@  $DGI2;25V#:2.0_:#^.W@?]F[X3ZK\7/']WLL]-A_<VR,!)
M>3MQ'!&#U=VX] ,L<!21^17@+PE\9?\ @IO^U[+/K-XZSZQ<_:M9OD4M#HVF
MH0-J ] BE8T4_>=AD\LU='_P4%_:Y\3_ +;WQVL_A]\+8;N\\,Z9J'V'PIIM
MLAWZG=.P0W)3J6<X5 >53' +/7Z)_L#?L=:)^Q_\&H=!N8X9_%.L!+GQ3J4>
M#NFQ\MNC?\\H@2H]26;C=@?C&+J5?$CB182DW]0P[O)K:<O+UU4>T;RW:1^3
MXJ=3CW/UAJ;_ -CH.\G_ #R\O79=HW?5(]7^&WPZ\(?"3P'I7PV\!:2ECI&C
M6:VUC;)V4=68_P 3,269CRS,2>36Y117[+3ITZ--4X*T4K)+9);)'ZK"$*4%
M""LDK)+HET"BBBK+"BBB@ HHHH **** "BBB@ HHHH *Q[+_ )'>]_Z\HOYF
MMBL>R_Y'>]_Z\HOYF@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,?P/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV;_T*MB@
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M@O3Y8Y-0U:2>4F24ELNW)'RC [<U]35X7X!_Y2">/_\ L1-*_P#1C4 >N?\
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M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB
M@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\
MA!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?
M_A!](_Y^;W_P+:LS7/"NG6NHZ;#'/<D3W)5RUPQ(&WMZ5U=8_B7_ )"^C_\
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ME_R.][_UY1?S-;% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
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M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
M&/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M16
MQ10 4444 %%>9?M"?MI?LA_LF+:?\-.?M-^!/ ,E^F_3[?Q9XIM;&:Z7."T4
M4KAY #P2H('>NO\ #_Q3^&7BWQ?K/P^\+?$/1-1U_P .K;MK^AV.JPRWFFB>
M)98#<0JQ>$21LKH7 W*01D4 ;U%%% !1110 4444 %%%% !1110 4444 %>%
M^ ?^4@GC_P#[$32O_1C5[I7A?@'_ )2">/\ _L1-*_\ 1C4 >Z4444 %%%%
M!1110 4444 %%%% &;XQ_P"18O?^N!JYIW_(/@_ZXK_(53\8_P#(L7O_ %P-
M7-._Y!\'_7%?Y"@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z": -BBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q[+_D=[W_ *\H
MOYFMBL>R_P"1WO?^O*+^9K8H *\P_:T_:E\!_LE?"2[^)'C&59[MP8="T=9
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M;_T*MBL?P/\ \@B7_K]F_P#0JV* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#-\8_\ (L7O_7 U<T[_ )!\'_7%?Y"J?C'_ )%B
M]_ZX&KFG?\@^#_KBO\A0!-1110 4444 %%%% !1110 4444 %%%% !1110!_
M.G\??V=O@-^TS_P1@_:^_P""G7Q^TB#Q;^T9)\4[[3-8U77+AYKGP0EKXCL[
M2WTJUA9MMJJ697!"ARDVS.U0!]V_M_?"KX5?L\?\%>OV/_VJO@!<OH_QB^+/
MC0^%?B'ING7S_P#%4^%DTL)/<75ON*L+18K?:X4<B,MDQ(5^<_\ @I5\-/\
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M-3_9'&=O=]Y23?3FTBTO2_;S/@?^(K4)4I_[*U*WN^\FF_[VD6EZ7[>9Z?\
MM>_M7_%K_@H9\;K#P1X T._;15O_ +-X/\+0<R3.W'VB8 X,K#)))VQID9QN
M9OT6_8"_8<\-?L=?#@_VC]GO_&6LQ*WB'5XUR$'46L)/(B0]3P7;YC@!57F?
M^";?[ /A_P#9;\&1?$?QK':ZAXZUNS5I[J)UEBTRW<!A;P.,AB1C?(.&/"G:
M,M]2U])P9PKBZ6(>=YP^?%U-4G]A/\I6TT^%>ZNI[_"G#>)IUWF^:/FQ-35)
M_83_ "=M/[JT74****_2C[X**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K'LO\ D=[W_KRB_F:V*Q[+_D=[W_KRB_F: -BBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_ _P#R")?^OV;_ -"K
M8K'\#_\ ((E_Z_9O_0JV* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?2/^?F]_\"VK8HKZ8^@,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
MGYO?_ MJV** .4\*^%=.U#3I)II[D$7,B@)<,HP&K3_X0?2/^?F]_P# MJ/
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M;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
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M_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;45L44 %>!_MP?\$P/V%?\
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M()X__P"Q$TK_ -&-7NE>%^ ?^4@GC_\ [$32O_1C4 >Z4444 %%%% !1110
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M]_Z\HOYFMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF33?!EVT<D2MK(D EFO?+=R-RY((993&WDJ ?K-1110 4444 %%%% !1110
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@#-\8_\BQ>_P#7 U<T[_D'P?\
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MSW5UXQU3Q3.M[?\ B>\N4V7-S?R%0)GD0!"-H0* H4#.0!/^"<'Q(\(>)/\
M@FC\$/B;::S;1Z.WP7\/W4]VTH$=ND>EP>:'/1?+*NK9^Z4(/2OD[_@U,T?4
MA_P2PG^(=S92PV/C;XM^)M<T;S$*[[5KE+<$9[>9;2CZ@TMS_P &[NH^'O!N
ML?LR?!7_ (*>?&OP3^SSK]W</J/P9TU[2=8+6XD+SV%IJ,JF:WM7+.#$5<,'
M;>9"SEOOSX%?!#X7_LU_!WPW\!/@MX4@T/PKX3TB'3=#TNW)(@@C7 RS$L[D
MY9G8EG9F9B22: .LHHHH \2U3P+^WI+J=S+I'QW\$0VC3N;6*7PO(S)&6.U2
M=W) P":X;X!:+\;]._;9\<6?Q'\;:-J.L+X+T\W-YI^FM#$\9E/E@(3P0-V3
MWR*^IJ\+\ _\I!/'_P#V(FE?^C&H ]<^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@
M,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9
M?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@
M,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#F?$MIXM30;
MI[[5K5XA$?,1+<@D>QJS96?C0V<1BUFS"^4NT&V.0,?6K?C'_D6+W_K@:N:=
M_P @^#_KBO\ (4 9OV+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (UL44 8_P!B\;_]!NR_\!C_ (UF:Y:^*5U'35NM4MG=KDB!E@("MMZGUKJZ
MQ_$O_(7T?_K]/_H)H /L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L
M7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW
M_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L
M7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&OF[]O
M/_@H%#^R)HQ\)Z)K>FZQXXOH-UGI*092Q1AQ/<<_*.ZI]Y_9?FJO_P %$/\
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M!C_C6Q14C,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** .4\*VOBF33I&L-4MHT^TR K) 2=
MV[DUI_8O&_\ T&[+_P !C_C1X'_Y!$O_ %^S?^A5L4 8_P!B\;_]!NR_\!C_
M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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M\5]_T4 %%%% !1110 4444 %%%% !1110 4444 %>%^ ?^4@GC__ +$32O\
MT8U>Z5X7X!_Y2">/_P#L1-*_]&-0![I1110 4444 %%%% !1110 4444 9OC
M'_D6+W_K@:N:=_R#X/\ KBO\A5/QC_R+%[_UP-7-._Y!\'_7%?Y"@":BBB@
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M3E_9X_9U^SZX-$_X27Q%#AO[<UR)7\IQW@AY2'GH?F<?WS7OE%%0VV4%%%%
M!7\Y'_!>7_E*[\5?^X'_ .F+3Z_=']J[_@H'^R1^Q9I+7GQ^^,.G:=?F+?:^
M';1OM.IW((^79;1Y<*>F]PJ#NPK^>#_@H[^U%X5_;/\ VT?&W[2G@?P[J&E:
M3XCFL186.JE/M"1VUA;VFZ3RRR@MY!?:"<;L9.,T%1W/$****"CZ]_X(-?\
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MB\,_%'Q.;VPM)'G@E%Y&A/$RB%HPW]V:0=Z /+?^#7;Q5I7B'_@B3\(M&LI
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MB@#'^Q>-_P#H-V7_ (#'_&LS7+7Q2NHZ:MUJEL[M<D0,L! 5MO4^M>6_MO\
M[?WPV_8ST2#3[NP.N>+-2@,FE^'H)_+VQY(\^=\'RX\@@<%G(( P&9?SU\<?
M\%>/VT_%VNQZQIGB[1]"B@F\RWL=,T"!XT[8S<+*YX_VORKXG/\ Q X=X>Q/
MU:O*4ZBWC!)M>K;23\KW\CY'.N-LBR/$>PK2<IK=02=O6[2^5[^1^M_V+QO_
M -!NR_\  8_XTV2V\9Q1M++KUBJJ"69K<@ #N>:_._\ 9G_X+:^-;'7K?PY^
MU%X9L[_2YG"/XBT.U,-S:Y_CDA!*2KZA C 9(#G"UYW^V]_P4X^)O[5.H2_"
M;X-6FH:)X/N9A;K9VX/V_6RQV@2[,D(V0! N<Y^8MP%\_$>*'#%/*_K5&3G/
M94[6E?SW27G=KM=Z'%7\1.'H9=]8I2<I[*%K2OY]$O/5=KO0]F_;B_X*TZAX
M0FOOA+^S3XIL]1U !H=1\7VUN&@M3T*VI.1*_P#TUP4'\.X\KX3^QG_P3E^,
M?[9&L-\5_B3J5[I7A6YN6GNM=U%F>[UF0ME_(WY+9.=TS97.<;R"![=^P;_P
M2&\MK+XN?M:Z4"1MFTWP0YR!W5[TC\_('MO/WHZ_0RTM+6PM8K&QMHX8(8UC
MAAB0*D: 8"J!P  , "O%RWA?.>,,9',^(VXTUK"BKI)?WENEW^T^K221Y. X
M=S7BC%1S#/O=IK6%)::>:Z>?VGULM#B?A9\'+3X*^";/X=_"^QTG2-(L4Q#:
MVUF?F;N[L26=SC)=B6/<UT7V+QO_ -!NR_\  8_XUL45^N4J5*A35.G%1BE9
M)*R271(_3J=.G1IJ$$E%:)+1)>2,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&
MMBBM"S'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
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M[?LY_M>?#[]I[3U/P[^(UC%JJQ[KGP]J5MY-[#CJ=FXB11_>C+*,\D'BMO\
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MXUL5SOQ/^+OPL^"?A6;QQ\7_ (BZ+X8TB#_6:CKNI1VL6<9VAI& 9CV49)[
MT@+7V+QO_P!!NR_\!C_C2&R\; 9.MV7_ (#'_&OSP_:O_P"#E/\ 9A^&(N?#
MG[+_ ()U+XBZLF435KL/IVE(W3<#(OGS8/81HK#I)SFOSL^+_P#P4(_X*?\
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M* "BBB@#-\8_\BQ>_P#7 U<T[_D'P?\ 7%?Y"J?C'_D6+W_K@:N:=_R#X/\
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MW*PQ1+ZL[$ 5\C_M)_\ !7OX7> ?M'AKX!:2OBS54RAU:YW1:="WJ.CSX/\
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MHH **** "BBB@ HHHH **** ,WQC_P BQ>_]<#5S3O\ D'P?]<5_D*I^,?\
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M2U#_ ()(_P#!7#X!WCZKX:^!/BJU=3N6\\&>);>=WQW M+@R?FH-5X_VW/\
M@LC^R'(L7B_XH_%WP\MNP58?'^EW%S&.>% U.)QCT XQTI_7W'^)!K^OD;?Z
MXU*'^]X2</Z\U$_HUHK\,_A!_P '+_[97@]XK3XN?#+P7XRM4(\V:*WFTV\D
M]?WD;/$/PAKZY^!G_!RC^Q;X_DAT[XS>"?%?@"Z?'FW4EL-3L8_^VEOB8_\
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M&B7M$ER-T<?^U;N@.>#S7V]^SG_P=">!M4\C1_VJ_P!GJ^TF4X6;7/!%T+F
MD_Q&UN&5XU'M+(<= >_ZB?$7X7?#3XO>&Y?!WQ6^'VB^)=)FYETW7M+BNX&.
M,9V2JRY]\9KXE_:)_P"#=3]@GXQ-<:M\,(-=^&^IRY93X?OC<V)<]VMKG?@?
M[,3QB@=TSZ#^ ?\ P4P_82_:72"'X3?M,^&;B^N /+T;5+S^S[XM_=%O=".1
MR#QE0P]SD5Z_XR\$^#OB+X=N/"?CKPU8ZOIEVN)[+4+=98W]#AAP1U!'(/((
MK\._CQ_P;1?MH> &FO\ X(^.O"OQ LT)\FW^T'2K^3T_=W!, _[_ ->))I/_
M  6._P""?+&"VM?C'X(TVTZBV^U7&C\?[GF6CX_'CV- K)GZH?M/_P#!'>";
M[1XM_9=UH1MR[>%-7N/E/^S;W#<CV67/_70=*^?/A)^U/^UE^PIXM?P%J<%]
M!:6LF;SP?XFA<P;2?O19PT6>2'C.UNI#"OGGX7?\'''_  49\!1QV_C#4?!W
MC2-.'?Q!X:$,K#_>L7@ /N5/N#7IOBG_ (.(_AS\>_#2^#_VIOV M+UR *?+
MU'1?%[03VK'JT(>V9T/TE .,'(JU+HQ.#Z'H?_!2[_@LQ^TDO@7P#XK_ &)/
M$6J^#;J/^U%^(EC+X?L-25#BT-HZR7,$N8_^/H;E"'^^/N5\?Z5_P7/_ ."M
M^NZE!H^C_M.R7-U<R!(((O FA%G8]A_H-66_:L_9V\?>.HM"^%NG>+-/@OW(
MM;3Q':P2/$Q/$?FV[GS._P QCC [CO6KH_PS\!:!XEG\7Z+X6M+;4+B/9+<0
MQXX[X7[JD]R ">]'*GL'-9:HN?$3_@JQ_P %A_@QH]IJ%W^U%'+9W0W7$MMX
M(T1EMYVY,;$V7Y-T-<A;_P#!=W_@K+=SI;6O[4CRR2,%CCC\":&S,3T  L>3
M7<:KI6FZ[IL^CZQ91W-K<QE)X)5RKJ>QKD=%\ _![X#Z/-XB2SMK!(_];J=X
MQDEY/"ACD\]-JCGT)IN E/R/UT_:3_X*V?!GX7_:/#?P8M5\9ZTF4^UQR%--
M@;U,HYGQUQ&-I_OBOC#Q!X^_;+_X*#^-QH<8U7Q$4E#QZ1ID?D:;IX/1F&1'
M&.WF2,6/3<:^6O /[>/[*?@_6#JWQ ^$GB[QG' Y\K2+75(=*MIR#P7G EE*
M$=E2-AZ]J]K;_@Y4\?> O#J>$OV</V*_ ?@_38 ?LUG>ZE<7J*?[S"!;;>Q[
ML>3W-*\8[!RR9]P?LV?\$=?"7A_[/XG_ &E/$0UJ[&''AW2)7CM$/I+-P\OT
M78,CJPK[.\*>$/"O@308/"_@OPY9:3IMJNVWL=/MEABC'LJ@#ZGO7\^WC[_@
MOU_P5 ^*%P=,\-?$_2_#GVIMBV?A7PI;;VST5&N%FE!_W6!]ZYD_!W_@M!^V
MZ-NM>&?C;XLL;S[C>(;F]MM-8'^Z;IH[<#GM@<U+;>Y2C8_>/XQ?M\?L6? %
M9E^+?[3_ (+TBX@SYNG'7(I[P8Z_Z-"7F/X)7R1\;O\ @Y8_8?\  *36?P?\
M(^+O'MXF?(FAL1IME)]9+D^<O_?@U\6_!_\ X-JOV[_')AN_BAXE\&>![9L>
M?#>:JU_=I]$M4:)L?]=A7UI\%/\ @V)_98\)&&^^.7QK\6^,KB/!>UTR*'2;
M23U#*/.EQ_NRJ:0:'RC\=_\ @Y6_;;^(?G6'P8\(^%?A[9OGR;B"S.IWR9]9
M;D>2?^_ KQFT^$?_  5]_P""E=W#>:EH7Q2\=:?<R![>[U^YEM=&0]<QM<-'
M:)CKA,?3I7[O? C_ ()U_L0?LU>3/\&_V9O"NF7EOCR=6N=/^VWR$=Q=7)DF
M'X/7M% 71^+7[//_  ; ?&/Q#Y&K_M._'S1O#=NV&DT?PK:MJ%T1W1II?+BB
M;W42BON[]G3_ ((@?\$Z?V='M]3M?@JOC'5K?!&K>/+C^T6)'0_9RJVP.>01
M$"/6OK>B@+LAT[3=.T>PATK2+"&UM;>,1V]M;1!(XD P%55 "@>@J:BB@044
M44 %%%% !1110 4444 9OC'_ )%B]_ZX&KFG?\@^#_KBO\A5/QC_ ,BQ>_\
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MBBB@ KPOP#_RD$\?_P#8B:5_Z,:O=*\+\ _\I!/'_P#V(FE?^C&H ]THHHH
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M_@#1-)2)0(DTW2H8 @'0 (HQ6W115V2.I1C%62"BBB@84444 %%%% !1110
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M._Y!\'_7%?Y"J?C'_D6+W_K@:N:=_P @^#_KBO\ (4 34444 %%%% !1110
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MO[*W@?\ 92\'^([[6=*\#:#'I=EJ6J(@GN8T+'=($ 7)W=AB@#Y._P""<?\
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MZ7XL\0Q8DCL9K9GTVS?VC;'V@C^](-O^P",U]>1Z=XSAC6*+6+%54 *JVI
M'0 5M45^G91DF5Y%A?88*DH1Z]V^[>[?K\C]"RO*,NR;#^QPE-177N_-O=OU
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**]4](Q_L7C?_H-V7_@,?\
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M+Q!XTC"^VY;2!S]06E';*=J_*.RL_$/B[5VM](TZ^U:_N'+M';0O/+*Q/)(
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MI24D^J=U^!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44S0Q_L7C?\
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M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
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M61^75:G@<^*E\::.W@43G7!JEO\ V,+4?O?M?F+Y.S_:W[<>^*E_X5U\0?\
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M/OVBOD3PY_P79_X)<>(L(?VE382G_EEJ/A/58\?\"^S%/_'J[WP[_P %3_\
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MP*.-YLKWY9">N5EC7T&#Q]J?LZ?\%A_^">G[2_D6'A#]H/3=$U:? &A^,?\
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MP%N;3?;31ERJ[)D!R<";/  KVG0_^#7/^V;1KK_AN7R]LSQ[?^%99SM.,_\
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MO#_@L_X1.+WXJ?%RWQQ_Q,M#F?K_ -=8#7]%U%+ZC);5&'^J%>/P8VHOO_\
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M/%7@[XOCP[%97'AB\DM4?^Q;^2,XN3M# 2MOE;,+%AO9$ /TJHKX4_X*]?\
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M %P-7-._Y!\'_7%?Y"N?ZCA?Y?Q?^9XW^J/#W_/G_P FG_\ )'P[_P $T_\
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MP3J&EC_@GU\"AH>S[$/@WX8^Q^7]WRO[)MMF/;;BOC'_ (-10W_#LO7S:_\
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M_P $T,0IS(?^%9>(TX_WC,0/RK]>J* NC\A?^'YG_!6.S_TG4_\ @FUB!?\
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MK"&;;G;YL0;'TR*I7?@OP=?L'OO">F3%1A3+81L0/Q% 71_-1_P4W_;\U?\
MX*)?M$1?&27PI<>'])T_0[?3-&T&?4?M/V5$+/(Y<(@+/)(Y)"@X"@YVBOG6
MOUU_X.*?^"<7BF^UFQ_;=^!_@O[3IEMI*:?X]T[2;0;K-8BQAU#8@YCV-Y<C
M?P".-CP6*_D504M@K]'/V5O^"8?[?O\ P4F^ OA3XH?%K]KK5H/AU=VAMO#^
MFZAJ-YJDL-O:2O:@+9O)'"@!@(!\S) !-?#_ .S9^S9\7OVL?B]I7P3^"?A6
M;5-9U28 E4/DV<.0'N9W (BA0'+.?8#+$ _T^_LQ? ?PY^S#^SYX0_9_\*3F
M:R\*:%!8+=,@5KF15S+.0. TDA>0CU<T W8^)?@1_P &]G[#/PN\F_\ B;X.
M\9?$.^3#2#6]8%I:;AW6&T\ML?[+R.#WR.*^R/@_\%?@M^S]IO\ 97P0_9GT
M3PI"4V2'0='M[9Y1_P!-'10TA]V))KTVB@@Q_P#A)=7_ .A0O?\ OI:/^$EU
M?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\ X275
M_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"
M]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+
MW_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_O
MI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\ X275_P#H4+W_
M +Z6C_A)=7_Z%"]_[Z6MBB@#E+77-17Q3=72^&[EG>VC5H R[E )Y-:?_"2Z
MO_T*%[_WTM%E_P CO>_]>47\S6Q0!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]
M]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7
MO_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_
M -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A
M>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]
M]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7
MO_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_
M -]+6Q10!C_\)+J__0H7O_?2UF6NN:BOBFZNE\-W+.]M&K0!EW* 3R:ZNL>R
M_P"1WO?^O*+^9H /^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\
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MH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EHK8HH **** "BBB@ HHHH
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M .@F@#G?@1^S'^S[^S#X<D\*?L__  @T+PI93E3=+I%BJ27+*,!II3F29@.
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MB@ HHHH **** "BBB@ HHHH **** "BBB@#'\#_\@B7_ *_9O_0JV*Q_ _\
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M8SX[_P# F"C_ (:Y^.'_ $8SX[_\"8*]ZHH \%_X:Y^.'_1C/CO_ ,"8*/\
MAKGXX?\ 1C/CO_P)@KWJB@#P7_AKGXX?]&,^._\ P)@H_P"&N?CA_P!&,^._
M_ F"O>J* /!?^&N?CA_T8SX[_P# F"C_ (:Y^.'_ $8SX[_\"8*]ZHH \%_X
M:Y^.'_1C/CO_ ,"8*/\ AKGXX?\ 1C/CO_P)@KWJB@#P7_AKGXX?]&,^._\
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M#P7_ (:Y^.'_ $8SX[_\"8*/^&N?CA_T8SX[_P# F"O>J* /!?\ AKGXX?\
M1C/CO_P)@H_X:Y^.'_1C/CO_ ,"8*]ZHH \%_P"&N?CA_P!&,^.__ F"C_AK
MGXX?]&,^._\ P)@KWJB@#P7_ (:Y^.'_ $8SX[_\"8*/^&N?CA_T8SX[_P#
MF"O>J* /!?\ AKGXX?\ 1C/CO_P)@H_X:Y^.'_1C/CO_ ,"8*]ZHH \%_P"&
MN?CA_P!&,^.__ F"C_AKGXX?]&,^._\ P)@KWJB@#P7_ (:Y^.'_ $8SX[_\
M"8*/^&N?CA_T8SX[_P# F"O>J* /!?\ AKGXX?\ 1C/CO_P)@H_X:Y^.'_1C
M/CO_ ,"8*]ZHH ^8/A9^VY\3/%'AV?4/"W['7B_4[=-3N(7N+*]A9%E1\.A)
M ^93P:Z7_AKGXX?]&,^._P#P)@J;_@GO_P D3U;_ +'O6?\ TI->Z4 >"_\
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M 4444 %%%% !1110 4444 %%?)/_  4\_P""NOP1_P""=&D6WPZL]"U'Q_\
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MQ3\': =(GFDM%E>YLKZR#-&A$<$KJ\? P@)?S"(OT.H **** "BBB@ HHHH
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MP_H,=R+.P18&FNM3O6C=X[.UA0%IIG6-R%&  K,Q559A\B_\$0?^"IW[2_\
MP4L_:0_:=MOCA\-[KP-X=\":GX87P#X#U;2EM]1T:TO8-0=C>,5$CSS);V\S
M*V1&7*IQR0#]%:*^3?\ @L5^TY\;/V>/V;O"W@[]EWQBN@?%+XM_%CPYX#\!
MZS_9UO>&PN+V\5[BY,%S')$ZI9P7.2Z%5W!CT%>.?%[]L+_@I!^V?_P4$^(W
M[!'_  3>\:>#?AGX;^"6F::?B5\7/&OAEM7NKO4[Z)I(+.PLR4B*@)*'9Q]Z
M&3#* BR 'Z*T5^?O[%?[<_[<GPH_X*-7O_!*/_@I/?>#_%?B+5? 3>,?AC\4
MO!&EOI\6MV$<SQ36]Y:%BL,ZF.8C9M4"$@[MZ,>2T/\ :X_X*C?\%1?VCOBU
MH?\ P3>^,_@#X0_"'X,^,9O""^-?$_@_^W;[QAKULH-VD<;,(X+2,L@#K\Y6
M1'!?>5B /TOHKXZ_X)-?\% /C5^U1/\ %/\ 9?\ VQ?!NAZ!\<_@/XIBT7Q[
M!X9=_P"S=6MKA&DL=4M5D)=(YTC<[#TVJWR^8(T^Q: "BBB@ HHHH **** "
MBBB@ HK,\:>,_"?PY\':M\0O'OB*ST?0M!TR?4=:U;4)Q%;V5I!&TLT\KMPB
M(BLS,> %)K\M/ O_  7_ /%?[8'_  6)^!'[+?[(7AK4;?X">*KKQ-:ZIX^U
MOPXT*>.+JQTFYN"-.:= \=M;31PYD&UY&D*L%4 . ?J]17R+_P %=?\ @H!\
M8?V*O 'P^^'7[+7PUTSQ3\7_ (T>/+;PA\/+/Q TBZ78SRD"2^O#&0QBBWQC
M:&4DR!LX1@?FC]JS]I/_ (+9_P#!(;X=:;^VI^UC\??A?\=OA38Z[86?Q.\+
MZ!X%_L+4="M;N=(%N-/G5\7&V61$_?#)+J"@#,\8!^J-%?-?_!4S]LG4?V1_
M^":GQ'_:I^%6IAM>B\*)%X!N$M5F:35M0>.TTYUAD4B4B>YAD\ME(8*01C->
M$?M"_M(?\%5K[XU?"3_@F5^RC)I-K\0IOA3;>(_C/^T/XX\(F?2K%XECMYUL
M[>!(K6:\EN?G,2CRT6>,!5&YHP#]"Z@CTO3(M0DU:+3H%NY8PDMTL*B1U'12
MV,D#TK\__P!EK]M3]O/]GC_@I7H__!+C_@HMXL\%_$*;Q[X%NO$OPQ^*?@S0
M6TF:Z-J9#<V5_9;VCC8)#*ZO'@ *H)<R'RO1O^"I/_!8/X+?\$Y]&3X9:#H%
M_P#$+XW^(M'>[\"?";PW:2W%Y>+B4+>71C4_9K-6BD+R'YBL4FQ6VL5 /L&B
MOE#_ ((>_M7?&?\ ;@_X)<?"W]J3]H77+74O&'BJ/6'UB\LM/CM8G\C6KZUB
M"Q1@*H6&"->!SMR<DDU0^.W[6WQ:M_\ @K;\-OV3?AWX_&C^!_"7P=\0?$;X
MVP+I=O<?;[)I%L-+MS+)$\D!2X6><B%D>14 .5!! /KZBORT_9B_: _X+A?\
M%9?AK??MH_LN_';X8_ 3X8ZCK6H6WPQ\(>(_ 3:UJ6M6MI<26YGU*=W_ -&W
M312)^Y7(V-A" KR?1?\ P1^_X*(_%+]N3X:?$+P-^TW\/M)\+_%WX*>/[SP;
M\2['0)G?3;B[@)"WEJ79F6*3;(-I9L&(L#M90 #[ HK\C_VK?^#B\^/_ -MS
MX#_LU?\ !.2*;7O 7B#X_P#ASPG\2_C$^AF71[\7=Y%%+HVG2RIMED:%Y)'N
M%P5"(8BP;?7ZX4 %%%% !1110 4444 %%%% !1169XT\9^$_ASX.U;XA>/?$
M5GH^A:#ID^HZUJVH3B*WLK2"-I9IY7;A$1%9F8\ *30!IT5^4/@7_@O_ .*_
MVP/^"Q/P(_9;_9"\-:C;_ 3Q5=>)K75/'VM^'&A3QQ=6.DW-P1IS3H'CMK::
M.',@VO(TA5@J@!_J3_@KK_P4 ^,/[%7@#X??#K]EKX:Z9XI^+_QH\>6WA#X>
M6?B!I%TNQGE($E]>&,AC%%OC&T,I)D#9PC @'UU17Y7?M6?M)_\ !;/_ ()#
M?#K3?VU/VL?C[\+_ ([?"FQUVPL_B=X7T#P+_86HZ%:W<Z0+<:?.KXN-LLB)
M^^&274% &9X_KW_@J9^V3J/[(_\ P34^(_[5/PJU,-KT7A1(O -PEJLS2:MJ
M#QVFG.L,BD2D3W,,GELI#!2",9H ^E**_/3]H7]I#_@JM??&KX2?\$ROV49-
M)M?B%-\*;;Q'\9_VA_''A$SZ58O$L=O.MG;P)%:S7DMS\YB4>6BSQ@*HW-')
M^RU^VI^WG^SQ_P %*]'_ ."7'_!1;Q9X+^(4WCWP+=>)?AC\4_!F@MI,UT;4
MR&YLK^RWM'&P2&5U>/  502YD/E 'Z :?I>F:1 ;;2M.@M8VD9VCMX512Q.2
MV !R3U-3U\??\%2?^"P?P6_X)SZ,GPRT'0+_ .(7QO\ $6CO=^!/A-X;M);B
M\O%Q*%O+HQJ?LUFK12%Y#\Q6*38K;6*Z7_!#W]J[XS_MP?\ !+CX6_M2?M"Z
MY:ZEXP\51ZP^L7EEI\=K$_D:U?6L06*,!5"PP1KP.=N3DDF@#ZOHKY!^.W[6
MWQ:M_P#@K;\-OV3?AWX_&C^!_"7P=\0?$;XVP+I=O<?;[)I%L-+MS+)$\D!2
MX6><B%D>14 .5!!^<OV8OV@/^"X7_!67X:WW[:/[+OQV^&/P$^&.HZUJ%M\,
M?"'B/P$VM:EK5K:7$EN9]2G=_P#1MTT4B?N5R-C80@*\@!^I=%?GO^Q__P %
MI/%GB']A/X^?&?\ ;)^$=II7Q/\ V7=;U30/B;X<\(RN]GJ]_: B![)G+F-+
MB4&(;BP5E+YVD <+\,-8_P"#D3]H[]FO3/VZ? W[0/P1\,W'B7P]'XE\)_ 2
M?P!)<07-A-$+BUM;C4GE$\=Q+"4R%(4.X!:/G8 ?J%17SK_P2F_;]T7_ (*:
M?L,>#/VN].\*?V!>ZY'<6NO:&)C(ECJ-M,\$Z(Y&6C9D\Q">=DBAOF!KZ*H
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M/6[?PC_PAWAR]V".ZUCQ#KUU]EDN8UR=KF>]FG1,G8D87)"<^"?\$^_V0O\
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MI \-?&WQ1X<O_!)L-0,MP8;*VO8Y_/CVCRCNGCVC+9&>F* .7^/I_P"&GO\
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M^R?^U/\ M!?M?^)/^"TO_!0GP:W@_P 8>*O"R^&_A!\*'<M)X+\,&3S0;HL
M?MDQ)9E(4IYTQ94,@BAQ?^#4Q67_ ()L>)_[0'_$T/QT\4?VWN^_]KWV^[=_
MM;=G7VKV;]C/QW_P7=U[X[6.G?MX?!#]GC0_ARUE<G4=0^'>KZG-JB7 C)@"
M+<3NA4R8#9&<9Q7C6B_LC?\ !4O_ ()=_M&?%O7O^";WPA^'_P 7OA!\9?&$
M_C >!_%/BTZ%?^$-?N0HNWBE93'/:/M0A!\X6-$ 386E &?L3!_^(FS]M%M(
M_P"/0?#3P5_:NS[OVK^S;#R]W^UY>[]:_3*OCG_@DO\ \$_?C7^RM/\ %/\
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MCX4.$7R/_@IE_P %-/B=\1?B/J/_  2D_P""4^FIXS^/GB*SDL_%WBFVE/\
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M_##X;_$QM'?XC> -&U\^']9CU?0O[9TR*Y_L_4(XY(X[N'S%/E3*DTJK(N&
MD8 C)K\\O^"4O_*<O_@HO_V&? '_ *;+ZOTJKXW_ &%_V&_CC^SW_P %-/VN
M_P!K#X@KI \*?&O4?"DW@HV.H&6Y*Z?97,-QY\>T>4=\J;>6R,]* /H#]K+]
MKC]GS]B#X'ZO^T1^TU\1[+PSX7T=/WMU<MNENIB"4MK>(?//.^"%C0%C@G@
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M>WMWDCA'O(ZJ@'<N!7C/_!$K]G_6_P!G+_@E]\)?"GC+S'\3:_X?/BOQ=<7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-_["OQU/@.3XYZ=XFLM8EN].BO+>V5K2SVW[Q,,RRV<4\]Q$@95:6- V5R*
M/U"KY*_X*K_\%48/^"8^G?#*.S_9PU_XG:U\5/&7_"->'/#_ (<U..WN)+Y@
MGDQKO1O,:1Y%15&.2*]!_P""?_[+GQ^_9*^#VH_#;]HC]M7Q/\=-5N/$,M[I
MWBGQ7I<=K<V=H\,*K9X621I LB2R;V<G][M 4+S\'?\ !S]XV\0?#7XF?L1_
M$;PE\/M0\6ZKH'[3.FZEIGA726"W6LW$$UK+'90D@@2S,HC4D'YG'% 'H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/"K;L>KMD _2RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#!QQ^P;H7C'1;?4+.#0/&FHQV]S$'07-IIL]U;R8/\4<\,4BGLR ]JO?\
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M)7C#X+ZAJ5IXJT_PX\NB7.D1%[F.?>@!C4 DM@GL:]KHH _G'_X;R_X+2_\
M15OB_P#^".;_ .,4?\-Y?\%I?^BK?%__ ,$<W_QBOZ.**!W/YQ_^&\O^"TO_
M $5;XO\ _@CF_P#C%?.7QY\>_&GXG?%?5?''[0^K:Q?>,;[R/[8NM>@:.[?9
M!''%YBLJD8A2,#@?*%K^L6OYR/\ @O+_ ,I7?BK_ -P/_P!,6GT#3/D*BBB@
MH]>_94^//[:7P1_M[_AD#Q7XOTS^T_LO_"0_\(I8O-YOE^=Y'F[4;&/,FVYQ
MG+=<5Z]_PWE_P6E_Z*M\7_\ P1S?_&*^OO\ @U2_YKQ_W*__ +EZ_7J@EO4_
MG'_X;R_X+2_]%6^+_P#X(YO_ (Q7M?\ P3G_ &Q?^"JWCS]N#X:^#_C1\1OB
M;=^%M0\2)%K=OJ^D2I;20;')$C&$ +D#N*_<VB@5S&^(WC?3_AG\/=>^(^K:
M;?7EIX?T:ZU*YL],@$MS/'!$TK1Q(2 \C!"%7(RQ R*_.6Q_X)H?\$5?^"_7
MPCTS_@HCX!^$NN>&=8\87-R\WB[PIJ8T77(KR"=X9#>00O-:FYWQ[_,='=E9
M&+$,*_3,@$8(R#U%?G!XX_X-W= \!_%GQ%\6O^"<7[?GQ:_9I'BW4&OO$/A#
MP5>+=:!+<L<M)%9,\8C)YPI=U0';&$3"T"/)_@AI?[7_ /P1G_X*T?!']@F;
M]M7Q;\<?@M\?M/UB+2M ^(=S]LUOPE/86YE$J3Y)\G.P?*(XF4S_ +H-$KG%
M\/? .;_@XE_;A_:>^'G[9OQA\2Z7\(_V??&]SX(\!?";PMJILD&II]KMO^$A
MO0!F>4-"\D <%<LR'Y$=)?L3]@__ ((P?"S]D+X[7O[8'QA_:"^('QT^-%YI
M;:;%\1?B;JGVB32[-LAX+&#D6RL"5)+.0K,J%%=U;&_:>_X(F:5\1/VJ-:_;
M8_8S_;%\?_L[_$?Q=9I:^/+WP1%!=:=XB5  LUQ9387S\ ?O V,C?MWL[L ?
M O[-'[??_!3S_@G5^T)\*?\ @WMG\,>%[_QGHWQ2T^R\-?$K5K)7T_5_AU)'
M<2,WD++&RW$:*61@Y;]PT!#.NZ3UO_@M_P#!GQ]^T)_P75_8R^#WPP^/FO?"
M_7=9\)^+%L/'?AB-7OM+,=G/,YB#,H.](VB.2/EE:O5?$7_!K[^R!XV^%^KW
M7Q ^/OQ2U_XX:MXAM=?_ .&B]6\1-)XCLM1MO]3]GQA([=1QY7+<(1(#%$4^
MFOB7_P $S_A_\4/VU_@5^V_K_P 6/$\OB#X$:!J&E:19W+02IK0N[.2UDGO)
M"@8RXD+DIM!;M@XH ^8_%_\ P;W_ !U^.NBO\./VL/\ @MA^T3X[\"WQ USP
MC#>0Z?%J<0(/DS-NE5XS@95D8=#P0"/T(^!WP3^&'[-_P@\.? ;X+^$X-#\*
M^$])ATW0M*MB2L$$:X +,2SL>69V)9V9F8DDFNJHH ^,O^"AW[-'_!*_]LO]
ML?X%_!+]NK5TU?X@Z:NK:I\,/AY?7EQ'9:Y&8TDN_/C1/*G519(YC=USY6TA
ME8JWR'_P</?L?_LT?L)_"[X/?MY_L-?!?PO\+OC'X1^,^BZ;X6D^'NB0:2->
MCN%G,FGS6]JJ)<!EC&=RDF,21G*2,*^]O^"B_P#P3$^"_P#P48T'PI?^+?&7
MB7P1X\^'FKG5/AU\2_!%\+;5O#]T=A;RV8$/$YCC+H<$^6I5E(S7E/P=_P""
M*5W/^T3X1_:>_;Y_;E^(/[1?B#X<W)NOAWI/BNPM--T71+O(*WHL;4;9;I2J
M%96/5%8J2B%0#SC]FI/^$!_X.D_VC]#\2,()_'GP \.ZWX=$QV_:;:T^Q64O
MEY^]B5'X']QO0TG_  5P4?$+_@M5_P $\_A/X983ZOIGBKQ9XCU&",Y:VL8+
M2SD\QO16%M. 3P3&17T;_P % ?\ @EMX"_;>\=>#/V@?"'QG\6?"7XP_#H31
M^#?BAX&EC%Y!;2Y\VSN8I 4NK9MSGRVQ@NXSMDD5\G]A[_@DUH?[+WQ_US]L
MKX_?M*^,/CG\:==T1-%'CWQK#!;II6F*P<VEA9P#R[1'89;!.>=NW?)O /"?
M^""R#P7^V7_P4!^#VML(M;M/VHM0\0RVTG$AL=4>XFM)<==K(A(/O[TCH/B5
M_P '8XO_  RPEA^'?['Z6GB.2/E8+B?6)98HG/9VCO8G"GDJ">@KVC]K[_@D
M-;?&[]IYOVW_ -E3]K3QK\ OB[?:&FC>)O$W@ZUM[VT\164841+?6-P/+GDC
M"(J29&%1,@E$*]I_P3O_ ."97PO_ ."?T'C'QE!\2?$_Q&^)7Q)U2/4/B)\4
M/&]TLVIZS+&&6&(!0%AMXPS;(ESC=RQ 4* ?2M%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$[OA1_P4[_X+0_MQ>%_VC?BM\3;+3_A[XJ\/GPU9^#_',^G1Q?;+:Y\X,H#
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M_$.I:EX>\">%KSQ#J&EZ:;O;'<7;*=EO$=K;0[AL#(7:03^M?[%W[;G[-?\
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M4?\ 8K_8%\>>'/A]^U9\5'\+7?BK1-2U72+B73)IH)(+%5:9=T2L?-8NB1Q
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M69F)))Y))KWSX+?M]_\ !2;0?"MA\*?@5\>/'LFEZ#8+%8:/HL;7(L[93A5
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M=Q_P3Y_X)5_"[]A+QGXS^.^L?%CQ;\4_B[\1FC'C;XI>/;I);^[@CQY=I B
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M%%% !7G/[7.O>-/#'[-GC'Q!\.KJ\@URUT=GTV:PC+3+)N7!0 ')QGM7HU%
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MO^&--M-2L]=TY&4I'=6=VI21UV1@,25Q%&=FY U 'P_\7K[_ (*$W'_!?_\
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ML>>%_B/_ ,)1XQ\1?%CQA\99-WQ:\<_$:>.ZN_$<8ADA6U>-5$<=JL<LJK"
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M>-+>6.SUK2;JTWBTOK>2-2D4\4;^7G:59=P92&(K\T/^#AK_ ()C?%OX)?\
M!,;6/C=^TO\ \%&/BI\<+WPAX@T>S\#:3XJ2VLK#2Q/=I#+<S16XS?7?DEHQ
M/,Q(623@EL@ _>2ORM^/U_8?LQ_\'57PG^+/Q,G2R\._&OX"W7A'PSK%XVR
M:U;W+R&T#G@.P2V51U9[Q%'+5^J5>&?\% /^"=O[,O\ P4J^"0^!_P"TOX9N
MYK>TO5O_  _K^BW?V;5-"O5!"W5I/M;8^"05961AC<K8& #V^\O+33K274-0
MNHX+>"-I)YYG"I&BC+,S'@  $DGI7XR?\%J/^"FWP^_X*,_\$(/BQ\5OV7=(
M\8:=X+TKXQ:;X/\ $VNZI8Q0Q:K9P7\#O<VC12R&6U=VM,,P0DOL*YR*]OUW
M_@WX_: ^)?A@_!3X[?\ !;?]HKQ9\+)HQ;ZAX->[@@NM0M!P;:XORSM.C+@,
M'C(([=,?9&E?\$]OV/\ 1?V*W_X)ZZ9\%=-B^$DOAY]'F\*AGVR0.Q=Y&EW>
M8;@RGSO/W>9YO[S=N&: -7QQ\)OV:G_8OU7X,ZGX>T./X2)\.9M.DL(XT-A%
MH:V17Y?X?+6 9#=L Y[U^!>IP>(/BU_P:Z_LA^$/BRDU]IE[^UC8:/9B\))F
MTHWVN0B/)Y*+F6)?14"C@"OTB;_@WT^(5W\,D_9/U?\ X*Y_'JZ^ *0BS'PO
M9K!;I]-' TYM4$7FM:[ (_*\O9L^4*!7O_[4?_!);]G/]HK]EWX5_LA>&;R^
M\!>#/A#XWT7Q'X6L?#<<;X;38YDBMW,P8LK^>S.Y)D9LL6))) /F/_@ZV\!>
M#M:_X)G^!_"M[X=M!I\'QS\+VMK;10JBV\+I=0%(PH'ECRG9,+C .*N_\'4O
MAW0=$_X))6=KHNC6MI%H/Q/\+'1(K:!8UL-D[1)Y(4 1[8V9!MQA21TKZW_X
M*-_\$_? 7_!2+X&Z3\"OB+XZU?P]8Z3XUTWQ)%>Z+'$TKS6;.4B(E4C8V\YX
MSQQ2_P#!2;_@G_X"_P""EO[-$G[,OQ'\=:OX=TV3Q#I^KG4M$CB><26DOF(F
M)5*[6/!XSZ4 ?(/[8?@SX9^-/^#G_P#9<A^(]E9W4FF_!+7M1\-VUZJLK:G#
M+>M$ZJW!>-/-E4]5:(,,%01)_P '$EK8Z+\7OV(?B'X#@C7XF6O[5^A:?X9E
M@ %S)ILY/VZ'(Y,+.EHL@^[AN>M>>?\ !6#]E[1?VOO^#AC]G+X.:I\2/%/@
MVZ/P1UK4M#\7>"]3^R:GH^H6L]Y/;W,,A#*2KH R,"K*64XSD?4G[-G_  1P
MC\#_ +46B_MG_MF_MC^//VA?B'X/LY[7X?W7C*TM;'3/#22C;)-;V-LOE_:6
M7Y3,3S@-MW*C* >+?\$@M.TCQ7_P6K_X*!_$/XEPQ7'Q TKQEH.D:1/>@&YM
M/#Q@N1 D.[E8I$M[0MC@^5%GME/VY;'1O!O_  <Q_L;^(_A7#%;^*_%?@/Q;
M8_$%+,!7O=%AL;A[5KD+]Y5E6<JS?Q0( ?D 'O?[8W_!('PS^T!^TK#^V]^S
M9^TWXW^ WQG.CKI&L>-/ RP3P:_8J%$<6H64X,=T4"(%8D<1H&W>7'LO?L-_
M\$D? /[)WQUU_P#;"^,'QZ\9?&OXV>)-+&F7GQ'\>R1!["P!!^R6%K"HCLXB
M5!(&X]0I5692 ?'/P/\ V=?^"J_[".N?$3Q]_P $8?C#\!OVDO@7XS^)>J^(
MY/!FL:Y&FIZ?J=PR?:K6+4+>98'D39'&6EGXV F%26SQOQ@_:I^!'[1W_!O!
M^U[X;^%W['%O\!?%G@?Q'/I?Q7^&UH(VBMO$/]H67VBY66-$$OF;-I)565H2
MO*JCM]7:E_P0T\9_"?XG^,O&7_!/G_@I)\3_ (!^'/B!K\VM^*/ .AZ58ZKI
M*:A-_KI[*.Z4&R+X&=NXC:J@A$14['1/^"('[-7A;_@G3\1?^">GA[X@^+WA
M^+%_+JGQ!^)&L7L=[KVM:K+/#-+>S2.@1G8PJH7;@#).79G8 ^3_ /@H]_R0
MO_@E-_V7[X7_ /I+:5F_\%3Y?VQ?%'_!R7\"O#7[+^A?"_5?$?AWX!WFL?#S
M3/C+/?+HGV^2[U%+Z>$68,AO%MXHV7'18 YP54U]N?MH_P#!(WX7_MD_LB_"
M_P#9AO?C+XM\(:G\'+_1M1^'_C_PU+&FHV%_IMK]FAN""-I)7YR%*%75&5AM
MP<O]H?\ X(W^!?VI?@/\+O"?Q?\ VE_B"_Q<^$&9O!G[06BWL=GXDAN6;+O(
M0&21'VQAXSR?+!#*68D ^.OV_/V>_P#@M!^T-X[^ WC/]LGQQ^Q-\,;CP!\:
M-*UGP1XHTGQQK.FZI>7J$L^E6SW\;)/YZ)O-N@W2&V3LK9_8^OA/X2?\$3+R
M]_:0\'?M1?M[_MU?$/\ :(UWX;7;7?PZT?Q386FFZ/HMWN#+>?8[5=LURI2,
MK(2/FC4E6*IM^[* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OE'
MQ!_P1!_X)@^*]>OO%/B3]FN:]U'4KR6ZO[RX\=ZZTD\\CEWD8_;N69B23ZFO
MJZOQG_X+3_\ !:?XM0?%K6_V1OV1O&UQX<TKPY</8>+/%FDS;+V^O5RLUM;S
M+\T$4391G3;(SHP#!!\\2IPG\23.>O@\)C+*O3C.VW,D[?>?;W_#B+_@E/\
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M#XTZYKNK>,?&+N/"/P]\#^'YM8UW5PIPSPVL R$!!&]RJL58*25('&_L]_\
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MQ(;"4VUG?L\,Q>SE'FF7.PDJOSCN ?JA17S[^W/_ ,%._P!D7_@GG%H.F_M
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MLO 'A(7NMZMXD^(7B0WDMI$Q\R5Y+AP"4&/E7&>@&20* /=:*^"M"_X.0/\
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M[H?BC19I$DFTCQ%I,-[:R.AW(S13*R$J0""1P>16Y10 4444 %%%% !1110
M4444 8=_\,?AMJOCVQ^*FJ?#W0[GQ1I=F]IIGB2XTF%[^TMWSOABN"OF1HVY
MLJK '<<CFMRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OEG_@J5\4?^"@OPN\!>%;_ /X)]_#K_A(M8NM8FC\0P_V1'>>3;"(%
M&P[+MR_&17U-10!^0O\ PUU_P<J?]&Q'_P (JW_^.T?\-=?\'*G_ $;$?_"*
MM_\ X[7Z]44#N?D+_P -=?\ !RI_T;$?_"*M_P#X[7Y,^-I?%$_C/5Y_'"7"
MZT^J7#:PMVI$HNC(WFAP>0V_=D'OFOZX*_&?_@M/_P $6/BW<?%O6_VN?V1_
M!-QXCTKQ'</?^+/">DP[[VQO6R9KFWA'S3Q2MEV1-SJ[L0I0_(#3/RCK4\$3
M>*;?QII$_@>.X;6DU2W;1UM%+2FZ$BF((!R6W[< =\5+_P *Y^(7_"2_\(9_
MP@FL_P!L>;Y?]D_V7+]IWYQM\K;NSGC&,U^H?_!%C_@BQ\6K?XM:)^US^USX
M)N/#FE>'+A+_ ,)>$M6AV7M]>K@PW-Q"WS011-AU1]LC2(I*A!\X-NQO?\-=
M?\'*G_1L1_\ "*M__CM'_#77_!RI_P!&Q'_PBK?_ ..U^O5%!-S\A?\ AKK_
M (.5/^C8C_X15O\ _':^I?\ @EK\:?\ @JA\4?'WBJP_X*"?"?\ X1W1[71X
M9/#TW]@Q6?G7)EPZY1VW83G!K[5HH"Y\"?\ !T)_R@L^.G_7/PW_ .I+I5<!
M_P %,_V#?BQ\5?V._@C_ ,%%?V(XFLOVB/V>O!NE:SX4DM(2S^(M)2SC>\T>
M55P9@Z&1DCYW[YH0!]H)'VA_P40_8F\%_P#!1;]CKQC^QM\0O&.J:!H_C);
M7FKZ-'&US;_9=0MKU=@E!4[GME4Y'1CCG%>I?#SP;9_#KP!H7P^T^[EN+?0M
M'M=.@GF #R)!$L:LV.,D*"<>M C\<O\ @EA^W9\+?^"C_P#P<+O^UA\*@;>W
MU[]BN.+6=&DDW2Z/J<6N6*75E(<#)CDSM; WHR.  XKT']DO]K7]I/XS?$/X
MR:I_P0M_X)M?#32_ E]\5]2'C'XQ_%KQU=P0^*_$:[/M5VEG )+GROF5QAMI
M$I.U':1!]-_LK_\ !$S]F']CC_@H_P#$'_@HS\#]?UC3-0^(FA7FGZAX'2*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>dxcm-20231231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dxcm-20231231_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8\@;WA)$BKD@;BN,\9KTB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **\K^+O[;G[*GP%^*>D?!+XO?&C2]"\5:]#;RZ1HMW',
M9;E)YG@B92B%?FEC=1DCE:]4H ***^>/C;_P5@_X)X?L[^*9_!/Q5_:CT*UU
M:TE,5Y8:5;76J26T@."DHLHIO+<'JK8([B@#Z'HKQW]G+_@H#^QI^UKJ#Z+^
MSY^T%H7B#44B,AT@-):WIC RSBVN4CE91W8*0.^*]BH **** "BBB@ HHHH
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MGW\/+7QQ\;]5NYKO5)7BT'P[I$2RWVI2( 7V*S*JHFY=TCL%7<!RS*I_-/\
MX-PM._8.\2?$BZBUSP/?1_'#1;66YT>_U[5%GM+BU(*RR6$01!#,BMAU?S)-
MA+(^TR*G*?\ !<O6_'7BW_@L'X(\'0^!XO%8TZR\.VWAWPC?S".VU=I;MI#:
ML6(4+/*YB9B1Q@$_**![L^J_@[_P<F_LP>,_'>G>%?C#\%_%O@'3=7918^([
MYX[JU16; EE"!76+U=%DQWXR1[S_ ,%#?^"I/@#_ ()XV7A'7_&GPEU_Q3HO
MC&.<Z=K/AVZMS DD0C;8Q=A]Y)%=",A@&Q]TU\0_\% O#W_!6G_@H+\%M/\
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MZ7J%M\*Y-0T?Q+HT*S:OX4UY$2ZCA+!1/&R,RS0[B%+*<J2H95W+GZ2K\?\
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MQ#^[@15')=E591&N/F&]U..H7I7UC^P5_P %%/V??^"AO@&_\8?!>XU"SO\
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M_%7XIS:';2:X-6L-,@U&2(&6&V$4DK1HQY579E+ ?>\M,YVC'G>G:%I7@O\
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M^VGXXOO##^#_ !3K'B6ZTR*QU622]"7]Z9X-\9B55.P_-AC@],U8_P""W/\
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M_@H7^P!XRT7^W;JYAO+G3-7NT@ELKM;86LA3S5,4T$L0.Y696!D< $$$>?\
M[7W_  1V_P""KO[<NE:/\7?VA/CUX'U3QG:RFTM/"4$CVNG:/IY4LS)+'"0\
MSR!=PVG@#]XP 5?U[HH'<^"_^"K/_!/']J#]N[]E3X4?#7P&WABT\4>%Y8;G
MQ/'J6KR1VRR_81%(L,BPL9 )<X)5<K@X'2OHWPM\!/'.C?\ !/+3OV7KN6P/
MB6U^#$/A:61+AC:_;ETD6A(?;GR_,'WMN=O..U>ST4"/A;_@BI_P3A^.?[!'
M@'XB^$?VB'\-WG_"6W]E):1:+?O=1O%'%,DBR"2),9\P#&"",U\\:G_P1V_X
M*0_L-?M*:S\3O^"77QATF#PYKY>-+35;V%9K2V9]XM[F&ZBDAN%C)PDHS)@$
M[5).?UPHH'<_(+QC_P $,/V__&'[3/@7]IWXE?'?PWXV\3/KMAK'Q"U*_P!0
MD@6&6"[1A;VB+;@/&D$:!>(ES\JHJJ"?U]HHH%<\_P#VH/V9_A5^UY\$M:^
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M:=;B=FD=$,LTDJ1DD(JIL(4L&)'W;10%PK\]$_X)?_M)K_P6W_X>#F^\,_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'3]/OM?O!=:W>6MLJ2WLP& \C 98@9QGIDGN<^(?\/7_ -@+_HO?_EK:K_\
M(M'_  ]?_8"_Z+W_ .6MJO\ \BU$N).%9R4I8RBVMOWD-.FFNFA,L_X<E)2>
M*I-K;WX:>FI]$T5\[?\ #U_]@+_HO?\ Y:VJ_P#R+1_P]?\ V O^B]_^6MJO
M_P BU?\ K1PS_P!!U'_P;#_Y(K_6+A__ *#*7_@R'^9]$T5\[?\ #U_]@+_H
MO?\ Y:VJ_P#R+1_P]?\ V O^B]_^6MJO_P BT?ZT<,_]!U'_ ,&P_P#D@_UB
MX?\ ^@RE_P"#(?YGT317SM_P]?\ V O^B]_^6MJO_P BT?\ #U_]@+_HO?\
MY:VJ_P#R+1_K1PS_ -!U'_P;#_Y(/]8N'_\ H,I?^#(?YGT317SM_P /7_V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KP'_@J/_R8;\0?^O2R_P#3A;5[]7@/_!4?_DPWX@_]>EE_
MZ<+:O$XE_P"2<QG_ %ZJ?^D,\C/_ /D18O\ Z]5/_26?BS1117\9'\I!1110
M 4444 %%%% !1110 4444 %%%% !7O\ _P $M_\ D_+X?_\ 7U??^F^YKP"O
M?_\ @EO_ ,GY?#__ *^K[_TWW->WPS_R4>"_Z^T__2XGK9!_R/<)_P!?:?\
MZ4C]I:***_LT_JX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP'_@J
M/_R8;\0?^O2R_P#3A;5[]7@/_!4?_DPWX@_]>EE_Z<+:O$XE_P"2<QG_ %ZJ
M?^D,\C/_ /D18O\ Z]5/_26?BS1117\9'\I!1110 4444 %%%% !1110 444
M4 %%%% !7O\ _P $M_\ D_+X?_\ 7U??^F^YKP"O?_\ @EO_ ,GY?#__ *^K
M[_TWW->WPS_R4>"_Z^T__2XGK9!_R/<)_P!?:?\ Z4C]I:***_LT_JX****
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M***_C(_E(**** "BBB@ HHHH **** "BBB@ HHHH *]__P""6_\ R?E\/_\
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MO_L)_L+6G[+OPIUW0_B'J\&O>(_&C;O%=S$6,+1[746Z,P#.H\R4ER 6,AX
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MO>)_[(T:.YC@>\^Q3W&)')"KLA1WYQUQCUKR'_AZ_P#L!?\ 1>__ "UM5_\
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MO_L!?]%[_P#+6U7_ .1:/^'K_P"P%_T7O_RUM5_^1:/]:.&?^@ZC_P"#8?\
MR0?ZQ</_ /092_\ !D/\SZ)HKR'X,_MX?LI?M!^-D^'7PA^*G]KZS);27"6?
M]AWUOF- "S;YX$3C(XSGTKUZO3PF.P684O:X6K&I&]KQDI*_:Z;5ST<+C,)C
M:?M,/4C..UXM25^UU<****ZCH"BBB@ HHHH **** "BBB@ HHHH **** "O
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M=Z_ICPD_Y)67_7R7Y1/Z!\,O^2;?_7R7Y1"BBBOU _0PHHHH **** "BBB@
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MH<C\+O@;\+/@[X%_X5]X \#:7I>GRP[+Z*PLUB%VY3:SR$<NQ'=B3CC-<?\
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M^6MI7_R+1_P]?_;]_P"B]_\ EK:5_P#(M?.U%'^M'$W_ $'5O_!L_P#Y(/\
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M **** "BBB@ HHHH **** "BBB@ KP'_ (*C_P#)AOQ!_P"O2R_].%M7OU>
M_P#!4?\ Y,-^(/\ UZ67_IPMJ\3B7_DG,9_UZJ?^D,\C/_\ D18O_KU4_P#2
M6?BS1117\9'\I!1110 4444 %%%% !1110 4444 %%%% !7O_P#P2W_Y/R^'
M_P#U]7W_ *;[FO *]_\ ^"6__)^7P_\ ^OJ^_P#3?<U[?#/_ "4>"_Z^T_\
MTN)ZV0?\CW"?]?:?_I2/VEHHHK^S3^K@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OB7_@NE_R;=X3_P"QXC_]([FOMJOB7_@NE_R;=X3_ .QX
MC_\ 2.YKY#CW_DD,9_A_5'R_&G_)+XK_  _JC\M:***_D8_F,**** "BBB@
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M7_%^C/U)HHHK^NC^G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^4_\
M@LM_R91>_P#8QZ?_ .AM7Y#U^O'_  66_P"3*+W_ +&/3_\ T-J_(>OYF\6_
M^2JC_P!>X_G(_G[Q-_Y*1?\ 7N/YR"BBBOS _/ HHHH **** "BBB@ HHHH
M**** "BBB@#ZM_X(S_\ )ZUG_P!BWJ'_ *"M?KO7Y$?\$9_^3UK/_L6]0_\
M05K]=Z_ICPD_Y)67_7R7Y1/Z!\,O^2;?_7R7Y1"BBBOU _0PHHHH **** "B
MBB@ HHHH **** "BBB@ KP'_ (*C_P#)AOQ!_P"O2R_].%M7OU> _P#!4?\
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M=_A[^U/^S1_P4"^'M]K'C+6?BK=R:A#<>"Y-4O&,EY 92LMK\[,L##<V6'R
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M6W[.OQ,_8F_:I\<:GX.FU[Q,FHKXF_LJ74#!>Q2P>=%-'%EV;?:IST.Y\LI
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MZUG_ -BWJ'_H*U^N]?D1_P $9_\ D]:S_P"Q;U#_ -!6OUWK^F/"3_DE9?\
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MH **** "BBB@#Y3_ ."RW_)E%[_V,>G_ /H;5^0]?KQ_P66_Y,HO?^QCT_\
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MY;!KB-YH0DLTL>'#;+F'T VOD$D8R?VV_P!C/P[\._C_ ."_!G[.UA>RZ?\
M$C2;.[T#2+V<R26LTTGE^3O.24&4;<Q)&6R2%S6%7AC,:66K&)QDGROE3;E:
M<I0C*UK-2E%I6;>UTKF%3A['4\ L4G%IV?*FW*TI.,9;6M*46E9M[72N?,U%
M>Y_M[?#_ .!/P7^*6G_ SX+Z,INO"FCPVOC#7S?3RMJFJ%%,IV.[)&$X&V,+
MAF=3G:,>&5Y&88*IEV-GA:DE*4'9N+NKK=7LMGH^EUI=:GF8["3P&+GAYR3E
M%V=M5?JKZ;/1^:TNM0HHHKC.4^K?^",__)ZUG_V+>H?^@K7Z[U^1'_!&?_D]
M:S_[%O4/_05K]=Z_ICPD_P"25E_U\E^43^@?#+_DFW_U\E^40HHHK]0/T,**
M** "BBB@ HHHH **** "BBB@ HHHH *\!_X*C_\ )AOQ!_Z]++_TX6U>_5X#
M_P %1_\ DPWX@_\ 7I9?^G"VKQ.)?^2<QG_7JI_Z0SR,_P#^1%B_^O53_P!)
M9^+-%%%?QD?RD%%%% !1110 4444 %%%% !1110 4444 %>__P#!+?\ Y/R^
M'_\ U]7W_ION:\ KW_\ X);_ /)^7P__ .OJ^_\ 3?<U[?#/_)1X+_K[3_\
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MZ[U^1'_!&?\ Y/6L_P#L6]0_]!6OUWK^F/"3_DE9?]?)?E$_H'PR_P"2;?\
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M1110 4444 %%%% !7Q+_ ,%TO^3;O"?_ &/$?_I'<U]M5\2_\%TO^3;O"?\
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M;]#]DXY_L/\ L.7]H_\ ;EOBYNG+^O2VY[11117\HG\TA1110 4444 ?5O\
MP1G_ .3UK/\ [%O4/_05K]=Z_(C_ ((S_P#)ZUG_ -BWJ'_H*U^N]?TQX2?\
MDK+_ *^2_*)_0/AE_P DV_\ KY+\HA1117Z@?H84444 %%%% !1110 4444
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M1117Z@?H84444 %%%% !1110 4444 %%%% !1110 5X#_P %1_\ DPWX@_\
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M_P"1[A/^OM/_ -*1^TM%%%?V:?U<%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5\2_\%TO^3;O"?_8\1_\ I'<U]M5\2_\ !=+_ )-N\)_]CQ'_
M .D=S7R''O\ R2&,_P /ZH^7XT_Y)?%?X?U1^6M%%%?R,?S&%%%% !1110 4
M444 %%%% !1110 4444 %?;?_!"W_DY'Q9_V(\G_ *66U?$E?;?_  0M_P"3
MD?%G_8CR?^EEM7UW ?\ R5^#_P 7Z,^GX,_Y*C"_XOT9^I-%%%?UT?TZ%%%%
M !1110 4444 %%%% !1110 4444 %%%% 'RG_P %EO\ DRB]_P"QCT__ -#:
MOR'K]>/^"RW_ "91>_\ 8QZ?_P"AM7Y#U_,WBW_R54?^O<?SD?S]XF_\E(O^
MO<?SD%%%%?F!^>!1110 4444 %%%% !1110 4444 %%%% 'U;_P1G_Y/6L_^
MQ;U#_P!!6OUWK\B/^",__)ZUG_V+>H?^@K7Z[U_3'A)_R2LO^ODORB?T#X9?
M\DV_^ODORB%%%%?J!^AA1110 4444 %%%% !1110 4444 %%%% !7@/_  5'
M_P"3#?B#_P!>EE_Z<+:O?J\!_P""H_\ R8;\0?\ KTLO_3A;5XG$O_).8S_K
MU4_](9Y&?_\ (BQ?_7JI_P"DL_%FBBBOXR/Y2"BBB@ HHHH **** "BBB@ H
MHHH **** "O?_P#@EO\ \GY?#_\ Z^K[_P!-]S7@%>__ /!+?_D_+X?_ /7U
M??\ ION:]OAG_DH\%_U]I_\ I<3UL@_Y'N$_Z^T__2D?M+1117]FG]7!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?$O\ P72_Y-N\)_\ 8\1_
M^D=S7VU7Q+_P72_Y-N\)_P#8\1_^D=S7R''O_)(8S_#^J/E^-/\ DE\5_A_5
M'Y:T445_(Q_,84444 %%%% !1110 4444 %%%% !1110 5]M_P#!"W_DY'Q9
M_P!B/)_Z66U?$E?;?_!"W_DY'Q9_V(\G_I9;5]=P'_R5^#_Q?HSZ?@S_ )*C
M"_XOT9^I-%%%?UT?TZ%%%% !1110 4444 %%%% !1110 4444 %%%% 'RG_P
M66_Y,HO?^QCT_P#]#:OR'K]>/^"RW_)E%[_V,>G_ /H;5^0]?S-XM_\ )51_
MZ]Q_.1_/WB;_ ,E(O^O<?SD%%%%?F!^>!1110 4444 %%%% !1110 4444 %
M%%% 'U;_ ,$9_P#D]:S_ .Q;U#_T%:_7>OR(_P"",_\ R>M9_P#8MZA_Z"M?
MKO7],>$G_)*R_P"ODORB?T#X9?\ )-O_ *^2_*(4445^H'Z&%%%% !1110 4
M444 %%%% !1110 4444 %> _\%1_^3#?B#_UZ67_ *<+:O?J\!_X*C_\F&_$
M'_KTLO\ TX6U>)Q+_P DYC/^O53_ -(9Y&?_ /(BQ?\ UZJ?^DL_%FBBBOXR
M/Y2"BBB@ HHHH **** "BBB@ HHHH **** "O?\ _@EO_P GY?#_ /Z^K[_T
MWW-> 5[_ /\ !+?_ )/R^'__ %]7W_ION:]OAG_DH\%_U]I_^EQ/6R#_ )'N
M$_Z^T_\ TI'[2T445_9I_5P4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#2D?M+1117]FG]7!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1117Z@?H84444 %%%% !1110 4444 %%%% !1110 5X#_P %1_\ DPWX@_\
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M 4444 %%%% !1110 4444 %<1\=?V<_@U^TKX;M/"'QL\'?VUIUC?"\M;?\
MM"XMMDP1D#[H)$8_*[#!)'/3I7;T5CB,/A\71=*O!3@]U))I^J>C,JU"CB:3
MI5HJ47NFDT_5/0^=O^'4'[ 7_1!/_+IU7_Y*H_X=0?L!?]$$_P#+IU7_ .2J
M^B:*\C_5?AG_ * :/_@J'_R)Y?\ J[P__P! =+_P7#_(^=O^'4'[ 7_1!/\
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M_(^=O^'4'[ 7_1!/_+IU7_Y*H_X=0?L!?]$$_P#+IU7_ .2J^B:*/]5^&?\
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M_P!$$_\ +IU7_P"2J^B:*/\ 5?AG_H!H_P#@J'_R(?ZN\/\ _0'2_P#!</\
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M.H/V O\ H@G_ )=.J_\ R51_PZ@_8"_Z()_Y=.J__)5?1-%'^J_#/_0#1_\
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MG?%#XBSG9]IE%[%;I:0.IVQH\\D>0K--(G)6-!(& L?KM17S3_P1WO;W4?\
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MBU0P>2TNZ%6*R02>9L*N&>,E"KEL%0=C]MJ*_,/_ (+,_'WXX_&#]L+X0?\
M!,KX,?$K4O!MGXX%G>>+]2TN=HYV2ZN9(5B<HRLR1102RF(,%D+IN^Z,</\
M!IOBY_P2)_X*V^"?V-HOCSXB\8_#+XHZ=:>38^(KDR&"6ZDGMH9%7)2.9;J
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M (*>_M^G[/X7LITN?AEX$"D0RQ1OO@<1M]RT1L.-WSW+C>W[O_69_P"WU&/
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MP#-83VMW<F*3C+;);<%.?E\V3^\:^T_^"9?P6\ ? K]A'X8>$_AYHXM;>_\
M!]AK&HR'!DNKV\MX[B>9VQ\Q+N0/[JJJCA13?^"AG[ W@3_@HE\'-*^#/Q!\
M<:OH%GI7B:+6HKS1HXFE>6.WN(!&1(I&TBX8^N5%>L_"?X?6'PE^%GAKX5:5
M?S75KX9\/V6DVUU< "2:.V@2%7;'&XA 3CC)H'T/F+_@O+_RBB^*O_<#_P#3
M[I]7O^"'7_*+#X3?]>.I_P#IVO:]?_;-_9<\,?MH_LV>)/V:/&/B6_T?3?$O
MV/[3J.F(C3P_9[R"Z7:'!7EH%4Y'1CWJ;]D#]F?PW^QY^SEX:_9O\(^(K[5M
M.\,PW$=MJ&I(BSS"6YEN"6" +PTI P.@% C\W?#'_*U%K7_7B?\ U$8:^@_^
M#AWXO>!O!'_!./Q#\--;UVUCUOQGJVEVFB:<TR^?-Y%]#=RR*F=VQ4MR"V,
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M)7> _P#@I#K'A>^^(_QF\3:!:>%+:YCL=-T6*!HGDG9#),WF*3NQ&B^P7W-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\0?B7)J/@K0+:33?AYHOVVXM%%AI[^;*N1M0XVY]2!7ZB5\1_LY>"_&.G?\
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M%;'3K(PZK%>,\:B'SI1M )S*P'4D9!GZE4444""BBB@ HHHH **** "BBB@
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MQOZV2N=>$RS+<!)RPU"%-O?EC&-_6R04445Z!W!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7D'[;'[$_P6_;N^"UW\'/C'I/]Z;0]<MD
M7[7H]WMPL\+'\F0_*Z\'L1Z_10!Y!^Q1^Q/\%OV$?@M:?!SX.:3_ '9M<URY
M1?M>L7>W#3S,/R5!\J+P.Y/K]%% !1110 4444 %%%% !1110 4444 %%%%
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M/K3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>dxcm-20231231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dxcm-20231231_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Y!^WQ^TE+^R)^QYX^_:'LK>*6^\/:(3I,
M<XRC7TTB6]MO'=?/FC+#N :_*K_@CA_P3'\$_P#!1]/&'[9_[;NM:UXKMKCQ
M-+96^G2:K+ ^K7@C26XN;B:)EEV#S8T18V3D/SA0*^_O^"YG@C7/'7_!+SXG
M6/AZW>:?3X-/U*6*,9)@MM0MI9F/LL2NY_W*\B_X-HOB-X:\2?L*:S\/;*^B
M_M7PUXZNSJ%F&'F+#<0PR0S$?W6*RJ#W,+>E ^AYK^WK_P &\-H/$?A?Q_\
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M%_B/_P '.,GA;QEH]O?V!\:+=O:740>-Y+;0A<Q%E/!Q)$C8/I0%CZ>^%_\
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M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?"/_ (*^>+_VY/%5]X8;P7KFL:]=645IJLCWH2\W^3NB,04'YAN^<X]ZU/\
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M_$7A!=.U"WCUB?4I&U2_FN(US/+$8]JEY-[$>8Q (RS')/1:5_P2X_:6LO\
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M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2_#WAW3TL]+L8V+>7&O=F/+NQ)9F.2S,22230,^1OB+_ ,K GP__ .S<[O\
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MQ#\2?B9XMMX[;7/'/BDQK,+1""MK;PQC;;PY5"4!.2B\@*H !XY_P0Y4>&/
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_
M #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\
M_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_
M (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 5]-TZ#2K46EN
M\C*&)S*Y8\^YJQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?')RMUVO8]S*<MCE6#^KJ7-[TG>UOBDY?A>P4445ZQZ84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 445XC^V)^VMX;_95AT?PW8^#=1\4^+O$ID70/#NECYI N 9)#@E4
MR0  "6(.!@$CCQ^/PF6866)Q,^6$=WZNR22U;;T26K9RXS&X;+\-*OB)<L5N
M_71:+5MO1)'MU%?+W["W_!1BS_:;U2V^%/Q,\%3^'/&K:*NHP 1E;/5H, F6
MWW'<ORD,%);*@D,<'%OX]_\ !2?PK\+OBI??!7X4_!KQ-\1_$6C0&;7[?PU
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M[*'[>W@7]IOQ7JOPNU/P/K/@SQIHL9EOO#'B"/;*8P0&9"0I)4LNY656&X$
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M?_ 9_P#RP/\ B*7$'_/JE_X#/_Y,_9O_ (>O_L!?]%[_ /+6U7_Y%H_X>O\
M[ 7_ $7O_P M;5?_ )%K\9**/^(P\3?\^:/_ (#/_P"6!_Q%+B#_ )]4O_ 9
M_P#R9^S?_#U_]@+_ *+W_P"6MJO_ ,BT?\/7_P!@+_HO?_EK:K_\BU^,E%'_
M !&'B;_GS1_\!G_\L#_B*7$'_/JE_P" S_\ DS]F_P#AZ_\ L!?]%[_\M;5?
M_D6C_AZ_^P%_T7O_ ,M;5?\ Y%K\9**/^(P\3?\ /FC_ . S_P#E@?\ $4N(
M/^?5+_P&?_R9^S?_  ]?_8"_Z+W_ .6MJO\ \BT?\/7_ -@+_HO?_EK:K_\
M(M?C)11_Q&'B;_GS1_\  9__ "P/^(I<0?\ /JE_X#/_ .3/V;_X>O\ [ 7_
M $7O_P M;5?_ )%H_P"'K_[ 7_1>_P#RUM5_^1:_&2BC_B,/$W_/FC_X#/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-?2'[1'[/G[5_@G1_AY>_L3_ !%\N#P)IEOIMUX.U>_,5IJT$**L;R8*J[$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/QJ_P"2.>+?
M^Q9O_P#TGDKIJYGXU?\ )'/%O_8LW_\ Z3R5SXO_ '2I_A?Y&&)_W:?H_P C
M\ :***_A\_D(**** "BBB@ HHHH **** "BBB@ HHHH **** "OW"_X)]?\
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M*_.W_A_C_P!6H_\ E]?_ '#1_P /\?\ JU'_ ,OK_P"X:\3_ (B5P3_T%?\
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M\7_NE3_"_P C#$_[M/T?Y'X T445_#Y_(04444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **Y/XV_'3X1?LX?#J]^+/QP\>V'AOP]I^T7.I7[G&YCA4
M15!>1V/1$#,>P->!?LS_ /!9#]A[]I_XH3?!_P *_$.?1]=N-8:R\-6OB'39
M[-==0)&R2P/)&$5G+E5A<K*2HPIW"@#ZIHKC?C;^T)\$?V;O"]MXU^/'Q/TC
MPII-W?K96M_K-T(HY;AD>01*3U8I&[8]%-<-X!_X*.?L*_%+QEIWP\^'?[4_
M@[6-;U>Y6WTS2['55>:YE/1$7N30![717 ?M!?M3?L\?LJ^&[?Q;^T-\7-&\
M*65Y*T=DVIW!\VZ=0"RQ1(#)*0""=BG&1G&:G^ W[2WP$_:@\)R>-_V?_BMH
M_BO3()O)N9]*NMS6\F,A)8SAXF(Y =02.1Q0!W%%>4_M$?MQ_LE?LGW]EI'[
M0WQXT+PQ?:C'YEGI]W,TES)'DKYGDQ*[B/((WE0N01G@UVOPM^+/PS^-W@BS
M^)'PA\=Z7XCT&_4FTU72+Q9X9"#AEW*>&4\%3@J1@@&@#H:**\-^(_\ P4M_
M8,^$?Q-D^#OQ&_:E\*:7XB@G\B\L)KTLMI+G!CGE13' PSRLC*1WQ0![E14-
MA?V&JV$&J:7>PW-K<PK+;7-O('CEC8 JZL.&4@@@C@@US7QJ^.'PH_9U^'MW
M\5OC7XUM?#WAZQEBCN]4O%<QQ-)((T!"*QY=E'3O0!U=%<W\(_B]\-?CQ\/-
M-^+'P@\86FO>'-721M-U:R+>7.$D:)\;@""'1U((!!4USG[0_P"UU^S;^R=8
MZ7J/[17Q;TSPK#K<TL6E-J D)N6C"F0*(U8_*'3)Q@;AZT >CT444 %%%% !
M1110 4444 %<S\:O^2.>+?\ L6;_ /\ 2>2NFKF?C5_R1SQ;_P!BS?\ _I/)
M7/B_]TJ?X7^1AB?]VGZ/\C\ :***_A\_D(**** "BBB@ HHHH **** "BBB@
M HHHH **** "OW"_X)]?\F5_#?\ [%B'^;5^'M?N%_P3Z_Y,K^&__8L0_P V
MK]?\'/\ D=XC_KW_ .W1/U#PK_Y&]?\ Z]_^W(]BHHHK^B3]T"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'Q%;?LE>)?C5XCT>>Q/Q7^*>M^+]-M[E-L@L[AHHHB1Z-Y#N#W5P1D$&F?\
M!P1_RBZ\;?\ 87T;_P!.,% ^ID?\$=Y9_P!G_P >_&7_ ()\ZQ,RQ>"?$D/B
M7P4DS$EM#U6%9DC0_P 0B?:&/]^<_0?(_P#P78NKO]I+XB?$[XAQ7+R>&?@-
M;:%X4TO:Y\J77-3N!=7LBGNT<$<<#KV(4U].?MX^.K#]@_\ :H^"/_!1B\LY
MO^$;U+P?=^!/B$+5#F6-K5KS3^G5C/&Y)(Z0J/3'A'[7OPJ\2> /^"!C>/\
MXAQ?\5?\4OB!9^._%TS+AI+O4[HSID'D%;?R%*GH5/3I0"W/U]HHHH$%%%%
M!16=J7AG3]5NC=W$]RK%0,17!4<>PJ#_ (0?2/\ GYO?_ MJ -BBL?\ X0?2
M/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8KF?C5_R1SQ;_V+-_\ ^D\E7O\ A!](
M_P"?F]_\"VKFOC+X+TJ'X0>*Y5N;S*^&[XC-TQ'%N]<^+_W2I_A?Y&&)_P!V
MGZ/\C\&****_A\_D(**** "BBB@ HHHH **** "BBB@ HHHH **** "OW"_X
M)]?\F5_#?_L6(?YM7X>U^UO[ WA'3+W]C7X=7<MQ=!I/#4)8)<L!U/05^O\
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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M17XF?D@4444 %%%% !1110 4444 %%%% !1110 4444 ?N%_P3Z_Y,K^&_\
MV+$/\VKV*O"/V!O".F7O[&OPZNY;BZ#2>&H2P2Y8#J>@KU__ (0?2/\ GYO?
M_ MJ_M/(O^1)A?\ KW#_ -)1_663_P#(HP__ %[A_P"DHV**Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJ]4](V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P
M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V
M**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W
M_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;
MW_P+:C_A!](_Y^;W_P "VH V**KZ;IT&E6HM+=Y&4,3F5RQY]S5B@ HHHH *
M*** "BBB@ HHHH **** ,+XD?#+X=_&+P9>_#OXJ^"=+\1:%J*!+W2=8LDN(
M)@#D$HX(R" 0>H(!!!&:\!_9/_X)1?LE_LI?$?Q%\5/#/PJ\/W>LWOBF?4?"
ME])IKM)X=LGAA1+. RR28*NDS^<H5B)RO0<_3=% '(_&GX"?!?\ :,\&M\/O
MCI\,M&\4Z.THE6QUBR658I "!)&3\T;@$C>A#8)&>37-?L\?L2?LG?LH3W=[
M^SS\"-!\,7=]'Y=WJ%G;L]U+'D'RS/*6DV9 .S=MR <9%>IT4 <#\?\ ]EO]
MGK]J?PW;^$OVA?A'HWBNQLY6ELEU2VS):NP 9HI5(DB)  .QAD 9SBI?@+^S
M3\!/V7O"<G@?]G[X4Z/X5TR:;SKF#2K;:US)C >60Y>5@. 78D#@<5W-% 'E
M7[0_[#W[)?[6%Y9ZI^T-\!]!\3WNGQ>59ZC=P-'=1Q[BWE^=$RR%,DG86*Y)
M..37:?"SX3?#/X(>"+/X;?"'P)I?AS0=/4BTTK2+-884).6;"CEF/)8Y+$DD
MDUT-% '*?"OX%_"#X'Q:O#\(_AWI?AY-?U:34]973+<1B\O'QOGDQ]YS@9->
M<_$C_@FK^P;\7?B7)\8/B/\ LM>$]5\13W'GW=_-8E1=RYR7GC1A'.Q[F16+
M=\U[C10!#86%AI5A!I>EV4-M:VT*Q6UM;QA(XHU "HJCA5    X %8/Q9^#W
MPO\ COX'N?AK\8O VG>(] O)(WNM)U2 20RM&X="5/4JR@CW%=)10!R?Q8^!
M/P<^.O@,?##XP_#C2?$?A]98I5TC5;42PJ\?^K8*>A7G!]S1\4_@5\'OC=X!
M'PL^+/PXTK7_  X)(771=1M0]N&B_P!60G0;>WI7644 %%%% !1110 4444
M%%%% !7,_&K_ )(YXM_[%F__ /2>2NFKF?C5_P D<\6_]BS?_P#I/)7/B_\
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MXU?\D<\6_P#8LW__ *3R5^ -?O\ ?&K_ )(YXM_[%F__ /2>2OP!K\#\9_\
M>\'_ (9_G$_%O%?_ 'G"^D_SB%%%%?B9^2!1110 4444 %%%% !1110 4444
M %%%% !1110!^X7_  3Z_P"3*_AO_P!BQ#_-J]BKQW_@GU_R97\-_P#L6(?Y
MM7L5?VGD7_(DPO\ U[A_Z2C^LLG_ .11A_\ KW#_ -)04445ZIZ04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*_HD_= HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M *]P_P#24%%%%>J>D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGU_R97\-_P#L6(?YM7X>U^X7_!/K_DROX;_]BQ#_ #:OU_P<_P"1WB/^O?\
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M_I*/ZRR?_D48?_KW#_TE!1117JGI!1110 4444 %%%% !1110 4444 %%%%
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MOX[_ -5^)O\ H!K?^"I__(G\L_ZN\0?] =7_ ,%S_P CY\HKZ#_X=7?M[_\
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M7_\ D.C_ (?Z?\$Q/^B]S_\ A):O_P#(='UBA_.OO0?VSD__ $$4_P#P./\
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MWLG8^?**^@_^'5W[>_\ T0";_P *'3?_ ))H_P"'5W[>_P#T0";_ ,*'3?\
MY)K\A_U7XF_Z :W_ (*G_P#(GY=_J[Q!_P! =7_P7/\ R/GRBOH/_AU=^WO_
M -$ F_\ "ATW_P"2:/\ AU=^WO\ ]$ F_P#"ATW_ .2:/]5^)O\ H!K?^"I_
M_(A_J[Q!_P! =7_P7/\ R/GRBOH/_AU=^WO_ -$ F_\ "ATW_P"2:/\ AU=^
MWO\ ]$ F_P#"ATW_ .2:/]5^)O\ H!K?^"I__(A_J[Q!_P! =7_P7/\ R/GR
MBOH/_AU=^WO_ -$ F_\ "ATW_P"2:/\ AU=^WO\ ]$ F_P#"ATW_ .2:/]5^
M)O\ H!K?^"I__(A_J[Q!_P! =7_P7/\ R/GRBOH/_AU=^WO_ -$ F_\ "ATW
M_P"2:/\ AU=^WO\ ]$ F_P#"ATW_ .2:/]5^)O\ H!K?^"I__(A_J[Q!_P!
M=7_P7/\ R/GRBOH/_AU=^WO_ -$ F_\ "ATW_P"2:/\ AU=^WO\ ]$ F_P#"
MATW_ .2:/]5^)O\ H!K?^"I__(A_J[Q!_P! =7_P7/\ R/GRBOH/_AU=^WO_
M -$ F_\ "ATW_P"2:/\ AU=^WO\ ]$ F_P#"ATW_ .2:/]5^)O\ H!K?^"I_
M_(A_J[Q!_P! =7_P7/\ R/GRBOH/_AU=^WO_ -$ F_\ "ATW_P"2:/\ AU=^
MWO\ ]$ F_P#"ATW_ .2:/]5^)O\ H!K?^"I__(A_J[Q!_P! =7_P7/\ R/T_
M_P""?7_)E?PW_P"Q8A_FU>Q5Y!^R)H/C_P"$W[,_@OX;^-? -W;:MHVAQVU_
M;K<12".0$Y&Y&93UZ@D5Z/\ \)+J_P#T*%[_ -]+7]<Y+3G2R?#0FFI*G!-/
M1IJ*NFNY_3N50G3RNA":LU"*:>Z?*M&;%%8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2UZ1WFQ17RY\:_^"Q/["7[.WQ/U7X,_&3XJ7&C>)=$DC35-,;P[J,Y
M@:2))4&^&V=&RDB'Y6/7!Y!%<M_P_P!/^"8G_1>Y_P#PDM7_ /D.LG7HIV<E
M]Z//GFV54YN$\1!-:-.<;I_>?9E%?&?_  _T_P""8G_1>Y__  DM7_\ D.C_
M (?Z?\$Q/^B]S_\ A):O_P#(=+ZQ0_G7WHG^V<G_ .@BG_X''_,^S**^,_\
MA_I_P3$_Z+W/_P"$EJ__ ,AT?\/]/^"8G_1>Y_\ PDM7_P#D.CZQ0_G7WH/[
M9R?_ *"*?_@<?\S[,HKXS_X?Z?\ !,3_ *+W/_X26K__ "'1_P /]/\ @F)_
MT7N?_P )+5__ )#H^L4/YU]Z#^V<G_Z"*?\ X''_ #/LRBOC/_A_I_P3$_Z+
MW/\ ^$EJ_P#\AT?\/]/^"8G_ $7N?_PDM7_^0Z/K%#^=?>@_MG)_^@BG_P"!
MQ_S/LRBOC/\ X?Z?\$Q/^B]S_P#A):O_ /(='_#_ $_X)B?]%[G_ /"2U?\
M^0Z/K%#^=?>@_MG)_P#H(I_^!Q_S/LRBOC/_ (?Z?\$Q/^B]S_\ A):O_P#(
M='_#_3_@F)_T7N?_ ,)+5_\ Y#H^L4/YU]Z#^V<G_P"@BG_X''_,^S**^,_^
M'^G_  3$_P"B]S_^$EJ__P AT?\ #_3_ ()B?]%[G_\ "2U?_P"0Z/K%#^=?
M>@_MG)_^@BG_ .!Q_P S[,HKXS_X?Z?\$Q/^B]S_ /A):O\ _(=>N_LO?\%
M_P!G3]L^UUJ\_9H\1W7B:/P]) FL,FE75I]G:82&(?Z3%'NW"*3[N<;><9&:
MC6I3=HR3?J:T<RR[$5%3I5H2D^BDF_N3/;Z*Q_\ A)=7_P"A0O?^^EH_X275
M_P#H4+W_ +Z6M#M-BBL?_A)=7_Z%"]_[Z6O*/VH_^"@7[.G[%UCHVI?M,^(K
MKPQ!X@EGBTAWTJZN_M#PA#(,6L4A7 D3[V,YXS@T >WT5\8?\/\ O_@E_P#]
M%^G_ /"1UC_Y#H_X?]_\$O\ _HOT_P#X2.L?_(= [,^SZ*^,/^'_ '_P2_\
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MT#1[806EC;1V]K"IXCC10JJ,^@ %3QPQ1%C%$JEVW.57&X^I]3P*=0 4444
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M_(II_P"-?^DR/E2BBBO$/R<**** "BBB@ HHHH **** "BBB@ HHHH ****
M/V#_ .#67_D6/C7_ -?^@?\ H%_7ZRU^37_!K+_R+'QK_P"O_0/_ $"_K]9:
M^AP/^ZQ^?YG[;PG_ ,D]0_[>_P#2I!11176?1GY.?\'4/_(B?!C_ +"^M_\
MHJSK\;J_9'_@ZA_Y$3X,?]A?6_\ T59U^-U!:V"BBB@84444 %%%% !1110
M4444 %%%% !1110 5]3?\$3_ /E*+\)/^PO>_P#INNJ^6:^IO^")_P#RE%^$
MG_87O?\ TW75 /8_I.HHHH,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^<+_ (+=?\I2/BQ_
MU_Z;_P"FJSKY4KZK_P""W7_*4CXL?]?^F_\ IJLZ^5*^8K_QY>K_ #/Y_P W
M_P"1MB/\<_\ TIA11161YX4444 %%%% !1110 4444 %%%% !1110 5^P?\
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MH **** "BBB@ HHHH **** "OJ;_ ((G_P#*47X2?]A>]_\ 3==5\LU]3?\
M!$__ )2B_"3_ +"][_Z;KJ@'L?TG4444&84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_.%_P6
MZ_Y2D?%C_K_TW_TU6=?*E?5?_!;K_E*1\6/^O_3?_359U\J5\Q7_ (\O5_F?
MS_F__(VQ'^.?_I3"BBBLCSPHHHH **** "BBB@ HHHH **** "BBB@ K]@_^
M#67_ )%CXU_]?^@?^@7]?CY7[!_\&LO_ "+'QK_Z_P#0/_0+^NO ?[U'Y_D?
M2\(?\E#1_P"WO_26?K+1117T)^UA7Y.?\'4/_(B?!C_L+ZW_ .BK.OUCK\G/
M^#J'_D1/@Q_V%];_ /15G0-;GXW4444%A1110 4444 %%%% !1110 4444 %
M%%% !1110!]3?\$3_P#E*+\)/^PO>_\ INNJ_I.K^;'_ ((G_P#*47X2?]A>
M]_\ 3==5_2=03+<****"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYPO
M^"W7_*4CXL?]?^F_^FJSK^CVOYPO^"W7_*4CXL?]?^F_^FJSKSLS_@+U_1GP
M_'O_ "*:?^-?^DR/E2BBBO$/R<**** "BBB@ HHHH **** "BBB@ HHHH **
M** /V#_X-9?^18^-?_7_ *!_Z!?U^LM?DU_P:R_\BQ\:_P#K_P! _P#0+^OU
MEKZ' _[K'Y_F?MO"?_)/4/\ M[_TJ04445UGT9^3G_!U#_R(GP8_["^M_P#H
MJSK\;J_9'_@ZA_Y$3X,?]A?6_P#T59U^-U!:V"BBB@84444 %%%% !1110 4
M444 %%%% !1110 5]3?\$3_^4HOPD_["][_Z;KJOEFOJ;_@B?_RE%^$G_87O
M?_3==4 ]C^DZBBB@S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /YPO^"W7_*4CXL?]?\ IO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_G"_X+=?\ *4CXL?\ 7_IO_IJLZ_H]K^<+_@MU_P I2/BQ_P!?
M^F_^FJSKSLS_ ("]?T9\/Q[_ ,BFG_C7_I,CY4HHHKQ#\G"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#]@_^#67_ )%CXU_]?^@?^@7]?K+7Y-?\&LO_
M "+'QK_Z_P#0/_0+^OUEKZ' _P"ZQ^?YG[;PG_R3U#_M[_TJ04445UGT9^3G
M_!U#_P B)\&/^POK?_HJSK\;J_9'_@ZA_P"1$^#'_87UO_T59U^-U!:V"BBB
M@84444 %%%% !1110 4444 %%%% !1110 5]3?\ !$__ )2B_"3_ +"][_Z;
MKJOEFOJ;_@B?_P I1?A)_P!A>]_]-UU0#V/Z3J***#,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH _G"_X+=?\I2/BQ_U_Z;_Z:K.OE2OJO_@MU_RE(^+'_7_IO_IJLZ^5*^8K
M_P >7J_S/Y_S?_D;8C_'/_TIA11161YX4444 %%%% !1110 4444 %%%% !1
M110 5^P?_!K+_P BQ\:_^O\ T#_T"_K\?*_8/_@UE_Y%CXU_]?\ H'_H%_77
M@/\ >H_/\CZ7A#_DH:/_ &]_Z2S]9:***^A/VL*_)S_@ZA_Y$3X,?]A?6_\
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M_APW_P $HO\ HU7_ ,OG7?\ Y.KZ]HH"[/D+_APW_P $HO\ HU7_ ,OG7?\
MY.H_X<-_\$HO^C5?_+YUW_Y.KZ]HH"[/D+_APW_P2B_Z-5_\OG7?_DZC_APW
M_P $HO\ HU7_ ,OG7?\ Y.KZ]HH"[/D+_APW_P $HO\ HU7_ ,OG7?\ Y.H_
MX<-_\$HO^C5?_+YUW_Y.KZ]HH"[/D+_APW_P2B_Z-5_\OG7?_DZC_APW_P $
MHO\ HU7_ ,OG7?\ Y.KZ]HH"[/D+_APW_P $HO\ HU7_ ,OG7?\ Y.H_X<-_
M\$HO^C5?_+YUW_Y.KZ]HH"[/D+_APW_P2B_Z-5_\OG7?_DZNJ^"?_!(7_@G?
M^SK\4=(^-'P;_9Z_L?Q-H4SRZ5J7_"6:O<>0[QO$Q\N>[>-LH[#YE/7/4 U]
M)T4"NPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH _G"_X+=?\I2/BQ_U_Z;_Z:K.OE2OJ
MO_@MU_RE(^+'_7_IO_IJLZ^5*^8K_P >7J_S/Y_S?_D;8C_'/_TIA11161YX
M4444 %%%% !1110 4444 %%%% !1110 5^P?_!K+_P BQ\:_^O\ T#_T"_K\
M?*_8/_@UE_Y%CXU_]?\ H'_H%_77@/\ >H_/\CZ7A#_DH:/_ &]_Z2S]9:**
M*^A/VL*_)S_@ZA_Y$3X,?]A?6_\ T59U^L=?DY_P=0_\B)\&/^POK?\ Z*LZ
M!K<_&ZBBB@L**** "BBB@ HHHH **** "BBB@ HHHH **** /J;_ ((G_P#*
M47X2?]A>]_\ 3==5_2=7\V/_  1/_P"4HOPD_P"PO>_^FZZK^DZ@F6X4444$
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?SA?\%NO^4I'Q8_Z_P#3?_35
M9U_1[7\X7_!;K_E*1\6/^O\ TW_TU6=>=F?\!>OZ,^'X]_Y%-/\ QK_TF1\J
M4445XA^3A1110 4444 %%%% !1110 4444 %%%% !1110!^P?_!K+_R+'QK_
M .O_ $#_ - OZ_66OR:_X-9?^18^-?\ U_Z!_P"@7]?K+7T.!_W6/S_,_;>$
M_P#DGJ'_ &]_Z5(****ZSZ,*Q_B%XST[X<> -<^(>L02RVF@Z/<ZC=1P#+O'
M!$TK!1ZD*<>];%9'Q UWP9X7\":UXE^(U[:VWA[3])N+C7;B_7,$5FD;-,T@
MP?D$88M[ T ?C3X9_;H_X+"_M6?%CPG^T9\"/%N@0?VQI/B.Z\'?##3QOMKB
MRL+BUCN(+B-@!/.WFKL=W5\1N4,0D /Z/_'G]MSQ;^S5_P $[;K]KCXX_#(>
M&?&5MX;B\SP;=7*R!-;E(ACMPT;-NB,Q#Y!+"($G!!Q^8/Q'_9.M_P!G_P"/
M^A_'C_@D!^UL6TC5?!GBOQ5I!O)EDM[&'2VA%[9))(C+*'&%59XQD0IO=@0X
MZW_@I/\ M<>._P!M?_@D1\ OBAX_T^+3KGQ3\36MO%!L4,=O+/9K>VPE49.%
M<;I-N<*V0/N@T%'UYXP_:<_X*'? K_@F/X ^(^D_#G5_BW\:_&\5M+=26OA0
M-;Z)'>*]PLEQ!811JJPQ-%#\VT&0EF8JI!\\^&G[<O\ P4I_9,_;G^'/[*/_
M  4&O?!'B_3OBND2Z5J'@ZW\N;29I9#$@)6*(,JRX60,C#:VY)#M*G[O^*GQ
M]^ ?[.&GZ-;?%_XH:#X3@U6X%CH46K7Z0?:I%V@11*3EB RYQTR,U^87[7/P
MW\4?\$O_ /@I5\)_VM?%?Q(F^,,GQ(U^]TZ2S\:Q22WV@1-<0JW]G,96"!$O
M=L0QA-I7&). 2/J7_@J?_P %:O ?[$/AO5/A%\-(+G7OB]>Z&]SI.DV^G/)!
MI$+1NPO[IBNPHBH\@C7<3Y?SA$):NN_X)H?M9?$;XX_\$U]!_:L^/VJ#5M;-
MCK=YK$]A810&:.SOKM%5(HPJ!O*A5> ,D9/)K0_X*3_"KX::=^QO\=_BY8^
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M>CPF.SMFLII+3_1U))6)O)#!225W;26(R0&>>_\ !4[_ (*%_%;]E[Q%\/\
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M@?N9/U1\0M7OO#_@'7->TN4)<V6CW-Q;N5#!9$B9E.#P>0.*_.[XK23>%_\
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MGP_'O_(II_XU_P"DR/E2BBBO$/R<**** "BBB@ HHHH **** "BBB@ HHHH
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M%FJ^!?"W@K6+>_TJ;1T6:=S%!<QLLAD(W&1KJ25WZE^>]?4-% [L^=?VV/\
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M#_32!CD")!7VA10%V5=#TN/0]%L]%BE,BV=K' KL,%@BA03^56J** "BBB@
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MH!XH"Y[S1110(**** ,[4K;Q-+=%]+U*VBBVC"2PECGOS4'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
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M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/
M]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+
M_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!N
MR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O
M&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V
M+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6
MQ10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_
M  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+
M_P !C_C6Q10!_-Y_P6K2]C_X*>_%5-0F2287^G;WC7 /_$KM.@^E?+5?UT45
MY<\MYYN7-N^W_!/S_%\"_6L74K_6+<\G*W)M=WM\1_(O17]=%%3_ &7_ '_P
M_P""<_\ Q#[_ *B?_)/_ +<_D7HK^NBBC^R_[_X?\$/^(??]1/\ Y)_]N?R+
MT5_7111_9?\ ?_#_ ((?\0^_ZB?_ "3_ .W/Y%Z*_KHHH_LO^_\ A_P0_P"(
M??\ 43_Y)_\ ;G\B]%?UT44?V7_?_#_@A_Q#[_J)_P#)/_MS^1>BOZZ**/[+
M_O\ X?\ !#_B'W_43_Y)_P#;G\B]%?UT44?V7_?_  _X(?\ $/O^HG_R3_[<
M_D7K]=O^#7N#79O#/QG_ +&OH(0+_0?,\Z+=GY+_ !C]:_7*BMJ& ]A54^:]
MO+_@GIY/P?\ V5F$,5[?FY;Z<MMTUOS/OV,?[%XW_P"@W9?^ Q_QH^Q>-_\
MH-V7_@,?\:V**] ^U,?[%XW_ .@W9?\ @,?\:_*?_@Z+@UV'P-\'#K%]!,#J
MVM>6(8MN/W5GG-?KA7Y.?\'4/_(B?!C_ +"^M_\ HJSH&MS\;J***"PHHHH
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M&>QA.7[CE7,K+=\]G??>*6Y]F?L^?\%X/A[^T5^VK8_L@^$_@)?Q0ZGXCO\
M3+#Q8WB*-XI8[=)W6X\@0@XD6'(7?QOZG'/WQ7X-?\$_O@K_ ,*6_P""A7['
MOVNT\J^\6?#F;Q)??+C?]JGU[R&_&U2WK]Y:O"5*E2#<][_HCIX:QV.Q^%J3
MQ3O)2[)63C%VT[7"BBBNL^C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^1?^"X?Q@^-'P2_
MX)Z>)O%OP/U:^TS4+C4[&PU/6=-=DGT^QFEV22(Z\QEF\N+>,$"8X(."(J35
M.#D^AS8S$QP6$G7DKJ*;LO(^I/#_ (\\$^*]9UCP[X8\6Z=J%_X?NTM==LK.
M\2273YVC618YE4DQL496 ;!(8'H:UJ_%S_@F3^QC9?%3XYZM\9?V(?VW=0TB
M_P#!OBK2Y;F75W:<^(]-ETZVFNEN+56C=LW33Q,'RH!QG<@8_4G_  5R\<:E
M\?OVG?@=_P $O=#U"6+3_B!KT.O?$*."0JT^CVTCN(./X6%M=2'T:"(^M80Q
M,G2YW'R6N_0\;#YY5J9=+$U*5G?EBE)-2;?*K/UWT\U<^_Z*_+#_ (+Y?%33
M+7]H/X#?LTS_ !MO_AOX9:*[U#Q7K>C2S)]AL))88(Y!% 09-B6]QL0 Y+8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.WXZ+4^?OBYI/_!0"X_;F\":I\(_$^CP? V+1D'CO3;F.T-W->[[O<T9>(S
M;3:?<=1\K<=<_!_[3G_!.7_@K;\8OV]]3_;'TGP[X%U%M+UN3_A ['Q%K,%U
M;:=81,ZV8^SR*4#JI$IR,><S/][FOUQHJ*F'C45FWO?<YL;DM#'QY:M2=N;F
MTEL[65M-$MTN[;/F#]A;4?\ @H_X3L/&_B+_ (*5:]X173+&QMKGP_<^'_(5
M8$C%PUX\IB4<!1"1GT;'>O%O^#?GP1K.N?#GXN?M@:WILEI_PMWXDW-YIR2K
MS):V\L[>8/4>?=7,?UB-?<7QE^%/AKXZ?"K7_@[XRN[^'2/$NF2:?JC:9=F"
M=K>0;9$60 E0RDJ?]EB.]2_";X5^!O@?\,]#^$7PTT---T'P[IL5CI=FASLB
M1< L3RS$Y9F/+,23DDT*DU.+O=*^^]V$,MG#%T9.;E&DI6<G>3E+35]DK_?Y
M'A7_  5K_9>^*W[8?[%>M_ WX+VEC/KU]JVGW%O'J-Z+>(I#<+(^7((!V@X]
M:^1_^"C?_!&W]I#]IOX>_ #_ (518Z"/$7@KX8V/A7QN;[55B2+[-#!Y1C;!
M\U1(]WTQQMQUX_4ZBBIAZ=5OFZ_H/'Y)@LQE-UK^\HIV?2+NK:;Z_<?#7Q+_
M ."=WQ<;_@J+\!_VB_AGI.F+\-_A=\.;7P[>/-J*I<Q>0FI1HJ0XRP"W,'(]
M_2ON6BBM(4XT[VZZG9A<%1P;FZ?VWS/ULEIY6044459UA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>!_\%)/VI_"'[(7[,5_\4/B/\"[KX@^&KN^BTG7M$A$)A6WN%=?,N!,K
M*82X2(@@Y:9!CFO?*H>*/"WAGQOX=O?"'C/P]9:MI.I6S6^H:;J5JD\%S$PP
MT<D;@JZD=0014S4G%I.S,,33JU</*%.7+)K1VO9^CW/Y\?CG8_LJ^'?'WB/]
MH#]@'XDWFA^,H?BWH\/PE\,>&;MVDGT^YTR*:5A"V98V2[;RL%MNYWAVGHOW
MI\3(]6TC_@X\^$FH>-XEBEU3X42_V>5.8UE^P:JKJI_WTF _WAZU])?LP_\
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MQL9MP4%-332M.Z7PNVC7=[VZ'Y+_ +67_!0?X=_\%1_VH3\!/B!^TA:_"O\
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MI<M;W<SJ0I !^T6]\/7Y!7[Z> 69_ NBN[$DZ3;$DGDGREK^??XK^!]<O_\
M@C=>_M4^-(]VN?%K]J-=2N+K'^OAAT[5ESD]?])DO?S^M?T#_#__ )$/1/\
ML$6W_HI: 9KT444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?@QJ/[//@?X*Z%I/@S6+>6'5]!L;3RXKY)%VR><P.^4LN%+,Q8@ 9P,5YO\
M\.B?^":O_1G?A#_P'D_^+KZ.HH \EUC]A+]D+7_@AI7[-VL_ +0;CP+H>IMJ
M.D^&9(G^S6MTQF)E4;L[B;B;O_RT-='\8/V;/@+\?_A[%\*?C1\*=&\2>'[?
M9]DT[5+0.+9D7:KQ-]^)PN5W(0V"1G!-=O10!YG^SO\ L<?LO_LFVEY:?L[?
M!/1/"QU':+^YL(&:XN57E5>>0M(R@\A2V 22!S7S[^PC^S1\5==_;G^-_P#P
M4%^/W@6]\/W_ (EU$>&_A]H^IJ%GBT.W$2?:F0$[/.6"WP.&!67/# G[.HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?,'_!3#]DWXU?M
M :5\//C'^S/J>DK\0_A'XP3Q!X=TO7W*V6JKA?-M78?<+[$PQ('##<FX.OT_
M7S!_P4C^(W[8?P+E^'/Q]_9PTG5O$?A#PQXD=OBQX'T#2X;F^U72Y!&%FA#(
M9,P[93MC9<F56;Y48J CY>_98_X**_#WX<?$+XB?"_\ X*&_LN:OX+/C/XX3
MW,VL:I80:MX<TK6#I^GQ?8I;L HLJB)90ZJP5)U9BJ@O7L__  4%U:3XP_\
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MP33\9>'/!7AC4=8U&;5=(:*PTNRDN)G"ZA S$)&"Q  ).!P!0'4Y?_@G@O\
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M)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\
M#=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P""
M:#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[
MOV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P3
M0?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IO
MA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1
M/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK
M_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU
M)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\
M#=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P""
M:#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[
MOV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P3
M0?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IO
MA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1
M/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK
M_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU
M)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\
M#=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P""
M:#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[
MOV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P3
M0?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IO
MA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1
M/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK
M_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU
M)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\
M#=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P""
M:#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[
MOV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P3
M0?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IO
MA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1
M/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK
M_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU
M)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\
M#=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P""
M:#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[
MOV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P3
M0?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IO
MA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1
M/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK
M_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU
M)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\
M#=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P""
M:#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[
MOV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P3
M0?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IO
MA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1
M/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK
M_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU
M)_\ $5W7_"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\
M#=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\ $5W7_"IOA7_T33P__P""
M:#_XBC_A4WPK_P"B:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*C@_;
MU_9 N4,D?QVT@ ,1^\29#Q[,@_.N^_X5-\*_^B:>'_\ P30?_$5XG^P5\//
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MC\'O#L_A?P7#.EI<:E<7T@N)S(WG3/O<Y/;/0=JZ2B@ HHHH **** "BBB@
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M7_!?#]B'Q%XH\&Z5_P %"OV?O-T_Q_\ "LQ7>KW.GC;-/IL$GFI= CK):O\
MO,_\\C)DGRU%?H[7DG[?>DZIKW["_P 9=$T/3;B]O;SX6:_#:6=I"TDL\K:=
M.JHB*"68D@  9).*!K<_-S_@ES\-?BG_ ,%9_P!MW4/^"E_[5FEV[^'_  *]
MK8>%]'B1OLCZG!&K1QQ*Q)\N N;EN>9IT/(W"OU^KX+_ .#=/P-XV^'W[!&I
M:%X^\':KH=\WQ&U&5;/6-/DMI3&;6S <)(H.TD$ XQP?2OO2@&?DG_P:L_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<A^T'\5O^%$?
M/QQ\</[!_M7_ (0WPAJ>N_V7]J\C[9]DM9+CR?,VOY>_R]N_:VW.=IQBORT_
MXBK?^K#O_,H?_>R@=FS]>J*_(7_B*M_ZL._\RA_][*/^(JW_ *L._P#,H?\
MWLH"S/UZHKD/V?/BM_PO?X!^!_CA_8/]E?\ "9>$-,UW^R_M7G_8_M=K'<>3
MYFU/,V>9MW[5W8SM&<5U] @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^,G[?-E\$R\&DQ>!["]N?[/X2WU&73F-U(NW[LAWW;L1@[D.?NB@#Z0\3_\
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M=[?? DW'B(6X +7GVT(K/C^,VZ6_7^$+ZT ?:A(4%F(  Y)K\_?@GX&\0_\
M!8/Q?XO^-WQL^(_B*P^#6C>(Y]%\"^ ?#^IO90ZHL(4M>WC)\TFX.I SD,S*
M&54P_P!]:M8+JNEW.EM*4%S;O$77JNY2,C\Z^,_^"&NL6_A_]F'Q%^SQKNRU
M\5?#OQYJ6G^(M+8XEB+2;ED*]=K,)4![F%O2@"GX^_X)U_$G]COQ)X>^,?\
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MPGT/X&_\$@/&OPH\-:UJVHV.C6VE16][KM]]INY0VN6CDR2X&\Y8@''0 =J
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M: "BBB@ HHHH _ET_P""@7_)^?QM_P"RN^)?_3I<UY%7KO\ P4"_Y/S^-O\
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MGJFN7A^(-G]J\&^'=*T">XU75(<!O,2V0;E7:0VYMH((P<\5\->)M>UCX<?
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M-!<=@HHHH&?U+?\ !/G_ ),(^"'_ &2#PU_Z:[:O7J\A_P""?/\ R81\$/\
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M@BN=7_@F>FM_LXZ3^SC\2_VF/%_B:RT'QI8Z]HNJ:E%";BTBM(1%#8KG</)
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MV=/#W[)GP \/_L^^%?$%[JEAX>6Y%O?Z@J+-+YUU+<'<$ 7AIB!@= *]$HH
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M"GQJ^/\ \,_V@M9\4ZA9W_PQN;V;3+"U2,PWAN4C5A*6!88\L8VD=37K%%%
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M[=_Q*T;X:F>5H/"-A%9K<VT4CL[PQ:@8S+$A+-]P+]XGJ2:ZKX-_\$S?V?\
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M$,MM!%$H2&+*HQ49R4'( Q7MU%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220945984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DEXCOM, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0857544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6340 Sequence Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">200-0200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DXCM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,515,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents incorporated by reference</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement relating to its 2024 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) are incorporated by reference in Part&#160;III, Items 10 through 14 of this Annual Report on Form 10-K, as specified in the responses to those item numbers, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001093557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220870272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796218698704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 566.3<span></span>
</td>
<td class="nump">$ 642.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities', window );">Short-term marketable securities</a></td>
<td class="nump">2,157.8<span></span>
</td>
<td class="nump">1,813.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">973.9<span></span>
</td>
<td class="nump">713.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">559.6<span></span>
</td>
<td class="nump">306.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">168.3<span></span>
</td>
<td class="nump">192.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,425.9<span></span>
</td>
<td class="nump">3,668.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">1,113.1<span></span>
</td>
<td class="nump">1,055.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">71.4<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">134.5<span></span>
</td>
<td class="nump">173.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">419.4<span></span>
</td>
<td class="nump">341.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,264.5<span></span>
</td>
<td class="nump">5,391.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,345.5<span></span>
</td>
<td class="nump">901.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">171.0<span></span>
</td>
<td class="nump">134.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Current portion of long-term senior convertible notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">772.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liabilities</a></td>
<td class="nump">21.1<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,556.0<span></span>
</td>
<td class="nump">1,839.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Long-term senior convertible notes</a></td>
<td class="nump">2,434.2<span></span>
</td>
<td class="nump">1,197.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">128.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,195.9<span></span>
</td>
<td class="nump">3,259.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 800.0 million shares authorized; 407.2 million and 385.4 million shares issued and outstanding, respectively, at December&#160;31, 2023; and 393.2 million and 386.3 million shares issued and outstanding, respectively, at December&#160;31, 2022</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">3,514.6<span></span>
</td>
<td class="nump">2,258.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(16.7)<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,021.4<span></span>
</td>
<td class="nump">479.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 21.8 million shares at December&#160;31, 2023 and 6.9 million shares at December&#160;31, 2022</a></td>
<td class="num">(2,451.1)<span></span>
</td>
<td class="num">(595.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,068.6<span></span>
</td>
<td class="nump">2,131.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 6,264.5<span></span>
</td>
<td class="nump">$ 5,391.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale And Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220862320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">407,200,000<span></span>
</td>
<td class="nump">393,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">385,400,000<span></span>
</td>
<td class="nump">386,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, at cost (in shares)</a></td>
<td class="nump">21,800,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220956640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 3,622.3<span></span>
</td>
<td class="nump">$ 2,909.8<span></span>
</td>
<td class="nump">$ 2,448.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,333.4<span></span>
</td>
<td class="nump">1,026.7<span></span>
</td>
<td class="nump">768.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,288.9<span></span>
</td>
<td class="nump">1,883.1<span></span>
</td>
<td class="nump">1,680.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">505.8<span></span>
</td>
<td class="nump">484.2<span></span>
</td>
<td class="nump">517.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_CollaborativeResearchAndDevelopmentFee', window );">Collaborative research and development fee</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">87.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,185.4<span></span>
</td>
<td class="nump">1,007.7<span></span>
</td>
<td class="nump">810.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,691.2<span></span>
</td>
<td class="nump">1,491.9<span></span>
</td>
<td class="nump">1,414.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">597.7<span></span>
</td>
<td class="nump">391.2<span></span>
</td>
<td class="nump">265.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">112.7<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">710.4<span></span>
</td>
<td class="nump">390.8<span></span>
</td>
<td class="nump">256.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">168.9<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">39.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 541.5<span></span>
</td>
<td class="nump">$ 341.2<span></span>
</td>
<td class="nump">$ 216.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share (in usd per share)</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net income per share (in shares)</a></td>
<td class="nump">386.0<span></span>
</td>
<td class="nump">389.4<span></span>
</td>
<td class="nump">386.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share (in usd per share)</a></td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net income per share (in shares)</a></td>
<td class="nump">425.5<span></span>
</td>
<td class="nump">427.5<span></span>
</td>
<td class="nump">428.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_CollaborativeResearchAndDevelopmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Research and Development Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_CollaborativeResearchAndDevelopmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220744736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 541.5<span></span>
</td>
<td class="nump">$ 341.2<span></span>
</td>
<td class="nump">$ 216.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Translation adjustments and other</a></td>
<td class="num">(9.2)<span></span>
</td>
<td class="num">(9.8)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable debt securities</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss, net of tax</a></td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(12.1)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 536.4<span></span>
</td>
<td class="nump">$ 329.1<span></span>
</td>
<td class="nump">$ 214.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796213306224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period ( in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 1,551.9<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 1,726.5<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="num">$ (78.2)<span></span>
</td>
<td class="num">$ (100.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for Employee Stock Purchase Plan</a></td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone', window );">Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt', window );">Tax benefit related to Senior Convertible Notes</a></td>
<td class="num">$ (2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of 2023 Notes (in shares)</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of 2023 Notes</a></td>
<td class="nump">$ 57.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SharesReceivedFromExerciseOfNoteHedge', window );">Benefit of note hedge upon conversions of 2023 Notes (in shares)</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue', window );">Benefit of note hedge upon conversions of 2023 Notes</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">113.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee', window );">Collaborative research and development fee</a></td>
<td class="nump">87.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">216.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">2,042.1<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">2,108.7<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">138.7<span></span>
</td>
<td class="num">(206.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for Employee Stock Purchase Plan</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone', window );">Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares)</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones', window );">Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt', window );">Tax benefit related to Senior Convertible Notes</a></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of 2023 Notes (in shares)</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of 2023 Notes</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SharesReceivedFromExerciseOfNoteHedge', window );">Benefit of note hedge upon conversions of 2023 Notes (in shares)</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue', window );">Benefit of note hedge upon conversions of 2023 Notes</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock</a></td>
<td class="num">(557.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(557.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">126.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones', window );">Capitalization of sales-based milestones</a></td>
<td class="nump">152.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">341.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (12.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">386.3<span></span>
</td>
<td class="nump">386.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 2,131.8<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">2,258.1<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
<td class="nump">479.9<span></span>
</td>
<td class="num">(595.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for Employee Stock Purchase Plan</a></td>
<td class="nump">$ 26.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone', window );">Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares)</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones', window );">Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs</a></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(323.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt', window );">Tax benefit related to Senior Convertible Notes</a></td>
<td class="num">$ (4.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of 2023 Notes (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of 2023 Notes</a></td>
<td class="num">$ (13.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SharesReceivedFromExerciseOfNoteHedge', window );">Benefit of note hedge upon conversions of 2023 Notes (in shares)</a></td>
<td class="num">(12.2)<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue', window );">Benefit of note hedge upon conversions of 2023 Notes</a></td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,496.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,490.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of treasury stock</a></td>
<td class="num">(689.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(689.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax', window );">Purchase of capped call transactions, net of tax</a></td>
<td class="num">(76.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">150.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">541.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (5.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">385.4<span></span>
</td>
<td class="nump">385.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2023</a></td>
<td class="nump">$ 2,068.6<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 3,514.6<span></span>
</td>
<td class="num">$ (16.7)<span></span>
</td>
<td class="nump">$ 1,021.4<span></span>
</td>
<td class="num">$ (2,451.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Capitalization Of Sales-based Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Collaborative Research And Development Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid-In Capital, Purchase Of Capped Call Transactions, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Tax Benefit from Equity Component of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_SharesReceivedFromBenefitOfNoteHedgeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Received From Benefit Of Note Hedge, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_SharesReceivedFromBenefitOfNoteHedgeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_SharesReceivedFromExerciseOfNoteHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Received From Exercise Of Note Hedge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_SharesReceivedFromExerciseOfNoteHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Achievement Of Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Achievement Of Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221818688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 541.5<span></span>
</td>
<td class="nump">$ 341.2<span></span>
</td>
<td class="nump">$ 216.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">186.0<span></span>
</td>
<td class="nump">155.9<span></span>
</td>
<td class="nump">102.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">150.8<span></span>
</td>
<td class="nump">126.5<span></span>
</td>
<td class="nump">113.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_CollaborativeResearchAndDevelopmentFee', window );">Collaborative research and development fee</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">87.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized (gain) loss on equity investment</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(55.0)<span></span>
</td>
<td class="num">(21.6)<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income and expenses</a></td>
<td class="num">(83.9)<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
<td class="nump">43.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(260.1)<span></span>
</td>
<td class="num">(199.9)<span></span>
</td>
<td class="num">(75.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(252.6)<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
<td class="num">(112.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="num">(131.6)<span></span>
</td>
<td class="num">(21.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">466.5<span></span>
</td>
<td class="nump">295.1<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and related expenses</a></td>
<td class="nump">37.2<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability', window );">Deferred revenue and other liabilities</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">748.5<span></span>
</td>
<td class="nump">669.5<span></span>
</td>
<td class="nump">442.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(3,200.4)<span></span>
</td>
<td class="num">(2,266.3)<span></span>
</td>
<td class="num">(2,473.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturity of marketable securities</a></td>
<td class="nump">2,947.4<span></span>
</td>
<td class="nump">2,127.8<span></span>
</td>
<td class="nump">2,666.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(236.6)<span></span>
</td>
<td class="num">(364.8)<span></span>
</td>
<td class="num">(389.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(30.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(17.6)<span></span>
</td>
<td class="num">(14.3)<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(507.2)<span></span>
</td>
<td class="num">(521.5)<span></span>
</td>
<td class="num">(216.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">20.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(688.7)<span></span>
</td>
<td class="num">(557.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="nump">1,230.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PaymentsForPurchasesOfCappedCallTransactions', window );">Purchases of capped call transactions</a></td>
<td class="num">(101.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payments for conversions of senior convertible notes</a></td>
<td class="num">(787.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(17.3)<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(318.6)<span></span>
</td>
<td class="num">(552.5)<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(75.8)<span></span>
</td>
<td class="num">(410.3)<span></span>
</td>
<td class="nump">235.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">643.3<span></span>
</td>
<td class="nump">1,053.6<span></span>
</td>
<td class="nump">818.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">567.5<span></span>
</td>
<td class="nump">643.3<span></span>
</td>
<td class="nump">1,053.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash, end of period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">566.3<span></span>
</td>
<td class="nump">642.3<span></span>
</td>
<td class="nump">1,052.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">567.5<span></span>
</td>
<td class="nump">643.3<span></span>
</td>
<td class="nump">1,053.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Shares issued for repurchase and conversions of senior convertible notes</a></td>
<td class="nump">1,501.9<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
<td class="nump">157.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge', window );">Shares received under note hedge upon conversion of 2023 Notes</a></td>
<td class="num">(1,490.3)<span></span>
</td>
<td class="num">(33.5)<span></span>
</td>
<td class="num">(130.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Acquisition of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">45.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the year for interest</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the year for income taxes</a></td>
<td class="nump">$ 212.3<span></span>
</td>
<td class="nump">$ 114.2<span></span>
</td>
<td class="nump">$ 16.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_CollaborativeResearchAndDevelopmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Research and Development Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_CollaborativeResearchAndDevelopmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Assets and Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PaymentsForPurchasesOfCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Purchases Of Capped Call Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PaymentsForPurchasesOfCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Value, Benefit Received From Note Hedge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796226322576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;border-bottom:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. Organization and Significant Accounting Policies</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DexCom, Inc. is a medical device company that develops and markets continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Unless the context requires otherwise, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;company,&#8221; or &#8220;Dexcom&#8221; refer to DexCom, Inc. and its subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of DexCom, Inc. and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. We have reclassified certain amounts previously reported in our financial statements to conform to the current presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash. For international subsidiaries whose functional currencies are the local currencies, we translate the financial statements into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. We include translation-related adjustments in comprehensive income and in accumulated other comprehensive loss in the equity section of our consolidated balance sheets. We record gains and losses resulting from transactions with customers and vendors that are denominated in currencies other than the functional currency and from certain intercompany transactions in other income (expense), net in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires us to make certain estimates and assumptions that affect the amounts reported in our consolidated financial statements and the disclosures made in the accompanying notes. Areas requiring significant estimates include rebates, excess or obsolete inventories and the valuation of inventory, accruals for litigation contingencies, and the amount of our worldwide tax provision and the realizability of deferred tax assets. Despite our intention to establish accurate estimates and use reasonable assumptions, actual results may differ from our estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Uses unadjusted quoted prices that are available in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Uses inputs other than quoted prices included in Level&#160;1 that are observable, either directly or indirectly, through correlation with market data. These include quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Uses unobservable inputs that are supported by little or no market activity and that are significant to the determination of fair value. Level 3 assets and liabilities include those whose fair values are determined using pricing models, discounted cash flow methodologies, or similar valuation techniques and significant judgment or estimation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of most of our cash equivalents using Level 1 inputs. We estimate the fair value of our marketable equity securities using Level 1 inputs and we estimate the fair value of our marketable debt securities using Level 2 inputs. We carry our marketable securities at fair value. We carry our other financial instruments, such as cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities, at cost, which approximates the related fair values due to the short-term maturities of these instruments. See Note 3 &#8220;Fair Value Measurements&#8221; to the consolidated financial statements for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments with a maturity of 90 days or less at the time of purchase to be cash equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have classified our marketable securities with remaining maturity at purchase of more than three months and remaining maturities of one year or less as short-term marketable securities. We have also classified marketable securities with remaining maturities of greater than one year as short-term marketable securities based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate realized gains or losses on our marketable securities using the specific identification method. We carry our marketable debt securities at fair value with unrealized gains and losses reported as a separate component of stockholders&#8217; equity in our consolidated balance sheets and included in comprehensive income. Interest income and realized gains and losses on marketable debt securities are included in other income (expense), net in our consolidated statements of operations. We carry our marketable equity securities at fair value with realized and unrealized gains and losses reported in income (loss) from equity investments in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in various types of debt securities, including debt securities in government-sponsored entities, corporate debt securities, U.S. Treasury securities, supranational securities, and commercial paper. We do not generally intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. See Note 3 &#8220;Fair Value Measurements&#8221; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-Term Marketable Securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 4 &#8220;Balance Sheet Details and Other Financial Information&#8221; to the consolidated financial statements for more information on our marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are generally recorded at the invoiced amount, net of prompt pay discounts, for distributors and at net realizable value for direct customers, which is determined using estimates of claim denials and historical reimbursement experience without regard to aging category. Accounts receivable are not interest bearing. We evaluate the creditworthiness of significant customers based on historical trends, the financial condition of our customers, and external market factors. We generally do not require collateral from our customers. We maintain an allowance for doubtful accounts for potential credit losses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a customer account is uncollectible.&#160;Generally, receivable balances that are more than one year past due are deemed uncollectible.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Significant Customers</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term marketable securities, and accounts receivable. We limit our exposure to credit risk by placing our cash and investments with a few major financial institutions. We have also established guidelines regarding diversification of our investments and their maturities that are designed to maintain principal and maximize liquidity. We review these guidelines periodically and modify them to take advantage of trends in yields and interest rates and changes in our operations and financial position.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the percentages of total revenue or gross accounts receivable for customers that represent 10% or more of the respective amounts for the periods shown:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer A</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer C</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer E</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Less than 10%</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">** Total revenue for each customer is net of fees, cash discounts, and rebates directly allocable to that customer. Rebates paid to other entities are excluded; therefore, the combined value may exceed 100%.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value on a part-by-part basis that approximates first in, first out. We capitalize inventory produced in preparation for commercial launches when it becomes probable that the product will receive regulatory approval and that the related costs will be recoverable through the commercialization of the product. A number of factors are considered, including the status of the regulatory application approval process, management&#8217;s judgment of probable future commercial use, and net realizable value. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record adjustments to inventory for potential excess or obsolete inventory, as well as inventory that does not pass quality control testing, in order to state inventory at net realizable value. Factors influencing these adjustments include inventories on hand and on order compared to estimated future usage and sales for existing and new products, as well as judgments regarding quality control testing data and assumptions about the likelihood of scrap and obsolescence. Once written down the adjustments are considered permanent and are not reversed until the related inventory is disposed of or sold.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products require customized products and components that currently are available from a limited number of sources. We purchase certain components and materials from single sources due to quality considerations, costs or constraints resulting from regulatory requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our inventory reserves have been adequate to cover our actual losses. However, if actual product life cycles, product quality or market conditions differ from our assumptions, additional inventory adjustments that would increase cost of sales could be required.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization. We capitalize additions and improvements and expense maintenance and repairs as incurred. We also capitalize certain costs incurred for the development of enterprise-level business and finance software that we use internally in our operations. Costs incurred in the application development phase are capitalized while costs related to planning and other preliminary project activities and to post-implementation activities are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate depreciation using the straight-line method over the estimated useful lives of the assets. Estimated useful lives are generally <span style="-sec-ix-hidden:f-509">three</span> to five years for computer software and hardware, including internal use software, <span style="-sec-ix-hidden:f-511">four</span> to fifteen years for machinery and equipment, and five years for furniture and fixtures. Leasehold and land improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Buildings are amortized over the shorter of the ownership of the building or forty years. We include the amortization of assets that are recorded under finance leases in depreciation expense. On retirement or disposition, the asset cost and related accumulated depreciation are removed from our consolidated balance sheets and any gain or loss is recognized in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the recoverability of the asset by comparing the carrying amount to the future undiscounted cash flows that we expect the asset to generate. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record goodwill when the fair value of consideration transferred in a business combination exceeds the fair value of the identifiable assets acquired and liabilities assumed. Goodwill and other intangible assets that have indefinite useful lives are not amortized, but are tested annually for impairment during the fourth fiscal quarter and whenever events or changes in circumstances indicate that it is more likely than not that the fair value is less than the carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business, and an adverse action or assessment by a regulator.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with Dexcom&#8217;s reporting structure and the availability of discrete financial information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform the first step of our annual impairment analysis by either comparing a reporting unit&#8217;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#8217;s fair value from the last quantitative assessment to determine if there is potential impairment. We may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#8217;s estimated fair value was significantly in excess of the carrying value of its net assets and we do not believe there have been significant changes in the reporting unit&#8217;s operations that would significantly decrease its estimated fair value or significantly increase its net assets.&#160;If a quantitative assessment is performed the evaluation includes management estimates of cash flow projections based on internal future projections&#160;and/or use of a market approach by looking at market values of comparable companies. Key assumptions&#160;for these projections include revenue growth, future gross margin and operating margin growth, and weighted cost of capital and terminal growth rates. The revenue and margin growth are based on increased sales of new and existing products as we maintain investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements&#160;to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including the timing and probability of regulatory approvals for our products to be commercialized. We also consider Dexcom&#8217;s market capitalization as a part of our analysis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the estimated fair value of a reporting unit exceeds the carrying amount of the net assets assigned to that unit, goodwill is not impaired and no further analysis is required. If the carrying value of the net assets assigned to a reporting unit exceeds the estimated fair value of the unit, we perform the second step of the impairment test. In this step we allocate the fair value of the reporting unit calculated in step one to all of the assets and liabilities of that unit, as if we had just acquired the reporting unit in a business combination. The excess of the fair value of the reporting unit over the total amount allocated to the assets and liabilities represents the implied fair value of goodwill. If the carrying amount of a reporting unit&#8217;s goodwill exceeds its implied fair value, we would record an impairment loss equal to the difference. We recorded no significant goodwill impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in goodwill for the twelve months ended December&#160;31, 2023 and 2022 primarily consisted of translation adjustments on our foreign currency denominated goodwill. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are included in intangibles and other assets, net in our consolidated balance sheets. We amortize intangible assets with a finite life, such as the customer relationships, acquired technology and intellectual property, trademarks and trade name, and other intangibles, on a straight-line basis over their estimated useful lives, which range from <span style="-sec-ix-hidden:f-519">one</span> to seven years. We review intangible assets that have finite lives and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For transactions other than a business combination, we also capitalize as intangible assets the cost of certain milestones payable by us to collaborative partners and incurred at or after the product has obtained regulatory approval for marketing. The intangible assets associated with these milestones are amortized over the remaining estimated useful life of the underlying asset.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded no significant intangible asset impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. The effect of a change in tax rate on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under tax law and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal and state income tax returns in the United States and income tax returns in various other foreign jurisdictions with varying statutes of limitations. Due to net operating losses incurred, our income tax returns from inception to date are subject to examination by taxing authorities. We recognize interest expense and penalties related to income tax matters, including unrecognized tax benefits, as a component of income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income tax expense for basis differences related to global intangible low-taxed income ("GILTI") as a period cost if and when incurred. GILTI is a category of income that is earned abroad by U.S.-controlled foreign corporations (CFCs) and is subject to special treatment under the U.S. tax code.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Warranty Accrual</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated warranty costs associated with a product are recorded at the time revenue is recognized. We estimate future warranty costs by analyzing historical warranty experience for the timing and amount of returned product, and expectations for future warranty activity based on changes and improvements to the product or process that are in place or will be in place in the future. We evaluate these estimates on at least a quarterly basis to determine the continued appropriateness of our assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. We review the status of each significant matter quarterly and assess our potential financial exposure. If the potential loss from a claim or legal proceeding is considered probable and the amount can be reasonably estimated, we record a liability and an expense for the estimated loss and disclose it in our financial statements if it is significant. If we determine that a loss is possible and the range of the loss can be reasonably determined, we do not record a liability or an expense but we disclose the range of the possible loss. We base our judgments on the best information available at the time. As additional information becomes available, we reassess the potential liability related to our pending claims and litigation and may revise our estimates. Any revision of our estimates of potential liability could have a material impact on our financial position and operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income consists of two elements, net income and other comprehensive loss. We report all components of comprehensive income, including net income, in our financial statements in the period in which they are recognized. Total comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net income and the components of other comprehensive loss, including foreign currency translation adjustments and unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive income.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate our revenue from the sale of disposable sensors and our reusable transmitter and receiver, collectively referred to as Reusable Hardware. We also refer to Reusable Hardware and disposable sensors in this section as Components. We generally recognize revenue when control is transferred to our customers in an amount that reflects the net consideration to which we expect to be entitled.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining how revenue should be recognized, a five-step process is used, which includes identifying performance obligations in the contract, determining whether the performance obligations are separate, allocating the transaction price to each separate performance obligation, estimating the amount of variable consideration to include in the transaction price and determining the timing of revenue recognition for separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contracts and Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider customer purchase orders, which in most cases are governed by agreements with distributors or third-party payors, to be contracts with a customer. For each contract, we consider the obligation to transfer Components to the customer, each of which are distinct, to be separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Price</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for the Components reflects the net consideration to which we expect to be entitled. Transaction price is typically based on the contracted rates less an estimate of claim denials and historical reimbursement experience by payor, which include current and future expectations regarding reimbursement rates and payor mix. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include an estimate of variable consideration in the calculation of the transaction price at the time of sale, when control of the Components transfers to the customer. Variable consideration includes, but is not limited to: rebates, chargebacks, consideration payable to customers such as specialty distributor and wholesaler fees, product returns provision, prompt payment discounts, and various other promotional or incentive arrangements.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our provisions related to variable consideration as a reduction of accounts receivable when we are not required to make a payment or as a liability when we are required to make a payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the adequacy of our estimates for transaction price adjustments and variable consideration at each reporting date. If the actual amounts of consideration we receive differ from our estimates, we would adjust our estimates and that would affect reported revenue in the period that such variances become known. If any of these judgments were to change, it could cause a material increase or decrease in the amount of revenue we report in a particular period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to rebates on pricing programs with managed care organizations, such as pharmacy benefit managers, governmental and third-party commercial payors, primarily in the U.S. We estimate provisions for rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or trends and channel inventory data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in chargeback programs, primarily with government entities in the U.S., under which pricing on products below negotiated list prices is provided to participating entities and equal to the difference between their acquisition cost and the lower negotiated price. We estimate provisions for chargebacks primarily based on historical experience on a product and program basis, current contract prices under the chargeback programs and channel inventory data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration Payable to the Customer</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay administrative and service fees to certain of our distributors based on a fixed percentage of the product price. These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price. We accrue for these fees based on actual net sales and contractual fee rates negotiated with the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of their distribution agreements, most distributors do not have rights of return. The distributors typically have a limited time frame to notify us of any missing, damaged, defective or non-conforming products. We generally provide a &#8220;30-day money back guarantee&#8221; program whereby first-time end-user customers may return Reusable Hardware. We estimate our product returns provision principally based on historical experience by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Additionally, we consider other specific factors such as estimated shelf life of inventory in the distribution channel and changes to customer terms.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Payment Discounts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. We estimate prompt payment discount accruals based on actual net sales and contractual discount rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Various Other Promotional or Incentive Arrangements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other promotional or incentive arrangements are periodically offered to customers, including but not limited to co-payment assistance we provide to patients with commercial insurance, promotional programs related to the launch of products or other targeted promotions. We record a provision for the incentive earned based on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenue from sales of Components upon transfer of control of the product to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where our free-of-charge software, mobile applications and updates are deemed to be separate performance obligations, revenue is recognized over time on a ratable basis over the estimated life of the related Reusable Hardware component.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales of Components include an assurance-type warranty.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable and deferred revenue. Payment terms vary by contract type and type of customer and generally range from 30 to 90 days.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December&#160;31, 2023 included unbilled accounts receivable of $8.0 million. We expect to invoice and collect all unbilled accounts receivable within twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record deferred revenue when we have entered into a contract with a customer and cash payments are received or due prior to transfer of control or satisfaction of the related performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations are generally satisfied within twelve months of the initial contract date. The deferred revenue balances related to performance obligations that will be satisfied after twelve months was $7.4 million as of December&#160;31, 2023 and $19.0 million as of December&#160;31, 2022. These balances are included in other long-term liabilities in our consolidated balance sheets. Revenue recognized in the period from performance obligations satisfied in previous periods was not material for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Cost of Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred cost of sales are associated with transactions for which revenue recognition criteria are not met but product has shipped and released from inventory. Deferred cost of sales are included in prepaid and other current assets in our consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Compensation Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expense incentive compensation associated with our internal sales force when incurred because the amortization period for such costs, if capitalized, would have been <span style="-sec-ix-hidden:f-535">one</span> year or less. We record these costs in selling, general and administrative expense in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Product Shipment Costs</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the amounts we charge our customers for the shipping and handling of our products in revenue and we record the related costs as cost of sales in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We expense costs of research and development as we incur them. Our research and development expenses primarily consists of engineering and research expenses related to our sensing technology, clinical trials, regulatory expenses, quality assurance programs, employee compensation, and business process outsourcers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology includes certain software that we develop. We expense software development costs as we incur them until technological feasibility has been established, at which time we capitalize development costs until the product is available for general release to customers. To date, our software has been available for general release concurrent with the establishment of technological feasibility and, accordingly, we have not capitalized any development costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into agreements with collaboration partners for the development and commercialization of our products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we account for these agreements, we consider the unique nature, terms and facts and circumstances of each transaction. Below are some example activities and how we account for them:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Payments to collaboration partners through issuance of common stock as consideration in an asset acquisition are considered share-based payment to non-employees in exchange for goods within the scope of ASC Topic 718, &#8220;Compensation - Stock Compensation.&#8221; The amount and the timing of the cost recognition of such milestones in our financial statements is driven by the accounting for the specific type of equity instrument under ASC 718 that aligns with the terms of the agreement, including any performance conditions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The value associated with in-process research and development (&#8220;IPR&amp;D&#8221;) in an asset acquisition incurred prior to regulatory approval is expensed as it does not have an alternative future use and is recorded as research and development expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The value associated with IPR&amp;D in an asset acquisition incurred at or after regulatory approval is usually capitalized as an intangible asset and amortized over the periods in which the related products are expected to contribute to future cash flows.</span></div><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense costs to produce advertising as we incur them whereas costs to communicate advertising are expensed when the advertising is first run. Advertising costs are included in selling, general and administrative expenses. Advertising expense was $180.8 million, $160.6 million and $150.1 million for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Lease right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Lease right-of-use assets and liabilities with terms of more than 12 months are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to determine the present value is our collateralized incremental borrowing rate unless the interest rate implicit in the lease is readily determinable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, lease expense is recognized on a straight-line basis within operating expenses over the lease term. For finance leases, lease expense is recognized as interest and depreciation; interest using the effective interest method and depreciation on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. Short-term leases with lease terms of 12 months or less are not recorded on the balance sheet and are recognized on a straight line basis over the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and lease liabilities are presented separately in our consolidated balance sheets. Finance lease right-of-use assets are included in property and equipment and finance lease liabilities are included in accounts payable and accrued liabilities and in other long-term liabilities in our consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lease agreements may contain lease components and non-lease components. For certain asset classes, we have elected to account for both of those components as a single lease component. We use a portfolio approach to account for the right-of-use assets and liabilities associated with certain machinery and equipment leases. Variable lease payments may include payments associated with non-lease components, payments that do not depend on a rate or index, or other costs. Variable lease payments are recognized in the period in which the obligation for those payments are incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value time-based restricted stock units or RSUs at the date of grant using the intrinsic value method. Certain RSUs granted to senior management vest based on the achievement of pre-established performance or market goals. We estimate the fair value of these performance/market-based RSUs, or PSUs, at the date of grant using the intrinsic value method and the probability that the specified performance criteria will be met. We update our assessment of the probability that the specified performance criteria will be achieved each quarter and adjust our estimate of the fair value of the PSUs if necessary. The Monte Carlo methodology that we use to estimate the fair value of PSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the PSUs at the date of grant must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the assumptions used change significantly, share-based compensation expense may differ materially from what we have recorded in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for forfeitures as they occur by reversing any share-based compensation expense related to awards that will not vest.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to common stockholders is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the period and, when dilutive, potential common share equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares consist of shares issuable from RSUs, PSUs, warrants, our senior convertible notes, and collaborative sales-based milestones. Potentially dilutive common shares issuable upon vesting of RSUs, PSUs, and exercise of warrants are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our senior convertible notes are determined using the if-converted method. In periods of net losses, we exclude all potentially dilutive common shares from the computation of the diluted net loss per share for those periods as the effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per share for the periods shown:</span></div><div style="margin-bottom:10pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">341.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income - diluted</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">554.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">352.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per common share</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.30&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.82&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.53&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">389.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborative sales-based milestones</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units and performance stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior convertible notes</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding anti-dilutive securities not included in the diluted net income per share attributable to common stockholders calculations were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units and performance stock units</span></div></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08,</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This guidance is intended improve the accounting for acquired revenue contracts with customers in a business combination. The new guidance requires that the acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The amendments should be applied prospectively to business combinations occurring on or after the adoption date. We adopted ASU 2021-08 in the first quarter of 2023 and there was no impact to our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity&#8217;s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. The ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The ASU should be applied on a prospective basis although retrospective application is permitted. We are currently evaluating the impact of this standard on our consolidated financial disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796226303648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Development and Other Agreements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. Development and Other Agreements</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Verily Life Sciences</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2018, we entered into an Amended and Restated Collaboration and License Agreement with Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited (collectively, &#8220;Verily&#8221;), which we refer to as the Restated Collaboration Agreement. This replaced our original Collaboration and License Agreement with Verily dated August 10, 2015, as amended in October 2016, including the royalty obligations provisions under that original agreement. Pursuant to the Restated Collaboration Agreement, we and Verily have agreed to continue to jointly develop a certain next-generation CGM product, and potentially one or more additional CGM products, for which we will have exclusive commercialization rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Collaboration Agreement also provides us with an exclusive license to use intellectual property of Verily resulting from the collaboration, and certain Verily patents, in the development, manufacture and commercialization of blood-based or interstitial glucose monitoring products more generally (subject to certain exclusions, which are outside of the CGM field as it is commonly understood). It also provides us with non-exclusive license rights under Verily&#8217;s other intellectual property rights to develop, manufacture and commercialize those kinds of glucose monitoring products and certain CGM-product companion software functionalities. The Restated Collaboration Agreement requires us to use commercially reasonable efforts to develop, launch and commercialize the CGM product(s) that are the subject of the collaboration according to certain timing and other objectives, and provides for one executive sponsor from each of Dexcom and Verily to meet periodically and make decisions related to the collaboration (within a limited scope of authority) by consensus.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of Verily&#8217;s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we made upfront, incentive, and the product regulatory approval payments, and will make potential payments for contingent sales-based milestones upon the achievement of certain revenue targets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the contingent milestones payable in shares of our common stock as equity instruments within the scope of ASC Topic 718. The product regulatory approval and sales-based milestones are accounted for as performance-based awards that vest when the performance conditions have been achieved and are recognized when the achievement of the respective contingent milestone is deemed probable. The value of the contingent milestones is based on our closing stock price on December 28, 2018, which was $29.57 per share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront and Incentive payments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the fourth quarter of 2018, we made an initial payment for an upfront fee of $250.0 million through the issuance of 7.4 million shares of our common stock. We recorded a $217.7 million charge in our consolidated statements of operations during 2018 relating to the issuance of this common stock because this milestone payment did not meet the capitalization criteria. The value of the charge was based on our closing stock price of $29.57 per share on December 28, 2018, the date on which we obtained the necessary regulatory approvals and represents the date the performance- based awards were issued. In 2019, we made a cash incentive payment of $3.2 million due to the completion of certain development obligations and we recorded these payments as research and development expense in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent milestones</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we determined the achievement of the regulatory approval milestone to be probable and recorded an $87.1 million research and development charge in our consolidated statements of operations. This charge is associated with IPR&amp;D obtained in an asset acquisition prior to regulatory approval and therefore does not have an alternative future use.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we received regulatory approval and issued 2.9 million shares of our common stock in connection with our achievement of the related milestone.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we received FDA approval and determined the achievement of the sales-based milestones to be probable. As such, we capitalized the full value of the sales-based milestones, $152.4 million, as an intangible asset. The sales-based milestones are contingent upon the achievement of certain revenue targets. The value of the sales-based milestones is based on: 1) 5.2 million shares of our common stock, as agreed upon in November 2018 and 2) our closing stock price on December 28, 2018 of $29.57 per share. December 28, 2018 is the date on which we obtained the necessary regulatory approvals and represents the date the performance- based awards were issued. The intangible asset will be amortized using the straight-line method over its estimated useful life of 64 months through March 2028. The related amortization expense is recognized in cost of sales in our consolidated statements of operations and disclosed in Note 4 &#8220;Intangibles, Net&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we issued 3.7 million shares of our common stock in connection with our achievement of the first sales-based milestone. See the effective tax rate reconciliation in Note 8 &#8220;Income Taxes&#8221; to the consolidated financial statements for more information on the tax benefits related to the collaboration agreement milestone share-based payments for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All milestones may be paid in cash or shares of our common stock, at our election. If we elect to make these milestone payments in cash, any such cash payment would be equal to the number of shares that would otherwise be issued for the given milestone payment multiplied by the value of our stock on the date the relevant milestone is achieved, and adjusted to give effect to any stock splits, dividends, or similar events. We intend to pay the remaining sales-based contingent milestone in shares of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon achievement of the first sales-based milestone event and payment of the corresponding milestone fee by us in December 2023, the term of the Restated Collaboration Agreement was extended from December 31, 2028 to December 31, 2033.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796225700944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. Fair Value Measurements</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our Level 1 financial instruments, which are in active markets, using unadjusted quoted market prices for identical instruments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain the fair values for our Level 2 financial instruments, which are not in active markets, from a primary professional pricing source that uses quoted market prices for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Fair values obtained from this professional pricing source can also be based on pricing models whereby all significant observable inputs, including maturity dates, issue dates, settlement dates, benchmark yields, reported trades, broker-dealer quotes, issue spreads, benchmark securities, bids, offers or other market related data, are observable or can be derived from, or corroborated by, observable market data for substantially the full term of the asset. We validate the quoted market prices provided by our primary pricing service by comparing the fair values of our Level 2 marketable securities portfolio balance provided by our primary pricing service against the fair values provided by our investment managers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2023, classified in accordance with the fair value hierarchy:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,612.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,612.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">331.1&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,488.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2022, classified in accordance with the fair value hierarchy:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">420.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,530.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,530.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,813.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,813.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386.1&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,858.7&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,244.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes assets which are held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 securities during the twelve months ended December&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Senior Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value, based on trading prices (Level 1 inputs), of our senior convertible notes were as follows as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements Using Level 1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,136.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,262.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,314.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,281.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of outstanding senior convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,544.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,451.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on the carrying values of our senior convertible notes, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Convertible Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 5 &#8220;Debt&#8221; to the consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency and Derivative Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency forward contracts to hedge monetary assets and liabilities denominated in foreign currencies. Our foreign currency forward contracts are not designated as hedging instruments. Therefore, changes in the fair values of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The duration of these contracts is generally one month. The derivative gains and losses are included in other income (expense), net in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2023 and December&#160;31, 2022, the notional amounts of outstanding foreign currency forward contracts were $71.0 million and $62.0 million, respectively. The resulting impact on our consolidated financial statements from currency hedging activities was not significant for the twelve months ended December&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency exposures vary but are primarily concentrated in the Australian Dollar, the British Pound, the Canadian Dollar, the Euro, and the Malaysian Ringgit. We monitor the costs and the impact of foreign currency risks upon our financial results as part of our risk management program. We do not use derivative financial instruments for speculation or trading purposes or for activities other than risk management. We do not require and are not required to pledge collateral for these financial instruments and we do not carry any master netting arrangements to mitigate the credit risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, we measure certain non-financial assets and liabilities at fair value on a non-recurring basis. These measurements are usually performed using the discounted cash flow method or cost method and Level 3 inputs. These include items such as non-financial assets and liabilities initially measured at fair value in a business combination and non-financial long-lived assets measured at fair value for an impairment assessment. In general, non-financial assets, including goodwill, intangible assets, and property and equipment, are measured at fair value when there are indicators of impairment and are recorded at fair value only when an impairment is recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold certain other investments that we do not measure at fair value on a recurring basis. The carrying values of these investments are $38.5&#160;million as of December&#160;31, 2023 and $19.0 million as of December&#160;31, 2022. We include them in other assets in our consolidated balance sheets. It is impracticable for us to estimate the fair value of these investments on a recurring basis due to the fact that these entities are privately held and limited information is available. We monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant effect on the fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant impairment losses during the twelve months ended December&#160;31, 2023. During the fourth quarter 2022, we vacated a leased building and made it available for sublease, resulting in an impairment of its asset group which consisted primarily of leasehold improvements and right-of-use asset. We recorded $23.0&#160;million in impairment losses during the twelve months ended December&#160;31, 2022. See Note 6 &#8220;Leases and Other Commitments&#8221; to the consolidated financial statements for more information. There were no significant impairment losses during the twelve months ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222269216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Balance Sheet Details and Other Financial Information</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. Balance Sheet Details and Other Financial Information</span></div></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #58a618;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Marketable Securities</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term marketable securities, consisting of available-for-sale debt securities, were as follows as of the dates indicated:</span></div><div style="margin-bottom:7pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></div></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,611.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,612.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.4&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:7pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,535.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,530.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,819.0&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.3)</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,813.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the estimated market value of our short-term debt securities with contractual maturities up to 12 months was $2.16&#160;billion. As of December 31, 2022, the estimated market value of our short-term debt securities with contractual maturities up to 12 months was $1.81&#160;billion. Gross realized gains and losses on sales of our short-term debt securities for the twelve months ended December&#160;31, 2023, 2022 and 2021 were not significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review our portfolio of debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For debt securities where the fair value of the investment is less than the amortized cost basis, we have assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities at December&#160;31, 2023 were primarily due to increases in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, we have not recorded an allowance for credit losses. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended December&#160;31, 2023, 2022 and 2021, we had no unrealized gains or losses recognized during the reporting period on equity investments. Realized gains from the sale of an equity investment were not significant for the twelve months ended December&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">983.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">720.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: allowance for doubtful accounts</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts receivable, net</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">973.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">713.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserve for prompt payment cash discounts recorded against accounts receivable, excluding allowance for doubtful accounts, was $13.7&#160;million, $8.3&#160;million, $13.7&#160;million as of December&#160;31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">319.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended December&#160;31, 2023, 2022 and 2021, we recorded excess and obsolete inventory charges of $16.6 million, $13.9 million and $28.1 million respectively, in cost of sales as a result of our ongoing assessment of sales demand, inventory on hand for each product and the continuous improvement and innovation of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation plan assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land and land improvements</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">190.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software and hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">683.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">449.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">264.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">328.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,622.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,418.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(509.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(363.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,113.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,055.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment for the twelve months ended December&#160;31, 2023, 2022 and 2021 was $147.4 million, $144.1 million and $96.3 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on disposal of property and equipment during the twelve months ended December&#160;31, 2023, 2022 and 2021 recorded in operating expenses was $0.7 million, $2.2 million and $24.5 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;Intangibles, Net</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of gross intangible assets, accumulated amortization, and net intangible asset balances as of December&#160;31, 2023 and December&#160;31, 2022</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verily intangible asset</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31.0)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired technology and intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.6)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, other</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Useful Life<br/>(in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verily intangible</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired technology and intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.6)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, other</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 2 &#8220;Development and Other Agreements&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Excludes Verily intangible asset.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total amortization expense of finite-lived intangible assets for the twelve months ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense included in cost of sales</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense included in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents estimated future amortization of the Company&#8217;s finite-lived intangible assets as of December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term investments</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable and Accrued Liabilities</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable trade</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">276.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued tax, audit, and legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued rebates </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax payable</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation plan liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,345.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">901.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accrued Payroll and Related Expenses</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued wages, bonus and taxes</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued payroll and related expenses</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171.0&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accrued Warranty</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty costs are reflected in our statements of operations as cost of sales. Reconciliations of our accrued warranty costs for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51.7)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43.1)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40.3)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Long-Term Liabilities</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease obligations</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset retirement obligation</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income</span></div></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity investments</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.8)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221966544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. Debt</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Senior Convertible Notes</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of our senior convertible notes were as follows as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amount:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">774.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,207.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,207.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total principal amount</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,457.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,982.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount of senior convertible notes</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,434.2&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,970.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our senior convertible notes for which the if-converted value exceeded the principal amount, the amount in excess of principal was as follows as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,361.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total by which the notes&#8217; if-converted value exceeds their principal amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,395.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our senior convertible notes for the periods shown:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash interest expense:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon interest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense recognized on senior notes</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective interest rate:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest on the 2023 Notes began accruing upon issuance and is payable semi-annually on June 1 and December 1 of each year. Interest on the 2025 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year. Interest on the 2028 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effective interest rate presented represents the rate applicable for the period outstanding. The Senior Convertible Notes due 2023 matured on December 1, 2023 and all outstanding principal was settled as described below.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Not applicable as no notes were outstanding at this date.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt Summary</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key details for our unsecured senior convertible notes due 2023 (the &#8220;2023 Notes&#8221;), unsecured senior convertible notes due 2025 (the &#8220;2025 Notes&#8221;), and unsecured senior convertible notes due 2028 (the &#8220;2028 Notes&#8221;):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Senior Convertible Notes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Offering Completion Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stated Interest Rate</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Principal Amount</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Proceeds</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Initial Conversion Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(per $1,000 principal amount)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Conversion Price</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(per share)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Settlement Methods</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November 2018</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;1, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.75%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$850.0 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$836.6 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.3476&#160;shares </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$41.07</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and/or shares</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November&#160;15, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.25%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.21 billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.19 billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6620 shares </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$150.11</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and/or shares</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028 Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May&#160;15, 2028</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.375%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.25&#160;billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.23&#160;billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.1571 shares</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$162.41</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and/or shares</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Net proceeds is calculated by deducting the aggregate principal amount from the initial purchasers&#8217; discounts and estimated costs directly related to the offering.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Subject to adjustments as defined in the indentures.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The senior convertible notes may be settled in cash, stock, or a combination thereof, solely at our discretion. </span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the if-converted method for assumed conversion of our senior convertible notes to compute the weighted average shares of common stock outstanding for diluted earnings per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No principal payments are due on the senior convertible notes prior to maturity. Other than restrictions relating to certain fundamental changes and consolidations, mergers or asset sales and customary anti-dilution adjustments, the indenture relating to our senior convertible notes include customary terms and covenants, including certain events of default after which the senior convertible notes may be due and payable immediately.</span></div><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Note Hedge</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the 2023 Notes, in November 2018 we entered into convertible note hedge transactions with two of the initial purchasers of the 2023 Notes (the &#8220;2023 Counterparties&#8221;) entitling us to purchase up to&#160;20.7 million&#160;shares of our common stock at an initial price of&#160;$41.07&#160;per share, each of which is subject to adjustment. The cost of the 2023 Note Hedge was&#160;$218.9 million and we accounted for it as an equity instrument by recognizing $218.9 million in&#160;additional paid-in capital&#160;during 2018. The 2023 Note Hedge expired on December&#160;1, 2023. The 2023 Note Hedge is expected to reduce the potential equity dilution upon any conversion of the 2023 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2023 Notes if the daily volume-weighted average price per share of our common stock exceeds the strike price of the 2023 Note Hedge.&#160;The strike price of the 2023 Note Hedge initially corresponds to the conversion price of the 2023 Notes and is subject to certain adjustments under the terms of the 2023 Note Hedge. An assumed exercise of the 2023 Note Hedge by us is considered anti-dilutive since the effect of the inclusion would always be anti-dilutive with respect to the calculation of diluted earnings per share. See below for a description of conversion activity related to the 2023 Notes and shares received as the result of exercising the remaining portion of the 2023 Note Hedge.</span></div><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we also sold warrants to the 2023 Counterparties to acquire up to&#160;20.7 million shares of our common stock. The 2023 Warrants require net share settlement and a pro rated number of warrants will expire on each of the 60 scheduled trading days starting on March&#160;1, 2024. We received&#160;$183.8 million&#160;in cash proceeds from the sale of the 2023 Warrants, which we recorded in&#160;additional paid-in capital during 2018. The 2023 Warrants could have a dilutive effect on our earnings per share to the extent that the price of our common stock during a given measurement period exceeds the strike price of the 2023 Warrants. The strike price of the 2023 Warrants is initially $49.60 per share and is subject to certain adjustments under the terms of the warrant agreements. We use the treasury share method for assumed conversion of the 2023 Warrants when computing the weighted average common shares outstanding for diluted earnings per share.</span></div><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 Capped Call Transactions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, in connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions (the &#8220;2028 Capped Calls&#8221;) with certain financial institutions. The 2028 Capped Calls will cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2028 Notes, the number of shares of our common stock that will initially underlie the 2028 Notes. The 2028 Capped Calls are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes and/or offset any cash payments that we are required to make in excess of the principal amount of converted 2028 Notes, as the case may be, with such reduction and/or offset subject to a cap. The 2028 Capped Calls have an initial cap price of $212.62 per share, subject to adjustments, which represents a premium of 80% over the closing price of our common stock of $118.12 per share on the Nasdaq Global Select Market on May&#160;2, 2023. The cost to purchase the 2028 Capped Calls of $101.3 million was recorded as a reduction to additional paid-in capital in our consolidated balance sheets as the 2028 Capped Calls met the criteria for classification in stockholders&#8217; equity.</span></div><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion Activity for Senior Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2023 Notes, Circumstance 1 as listed below occurred during the quarters ended December&#160;31, 2022, March&#160;31, 2023, and June&#160;30, 2023. As a result, the 2023 Notes were convertible at the option of the holders from January&#160;1, 2023 through August 31, 2023. Circumstance 5 was applicable to the 2023 Notes beginning September 1, 2023. The 2023 Notes matured on December 1, 2023 and were completely settled. See the following table for the details on the conversion activity:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Period</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Converted Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Principal Amount Converted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Issued for Settlement</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Received from Exercise of 2023 Note Hedge</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/1/2022 - 12/31/2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 Notes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.5 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3 million</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/1/2023 - 12/31/2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 Notes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$774.8&#160;million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 million</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion Rights for Senior Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our senior convertible notes have the right to require us to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the notes). We will also be required to increase the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or following the delivery by Dexcom of a notice of redemption.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the conversion options related for each of our senior convertible notes:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:16.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Conversions Rights at the Option of the Holders for the 2023, 2025, and 2028 Notes (&#8220;Notes&#8221;)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion Rights at the Option of the Holders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes have the ability to convert all or a portion of their notes in multiples of $1,000 principal amount, at their option prior to 5:00 p.m., New York City time, on the business day immediately preceding September&#160;1, 2023, August&#160;15, 2025, and February&#160;15, 2028 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively, only under the following circumstances:</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During any calendar quarter commencing after the applicable period (and only during such calendar quarter), if the last reported sale price of Dexcom&#8217;s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable conversion price for the Notes on each applicable trading day</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each trading day of that five consecutive trading day period was less than 98% of the product of the last reported sale price of Dexcom&#8217;s common stock and the applicable conversion rate of the Notes on each such trading day</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we call any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date (only with respect to the notes called or deemed called for redemption)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 4</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of specified corporate events</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Circumstance 5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2023 Notes and 2028 Notes, until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding the maturity date (for the 2025 Notes, it is until the business day immediately preceding the maturity date), holders of the Notes may convert all or a portion of their notes regardless of the foregoing circumstances</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Circumstance 1 is available after the calendar quarter ending March&#160;31, 2019, September&#160;30, 2020, and September&#160;30, 2023 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively.</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Circumstance 5 is available on or after September&#160;1, 2023, August&#160;15, 2025, and February&#160;15, 2028 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Conversion Right at Option of the Company for the 2023, 2025, and 2028 Notes</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conversion Right at Our Option</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dexcom may redeem for cash all or part of the Notes, at its option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Dexcom provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Dexcom does not have the right to redeem the Notes prior to December&#160;1, 2021, May&#160;20, 2023, and May&#160;20, 2026 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively. Dexcom has the right to redeem the notes on or after December&#160;1, 2021 and prior to September&#160;1, 2023 for the 2023 Notes, on or after May&#160;20, 2023 and prior to August&#160;15, 2025 for the 2025 Notes, and on or after May&#160;20, 2026 and prior to February&#160;15, 2028 for the 2028 Notes.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Agreement</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Terms of the Revolving Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into the First Amendment to the Second Amended and Restated Credit Agreement (the "Amended Credit Agreement"), which we had previously entered into in October 2021. The Amended Credit Agreement is a five-year revolving credit facility, that provides for an available principal amount of $200.0 million which can be increased up to $500.0 million at our option subject to customary conditions and approval of our lenders (the &#8220;Credit Facility&#8221;). The Amended Credit Agreement will mature on October&#160;13, 2026. Borrowings under the Amended Credit Agreement are available for general corporate purposes, including working capital and capital expenditures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to availability and outstanding borrowings on our Amended Credit Agreement is as follows as of the date indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available principal amount </span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Letters of credit sub-facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding borrowings </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding letters of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total available balance</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving loans under the Amended Credit Agreement bear interest at our choice of one of three base rates plus a range of applicable rates that are based on our leverage ratio. The minimum and maximum range of applicable rates per annum with respect to any ABR Loan or, Term Benchmark Revolving Loan, RFR Revolving Loan (as defined in the Amended Credit Agreement) under the captions &#8220;ABR Spread&#8221;, &#8220;Term Benchmark/CDOR Spread&#8221;, &#8220;RFR Spread&#8221;, or &#8220;Unused Commitment Fee Rate&#8221;, respectively, are outlined in the following table:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:17.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ABR Spread</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term Benchmark/CDOR Spread and RFR Spread</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unused Commitment Fee Rate</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.375%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.375%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.175%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximum</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.000%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.000%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.250%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Amended Credit Agreement are guaranteed by our existing and future wholly-owned domestic subsidiaries, and are secured by a first-priority security interest in substantially all of the assets of Dexcom and the guarantors, including all or a portion of the equity interests of our domestic subsidiaries and first-tier foreign subsidiaries but excluding real property and intellectual property (which is subject to a negative pledge). The Amended Credit Agreement contains covenants that limit certain indebtedness, liens, investments, transactions with affiliates, dividends and other restricted payments, subordinated indebtedness and amendments to subordinated indebtedness documents, and sale and leaseback transactions of Dexcom or any of its domestic subsidiaries. The Amended Credit Agreement also requires us to maintain a maximum leverage ratio and a minimum fixed charge coverage ratio. We were in compliance with these covenants as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we also have a guarantee facility related to our international operations which is collateralized by a $5.5&#160;million term deposit that is included in non-current &#8220;Other assets&#8221; on our consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220707504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases and Other Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases and Other Commitments</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. Leases and Other Commitments</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have leases for certain machinery and facilities, including office, manufacturing and warehouse space facilities under various domestic and international operating and finance lease arrangements. We also have land leases in Penang, Malaysia that expire through 2082 for the build-out of our international manufacturing facility. Our leases, excluding our land leases in Malaysia, have remaining lease terms of up to seventeen years.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the leases include &#160;&#160;&#160;&#160;one or more options to extend the leases for up to five years per option. Our lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of our operating and finance lease liabilities were as shown in the table below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of future payments</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1051">Less: Current portion</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.1&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain lease agreements require us to return designated areas of leased space to its original condition upon termination of the lease agreement, for which we record an asset retirement obligation and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, the asset retirement obligation is accreted for the change in its present value and the capitalized asset is depreciated, both over the term of the associated lease agreement. Asset retirement obligations of $15.7&#160;million and $11.1&#160;million as of December&#160;31, 2023 and 2022, respectively, are included in <span style="-sec-ix-hidden:f-1058"><span style="-sec-ix-hidden:f-1059">other long-term liabilities</span></span> in our consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset impairment</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the result of the Company&#8217;s transition to a flexible working environment, we vacated a building in San Diego during the fourth quarter of 2022 and made it available for sublease. This resulted in an impairment indicator. We tested the asset group as of November 30, 2022 consisting primarily of the leasehold improvements and right-of-use asset for recoverability by comparing its carrying value to an estimate of future undiscounted cash flows. Based on the results of the recoverability test, we determined that the undiscounted cash flows of the asset group were below its carrying value. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the asset group by discounting the estimated future cash flows using level 3 fair value inputs under ASC 820 as described in Note 1. As a result of the impairment test, we recorded a non-cash charge of $23.0&#160;million for the twelve months ended December 31, 2022 in the &#8220;<span style="-sec-ix-hidden:f-1083">Selling, general and administrative</span>&#8221; caption of our consolidated statements of operations. The fair value of the asset group immediately subsequent to the impairment was $2.5&#160;million and was categorized as Level 3 within the ASC 820, &#8220;Fair Value Measurements&#8221; fair value hierarchy.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to our leases is as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0 years</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 years</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.9 years</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of operating lease right-of-use asset included in cash flows from operating activities in our consolidated statements of cash flows was </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.5 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.4 million, and $18.0 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></td></tr></table></div>We are party to various purchase arrangements related to our operational, manufacturing, and research and development activities. We had approximately $793.0 million as of December&#160;31, 2023 and $442.7 million as of December&#160;31, 2022 of open purchase orders and contractual obligations in the ordinary course of business, the majority of which are due within one year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases and Other Commitments</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. Leases and Other Commitments</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have leases for certain machinery and facilities, including office, manufacturing and warehouse space facilities under various domestic and international operating and finance lease arrangements. We also have land leases in Penang, Malaysia that expire through 2082 for the build-out of our international manufacturing facility. Our leases, excluding our land leases in Malaysia, have remaining lease terms of up to seventeen years.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the leases include &#160;&#160;&#160;&#160;one or more options to extend the leases for up to five years per option. Our lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of our operating and finance lease liabilities were as shown in the table below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of future payments</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1051">Less: Current portion</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.1&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain lease agreements require us to return designated areas of leased space to its original condition upon termination of the lease agreement, for which we record an asset retirement obligation and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, the asset retirement obligation is accreted for the change in its present value and the capitalized asset is depreciated, both over the term of the associated lease agreement. Asset retirement obligations of $15.7&#160;million and $11.1&#160;million as of December&#160;31, 2023 and 2022, respectively, are included in <span style="-sec-ix-hidden:f-1058"><span style="-sec-ix-hidden:f-1059">other long-term liabilities</span></span> in our consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset impairment</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the result of the Company&#8217;s transition to a flexible working environment, we vacated a building in San Diego during the fourth quarter of 2022 and made it available for sublease. This resulted in an impairment indicator. We tested the asset group as of November 30, 2022 consisting primarily of the leasehold improvements and right-of-use asset for recoverability by comparing its carrying value to an estimate of future undiscounted cash flows. Based on the results of the recoverability test, we determined that the undiscounted cash flows of the asset group were below its carrying value. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the fair value of the asset group by discounting the estimated future cash flows using level 3 fair value inputs under ASC 820 as described in Note 1. As a result of the impairment test, we recorded a non-cash charge of $23.0&#160;million for the twelve months ended December 31, 2022 in the &#8220;<span style="-sec-ix-hidden:f-1083">Selling, general and administrative</span>&#8221; caption of our consolidated statements of operations. The fair value of the asset group immediately subsequent to the impairment was $2.5&#160;million and was categorized as Level 3 within the ASC 820, &#8220;Fair Value Measurements&#8221; fair value hierarchy.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to our leases is as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0 years</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 years</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.9 years</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of operating lease right-of-use asset included in cash flows from operating activities in our consolidated statements of cash flows was </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.5 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.4 million, and $18.0 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></td></tr></table></div>We are party to various purchase arrangements related to our operational, manufacturing, and research and development activities. We had approximately $793.0 million as of December&#160;31, 2023 and $442.7 million as of December&#160;31, 2022 of open purchase orders and contractual obligations in the ordinary course of business, the majority of which are due within one year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222076016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. Contingencies</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between June 2021 through the year ended December 31, 2023, we and certain Abbott Diabetes Care, Inc. (&#8220;Abbott&#8221;) entities have served patent infringement complaints against each other in multiple jurisdictions against certain continuous glucose monitoring products of each company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainty surrounding patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time. We intend to protect our intellectual property and defend against Abbott&#8217;s claims vigorously in all of these actions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222047936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. Income Taxes</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes subject to taxes in the following jurisdictions is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">732.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">318.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(72.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">710.4&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">390.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income taxes</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(93.7)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.3)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.0)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant loss and tax credit carryforwards and years of expiration are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year of Expiration</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other states</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UK</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credits</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California AMT Credits</span></div></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of net operating losses and credit carryforwards is subject to an annual limitation due to ownership change limitations provided by Section&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. An ownership change limitation occurred as a result of the stock offering completed in February 2009. The limitation will result in approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.5 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of U.S. research and development tax credits that will expire unused, and is therefore, not reflected in the tax credit carryforwards above. In addition, the related deferred tax assets have been removed from the components of our deferred tax assets as summarized in the table below. The tax benefits related to the remaining federal and state net operating losses and tax credit carryforwards may be further limited or lost if future cumulative changes in ownership exceed 50% within any three-year period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below. Significant judgment is required to evaluate the need for a valuation allowance against deferred tax assets. We review all available positive and negative evidence, including projections of pre-tax book income, earnings history, reliability of forecasting, and reversal of temporary differences. A valuation allowance is established when it is more likely than not that some or all of the deferred tax assets will not be realized. Realization of deferred tax assets is dependent upon future earnings in applicable tax jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">211.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed and intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities and reserves</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">741.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(264.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(78.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net deferred tax assets</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">406.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets and acquired intangibles assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(69.9)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60.4)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70.2)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">416.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we completed an intra-entity asset transfer of certain intellectual property between two of our wholly owned foreign subsidiaries to align our structure with the expansion of international business operations. We recorded a $193.2&#160;million deferred tax asset, which represents the difference between the basis of the intellectual property for financial statement and tax purposes, applying the appropriate enacted statutory tax rate. Based on available evidence, management believes it is not more-likely-than-not that the additional foreign deferred tax asset will be realizable, and is therefore, fully offset by a valuation allowance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a valuation allowance of $264.3 million against our California research and development tax credits, foreign tax credits, and certain foreign intangible assets. During the year ended December&#160;31, 2023, the valuation allowance increased by $185.5 million primarily due to generation of California research and development tax credits, and establishing a valuation allowance against the fair value of certain intellectual property located in Ireland in connection with the intra-entity transfer of this property.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between our effective tax rate on income (loss) from continuing operations and the statutory rate is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal statutory tax rate</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent items</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credit</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock and officers compensation</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreement milestone share-based payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(72.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(52.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in statutory tax rates</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.0)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property transfer</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes at effective rates</span></div></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our gross unrecognized tax benefits:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at January&#160;1, 2021</span></div></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to prior year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreases related to prior year tax positions </span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to prior year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total unrecognized tax benefits at December 31, 2023, 2022, and 2021, $37.0 million, $32.5&#160;million and $29.5&#160;million, respectively, would affect our annual effective tax rate if recognized. Also included in the balance of unrecognized tax benefits at December&#160;31, 2023 is $0.2&#160;million of tax benefits that, if recognized, would result in adjustments to other tax accounts, primarily deferred tax assets. Interest and penalties are classified as a component of income tax expense and were not material for any period presented. Although the timing and outcome of audit settlements are uncertain, it is unlikely there will be a significant reduction of the uncertain tax benefits in the next twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our global business activities, we file income tax returns and are subject to routine compliance audits in numerous jurisdictions, including those material jurisdictions listed in the following table. The U.S. net operating losses generated since 1999 and utilized in recent years are open for examination. The years remaining subject to audit, by major jurisdiction, are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States (Federal and state)</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1999 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 - 2023</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate under a tax holiday in the Philippines, which is effective through April 30, 2023, and may be extended for another three years if certain additional requirements are satisfied. The tax holiday is conditional upon remaining in good standing, committing no violation of Philippine Economic Zone Authority Rules and Regulations, pertinent circulars and directives. After the expiration of the tax holiday we are still entitled to a preferential rate for a period of 10 years. Therefore from April 30, 2023 through December 31, 2023 we are still subject to a reduced rate of tax. The impact of this tax holiday and preferential rate was immaterial in in 2023, 2022, and 2021. We have been granted an investment tax allowance incentive by the Malaysian Investment Development Authority (MIDA) in Malaysia, which will not be triggered until we meet certain milestones related to the commencement of operations. The tax incentive had no effect on foreign taxes during 2023, 2022, or 2021. As of December 31, 2023 the tax holiday in Malaysia has not yet been triggered, therefore we are subject to the statutory rate and the related tax expense has been included in total tax expense for 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have approximately $36.5&#160;million of undistributed earnings attributable to operations in our controlled foreign corporations as of December 31, 2023. We assert that any foreign earnings will be indefinitely reinvested. Accordingly, we have not recorded a liability for taxes associated with these undistributed earnings. If we determine that all or a portion of such foreign earnings are no longer indefinitely reinvested, we may be subject to additional foreign withholding taxes and U.S. state income taxes. Determination of the amount of unrecognized deferred tax liability on these unremitted earnings is not practicable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220798448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans and Stockholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. Employee Benefit Plans and Stockholders&#8217; Equity</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer various defined contribution plans for U.S. and international employees. The largest defined contribution plan is the 401(k) retirement plan (the 401(k) Plan) covering substantially all employees in the United States that meet certain age requirements. Employees who participate in the 401(k) Plan may contribute up to 90% of their compensation each year, subject to Internal Revenue Service limitations and the terms and conditions of the plan. Under the terms of the 401(k) Plan, we may elect to match a discretionary percentage of contributions. We match 50% of contributions up to 6% of eligible compensation. Total matching contributions under the 401(k) Plan were $14.9 million, $11.1 million and $9.9&#160;million for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively. Our contributions for other defined contribution plans are not significant for the twelve months ended December&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2015 Employee Stock Purchase Plan (the 2015 ESPP), amended in December 2019, eligible employees may purchase shares of our common stock at semi-annual intervals through periodic payroll deductions during defined Offering Periods. Payroll deductions may not exceed 10% of the participant&#8217;s cash compensation subject to certain limitations, and the purchase price will be 85% of the lower of the fair market value of the common stock at either the beginning of the applicable Offering Period or the Purchase Date. A total of 6.0 million shares of common stock are reserved for issuance under the 2015 ESPP. The 2015 ESPP shall continue until the earlier to occur of (a) termination of the 2015 ESPP by our Board of Directors, (b) issuance of all of the shares of common stock reserved for issuance under the plan, or (c) May&#160;28, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued approximately 0.3 million, 0.3 million and 0.3 million shares of common stock under the 2015 ESPP during the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively. As of December&#160;31, 2023, approximately 2.5 million shares remained available for future issuance under the 2015 ESPP.</span></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2015, we adopted the Amended and Restated 2015 Equity Incentive Plan (the 2015 Plan), which replaced our 2005 Equity Incentive Plan and provides for the grant of incentive and nonstatutory stock options, restricted stock, stock bonuses, stock appreciation rights, RSUs, and PSUs to employees, directors or consultants of the Company. On May 30, 2019, our stockholders approved an increase to the maximum number of shares that may be issued under the 2015 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue up to&#160;39.2 million&#160;shares of our common stock under the 2015 Plan. As of December&#160;31, 2023, approximately 13.9 million shares remained available for future issuance under the 2015 Plan. We issue new shares of common stock to satisfy RSU and PSU vesting under our employee equity incentive plans.</span></div>RSU awards typically vest in annual installments over <span style="-sec-ix-hidden:f-1286">three</span> or four years and vesting is subject to continued service. PSUs are granted to a group of senior officers and the number of shares of our common stock to be received at vesting will range from 0% to 200% of the target award based on the achievement of pre-established performance and market goals. PSUs vest approximately three years from the date of grant, subject to continued employment through that date and certification by the Compensation Committee<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program and Treasury Shares</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchased shares of our common stock are held as treasury shares until they are reissued or retired. When we reissue treasury stock, if the proceeds from the sale are more than the average price we paid to acquire the shares we record an increase in additional paid-in capital. Conversely, if the proceeds from the sale are less than the average price we paid to acquire the shares, we record a decrease in additional paid-in capital to the extent of increases previously recorded for similar transactions and a decrease in retained earnings for any remaining amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our treasury share activity for the periods shown.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued in connection with 2023 Notes conversions</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares received from Note Hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued in connection with the Restated Collaboration Agreement</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares repurchased under the 2022 Share Repurchase Program</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares repurchased under the 2023 Share Repurchase Program</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares repurchased with 2028 Notes proceeds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2022, a duly authorized committee of our Board of Directors authorized and approved a share repurchase program of up to $700.0&#160;million of our outstanding common stock, with a repurchase period that ended on June 30, 2023 (the &#8220;2022 Share Repurchase Program&#8221;). Shares of common stock repurchased under the 2022 Share Repurchase Program became treasury shares. We repurchased approximately $557.7 million of our outstanding common stock throughout the duration of the 2022 Share Repurchase Program. The 2022 Share Repurchase Program and the remaining authorization of approximately $142.3&#160;million expired on June 30, 2023. There were no share repurchases under the 2022 Share Repurchase Program in 2023. On August 1, 2022, we entered into an accelerated share repurchase agreement (&#8220;2022 ASR&#8221;) with JPMorgan Chase Bank, National Association (&#8220;JP Morgan&#8221;) to repurchase up to $700.0&#160;million of our common stock on an accelerated basis through September 29, 2022. On August 3, 2022, we paid $700.0&#160;million to JP Morgan and received an initial delivery of approximately 3.0 million shares of common stock. The final notional amount under the 2022 ASR was $557.7&#160;million or approximately 6.6&#160;million shares of our common stock based on the daily average volume-weighted average price of our common stock during the term of the 2022 ASR for the period from August 1, 2022 to August 31, 2022, less a discount. The 2022 ASR concluded on September 1, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 24, 2023, our Board of Directors authorized and approved a share repurchase program of up to $500.0&#160;million of our outstanding common stock, with a repurchase period ending no later than October 31, 2024 (the &#8220;2023 Share Repurchase Program&#8221;). On October 31, 2023, we entered into an accelerated share repurchase agreement (&#8220;2023 ASR&#8221;) with Bank of America, N.A. (&#8220;BofA&#8221;) to repurchase $500.0 million of our common stock on an accelerated basis through December 14, 2023. On October 31, 2023, we paid $500.0 million to BofA and received an initial delivery of approximately 4.7 million shares of common stock. The final notional amount under the 2023 ASR was $500.0 million or approximately 4.7 million shares of our common stock based on the daily average volume-weighted average price of our common stock during the term of the 2023 ASR for the period from November 1, 2023 to December 14, 2023, less a discount. The 2023 ASR concluded on December 14, 2023. After completion of the repurchases under the 2023 ASR, no shares remained available for additional repurchases under our 2023 Share Repurchase Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 ASR and 2023 ASR were forward contracts indexed to our own common stock. The forward contracts met all of the applicable criteria for equity classification, so we did not account for them as a derivative instrument. We have reflected the shares delivered to us by the financial institution as treasury shares as of the dates they were delivered to us in computing weighted average shares outstanding for both basic and diluted net income per share.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we used a portion of the proceeds of the 2028 Notes to repurchase 1.6 million shares of our common stock for $188.7 million, excluding excise tax due under the Inflation Reduction Act of 2022, for an average per share price of $118.12, via privately negotiated transactions, independent of the 2022 Share Repurchase Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchased shares of our common stock are held as treasury shares until they are reissued or retired. We have not yet determined the ultimate disposition of repurchased shares and consequently we continue to hold them as treasury shares rather than retiring them. Authorization of future stock repurchase programs is subject to the final determination of our Board of Directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Award Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU and PSU activity under the 2015 Plan for the twelve months ended December&#160;31, 2023, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:22.5pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nonvested RSU and PSU Activity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except weighted average grant date fair value)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Available for Grant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted&#160;<br/>Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.88&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.47&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.88&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.90&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94.08&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88.57&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.98&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total vest-date fair value of RSUs and PSUs that vested during the twelve months ended December&#160;31, 2023, 2022 and 2021 was $157.8 million, $160.1 million and $284.5 million, respectively. As of December&#160;31, 2023, 2.6 million unvested RSUs and 0.3 million unvested PSUs were outstanding under the 2015 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share-based compensation expense is associated with RSUs, PSUs, and ESPP. The following table summarizes the share-based compensation expense included in our consolidated statements of operations for the periods shown.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total tax benefit related to share-based compensation expense</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, unrecognized estimated compensation costs related to RSUs and PSUs totaled $199.5 million and are expected to be recognized over a weighted-average period of approximately 1.7 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value RSUs at the date of grant using the intrinsic value method. We estimate the fair value of PSUs at the date of grant using the intrinsic value method and the probability that the specified performance criteria will be met. We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.20% - 5.47%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.60% - 3.34%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.06%&#160;- 0.07%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility of Dexcom common stock</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34% - 48%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45% - 55%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36%&#160;- 45%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796224642944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Business Segment and Geographic Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. Business Segment and Geographic Information</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An operating segment is identified as a component of a business that has discrete financial information available and for which the chief operating decision maker must decide the level of resource allocation. In addition, the guidance for segment reporting indicates certain quantitative materiality thresholds. None of the components of our business meet the definition of an operating segment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently consider our operations to be, and manage our business globally within, one reportable segment, which is consistent with how our President and Chief Executive Officer, who is our chief operating decision maker, reviews our business, makes investment and resource allocation decisions, and assesses operating performance.</span></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We disaggregate revenue by geographic region and by major sales channel. We have determined that disaggregating revenue into these categories achieves the ASC Topic 606 disclosure objectives of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</span></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by geographic region</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended December&#160;31, 2023, 2022 and 2021, no individual country outside the United States generated revenue that represented more than 10% of our total revenue. The following table sets forth revenue by our two primary geographical markets, the United States and International, based on the geographic location to which we deliver the components, for the periods shown:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,625.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,142.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">997.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">599.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,622.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,909.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,448.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by customer sales channel</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our CGM systems through a direct sales organization and through distribution arrangements that allow distributors to sell our products. The following table sets forth revenue by major sales channel for the twelve months ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.446%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributor</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,095.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,470.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,024.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,622.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,909.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,448.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our long-lived assets, which consists of property and equipment, net, and operating lease right-of-use assets by geographic region:</span></div><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">544.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">686.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">515.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">346.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other countries</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-lived assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,184.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,135.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220798448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</a></td>
<td class="text"><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DexCom, Inc.</span></div></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE II</span><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8211; </span><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS</span></div></td></tr><tr><td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for doubtful accounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning Balance</span></div></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-offs and adjustments</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending Balance</span></div></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796223198352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 541.5<span></span>
</td>
<td class="nump">$ 341.2<span></span>
</td>
<td class="nump">$ 216.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796219572992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2023, the following Section 16 officers and directors adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408 of Regulation S-K of the Exchange Act):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Action</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Action Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Number of Shares to be Sold</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Date</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Matthew Dolan</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Strategy, Corporate Development and Dexcom Labs</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/15/2023</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,326</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/15/2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paul Flynn</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Global Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/15/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,253</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/15/2024</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Girish Naganathan</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Chief Technology Officer</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/20/2023</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,137</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/20/2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Steven R. Pacelli</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President and Managing Director, Dexcom Ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/27/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,000</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/23/2025</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barry J. Regan</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Global Operations</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/4/2023</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,430</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/4/2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin R. Sayer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairperson,&#160;President and Chief Executive Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/12/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,965</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/12/2024</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sadie M. Stern</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Chief Human Resources Officer</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/12/2023</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,825</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/11/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sadie M. Stern</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Chief Human Resources Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12/12/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,708</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/8/2024</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jereme M. Sylvain</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Chief Financial Officer</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/21/2023</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,863</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/21/2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The actual number of shares sold may depend on the net shares vested as a result of tax withholding obligations, the vesting of certain performance-based stock units, the number of shares purchased under employee stock purchase plans, one or more limit orders, as applicable, and therefore, may not be determinable at this time.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the date listed in the table.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 12, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect, under the Exchange Act.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Rule 10b5-1 trading arrangements that were adopted in the above table are in accordance with our insider trading policy and actual sale transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=dxcm_MatthewDolanMember', window );">Matthew Dolan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Matthew Dolan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Executive Vice President, Strategy, Corporate Development and Dexcom Labs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">12/15/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">366 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">15,326<span></span>
</td>
<td class="nump">15,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=dxcm_PaulFlynnMember', window );">Paul Flynn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Paul Flynn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Executive Vice President, Global Revenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">12/15/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">366 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">31,253<span></span>
</td>
<td class="nump">31,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=dxcm_GirishNaganathanMember', window );">Girish Naganathan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Girish Naganathan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Executive Vice President, Chief Technology Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">11/20/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">366 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">5,137<span></span>
</td>
<td class="nump">5,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=dxcm_StevenRPacelliMember', window );">Steven R. Pacelli [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Steven R. Pacelli<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Executive Vice President and Managing Director, Dexcom Ventures<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">11/27/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">423 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=dxcm_BarryJReganMember', window );">Barry J. Regan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Barry J. Regan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Executive Vice President, Global Operations<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">12/4/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">366 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">28,430<span></span>
</td>
<td class="nump">28,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=dxcm_KevinRSayerMember', window );">Kevin R. Sayer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Kevin R. Sayer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chairperson,&#160;President and Chief Executive Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">12/12/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">366 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">100,965<span></span>
</td>
<td class="nump">100,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=dxcm_SadieMSternMember', window );">Sadie M. Stern [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">455 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=dxcm_JeremeMSylvainMember', window );">Jereme M. Sylvain [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Jereme M. Sylvain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Executive Vice President, Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">11/21/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">366 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">6,863<span></span>
</td>
<td class="nump">6,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=dxcm_SadieMSternDecember2023PlanMember', window );">Sadie M Stern December 2023 Plan [Member] | Sadie M. Stern [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Sadie M. Stern<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Executive Vice President, Chief Human Resources Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">12/12/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">12,825<span></span>
</td>
<td class="nump">12,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=dxcm_SadieMStern2023PlanTerminationMember', window );">Sadie M Stern 2023 Plan Termination [Member] | Sadie M. Stern [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Sadie M. Stern<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Executive Vice President, Chief Human Resources Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">12/12/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">4,708<span></span>
</td>
<td class="nump">4,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=dxcm_MatthewDolanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=dxcm_MatthewDolanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=dxcm_PaulFlynnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=dxcm_PaulFlynnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=dxcm_GirishNaganathanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=dxcm_GirishNaganathanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=dxcm_StevenRPacelliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=dxcm_StevenRPacelliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=dxcm_BarryJReganMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=dxcm_BarryJReganMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=dxcm_KevinRSayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=dxcm_KevinRSayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=dxcm_SadieMSternMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=dxcm_SadieMSternMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=dxcm_JeremeMSylvainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=dxcm_JeremeMSylvainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=dxcm_SadieMSternDecember2023PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=dxcm_SadieMSternDecember2023PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=dxcm_SadieMStern2023PlanTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=dxcm_SadieMStern2023PlanTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221763472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of DexCom, Inc. and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. We have reclassified certain amounts previously reported in our financial statements to conform to the current presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash. For international subsidiaries whose functional currencies are the local currencies, we translate the financial statements into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. We include translation-related adjustments in comprehensive income and in accumulated other comprehensive loss in the equity section of our consolidated balance sheets. We record gains and losses resulting from transactions with customers and vendors that are denominated in currencies other than the functional currency and from certain intercompany transactions in other income (expense), net in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of DexCom, Inc. and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. We have reclassified certain amounts previously reported in our financial statements to conform to the current presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash. For international subsidiaries whose functional currencies are the local currencies, we translate the financial statements into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. We include translation-related adjustments in comprehensive income and in accumulated other comprehensive loss in the equity section of our consolidated balance sheets. We record gains and losses resulting from transactions with customers and vendors that are denominated in currencies other than the functional currency and from certain intercompany transactions in other income (expense), net in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires us to make certain estimates and assumptions that affect the amounts reported in our consolidated financial statements and the disclosures made in the accompanying notes. Areas requiring significant estimates include rebates, excess or obsolete inventories and the valuation of inventory, accruals for litigation contingencies, and the amount of our worldwide tax provision and the realizability of deferred tax assets. Despite our intention to establish accurate estimates and use reasonable assumptions, actual results may differ from our estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Uses unadjusted quoted prices that are available in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Uses inputs other than quoted prices included in Level&#160;1 that are observable, either directly or indirectly, through correlation with market data. These include quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Uses unobservable inputs that are supported by little or no market activity and that are significant to the determination of fair value. Level 3 assets and liabilities include those whose fair values are determined using pricing models, discounted cash flow methodologies, or similar valuation techniques and significant judgment or estimation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of most of our cash equivalents using Level 1 inputs. We estimate the fair value of our marketable equity securities using Level 1 inputs and we estimate the fair value of our marketable debt securities using Level 2 inputs. We carry our marketable securities at fair value. We carry our other financial instruments, such as cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities, at cost, which approximates the related fair values due to the short-term maturities of these instruments. See Note 3 &#8220;Fair Value Measurements&#8221; to the consolidated financial statements for more information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments with a maturity of 90 days or less at the time of purchase to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have classified our marketable securities with remaining maturity at purchase of more than three months and remaining maturities of one year or less as short-term marketable securities. We have also classified marketable securities with remaining maturities of greater than one year as short-term marketable securities based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate realized gains or losses on our marketable securities using the specific identification method. We carry our marketable debt securities at fair value with unrealized gains and losses reported as a separate component of stockholders&#8217; equity in our consolidated balance sheets and included in comprehensive income. Interest income and realized gains and losses on marketable debt securities are included in other income (expense), net in our consolidated statements of operations. We carry our marketable equity securities at fair value with realized and unrealized gains and losses reported in income (loss) from equity investments in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in various types of debt securities, including debt securities in government-sponsored entities, corporate debt securities, U.S. Treasury securities, supranational securities, and commercial paper. We do not generally intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. See Note 3 &#8220;Fair Value Measurements&#8221; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-Term Marketable Securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 4 &#8220;Balance Sheet Details and Other Financial Information&#8221; to the consolidated financial statements for more information on our marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivables and Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are generally recorded at the invoiced amount, net of prompt pay discounts, for distributors and at net realizable value for direct customers, which is determined using estimates of claim denials and historical reimbursement experience without regard to aging category. Accounts receivable are not interest bearing. We evaluate the creditworthiness of significant customers based on historical trends, the financial condition of our customers, and external market factors. We generally do not require collateral from our customers. We maintain an allowance for doubtful accounts for potential credit losses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a customer account is uncollectible.&#160;Generally, receivable balances that are more than one year past due are deemed uncollectible.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Significant Customers</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Significant Customers</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term marketable securities, and accounts receivable. We limit our exposure to credit risk by placing our cash and investments with a few major financial institutions. We have also established guidelines regarding diversification of our investments and their maturities that are designed to maintain principal and maximize liquidity. We review these guidelines periodically and modify them to take advantage of trends in yields and interest rates and changes in our operations and financial position.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is valued at the lower of cost or net realizable value on a part-by-part basis that approximates first in, first out. We capitalize inventory produced in preparation for commercial launches when it becomes probable that the product will receive regulatory approval and that the related costs will be recoverable through the commercialization of the product. A number of factors are considered, including the status of the regulatory application approval process, management&#8217;s judgment of probable future commercial use, and net realizable value. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record adjustments to inventory for potential excess or obsolete inventory, as well as inventory that does not pass quality control testing, in order to state inventory at net realizable value. Factors influencing these adjustments include inventories on hand and on order compared to estimated future usage and sales for existing and new products, as well as judgments regarding quality control testing data and assumptions about the likelihood of scrap and obsolescence. Once written down the adjustments are considered permanent and are not reversed until the related inventory is disposed of or sold.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products require customized products and components that currently are available from a limited number of sources. We purchase certain components and materials from single sources due to quality considerations, costs or constraints resulting from regulatory requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our inventory reserves have been adequate to cover our actual losses. However, if actual product life cycles, product quality or market conditions differ from our assumptions, additional inventory adjustments that would increase cost of sales could be required.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization. We capitalize additions and improvements and expense maintenance and repairs as incurred. We also capitalize certain costs incurred for the development of enterprise-level business and finance software that we use internally in our operations. Costs incurred in the application development phase are capitalized while costs related to planning and other preliminary project activities and to post-implementation activities are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate depreciation using the straight-line method over the estimated useful lives of the assets. Estimated useful lives are generally <span style="-sec-ix-hidden:f-509">three</span> to five years for computer software and hardware, including internal use software, <span style="-sec-ix-hidden:f-511">four</span> to fifteen years for machinery and equipment, and five years for furniture and fixtures. Leasehold and land improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Buildings are amortized over the shorter of the ownership of the building or forty years. We include the amortization of assets that are recorded under finance leases in depreciation expense. On retirement or disposition, the asset cost and related accumulated depreciation are removed from our consolidated balance sheets and any gain or loss is recognized in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the recoverability of the asset by comparing the carrying amount to the future undiscounted cash flows that we expect the asset to generate. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record goodwill when the fair value of consideration transferred in a business combination exceeds the fair value of the identifiable assets acquired and liabilities assumed. Goodwill and other intangible assets that have indefinite useful lives are not amortized, but are tested annually for impairment during the fourth fiscal quarter and whenever events or changes in circumstances indicate that it is more likely than not that the fair value is less than the carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business, and an adverse action or assessment by a regulator.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with Dexcom&#8217;s reporting structure and the availability of discrete financial information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform the first step of our annual impairment analysis by either comparing a reporting unit&#8217;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#8217;s fair value from the last quantitative assessment to determine if there is potential impairment. We may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#8217;s estimated fair value was significantly in excess of the carrying value of its net assets and we do not believe there have been significant changes in the reporting unit&#8217;s operations that would significantly decrease its estimated fair value or significantly increase its net assets.&#160;If a quantitative assessment is performed the evaluation includes management estimates of cash flow projections based on internal future projections&#160;and/or use of a market approach by looking at market values of comparable companies. Key assumptions&#160;for these projections include revenue growth, future gross margin and operating margin growth, and weighted cost of capital and terminal growth rates. The revenue and margin growth are based on increased sales of new and existing products as we maintain investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements&#160;to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including the timing and probability of regulatory approvals for our products to be commercialized. We also consider Dexcom&#8217;s market capitalization as a part of our analysis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the estimated fair value of a reporting unit exceeds the carrying amount of the net assets assigned to that unit, goodwill is not impaired and no further analysis is required. If the carrying value of the net assets assigned to a reporting unit exceeds the estimated fair value of the unit, we perform the second step of the impairment test. In this step we allocate the fair value of the reporting unit calculated in step one to all of the assets and liabilities of that unit, as if we had just acquired the reporting unit in a business combination. The excess of the fair value of the reporting unit over the total amount allocated to the assets and liabilities represents the implied fair value of goodwill. If the carrying amount of a reporting unit&#8217;s goodwill exceeds its implied fair value, we would record an impairment loss equal to the difference. We recorded no significant goodwill impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in goodwill for the twelve months ended December&#160;31, 2023 and 2022 primarily consisted of translation adjustments on our foreign currency denominated goodwill. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are included in intangibles and other assets, net in our consolidated balance sheets. We amortize intangible assets with a finite life, such as the customer relationships, acquired technology and intellectual property, trademarks and trade name, and other intangibles, on a straight-line basis over their estimated useful lives, which range from <span style="-sec-ix-hidden:f-519">one</span> to seven years. We review intangible assets that have finite lives and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For transactions other than a business combination, we also capitalize as intangible assets the cost of certain milestones payable by us to collaborative partners and incurred at or after the product has obtained regulatory approval for marketing. The intangible assets associated with these milestones are amortized over the remaining estimated useful life of the underlying asset.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded no significant intangible asset impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. The effect of a change in tax rate on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under tax law and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal and state income tax returns in the United States and income tax returns in various other foreign jurisdictions with varying statutes of limitations. Due to net operating losses incurred, our income tax returns from inception to date are subject to examination by taxing authorities. We recognize interest expense and penalties related to income tax matters, including unrecognized tax benefits, as a component of income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income tax expense for basis differences related to global intangible low-taxed income ("GILTI") as a period cost if and when incurred. GILTI is a category of income that is earned abroad by U.S.-controlled foreign corporations (CFCs) and is subject to special treatment under the U.S. tax code.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Warranty Accrual</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Warranty Accrual</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated warranty costs associated with a product are recorded at the time revenue is recognized. We estimate future warranty costs by analyzing historical warranty experience for the timing and amount of returned product, and expectations for future warranty activity based on changes and improvements to the product or process that are in place or will be in place in the future. We evaluate these estimates on at least a quarterly basis to determine the continued appropriateness of our assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Loss Contingencies</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. We review the status of each significant matter quarterly and assess our potential financial exposure. If the potential loss from a claim or legal proceeding is considered probable and the amount can be reasonably estimated, we record a liability and an expense for the estimated loss and disclose it in our financial statements if it is significant. If we determine that a loss is possible and the range of the loss can be reasonably determined, we do not record a liability or an expense but we disclose the range of the possible loss. We base our judgments on the best information available at the time. As additional information becomes available, we reassess the potential liability related to our pending claims and litigation and may revise our estimates. Any revision of our estimates of potential liability could have a material impact on our financial position and operating results.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income consists of two elements, net income and other comprehensive loss. We report all components of comprehensive income, including net income, in our financial statements in the period in which they are recognized. Total comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net income and the components of other comprehensive loss, including foreign currency translation adjustments and unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate our revenue from the sale of disposable sensors and our reusable transmitter and receiver, collectively referred to as Reusable Hardware. We also refer to Reusable Hardware and disposable sensors in this section as Components. We generally recognize revenue when control is transferred to our customers in an amount that reflects the net consideration to which we expect to be entitled.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining how revenue should be recognized, a five-step process is used, which includes identifying performance obligations in the contract, determining whether the performance obligations are separate, allocating the transaction price to each separate performance obligation, estimating the amount of variable consideration to include in the transaction price and determining the timing of revenue recognition for separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contracts and Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider customer purchase orders, which in most cases are governed by agreements with distributors or third-party payors, to be contracts with a customer. For each contract, we consider the obligation to transfer Components to the customer, each of which are distinct, to be separate performance obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Price</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for the Components reflects the net consideration to which we expect to be entitled. Transaction price is typically based on the contracted rates less an estimate of claim denials and historical reimbursement experience by payor, which include current and future expectations regarding reimbursement rates and payor mix. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include an estimate of variable consideration in the calculation of the transaction price at the time of sale, when control of the Components transfers to the customer. Variable consideration includes, but is not limited to: rebates, chargebacks, consideration payable to customers such as specialty distributor and wholesaler fees, product returns provision, prompt payment discounts, and various other promotional or incentive arrangements.</span><span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our provisions related to variable consideration as a reduction of accounts receivable when we are not required to make a payment or as a liability when we are required to make a payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the adequacy of our estimates for transaction price adjustments and variable consideration at each reporting date. If the actual amounts of consideration we receive differ from our estimates, we would adjust our estimates and that would affect reported revenue in the period that such variances become known. If any of these judgments were to change, it could cause a material increase or decrease in the amount of revenue we report in a particular period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to rebates on pricing programs with managed care organizations, such as pharmacy benefit managers, governmental and third-party commercial payors, primarily in the U.S. We estimate provisions for rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or trends and channel inventory data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in chargeback programs, primarily with government entities in the U.S., under which pricing on products below negotiated list prices is provided to participating entities and equal to the difference between their acquisition cost and the lower negotiated price. We estimate provisions for chargebacks primarily based on historical experience on a product and program basis, current contract prices under the chargeback programs and channel inventory data.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration Payable to the Customer</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay administrative and service fees to certain of our distributors based on a fixed percentage of the product price. These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price. We accrue for these fees based on actual net sales and contractual fee rates negotiated with the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of their distribution agreements, most distributors do not have rights of return. The distributors typically have a limited time frame to notify us of any missing, damaged, defective or non-conforming products. We generally provide a &#8220;30-day money back guarantee&#8221; program whereby first-time end-user customers may return Reusable Hardware. We estimate our product returns provision principally based on historical experience by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Additionally, we consider other specific factors such as estimated shelf life of inventory in the distribution channel and changes to customer terms.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Payment Discounts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. We estimate prompt payment discount accruals based on actual net sales and contractual discount rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Various Other Promotional or Incentive Arrangements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other promotional or incentive arrangements are periodically offered to customers, including but not limited to co-payment assistance we provide to patients with commercial insurance, promotional programs related to the launch of products or other targeted promotions. We record a provision for the incentive earned based on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenue from sales of Components upon transfer of control of the product to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where our free-of-charge software, mobile applications and updates are deemed to be separate performance obligations, revenue is recognized over time on a ratable basis over the estimated life of the related Reusable Hardware component.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales of Components include an assurance-type warranty.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable and deferred revenue. Payment terms vary by contract type and type of customer and generally range from 30 to 90 days.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December&#160;31, 2023 included unbilled accounts receivable of $8.0 million. We expect to invoice and collect all unbilled accounts receivable within twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record deferred revenue when we have entered into a contract with a customer and cash payments are received or due prior to transfer of control or satisfaction of the related performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations are generally satisfied within twelve months of the initial contract date. The deferred revenue balances related to performance obligations that will be satisfied after twelve months was $7.4 million as of December&#160;31, 2023 and $19.0 million as of December&#160;31, 2022. These balances are included in other long-term liabilities in our consolidated balance sheets. Revenue recognized in the period from performance obligations satisfied in previous periods was not material for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Cost of Sales</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred cost of sales are associated with transactions for which revenue recognition criteria are not met but product has shipped and released from inventory. Deferred cost of sales are included in prepaid and other current assets in our consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Compensation Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expense incentive compensation associated with our internal sales force when incurred because the amortization period for such costs, if capitalized, would have been <span style="-sec-ix-hidden:f-535">one</span> year or less. We record these costs in selling, general and administrative expense in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ProductShipmentCostsPolicyTextBlock', window );">Product Shipment Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Product Shipment Costs</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the amounts we charge our customers for the shipping and handling of our products in revenue and we record the related costs as cost of sales in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We expense costs of research and development as we incur them. Our research and development expenses primarily consists of engineering and research expenses related to our sensing technology, clinical trials, regulatory expenses, quality assurance programs, employee compensation, and business process outsourcers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology includes certain software that we develop. We expense software development costs as we incur them until technological feasibility has been established, at which time we capitalize development costs until the product is available for general release to customers. To date, our software has been available for general release concurrent with the establishment of technological feasibility and, accordingly, we have not capitalized any development costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into agreements with collaboration partners for the development and commercialization of our products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we account for these agreements, we consider the unique nature, terms and facts and circumstances of each transaction. Below are some example activities and how we account for them:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Payments to collaboration partners through issuance of common stock as consideration in an asset acquisition are considered share-based payment to non-employees in exchange for goods within the scope of ASC Topic 718, &#8220;Compensation - Stock Compensation.&#8221; The amount and the timing of the cost recognition of such milestones in our financial statements is driven by the accounting for the specific type of equity instrument under ASC 718 that aligns with the terms of the agreement, including any performance conditions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The value associated with in-process research and development (&#8220;IPR&amp;D&#8221;) in an asset acquisition incurred prior to regulatory approval is expensed as it does not have an alternative future use and is recorded as research and development expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The value associated with IPR&amp;D in an asset acquisition incurred at or after regulatory approval is usually capitalized as an intangible asset and amortized over the periods in which the related products are expected to contribute to future cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></td></tr></table></div>We expense costs to produce advertising as we incur them whereas costs to communicate advertising are expensed when the advertising is first run. Advertising costs are included in selling, general and administrative expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. Lease right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Lease right-of-use assets and liabilities with terms of more than 12 months are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to determine the present value is our collateralized incremental borrowing rate unless the interest rate implicit in the lease is readily determinable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, lease expense is recognized on a straight-line basis within operating expenses over the lease term. For finance leases, lease expense is recognized as interest and depreciation; interest using the effective interest method and depreciation on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. Short-term leases with lease terms of 12 months or less are not recorded on the balance sheet and are recognized on a straight line basis over the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and lease liabilities are presented separately in our consolidated balance sheets. Finance lease right-of-use assets are included in property and equipment and finance lease liabilities are included in accounts payable and accrued liabilities and in other long-term liabilities in our consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lease agreements may contain lease components and non-lease components. For certain asset classes, we have elected to account for both of those components as a single lease component. We use a portfolio approach to account for the right-of-use assets and liabilities associated with certain machinery and equipment leases. Variable lease payments may include payments associated with non-lease components, payments that do not depend on a rate or index, or other costs. Variable lease payments are recognized in the period in which the obligation for those payments are incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value time-based restricted stock units or RSUs at the date of grant using the intrinsic value method. Certain RSUs granted to senior management vest based on the achievement of pre-established performance or market goals. We estimate the fair value of these performance/market-based RSUs, or PSUs, at the date of grant using the intrinsic value method and the probability that the specified performance criteria will be met. We update our assessment of the probability that the specified performance criteria will be achieved each quarter and adjust our estimate of the fair value of the PSUs if necessary. The Monte Carlo methodology that we use to estimate the fair value of PSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the PSUs at the date of grant must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the assumptions used change significantly, share-based compensation expense may differ materially from what we have recorded in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for forfeitures as they occur by reversing any share-based compensation expense related to awards that will not vest.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to common stockholders is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the period and, when dilutive, potential common share equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares consist of shares issuable from RSUs, PSUs, warrants, our senior convertible notes, and collaborative sales-based milestones. Potentially dilutive common shares issuable upon vesting of RSUs, PSUs, and exercise of warrants are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our senior convertible notes are determined using the if-converted method. In periods of net losses, we exclude all potentially dilutive common shares from the computation of the diluted net loss per share for those periods as the effect would be anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-bottom:1pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08,</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. </span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This guidance is intended improve the accounting for acquired revenue contracts with customers in a business combination. The new guidance requires that the acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The amendments should be applied prospectively to business combinations occurring on or after the adoption date. We adopted ASU 2021-08 in the first quarter of 2023 and there was no impact to our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity&#8217;s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. The ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The ASU should be applied on a prospective basis although retrospective application is permitted. We are currently evaluating the impact of this standard on our consolidated financial disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_ProductShipmentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Shipment Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_ProductShipmentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220707632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Total Revenues and Accounts Receivable by Customer</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the percentages of total revenue or gross accounts receivable for customers that represent 10% or more of the respective amounts for the periods shown:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer A</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer C</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer E</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Less than 10%</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">** Total revenue for each customer is net of fees, cash discounts, and rebates directly allocable to that customer. Rebates paid to other entities are excluded; therefore, the combined value may exceed 100%.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per share for the periods shown:</span></div><div style="margin-bottom:10pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">341.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income - diluted</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">554.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">352.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per common share</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.30&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.82&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.53&#160;</span></td><td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic weighted average shares outstanding</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">389.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborative sales-based milestones</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units and performance stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior convertible notes</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Anti-Dilutive Securities Excluded in Diluted Net Income per Share</a></td>
<td class="text"><div style="margin-bottom:1pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding anti-dilutive securities not included in the diluted net income per share attributable to common stockholders calculations were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units and performance stock units</span></div></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222056656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy for Financial Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2023, classified in accordance with the fair value hierarchy:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,612.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,612.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">331.1&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,488.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2022, classified in accordance with the fair value hierarchy:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">420.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,530.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,530.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,813.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,813.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386.1&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,858.7&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,244.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes assets which are held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock', window );">Schedule of Fair Value of Senior Convertible Notes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value, based on trading prices (Level 1 inputs), of our senior convertible notes were as follows as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements Using Level 1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,136.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,262.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,314.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,281.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of outstanding senior convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,544.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,451.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about fair value of asset and liability not measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796218478272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Short-Term Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term marketable securities, consisting of available-for-sale debt securities, were as follows as of the dates indicated:</span></div><div style="margin-bottom:7pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></div></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,611.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,612.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.4&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,157.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:7pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Market<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities, available-for-sale:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,535.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,530.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt securities, available-for-sale</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,819.0&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.3)</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,813.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-indent:-7.2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">983.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">720.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: allowance for doubtful accounts</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts receivable, net</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">973.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">713.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">319.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">306.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid and Other Current Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation plan assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land and land improvements</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">190.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software and hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">683.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">449.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">264.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">328.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,622.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,418.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(509.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(363.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,113.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,055.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets and Weighted Average Amortization Period</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of gross intangible assets, accumulated amortization, and net intangible asset balances as of December&#160;31, 2023 and December&#160;31, 2022</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verily intangible asset</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31.0)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired technology and intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.6)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, other</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Useful Life<br/>(in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verily intangible</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired technology and intellectual property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.6)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, other</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 2 &#8220;Development and Other Agreements&#8221; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Excludes Verily intangible asset.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total amortization expense of finite-lived intangible assets for the twelve months ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense included in cost of sales</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense included in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents estimated future amortization of the Company&#8217;s finite-lived intangible assets as of December&#160;31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term investments</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable trade</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">276.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued tax, audit, and legal fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued rebates </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax payable</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation plan liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,345.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">901.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock', window );">Schedule of Accrued Payroll and Related Expenses</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued wages, bonus and taxes</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued payroll and related expenses</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171.0&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Schedule of Accrued Warranty</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty costs are reflected in our statements of operations as cost of sales. Reconciliations of our accrued warranty costs for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51.7)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43.1)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40.3)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock', window );">Schedule of Other Long-Term Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease obligations</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset retirement obligation</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense)</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income</span></div></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity investments</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.8)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accrued Payroll and Related Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796223155216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of our senior convertible notes were as follows as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amount:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">774.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,207.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,207.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,250.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total principal amount</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,457.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,982.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount of senior convertible notes</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,434.2&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,970.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Converted Value of Notes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our senior convertible notes for which the if-converted value exceeded the principal amount, the amount in excess of principal was as follows as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,361.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total by which the notes&#8217; if-converted value exceeds their principal amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,395.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the key details for our unsecured senior convertible notes due 2023 (the &#8220;2023 Notes&#8221;), unsecured senior convertible notes due 2025 (the &#8220;2025 Notes&#8221;), and unsecured senior convertible notes due 2028 (the &#8220;2028 Notes&#8221;):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Senior Convertible Notes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Offering Completion Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity Date</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stated Interest Rate</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Principal Amount</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Proceeds</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Initial Conversion Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(per $1,000 principal amount)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Conversion Price</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(per share)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Settlement Methods</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023 Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November 2018</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;1, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.75%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$850.0 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$836.6 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.3476&#160;shares </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$41.07</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and/or shares</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025 Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November&#160;15, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.25%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.21 billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.19 billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6620 shares </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$150.11</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and/or shares</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028 Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May&#160;15, 2028</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.375%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.25&#160;billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.23&#160;billion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.1571 shares</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$162.41</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and/or shares</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Net proceeds is calculated by deducting the aggregate principal amount from the initial purchasers&#8217; discounts and estimated costs directly related to the offering.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Subject to adjustments as defined in the indentures.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The senior convertible notes may be settled in cash, stock, or a combination thereof, solely at our discretion. </span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense and Effective Interest Rates of Senior Convertible Notes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our senior convertible notes for the periods shown:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash interest expense:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon interest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense recognized on senior notes</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective interest rate:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2025</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Convertible Notes due 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest on the 2023 Notes began accruing upon issuance and is payable semi-annually on June 1 and December 1 of each year. Interest on the 2025 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year. Interest on the 2028 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effective interest rate presented represents the rate applicable for the period outstanding. The Senior Convertible Notes due 2023 matured on December 1, 2023 and all outstanding principal was settled as described below.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* Not applicable as no notes were outstanding at this date.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock', window );">Schedule of Conversion Activity for Senior Convertible Notes</a></td>
<td class="text">As a result, the 2023 Notes were convertible at the option of the holders from January&#160;1, 2023 through August 31, 2023. Circumstance 5 was applicable to the 2023 Notes beginning September 1, 2023. The 2023 Notes matured on December 1, 2023 and were completely settled. See the following table for the details on the conversion activity:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fiscal Period</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Converted Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Principal Amount Converted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Issued for Settlement</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Received from Exercise of 2023 Note Hedge</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/1/2022 - 12/31/2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 Notes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.5 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3 million</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/1/2023 - 12/31/2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 Notes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$774.8&#160;million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 million</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 million</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Availability and Outstanding Borrowings on Credit Agreement</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to availability and outstanding borrowings on our Amended Credit Agreement is as follows as of the date indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available principal amount </span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Letters of credit sub-facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding borrowings </span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding letters of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total available balance</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">192.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The minimum and maximum range of applicable rates per annum with respect to any ABR Loan or, Term Benchmark Revolving Loan, RFR Revolving Loan (as defined in the Amended Credit Agreement) under the captions &#8220;ABR Spread&#8221;, &#8220;Term Benchmark/CDOR Spread&#8221;, &#8220;RFR Spread&#8221;, or &#8220;Unused Commitment Fee Rate&#8221;, respectively, are outlined in the following table:<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:17.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ABR Spread</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term Benchmark/CDOR Spread and RFR Spread</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unused Commitment Fee Rate</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.375%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.375%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.175%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximum</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.000%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.000%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.250%</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Conversion Activity For Senior Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796218499824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases and Other Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of our operating and finance lease liabilities were as shown in the table below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of future payments</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1051">Less: Current portion</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.1&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Finance Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturities of our operating and finance lease liabilities were as shown in the table below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of future payments</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1051">Less: Current portion</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term portion</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.1&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense and Other Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use asset impairment</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to our leases is as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0 years</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 years</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.9 years</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796213301984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) before Income Taxes Subject to Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes subject to taxes in the following jurisdictions is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">732.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">463.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">318.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(72.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">710.4&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">390.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income taxes</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(93.7)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.3)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.0)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock', window );">Schedule of Tax Credit Carryforwards</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant loss and tax credit carryforwards and years of expiration are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year of Expiration</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other states</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UK</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credits</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California AMT Credits</span></div></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Operating Loss Carryforwards</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant loss and tax credit carryforwards and years of expiration are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year of Expiration</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other states</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UK</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credits</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California AMT Credits</span></div></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">211.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed and intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities and reserves</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">741.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">485.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(264.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(78.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net deferred tax assets</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">406.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets and acquired intangibles assets</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(69.9)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60.4)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70.2)</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">416.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation between Effective Tax Rate and Statutory Rate</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between our effective tax rate on income (loss) from continuing operations and the statutory rate is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal statutory tax rate</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149.2&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent items</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credit</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock and officers compensation</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreement milestone share-based payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(72.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(52.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in statutory tax rates</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.4&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.0)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property transfer</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes at effective rates</span></div></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.6&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our gross unrecognized tax benefits:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at January&#160;1, 2021</span></div></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to prior year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreases related to prior year tax positions </span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to prior year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock', window );">Schedule of Years Remaining Subject to Audit by Major Jurisdiction</a></td>
<td class="text">The years remaining subject to audit, by major jurisdiction, are as follows:<div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fiscal Year</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States (Federal and state)</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1999 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Germany</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</span></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 - 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 - 2023</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxExaminationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxExaminationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796214108080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans and Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock', window );">Schedule of Treasury Share Activity Table Text Block</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our treasury share activity for the periods shown.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued in connection with 2023 Notes conversions</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares received from Note Hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued in connection with the Restated Collaboration Agreement</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares repurchased under the 2022 Share Repurchase Program</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares repurchased under the 2023 Share Repurchase Program</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares repurchased with 2028 Notes proceeds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of RSU and PSU Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU and PSU activity under the 2015 Plan for the twelve months ended December&#160;31, 2023, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt;text-indent:22.5pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nonvested RSU and PSU Activity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except weighted average grant date fair value)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares Available for Grant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted&#160;<br/>Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.88&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.47&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.88&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403.8&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.90&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94.08&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325.6&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88.57&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105.98&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expenses</a></td>
<td class="text">The following table summarizes the share-based compensation expense included in our consolidated statements of operations for the periods shown.<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72.7&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.9&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total tax benefit related to share-based compensation expense</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions for Employee Stock Purchase Plan</a></td>
<td class="text">We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.20% - 5.47%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.60% - 3.34%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.06%&#160;- 0.07%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility of Dexcom common stock</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34% - 48%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45% - 55%</span></div></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36%&#160;- 45%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_ScheduleOfTreasuryShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Treasury Share Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_ScheduleOfTreasuryShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796223189488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue from External Customers by Geographic Areas</a></td>
<td class="text">The following table sets forth revenue by our two primary geographical markets, the United States and International, based on the geographic location to which we deliver the components, for the periods shown:<div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,625.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,142.0&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,849.4&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">997.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">599.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,622.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,909.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,448.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our long-lived assets, which consists of property and equipment, net, and operating lease right-of-use assets by geographic region:</span></div><div style="margin-bottom:6pt;margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></div></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">544.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">686.1&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">515.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">346.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other countries</span></div></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.0&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103.2&#160;</span></td><td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-lived assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,184.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,135.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text">The following table sets forth revenue by major sales channel for the twelve months ended December&#160;31, 2023, 2022 and 2021:<div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.446%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%<br/>of&#160;Total</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributor</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,095.6&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,470.8&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,024.3&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83&#160;</span></td><td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,622.3&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,909.8&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,448.5&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bcedaf;padding:0 1pt"></td><td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215260032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents', window );">Maturity threshold of investments classified to cash equivalents</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life (in years)</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod', window );">Sales return period (in days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled accounts receivable</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="nump">19,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 180,800,000<span></span>
</td>
<td class="nump">$ 160,600,000<span></span>
</td>
<td class="nump">$ 150,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ContractPaymentTermsNumberofDays', window );">Customer contract payment terms (in days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ContractPaymentTermsNumberofDays', window );">Customer contract payment terms (in days)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AmortizationPeriodForIncentiveCompensationCosts', window );">Amortization period for incentive compensation costs (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dxcm_ComputerSoftwareAndHardwareMember', window );">Computer software and hardware | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dxcm_ComputerSoftwareAndHardwareMember', window );">Computer software and hardware | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (in years)</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AmortizationPeriodForIncentiveCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Period For Incentive Compensation Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AmortizationPeriodForIncentiveCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_ContractPaymentTermsNumberofDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Payment Terms, Number of Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_ContractPaymentTermsNumberofDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity Threshold Of Investments Classified To Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_RevenueRecognitionSalesReturnsCoveragePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Sales Returns, Coverage Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_RevenueRecognitionSalesReturnsCoveragePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dxcm_ComputerSoftwareAndHardwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dxcm_ComputerSoftwareAndHardwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215233712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Schedule of Percentage of Total Revenues and Accounts Receivable by Customer (Details) - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Customer D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Customer E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Gross Accounts Receivable | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Gross Accounts Receivable | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Gross Accounts Receivable | Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Gross Accounts Receivable | Customer D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dxcm_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dxcm_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dxcm_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dxcm_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dxcm_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dxcm_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dxcm_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dxcm_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=dxcm_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=dxcm_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215790800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Schedule of Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 541.5<span></span>
</td>
<td class="nump">$ 341.2<span></span>
</td>
<td class="nump">$ 216.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDiluted', window );">Net Income (Loss) Attributable to Parent, Diluted, Total</a></td>
<td class="nump">$ 554.1<span></span>
</td>
<td class="nump">$ 352.2<span></span>
</td>
<td class="nump">$ 228.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share (in usd per share)</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share (in usd per share)</a></td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding (in shares)</a></td>
<td class="nump">386.0<span></span>
</td>
<td class="nump">389.4<span></span>
</td>
<td class="nump">386.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">425.5<span></span>
</td>
<td class="nump">427.5<span></span>
</td>
<td class="nump">428.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dxcm_CollaborativeSalesBasedMilestoneMember', window );">Collaborative sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dxcm_RestrictedAndPerformanceStockUnitsMemberMember', window );">Restricted stock units and performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (in shares)</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Senior convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (in shares)</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">28.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (in shares)</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dxcm_CollaborativeSalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dxcm_CollaborativeSalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dxcm_RestrictedAndPerformanceStockUnitsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dxcm_RestrictedAndPerformanceStockUnitsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221758976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Schedule of Outstanding Anti-Dilutive Securities Excluded in Diluted Net Income (Loss) per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dxcm_RestrictedAndPerformanceStockUnitsMemberMember', window );">Restricted stock units and performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dxcm_RestrictedAndPerformanceStockUnitsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dxcm_RestrictedAndPerformanceStockUnitsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215835808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development and Other Agreements - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DevelopmentAgreementsLineItems', window );"><strong>Development Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_CollaborativeResearchAndDevelopmentFee', window );">Collaborative research and development fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 87.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement', window );">Shares Issued In Connection With The Restated Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 195.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195.5<span></span>
</td>
<td class="nump">$ 195.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=dxcm_VerilyLifeSciencesMember', window );">Verily Life Sciences | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DevelopmentAgreementsLineItems', window );"><strong>Development Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">64 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementInitialPaymentMember', window );">Collaborative Arrangement, Initial Payment | Verily Life Sciences | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DevelopmentAgreementsLineItems', window );"><strong>Development Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_CollaborativeArrangementUpfrontFee', window );">Initial payment on collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with acquisition, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_CollaborativeResearchAndDevelopmentFee', window );">Collaborative research and development fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.1<span></span>
</td>
<td class="nump">$ 217.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementMilestonePaymentsMember', window );">Collaborative Arrangement, Milestone Payments | Verily Life Sciences | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DevelopmentAgreementsLineItems', window );"><strong>Development Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_CollaborativeResearchAndDevelopmentFee', window );">Collaborative research and development fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues', window );">Potential future common stock issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues', window );">Potential common stock issued shares (in shares)</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_CollaborativeArrangementUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_CollaborativeArrangementUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_CollaborativeResearchAndDevelopmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Research and Development Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_CollaborativeResearchAndDevelopmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DevelopmentAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DevelopmentAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Common Stock Issuable Or Issued, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PotentialFutureCommonStockIssuableSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Common Stock Issuable, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PotentialFutureCommonStockIssuableSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued In Connection With The Restated Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dxcm_VerilyLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dxcm_VerilyLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementInitialPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementInitialPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796219675984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 315.9<span></span>
</td>
<td class="nump">$ 420.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2,157.8<span></span>
</td>
<td class="nump">1,813.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">2,488.9<span></span>
</td>
<td class="nump">2,244.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">315.9<span></span>
</td>
<td class="nump">375.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">331.1<span></span>
</td>
<td class="nump">386.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2,157.8<span></span>
</td>
<td class="nump">1,813.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">2,157.8<span></span>
</td>
<td class="nump">1,858.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,612.5<span></span>
</td>
<td class="nump">1,530.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agencies | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agencies | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,612.5<span></span>
</td>
<td class="nump">1,530.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agencies | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">184.7<span></span>
</td>
<td class="nump">119.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">184.7<span></span>
</td>
<td class="nump">119.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">360.6<span></span>
</td>
<td class="nump">163.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">360.6<span></span>
</td>
<td class="nump">163.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796218607168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_FairValueAssetsLevel3TransfersAmount', window );">Transfers in or out of Level 3 securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying values of investments</a></td>
<td class="nump">38,500,000<span></span>
</td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Foreign Exchange Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Term of derivative contract</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount of outstanding hedge to currency risk</a></td>
<td class="nump">$ 71,000,000<span></span>
</td>
<td class="nump">$ 62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_FairValueAssetsLevel3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Assets, Level 3 Transfers, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_FairValueAssetsLevel3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796218585488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of Senior Convertible Notes (Details) - Senior Notes - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of outstanding senior convertible notes</a></td>
<td class="nump">$ 2,544.6<span></span>
</td>
<td class="nump">$ 3,451.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Senior Convertible Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of outstanding senior convertible notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2,136.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member', window );">Senior Convertible Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of outstanding senior convertible notes</a></td>
<td class="nump">1,262.8<span></span>
</td>
<td class="nump">1,314.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member', window );">Senior Convertible Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of outstanding senior convertible notes</a></td>
<td class="nump">$ 1,281.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221689440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Short-Term Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,157.4<span></span>
</td>
<td class="nump">$ 1,819.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Market Value</a></td>
<td class="nump">2,157.8<span></span>
</td>
<td class="nump">1,813.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,611.8<span></span>
</td>
<td class="nump">1,535.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Market Value</a></td>
<td class="nump">1,612.5<span></span>
</td>
<td class="nump">1,530.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">184.8<span></span>
</td>
<td class="nump">119.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Market Value</a></td>
<td class="nump">184.7<span></span>
</td>
<td class="nump">119.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">360.8<span></span>
</td>
<td class="nump">164.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Market Value</a></td>
<td class="nump">$ 360.6<span></span>
</td>
<td class="nump">$ 163.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215911456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt instrument (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current available-for-sale securities</a></td>
<td class="nump">$ 2,160,000,000<span></span>
</td>
<td class="nump">$ 1,810,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss', window );">Unrealized gains recognized during the reporting period on equity investments still held at the reporting date</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount', window );">Cash discounts reserve</a></td>
<td class="nump">13,700,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
<td class="nump">13,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">147,400,000<span></span>
</td>
<td class="nump">144,100,000<span></span>
</td>
<td class="nump">96,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of machinery and equipment</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">24,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=dxcm_ReceiverProductComponentMember', window );">Receiver Product Component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 16,600,000<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="nump">$ 28,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Cash Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 6)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=dxcm_ReceiverProductComponentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=dxcm_ReceiverProductComponentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221584368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable</a></td>
<td class="nump">$ 983.2<span></span>
</td>
<td class="nump">$ 720.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(9.3)<span></span>
</td>
<td class="num">(7.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Total accounts receivable, net</a></td>
<td class="nump">$ 973.9<span></span>
</td>
<td class="nump">$ 713.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222635184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 319.5<span></span>
</td>
<td class="nump">$ 159.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">210.1<span></span>
</td>
<td class="nump">130.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 559.6<span></span>
</td>
<td class="nump">$ 306.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796213247120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Prepaid and Other Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 58.7<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PrepaidInventoryCurrent', window );">Prepaid inventory</a></td>
<td class="nump">31.5<span></span>
</td>
<td class="nump">67.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DeferredCompensationPlanAssetsCurrent', window );">Deferred compensation plan assets</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">38.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">49.3<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid and other current assets</a></td>
<td class="nump">$ 168.3<span></span>
</td>
<td class="nump">$ 192.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DeferredCompensationPlanAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Plan Assets, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DeferredCompensationPlanAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PrepaidInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Inventory, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PrepaidInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796218660720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total cost</a></td>
<td class="nump">$ 1,622.5<span></span>
</td>
<td class="nump">$ 1,418.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(509.4)<span></span>
</td>
<td class="num">(363.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Total property and equipment, net</a></td>
<td class="nump">1,113.1<span></span>
</td>
<td class="nump">1,055.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land and land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">34.5<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">190.5<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">36.9<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dxcm_ComputerSoftwareAndHardwareMember', window );">Computer software and hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">65.8<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">683.3<span></span>
</td>
<td class="nump">449.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">283.4<span></span>
</td>
<td class="nump">264.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">$ 328.1<span></span>
</td>
<td class="nump">$ 542.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dxcm_ComputerSoftwareAndHardwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dxcm_ComputerSoftwareAndHardwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220778704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Intangible Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in years)</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 195.5<span></span>
</td>
<td class="nump">$ 195.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(61.0)<span></span>
</td>
<td class="num">(22.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 134.5<span></span>
</td>
<td class="nump">$ 173.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dxcm_VerilyIntangibleMember', window );">Verily intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in years)</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 152.4<span></span>
</td>
<td class="nump">$ 152.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(31.0)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 121.4<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 24.1<span></span>
</td>
<td class="nump">$ 24.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(15.0)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 15.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dxcm_AcquiredTechnologyAndIntellectualPropertyMember', window );">Acquired technology and intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in years)</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 14.6<span></span>
</td>
<td class="nump">$ 14.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(12.6)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Intangibles, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dxcm_VerilyIntangibleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dxcm_VerilyIntangibleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dxcm_AcquiredTechnologyAndIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=dxcm_AcquiredTechnologyAndIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796223235840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Amortization Expenses of Intangible Assets, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales', window );">Amortization expense included in cost of sales</a></td>
<td class="nump">$ 30.5<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense included in operating expenses</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses', window );">Total amortization of intangible assets</a></td>
<td class="nump">$ 38.6<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Intangible Assets Included In Cost Of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Intangibles Included In Cost Of Sales And Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220609152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">30.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">28.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 134.5<span></span>
</td>
<td class="nump">$ 173.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220937968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Other Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">$ 38.5<span></span>
</td>
<td class="nump">$ 19.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_LongTermDeposits', window );">Long-term deposits</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OtherLongTermAssets', window );">Other assets</a></td>
<td class="nump">22.1<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 47.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_LongTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long -Term Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_LongTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_OtherLongTermAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Long -Term Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_OtherLongTermAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221680656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable trade</a></td>
<td class="nump">$ 276.4<span></span>
</td>
<td class="nump">$ 237.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AccruedTaxAuditAndLegalFeesCurrent', window );">Accrued tax, audit, and legal fees</a></td>
<td class="nump">42.6<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PharmacyRebatesCurrent', window );">Accrued rebates</a></td>
<td class="nump">950.7<span></span>
</td>
<td class="nump">556.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Accrued warranty</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Deferred compensation plan liabilities</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">39.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 1,345.5<span></span>
</td>
<td class="nump">$ 901.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AccruedTaxAuditAndLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of accrued current tax, audit and legal fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AccruedTaxAuditAndLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PharmacyRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pharmacy Rebates, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PharmacyRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221753568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Accrued Payroll and Related Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AccruedWagesBonusesAndTaxesCurrent', window );">Accrued wages, bonus and taxes</a></td>
<td class="nump">$ 139.8<span></span>
</td>
<td class="nump">$ 96.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Other accrued employee benefits</a></td>
<td class="nump">31.2<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Total accrued payroll and related expenses</a></td>
<td class="nump">$ 171.0<span></span>
</td>
<td class="nump">$ 134.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AccruedWagesBonusesAndTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Wages, Bonuses and Taxes, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AccruedWagesBonusesAndTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221609296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Accrued Warranty (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInStandardProductWarrantyAccrualRollForward', window );"><strong>Movement in Standard Product Warranty Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Beginning balance</a></td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses', window );">Charges to costs and expenses</a></td>
<td class="nump">51.5<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">41.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualPayments', window );">Costs incurred</a></td>
<td class="num">(51.7)<span></span>
</td>
<td class="num">(43.1)<span></span>
</td>
<td class="num">(40.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Ending balance</a></td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standard Product Warranty Accrual Charges To Costs And Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardProductWarrantyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardProductWarrantyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222553152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Other Long-Term Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations</a></td>
<td class="nump">$ 58.6<span></span>
</td>
<td class="nump">$ 59.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Asset retirement obligation</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_OtherTaxLiabilitiesNoncurrent', window );">Other tax liabilities</a></td>
<td class="nump">38.7<span></span>
</td>
<td class="nump">32.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 125.6<span></span>
</td>
<td class="nump">$ 128.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_OtherTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Tax Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_OtherTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481999/410-20-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215267408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details and Other Financial Information - Schedule of Other Income (Expense), Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest and dividend income</a></td>
<td class="nump">$ 135.0<span></span>
</td>
<td class="nump">$ 23.8<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(20.3)<span></span>
</td>
<td class="num">(18.6)<span></span>
</td>
<td class="num">(18.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesGainLoss', window );">Income from equity investments</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">$ 112.7<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (9.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220894320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract', window );"><strong>Senior Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="nump">$ 2,457,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,982,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(23,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Carrying amount of senior convertible notes</a></td>
<td class="nump">2,434,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,970,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Convertible Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract', window );"><strong>Senior Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Convertible Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract', window );"><strong>Senior Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="nump">1,207,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,207,500,000<span></span>
</td>
<td class="nump">$ 1,210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Convertible Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract', window );"><strong>Senior Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796219596064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Converted Value of Notes (Details) - Senior Notes - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Total by which the notes&#8217; if-converted value exceeds their principal amount</a></td>
<td class="nump">$ 89.7<span></span>
</td>
<td class="nump">$ 1,395.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Senior Convertible Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Total by which the notes&#8217; if-converted value exceeds their principal amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,361.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member', window );">Senior Convertible Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Total by which the notes&#8217; if-converted value exceeds their principal amount</a></td>
<td class="nump">56.1<span></span>
</td>
<td class="nump">33.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member', window );">Senior Convertible Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Total by which the notes&#8217; if-converted value exceeds their principal amount</a></td>
<td class="nump">$ 33.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796219498784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Components of Interest Expense and Effective Interest Rates of Senior Convertible Notes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_CashInterestExpenseAbstract', window );"><strong>Cash interest expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual coupon interest</a></td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_NonCashInterestExpenseAbstract', window );"><strong>Non-cash interest expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense recognized on senior notes</a></td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Senior Convertible Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_NonCashInterestExpenseAbstract', window );"><strong>Non-cash interest expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member', window );">Senior Convertible Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_NonCashInterestExpenseAbstract', window );"><strong>Non-cash interest expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member', window );">Senior Convertible Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_NonCashInterestExpenseAbstract', window );"><strong>Non-cash interest expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_CashInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_CashInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_NonCashInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_NonCashInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215543776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Key Details of Convertible Notes (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,230,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,457,500,000<span></span>
</td>
<td class="nump">1,982,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Senior Convertible Notes due 2023 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible notes (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">774,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 836,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0243476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of convertible notes (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member', window );">Senior Convertible Notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible notes (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,207,500,000<span></span>
</td>
<td class="nump">1,207,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.006662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of convertible notes (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member', window );">Senior Convertible Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible notes (as a percent)</a></td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total principal amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="nump">$ 1,230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">0.0061571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of convertible notes (in usd per share) | $ / shares</a></td>
<td class="nump">$ 162.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796218635360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - 2023 Note Hedge (Details) - Senior Convertible Notes due 2023 - Senior Notes<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of convertible notes (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares', window );">Stock issued upon conversion of senior notes (in shares) | shares</a></td>
<td class="nump">20.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of 2025 Notes issuance, net of issuance costs | $</a></td>
<td class="nump">$ 218.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Associated Derivative Transactions, Number Of Shares1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222998304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - 2023 Warrants (Details) - Senior Convertible Notes due 2023 - Senior Notes<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Stock counterparties to acquire with warrants purchased (in shares) | shares</a></td>
<td class="nump">20.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of trading days | d</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of warrants | $</a></td>
<td class="nump">$ 183.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in usd per share) | $ / shares</a></td>
<td class="nump">$ 49.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796218652016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - 2028 Capped Call Transactions (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 02, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PaymentsForPurchasesOfCappedCallTransactions', window );">Purchases of capped call transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member', window );">Senior Convertible Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare', window );">Capped call, cap price (in usd per share)</a></td>
<td class="nump">$ 212.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage', window );">Sale of stock premium (as percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price (in usd per share)</a></td>
<td class="nump">$ 118.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PaymentsForPurchasesOfCappedCallTransactions', window );">Purchases of capped call transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DebtInstrumentCapCallTransactionCapPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Cap Call Transaction, Cap Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DebtInstrumentCapCallTransactionCapPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Capped Calls Initial Cap Price, Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PaymentsForPurchasesOfCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Purchases Of Capped Call Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PaymentsForPurchasesOfCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221632000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Conversion Activity for Senior Convertible Notes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Repurchase and conversions of notes (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Repurchase and conversions of notes (in shares)</a></td>
<td class="nump">12,200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Senior Convertible Notes due 2023 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled', window );">Debt instrument, convertible principal amount settled</a></td>
<td class="nump">$ 774.8<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SharesReceivedFromBenefitOfNoteHedge', window );">Shares received from Note Hedge</a></td>
<td class="nump">12,200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Senior Convertible Notes due 2023 | Senior Notes | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Repurchase and conversions of notes (in shares)</a></td>
<td class="nump">12,200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Principal Amount Exercised And Settled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_SharesReceivedFromBenefitOfNoteHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Received From Benefit Of Note Hedge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_SharesReceivedFromBenefitOfNoteHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215313968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Conversion Rights for Seniors Convertible Notes (Details) - Senior Notes<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>d</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>trading_day </div>
<div>d</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Senior Convertible Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DebtInstrumentCovenantRepurchasePricePercentage', window );">Holder's repurchase price percentage in event of fundamental change (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of trading days | d</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Senior Convertible Notes due 2023 | Debt Instrument Conversion Term One | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Proportion of applicable conversion price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member', window );">Senior Convertible Notes due 2023 | Debt Instrument Conversion Term One | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member', window );">Senior Convertible Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock', window );">Proportion of conversion price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member', window );">Senior Convertible Notes due 2025 | Debt Instrument Conversion Term One | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member', window );">Senior Convertible Notes due 2025 | Debt Instrument Conversion Term One | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member', window );">Senior Convertible Notes due 2025 | Debt Instrument Conversion Term Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member', window );">Senior Convertible Notes due 2025 | Debt Instrument Conversion Term Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Proportion of applicable conversion price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DebtInstrumentCovenantRepurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Repurchase Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DebtInstrumentCovenantRepurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Covenant, Percent Of Conversion Price, Last Reported Sale Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DebtInstrumentConversionTermAxis=dxcm_DebtInstrumentConversionTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DebtInstrumentConversionTermAxis=dxcm_DebtInstrumentConversionTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dxcm_ConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DebtInstrumentConversionTermAxis=dxcm_DebtInstrumentConversionTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DebtInstrumentConversionTermAxis=dxcm_DebtInstrumentConversionTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215928800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Availability and Outstanding Borrowings under Credit Agreement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Total available balance</a></td>
<td class="nump">$ 192.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit available</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding borrowings</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused capacity fee (as a percent)</a></td>
<td class="nump">0.175%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Minimum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused capacity fee (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Maximum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit available</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=dxcm_LondonInterbankOfferedRateLIBOR1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=dxcm_LondonInterbankOfferedRateLIBOR1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215812672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Revolving Credit Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt instrument (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposit assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt instrument (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit available</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount', window );">Option to increase revolving line of credit</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Option to Increase, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220895616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases and Other Commitments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>extensionOption</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Asset retirement obligation</a></td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Selling, general and administrative<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ImpairedLongLivedAssetsFairValue', window );">Fair value of impaired long-lived asset</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_LesseeOperatingLeasesLeaseCostAmortization', window );">Amortization of operating lease right-of-use asset</a></td>
<td class="nump">16,500,000<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear', window );">Purchase obligations</a></td>
<td class="nump">$ 793,000,000<span></span>
</td>
<td class="nump">$ 442,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm', window );">Term of purchase obligations (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms (in years)</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend', window );">Number of options to extend (in extension options) | extensionOption</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_ImpairedLongLivedAssetsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impaired Long-Lived Assets, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_ImpairedLongLivedAssetsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Options To Extend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_LesseeOperatingLeasesLeaseCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Lease Cost, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_LesseeOperatingLeasesLeaseCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recorded Unconditional Purchase Obligation Due Within One Year, Maximum Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481999/410-20-25-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796219601984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases and Other Commitments - Schedule of Maturity of Lease and Finance Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 26.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease cost</a></td>
<td class="nump">117.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future payments</a></td>
<td class="nump">101.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(21.1)<span></span>
</td>
<td class="num">$ (20.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">60.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future lease cost</a></td>
<td class="nump">91.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(28.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of future payments</a></td>
<td class="nump">63.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(4.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">$ 58.6<span></span>
</td>
<td class="nump">$ 59.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796225709712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases and Other Commitments - Schedule of Components of Lease Expense and Other Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">22.6<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Right-of-use asset impairment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 43.3<span></span>
</td>
<td class="nump">$ 49.3<span></span>
</td>
<td class="nump">$ 38.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222467120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases and Other Commitments - Other Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 28.1<span></span>
</td>
<td class="nump">$ 26.0<span></span>
</td>
<td class="nump">$ 23.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for finance lease liabilities</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 16.1<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term of operating leases (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term of finance leases (in years)</a></td>
<td class="text">14 years 1 month 6 days<span></span>
</td>
<td class="text">15 years 2 months 12 days<span></span>
</td>
<td class="text">15 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate of operating leases (as a percent)</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate of finance leases (as a percent)</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796214128848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income (Loss) before Income Taxes Subject to Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">$ 732.4<span></span>
</td>
<td class="nump">$ 463.5<span></span>
</td>
<td class="nump">$ 318.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Outside of the United States</a></td>
<td class="num">(22.0)<span></span>
</td>
<td class="num">(72.7)<span></span>
</td>
<td class="num">(61.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">$ 710.4<span></span>
</td>
<td class="nump">$ 390.8<span></span>
</td>
<td class="nump">$ 256.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215232912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 149.1<span></span>
</td>
<td class="nump">$ 32.6<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">18.1<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">56.7<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income taxes</a></td>
<td class="nump">223.9<span></span>
</td>
<td class="nump">71.2<span></span>
</td>
<td class="nump">24.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(93.7)<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="num">(17.6)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income taxes</a></td>
<td class="num">(55.0)<span></span>
</td>
<td class="num">(21.6)<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes at effective rates</a></td>
<td class="nump">$ 168.9<span></span>
</td>
<td class="nump">$ 49.6<span></span>
</td>
<td class="nump">$ 39.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796221860048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Tax Credits and Operating Loss Carryforwards (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 20.4<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | R&amp;D credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Foreign tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">167.7<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | R&amp;D credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">111.9<span></span>
</td>
<td class="nump">96.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | AMT Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Other states</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">90.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Other foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=dxcm_ResearchDevelopmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=dxcm_ResearchDevelopmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=dxcm_ForeignTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=dxcm_ForeignTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=dxcm_AMTTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=dxcm_AMTTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=dxcm_OtherStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=dxcm_OtherStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=dxcm_OtherForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=dxcm_OtherForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220712256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_UnusedExpiredFederalIncomeTaxCredits', window );">Tax credit carryforwards subject to expiration</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Capitalized research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance amount</a></td>
<td class="nump">264.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, deferred tax asset, increase (decrease), amount</a></td>
<td class="nump">185.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="nump">$ 29.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets', window );">Potential adjustment to other tax accounts, including deferred tax assets</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PossibleExtensionPeriodofTaxHoliday', window );">Possible extension period of tax holiday (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_PreferentialTaxRatePeriod', window );">Preferential tax rate period (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed foreign earnings</a></td>
<td class="nump">$ 36.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance amount</a></td>
<td class="nump">$ 264.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PossibleExtensionPeriodofTaxHoliday">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Possible Extension Period of Tax Holiday</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PossibleExtensionPeriodofTaxHoliday</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_PreferentialTaxRatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferential Tax Rate Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_PreferentialTaxRatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Potential Adjustment To Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_UnusedExpiredFederalIncomeTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal income tax credits likely to expire unused as a result of limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_UnusedExpiredFederalIncomeTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482620/740-10-25-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 740<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481141/942-740-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 740<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480135/944-740-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796219507280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 18.1<span></span>
</td>
<td class="nump">$ 46.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development expenses</a></td>
<td class="nump">233.4<span></span>
</td>
<td class="nump">211.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">71.4<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets', window );">Fixed and intangible assets</a></td>
<td class="nump">279.8<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities and reserves</a></td>
<td class="nump">91.0<span></span>
</td>
<td class="nump">105.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DeferredTaxAssetsConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">741.3<span></span>
</td>
<td class="nump">485.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(264.3)<span></span>
</td>
<td class="num">(78.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="nump">477.0<span></span>
</td>
<td class="nump">406.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets', window );">Fixed assets and acquired intangibles assets</a></td>
<td class="num">(60.4)<span></span>
</td>
<td class="num">(69.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(60.4)<span></span>
</td>
<td class="num">(70.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 416.6<span></span>
</td>
<td class="nump">$ 336.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DeferredTaxAssetsConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DeferredTaxAssetsConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Fixed Assets and Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Fixed Assets And Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796218750896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation between Effective Tax Rate and Statutory Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="nump">$ 149.2<span></span>
</td>
<td class="nump">$ 82.1<span></span>
</td>
<td class="nump">$ 53.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_EffectiveIncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(28.3)<span></span>
</td>
<td class="num">(23.3)<span></span>
</td>
<td class="num">(28.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">Foreign tax credit</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock and officers compensation</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(20.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment', window );">Collaboration agreement milestone share-based payment</a></td>
<td class="num">(72.1)<span></span>
</td>
<td class="num">(52.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in statutory tax rates</a></td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer', window );">Intellectual property transfer</a></td>
<td class="nump">63.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">14.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes at effective rates</a></td>
<td class="nump">$ 168.9<span></span>
</td>
<td class="nump">$ 49.6<span></span>
</td>
<td class="nump">$ 39.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Collaboration Agreement Milestone, Share-based Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Intellectual Property Transfer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_EffectiveIncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Permanent Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_EffectiveIncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222482288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of period</a></td>
<td class="nump">$ 52.0<span></span>
</td>
<td class="nump">$ 46.8<span></span>
</td>
<td class="nump">$ 36.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of period</a></td>
<td class="nump">$ 59.4<span></span>
</td>
<td class="nump">$ 52.0<span></span>
</td>
<td class="nump">$ 46.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796212783328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans and Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Aug. 03, 2022</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Jul. 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum payroll deductions (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_EmployeePurchasePriceFloorPercentage', window );">Employee purchase price floor (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized', window );">Stock authorized in ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased under the Share Repurchase Program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,700,000<span></span>
</td>
<td class="nump">$ 557,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=dxcm_ShareRepurchaseProgramMember', window );">Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 142,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=dxcm_AcceleratedShareRepurchaseASRMember', window );">Accelerated Share Repurchase (ASR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount', window );">Accelerated share repurchase agreement, authorized amount</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Payments for repurchase of equity</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased under the Share Repurchase Program (in shares)</a></td>
<td class="num">(4,700,000)<span></span>
</td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="num">(4,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dxcm_A401kPlanMember', window );">401(k) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum employee contribution (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employee contribution (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total matching contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dxcm_EmployeeStockPurchasePlan2015Member', window );">ESPP 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock available for issuance for future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dxcm_EquityIncentivePlan2015Member', window );">EIP 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock available for issuance for future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="nump">15,300,000<span></span>
</td>
<td class="nump">16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,800,000<span></span>
</td>
<td class="nump">$ 160,100,000<span></span>
</td>
<td class="nump">$ 284,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember', window );">RSUs and PSUs | EIP 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock available for issuance for future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs recognized weighted average period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | EIP 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Common received vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Common received vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | EIP 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchase Agreement, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_EmployeePurchasePriceFloorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee purchase price floor, percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_EmployeePurchasePriceFloorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan (ESPP), Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=dxcm_ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=dxcm_ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=dxcm_AcceleratedShareRepurchaseASRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=dxcm_AcceleratedShareRepurchaseASRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dxcm_A401kPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dxcm_A401kPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dxcm_EmployeeStockPurchasePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dxcm_EmployeeStockPurchasePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dxcm_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dxcm_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796220619248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans and Stockholders' Equity - Schedule of Treasure Share Activity (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_IncreaseDecreaseInTreasuryStockRollForward', window );"><strong>Increase (Decrease) In Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued in connection with 2023 Notes conversions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SharesReceivedFromExerciseOfNoteHedge', window );">Shares received from note hedge (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone', window );">Shares issued in connection with the Restated Collaboration Agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased under the Share Repurchase Program (in shares)</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dxcm_A2022ShareRepurchaseProgramMember', window );">2022 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_IncreaseDecreaseInTreasuryStockRollForward', window );"><strong>Increase (Decrease) In Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased under the Share Repurchase Program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dxcm_A2023ShareRepurchaseProgramMember', window );">2023 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_IncreaseDecreaseInTreasuryStockRollForward', window );"><strong>Increase (Decrease) In Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased under the Share Repurchase Program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dxcm_A2028NotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_IncreaseDecreaseInTreasuryStockRollForward', window );"><strong>Increase (Decrease) In Treasury Stock [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased under the Share Repurchase Program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_IncreaseDecreaseInTreasuryStockRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Treasury Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_IncreaseDecreaseInTreasuryStockRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_SharesReceivedFromExerciseOfNoteHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Received From Exercise Of Note Hedge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_SharesReceivedFromExerciseOfNoteHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Achievement Of Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dxcm_A2022ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dxcm_A2022ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dxcm_A2023ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dxcm_A2023ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dxcm_A2028NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dxcm_A2028NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796216161584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans and Stockholders' Equity - Schedule of RSU and PSU Activity (Details) - EIP 2015 - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant at beginning of period (in shares)</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested', window );">Vested (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant at end of period (in shares)</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dxcm_EquityIncentivePlan2015Member', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant at end of period (in shares)</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares)</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares)</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160; Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share)</a></td>
<td class="nump">$ 94.08<span></span>
</td>
<td class="nump">$ 76.88<span></span>
</td>
<td class="nump">$ 45.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">112.01<span></span>
</td>
<td class="nump">96.79<span></span>
</td>
<td class="nump">87.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share)</a></td>
<td class="nump">88.57<span></span>
</td>
<td class="nump">63.90<span></span>
</td>
<td class="nump">34.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="nump">106.34<span></span>
</td>
<td class="nump">92.54<span></span>
</td>
<td class="nump">69.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share)</a></td>
<td class="nump">$ 105.98<span></span>
</td>
<td class="nump">$ 94.08<span></span>
</td>
<td class="nump">$ 76.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate Intrinsic&#160;Value</a></td>
<td class="nump">$ 361.2<span></span>
</td>
<td class="nump">$ 325.6<span></span>
</td>
<td class="nump">$ 403.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dxcm_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dxcm_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796222388800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans and Stockholders' Equity - Schedule of Share-Based Compensation Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 150.8<span></span>
</td>
<td class="nump">$ 126.5<span></span>
</td>
<td class="nump">$ 113.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Total tax benefit related to share-based compensation expense</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="nump">43.2<span></span>
</td>
<td class="nump">71.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">41.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 90.7<span></span>
</td>
<td class="nump">$ 72.7<span></span>
</td>
<td class="nump">$ 63.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796219573840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans and Stockholders' Equity - Schedule of Valuation Assumptions for Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (as a percent)</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of common stock (as a percent)</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (as a percent)</a></td>
<td class="nump">5.47%<span></span>
</td>
<td class="nump">3.34%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of common stock (as a percent)</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dxcm_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dxcm_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215305952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment and Geographic Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>primaryMarket </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_NumberOfPrimaryGeographicMarkets', window );">Number of primary geographic markets | primaryMarket</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_NumberOfPrimaryGeographicMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Primary Geographic Markets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_NumberOfPrimaryGeographicMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796213668336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment and Geographic Information - Summary (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,622.3<span></span>
</td>
<td class="nump">$ 2,909.8<span></span>
</td>
<td class="nump">$ 2,448.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_RevenuePercentage', window );">Proportion of revenue (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember', window );">Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,095.6<span></span>
</td>
<td class="nump">$ 2,470.8<span></span>
</td>
<td class="nump">$ 2,024.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_RevenuePercentage', window );">Proportion of revenue (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember', window );">Direct</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 526.7<span></span>
</td>
<td class="nump">$ 439.0<span></span>
</td>
<td class="nump">$ 424.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_RevenuePercentage', window );">Proportion of revenue (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 2,625.3<span></span>
</td>
<td class="nump">$ 2,142.0<span></span>
</td>
<td class="nump">$ 1,849.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_RevenuePercentage', window );">Proportion of revenue (as a percent)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 997.0<span></span>
</td>
<td class="nump">$ 767.8<span></span>
</td>
<td class="nump">$ 599.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_RevenuePercentage', window );">Proportion of revenue (as a percent)</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_RevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_RevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796219489920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Segment and Geographic Information - Geographic Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets</a></td>
<td class="nump">$ 1,184.5<span></span>
</td>
<td class="nump">$ 1,135.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets</a></td>
<td class="nump">544.1<span></span>
</td>
<td class="nump">686.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MY', window );">Malaysia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets</a></td>
<td class="nump">515.4<span></span>
</td>
<td class="nump">346.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=dxcm_OtherCountriesMember', window );">Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total long-lived assets</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="nump">$ 103.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=dxcm_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=dxcm_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139796215771920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments', window );">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction, Write-offs and Adjustments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesRecoveries', window );">SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the write-offs and adjustments in a given period to allowances and reserves for doubtful accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dxcm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from recovery of amount previously written off or reestablishment of reserve previously utilized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M)E5O8TY3U7X"UP'J^I(QN1WH!J=I:*,_4$L#!!0    ( ,^)2%@#>/4]$04
M ( 4   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK5C;;N,V$/T5PET4
M62"11>J>.@82J]OF(=T@[K8/11]HB[:%E427I.WT[TM*LB2+E!*@\8.MRYGQ
MG+EQR-F)LN]\1X@ KWE6\+O)3HC][73*USN28V[1/2GDFPUE.1;REFVG?,\(
M3DJA/)LBV_:G.4Z+R7Q6/GMF\QD]B"PMR#,#_)#GF/W[0#)ZNIO R?G!2[K=
M"?5@.I_M\98LB?BV?V;R;MIH2=*<%#RE!6!D<S>YA[<QLI5 B?@C)2?>N0:*
MRHK2[^KF,;F;V,HBDI&U4"JP_#F2!<DRI4G:\4^M=-+\IQ+L7I^U?RG)2S(K
MS,F"9G^FB=C=3<()2,@&'S+Q0D^_DIJ0I_2M:<;+;W"JL?8$K ]<T+P6EA;D
M:5']XM?:$1T!Z \(H%H ]07< 0&G%G#>*^#6 F[IF8I*Z8<8"SR?,7H"3*&E
M-G51.K.4EO330L5]*9A\FTHY,5_0@M,L3; @"5@*^2.#*CB@&_!U3QA6P>'@
M!GQ;QN#JTV? =Y@1#M("/*59IEY>@T_=V]E42+.4\NFZ-N&A,@$-F  1>**%
MV''P<Y&0Y%+!5/)I2*$SJ0<TJC$F:PLX\!H@&SD&@Q;O%T<&\?C]XG"$C=.$
MR"GU.0/Z'HLUS4D;'/#7_8H+)BOF;Y.S*V6N69EJ([=\C]?D;B+[!"?L2";S
M'W^ OOV3R5$?J2S^(&473G0;)[ICVN<OY$B* S$YK!+T2D'5)H]SQT?(DHES
M[+I"AZ'(CJSP$A8;8*X;6EX#NS#?:\SW1LU?4"Y437*<$6.)5>)!YV^AXSB6
MVR-A@-G(MX(>B0KF=V"!'YH9^ T#?Y3!+XQR#O:,;E)A(N!KEB$4AE;4(Z##
M8!@Z%NP1,,#\T!Z*0M!P"$8KL>Z(Q1:05[GP<L)O352"CZS CU06?Y"R"^>%
MC?/"-RJ0$\S6.X"+1*[,1SER[%4[,WDPU,+GV5Z_U!8ZR@U="_52P: +!IV$
MN2 3-62B-^HQR_"*JFPX$L &J($-,7:<2"LONT?M340<:;3"P+*C[L=,$=KM
M:&"/DES*:4PF^S78DD(F?E;2PXF<0E*U_BCJQM7>UHL/AI[6BTPXVPZT9F3
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M/4=[=I?5SO9*OY@"P)+74D@S]PIK-[=!8+("2F9\M0&);U9*E\SB4J\#L]'
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M:6'GN!U9U0=?\V'6]?9:77U/SF^M:_->G*8\D7%6QLT->7G*!1*HTMIPHKH
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M%N^>5/FF^<;<V[RJ\G7S<,7B)2OJ!OSO=WE>/3VIOX1W_\715_\%4$L#!!0
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MO*SPOF9Y+@>MO)I7L@O*T#QI?NY3_7-XY.<0]K[RHMJ5WL]%RM*^@;GL>TL
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M'"-DRZ)@9.7!1O-@M^:Y:9A(=D**5<U.L%R74UQK#[9%"UD,U_X-@%I:RAL
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M990W6'M;69II P$)L80U:(_X8U=-J-&5]-1Y9EM0'2\9JQLH^3&MZWCQ#YR
M4ELARLQAI5I 1P96;0- T5&Q&1BQ&;BK>KTLI'/.-I<VLJ)^*$'Z";Z+>M$B
MWT6M19>RUO>H$;'!:1'KZ5L/Z5'H9+UCW@N+A<XUKY?K0*<"&A-;ARXP:GCO
M#$*-7CL+C%H-W 6^4^3<=]$:X_V+UY8XV@ PA*A-$8"%5HJ8=YZNV#/QH)]2
M*3T=U/5S"NVG[9,P-_KYC\'GG]#'J'Z>Q9BI'Z_Y&@NY"RN]G&VE27^VD%T2
M]1,K]9N*'_0S'/>\JOA>O]RQ6"9=!9#?;[E,K,T;]0/M<T/K_P-02P,$%
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MV+O2'_ /L>JY!O)U:M6_,JO^UID*\NQ'>0!TT&223T/:LDC\&!_?1!<I]8\
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M&L 'X/M-T_3Z!VYP;-KW!-Z+_P=02P,$%     @ SXE(6$0?X_:R"@  *1X
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MI+EYRI+2EDNGJB@80,"13Y!&S!-PP,V.>/S;R7R^_S(NYB^SET]A0*FSDLP
M<< R,L$+^&B3ZKVZ4_&EU![;F@J R(5MG;!.+[61U8/-S?FDLW8)<A"SZ-VC
M'5)%)F]J(SYDP4;OSY[MX$%6M3D@SMHZ>R.K<"/LHM)+/M6+QMDK[?EC"QDP
MKI1AT%$.EGQLG6\E=(+YOV([QWWD^E)>J2@O)Q$9YUZKZ/,W"UR0A1&'0HI,
MN8#"(HRZ#KM(4)6DG__QCE3.VPSR27AC \[2LL)V:Q0T%[5%!LL\U[2#_#SL
M\3L"Y6R(YTI7551,7<-3'C" 8G6M7 :1^C_Q4$<$[RF6/[=:R,K;Z-4<H&Q]
M#"%P.9Q0I3##\A;_8+MB$+90%CL;V YCBLYQ(!%4&@IBX6S-OL_&AT='=!Y+
MFQI)?O$$ =Z1#RF^@S)BV@+L1E3'>^^9C-,7E;7Y+A6^G+Q*6CH?-/E:+*LV
MLU"]MD8'@ 6Z=1Z.[H\AHZ \\>WB&XSCF"<=DRL NBZW)/:@<_!P&IU-&E/8
M"JVJG!"N@T >D9[60"A#%272YD^GXG*3TXTUN_>]'J.9T#YD^NSXI1>6B6]]
M0-(^F)%\N=V/"&])+OJN3>[)IFT^&P<0=N^F'T@@*(P"XFT15N2EHC59!#9"
MH7X5E4[]:+6+ODFP&Y1EC$D/F8L*F5 @1>X86DF<6JZU48WSZXE_&@F$-*7?
MNN"GF&:W*2_+K(OL-& C@)GQA(Z*T; L 1'T*>.[,%,F4\JK:Y6UM$#X!I#"
M4\X3):$QSKT !/!UQ$0XK::V%W'5-M<9>X!^K^5WRI0L$2+5BA#9ZK[R3PAB
MT%<"6+&6^ Q(H1-EB] ['5!Z%C=$=![ :Q&J2\/?H+WKT^P. J$3-]PH:?2K
M1B#&=-UQM(J<.4YK@1IC.D?_G)QI54H)+Y8.Q!XM;2,:Z6<N*RPZ2;U?%ICD
M:XFL;1MXG1Z@YA C7ZF=7E '9Z>6+5QJ'=S=4!PIO^1-'9F*5C,A<QAZ8N]7
M<,"SKF4+PLM*^410M<;G #3 10!!5#\K-=S3&= !S.$9UQWIEHIH_2_%2&RQ
MC$Z(H>Y/&4F&(IPA$.)+2=D$L532(R\)+,N^$UM1LH$QM$$3V4;=$UHX)SJ<
MG'T^%U]LHS-Q/#N)B;S-4^2?#393NB4;\ -9(6]!*>V08)#<QPQ%/J&]*%74
M:0P[&!]KIX^E<:&4Z9P9.S8ZSJG,+@TX(!^DW/$X]QS*-S%]USJ56#TG*'%>
M+\B]T1$PN%4#;:P+![:FZF1B%-"\$W7$,#1.4PH9Y'^6&M*3OB&-]1\^>C1_
M/CTZ)O-C2*?B:\0QVWG907G X&6TM,"!J# _6ND"<50QM+J<#<A$;?08OC$J
MILL342@V[]'\:'^Z3V95FG'K;+LL^0SMJ=^*/' \/>S7;,8>8YD"X[BWAO#9
M\?2XWYB5!'F";]P(KJQT["J9+:*%)+=)!(7@M%RIR+K(AXFN[RH8RKX^IP L
M5":ISO O0\ [=^0Z1X$.D8DYR++18>A ,A HJ%&N@T.T@^+W<P 4]V*\ 13<
M)<$+]'/?(-H%<8:*-&:PR7OI;M:E9Z1-=/HT\Y$?>WEW\FM7W$K&%>8B]J3*
MN4! F><C',$MOAPXM7<?V74PG?>QS6,G';.E;BK5U9>.]L:58EQ1F'5'J($$
M/\*[I#+HE72I_(_%J.N&.ZJ' &HZ#-VWDGE+7LUG[(]<X4G=!V,MU]PGS0%X
M\,Y"]2R3HM6EBA&/3HZGL]Z=&VW^&SF4AL!N)_G46S10M(?[U,N/GQ[+NGEY
M,<"-&@M#"Y$<,D,Y\<S(!&K+ ^BF D$MDRJH!<\MW$H9%@<O2*O@0",91D7+
M32OR<]J[7J.CON/Y^4["AM+$_9L.C? 5\^GS7R IL@U^,^EVCCU :]8&-#9@
M?1"G6W%R1]O?+\YNJ_ES!&THK[>A,Q5G'HUM5O)Q/6TEJ46+#N867:T7NB,>
MS8[F ZW'09[*1I!FJ1FB%/[(?UOJ_J@X/KCUN4>M&\X9E=H78O94'(V89W.D
MHTEQXF?5]*WK(504BLK\Z8.J]SI&GZY9IOW_!:.3A^^&-':Y"VJP,6DQ<EK?
M7=+0O2--FKMT3X?JB%$";K^BL10J(""ZYIQ Z@)J:.$+#MZS0QHLZ?*U:R'>
M,7\A+5)KV253.C16V9["_;BAXPSU#!T&Q,-:!DZU>)<:9;U'*R\.N\NUR]X;
MR('W*J1KMJ%ZC<XH,&T8FC7'IT'B1Z2]N+S<P>RO:G'2-R!GQM#,_DDUL'$[
M61QP]B;F.AAU2?\3YHIDNC:;IN*SBA#"I)U:XR"OA2-D41!@<*5C>#KGG0S.
M@T)*?)'7RC_8<45W.:9-?*G#+4+T$6FP4$85A+*M@V\_^XUJ*_LL&7IK7$N9
M@C&;KAHYCR@KSJIJ3"^UO&&"E3IBCUH>Z[8S2^"'W4L>Q+K@>^8J737Q#!E[
MF7N]I^\.H9GSAJD\GMDU5RO;5CEIA$$.+DQN,"TS#"5%5(SGJ+B6KRI6VM.T
MU(&JLW^)")LU'7!-MWI-I;%T<<,K>RHFTR+D4GAZVD%HU)6\.T)UTUD<HF7^
MK?4I?G1X AK?6Y.]+-CC9)JZ<TVW*2;'1W*YAEP)OUZ1GWB>H-LPP[*@>-*!
M7OHQ68\ OGZ\VSZN?&VL>6#Z1-7B3=#0"T>8.IHV:7J%:L,&FK3@X);#/A0*
MI@"&/IJ"7[TWX:%#78=XW\[W3+W$]*+JA%QUY^'!P73=NY^]T>N[6J$FTTM*
M&J,PQ\<W>?W3_CWH67S]-RR/+U'!]DL-\JU4@:W[T^.C2;RQ[+X$V_#+P(4-
MP=;\L508,1PMP.^%!=&D+W1 _W;X]+]02P,$%     @ SXE(6,A]HWA/"P
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MA1Q82*\#[FARVVDV7#J-'%CZM>D$G<'4%!H D05\2CV;MYQ) OH.V^W]NGI
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M]Q+BC^OX8L^X7J>>; WF#P2"D(^B0)8[;72_PXM3OP*Y[/SR!SWXDG_?1#
MM'4_ FJ?MC^ANG:_'-HM=[^_>H.THE/W7"ZP%=4D.1/&_:;)W5A=\N^(9MJB
MX>?+E40A,[0 [Q<:G;&_(0;M#\N>_0=02P,$%     @ SXE(6-E=#[_2%
MPT(  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULQ5S[;QLYDOY7"*^S
ML!=R6]VR;,5Y (XSV<EB\T"<V<'A<#]0W93$33^49K<5WU]_]2#9;*DE.S>#
M.P2()34?Q6+55U\5*;W<5/4WLU*J$3^*O#2OCE9-L[X^/S?I2A721-5:E?!D
M4=6%;.!MO3PWZUK)C#H5^7DR'E^>%U*71Z]?TF>?Z]<OJ[;)=:D^U\*T12'K
MAS<JKS:OCN(C]\$7O5PU^,'YZY=KN51WJOEM_;F&=^=^E$P7JC2Z*D6M%J^.
M;N+K-Q?8GAK\2ZN-"5X+7,F\JK[AF_?9JZ,Q"J1RE38X@H0_]^I6Y3D.!&)\
MMV,>^2FQ8_C:C?Z.U@YKF4NC;JO\=YTUJU='LR.1J85L\^9+M?E5V?5,<;RT
MR@W]+S;<-KDZ$FEKFJJPG4&"0I?\5_ZP>@@ZS,9[.B2V0T)R\T0DY5O9R-<O
MZVHC:FP-H^$+6BKU!N%TB9MRU]3P5$._YO5;-6]>GC<P$KX_3VVO-]PKV=,K
M3L2'JFQ61OQ29BKK#W .(G@Y$B?'F^3@B&]5&HE)/!+).)D<&&_BUS6A\28'
MUB7>:I/FE6EK)?[S9FZ:&FS@OX96RV-=#(^%?G%MUC)5KX[ \(VJ[]71Z[_^
M);X<OS@@Z867].+0Z'MWX'"O:21HB7>JU%4M;JOR7M6-GN=*?*P:9<37E1*I
MK.L'72Z%+*JV;(RH%J)JP26Y4QIT*JG31H&JI!&+*@=O-?@2NC0P5";QN2XS
MG<*K[!IF3U4Q5S5MVLG[$HPSS\'/S"EM(?Z7B,^U+E.]EKF5X'J_O%FKN..Q
M^.M?9DF<O(!75U<7T>S1/E,1CY+Q5=3]?:S'#%M.Q]'8S_6U:D#*]9:\(AE=
M3'G@Y[,DFHC?2G@ (_ZWRL#W0?_:F%:6*>BZ,J#@DV0234[%29Q$XU-QV]<_
MZG*OZH]QKLE%E, KF.UJ#+,![AS>+P!EL5GI=$5[I!=GM@E(=R]S6*OZD2H%
M'DK/MU<WHD^M;+JDQH9VO&NYD>;/-(B?V_YX-+F,G["=4S&]C&(QF4273]AZ
M:M;?]_E#H$92+3V_>K%?IP;;ZGK79([%['ETQ=(_GX)8Z(FL/S2%1J)(' /!
MC&@8V-EB797*NJ@N&_!#T\!,$'L-;%')&Z@6"T51K&M22V<'2H+\CSDX-B13
M4+6N8 UF56W*:_%UHW(8-<3TO5L(_\5@V6:U(^<U:IU M@5UI%4+:^H:G<2G
MH)3GH!#0$'@UOI[ WI1GZ?!@-^QIDJ(W+&S(WZY@B&GT7%R"*_-6[BBO5FFU
M+,EC81RK&>=S\65T@7\N>,>F,-POPTI^"G2=)*<BA@4^Z_W_N/6.P<:?]?Y_
MW(K'(/$S\3?XAXI][T2%)>+^DCC<8ZZ6$ME/6K=H?[PI3HMH6=J(M7Q@LU2%
M/I-E"?N7/^!8_VA+)6)JYOT[QLT@:WM0LHZ&YI[^&7-_D ^P(]3L8W5OYYX^
M/OGL_VQRW.^O^_U2$%LH$3EJ95^SO]-3N5[G )XX?=\MP84;T\#4('9$$SQN
M>L!/@>:0B7<;Q6R*%@'K"H?=0GBCFB:'WO R4R:M]1S>S)&Q1V!@,%4H+#0J
MJY PA./*!A8"BL7P$/4$9KK"W/\IF/A-/8 PC=0YPQ;B6@L.G=(Z]R)<YXPX
M",)X,G[1N0-]$+\X'?W$6-/ML:;;8Z&&GS[>;'N\67^\ U#S"2RM1I7=0L3(
M%4'C6S2F#[C_NGG@=W<-QN3..;[@AS?+90TN :\Z6G;#,>LC9'^?ZXKC&N.)
M;C0\9PDH Z,QT.)/P$K%<3P:C\<[T>\T[ '3@*=1<[.2M3J%=:&=04[7B ^J
M66$$.IF<AFCEG2T9Q[-=4P;4FSX3QS/B;C8ZP=O))81T]S:YB"875Y<\)X#\
M11R-KSABP3Z=5[5[$@ 5NCN\'8?./G+@G."4<01A;^YF!&1_[M_!Y)?0U<T7
M@W!QO&?"67_"B06:D0/UR96=;!I.!NVZR>+I5=Q-=IE$%X.3X3;BOJ[=OH)7
MIC)/VYQL8X[>E;4 6^B R .]>>Q0FD5=%<PPK5FLVSI=02Y<>YZ40:K%.0;Z
M MB<+F@:#M.9ABC< ++6BF=O*AJOLN;,4'K7SO\-S?"AS/X-N6]!@$F@M(#\
M)T.2RF)D\ 1\S41D/X@F>YVN  7/E8<X& +YQDA :IU^&PGH(Y%_S77)3 ,F
MJ%6U@ 95KD!D0#2$'EQ@30X7B=^5:(%9['#N@FR:T$I"H"EH_=X='N-FL&SD
M@6W#(V^HH("@#.WD4KE]A6&@68%<!E?00U^<.=-YB]T@0I7PF1'>_R*PO6!S
M(?99!0.&(S39$+I70.B*<:KB8 -@$XE/J"WH);%" PFVIEJ+X7TFRX)%P2@2
MU+YHRTSBC$@.H<=2L;' 1*!JG9'ZS0BT6"]!98*U"!9L9.Z:4D$$ X@L&WU&
M2Z7:3F<NH[Z%]"0YJ'Y02]YF*I@#P+-P(MZK4M+HW P'=.M2]XZXVVJ0D OH
M&F04C]DF*A^G<6Q$%V Z&APE!Q5[<!2_J@S, &@Y#%3:JM9&-ZN>*[G\K,-4
ME'D+5S? 62@VH#^0W?4E$RN:"KA\::3=4IYI4[D)=K%@=^K=('R+(*'JM839
MNHB'TF@L& )-(T=P@P)KP[<)LEV'[YT?X'[V? %\59:=9!1_H)T- =X11CY9
MXCT"9#1#V,/D"R%L9VEV,Y \'2?Q#%(0)QYN).@7>"<ME>% -PAC()OZWF*4
MUB4X2TN!</[@4Q1<_]9H&HT[T[@%Y+(Z.R,$6VMTHZRE+<<]95FWY8,D2.^A
MA<,=0!68.*46I&L,$8Q':VA4DE[M&KSW$;.6Y<,6V&V9@HU.8*?HT]0<@Y9'
M(=09^2N,7O/LA?RF^H6)H3(&(Z+#X&!&[2H5&F#\OLI!WV<[J,I&XDUCT*R"
MC%\@R'U3G6T-6 5K]@D-G:7FJ+H:C!H4F1D7' -M#@]B7!83&*\#I3"  NXJ
MSB\8T?9)?5/ZL*5^J#K59J_@8+0M,PJ !IT1D@20#)F0T:4U',Z..M@ _*1%
M;:HVQ\1D(Q\P6=OJ3W"#*K$+(XU8^N(* @<BW9U2G,!P-+9IS=IU#71+YP)H
MSUO<9$O-%G7 516(1ZD297+*(.)C7L@J<W2J5G@D0JD6EC$&7,*IG3[X7=8U
M!AB$]QY6C\@Q<E,A'P%D<>U"*?N@2AB6DA?]''P&B.#%L>XH2HS#Y""FX_"4
M6"+!I(0V$V5+8B.NNOX;F-6B$(*0PUT4_1(H<PJ!ID5:!J&&@FJ&Q@!\IJ:8
M38DX1 *+61=$O?P6',>S230+H9(1Q1%>3UN10/34[Y8WL@%@PV6B.F."^-.(
MZ]65DDVO %S0YIPM.P\H2>6[YNHV4_U B$4ZU3BD2X<1R8HAQ1+&+X$R23SE
MH$VQ-80G89:3^Q'$\LO3)H"LXXOG$>QAMXH_A$;68B -J14MQ/1X=E/3$A_L
M5(\R[5W9-RM56H+M?'0G&#@=6Q?Y"69-Z=NM7*_A^2T66[Z&W.E]Z1,^8F-/
M)' S1^"V^1ILT3W10_#+9=5H3K5X]A1G[S&WG6I#(&='P4@0S]4A&X(@2_54
MR.4:"O3&6WQ_"'9RY,CUJ$>D]G%T;(2:M89D-+BPK-D+*M.KC'4PYY5!-7J/
M- ?8(/D1R=89+5E?KM76J/M6AK;F^=!2E6 F.$K'C#I6Y!=J$XV>*$21!BUT
M]D1ZQ(OYTSB2UZ:-8RF2;4Y'1FP*IDU7O,K&TMI OG"7T?#VZ8^1L*/DT#2@
MY4F<1)=)R,L':;B'Z:"*BF%'%;HM<*#9^)E Z^.5Y)6Q%<X]X(E3QX#?<1+R
M/DY^/TJ3R>_B[WDU!W'OZ/8 QJ!OJG%EX23DSY0<A E+,Z@'FG(<1Q,?K3!S
M\#$'<X- U[3ZO2%(EW9)+FW&:H[,J:Q-%P&,V]1=.0 W64F0O@/:2,*U- <,
MU0L\R+-QE/2T KX15'B8]4=A@>_&42<<96_-\ITM;H<9Z:VNT[9 #$CI?,&(
M7)O&%9U%E:9MC09NXQQV_]X"*< L4]'Q5.^X$0^F1I8JN$L$7)6E XS)V&W9
M#2L:.=MHF^51+3O,A&T4KM8A?;-:87+Q#UFV6"EPY<EF55?M<B5NVB78KA<E
MZJ]WRJ>J0R 7'-KHDMCCG5HWA_(V\VCIWZZ+ZL48,FPEC#ER,U"(=Z<1KOIN
M76. ,U^+=]I P!&?F73<>HAAT0Z4G+NF=XS@[R&.VVPY*!/;AU\<YR.U_Q)D
M)]N927P>G],YY9F(D_.)?1.HZSC& WWGAN/H(GC=N:<=9A(.,^D-PW<3?/LD
M2H;?A"5TI!OFL+?\:NWKL6HA(2LE&C@H1R3+^0V_\Y!$/DX%8CP$PFRHGY)H
M=QX*!A^/$4O=Q[LW!M:0O%%THG,UROKPZ ,QRA]^C3C<D>^P(Y>,Q'*@!BA.
M#M1W>]4[?S9_2LR0 CLE1O-^1 21D2RJ;:.E0S?4A7/AS<I7OGIJ&"!HAVJ8
MO$8;<JK:B>J*I'04AFH/W(R<*P>#!NR 5/HM!.^J8 V!"#9NP7)4L>:*\]!Y
MF;UB9[;7R7AE?#[[U,L!U_YT#AIV5FN<V5HX_-2#0V>NBP#D^>"$\3=@.">6
M@O;.N@;<X^ \@7M0N.[[@ISK'%7>E30?M7G8U *B@5[GRH;IP8.MD14+^MEX
MX#=[>HWMHR(:B8]J(_ZCJK\!WJ,4N@!*8SUAWAK<+#P9?0@+O,AC4I4-0OW(
M!1)W&,4Z?:?F-8<==VZT& BQW>G6]DZ,7%T%##!_0 D=,=X*!VD0M< \MH(V
M'C"]M7DHT=4<(C/0>!NHB7.!Y]-S*HC3#G51SR:J)R@<B6"#/1'/[=%.1ZZ<
M!V2E072K*'A0:N^I'CN292RFS_HH5VQ$KK!_,NY7'$X@.Z2C#+X;0N1*I92]
MGX8DQ!W0+X!3A(WZHRG.&>W.D\#!<U\)&S2"'35"1@U!5#;NG 6]^3M>L '3
MBR<>K4/-[E0.G7VPN[@Z3,A  O%ZVYRX+2;+P)7V#-GJ@_<7K8":[%&,:PTN
MUYV-N.=='7:/!_9=WH/:CF)ACY\B!%*P')=!2GT^>]:E3A7R</?V?VMN[L[6
M\+90+.HMR&T*6?_>[9B(]PO, BG)1WVC42/";>NF"QXC/A5A..J'*$R52 R_
MI^X(<*@NM\=@N=CI9N-H=T+^/%3"9=!%\9&QUA &56&+%C94=6.=]M=^(7X;
MIA4X :0O5 .J8:-0 GLHM\6[\91Y-QW9@4>P-IT_$=?!QBHL#_^DQOKLX"0
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MOC'2F[-[#%YZYK4.K80A\U<(<2'/^_9")ZFL0#"[_?WQAWD8A.^)F:^Y?DB
MNO9_1RS8;0RD(6;^BKKOV+;S?([[<V":X<\S7N<A#!L[;IV<NW_C.<((Q8'W
M"Z:B"6^B$_U-(?*-PW+V'C/0(EC/$4A)0<M4/BE6S>\+;+G,'Y71N6<'<,*C
MB#P#^1: IR"P'I#?'Y1<:8I]R6==2]0<9 GRW3!A T$;%)E G43E$X]"I<Y4
M#B^DN#-J@&!T-9&1^\B%_(Y;%5@&,+1Q;4V)S91QAPQ6:%B*.EE^1I+ZT!S5
M00E6M,JZ;2T,V,<H%-TN'R8ZC5F;X:4N&1CRR^!RF)DC00,^@#:TV+@D$LX)
M3# 1NK -#SS#L)/SEO8Z%08=G[(1,R1,B81-L!7(E '=.H+7>6<S;0-W1SD[
MPFU2+#W7.Z^@7^"YKRCHT%;K.9>MKM+O,<&Y?$N!W$/>77'P2:.Z"8T.[WOS
M.X JZS,.%$;CKFB5HW8WO?'-PQW-PQ'O,NIB9-3"!\K/&FX-7&LD=F*_$T"M
MIWR)<_&<Z_S4P4"%,"MGR4G(--"P[]]AP+!IFSC3PA&R'N_6BGOLE<0+ Y=&
M+ILQ?*CX98L9NWX%4;D_3O!O]JGS$L)&MZVS*VM_Q:4?\)0;5G6 4^_86OC$
M%T=?G^U6P7!]))163;U:OJ3,BPY/=K9Q:736Z3AKZ.@"YZ[_"9G(3CR'OKY^
MJT=MR#D@[N=\0?@/%J$3(]35*3K&\SUTC0Q8<!/F#<9+B>\/V",'3:VEGT%P
MP,4E8& ?MU5SP0GQBQXS<)5H@N1A!!QPG+BK_:\V>_1,X2[_"L*F[%[MZ VX
MSODGP!8^7Y[7ER]0- E*T"KWJ&<#WKCB\\9!>;.KDGMU?A2TO[O5>2<6]A%J
M-_1>#R5W6.6K-?<TR NF=)VJV.6*+?$O:YJ8CI@UDN8DX':@R>B^&T^:<;]N
MN>;_9=+OMCW;[=B [BN#Z++R]6.+K5.1:7LJ,OV?GHH<EG8\%3F>BAQ/18ZG
M(L=3D>.IR/%4Y'@J<CP5.9Z*'$]%CJ<BQU.1XZG(\53D>"KR?SL5&78^Y,DD
MN(@_5P(/\P;Y;WK:N^T743?^0Z#GZ?YSJB^@,H7F,I5++!T-SJ8][_AF4.K"
M?1:$AK;4F;M,)*JSX0EXOM0@U'K "MKOQ*[_#5!+ P04    " #/B4A8/6A@
M%:,$  "]"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RU5MMNW#80
M_15" 8(6,/8BV[%A[R[@2XNF:  C:9N'H@^4-%HQH4B5I%;>O^\9ZN)-NK:?
M^K(KBIR9,V?FC+CJK/OJ*Z(@'FMM_#JI0FBNYG.?5U1+/[,-&>R4UM4R8.FV
M<]\XDD4TJO4\72S>S6NI3+)9Q7</;K.R;=#*T(,3OJUKZ?:WI&VW3I;)^.*C
MVE:!7\PWJT9NZ1.%/YH'A]5\\E*HFHQ7U@A'Y3JY65[=GO'Y>.!/19T_>!:<
M26;M5UZ\+];)@@&1ICRP!XF_'=V1UNP(,/X9?"932#8\?!Z]_QQS1RZ9]'1G
M]6=5A&J=7":BH%*V.GRTW2\TY'/._G*K??P577_V/$U$WOI@Z\$8"&IE^G_Y
M./!P8'"Y>,8@'0S2B+L/%%'>RR W*V<[X?@TO/%#3#5: YPR7)1/P6%7P2YL
M[JP)RFS)Y(K\:A[@DC?F^6!^VYNGSY@O4_$!'BHO?C(%%=\ZF /+!"@= =VF
M+WJ\IWPF3I<G(EVDIR_X.YT2/(W^3I]-L*Y50!L%+Z0IQ#<)BWOE<VU]ZTC\
M=9/YX- E?Q^CH0]R=CP(*^?*-S*G=0)I>'([2C9OWRS?+:Y?2.%L2N'L)>^O
MU^AE\XO9=TG_IH+:RBB*SR0D<O=M]@4R$<&*G73*ME[D6JK:GXC<U@T>1_HT
M;:6.6K+&BU#)  ?*DRB=K46 7ME)_%<&^R0,BT?#3^MPS)8B:ST0>OA6)M=M
M 6 <I2:7*QQ4!N60)J<3T3A;M("EE<R45F'/)@$*!M861['?D O[B(R T^ZY
MT!@66@8JH),0R/F9> _Y%X5BT"='D':$HWN1N0@E)BZL0RQ8P)'0LO.M8@:V
M8,*'B:10*5>(1KK O'8J5(CMFX'*(7PDB#UC)G+^3(IU2!M#\( 6/+Q&S6MI
MWE+HB(SXM37$^EDBEK/MMHHQ]R2=():I@,BHSLA-0CMA#MA]#CZ1H[C),AL"
M]"$S"LCM#FUR AXASA_>OKE,T\5U?R0NEM<_PG-0D89*[M!1K &F)C!294KF
MEB+LPXX:^"295\(")),N:DQ4U6@27UHP5ZBAV<;#(\0\-G7+==CJ-K>@L;8H
MF8UE''K',[71/8>59C\3]VVL?&L&1^@?=!QX,I'O ;)^$@E<Y51@1OBI)0J1
M[<'B(YQ&V@:Z!KJYT,>3Z'F&XEHC,QUQX%/J+:_V@CS:D1N.R\7V<0%O"!-[
M!/C'#CK -_49 U ^]O2,I<UB 3@$00J!NY*;['D)X6O&YT>BGPJ\O+@>)X+8
MJ:U%EAYX402I]8 (] ]C(<8N+)0?1$9:T8[&M%DJ>P84,XD%S\$]"(<[7#1B
M!?H9$UDG?@'6HF:>>.@J%2O:ZJ)O-\DDD(LB*7;$DJ*RC!F;[Y150G@FR@D-
M-,X$J!WE!>6Q7Y@2.:3R.S"2R*5!*LA(2#^,IW[XT:/R(8K;B;(-_"'Y#_QI
M  P3\8CX1WCL)M+2\4SM%-AE%O_?'(]]HN8'5PJ,GVV\.'E&;$)_NYC>3G>S
MF_Y*\G2\O]A]D&Z+?@(O)4P7LXOS1+C^LM0O@FWB!86[S=;QL<+]DAP?P'YI
MT;S#@@-,-];-OU!+ P04    " #/B4A8,V!P& @/  "J)P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6RE6OMSV\81_E=N%#5#S5 4 ?"IV)Z1);M5
M4B<>/YII._WA"!S)L_%@#@=1S%_?;_<.#XJD4C>_"")PM[?O_7:!%]O"?"W7
M2EGQF*5Y^?)L;>WF^NJJC-<JD^6@V*@<3Y:%R:3%3[.Z*C=&R80W9>E5.!Q.
MKC*I\[-7+_C>>_/J15'95.?JO1%EE672[%ZKM-B^/ O.ZAL?]&IMZ<;5JQ<;
MN5(?E?V\>6_PZZJADNA,Y:4N<F'4\N7937#]>D3K><$_M-J6G?\%2;(HBJ_T
MXSYY>38DAE2J8DL4)"X/ZE:E*1$"&[]YFF?-D;2Q^W]-_2W+#ED6LE2W1?JK
M3NSZY=GL3"1J*:O4?BBV?U->GC'1BXNTY+]BZ]9&T9F(J](6F=\,#C*=NZM\
M]'KH;)@-3VP(_8:0^78',9=WTLI7+TRQ%896@QK]PZ+R;C"G<S+*1VOP5&.?
M?76?QT6FQ"?YJ,H75Q84Z?Y5['>_=KO#$[N#4+PK<KLNQ9L\4<D^@2NPTO 3
MUOR\#I^E>*?B@8B"O@B'8?0,O:B1+V)ZT1_*)^YT&:=%61DE_GVS**V!1_SG
MF,R.XN@X18J2ZW(C8_7R#&%0*O.@SEY]_UTP&?[P#+^CAM_1<]3_T![/[YX-
M1)= _:,'L<L+L5 (8B6TNVEY15DMOB! A"W\#9T+NU9B6:2(5YVOQ)?*Z#+1
M'$1X7 I9^J?EM?BT5>F#VG,"T;O/X:EI2NLOV([T)Z0_@?B<:XLU'ZVT..Q<
M3*-P,,)U-(D&8URC8#8(Q2^5+76B1+%D9O8W]<)P,+P0O6DXF.(R"0:C"_&I
ML#(E>L&0Z47SX6"&:SB>X/I1KW*]U+',K8#PFR)7N2UK\AM3/&C.,M#/OGHD
M]/6GY+VMC,%9U^*M2I1A%H/1?! 0B^%@@LMX,'62"8@>B'""/[-!))!TD%)R
M 0&F(@BA'8@6>$%C1W:?V3",!G-H  H,1UAZIY8*RY+V\-X\8IV-!A$XC0;#
M^N016.D%T\$$#X>#\*(YG0D-P4YO2DIWIR>>\/[QO?&8[1(&1"880^^U58+)
M#)S!RG,6.9KC5]<FY)]"Y@E1$C$H:]A)&K.#0;;2).[A3DG#1E./&VVDR^I/
M#(3\H;*%,IQ#_HD-M/Y-N_Z4L7Y&_4.EHU7P>>*G:[+0.54X@RFP?"9N9:K!
M6ZXE9)N2@680'L\B."]\"F7/.>L46IC!=KSK\T_B^^]F81#^(.">8X0G-*G)
MN?VFI=?Z!+3F[JPIYRZGDPY/'[Z7V>:'N_I!0[>^UO9K%5H*<I_Z>4> IZ2"
M((!YYA.(W&&PL^'FW2=QZQ>?BR'';4VWL^.SU:G^W:D=1L@/-*R<68_:6^^E
M)@E#YWD%N5.=:>MH)I6B9\4V5Z9<ZXV(US)?J<Z2TH4V!>EB)SYZ(!#-0CXW
MFD5U!KC/K3(YJ54]J!QT;PN7?8+Y;-(G!Y, (J#3YYTE3DBEMW&;/LJ!N,F?
MXT<4,0=NPA2!:4I@AYH'E/KX*WX@M$A!E*9293G(8/6%J8"9X!##^4!\6N]1
MW<*?:V)8+#?@Z%$#L:AT)\X#V,=[/!WU>?!Q0(L1&O&:I4D@<UIL,LHG77>Q
M:VD=;8XW):J\*FL5:'JN#%>4OL@+2PB-H)9CF 0Z'<N+XD%1I1(RP5,PUN<-
M1J62]C?IA2A(^ F864NDW852A 0S;$_$TA09;]M/Z$5ECA*0I0>>^O<NBXN4
MR")W.*W2AH7*X<+84O-#M9'9(Y!+MEGZ(&1?8!\XZ=PGE9#)'4X2R\IPY+,Y
M<18*$';#CDL\LH15XBJKP >PJW<HKM&MEZG'6&'C>/@7&,NNR0'R'1@V2EU2
MQA1@2Q?)X)DB>%)G$"#5<H$XMEJQ#K%Z+\5R!J5UG$4I&Y=K\%;KM'OFERI9
ML9-I4NUOE39.M^I!IA4ID92<DRQ4AJ5PMSG)4W*7>8Q4OX()H)XCW [$KV2C
M!^H$L$'(!XD@)?MNBE*S_HC/7*V<,A4E!M#L4Q5+JX0,A\#YHCS2@:3 =Y?L
M$6@J?*WK"ZB4G  NJ1&R9M<G/_%*VM$N"HE8EN0)+E; %&P%?Z%(5U"\H5!.
M-(4Z<4!YXZBT4)0JR4<U 'XBMFNXOV;]903D4OV5(AQQFG,$<L"65)!)?VE:
M9Y9CIN6XIDT+4AIR.Z)B@/0GNRG[V$8<GJ@-)4-8LMH0:')^VNC%I: 41B?E
MT]8]"#G8=Z!3!?GN\.SK(U7Z252=.Q!%>!+EZU9ND"-9MM,I#\D-/2;!IRC"
MGI"K7Z?F$J :":#,0'Q<P\$OJ0E,.(*PS^DJ!#@"$$"M?ZL?*;U3ALPMHE63
M#KSJPND<*Z(1R-W$L:G4D^C*'9=H*$HQ#XCB< SD=5OD\!_+E!*UL(1&)H '
MD8=7*T-Z.&:KZ2C JA&@22C^K@C2'/.R7CAA/-B;S@@<.J*4T(Z1'$U)U-%P
M@JJR9Z*.)->U%MHL(F,?[ZU6ROIY;S(D!-^; !5>>"!4PPF T>@ =3XYKB$P
M9>3Z\PG.>YTM%^0AL!>#T6@")<$+;ZH5^FUVP;[8JDX%1GR!;R,OX2\4Y$Q1
MX$9>XAR*E!@&0F:B92JE,DA8!=D$OFHIS]LME2Z[+>ITNUT#L>XXC2<-[ /B
M0=NC4:,@%<&>E.[2<G2K5<QA1CF>HQI^*]UL!"2U S!D61R\J$HTAG *'RL<
M=9P=X\(0&I* !6@%P@88'"H,*EAKA(M1W.7F# A4)VNU4N$V8D(W_=1Q)5!2
M!S*$RVG<YK+)\5=7R4UED*A5V>?LL:, )V*,9C9&4X%0N62 09LKRKV\$1("
M3;SFJ"3';O)^F^$SF<N5.PZ%22N*,)=(*052,KUTR?22DNEEDTR9 8]1P'1M
MIT-MN7S:Y%(Z_AA.6E9L].62M@"2'BUR;"J"&NQ1Q^L@-'W.8=M8L*Z,Y"T=
MK/Z_(+U^(]C>3<;FWJ_K!0=)#=F\,K6M&&XP3CX$"0[B':UR.8YDZRT(KB);
MM8 5AB?(!J5YM+\".#--@?IF0>EA4U*)[>=A!D]"I#:\2/UQH*=%+#T"OB?T
MR&4 B23/?>_11.]>/NEF$B"XLB'H0"F%+:(&^8MIU'%'EE:(1IYK-I% (:#W
MQCX,E$$!-;,BD=NDX&*/>X\ZH)C$GQ[R4(]1@^3#8/4SD!#76<C5>DR#"S>*
M:$<*?8>JEPTE#\RYIQZCB-),X;TR"&Y&E<@G-!RB&D8%DHK>AU-.4=?V'EIZ
M*GUAY"XS*D&'O?-!>]WC.4J]D(6J,Z.E],;3CW#*+3R+1KT=,8'8U_"A<A\_
MC'G\0M6K%W(MNX7NT2;50XX5P#SS#97#?8'< ;-;++*1.WY*([$ -,8AB=&T
M^JX-A2,>F@+=_AR:)+#1"X8TOKD_ZMB-AT[(4D^UX6HV38D(;_2<!,VIQP*,
MSF+[!2,>,W1';K;CU<:/"8\-D#[MC2E=*]>T>*Y:\<R?(JS3RE'8.,A4Y119
M:%!^]ZF\[ORNG[CW:YFZM&#%CS+G1MQE-1[C$8RX]SELKVE$\D+-XZ3(!8[;
M$ J[H9/Y<$<]UCNRAZ!CAX^G^34@Q#NCV]_ !RPUO_AF3FA ^0PGH8#[#;]9
M([/_@X_)<WQ$E%?(N7]QJ,0RB#QI\Z,DG$#]NL'%W?.(\*]W#?H9=JH5+3L/
MY^T=Z@W+C?/E%)WBMJA2H"]V;W9$/]4ZDL;U4K2<HD%,R\(WJNWX8N&E1X[\
M-KDHPY\/._B/"D]W$Z&?_CX/-?>=05/R!8 Y<]@0@<59@"%1'!=53O6V4[^/
M=>P\=T-"8\TA'<K4=4(T]DBQ2"]U/2QK)A8.[M8)HV[?F,(6Q!RB@P:-=HB-
MQR%N!B(\E'4*M>NB6KEJ;'7&8( 2=&69-DZ1%:5^<&I3Y:24/ 7S&*#O(625
M-XVX8H#ND* 496?X <FKN(8M=&1#9E_QWK*Y>@3Z<'4WX[I+0$LU^2LM%EV<
M[_.<)O2,SF6)*M'5D5%H'7RYYQ%-.UDUD!<T7+.C72Q5B><DKS*%!>5^ ]\=
MF$"'I6K5O?^N"!BK,PY\DJH=M&&D<'1XYH$>H7W-%6,^G[, %8^5'5UX9YT<
MG''H934;73U*F)3+CCO)K6EG>-WI,@G<)_29R2_8VY6B?_"&X<?.4S2Z90RY
M^47#D[=4;Y\."2^<#)<N O_*P(4FND%SSU/X"?PEP&RX-ZP?W:*#2>3>ZG>(
M_EVII4O__N:ORJN2/ P,P W) ]!MZD3N:EN\7T.'FPTY3]WGT:RIS4)KP[%Q
M@_A-132LLR')X@>7<%"']%V(^>"GJ:-7M6[!<J>%\H._-IP( 944YNT MF&6
M4%+>;.5A4VM T%T5!>LV3WC6!A_.M&4GR@OQH(NT:11:@<4;T"PR'8M_$8RZ
MJ>#"AB#"ARKU0Y@/:E6YK93!:/3">2?6)L9]XQ8ED(*51=.[I67A5??-E(_S
MKD (31;9\E"=L'_JJIRDS-2B1S:?&X+ZQ$6O(H9.L:PGUU Z:+]OI,9VATE_
M[_BN_[OL1$,R;B"X%CASZ&PC8]OT)5UA.&4?<+U%J.BL20C<*1TMI=SEME/]
M%0!F,VJ!4FW3N^TUBG04;>%DVT0 NJUVSUT'YK?6[;V[O[NY(&;J3;7C=R>A
MUNC52E&50OF"4J&QC+Z,J1VY@=\'+P?(]VC6D/D*U9V\U'[=\K^6";FH\D @
M[S;@H)VXEKJK-CB#T]K-B1G\4U_K2(KCW*!C1U,''MG4<O;;Z43C'ITO @Y;
MP[IC;,3OE& ZALGOX12&7=UE2R=+U'K DS=6T63_E142&2J)T8N*3FSFS-*Z
M>V[,7'3[6NVZ8VIZ#?)V9\06%V93-.WO<5TR8P11C!\#49ZN"33'UW5>-V\\
M4^HSG/<RPHAIVH:UC/R\J.Y-63.&:U\<D%9\ U261:Q9N_6XH%0GE  (M23:
MB4+ 993>',,T_.?T49@Z&945G/U "LF("447S9HY)0NS[_-^-V\<3L:(87B@
MPP9.&C@,5_GR27NO^$V 8WLO8\J,P.,!J#TZ_MU1\-0*0FU ^N^ZB!_P;>A3
M'_<^8G#L&YVKSO=30#PK_DJ,B@_X<)]2-7>;#]%NW/=7[7+W%=L[:5::L(]:
M8NMP,!V?">.^#',_;+'AK[$6A;5%QO^NE42EI@5XOBP*6_^@ YK/\U[]%U!+
M P04    " #/B4A8G7KS*E4/   "+@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6S%6EES&[FU_BLH14ZD*JK%YB9RO%11MG/CJ9H9EI7)/-S* ]@$
M2<3=#0;H%L7[Z_.= _3"1;0R=FX>)++9P,'!6;ZS &^VQGYQ:Z4*\92EN7M[
ML2Z*S0^WMRY9JTRZR&Q4CC=+8S-9X-&N;MW&*KG@25EZV^MV1[>9U/G%NS?\
MV\R^>V/*(M6YFEGARBR3=G>O4K-]>Q%?5#]\UJMU03_<OGNSD2OUH(I?-S.+
MI]N:RD)G*G?:Y,*JY=N+:?S#_8#&\X"_:;5UK>^"=C(WY@L]?%J\O>@20RI5
M24$4)#X>U7N5ID0(;/PST+RHEZ2)[>\5]3_SWK&7N73JO4E_TXMB_?9B?"$6
M:BG+M/ALMG]183]#HI>8U/%_L?5C!QB<E*XP69@,#C*=^T_Y%.30FC#N/C.A
M%R;TF&^_$'/Y01;RW1MKML+2:%"C+[Q5G@WF=$Y*>2@LWFK,*]Y]S#:IV2DE
M[E6NEKH0LU3F3LA\(1X*DWQ9FW2AK/N3^/C/4A>[-[<%%J6IMTE8X-XOT'MF
M@;@G?C)YL7;B8[Y0BWT"M^"V9KE7L7S?.TOQ@THBT8\[HM?M]<_0Z]<BZ#.]
M_C/T'M;2JIM[J'8A9G('BRO$U%J9KQ1__]_IW!46YO/W4[OWM >G:9-+_> V
M,E%O+^ S3ME'=?'NCW^(1]W79S@?U)P/SE'_'LH[O\ D$B]<XX]_&/?BN]=A
M)?$!0W/(\SU4;_6\9 _T,W]3PBR7RHI':;4I'?D0CTW:8S<\%J C?HT>(EY.
MYX6RN:37,A4J\.4B\=>U$JFT*^6*YXD)[42!@8-N?/7E&GA2:.OURV^O6N^(
MSVM0>%16YRO@%?0O\T++--T)_&O6!D],]-=<%XH$(@M%R\A"9(2HB;(%@%$
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MQG*Q3%8BXS/S]3J9BHRE/YRF"+IFL)3!TC1->U/K= VYXSS/5\F\GY_0M/M
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M-MV&G8<P%'R16XWY M+U]:\!!X';.(1GD2L\XEDF;6&0]+?N42U2VM#F&5[
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M_<$G4Y-LQ:XUM&C<]5\(;<3$+2OS?P!I \S^4@B],VR"_H^3_0502P,$%
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M9!?'!)(J4;^<[T^!&L5;CD1>P<JZ;[(?:6&7M.&KY[^B]!QJ%O(PUN]#@_\
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M>UA82:H JV%@1:&E@=1 R'\*[9ZFR'[(+0S&W; 5@0\K@T%Z> ;&K!M=$QT
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M]HECL.V08^ A9T(^.EXU_O28'0,&^LA+/WH7_#*^=Y>WZ&//^OV6J7,$S9F
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M^UL/!F"F>51166/F,4E4&T$E8,ZK/7H#S)K&.!X"8*A+2;6TM)0*=BL.J5=
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MIX\X84-OHL@B&:HJ)QT^E@:C%DR1=(WN8XDS*5.!^Q.JGU>X:Z)FVN;1(OG
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M,.$!"[3E4"ZA:B2P7+\R;MF#L13NQ*(KE>2[T>W,Q%CD0!AJL3Z3!)J /6:
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M0UAL^N@:Y/I=,\$3S#IW)Q?6&L,G57WT7BII<H3"&"B]DRXUQTA+KKI3*GD
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M>0WD'JBN%6#$C28G3W3.09].!@:MV+V#K$6\:A"C XAA1.ZE,(4F/XH<\FV
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M]3#L>5%O.' RD?)Z@></D27UG/S4E:J>67L2YEO1T%_+#_J'CL#W0A(9>&'
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MA$>V]O<8W[&J<'>'A;)X$W'-%5[]A*8).)XH93<=<E!?)N?_ %!+ P04
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M.D O:A6-++WHFXJR"ZF3K-25$NS?9PMM%*#QGWTZ.XJC_10I7H[TAB?BI(>
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MA+OY0[7,.C=BG)B])FZYY=:]"GO]9$CIRH)F1"?(2'96>71]U33[E%_M/#%
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M;:BL GU?2VEV@@TPW .7?P-02P,$%     @ SXE(6-Z&M\^5!@  JS(  !D
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MU(G*9U;&T>[*V#TDJ8<,=Q?&:)/-",SFVG[YM6V%K'8(LF"*RZPJ!\=\:S7
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M$_THCC_QJJ!ASHM$HHJ_Z%C%]@(4[946:95LKB"-L_(_^U0)<9* 1V<22)5
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MW2:3PB:3[RYI/04N&_Q7$$-<7STGS2OTA] DMO&<M!U@/!HV6-RWI?PQ;CE
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M)LA.C4J8[!#K(Y$[QA6*Z18@H<:'ZD=FYT+9C1:']*1D([0627JYIR2BT@C
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ML/PXE>W <SJ,W+;7;*'I<5!:A_1K6X58W5>QA:8'K[&S DNO2U.>G%?J379
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M%;N7\G87>;HNWVN;I7F>QN7'%6<++@H#^?LR3?.GB^)5N?K5R.G_4$L#!!0
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MS<+S:U#>D&R=W23F3*I[2?:Z4E='X#I C2^8*KMHZ,M)>1D-_@%02P,$%
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ME]4]KGK1HK0WFZ70>$^RCQG>?4&: /R^$D(_O9@.FMOT]%]02P,$%     @
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MG'!NN<%O$"B;@.<K*<WCQHZYYJN6_ -02P,$%     @ SXE(6/TR<]RP @
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M>%55[*IC9.F*WEP:+*&NN<)'#I0-P/F%E.:I8^MH\VRF?P!02P,$%     @
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M<6>:#VDD$C#3[&6A:DMTW,AA/ A.\FS:-%,(.X.YM#UZ$JMQFU3<)IW<0MB
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M['];J2MRASD6.<M<X4QA'R4HX-I-8/E^E7B.DX!G6BORY7:AM,13^;6M0"Z
M3GL YJ:Z41N:PMC;F+7D#KS)WW]%O?!U6W+_I-CL#XD=)+Y3);YS3GURSS6@
MJK99SMB.98 /S)Z+MBPZM2BT<N9^WDVBI#L*=O7L.*-NS29._,&AT:QI%/G]
MRN8 IEO!=%\& ^X\MP$XA7YMV>LX]),C@A:K:.#WCA#:K0;M$+T*HO<;"'LG
M+:4H"'S?,OT#R[%#*KO)VY!ZC3 B?W@$U+0)_?@(IT4GJC$?T/0KFOY9FG^$
M4@3/+#QIQE=;IM8&PQSA#!:ZC<;I]>J1'K'\UF+6;Q8F]*-VDD%%,CA+XKX8
MY<ZZ(AQ:HQ\T5TX:Q6@QZC;.1ZM2IYUA6#$,SS+\*S1>F<*2L/+;!]6W[P32
ML'E0H[AV5!U3TPI3WCEB&C9OC^OA$5)0:PP*D"O;8"F2BBW7[O-8S58]W*UM
M78[FI]C;N5;LEXQK#!^H7#&N2 Y+E S]/H8M7;/E!EIL;/NQ$!J;&?NXQOX4
MI#' ]TLA]// +%!UO).?4$L#!!0    ( ,^)2%@[)GPG'00  %X;   9
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M9.X>FE7X/<@/9^.17X>U](UK?>->?=5YJ,X.V>BC5)Z-5"MYP'O+7LC'[NY
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MIMM&$"9 O]]R7<!J8!:H&]'X%U!+ P04    " #/B4A87NKEQQ($  "B%
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M;,6;76_;-A2&_PKA%4,*=+9(V;*3.0::Z&/!UB)HUNUBV(5B,[%02_0D.FF
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MZPP.0F@T"GOCHWAL$?-'O<%1.'8;_:ND'%2]?G?8FL2C/EP24)\=*5IREIL
M19\@74&K^_ZE&:E%LM^6DKIM_%4.@CT'@=74I887%1;=R[XV$JVBQ;;0FI3O
M*WC?;@GO6ZWAK:+%MM":5.[+>/^WU_'^:?E]+J)/)5N+C&Z;7\N)>_!9GP-?
MF?:(4*ZJ1%U^!->S=0OFUC0>CN;O=&O&M OV,&5?YP'SE7HWH R6"M+KC53:
MYF6KI!Q(5ICFP8))R7)SNP:< M<"ZOF2*::K@5Z@;EA%_P-02P,$%     @
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MG(0P<V0OX, VX,Q__,$?>;]VL;<$UF)_TK _*=$#4[Y>95RP0C83@?[Y0PY
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MCCK]H;_>)F.=[D@RO8I,STJFOII-'*SVAZZ;([ :U7Y%M=]*XO9=!L 16"T
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M=FPE.K6BYIQ]3&)WNO0>VSGJVTS=^-1FT[>9N$%C<T(T;8BFHT0W7!/(DT8
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M8W3Q[A*]0[1"][0HP$!,'0EQ*74G:6*XJV/PC\3@^>B>53(7Z,\J)>FA@ -
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M*P&YR$#2M<=0-WG=7=4WDJUUO[%D$KH7?9E#1TJX,H#G&6-R?Z->T/:X\_\
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MK9WHH)WF:C>5A]8S90I-GYEH_W1\;^]T]E'!>V]PMF-G'X6'40=5VW$[9;<
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MZB"O+RD5^X;:,:EVR*;_ 5!+ P04    " #/B4A869/RT;X$  !3&   &0
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M&ZCV)5-9KKG1';2'.?-_ 5!+ P04    " #/B4A8%#8&*DD%   I&@  &0
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M@9"_H)L?>ZJ>T&>TUH]>M&> ^ :M8R+@\T+'/4)+GNB'49(LG3>/9@P2?0Q
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MN*+4T=$[JFZBPJ/A=!M4M=2.-!J6#3V*:'P [:^T=EO#%QB>V>(/4$L#!!0
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M"E#?KQB3QYOT!\K_(LS_!U!+ P04    " #/B4A8K5;5BQ #   0#0  &0
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M+W=O<FMB;V]K+GAM;"YR96QSS=I-;J- $(;AJU@<(.VNZJKNC.*L9I/M*!=
M3OM'L8T%C":Y_5C.PO[0+&83\:U0@RC>!7J$@*=?]=".^^XT[/;G8?%Q/)R&
M5;,;Q_./$(;UKA[;X:$[U]/ER*;KC^UX6?;;<&[7[^VV!EDN/?3W,YKGI_N9
MB]?/<_V?B=UFLU_7G]WZ][&>QG\,#G^Z_GW8U3HVB]>VW]9QU82/PVWW$*Z;
M^'"9W"Q>WE9-__(6FS!WD$"0S!^D$*3S!R4(2O,'&039_$$.03Y_4(:@/']0
M@: R?] C!#W.'Q27*..2(&F"-8'6$;F.!%Y'!#L2B!V1[$A@=D2T(X':$=F.
M!&Y'A#L2R!V1[DA@=T2\(X'>@GH+@=Z">@N!WC)YV";06U!O(=!;4&\AT%M0
M;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;46\ET%M1;R706U%O)=!;)R]+"/16
MU%L)]%;46PGT5M1;"?16U%L)]%;46PGT5M1;"?1.J'<BT#NAWHE [X1Z)P*]
M$^J="/1.DY?=!'HGU#L1Z)U0[T2@=T*]$X'>"?5.!'HGU#L1Z&VHMQ'H;:BW
M$>AMJ+<1Z&VHMQ'H;:BW$>AMDX^5!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>COJ
M[01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>OOD9Q,"O1WU=@*]'?5V KT=
M]78"O3/JG0GTSJAW)M [H]Z90.^,>F<"O3/JG0GTSJAW)M [H]Z90.\\^5F0
M0.^,>F<"O3/JG0GT+JAW(="[H-Z%0.^">A<"O0OJ70CT+JAW^4Z]A_'S4(=;
MS]<:K_^=5(^7<^OM\M?EU\[)W7O%.=Q7#,]_ 5!+ P04    " #/B4A8]S F
M!B<"   R,   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-VTUNVS 0!>"K&-H&
M%LU_M8BS:;MML^@%6&D<"Y9$@F12Y_:EY"1 B]1(X )]&PLVR7DC#O#M?/W]
M,5!:'<=A2MMJGW/XR%AJ]S2Z5/M 4UG9^3BZ7+[&.Q9<>W!WQ,1F8UCKITQ3
M7N>Y1G5S_9EV[G[(JR_'\G/J_;2M(@VI6GTZ;9RSMI4+8>A;E\LZ>YBZ/U+6
M3PEU.;GL2?L^I*NRH6*O)LPK?P]X.O?M@6+L.UK=NIB_NK'L8L>!I?PX4*K/
MEWBE1[_;]2UUOKT?RY$ZA4BN2WNB/ [UJ>C5^>1<;IA.G_SB_*7,N<"R\S;Z
MD,K$(KT_[GDD\^EU*(4HYO[\*[XDEM(7OQ_-T^ZH>V-VN=Z?/AZ6>22V/"Z_
MX]]G_%+_G7T(D#XD2!\*I \-TH<!Z<."]-& ]/$!I ^^06D$152.0BI',96C
MH,I15.4HK'(45SD*K!Q%5H$BJT"15:#(*E!D%2BR"A19!8JL D56@2*K0)%5
MHL@J4625*+)*%%DEBJP215:)(JM$D56BR"I19%4HLBH4616*K I%5H4BJT*1
M5:'(JE!D52BR*A19-8JL&D56C2*K1I%5H\BJ4635*+)J%%DUBJP:15:#(JM!
MD=6@R&I09#4HLAH460V*K 9%5H,BJT&1U:+(:E%DM2BR6A19+8JL%D56BR*K
M19'5HLAJ461M4&1M4&1M4&1M4&1M_J>L/[P__./XY5F/KI^>\]GR5X&;7U!+
M 0(4 Q0    ( ,^)2%@'04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ SXE(6)UYMDSN    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MSXE(6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #/B4A8<+6Z&$P(  !B,0  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MSXE(6+S[V5<\ @  O04  !@              ("!CQ   'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,^)2%@QI_%O]08   \>   8
M          " @0$3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " #/B4A8*\WK\A$#  #<"@  &               @($L&@  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ SXE(6 -X]3T1!0  @!0
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M965T.2YX;6Q02P$"% ,4    " #/B4A81!_C]K(*   I'@  &0
M    @('W9P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M ,^)2%C(?:-X3PL  &@A   9              " @>!R  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ SXE(6!_5&^+ #0  9"8  !D
M             ("!9GX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " #/B4A8V5T/O](4  ##0@  &0              @(%=C   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,^)2%CC%X8"U @
M #,F   9              " @6:A  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ SXE(6#UH8!6C!   O0H  !D              ("!
M<:H  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #/B4A8
M,V!P& @/  "J)P  &0              @(%+KP  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,^)2%B=>O,J50\   (N   9
M      " @8J^  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ SXE(6!)NVFE:!@  :@\  !D              ("!%LX  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #/B4A8^J8*)MP"  !8!@
M&0              @(&GU   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( ,^)2%B!PR@Q6@(  'T&   9              " @;K7  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ SXE(6(6>U^(Z
M#   UU(  !D              ("!2]H  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " #/B4A8YE'?0L4Q  #[K@  &0
M@(&\Y@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,^)
M2%BX6(:/@ 4  *0-   9              " @;@8 0!X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ SXE(6+0%?Q[-!   N0T  !D
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M=#(X+GAM;%!+ 0(4 Q0    ( ,^)2%@FDBV(,P8  'L/   9
M  " @:Y% 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MSXE(6"'K0CTT!   $PH  !D              ("!&$P! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " #/B4A8WH:WSY4&  "K,@  &0
M            @(&#4 $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( ,^)2%AX*Y(8W 0   \E   9              " @4]7 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ SXE(6!V:2MIZ!0
MJ1L  !D              ("!8EP! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " #/B4A8[I=B  8#  #3"   &0              @($3
M8@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,^)2%CX
M3IV3WP8  *-!   9              " @5!E 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ SXE(6"65V+'W!@  )CD  !D
M     ("!9FP! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,^)2%CI5]$ON@(  .$&   9              "
M@>F# 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ SXE(
M6/TR<]RP @  " <  !D              ("!VH8! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " #/B4A8^4<O6Q8#  #!"   &0
M        @('!B0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( ,^)2%AF_I9[EP0   $9   9              " @0Z- 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ SXE(6-! 6_J;!0  02
M !D              ("!W)$! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " #/B4A8/(I^^B<#  #H"   &0              @(&NEP$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,^)2%@5?Q[I
M#@,  /0)   9              " @0R; 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ SXE(6 5B1>^\ @  0@<  !D
M ("!49X! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #/
MB4A8879"B=X#   L$   &0              @(%$H0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ,^)2%C[)?RUR (  /,&   9
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M970U-"YX;6Q02P$"% ,4    " #/B4A850NT1V(#  "4#@  &0
M    @($8MP$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M ,^)2%A>ZN7'$@0  *(4   9              " @;&Z 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ SXE(6/+OY'B2!@  /3T  !D
M             ("!^KX! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " #/B4A8%R5]T0 #  #W!P  &0              @('#Q0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,^)2%AJYJ-R_0(
M  0'   9              " @?K( 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ SXE(6)0KS5#7 P  \!,  !D              ("!
M+LP! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #/B4A8
M<)-O:,L#  "\$@  &0              @($\T $ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ,^)2%@+]*Z7P00  )D?   9
M      " @3[4 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ SXE(6.RD"F3>!   J!X  !D              ("!-MD! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #/B4A8!UZ=+T0#   V#@
M&0              @(%+W@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( ,^)2%BIJ7:L^ 0   88   9              " @<;A 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ SXE(6,Q\E5.U
M!   8Q<  !D              ("!]>8! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    " #/B4A8- ,O2'P#  !_"P  &0
M@('AZP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ,^)
M2%A;8"LV] ,  .\.   9              " @93O 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ SXE(6(T(5)[G @  6P@  !D
M         ("!O_,! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
M    " #/B4A8LBCL*K8#  #K#0  &0              @('=]@$ >&PO=V]R
M:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ,^)2%AO$,9:: 0  "T;
M   9              " @<KZ 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL
M4$L! A0#%     @ SXE(6%F3\M&^!   4Q@  !D              ("!:?\!
M 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " #/B4A8/U?T
M3S($  #^#@  &0              @(%>! ( >&PO=V]R:W-H965T<R]S:&5E
M=#<S+GAM;%!+ 0(4 Q0    ( ,^)2%ACP9=YM@0  ,,0   9
M  " @<<( @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
MSXE(6!.<E,)< P  Z@H  !D              ("!M T" 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    " #/B4A8W_R)R$L1  #Y( $ &0
M            @(%'$0( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4
M Q0    ( ,^)2%BM8M%[?00  -@9   9              " @<DB @!X;"]W
M;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ SXE(6!0V!BI)!0
M*1H  !D              ("!?2<" 'AL+W=O<FMS:&5E=',O<VAE970W."YX
M;6Q02P$"% ,4    " #/B4A8U*P[I 4$   !$P  &0              @(']
M+ ( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( ,^)2%C;
M^F7$XP,  "T1   9              " @3DQ @!X;"]W;W)K<VAE971S+W-H
M965T.# N>&UL4$L! A0#%     @ SXE(6'Z\#0EC @  <@4  !D
M     ("!4S4" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
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M  "!%P  #0              @ &60P( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( ,^)2%B7BKL<P    !,"   +              "  2=' @!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( ,^)2%B0]NBM$ 8  +TW   /              "
M 1!( @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #/B4A8DS&\_8 "  "3
M,0  &@              @ %-3@( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #/B4A8]S F!B<"   R,   $P              @ $%
L40( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     7 !< #L9  !=4P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>333</ContextCount>
  <ElementCount>504</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Development and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/DevelopmentandOtherAgreements</Role>
      <ShortName>Development and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Balance Sheet Details and Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformation</Role>
      <ShortName>Balance Sheet Details and Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases and Other Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/LeasesandOtherCommitments</Role>
      <ShortName>Leases and Other Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Employee Benefit Plans and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquity</Role>
      <ShortName>Employee Benefit Plans and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Business Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BusinessSegmentandGeographicInformation</Role>
      <ShortName>Business Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Balance Sheet Details and Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables</Role>
      <ShortName>Balance Sheet Details and Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/Debt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Leases and Other Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/LeasesandOtherCommitmentsTables</Role>
      <ShortName>Leases and Other Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/LeasesandOtherCommitments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Employee Benefit Plans and Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityTables</Role>
      <ShortName>Employee Benefit Plans and Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Business Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BusinessSegmentandGeographicInformationTables</Role>
      <ShortName>Business Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/BusinessSegmentandGeographicInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Organization and Significant Accounting Policies - Schedule of Percentage of Total Revenues and Accounts Receivable by Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Schedule of Percentage of Total Revenues and Accounts Receivable by Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Organization and Significant Accounting Policies - Schedule of Basic and Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Schedule of Basic and Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Organization and Significant Accounting Policies - Schedule of Outstanding Anti-Dilutive Securities Excluded in Diluted Net Income (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Schedule of Outstanding Anti-Dilutive Securities Excluded in Diluted Net Income (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Development and Other Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails</Role>
      <ShortName>Development and Other Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Senior Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of Senior Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Short-Term Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Short-Term Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Balance Sheet Details and Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Intangible Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Intangible Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Amortization Expenses of Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Amortization Expenses of Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accrued Payroll and Related Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Accrued Payroll and Related Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accrued Warranty (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Accrued Warranty (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Other Long-Term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Other Long-Term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Other Income (Expense), Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails</Role>
      <ShortName>Balance Sheet Details and Other Financial Information - Schedule of Other Income (Expense), Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails</Role>
      <ShortName>Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Debt - Schedule of Converted Value of Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails</Role>
      <ShortName>Debt - Schedule of Converted Value of Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Debt - Schedule of Components of Interest Expense and Effective Interest Rates of Senior Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails</Role>
      <ShortName>Debt - Schedule of Components of Interest Expense and Effective Interest Rates of Senior Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Debt - Schedule of Key Details of Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails</Role>
      <ShortName>Debt - Schedule of Key Details of Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Debt - 2023 Note Hedge (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/Debt2023NoteHedgeDetails</Role>
      <ShortName>Debt - 2023 Note Hedge (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Debt - 2023 Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/Debt2023WarrantsDetails</Role>
      <ShortName>Debt - 2023 Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Debt - 2028 Capped Call Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails</Role>
      <ShortName>Debt - 2028 Capped Call Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Debt - Conversion Activity for Senior Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails</Role>
      <ShortName>Debt - Conversion Activity for Senior Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Debt - Conversion Rights for Seniors Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails</Role>
      <ShortName>Debt - Conversion Rights for Seniors Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Debt - Availability and Outstanding Borrowings under Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails</Role>
      <ShortName>Debt - Availability and Outstanding Borrowings under Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Debt - Revolving Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails</Role>
      <ShortName>Debt - Revolving Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Leases and Other Commitments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails</Role>
      <ShortName>Leases and Other Commitments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Leases and Other Commitments - Schedule of Maturity of Lease and Finance Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails</Role>
      <ShortName>Leases and Other Commitments - Schedule of Maturity of Lease and Finance Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Leases and Other Commitments - Schedule of Components of Lease Expense and Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails</Role>
      <ShortName>Leases and Other Commitments - Schedule of Components of Lease Expense and Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Leases and Other Commitments - Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails</Role>
      <ShortName>Leases and Other Commitments - Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Income Taxes - Schedule of Income (Loss) before Income Taxes Subject to Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income (Loss) before Income Taxes Subject to Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Income Taxes - Schedule of Tax Credits and Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Schedule of Tax Credits and Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Income Taxes - Schedule of Reconciliation between Effective Tax Rate and Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation between Effective Tax Rate and Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails</Role>
      <ShortName>Employee Benefit Plans and Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of Treasure Share Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails</Role>
      <ShortName>Employee Benefit Plans and Stockholders' Equity - Schedule of Treasure Share Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of RSU and PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails</Role>
      <ShortName>Employee Benefit Plans and Stockholders' Equity - Schedule of RSU and PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of Share-Based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails</Role>
      <ShortName>Employee Benefit Plans and Stockholders' Equity - Schedule of Share-Based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of Valuation Assumptions for Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Employee Benefit Plans and Stockholders' Equity - Schedule of Valuation Assumptions for Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Business Segment and Geographic Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BusinessSegmentandGeographicInformationNarrativeDetails</Role>
      <ShortName>Business Segment and Geographic Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Business Segment and Geographic Information - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails</Role>
      <ShortName>Business Segment and Geographic Information - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/BusinessSegmentandGeographicInformationTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Business Segment and Geographic Information - Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails</Role>
      <ShortName>Business Segment and Geographic Information - Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="dxcm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS</ParentRole>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="dxcm-20231231.htm">dxcm-20231231.htm</File>
    <File>dxcm-20231231.xsd</File>
    <File>dxcm-20231231_cal.xml</File>
    <File>dxcm-20231231_def.xml</File>
    <File>dxcm-20231231_lab.xml</File>
    <File>dxcm-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dxcm-20231231_g1.jpg</File>
    <File>dxcm-20231231_g2.jpg</File>
    <File>dxcm-20231231_g3.jpg</File>
    <File>dxcm-20231231_g4.jpg</File>
    <File>dxcm-20231231_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="1215">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="56">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>116
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dxcm-20231231.htm": {
   "nsprefix": "dxcm",
   "nsuri": "http://www.dexcom.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "dxcm-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "dxcm-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "dxcm-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dxcm-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dxcm-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dxcm-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 436,
   "keyCustom": 68,
   "axisStandard": 29,
   "axisCustom": 2,
   "memberStandard": 50,
   "memberCustom": 46,
   "hidden": {
    "total": 24,
    "http://xbrl.sec.gov/ecd/2023": 8,
    "http://www.dexcom.com/20231231": 1,
    "http://fasb.org/us-gaap/2023": 11,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 333,
   "entityCount": 1,
   "segmentCount": 96,
   "elementCount": 822,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1215,
    "http://xbrl.sec.gov/ecd/2023": 56,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://www.dexcom.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.dexcom.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.dexcom.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "dxcm:DebtSecuritiesAvailableForSaleAndEquitySecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.dexcom.com/role/ConsolidatedStatementsofOperations",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.dexcom.com/role/OrganizationandSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Organization and Significant Accounting Policies",
     "shortName": "Organization and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.dexcom.com/role/DevelopmentandOtherAgreements",
     "longName": "0000010 - Disclosure - Development and Other Agreements",
     "shortName": "Development and Other Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.dexcom.com/role/FairValueMeasurements",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformation",
     "longName": "0000012 - Disclosure - Balance Sheet Details and Other Financial Information",
     "shortName": "Balance Sheet Details and Other Financial Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.dexcom.com/role/Debt",
     "longName": "0000013 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.dexcom.com/role/LeasesandOtherCommitments",
     "longName": "0000014 - Disclosure - Leases and Other Commitments",
     "shortName": "Leases and Other Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.dexcom.com/role/Contingencies",
     "longName": "0000015 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.dexcom.com/role/IncomeTaxes",
     "longName": "0000016 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquity",
     "longName": "0000017 - Disclosure - Employee Benefit Plans and Stockholders' Equity",
     "shortName": "Employee Benefit Plans and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.dexcom.com/role/BusinessSegmentandGeographicInformation",
     "longName": "0000018 - Disclosure - Business Segment and Geographic Information",
     "shortName": "Business Segment and Geographic Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS",
     "longName": "0000019 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)",
     "shortName": "Organization and Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.dexcom.com/role/FairValueMeasurementsTables",
     "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables",
     "longName": "9954474 - Disclosure - Balance Sheet Details and Other Financial Information (Tables)",
     "shortName": "Balance Sheet Details and Other Financial Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.dexcom.com/role/DebtTables",
     "longName": "9954475 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.dexcom.com/role/LeasesandOtherCommitmentsTables",
     "longName": "9954476 - Disclosure - Leases and Other Commitments (Tables)",
     "shortName": "Leases and Other Commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.dexcom.com/role/IncomeTaxesTables",
     "longName": "9954477 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityTables",
     "longName": "9954478 - Disclosure - Employee Benefit Plans and Stockholders' Equity (Tables)",
     "shortName": "Employee Benefit Plans and Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:ScheduleOfTreasuryShareActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:ScheduleOfTreasuryShareActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationTables",
     "longName": "9954479 - Disclosure - Business Segment and Geographic Information (Tables)",
     "shortName": "Business Segment and Geographic Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954480 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)",
     "shortName": "Organization and Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:MaturityThresholdOfInvestmentsClassifiedToCashEquivalents",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:MaturityThresholdOfInvestmentsClassifiedToCashEquivalents",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails",
     "longName": "9954481 - Disclosure - Organization and Significant Accounting Policies - Schedule of Percentage of Total Revenues and Accounts Receivable by Customer (Details)",
     "shortName": "Organization and Significant Accounting Policies - Schedule of Percentage of Total Revenues and Accounts Receivable by Customer (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-65",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-65",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails",
     "longName": "9954482 - Disclosure - Organization and Significant Accounting Policies - Schedule of Basic and Diluted Net Income (Loss) Per Share (Details)",
     "shortName": "Organization and Significant Accounting Policies - Schedule of Basic and Diluted Net Income (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestOnConvertibleDebtNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails",
     "longName": "9954483 - Disclosure - Organization and Significant Accounting Policies - Schedule of Outstanding Anti-Dilutive Securities Excluded in Diluted Net Income (Loss) per Share (Details)",
     "shortName": "Organization and Significant Accounting Policies - Schedule of Outstanding Anti-Dilutive Securities Excluded in Diluted Net Income (Loss) per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-97",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails",
     "longName": "9954484 - Disclosure - Development and Other Agreements - Narrative (Details)",
     "shortName": "Development and Other Agreements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:CollaborativeResearchAndDevelopmentFee",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-111",
      "name": "dxcm:SharesIssuedInConnectionWithTheRestatedCollaborationAgreement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails",
     "longName": "9954485 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9954486 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:FairValueAssetsLevel3TransfersAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:FairValueAssetsLevel3TransfersAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails",
     "longName": "9954487 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Senior Convertible Notes (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value of Senior Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:ConvertibleDebtFairValueDisclosures",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:ConvertibleDebtFairValueDisclosures",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails",
     "longName": "9954488 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Short-Term Marketable Securities (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Short-Term Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails",
     "longName": "9954489 - Disclosure - Balance Sheet Details and Other Financial Information - Narrative (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtInstrumentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-7",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails",
     "longName": "9954490 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accounts Receivable (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails",
     "longName": "9954491 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Inventory (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails",
     "longName": "9954492 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Prepaid and Other Current Assets (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Prepaid and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "dxcm:PrepaidAndOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "dxcm:PrepaidAndOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails",
     "longName": "9954493 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Property and Equipment (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails",
     "longName": "9954494 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Intangible Net (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Intangible Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails",
     "longName": "9954495 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Amortization Expenses of Intangible Assets, Net (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Amortization Expenses of Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails",
     "longName": "9954496 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails",
     "longName": "9954497 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Other Assets (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails",
     "longName": "9954498 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails",
     "longName": "9954499 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accrued Payroll and Related Expenses (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Accrued Payroll and Related Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "dxcm:AccruedWagesBonusesAndTaxesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "dxcm:ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "dxcm:AccruedWagesBonusesAndTaxesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "dxcm:ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails",
     "longName": "9954500 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Accrued Warranty (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Accrued Warranty (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:StandardProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails",
     "longName": "9954501 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Other Long-Term Liabilities (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Other Long-Term Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:FinanceLeaseLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "dxcm:OtherTaxLiabilitiesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails",
     "longName": "9954502 - Disclosure - Balance Sheet Details and Other Financial Information - Schedule of Other Income (Expense), Net (Details)",
     "shortName": "Balance Sheet Details and Other Financial Information - Schedule of Other Income (Expense), Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentIncomeInterestAndDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentIncomeInterestAndDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
     "longName": "9954503 - Disclosure - Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details)",
     "shortName": "Debt - Schedule of Carrying Values and Estimated Fair Values of Debt Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
     "longName": "9954504 - Disclosure - Debt - Schedule of Converted Value of Notes (Details)",
     "shortName": "Debt - Schedule of Converted Value of Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails",
     "longName": "9954505 - Disclosure - Debt - Schedule of Components of Interest Expense and Effective Interest Rates of Senior Convertible Notes (Details)",
     "shortName": "Debt - Schedule of Components of Interest Expense and Effective Interest Rates of Senior Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails",
     "longName": "9954506 - Disclosure - Debt - Schedule of Key Details of Convertible Notes (Details)",
     "shortName": "Debt - Schedule of Key Details of Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-198",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
     "longName": "9954507 - Disclosure - Debt - 2023 Note Hedge (Details)",
     "shortName": "Debt - 2023 Note Hedge (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-198",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-204",
      "name": "dxcm:DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.dexcom.com/role/Debt2023WarrantsDetails",
     "longName": "9954508 - Disclosure - Debt - 2023 Warrants (Details)",
     "shortName": "Debt - 2023 Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-199",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-199",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
     "longName": "9954509 - Disclosure - Debt - 2028 Capped Call Transactions (Details)",
     "shortName": "Debt - 2028 Capped Call Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:PaymentsForPurchasesOfCappedCallTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-206",
      "name": "dxcm:DebtInstrumentCapCallTransactionCapPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
     "longName": "9954510 - Disclosure - Debt - Conversion Activity for Senior Convertible Notes (Details)",
     "shortName": "Debt - Conversion Activity for Senior Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dxcm:ScheduleOfTreasuryShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "dxcm:DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
     "longName": "9954511 - Disclosure - Debt - Conversion Rights for Seniors Convertible Notes (Details)",
     "shortName": "Debt - Conversion Rights for Seniors Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-146",
      "name": "dxcm:DebtInstrumentCovenantRepurchasePricePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-146",
      "name": "dxcm:DebtInstrumentCovenantRepurchasePricePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
     "longName": "9954512 - Disclosure - Debt - Availability and Outstanding Borrowings under Credit Agreement (Details)",
     "shortName": "Debt - Availability and Outstanding Borrowings under Credit Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails",
     "longName": "9954513 - Disclosure - Debt - Revolving Credit Agreement (Details)",
     "shortName": "Debt - Revolving Credit Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtInstrumentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DepositAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails",
     "longName": "9954514 - Disclosure - Leases and Other Commitments - Narrative (Details)",
     "shortName": "Leases and Other Commitments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:AssetRetirementObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "dxcm:ImpairedLongLivedAssetsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails",
     "longName": "9954515 - Disclosure - Leases and Other Commitments - Schedule of Maturity of Lease and Finance Liabilities (Details)",
     "shortName": "Leases and Other Commitments - Schedule of Maturity of Lease and Finance Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails",
     "longName": "9954516 - Disclosure - Leases and Other Commitments - Schedule of Components of Lease Expense and Other Information (Details)",
     "shortName": "Leases and Other Commitments - Schedule of Components of Lease Expense and Other Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails",
     "longName": "9954517 - Disclosure - Leases and Other Commitments - Other Information (Details)",
     "shortName": "Leases and Other Commitments - Other Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails",
     "longName": "9954518 - Disclosure - Income Taxes - Schedule of Income (Loss) before Income Taxes Subject to Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Income (Loss) before Income Taxes Subject to Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9954519 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails",
     "longName": "9954520 - Disclosure - Income Taxes - Schedule of Tax Credits and Operating Loss Carryforwards (Details)",
     "shortName": "Income Taxes - Schedule of Tax Credits and Operating Loss Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-226",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-226",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954521 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:UnusedExpiredFederalIncomeTaxCredits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:UnusedExpiredFederalIncomeTaxCredits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954522 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails",
     "longName": "9954523 - Disclosure - Income Taxes - Schedule of Reconciliation between Effective Tax Rate and Statutory Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation between Effective Tax Rate and Statutory Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "longName": "9954524 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
     "longName": "9954525 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Narrative (Details)",
     "shortName": "Employee Benefit Plans and Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails",
     "longName": "9954526 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of Treasure Share Activity (Details)",
     "shortName": "Employee Benefit Plans and Stockholders' Equity - Schedule of Treasure Share Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dxcm:ScheduleOfTreasuryShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-260",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dxcm:ScheduleOfTreasuryShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails",
     "longName": "9954527 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of RSU and PSU Activity (Details)",
     "shortName": "Employee Benefit Plans and Stockholders' Equity - Schedule of RSU and PSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-288",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-290",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails",
     "longName": "9954528 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of Share-Based Compensation Expenses (Details)",
     "shortName": "Employee Benefit Plans and Stockholders' Equity - Schedule of Share-Based Compensation Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails",
     "longName": "9954529 - Disclosure - Employee Benefit Plans and Stockholders' Equity - Schedule of Valuation Assumptions for Employee Stock Purchase Plan (Details)",
     "shortName": "Employee Benefit Plans and Stockholders' Equity - Schedule of Valuation Assumptions for Employee Stock Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-313",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-313",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationNarrativeDetails",
     "longName": "9954530 - Disclosure - Business Segment and Geographic Information - Narrative (Details)",
     "shortName": "Business Segment and Geographic Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails",
     "longName": "9954531 - Disclosure - Business Segment and Geographic Information - Summary (Details)",
     "shortName": "Business Segment and Geographic Information - Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dxcm:RevenuePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails",
     "longName": "9954532 - Disclosure - Business Segment and Geographic Information - Geographic Information (Details)",
     "shortName": "Business Segment and Geographic Information - Geographic Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails",
     "longName": "9954533 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dxcm-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "dxcm_A2022ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "A2022ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Share Repurchase Program",
        "label": "2022 Share Repurchase Program [Member]",
        "documentation": "2022 Share Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_A2023ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "A2023ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Share Repurchase Program",
        "label": "2023 Share Repurchase Program [Member]",
        "documentation": "2023 Share Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_A2028NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "A2028NotesMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028 Notes",
        "label": "2028 Notes [Member]",
        "documentation": "2028 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_A401kPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "A401kPlanMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) Plan",
        "label": "401(k) Plan [Member]",
        "documentation": "401(k) Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_AMTTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AMTTaxCreditsMember",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AMT Tax Credits",
        "label": "AMT Tax Credits [Member]",
        "documentation": "AMT Tax Credits"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_AcceleratedShareRepurchaseASRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AcceleratedShareRepurchaseASRMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Share Repurchase (ASR)",
        "label": "Accelerated Share Repurchase (ASR) [Member]",
        "documentation": "Accelerated Share Repurchase (ASR)"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_AcceleratedShareRepurchaseAgreementAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AcceleratedShareRepurchaseAgreementAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated share repurchase agreement, authorized amount",
        "label": "Accelerated Share Repurchase Agreement, Authorized Amount",
        "documentation": "Accelerated Share Repurchase Agreement, Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails",
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable trade",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r27"
     ]
    },
    "dxcm_AccountsReceivableAllowanceForCreditLossCashDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AccountsReceivableAllowanceForCreditLossCashDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash discounts reserve",
        "label": "Accounts Receivable, Allowance for Credit Loss, Cash Discount",
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Cash Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r338",
      "r1056"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r776",
      "r833",
      "r1056"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other accrued employee benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r190"
     ]
    },
    "dxcm_AccruedTaxAuditAndLegalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AccruedTaxAuditAndLegalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued tax, audit, and legal fees",
        "label": "Accrued Tax Audit And Legal Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of accrued current tax, audit and legal fees."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_AccruedWagesBonusesAndTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AccruedWagesBonusesAndTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued wages, bonus and taxes",
        "label": "Accrued Wages, Bonuses and Taxes, Current",
        "documentation": "Accrued Wages, Bonuses and Taxes, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r138",
      "r245",
      "r661",
      "r684",
      "r685"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14",
      "r42",
      "r571",
      "r574",
      "r615",
      "r680",
      "r681",
      "r944",
      "r945",
      "r946",
      "r957",
      "r958",
      "r959"
     ]
    },
    "dxcm_AcquiredTechnologyAndIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AcquiredTechnologyAndIntellectualPropertyMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired technology and intellectual property",
        "label": "Acquired Technology And Intellectual Property [Member]",
        "documentation": "Acquired Technology And Intellectual Property"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing transactions:",
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Details and Other Financial Information",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r518",
      "r519",
      "r696",
      "r957",
      "r958",
      "r959",
      "r1036",
      "r1062"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dxcm_AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalization of sales-based milestones",
        "label": "Adjustments To Additional Paid In Capital, Capitalization Of Sales-based Milestones",
        "documentation": "Adjustments To Additional Paid In Capital, Capitalization Of Sales-based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative research and development fee",
        "label": "Adjustments To Additional Paid In Capital, Collaborative Research And Development Fee",
        "documentation": "Adjustments To Additional Paid In Capital, Collaborative Research And Development Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity component of 2025 Notes issuance, net of issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "dxcm_AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of capped call transactions, net of tax",
        "label": "Adjustments To Additional Paid-In Capital, Purchase Of Capped Call Transactions, Net Of Tax",
        "documentation": "Adjustments To Additional Paid-In Capital, Purchase Of Capped Call Transactions, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r483"
     ]
    },
    "dxcm_AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax benefit related to Senior Convertible Notes",
        "label": "Adjustments to Additional Paid in Capital, Tax Benefit from Equity Component of Convertible Debt",
        "documentation": "Adjustments to Additional Paid in Capital, Tax Benefit from Equity Component of Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising Costs",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising costs",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r863",
      "r873",
      "r899"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r866",
      "r876",
      "r902"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r867",
      "r877",
      "r894",
      "r903",
      "r907",
      "r915"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r524"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r340",
      "r378",
      "r381",
      "r382",
      "r1056"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "presentation": [
      "http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r447",
      "r593",
      "r951"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails": {
       "parentTag": "dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization expense included in operating expenses",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r72",
      "r76"
     ]
    },
    "dxcm_AmortizationOfIntangibleAssetsIncludedInCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AmortizationOfIntangibleAssetsIncludedInCostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails": {
       "parentTag": "dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization expense included in cost of sales",
        "label": "Amortization Of Intangible Assets Included In Cost Of Sales",
        "documentation": "Amortization Of Intangible Assets Included In Cost Of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAmortizationExpensesofIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total amortization of intangible assets",
        "label": "Amortization Of Intangibles Included In Cost Of Sales And Operating Expenses",
        "documentation": "Amortization Of Intangibles Included In Cost Of Sales And Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_AmortizationPeriodForIncentiveCompensationCosts": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AmortizationPeriodForIncentiveCompensationCosts",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization period for incentive compensation costs (in years)",
        "label": "Amortization Period For Incentive Compensation Costs",
        "documentation": "Amortization Period For Incentive Compensation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_AssetRetirementObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetRetirementObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails",
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset retirement obligation",
        "label": "Asset Retirement Obligation",
        "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r243",
      "r274",
      "r315",
      "r324",
      "r329",
      "r375",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r565",
      "r567",
      "r584",
      "r659",
      "r725",
      "r827",
      "r840",
      "r996",
      "r997",
      "r1043"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r251",
      "r274",
      "r375",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r565",
      "r567",
      "r584",
      "r827",
      "r996",
      "r997",
      "r1043"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value on a recurring basis",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "dxcm_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.dexcom.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r859"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.dexcom.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r859"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.dexcom.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r859"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r386",
      "r658"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt securities, available-for-sale",
        "terseLabel": "Estimated Market Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r386",
      "r654",
      "r966"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current available-for-sale securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r386"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dxcm_BarryJReganMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "BarryJReganMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Barry J. Regan [Member]",
        "documentation": "Barry J. Regan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets",
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r237",
      "r793"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r153",
      "r272"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash, end of period:",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r153"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1055"
     ]
    },
    "dxcm_CashInterestExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CashInterestExpenseAbstract",
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash interest expense:",
        "label": "Cash Interest Expense [Abstract]",
        "documentation": "Cash Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants or rights (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Other Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r203",
      "r214"
     ]
    },
    "dxcm_CollaborativeArrangementInitialPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CollaborativeArrangementInitialPaymentMember",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Initial Payment",
        "label": "Collaborative Arrangement, Initial Payment [Member]",
        "documentation": "Collaborative Arrangement, Initial Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "dxcm_CollaborativeArrangementMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CollaborativeArrangementMilestonePaymentsMember",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Milestone Payments",
        "label": "Collaborative Arrangement, Milestone Payments [Member]",
        "documentation": "Collaborative Arrangement, Milestone Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_CollaborativeArrangementUpfrontFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CollaborativeArrangementUpfrontFee",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial payment on collaborative agreement",
        "label": "Collaborative Arrangement, Upfront Fee",
        "documentation": "Collaborative Arrangement, Upfront Fee"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_CollaborativeResearchAndDevelopmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CollaborativeResearchAndDevelopmentFee",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations",
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative research and development fee",
        "label": "Collaborative Research And Development Fee",
        "documentation": "Collaborative Research and Development Fee"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_CollaborativeSalesBasedMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CollaborativeSalesBasedMilestoneMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative sales-based milestones",
        "label": "Collaborative Sales-based Milestone [Member]",
        "documentation": "Collaborative Sales-based Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r834",
      "r835",
      "r836",
      "r837"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r117",
      "r660",
      "r711"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r778"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common\u00a0Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r831",
      "r832",
      "r834",
      "r835",
      "r836",
      "r837",
      "r957",
      "r958",
      "r1036",
      "r1060",
      "r1062"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r712"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock outstanding (in shares)",
        "periodStartLabel": "Balance at beginning of period ( in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r129",
      "r712",
      "r731",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, 800.0 million shares authorized; 407.2 million and 385.4 million shares issued and outstanding, respectively, at December\u00a031, 2023; and 393.2 million and 386.3 million shares issued and outstanding, respectively, at December\u00a031, 2022",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r712"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans and Stockholders' Equity",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r172",
      "r173",
      "r174"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r256",
      "r258",
      "r264",
      "r655",
      "r669"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_ComputerSoftwareAndHardwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ComputerSoftwareAndHardwareMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software and hardware",
        "label": "Computer Software And Hardware [Member]",
        "documentation": "Computer Software And Hardware"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r110",
      "r111",
      "r337",
      "r777"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r110",
      "r111",
      "r337",
      "r686",
      "r777"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r110",
      "r111",
      "r337",
      "r777",
      "r928"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and Significant Customers",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r206"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk (as a percent)",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r110",
      "r111",
      "r337"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r61",
      "r62",
      "r110",
      "r187",
      "r777"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r110",
      "r111",
      "r337",
      "r777"
     ]
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails",
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Statements, Captions [Line Items]",
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r228",
      "r229",
      "r230",
      "r279",
      "r922"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r802"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_ContractPaymentTermsNumberofDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ContractPaymentTermsNumberofDays",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer contract payment terms (in days)",
        "label": "Contract Payment Terms, Number of Days",
        "documentation": "Contract Payment Terms, Number of Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r471"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, long-term",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r471"
     ]
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerSalesChannelAxis",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Sales Channel [Axis]",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "documentation": "Information by sales channel for delivery of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r999"
     ]
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerSalesChannelDomain",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Sales Channel [Domain]",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r999"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of outstanding senior convertible notes",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior convertible notes",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Converted Value of Notes",
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term senior convertible notes",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "dxcm_ConvertibleNotesDue2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ConvertibleNotesDue2023Member",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/Debt2023WarrantsDetails",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Convertible Notes due 2023",
        "label": "Convertible Notes Due 2023 [Member]",
        "documentation": "Convertible Notes Due 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_ConvertibleNotesDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ConvertibleNotesDue2025Member",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Convertible Notes due 2025",
        "label": "Convertible Notes Due 2025 [Member]",
        "documentation": "Convertible Notes Due 2025"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_ConvertibleNotesDue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ConvertibleNotesDue2028Member",
     "presentation": [
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Convertible Notes due 2028",
        "label": "Convertible Notes Due 2028 [Member]",
        "documentation": "Convertible Notes Due 2028"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Carrying amount of senior convertible notes",
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r193",
      "r1054"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term senior convertible notes",
        "label": "Convertible Notes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r822",
      "r1059"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r650"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r277",
      "r278",
      "r429",
      "r455",
      "r616",
      "r799",
      "r801"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r955",
      "r1033"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r955"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income taxes",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r552",
      "r558",
      "r955"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r955",
      "r1033"
     ]
    },
    "dxcm_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CustomerAMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer A",
        "label": "Customer A [Member]",
        "documentation": "Customer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CustomerBMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer B",
        "label": "Customer B [Member]",
        "documentation": "Customer B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CustomerCMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer C",
        "label": "Customer C [Member]",
        "documentation": "Customer C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer concentration risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r337"
     ]
    },
    "dxcm_CustomerDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CustomerDMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer D",
        "label": "Customer D [Member]",
        "documentation": "Customer D"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_CustomerEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "CustomerEMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer E",
        "label": "Customer E [Member]",
        "documentation": "Customer E"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_DebtAndEquitySecuritiesGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtAndEquitySecuritiesGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from equity investments",
        "label": "Debt and Equity Securities, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r144"
     ]
    },
    "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains recognized during the reporting period on equity investments still held at the reporting date",
        "label": "Debt and Equity Securities, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r769",
      "r770",
      "r771",
      "r947",
      "r948"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for repurchase and conversions of senior convertible notes",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock counterparties to acquire with warrants purchased (in shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r273",
      "r425",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r441",
      "r448",
      "r449",
      "r451"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/Debt2023WarrantsDetails",
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r123",
      "r124",
      "r189",
      "r193",
      "r279",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r594",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r953"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate (as a percent)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DebtInstrumentCapCallTransactionCapPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentCapCallTransactionCapPricePerShare",
     "presentation": [
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capped call, cap price (in usd per share)",
        "label": "Debt Instrument, Cap Call Transaction, Cap Price Per Share",
        "documentation": "Debt Instrument, Cap Call Transaction, Cap Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DebtInstrumentConversionTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentConversionTermAxis",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Axis]",
        "documentation": "Debt Instrument Conversion Term [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DebtInstrumentConversionTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentConversionTermDomain",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Conversion Term [Domain]",
        "label": "Debt Instrument Conversion Term [Domain]",
        "documentation": "[Domain] for Debt Instrument Conversion Term [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DebtInstrumentConversionTermOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentConversionTermOneMember",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Conversion Term One",
        "label": "Debt Instrument Conversion Term One [Member]",
        "documentation": "Debt Instrument Conversion Term One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DebtInstrumentConversionTermTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentConversionTermTwoMember",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Conversion Term Two",
        "label": "Debt Instrument Conversion Term Two [Member]",
        "documentation": "Debt Instrument Conversion Term Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued upon conversion of senior notes (in shares)",
        "label": "Debt Instrument, Convertible, Associated Derivative Transactions, Number Of Shares",
        "documentation": "Debt Instrument, Convertible, Associated Derivative Transactions, Number Of Shares1"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage",
     "presentation": [
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock premium (as percent)",
        "label": "Debt Instrument, Convertible, Capped Calls Initial Cap Price, Premium Percentage",
        "documentation": "Debt Instrument, Convertible, Capped Calls Initial Cap Price, Premium Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price of convertible notes (in usd per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r428"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r85",
      "r167",
      "r168",
      "r428"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total by which the notes\u2019 if-converted value exceeds their principal amount",
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "dxcm_DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, convertible principal amount settled",
        "label": "Debt Instrument, Convertible, Principal Amount Exercised And Settled",
        "documentation": "Debt Instrument, Convertible, Principal Amount Exercised And Settled"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023WarrantsDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of applicable conversion price (as a percent)",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DebtInstrumentCovenantRepurchasePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentCovenantRepurchasePricePercentage",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Holder's repurchase price percentage in event of fundamental change (as a percent)",
        "label": "Debt Instrument, Covenant Repurchase Price, Percentage",
        "documentation": "Debt Instrument, Covenant Repurchase Price, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": {
       "parentTag": "us-gaap_ConvertibleNotesPayable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r115",
      "r426",
      "r594",
      "r811",
      "r812"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r113",
      "r452",
      "r594"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate on convertible notes (as a percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r427"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/Debt2023WarrantsDetails",
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r594",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r953"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/Debt2023WarrantsDetails",
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r279",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r594",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r953"
     ]
    },
    "dxcm_DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of conversion price (as a percent)",
        "label": "Debt Instrument, Redemption Covenant, Percent Of Conversion Price, Last Reported Sale Price Of Common Stock",
        "documentation": "Debt Instrument, Redemption Covenant, Percent Of Conversion Price, Last Reported Sale Price Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price (as a percent)",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/Debt2023WarrantsDetails",
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r85",
      "r86",
      "r112",
      "r113",
      "r115",
      "r119",
      "r166",
      "r168",
      "r279",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r594",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r953"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails",
      "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of debt instrument (in months)",
        "verboseLabel": "Term of debt instrument (in years)",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DebtSecuritiesAvailableForSaleAndEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAndEquitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term marketable securities",
        "label": "Debt Securities, Available-For-Sale And Equity Securities",
        "documentation": "Debt Securities, Available-For-Sale And Equity Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-Term Marketable Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation plan liabilities",
        "label": "Deferred Compensation Liability, Current",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r171"
     ]
    },
    "dxcm_DeferredCompensationPlanAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DeferredCompensationPlanAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation plan assets",
        "label": "Deferred Compensation Plan Assets, Current",
        "documentation": "Deferred Compensation Plan Assets, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r955",
      "r1032"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Total deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r182",
      "r211",
      "r557",
      "r558",
      "r955"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r191",
      "r546"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r1032",
      "r1033"
     ]
    },
    "dxcm_DeferredTaxAssetsConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DeferredTaxAssetsConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Convertible debt",
        "label": "Deferred Tax Assets, Convertible Debt",
        "documentation": "Deferred Tax Assets, Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DeferredTaxAssetsFixedAssetsAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed and intangible assets",
        "label": "Deferred Tax Assets, Fixed Assets and Intangible Assets",
        "documentation": "Deferred Tax Assets, Fixed Assets and Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development expenses",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1031"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets (liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1031"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r1031"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1031"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1031"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1031"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance amount",
        "negatedTerseLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fixed assets and acquired intangibles assets",
        "label": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets",
        "documentation": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1031"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total matching contributions",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee contribution (as a percent)",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer matching contribution (as a percent)",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum employee contribution (as a percent)",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit assets",
        "label": "Deposit Assets",
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r78"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r319"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r703",
      "r717",
      "r718",
      "r719",
      "r721",
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r729",
      "r740",
      "r741",
      "r742",
      "r743",
      "r746",
      "r747",
      "r748",
      "r749",
      "r762",
      "r763",
      "r766",
      "r767",
      "r830",
      "r832"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r701",
      "r703",
      "r717",
      "r718",
      "r719",
      "r721",
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r729",
      "r740",
      "r741",
      "r742",
      "r743",
      "r746",
      "r747",
      "r748",
      "r749",
      "r762",
      "r763",
      "r766",
      "r767",
      "r801",
      "r830",
      "r832"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount of outstanding hedge to currency risk",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_DerivativeTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeTermOfContract",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of derivative contract",
        "label": "Derivative, Term of Contract",
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dxcm_DevelopmentAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DevelopmentAgreementsLineItems",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Agreements [Line Items]",
        "label": "Development Agreements [Line Items]",
        "documentation": "Development Agreements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_DevelopmentAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "DevelopmentAgreementsTable",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Agreements [Table]",
        "label": "Development Agreements [Table]",
        "documentation": "Development Agreements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r859"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r859",
      "r895"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents incorporated by reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net income per share (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r297",
      "r299",
      "r305",
      "r306",
      "r307",
      "r309",
      "r578",
      "r579",
      "r656",
      "r670",
      "r804"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net income per share (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r299",
      "r305",
      "r306",
      "r307",
      "r309",
      "r578",
      "r579",
      "r656",
      "r670",
      "r804"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "dxcm_EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement milestone share-based payment",
        "label": "Effective Income Tax Rate Reconciliation, Collaboration Agreement Milestone, Share-based Payment",
        "documentation": "Effective Income Tax Rate Reconciliation, Collaboration Agreement Milestone, Share-based Payment"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property transfer",
        "label": "Effective Income Tax Rate Reconciliation, Intellectual Property Transfer",
        "documentation": "Effective Income Tax Rate Reconciliation, Intellectual Property Transfer"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_EffectiveIncomeTaxReconciliationPermanentItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationPermanentItems",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent items",
        "label": "Effective Income Tax Reconciliation, Permanent Items",
        "documentation": "Effective Income Tax Reconciliation, Permanent Items"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_EmployeePurchasePriceFloorPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "EmployeePurchasePriceFloorPercentage",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee purchase price floor (as a percent)",
        "label": "Employee Purchase Price Floor Percentage",
        "documentation": "Employee purchase price floor, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedPayrollandRelatedExpensesDetails",
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and related expenses",
        "totalLabel": "Total accrued payroll and related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation costs recognized weighted average period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation costs related to unvested restricted stock units",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total tax benefit related to share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_EmployeeStockPurchasePlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "EmployeeStockPurchasePlan2015Member",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP 2015",
        "label": "Employee Stock Purchase Plan 2015 [Member]",
        "documentation": "Employee Stock Purchase Plan 2015"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock authorized in ESPP (in shares)",
        "label": "Employee Stock Purchase Plan (ESPP), Number of Shares Authorized",
        "documentation": "Employee Stock Purchase Plan (ESPP), Number of Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r231",
      "r260",
      "r261",
      "r262",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r296",
      "r310",
      "r376",
      "r377",
      "r458",
      "r517",
      "r518",
      "r519",
      "r553",
      "r554",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r577",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r615",
      "r680",
      "r681",
      "r682",
      "r696",
      "r752"
     ]
    },
    "dxcm_EquityIncentivePlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "EquityIncentivePlan2015Member",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EIP 2015",
        "label": "Equity Incentive Plan 2015 [Member]",
        "documentation": "Equity Incentive Plan 2015"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized (gain) loss on equity investment",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r983"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying values of investments",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r863",
      "r873",
      "r899"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r860",
      "r870",
      "r896"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r583"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r583"
     ]
    },
    "dxcm_FairValueAssetsLevel3TransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "FairValueAssetsLevel3TransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers in or out of Level 3 securities",
        "label": "Fair Value, Assets, Level 3 Transfers, Amount",
        "documentation": "Fair Value, Assets, Level 3 Transfers, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy for Financial Assets",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r186"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r581",
      "r620",
      "r621",
      "r622",
      "r811",
      "r812",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Senior Convertible Notes",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r473",
      "r478",
      "r581",
      "r620",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r473",
      "r478",
      "r581",
      "r621",
      "r811",
      "r812",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r581",
      "r622",
      "r811",
      "r812",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r620",
      "r621",
      "r622",
      "r811",
      "r812",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r606",
      "r826"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r610"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of future payments",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r614"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost:",
        "label": "Finance Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Current portion",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Finance Lease Liabilities",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails",
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease obligations",
        "verboseLabel": "Long-term portion",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future lease cost",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing cash flows from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r610"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r606",
      "r826"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate of finance leases (as a percent)",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r826"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term of finance leases (in years)",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r826"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r379",
      "r380",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r450",
      "r456",
      "r576",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r668",
      "r808",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r979",
      "r980",
      "r981",
      "r982"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset, useful life (in years)",
        "verboseLabel": "Weighted Average Useful Life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r402"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets Amortization Expense",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403",
      "r651",
      "r652"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails",
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r652"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r75"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails",
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r651"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization period (in months)",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignExchangeForwardMember",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Exchange Forward",
        "label": "Foreign Exchange Forward [Member]",
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r723",
      "r728",
      "r742",
      "r748",
      "r764",
      "r765",
      "r766",
      "r832"
     ]
    },
    "dxcm_ForeignTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ForeignTaxCreditsMember",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax credits",
        "label": "Foreign Tax Credits [Member]",
        "documentation": "Foreign Tax Credits"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r867",
      "r877",
      "r903"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r867",
      "r877",
      "r903"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r867",
      "r877",
      "r903"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r867",
      "r877",
      "r903"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r867",
      "r877",
      "r903"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UK",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of machinery and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails",
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r83",
      "r84"
     ]
    },
    "dxcm_GirishNaganathanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "GirishNaganathanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Girish Naganathan [Member]",
        "documentation": "Girish Naganathan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r396",
      "r653",
      "r809",
      "r827",
      "r985",
      "r986"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets and Other Long-Lived Assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r70"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment charges",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r397",
      "r398",
      "r399",
      "r809"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r274",
      "r315",
      "r323",
      "r328",
      "r331",
      "r375",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r584",
      "r806",
      "r996"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r569"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r859"
     ]
    },
    "dxcm_ImpairedLongLivedAssetsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ImpairedLongLivedAssetsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of impaired long-lived asset",
        "label": "Impaired Long-Lived Assets, Fair Value",
        "documentation": "Impaired Long-Lived Assets, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment charges",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r21"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment losses",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r77",
      "r161"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r559"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r140",
      "r195",
      "r315",
      "r323",
      "r328",
      "r331",
      "r657",
      "r666",
      "r806"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofIncomeLossbeforeIncomeTaxesSubjecttoTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside of the United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r559"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r408",
      "r736"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r736"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r528",
      "r538",
      "r543",
      "r550",
      "r555",
      "r560",
      "r561",
      "r562",
      "r694"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "totalLabel": "Income taxes at effective rates",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r212",
      "r295",
      "r296",
      "r320",
      "r536",
      "r556",
      "r672"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r532",
      "r533",
      "r543",
      "r544",
      "r549",
      "r551",
      "r690"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in statutory tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r537"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock and officers compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofReconciliationbetweenEffectiveTaxRateandStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid during the year for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r52"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivables",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r942"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and related expenses",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherDeferredLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherDeferredLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue and other liabilities",
        "label": "Increase (Decrease) in Other Deferred Liability",
        "documentation": "Amount of increase (decrease) in deferred obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_IncreaseDecreaseInTreasuryStockRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "IncreaseDecreaseInTreasuryStockRollForward",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) In Treasury Stock [Roll Forward]",
        "label": "Increase (Decrease) In Treasury Stock [Roll Forward]",
        "documentation": "Increase (Decrease) In Treasury Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease right-of-use assets and liabilities, net",
        "label": "Increase (Decrease) in Operating Lease Assets and Liabilities, Net",
        "documentation": "Increase (Decrease) in Operating Lease Assets and Liabilities, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive potential common stock outstanding (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r307",
      "r485"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r867",
      "r877",
      "r894",
      "r903",
      "r907",
      "r915"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r919"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r919"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r919"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r197",
      "r263",
      "r318",
      "r592",
      "r737",
      "r838",
      "r1061"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense recognized on senior notes",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r445",
      "r453",
      "r813",
      "r814"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual coupon interest",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r446",
      "r813",
      "r814"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Interest Expense and Effective Interest Rates of Senior Convertible Notes",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAttributableToParentDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes",
        "label": "Interest on Convertible Debt, Net of Tax",
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r303",
      "r307"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid during the year for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r270",
      "r271"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r796"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails",
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r794",
      "r827"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r236",
      "r247",
      "r390",
      "r391",
      "r393",
      "r649",
      "r803"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r798"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r797"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-down",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and dividend income",
        "label": "Investment Income, Interest and Dividend",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "dxcm_JeremeMSylvainMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "JeremeMSylvainMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jereme M. Sylvain [Member]",
        "documentation": "Jereme M. Sylvain"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_KevinRSayerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "KevinRSayerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kevin R. Sayer [Member]",
        "documentation": "Kevin R. Sayer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and land improvements",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r826"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Expense and Other Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/Contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases and Other Commitments",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future lease cost",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dxcm_LesseeOperatingLeaseNumberOfOptionsToExtend": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfOptionsToExtend",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options to extend (in extension options)",
        "label": "Lessee, Operating Lease, Number Of Options To Extend",
        "documentation": "Lessee, Operating Lease, Number Of Options To Extend"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease terms (in years)",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term (in years)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "dxcm_LesseeOperatingLeasesLeaseCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "LesseeOperatingLeasesLeaseCostAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use asset",
        "label": "Lessee, Operating Leases, Lease Cost, Amortization",
        "documentation": "Lessee, Operating Leases, Lease Cost, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases and Other Commitments",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding letters of credit",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r274",
      "r375",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r566",
      "r567",
      "r568",
      "r584",
      "r710",
      "r805",
      "r840",
      "r996",
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r194",
      "r663",
      "r827",
      "r954",
      "r984",
      "r1037"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r235",
      "r274",
      "r375",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r566",
      "r567",
      "r568",
      "r584",
      "r827",
      "r996",
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding borrowings",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r193",
      "r1054"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit available",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "dxcm_LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to increase revolving line of credit",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Option To Increase, Amount",
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Option to Increase, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total available balance",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r953"
     ]
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused capacity fee (as a percent)",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_LondonInterbankOfferedRateLIBOR1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "LondonInterbankOfferedRateLIBOR1Member",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "London Interbank Offered Rate (LIBOR)",
        "label": "London Interbank Offered Rate (LIBOR) 1 [Member]",
        "documentation": "London Interbank Offered Rate (LIBOR) 1"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_LongTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "LongTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term deposits",
        "label": "Long -Term Deposits",
        "documentation": "Long -Term Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/Debt2023WarrantsDetails",
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/Debt2023WarrantsDetails",
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtRevolvingCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r80"
     ]
    },
    "country_MY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "MY",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Malaysia",
        "label": "MALAYSIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r818",
      "r999",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dxcm_MatthewDolanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "MatthewDolanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Matthew Dolan [Member]",
        "documentation": "Matthew Dolan"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_MaturityThresholdOfInvestmentsClassifiedToCashEquivalents": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "MaturityThresholdOfInvestmentsClassifiedToCashEquivalents",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity threshold of investments classified to cash equivalents",
        "label": "Maturity Threshold Of Investments Classified To Cash Equivalents",
        "documentation": "Maturity Threshold Of Investments Classified To Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails",
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r480",
      "r647",
      "r679",
      "r702",
      "r703",
      "r755",
      "r757",
      "r759",
      "r760",
      "r768",
      "r788",
      "r789",
      "r807",
      "r815",
      "r823",
      "r829",
      "r998",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails",
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r480",
      "r647",
      "r679",
      "r702",
      "r703",
      "r755",
      "r757",
      "r759",
      "r760",
      "r768",
      "r788",
      "r789",
      "r807",
      "r815",
      "r823",
      "r829",
      "r998",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInStandardProductWarrantyAccrualRollForward",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]",
        "label": "Movement in Standard Product Warranty Accrual [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r818",
      "r999",
      "r1057",
      "r1058"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAttributableToParentDiluted",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations",
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r155",
      "r196",
      "r233",
      "r254",
      "r257",
      "r262",
      "r274",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r304",
      "r315",
      "r323",
      "r328",
      "r331",
      "r375",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r579",
      "r584",
      "r667",
      "r733",
      "r750",
      "r751",
      "r806",
      "r838",
      "r996"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToParentDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToParentDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss) Attributable to Parent, Diluted, Total",
        "label": "Net Income (Loss) Attributable to Parent, Diluted",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Guidance",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_NonCashInterestExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "NonCashInterestExpenseAbstract",
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofComponentsofInterestExpenseandEffectiveInterestRatesofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense:",
        "label": "Non-Cash Interest Expense [Abstract]",
        "documentation": "Non-Cash Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r867",
      "r877",
      "r894",
      "r903"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1065",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of property and equipment included in accounts payable and accrued liabilities",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ]
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total long-lived assets",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "dxcm_NumberOfPrimaryGeographicMarkets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "NumberOfPrimaryGeographicMarkets",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of primary geographic markets",
        "label": "Number Of Primary Geographic Markets",
        "documentation": "Number Of Primary Geographic Markets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r323",
      "r328",
      "r331",
      "r806"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r826"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset impairment",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of future payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets",
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term operating lease liabilities",
        "negatedLabel": "Less: Current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets",
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofMaturityofLeaseandFinanceLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Long-term portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r610"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate of operating leases (as a percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r826"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term of operating leases (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r826"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "documentation": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r183",
      "r687",
      "r688"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other accrued liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r827"
     ]
    },
    "us-gaap_OtherAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails",
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "totalLabel": "Total other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Translation adjustments and other",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13",
      "r184"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss, net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive loss, net of tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13",
      "r184",
      "r255",
      "r258"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable debt securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r373"
     ]
    },
    "dxcm_OtherCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "OtherCountriesMember",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other countries",
        "label": "Other Countries [Member]",
        "documentation": "Other Countries"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_OtherForeignMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "OtherForeignMember",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other foreign",
        "label": "Other Foreign [Member]",
        "documentation": "Other Foreign"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangibles, other",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails",
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "dxcm_OtherLongTermAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "OtherLongTermAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Long -Term Assets",
        "documentation": "Other Long -Term Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-cash income and expenses",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other expense, net",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherIncomeExpenseNetDetails",
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Total other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dxcm_OtherStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "OtherStatesMember",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other states",
        "label": "Other States [Member]",
        "documentation": "Other States"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Sundry Liabilities, Noncurrent",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r192"
     ]
    },
    "dxcm_OtherTaxLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "OtherTaxLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofOtherLongTermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other tax liabilities",
        "label": "Other Tax Liabilities, Noncurrent",
        "documentation": "Other Tax Liabilities, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r865",
      "r875",
      "r901"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r868",
      "r878",
      "r904"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r868",
      "r878",
      "r904"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dxcm_PaulFlynnMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PaulFlynnMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paul Flynn [Member]",
        "documentation": "Paul Flynn"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other investing activities",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r949"
     ]
    },
    "dxcm_PaymentsForPurchasesOfCappedCallTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PaymentsForPurchasesOfCappedCallTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of capped call transactions",
        "terseLabel": "Purchases of capped call transactions",
        "label": "Payments For Purchases Of Capped Call Transactions",
        "documentation": "Payments For Purchases Of Capped Call Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Purchases of treasury stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for repurchase of equity",
        "label": "Payments for Repurchase of Equity",
        "documentation": "The cash outflow to reacquire common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r692"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r266",
      "r341"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "dxcm_PaymentsUnderCollaborationAgreementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PaymentsUnderCollaborationAgreementsAxis",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments Under Collaboration Agreements [Axis]",
        "label": "Payments Under Collaboration Agreements [Axis]",
        "documentation": "Payments Under Collaboration Agreements [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_PaymentsUnderCollaborationAgreementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PaymentsUnderCollaborationAgreementsDomain",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments Under Collaboration Agreements [Domain]",
        "label": "Payments Under Collaboration Agreements [Domain]",
        "documentation": "[Domain] for Payments Under Collaboration Agreements [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_PharmacyRebatesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PharmacyRebatesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued rebates",
        "label": "Pharmacy Rebates, Current",
        "documentation": "Pharmacy Rebates, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "dxcm_PossibleExtensionPeriodofTaxHoliday": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PossibleExtensionPeriodofTaxHoliday",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Possible extension period of tax holiday (in years)",
        "label": "Possible Extension Period of Tax Holiday",
        "documentation": "Possible Extension Period of Tax Holiday"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_PotentialCommonStockIssuableOrIssuedSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PotentialCommonStockIssuableOrIssuedSharesNewIssues",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential common stock issued shares (in shares)",
        "label": "Potential Common Stock Issuable Or Issued, Shares, New Issues",
        "documentation": "Potential Common Stock Issuable Or Issued, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_PotentialFutureCommonStockIssuableSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PotentialFutureCommonStockIssuableSharesNewIssues",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential future common stock issuable (in shares)",
        "label": "Potential Future Common Stock Issuable, Shares, New Issues",
        "documentation": "Potential Future Common Stock Issuable, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_PreferentialTaxRatePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PreferentialTaxRatePeriod",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferential tax rate period (in years)",
        "label": "Preferential Tax Rate Period",
        "documentation": "Preferential Tax Rate Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r454"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r712"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r454"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r712",
      "r731",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December\u00a031, 2023 and December\u00a031, 2022",
        "label": "Preferred Stock, Value, Outstanding",
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r712"
     ]
    },
    "dxcm_PrepaidAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PrepaidAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid and Other Current Assets",
        "label": "Prepaid And Other Current Assets [Table Text Block]",
        "documentation": "Prepaid And Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "totalLabel": "Total prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r394",
      "r395",
      "r795"
     ]
    },
    "dxcm_PrepaidInventoryCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "PrepaidInventoryCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid inventory",
        "label": "Prepaid Inventory, Current",
        "documentation": "Prepaid Inventory, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of convertible notes, net of issuance costs",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financing activities",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r950"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale and maturity of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r967"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r650",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r791",
      "r816",
      "r828",
      "r930",
      "r991",
      "r992",
      "r999",
      "r1057"
     ]
    },
    "dxcm_ProductShipmentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ProductShipmentCostsPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Shipment Costs",
        "label": "Product Shipment Costs [Policy Text Block]",
        "documentation": "Product Shipment Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductWarrantyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductWarrantyAccrualPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Costs incurred",
        "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments",
        "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r650",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r791",
      "r816",
      "r828",
      "r930",
      "r991",
      "r992",
      "r999",
      "r1057"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation and amortization",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r929",
      "r989"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails",
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r987"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r941",
      "r988"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r239",
      "r665"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r207",
      "r210",
      "r664"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Useful Life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails",
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r472",
      "r480",
      "r511",
      "r512",
      "r513",
      "r623",
      "r647",
      "r679",
      "r702",
      "r703",
      "r755",
      "r757",
      "r759",
      "r760",
      "r768",
      "r788",
      "r789",
      "r807",
      "r815",
      "r823",
      "r829",
      "r832",
      "r990",
      "r998",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails",
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413",
      "r472",
      "r480",
      "r511",
      "r512",
      "r513",
      "r623",
      "r647",
      "r679",
      "r702",
      "r703",
      "r755",
      "r757",
      "r759",
      "r760",
      "r768",
      "r788",
      "r789",
      "r807",
      "r815",
      "r823",
      "r829",
      "r832",
      "r990",
      "r998",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivables and Allowance for Doubtful Accounts",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r963",
      "r964",
      "r965"
     ]
    },
    "dxcm_ReceiverProductComponentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ReceiverProductComponentMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receiver Product Component",
        "label": "Receiver Product Component [Member]",
        "documentation": "Receiver Product Component [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligations",
        "label": "Recorded Unconditional Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "dxcm_RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of purchase obligations (in years)",
        "label": "Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term",
        "documentation": "Recorded Unconditional Purchase Obligation Due Within One Year, Maximum Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r860",
      "r870",
      "r896"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments for conversions of senior convertible notes",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r429",
      "r455",
      "r616",
      "r800",
      "r801"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r527",
      "r1051"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "dxcm_ResearchDevelopmentTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ResearchDevelopmentTaxCreditsMember",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D credits",
        "label": "Research &amp; Development Tax Credits [Member]",
        "documentation": "Research &amp; Development Tax Credits"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r861",
      "r871",
      "r897"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r862",
      "r872",
      "r898"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r869",
      "r879",
      "r905"
     ]
    },
    "dxcm_RestrictedAndPerformanceStockUnitsMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "RestrictedAndPerformanceStockUnitsMemberMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units and performance stock units",
        "label": "Restricted And Performance Stock Units Member [Member]",
        "documentation": "Restricted And Performance Stock Units Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r952",
      "r1052",
      "r1055"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_RestrictedStockUnitsRSUsAndPerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "RestrictedStockUnitsRSUsAndPerformanceSharesMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs and PSUs",
        "label": "Restricted Stock Units (RSUs) and Performance Shares [Member]",
        "documentation": "Restricted Stock Units (RSUs) and Performance Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r169",
      "r662",
      "r683",
      "r685",
      "r693",
      "r713",
      "r827"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r296",
      "r376",
      "r377",
      "r517",
      "r518",
      "r519",
      "r553",
      "r554",
      "r570",
      "r572",
      "r573",
      "r575",
      "r577",
      "r680",
      "r682",
      "r696",
      "r1062"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails",
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r322",
      "r326",
      "r327",
      "r333",
      "r335",
      "r337",
      "r469",
      "r470",
      "r650"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r790"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue from External Customers by Geographic Areas",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "dxcm_RevenuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "RevenuePercentage",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of revenue (as a percent)",
        "label": "Revenue, Percentage",
        "documentation": "Revenue, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_RevenueRecognitionSalesReturnsCoveragePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "RevenueRecognitionSalesReturnsCoveragePeriod",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales return period (in days)",
        "label": "Revenue Recognition, Sales Returns, Coverage Period",
        "documentation": "Revenue Recognition, Sales Returns, Coverage Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for finance lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r826"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r826"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "dxcm_SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction, Write-offs and Adjustments",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction, Write-offs and Adjustments",
        "documentation": "Total of the write-offs and adjustments in a given period to allowances and reserves for doubtful accounts"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_SadieMStern2023PlanTerminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "SadieMStern2023PlanTerminationMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sadie M Stern 2023 Plan Termination [Member]",
        "documentation": "Sadie M Stern 2023 Plan Termination"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_SadieMSternDecember2023PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "SadieMSternDecember2023PlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sadie M Stern December 2023 Plan [Member]",
        "documentation": "Sadie M Stern December 2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_SadieMSternMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "SadieMSternMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sadie M. Stern [Member]",
        "documentation": "Sadie M. Stern"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesChannelDirectlyToConsumerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesChannelDirectlyToConsumerMember",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct",
        "label": "Sales Channel, Directly to Consumer [Member]",
        "documentation": "Contract with customer in which good or service is transferred directly to consumer."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_SalesChannelThroughIntermediaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesChannelThroughIntermediaryMember",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor",
        "label": "Sales Channel, Through Intermediary [Member]",
        "documentation": "Contract with customer in which good or service is transferred through intermediary."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofPercentageofTotalRevenuesandAccountsReceivablebyCustomerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r927"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Payroll and Related Expenses",
        "label": "Schedule of Accrued Payroll and Related Expenses [Table Text Block]",
        "documentation": "Schedule of Accrued Payroll and Related Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofOutstandingAntiDilutiveSecuritiesExcludedinDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Outstanding Anti-Dilutive Securities Excluded in Diluted Net Income per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationNarrativeDetails",
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Statements [Table]",
        "label": "Condensed Financial Statements [Table]",
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r228",
      "r229",
      "r230",
      "r279",
      "r922"
     ]
    },
    "dxcm_ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Conversion Activity for Senior Convertible Notes",
        "label": "Schedule of Conversion Activity For Senior Convertible Notes [Table Text Block]",
        "documentation": "Schedule of Conversion Activity For Senior Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Income (Loss) Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation between Effective Tax Rate and Statutory Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Expenses",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r75",
      "r651"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets and Weighted Average Amortization Period",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income (Loss) before Income Taxes Subject to Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r135",
      "r136",
      "r137"
     ]
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Availability and Outstanding Borrowings on Credit Agreement",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Long-Term Liabilities",
        "label": "Schedule of Other Assets and Other Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Assets",
        "label": "Schedule of Other Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Nonoperating Income (Expense)",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Warranty",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r139"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU and PSU Activity",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r484",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions for Employee Stock Purchase Plan",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dxcm_ScheduleOfTreasuryShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ScheduleOfTreasuryShareActivityTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Treasury Share Activity Table Text Block",
        "label": "Schedule of Treasury Share Activity [Table Text Block]",
        "documentation": "Schedule of Treasury Share Activity"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r283"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Percentage of Total Revenues and Accounts Receivable by Customer",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r61",
      "r62",
      "r110",
      "r187"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails",
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails",
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r335",
      "r336",
      "r698",
      "r699",
      "r700",
      "r756",
      "r758",
      "r761",
      "r772",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r792",
      "r817",
      "r832",
      "r999",
      "r1057"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Segment and Geographic Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r321",
      "r325",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails",
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorLongtermNotesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorLongtermNotesCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Convertible Notes",
        "label": "Senior Notes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.dexcom.com/role/Debt2023NoteHedgeDetails",
      "http://www.dexcom.com/role/Debt2023WarrantsDetails",
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtConversionRightsforSeniorsConvertibleNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails",
      "http://www.dexcom.com/role/DebtScheduleofConvertedValueofNotesDetails",
      "http://www.dexcom.com/role/DebtScheduleofKeyDetailsofConvertibleNotesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueofSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested awards (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted\u00a0 Average Grant\u00a0Date Fair\u00a0Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of vested awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility of common stock (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r484",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum payroll deductions (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock reserved for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock available for issuance for future awards (in shares)",
        "periodStartLabel": "Number of shares available for grant at beginning of period (in shares)",
        "periodEndLabel": "Number of shares available for grant at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "dxcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares Available for Grant",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r489",
      "r508",
      "r509",
      "r510",
      "r511",
      "r514",
      "r520",
      "r521",
      "r522",
      "r523"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.dexcom.com/role/Debt2028CappedCallTransactionsDetails",
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing stock price (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program",
        "label": "Share Repurchase Program [Member]",
        "documentation": "Share Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common received vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofRSUandPSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic\u00a0Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofValuationAssumptionsforEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "dxcm_SharesIssuedInConnectionWithTheRestatedCollaborationAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "SharesIssuedInConnectionWithTheRestatedCollaborationAgreement",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares Issued In Connection With The Restated Collaboration Agreement",
        "label": "Shares Issued In Connection With The Restated Collaboration Agreement",
        "documentation": "Shares Issued In Connection With The Restated Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_SharesReceivedFromBenefitOfNoteHedge": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "SharesReceivedFromBenefitOfNoteHedge",
     "presentation": [
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares received from Note Hedge",
        "label": "Shares Received From Benefit Of Note Hedge",
        "documentation": "Shares Received From Benefit Of Note Hedge"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_SharesReceivedFromBenefitOfNoteHedgeValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "SharesReceivedFromBenefitOfNoteHedgeValue",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Benefit of note hedge upon conversions of 2023 Notes",
        "label": "Shares Received From Benefit Of Note Hedge, Value",
        "documentation": "Shares Received From Benefit Of Note Hedge, Value"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_SharesReceivedFromExerciseOfNoteHedge": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "SharesReceivedFromExerciseOfNoteHedge",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Benefit of note hedge upon conversions of 2023 Notes (in shares)",
        "verboseLabel": "Shares received from note hedge (in shares)",
        "label": "Shares Received From Exercise Of Note Hedge",
        "documentation": "Shares Received From Exercise Of Note Hedge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r826"
     ]
    },
    "us-gaap_StandardProductWarrantyAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StandardProductWarrantyAccrual",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccountsPayableandAccruedLiabilitiesDetails",
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued warranty",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Standard Product Warranty Accrual",
        "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r995"
     ]
    },
    "dxcm_StandardProductWarrantyAccrualChargesToCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "StandardProductWarrantyAccrualChargesToCostsAndExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofAccruedWarrantyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Charges to costs and expenses",
        "label": "Standard Product Warranty Accrual Charges To Costs And Expenses",
        "documentation": "Standard Product Warranty Accrual Charges To Costs And Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StandardProductWarrantyPolicy",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warranty Accrual",
        "label": "Standard Product Warranty, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r38",
      "r231",
      "r260",
      "r261",
      "r262",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r296",
      "r310",
      "r376",
      "r377",
      "r458",
      "r517",
      "r518",
      "r519",
      "r553",
      "r554",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r577",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r615",
      "r680",
      "r681",
      "r682",
      "r696",
      "r752"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails",
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails",
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails",
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r226",
      "r335",
      "r336",
      "r698",
      "r699",
      "r700",
      "r756",
      "r758",
      "r761",
      "r772",
      "r775",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r792",
      "r817",
      "r832",
      "r999",
      "r1057"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r310",
      "r650",
      "r689",
      "r697",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r712",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r721",
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r732",
      "r734",
      "r735",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r752",
      "r833"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r310",
      "r650",
      "r689",
      "r697",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r712",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r721",
      "r722",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r732",
      "r734",
      "r735",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r752",
      "r833"
     ]
    },
    "dxcm_StevenRPacelliMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "StevenRPacelliMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Steven R. Pacelli [Member]",
        "documentation": "Steven R. Pacelli"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r864",
      "r874",
      "r900"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_StockIssuedDuringPeriodSharesAchievementOfMilestone": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesAchievementOfMilestone",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares)",
        "negatedTerseLabel": "Shares issued in connection with the Restated Collaboration Agreement (in shares)",
        "label": "Stock Issued During Period, Shares, Achievement Of Milestone",
        "documentation": "Stock Issued During Period, Shares, Achievement Of Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.dexcom.com/role/DebtConversionActivityforSeniorConvertibleNotesDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversions of 2023 Notes (in shares)",
        "terseLabel": "Repurchase and conversions of notes (in shares)",
        "netLabel": "Shares issued in connection with 2023 Notes conversions (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r37",
      "r85",
      "r169",
      "r442"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock under equity incentive plans (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r128",
      "r129",
      "r169"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in connection with acquisition, shares (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r128",
      "r129",
      "r169",
      "r691",
      "r752",
      "r773"
     ]
    },
    "dxcm_StockIssuedDuringPeriodValueAchievementOfMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "StockIssuedDuringPeriodValueAchievementOfMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs",
        "label": "Stock Issued During Period, Value, Achievement Of Milestones",
        "documentation": "Stock Issued During Period, Value, Achievement Of Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversions of 2023 Notes",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r38",
      "r169"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under equity incentive plans",
        "label": "Stock Issued During Period, Value, Employee Benefit Plan",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r128",
      "r129",
      "r169"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r132",
      "r133",
      "r156",
      "r714",
      "r731",
      "r753",
      "r754",
      "r827",
      "r840",
      "r954",
      "r984",
      "r1037",
      "r1062"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r104",
      "r231",
      "r232",
      "r261",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r376",
      "r377",
      "r458",
      "r517",
      "r518",
      "r519",
      "r553",
      "r554",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r577",
      "r586",
      "r587",
      "r591",
      "r615",
      "r681",
      "r682",
      "r695",
      "r714",
      "r731",
      "r753",
      "r754",
      "r774",
      "r839",
      "r954",
      "r984",
      "r1037",
      "r1062"
     ]
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r180",
      "r181"
     ]
    },
    "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxExaminationsTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Years Remaining Subject to Audit by Major Jurisdiction",
        "label": "Summary of Income Tax Examinations [Table Text Block]",
        "documentation": "Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r179"
     ]
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Loss Carryforwards",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfTaxCreditCarryforwardsTextBlock",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Tax Credit Carryforwards",
        "label": "Summary of Tax Credit Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofTaxCreditsandOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks and trade name",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.dexcom.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r450",
      "r456",
      "r576",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r668",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r979",
      "r980",
      "r981",
      "r982"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average share price (in dollars per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, at cost (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock, at cost; 21.8 million shares at December\u00a031, 2023 and 6.9 million shares at December\u00a031, 2022",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r87",
      "r88"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityNarrativeDetails",
      "http://www.dexcom.com/role/EmployeeBenefitPlansandStockholdersEquityScheduleofTreasureShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of treasury stock (in shares)",
        "negatedLabel": "Shares repurchased under the Share Repurchase Program (in shares)",
        "verboseLabel": "Shares repurchased under the Share Repurchase Program (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r129",
      "r169"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of treasury stock",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r87",
      "r169"
     ]
    },
    "dxcm_TreasuryStockValueBenefitReceivedFromNoteHedge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "TreasuryStockValueBenefitReceivedFromNoteHedge",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares received under note hedge upon conversion of 2023 Notes",
        "label": "Treasury Stock, Value, Benefit Received From Note Hedge",
        "documentation": "Treasury Stock, Value, Benefit Received From Note Hedge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationGeographicInformationDetails",
      "http://www.dexcom.com/role/BusinessSegmentandGeographicInformationSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofShortTermMarketableSecuritiesDetails",
      "http://www.dexcom.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agencies",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails": {
       "parentTag": "us-gaap_ConvertibleNotesPayable",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/DebtScheduleofCarryingValuesandEstimatedFairValuesofDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnbilledContractsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnbilledContractsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled accounts receivable",
        "label": "Unbilled Contracts Receivable",
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undistributed foreign earnings",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r529",
      "r563"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r539"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreases related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "dxcm_UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential adjustment to other tax accounts, including deferred tax assets",
        "label": "Unrecognized Tax Benefits, Potential Adjustment To Deferred Tax Assets",
        "documentation": "Unrecognized Tax Benefits, Potential Adjustment To Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "dxcm_UnusedExpiredFederalIncomeTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "UnusedExpiredFederalIncomeTaxCredits",
     "crdr": "debit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards subject to expiration",
        "label": "Unused Expired Federal Income Tax Credits",
        "documentation": "Federal income tax credits likely to expire unused as a result of limitations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r202",
      "r204",
      "r208",
      "r209"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance, deferred tax asset, increase (decrease), amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r282"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://www.dexcom.com/role/SCHEDULEIIVALUATIONANDQUALIFYINGACCOUNTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from recovery of amount previously written off or reestablishment of reserve previously utilized."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/LeasesandOtherCommitmentsScheduleofComponentsofLeaseExpenseandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r826"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.dexcom.com/role/DebtAvailabilityandOutstandingBorrowingsunderCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_VerilyIntangibleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "VerilyIntangibleMember",
     "presentation": [
      "http://www.dexcom.com/role/BalanceSheetDetailsandOtherFinancialInformationScheduleofIntangibleNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Verily intangible asset",
        "label": "Verily Intangible [Member]",
        "documentation": "Verily Intangible"
       }
      }
     },
     "auth_ref": []
    },
    "dxcm_VerilyLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dexcom.com/20231231",
     "localname": "VerilyLifeSciencesMember",
     "presentation": [
      "http://www.dexcom.com/role/DevelopmentandOtherAgreementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Verily Life Sciences",
        "label": "Verily Life Sciences [Member]",
        "documentation": "Verily Life Sciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r831",
      "r834",
      "r835",
      "r836",
      "r837"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute diluted net income per share (in shares)",
        "totalLabel": "Diluted weighted average shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r307"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.dexcom.com/role/ConsolidatedStatementsofOperations",
      "http://www.dexcom.com/role/OrganizationandSignificantAccountingPoliciesScheduleofBasicandDilutedNetIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute basic net income per share (in shares)",
        "verboseLabel": "Basic weighted average shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r307"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "740",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481141/942-740-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "740",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480135/944-740-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-22"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "(m)",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "5",
   "Subsection": "04",
   "Paragraph": "c",
   "Subparagraph": "Schedule I",
   "Publisher": "SEC"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "7",
   "Subsection": "05",
   "Paragraph": "c",
   "Subparagraph": "Schedule II",
   "Publisher": "SEC"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "9",
   "Subsection": "06",
   "Publisher": "SEC"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481999/410-20-25-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2E"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0001093557-24-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001093557-24-000021-xbrl.zip
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M1UWOEQG]L9;^Y5'(^_9"4"]5Y.[;BS:] ."]/*CCOKUHUPO@@Q*I8'O1MA?
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M9^7'P@,56'C*I)P.0GG/I)?CK6L><2;=T1F_XWY(4]?3GY1F$FN[\TH IA=
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M^'WDM)KP"C0%S&GMISF>>CG7*>C]$4Z6@TV.:W/=G]0.1!/8$+" R:M :$G
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M><3<''&V\IQ-$.=P"54J0?5<)Z1;$%2]2E+MC@[7(OKN?&1N',I*6EDGK8!
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M:HN3> 2Z61N,!<UJ;,%/A]A+AOYIP\!!G16W S,'3$Q,YE.3/&!7[ID2A<H
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M.U;NQC9YYTQ$KN1Z$@C:,-2*WN>[8)Y>RC6HT7(0KP:$V\=_PR5R:1:)X:O
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MT;91B=9N%RO1=)99,?GMTQ'E/!8*;'^F@.TH+6#3_(M<S^^S@J[/)IG9Y+S
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M5D1@BRA3'SW%H<I(=\'S @MH#%:2JIP TT<%RL"8,QX2[!_:V 8,TOZM>K3
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MY<[TT\K6:(9HE3?*8/T9[:7-]K.!=_\DY[+FW$H>%))RB7S*:]W%X5V(?&,
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MG>&LD)WB[V/M\6*;>5;.8L>Y;3Q=N'#NF&^&4P??L_Z7RH?/@J.K_K*0X C
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M'X((/6+L_O+=_8=W V/W">^$",8.MFBI!*'(];7J(0C%C#+MN IYRYV"+,X
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MZ^PK03F_KOMWDQ]$P@OZ:1ODP3E1]VYGH@ZR(QR,]T7WO1+F)45C^T#?:H<
M94.<TKVN\-4P$5)(%B1B@GWN0XXC+QL=0?^L&Y"R'ABU?KO<Q"8ZXON1OEX*
M@9?66)Q:S"D'\OZ(Z;PI#N/^O2,.XWBI(P[#"ENQRAV>\ZXB,7[Q8$-7MQ_T
M4$FO1PA\9@HC8RKS37C*9W6U:(O)69B&8.<;E9'7+ZS\$,$@&L=&^/++JB^+
M27B%?X5C@E]Z534EJGTO2]!I 6@8>YBFKORO%'K@1/RU7@G:[:M'15B1DQY/
M5TWF5<4<T]*@$SM)91MY@_OB_4>/BJ_WOZDZV#A_JN:R#D$@X;==VVHGUX-[
M#QY&9,>2)6HI@4OU>WV1&+H$_NNZPX!!T;%@RYR];]+C"H&F5^;*QS&7\Q(V
M"\.?9)?-!A@%S;!=JLEV/9@6,&E,C6/#B#S.JP4ZS 9/7^X]^PM4%9N9/%,3
M09\Q'>X^;W0-^#6>+=V8#W82'HQ\)&'CB_QP*1*JXT][1YRAMUS!%#:(2/'I
M!2K\S2(#(>/=QM^T #!FIG66Q%N#D3VXOQP[RJJ2E))S[)4Q:R4@W 5$/61]
M!S=(6Q/8[31^\6*"KPM/AU 6R;Z2HB#].J-79>>G$FH6^"$\DS&^K"/V:K)#
M_YNB(BPSKSM0+MTK_#0!0V+'F_.3I E-G$PB N!]"O',2IE\I&4C5F'\"[:Q
MU5FY8@17:\PU^ER%/JRN9/*EK;>;]& 4X.:=D$,*=\KODE3^4BL=D"*S,*;D
MZUL1+>LCX4'#G4?OB%<=VQ\OVBO ?VB6R@8NX6*+8N^FTAVI=^,V4X]1MK@0
M8RU:K1=>E=UL3"G9S9EUNMX(>[':(ND/WM6!XQRM+$U?B ::S-XBX%>B4L7=
MF9"3(#<X%R=^W9PLPZ>U#MELPCYN!*?W+%<]]/T>:4!/Q$(>W%643D8)$^/G
MV6QT0^D1@.Y.(Y'VALP%18!+)VMX4<>NLJZB<K2:V_2%)%Y2Q"T2MT4QNFN2
MP0DKNP=0:<E. %-\32T?@S=."/4[8F1_J?9<EW&:5("%%.B <[MMV.?*75$+
M/M3*])=HW,M49MP7A#LKOZE"M,)6.9W\K=K=_..QXYM](V$5:6>1(BY$;%ND
M1:V\KM=5TUBM0@RI9?9UB!,O^'4&FX.WH94B9ZE^+:P<P!P+8Q16'9YZK9T'
MC<2F"<FJ\,[TT A$M[TG?16]\3+1-&HM(Y<TOT,E?AO3L:4CMD2YQ(6M=<_D
M<R8$Z#JQ[OV9V VW;1V_'_IBR!K>)>N\Z37BCU=TYWE47/8'>[#?/$:>A7E8
MG0.A=O^K>T\>WB_4=Q7&Z\%SV;3JEA!N0T?;>1+)PAT(;UIWTRWZ9NW]V0CK
MR-H*4A3JWPV.8E=MNXQH0^G1]<,X^W8-X+X\ N1O0' JJ_D>R?OIY'#ZZ4;Y
MIN(32S@)2VKPVLG4D=!2:8:DPW\C4^C5E#KQUI2$(YS0E]LE($":(U)G(&S-
M;KO6A1>.*W2RK\+ 18<'E%&,<FHC$_R"'5BHMLR7Z&RT92OF8=INE^!X[E8<
M9).Y_?TEW@]GO/Y\2,E'AY&2'Y "_/*;Q)3UR0,LCUG'/]VE/HFLXT<G<[Y9
M.O(M#X=7/!S.3*<39\-K#Z:ZJWG*IZAY#+"R4C+9%4F6=+]AGJ[22WX/?4KR
MKWJ67*:4_8C06"OZ2[*@[9P</&G[]Y5,_?=$U+066O1((U49=Y&R.HBFP6E\
M-'D'(3!/,<L>88">^JY=WTMT&$C7Z-=3]\VSK1S[+W4$GUL&A\C?9R^?%\9^
M,@'+V")XE:>35UVX3HCL$?WGSXFQQGWQI%<E^M.1P[@LZZ4Y%_'SD:P+H>>F
M?%=Y?J N.&*SX(9JAYWV64QFY0[R)1K(XR;[$K/Q!O+<(7SO8O$L:3NZ!OG4
M#R\AU4\M!B+NE&<5R(SK1CW%<(>?SIX5*9%YQD.[S^_]'^5J_20MJC>*O@;@
MM"K5&7X:%LR2/K>2>_;I^WBU.* B_9(&3(C:8L_^#^CB1FB%IPG/IDAS4%'U
M^:S$*R#%LQ'OSP:WGGNJ?<EH3"[J7N*(N>7H2C!%7>S6[6*Y"^%#74J"%W?4
MOBR]GRRQZYG(,/IQC.(W,=-9*O[+1VC"^IBT^K=NDJX-KZH)/WV-WUM5#[Y^
M\.5'?[#)[^]JLZK=;ZZ1>2:Q!+98I%MJMA@W*9)<DJX-?1](8V*%U7V_K<84
MI\W>F9UZ/UM3I '/&/@B,UZX"DA!>+-F W+N\,^.- BBE+5<RB.S*W1?O]H>
M*.8)#I, (L,D734K+AK7Z>AR=#5E9+S!RZAPRQZZ.4F)A1%W)*0?.?X.3TK:
MU8YL@VQTFH3*K[:IRA6J%]TBMMZ5VON<!Z=V1QTAQ*3GFCK1Z32*2&/PEH'/
M.C^-06U U.Z$;9;U.3I:D!K87R=[_45I'>[3^+]'PERLW!HQ;3G=):(PX=Z#
MO@E.NA$TX1TQ9==#=OP@9@.UEU#!_[JD2NP,1E<3*Q6?(*@'S]L')UF8:<("
M>]754TO'C_K.GT(&XZ8!^Z.OCIB=XZ7N4/1\NT'R"XJ<0&$DF+E7'6J^F]U=
MC8G#\V^JK!I;^]=;Z^LQ%IV(N-X"Q"$*)XW'G&5H>?AV<,4!ND9X?:[Q$".#
M<F.D7>M=A\= RSP:-^'GV[\G3;FJX@_![G<5/M>T#50EERW!!9YC-K&NB/:F
M\"-&LE05RL-[[NN8\2'NR!$+;4$9P@ER O/@IK0IKF] 8 ?W5=U>Z201U(=^
MRXNG158)X>B:N91_=*_)=)(2"%)S68217X3KT?V-O:L4%27B0V$;EK>81B6'
MB(ZPI986#1\BKHX04 +;BO]=H=4O++(*$)'T@:AJ1#:TV .%U?C@GI!U),7*
MF3BNX,KLD/C(QH&YAWD=' HAXD&?\C3X(\KEH .'H,.TXDR 2[0>=;#UT?#(
M!P,Z(4.N-BH@A&)_R^+FA'S2^"*?O)!'#U_YTASYW@B@>^VCID/+U^G2L(2_
M/[CWY8.,UPCD)2K\&"9]$(*#EQ@K)DPH9#01/W$F_)9T?WN^A3D@90G5DC:[
M[)-2R SW4TH,^Y->HG.\?+8NTV>RI5DR]7EP11Z(PC+&[NK7L"V8O\']4']*
MOQ&(4J+'"V=2,%(=:JCPTW O6YK*)RBHFW)"UA_P?^_VE+1B-G#<@(JA(3%)
MW]\=YI5D<B)O_IXA"1[[.]57H8TMN5J3"!H"FTQ"6C7DLN$SCO'(DM,VZ)>[
MB6#ZGD)!Z^VD%->24NK6T/&)E5SGQKV"C[WU^ A7R@&5B6GHKX*9*OR-LQ$R
M=+V4W\G&DYD-)?-I=G&L1<* HA-5%3^.,!'/"C.DO[)+^R>_;@7&)"#B3>X=
MWX[0)(XRQ.C(8W1DB#_?.?E8?44@FA::ZXS3I\_O^@FV:U*!U?,$6@0PS+VL
MOLH&#*-F9=-G)>'AR7Y*2/A(1O(RN($<EVU3->2]+PE)<6LU/2:OG>; X_YF
MY8K)?Z#6E'FD^:=J/9BP&FO2ZX[$HTH,EL X7->EP"4C65P,_MF//G;?3BG<
MU^4NZ@G01<[8_HT>SN'G1!S=#0IED&#9T1 %^VJJR$+WT=?!)I11TU@IZ)UH
M.-E"+ML:BI)I(B7/'>P_--34SB(#W[B%YP:D[I/._/M\RD+A>-OP6(0P#5*_
M)&&3A#P!L-0,+*_ZT26_[]-AE8B>>9E\G4QY-9Z%[++I&,,'X]Q.Z\0+=< ;
M;N:P//0_[X@AMW<UWWS@7">@'VA53BZ4;DI7H.RUV$PY$&:,>3^%EB9:&36^
M'.GA*3&<-9\P2N[H^/@'BY#</P$L&7J]6JV7[:ZJA!D86ZXTFF"F!YF^B\"7
M(L+;>AX%A"4Q,Z&H?Q]=E+/+NM=<9/5K-=UN1 O-1R4"IPL;W"IU@'(V0U4,
MZ6$C1M\^)RE=>7KY'?!$"P5L!GN9OAVY[N*[ZC)NN_.::-"5>)#G&!5G-X8[
MA+?U-H06..V+X1@SHSJO85EJ 9V1M4<=?J*UP.?L7E1]\.P>,#0*[#/X;[RF
M:&6ZJ\K3C".1W>L3!.OO(ET YYA9R9?O/?H1T?/=_:^.W&<W&";QV6U/^_I3
M[_,0 (A#JK!R:0B>E .C=^ PW#;E=G/1BKL5#W5Z>\B6#+UJ[UIH880LVJ1H
M=W)3BAM&R-Y1WMS9@7^?3_O+!X^/.>'CI3[QG'"T.;]/8OA-")S"/E3ZSX&%
MNV-YX3U:.H. B,PU^9$C7V_5)[MD*:4>MN^B75+'ALRF]Y^XLJGA2PK2HT >
M$,Z8<]ZD!8;>FL66JM%-PVA7E$:H7CNALL[ZWJ9#VG$:!.C:!"48*050#;.1
M2:RCIT;Y"9-_(=#<2N_8K!5]/[#XA/>3-)9@\6.Z@Y_NOYW\A-19"(]#J-:\
MFWQ?+XK)]\ )(3Y+@2HP/UKT?4%(/+4%W_)\D2LICZ-T^E1EYT!@?LUY<9)_
M/R[Y\Y%M?%"Y=XQ^0^;Y]R_NQGW@]FM8_$L^CF8M)9=E0 _;3'&K);C$LMPV
M4_3JE Y7XS6J0@#44D!T3I%T4,'/MFC*6(9_A9OMDR!=55G?X=!CIZ(F1D,"
M W9"9G<W0&%ZBDAJ:DC!_62PBS17+4G"R4C+C -"0#8=E'4GK*6BR%4AG@!C
M+,B[LZ2[M!XMFM_4+WS<4A^\I:+)_ .@:&Y7V6*2'OG)8MF>YR!?$?BZG@NL
M--H!\._EJE'R;=VF&7F]1TJN1-C)GW'9D<4#3PXYV2)U[YM@&</[\U!S.R \
M0^6PW&S!ZIN4804$'9X%H709C,EQZ?^.2S]S$?[8Y2]P;;?\8N.P4Y>U%7?.
MVNKT K^<.7L>U0EEV\@V"/$=.L%2J;><_)=>^V5L5)Z\$3T#NX/UD&T2K%(+
M+:(F-4I/(">1U+![5TM:[JR,(/WYL^,B_QT7^9C3:^[,'^!(_4(I!C90,.=B
M-?;@ZD]E!4F7!P$-48U1.$Y<2O;[%FD60 "H3&()Y.=,%R/C^5.B9GM;E2LZ
M+*KOC-6</*0-$KHHO -&LUUNE%%#@Z_D\$_P,ND!SMH9/W>FLGBX^_=V3#SG
MVXPB=EUWICI;41M2"VLR%BS,I$N7,]1F5 K ;446:N0462@C_%TI>:/@]?=6
MVC@4POECFOHS-8:Q469DQKF*JGB,7M95&(QGU:]AC*/&!\M-13C-X1QK5%M$
MA!7^;3YO$?'(R7]%2ZXF&<,U"/9@O"K8BL1'[M$+(3!=MW0=!D'CBL)]O>!9
M$DG$">5'P@O;U_+\QN1-& 267>*0%-[*!IM:]\+'22( +:8J.V%OY (=ORXE
M]6+R\SHUL/]UNP+4I%S#R!23'^K&>H?#)EJPA0MI4F6@J=G<#B5):@>&$1@7
M:.FKS<9*(L1[ATVGH[[;0]N\;\@FGSFDC6@119(^-OR$HW#N-O_/@!PHG4%F
M:C8W6W.?%PG6Y@6$TQ)1M(*ND@^:_\EGBJ@>K-2#"^"5W%WQQ9^GMZJJR)&2
M.BA$7'(M/6RQ.OR!]Y)R] <LR3 ":T/]<[%=,R,1(A(5J[;K62F:H\B>1X&V
M0P/YWNE0C<T;6I?Q\^2.6%'8DL'LO*Y$S[AW;7Y N6PVZ_[;+[Z(&;_3&1?%
M:?C/%^G0=?\\F;73+??]%\[DZ/3-E/U_KN>2]!6*E R*B"'TLODCM"1]DLE-
MIO:>BF2I/G!8J3\$@SJY?^_D;[^A9'+OP;%D<KS4)UXR^?VJ)3\FRKC7T4>\
MJS!ZBI%FG>7CE$U$ #O1T?CBU!4U +>+8\_#.91+,>$ @0B7$=.7TI6=8Z?<
M%8(WU^ HLH*"_1PQ'>[YA*MG[T6$"]A4%M_CY6N<9(^J0"%I]5(]S")G-RI
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MCNH#W7('QCQO[F/Q('U'EY.M=)-4B&TFY$@N6-Q,!/,ZR0*VG@X::LS*85+
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M;9=$34AMN\.9@/P'QNR.;-L7X[%6@DE"82\BFX:X.\' *NZ5IPX==1GX,<"
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M1\X*3=RR*%N2@@H^H&WI>!Y>$51.9XIX$V_D//IF)#C.<[.M#]N\I5"DFR#
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M5E/(EXI1K.[OXP:/]_N)8>A.&88RC$%&5R/]VG7XF<$42*)8&MECN]5&@TJ
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M6QZ.++:T?=(2@DEDV2])<-]T70K1C@\#$07^.Y]R$O'2!02V&H=DY.%"(1W
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M$4E8GS@()$M 1Q5)I[)H,9G3)"@G:V1'0C,(R'7XLC"J$2X?A:K5%?=Q: <
M6FBNHJ_2>KFTWK?@:GQ&LR4%.E2$_'U&K6!],8=CG;N11B\X*GP5/;WV*.'&
M#3PX-&&]Y6J-4/FS<C?W+>4M+?*^^+H^B/GM#!XS:*":$EKY%I\:A#*]]W&K
M-*76@W\<]-Q&&F!;0AT$'IKQ"6PK@3Y2LK#*Y[-"1S0CEE7"Q%FLYZ'?5=*-
M9.YXQEOKZ!+1[21B0OX>0TH4LL<;HPE67]AWYE1<[6MR;X3+JQR&<O4.#5V7
M\1\T*9^FU"B[RQI5M!)?N);#MKN(CJP433^+RZ3J]L"N;.G8H^RPAM&JHZ0S
MFTUL_!^>UT7HNK8K./*O-_']%?'*[J%7G -ZT1RD 6(70 X.0KR$&1*7.VMN
MHWR3R&%DV3AKHG9@2D%IM]2=M:T$JJV+U;*4?A;$V4/E.V-'7+'7ITJ"Z"GA
M/,5:]/TPPFT=_+/PSXHL,Z##02CC<9Y@7%CA<X[+*POU/KE%L1 @M::F]Z!_
M@E?L4^>"\^:$+0B3;L[8N_/4Q8:^16G4" )0*E-)L?2*)B];;_J04"RWI9QB
MOH==RE0>#3V+(,[HKHJ,'<MKS*M'>D\.*=:KF?.)<HV@P@PZ-MB+'TTP2 ??
M@F)8UCWUM_PSY--C\]^$.C5?"J #6B=D%F[J("8D.B<X$S1F;T0HS+.)QW@7
MA  A)07BC%7AFM^-";C(CN5D%=)\71[:O!Q*4'6$?P6;,6:_.I(B.F"3I1;7
M!/.GX=E4LFJE1;O=;$BJ,[@, :?"2\?'@.( [\:VLV?>YZVE1R']H0-1I!TO
M872%U,!=^%U'=TH4D9FS]JOTZWYA9^!8SDHGEWL@$O^I8<8M!35S"FZX%YE'
MVDNA:H%OYIAW"V+6:F7G@ER3.V5=&A9VV%^5\FWZ(&DW_#:6UP=/^^ZNC&^A
MIE?^[*UOVRVRWI/Q8CVV4'NW4K4W04\TM!W$^WU V_[;XD'>CNL.;NEZKT>V
M:N:.C%=#%C*F139N.!N%;3JAVGXDJ2#^5=[X[,-4U\)\3\Y+<NE_>/'ZZ=/$
M<_=F7UL:N.?%1^Q PFKAG1LN&Q2Y2VXXX3YG'!B?O[O+0U_A!,+.(W<= 4'.
M3. W/_FP%XS/&6,LD)6X*JO:->_<: NQ=&(<$BA.[5K<FKB[0 6Q+A0AN9;H
MAGNV:%]R;#.@ ?#9:&Q2O<]GT;EFB;V;6=A]'Z;F]?T/O0W4-H#Z6-A4B0/6
M:I)[(R[],__A;[Y>3;-;2"_FI*Q?+%X]>\/X^_68Y#.!9N9_2=\!F8QQO-CW
M&!LZ0A+SJK-UAG>;6T0R?&8*.+ZINGQE'I)7<D]V7LY^QJ/!"&6#@6DF"Z9G
M7,&FG4NS)67]7M #.1!.G,O>%U$X03X1$O7P@'BFQTL7@IB)+BGSV-GB[06=
M\-30"0J<(5>/:]!,XY1ZH(4R Z?FU<R[8P$,E]B S?BP5ZA)SZ5=IU @%><Y
M: 9X3[2#XPB;FB]R#HG*=IE,(,,'B2MN@ZZ<^"IX8#P#8_K%[6 [$3<BOY O
M"]9E4R0ZCF6HP3[,WU#AUL%,\<Z!.%/MVA,:+EF@M0M:#VI #">H*PPEK0T+
MCEW2E[/1!,#@-<2W)+,@B .ZZT1=4(NE&0Z^YY[C?5X#' TI2JQ22KTG6Y.'
M)''Q$8A?@R-!WVSJMNT$?S-INK):7@XHG5NC4R8=[>V(\2@Y=FC$/WCT5M7T
M[:;L**DYD ("'3IHHPM('J$RF(K:J OR@OUWBKV,X<GS [GX=][R=G/W-ZK;
M$>A-\%-D.A5:Q/TN,I$82^]>S. V?T40E;PCVJ,TD=HK""8#>J;$UL[;G.LG
M;H8=RG3^)K? I.F7J(!+7./YS2[W6YH0=F1!.!#*SO-&3O&P5A-U8F(,"I7.
MYE33G_YXSJ)9]PQN*AG9^;HV;\CD@8LU<K=T!^,$HJ3@E1^!NR.R9LE-[\&J
M,/3IW4ZEW6\>__%4VKW%,+E=D)"7['J_E;]_J=FI? $^510#J5$36&:*RQS[
M2TK0I=O(^4^&4#",WOTX8U,R; RP8'N ZK)RKHMM)%B3UO1^'Z>9@XLKO@TH
M<L#")0U4@F^3/'A. *E.2I))<<CZE!1/,/MGK]_<]FJ/V6>D^S/"#S]UJ',J
M]B&G)Z2*,K?BR#ML[Z9-$5Q.W*A)-_U51^.!N,^-AH4"_L3E9F7BZ:/,'%)\
M@V^_\*R61L.35;W2RP&UBW?H%_(&@UZ=8F!>J@Q(BZMSCRPCYP7EY?2F?G-*
M$V@<> \H%'P!ZD6SO=89Z'@41V=@1W+@I6)X* 0L;%C)I'X&=LCH=1+:F7J3
MZD!<LS%JX.YIHN[S$+UV[3#"JH"4X-=5GRFKB7I7-21QK\1FSD/,:\OT0;+E
MY#RLW'=@WZ3+@Q#Z,J(6R[AP5@[/?$A5]E2O]MU31DGDP"%'P">Z<T#NG<*<
M$9",";J04)2B:H[[2"L8 Z'MP+38?%N25#1U4*^"5TSSY#.Z\N>1GC&0;R6P
MG.EO(FM:^'+'U*L:(U_)1:ZEU<AOYJH1[!RG?)3F(R$'?@K"TY=&V-V&!S@A
M/HT',+,>632LL7WA GMIK3=U@RP2=8%]UE0X)32])P?H3V[MN-K_+&C4B[89
MM!/6U[#^?I1-I$]/Y!0*8>P$MC"3FW1.?-MP' 8'GAA,X<^LK9%346-N"3O
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M4L B_Q(]E?C$9^WF3.V_G16*&DU_<: )"R,3HC0)U-AM_AU*-38W#A&L=I'
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MWWMQFH??=!ZHN#RS&TX#?W>T%I5 82"N:$((X(#>+[=5K[E3X1%3;OC3!OG
M#:2N74>\K<MJ)^FM!*=QB<,N;$)'_1>2O#Y-SEV" ?8K%Q22!-40>FHC8)EQ
M"FKFYFB$>)(LK,^YGF;M[H #Y3)P R?0_D/5*R$A->>U@\\,GZ;A3H_^&(A3
MAB5T4-7C'2!9X)-']MM,2];BI^=,>= :RPWF#-:L'\IWX;*MUR>0^MW.TDA)
MSXL \DY11E%NVIK('4M-BMO'M7BEV+:Q5(:<5VG&C3;4%5Q.TWUGTYU7$!/+
MQQ6G5Z6/^S0!=XEENZR6E0 ^F\6[:O5NR8W,>9?JT[AISOXBGT(;?6^LIYQ3
MUP3JYRB56@[U-'EWER:E,N_J,CKJS"Z,]@\4?]W!I5Q54DPX3<?=[25U(>8]
M"-\!8E3ICG/=\X><9NG.9HD )&.V^QOIPD]S<8>GC_&US]"T>XVSTX1\&'0I
MBRL9J:@QNJ-&*@6YT_C?G3_<+DFG)8]53^-]=P9(X'4.8$B2M'0VL-C?:;U_
MD/$'+4DSG$;Z[NHM94W06Q2]?@DWZFFH?P45^"H0'VVX/ZBK/LSBGP!ZCQ-+
M48G( 9*<=/P6U,6A<"V(\'X@03#(LH!Y[\68SP;7VK1[YEED,MC@-$^.0K2(
MC>HH0DM0R R:8\) 1W'Y+[(O%0IY5A"@$[ :I1WI!8S@UFEBU0>71UG%!V.F
M7).2==! Z:PMN.^Y8)P@JM7S0$&E.$,2V[""-%RG#KAOOGAT+SO@/O367^UI
M#=5>'LJ!1A<.3^P5X5B:@"D]B7.69%MY<R*8QM+?@@V0+L[J:XNV"5W\8ES>
M\9Y,3=<(3(G)Y[3]@[M_')PV68UE4 W[U0CI[+2+<Q[6'_6J1(H;&!FRYX86
MVZ])=6G6Q%2]/7,B8$4/"J&&T>,!X4(S95LFVV,)NA#W[Y[M -AOH24JO_::
M?0QYA'&Q=I!X5^K=L'=+S+2$>H4U(_8D4/5L ZVB"\=:F*0X287=,^_E#7#<
M^X1R?6^6.BX#E/DS5F%[A7N'*O[N^=-B\>SEVV+QZL7W\?\\>U,LOOOQ6;%X
M'FAX=0/\GSW5:X,</3TY%0^_>D)]EFW7A$.O2&27X<OHSOTLEDHU*"<+LRG.
M+3 *-_9]#_7Z>#506=*7_]Y VO8MGJ48M5MYC=_.Q+<#_W* :"V]44,Z(;1!
M<UPYE=%21\!8#+(F*LRXECQE^X:>/9-#%R'&^.#,I5QM=T0JU?<@KFTWFS,@
M$A1](%VJ><]8H9E0UB%JUBKENZE!4BC;1) _\??*-Z_<LEFJVR3XF"O:P[V\
M_PO05X;C=\P)YPNGE?H.M:BX:43T\>;^ &X"8*+2;E^SL0(HMJ5!$2)C,A;T
M1T\#J/2P65N;-I+IIO,VBNBA C4/UJ((<TF3!O).8 M4RH]--=&3$]UIR\G.
M=!VRC]&\U=6[:!TNVW:-KF*:_C3M%! [<UOU-UE!OI^Z)E-Q %[_:=BD4\&+
M)VJM5C3?.P:QJ'1.2QV,\64WZC:Z83RR;M$)Q_.3]:35K"A_39+T:V*FO>3S
M"TZI2HYZ^ID%22UOF3A;?R8'EWLE]T#+=CW7X?81&TEKQ(S&40?$<U2.;)!M
M;3YHZ0*791\GK2W79@P/N$0R6PK*=[PF9$3ZWGK7LUOVY29((ZT1N-):^<R^
M2O<]X\[$.".(!*.GJH^&R$&04?CLX1.*&J19E]Z3'GGTL'(1!Z32GVZPD?IA
MTLC\:74>S@ML%_EU/*9)<3K:</VQ63VLR1*]I_UG]V2)/&U,6ECU)_;NL"B/
M.E1Y0;A >5^ZKI(0.,E,D&#QVBY>D00J-]*75+79]Z+R3B3!KNN)&8I-M)F+
M.S1O,"V)%D%.\SY)^2;^!(18LUKV^:$R$B89Z9'H=^_)A&:,V4>]$VYDEOYB
MYLE7+@9KPD(7,)-'CQ4+^(#8DYOB>X9OU TY7SPE^J,J^K:C66 ">O*+W:H:
M^\].0QS]?\IV*4082?;^)OY_!$!/Z[XMQJYZ:*ZJKI4CY^A1YL?$^JQQ;S4+
M>(7T"#S._7L[]W[;)LL7V+8"FH<,2"6:5]9V0I"ZN6[*MKEHF3C;AM+':FA-
M9ZN 7;9OXA+BC$< A)792ZT[/;6TBV@ PRDM:G0I'QUQI36C:ZR[>(37:>/S
MN71/=BZ98J6AR@C!VR4<KW3(:L-^D3KYL>Q\A]WB4SWU4_+,"[-70Z]W@ZGP
M#4:%!QC3?Y*8C!"KZ$-\%@>\KL?ZX"V$EP'5PTZ7<F_5KJ%X@P@7$R9.IGHG
MV@U@BRAZ69SM&].9NZNH'<FD:I)P0<$+E;"&<?$UZUJ1TT<0:93AZX<S'=S4
MCXAB:38B0J@GHPHQ.CK[93S-;[+#28E7GK.[]";=,O[TY?,W16:<90-9SH2?
M4+U2'K*DODZ&B$?);2",&'8<CMFUJ@A@AGD!D DM:=N!.P+YGJKYQ[X[\)Z=
MOVBM:B^< "IH;_-&LT_B$S,C1$>HSOB-^ [8O@A(#G+N9\]SX^/<D]W[8F.S
MHT>3DMY MX1B+%*!+PGZ@+QS-'ZECQ]+]:8M:*:%=;F/RQL,*=?.;9(A2AIJ
MVJ3AI0 @I1/'E(UI=)B:U8&W$L%LB58%U"U9:R%72QU7*E@5>-O01ENKC:?>
M;/X04E#&"+,.M"QE_ND[I2V?J[;>-T/94=N^].=7<EWQO**S& \'>DZ?E(B'
MQHJT<S!L1DC";SP2JH*[B?.#54M,Y\5D9)P0C$80Z4<6LS,0^3SN5'J'?H+O
MYP-)/%*,KF?MREU4YV,V1S3ODMYH,2=*5-QWS35D,R1_(..3W R00-'2\30(
MWL<81M;TOZ7I0N2X$A4&)O"_W[XIIF>*JRN!7Y.M5H@'IN#)U^UJCX2?BW5D
M$9$D4"\GA#LQA:2;=/AJ!ZW)XUSO3.$'<:5B06KG2(R26>4RK4?*GZW>E1?X
M9Q^_#E&4Z6$6/[RL=CL]UC@!/-.9FN)XVJ4^<QG'RNA'*<4537@<_D_U3[MH
M9+K,''PF^M7V77>FWY/E..93>8\'"R6@9= Z:2$QJ>D)Q;#SC*6;42)5!<CH
MW^Q9(JH)TR4_]JQ'"[YG)/9,Z79-_/ZD4Y7R=,B"TZ\#B)ZR;/5-GE72CX-G
M06E1U9!#+8).$AS,5 )9TN+24)^-GP5C<;=M6UIUFNUL+I( *!>!Z[J]QC+E
ME7)BV;@SG,)UV4$ H@[,+(?M.E0#5>ST;Q*PLI-)C&F<?Y/9.8[7^1U5FA_?
MCTKS:8/\<C0L2)V1O4&@IU%8%S;[&.;"XG'6F87"GGW_4M7+3DBVNV0.D/.*
M\33D+4W@-*?QO[L&BBPO!Q<GAAX4)IT&_<X&G3QR9W8X*J<PB=UMYGP3!)VK
M0!)W5I R)3%P2DW$8E.DHT@!F(*M7##R-)EW-IG]GHF!6+/2):-!2^.SM)I?
M="E0RSM,_/33C-VYY(/ELF($7?TSVKS3F-^A8B8'L!TK\JZ#9,U.0WZ'O#\D
M:)UD-GP*"Z D8E\RXU6HYG8,%D.2WLU^=YJL#S993'&VH\R0 &1%"QTE3CKV
M21(B);<MQ72:HSN;HRP/;R7HTX#?(7_,OK-V,BHP=>'D&-UQ7(+*7L]EO%U9
M=52AWM4EE2DD62+H BC,1MLD*+C3M-SAV? /*;&?FOWNV.!8ZBF!ZN])=>M'
M(---H$.JS(K<!.*%2UJ9^ L5N$R<F#;]_^XI'[0YH.<OE7+Z8+J1BO)H5SG*
MX[+LMJ.:-N?U&/;AT"24H^@55[.I!@-#M-&-(20\>B82F/&:>B&B<W-E[^%0
M?\O NI;5IB)H2B^@&4 &Y-L0^B%L:;S!R^=O)CV11DC/@'>^ -?91D1RT$*1
M1L)&OEX?!'S$B#9[*H*>+VIJW2!,P$53#01BBD\>QW]_<1$]B%3*:_;;90#%
M[7#8!: .XH-&9P\-5R@IGB^^X[8EPOT7-WF */92UX(H$C$RGH#.^G<&:P5I
MPJ+NPU%IU $ACU1'[\FN^%; R1Y;JFD8**):?F;C\"I5O[B(?XX35&@_P,Q/
MYII1M]6@K0J-2#&MD=+#VND=O,_!'/5*#+%+F"T"3605Z0T^Z&E&@5A+P$#!
M*2"7L>^N0E77>$;2E6 E*8XH&'U/8E@>?*\!A\'8_DJX''0RM=IE1J+EA#S"
M+GG74&QX$XHS@7CZ=C-<<T,/E8?SA'.&R/,06OO+9O2+GEIX*GZ)3<>0I\,8
M#*1/-BYV^UK[L;*_@OD%)E&(R?# /6$73%.07R%'+.=PU28##/:\+8^@&/-<
M8H:+'0%="X-8'>2*&5RK3\@.K?H*=I;:"4D ZC-K5/;IS-E]D_2G-&V&Z387
MA;=,M=62+^+7X[6=(O^S.W?S0P"Z7AXZ 6!51WN=810L6Y6VA&++>M69J#HY
M>48H&<6WLG$LUY=!%XLIZQ32EI"CU/UV9R!?)R].>[B1>Z8GXK:SCPX$KJBJ
MT1$6[=PZH?FP6K1YIPYH94T'/5%MQ>._4'[I>MI;,8]_2_T8 FW#Y!A>?A84
M)UY%?[G8U.WU?3F)=)3CV0*32NLDNBGLE>Q[D\)9[?OXM'2,K_>FKZ; 6!Y>
M'  YX-.R=&KM9K1U(-I&?6\LTVB^HOXR.@#BB G4TI9T<XGN1.W_4'"<ZUD=
M8<1G>D//%V\K;0'=5%T_>&V7NHS6XW("MHSW>_3@P1\*ZR*X+!VJ/#I\<9TI
MJM-#W">,S([@(75+IR.*K3NW%T*IT="C\I\).KKLVG?!!!T+%?WK/!":+$J\
M,'E/970 M_(,M&O<E4IRI0DFV^.9!&OKU"'MN^>+'V_&18[Z^.RP&G5D;$8B
MF!A2=C'="#C?+Q]A:J 9+G&*.(]<KT,X,MZ:M&3B?UF_PJZK0 XB2$D5@NU"
MG!^!,!++:*B%HXFZ^K,;&_4';B2';[[<^[PWZ7SQ6CZ7I/88 9R?N4U+BHF@
MI&NP- 1#G.#!UOX<O3B!R1MF;L0]R#<^T^4H&IC=Y -/CC?F 1CY4CC\#^/(
M:X3&(Y#QOB$3[4PEGI3 ]/%WA>'"XW.2N*;P-:G2Y\WVOSCF.N!B+2.GDROM
MCPJOLU7,'+WC%YD:).U.;YB8=E_=FP D5_=T/MR<G,]V3RDUFEV1NHL78E-/
M>&/EWJ (I,GZULC+KYJX??X9A%^BSD"@!]I.9YZW_@R^"QK_*="@C0>"C9]"
M^:Z!^RD3 28U>0"XEC%P'.#E[ 5KB@8E=;70)H> OZ3 J*<##F=,-/2$L;X(
MG#*4X,,AE;D5C6P'O##IP0-A.,5!Y/@U%_2RBI^6A[).,WL1#*TMYC)N0(F7
M4U]/-%QUNS.,?CJ)M(=*7+44S0,]1O&@-&?E*0\[8_70G?5FCB_9WQ' \HO[
M ;#\[9N*G(KE-H0!"2?/7B5&4K<#;;5UJ23YN0?4!95,^H=D!8\[]:,,7MH
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M)Z>LRX=,3L/L<C_MIF*GSZ#B,RZ ].NTW&+&--W[)M6R2JZ4>Q68^.O5X:1
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MJN5Y1<4?>'0(L9QG;]YKI*&[)2J3:EB:_'"64?N#:X459,%;FI9!4V2:E)G
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M"?J2VF[;1_D"UK&)PJ3$E9]^021J#N.$N/7%I0Q).?'1$$1I$"YI5LL,?$(
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MU<_BC0G?O*&W(=562M6OH-XL9/U\1=P$<-B/VN=O1-$_@+/PM^F7C(1[S1[
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M)09B,/* #R?A9BECPXP"V*M@?EK"K/7K]GK97A,9)3$V12D>,IR.7A4PTH(
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M&!TDB'J3X/+D@HGX1UB8'[[\B(PKEB8CLI4%5N$AEL4*5Z MKN\;?EO7^+%
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MGG#BAY41X6$%:3;//*T'2\3#=4Z(LQ^8)?X9?>0$I(VLDT0H#LE"]&6H?J>
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M*]LDB&T^Q<K9?F(V\2<H,,H.-R,*%H)@X#CTA9#M[W_[E.3KI1[21\;-V-Y
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M,7U[_\RD=6/ X+J\2;30&Y>V<.)$5#/8;!FGA'YMBLN_#FNRW1Q(]$*CE#0
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M+ZHM([$0X7QYG,?[FL=MV_?"NDKH_1BN[@$SHWNOW&@W;&Q\5VL$KD%%.P_
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M?/:5NS981T-@6O1;EW@J"W'D"_66%H;77X^4-&3R7;XO\C"&Q#:$(E7-)9:
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M=ZO[TRJ&8R13RG!3/T*;6\EZV;E ;C.RJ9.PS]-#6%JC4B=0:Z'NZ-2Y(TZ
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M7G?S^RVH@33MNT:+=!;  F\\M.+(^?L[]]X9'R#WJ,/__N^P6?US,GP'])&
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M^*,K8B?R^@+7QDG%\N:NX)/69U@OC&)U>[#?2SM*K+.*=0;[L^I'&KJYP=5
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M70)P<P!V6[T% -R<OR\-%ZZ?3[+NT0]7"IFE$ZO1^BO71N+\G *K?*=1:&^
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M)\550'_P N"UL.L*2UY4=*(?(J'/>P&\,>9W9ZAW9C>@FCM2X>(._#'0A3<
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MV*&6I5Z0$Y:O2MB@\N"*[* Y^+"UC;\F<\;,P4%6N%#)X!PXN:C,B9N-T1.
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M\1_S[K\!TZV.SF'(!Q3-B:T;;>3<&/!?B/5DWN5[*H"V+&(G\OH8LH-OWE&
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M#\$L)T-1(AR_1 ,O:+K6*(-QIB;'"T"M2$(9&X/\GK.V,@%?![7DI3DEZ*-
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M^-T,M-OOP-1WO+'MQW]_=W;^>1[X6=X7J$M'..CD:)SD43M(QP=N2-V5<24
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MK(B]11Z*GJP!J9<>BL<(^<;SI$CV&N\^=2J]SE;K//<%WS6:ED4@ZL\2/MQ
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MC51AK_OTQUVG6S G9$[4KF1$P'F9 8T#1.Q]KQ ?.IZ(A>C2Y#P8^"LS_1;
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MF070L/J6#?)C4?I-@3[2'69SPYT5\L 1L'"7Q1W:F.9 <7?1VEA^7.*(IDP
M$.,<[E<(L#UT,B7CB(/G1!@TBXS;#O*$F"GW<XZ->F5ZT\Z(9MP'TIK+IN%W
MQ IATDAQ(B+62!8N6@?4!-%*_%F#15M_F]F,^GC,QLISYSRF/J,OV$A#>Y'I
MMK<-G3Z2S^E\1#63AV9H@'B8$3.]L.9S)<]1-]OIMS$AH\:@;TP[,LMNH?LI
M7WIX%=#2[0<Z>R$3:[[K<%+H3#IZ_-5ZWPW9(X:4-WI=M .66&3@1?)S:C\
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M*0BF+L19:$].M7K4H$Q1]N$4IT.#G61N6BOJ//ECBY4]6<FGZ4+>TR!VIQ,
MWRRUFO4<X"Z.<8T0V6:69H.(+$FE5IV)1#1'CTKQNTE"+=J=667@=.D8KI,
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M0H=R8GL?]&C.%4K;O-X#84GEF0A2/;<C^(@E ;"TQ3M.BZ55N%298I;SV[-
M-SE]B2=W9:.BP,7_CJ^KI_M ,?HS%[]M1CMZ37G_0"-6\2L WK8I]/T!!ST9
MRE4&N+SJC2/@SAIP6[3^_H#CK1"J<C6WM%6Q<A;.YC3H+&?!XLU;,%7Q$(;
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M_%=MGO3E_,4Q=Q!UV=J#G!)V38#=:DX%PNXL89>IV\@)8:=*<+9FG^8E8MG
M@ML=OSL>92__#S7)BVXYY!,8PY\)0]-(]W[2:#?<I/V ^-0(/2NP-K0XP>+"
M!XGWK6/)&>U^=6U8E5\8!<'#?'!Z4V*QJ?CLJQOVI_/RR.;BFA/&3.(^N=2J
M5F1!:A,CMD0P. X!,ZAP6%D]N8*=S,X28?O:%H= &*_#MMI8\5Q[H/'W*EJ4
MRRF>&?'L!KH=!2JV!-=.&<<H1J.@HP8Y@ MW-.2KI9:68$ID-N1%+_>,"#RL
M_;$'!#6F!!3$(&)P7PME#PQ"<[2]#!'LBK8/3A8/ NR1=;7!!=AVS\8#9=+B
MF;(=6%*0E4Z? I#_LH@HH7*, "5(I$V^3YU97FHM[[IX.=#I1"XZ\B?RYV$S
MUS(R*%015)JYQ5F109%!+YU!MV3@9630)N3C5?=/-!6"0;&F0 %J"M3RJ2F@
MYE%30*V=34&!6EW+>KA:5BMJ-:>#OD5_5%6NR%L>E1A:F#M[?(G5%PXY_>/-
M?$/YA5[@&C^'KLWXV_^?OS04N?Z5=/\,K>"C.$485*VB-3:?XD__N5K-=L>Z
M0=4JC2W%4'!,\'F]HJBJ8&-J5%19$VQ,]4JCH0@W)O%H5Z]HM<WKE-PH4ZEO
M:)2Y[2R%Y[XM[_ILO*4I1L&/1DKM,AJY3N1O<762P^GZ#0LF\$JTV0C!2=%M
M;EP_ZI9Y=>?PWSOZ&$H5;%J:K" YWV4RC' 4VMP:B8YY)16!(I]@+V]CJ8:+
M6;$G&NCL0Y-,BDZ33_.+>$,'EF$%N%;1 2VJ^Z'W0;;*HLM9$DCZXF(HP=SG
MGZ\S^5?[12LIU. )(K?3A>"/.5Q9&'$K_:2#0E2F]>++(J545"/F[@>[F#-G
M6!(GW9)\TVW=,2C1 S)?T(THDB)AQFCJQ<VG8'-CZU8*,\RYR$]3G;DJ0<NT
MZO[9")B*=V;P2MJFVX*M>4,B,AZ2$,4;GR">$$]72C,[G@:N-]*#_RM9[\&U
M$XZN3#>XBI^1!#:EU)++=:666SDM!-P9 TZ5\A!@*E.)N56Q0CP)AJ=,J>EJ
MVA,ZZ9!5+;7JC3R*A2"JSAI52JZH@G,TL$F*L"H<K#*A2CVXM54#:TO3Y-Q*
MX>&QF5U0<>?[(0_(N ,XS\O\??9:1EP&#[::A'+BPFD:ZD"B'1G;[%V771?D
M(+$8M9J"XX!8U)P_&!_%9;JCL>U^4/J-.G1@!8^,1DDL![4G<VMH+T R>1%A
MPS=5E*]($Z0)T@1I@C1!FB!-"D:3/(\[K;$+_]#MD"::A?-NVL!ZI^;5?ZCG
M)IF+C2EZ!#$9"[ IGM$)8\0B$RI&^4CD,?2,H>Y3 N2\[%K1XCIB_*()I8!0
M2;T JDW8W5RMC7>V+2Z*B)[=]"?21!3]J6K[Z\\5;DY@9DV"+GC(S6(C![D9
M:8(T09J<(TV.[36FTGJR4%JOL+MTS_H[Z4=>/.$U+ZA) I?TJ&.Y</K)X2.$
MH]3W"W4T<'\. V-($Z3)T;*1UGA;YKLQNIXUC/&?W=E15SCE>N?$YUN9H(NC
ME;>>.XI22^!PI^NPVQX&<Y+NAO:3JK!JO.' /OE+""=D<:0)T@1I@C3)M1+Y
MT56A*H@J+.R^740#'\Y^P]:=(BGJ'@X8QC,.MB\W(]0"X\QZ#B6Q3Q4:"^5U
M^!"#8@*I2:2)*('*?;;G=F)J#0IR5VK(U2(C"+D::8(TR5G2;FELD+NDA79(
M592TQ4'0/IN*.R$(NMO4<SL]CYN+:S 01QG @X4J_&1(S1=*PC&#@Y&K@XOA
MHIT\7!XQBOS8)VI0ZY6:/"+T3CW#\NG# "CR*Q MB8D:X,4*$ 1"D&"<]TQH
MLI\#NU1_80WWQD)WCGFYGDSBX";C8%6J- 0YA8&@049&FB!-CI)/LL9IW5NH
MUJ1U0A4-(S%PDMM>:P:8I#X;69/Q;.21<,#)=]77?0H3&XVIX^L<$/0=?M^M
MQ?.%17DP=HLT09H<=^<R38H/EVU<M'7F)-L3%-WRK8#VJ/=J&30*HS(%YKXX
M_"EKC1JH8"NKF+,@-LJ0\Y$F2!.DR3G2),_]PE-H2%4L#5G8/<4.M&[MNQ[O
MSDV8_TUUSQ@2W3$9)%ZI[8Z![F1 =_/?+BP6@G%,I G2Y#C^6^KS&0LB[BF6
M<&W'O)G)MUN:J(2JI5:C7I$%B1PBEI"_D29($Z1)86ARU'.*N^M!32@]6-@=
MM'L:0 ,'=X1[91AU0IH@39 F2!.DB8"VF+HE8LXT^1U7Y-]=/^G$3 W.7,FU
MW%IJ(22032^$)GEN;&UET[I8;%K87:B'8$@]GC7HT2%U?-B+LAE-RL2A_+Q;
MH+_C_A/&>) F2!.D23%IDNV\22-E-V6N63KSBF6F\9GZ?Q@\Z^^/K@<O; >!
M9_7#0._;]-E]U#WJ)%5KJS6@6EL=SZ,(BB/D;:0)TB1G>;OJ21U/WC8%D;<%
MV'>J)]<5T6W>U$X/R TUZ*C/?#%5+D,5$?F4.U&I&\6+S&99:XLT-X<L.KSK
M(*_@$YV7? @#/] =6(L$YJE+I9;::"34%=DM@I&:)&<0\2HVO)*,YBW8XJ@:
MNC9;%3\J8YR$*!F:(>:5EXUX.F,\5:7L>)H_N>V$HRO3#:[B9R2!#9I$E&6I
MD:#_$7"7!S@Y#P&F@@#3$$^(IZJ2!YZ@_+B*$JJPB,KD*%?5E(YR.FQIT+:O
MEE!:,[WWB[ 2$U:94)6FI\)^EA9DI)2EJK)_FN\Q %?8G7 HR\N#,>X ]L.9
MK\]>RXC+X,%6DU!.7,@2I@X_L3F&GO6X-9Y['*:Z6[^#*"8SZ<P:UZ]:TY.U
M7H>*KWO7W<8H.>Y<($V0)D@3I G2!&F"-#EH2O$>W5D2S<+4I4SK#2QE>FHG
MC!&+3*A(.*G)8^@90]VG!,B)YS;%=,3X11-* :&2LOWK3=@84 7)]4?TX)&<
M,Z%)IDAF#OISA9L3F+DAE5J*DMLV'R('N1EI@C1!FB!-3N0UIM)ZLE!:[_)V
MZ2S>BM&A$23>K&!(=&-HT5?*RZBRRSWZ$MIZX'H?1!^//?=5MPD;%F7W.W1Z
MWM6:O,!P_0#W]X[G5D:=:#;YE.T9/1\&/R:42V)&2%[<_^PXQO[$TZQ($W$2
MKE94:V)?QPT*-IFADR)$#:A*WF@FQ(CP\*<8T$%V1IH@37(.V6ULVI>/8*U&
M@G7O%O*(&F$4\ZK/>T#%K,'6S6KF*IX1SHOTD\"#SZLQ>53W0^;!<J<7-SWW
MX9S==CV?8PK,'01N&W^&ED?-)/:HE5JUA$S3S(<(,)0HD(6$-$&:($V0)D@3
MI,D^ ;0M15(73(W8+H\LC8[K!S]H,'03;8YZJ:5I];T*]R!*A$')MAW,75'2
M$ 8EA=VL?-;?23]*.28>M?6 FB1P28\ZENN1CNOP$?9M2N[=@.)F(X8TD29(
M$Q%V\C(VN&*"+CY:<>NYH^@</)0B=!T>09R3=#>TGU1JL-%,KFV%NWMBP E9
M'&F"-$&:G"--<O&VCJ<*FY(@JK"P.VH1#7RVJ'Q/39$4=0\'[,)B%\<\1#@C
MU +C]*C!+@VLQ WI9JY54C$ )I":1)H(DYBTQZF*G9A:*;6J^^<H(8"0J9$F
M2),S$K1;M@AS%[209Z^BI"T.@O8Y +D3@B"AN"Z, 5[8O<4XR  .K,-\5S*D
MY@LEX=CEYR!S]&\Q6K3'<49^RQ,UJ/5*31X0>J>>8?GT80 4^16(EL1$6G)!
M'-P.$0,D&.85CR8'.+JXPKVQT)UC7JXGDSBX5FJIZO[U ! SR,=($Z2)J$91
MYE.+^\C4^AJ9BF:1&##);:,U TI25W%M8A778^& D^^JK_L4)C8:4\?7.2#H
M._Q.<9\5([=($Z3)Z=V^Q5AHFOP>+MNX:.O,2;8G: _D6P'M4>_5,F@41&4*
MS'UQ^%/6VC3-4DM6:L(4CD.4(><C39 F2)/"T"3/W<+C:TA5DL32D(7=48S)
M9_TG\M7< ?$9*?S8CYM62L5=1 QB(DV0)L)X;ZF/9BP*N(=!#\3;-Y!NFTJ<
MJ9+,%)"F[)_2@E!"]D::($V0)DB3 VV<'5(-*F*IP<+NGMW3 -K,NR/<)\.(
M$]($:8(T09H@300TQ:J-S=%RILGON"+_[OJ))I5::JE5&8];B0T)9%/Q:)+G
MIM96-JV*Q::%W8%Z"(;4XQF#'AU2Q[=>*;$93:;-^0+]'7>?,,2#-$&:($V*
M29-L1TV:6\[Q350\URR=><4RT_A,_3\,GO7W1]>#%[:#P+/Z8:#W;?KL/NH>
M=1+*M*F2!FDI(G0^0B A<R--D"9"M)8[H,"MB2)P"[#S5$^N*:+;O/6Y'I ;
M:M!1GWECJER&"B+**?>B^JYG4N\J<,?70"_?M2V33-;@7/@L8UT13=H<M&"\
M-7*=N2YT#V'@![H#:Y'$/7!VME%+J"FR6PPC-4E.%/,Z+*3$")?\U\&(EII8
M(O!/@IK:QCR<;8:NS5;#CTHT)[%,(\]*LL@PIX<0,LQ:AI&S,\S\R7LG'%V9
M;G 5/R.)FYJEEE)6M$:"!8<<A1QU#AR5R572E)2N4BIE),,I*#F/3L+(-J<'
MTF6Q32:N47.PW&2YU*K6FY4F:AIDF;-DF6R:IIJKIE%*+:VI5214-<@WY\8W
MF6+9:5K3[.7SR"KX/+(J5QKGH(D*FU<$Y<UY8-L=0';1R(77,N(R>+#5))03
M%\Y<4"> G*.QS=Z%B4;YQ[3W:0;5'8UM]X/2N!+@(Z-1$LM!^7EASB@A;' ;
M&&F"-$&:($V0)DB3"Z))%D\LS>;3FA9%B59AVIK0JJQA3>A3^V",6&1"1<))
M31Y#SQCJ/B5 3CP$+Z8?QB^:4 H(E71T2JXE-S+"LW0"H0?/-XI'DTSQ_SU:
M_*WEYB1FKI=:2BUA#QJ1(Q!RD)N1)D@3I,DYTN3(3F,JI=<02NE=WAZ=Q1O:
M.C1"Q)L5#(EN#"WZ2J',W=HRU=.: =;DP8;K![BK=SQO,NKDM<F5;,_H^#"8
M%A],8L)FJ:56ZH+$:! V&(4]$YIDRR-+UQ5W@V)-9NBDP) B,8Y6U(2=>CP_
M+P9TD)V1)DB3G"-U&UOCYB-8Y4BP[EVL#%$CC&)><74/J)<5V+!9!0\66<B+
M\I-X@\\+VGE4]T/O(_)URY"#:H<P?D+?#<NG.U>\N[# T7IVVFT']#FFRUQ]
MA;;Q9VAYU$QB&K742BJMD/G !(85!3*;D";"*,!M.YP+[!IKO(A;.ZX?_*#!
MT$WDV^J^R@XQ@GR+-$&:G),L7>.#[BM+-68#-9IY'!M%E)P>)5MV5W<%22T"
MB0 JM[ ;J<_Z.^E'V=#$H[8>4),$+NE1QW(]TG$=/L*^3<F]&V W7PR[(DV0
M)@+Y=*G[&#)!%Y_ZN/7<471"'RK.N@X/<\Y)NAO:3ZHHJ]1+K2KN0 H+)V1Q
MI G2!&ERCC3)P]DZHB9L"*()"[OK%]' 9XO*]_T425'W\+\N+')QS..-,T(M
M,$Z/&NS2P$K>-&_RU@2B](=#%&'D^DQHDF]^:IJS'[OPMPK%=]6]6H\@C)"U
MD29($Z0)TN2 F: 'TX"R*!JPL/MVL0</WJ'#'$,RI.8+)2%SX@$#.3J/&(G9
MXS@CO^6)&M1ZI2:/MKQ3#S)U'P9 D5^!:$G\HZSQ$'&O00R48 Q5/)H<X.SB
M"OO&4G>.>[F.S%KI6U49?Y>KS5I%PW,W(F,*^1QI@C0Y4DKI@65N-9*Y2?4%
MT:P2 T;YGW),CZ95P$"*LC '8PN[U3FMW@J5?/3QF++YZ;9- H\],UIR?UJ=
M!\\W8N .:8(T$6,_,6/>S432/0PZ7,YUF)A[GI-R]Y2II6?]/4D7U4JM.IX9
M%A=)R-U($Z0)TN0<:7+4Y--]E&!=%"58V%U%[B_'M5$-=S2FC"X<$O0=?J>X
M@XCQ2:0)TN3T^W6+"2QI- ^7;5RT=>8DVQ.T<_6M@/:H]VH9-,I\>:*&^^+P
MIZP-#S9*+5F3]N_5BRA#SD>:($V0)DB3@_6W.(6";(JE( N[@\9<9J@$ZHYV
M<\\N+-J!$2BD"=($:8(T09H</8S1V&RE,4U^QQ7Y=]=/.E=3E4HMK2KOGS6,
MD$ VO2R:Y.A+;>5262PN+>QNU4,PI![?I_+HD/FKUBLE-J/)WNF"%Q9GP-@/
MT@1I@C0Y1YID2^%LICP0SS5+9UZQS#3^)$/ET?7@A>T@\*Q^&.A]FSZ[C[I'
MG:2::56%&05[G8A''"%O(TV0)F<D;]/6'SF N%4%$;<%V'6J)Q<@T6W>)UT/
MR TUZ*C/7#%5+O-R(Z?<A^J[GDF]J\ =7P.]?->V3#)9@W/ALHQ%2&K2YH@%
M8ZV1Z\QUIWL( S_0'5B+).:IEEIJ0TNH\+I; ",U24X4[SHLI,2(E?S7P8B6
MFE@B\$^"DMK&/)QMAJ[-5L./BB4GL8P&O>&089!A+H!AML3'DQ@F6ZV&:HTI
MH+(F5RLUY"CDJ+/DJ$R.4DW)4JEQJS*JEUIRK5+?_Z 4LLWI@719;).):]2#
M*R(XY%&6%!E-.^2H,^6H;(JHNH<BRLA;S5)+*5<U.8\ZP<A6IP?:9;%5%JY2
M5K@J;V;2)& FJ=8X#X^)1\6_\" ^^]>T7EM_93\F8YI[CD'9.GKYT+69[@@\
MI40W(*E(=S[8''EY[5GI[.6QQO>J-?;PL>OS$S'7O)&N]4J_OEEF,+R6)0Z8
MN;NBE;B69K?H?;;"8;#^E@,MBBRE6I7;J_KB$LS_A%$"#JVZ-&AJ=562#4.M
MJFI35Y1!36DV&XIA2G6U^B^YR3S[^*ZA-QGZ6'^A5WV/ZC^O] &;V;5NO^D?
M/@!E;@%&EG,UO]K+"Q4M1^NO?0\ MCK6+6O)P3BC#P<_6U-;'_OT>O++5]/R
MQ[;^<6TY?(WX35]'NO?"!A<351NO )^_+_HZ'G:S6=%J,HP\WAN*7QQ/JL(F
M]27A\T:EJB9_)57DY%LN]5&*5*DW-C\J<6].UC9H>%7137E%_*56Q5.4+C%M
MO->8GFF55%MT-_2]XX[*Y,XQ*DL< 4K@Z-,_WLP[KL,5%F]GW@O8/_SH(^2$
M=G1_2&YM]VVQ'<)FC;3(X2!]XD] /=86E^!$$H4)PHH4"<,L(J56K<A2-1_F
M90.0DV]9]ZCUGVMY211A![5YT6/F7#(S%)5Y%"L.B<? O+0]OG$7?9['(UC&
M0-MJZ*WB_/2)",]OU'ZEY >[<.B3KF-2D]L \UD)JZR^LK2REK2TB\N4RA@6
M<8W2)F6DF68BI JU5 HN5=JEDI,X:]U\3YC3-/7]^&.NH=R!9:0)GMTYA#W=
MAM)T*T&I \$B3_2<XE5GF/*V'!I(QOO#F'K,KW=>"$167GGWLX.ENEWB_6=X
M4BU=4&E]B8Z]\X+%F&#ZV&_2O(X:WDTWH2.>%]7R.B\J3N8[HOK\4:ULJ;FX
M%=9*J:4R6(O2005AC; &6*_I/I4:UBIS?.1:I2D(K M@;2<3=:YD'0E<XE%&
M1\.R*3_<'QE3\+D!\=RQY[Y:)C5)_X.X"5;Z-9KIXIGID8!4*HHF(OQNZ)A!
MSHK*G^N.2?01G$#[#_]@+9S.XJ3?T2W@^;5DO]N4G^1SS/;<DB:)6FC9UZA5
M)$%$[<4="3V^4;DK4C2H-:H)HY01*0>WTW9%2HTA15*$D2DYF6]BZ])U;45V
M4J/"%!X[NAKER_AMN4!S$LCK.95>QIITHD!CF^),CPTXTJ#DT'D>L2$,-K:H
MRO38@)+MLIK;81=!*A>*K1P[D G6=SV>,4P\ZE/=,X;<Y33I*[7=,<1 R(#F
MTGVK&(C?U(5N83V?XN5DAN'-;#%OZ5+[^('U3LVK_U#/3>"*FC0M1;3"%P<K
M+WEQ)%VGX Y$4QEI>CK%E(FFJ[132JU&/>'46)9<I&(X5K!'07A[1@AXAY8_
MY+K"';!E[P?H7F5RKW[1+<>'%:7^@]-=6-&'P0U;SRSR15TO7]#./E/\;//!
M<@50%0%4/ "MZ,,UIZM3(&D5,;P$U:I61-?M<&E]KG/%]Y\M2,BF?K"U3_*%
M!O.W:-ZH#=UOEL-^1@N9A.]:J547IIL<[O <7)VF0T6]U$KJ"8^H.%=4; EF
MID-% V2%*)F'6W3AY 0H&RA=#Z)SN0HG6[0@PQ-E;_X/-<FG%V:6?N8M=GC0
M@5<J8;;/*XWR]"XAWK!?_?-%41:5>NE1(_1XEN+MZ[TU66SP -9DH-9@ER8A
MU25ST23T"$\/D6U&T(X8J4O@#*XJ0,3(.6)DBTFT*T9DV.U-*!AU=) <^]S?
M7&6/^!%7</TU6PTE*@-PQ#3C ?4\IEPG&>WZ^W*UJ2('$0[23F2RIM$YCF?]
MO1M%9;Y1APZL)'^A#MV9M(2D0&S/=(8X6=6I^0&%G_[92V8B4,XEU+ #/.#$
M@B9,D/(BW-.H"ZPS"\5S/0KI4W$P?GV-ADLU*+?XI7Q%[UT'UC/"?@S\),1K
MI59#16]46& <1'%F0@@T\Z@F="/ ;>QSA4G:;>Q,,*F76E4UM_+%@KBD8JO.
MSE!W7JC/=.;\J6G?IX'/%:AMZ7W+WN,$=<Y9D86Y/T_#3-$J=2'1U38,-@4&
M)8\:U'J%PJ9E.+R/YE@V<XQ)3H_J/KVAT;]WSF1EGZ8+FR10&\Q5K25E!*%I
M=H8@V;91L"M*8#.IV40#OB HV1+2V!$E#:G4JFL)9P;/=:M ;,UYY[Q2)W"]
MCTO((SRLJIPLI463ML :,M.1FH+Q7&'1<9#P16:8*,PW;6*6H=A0.;"BW (1
M%3;3E;U2+@2,^@NK(A\].M8MDX<I7+X#$,4M+L&Y/,2>^2K>XQ6>;(+%D;NV
M8_*H7INO=A(CP!98#K(2G0IQ9&5FUW-7[$ 9+U6(E"3$S2ET[*ZXJ?&LC%69
M@^[I07;<IWL%-I"-\#6Y<@=7(?LC>?M@]\!OD8W0365,EIG#<J;+_AW^CIB!
M+?/WV2K?TZ2DE ;LK.T5NT&_11C(;"R3DB-F&J564AX38N8<,;.I#$N.F&DF
M'T!'!_B@NZMC_8,WFN0UJ@W#"^F"YD6'.*?-UL=HG:'$;+3*<PR1P U-B6G=
M&M99+!!T=M^"S8H=V)9H:L(4\T#L'#S7/#_LP%&6QO[UK=$ASJ2+N=IEJMAS
M;9NK8H_:O/OT7DGH9V:5'E0/=T=CV_V@]"E:V"U<H)9:JC@5(-"+.8'RS0:8
M:JG5*%(+OHO'2V:%FPTOL%4A[5\I&UW>'<Y*>_25.B&=V_R],(?W(,>F5SF"
M[[I,5GW"#Q])W  ;,+AM)RQ>#JMHT\.DSBM.H%M;'+!DUK+IP=( BTR48X,%
M.P^6W. >VI2GZJ>YCS/;=SV3>E>!.[Z&!?%=VS()3*B0#+*]-WB'+?ACO-[?
M/G[WH=[ = NF/5WR) YIEEKU:GY>2SK*G($_<UD02]&H>V>,L=&56K5:$S%V
MX1C;WC5[#XS)I5:UJIP!Q@K0;#M9\]_Q(IXIE7R*"6\GP:FZ61=B9,<NF'>\
MM/[0,X:04^@.R$CW?M* YS;XT]J&E["-DN>)N$?] TKS^L]NV_@SM#S:?M4M
M&Q;UUO5Z3!#/RD:N=BAQPM&5Z097\0N21+=2:JEE14J*A&*NV!G":7M1_L/B
M">KKE95:4DE_Q-,YXFEK.?_#XJD*>*K6U0+E)0JHM3W7H-3TR<!S1\37XVQ$
M1B<@W4>^RKS T=1MNCQ>YENVRL :;<?\$2_QPV ]WV3F&0UXIEFM"],'& /U
MAV^V<R1LP49A659R:.2$V!(&6]MT_)&P50=LU1)MQ[/>-!)0X<=NN@^J?>S!
M%A%3\[SF+C/BQCLW@RFR)9S547^,E_71UIV L4QWLK))T(=:;VH-Z]@4 RJ9
MG?!,6&F66FJMBH?["H*5K YV%JS($L-*HUF@JC;BZ5).%M^"58V.R8-.Y5D8
M>D0P$]WD_33IM]!G[X-FRO<T>!C 1F7\C9F^(W=5EK$C]UE Z;"J=B.85D$#
M^R-87+4@6,FJ:C-B!<XL"=&TK[!^:]0KQLJ2['"I=F5*)7OK>O/A';[ TV22
MC5D_,A2*JZ/+6@RXI-6C>^ %3EQ5<5]86+P<I(5,#KBI\9-Z>Q\Z$<N//9.#
M!*'/6YOFIW)3Y\J)SBT'.<*W)@TW):/42RU-2CHTG]D /7V6=TY^S(7A+'4%
M]?V !L7E%#F/=A((M#,%6EK]OQ_0FE 7MI9'"R2!SA2(YVPG&P&WEJ,[1@YG
M"E(?ZSA5?[="C*RP&RQ@C(X7,A0MWP\9-/DI \,=C5P8B&O\Q(V6G?,1[^(E
M?1AT^(+V8#T31+(B05<Z8=I\8EC\J)F%J5$"!1!S.!"(*!$&)1ER!%.C1&$H
MD3#;[ZC9?@'4\0B]CSTTYIG%-0^T;?)$Q_&Z;L6Y6FK5&DFU4##T?880R;!5
MD@$CU5)+T^J($6$Q<HA,@TT029W8I&BY)3:)M4<BH";=X(8Z?'1P0,YQ SI+
M!9Q>9;@^]K?;PT7MS)9XEZ.D"NPCEA550N>U./#)XKQNQ,]F"5O'U-'B02>#
M1[L'=!JB0>?8;JYIO9[*US7T\9BR6>JVS?Q>]M!HX6=*F(\-?=\4[>SF\W@F
M2PP9L;# ';:^SW/+F\0&34CBV:_%([HWPHC.34WLLB$EM2!5)=&\' 32P73P
M08&4WSF@,W67CZR18S("A6(WV0>2@8+VJ6--/YUSGO=0T&=FL>89G'ZBXWBM
M(92T9+&N\H%2:M4;=1&Z+J,W<W!'>",VTLM.531O!J%S<$<X)^A418/.%K5K
M6O[8UC]@H'0]TL[E*IRL2 ,\XF3/-VTA.NPYR)*%>J%N5(9-E#FGBJ_O-,EW
M8R*V"F?WL+N>V(@YS$F1',!3XP>%,?17#."D/OFY/W#JI59SK^(;8@5HSN3,
MYWSSJ$_Q =#/^>GA;0=R"GMF:L]#H"EYIE%JJ7(CCUZ.J2ET!G[[I1W/V_,<
M:$JL-2%G,2G-7Z#C>0BT$X:.]H)75<JG13.> -T5"MW!@!H\B9&^&T/=>:'$
MTP-*HM]]PM !%D,YLAN@=/ KHR'L]4 I88_Z@6<9 <_ \(<'Z3E95,;:XM%'
MA'D8=&.R/#&J/#C :O#_[HP03U,:\.)ECKGXP=R520PHY^GU"V%.Y.39G;^4
M/XPY<21<*LSNR*/^\>FM#L3C06,01\*C"G(RAP9J IDHXIW(6-?X,FI,3CZ9
M<8ORSU"OZL!F"<8PMC#>7BSVR.;AFJNMYPT[A!6=9^:(P9-XLEIJU?=3$I<4
M!BDL8%.;+J='K%9J5>6DX_ (V7.';)XQE=,#%7J J=KA S,8F]D J4YJ"Z=,
M^O3%<AS8NX%V3QP"F$*QQ'7: ;DNB8GJI5:MJNY?_ 2WQD6!$#,Y#PFA;*>=
MJPTX[2QIZOZGG1%AHB!,58\LI)JE5D-N)%04OHR#,D>+8F11YI1]N%:-']::
M%L/R^:_#3?K,Y8-R6 VT(A\TJ=32:O7<ZOR)[K<B=UTT=QW91=#DG%P$Y"[D
M+N&Y2RCO25-R\YZ.&.2:#&)" V"M?/VN;!7+5385TPWA5/?R3 6HIW[^HRNL
M._1$F6PP+-O2N=B(^^GNY"!=[]2Q(,W>Q27>7^AH.D?3,L3V"7$4P@Y)FM>9
MFQIIW&1F32S9$.V@HWO>!UN$/W0[I$E6@PKN<*U(,7V$>P'@GL)OW0GN5?!/
M%80[PETDN*=Q)%/ /:/#J$4.HR+,=EL!G(-D+#SEE[]9Q#W";<;-8HPD"<IP
M7'__+3^L[R0,(K;H_^V(J ,B)$1$41"Q345N1T1#)$04("J1' =[=@/=WN,L
M0\IX8S2QY9#C/H>*Q+ 4,IO!N:S'F<N&H^<0-'/*(<B1AH)ZG\BNR*ZG3DJH
M2?GF+2.[(KM>$+L*E>50D_/.$3\5-W,/X$N@LU=-BL:S'TOY$&J-D7/L^A9,
M\-JCMAY8K_3KFV4&PVM9XJ2<NRN>A#2[1>^S(8?!^EOF!FPP@E O'QC*4BH<
MWEXUENKFS_T<3K-#QOH+O>I[5/]YI0_8&*]U^TW_\&$9YZ8RLIRK^75;GG(T
ML=9?^QXL_^I;YQ^E>R_L:?%ZPL/B3P (M471-ETV3LL9*3APV/+9^MBGUY-?
MODYJX5H.7PY^T]?%]T&MO27<\/=%7\_F59&BN<5^9/SF^.L*^^K+ZN>U:D66
MJHE?214Y\?-UCY+9 .3D6]8]:OWGFIK\DN(,:O.B)^=#*>J&?*B-82)96[DN
M02U'V#VD/FJDBQJ\4?N5DA_LPJ%/NHY)3<ZF-]2@HS[UB"J7%P3[EOA)VBR2
MM<E+FP(MHBR:(BEJBE2A2UD+!==BNA9R$K,LRY;JKK(E<:'6F$=;'G"^[RG
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MO^])5Z[PN8QK*#F@SE1J.=T33@K%TAJNBZ$8CF1[K,H#.T(E'&@(@>;>R4S
M,"'+BEI_8(CH+L+^&Q6\D<R!S-(AAA()V8#&Z7;^PU&>.YEH#]^L!1=#J )G
MU7V.60:% !^")U7P/*\&"3C=[C!>UU$A!R-0/ >-:%B3]F@ZK+72]L^'_6:T
MOI>]IVZ[VZVWTGG!:=S9_>X]\\1VCH3=J=?+!L.2%>Y0ZUE&'G/ZR>2@#L.?
MF4O^YW\>, )X)UBF+PDJ_R"!4>%QW=^J?ANX]FD-1;"7T0P%Q%E"\^N#6(+
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M<\BW'*L)MR2$E.5NL'%P+"CN &U%U"7P1'<!7:P4F[E5C 'AZ!/))*J=^'6
M#'Q_V>T5 /7#)WY56)MLF>ZT1?O5MNC@A&=R99/SUM6:-#)AX*R@QM*?&%=
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MH<61B!QVRWQP2E&.\$5Q5J3&C7%R/\_<NC*I63NQT($V!S'))?DA1@(=+@Y
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M/+[L]TM+T,>#&K[HZ0]PITZG[4%W6->;VIVTIYV&?(1VJ6KN87@W\R&@+H6
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M?5N<?]A2K[D._B0W98OSJXOS>W5J/6UQ_LG?KRW.M\7Y)PA$6YS_,HKS3[0
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MZTG%!3_@5("?DZU<]7&'&OSPJQH=<E6.N[.TB>MALFR[2&#V-'+79:.IPEB
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MA+F0W3?!NNC)N0//K6R=+J:;,_J73K'[IMA=41N4(\DFE=A]I_-)?KMOVL<
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MF:V^=Q;NFJ #' 6/!3G7ZI;>2 [/CIOB,<(H"5[-T<-]()Y%>39HQ2O<KNQ
M7?[M&E)==.AUEDLL-<9"^D"6!&B#RUHC;AXKB]K8\'Q;4*51 NNP+<R7H2LB
M@MXEZ!D5G;P>X4.<3R::+7 VF,DKW+H,O7'JUHUAZ_I96_>&<U7R7=7>@!?O
M'..^8$*MR=#7:1T"!Z5T1X0#0__]RL 49!"L!CR2JWJ]"(]@Y']:FT#I-?68
M&?MU19@;%6C*2EL)^L>Z"=I93%$]61JO18K5*N'0T R]DH3X=L+UC>D&-_P)
M J4SQK[]KCX8EC^;*M_<)C:S2:&60EVTA"J'4!_*K=J93?L53/*NA=2>O?5M
MDJ?U316WOFFR]4W>2K:^G=#Z1LUG4'(>L#PUJ;\AICU\%LT[KZ3MC58=[/2\
MX7/Y8T&W\H=&STSI=QMKLM]-]KO5N]-']KO)?C?9[W9=_6Z\<.N)^%UE[CJA
M3P_2 -.Y$O&YJB4WWN',T:OP!_+0K\A!Q >K**,@8(S%2?JTO'\IX9];)SOM
M$Y\<71P%Q6?0F8%??G;IJ2SXTLJJGMV,-UEO;/>5$&5.'+*4N- G%P!^Y(3\
ME=/QB!@,:3-375"!91GTQ:H."_#("'A$5"K:Z#+HIJ2]J6;<)$)T'@_1D?T0
MW=F'<;;>DBI-D\;KCHSS)5(:/&*;+Q&&98=CM>JI&V7WJMZ>C)1.*9V%3_:3
MI'/"1CWKS9?.<^>H)]HH3Y):$R>I=9FDEK>J;9*Z#GGH/T3-SX+A[2="K>ZU
M?<8-$VGIYNE!NKF8^%[N#(F6!+3P U\Q/ ).PM(F"^0,RU'<$&>PPY% YZ(I
M[E)Q-\2CB@NN]NG/\%,?S@:_IWPC0-,%T(9?@=>'VRC-R^[3EJZG!"NB!"_$
M?B;*&MYVY2O$,>'2*!W*CA)=[2J81:/_U:@O _]0E1<"+VS@G6S;??'?[]8<
MU%EGGE@1,"J>QF]>14 M7VJ2=:LF=CP=C8(E#H\&9(X?F1+YC2F1CU2)_,?<
M^WMZ8<4;T/D:BS0:4G90JD*C='E&0XBDO2F1FD,G]6R*1K;#YC%K?R5@CSGP
MCLK<L UG(6&D955 H7A88<"?2;\:P!\))"WEIP'R,Z@:5&VBIH#42/F1\M,^
M^='UJN6'#;&M"F#@#>2G@?9P8XKE[E:&]T1\)7"C0*^37@5R]650ZI&*T>."
MR>G\Z-XAE6^=N#%-)+%Z9S94:U,;)>OG*O J1I?A')R)JE<VFUAR3@TX9WP9
MSAD"Y]1=YS30$&A,8(SRB&*Q@<OF56##O:O@Z(_,<K$$?C5>:7I<)' C>L@?
MFN4'*953:I E+-R%V2/M@#^=/\;T*#\<;R[YHY'\D7*,G\X?#%ORL,2R)OS1
MP+.ZD5"&'QWSE&R61#6[$%GJJ+G>=$C*9%KID!0)/"A%]-I%M.J4];2BE+44
M42FB4D3/DA6?5I05K[&(UL2#V.T3.6@!*]/\I:MY>K]T<>_70/9^R5O5MO<K
M!:!4>W. 4H8.\]EUGFX>B;=6/@MP_LO@DA[VB#&49]\G- =#_TH\-*53;"J!
M2>O;\2.!224PJ00FS;O,]C=U7 LPZ2?+P2"S8A/#)XH[A_=@[;RRB4(6L18)
M&G-&^HQ\%/?,?W%9\8$04F2*-7&3\E%C604N!:@) I01TCU!@ 8@0--F"%#[
MQH4VIAX\'HGLD6?BA*2KV.@J@Z6UEM7@!4^Y.[@:[_.'%:SN0A^6LO7\,X1U
MB'/4![4NQI1EO%4J]!*\@L.SI[6I^;ZT]T-C=9?;<QK' ^486!Y%/DIX08+P
M85M+WRJ%ET:*?HL)^A#34\3K8SHHOB[#<F5EY 60I8NPQX2V.A[6S-9REK(T
M8\_'@2S+$Q@_CLUQED;)L0$RE(2/QH]$KNJX'8*#S"?E=;,T6NO#'\<FI!3D
MCVF_#_RAU88_VANE9[JOK-YKM<V189)2"GX'8GBON;E;[<R&Y4>>2,.T/DR2
M89B>PB0:,DE52#8UF0!5\_X8-O/$93HQ"F4>TXZRV%<6^U[@>,FM,W DHS:4
M_3*R&%_*YP5/]MSR.4#YG)2?=5(+^3QYW E?%M^3 ?AY: YL7-_":][3^6+6
M,]D6E_ZT6R3,U]O?_L28P]+"(/TG![5@EZV%NM'&>Q'_Q'\+- %H"+W"?[;R
MMC623^1F[A'CKQMC"6M[;]@OQJN/>Y0LK;:<FSV2[U.+T61& <]%[WND\:!(
MA\'T+3H,IKV!.I0=!K+#(-%A,*E)A\&]LW#71'G',9=^[BI?2'#.#@,XI?@$
M%N>)/9P_6MQA,.T/F]EA( >=O-5+'1]T(@>*R(:(ZQX"(D=]7!LIU#=M_+AP
MZ=,]DIWX 84(AF=;)G%P%!R:&N+:IY.+B%L8ABFVY*:'6#+0$N^=9V DK.=A
MEFK$6K>.^8$SEBC4@I6.^K#JH<^-GNDL9:=ULI,%)7FB\(SAQ-+//X9&RHZ4
MG3>4G0R8S1-E!^M*SS]!HRX9_=H;H'P^18F"^Z95[54)51V1D8<'1?P^1>^F
M%+:LK.*L#S]D&Q19#*$B(*"H^UHR1",9(O.4S&0(E3+$H35Y<89H;QTOSR M
M/7>MD'^%5O"J6+'Y(HMZ"YYZ'\@<K;R/E)#?R2+T:&W'?QJ6\]GU!0CK4Q4'
MI]6F6E.6])[?LSZ!1_3.K"_+OMO$(QEGXPD\,J!=B54A;S3-2;S<-B/]%=A>
M>#%XT=#R5ZQ#>PD;.@]..C";9@96>& B1_M(4N(_.!]W2/JP1"GH*$O76QO!
M_^E8/X+W2^L',6_^33Q7) +##G#[1%.U7VK2_B7]B/,?IY5RT$AR4#,XJ*0G
MZL-KP[].X*5#GAFC<59F@E9#?=0+QV59P2,/RG851UCGV%;;LLK([$$=YY$
MS*0STP7.:4VF?TF?H]((;1'&F&*/:9G G&2,&C%&AC=:@#$TQ%\08,I=G#'>
M($NY5Y9X@]?SH1AOTXEL\>X $G<'I)Z:660YVC!V5:4.51*DCIKCG);&3L>(
M2'M@PD>M#KZEBDUJ8@.R%,@6"61)&R_%U2TNFQKZN65.=BF44BBO4RCSQI^*
M"Z7>F8E0>1LCE!(*H  4P*02* !]_,9( /F;CS'D^L'R%[;KAYZ@NQ@Q</:F
M%L)G>)^]GF/Z:(D;<'6WRL0-.-"')?$"!/J :]@3( &.-@8.>\J'_81SCE&B
M!11%?[K%#!$#>'!A$XB@)H7N:F_U9F =;XG'\9TXENLI=ZY#WPZ9_HL;[ '_
M">3S1#"..\/S7H%&_S#LD.#$SX]^ /8E4/&387GL4Y:RO'=\. 1I-6<*1H=V
MB-%1;.3O!:.;*Z(L^-(58PV*._"Q],8-P9)A.[!([("#.Z"\$(\HAJ\L0=NX
M+S[^$WX"IK9B&OB]Y9C 34"Z][L&BQC[Y2VF',LQJ7),JAR3*L>DRC&I<DQJ
MM-2OGN4LK(UA\W/P?1X6*35H+XMW3DJZ5_YRUP$XG69N*F9(%)'"*%WY5Y.%
M%PY!USZ47"CA.LC17+*U^#\9"W)+M4.!(EBMC46PDOW;P?XY^F;$['_(YN/.
M;#P>E,<JJ5?Y;L//K:'L.#W@^4D5*M\)US>F&]SP.XD$ O%'NEI_W!O6I(E,
M%G=6P3[3"['/M&[L(ST!U*B3DS1JT_J!"HG$L'\9D=#[5"2&_=K,39;M9%6P
M3PX0B)(^F*[6S0>KTCS5AJQVI'[*E%7/;_9":V5LTA)%?\T4#NU"NE7KS+3N
M8%B=N?'VE:<5V;%7QW+ZA5@.AZ1UIQ.M_!BFUH$T7HXU?H?-=>$E_DU,BKBA
M6+X?&LZ"P#K]$Q&KFF:N%&L'SE+)"8I24>'T3*\ZU@<4Y5<B-[:%03(4:'$&
M&>*XNBKJTNMDMJIZ+17BW6X]%-8VI95"G7@^R2F79R-+'95'I8=+(BY%PU)?
MC5>L@BML>XVHN:\/*H/!:\:(VO+X\U)XI?">>O!7);QCZCB-16#?313>'&T6
MA<JZ$V1&^RJE3%N?''9:Z!-QLY.@;ADKVR_;L 86R-&Z;& BY65E+5:T%MM:
MWO!+P+%[Q@)VA?Q8$()S[_#[_:!<EW[*;1[+H1?[M+)[>^6+X5=3^'VL^EV6
M@K>B%/PTIW%:*J12E[)963PNB\=E\?@5%8]75SY<I$:[K;[$-;@*DT))E@1C
MW2_O(K..MB7>.Q^II?:PC#L8BB3&IY4EQHON8;W=?"EYK96\P:4D+]N3']"*
M)GVDGC_K7IFCWLHLZ'GJJ)N6YBHF1\-SRM&AJ*B=V7 D  :7E7_-9:%"W5?E
M64CKS'2]_$R7>N52&ZA-3ZNA;G5;P:10)U9Y4="K$079F5(C%BK4V'0VEW(P
MJ-JEK(G96O/&%59K/7]-Y(!H7HCNQ?B7](20C]=:7F:9=A:Y)%KKM:"U%E-+
MA1KFRI]LP\YL,I60YU)>I;R>)*_30MU\9XZ/C6A\;#JLS.^O!S!S^1J7:-HW
M0[2^=<R]\=\)F%]Q^0M"/S0(I9#5G&!9+J\/"=?P1G 3:KT M=8;UR$<OM#B
MM(C&FRF&PXI>R'))%HACO;W$,Z+:&6* V90%?H@7TO(96(H+II._<E^<]M>[
M#,>]_F1<36F)UM.'Q:I4+E#O4MN7TL^&QYB D&U -<'C"[%!;G^#"U>^\M$Q
MB4E!T2]=:U/5F,9J"V[$(QMSU)(TI)"D5,U-Z8*;AA!)DT3*)I)Z)25)=X:_
M.C"$)*AE UZN+J,6596&.B_+M7 %.GBA8</:PPV.1N \'+%N!2\SZ@USO(U@
M^@WNX(W>$UC:<\,G>(/.3'FGIIS+I9.\-5$M5PZ:>#P\LN^'DSG\<V&'2(!;
MUO9+1WZ(HAT3G#[5H@H'R?!M8/BL.==E.'[:F4UJ QDJ.5YR?*X!WB4X?MA'
M'5^Z;U.6(&5L]Q?7N5E4[@*]M2-1N]]?1VE%4J8Q0W"M.$D5FLE)DCXL/UD.
MD!)H<(>T%*E-M3,;UT9MRN+?\UN511E$PQ&.4\D@[6&0#".L*(/HG=FH-L#!
MUP3_>I"-]\C"?7(HXB#P $^UEP'4NHHBI6)+;KKT%X^RB61^T)FIH]Z@]O"B
M;]G7*D6EX:)R0GQ.)"N(,3DH7S<K9:4._"-EI;+(GDA6L"QUV!S8ZN@-(K*Q
MK&Z53DJ.WR=6N5]V6_;6\M5."\8U)IK[45RW*V.Y-8SEEJ\[N32R8B9ZD]*4
MVI-W6E9)Z%5$DYP0*X(/.UMVG$K]>&-+9 E\ ST3JY^OQ,-21N-IB])^HVW-
M L1EK4?]QB6WX:>3M+ ,?68PJW9F9IU(9I7,6A6SZF=FUJEDUFN8O2''&9\D
M?8/S2M^HWYGUZS&&MOY'A82HR6#6X9F9597,*IFU*F8=G9E9-<FLU=80-M.N
MN?*AXFG2-SZS].DH?54A!354^BZ<SS@2+*X+??ZWI$\!^HA3C,<RC#E)U*C+
MA&>8.JD";2*Z10(X9@QWV$F9:%HOK@"T'!-4WON;:559E&%O4BYEH1[/6:@_
M5YE?F>;BX>BTP )$A/.A61YV),_)$[R$L5AX(<(-L1[DJ-8?@80L7]FPP6V*
M3];6C>$XH6';KWBO_PX=HJCTLAB81,66 0HN]$H,KZ<(GCVLXMF_&:^*.J27
M?7&?^;.'V0^?7.KA@M34!>2F/8*BO8&@/*:C9BD;^"<">YB*1_B_&1H7_=;8
M;&Q8!W+++FB6XH:!'P"GP*[T%'Q =@)V;02AQ^J%MW+59=\ASP$;)F^[-[/.
M)T%@PZ_AGR;Q%YXUAS_FQ'9?WH@G=T' +JC+\VWZ_T;R)S<0".>X' 'M!3A@
MA]9& )L+N@&' *;2\SCT'?[-9S'2>OX=8O%7&VBLS/U0>F)DLY]VJ<QQT?K;
MGQASW[7#(/TG!Y@UEQWQ>*--]PB8^"^^)GHNUKB_G ['>E]=+/2!KD\-35N.
MM.ETHBW,_E@?_(^.\-[\5RMOR[=/Y&;N$>.O&V,)2WMOV"_&JX_F2Y(U@2_W
M*+Y/+$:2&87?$KWNWF9&[I8V0-]K?^0F?*I7@3VH:X:IGK0E]#[Y ;B26@I=
M4.4[A2)\W:5$"@WH@-%&(RW^15Y!B0:&93,P1$1+#!V?+*A^3L5-C#7Y.[P)
M8E)K_5^V5A?]0/WEYVZ!>PWW[S7<OQ>>#/GO-]F_WV3W?IDHCPW#=)ST1M-A
M)4"%TYXVJ6SNJ*X=GSN:]U85(E:J/;6J]6D]K5]LV&OJK?2>/CZ.#GEY3ICT
MM-%Q2M4<EC$?CER:P9H;C[$9RWP P]_#D^#.76]L0@^R#V#EM6R9OZ%S806O
M;5S;]P '<F_=_F_M6^+MTY-'GM#EC''&E=O="1;M6.@7$L 273JSH\) P+"G
MY7A\6M1"ZTTRHGLMVX5[!\@ +,:4OX\Z,2E4M=^0_1+QRU+OW89XRM_4+MSZ
M8.!,VS@EP2&@F1;DS>GNKPR/M(W*WVEP#U/ RF\D6+D-THVZ:"_$"37]6,O>
M^3&=Y0W:=8,S>6$7BU!O(T<YDO5OK<?R+2E.FVE]==(8'9UO;5'.AE76\,1-
MR]98N+II9USC_9=/^>N;F%.74=PTH,5-A[6%/[6,[G\K-MVJ&-4_&0O"?,FB
MHZM&.(=NV!<@3D7C.ZY['S*F D9^[B?/72?"; R0H>!.C& G])%@V&U+=T(;
M]/3!>,24+;7Y?:5E2SS*;* 8O^.J,X1?RSW9;NO(43].C9FLOV6R<6<V4'O]
MPVK2LU/^8D2G(T4,Q_R[RUU)7U8"UN.RXJ07^PKFU)R8HW+^AKS']=VC!>[D
ML&7N)!9DPK+Z+3OX(R^9>Y+#[FY;<#L66="5U/K]\[J2$W0E->E*'J/ZS;A:
M3W*Z)3\%/] .T0^4>2O=EX*[H![?A=*.Y'8CQGV*0G$(,M[2C0"7>:3U%>E!
MILE\I1[D6$50R7Y//11TZ4)*%U*ZD/(>;;Y'"US(23M=R+8EZF!9.]YCVY*M
MA;U'[:S>XYABG.@R$WF4[.=S'\<Z=1_30&;:Z;H4W K]<C[D@.Y&&G1\.W=C
MU%.'8W7?X&_'VD[T([7S^9$XR&.D]0;2CY1^I/0CY3VNZQY"/Q+'OM3D5#D_
MFL[%,4(4;$S:<!L)46+@Q1:A31O/YM@M;H9P_F!#^8HH1MRMM=_^H2S!O*+7
M6+S%9A-ZBQ4LS:,]V.KX%\6T_ 5>Z]/>;O!"X 3%Q] 9O/"M1Q:!_:I0FL''
M@4OOY_(^QMQH'U?$+]H;\,OW</XG;!1NCV'^&?K!FD+'4'B6)5QN @=P1D#\
MDQ".=[EUHO:1M\$#2@526!NORIS$<#NPB3B"O0LOYB[^ZBKP&P-^M9Y;#@/%
M@"WVB+OLHDXG(+9&0.$D4,@]VFW<$V6=4O!D4O%CWA!/XP^BA#YAK+R\X00#
MRJQIHQ+%SS!\'XQ\DU/3YQ/&D0RI9 :Q 2INPH#=F;T!PAO!=<83B1)V<!NX
M;(TC5I'^.Y@]^&330B@<T**&Y\!GOA*WB.T)6SUH^<5-G!@;XY7K#(]0_ X.
M9Y9*,_@I@E"Y#$G*"EY[R@.R'_P*%H#Q+/"GD'5\=GC0XPKH#'<Q@(^7H6,:
M^$1X-AQ)SA-A)Q \B-HCE.O\+FRL]P2[J+"-A6/1!^^,7PIZSD6@&/@KL&XH
M]7&W$QJPNZOT=M[D*$< 6>S0)(EG!,1;1Z_X3!R#WIU=AC>,UD6>*17I3/NE
M$=J!0J&!E)>5M5@=IR@7=B0^/B9"AK/6P,T6G+[V:SDVNAB@3]Q+I/P7,9\.
MNS1KP/OW#FZ 0UB$X<4*5CMV#>[?+HHA[K6RTU$$:D*AB%94,5,5LKNCR@I7
MKP0>O*?!18$]Z<6-'G!HF!T^^A#AYPXM-N)M#'C:%DX'W\8*; HU2'5:=%,E
MW,"?'(0W+;C"=-QA7&4@;BLP?RS6Z5&56]]W%\BSY@>@YS,]@Q\3=/A" ^</
MR^_\H<7Z#\8CY#$!SG#4?K!3J,^5_X[FAG,1."TF/D9^X#KVL]I5PH]3*^'9
M"\>G3)=!0\*"F;8!Q\$7&88,(Q M_ -F8Q*+&'\YB''(+,.,"?-;S?SHWH(M
MB;<T[*^&9=X[=\8&-<S'?X5PF" ^BNO A0_+DLTJXPDPBSKI"8J,.+=0;0O"
M;"RH)T28&6$%:#X#EQ#Z0L LT>ZA"Q9-7$=A:P&-IIDTLKA0&?$;P0%EF3?4
M)*4OQ;XW0ZH_44$R-MMG+?)C8^T!3^XT,8I_!:R,P^X7W ?UT -FQMH&+G*H
M&/.-BNT BK=J.*][EN"><N4Q3]#\:%W0RS$4&MM#R!C4<H"[>^SI:^,OU-SP
M1@OBQPK[P/NFYF)DH":>:+'K30,.,^79M8&I;@Y,3J:38M$6:C%\/@8(J%4!
MYM9?)%9E(JGN,3H_YKLZTHXVTL\#10K4-/TH ) @J?@F?@1PF]! D8V4=%'!
M#"0,RY096"FOKMPZL6%/?A!O8?FI+P[B&;*H"9PTEDD/Z(2%^ S+MQS./0R)
M=7L:@SE'%_7BAC:"H"*>(QIEN[^GISB2A"^,4H2':#B7'?$%E.^$,+!4YJ]P
M"-5-]-,$;5$*GY&I]^(O>V3F)QTH)0*O1V%9*6HL\=$ 1<A@1K(H9.21->P#
MA75UO4 D%YSL#;(W_S \#XWRFEJ;.Z9CEVH5VW?13X>SA[_ZSN[NVGCT %]0
M%53"FLML$L7#8VN1W$7::VNY,(/M'B21F&K18V;2S[#;E'23+7$L1#L=Z63%
M0;>0:DE_"UU"08PQB$K!DTV%U6I0XRCZ_0L\E9]'>!Q%QA-N02IALQIO,ZL]
M$D?UXPH6NP(.@,\04Y-;R>A/?@"]([(%)VIG-A)T0/L+<#9"C!$%[ 9PO(#F
M\@-D'_1G$% <O('D43OH*7^06&F<8.\5ZCF^Y\#G#\MH_PJSC]:9J1.]-\FP
M^WF4;!M C\/@&#O84771JW2YQ?Q"Z8'I$3.'Q:.(C9V8/Q?T$%G!D8Y*/CH\
MHB/'H3Q^>#Y$6@#HC'P<K"@<=.*P/K #^&L8RA/<WU'6Q/!#CTD!!PC/92E$
M[\V6DGD9GK!;&^$L7M.=#6=^S# /WC?4J1_Y\4_]I2TW\6_%4J.#!S7MB01G
M2_92]@K7*8KQY!%*>9\*5Q2K##RZ)Z_\49G1RD-BOZR(PX.4T2E^8#-&3,&5
MZ*G128D=SK'#]?U>O\1_:X4"K@M1P ?'(/+?WF2;*.#-;H A[W#60#(Z5%,3
M+JK>I:' G-'#210]W \6;FA8#',T#GER XLE71E!%DB0G;#A 8YV@G3;^!]]
MD3C ;CEPW*)?C)$+*Z ^L1\?4[NW8*80!K:][D[,*"VPCA>A=N':W[> T(;'
MCB[7WYE5L35J8V+@WUM[[$B<CAY^]-VV)PW5P+9%]NZ:MC+4MW'HX(DXH"KQ
M+ML@PC: $"^49P=V7H5&$X1:>I(SDL 64UDX(:8F]_86&.EE.80N8P4_7*S8
M*@,>YDJ\7W*7D?'2Z,?,EVVP%"[=&@4GUNJ-4BQF45#9V.![)-0#?$*/_NWM
M#\_[ <:SM-Y(.W+@=\7!T=@63(Q@03^"K*UPC6LN7 U>9+6)P##=!+H''" U
M7CA[E^-%XA-$2SJT=WY24,89O]@N#0BDVY6G;_ XPR6B/Z.+$>W>".Q\L*C5
M8[L7Y2>_&+YI_$OY3]N= W-^)S9N*+@Z?Y& 3U%B5KR6C"[2T'<R01((63]K
M_5EES[O)DJ]<#WQRO:_\N6#;;K<Y>0(6=HW&0+*^VCNL@HY=:QS;$_LV&-E.
M: 8J *E>CN5PUH@RLUB%9-ATBI6_(H05FHA)")8N8S;/@L//,J@END"SWEK"
M^<#L&,YOZ DG*I-8.+<A(:@$,NUM%+/#I>;#M:^'B?.)#Y5*)CWO+&\1KO&D
M7] Q;+YB6WX0#7M2W,4B]/ 8XRXH_OQ?H0%'E.>#O8.LMAODUUGH :0Q$8[@
M'^ILO@A.?..?]R.A_8^=\4;[7N2.F'WGD9 H*8)[$FT)K)!M2&(_Z$(?T5)Y
MA%O^:@,C;L5J<FA83W#@C$) !#?HHG@AZ<QNF3AAM+6['Y^ETYV2J6'NSKMQ
MO!?_XKS/0A7_;8")[[WNI$7@*L\-GU;*;?@$)Y6BQ^F2G2T:4CD76E^)<7R6
M0X._W\DFV)G\M9=[\3.GA/'%T5D&:,OR0B46X@X$LV^BP671P!NNQ04A[_>'
M,ZV2(I/B#$W2Q@$U;)2,!CZB7MF$E*E>S3 2.)3U047#5JJ[%=!*'1P?3%/1
M1.R: G9_LM @4+[26%\36E**H+WC85-!%_#99_V6':VAQ,MMQ4)9HDAAF2)N
M"D6YF38M\%N4<Z4G]\=$:CJM"NY$2/HT%96*4=ZO .>\]?=HZL&0TZ17_Z[^
M'<UMY491M;_K[(_&](OF7*0 NOZ,*Q,D)ZA&NJBK5BQ-.SFIAC,^H-CY%*DV
M\]8QF2HW"T<I$'=MW#MLG+\D;'0M]J]P%6X6R/IW#*"PP_8#=<69,<@.J:TC
MO%,I^!W'>%I875)T(Z=]1* 8R'TL6G^S*XG[L6"V6Y%%@443OQ*'+*W@88GJ
MC9H1A;=*I6 A1;:J0N.D'AW4I1JM*S3*ZM[I6Y=[7(=1IB>-LN9 0DFCK"*C
M[%BNZ()&V53KS,;C@:"JCL6?Y9&>89IEE7]>V#1#<"JM)TB=RHW,L,WTB]MF
M@^)[=?(P0YZT*'N$7_EM<K7*%V^>%Q7]76O1I=J0HLN!L.AR6..BR^2 95HK
MW;@2A?_B:?(L0 =:M$8[G?#'K-B/-\_X[*^X](<6I%#P,]MF@!J[/5&6Q^]I
M!$5+O]1!H=(OABKP+7ZUJ,KM2)77%*'I^L(RK^CE]^L(N\K&#GU:GF@L%EY(
MF^-,6 J6_6!M*L4B[;)Z1UJHP&H\'%8D9@B0&Y1W1X!F=C 7:.$G4O-G6AY/
M*SMI']1\MR027ADKYLE^<0"V\M =B^HE7E9QW_W.9@DJ=(\A3[ U\FHXUXM>
M-8*V4+#H"9DC4<Y BQAL4+[>*W8<?B _%NZ:40A>@9?4P7+(FA9ZU!(!Y%%0
MH>&&""% _'W2LWH5/^Y$Q%V(.J:.R>+[_ N_;&7&=-I3-:UH888ZZ@V&XOJ$
MM+J%],_UR;22"HA)OS<>':\6$<94IF<R]L]J.*2D8\,UA6D!;MP><WYTSO&:
MJX>=FJOH,%DFZM[8]"-6B)8H[7[':^_I7U&]?6[K?'3*J/$FITT+<A,\]"P!
MJE3SZ%B]2=(\.L8VA?WHG.'H-Z997O.+UE[OVEK&W++QL-Q"X63:5' <KT,[
ML#8V:P#YF]J%]Q;8+$9TO/.RR?B8'K['ZWOK7E?Y0EZ4?[K>7\H=?0MK3;I1
M?>$\]/%,\[$K-@FHA'7]"V+N%$/NE%UV>;WE[G0TIA\^D;F7J-/DV/<[ZB0J
MH]V.P]M7+=T(1P L"?L57SAJ<=FKGUPDRCSW#]43(P/URZ>T,5U1+\%.47T[
M9=X58B".>ON C:(72 =LS O-^M9:>,^FY78H\/HO"2M7O[!Y_X'WA=-.-)N
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M#K?KU!)61 P@LN6=7]Z^;7Z@#@L'T2:]:;^B>0;R5F+S YV05(UCPC_!^HS
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MG*<@2R+^0?*1\6AKX3K8JNE;!Q;Q*/@DJ*G=:W: !!10SC:V@&Q ,;YRW(>
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MGT%23=KAYO\7L<U/KO<[ENL7Q#*;:+2.,2VT%F&9Y4&Q4CB E89TQ(OQA-/
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M /A(R"K)X"=TTQWE\!%P> 7E;Y+#)8>_73?@40X?M[&;OK$6V#()\RSQV"K
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MW\6_7K=3O.EX;3L:Z1T&\!@J;4#D>+#X]OUBB<47L'RJ':COCVK'H1$%6$*
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MPG]$5+V-B"KD>\QAC08"K7C0M"*MV2:P25&-F)--QG!XBH;&7YQ+KLE,1'B
MBHW$W+U3M1:)LRK.+T3LSDW 0AA7E^XOTL56=^/R"KFJJ)Y-XZHI<%5_5!E0
MW%FYJKW#@7;Z%!.IK'9-"JHT(ZG7<B-Y#<<6%\18</".;4V'?TW!EDJ<C/T8
M:"(O5#A-K_7[G=FH+TC3Y[<E90BF1CR3LZJC',^HP#-30:O&Q7FFTAQC/74H
M'8%[%1&8,_D1"5:GM"P G*KUM3:/&FH3\YPK+G/(/0(NT1%=N@9!NVL*QY@I
M3H*,QYPEDATCJ1ZO0M+Z@ZKL21F2:39CY=2QN1EKV)F-^X*48+T8J[U1F2_B
M^+?R+J%\"Y]X?"\XLB%8X(KIAEA+AZM(WZGV0K!40I Z*H^S9@D2ND,<VM7Z
MH\YLH(XJJQ:L8I]J"F\D95+*9 4YEAPR.>[,='U4657F6\EDCAD==87WOG>4
MV_ I] ,*Q]U57DABQ@2\A.4$GG%#G  1JNF!K\ 'C@][C3#/"R")8='+B(V3
M W DQ\9#C,$ H?&#%T3[#U[<"##\9>7:]BM%OJ=@W? N#@[V\"W3,CQL5\+I
M'DA?>KD?>.&"8D0C+#Z%I"8_@#@^AYFVV(@.Y!EX\#ST88&^'V$<TN$;%-I[
M@7L/"RHV;4(;E.\.$H2<LL=.:'T<.S'54PO@.):MP!Z#+5Q9BQ6L>8--7PZ=
M 4$2D.';78&/YX9O^1'8MW@3$5%]:3F&LP!F4^BD!(JR%0U&V(3>QO6)WZ70
MW:\(+(DWH_-&-L"@ 6R98]"9$OCC$('/Z0]AATA/H4W8"E:;Q:#K6WCUM>$8
M3^QQ<V);Y!GG)E 4<\0?1R3S&X9D?H-(YC<QDCE] 3Z6 EXZXK-#:C$P\QC(
M'!\O&HVQ#"G3+I?XD_FK&&%^#YV\KA(/\H C,*C8BI'R@1T*BLE9RIRT_C2M
M&B["<HY!_5%7)*8$YAF-THW98N=#.H"(:[7H@H,&])[R(?0B3J?S.>@<H)0A
M!VPPBA"EWX'G4@$ IJIB$$Y$\4,"[^_!'1U#<N^DSLS35(KK.3PR_ :4A(7#
M6$ V^.RE)^)PS8M<5'A'\,MX; '2]_@H!R3KTK \>A')/H]L=V'PV3;W. B%
M8@L@81TVN6%[R.P<>\D#+UA9?GQ#P3B6Y.2/ZQW(,F[*0!9-/)!%[YP\7>(C
MG+,+W- XKO4->.X;6"!P@-H6?8.4$1.:JI8<,7'!&/R*F57;1<5V!>IB$E$A
M/NGQB&=S4)1W"#S],YO]Q*F/LKXUVIAM0:>?108#O85%A\DL750$B6*@$X[;
M1LSB&&D]?5CAV(M:SN*HX4N-^L=O569 B#ILTH20QQ=B@PS_!A>N?.4CVCA4
MR\K)(7)RB)P<<C Y1)+J"*G4*QFR0F=S1L,E#R,>9TM6MB/B7GC530^K9SCR
M6R]BQ]B./^911HYK>!OPN;??([[;\4*$7KX&7OY@6EFK;=VK-DY^_RL4MG9)
MFC9Z:U'3.[.)5A['N="V23&38G99,1N_M9@-.K.A7MD@B3.GC5M9*O:=SE/G
MX3ZP?+MLMOHRMHOY>';9UE")-4C)C5.,75AH?(VXC%+%,DH)Y-LBGCG1KBG$
M-"-0J;6!\I5,\V:G="&F&8.Y6_X8KE=K3 T/VZ_$6QL.YM*M@*QE'W7VH2K"
ME!3D;7<X/Z;R/1)9R.\(DE\*E$<V4M='/Z8<JE7QRA0[!DO7HDN&J0_#I!RH
M%3&,UD<+K&5XB#4\3+^EU:E=TY3$<J=K+D,RGGX7CP@5<KT*1^JD#IW5TN>H
MHB7T-$\U)Z_0P<.25]K"*Z<YJ#EY1:=ZI0R C71+L\J #ZKKK\(SO>31R4E<
M!-!&&U0&:".=C]HP4NF#]11.&DI.:@8G7?;<C5E)P#*CSDRO0X2LO?YK=.K2
M?HFHZ3. VUZ%XWK^PY?3=Z<(X4."S$*VQ_'!0YES;1'SG'C@GL0]=/:N0&M*
M[FDL]YQVQI[$/5,Z(T]F8<]?\N0N_J)18W>YM!;$\RF01C1:7OJ^E1R_7USL
M00L7=-0?KQ3\OC(\0F$D[A($OW-]85>[3A,I,O-6;TXJ&5;>2_"?GZEP]&X5
MT(22G^K 3P?'\\7YB4VVK0$H?WL]Y3OL\I^['*W$>/(( QJ"!Q _<!VB^+AG
M-W.*S[(Q7O';J_"B+U)<=0"*L;,?M]%V_!;MQE: OK*M$,J-WIF-11TV,@?8
M1-[*/-@ORUS85Z+5(6DHF>OR]5H5L%3^W(I>76Y%.NY9=@ %0D,@L,-F_>LH
MICZ_VQZ!S7UD0)!'FO?T$0)?EF\UD?Y4;5CFQ%AY 9[!_$IEDT ER]3!\BOI
M@A=@'D3:[0NXI_6N=HR<>)G]OQ="<D;8FGNXC6UVKRLX;G,;J4FB?^4T?^0D
M%TK#M#,;5= [+QV=VK!0T4ZF@CR4WZD9].OFU$CVJH$?71E[J75CK_;ZS*?/
M)&V:U7I^WYC2\M;\,_0##!,)N_\&FGC I/1PFLHK)SK%N9A%1W=8,DN]F>6B
M[G NMAF@CI$IYXN$F@53+:XBM7RY4/.),V<&PY1PD/10FLI')>//IS+2J$[H
M1Y*/WJQJNRP?87)C4!OLM4O[M/M3C2S'! /FO3JY^)S$",N2^(H1) ;<[.:)
M=\+7640Y.J\25W'5X.]5D*7I.B>O#;0+FBO4(YCG&E5P(E6^2?5&J);"*86S
MK&&90SJGG=E@6EE;BA1.*9S7+IQYK?5LX1SV.S-]VI*3,\>L\F*3+\/UVO!>
M'Y8Q0>]<'.GX1, %(OXC.9AR.6S6E$LV;M+"8;]L:"1=,-R$#=9&5GC&*;%T
MD"O.EG;I!$S8>M\'#L4AF4\.7,ZF3G/@^RN87CD9]<:C8M,=4V<RPA?Z\5O)
MP8,'Q^@;N.J7E,U?#9L-@PZ4_S:<$'004\=LZ+9ZFD?>6LN@56>[KA\_VW]/
M:%TXD/C1+LQZ#34XVT>UZ0=O?0THFW?O)T_+C6>YGO)*#(^>D-&8\Y28F@Q#
M9QBV*<P?D_X;\4,;#;1/GKO^BK3_"B_MXK5?(](+)447YX>O)@[]YH*R"#U$
M>JE65)I6-_%FHG+'J)]36 :=V;0\XE>]3A7&%EI/&];2)DH8A,GYY,K![.&"
MITB)485-%)K!H#KC:MB9#4:5 =_5:!)?LTX3$(?\9I=R18=)I>CU*8(1$_]D
MPVN$AE<9V(%Z'2-UE9++V5RM=D].DY(J;*YQ9S8J/UVY7@Y*<VTNK4Q_2+GT
M72/E9EB=V36A0#55-<2?/QUU96>*#'A560-UMG@7'=%7%]#NEGLH,MY5-TDI
M9'J-^FAZM2R)TES32S\QLB++J<Y&EJ:K%JVZJ.!(!?.T HBORC?I3.54=2UN
M>EC2 J; #0P[O5!)J%^8@]>E</<87N\J?[L ,SVNC. /-[3-^_4&GA*#2\3H
M3DFP""=<WYAN<,.?(V1$S/V/!7Y25'=3=%FGN7"5+TN'96F]88I\\;71O2NT
MO!,3 Y4O;]"9:=.LY77!D/0W[$GV:U=YP3=0#/IP6I]G. X"46W[>"+,1\5:
M*MN%])1;VW<5RUG8H0FB83E4:.;\\'67^22'O5LD/HKE5R,P%&0EA>Y?W8"-
M!=GV?3^Z!TUHQ<D_1+<H;1!UQ%Q EQU2!, $W5W*1GOB4:L3"6ML&]1I%24V
MK=/;&(L%*/[ [Z+KC,67]BN0@ZV$74#7TE,02P;N%U#FWA#' ',6^[4\HBQL
MN,A:6O + SZAPSE<'+F-[VK%W5T*8>7 ] XO<#/%<0,%"$10X2*QX)M7N#>:
MQ? ZQ(=;,#8)5F[XM&(ZU5ICP2B=!A(&]-[P%",T+3A_2!#8A*T27RP$/O("
MPP*6A6\MK!FUK;^ :?%.\/T+D!0(":^,/?^P@H4!+^TQ@'E.ZE7B-KN$Y_SJ
M "\IP0NQ@='7P%HKOU>F /6"J:N0Q!6UM@MBI\Q#'Z[R_:CR%C886(DH2\LF
MR8WT2!!ZCD\W >GLA_,_4?CA;F!&@)M#* _8%K.B<6\HN1P\M]W05_X,/<LW
M+4IE> 13 ;0.>.4"@\0\L7.=8EM^L-43>\7#/04KBG_O?>_!C@#G 1L9Z' I
MMNNC\_L$V^91]Q?6"&^E3J=3N@!X7YLJ&+@OB%#D%3,.@MLXE#/)#R"\0WM*
M>TK9,NZ/VYN)JKA'(Z:D+"<DYFT0?7AS4-R-*V;OZI$U\"<N-[$7E/!=9?X*
M!/T3UI"D9I<N#\25D1&+IO=LJQT>AN_X&S%HA>VKPEO)&NMKJ+'FNF0LU"7_
MG6"M @75@O6@ !+O[5?TR<(#6ODGB-?.@MJ+//8[6$F@!K\'V'6MO/M$0"Z!
M J@C$;Z;Y*F4+Y[IJ*Q]/>%37I1L]""YV8T-;6.G[47<^4\"QJWS>A)3E,\T
MU6+KM;Y:Y=8W35/\7WA+TUV740O-YP"M?XW"?V<XAFE(V:^+[%\XI_B; 9:Y
M;QD9R<+K4 !J!AL<AK"3KI3HD\3B^,,&6F^,WDZ4IGU/<[G6,]DZ.3_M4H6[
M2/WM3XPY6%UAD/Z3 RO\LN/5;_3)'@D3_UUY6]_AB=S,/6+\=6,LX27?&_8+
M,"-Z44DW%+S$/=KM+YLM;O8?<^_O,]&#4WQ>59W>Z#5NK/Z#\. '!J[ YE8,
M&K-9H<5MO$;1DZ\KR[8V&PSW=)67E;5887PL$;)=>33D=KOQ+%O1^U%R KV!
M-=QF3A3@%H+3&'GDCL44\X5&:'#UJ^O[;(PCW,<'"K.$N+M\-'[\%WO;G1 J
M$&3QW@R]%W E?.(DXB7CS@S>E_!@R'XD V.C40 /M0UN)O@U'OE7:'F):"'.
MC?0QBLE"23M$PXG#3OS3<.,ZB9 +W/?)=:F7Y* RZV+T:VT%-/SDN,JSY=I&
M%%#<$E[Y"/=TUT"E_Q]'(MZ&P<KUL-W]6V@3%ES[1IY"]E,,T*(JI&'5A>4M
MX'./763"*NBF^3WE%B6";C#YL;$\(QG&3"[HA; E!Q@!Q5AV8+/"$ ,#K_'8
M:Q:UI_L;Q67A9D7V.'$SGI5@NRS<6=R^Q+;2\2$'NTGWF&X1W-N%12P]=[W'
MIS'['J37=E>>#):QN"]0@:Z91=D9)U@TN\+(")R0I",-AA\0[,7PX4=Q%!/X
M _Y?E-SK*2"M*P/D;4X(<)%G8,0;OH8?P'[2@#V+PD<X=A@KQ4?A3V@86XG.
M8D>YW_[F WDFMKNA_]XRUKO?[C_<_HPO$_THDGT:"<=P/,AU *?H$\'X?P@/
MLI%B:T*"6(;B*9X[%47X*LCV!-YOS6/_/ @+W+L5J>W[KPP3I8/PQ!&-LX(B
M<S@2'/ #RD^2;,"'C&JW/M[^<'/WV3RQ4GB<3U?X2@)&[7B=798.H,P4L<>6
M,?">V_%E=']Q^_#C>/F)Y 8^AMY^)Z]%$\')RY9L+7I#<@41FQJ;C>?^L)"U
M[=>J,].FY<.>S,%$,3\:'JI6_V'YB3'%]W#N6Z9E>!8Y(;$VI9WH66E;FG%,
MO(1"^%LH1L ^HX%KS)G$C(V[BQD47*OGVC8[#BD;+UQOXT:7&6*.I0H 4VQ>
M0!-Y- ,6W2!^?)2G0H3&I87.MXV@*$Q'T S9 AZ&1P_-Q_*]0F;'G*"'3&@H
MMF7,X>@)Z/TCM$7?=Q<6Y>$7*Z )-I^D$*&GW"_QWB8!M;;&\XN],+P:.Q]<
M+SIM_!!4RL$J#)KQ4VS7 :E+6PM]?6Y@)+7S]MR.[HLO#'+.TD9L-2"6- %$
MPY6)A!6>C!_X:^\<B<8:DY\'J>:=!.B6;JX3$P@.?SC?DRQB,>VRH:RUH!FI
M/:-2FOG<S)^FF_GXFBBUUKB_G ['>E]=+/2!KD\-35N.M.ETHBW,_E@?_(^.
MQ0IOZASDSP FYY+?.N;']<9V7TF$B_75-H1IP'%?D 8<]P_3@+E/C>D;I-^F
MT]YPI!;-OJF3WD 7?U4X^];V6VG]WGAR_%;"<)0Z/!*>T37#5$]/S@CT"8_[
MY=<G6JX\W;2G1/*D<(%2J$31X^![ "*%IP3Q?#K!:/R+\A'\ON#U,*F776J8
M3S-IT_&XDQ%$X'(L$F^MBM@"W[X3E#>]CPA*2TS^#WB(PSF(R'348L!%4OHW
MQK!UP0'QE&<P+;$TQ>0+6B07M*$,A783M2^0LRP\.9DU@;5NG 6YHP.^^1/6
M2J7>#,T%-$ &??7=7S]C00T/1;!OWR6^0V+^#'< 4>/U'1AG0&<3#">TON)G
M1[&=W40NM=)V'#@X(W>B'UL) E-SY2H; X7:VC C2ME[%VJ=Q0L"8VB#!EJJ
M)P#F^1RGC>T[ SN]K/=?/NV?F9RQDGR%3__- .\C7-_2$L/DE_Y7XD7+@'\N
MDI/F0::V@J>"SCBL2_V)FX261TN7HM,:[#LP93'DT$V:H_=L\VWEV_]K[]I_
M&T>2\[]"*-E@%[!UXDN/V4" Y[7QX6;LC&=WD9\"FFI9O*5(A:3L\?WUJ>IN
M/B0U15*D+%)J(-GS2"3%[JY75W_U%>RS07^5!Q(\.[ [=QV("^.0G^\2,>YD
M_TIR2&$<@.)J]V'!9CQKPZ[E7V8F/0F+B<M? ?8_\&:6 G[:1O$!,0PH> Y'
MCBL,#\F*74BW&NRNMUHLOA[!%_Q5$-Z-[]F;WLWIE^*E E-HYBS5QM#>6 9+
M#$L\'KTWW2WDH<,AX#XQ%[HA?&!+:-Y@R7]G>]")U&2UDP(K*V[,"^K*<Z;A
M@Q]&WY)-DVC?/3)H@X5=?H5#4>!& >M0R3>MF#X88>,:55#^KAP,^$;.^%.,
M9(@!4Q[;;CP:FA] 8Y0%M2HLUR]&7;,$7:9F(8L0[RMW<8(DD5W\"79@L,??
M6APBG 7GUGZW4KORLH$>$K<5!WJ:.-"K<HBDGCS02X)L&E(K]^O 7E@A84;G
M9XRMM<&OGQ[N[^F?ZJ^_="/^2UVO-E!-9?\HT\M@G+]<*:"Q'L_P)ID]Q 5<
MI?8\#<[0>Z_BYX4+$&[JZ%GR< F"# /&W[00Q[YTKGD5!8TSG\%*)&<:["#&
ML2%.>\64(Z@0!ZPG2?-8J>XPM,4/V*$+Q #WN_?@BZ&:D1\V@7LJ>]$")_J
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M3:)G.YROU(E8JRD!UYJ5L$?/> =%\LHF;OO)M+)CN5HS;LUMM8N5.!/%X>!
M1!;47]MT:6:.2_ML>R2*6U:#MK&;.R)N"6$YCRG6-%.=[0B^0>V6&IGX2'TS
MB*MLN0N.*QJUW*;X0+F,Y<;%K^AJ"T9V#%<[A &.QWN<TQ5VB@+;C?(,?SDA
M[;$.KB1+SGSKS5V6L?P6=YI2;FQ*I,?VOHSS+G51L<BGSFKO5-V3@*YDP91I
M>V4AEH(;]A+87"]][FZN64,P@3KNJ[OUI%?*,]BZ%;55&'QXY E"+QJ99]D
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M F)'?&Q^\&1YSK\X4:TW2ZZ;.6$4.(]K]D5*J\]I;Y%'\R6]R \H\6GRRZO
MGZWM**S*JK9)%XDDIG11\OC3=!%_FEZ+/TW WIAP@1W,:7<@;Q@=B20(.Q-"
M)_E.\IW>G" L_C+Q$:SMPV8,'?@OV_&P)!#;2R!6/*UGQ>LDV<(D6UCS4R79
MPLZ+;$8R\TB.)RE)4I+:-#E2DB1;6 E7_3%-9$FNL*:&W,8,>K5B JT%QW=#
MQ& .)F:_Y078LI;_+>H3Q.W7JYR[C7K3<<,GP>=3RR^Y7Z2_J.$O]!;XBS&%
M>XP&32,:I;]HLSCF^0N]MK^82'\A_87T%T?Q%\;I_84Q0'\QT S)12S]Q99$
M'N(O#!7\1<M%J4.5T9WA"OM(4662)&Q'H\PW(:0PM-[4U(;]41N8!R0A17,&
MV:QMD/7>5*T=P'>;D$)*8Q.6[!CUF@)+9O2FL.N4=(==E9T\2U:[*M(PI263
MTMB$)3M&69[ D@W!DL'&NG9G%FG)VF7):A>_&2.P9*T(U3NT%98D8;+ 7!:8
MMXXDS!A+DC!97]ZPCZU-$H:%R[*\O"-GF]+!20?78I(P<R!)PJ2':]C#U4^'
MF:IT<=+%21?71C'K&DF8J4F2,.GBFG9QM?.DIBY=7!-IUJ.2A.FJ7H8DK%ML
M8+\1_RFP5@O'5FX]9DQA/.5HFU039+B]#&$B+JQ50$)*[H7D7:[O/5V[SC.9
M*5:(+%E7R@M,Q +5.W1"O&J.#%\K$/57RG%%_F_MK) =[$KQ"/P'/\.O85[@
M)UQBA42AZG'MSZ_7\ _V7.3;>DHG.B!/,(WO#N-98R+SME178)KZL$)5N:Y&
M>G\R$']5E0=(A2]THS%RH@9?JA0[T4'%Z9.=RUI<4EU$)"3I3CI;+7]T7J2S
MFBKM&(>_I=6"NI*W<[&_0V ,WO,ALB(2;OJSVM#W2T@+7,"N7]?&^[?]7WW/
M7@<!:/ -#9:$VW:C-S4-HWX;PJK3?Z(]N52:2U>:@I;KI90&=J+#\; ;2O/6
M!4-O["B_6+ /"QU+[",O"VTHDG>]H#%W*7D?@I-0S7XKFI)*&&I#@E& _"HE
M&*/>5#>&]7%;#0G&F6\*[J(%"6!@:R\*G+QM0953AS.5[ +2K5*2/>Y-5<VL
M7T.T!W/<XN.H,Q6, G:=4H)!88%Z_9*,A@3C!.'=5H;Q&J_'E"T"Z$\ C=\Y
M;*B8+N$3(F$6QYZ6KMN/(K*57?-1$4,QQ+[$5^K8J(^A:'SU3A2G2ZV56EM3
M:POH,^IKK4JU5F^ 7[456EL#[\$'QM?*T/HC/ 5?^:&#U[P+B L7/Y/T\/NG
MS8B"CWB0WF(]PN#64?XMHG95;R>(GZ\-?2O<R/RW @1F-$P0,(L@#;">R/5C
M0*R_KJTY#.V=Y;Y8KR$N4A;4X'C76S.^/5EL2J:4G%OTNJ4ZK(5!].[!7I#9
MVB5W\S\LEZW\C3?[[S4LP/P5$80VW9V&'YW0=OUP'8AZK@VU[>9J HP&RK9V
M D3&9-(W5+,J($,=-P?(D(\2;VI4<T\(P6%=32=RN$$N;S:TDIB.'Q_\Y95R
MZ]E]P6[EW(?_\.&_/GW\_1^?E-O;>/3'^'&QR5;^X]_&FJK^JASSI\7C_N/F
M'[_??+^]^ZK<?/VH_/?O-_^X_?P_MU]_4VX^?+C[_>OWAS;(0J/341$SF0\
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MFGJIFGHTO-9H= 2\5KLJK]/2W,NMLC;RJZS_]NC/7N%_%M'2G?X_4$L#!!0
M   ( -")2%@FJF3V,QH  *DJ 0 1    9'AC;2TR,#(S,3(S,2YX<V3M/5MW
MX[;1[_D5_/SR)>=4ZWO6WI--CRS;6;5:2Y7LI'G*H4A(0I<B59"TK?[ZS@"\
M2;P H"2;J=33=BT)<P%F ,P,!H.?_OHZ=XQGPGSJN9^/3C^<'!G$M3R;NM//
M1T^/]ZVKH[_^_-UW/_U?J_7/FV'/N/6L<$[<P.@P8@;$-EYH,#."&3%^\]@W
M^FP: \<,)AZ;MUH_<[".MU@R.IT%QMG)V47<+/Z5?3(O)^/+B7W1(I?G%ZV+
MC]9UZVI\^F/K>FQ:5]?D].KD1_,OTT_GYQ<_VE>G5NO\_.RJ=7%]<=&Z.KO\
MV+*NS8G]\>S"LDZO.-)7_Y-OS<C<-*!KKO_IU?]\- N"Q:?CXY>7EP\OYQ\\
M-CT^.SDY/?[GU]Z(-SV*VCK4_;;2^G7,G+C]^3'^/#9]$C>W7ZWY2G.;O%K>
M_ /\#P#.SD_AOW%;Q$0K<%/7#TS72G$'K!4L%\0_+0:"WX_Q=R1TTCHY;9V=
MYD#ED&>MD_/6*I-VD(!E.;P\%C\>&680,#H. W(/4KXE$S-T "1T_QV:#IU0
M8H,*.0259*5!YN? 9%,2/)ASXB],BTB'\.?O# /E2N<+CP6&FP.<F/Z8,^JS
M@(,=&4('>IYE!ERUL:4?]RG7_I@X@8^?6OCIPZMO'QVK4PW]UM0T%UJ4LS""
M>O2-#@<9A3Z]OKX^?D4-+>:@4.EX^Q;^V3H] SW0(%NFO>JTX5,KAML&#^GL
MU.,AAMN0A\()6:8+,DC^V=^4C61V:[,106JQ4;Q:*,HB!D A7.H0](GU8>H]
M'UM>Z 9LJ3('BT#B#SJS;P693:@.[;@Y_E&;)K%L'9IQ<_RC-DT_6# =HDE[
M_E<!6=-UO8!CP&^B[Q8+ZDX\\05\A5/T4SQ/AV02;U>Y_;I@,>3_?#*9Q3Q'
MLG(>+YBW("R@Q,_N]1S!C)')YR/<\5OQOO3'@I$/P$G<)$=@=;'!GX$"\6%G
MY/WMI1V*4>!\^WSD@R@<(H:HR?VWR42W_P!"7?H_T7O''.OV'D"(\Z?ON&4Z
MNAT'$"MTZF@]@C_"[P:U/Q]U/'!5!N84V,/OGX;=,MN14TV;QSACK*D:_GS"
M_W-JM%+?IF5P2 -!?SI>!UA#%?K$[KL_\[_79W<$'#6I %P;'V6XU>E4"!9]
M&8]CQ>BV0YL&71>=-\Z)VB#GH*1C?;8ZUAR!D<&P1T/>\5S?<ZB-KO2-Z: I
M/)H1$OBJ"EX&+A7".8S\"(:-)!J?HC(B7(9 =I!'X ],!KV:D8 "GQL*9Q67
M5%(7ZI(ROE_!_<.>2BX9+=^;]&%GXZS5F%(E>*02NZR26(K4\"9&BO8@JTG'
MFT/'9L3UZ3/INB 3Y8U>':%4>C^J2V\%OR$('.0X&06>]6WF.39A_MV_0QHL
M-Q-C 3ZI%#^J2S&+_O\-0> @Q4G']&?WCO>RX<*9HI'*[$ICY@%6@Z/=(TGU
MV=1TZ7\X%Z9KC^C4I1/8Z-V@;?'X%76G Q@P"SPY-:%I893*[QH->^I;CN>'
MC,"'+'H#\!L9 D9*P8A)[)$L;\DS<;P%*C0,3!],-M:>,B(T7$UXU2ADTCH]
M69=6!A\7%L=HI"CW2#KW)F6_FDY(OA(31T=#*L6@4FF<KDL#\1@<D9'%M$="
MR#I-MR0PJ>/'>GY/8;FRJ.EHARMTD4H%=[8NN!67S(AH9"940F9/8QZW9!RH
M+G#04BJ \_PZ-@[V:#Q[L#J01(G!)9G30&.]*@>7COS%^L@+7!E=SZ#;(XF
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MG-M _>>:K9=U9NMELV9KSJ*/:P_4\P<*H=][:RZPU\!:7;79BB[K\I3YR:J
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M<I>&IL.!,N \Y[*]\PJO9B24J<6I?MV,2Z6?I.@]_ZP"I7/P69!KI_GKY>\
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MWQ7#7;?U,*+#;[19XQ)7ZXL!YEBB4-E#CLKWXR<"4B.#'7QRPEHK"W*GEVY
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MTXY;\.<_[U\R:<+_^+?_'U!+ P04    " #0B4A8?[1*LX=W  "W5@4 %0
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MG*U/M@M@LLCD54AD @5%AYK)$$,J8%FP:) $45I?F6P$<PSZ;R/INQ10NU*
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M7\)I_151+IC@R%OG(3A03E@(Q:JJ)QUX4MJG6Q[0AMN0K2&,I_>]AI#&4=$
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M#CM2'58[H*,6< TDWQTKOZZ=F!73?-V'8[+XQ]5+8KQD%D,$@795Z)G D[C
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M24-OCT7ZUG,CI-(R#A">V -=^ALC([*ECQ8&8,E%B'YUZ_0;7A:)VFP+ABR
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M7<XFI (N5O_;:0->F0R2CA"KH@VI>0?9PV?JEI..#H>H/91Z()..F!%!LFB
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M#9[7RG5&WE#2(# PFU$$SKN5YCR5))A>JNC1W;R''%M?@MV/3%\@,])A8C$
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M>6;L9+(S8Y=L)Y4G%BX-B1N9])*4,\ZGW\8A=1>E0Q*'I"17)1Y9DHE&]P]
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M<YC-OI?I[#]AEN<[I)"U6';GY++F>V^4=K9^U6L0<S+\A1((,:5$(.8>',H
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M\7PQ&\>+!9EL859G5\S?EU4^T,>+.!_G<9B-<3ZR@4<RXUP=G$*4JJJ49^W
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MB84./MUR(R%,!^+@,0V-N:J7N>&8/1G/__UNAK6, &<X7YR$!8[H'%C&:^V
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M $$ L+#R=-/04=(%,$5548'%$],(^+MR,@Z +NM1/I5'+"S GROD5FX>7@
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MWP. ^#'&-G'_?<XR#0!J0P& =O*_S[&]!0!2S+C5#/V-/M<NYXN]EY>;I("
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MCA=\TRF\'IG.=^?\0_I.@\#8];]Q@)6W^!B)-OO&>.[>3%;'T9<HGV\]PJ%
MN>'W>L(KV.(,UL^R%RL+9>\OGW.@=AXXC>E:KIY$&?O,]IC ?3&1L@TSL#N8
MJ1&R<!DJE]" L\Z.0#WD0!DS0"6Z<BD0+P@<0T;#AC" #HDP1P-S=9"S"^8I
M*H0ZS!P9!_E_;?Y?F_\;VPB7_@*BA)MDGQ),55UW,$"4(M6$ @-$PP>%1,OG
MH^:729;2M1U/:Q,UCS08D\YB241\.9DYZ3"/9-<V#]]LP&_/HND@H7AL/CG
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MWH7'NIM*[U<C-60+/S2Z1AXK/?LCZSS4,-C2Y^C5M''Q)>W![7M%15$IEG[
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MH3>KEJ?BAQS=4=-:Q?/<N[^4]_B&_1%X2RI[5H()6:AB-&!& SEGWTJE1DI
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MB+:%VAWW#WZI-BV?H$_JI0SZ>YQ\K:KL?&<C>0T7OMQ7['N@$<S/+!)UE-.
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MIHO7O]SN8)>**1)K=QO/*6=?IY=$^$HU[8JUBBU75R'FT598A'T]$=T_L[0
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MFT-.I,X4;YKHI&_U5RK+CTKVJ/Y5+3E0/3KB<ZRJ]THSOY/9Z"LCH[OP#GV
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MZ8JT%8Z[DF UMQ0?O+;[9XW._S:<0HK>MB;4H-E7OH=,Y3CN1"K>7/YF'7>
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M\RZDBFPHXPFREM\D.\UXXES>D17AJ-7Z.1FPE0&N54YV,5$;R"TP&E+]2]<
M!_;!T#D)!X2)(/L/)MU)OUCY=)$N-.*J/,E;=;%0DY8M3O+C\HW]SR*YK8\.
M8N:U/-QL-#3.D >YHHOCAP)0^?G$OB*@MBS3B ?'"V>1'AVE;)[)MUBL=/4L
MSY.#S;:BK@! &C/S?:^,4R*)9W06R9;0$I_R&_M^V"O NXD<W.G7?O$;_=II
MU\9Q/:O"[^Q29OW;#H;6V7%-;UI/24:Q5KLY82<G0MX Z98>RH.E4S\;30Q'
M%@G7P6/M3#SJCV^T2LOWH82C<XBDWI42S]Z5W?1^';X0EU"7YOIQW^M/>CIF
MT5>5Z]3]#I\$3"Q%@*38;K!/ PAX?>FTE%[)+;T-^42_6>FQ8V!344C; "8V
ME% (MH06_Z% P(\NO2.E_]1TG_A!^0I3V1BW<\/PDFET$\JN>IA/NJYYX:'U
M]*38NR&U$./AH44"1[2=B57SX?Q6>\Q6' ;74KD5C7;=NKH;=90@!UU&9)N+
M#5S6.^-1TW_V#BOWS4 A-E9C[37 Q-/^TK)!\*,WBE]M^NOF)\+(D"UXFFV>
MO*Z0%O+R4/X@3R19W04_0)@JJ5C8-=7]8XR4!94;5J[D9VP^$>1?=(F_OMY6
MTWOBL"LGEHD9GZC5"F^Q#PC(:4TQC0^>=+^Y&_6:2UD(S819N3Z6<K8F\E9^
MG98>+GBU:40+(0P63"]-RXYX?=24MW1>Z"/#-#::3V4L7IK5&WF3.(_#X.8]
M0S[.]\A_^MM\_R>;[_.TJQQCJD_1)[L0"V'G_*1L/NHD6O<>@9P3TIOB_-CV
M67D@24+5 1PW=H$H76=MNCCK!:1="?3B>*1E>[M.54N5"+Y+RC#K=GB9Z?!T
MM[6XBS$*.0ZSG''0D8U)RBFXHF$C<>/2$.820,+XV!GE1U]'G;5[3)C=WH^3
M$"ON%!?@_5%/);F3]!L^^?FMD>DI4 @PXI?3L&6%<6'=_164$VCS29V)=^IT
MS0,%$9W&"@<[WA8WPR_=:Q1!<C<U6MJK1ZGT>BV#RZ>]X5HX';?>WMR$_*[%
M<WD4ZI+(OYC@];RP5;J[^S$,_LCQM>Q_$3&8^CE\@5CA6?#&J,4V($$=<[U\
M&W (.!HR$3)HOSRBL0U V&X#VM2&M=5FON$._'L99D((SHO\/FG+FFN6\/QR
MM'Y0V61T[UOLC,S;NJE;-=*-+R67'GC%T@-[/+*W8,);I[N;W,BF*G&R;!/Q
MN?T;=E[=44YKNH/ CE_I"V>\TQ?NR#_[PM6(C8>PZU"Y<!B%<C>4CS&1RH6=
M:TY-V#@\]RX%G'C\Z7/%J<Y$1=FV?L+7B:JQ49_GL8-AQ/Z%XFW Z-"+<40E
M\/2@IU+'QPZ;=SG<1]A-D'L3Z-Z\NL5XZ?T&P,:Z67'J,73_$8.N\'"\FU#-
M6,&"<983^V3G#,)#*.#C4/0R2LI_6NKGXB_7/A)2QH8(B-*+<91Q%*1;\ZZ3
M\_R44_8ZT!B;E7J@-.PE)7(_W2I3KM;RNB$L:GJ=555#T!-U#>@.3E@C(;V.
MD8U_JP:A[[]J$'[XS1J$?\0>@S&Y9_+.E(S%W39__L,#'YY+@"7O$R=ECY49
M\WI$E'&R>Z^XXM<ZPPT6-WDP-U;O+*6EOXP!-UE[5)W'5)GO=B[KQ[L^H502
M.*@*<7T; )6-<1WM#:%J!+D_AZH1+&7-"Q/6TS/VYH;J4<910\L$#I=R1XAT
M,U%!<7C,A6H?@,?6==&?R8*_GZO_T_X%DC]N@!?!S(:+44W!POP\%4OW^X]"
M%"9\*WTWSU>SHQ47NBM,U:?2-DH^8WX@#$]!)2N9I5?%NF;MDS,6S=,1Z$V#
MY8X5F36FN-W<]AY@;XM*S*V5S#CV^;P^R=<'GF-5!!I81T+K9?)E D>>7J-=
MPFX5M 41)3?SNT=:^NQE;.)/[<-!)B]("Y<E]@NTROT\S_)_</'8#NB7[8 ^
M>9@2[$[:9"8IP_S!,4#&1EB(!@4-V@;<-J/53XG=;;7?;P.RSJ1>SB?$I4L\
M"E9Q.V(KY::EX!!K/''S.=UKB14:/J!:N'(>;^ME"G$;$ 94&N4/JDYRYSL1
M%:,.VK$]@\SK+X9_"B/_DBCY]QR%^1X>PS#B"S6%R>[F$?TN'V3]A\S$UK]B
M]+%\$3D0./&PD KO^X#KCLQ+$]N 2M@H+!:4/0H>;Z"48,C\#+,97FZ$7R9Q
MJ79(D])%X,"!7DW$0)?S^BLD1()BKCVWL7>!I0W&R^-$JD%54U\F4Z&SP/9U
M(/>8KGS+X4&*5+4AW(RZLYA&?%BQP^1N'OX"O*>B$M-+R!N*;SJ5W%G@-&"[
MR',0FV9/@^<)??LP]MSHTPPXC"_5HF 3[+\->-J+(PF PY(^I)2PX8>$3;#A
MD/9:\CE$!A#T$WT*PEC+J;/D>ES1>G*7=_IMP/-ZA6/IL>.T]/=9>(ZAGEZ5
M6A%[Q4M75 A> I%:5V6UU?C50K2O)$\DM%,M7^@W^ZQ1UV&S>_;%^K?"Z<?&
M,2_=(14!6D4=ICK572+5>T7KM0&?;]T2M*]G6LF\(<8_^4+.\Z9Y>AVI"'/C
M.6MPBD_(Y<%<9P-PF(&+8=R3D!KPF:UR"(>EBTSLN-7 +1UAAL> $Y=K-1DL
M?S#H^2&K 'O7D_G_ZLOO/_X[^O)_3[#^W]'<+Q>?7%5ZL.518!%E?S4DKI6$
M8.6ST6MX+0K!WX=4+QPL+.,J^C1FIC3J3-(>6"HZ$WSL4KH/A3T:<_?4;$:T
M)0%B]?8,[^K=S4"A4_/WXE5>Q0#%\FWWG^A+3. 4O*5 HRT+$."/,%$;4EV8
M1KR,Y])OMP&AH"[9"WF]YKN-3-P$/0/2V:"%#&RLO\Y^_7*LF8%G YO00G]=
M)+R^.DELSVUN@H[@L4KY5CU,JQL%#/]J(GTG"[M(1YZ%!K1@!]=!&^%7OU[T
M%+9BCGBC<K!8(%^J^_UI$%^8<ITI3XZ(H#)/--'2L5/<)$%IX;AYM<]]SL]A
MK<+SRUXNIB7F3W8GFS1;:F,'+4%'#?7!=XXK.UP.E[IWW2\TX/7[,+OP:F6I
M):LU]_!I&U Z9+F# OL=R7,TD.KWXP-@_7!*-^)C';2;3(4@),>'E1 2U:4I
M@!'=-DN\1 @L?Y -4]\3/%;B0#GJ=7UN&V 6A8MY9=H;U^]9(XQTIK>+-:.5
MLQ58\\_!A=DO]1,'6TJSQ$MR)Z_H1:M'( >1DP.[ME#]KCSJ/^W3JYTLZ,-.
MV#QE>1N@) ?U\*?P8*J$F^"^IL":'>'FVP8DBWEG:C3OMEII&*,F]=/ RB#V
MH+PEP<G@L\]<I,PGN9]>Q7,[UY6.L]8!B _NA*4B='+1Z]L 'B^7_1WW$&:X
M#SPE$%:HFMG<1:]0PD^YPG>6XG^'O_^_GT*G0NQ>[2FSM5\69O['-(?XARV8
M:EE,26XZD67FV/#2. ?;FBWMFNQL%SCQ\/8+'H"+K3(#!V^L0FI*:_6P VPJ
MI%$J,T;32"CX!*A)>>>@)/>XY0K3R]UV4W/K=(;R^ZVH.]&<R=%S4K<>WNJ7
MQNJO*)W5CUA@HWLFRF3#Z!G!U>V()@,UNNOYBW3\K6$RNKBHHFT PP>B.!@*
M'?JKG+'SM)MHS!W@AU]&C3ZD6>83>"[:.0G:7G\[R!/\*2 ,T" ",'Y-#^+Q
M[NBHO\VXV.OBSMJ1>LHJ^BY/47[8(DI6N&HX=].O^%RUB&UW&/T]]<Z;3_>@
MD/OVZ;P]1-.W4!8LL=+OV5<8(>,%H9R&G3XYYDGA>WEI_?+4E$L?(UG8(S^!
M MJ0?[(:L@CW\BB2XVJ[XBC_^)6I_).WLHISSRVY@W72W1K"&#A/#RD\&0.-
M: UKIV.QX%=K+)G\L;G)S*<WHHI)<;G*>'D3 BE@#'Q\V+5\-#-OWT3!NYRU
M*V: +.LT&:X]E3[WF!U*]Q3+_,- ;/5MO1KC;9*8("*G/80:#")?[@I*WQL'
M__'R[U9(]W-1&)3?2Z(:^T*G0N2-E.NE("GV\.[Z %G6O=4@@5.O&_>=#YE]
M^ 5TF*A@LPU0F,9#8=?>3(K6-.0>VTPF" ,;7%J!77=IK^Y,Y=324A.46,GL
M&3=\ZB0;K\S'^S:LL3*+)\QJ,;7]?F?D*XXO:HFGCMQ[EJVR,^]O8S!ZX\.7
M;V+Y-TMCJ'#RG%+IKM^J-^=RI\!/^>*X8NWDV /6:K%0;W[VUS2#93SL7HIW
M3[R!*[81$11S,H=/:MZIL)D!=:B%,H9\@<-1NXT#^@=#P.Q,57>UB<>N=632
MH6\DQU+T8W#,KS\<67SRC+WPWEMIP:OLH?H%J?;757&;AB@K:^"QYD9+#QFQ
MB$7SV\VXKJ:+'D-=:\!CZ=^$K.]V]7ZL91%T9_)W.O]84//CL:.5QXH<'\3:
M,M#$^BZ=!(39@\K&1^NTE%TP0^%D4)58T>U(+@N8^,8R3](VX.0W:UD\A!?P
M&4KOMU+N1M^KTC7:RTAS)471EXG'EK7,9M3^*A^ P+(/JQG@M;B9#DU!AFG>
MSSH,P6>DN/$Q;Y6 >M*(%;B?5D]_7RWW[RN*0E.)U\]7^%\3<V8$D XC&ENF
M=^U0_!]QQ/\?INL[>H&96^@F]?%6:FLM9IOS*',_H<UK?7ZAC([]\*&]G)MT
MFM6J!\6+7,#<MYU.2U]04CH1#;48M($N=\_RK1_^2_P9ZML/$<B7*'X_^97H
MJG UA,E5Q1;5<;&SZP:;8M!4;:;8Z];*T]TLG)$ 6FS8/L!J1[5&2G$D;HDR
MZ>RFN:9[7/Y"C9)I^)3+FAI*SYEJL("+Z6;'7=L63,.N(];TLZL_]; =ZNF[
MP=FL(C33#* IK,>+BT7@-/"S>,-M@#=V*UC 'XQZ;M,REJV\WBH-;M&<\\2/
M@?L2*REG!U)EG4-S35@OCN^/G18\ Q)5\&3?$XRRW5MA#.?_:*;N99VB0'&!
MO5J+V HXHFV:$)V7D+&&0H%:$1=!M)WB>D$VI@5%D<I3GC9A2F;.I0"3MV&V
M %J^IX 9@:8WL8/]J*4->>=DY?N>;=;(SOQAZ][=>NW]5US[P^A=)LJ1(/FN
M"M@[G)7KA^$@5''N/I2-JEC@.-]I4:MU]WLX.[6%,&)$R/"7#J] [OW#D2)!
MN%[>Z9[A#-6GOV9JN,%4PJ1F=3%B046\N"'_5O^'TTK<KZ^5:=&)?CFPE_-4
M<[*XVH.Y=T&6(HB3^](_YH$(1/C=5KSD*FHDJ+O\2D9#D;6,*=>^VHDSZ/L%
M([?H;5T?'#]Q;Z\CZ%7U2/SIS8!>2DC+&@G#T93][B'OT$%B-ID#/ETT%^7;
M'>VY]:L(S] *_X%*93R6_?6$SP%-V^EB=&]0LN^)%5S=RSD2Y-O/F!2[C_4T
M0_KSALF7G;-LRYT$&'S::#;[<[!KOS+Q"YH,]K# HEK=>A,WQ'Z+%<K\@Q7.
MW_^=K/ WS6$,M)H#*TR%@&X2G'".D7@ O@4A@;"O""F,VX ]X(W5;<#LI5W:
M*/WV!1^.0W8#LSU%>*Y(>F6.L3C$/NF[0\QZCB)K#=AMYL1?\O3L\LQ='$PF
M4%[4KUZ$F+VP'&9/Y #E4>&A?^J;Y9S?!>7_+4U8,5P\E2:@[E%]8!CYG#^:
M390BB 83;@/9QI@VWU%1 4ZX":)%7,+O%F/]VI:GG*OR,C.CW_CKK3#%'@:K
M1'J-9WNE.-D/7UO:FQX8>\K*<0FM^&9.QEX]./CB95)[T0!Y&-$&FN'\VZ+]
M_]FB[9;Z^SZB3R4:"J2+1)/9USVET6].!KEFI36N)@D&SY?9$6M746S^OC3*
M_*( HPW''-=/F<;+UD^B\(GKQ<#C[?=N)\!%;R^>SQWV&D?C\F-V)D3V4G8F
M1%IM XB;3-L C@Q8_@5<U  &SYU"MOQ RB$F;@/J7I D8#L3(ONV 10RE</4
MS%!Z4OK ]MN B>?_,W_UEM"]F)Y<QB(A(:FA7&!B:CYZKT#Z;.A'GFE:FZ^7
ME =$GL>NO47X2LZ;X/6K$<SM*@,^,9B^7,T2C:C)-5E(%4>^?&$:_M6C@R6Q
MUDBCATVB1C^@S2JMP_9."1T?7SZX4:8M&8L^'C6V#3@-I*VHM%.P&+RF**#B
ME7JQJ 2(-2C>D/=<=:D,,JIYHIKL=GGN@5[#Q9?/^1</9 EQ:P0&ICVSK\16
MPODSN9R@YX:C0"BC:1$I0@%B3+D$8C7KF)&=#>:Q8VZV_;8!H?>+2M:W<KA8
M\ED=)#;]Q"[Q2CX-'^/[\*?[I-@!H&O:+(4H7I=>2PO5V#1YG8_],^$0="WY
M$!D.,XU<20I(FP]-+59L*D%K=AUE.EJHKIFTS$+WV8@I_)PL(K749*AE*)Y\
M K>VL=C?#6G+UG_1 [1XX%%'S&I-GEIT'+;I7T;VB:\S#/Q6V.Y/5G![;F%6
M\N='M9)P;>E>D8K.N6_CRF]YCPON"1&YMD>AM,*>OEH1XE,U&G]&R\,1"IX>
M(.F)-21[?QJCG!@6&)I?TLU,7S?'IHW)_HIS\&,N&&Z\%<XU=^I9KKN^=>FD
M[N2;D80S"9=<PZXU.YPZ38P6-J-YBJ.LHSE:* PN6$/P@[ )! M^.ODRF1UN
M,CE(BD1:;1QM:[NRMXU%S2A8G/'E>_ZT3Z6:M$\!(S2E[-J]O-9'")6/$S[G
M*C_@3<AZ_&Y77/G-] \5M3\.4Z$G8!.XL3/3[=4S= 4?A:IYQT@)T-1R3&D4
MV1-&N,/TBY*$WW&15R13S<<$.'\;@-BB N"=C=%IC@KP&/A-2- 88D2)@A8F
MGS.;NNOIAM^UTO?/UZK\$XBX@1;+>+8\)J++-J#-/'TT1WBL87+'!JVB.;<!
M;G!R(?6'F]_*AU)O8 ,]95 '^S";L].!7*=?#'6TL;'U@F E5EDVS(TOFGSL
MP/)>)"F+^DKH/:KW'PYEM#^WGENN#^XK.K3RK[=O?U<)_?DJH>]QA'9-T'T'
MZ?N=E]_;KK(+?!!C[ 6J1 F)FQ)_R.H;,J35EXE+88,N/%"O$%))S#QU5&"@
M8E(]/F=3VZ9$?CD^/0O'<NA4JFY;^I)2/M9#+E\7[*4QQ#<#?$[ZX:,K_3'Z
M=]:GBR2'^/>YE#V6K*U$C3M8#]282[&P:W>H?SC%WZI%02U!0WS+VLO3-?Q#
MIC8'44ATE/NO%/K^)%@5$BS+9+1ZM%IE_]9F)2G]T!E)5BK8/\^K5F7B?*;Y
MG%LT5D MR!S; )G7"#CIXR=TZ)@V:!E4M$:5+7>.4#BS//.P)Q]: GG#$Q2)
M+%#SB6"PZ[8*?#JCS']K,C2T?S1+Y\&C23.DTC!A+J1ZC;W(E17;<)_"ZFA%
M(F;&1T(:K0*QOPPM_T._$JDFSZQ7GJ>VR.]]QIDH-EMIK4(3J?,O/@6>X7GM
M$%O] CH5T%OZ4 Y3(OR"^C[>@Z2HJ"[C0H%J>;?9NT EOEXW%QAO1A_Y9FYN
M</EEO^,ZXT'7$\XSIJ5=8KXZ I "V#(PXY3U;D*S=I^,^$>1/A.6PT3REX&1
MBV&S=_(VI2$KB=2W:GM'%*;Z5J@;E&'J#Q,>D^YF7W_'OOSDJ;7#^3!2 &Z8
M:D,X**_BBV7'MZQ(*MC0U6)-TEZJ"E=1<;:15(<( 0KL#K3?'YMFF 0O0CYL
M XRWXI612T2#8C$CEMY<%HEI/A="1N_XLA&[,<G0ZI!NU%(X&7@#*\^;N+!Z
M<'@\T&06!\/UDUK>"=3(W]]5K_Y<+N_O<Y__8><^OY_W>,RO5Q!^TM/SKQA*
M_6L7CKND*^2(O!;6,;TR<MP3A[4[28W0%?S#^B\5YQD:14B?3[L$"_143(:G
MIV]JQY/=87$A::4KBT\4LS>YR9/+3D09N6X]\Z5,Z'.2Y)9"$NGBBX8O :)Q
M_4O&C.T%CP^UC6KOE<@\<AU1S_)L\BU9D6/? 9E-K9*AZ9FM ]GQ^W3W&T#X
MS/B@4=GM"@GMF83X7_;+_8_#==HY8.\FSBM\[$[ )TO&UED[)&V$5:3&LY?N
M+\O&E!FD&\U=ELQ+8NEI^XEM6S#@UNGA.C<O4Y6P8J/I^#?MZ_9>45$N6-U!
M1(>*RJT%[EN/%(*E.OBYGJ:E)=+</P2@?<H L ,;1^0JS1_Q]\]NY36.]/_V
M?-__%LQO-INCPMX\?(&*C5S!<*J0<1 T+GHUZY'.DZB"_A':0/U@Z2M5AJD_
M%9[!&[Y;_V;&Y1L/QDHN4N_+14:2837;@ 0S!)/4SF'@HZ0D3P@S; ]P8Q4V
M*P84M1IOJ=\U-_<75/D>I\%'$,VHQJ',F@H85'6>F9V?$ L9$UY!-"M->FJ2
M7*GV)6\;D'P'?Z*8>_R7,9[O>(U_3;G>OZ[0XC^_K>'WVL'=B@F^DPO\YN4,
M?J4?9]\MS[40TT#DC;$&FL<R#Z18-*J1\:(9A6R3K[XH11]T=_5$.^7UNL N
M1AF095L22HTULYR=)P.(ZNUW)?1*3G?5;<IO [;TB/(S5)KSSH9+JP#->*TP
MZM/ >V#D\\FKMK90BSTY9T/?A()!?J77_=*U!REQ&*#8NCZ*-_G99E2)@">H
MB6<A'QS0F9[KD>RNA/YC'F S/$\A.:C;C\^JNF>UCDWOR&8@OF]/JN/!-T)L
MRT_N8ND>/]6.>/>IR(9\"HD8*@)/(FY,N?I?BCR]-FL:"ZO*[]9N12V;N)@9
M86W0G*2?'Y"GBH3JEOAH \>)>9R63(!U7N1U=DAO@8_IK4TGM@'^1[8USL?]
M.(,;3TMU?$J\&+-L$^,Y]"(]XJNO>ZLOR+?$":G8AHG)7LZ,AN=(1(;V*+XN
M#V"W^W1?@4934W'/)W8  ^ 08 Q-%C /Z1]G9C9)N%UWD3G@>/UOTBZF,D92
M(\5M=W? '+U_UG;V#%O;N+=SXH.*LZQ\TQ$WL\\HRZ)RC-XW P  X-6R*L58
M:U(J>6YYU6Q)6E-<U?<R)DQXFK=Q&W"B9;=Q5K_U/E$PJ\$3=S4J%(WY3W3-
ML2;1Q4:<_4!C>TAU]OZ:=ZY(LRU34,R-Z#CBY6V . '.5]D1N[()-K6#M.M0
M[)5^K7GP]X9B1#%/M@%XEHM47Q!(/BWGZ6='4J PXVM)"']," <!AUE/A7-U
M^WC^LJGDGWW\WS&7OV,N_Q,Q%UHCA17R]"N>2SW]30Z<ZE5G@Y(>OG^JXT,W
MSG-@O8ZVQ(+1QEU!<@:!9U/_P-_\556U.U?#9IB[5U:8*+8%KZ3H>84OM"JC
M-J.$N/N10*B\*2OW?B+:GFWI=.>PRL54C>3PN762)(G)@>GU8P&]P4E50EV_
MU5)>E.JP7TJ1JQ*./_2M?);GAQL2C_/4582&W[PR5LM=FD-K'$ST:_!$1PC&
MX(?K@5/4;=]<&3B_F2Z/NI&'JA.P(G?/9\(U78^-?/1=F8W48],D7M7D,'_]
MCK=6/?FYQ$V3YQ+;@/-<^79( ,WBO;+RX"S=37?,%H< A\'S>O-1<1^G[,UX
MA!78 .%E;16?;I"2^0>MW(Z_;V>TLE2M0L1+W(SE#S94DNYGMPHM;#[$   \
M\$_(.2"@%<2RI@*9OQ%P,L#OZ"$'9Y5E2#;5]7KQ#W^?'^RI@Y;45C)6CD B
M-=Z\8GK4[A"[9^FJX-51-;635'\_]3&O"U*AGS#70O7WJUUGUU1NHEG654A$
M-#I297=_/\O"A=?GU66AUCHV>B5US8@W$Z*AM9S8O1-G+%*LU=3" XI:4QR[
M@J?GA!>(Q&M*J^?$VS?H=39N=3\OSZC_-/G5\2A-8VBPR+O#3P:RO")I.1;)
MO9Y@..G,_%0Q1J?.(3E0/[PMP=!?I6AM"6VEDOR+ 6Y_/(CS_;GF;]D.6G(*
M9D*M [@X3'6O'B/$1"G'T6""NKS'2^ @]<8VL%F[;YW>_LM<_0JBY4SVM32=
MX:-H_:X,QL"XL@^A<:]8JO>^<QX)?]U+2PODBRUO4U_*V+Q"29G2UU9.>PU7
MVN\V='$G12I<N56$]MQZN*O6_IFHRM\ES__UR7]2R?-W<#9& 'D9T<XT\Q,)
M^AX_8G?USIR!T7B"QDY35&-L42)PJ?V>2\T2^"FY0>G^N&(S5M8E/_HD7 !^
M%M^#,Y_H\4?F\J:L>< )F@BL7-15<F!>^M0KA(VU=:)3H[=*@Z!QYO4%QD^5
M[ */[R:&L7ZA6;\PL>:1B\9M Q2VX@?/,*<+.-2+W+6RJLN0R N#0C>36YY\
M!1I=/%'UV*H_)OW=D1Q.]5 %SH.O47MR/G$S]H3;3?CI/Y5C=),]L8@I%.ZD
M\)4H^5HH#F#?1+OWM8(,,DR[X26S1KV7@4_1+"O4I_#=15IOM<0>K):89O-<
M.S=4O%B])!9[P/UP:;M?*U@.=B5^D#V&Z3;.QXD"@5&1I02ME-EMM_ M#/C5
M>$3MUGC-">"A!6,,)MQ8N?S3Y(1#7%9U(5OLR(@MX(>W:0*7RO/,6T,NYU-R
MI;)<"QYQ3DL:HW%$8>"6RP<\ZZK&6/)F5<"XDZ/SS7=Z'D[2MU[C3DM*EPI-
M[*D\Q,Q\!,K&[!_)I>WA:(#)_$R"B#2:!<,OYZJ,AMS$M*#F9XV+JPM:=@\]
M_EXS,K-9"NESH!R3CE+I"K0;1'<BXQ0[WGVAKV$MKZ^)$,ACC_/_5'8"]+ET
MRK 3VZ+4NKD->+XE5P)3K2MX/L_4VYD=CA3,!]7A("E*V<I]VP#C;K37-ZN.
M?S,^2U7L0DHC$'M^=AN 6Z4"J&CWP"2F/*1EYRSF0C&0LLA$I.Z82NARQ"S\
M^A]EM0Q$$*PV\1.L'T-Y4V5H:D*ZX(E93_+</ Q#@2@#5!T>@RIJ5W $[?[2
M?T%)U7>ZD[\+\W[1.OM_W?__GNJ?/_D__@;U_;UV;V:_@5*"#/4[:\O^PUCA
M.<S&J OU[PT+[< 545LF>+'F1IBW!J6$*H[*9F/64'?H\5UWRLN)R *K+7.@
M"L51V,R,P&#=-N#E-H#Z4"FX23FF)HKL 2/<9VK7):QM7-U%4KX/X#E*-@B/
MR ?^N@ 48@7V- _(<>=A^\6D B=BU=6][PXHXEE\[BQ:H][:<-/R^0]%[--R
M]L=L#!LA]S]/]7=..2E<!T$YJU@+;<A)4EA?5 VO,VT#Z@(@E"L&\-X\6-1J
M"#X>0<"\HH!(\1RDU["*2ULHBC>5CXM8;P-JS"E-Z21,(*P1V$D"86$3*SO%
M3C^]C1+.&CQ),J(\HB#&8%2CS/=B&\##L=(H3]6C]S#*'3W8:A\PQW(;(#S.
ML<:T 3M&@N-E@7A.*M=\M.I"IMT&8!]3S79P*SE&&P]CH:XV+'T+/D&].U6-
MZTZ= B^DCF5<-PE6T5ELS7EG',\5\!3$=2X47TW?*1L:>R!4K7X.::77E$<P
MB-88;;PS&'O?<R 10HJHHS!86Q!/6H5P[<O\K"5:X2%P>^&D;(3&43].^^/9
MSUP'9((CPEO20\8IMY9"&+O0V;Z(C-@89 H_9J@$=+<5]EA/BN<<42W:'!<K
M>.FS(!LW74YN::"Q==^A6U?\+GF<#>==5<8H0)JGTU5\QN 8B4YTXWT#LE[4
MY)I<SE5RC.?%49R_0M:#I" [M(O;C3B4BNR3(36^\,T]?I.:MB(S&@VI-Q:&
M!OMA?L/>RVJUMNN?\4)M0W?K";J+D@U;[CH;@R<K<%"VP HCR,%<DX#C?N)!
M*H=I'A^FB06(=0,.=0XR6IY2X)W)P)]IXC^2D$&7@/!0X$%@Q>=O[.KC_J[+
M(:6:,U)96RY&O&12#)<JLY(P=^QBL'CMP#0#[5. 8)7: S_F=,5 MV3DQH>J
M@*J*?0S2*-Y-9*_;-J"BA*FVQ1_.+(P6!+.E)V;SU/?WI];??/%EMK"9QH7S
M!*?MIT\!*SV?[V<=1?4G+)*=S,;=@HUD'?')"> #[KP4KV&P"N^4>+7;M6];
M>((P41K:BNFG& 9D*%,BRO7T=^;"]BB=!6*[LZ6W 7J;H&5;$T(QYM+T)A]&
M:;@.3X&B*%&A9NBNCC2,AWG=!A;J!0<;4'H0'^07?IW(KUS'B 'C=\\8=+;T
M7M$-N;^2>_C]PZX<T $?[V=5C:69^VK[^8-M7>A9JO<1]3,].\(6^D@0 AQA
M.Z@I*Z.R4*],&([!ALF'(_0)3__@WJP)!YW2E\'X;=R:-JC-=[A%?PL_IB%H
M]HSID'_/C-VSO3QG9(WOI]9O ^J'!S(QQ]T>9(BK^][<!H2!IID;,<=#JOI(
M))+4[E[M]Y]&!4#[N^V*H^^?[:A-=VQ\Q_:LT$?@2 <]?YGR2,1#&7;/:D<*
M,T6XG1327)!_>[W[_L?%KI;(X7#BNQ4OSU;\RNY1O18+B],^%@?.9]6<\KUY
MCUGS_D-^[U* +6#DD,!Z;D8"\ /W-X*Q_QJC]Z^JCOX52?U==,]]3[?:3##U
M"[+$,23UCQ%D5RH3FHG*U-=>F:2P0N^LY7",W*<N!]6$MCW8B@''PWUWEP*#
MG>+\2_K;@&X?.$&&<=,>-@9<P33S]=HB5B>I_\(P)8)VO0M=3+ZWBQS^>=>H
MGW0Y-W@;H-_^:&=6$CI?6Y$F(B+YGJ;WR#,ISA4EYE8_[5@-BCG%?+E4X7;N
ML4Z9UW?E- M#?]DH^3O)8<*6]*BYY]GW/?TU#+T35JY)<8P1#E<2WMV)05L3
M"\ZB9V@ C!^49EANWXX]FI=[EY"72@S6?J'C?LE?/Z-:Z':79Y/ $('Z0.=^
M[G:K+QN[(L^?NDQXVHT'<+QP%@4/UV7SC-ZWQTHW]XSK!S7;VDH!]C1J,K]]
MI)MK7A.M!]-EURG6O_3:(28;[.$5!2==^4H*W$I=52>.5:T6%5WANI-14A2;
M=,OC4$SLR$E[FL<,C/XO,0?]JU2.")04"0UW:T$EWTZ)U8"B=7E7:A+ TX,;
MZ]F&1OIF;WZ=N/WOP?JW2_K/TZZ#<7S=\JTI<R?81"8&E"1(Y&4Y">O^8 F\
M=+.JBQ$M!*@=KKKZQN,R90/RE2SL,V]XS#<_C(J:E1D_=J7M9U[G&_R#Q)6!
M]O?D0E6_G0O]2^)JOD3CP1J[L?.:IQ\D9KTR!CQ3"PPKT*+]T%??([MH(K<7
M$=PT."=\'M&4@XV_$.;46:3A#P5%@[ 6\'/=+SU==[FI.Z)T\<1=C\HB8Q'F
M TBU1I6C]#U,L>-/W?A]A!_WT'F'7;&]-YUZ')6R:44X@U93[JS44,&W=^=Z
M36]=9.I-(Z[A5OXMP/7OHR?_HJ,G7I)$'G-8WQ!?L#416@>YW%/MLK3G8&%M
M/P7I[$8LJ)$^4ZUYR#)J(88,U)@KL S)K>2#/1.-0O12GX;  C4%%IFZ?R)
M8[!^HQM$17C*\')-N!W/%9'-XO5AE+-K_\0XB_1@;% Q">>POUITH8_8N0VX
M,2J5'32Z;]A"JI]$]02(9F-01^UZCNC?R_&^Z\(02[J]E?R1Q)^G%W<M1E2B
MYT,@?>1U$91E6"+CH0>O&*58!VHSZEY6UAQ""(?IQ9L"15*\0RX32HYV8NYJ
M#8+G6O'*OQG+$OB_8UDO_D LZR<)1(5M@)EPGR01UM#JE IL*U"QB@+.H_9.
M\%%T<4K >>@L>>D 1CMJBITRL3E#Q .!+=VP-JS@9E]?A/:R-:L\&M22,S^/
M^0W@9!BE3T]N2M!7L;)%G7NF]&.[8);T \^NE=$9'V5ZK "U/E\@$3_;2PJ9
M[GLS*"W5H'2BW="B=\&L@W67FS+T ;.T\GA.)6^\W#_99)DC4C9PBI7Y.&WL
MPU<QSM>D]S^[Y+#.>GF1[\S<-L !.>?5PJAIF33:6DYQ"5"&S8)6@$KI\TSM
M?] XT])6N7.0> A>G7Y4%KPH@:W L.7C7VHX#P2.2U<KNAMK:3Y:Y!H?W)F;
MOA4MWW?4=[&)59&X%(U=@I[LGF88^64\_CL!YI\X$[B3UK'Y1UI'.0'AUX@)
M$(ZBA(54;STG3\%PTY308Z7SC?*[S>^43R2_SM79 !U]%?O%2N_!Q\ ]EW0B
M?/QJI=E,C*H/C:1(U<HW:_RHHZ2H.2^S VT:E0;DM\H( VZ\,CPU F<V_U/(
M^;N>Z@^%^_Y=ZJFBP?E! R&9NN4&@5://Z>&YXHUG#>E?2_(?.-('>/[=18\
M^RAQ%N:R 9N ZE6I0_L$$C[&%1G4:Y.B!D)"K,KD=VMT*+\-(+]RI+^U<?K:
MF,'GKV7',1>>?#*+8%BE6;NNEY#5WX'@ (5K;"7/A)/ ,]" <D?'V+YYEI3D
M=9051H<PVT,L1[\AT_WDCD_(GQVIPKH?)!9YT.KR,44:%D']ZS>,V8.RL\89
M;#5BC3FX+[\0/[=3^\(&36E8Y>65O0)9J+_H/AR%#0>>GQ\+J=T]%O#+,_??
M<UD3]H<S"T*/]<2D)Z*U=T(H%?7C7^;SZ*^Y</K2V3;7!M7X5RDQL940J)O=
MK>7V(-CHP 'IY'38 7>JE@R#]/CPK.,A[&#/F^B=SI]8#&.B3Q#]3N?/Q6OA
MWG4\D8^;&VM&T[4B+!Q48/,W5HL-A5P+"YL&,85"#0V4TW/VS-Z5/Q?&)?A!
MF%F<U9AONF$?_E*_7U^8OMC[-X%^V/+$L..!)SB%%C[QI/NN?]G:UZVMI=),
M(-?!KSVMXQ\W:F'C]6*/T5ZVXD/"HI1L^,:8*N1 HT&ER(Z$7HR=O\+9Q C-
M+P]8H'3I/S@=2 YU.;#677'[>6Y4X@Q5[(I'JD?X'R8WJ.ENY@Q>N6*^#5 R
M2RO2ECHU*3OR\SW 4.BA':MOQ]I(5Q>G;'3&2IXP\U^KZ6.)?7;H9-/$I;-)
M_7D3D)0R4P_%E'KP- 4&<UC73WP9$2&SK-<+2L:4X,$(O0?(35^O"X1=._#_
M*.A!F#.YP"VE8E#J#0QT_KF$'9+#?(]701T1;4IUHTZ(><<R>=?<"$N*BJ.0
M81JK@E,AV95W#3>C)"$!0R1AH]ITG]5=](]V%MA[13=<9?7.X??JR'LM!WR>
MO_YPH#1S;]G@T6![B4B6YKT;V$)LITJ1U0IFQDOI8*=M)0^ZPQB>7(B12MRP
M1W>07?^PE)&4ML+?"_MNI!-Y7GT(9DN-/-_O?%.O+B 2__)";OI1EPL'PV.[
MIUW]H<WV>@]0[F!0*8F;0ZE',_9HMD9$.+J['2;P8&-@3"!V9#>-Z ;VAFM2
M.E<R(F<]>[G6'GNBI^YFHRMME/45-2QC'S$^M*[R:M83LE31ZYM?A26CE1:*
M@1KP@P=MND7=A[K"LXD9)GV#3)Z(.X1O5XPQHX4'ZSS&+JHE.SN?[&;<?U2U
M(S3T)%_V)\;$]_< (XPDXHEE=6V*&;Z')"86'N$>U;T9KHM3M_"J>W#&0?_%
MV]TV^,=&HE&7M0AQ[4)GPU1<=_IA12K^I!^66KA",E]K+GI^&Q"]TTC46C&I
M2/(X/%I]!R3_;B3Z_T@C40F2>S=P].RJ?+)$4XS- :GF!7+L7DDSVF4WCRR2
M=+6J*)3AM+Q[&-29F$MFJLR)'NH^(FFEJU]"X7!9S6OARCQ6O9M:=+7T>EPU
M8"KORIB\K*Z?FU.'LA5\4)\X6D3_RJ@?R=C@QSJ@3 S,AO/RMFU"EK<!/"$]
M!>XAV14U*M*2?![S+L8;E#DM8LO[^0[YGPS#NR2K_>,(H91!G9T10A#!'T<(
M^?Z?$4(F6F?:A.3:P>Y9+:\2%S^<-QQH?0-!SR*$ID>]H+;0/;MG.#M(G*C@
MS8HBO9MS<X+6'1&<076G$C.5G!YJOKA7^KQ6G'#HR%"L-2D=FT6,?\#+?WP1
ML322NY003HS.D3M5U'+GK["'L@UC*54J'#ZX<W,SRQ'8?-R<+;9@06;QVFN#
MVK/7V,6RN>W&LM0JJI>A 9B-SG@MH[<5M(<L+(<KSE!9;Y1+>U<=1=%UO.;D
M\!'A) PFW!-1_FF4^]I.4<"5>\8C]LJ\;W-R1+8L.Y-U]=N&"5])D),!\4(V
M#BZ0)95L[$YI6:SO0[M?4%,EHCRE)=M3.=3IX#5=.2&)$?L,^WI;-28U%EEE
MSFGIH$/DII,Y3TL]8.Y@)JJDTJ+PPL*?Z^RU SW7VJ*AP:!L[!)%12^/\.K;
M >Z%G?E-C_][?M.4I]V(!\?+2%$=< V:;U+'=K6@N9?[R>E,45LWNJ.?65G?
MC.L&6BE%ZL%T8]\6\XC8VD87P=R]NN$DL:\DZ]4:[V7TZ6'E1[ S=1H1C^IO
MO;AB'/1%\FQ9V<@SQB_:6FHKXI_J PM-,!NI6_'"^V1Y!LY][A[H=IJD>I$;
MTHRE8S_?&Z(9SIZ<"/LB6W)2-YQ\TB>_T(&2\B7X.FPRRMB!DKX$'WQ8M2X-
M?52W!+()089C2242Q.( .9Q6LB81I0A*"<<N$-RM"1?!6M#(;\6DQHF66X]O
M(02=KA74\%Q\,GRV+XCM<D!4L^B88E\2[<N>9V[]V-XFN?NH=*\^BB2)J:D
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MPJLP%4V&70[Y.-I':3@<&1EMYT+L+.Y7]EPL)-2 ;:"EWW"&0L<.6@(/]@Z
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MA$NN"5=9X'5(*:]6AIJSX<I5SD/R\V 7X>%-SQC#LZNCNR@8[N2"]=ADFWA
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MW)($JH\^ >4FS6*R+DKD);M 2B013E@B?<GXXA^.US!5PEZ=.0+98W4RVN+
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M0TAZKQ+:"ON&/O?F#Z^7EPN__YC*9'#F(B,IG$[@>D44S$+LY+?786"%4/=
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M[4H&AIQPUCBQ?M57_[:!(M=?1[CW .J%OZ]85VCL?7XK211E:?W.Z>=L.6*
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M=$SB)VQ06)M\7@<K4 (7)T<ZFVD (>,(SU$\MC!T2IA[(7K)K#XOFRR12X#
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MCBZ!!GA)\D%DN0Q:+EOC,ZH'4LN,PF@ <Z'2(:&4S"&Y5833[U<*WVGJ#QJ
MA08HS;^(><177=:HP+L=-+(#Z:#;T!IQR3&M'HTNOTY:QK%V?L#H\F7JU=
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M-HX47+VYMVV)S&Q?TIQQCSCX:,U?@(SUC3\DJ_7W3=,/NG*-7>6*F&P5D'
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M;%V8H-FOK%,[I0TMM$CNFADO0Q6-NE:LJL>*2K]*O33Q2*A:6<.0>XG5@["
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MJ;=US<RCS!4DMJR;T0!F'D#M#D6W,RJ+Y4EE_=[^70X4=XQC>D^!XZAJZ^^
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M,"E2;N>\*M& Q[X,G>+^UF)Q=O #)>D#2I8Z]RR3V?Q'MTP9R9;;')( \X_
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M]3_MO',:PKA=^T:]\F<IB9M?+5APII9(%</C/ZLVQL^J=O36 9\>;N3*D !
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M22(W_06/IUF[$L]NS6EZ/;RGC[2YU-G%(3]_V@,6#YYG@F^>.F[XGIOOJKM
M2)CBU>2-?1E^MTVN_#A1";O$W\UBMC.OFS:S.5!CM$OWC[_NO9MW<$#QX.IE
M"\;_XJ# W.9O:4&BC58J7*\7#5K+%>F/7ZPIPB7:)"K3LTX7-:!7K1K*51-
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M91^211T#G%5'HY4)-X?FF^(;\;Y_IO^IWMT"HXRP'19:<<Z[IT_!TH ^<FU
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M5?7Z\3]!QN6XK8,IM@0YR6ZWMOG];@+,F=@+NLP<8;#'EF=O<]+\7;D9Z6>
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M+&?;/<GO^%!:_)@U=#\/_>M,'QN5C&9.1+%8%,IM54#2/PD/F_V X-J_%P$
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M[EXV3-V(&V92*/S)B_PTP$5Z$2D$4-J/ #[1^J6W+>Q6(H"R800PS)A)G8(
MB,47#2_58K*:&P_^TK,.;NT*B')%ZOBXBS5+M[*E^NS0>M&]V;05RL??WCEC
MO08\"2)\A///5839MXV&ML!ZWV*Y1*)9.PD].\W9OB\S@U<#U07T@FE44745
M?MCYV'ZQ2?:"03[NL$UW3G/M%CUL#=/_0<U&+NG8<;M/_8YA$A.GR# =I2HX
MO6^CQ-_$-]_IR*>%!Y@Y%VZL> +2;]E10ELK^#SM08QT?HU#HS.T<]ON!)RA
M<4GFM1J3 T00MJ@4[.\]%^%D@*CS7^[;_OM?R)D/@F>4A2P"<82K,3I88V"Y
MID2G?1TMBT0[;[ M8WB#G_*@* /JJ)\ (Y1M=+P W_\VTX_W,1@BWGJC;S#!
MZ)G37=FY=?;.7A\!G'W'8#B>]+4.7#AWT9+WEZ\9526L#=<.^%EV9F9XCA%B
MV!I+HO;/43!<9C]' ,FW* @@:[CEV8#_0I'_K/@-+^K.5XK=?00 ;3FN(ZQ>
M)/_XMX%_]I"[%:6X;>"_#4B\!&'[UP_>ML@A .D\GQC+:RL$$.B_H2(4<7G4
M_I<:%QT>;ZI:$_M,)'V5\121%:FET@"!+!YFV]SI>&XW&" MT54->(J'\"I^
M?>,FJJHX;G]B&_M49B"3,@:?7DR^EO6J-EE@+F!PK#S]<V"3G1MHL5]**497
MN'=&[NJ]MP-M#MU;&2JF7KQ _[%T&%_EXQR7. DBP_T(&_])M$5)M,+IS-/!
MN$3T_J.7%\(A!/Y)8I!;@U&4 C<7MQ6Y'2&:BH:*ZJ]UNENA#:$]Y&:RK0Q9
MC_I"7?C6#!,P^60Z 5&5?UE%C,L.QRT4UD^[$B.F5B\?L^DB8RG[QG\^9_LO
MYP"/^AM!3J*-,')&Y;C18W,C]<!3RC@)<HK%F8)KE!+QH+(>6^8:KHTCG+EZ
M.B^?\^FV<PN]P'#N-]CN_US683YK50-R)LK[X%+#!1(8 % #OKFB5GOB5_31
MT667&63RK-HV>Q9-,93@@:=HLX0+EK=4(O(5W".:DED,=F]4O2LHSJ7>BJ\G
MWXK3(P "/00P.4EQ@4P>$ID0P*%%ID&[O_BM'/;M*_$ELJ\((,/P_#KS6I_B
MSR\R/MF60OX-1_X;_O(69P;[8A7IOWH00,?0370@ L@4OU I0P!T%/_W6?_W
M6?_B9\ECR#&\?=QU9UL%A /VI,1<#1<%RA2Q0W+?O\\-^<"B5Y?:F%LD8W!H
MMYT<UZ-1O-7L5;K#_#8IM3D<9%ZXS?&_VE5Z(%<V?RT)10!Y&N@G,BWG]4;>
M^G^U>_?/JS-2*T(8YL,GU(<W2<=W5D*49LP63Q& :MQ/2>O G;]>\\%47A;E
MF$_GWE&Z*??@2,$3<\3Z\6#UZ_-IKLEU4F)@^F_>%LOFJOV'CF $+S=7&B[6
M&/H/4M*XXZXF'W+Q\*_G3#'!]X6.(JM2P4%/='.997I*:Z(;^+S5N#833?+Y
M/F5,:/J[C35?79"N5:Y<N/[4D)-[4);#&A+##WQ9N6M,-M."(M!%@R6EH=LN
M\!9FB\U0SYO91L2S0C_-K7'6F&;JE^Q%M,R!S[&5SBO .CU4QM?@Q;^F]D.,
M>>.R:=DZ64G/^LPY]DOEETFMF]&YV.\?]QOBG@L \$!#,T_Z@A__F'N\NQ+_
M#0^E<V.>KW+LI(!'CD6!$NJ94ZL!0Y>ACFK/)G06Z:L,:8V#WH5_N><]2*#?
M=-*9F3W)]VG\F=@0M4+2S]*M.M,/SH)QIX=^F^^_&W^GQ"V+*?8O%X=&=%.C
M]W(8><Y[^+-WHPJPM@2X1+?PHT8 ,;T=4&OO>R&5)JXK7H2ZTFRX2T0_[#D%
MU139Y!N_7+PGQP__2X<:_Z,E/74QA[#^VX[0V^Z6E3?8-G]/\$!/\]$:"?F\
MU%#*=7JKM[6MW+F" /RF$,"-]B>LT.^@==4?V_;ALX-VCUTFV")P!F].2R3(
M>/]:H#M$R\WJ\&8/+PMG=LM;H/DA312H-*'Y<.O[+E^B0+>9WN,'>>BCY/BC
M9F-5D<)3M6!OC_2;R2^S?E'.4N4Y:+.570":I-K=1?MGSKYH3OV ()F>O0JA
MU_NX2R74+W^YAX=?*[VD>#7.PZCVKOOLB_63,G3!,A8V5!P=B(WL0\:2D;0$
MMB;!,K]0>]R'N1XO= WVX) ;;(:R=>J]8 V&EXS?T2ECVET+H]*(TTA4Y'G&
MHWD+;?LY>5(KQT31K@VK^;WN-1<&L)R"OS,X"JK'VE&2M_5Q9A9&W*9_'_.(
M$B5]U<R44-!_"7NH>"0N7(2OD+-8$Y63W%/E=9KNP8NA93^Q.XCG_"'[D_'U
MUM?VNG](I%(BC$XD+REGP8R2I%%%=^YW?R="+^\'/#N2,AURSVN8=06&[YL.
MD3)1/LR^X1-7R#FA@<?WT*3]0&,-@7@NB^IJ- WO#L24#[PUPY&L:#S\%OCF
MD"6'R8@#Y^.85E0F-[63D<M!/ZD7?GIQ7+&I[ $F'_1-;@JM51Z==H^)5CC&
M.]"3(T>.6B64G^3BPGE#IF\\\[5KC+O$=%B:[;&P":G% W=B X[_RYF,_[!_
M%!6YR5[FG5)X]92)\/1N;LM6,BJ%X<N0OW+<U']ZN9-[D^ 5757C@MGE1-*^
M<I.LDG_,@P(WO.O&+BR3J>".>4K  I!E)Z^IB*:^_AAAY/WZ+_M>1AO0P89&
MO$%_N_N02,E,D$H[MDL4MA=PT28]8@[YGMI9[=+?6?3L8Z9:A)'+>;?%-9"'
M7GTMYGA+-M*]8T=X L>D&/4CNT<IDEMUW^_9.50E5-53OB8M'(^1)'CRN;H
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M&!2]$+M/+ 6-V_,IF-B?<!)'N6)AWQX_[Z8\O$_][OY/:Z#J=_V">MD% 3Q
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MZVO07K^<-J*P?#\=,.C6P7MWK:GYM76C9K'"#K7!;(@I&-?R]?H03B*>-U.
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M5C3L$4#?Q<0<FUF3,D?'1-X>,1@!0#/YEYBSF#\\W>)7(3(XA7.;/J.UF@A
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M=D[4A6^ G:*6/N'YFU# 50N1K68I#?C0C=*N7<%8[XXB,U8'?6:CY#+'@V^
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M0K-W<S5_?A&O]LV\^#GAKME[F'*3AZA%V;MW&TX$>J=VH9>&^87(66N%P\M
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M\$%CF<$'[.O9-3':UUP8E).CMR>U?;TCA^1^('-_EUHL=($![G]65GX76HK
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MIM&8,/A^^7?[\2.=.@Z?=M,<=QW3;[J*MA7@]CT3I]0/N]RC/C-U'<S[BYX
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M#9-V#8R;=!:>CO2!5&.&"8E+P_,>F'%%Y&P:%8WZL$KY!)DK)5%P&ZTJ)WB
M3?:*+O#TGV&\.U".6TH2>D\X W9P=0VYQP@29H!*,7*\?KGXBIOQZ:T/VS2(
M#,LCI@@#VP[(H*F;8T]X%->'$C\!9HFY/G/+VDVI8L"NYGB#! SO5+5$=OJQ
M]R(XW.Y*H*-XGM7E8<HWG5=MN]I6/S5JQ^5Z@&Z+S]AO8RJZC;(/V,//!4?=
M<W:IR:5)%/% ':LL=Y7,B<_GFA!OBZM=^E5AUH)6))BV=+6WL^L^M_,MXN3F
M>'TU:S0L2S>KONW"U!7-O"4R6K=/"[CIV['DO::=K[TM7%=9KYV+AU:C6^'J
M63-+7C01KF<F,$ R.T==:VD#L,W.+D+B7+R%19?CF05'>1/F#_L(*Q4%*A6-
M%:ON?='!2=]MP0_]^=6V$]:2.V4K<[U/?6^= .X6*.POX082*(]F$G=_?@M8
MH3L!-$0[K'F\#9C@J5'M*C]*?\UW<YR[O7/08RQ=3&AG+<*]T^O[_J&ER59K
M6''Y=+DVM*VCS'YGQNB 32/L^Y&-3:Z"0&:6/62)@-E+=)9C4^W%,O_@1WOX
M$!VS0\Y07=PQ5;IF:2GE$AM+6(Z8.3T\XIHT"S27=8EX+&1840*Z,G88BE!)
M@#"J(%2K('X/V@)"3@=GUV4]GM?V%*&L'=R^M5%$<Q0P!;9AQAWUQ0\;M6]\
M-_G\KH;4XI"0(7VCF+>RYJL$#T>L#9G84U%AK&I<_>;8.6*NM3Q_LBB3  ,:
M&=4,$R /U+SGL[;D+NPHKM$3AG]D-U1\D4ATF^8:)"P>((029ATZ(7T\O_Q8
M63U]=914&-[D>X_DWBM#![@YC^<@]T6(&=(,2=5.]8U/(>KQ^H3C,5V<FL.<
M\T-/]T&U-5]OQ\C7Y6;ZYG&7+@R@K49^O&L!MQ@-2UX&<L,WV$."^>M$I;1R
MJR,P)*L+2RN8M,&EZC3GC,MZ_8KX>M>T_,XKP^-E(T<Q/9Z9*X]6$7.*O9E5
M<#<E"P)3(XLYK_A=1;7I@NMG YM7))D?K31V70K\&IO!V H41](S-$/IX35E
M/K;]2^Z35B%UVF59C"I \<(XLXIN_8(YXLB6#^,X;:W4JROOI2O2KW_7_RG<
M=/9NU'-+K6^OGIX%[#WB$!I+H7Z5]"I/,<Y)]%Z6>ZSJLRF.$?>1>8+]_I)Y
M='UOI.3D_49%LI' #37Q\I$=\K@F*2<\>U?DN9JJ-AK2EE3G"^/%==U;UHM[
M^/IEV"6/']S4SOXZ3'7!U#CJ$H:/IW8$RA$[H++ (X.P\,%L^BL/B+[Y]96W
M_U>N%$0QMK_@:\$8']_8G@*'W>Z3\<=K]U1]KD0(*5_._E;-\?']69VL\^YO
MOW]2R;?G:UV]M/!#B2I<$\DD%%&N&:X"A%@Q%_#M<?K81$5P. [%\Y8@Z#8U
MPX&(821_\70\.5]RA<+S"4&WLAI;J[:]W2OK5"<2XB83]:A)1[NHCT5(DOT<
M9=MWTPEC-SX=\'NNGK!A5%&>J\J D</.WI L/V^KFPU?G;"U4HW!0@VGK2 N
M72<7,D^\D[1D[RK%?\]"WG!FO+63<DVZ*43\>*5S(IIB(VBN)Y+E12K39RG-
M<..E42GWY3XP'[D V^PGV=, [$FC[]7M,4RI\;#AB]_N'UU3IYV;?=S']8WC
M6VA(DYS*0^KWJQ?<OUV)DC@7ML>OQE:@DWJ[SSBZVF9QUJHX:4,RS 1<P L9
MGCO(S3]DQ5IR.K-D_)=A YT#67Z0M?^[A91F@'$::L'4R40KKXMCE*D<AL8O
M(@87NI0N?=Q'@JR-&@N #WXL$@Y;N7K6?]G!GU\:O9J[?F[OF'Z>7Y>2^BB'
M*2+U>5ELMT)**E9UQJ-0\7K0;'U/+'RXS6('?TPUPQ7+ +2DVM$.9GL$.>0M
MDXYR=>P,H,N<.3(([VTS^>[U?C3OI?,NXA;W0I_[^N"JA"VI*^V_B-I\=Q][
MLK;._#S+Q).@.?8Q_BQ KAEV&H=X@D=>]V*DXY"%EHB -3Y_EO30K23M%9#K
M?AZ/R:'*^('#I/>6W^/-O^H7%RB,.4O3=:!7N82-GI^IC+6_K)C1+2YBW_(I
MB3Z0+&FL%_3VD0A*G0EB/:AN?@5#.MQ>*)8>KN.\%L)H\K#L"W7]C+91NY+,
MF[,[AYS>#MO@[16X?'V9_R'+%J',7L(K^5CM<^?R_;-1B5.J4,5Y?BYT[;<T
M5ZMW#G=I+P52?XLHJ.0OV*"#%E)*?KE:]_O5E5?:0Z^D5DJ&*<$5#:\:"#%E
M= H_Y'1Z^TBFBN)==%QG=I_U8P6W*O':R<S$M##UE<&,#?UR>*2D0'*L;0='
MXG'<\4;=XE1TPK^38#LCK8']*-'-D#!+'E1T.BZZB_+KVN,X<#)1,_)[>O%;
MY/%VP4PZK%?]AU(7L623/K%OM8WZ!!"JL:&*MSX&>ATTD7SQ&W\EH2B+#N^<
M *()Z?N3N'V&XEP\+E3KD&I#_@/O,<<)H XGPCLY,K+21'-E6?9#S=T@EK-.
M<5I+72CEE12/(FO%&^TL?+Y7LS#;WF^P]BUU&N_7.L7\;VD0#^3;9I:B#0>R
M!@5FH@:?1 U0";\5+:1C^,C!%GL'2A698>[_&'^.?G-K@%<X4I;%NBD>%8NN
M/GJ 0MH^WQO:O]Q&RZB8=O-AI(PMMX,':82@KR "WZWTL!YHK\VK_!6E)%3%
MLCGMNE5$/64@.D)(/P% K5BMD??%T K'(TV^&@IKG.6W:^=.O=9G\5+%!Z@'
M:\TG .48J<0#C,*:TFGH'A.Y&JL;1H1$RNM>WEB"\:]5?C%=D -=_G8NY8)<
MY31^45$X]9)H2N'43/\R!FJ9&"M56ITOG,HH(Z7?W#E8?5!XO ;WJ ]ON_**
M*]%,#])96E@SR)\_D?6HBLB2FD]X>]N]C,5"LXU7JX%'I36"*QOAE@]:TR4>
M< ?$>E].,]%,=>/1UXR(BRM" <?X'/QB<?BR+VLSV7#%,@01>%S$?M>_]NYK
M74D 3 =XYVJV64W9Y?P0[BNZ$"7X<63V.%XF]?-(6*0W/6<IYD@P]B!6_/"E
M[&.IL-GZV"Q"]966\U5X_+WG7MHANIIGSE02/EU5<YO$H@4-/E_*O8 RGCVF
M2$G(*Y:'V[N9^9<)ZO_*3C'H]TG?O>X,$9OM;=^(9F2[/JS_$17^V0*=&D?W
M^*(9^*HDK>()@$<#EAWQZT:0\56)Q;CY]<E\Q9>Q!H*0,=O#$F\Q9+FLH<G
M?"^I 21XW?9YFY_8L?8F^FEE6AW4I^Z:P= 9?N3Y;^><O[;;)S?-W'ULA/RD
M/&U>3+^DDE(BY<O3/0"BZP&K3MCLHZ'\71IU.JL:P0*OIZX()M;U;WE;6_IN
M>=AM:P&A]QL^U2C^8IF("?O6Y?]X!LOJZ$KB=28*-.[G6OJ^SYS'UT$:RX^T
MRN0D)J)#,WJX8'5K#8ZCGUJ6' ON,-R--EU\!W.\_(Z(#>)M5'R/4"PHM[),
M'@9:%^=78(VMT(EFYHJ@>*4W;=K$5E5<_F%M!UE](K+'F'GL.@E:+^1&W<7\
MO)+EX_1'(788H&X"U*.N10#SPO/(CFYT]@2PO:#$>(*&.HA@C1@>U!*$IZ/J
M.A27%\&WF+>=L*D5O4\K>B;E:4J\Q JVJ]H<-CBM.%X]6I^ZVKGLR7&>D6,5
MM=AC\C*;%%XXBUSAVNR=B"0X=/LUYP+]0,F>\"(#XKJ#FC@8BDL<=6:C/ %,
M#:P<5Y^J^@M\?=TA,'<W:T^DLQ5[.7W2)"9X-6Q9LMA>8'1B)E3EW'B;>26-
MK[C3W"6RH;YHGPWHRG K3[$\N'AV+Z5*&Y8G*3>J@U4W:<>PO2V>6KO4QS&4
M /38SN!Q(_F.BVG9>USHI(.=W;J3=F;88DOW :&U%99'EBI"&8[B(3Z;'D!W
M,3W>\!MDA(6:]NQ,-2$YB<_!/S7\!$#KT)188.T1F?I-1,;T-?FZ4B6-<]4Y
M(KH]WX=IU[OX3<5XIA/NEVUT>BGR2=:( 'K>+>![<C.1J7H-/.Q0GIIX\5I>
M?3Y)+P2LV<##DCHZ[?36JW&&07_*+]5.+ <)[>E>@-NW$L8A>[>BZKMNX<$T
MUGP0UW+OG.)<GRTIMFN[*KT_*K8'L3YRJY[)>!D5F;M7[FJ>+6W*=FR0T*&,
MC2%-.KJN7LL%IU:CPZ>[<_I3D)DV?#6XYWT;!1.O B-X-]"Z:[[5HB/]!$O8
M2O'S/K+LJZSTVT,0D_FKI>6/6Y[\\+AT-N&).M4]X7>HL"B0^EF,'92&S*N]
M^,H@-G*S&@P:-(J+A<BXR<D:/2CN#3:442N8]S'>KEZW1J96ATX(\.^> U7A
M^H?-O2K8^!^:R7X[N$9;K]R^]! 1![CJW?.CY[@]2[.")YODX"9Z3+=4.TWP
M,8(63=;U''<AI"M#8N/+JWVX+68(#K99<:M1X7DV,1T%UHF+4.?EI=7['+<X
MPT(?[P'L8-E9;VE8IFDD*)^@+&1!K*7O"= ??(ON@\+>^ION[@>=U ),*.T2
M.MZO'16C8#]H>\5@5IF<S&,_RS7.#PWNV_B+Q@S"XB< HQ:F9X0(&/"))/-5
M(-O3#YZA>4ILH,OBQ/GQ?F.5@<7<C.67;C,(EM=WLJ#+J4<Z(^BTM ^W5T]#
MYA)4_X/-17>=$&OTR$8]A>#EO"YV:RV&!>T;'5Y>;@8OBPV"Q>,L^'HWRCQ4
ML0EH"'O']_[<R_UO?A3IJZQNH)836P?6GU<M'4*W<T.8/V,[J>B2!H9X# ^_
M?'W?PA)A-4U(.1R:*8\3>?!FZG+,]$"/32JR6_0+*2"^MH-%Z'!9*,7+K1P>
MC.P%0<9)#B)X68A@]LZ,G+%VV@R=WHX2Z9>@?N Q6?OU38Z0,R%>4_0;DLWZ
M_:1&H(H3T,AY6,# >,&(N##;-9D*UAP*Y0'Q\!48C-3XY'DL%#T(/ %,BUF=
M<I.XW_WN!."%.!9E4-@)"YA4,E_3G(2HV5PR=0][7AY1<)>W?J=WDYT"7)"L
M\K*A[B543$T_UQ(SOZ64E82OJ[6XV:O=#W</H.LD &M0NY%9*-0O#;=K(]/F
MSL!HF.OM1_Z_3-E2I8RQ&,9ZL?IJ-RB9/6L9T6.+/P' A[9X5!CC*2\GS!K(
MSV_"MDX 8B5MOI(_32OZB@6V[G<7\V]?[/]N>D8 ^TR793.B8.JN(6UD_PSI
MLV<=2@\<YL9#B)?SKL%SGP#LAPE6,XX6F^Q,J+OZ#ZRI].5\QK)/ &2"?%?[
MIIJXD=<6Y?%/B(^?'!7_JXL"7)[1%&6T[W9*V?$L@E=\RM-X^OW'GHCJ]$%K
M<8D%_KBK&!JSY(;J8L)]15BU+M&DK1]GA+DJ?$@[5>"L*,+ /NJ7IM$\>7$_
M;#W?.JF^]P1@%S/3]:*.-?W@=93J9/%AB-*13_,AL;:=<#1[/!H]TZ4@<JQP
M5,76D3H>'3"M]^%X#+=Y>=N%9N=^P*A"RY;3^'+,"0"M<'<?E;&V\L$4*A<W
M^LS<A?67@N='3>50R1%_,^V*,W4IP7:]2!HR/\?M"U53K>2 \G@$&S>R?Z<W
MJW*A>7%7KUK A4_&)%_7:7U<=<_58N6#/U-R_:<7#\21[3/B;_J#Z"*?OA\+
M5%1EE*((BF+X-66'IN+GL"+;Y:O&5^;Z/#<>K(!CH>4;8M]?D4(B,(@XDF6/
M1RD81<[9(:P(^S,O.-'ZY3C0CC(G6;Z8XGAX425H)XR.(L*5_6NGE'-KR=$V
MZW:Z;#;F=D(J&>H'\L5F'I&I1@S787OSN3YZ9OJ[\]F>'>WW\W9>6U2,G "6
M@X-3V':Z*3&<U-WXYI'GG.7P7*OY-Q([V9S4C155D[!A%)6"ZG,<AKVY]KF+
MCY,?]W9<N%S[:\7E-./Q.'- $[WDG&?+G: 6L?6A).UX?3\S%2T#\2IH[JZF
M04!]NLS'>*"V_W">VIL15/D)X$I"^NK,_S)"^:-_!>&WAQL_1IHH)1TR6)P
M0#CEM&6%7_7%^Q[[S_ZE<>7ZVSN02L8*_H^0G\*Q>U9B]C=4E@7'EI9,.& U
MX>@L?NUK_]P7<GBG3+NTJH9B.<'B8['IO4??H_:XS&@.LHC87JY [06=A9DL
MA]6"XB.!H^8!TDN45-_"].^!4Q&/OUM$;5'^#/[]' JM.N[(2<Y/TJ7+6B',
M[QBUAD.<:<P[ %[ND1GZNSZ-UM9F:08!YLI+0/YU*4RX*TP*[V'GK/X-  "8
M6N]2\U0-9"LL@I#2Z.*$F$92])<V<C9E"OFIZ:KX^=Q#SF,] $D-EW)5!"8^
M*S]Z;EF/-73J!)  I>]E=1R QKD$D4I;.9O9(\ZD?_?X\<A; .#%UCC_"L+\
MAL#J ]*7-_9%1;ZOM#.]TG$3S.XTXN@.DS>7<M+.:SRT]S"P;<W<0\T71/9O
M]5:D_Z->/X"7A_H9NB[FFG^W_3<+]N?XM)+>0CPKO4#R0;F+Z2U,.\X+#^T]
MJ\?/TW?8KX_Y#1!JE,K>(6[.AA:L:H+17O;81>A8)AE9B8I0K)W"Y<FI>7T.
M6V_4B;>V]DM\7:YZ>-@EC['Z^'6A376IAC/39%"ST3GEKRZK\S5R3Q9!9@.Q
MJO;M#U]HBKZ.JN14YK J0=[5=$V=5WGIX*\[%5"5I:R=*F?=JN&P!S&)H>C%
M.\_H)V7'=.J/)EC*(T(YTIUM++BY2%P$GXKE\8+7%=.CV00']S'"7N+TP-8E
MLX=R_?7/%*FAHL$7-T<@]G(E$.DM0Z_;P$JR%8\!,;&D *E3I"15N3WC?E!L
M)N4&P4] ]*V2?CW*,+,VRGJ9=?GL3=ZS4;?.O>M!].?=SW=.2:%'WN*:1*+B
MR;F@ANJR.&U.*<D" T$U!+0<4SYWRP!)7K]89,^5)GHG'\A7'7CAS.7V1W>N
MGSF7T7@#J9FID2>%%XC+'C$._19O$*LBDI*=@,>78]62CZ]*/ZYZ@TIM*:2K
M%Z[)C;^71J)A+KUH2<&C\?.Z+?K\EK\'BU&/.PD&=<8K"!X1!V0>IM4G-=]P
M3:UZG6R(]/98WBZ9CYF'FXTUN\ECML-MO:[KD4E5P(NO35NI&)7OT+;0GHL2
MEA[\R:NMH]R7)I&6\CH[@S=T\2:\QMD#?+S@+H< P>!Y_":B]_KB.$6W0(O@
M!T<5L^?6*!L<=T..U#($'.R3Z3^R^UQ7?4CY">=*_18TNGFOUK#Y!HN.SA+J
M/7WLR/(.U,L.JQ0?U:!$J^$C9T[_^J!FX4C<A#T.-?"@\%8;JBJ-XGC)N24H
MK9;OC+$=GTY.E75?"OA-*] /G^9KTY>#O-3*5QJKNFH!2:XJ-NFHBIGQ-7>-
MZ!RZ7=J0XJ+?ZOQU+Q^(WX&B=THY>=0VU"H.*@B'JN+5F*U !K(]][M+>#V2
MJZ:?LNXYL>P_'M[I9)3%E3B:Y%2@"2>])]$/ Q&[PA$PT4(CO)69?E(H!\P9
MR T#3L?BQ<*A%80:[XH=.WS%&!&Y0&!65DRM0'_5_Q)%G)FDNWU3*OLYVZ/"
M\ZZ*& /;!'IN^F&54]#)32AE03V0DU$<W"2(UW"LRY-HT1 MLCG&+I+B;1$J
M%I?+&PUW=O8C0(^YG.-R5L0)RP2'->ZR?@?17[H]7LAZEF]AX(CKTM=I0Y1W
M"H)MXHKR0"_5_?4EQY???-7)4U=QB7/ \<,/DU2DF+AH&.^W.C,"*6A_!DI1
M>(?A)6YYUHB5&8A:)H,6%2ML,[+DT5\-WW)55WZZ2YTQ$_.6USG;(NHB^YVH
MQ].ZZ\6Z[EIY$K9B7L!A)+QF_N?P0($ IU2-33'7TL"8\@,Q9N2S( ]1]'EA
MNC;V%FW62B)(Y%V*-JAP8;@_!0&M.O4\52N>+8 0F&P$'[2=@"8"K0O&]03;
M(*&_-%TJ>(PN^#D67K#),$!RVKB<KB@>L2NJ_7M!0<YA9$:Q/6%D8_N@P\RH
M3.ML@<Q-\ZB4$J[2.))$A_CTZ1(>#*<@>+#6%>/NA  ?SO(^P<)+XF6J9^1>
M: K?B#;*MLRGYU8U<(X+J!LYA//2<ZO_]3UPY645[FY13H*[X:_6I6FK(JH;
M$5-P;DTWMSP>(+(JV?V <$D[5<U&11.]<>JU"LO85A6FMU?$3)QJRJYE2*XT
MF\6I)\Z*UP&>DF+B.A+@36=Q7_Z-Q*TQ\?1?AE4#6U0-0H9&AB\^Y.-%HW(7
M&#\B+8R1S]ND8V%+)"[L3 >G0>$@_ZQXC90X=J;]NTI*U,4Y/[YT:(2X.,U'
MMR<U5T@#Q&3?/:?HG$,P>,!VA#B J'%I'4_J)2\:$'O<R5T/-H3P75Q5(#-E
M;MCP@)Y^5LQ5G9_Q%O(9[RC8'&VRN"\@+O1"1)<&LYYS3?9ECMA:IL+W8HW&
M#6VN<M0D $>O9"#<W2]?NOO83!D <^KE2-O2RI,NAF<CN&V-U=#V@QZ]FKE2
MVK[]'-/;M<GV8R@JF8-4N8@$&-Y^&BIPH]Q.\?$/WL=-CR3G/]T/!O;X]B'N
M8XIO3I()JA3<O/:;TY/;M1#0^-V5O+&VA]5>,]:#[WABVM^>B6))K0]4,@Y)
M+M!H&Y'"=_CE<G?L$*?<N$ADENQI;/_8\<%H M3F>*(':&_/X1DU;0E7?.V@
MPQFJM?S09LR[U$8S3WQR.3DN6;W:HWN?;E$[%J25;*L]FFR]8S GMN4SSP7)
MK4S-C7C%*5P5HR3+ES":-2-[5CI="SB0/YTOU='Q)GMZ#[;N43UV-.EF(\53
MA<=#!:W<YE;<:N[48"IQ >(+^MRQ /N88<*Y+Z,-*=0IU ,N*0OR-C!GGU-:
M''2?_7U''BVE38&QU1\A74ZRWXJ$F%N7@ARH@BUY'TH[-=OTZ.1WRL:FC(*'
MG:'6%9&$)R3=[$2.7&[63C6D>'<-:\;$KBM?S?D#L4VXV.YS_<^&LJ^R-0))
M1OU&D(0SM]V7F]MZL!]H6/CG'U@9Z'D/J*BG-DH)5D"YTK;5#(YHG /K.^'3
M^7,ZI9J^RSRH@8[L7B*^P"2C6V^A&AQ(YDY"G>^WG[T;"@9[6&C2@@8_Y4>D
ME%4!7&<!.[T%3Q_D2E4O8("V66H5\;#NUK8.'*C9CK?[QQ-GMW@#V*!B,E3@
M9I2N,33M;)DT#L[X_NWRZ*4K-5*=RU5=4ITN)C?<TX7M=S KR(/QJG4)ZPVN
M%<S^.*:#1^P(]%H([^$\IWBY?#V>/>>B0(19->N]\D3^_#[;LA3X09']8K]M
M?%^R40K"H1U?9)[RO^%,U)>X!7KUMVC4L'.S6. :P+WFKWB'?/GG&_'KSC5<
M6^4^7CE^%P2%"YY>D>0:?\!7Z@!10L,MDMQL/2LIJDX KP.TWNV!;\L6W] "
MTY\_FG7X850,5Q*0K<:H&6B8$ ,R:PYZ1&D'GE/GWCD]BD+KM*<G1/L2(N5H
MA#7BQ2=$>R$Y\E_>_N751*RQ?IDX;F.L>TLU527[UJ\D:"7=9OMA7#RF, '=
MVSKFIPZ^H@89D=OW@N3A!_.]E9PF.AXOTR-)G'"A>.XBXGNVC":Y*)G+:T+:
M<4QYMV]T%ROL<L>$YF3V365Z*VCE%HMNU/UMXG+-OY:/$JLZVW^@B\:&DMUE
MK)@ES%.@73;[APG;2,Q_;$#W0%?9#^X4[__'_O,+9WZ6(:\XM!]4J%E-+QUO
M+DHDX3R@->YV*ZEC7\]=WZF3L/:3S\@RJ4@9S/#O9GPG2#MVH9OW@NOZ-.&'
MPD-NV/VS#KN/"W$E =\\@&4K>WNL'NFX]HV=@(#VV:/Q1 3@J?D$<T5MX($^
M#JH\%'(@:D;QCGX(*HQ'C;9Q$<_(/$E[=.&M3#Y@K2OBIOWV0*)I9 R0XYE+
M97E^8;93Q!DJ*PZ6^.^R4R27SQ*7=5S++>YC=V!JOICF/QNC(G\W1FW4_M$7
MY;''2FO"]-]O@3]#5\9QSC6"SN<$\+COF!XEK<.'5=%P]E=U )?NP7L1TL4)
M*8;IB0O;)B+\MA<[\[\2&,BCGD=2QV[+LCE.N3RMV5Y3MP2?%X4;+2-WQ/QS
MOZT/-UV/RV7U;&R+L46G]F-GBL39M]MZ[Y#N,E!6>+&UI[>6?\7FOM6V0*CT
MS-CF&RC@GXN-E>L\WS)D0@APZVR(]0NP36>F)UN.^>)__<_^'>N?A#SQDV;^
M0/RUO!(4,35X D"&;=TW7YS(6,K#.R.+8DG8:M^#,=9(?J@-[;:C;2*BG^P_
MOFH?JMM*K_F.[NQ#S]F-Q?T!FEO&FCJ<FB#@F&UFP,1NP+E;H4@>GFI8M8?!
M7'K.^+MDP<\#)P!,N25U+9D[B'P"&)#J\!$M8YA4</JL*$@#<BV</, <[XZ,
M)2WT-BOBEIU*PL-[D_C$9DX '08-)39KZ0FF9DZ#=Z84NC;H(PWS\W=6.\5,
MM]1$4W'<Z][;PGF)VL9;E$R?YBV+'?"':9A(Y6E]Q>F['[Y*%5]U):D8QM^;
MXNPN$&E.X51;[Y#$=NA'%[;\WKWOUCAKGKN<_@KU%].#KY>5YFBFC+>O WM)
MB[?V%G!:P_5 2>>M\,,MJ845F:CBNFTR9E96<"QH%':IN?><@L'Z&JS[L8,/
M3C!\0W94N_RET<I\[Y:,REKT_?MG48VCNEG"+%9?%M0GC#[["AAJV438)Y!K
M.#>.Z(<'E6BTKI&!1@*$[@?I>S::@<>01%9#J]9.B1M!4;.]T8_AFP6F7R=,
M^VW:"",+M&#P7$T!P</A:771]036*SKY&&119GS_ON#^CKM8P0]9TR\T?KN/
M/8LM7-Z<N4*WR"/W,?[L6YEI!J""1M36=I)H;ZYFHEZ'R@E@4M?$@_V@"]F:
MDRK5NY"-. &\XPL@%VZ-[ ?-/?D7,_O_77YR=&F19-A[L:"F&"^VBN;ZZYK
M^-P_W1, <IX $ JUJ]6[4Z3 _UZ@>#9X:P)UYJ5]3"==0/K7*8SW9UG>1BD5
M9Q)"S=BAS>@67@;[(2NXWN]5JY9O^:]B;E)1>M!@!NBV4,X]2)/@^-B2?';
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M92]VMO&W>[ Q<?[SGU=,+/7"ML]R4%_<D7>B/.HVL8Y]TK>@@RV%1^+JBD\
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M)+%NO<^S#KW\K3;D#4E,/5\&:SCZ>B&0ZA, WB0OE^K6<_.^K]QK]),Z8<'
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M1!^&YE$'8M^Q>".H'H++0MSN*'=/'IPG=UC'3CV^657UY0L.7&\\A'TX7'2
M7POQ]-&C%_9(JU'SIF]!_?>3*^JB?,N>O[?^'OW"2#?SBXO7C0 1(4SBDZ9M
M"@32'8GEF(,VMAD27V)9(&*PJU?-B0G$F%P5"**5#XUC2Y17=8V^.+-=KV6,
M_$ZKH!'X</]UMS=@@PT[]I PJMKQ=IZC \E7_QUU_R.-Z%,2)/0RGZ-^!;@<
M(.*F8CO9(>*\1<;=0ADL)T>I(&9A.I40B+?JB1-X$S#^7WW+(0GM,"&KWA60
MJQP9_J&\DZCY]AZ%_WL> <.HNE 3*5'V'@"E<JFOK!.M6]]=O*^@+0+"3Z*?
MWVP1X.U=YQ,0'B(^K]*L3G[<,HR5BJ 2CA454MY" [P5VA^T,PIM$056#"D-
M.D4JU*GIUEA=^LL;4Q-I7->G*):LM]6(2S!)W;C(*\VIM:D^L<I:0)(=DGYX
M<NV)9_TC4YI/012O$Z6=(U4)'G)TW!7L5D+HI_CIML[I.V\6JJVE*>]9[8OQ
M\'W6R<L432/4X@6[#.90[Y/C]6H?)6@8&$WOEQ[(?PG_5 HZ,YFB<2IWK]4F
M&.QUD>P"/;\OUEOP\I)@>#*?,+E'48W(/*FIR&"F<7K!;XA:;'D+E,O%HS'
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M$3KE_!,SZ[N^-R^=O,O:2 1L1S\>#9B*8<\V/=0I>#V1$X=2]+<^E^:P%>,
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M?^'O*YRS)4\JM_56V2EQ@;5=?(V:9P$S);Z7F\GA("!\VHO=C,W_C(Q6/*Y
MK,LM!Y& 0&AJS3C*>R)L&B;F<ZI"G^ ^P0TNT[@5E8TW[.58>*$W44#11K*<
M#NW#F6[5T]>&QZN#OI=7<T.-'BWU*:NH,HU;$#UQKM7US8U\Y"ZH]/J=&/[%
MS(-02ESA8K.+ GE"O &.TE[]K@G]HIHC3\FM'_91V3K #IVV@<47ZZ#(S?%U
MUWAX7+ZJ84%9F&3A -/.>%@+9=58<4V[2'[^U&9N]4PLC4<!<3=K,A-S>+%+
M7_QQ$%-B[R)!<%Z$%16L2/7NY6SQQSC5 8=XOX%CJCI]A'?NZ\YE?D4SMGK5
MIKQU B]-13F-_#M2$^/Q58T^*3<_$9*>VVY8EW_)-WE2O6 P_3CV,N_ZK%P;
MM'\F4'6N,U3G'=R<NF+M](1Y1]-4^+"+7SE5VL@>#;CN+H7[" XLP4T9*PIM
M5]V^H]VLJ/9]W$,M1<8U]52G4NGP4_'B+F%8$]#S\)J/D<GCH[W[2?-LN3=T
MQW=S0,I<O0:,UQXZI<T$2SB9\12!DKB[:FZ)U>7\4.PLC?3]:7+4DF(I'4VH
M499LV712V%:\]:C0-<'NL3Z[AHV!SHTR'JU"G8;4:-74H SD)!UE=2:[E1$M
MEUE"+9G-BAXVF\.C^P(57YCH!0,U)]6$S.'!;^.3*Y^K0>/4E)%H@'3WNPV=
M]E%HQC*[*DFF*=>SS=Q]C5S1&SDK4!UG&R-F!Q4= ;&B9A[(32^EK7;MFXZ>
M?N[43PA./"TB.OK1@$8KZH<:\>G8U<2W/DFZO&E?RE4M2<AGMG";2RP]:77<
MVOBIKYL*;G%]0IY\K)D=DBT,RF>"DK(7AO&?C1DM"%363#?JJ,<;U8::NCK;
MV-GXOOI11B#<"&Q*8!+0>QN:;/5SI ]^G;V)4$2@GTJAPXNV>H65HLTWT0D)
M6_<(#TJ:.:DI:VALU):VHC1.%!\_I-!Z]WFMMS"L?=2EZ+9RXE-$:W#\:>2Q
M"VQG#4JGJS*XWRMYK3P_K"1I*OQS53^#Y5(J/TTC103/3<-[G]?+-XVUJ?J(
M2&FUX([*$O1^F<"FS*KB!%MQM]GE6HWU_/ZDLJ=[267CJ0UE@37-@AI9!DEC
M:1(^!3Q3;R<0?#EYH,>(QLKGYG<:&\TDM:O:QX,4M9W/2-++O'8R+A;,WMQ)
M?\$OIJ1GSHE"Y>(]5W?;FM),%%8=N) V"=WW 7^?.A0-=$":%J(!KS9!LM(9
M_@RNSFOW[UZ/).IXUT_OLMNC=3T!&47ZNJ3(%/ZN8+= :'-P*'5[KE)QSC&W
M%B%!YV&4KMY3#IFJ.]?,#V^O[P2MQI^6:B1\7&)*M^>Q8Q>U;-XX9HEJ5)[@
MDM0JVQ('Q4KE3)3G[5$RV^D@4GQH4A2T*6\7U!&+K)>2/C"N45+6K>LT@<*]
M41 )0\2.ZCVB!'B=I&]\OC'I5E^RS2.=Z(8L.P[;S:G.OL2<?:MS'<,W':F9
M.<E,))7-Y$G=$N45C 9D)H\JB.K$^D.VC*C":I3"#.1\#T^4D]  %Q,P,!,_
MS^#M%Z5 6ZV#?4(]_?F3U2*7EOU4D/[V'J_LL66^ESMU_=[0C64;YOL_;LCS
M7MJMK?. E?QF(#[U%W)TT>.?1MI+"D;?RAS@?4(%4;WY]/M&CI#%+&1P/AI0
MQBYSXM?LC8 <6J!PT8#<I\CM")E9=LCW9S(GXV9;5#]=#S[_7["5_J];#.*'
MA&V[Y!VPD.<->F8IAVM@T'4]D8 /=1S?)1Y2/GZ[PLK*$B"F1G>./]I6^WR[
MA2["0"VWCZ8L*1;9.1L@Z.C1(__E!1\EY?$W?$S''EZ05V7F^$E.I*2?G6=V
MW<8=I]1/$ZY6EW,CX]?E(_X%A=/6Y=2-"- \R6)C^NW, (+B;AJ.P.[R#X0L
MYRQY/M3;Q]W39>FO3V0=UQ_0!_%)Y<7\M=R@SZHY8/WQQ:5/K7XLJZ<JV" %
MP 5BLJ%@NT\V'9!^[2$K10]=C7-$WB[.S$Z\XP%P6R<W.+JZ8RR(S7AVG)E"
M;F^7LR?7AS7OI\#XVIL"FV'$I$>RR*'YG:,O7';QWQS<L5G+AX1!N6*<@\3*
MC>'*AW(D%=\-GS5GTA/)Y>SZZVJ]A5LT5IO/Q4!>V#XFK/6+6]^Y\$3,/VW1
M[K>"I, <9ET;Q;J]I1)VAWIX#(R1I1/[/OIM/T_)I_U,MDG\RD1YJT[+U]=F
MDN/3TE)_ZD_>DL(%C9D=EW#S.##T4"\'ZI$S?IH-DY-WSF2+9!\POAMO-&9@
M$DAKZ$%^A]?J78=ZOH1)DKOI3;V=77962ZWFT3VWR2/'!TG3C[%Q$JE$IA6Q
M:NMP<0*QN@0(<Y]!V214Q%H&A-" >]["FR_-=OG&'X!NSJ2F0\7F]&J\:LLL
MJQ<T149ZER^11;HYF0]OV8=2SEAO>7QBQ:[OPO56#X^OUG"LU$&&:-=(2H*W
M!TE6W.KSF4D]*YM2=?S(010?P7,O0Y4;8PH+;UJ^=")]V,,4'X#+=,#.-%,Y
MWAQ;G$OE[)JF'J%A7QNGR%D[,\Q48[\1:W<AL+]+__*(Y4+;>17LN+9.70%?
M\7<>Y$]W'2F*,YQ-+TNKR4#M#D**U4]-]$^K+R/+=H$K.[L^)IG(VI;DEI\$
ML!%'1Q8? Q\P/)-[9EDA8U6EF!3&4& QW<%I?IL?<*SR&.3 '^YBD)-F.RU1
M<D;Z3 M?:,6XQ-8I5\)E4"/"E,=B@$Y/Y.,^R735.&<)5G7:6#T9MZ-8@UC'
M#5;B],AVHMV%WB.QS2$E(%-N3R^B-6D0#?!8K-"DY2V1JQ&5=517E1[0F[HX
M@R^HG'U[164Q-S9@AW-/6=('UA';J-!(0.T"T//(I+[_XL!9\3'(MR+<WB'.
MOL@Q/V;]'50)OUF_>D5)&YZ>3]%FV'M8G:8X9UO\PX#<'BE<9"17]<C"DTM5
MH#3IJ++\A[;F_6@GVW&J.)T(IM&I3[6MC*G@8(*$#/&ZU+OI1ND6^NGF69;I
M\6H]*9XB57H*WPR[#GK3!11R:5VP*+4!47B246^I!CH[CWJ$)N6*42L-&0K:
M@45RZNET(V\3/N[LYL3;;)5 9P-SQO[YEL;O_C?1@*^VD)]'\6B _,QD63(:
M0&:R"/FIJ398UW[9EGSYMAT-4-&6SB[+E[G];\E9!(3=XB>G9&C U+05\JW#
MQ]C$$&3C%ZHU@^"3:6E=-*"9W= *YSDN\XWZ3S+!U3Y>5C'&6Z.RKR:Y.E>?
M6L;FQ@CNL3P,#V)E30_$N_&>6DXB&G=;A&S;TQUL44CY(I9G35#(E<$Q3&&N
M_#.PMY(PN0YG$0<W_]M_W8]AI17;%!3K#IGRSM:'+K..>L=0;^4$2G4"P.1M
M0_?D\SI\V8OX:ELK4U9"#1<5BCM/H72W;G!76ZT_#A(0YY-JN4IQ6$M4 ZGG
MZUU94^1!66HC]ATE=U\6'O%%1BE\Z1'X6(LG87:?*,[F]>Z$QW.;0^[F8AL<
M]C.SR,=L/SD";JBQ1JFQQ)!9_Y,GCT];<%!U4@:+: !5$^)EUH:@;SO0))/^
MO5FF^.& =QW]LG)^/>\ _?5.R)YF<7WKM(U/\^5TJEU>HZWUYJ95@:V'B(N=
M#M6JP&RTP+37'C0:+VIK8/WK!AH@7KC3I?!2W+(ZFFOK,4%U83ZW&3-3M4I9
M:/6/D6Y:3Y-;;SM?/D@"?=8,(N_13]A0]4R 4C+O9%/*SSD83E;"? "'#K6^
MQO8=HQ0#9U.H@21^\#4UWDN=.=Q>:F2_%3!>;(!NOFP"[+ [U-=74N]H7SMC
M@&R_X 54JMGO;!84B]:<SF\5[(*!:$#HH:__/O/N*;<K;*QX]Y70E#WWCQO?
MEJ@ZWL4_96)TE>OX[)L?W1?!_U+ONUS@?6H:HAFQ+I)91O41X_&<\9]E(7+%
MS4:)T>_;)TI,2&_+&M(X_Y"I6F+7^+3D(V?#430MYWMLPVS=.6BX-SDN(WT.
ME= K20IQ&C4R_-XU.!D?<'M;!(\]Q(,C5XG?M='-JX^F$7S>W=?S6"?A0YIK
M\G2KO7&J@?&<IW1C\&*1I*J-K$:N7!.48FE39)Q5]6RMZ65"JJVBK/[HM+BL
M-9)E_..QB4K8O%#\SB3Q@(O+2$]@H!#EYRAAW#7UF!W2%A"UQWOVH@9;=FD]
M49XR.UZF1O?9E>4(+L2#R R;7KKI"/;A88V@L?I5-"#3Q4Y1PB5OI;"F"=8N
M<T1>@2E/&B&7-(EKZB@FF6[Z 7KW]VA _<O6'3H8*BUV#Q-(WCI(%H@M:A@-
M4#VN.I6I[#MKBK"_D-OGW4-.=<F$E/BD)Z!J!G:E+I T90A(FGV-#.?/0<&+
M6]_]U"[3IF:VZ>8SYR?.3K77%^9J]B?-&#N3850$[XYMHB9&C+?.%JQ363@?
ML#L[$7E&" 16E.$_>J"PT4_-<93(H3+BP*-EU3\1K:C4>U'26E3UK7=CM'ME
M18V:8CSH=NNMG8(!]D>NZA_A/#I[?7K-H^/Y32\GLH)*<R=>N=D_ 3'O?1PS
MAX59K2D^$#DV)]M:$ C078VG9ZHB=H.R@DAL-2>4H&&.'O46D^..\-FE_H(G
MU]_UEWLQ]SWV4M#*$-O$T]2RT?NTTSQE)*O'+$4<IK#>1-0=(4QS& U;GSG[
M,12"!H +T !GF1/HY*#,JOP;#&]JET)N_/JT3Q2_[2R/6PZO9>+JCC GD]^Y
MJ JVAH>2Y#\E<.E2*1C"S9;/S,#C*$US]E!"G<YI**LFS_^D>UI8+"(HU*&&
MI4:MFJ$+['7(V"CS,Y)S*F#);4K7:<@&VQ0>.X91O6L>1T;&<27QY19'\VF!
M4RAG!MKB&LUU;H<$:@8^Q&$[KHA?*^BS\F(FF]\MVLZ7]X'NBCF\R0X\;?KF
M7 ;2RJ:RKQN-2-"I:HKS_>;L'#?.4N*QMY ^F>[WSW=]X)8C[Z$!,6-HP \X
M*RH:5F;"B^)J_8P&G'S*RG .N0CBO;@9@DHM]GMBHNI/\6^Y(X1.N< +8EP1
MKSEFEMJFU:3H;_,Q(R]JBA19Q\C.P!"D$7\4,T+<;Q !<-$WIWI+1S,BK$?*
M"AOER:XCFH&FR);M$ULZZ;UI(+LM<IW:16%%Z/-VJ;"R";6=M^.I,G6XO7!N
M0WTZ8[%U%U]Y%V7@FIR#'B1(3M7I,W? C]3_=B4Z=GPWCT?'5GTA&\9@6]M?
MA@/%ZR<YII:6I^\(JJKX_.5YOP(NI^.AMQ^]B#3#Z-[+U@C>NX6),6;[2RD>
MJR??S36^1[Q\3R:SY*0B@P1OG!W_=))'O29) $2N+)#9,EIF?>C!AN%/LJA
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M:-B$6VESLO#^ ,71,;M)VJ[!O U3<0(=S2%I=S"/_MZPF:=7)C'S;1V[1*:
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MXL>'@?WE<Z9TB&@O0*&C#%#>,2P&G"ZYSNU'&HD./0)0!RP5NMD/0Z0H'17
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M5,F\?!VC+ $M?90@2#("W&MHB[E@:6U!'>L6X&KA:I\B@,1>4E7J@( K8?#
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MK[>;8/X*%O$!@G \651R2. S7Q,__SD'Y]>@('LRSM?XW6J(6D_)8@/3;]?
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M''6 UFH"\51ROY3&RK][.6A8RZ3:F<^Q:4LGG?H64Z)5=FM+UXDLP9CW'<5
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MN7TLC)TZTMB^RK17M7Q;\>AZ7$F"T6/^1LQ.@&"*#W8F-;,"H%B'H9VYN28
MJ 7O0Z;?U!N8-4AK1*0VJ4;6R'I-?W&K-HL(UQJO<)"5]:'M%D@QWGWY:!\,
M<"AF.!N3UGJ 9NRJ"X/,:F"\3U+JQR@GK)QKO%O7=#,A4&W6=Q/F]<:OR')#
M]-DZ9P,#P>);9 94DG"&AS.IAR*<A0B72NT4FK#<N0 H_&#)@C$7<IUFT2=8
M0T+O=<12%;TRKY.$3_T+XTD0N3A+5^IA:T. L-?:=/J'JAF>FF7#<:;.27DU
MW;K5=K##*-;1//TL3LY>OS'O@_;.\B?W]X5]Q4^W0:@:!;GZ!&0GB0=Q%Y$
M;BG$ZT;^2*FB\*Z);HR2Y%PH8E0=U/%S;_[,P=?BI95E+URS^"3L#(DAN??Q
MH5&@N11-JAM+@K/<H=L\!I=ZFS5TIR(_<\QI:N^O[#6R?"3R[(N7I6O3&QV9
MUE;]\\TJAF; *<1VM,N-!2"E52K+5%W5R6+!=:PF*FCBV\<5UP*%G)+# WO<
M7O]S_<5D:V&&X/6C'+DEGGAB"%L'((1S%"I1<WFN]5@J$6MZ&Q.UZJ[J(#J!
M>U/S]?V[AD>L4J'"H82+U_/]+]['K=L<A>= 0RZ2([_&*@%UMY@]P#@=-6W;
M2_10ZB5GQ709QW+-OA)NAX7$H P-Z34!.[HVE+0N3^Q55Y38+?@>*0V60_TJ
MD>,&1C/,-F$+HUN$T34[%B IG1POOI#\3:$F8CWBF,D!-;>]EUQBQ.NWI1T9
MG(DHS^<[$HV@?'W\" C @L;-JX7LZVB'IB($;*:/2F[Z$:@UI,1R3=WUKO-B
MUV'_YO:$HQ:YZ^PPJ'A9#: :^S!OJ%.3B^/$+(SLY\B]0 6LEWVFQXH\4S\&
M-T#OCM+4#;CQ_GCJ[B.DX^)/TF$<]D2["Q0/JW& \@61?:F8<1XIYH.*IQ4G
M\U3#6/]\6F.''-;6G4S#;6>]OU@]>*/=>FY4SC_%5_8(^F=_ U0A8VL*8$4_
MDG%R*"*L7T-WTM2SAZGM:1O_VL?R%WT;6;SE_2$5R\#&3BT(^.PQB@#!%T%)
M1#9 G6YFA=J<>?V(HW%RYZ[QGZN6%RMZ=F!O1)6K/;HDE.RN>%WD!W^"J)Z@
MC8 4 D(5\\Z=J".]2,:I+,>NF\ZI$;NFT$>81R[PIB=D?9=F=9B>#A+93X\=
M^J)0F[S_G?">+A@J::-72D,*M&H=[?+K)^%9*A,.%L:L!WC_48[!4A[W#+T8
M6%S>:%E!BD*J]6,,N"\JMI(9,V9&%N?IH8KZA[IONJ8TAE1?'XE;5$CX$GQS
MSY'^G'?\4E=UPOFZ NG( %#/:ZQS#T!8^Y>2RA%\W5/IAL*,+Y)=VNKN.^PX
M-PLJSYQ)*KSCU^(GOOUCN;/66XPI&C:Q"0O%@Q9$UE/N8U.=S(ILC @RN-:R
M8V?1 D$U/-IQ]=P)>^':L\'\RPC0*(@CS]OH13 BFA,1P5*"8*6GE!P:/<XQ
M+[>/??E%>:FQ-4=P_N6KLPEFW/0?<ZG+BWZO%2@(1E#^4G^6'*L?HG=RZ"#F
MR\;7H3YR8ZM_9F>=7"\642/>/)_<Z_M /R=[^U?MYE/@098@F,+4YHGQ,VU9
MII /CJ,FCK>I(KHAP&W]S,,%[!M\-Q'0DNC2FC;Y2U69WFCZ];(H^Y?PLCU'
MS7X3MKN(VP&LQD[BU[4F];=5<%0:F?P#S\S!6K:[[8*S6NB_5O<?/JJ*(96A
MY[Z(\#N_B9S6\6L^XGIHI>$FE'K"#IRCS*5[>$I%<>U\'G7K^H":G^4B'4T3
MZ[M]LRE A#OVJ<L=C.B.I42O)8[*9YJQ%,>2B\.'(>]J&$Q%K+:[Q-XN'PHJ
M_7)*]L9X-_M2,CU'RNA;QS!?[<2P2@5 ^*2ZF+4 =3;#I=48QJWNUB?FK=R7
MK\O%1\Q(1W]U19FNQ-ZQR+Z ?]#+_U[92N3Y]@K>]OM@%=.V"\DXAY_>A-DR
MS'NS +NZR4;]_M*@LA6Y6;OKB*9PHJQ..#^G#/M00U2!_0B94,R(7>*4045X
M $+C)\"_FW6X^588!0B-(BD1$'5!J^0%+ E),R1<1_*CKOQV[\"B+CVQD;/H
MOK<)VY&M:*H^,QF/^Q;$TN"V A&C,^:L*= 6*LQ8;ADZ"#?"6*(M]5G=)'KF
M+EQXYGADZ+R)RX^/;Q7U7XOBR6*;,,RGNW<>X29QH&4\:W"J79N]'Q3FB:XP
MWLWY@(\7A%-+.Z9,:LS,"FBW#WR\\,NH]Z3X06?T)WF8;/\(<0=Q*8J>QNQA
M=8 S4,O%@@!T7L)#::#"\62<*63$J3DY.X-YT:4_UKZ.")Q7/_8KV-,AZ]P1
MK/5B"-^#/0<-9.?=GDM]G^")Z;+EEP&&2_&,XUGNXS*0B$-I$=WPM9W8/@VY
M'*=Q0]GJRE?QL(O,A)A/Q-^O(>N@[$GP0A6SMD'O6+0 -Q4-9U_CN#"%\IF8
M%8>,<T13HXNT=Q-]\[4LH?U:#HU-N(_FL9;7<21GT"R/M;P)2R9#DI= 8YZL
M51#=QQ ,VH3)!Z5QWA_4ACHO>P?]F>=P_2UT"WM<ISU7$@V-A,):P < <07)
M%@4A)GJN$O;/E8!@' ]#@+JNJVWLT^AX!IF.8VH/;-QL7J72.O:H2<E_5#RB
MR);[8C1\.OO4AY>PYYF7]R_B(4RZ#"0B5!#A6-"T%$JP5!/CU&>[6I@5/=CL
MFRD9: 2F:([0$AQN8J7^LZ8G97XP0K==:]]5_^GH(NX*I'4^\.%P)P*8D6.Z
M\HKV5OW&\B3:)JYS@WBB#DRX_>?5DI:&-G"MJB<VPM(WUVWVV)A"S@.&C4""
M%(0-\WC*=-2LQV]6/W0C9]0)<A]/J_ LT[['8(8#IZEEM P-:7D*YGZ\9.@H
M';[8[-3[=$3^">,H6,$365A I"(8%P'P4.)"(7W9/&O],2X9(1'4BA2;'G@]
MQ!+UL(LP/C6\LQU?]%&\JI306ZF6&^\Z\$R<^[H=XAU"?S&?R,VNJR+U9$($
MK5C,"PJ"I.[9$9WXW ]59?/\8R(3IH<K C^*SVIQ!K;A+P.4S]AI/$_%EB=J
M1\5IH!(=V(A4GC'Y/8WK4';:8N94E6*QQJT7C5EZ_+6M@ >,DPI9Y(HA2$+9
MX<Y] P0C1=&!W([V&PP:L6M^YXT_%1-HF[Z9=_CV$Z>=]6&:2='-;/(IKC4W
M T^90R1NS?MT9PH6.P]-"@DOT7;,\K5[L8/KA]!&KT*G?A%>_;V<)Y^>M]\@
M,^_.3==%88Y,"N02]@& X+,)"\>2SO<@&BJRV^-?$"B -+?* > /C;LT:O#E
MA_E[S8=S'EY"L&-M<4G]9QP6X&_Q;X4Y:FILB/@2#N%#<=MY1+R M1''^S/:
MD?K0^,K;6J9/1_FHGV9K0]&4\WZC/]/^.CK#KK)[E;==.R B_+T/L$0RW'&@
MIA?$^.#381"+:]I( "@O\$J6-J^_>[Q\=OE3K!IYUPQO]O7L[#ZC'8_O7'SR
M=B!6@;N=N 1PU"'LU+< H7G,%PXY:_E?]QUK7<AF$X# E\=ZR2W$B &$8^U;
M=%@(K ^H#"V,#B-J*":OC=09!;T^6;)M=->BO>)"'- 9 E!>X1OMZ2W0I5O>
M[QJ% . "-P-CCN0<!F]0-@JD4JUWCB\5F+7?0A4XLC/RQ,OR;,5;9^W"6LXY
MO/UX]<,8)@4@O,/_NK=V!\DR(@/+4[_P^Q!7X*D\>>A^\9"#9O'JE@BV4Y@T
MZB:1!M&BU' .HOK'+Y&(Q#"EIJ*^NP<ZY0TSE)O//[F1+4U9@JD+TR.@7&M'
M;TV,,;S1?YLP.B0E0./B.[7LF?Q45IY91Y7;![O,HIJ..I4WZ+0(;W>O$]DT
M%8&JO6:RYC%_[%>1"Q%1O.VWH!M8+EN+@V/,"1\P=H&\C6.;3NR?UV98.DB0
M\D=J2A\&R214[8B7GM>V>"/O)/'XHFLP?$OE\U"CCKH'U&["5H69C@M2?1"T
MN$U[X!+6#=2UQG_$NIMZG[CEKMU4E^1\P$$GLY3_D/?PU<I>3"PDFU\LC Z@
MK$WKT1#]4M(AOSU#GAT$L[4_G?YPM"7]P_BAKT^MSHX8YO@#\MN/G!5>JJ!#
MJP@T,Q&KT+O@(_ P]%OW)T0D,MWB32+3;.)X$;M/J:BJ?"ZG$]_6%+TC;%<_
MJ>E'CY7C#N)/9XYL(D]DH P@&+8C%^"*(?C& 2Q&%ZZTW%2 #5M0/%=@?3S7
M&GQ+'[KQT/J#P>]F'M0O-F$&8;SW4+.28*3PGC5:<"NYU8A@O"!F$%^/R,:'
MC*9>XRL%U;HWBOHF?2Y?>K>O=_C^3L2 P6J6?5RL/!\(C6C"AKPQ1,, _3.D
ML4D'-P/PP\JL&%7P1O'BZ][Q?2[?/:K?&G@-!'%+7PWVRUIV%S!G9DND3SYI
ME5 ZQ#T#$;IKF[#(92#*&-2MN-ON1,N*Q;7[4DRMI9B9>8Z=(7L-<P24MCL/
MTXU*9T]^Q/S)TM,3PF]'4+*1S15T'-L<[0_BV3>6(3YHG(ILN-3(K M+-6[W
M+%UNS9WNJIMWC'G5A15Z>CU/-&C?3^^>H)ENRA+V,K2J#R(4KHKI*V9<Q*OP
M>I$J&%DPCYJ=P7PS[M  %P#[IVCS*R<G(SBS-=9F[-,N1X0;;CT\_EAZF.<P
M  T$MJAZ6G.?,D1[UP$ISCXL[4QGI^IM<V/JYRD]14. RO^N<)?DO#N7(K6!
M88SZA&T<P M:0JAI,(B*YQ&*V<^]7->\80J<&=ZG35C=4B:"4@HPKMOWK4VW
MN7,K+&,HMX7HS_X=P4N&YLI%1OQQ/'Q,YS05%O@14T;\\P@YO$3G9TO^YWD]
M0%F1RD36&VWT1TF#8E9'WT-Y+@I/&E2*5KLM]O%HHJ'UI>\WEH^JP1END(.%
M!XI!:#1%2O!($$":<Q3\: 'SE>B(L#*[TA]%3YKB#Q0FA]S+,8D7C%0X+6!I
MK'+)X? A0>0\0*$9D^H7C/OQH'D8RY_[*M;ITB:L![.'2<SD&+U>&2WY\CYH
MT3&:VN'A?NJ&OXS<.]D]_G?$UOO#J,@L\MNH;FBNAW,4\-W%$$A2:J]"WML@
M.'DO%'=WFGC'+9)4#)]=/!]C:5,6[Z;S-S+"+Q\>(FM@46=87(YDW+#4D&W<
MXJ(<@R:&A,?-8!=.^)BKG9..9J.GS?.P8S)2A;]N>)K19W_1^P\]E]K#?0A0
M9K&)Q>J(0'Q*L5J[(Y27M\''93^L]S/,\MX@EUW"6-_"E]KJTZE4M:6Y>R%B
MOT=W$(D\82@I,.W2 .7IS8U58VAB!?6=>V]?ZD&"CY0R\%1$PL_=4?1Y S=Z
M5NZ!0=</UCZ_#CX=1N$>X?V1H(D43[2*^9MU%O1E$OL1:KS#GJ$\4_!&R0JI
MIND1S5O%J*2EO3:9=B$-Z1#GUC-(L#TH#1N2&\&\A&)H@:<4XX7PE$?(>MV4
MU7*&6N^\WN?V(Q6AA84,'["5-4];+VO)&[XZ&B4@DR_\7$1$W>&YU)(]3TSN
MO[$"XB^"\5NE*/"%,4 ?8MI[C%GO[:,N3J(=@<KV> ^ E=T86X$H5'6H;=)]
M%]WV^HJ4PK\,.$<FG<P31;#Y,42X(MJ8'80^P>0N=K#-4"\_BJ!=#KE46'H$
M3 Y9&F:?>G]?Z(0([@E :8/_:B"O0KW$AP=%<A)_#D<$P#W;[[X"<3S1<K8M
MB+1ONH$SA=_M-&IJ2#8=LJP+)IY*%[[F=O?HUI/79QK&S* L/"7_F>9G3A M
MR]ZU#9E):G",?3W_/EK3IF+YGGZ0#D7VC,6UVV$$:VMH(/C6S-&(86QTL7AF
MGQ?&="<B)(HL0L]EN.KU*)V.D8Y(683]^7'0YP74(SS1-HRXK<TPDTQ\3QA<
MFF3=48*^W-DVV9#_\ 9CUFN9A$J(.U-B'AQT,3+I131G5_N1 =)\%D2ZI$(9
MU3Z"D]3)B9ZI[ME+11]LM#Q'(J@&!45F 8,2F=UF\.Z_MLD"9X4ADP4=0/4%
MQ.PMWO8G6)9Z,2N)B4UH1RQ(PL\XX-#FKP=K0KZ"(3AS>T7&HZ [_,5K<E-/
M(2&HAR5H<[8^V[#B?3!'-$>M_H7^UP<LW8NC=@!G&E,</INZ5T=&CO2N2+--
M&%X)_L?0$RK')*('KYG]SH(N/</-JP$BG<$CJE(S/ALT3"-EL-V]-&0,GX:V
M.-I>]\MRW\9AK,ZU^3,]HW,Q/BKLK0^=S=!6D#?2H44S4,(] .,<W7X N0,(
M0LH,L;*T?>J);PPC_5,MC(:O[5V6*HYJ<:=FGQP>&\RL.^%6";N]#JUJRJVS
MMN1-%#-"I>X@0M?@*T22:[:E+5"RJ_'U<J[ID^9KA-?.P41$ZVS]J+1H^ANE
MC7;8OCVC'%4[2#B4*=6'$PJ%,YS@)+\^UWJPK2<.6\,QF8Q]/_?&U$GKZ*ZB
MX?:4ZUBIAWK87 ]13^63?#@HL1(?OP /0WQJ+41I=4WQ_K-MJA7W1A.(1R\J
M:CL:OB0.B@\4?@N?I:>#Q2P&-XFGCQ: #+S.&T PO+'317H3EO&,4:IQ I$F
M4WNON,%SH&+6/N358 9VOSR\SFOW1U W<X=.)$2<$92,3A,03\.#QAOT-0I=
MFZ:[X!QBGK[ F/08^4(T\[@]R)0^"7]OE)5^ZILK7%_S2F<L(XK> 5EFL+6?
MY\T7M.,G(!AQ-Q>5UWM3CZ.OYDS"+'7_RP7/;9Q/6#8URS9U:\?1]>(2I$\#
M?A%W"_?$$Y]#4:G"PS6YE7A*?7&C.?U@!'5C_#Q-.*41+IVUU^%X\BB]:%7N
M8;Q41\/[YCBAZ"?;\]F?A0GD>Y?&^A2:NT>WGVCB:=W&"#IM_R*R'D3&G_72
M&[H^[__H"8:Q%MZ\ZXZ9I771UYN2F1B] I*30SA--;,@M%NQ./BWA&^+:-NA
MT4/]H7/R9_GL_O]]"8]LPJ 1&M1%KF[E\D70(8S1QBIFU)!)U]/\'_=H&'ZJ
M<#-U4G2';;^<GS-9FN3-/(E3"S_G>LW > EW%Z ,C\X4(9278SC7N>^L]4!R
MMX7)\V6>[*^==>+2 S\EOGV;3H&9/\BIA<<^H&!G*O7Y<QBX+F2BABBH'<(V
M _VH!5EA% -C*<#7$W1</<5"S'2ZYD84F0_FJ!ZXF!@4M]"F\X1W@1,.9=\1
MA#\WB ;5:R]\QH#5 &8P;A(OQ)FK"CU3<FEN/G%X'V%GKLK4WH?N_@^P7I>E
MID_I\U.=H9%QZYG$UB:6/6@'1%\Q['TU2*:9CE3-PG>@6DI"PJ_<O^*V2DF[
M:)28K?+Q[TG#SL"I/3?QZ4B&?=0]I *"4H61@'*J]D>Q(MHA@H837!:MF$'Y
MS*O%5'S1FO6>38XS6.1OHH]*?K;ON'W7#H:6HT*=>);EP1CE*!0!H(%=12]"
M%I&Z2/P9V\CPNN\)!)1S6,;AOR-%%_,63V[P+V["W.Q]T^E $!S4QG7#9]IX
M8K',@SRQ)"HYPUIGTM*)><2A_>TDQ_R6Y+NW]8YIJXN!:?G'[R7ZWXG42XD*
M90NEP\ >EA*DI %'E7L/B,1ED)N!N[Q]J&)/HO4^K]#<'_]VU0BVDMP>TT^'
M[MVY_WE,8S_A77$ASI1U&TJ!7C+$-2FI@)#UUHX'E_:MGN7--.X'Y,&!@6>[
M+=+J)V+?&16,GF"?/>FZNF@BBUD<DRR)]&,W'WZ_V%G.+>WD1TFQ2D#!!>.9
M(=KM4B>H0:N!D;_M/E_:9]F;3MN5^5Y%,RG'7/@$3_&B555#R1W$86ME@-""
M%.I4!0@FG;H 8>\"M]+RUFL4G&:<5FW:\\K'PYV+LV]I?M?PM*]3>_K<^0!8
MP.7H9.V"79UMW+N;,#^\"*8+46><L GSA_.!]>>(U[&"[E\\9T))K2>:S;=Y
MOG[C$*TL)A*2JJP.PUTNN6/-#VY-QEPTC%N,I[PD HSSQC/-"RD9[9*5H:W5
M&S='[S14W;HT%J7=>M8XXE1=E%L@>N3M#KM=4TXOI(T]V9"^"CQ)3!_ .+N6
M@6>X((4XEYEFM31XQEIU$^YYZ%7/FGPL*[M*L5PO=_#NQ_=:(FUI?QU&MSS,
M]S> #>4OX35$)UWI>FS;4'PC?'6-^;N_6,#2'8=TO%VM=V_\\*K&CW,>[M2,
MZ^=F&S*'/[XV+G#XZW)C% DUBH]0]H<@(#*CAQM(!4+7%#AGF:Y]N+2X0/OQ
MV#7%U(6FB<4<,:OA2RLM192J VFZ!4YM=2_<A'!C/_3YOV&W]J]R9%98YEMY
M#,HY,\AT;>K<L2'O3P4V5)P:*I1JM.YD8BU^7&5L/-CMSNESVA)?W_0?J:(@
M1 '"0W+]G_F=$S6=9A@R(&_I257?=3;<TE@P4S%0?X!3+W?R=^5N&/^WWA1U
MD4/:K.QT&+.0>P\#0]UB*1$1E&*X,'H_/ '-7P4*GV>4-S:EWBVK:^YL*A(-
MDMRU8/AU^)=)KF+0-?<A6:=K9(:C,[B+W(,#=8-6VX$ ?-(F3+H1+Q<",'+F
M5N"DFYRS9;R [M[JATD7X[#Z?IF_PK[_T^?_/4M=XJ@5LK71.R'[RK;ZFRWH
MSA3N;=6H4DHS-NUEJ)<IDF=$8V-##)74K)WWRSR[$2BB)C;2>/6Y/E>T!*J>
M"9X8%!R!@]QT@%*CV(K!,]O.?$8?6;BM.KK::H]%[S:)1AIUTKI)L3D:1Q[R
MU^]S]1YT;[*("N>$,8@\B2END5S_O\A&MA-F%I##Z'RWL,76HH)[-)XE:Y[0
M#,G,:^T_RG?/^KS,V!8&>NCS]R""1Z?Y*84#P/1!;TAI%!@Y"2IU%34GT3Z%
M^S(ZJD.OMYV<-[,1.V10/)=9(/ D]]J94"EP5\6J. 4![HI:S7G!&RR6;(^I
M K$.GW!K;YY_CAVD.3Y2_?%MZ7*WKOB=CT>[OAO,OWJ^K=V/)Z; 5MQZ@KN3
MK0$.L0Z!B0N2SD?'.$'JN3ZA))/HQI%W39W-[=X)1R]\J_E\QOZ$U<K,]^=2
M6W!R$].'D=SZ<  S\&P[-]L:CNHY3_P#"-FC"VYVUN\(B[FZ-^JGL1HJ4U Y
M+-GE[IC]S6(6FYMM"<5!D(^;8QG$AH,;?:T%266HJ7&2^)SGR9.DQ2^V\9*#
M^CJ"#D;;7@]^=[HE*<]'0S#. -/Q!.@-/KW6C:S%]^!5?G1JCG&T_B5ZA/Z;
MC*X9WH2%X=]UW*9IRD?<VEKKQ U<'C[4&#0+8QW<ZMDEQ0S&J KG&-,J?YV<
M9E(3YL6P>Z!8X3BY5"=M8/BX](# DZ.=P<(Z;?=MPHG?N?)\24S;K@*$?*<J
M*H-:4''+J+$Y]8]!QU[:(DR\MU"Z_?3*,W/8UTQF#O*^!9RCDL(V!@.%&Z'*
M66)BG=/MR3IQB"MI[K69]VLSG\3C9EJA//3DB7(AB)E&[^3>080!8IBI>45N
M/68/JH[=G<"Q>8[*I<U5O^G\[!L=.'_93OB;9\(*EF:'&R_2?[X=P;H''BG#
M0!,GK#V:P=^KVCB2E)*-AK\&;_[[-W)A)$*27ETPJB4DZ%@YZ.;OIQG8;LL3
MA>I9H!4,@,ZYW">FP$PSU;ZWYE:?15SMPI%BF9%78++^.=1BT=3X=*_ GJJW
M1B7[!C]Z=U0M0T5#,P8-(%"07J,T<Q35+H% -=H#_$S#B[QGL-1/61U"A8H'
ML9UG53\_:7FD)NA4N1!IS1P-_7N$I_G]/T^194$(Y._&X3EVF &7H_"'9$4\
M90:>"*@@KHRF(-Z.0M0V?"UMA.J<\DSO<^SWGZ?CKGG]:"ZL-FNGZX0CKB9?
MP 8KR[U_PL2.(V"@6C=9PE*\A&/*L,Y33TZCTG?-GAY;]87K-E;+&+J<Z/R0
M6FF=7P.U5@3$G07,P-V0R8*!&3RQ;XRU!>?T]OVTOY'G(H*@\NRH'5_7"L?T
M7=61>-Q59/SH+3"%8: _E[*W'A]MX3>!W&S<1YZMZB(K6SK7K!0K_30]''M;
MZ5+"7(2AT\^7IL+2#S\=)BU<_N(\1"QB6T/80(:6@59UYC[$4W#S:HR:YGXK
MP(V!3T7#XPU"K T9DU<?-S7D [>"-/-5?+2H.BK?5+:/\[^+*D<$.2=Y;,*Z
M1N]B%,##M*ATC^8LG.7^DIZ7S>F-WQ<\YQQVJFD7 (:"(7&"$EROA($"4Y++
M40UC=CRO"U$OQ9%/I%@15W^SSX/R/_Z9Y&746/P;C])B.[1=W%-XJ?[RPW*^
MA]=4W-VJJG;O ?8UK($'-EBQ>9X-GSCN[-N<BY/M@@$WEF91=N'T*[G[<T^Z
M3[>?ZI45KWEGF9>-XI:7W+'\S8KC/N#!>!^*Z^>SV(8<*3#*MPRE=GS"IY]H
MNWM)9^S]N^$)E0-!-]SGRH+>7UL]$X,L+%;#4SZNS<1X@;A*]$EN'A VFHH0
MKEZ_X;W$^/ET&WF65-IT6MIAL>= SX2H]@?[C=0N^-O)L\(]9(:#,ZB)6TW;
MRE;\9YXFQVRJ<50%?92XZI1=OA E][#W+4G)776>I/S 4*:MY&"N]_3S(8J@
MNE020,DFB[1#/4PPFJG$4?A!I(VFZ3*C4O\D3?RTW*UCM@F;&=-:+B#%?;O<
M&1GG:?"+? ,;[CH-,1L"H@[.4:.SC3 #2,8YN *4!"<YXDRIWL)_:ZEKL4-M
MQN)DF_!6#'9OQ?[<\WS'97UEOJ7QR_TZ&?/$-8P- PCJ&&E(QAH?2L[<A#5B
M[V ,P3SOSQC3T GRBH5/K6#K[/*:T9^-)-_]KZ[PG_E@+M>=O<Z"$.UO(J2M
M.-2U/?#^R%EG5MHD/DSJ'EF%X\Z(&;"@K\RO;%@K)1_),!@BCCY"O2W(HCX[
MYI!3^L @U^W-8F 8F>&$!\W46*>XB8A@1P1IB ;OVX0I<'S I++309]B$?)]
M.Q2+;K\_AP^3WAU?$"MP[X9N@&WRQ>V5*_]\H3K9\M5U"+BET;+0N0,%V8"0
M[MR#CF'&W]O+D2K_,A.R3'T8\?#TKGS=O?W^5Y3EE?L-OHV"B:44):Z.XT(*
M3Y"T"6,JL-7M8)@;J'B>Y!PH(T5_Q AB#8!9;#L4N8^(YV^'2 1_M\:.J9V-
M9LE6JKTV82:9<L,'U.X3:Q+X'GW<U^[ZW?I%Q73HE-RR1_D35[/F?0VN9K_[
MU76S[DI45R2(Z$C?3#P/@0>D(V'W%@,EB^ IN7 9WDX4CF(\$*7TXY]4KTX*
M_9D,L;39K,E98-RJ/<<R>$=#](BA^Y5X@X0;VVIX\WB&'9"(;";2<0PL:Y:Y
MU"\E]_TFL5LMR\);[\2X9G.8YT+(Z]L= OW']YHC!N-R?OU9[!PMN7/8&$L6
M:2@F"5.<LS#\8?]J^I*P61S=U\%*S5.A+\-044;^S3>D]^UQOW3LQ(D#0F'=
MD&K0J.3HG QGG%R;F?#D/L'(<1R)[1<KPC"F[Y@Z_U)22^[NR@ZI,:2?/K7S
MHO?=\+'D$]?H=*0+9.(S...B,VBNQH*FZ(1JWMB_(/I!IAYM(,-R9PT)=8UL
M/^G+Z#5[:75*/R!_H<#6)/SXBX#]/^'=J?M_$<GSTHSB%+0@U<JX:UYZ_,K;
M\>O>%N*2>_OY[C4W)9MF'YJ,$TM_?DML#.+5ZAQ[J /%\(95B=CU35BJARL=
MSXRR;V$JUD0#-Q0+FEST0P)NG/(_(7K6ZV[1RB8L< TTM:<4KLZQCX%*K*1Q
M1.1:IL4(^6X[LB*,13KQ.B8\ N=?WY)-]7VPQ[]_<5]-]E4G3/7844%4$$<>
M8,DS$!SYQZRC3,3J#:9:?RLNI0$K-^IK]+&FQ%[.JSLBRK?M;,E9U\7@BV?L
MCT6/W'HJS_<5^1983:(:3^NQ3C)<5],H2(4?%HMYE,>B->&-WN[:GAE)N8ON
M[[?(^X&<KN^"*")'P9XGDL%6! @>U[,L-F$+_?F5P3[[/]&=FE(6R&(C.RSN
MF7W+X!;Y:EG&[XO23;#XYH@H&"N\1O:%/)])E@(H(UM#E9SZ01=NZ=8&WC2R
M=/OATG=LJ>1+\P:",ML05P-#]/PS[_"+W NWGPLXI+T^2Q7NAB<C89W*W[?&
M(G!73\\S1<;\4_7LE)*0^ZO)XP([]-4=+'.''0_*#COH/,O^SPA6\M\CV&N
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M>Q3S(<NF/:>_ Z48:/JK(."%UM,;$^^_]UXTWSOM]5O9MV72[J]U)'DD$.9
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M2I\8J979.;?X\^M/8/_JV9;KSYV;2]_:3#W<E1ZC?$Y9_ISRV2AE2)Q0<)&
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MYR5[",I!?RGI!F.Z'$3LQ;C)[QXD= INI'Q:_%W4*Q]2:]>;_:^[H\D00HP
MR,ZBWJDUV"1!**W'N>M*11WC>*38*D,I9;;>& 2@2O#OQXH/K9\Y[[,7]F$]
M?JZ+8WYY]WDZ/I<? 7E;+_Y>3F <WXXAZRB45F,. @S?L>-_$<EU G7%@*]/
MU[G_-->MZ8.RH?""XYLTB1E)JQM28>PAT #>09A6A=:=,H]/0C3@>P36#'A7
MQ0&6?,B<]C#K]($KL0$!]1E;CLB<<)=(KR6J-YM;+3$-!DCT2AK;$74/L@)H
MPY&&9*2*T C,[<@"#3R:QHR*V9^M?D[ ;8(U#/_K:X?)R>.]>>NAT&,NE*Z!
M5KL&$PX ;'<@<TX67.7@&:B4_\?>>\<UN6WKPE&4+I&NB$2:H( (4E1*1*6)
M"*B U"A(%Q"I8D@ 0:0W 44E(B B)=*1%NE2E":]A! 4I2:4\$+:3=8YW[=<
M^ZZS[]K?=_>YY]QS_IC\WH2,F9EWS#G&\\QWS#$H6@6 R44["0\DN,/KVO4R
MF_P:@SPWTS)<WM/=N3['-DHPI'J&XE0I!ZEHC#?R(:RZ-UK[6%#4A>%&KL,:
M9*Z66MU*S*BWT!?JJJ-58+;_7M0M=CT!;E^8@]DYR LLX5HOH"X\ Z$(D$G%
ML:1*XORR#![#MI@4%#!H\&BPA==ZVS5]64X^;.X\KC?3]V'"WB!+BDX_@8N6
M(DULH8-V+R.!&&K"ZU!M%BHS"P*6#F) T&J9)7_"-=(9((JL$S1H,HC@^!GM
MDN=!,K,Q?/ NLB)FHJ=FW;1DMI15X]Q<YO:["1IW.S5AT_A*?R,#FF-%5*?4
MIL_=?N]1QS[V%<E9UW3$Y'+DC@/F-F-UBP*\9';$%T@9=BE#<<F1? :0UCPV
M\U/%HYLOO<2I)L7H[=C1NG0K#K=\S[$3<QOF!\S-Q9C/!6*9>XUP9J)C';@\
M$=:,CL (PG5GZV!"0>%:UBN+K7<_INA(G'L?82)]7;!Y/LL79L- I6FP*DN*
MB#]9A-8'.50)&0>37($Q/#@LF%;N([53G!@AD>!YLEO\J'[XOGY#SX9H^6C%
MM#&SO0_ %+Y4VKY%:CQR)BU+M0X8P]GYVA,9T.7YA)5"5+RFM<.^6P(O+E7=
MU<N^I<PCIN<F=:0LBG,I?Y4!$&>]1[=H[%$$1Q(S5/L1_ +C;YH[Y"#E&CX1
M M<1R<C,$@\?\ZS(>7 OU<"SU>!@0*['[MLO2_D:%G\JCF^1;@+^9#=$#T*=
MFM8H+]5RCM@;-3^HZ%+%Z5SI?##FN\)']'.!0M&")#U@Y$B"7#\#9WU!,TAN
M4RV&304,2*\^9F@QS1)3J9BH"MFSF*42U6IAW3:4AYKPRS<43RO.WJ5V7U%*
MXY-<TL GG>T:PCXHC7N$^J+BN>S&E!R-DX/X;GQ:<$*PH7[8];'6[@@0. _1
M]2\9CN08'3]#, /B;U"X1Q"L07)X6*RFOV=)4)E=@/&UMC6]D?T&I"K2=P&E
M4,WW"BW!W\:9IW+?,<9V"G$(V62)=/: C<7.HEKM?%M$G- QQ?YM7^NA HIG
MTMGSHQTEG)S&+RZ9'.R*V;&( 5$\F8<FU*$NGMH#<HPQ<O(2R]C%XZ1.MFB]
MSG5GW?V6(Q2$W]TX^J^5D24U&79P3S9A/KY>?0:52%,AK@4-D[IFO\,.&O%7
M/JLR?")O?T-4_85A[Y8N,P\=XAIM&$5PRU_R)*;BS;>6=Y&/P_V(Z(^>R.LU
M*0\6%=GV/#=.,.105JW7>)T^JB3U=,!;]O:>BRR"LV**C'%IP0T)4,-^FB:M
M&5.]^E@<6,9Y[S]1F>?1J#9X*]'X0XT>3\1]I6Z%^NRU=GWR^<: I^U&EBM:
M KO6.I89$')/U6]$1X(:K:E$/LF,,=M\5F\R&R)YN3QK<98M2CS6I+YZA&]2
MWR?$M?!@@DIRW+/('->NM+WWWG5O$_.031D85N>&<L)\ A/6\5?"]HS9<=PB
M5#8F>[/H?9B32I0OE;R97*,S2815,G!K:"_C*W'4EQ6*@$P X[;NZ0/T\R:#
MH#A:X8S=A19>[<QFF\(@M&2RRP?L"?C8V+<4"Y<O\PXF>4&H)A0@#OZX&LYP
M39=6F:G"CE5XQV?)U1.J$RHU8B=6^:=L)O:='\M+&>IJ?Q>NO*O25!D\K3VT
M92ZP"P<E&*-'U3]B",8F8_PMV#*VEL1#"],2 YH:@4BMQN+B#K[)+J^2;Q]N
M,GALI-NE.)Y0RSIF0EHPF1?9A$&51RV9D:4IWM3$#>]8Q#&B?A3MK-N]L:#P
M5>OJ*L,EP669*C!;>EC@VQ>UZ6S<,6Z84GW*H56R.JT54AK(8-NC(Q]1PIK7
M"JWA_OTE?AB^(-2UZDJ;"2,W>:<*W4BSW1!Y6Q.)%;;O2?,QY 6&!4?B BG[
M!V<RFGL!:;88Y$RJ"*P]4= 6N-9FJ<YO%_1F=GK4??^SDNP/X@(R&2WG!9R"
M^6%2;E"",W)IY-7HFXQL&A9[<*DX1RJO(3?=I_W#F=/F<;M2#-%CP;(L,\R,
M+-Z4_5$X%(4/@W?&$,N;8)7JK2:';1=I0B%\=J?:^9N'"9*V3= 76=8/,2?W
M;K2H,N 8P?"W76Q%0,H^&D_EQT$9Q#BH0/N(^W#&UNJLK$+?>#V7\KN.N7=S
MD-/S9W[(+8G(LJQ/D#XP ZCHH-O>X^4T3N%L9).>)8,PP,5GB]6M!U1#;/3[
MCE2IG6VCH<X:9/!%[R_3C!8P^V0:/VV_6M_3L0H[!%B/=(AQ#5$$'_A*G5P4
ML6N+&[S(^F/XQKARB^9MUD^?F4F/)9!-$LB9) @'E/%G7[T=81 GTX;D!4HF
MVG;FSKZ<ZGB,J]8/PT=UL6==>GM<7W,]<V?E-Q0]GOHO*>SR&4OW*46%\?<%
MD(-GB][HY:,H5P_,#L+/W-K[H91!+@*%#9Q<+AR9'.'.=Q.5;;,G"C.W"H29
M!JZD%DP1W,'/]D9+$KW"<ALBQ 0,%.B@\CR]@1*5J9XV^.1VH#Q%?=IL0I6Y
M3;!F0A%$T]B7R>K,<A+:!P#?C]A#J@TV+;75$94N]7V:EK@?./5T8M=SF4IM
M][(*Y>7HIXX:V7'A)W6:@$K&BC$&E(B^- Y=' :0&BXFQK:2&@4) S>*JV,4
M9JK.1F"=/WA$3A9EP>1'3]NGD?($=@%=&(+3UE*V5H2(4 '9#WX;9101JD(8
MECB)FC)U<(*1YZAR&XXT#@;QV]-&36;\I PHNQ=B/Z(+P?FA(O'Z!R/4?B#*
MJD[X;%;EV6/7'SP+?RLN\/Y&_U65R6^FPO>P.@P5)&-$H#/])F,H/-LR&QX]
M?A0Z<6'V3=B[H*VVS*R&M^,_"IQ$[W8^")3N;H[_MB);+,[B(P-RR0QL1@,J
MJ3.P9DR,V"$ Y41&4%PPSUN"-[,*]L5_&RIXA"N>-[SH'?%E^-C#A-:1Q4B!
M700]YJ'?O0 O,R7X0\:MAY B@9^SJY"@V"O#_*9]\$-%$^-O$M\\%2B.4WK-
M\-(G1I>3A0,_'[^?6%.^L@$#Y/0IO%LD;V9Y>,HQ9IFWU?CQQ@(<U;(YL]P>
M>-"6!4G@?^"><K1S&1-<5,R=[>ALZ^*G]%YS/Z+L=:CF/.D2 "Y&]$#*,R(P
M+E.^LZ1*?!4A(273$QVCJ2_@@0ST/"BQ]T7[[KK<!Y+8^)[]0MU"CC^^FIW;
M*_#?[9_9( R2:82<*87Q85Q@L=.2U 3DK=ZQX-79CC;8/HI:'3$J;M5+M:9B
M&=)D[7!^0'IH,D4NY+5=]FVA[O>U]3?/*%;E,*:$+;.ZIN8#\E7*]7XZR#%Q
MPH;D7@=<(SZX!KC=PD.Y.\70@J0TO+&8JUD\]47RV[4;<Z75TEU[G@A/\;\#
M,!1!%](E:CW2"3KNBT<S@QQ. 2ZO*%<(ENTFX:< ;[S,0]7#/BK+1KHVQF>*
M!\W+4TQ2KB>P#V6*?QC=CMF_8FERD3$()<8@3*"W3<81BE&P,DR\]IY%.H@'
MH14D@V--]<ZSHN@27@14UPXG[XMS]ZJH*T_/'!HYM:=+2-_%W-_R[JY)VAB$
M8!,+'8LBM7YE/FZ(A+Y'MBO&(^3ZZN6<2A9;< $)&2U7PK\]E>@*S;#7+*\)
MQ328\G@,T$$WH<P$$=@)6&N69!\\A+'0UH%!PA4MUG:N6 98B,D253NY$"]9
M]K2X$Z+QRK1'@U60R!:JS0R<]&8XEO!BQ BDPF2ID,"/0T4JU >6_-BQCR*R
MX//:B)4HPX'BK&&!0<\*ZH#AO&>"9;I)\OFW3?=\ENB@LD"*8 ;I-5$_IE$#
MT0*M3FQ"@0'FPM8E+&RU!0AK<]:F>X);=ZXV/5TMHI#<^#TZ6<V?1:_SG%<V
M% '=@3-#$N:"4EMA0A3?&<CH!1K'&!%*"N_3%G9?^ZFM3>R(\%:XLP&HLNNY
M5)2NE^W$]6_<CMMMN#=03K)Z %F:O[Q-/HV81)6UH9<?$)!M?-; ];9[JI\H
MYV+=?%]-VNSV*D:;EMZX'<%=W6/I9FEQO*OC.PQ0'6RV-HF"SD1#V3<+99L:
MB(>QCU7MG'^\:!CJ]@CLOY\07,Z>':U\?WLO7'IV590)MC N:$#>N\4$-&7H
MDNM&TZBN+Z^LTG!\9'Q_16&5%-:\$G<\24/V\%Y02 :4(JI1&!355-NQK$%P
MH7&$$?/;4>7M#_WO9F /5C2YL==45B=U^" ]WG0UNRV;%J8>N\W)6_VXZS2L
MD;:7X@7<(AM2Q C8#G0X[?A#&P(Z5N6QOP+X>NA^F7#=3UWON1/.6.CM2DM+
M"ST2LPX!CJZV>+,'P6@<V00H+CXKWO-H$F8O!>KIX]K/<KBY,^^C\XFSZD^_
M+(TMV,X7PU$,>OG&0R0'V23O H3XA\B3M#F ZEE/\,5UVZIN\QJCT!RM^NYH
MDZ%X$.+);_7,[*7?(;YB#MY1U7C.Y3U:W;YEUJ31<;C'4FW"V;25[:!7!'=B
M,0PP(E_U0/'5>[^#:PTWLGD@#@_Y%;*7?"__ZGWD/O<])<Z ;&F=CFO#H5K!
M,1UT4$0&@XUEG]^B[5A#<=(,[_7#M($.:DP/59,M0@*&_L@= 47D:EX.C<\.
M1HODPI)_NK(X_-,$C1*%%H3>5[;U1GH-J!QT<3$%47YVSL9;7.3)XJT7?Z3#
M4Y_X)53-]?_ R/YS"K[]3@S9K$]N@T:6).=YEA8:O"K=$.UC_2:82 =QG$#3
M0><C5ZD;%<AFHT(ZJ"_[ 1T4H@"Z8\8,.$Q9H(,V9.WI(*R1/D6J%D/E%,9L
M#?2QMOVW[!]E/6;)\Q\\5 F5_6D"I_2D;$.#19US_Z AT.CK4CKH5S4E_JZB
M5_MBY""_Z/>_)7^3S($)8[6ZK="1)7%OLS.5).98^O JNS[H.M)!ORH \JO>
MSAT2L(#^KKO^/^AM5^E_R_Z-[.'JV%6TI/(X8+V@RWV]S"#WMO]A=Y/_5-/D
M/X D'[ZM-K)(P<<79U,1SVHU]A4$/7LO*,<\F24_PIO]5M(%M.3ZJWV9_]%_
M50SCK1A9T+\VEK4H&N<ML@=B#/6^>EF0K!-TC83NT[PUBQU#S\XW33PWB<B2
M)?1&.-96$BS*5,9NI;=O+]_B>]VKDJ+^_-29B;GEKJ)&6";MXPCM! -69B&P
MT-+5CM4P[%Z*>39<F9K6R%GUG,'V&R7Z\@9?$\70_CEY*))36!+KAP29[=C$
M)W*]2=FSRK1/ !WT<?H@\'+&V!N'CO=;#\P)BC+X,*CJ8?X,?\K&A%_W.-OY
M@_<26NXEZ=UC5T&!-??BO",1H#[:@2#(%;5,Q4<;#^P4]2O<LB[L*ZXW$C"P
MZW1IEHCO,3S=*=7'-F^'H@@6,D]NA-^G#<&$$,SL=E84%OPA-(L]D+VI& 83
MA L2OMM,G5C534H6>W;WCJ1\M0]8_G!7CUWNI+GF&S@:D-EJQD0S'(B9"7!<
MOPW*+!N[&DJ3)K U%ZY&+!)Z<8AHO-V9(E48KY5FI^J7?(4Z>/]%@^1K@=S5
M7.&7/6%O54S9\-44_G+26A5C(((4MF'HS%,ZJ'JU"1S#@23@6W<^ -=F81R
MT*)Y*7$X,3!0=8YUP)6UK4;96%;ID_FUX$+ELEJT$WD?LNF4]EG$()1@8C*.
M;8<Q*ZX<)8!;P1.*K6>'Z_*#'*TL^(.<^W-2R2*'*MN_!7WSE13?%>'$LC>D
M"VK^XQ7X4^\8BL85B*9UH-ZCHY .V 14:7Z[$OD*18T0H0WN;Q0=I4#KZV);
MJ]--%?+2OC7,'>_K]#R>JZP9FDI[WRYUB(OJS0#H)ZE1]0^8P0&,[[\3=&C&
MNUW G-BVE)%UA%AA>!R3_!9[95!E[Y,TYYA3 O)=ES*B8U+8T>A_C?:L5_P(
M74LR@=!!H]%YR!_M:#\T%P%,R>5GH!Z2A!ML1^DMRY3LZQC0W[;/Q$1*K#!F
M\^/09PV:#@$Y(D@[7P!TT'1CL3LS[M]?TD%' .AB#!TD?H[_KY8%MH!&(^<4
M&9QVY"?#C!K?^9O7#/?_#]073G2B@R0;5JGW=2F?[UAH95 2MC";WX3754O_
M.D=W'$-^6F7<6WLSY"D;P5][_ ?',H/<WF-$!\'*D3_,2V_0V.B@I(N83;(Z
M+=+FK_?R' _9%E)$+H859@92'C*X:XD<)?+:G^@A].@OMN4?:G^K_,(IN6;F
M&99C>XAT$/5QIB4MSAVT=4GV=2CGW[13S-2?$FVKU+NJOE<8/P\.V6Q#)KU#
M*-%!R0Y;M!J1#_G(3]K@G5G,)],]7\W^I=[=_ZH))L["MKE^T$&;.\@-?IL_
MOF3XU+_8#;/]VZJ\\]=+ MP@P=8TIAGS\0FL9[CMUR[_P<$ $)H.'Z.?)>R.
M(&.:A]%!<[R*5,1GAL.P:/O+W3C_Z7J[3ODS3;SB>/LGJ_BOM/]Y!FQ=(F!
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M_!]9<DHG-"&OQL]M65I'?C6[&#F78C1LKLLBE7(%Q-* T&<F6:6#W$/T217
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M/9=S)J.@UMNCWQJ/$DA/_P=[[QG6Y+:M#0=1:0I*D4Y40%":*$5I$9&V6("
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MD['0T+3\4<*9I?U0B6NJLBU(?^G=2"?'N>O_FUOP7Q[O(;"Z2>-?HXS'41P
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M/C0;!VOZB!T.'YY\O\XJ?Y<_>4L K\0!9U[S829CM**O>$JCK_@:O<@.K:_
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M&HWW56?*(K0L"MV=O&;#?55^+M ZDR/UZJIIBM"CV%(7EJ9,IN2A[Q9Q9_1
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M6Z&Y%K>7$,6=5#_H?K%O-3\NI6V^;WSV'(MU, HX@5MB)>R QF MR7!#<G%
M?51B=8.J^X_7_FD*9R:;G6&L\9%2+O#P2*V3V#,XR]'!NVZ<Q/D;$H$O=.".
MII9(9\C'JT/F$2%%!2ND_(-$]]%@].VM<E558_JC'9",%Z2^RO%BK&S98!+Z
M[^NU_X:68('50!H_'X.32K)B</21>?0 &!E""0+ZIN5*0O0UGE:OM)FSYA5Y
M[KWA%M>39O ^[N;SBP%XVANQM0ML,4Q8W+E;;QA">KX#:I-!W@FMARW#EB&
M 6*(DC77N];8E_D)UQ"PDAG@VPN'42\&E3$X6DA4!A<+58K9Z^<3@$4PF:\=
MK?1%!18C(M-JNSZ_]$/KS,B=U6LXZ6AE?1_O[MF.8^.*7^ I<0^F=63HI4C\
M)$082+<@1\4B\8^0XDK5VO;;GKT&%.3#YR$Q,_=6C7#D,PN?VE&^3IM_VE1>
MPX1NB3IB] (5I4A4.9+&:T[L:ET1!$8"!HGDM'*2MZBLEXOLX!G3^Z/WNO<J
MS,1'$)XIZC8WLRU*[Y9:4-\!M>A"\$6X<G4:GTD;R9SZ,]PF=JA=HS1+>S2R
M43!WK#>XT(-A>^=.Y%Y?_CL?+YLJ?GBPU_MCL@GSZAM,$5Z"Z$"2K,PYS(L8
MGY "-QI'58JX0I+X $V+FK2A*P,9UF#YQY^B;U[H<LLZ L3@U<SDUMP8G"'3
MO6 &!YU)^6WIKY#N*^.BA+Q:R ,==41O'T$I',/G5772GTN)V\/%E*J%O98D
M4E[M&3-B^$&X_:-/^;>;VST,#@L2E,$Q3#5VA$LQ;R,*T8<14"GQ)>:'HUF_
M(]C(]X/TVON?35N7)]B+6PY"7GPN;K#.:^EHM/V0<)=E';K\I_R5]#"DLU=
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M[7>LNG>II#@&E.:)4YA(Z$EA=WW2.?53&*+ROW]DTBH*.TUI %RI1VGGD,(
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MSN+7P"<7RK."Q9/:7J&#R,S%BG[9U['4H:76?R)[SM\L=/5_O85[]W, ^>M
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MS3S_FA9PZY94RFW6XM?_MO5[#V,J92'PS#Q8G';X8([9[,A)N)+D&0/;9<O
M>Q>:3[R'A=DK==(U*6/D#E0[4O0V-O$=FFNHMW<6E5>EK'7+:B;L$>G"9"KN
M.#KO+[.@C.IT3".W#XXA\4Q*+?*K@UTC,N._IO4\BA<;5*TBFH\>+G$Z=GCM
ML,('J1"12E>W:3VWPW%VE5PSBOU>B1>Z1O[JUK ;9 Q]_Q*&Q*17">!?'OR;
M1_-_F_]N\RW/-/1)1T-3AQ++L<E2HP=I>_;43.6/U-?_RC+"NN2DO@-Z.9G.
M8 63<WYY\"<WP^^AM2P3 X, LOR0BA/Q<)G7GO>]RZ?COJO;S9_<;]DAY*/=
M!9']4;")&D-X,-7 OD.[6Z2# BG0(1D 2JJ8';<BT[^<N^XCI7'J--$NRN!)
M^)-HZEG:>QL@G7*&'LU00$QA>+T94C2]D6HA^%GZRT$@J4/]CE/HQ1OW^INA
MFM_.S]39MG1W8Q.V4 (^B2>G(>7WI)>5+0>ZO<S1#;Z*)?,2]=\1R/875C';
MHQ0SLSHR[T!UE>:6HS\Z>;$T,G"ICRH/#]WU5-!N?('#B%F(I?F5D%D@OU/D
MX0^61)YD]N^#7LU7KLE[QN.]V#9\\2O-5*4P#,\20IBF&&XZY)>Y=TO2Q-+)
M!G+?3FAU5?E;^1P)Q)U$J&V#LL*/DDRCVC!1$F*U@U6A9PZ+YV95X%DFGV7;
M/?M6R6O":RR5,5GF]B@(PM5V1=P8XQZ-ZE(O&KWZ=*-Z,Z1[85MZ@=3%Y;S*
MJ?@&IQU,\T7<KRHK*<-<W0CE[:(*)C!9B+KK#BBLBW;[5T>>-V*I9Q<^(<N#
M<(SP "AP -F9](OO?_*P_L?:N"U'1CMD.M0MN@H=N!YX":?HL6!M9$"<0[^^
MFU_9D7\?4_0/T/I6*Y1L12AK;5*GNA#-D_P2.+\^M#2UNIPH#BR]BE8,C32%
M&_XI9M%42YI8M@<<@:MD2_1V3;V<3!RM?NNW=;2C9D((GV):S"46>1T5F'-@
M=?".Z=?=2NCLS,D=Z]G?_9;1QSS2<CZ0<Q!&5#KL7E0[MOSR+N+5-XF%_(*R
MU!V0&PRK1#1<ZB%S@J/!W/X*B5?TW\ZO\5Y'AY]7-L*\]2X,EJ")"U3$_M1^
MC9Y-?X&Y+0ZA9 '^;.W@J.Q3E9+1&PIJGDC<5_/X9V] C&-1!\Z+DW&A<9T[
MH'51YIQH=F&H FM48;@[&=-BGF1_HHR@)&Y[.V!T,QF[:+EH6?'5Q,-AEF]Y
M+_Z>GO_5E@_"96.AZI9#U9GL_H['&5Q%#M'M:9MJ@U&)5R2//7WRN#F16/'D
M3H_9;.#71M@.2+=!B;8?,FWXRP,'_BOQ?V>E@/ZGM\]HR7D2GZO,B[1=J4G0
M&3HJ)[4W:[Q.-9^B),JDI-X].R"6)&#@UY7*?T=*] _3?!49VVA-Z-L;=&^S
M8TIQQ&M]^:Q9K?L*S/L-EYCRVV^I=(W4YMFP\WW1VYVO\"M[%K)ER?FQZXNF
MISH'<M'OT[1CDQ/SF9![NV]/<=!9^R\T=X*V9@?B$#GQ>6@>%"LUHAY AAE+
M2CYDASSXP7YT#?H,68M:GB-"L*AV+P(/N[%/?I"HV?O>IZF\%1YG3A*)/DS!
M(Z,OALI\1=V/F$)(TM.T#-"'R/!TD:0'U:+Q4V,G%4YD24IX'P5OB_@Y?]BJ
MQTF6:V%1!7_C&6U)9;&-YZ>1W'9!#:T:O>B</ ^U1>VGR\4/<C+4Q XA\R\'
M:8U$Z!I _L:"O;S_7]2J?^?_V/4?0ZO9:/PA;2C2Y;)8AAPI?XG)J_:O\V#'
M6Z'<6H:^A#J=$T%YFV;O:CP7 ]O)MMW^SG=[A5Q0:?HW2HL_O.H,M6)PC%/-
M$&,2K$ ^H6]LK0U#\AK&+)%)5*=A-2"N R%.IJ0I^ T?KA,\:X^=?Y>9]H$K
MA8"&SZ+OT1\A\079,DSY[."!X4>Z,-\N_CFXJBM!1]P=)> _:478 <5IJ9,J
MG -&:@--Y; 3>I+LWP[WS 8'&BNON=P\<8X<2^6A.#-/L ($4C*!30(JK 9%
M,H5@,UL&@S(OJQ408:)P91,%.7--85K/\XZV8/?5Z7-:CS7[V:;\_EN6AS@I
M_/1*Y2&0L!3EY;ZR& P^!TRZ8JJ.;W6B':)G;Q@IP:_IZ14M)B=+:2A_=S%[
M;?( *'8K=3AU#@?(]M$$[#55T<!AJD)0M$J7G\AF?/$WHD[OP4SNDB_"4>;X
MN3D)?R;17]S-U[T(%G>K!'!47??-(P@>19DAO^<F4MMSY[F[5J3K&)M3J<!=
M[@5:3O3[6O"+Z6S#MNP-PS<+99%<):AT.S^L>AHNT^V%:4*O3Y+LAZ;Y)AD+
M+X&1OK7TC^HAOI!W;C2^MBY,C4Q,7\=*W*A]!"K\X*)I2,$U(YSGZ*T)DS<_
M3SQ5R%H36WM<=^<I_28)&=ZH0**V4G0X26;A7GGN]E[U+2[.;D)&!-U^ENV4
M8*F4>\9%]@;)N;=%'&NB7LV_LQNS:WZ'M;=OETP4^N)L87V!\R4(),99#G5H
M;90)(\!EI"'WB]'GF[Y1%0>6T-Y+VTYBA&)!;D*=.W58FFSZ _>]00F])/LZ
M=CMG_B\\;O^T"_'A!>$389QR'Q'RC'%4Q5P+3 W7B1%2J6F,.U;5JZ@7?$^4
M6OPX4A:)PVHOSIK'04CVDXH\:EUX9"N'F_>E^^DQ/RXJAB+Z.*22J![YV(RX
M&_4ZY%))(FI9F@3&O_AY!\2/D+N-O?2V =VE^C4D3:)HCW<R9I_J%I*8- ZF
M+-#?;KB1.A\0RPY=BWG/:"-9A[?NR>Y:FO[$'.K09S8FI$H&QUGJ59K14W]S
MT9;\($OL+9Q4_?!*UCW\QG'90/&ISQ\\ZBPG8^?Z(4>0^,H=$/LZCUH;?@?4
MUF33;E5ZT6G!DDOT#L55*%@H1$!O!:I*N\2</^F(,8RH*@]@2%,@GGV5.W0G
MZF>2?[A4W_<C5NA0W(]WVS;#& X,/A%361;>6(2+R6"4$ZFYG8"3>;D]D\27
M^H#/KCU)\MBV(N!:<!%0#GE(I8XP7&M@739V&;DTOC?F&_/NFR?F)F-4G.2N
M5[K-](4A\5G@&DQ7B0F#UYP/<)HS$;RD@L4DE&%/.DSF>*VE;IAWHI,!4^8$
M=P#<<X)M=D#""!D/^V]M!R@B*G)N,-2/RII-GQ]:E= [ \:]B1]H%'H3!)]>
M;Q/>> XAC_@DLI?89U8#'D<(V7U[_]@@)_.9B(';/3;%1ZDTDPF;C]#*I*5I
MLB 3,2;!2&N$C20MXP(/JY.K\D<_'Z@XO+5/K!P?*$G!OD=%00X@P' 5<EX#
M.$SKF/,;Q4+BYF4'H3T<<_<"SW>MBAUXP9+AX77L'@I,N\=\D\IV>H1H5?#8
M9E=E3R$6>VK*'7W,]3#.2' VZ-L%K;0;YPP.U$&"+Y1E(<3A(?0RR'4E44BX
M-^&+ROOIU%!<!%R7R]CU[IM5<CR>-6GCW;O/&LD=B&8;93(4W]>Z TJ4$$*R
MPZU)CFF5-\:4<[\@M>0-U#N.MK7CED_NCU D>'?%(SZ!259*83N@*L$QVGFB
M9C4I*<:U->'LU?<2^FW;NG?OEJ3&R^V[80;RKE[W1]Q%#.V 2$9@44!O64*>
MGKEAIZ67K^C8"$$LI/<GOD\ C)O7-:$O67J#YY8V_I0G^LT.R%7["AQ"[JV>
M:LCY:OQM H"U(VX&7CWJ;Y3K@^;=O[_KP$L_BY$H?@K7N.]&;.PJ= Q#&0&X
MJ.9V4DY[R1>J1RZ%E&J=+_2*7=7B_JG4Z*GAYN-W8FYLL1N%D<67_VY&W%^!
M/UL&VP[H\27,!E6=$>'PC^34#4Y:WD>]3MM+SY 79D@'#1Y[^VQS_+L&0@:=
M&1]OP/.!Y]:]HA4#_'U_A!^RQ84A2[N4WG4?V@K _=]@(B(*)]1B\J#A?K5Z
M14X&W/CS^[42WG=36]^O8,\R.$O(B].75@%S@D!C-O? #_#'!+_Y QE/^V5
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M>#S)G4YH&T>AY4J)@LX-#^9K5!<.&8]S#OVQ6.^@$BNKZJH_5B>O=%,48ZY
M1<OTW8(4#D3*"EK<3\]47H>9BU[ZOZX_6%*\: ^/#:Q=ZQ'T&A[6M2U[KN:G
MKG0M)X[/UOW6=MP]C^U=-@SU.+;>](3P3 M1;63I=Y=AG]ZW*>2W8HW3Q.*E
M$V(K<)H2*%EA@-,TK!+E/2V>2CPV=/E(D/?+/L_>FK=SJR!&"O%ZE=V%QIK,
MTIZ#7Q5@]*3"J]CG>[M21&^<?.,9L<Z5O#53^V<42M7QVOM+)7=A$[)%#_=.
M^_%S<IMA%<D1QF;H6C/"@G^#K0;^V@S5DEAPZ_?^]X0GVJ0]W+&MU'Y9.?/N
M$JIM_"4"-IA[)NM-=,?%NP<3DH/W3XYV2XZ R@+2.2$6922*VT/U(\LXR"L-
M9NS3=A!'50)9?>-Q2B"Z\[\?5:RR9,+3O %]&!B&A:)<S"L'BE5==GN[N=PI
M,Q?>4#ZRS:+7!M5^\WK%]ZFQ"NYN"3J.TC[&MF3T7$1*>LW'<KNO>OP>E1GP
M;.[!V36]FD<ZS&<Z/\_Q[)V7UGW)FY]?><LHS.&:K3[U9-_5*Y#7]_E?Y9!(
M9?U+^8-51J,E)=.)#>LBGX44;#INNWSB&1RL'K,M4Q5;J:%!MV(:M_@8IMLT
M/+F6L=+30BZ6XK.@&V/)J17[BGZV8;H3H9*A5V;GO*>7R7#NO@@@I21O0WVI
MB,Z'Z,WQ*;Z_G%B:]*.#+U>U\K!"7"SKTCF3PGU?.>EU==5EU:E,)E7_9IQ
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M%J'\FJ]Z-&5>2L"1+PUM3.BL'\*$8+Z2Z*=)TI/>S,E#G+<-EFXN^2<6%8"
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MR1'"IYX'IK*<!'":/<G82CV:-0N+;71L"*5[-;&8L2-H(WI%<R:\/<MO7W-
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M2#\"/TP/]IHO"04K6M#<XT6B=8\(Q^7,,CK*QPEF/>*2V="%]S=%VG'_F!>
M+,?C]>$M0(,:6N;- 6<V#J7VX->:]/91[W1,EJ;_59&96#I"%FC@D18$0K"D
MB7)'E<!1]$^4\7(^%"LY,IJ>-W$33E9@WM!,JCZ8(^U_/[G8R6[=YE]Z<>0K
M_#X\>59/5'FF'$0P#SMU*,D+^I!$@XN.VHZ4J.^K9Q(^[<?UUZG_S9V5 S1S
MQ/#M"ZL\9!V'IT5YEFPOR X6UNQYD4>.PH8ZGI</_^B4BTU-F\I+>"=TH'H9
MYB';,G1%=-DR.4_E5U\8,VP ?A?OA1CI8#Q@)U(_\" RG6D<C#3&QVNI1&_7
MZ'_/\H^SU6K?QJ&;UWVPF2%09;@0?O7YHN_^[SCM>/[)5U>L5?<%=Y^I&TGI
MYH>;VUN,G!S&GUCXPM*?H#H5K,9K,ZWQW^Y394M5=8N+=),@IYN3!\9K]>M)
M- 1Q!#_A=85FLQ!#WS\G!>\;@S\MS'J"IY9^XK%&C+4N.,>%"/Q&#JP5S81Y
MQ)5@R#VVP;!B$"\&5"GU+G"4T(, S<)OA,$(TVHEB:%,"[WN?R^>-"EZHSXF
M/BH7[H9I+S?GIW<&S(WV$YI4!P7)PMC]/LBR:-9!$PHRO."BD&8BQ=22LS_>
MV+]/THM)T1]14GA]8<,GM!Y/NX@'3XE@,NX&(L/+Y:"QCK=GFIV5BBTQ#Z+L
M7*&7LP;*@_DY0D'L3X'F&+H:(XZF$EO0H1+O%_*I2N1#XD@X.EIN[5[]I3KO
M^.\9DNB]C5?1 [+65CG3P\AT -/60N-O(8*'X0N?.H!WH%(+24K#\^SO.>VE
MJ.>T-M(:->C8%YD ]A^[QVM+I'DL+>#X&W*\+ ]DZW((Y=H/TWUS?).8UV.[
M)0UO*M]Y=XK_ZPN;7)0NSWTYPCTR5%U0UNS<&K>"Q/C)B]W4!_4$SC#[PQ.0
MH[&$Y-DR^0F2=LTONLYQ@+0#QS+QE],<!9.;*Y)FY@^=,SR /N%3?'"VQSJV
M:$W249A_IYS]P5Z;I K2*.L7B.'M.Y07APQ0KG)0_M%@M<:S;Y]-=>MJJARS
MF#.=[.2I3CV$@3L/+X6RQ(,8/<=0\$EX?.:ITFHNQ#;S8$EM1=%-H*[<^- V
M8'P"'\:10K?BBVT:L,H<,4Z7W,Z?[G$R=U=)@O:$"_*5+X\S8+]C<%?SM0LQ
M,Q@*D;7/A",024]B,EU:D$*G==551@+FG-7H?QWA4<:0[EUI]X#Q:P,\URP(
M)_?CI,SDJ\ AIK572K-+UU=:>:0"L]9?ERH'7_J%&QP^(5A"G^0('.-1GZOL
ME_C;&!XXQZ U0<T[00YTV+,T\Z]]:UUV<9?=^WRI4TH'!0\:GFV?C[:N]\6\
MW@Y7R-]L 5=H,A1#JA8MVPJ$TIL:L2-HB7X6AFJJ2NT9"1F_1A\U9'8$&4OL
M;Y%!?5&KX#_\ LCD0D"E^-P%)=H((Z(7[N$WF$Z6_1CA1YX?**6KQCHTIV6L
M5@S,ODH95JBL2E*//=ZN=F>\6_YF)/*MM,?W&Q9(>Z!!G@K<\HN!ELIAF3J<
M$3B$JC'O)SF>DQM5<[U.H7?![2L>==JZNZ"LU[_F>KFHP]VUQ &%O(WMF $H
M>,0*%^O*<V+6+.4PK1OE"0?8E44*CXN@=-U>->* QAK^[_V/'71;'1_J!/L-
M[* 7DH_##UHR#S1N*F+9J3GLJE"LXH],DQAXR+TE>7<[5[\W"5HW;T+XD9?2
M_[=DRZL%"O^D62]136_WCW@O^I4ZGKKYZ&U:*QYLH6&N[@U$Q*(/E0_NXD)*
M?5)F*_344B<>*_^[K#M=)$XOJ43N5373DA%/DRUOY&-GMS",>;_Y)O@+#RJ/
MY#..=I>P\Y@N+*7RX1$'*G1?:6_#ZC2Z=-MXV+\9][<-%T*[C@456S,2_9D^
M*%5?6,]4\'"[,T#>+Z>W::VQSA+#</94Y[Y%,%W!(W6W\=_Z=,<!,H2^U/U8
MK_I?(XE,53BY!$^[IK-_!Q=2-AX^I"!RO)%AAEV\Z".]PA'<RA7UJ8BOBYU_
M]/ZEP_IDJC>"O:MSDI[UT*,7^B^38*#B>4OEYQ%"9>JNF^#,9T?6!\YD0]KK
MF9Z9)R%;8@#/YW/VY'AA2T!\2X7M-<YDH^5>+.(M#IZKYRFH1H7^7;*+-$:=
M>LS>))_^4Y_/=?9/0?0>#32N\X1Q'\,Z4$Z$>W2CCX[=N@\C4E[O"JL+?863
M9I<#Y G,4/(D_T+E).XI%(*2I4,1=$3, RGU,36KO@?I)Y2S[-H).A():U-7
MENW-<\PSF(^$+XJ[\U/IO,^68%VDX3&!\$AHT;5'Q\8RW^B,. 6O7"]:Z9ZS
M4CA;\K2\25(^QG44FK1OKQIJC#;"$=X".(G!2JUPVLM@'&%3).[PB\^CLU7X
MR(+#\9/\B_G#"BJY4@T*S(CNNJ/OP[]@9CTX>[:.;W;3<*R#EA2%<3TP+,]A
M5GHZ\?2]X-S&@4]R89H>.[)W2:[<"BLHOK9WX>;EXA>PB'\D+31YCA %Q$[
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M!@^=A\<';[#<@C1SOF1W_!X#\YL/J-N'I<V\?#YY=QL7DF*>UQI0*NRS*L-
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M]X4*>%<ES^%%Z\XY!\>92W4FD3H^747XUZ3PT8_F@>)<".,]N/85W04OFDE
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M3[>O_WZ166GG@KP401C&EN2RQ*&</;-,DPUQN7WLK-6Q ]98B.=69ND8I_J
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M_OR5"['Y%J[COI\%;!Q'J]CSUM3!(]$Z#P15(]"29I>^>Z%T'NUA;/@9>#D
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MV#"4[^VYPY>PX^SC.O%*A+K%M+7X0 $L8V5!95R/%1"_:2"<M\_ 8:8P^US
M9\:NYB?2(HVPH^*?%MR_D1MIPM5DPC-;+F2U$:J7N I+3#P%$0]%BP6D(CJ0
M(!V*]:"3!F>Q&/;!D272Y3O\)(PV07]9WW/'SQ.I&#R&%X^GEU\EJ"&]D:G(
M:ON92_1.C%@DDQTU4-.MPDQ*K'XN?>LT;<JE^LZ>QU<->[M*.36&M'K9#0%4
MS5B;T2=D?9S*'T*,D"$']XQ>0M*+"&NL8P \9??VFJ).!D*$_W$E)]Z_/L>M
M]Z ?R2G#]=H'DKM<B=]HK?G\%FW*ZQ<Q/<*3FGDDK(+P- M>6KT4!PVJ' HU
MEU4.2J=F9LXO9SRC40R:PL][B%YT?'+30*ZHWY=^H146'2-,B/YA*M-KRDN%
M#E]VT,T2P*8/])$7?(^*U_VC]@H:X*- '16>ICO_)!5B 1N'AVNX"9],R_'V
M)OBF$#+]P?BN3S56" E<;X[*W-BH:=5+K=7#1UHT'9$^ MCB@#D:\(*#.H9N
ME^QT9UP33][= 1D[W)-^':+,9MQ)P_[-,XXGI2=%WJ[TF9@8G].^?=EQUG89
M]=.=?9Q73_:7'0OC1/-5DQA$KC;D/NDQ.9PPOG;$$/H<!Y7W50!K_RR/^?+5
M:<G"-V!71X_Z']*Q+LASQ%'*C)I8(H1^$OB431\$,)\?"J5/MUNA+GVPZUF]
M[K=5$6XKKNTF]RJX'X#P:,4MC7EJ(52E_>C4'(TZ]3#3AJ8H==%W_?V59]O5
MOWZ)?_M=0SKB9J3/1YN >U_9&I(@=UZIS:QB?;/_ALA6 ]S*TYSMSY%7]6>H
M[+?.GF;GL-EA:8QK]U.\*^OD4]UXT]1:Z+^[22'4&;,K"WO:F?B9;HXW_S-N
MBP"6$/98"KS"6=H62N\1;]JF0'S:&J;-/9LW>;9M7]D5M 396_9ZOLA<O0OG
M(K^7"D^Z;6T%&E >IJ*# W@/NE:A=/LE7SH@HQR(N8O(=+XF&/ZTY[$7=G_\
MH9J\?5^F *]ICJUJ^P/%@)WR^2\EB*8LQ$P2,.OT126ING/&I?W+Q;@-/0R:
M!=\*;74=F%_+0GHR-)Q:AF8B/M27O?6\5ZCUJ/B#ZT1]L6SRRK"<SV P^<-X
MVM=WW^M?YAQQ7?1UAI#T ;^=5H5*Z+F.]$>,SLTY!;+JW"6\-2DBU[5ODW*M
MNV<W?ADS^TI30-++:34!Z2W9_/4$.Z"HHL/U61 CJ!:B3CI-EPCA)XA=LNOY
M(VCY1<_>2%QSNU,Z;^@D=TJ<(8 A^%9' VEK!;#S-*HTD0M!IP1_,UAKR?\9
MY*7YKNY&_&=#E[NBM.OHQ_VM](L#@X;6>P:?.&K?GO.T84+9\)F=#^6/7[Q;
MI%WKDNKTE<25?8[3YP_7D;,674)95LS$YPRG[]C6XH9",^[U=^O7+IU?$5OU
MVI*_ SU>17D"7FAK:;NT!6QO5=YMM9$/QD7A/OWB3_OE#^;14> 6<:Z2../P
M#HH_Q_B7LG+I!U)R>(B36+(6W[,%LKG88S&E5+YP6UDUG*22S'V;I<&U V,F
M.CQX?L[/OWA^1G#7&. -!3#:!S+1IQ@XIK+2FL] ?@'6+]Z;6;:?M[Z UL!:
M$";!6YRP2+Q#VLN'> H:%KR[=43S4R<N^R($)\&6JM%?%UXPF5!R-$MQ76=_
M!C1A53'7437N<R.8N:&2W5D<XY.&?6U[ZOM!]S$RA(#TH=FU8^<)C.*9J.=>
M 5K^Q"3N-LU:VE&=AU%ABR,V]W[C9?'T+W!05R7^JD5*=99J9'6Y149TZ[KU
MI F_[*^R[:SGE[M>7$4/=V$_7TH9W9?S60!;-IEWWPL9P[M(#)U^@I>-I.>A
M5ULK&.)_FGDZ'<AU'W@B^FQ[T2T-PE+EGA<YR5 CJLC B9[,ARF?K$U8I.,)
MSWIRBD $1;G7P80WE*J Y-N$L$D3D]SU\WR)2>!U(8AB(P$31V7K-S4QJN&J
MBID3O[E#XC1+8A! N\$UHG^QO()?&QF"ZBM3^4V=J@U:[?NC!%:T>.8X_P]M
M,CZ1I6S F]08!C$KN_CV\Q N2+^#8#2/5_::A8S%F8.94L2Z<1/R.U+M17Q=
MN,3Z/>0C!I_XZM#8O89@QP6N%G4YL@XA%KE7=N?6&@;*QDXK]I3][CL"V"K1
M<3*VY%GE3_?Z7/]^>OJ;SH?O'+N7J\E.?-VO& H:-&O8Z%L'4CB>)K++(;X3
M1"G?N?RH+'XJL<!&J*M51P".H$6AVJL.LO#IGA?/A/"W!KID];4:=6B-(EW1
M$2X>[>*)B;T\U.DDZ:\G\8EQ.%+.]U'(+Z2A7D:^(C11-,BR>+_95524LG7I
M6-XJ@[=WVY\NB7R%+PU&ZQ3E/2.$:-Y+>'EQ__J$U U']9]DQHHT*NDHU?MN
MF'X9K5ARM$#]6&KJG"-NKYWB"35"#AJ.I'_&J^%Z"6K6SJP>!GR&-1FBI3?X
MG5S?3MGL9C3Y-<7D.7#K\<F!J\==J*^=4?QU8?R/;ZN@+DW\1F._28\F3YSR
M#5#MX=Y8)I+Q]"=DP 5] PX<(=^0C^2T#U4&K_PF:M^,=&^NO9/\?>"9K92)
ML?B'!(OMRQ?'(DI$'L0B,P0P)3Q] @'JS;; E;>3)U#JD?AFY8MG5 T7RM0I
MRJ2U\:\"ZAWS/N[2EI,]*G[H6Z2A2<0E+GJ9L,=&H2.X^^/Q"^-E\R@\=^T*
MGK\)(AJE$(7L\H;<;#>GF"]1S)&.[.=++ 'HHZ!J.>X3&L@/G"VMX2>1*;I'
M0DVZX W)^"+4.]7&F[(Y(:9)WVGMS4@ A09W_6K)UV:-YP&Y[.G>*\F&BU8W
M:JM9_ SQT>P^MXW;WB7I6%>B=K:_TCUVPS]G<<BCT\%(C1]=TK<ZJROH2Z/M
M_8^,:[X:WU_D*R=L"]M[:J6J6(RR?,0#/>8]-=<9,N_X@YL;>#MUN8=)XBH5
M0D;/L5H>:K#F%6/W1.#7[ _R4KM7XY''!%5#5\>90_E7@OUS)59[FRQHV=,4
M<2V'NYE<B9^N((+9_ ENJ0%1P;.L=FGZV-# X;GXD:CD2U-]=;+GNGBN+Q')
M2,4&5:[.IS&(\BG9; [$J?6[6M6LP[LE?I3/)%N_+%T9_EK,-22#EJ+LF0T
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M-G770B,RQY6^?1!UC\"7=S;\O:7A!("7,5A<2>W5KK7RWN#JENH8!;^)!*"
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MB#/'GF<=ISZK>G'807KR?662=E'U6D?Y?;$3QZ-O.ZU'+3A#J1$.#&)@TO"
M,S[-2QJ(J:ZB9<G:E]BOWIASR[#\<?TM19F3]^D785\G-7\MYSU^JK3R#4*\
M::$B'7_SS[J9R6DS%O+8V^'037WC EBCR><S%QYV>[?GG57-/&V4U)6!C[7?
MJ*$DM:R.#L,WO:6MLW9FHL%M1^*9>[2HKMYT 4SV9UTB<9>X3[O1T^Q+S_?L
M]'MS3#SF!F3,C[7:9TG_LGVOAC+8OS5I^[\QYU9%D:R_+5Z-_UM/^&^Z*_^'
MW=L%YG@-_+ZB7K(5:!W0[Y7SOWH&\:;4W&O+X+&/VF@)KQWR>M*J%R/_9:68
M_[0^:N#SYUD4QRV.+D_NB1JL4CWI)_\C,'/71(9/RJH7L4K'S\)VP[8%/E[U
MQSZ6O[G^30>)&7R%0O+JS9#7NEZ_SC$0P+ZQRO%SX3'A=@>>-^/7'YYL.0O<
MK[YW[5)>[7?'L5F;@Z^%\NGX)M-ZA8+@B 9%7MYV0__\]T\>/&8-O;8H^+F6
M$VH'!:O5?ZPH<0I0K,1U6IY+<8*#SHL?'>&+'+1;Y%\IV[M.Z]5<.+&T)>^;
MY?$G3W[LZ\1<W8T3OXO[0'N5-%W,4<B+Y'?A):$HJ@IU6NXT67@80<,[#FJT
M?E:7;S.9<XYF@WY#LEK^N&;/U50#AS9CMT,=TT6'[DD&Y^TJ:3U_NQ*MK>AB
M9V+[%RHZ?WN):*X_;MQQ_5ZBL-.GT$98*)+'"?G_K@:]R/'V5BT#WEVL34[.
M<-=P1B$J_-G3KKT^W9J/*C9ISSF>R5^&$L8_'[$5:TF[#J^"3W,X.\#+*$E<
MCP"VUA0A>>K(\2_;;_D\U^G4:PPJLKQ]3C36\W[J[Y)_0BWHOU_&T^2O$9"-
M$?7(#\K^=)Y*[;_Z@G^Z7D8CEC5G\;\^(+Z'^%3\38V/UZ7^D^V0[]79KY&L
M>M+[7N)>K7O+\D(%->&6<*P] ZT5C%3&>SN'.,3UN.;]OL 5>=G#]J^^EV)H
M^*P)97BGY=AYB0Z9@TIX+[W'02/\:_SUPIWB-,!E-IF_T1G9,KX6HK0WJB<N
M^KX>,B,H4#^F/IY(;3\W[]!>+B(I\=/^-$\H#Q\.944-<M"=T,]..D+$T['T
M5UW]K1X&4<ES[&58L.O&34I'%;[MR\WUBSJ/\3GU(,5F],^:7>8C+G:*:_]G
MDYK_ 0<U_.7EG@"*\X])0!DQ1]Z4R-LP^/O>7^C#1Q?]L_L _STG7/YQM;,0
MW(0%_ H/N2(!6=K?_/7/6\E_)HO]HRU<66BL4O"_V!B>9*T!O%$ FUN;PR>?
M@P)1J<\_78T)]J^"S O<7PS#T=4#_^Q>2'>&[@R-<P;?9(?$="/9N:RDQAXJ
MD:\XV408Y3#8=X"YGGW ]WCIE9Y4LQO#Y\__1FQ':&]V"O2][:*O?<"PM-;"
M=;Z"T\.72&!BP&W#B0UZW..\.V3Z$VH0*X-T'7'^&QC%8E H%4%7&W:^RM\S
MHW'3+KF/H=F;.-=FH:J8;;Q\&Q9SRPYW#!1EUT >]A-'PU?CVT<$L+.(%#*L
MWA+HF4"VK;-OK#M#D#<UVN=4^GXZ3N*!=JVC\MYLM_=C+6FQ]F:+/8V$%'PM
M:?H69S/6'F1!N' >S &&3[\%_-^QZW-HDH;;G]1F':RM/'5ZJ]/3C/RO'7="
M11,_QUL^EBT))'X@)-#4R?0) 8Q:Q3Z# K<%-&7!L7#@8UI9T&4PK1%?U5!$
M'\7H#%:[/##J8QX?KRP;;-%7-0_-J.]XO^.W/B%,B-GD4-IJ(8,C^\RNX@_S
MQ?IRG>-;'_J:%Q;6\WV#2, 'P--#N?'S^L"GDBW;KHR ZA6V6C3A9[J_7YCE
M7O?W;CD@\OON7PS>N;]$@^-_348D2OX)S/DC1O_KYSC&FO\SE?R_UY\\ST"K
MDV\?35N92UM^./*/C.)?NBK^15_^7VP+@.3&Z4#UC)(7]$=>XD4AJ-J,7N'E
M0N2P[)^OYC\ ET7 7Y#)0L0T[AA(H/?$-^S@?\:_(LZ$E$1JP>'@6TH.4KE!
M87RJ%_T#MW$(?N:5G-<%W9B[G6&F[COERGL>P/0JE9!0WM%D(H#1"P6P&G(+
MFMK.$.<JF/ E]P*YS0UP<) .EZ8PG)%>@%(7\4ED\8$HWZ29BR];Z@\333?&
M'63\MGZ=[H]J)0!'9T<P;"[4%G^N >]Q&?*<IW@S7 X9@$S'*U:C5#L+?S[\
M%;32$U\S6L,SZ[J4Z*K96MUO'XJY>>K>ZO/[EB_X<W3Y$DO"!9^\%^%95!JC
MF*M8Q9<\H9MHR-^,=0+.XZ0^-6B!6_E.:7"IR*#3%M$1=;M,SAQB'>SJN/I<
MIHD<5;E15I5W#T\?0Z7GBX&G& @9[#6H/678D-[%T("VTSG)988-8I%%]99%
M>V.N?NB)NIBAT!EUL54N^ZIG:H$BJZY>G8&<<>5X11;S)4R$&R:$VP]Q@P0%
M'=92!OE<?_%4-E[>+\G_([G Z\OOA-^VNB:&YI4JYW12NUYT3:?/+."GQSA(
MJ#_#D?1[^>N&D'ZHT<()# 5/E9IX>>W;XB0%I0KVM/<%G7X6CPDWZ I=U,L+
MNZ+L'L#K],NYK+'F>-8PV5L6W/*%1D&,IC%S$LBA AC\%$AC8&8<P_#A+.*9
M3S[&I]JV>S_<,/TRHL1;J>[S8=_++_8[-K]X$2NR@.0JE 3Y\B46 ;W :)L6
MFW6@[S0._66.7!E:ZSMVP8 )!\T4+;A6"+0Y>4X:J8X]<N5P3$_E\LW0,?Y'
M'L_J^QM"(AHR;SH#->K*/H,&MQ*;B*NQ6JPC*853E\&P1G2U>2%3XORSWH5]
MTE=G+ST['Z3V<ZU'<)1W+_9UDT*HH0!V!=^T"^\#%R*:I0 FA+1VOMA@[K'X
MYFLA&?8G;\L:U1@L?XM.*[W]QFI_MV'"T>R17 7="X&BGX4^PC)R91>!G=[/
M/X]XX%H;+.HR)<9W_?9Y4SNV,W'CKLXK&_UB0CY6(U*0FE?@5-D6O!9J.IYY
MRG=HP<K(V/1EH]86B7,[,=)[Q:^G2_N%$U^6/)85$\ 2WX#"[7@F3#)7(BX+
M#"%DPA=\;:R@!/F^P?A_LB(/<=I\*D$):TEW1IUAZ4[[,HULVJ@#[[IGOGPU
M4#2X-6\,NXF4[.LEGT>D+SW<4_2-,+V?F5*03;5(/?G[L?[/XW*4D<R0,MX;
M >QK+Q?B4V=5(+8P]):80)L[S(6><]8 Q5M_5^0K&AA&:B!_M&$C!+#K.Z#L
M:ET8B\)/#VC'@PIBT8.*(G3R?Y7X=Y5P-V-FC84QSJ4P$.NF5FC3X0R.58:]
M:^"57]&Y(_N_?)"[?2M6QD-C/G4%5X]@OQ+ ;H\"2'[[&_S"@Y)5\#^9AM[?
M&<Z[GZDP /U?1?[CBBS'._%(-EL]L<<&K1$A',W(!N=CPX?C0LK,$-XF^Q44
M:D9\15 70HK^[M9G?Y[)*/VB)]J$GRC'[<+WIH.S MBJLX5\M4EF$F]#3Z8
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ME.=I9")2#2<6*1^.U^!_LG!5[3_<.^L06(V>;G-5+JSW-"PXM\F>H&O[$C5
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M5>)9CULI%(0)%LFH7%;CYU>'ML=7K!G(ORJU E/]F4O.(/?I'$:7:C.@J^1
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MP'HR7!*M3I.<\RN"GK,B[SS>2"J-\MGUZN'>;3Y66PKJ7MCYQQ7^!"B0XF_
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M3&Y3:V$(Q!UF?\K*&>ET.!;89+/>>1TIWJ'^TF4%3>IEX<$UB@-H *=7L@U
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MBQ91RD$;AT>[$:G.7<9C(4U#M*N?0B]=U15D?WJ@,'W 16S4';8NRA)OF.B
M]KJ0-H[DO0\L%KR)>=J+%&'@\!2G6T\Z*])-[Q[PY.)1$8I'0S^X@.77N#3=
M7[61O2B&0[$H3\2A##/HIBB#7]9^B37/&[69!6ZJE,907RT](!L^35$_D8M8
MBC!@UVWIT=KML-P.K?XC1M:R+7/%FEO/V\'[R#,&59F51\=F;;)H\+B=!X#
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M\X3:D)40JQ.^\DZ29-<Y^/XHM1UIV5<O.QT0/JY+ KHAVDHI0(ORD<I'S."
M(]:6B>H+2T5+1ISZ!T_!2UN%W6H,NO.N/LGURI8CKB&+.V?W>BY&ZAUQ?((X
M/?:_6!G[_W2[&.-A.]Z\;!:CY#FAOW+M=YG1',FKI^&$CHI(0YUJW*J:S)4T
M>VW=PW?'@]XQ:OUYPGCVSN"V[JDPHG^QOJ;_W+D/K)^DW9NP*?ERUS>LV31(
M<Z%%<;NQ>QD;H LU.6ZU4^BL\US(K7:31*_ZC/=-OK.?B]0WIKX2.-(Y/%&I
M6JPD)%UE&+4>,CRBJI+AWU,TT,S\7/RLP/Y<=+-PM *,2EJ0+-W";JS)W7A-
MY0(GF-X)/C2\V,_K"S](N8]=G.7R5MHL* \$GJ5%5VL+(JR]O86V/+Q<_0'C
MONMNVZL!;6*A;8GX1;WLB@,=UV^5*G3/\#^S+&_^W75B6*NL\SSY/T=XNE^S
M0/W*90UF.XN?&=B5X\,M1?F;Y&)]GV#N;!LW4&V5["K9;Q"R[-=Y<4]\"+70
MK7O/<Z.M;V*#^7[C4[P=?.>))]Q6HE^8*&_LT KT) 'H+UG_N%LGV5Y@LS\S
M])O7Z=D+)3+9(2]>CEQC#KD=/Z\V5&3V]G6<R9:-E1/8:.@!T>#A_]R:%2&5
M038KA-O6X16YJ*S4S3,M)%-6^NQ]W)/^GI_B'.R_BPZ>41O*MJGW6!O$2-'?
MN@Z@S(&@=/PT>E&.(V/-(C  CEPU+3_UEIW#UN]FA[+H*Q5O:=7+9CU3Q_^@
M(Q9RE)M26MW3+5HO*TB&Y8QN0PR'RPNM:,@P_3E*\R]XDW?(',DPZNTJMN_<
MK_-@1;!'R\1^[&G/G^<#R($Y=/B-J^LC\F8R^G_E.\ILU0O!\Y1(CE0[U88C
MO<(3M6:'8]"L#+"6:3;B $;3"'"\F!N(&C3^,=;/&@G&'SP0^R9K-8 !DU]O
M^Q:+"GO.S]<(ZF31[2 F([@-M*?"0:U\CM0:JQUL#8M^BCTV<6M4BG.82<Q\
M]FF5(#,S^LW8HTFO^C530L@RY=B'(A7#S^RH8(NVYLPO/<P"-;&O0X8C#QY+
M3*?!LM,X[[B/.1=IZ03P4 XKCI$QFFKP93R$Z*^\+SA&?V7W;+]VOLU(S=5E
M9\NB^\9O_Q$J 4K#G9>5? ]8K4U80(S/B4^5C>TMX(F7MB$1P<8VZF?UOJCF
M/HQ_IK)8"-MP3P-'><*5[%,<0X@+4)*AQ0,"X:1@6FU+(O6]'(7U((J&D J>
M.ML=>2Q-%%'P]<%\[D5IX_:&%TE^,"K6\#\Y6BG%@(15&)4LBHEW2.$)CG?X
M8/-P8LS!/H=DE[:3<2\AO/.S3V[\Y9O=-Q31^N&?TF#LBC0F<=:%M<[-(U+P
M:/%K. W>)X3$V8R0FB"["A"PJY_XUO7_$/>F\5"^<=SH" G9MZQ3V;-,$9+)
MM$GREZ7%%E,ARV"29#!FI.RA"*%,A1"2?<UD+Y3LR\0LDHK)3&7<FL6YI^=Y
M\YSGO#CGS7E>>./C<FV_Y?N][M\R$5$XI>P9X^FF4)+_U_=V8Z3$<*LR8RV.
MR/ FSH0OH@>V(%*\X2+-3]:ZV/W,I+3E7W#U*TP4=7XJL6!U5N!J<Y;#H'N*
MV+/!T*O2?OGGXV(K;7!!J"V(K!E>%-_U*7HXNJBYTNYI(+X6WE;:GQGP:_@>
M<R6NOK0M2\/EZ>W;+0P1CR4$)97,<)4XQZKA=H"G67-W"R('MV7"W%4V^NP?
M\11(* WQ-_$]/7/:I8W#*8'7L:5I#GF^V 'S6=]LU>8#'R"X2F=D$H%Q8@0P
M<ET=_U<3WCJ;FMD?ZTI#]"(TRC(X)RJ"O#48N@DU\!/E@=&![23U/I+^+%IF
MCG2B)7AGPMPQ1#6^-I+>RC8#QQ[E"<_B1I%UQ%X]C@VULK+"\.N#ZI)XVN#/
M_2_L/9-]!6@Y)Y[M.R765I=[\>)NC5H;#+_-%-L3"&=)<^]U:N*FK77'A?]H
MB# ^-T_-A65??M-QM=:#E,N3T>Z]W^_Y6$179%?-"()O#ZI?@/,YXR"8<-;2
MO_CG2\SIWK5=6,>Q9TS%!Q1[M,+\=QR4451X,QYEA?+T]#^>^:7-BO-V&^E,
MO<'[W2(K?@J;[]E:_ TC0C(!'1&.O.Y) ,_6 X9Z%XYP'\!#GGE9I' 0BYF[
M3D2$,3;.I]LEK.)&]WXP=&GJFU5I<BXU62I.(9'P*#Q@.+#JQ][#N9;'"IDB
M4BV8:[UI#I:P=80 9Q_#8>%-^?>IC\^R[!/N[J!^KJI2^&P^?6J?PL/[4I7E
M-4_PEVN ?<C5%%"R532TQO#^(W(HQ04M1C"SCT86QK0?*[2?_).U%*\<LJ16
MH==SPU184R+^J#7T%;CP00+#_HAF7YON[8-$#8#H.;E.D'$L'BK[9BW6UEKX
M7Z[52.UFWNGB&Z=^+\D%1,:VBL:+0M@_4C<=62!5BA_$]2-J1_I/;T&NK<DX
M+D+5L:?98F1OC @5>>=G!-VE>S+.KV!IM^IE87<W@]>QKZJ;4?K6M]G2X,3'
M\7YX0 \9MPY3XPTO(/*<8@6=V"*I<,3+[V,S06T*9$1+>T/^Q=./Z,'F8@=L
MQ88OO!:@/[P DS6%):%GW>(-2W??&?]BQC?&0GR68,+["&4XUP"Z9U/8CKA1
MO K/M#EE74HVJ,E"Y#B0'XY"+WF.+ TD#S9)+I3!/XFL12@P":L@P! RY3X@
M7B%G'HZDRS"R::Y];^P]QXV,0^ATN"=3+.3X^UQ,@2Y,?/?.X[7[PKNZJC/G
M"#QQ6[8*;A#$S&7<1Z'!G!BF%$VQ\&KSPAY&7C=:T NU$:U>J7?%C!(7<C?$
M+Z0]+<'OZE.3+('U4H7?_^84=N>F(-#$9(^1'L0LDO9P06NB04K2?<6CF7-&
MMSEC03Q)K[8UYWS)MQ_OM0P%B_6%7/W9BK@YH@ "3;[=M 5I<%TEO2('62NU
M3?RLVM,Z<?.]D;8IZ?W2(+P5<EE04BH:LEY@L(1,1C8UKP:RD;QW^$9%$'N)
M:_9%1][E*<Q@ZKN(2HW5<F>SIEU&%\;Z(R:T:@,UP[1J^]X\?^ \T58C\>DW
M<><6!(T$=#=6^;G:/[D$>$@UYP;3%&O$+/BVH,00N<<)#!U;F(]]+JH5O^CR
MP.?><7B+;Y2.KXU3R7T]P=5! QHT"<FX[LJ1&Q\@R\%-*1(>^.0BJ3%..*X)
M)\#<R+16(W_74&<>' [;U=#Y9-M]CD*@$.K=>Z';WHUL'[YF;D&N$F>4!HK4
M@%CV1>QYO+@74'ERHM%K+\W+)/!IEKC"Q?S(DU78*>,4M:-*.?,7CFF)0?[*
MI@*>U#R.FCNXZB%F<PK\!!66C#-GHKOG;7L6-+(OL77[\-N] L:"HJ/5E(,G
M>\QZY.+NQVG?7[YJK:IN^R]ZH9>;A ^&SID@9FV[=0>\99GS/ )(Z9)N(I(7
M1%M'"=Z-Z<H+G@@K[N4=&6Q/'P7;/:=/O169.>@Z3&@:X"@065;<NYS8$NPN
M(*\2R.LE2Z^33*-*L8> <&K*^IM0E'/[!AT-Z75^4GU'TYA>=7[_1<T8EOJ_
M[[7O"0RG&"_<.$4D;7U7QPFJ0<*=OH4=S(MIYCG5WS)F9UEI=F\O5\<+OOKR
MSJ#]^FY(#%V!L9R!H% )@"[T[L]U@@0FW),Y<J_CW#-,Y?E/$3 A#/1M9$%&
MC7P;-D5]LN=HZC9/4;6]PZN5>R3E;O4/%'/X<>3MO#YD0^9J.@U!LJ)DIG8<
MHR$D,-9?/("RDV,<@TCSUA?S2NFXCW^C]^03-E)GCPZ>/[#S5A/$^O%SH@F1
M,HL$]'73$2$ULU(\&71FYP'F0&JGGF=0=&<]#2:/6M!HR3S;$N]PM,2)Y!V%
M"NY3&+7IT-HQ>5KL61CR1</_ G5=/R(T\)0L L.1,(>F=58R>Q:35K<@W&9:
M.OH=;V(20368K.Y8T]E!7^3.OQD[U9*J-[WD_*354BO[3X1M9"3J"LIH?7WX
M>M?.$*WQ,U27@X+:CXH@$-_LHU!-? ^_FOA#Y)\@XB9VA<AY8LLYA.:)@ECR
M5.46).]C^Q;D_205/'_0,/VL8*+.%U*5WH9$TX:Z6:Z"]+G)DFJUMH;R6=5=
MEZO$WLI\:H44[3?XC*<\(3*<#9#I%YN(PCBSH-H>&N C\SVZI&0?2D]D/K2;
M(O".9UW\./75Q9R^#Q6KB+JR556V'JX73R(SAA%B1.JN+<A=PBJ11&#".]^P
M'6<[UG1YULMYU\C6R-9FJ\V/VX]$I^X[]3\*WB$_1G)4PT )%0>A[]78F"X<
ME%L#]RH/0FY#!,)DR($X<>:MF@J[,&@2W--_?[/Y;[L]UF<N/4LXK1NHHRNT
M8_FMR!\?&UPP/_^B4X]ID<@SP/4P@,A>5Y8HGGT9<W6.:_AJ84^X^-G"XOOZ
MJI\VSMU'_4"08GAB46PM?!=B#7Z$FIG1:3#YD^-*6]3E[,4),?!)/\UBT:XR
M7%;JU+Q[O.2I#;V2> %^--&Q4:06;P#!\,B<:6=]!+[#5MNIY1WA%'3*B;,Q
M;,=M6!>&5W]*.=GCJ>&OMW6A=N8O\TCMN,EK8A?4JO"-NAS%=I89-P]G&82H
MM_]&EL'M!=:.-R4N]FFH @X4U3?1(=OU'QX,P8P*J-D\3)QM:1&2+3:X+_6J
MO$:9FXY KX'4<0.PC&2.L(*!0HV*Y]]=ZV8Q\4:GQNQ5WRC^U)8R5+I^]B7#
MI$)$*T0SYZIES9.G(-9+QU/RV_+2C?_$ZO9I6+8S(G)KN=FQS,1I*O<W8#W%
M:+FG5?#(H;Q]UK; =;!G._GUSZ=2[=]JAF& >0_K#H/8@P!V+R2QC_+&H H)
MB2E4KF=O9,$6)*7#KKP]#859%SWE]3DW=/"EB=V>\[)'7\VM\23Y^=+A@4ZS
MF/9>:WE@M!0CXE1T:)6W+P@OLJZ'M=KWCN1RH<7OMY@Y9J\AX>R$P%\IFRA'
MNC@;S0]3J1M9Y1?87>Y?N]=V-INQ7A7RJ@I[0K6Q.TC_^FWZU.2>G1NP????
MU28:MJ+;1*'&WOBN=V2&PYHHYO@6I&\+HG(5>,:8\9RQP9<$$J4[E9&!S=Z[
MZ[-H>L+]CZM*0S\='*T7"J&*QK8[I\;%_K91V*P'I2^,^P(12,X@-[MV(X&]
M(')AXK8@U/Y*IMSQ%J9C'S[EL/&I9\\QH9HFR2%:0KNNY5=_59VH3#2GF%2V
M/I4:"S+X;=^'9*!L.7)_2=U**@-=B&2R(D>5Z6%U*_L,T(=FZOP-N0*+_VJ5
MTK^>>JQCVXK*R5Y%L7?7;3\1&0YH#=X<Z,N(ETLG075^-52,\>GW%D1]BUA3
M^KS"<@'-SI&ZI+2++;DB![K[CW1MY/@L*2N?;W426 =7#P)JCAJX!:'AK.]F
MW_V!9U)Q?A.\+J6^[SR%'RBJ?^'PKX&_[ID85>#]O1@FTIXW3@3MP>P)U@G@
M!&4MDZABK4?RQ)@.%.F,'W24  K/0H/JBE! 2>[<K0(39Z."0T^&OZR*">AN
MCSOR(A5P[,(SP@@<.8-^J/)!6()%T7YF9M)-LJ*W*G(']B0S,M[X#U$"E;4L
MN+HQ+8 [?ETHHP(Z;-*SMY11QE%S %<YP?0?@$IAE3/[K,W&JSJN5+W*H:PE
M1Y-OPPPY9J^\ZN^>;.K,.;7NO^=DJ1!^OQ7KR83 QA&%W_[T!^ M!8%>[')F
M"@NZ Q$(2N!TM&1K)<;%"W^F*<VFI8T=TN;(BDB$:KN]O_Z+*JL@7%@#D3V
M\%T##,M6H]@>V'!$_?8G?HLC2619G7&2TQA6ANG?I>2Q_5FE>_FU0+IL6).?
M6!7[!'JFBG2K. ?RMRUULY!%XK<*X_5O05ZC,PZB[Y 50$@OC4FC226'I$^E
M,Q:I:XG+4XU#A6'M&UL0_[BK!ZT\MY_R(GF&TJO3I6;0/+$<]FY\U[%&J#3F
M! 69%N$)50).5S!=X^!^SQQ+4 4N69 L3_>WVB;GE8[_*'UX0#AN-_3D*%(>
M&\K/J<!UDT6LC8!"RM>$9U@G( U/B5FN8TZ5,8C4-U_KRS"WE@25][2UWA.2
M+#Q]/8%U?_#ZA;@W;#?>%)3A2":Y\D2E%C/G3)VXSSEV4ET2Z!/.U< X]1/&
M[(FE+$O!-\/R<F1BQ*.])G";^-I#7=OCK-\_)^XE4JK(C'/MCC,;]MP4GCCN
M(TB_<'I=U"?V_0N"4QV.%3- T-= CCUE*4+\VL:!X]:C42:DKYYZ3>_UL";R
MV8'LRL4:CH(]ZR"W '%-2AQ<BSH\_"4&?8Q9=Q*N_>R'M7J;5^2%HF,/F](<
M9EF95@]:S\05)OYJE1?XXZ7PRW\U'[SIYUP0W:'PZ<ZX#P4>P")U"])K1=+M
M&,4J,9%=KH<E6+7!M]/L W2$=;LKS?M"V!<>Z>_HP]7__Y_PV EBR?C?V !N
M=:<X1XNA6,'6QN3U'0XMCJ%9/6J,@AM=^WV:D7;]_*'SP<8_GUC6O-&K^M$U
M<2?UUB$FX+YX/;Q8N<4RMK1MBF?[NW@+(C$/[IVP!7E>P8P$E24<STQ%4-N)
M%%"__URP-@:M0P::=P Y&J$PL*Y"^,W<@B!-E_"3AOY<D?,<_*;FYN@6)/$G
MN**1+<CH>7Z+IGA+(M#G#^3QQ"SX30T9UQZ;X7=AHX#"DCEEH:LK+J\#-(V/
M[8F$[_:E,%=1?ZUKNM> 0Y6LB2U(PBS;;I8WU+ESLF-$DF,VSZW^TNFR[)%C
M6_CX.C:9U6M5V4![W>N4JT&P:,!/#_\R[2B6R;[L%>5S;7[L#-T+7*O7JY$1
MH_!+4W"'Z@5,=J]'R<9<XK,([0_K](G2I9:"4\:_K#3<\U.TBNQTWORF--/Y
MY;1T/F$-KC#***X#F1KO2[^9BRLD9C[OG][[<?:LPM$=P^4F\OYQ^[=O%\;^
M]AX'3VB36QU1,T-@U3+*!BI%\O^L6(W4 ;D?Y3XLY)O+TN!X.>'>9"D-WX 8
MUR=G'1Q0/K3]%TH=Y50G'LH_>9P=V1P[R2[Z_W#L2DGK7*6^:(G,5*Q%14],
M6=#%,"\W;\_.;\OQ)R6S]']6E4C'2ERJ\?EQ;@M"R/R[27CQ2K:O,2*#L @"
M,>C'3(Y%)$<1STLMZR-S9#YL0?H-UAR!W2-T"78$-@!H7IR'L1J9^'0SH\-#
M/;ECWT5I3XY0TW4MA X<'WWEB?;N</T^J7#S=7:9F:[YQ\\BDE>ON[V[F&L<
M[LPV9D5[;N93R SG-1*>%<6-0UQ#$3.@C8@[ZT_0;S?:JCOO5'L$_#6TH&C_
M!.K#Y,?VJH8/6MM]9+1[WC)8DDHE,()!UZ5)"VVPML"]+])B+K\%K=P/&?$/
ML%Z\"!REI5CE*S#F1LO[<"$YODIV_ODEGU"#-?R<.$6D&SI72!E()OJ/9'J+
M-C*5[F(OE#7F-I=X_10_Z)OHHGPZ8%[]PIC-G@>C[J?W2>!B@$B>Q!*PQO Y
M ]V)]X/QWS\5*-"D Z$9/5TO-F&>9^,(Z^;-VTYW#A<_#K[G4Z.KQ2*<OP'"
M9T?2"NL]]Z$1/@0]J\NJ <I!MAHA-2O5K=M;I,3\4ZO0,47W_*_UC;WXP,[A
M\:N[NHS'3K_RO_B@-\@V@7, U 0X_ZMH/!'?9763 .P;2-^"!'%1O<A&_]1K
M&@: ?Z5C^<MO&JKV!K,?.F^C XZE[LK_E'<#$6G].5X1;;5NP=K![TJ/&R*"
M2XF?V^A:2RCP+J/I8P.CC-9Z$0J8!7J$Q+F^2!,#@_<Q!GKN\I4M,@D[X -:
MB@]F.Z\V@$ ,8S9RE[%"%,?[X(%]K@/0.UN0'7"["H?(6!!D-5\?4<\L"C]X
M42E+QNCY_G??5J/;+=_O5DOBR$3RQ$W9(,?N<L2'." I&YDXA6_6XHR1[IH$
MIB?6:]RX.A(YM&C6F3M;,'KW:4_HCXQ^"]M?PSL+4R+"J8AZ\JHG:"=8W>#J
M2;AY!E:,2^3$,O0[$+012?,RW=O5Q?=7CL>@GNTJC'D%K]%G+2)6"CI)@,(6
M9/MO7"^(Q]!T)489ZP$W"VN_B$YJ(_94BJ[";12S:P[>&;A5)W*UH.(ZMM_4
MY%W?\<I]^X2<'NQZ4\/RY%<VQ![AYH!6G)RQ!6F22N#@JWY$$P>>V-IW3-\L
M!)XKSJ'<2KZE"=CL/"$Z\^0+=S05LCE W>"HDI]CLA?1=WGF.#*2X02]AVSP
MQ,A=<'#LQLDQ/Y8\",B=3CZA->91@3\8+T\Q$9E3Z'EUGI<Z:@/!Z6 O@_-&
MX3X@&2XPP)*TF-<M-7?'=@I]TTN)<BJMRFW@.6K\^R^CL703B,=I-U/C]R6;
MCLJ[6:^R>6)7P/TNX+M@H!.' KHC_>A,Y$ZX\F( UH8"\F255]7/AV*8VW@T
M^=;XV043IE7.@TB!'+@*5X0AQ9$KHZ[%(2BE.$M^C*P;9@OB3N@M.LP0KDF
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MZ(9 C21;'THU!PK+>5.=VHW,DM^W68WQ"G&DXYM?3F8-14O?%&I1-YC&^R$
M+=M^\FP]R!"2<.:82IX8DVW'L1O_H^\?DRD$+/?KK)R9Z,W]U:U(VXN[G'AL
M[U]X4,PY8@ 2T#P-7A0"O"@YECZWO@.\*&!Q8/\)I5XT<"+$"-U E'V4*/L5
M95#Z:^J;ON9'D4K3D(5?IG$@.%D5II 3BW;P6QIO04(D$-2<G-(JUR)!QHMG
MU1XS+ZO"?KA*GS#JD>X0>5#X ;>T=#5*IP;?56:R!Q3N8]^EMZM2@13:P9SP
M00N2:->?0[MY9LM0AJWC;'$/N0[&42ICM0/*U#5UH+ /<1F(H5I]L._E'9B4
M^%I62?8B=45&1(890_RSHDJ"(=OB(;L45E@(QE%Q<@)>IL-'=Y5?_D8?&&6@
MJ66]ZKA8GS[D3JSZD8H$8W\$T5S)13]&8G!;X@5_ :?0/?(0J3RB3_79'@]P
M83=!@.P5\63?3ZLT3V(J5$FGJ4AG\+UJH.M_53M^[-A]9^U2#=V'BDXJXF,T
M?JSP :P"\X9!%%RW"HL&(GUH-]LU!T,.>UJ]^WEB.;WSG'4XR>RO-AMDS5UR
M"'_8K"?K#+#)5N9H,P>2JSLTF90548RQAJ7_IRO$<7S]\*V?E'QL"Z.KU'#X
M<ZUE32:1 I+O6F0/^@Y(76 SQ2PA@OO$.E'T.[XA[TX'-"PV8G?BSU]]56O5
M3_*?0[3N97Q^M3]*7F!=A*.60X4ES.5Q9*P6X=[P\6"?QM&&=.OE'KI6$-%W
M0LZIR?Z<U,:N^N3.2WY:?M]Z78= ?(5%E'/X?73*\%WZTZSXL5/%U9<XNI.-
MZ3CULT?HW!HT=09],D,5&/NID*U[_YV4,_($C"-]<8V&3X6;/L?-@<21< ^J
M9JV$T;R8Y,0@=A-W-99<S/X@(HT/NG0TWN'<Y;7=+K.65NXYG2D 2):%V R1
M_BT(J9)20R=7819=:Z=XHFXKN6TZ"?[RISYR(ZPL&N\/NT>FIR[E!:IE8)Y*
M91 IKQ%2<+E%)& ,4LTZJ#QP[>.FWS3'YR YX+;G,,K 4[72:U9M,SSSP+%O
MO47K?.]XMZ&I$=Q5+S\R=7T(=3.#V1%#8T>VV?0TZ PY#ONUY6P69K(R*VHJ
MB8$@:%^+(P8ZDL0IKO1,&C_>^E8M0V/%DW!\+-@GF11DZ]*<*"JT]/#UCCW"
MMV3>6Y9R*X@4 F\;]R4QD'P;VBB5"MKI[P6$MR$QYR8/&IEW'[JG\C"O]IA<
MR=+$ZPO2^JH[+'T*()QZ;N8:OV0P7QD&</-0&?Q5@A@6,LEQ]6,JCMM,&W=:
M>/_X7CX;4,M]=G!FM;/;VC-P3[S))KM_![[-X#/"'S\[PA,SWH(PO!R%<%/(
MIJ1>_*QG=Y%."W"N/,!;DZ';C5?^(?H*DV=+NLZ:#KD2"\V_43MO*VT:*B9+
M4GL45U-,1(T FL1$GB5NO(RUR,WC5UE4XP@" Y$E.GDT*46,^N661J;$\WU5
M@>7\@+*E!RYF%[7"5$)W.HO]P'43&78(0=Q[J#IH%R]CO0#N(BP=J=)QX85Q
M7CGV%)/46^-75G&1K9Y>M=LV4$;O;IP;I\7EI?MID8]$1HC4;8Z1'XR>SM0A
MV31[H5VX-5CG%]X_]N[Y.H0*^3*TTZ:-[MK^).Y[OE0UGVU;!.:JB' 4=7EB
MB&<!4Q4AU^"Q%%)7B%C"L2-]+RH-QRZ'M7[.]?G\N.#O.$L(_'L<(,X3!6&_
MPQA<&(1S7HX@WE:,0&O\0%<.R!9:M:\G^#:G#3D_RGN_RRCWRY=1]OY_SI9M
MC)O<@FC@48B=F!77B49D9L&+]-A7WR.9O49_!L:?MB2:->L]2PZ[T=></7@O
M\JG40]#$CVU!-H\W@_9F%<44X3WVJQE["2SS1"O_)TBF/,)+<YQP4K@ILK39
M2.+A,6_K!$9V+WIG0>CM\+!P>7J84*J@XC;S>]AB TW%SV2SV/3_4<8V:H0>
M7H,9[X'6^]_#'F/\^/%+XL:TK?_XM=?W&H9TEKJ."KSOCW$M=CX*?8!@3$ 9
MSIE_->!X<//O$< D]'_[#:[=V?5CNYS/+UV>RAV>V($MR(F!3'XV+S^9[Q6:
MED>'LOV .]WU&%?:2"],*5W3F?N9U?;PQC'U=VJKB'UKZH._CMC@/KA:,GVH
MB-O6YH LFSK0&RMFQ37F':D[]1D>:KWZH/E\!#Q1W3I?/OQ5UR!.Z7QN7N1%
M)6>DV^?W.QGOZDX</'MA\?H-Y=-?I$\=4U@A-\%6(Q:)L[H#_F<F3^;QU(D/
M,N[4&&+L/H4OO<^0]5-W)2ZHW5Q? W31'+FFE46'R9I^8GKT^?O <66A N^\
M_?O^#MW9*&QI%KJ!SWRZJ-/0UMCG'_[A9LU</4], E]V(K($%,3YR?I^>%IR
MU9<<7^]\J:4GY$L%H%'@5_D2WK4%>;;(1\2&_R-O,J>TM#JAZJ*Y^6B/T(&J
MZSVRPJ<_[11V.@01B!.V<__]JJ=V4^[_>6@Q[AVY08D^0,N<.]>U  72:&3E
MD6?S03\*'GHD%JV(VS:VW/#9I3P0S=W_/,-OQE"!GX\O=)(;CY/G)ZN 8D*R
M)\Z>HW6@M@7QS)G" TGKC7?A<SJ5"N_-FT=O6MH>\A-"IW^Y=U]MFGX!RV_Z
M, C>:S0@R!--8AO,X@;Q$O"H*DRV?=U43836Q/H,S3XQ)A_>[[+WPB7!MXMF
MPM!4A (B= N21MR%M6%#P4D1Q)"$W!%6 K<($8(4_88S]:P0-R>^2!DU;,3,
MQYF*:N[0.!OYU3(%&N"$.$X,SIPK,C+EB:U)=?-C'SARBS9 ,]L1P%./9\IC
MCS']TTAVXW!MZFR9NV;355+'=&2^6O*DFM%'A<?PEYWM[-!_#O :E(1F30+V
M[&A,$G(*?F"1F!#]\TFY:OIV/3A1>L G1F&^2BG^I-8J9E[PF52=2\G]BB;$
MW&^>J*AN_\C<7S+K+S<7'RRE@MT!-.HFCA]E2A*IZ>;C+O73-[_XZ:M//IE[
M^&#:]_(![3!Y_VM?)(Y"I3C>_'B<NY_Q7: B7)E'\\1$E+I"++S:D$JPI ;'
MNU+E0]HY*6-?)&$_8:^O^=^Z'&^VH]WOA]MT!2:;=>E?<?>/Y*:U ?S< &]'
M&?LT5@*H*,5L]#$O@28/L1AKX]LQ9O9-TR]K-C3$=[ORL2@WFX.O=W'>5F6^
M/L!"@^"H:WLG-)#0Z-H#(]70$/0$IN, ?E>'P"N[F'+,4%]DTV^=VB#FKL2"
MIA25+I^ U-\/3\OO1^4KY_]J1W."P/F-@W[SQGG[N=7$*WA2.TUI=9.&3_[5
MA^AUL.@Y'%%45H+*<_XBWE3?YE7[6?KC?W&$_-DX83)&I'\!P6U^ ?#;>GSC
M$GD*A!ES,@O++84;44]V -,E 9'.7CJMZIQ@K8F$B=U1=^?>7U_6?FLW.64G
M6(O\- +H3'>39W\[_7OP5 -\T$\#IA%2C83;A\^@+F8]C\W]J5I]0&.SC*<^
M!J]O*/G]AGS(L@S7BV"<0=\FUBXG\#2W(-W.BR Q<V,F];M;8#V8([V!BVWM
M3+6KRGL\7=//VZJ_'#!\^3KN>IVT>YQ3IQ05I+4?D9!O%N1Z0@\4T$?VSPNR
M(B9A.EEL2D(IO7UW0\'QW]\__0@F!L8/'O]8(\L9SK)>OG;KA@!S8U6.V<PR
M_U=A=S(M!,7J JRBF(@N%4*OT;DS8QV"J BCCDZM"4_/7'L]^+O9_]PP)X<Y
M=.DLA9E]%J B=MER0,PMW,XO'RC4";3K]L-F?5AA@"[C)9D:L<$:23)#R"%1
M'G\4#8*Q[?:.=2_=;:_OR#AX;=.YB7H#4E-VTQ'8';E:C :'-^,!;==4+(J6
M?J[[.FI:92&=%F:X/ZC ^^F&8[@:(^>$AH^)R96'B:<N1UFJK8%^B0(B5D0
M(3$2#WHN=":P#]V/O&>]4\4W=\XU84%<77'VVJ]!TKQWXW/E1OW+L=FZA#WG
M#,]\?&52(KB(3PXC89HI:QR9LK=$N5N7.(B)T#^M9D.>:P5CL1<E3.V]]EE>
MZ+RHO7#S EQZN*5K;V<N"-=;.,J,<?"J;&/QO;R#=?4A_D>9KY+"*.R4'.S,
MFE:[F[;;^^6OC5E?[A^^^YY=##T.E/%VT-D6'*=_?5@1/-$:9G9O-._-,T"L
M>PPFBAE;<%M=K];Y,8YIZ&S.,M.79Y[B>=_*\?NL?/JJP>\3/$E^EJH/UA/@
MOP'T3UE;X,;XF0:9J00U&'8/34)CY.V<8VK6W&"/O=Q\B<GG#PHM'];)61X'
MX,.GW;4HN>\@W"\U@^3,:1:T'LI1O\ @@"[J_=A0#U&%MVT>8]MSN&\Q. YU
M<0.VIT$2(]EEE&-[,:;7><CU1P[&GR,/&DD2VP2\YC.=HE*@HVX@)H9^;6YX
M Q)EJ96_1N391@>Q]6/B$8'64S. EH*?[Y7TP9E=$!9[:,CA\)C7":>V#'&,
M9J!ND;_8@^?WZDTU(!!9N^_(>P2&1R:@W]RS!NB-<*3OT ;ZT+.1IYF)3RAO
M#!85"_G5/U%MI?><^E[.=N$%WWPHMC%,]'2]U="S_[C]JL'C5!8WDB<!<)]:
M:P.7.?( '13!9N[S#G=&74!?YS/*='N\>/7Q3]=#7L&&K,[>:]FI8;*#/@[U
M#40R'-$S6Q ;;BJ9)[KR JLP?A6P@R41; N[GQ&"[ULI1:EX+5QI,2%8C<Q_
MC2)VS+=<BS/#AC$*64'X&>(%P+0"B#F12=V+M2P\F]5]Z-.,S;/J!\@\ -L8
MYVL1+%BT#BA5=-&DTI ,5,UJ$E4J3=^,E1_#=IL)8%UE9%T;2V>U[LC4S4K+
MOXJT.5H<9_ GA4@A.R:[XG=FLQS_Q1[@-5YU0DKV#F-AUUY[EHW;"IX-<;+Y
MVOCJK>:OCC>%UDY/78F\"3S##CT[PDKEYN$4>.^\E3LZ&4IWK*4!L@T3FE"%
MM5!#)X[[Y.]M#M]_=9 78]JJ<RJX]JJ=EN!7!'"8]-9;<HI(R>>),*K7DD*V
M$T0&$.)S<R0;L>>D[N\1 J>[;R]EZL_N;WE[J)+(B( EW527XXEJ^Z.>?YMJ
M>A" D.,8WCQ=_=1MJL>7+ANUYZ@,/3U_^^<K=NH&*WA C_SO09#A KO=YOBV
M)KGS\"3GB$\),.W U')M,PP[6&-6:'DZ.>?T#.DC9D3-A>_!_W$ 4,IS>1]D
M<<-$&4Y$)1#ID-U[&/<JPDCV4%&8=DGG51UMEW8W!F:D%(*]P[X"F%()Z0C*
M\A9D]@8TF74QTB60*-1(M^VY-?VRJKJBQVCEY(_J+LSXAQS'"P%W=BH(@3!!
M1-9CYAM1B7@5FHP3C#<#\E%LUV\>^$2_.(%PG4)+1&B29K;X80_#.S^IK2O>
M?*-VF9O7@)QC\R1W<1]W2@819.'G**1BAJW'1 -""0,[Q]8I*_ZA6+_@B [?
M>=<DZU6<R?Y]@^YG31^LZ_([< A=SWR[!6E43&/[\V:)38A,1  R&2=57S1-
MY4[?JS8*OCDBH54<G.TY0X+EL7*1#X<=#TDTWRC6$TG#=^UNH&OVX1D>1$ /
MVHM(N=X7QA0\P\R]4Q(HMQ 7&@*'7VZ5UK)J=2NQCSD^0]ET]F\ZQUJJ'>U0
M!3=Z@-?/TP1<=U[D&3"1<1Q/'Z:PX5O7-Z-7:EMB+K:*;^3XN0_6X^5W"&Q"
M-#;8/N!D6%/V4=S8:QZ)7.]/MUC$QY&5/V:TG:I==!0TE.NJF2EW5O-(>$@9
MN.FT5_BJK<S3D(5+,3!<#RB&4 CO/5D] F2BXHLB S7*6!0P2W,P#,PCR'!B
MM(ZM&@J(K.8JOB[/^+CWO.SVQ0G]"]=<!)@CX,',3O/$:M@[5@@R<'X"P!6@
MAZ'*R@*4%A$IT37)7QC7:E^=*B@B5'PVB7TY971\P>_V%X<'_1[NP(QH@ETP
MD[@+$42X#6V(Y*AVL;T!-#5R-0S-4.HK$F&J_47VX1.GXLU32;V(.45D0*N[
MSTG9S4+SK ON'K(=+XN;)T%V+SW>CQ?EZ0)#_4C^RYF^+DARXW!JP.V:#]5
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M(/EX$$$0V27P.\]M_ NQH]%MYD:U9O>>=\O!'U:0[6:_EU?#_A7&PK.5.6'
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MTD3\W#I5>%):#$P@,:!KI\020%)_\B()^& 62%)BC77&,3#E5$XIM#61B]U
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MH2U7#B7\?MZ$\6\O]?\IP-+P?P%02P,$%     @ T(E(6%E* K%!L   2>X
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MVCIB0;Q?]NC&D=4E[R;)9SLFZ=9TB%VL5/!MI*O]^6J%XNFMTNU1.H2)F5J
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MO(+9<E_:B46PUE'U3-+[QHQC(YTU%R4;GUWX,O>:3<33ZN@UI>7Q1-;KU(M
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M4,O -FXK5=ZUY%IKLL[-_A\>OZ7N-'*G]S2VH#JE0,92<(F:2 G 5V$1I.=
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M\JT(%,$MU_^-GEA_/$7E;O6:P\2)&)[%85^!"0N1ZU>8^G9A(9@PY >+R[<
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M24U4SBY]M_?SS+K[<RSE;*+UJA7VQO9X_J5;UC9;<[[JZ2;:#3:@@Z.0<[N
M,WZ%=)GZ8B]D&GD:R'7H SS3_&E?>)6$#18;F5AUTU+SGW;P;Z _<FT5TR$U
MAEL'ODN<(7B1E%"KYDCC'LNKH0:-/!*RF?'-A1*5X3S"<9IWVR\">J#=]O^B
M;@0KL?(-$;H<GT21=JWR>KH96>XT/[<X<BIT<2URN"[66%,!SM22@=#3)\S1
MV!SQRK/*?6@NI 1 UIO0":U$&/H6>=G^[O3*S@LJ2R!,$0P8GTN9W[^.>V[
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MM['02+8\DOO![ZUG%?HL=]\W:=[+Q,_YW\O:]R'ER16V%4VQR14^_M^^$Z#
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MKE7CU\#T3:X;R[#J7*Y*-'X6MV5KW&SUI(+4S\]3(UY6M"N^TFV05M4=BN"
M\\!8".D^4Y/HL$)/;5$7E@/^WC6N;[>QG^YJ"#-4VMRK8Z8\(RL3=[5J!^I.
MD%?Z+,L_?CIIJ6U?=%"??91M5>_;E0]3,DXL'[]E/$LWGJF>K?1W=7VC9,1N
MS<Z@KX2'QB\E_L1_CMS#G)C?8L[>9UN7QB1)!PGI =!@PXNB@SZ4PV\.+K52
M3IO1[J1MT5J4 7"]Z4@)1L^ZG@; )@])]4?.\6_O-HUOBW+L7?.EA8JO'UC_
M\INEFP.+XV1^""6U'$4-\PNF!93OK$*CP 0UQ+:R$V3W]"8S]9#3YA@F2TF
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M=E(S9EL,T)N64]M?:7#B99JFZM]O  Y&^4(A_(Z>[532C@ :3[C0C@ZR'OL
MJ-Y">,W@M#KE%(JF:]I-:_Y\$]"^IE1O] +R*&0Z+H$*2YAAW6%HE-X6&M^[
M/@FPL\T#&S*_W5C;>^4>,*SM%050>&@M::J"F3'&^#G0^7I YS?"^0#"DYE
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M0I^7[S05)7TI5K1Q*F6 Z+'%+VIA*NL_G/K4(1HGTENHQ'[9(!5:,S.;(*E
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MT[B3OC8 U#-MLQW^G8 *D6-F\,F^0WP:?:VFM_R(JZ26)\LMW" D-)3*3\V
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M>'%<C>X1V&."-VD@Q08FO7<(1YF49,6=4V]4Y@74(.(?ZP4\^C*?;A@IA*N
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MDB;9>0XKB8OOUBO_,,_O(1IS( ^D=_A0VYZ+&$H<]%:/I?0.NA&R<0 (7H>
MN!BEA-KT!CIE_D0"C2EX&ZSX'YY0_Y7OL"'R* !3NW8)0;@'V3Y)!QG[(&C/
M%Q 3GQ!1?\X*]7\T@ODO&_Z$#18,#>-D8>2R+\&LM1K1M/H*<012ZM4E^K-
M&H/C^R&T%M;24]DFV<AO>S98S&^NZ+B_-KOG)]=@^WL1FCY7]6)-'?*>:,OE
M.62F6W!YKIV)C%-5L'+(%?8$ -?I44J9/0"J).3]__Q_0E2APC&,,&EB!\X2
M0PAN>37CV7UR(=IDM,/V2JB/-W/\_63W:'YG+Y?.]]\9M%7AZHAZ&3K(8?4U
MA*"-&A%N11%T(".NDVSY:;H>4NDX!-M20L2T0"['VY*"Z.*10UTEAP\(/RP^
MV#+GISLT13N-H)P6IS$Z3#)CUYNP=956!!M<\\9='X2:6975*TI#<P'>8A]C
M<\AEC\ :G@'^M>J)L\A!,7'B$HT1H/('0UV'+Y+,B%MX5QQJA&>2-QN186EJ
M?C/MI_GV4SSIL\[8SP1WE0EVEZ.<*VE% *A<Q$Q$00F]XZ4)C4@L'=0$K1!N
M4N2A:JYH;9>)2,$Z'CA[';4^M6(W:OCRP!4:\3WS8*@X49>401:?A(XPT$[L
M)R*72_V)E<V\IWLV[SO;[NJ$P+8K9<@NV+FC7 \P%X4AJZP#98C'JT/&I"8@
M4*B0U76HQ730(]<1CV;+\[UEGZW'1II,=8IGSY]OW[5Q2+NH9'SW(CXB+LY$
MZX/YG,@AY'"U^#?$0U<LLR8U#W@.<0C^':OZNDR7W5YFS-PDW^7TX)D,0B#E
MNI#&25Z<!Q2"J+>B\ /SZQ0YFS#5@&&@@QY0Q6C8/HL?,[S*1*FXHI&AT2$L
M.K;X5N:LQAT72^,W#4S6H Q<^T?^93]QHC )1SY 1-"./)O"!(USTT%VZ)$#
MS6."/Y14<W5Y:W __:9?E]]DB.Y=";I?\$9C]K$8+E7V;GY\/=0/:%XGY1EY
MBAA(:B#O9>NTDR\0Q?4)SJC(0RES89N24D\CGVKEOSMW/SE=7%:5C:7=^MCI
M&PLU*^$'BG=\5>&J%&[7,!3A-HHL[AJ L+&O4R*'M4".U8DL#*1J(U\7W7EU
MU"4C%<O%[JY_)7X1Q,1G0=1XQ05"&E*+(-8HLH@TA8V!1,40P,U@3C(*-[>\
MGKXP/>]==V:P\'7_6?[PT_;6;RM1 MWGCBOY1(H0#NO<9P*G;QA/;U%879O'
M>3 V2+(X.A0(/(E/8%X#\',P"/)._'VHR2>'R"2QH6:_:!&)!@Z+V3'5&Z>&
M7XAQ@JJ@!!,(6:05+T=$U&/8,':KPXT3LS4?*"IDC_RL%.+-28DY.ZPM1[%9
M9L:)[,?VZVV\-TJUS[L;76(YO+]UJ9Q]79=R:HRTI0=TG#V,O^Z'U$RJ@Y*R
M:+1#AD0G?! BD*K]3/+:?_JZ6N@L7)8B2L"T2@<!0]  YN:)ZU.ZF:5AYR$9
M.RN*&U4QL79KOQU1WE\C&PB-1Q'N0+#^D\P45CM2&W&.PHHDC9"#Q.9C1CMR
MR-#FJS-3OD?%5&<E\@4*GM9[/'[QO&U8XOJ%JK'G$'-[]-?Q_XZ'3EW\K_OF
MBR%J4!KF'# 8[\8)M]%D!]?A#EPK'C$I/<(Z>3:"ENDM2,&R<:C8?I2O?EE\
M9.OBBEC#OF0ZR&>08U<?!JAF/*#3&/;YM)),/I-')I%,]CL%\B74[%MUL)&W
ML,O.'B_#/T+?Q:"V0I:N@<MCC:>$\2F[C+0A%$%]_,C"> 5DN6O7Q2>_R=0H
MH<!LQ"=,8T"IZ98)]+'S)36[T,7#SXI+2O)%/<639R"&?]XYKR'5TNH4@-%N
M)*O3&/F)NKC6(#@SK7['D%J>59/;KN0_:2%N45E<55P.%;4.T>J,?CM:BS[W
M\G33/HW&.->7$!?P<P@'T"?!8XID"R*:Y$?]J&0Q:7&SR326N%1W=K#H=M@]
M&5])J7G#T+:#J8\:BKBF!!FK'K,SV)"PH93&_[Z# MSK<-+D'(5%F,8X,H$:
MPDHC5<X3D8W2H5>]LF-L)L5CS@68Y0I7O%(UCXVTK7Z^_RL'3-_JU34^)G!1
MK/$< ]YMEPU V^N(B?>02CP=])PF0FX%\) 98I<"UA6^^9DP^_FQ6L["F0>E
M-]F::[>%?(\X3#6YJ3^7=1_S!PP=(7JWK )SCW%I$D,62@:?]4*]AC)/]0G&
M<PRX<-MDM5=<L,P(99()&O2MC+K[\ND#S5<@D=.0^_;H#I,]A\94SE'8;I+>
MDX.GD".-D\CP.BXR1+NFM;&0H7%GL[!)FJE-)+CCME"TP-I4Y$5QV1 !!W5^
M!FX,X;HTEGGJ\V +<SBF&-F$#DVH4R)L-4:H]C76"=9]\AT^:!QC6I(1V3EV
M)R_L_#EK5AOGB<3]K0N%;'K_B>.*OR-W$+(;Z* S=>Q+=- 1F+V+\1WBB7>"
M*9T5!F^S@Y]LVX:TBIZ7'S1:;C\.\OQA/.U-864FI>ZM/QP<II; ?(&?4]0*
MVCG-:H$MV445#J).E<_8#<THWS"Q-O&S'\U'^![(/M4Z><?%.X,:"<$!'EAO
MC9G(2N6CHI6T\Y>>@@^KG(&J,@1OV-;$<[IV2IA^Z_]^LN!^C+>"8O%G:XAX
MT;XAJGL:AA=X!D&XG46-@=ABP/ !&A>UN.[<HO>.ZDQFTU7)_NX$EW&G'WC\
ML#?_RCZCB:C(1;%5"JLB[2A K(]+[EZ!*5#1%-5=:]C-8LR/HFE,THV N<Z*
MPX-WX\_QSCYKOG_M(FJ5&T3U2<, ,\11-Z!.D/H1,3$AS4GKN(SA@>GAG,&&
MKP:@9?,)W4D>S*_P14^BXIG693UH1&4G==(W:A#BL2Z9?_6EY^H(F/2(6JED
M."DIKC4@B:]5S5CBM3XO@:Z03^2_V.QU0&5HV,0PMIK]F_OS^]2DM-HYDAKU
M_08:BR;9$8SQQS/NA]TB&@4>GVE.K, YN[7K'H$TL3R,VK?"(;>^13D-;H 0
M],"AB!-*X@0$B;D7C2^4^ZFC-S7.LF"*_QS1%9&WK<6F:?DPMF5FQO<87P4?
MH\Z9_/TJK6D8%L1_UV^WT&2)[M;Q2 @GY+'T2S#A#CH0S%(N?7B8/&$RYH/1
M[YVSGWM8717-'M(N6RJ@=UTBBZ_^H512W?P717!VK/$TM#Z+7 7,DQ# \RO(
MPB3YL*GNU[4VA([)R!2'Z2%RZ/37!_&+&O@/4<:"_.]<WH-*#HVSO;5Z<V03
MBITBB0)/!0"SYAK"=80.VD?1(R)#:+SP[JLJJ3K!_K@NOZ$(O5Z%^D>O1,-\
MU^ZLG>QK?3V)!#V<>5Z\ U&%ZR+JY2D6Q!K2'N!5D]&TH]D,K19VDQR-Y(TV
MVZ#-I%=O%TH*PXUSSP=TGO,:<YZ^=^[L6Y8/SYEZ88#X"W"$_U_MO7DTE'_<
M/SQ"MC2R9#<)2;:RI&Q#LB5))4J9RDY,2*:,F5!V#0E1C)*4;>Q3D3'6"B$B
M2V:Q1,UD1C5=-8OG\KU_]WG._9S?<[[W?<[SS^^<YX_/.7/F7)_M?;T_K_?K
M=7VV27Q+93\E':&\#D$2IN=^T @WKSX_+U#W!>)[&EJR:SO^'(W8V?;88=%1
MS5U+P3O_B;8EL\P 4SJ**,&R(@E,':X]+QI0G"=M1ONS@\KI"3#R67XM_A;O
M9)6K=N.LLW9T<^O<9;Q9IHS+>0?9=T3-F.;=L,?W));_[9OL?R;,6= X(_C-
MUD(Q+*E.>/.^T2[4TX$^"=HH5D.HN"O>MRU/_F%@JUND9,S:GT8L:G(:RSI*
M2IJ#  I<<=Y>%KY[2.WL# 6P[?89#SA@<MYOSK<_ROK]IS_I<3NPL5ZGKCS>
MN)9S"S^Q'904HK+ P0JT,I \GXVP:_K0[KZ]16$I6\U=?T#]=<\F$^T3^W.O
M](-$> (CQ[.M!]Q83=T(R>;J/W6U:%,:UW#7]%>JD/;HC%U.=>N!V4.;HOK<
MA9?1O6"YB^N0>YYHKW7("Y@ ?_7O:]!=+,&_?-"[UB$$=8]UR+')%A"@6I&,
MES3<C#/G,EN7,3H/DZ4L_T6F8_HY)<Y'#X?2N#8+BF[-!_0'[*JB+?>MGL2\
M@37!4]8A_L-3 ]V()NPMM&-"=>B<<@K=*L+AQ.$S2[*S U?<1(10H2Y*ZI R
MYZ75%/ABF&&XH-U#\'COY B6=66U=U48I260Z*?#4HKGVL(UB/,VOF[-HV9+
M1>@_[9G+D8NY)ZU:]_CF^"J)CLL5*".946#;M0$+KB]FK%2+_^P7"2<P97$:
MZ*9A0<VC)V:=Q7*#I9]]&FP3!-Z2R_N("^L##,&XMHCI@V\5:)[E'0)*YG%*
MO$/Q>A,A5_';SG<5G#Q@E5J:ZZ1QL:VDHLM",S]Q9^)R/(*WK9NVFB90PI)-
M,;(HW]YK=^VO[TK>7[[P[D5@QMH:?<T@>>SWR4KUZE=\(BG"^!:I/K4SP6$>
MUQN?FN\?%?$XI/6#4%0UPB1/O?WZ2DY%T1O-;6?JKPC]^G0Q94Z>2$SWSY;?
ML]-H4V(G9&M2!QB^DK*Q9/UVD,B+:DY8&R>P8?,6Z<U2'I*^Y_K]GRXWV(U:
MYS4J[T+N<_V<-IJ0Q"T6?KZ6RE#G[L",4%@GAZ=UW3;NE190*AD"Q<82(XPR
M2D9/9D >V2&VC3C;[-2=3;$9R&9R2;^*UB'$<?].&"L*UDE00MVUWXRO\5E^
M'AJCUZ48GSE@5V0=/*C?S_6?>(4#;@]P M<AY??8%,&F,UCVJ[_]G)]@-8%H
M"3X) UO&J #IS[[>V-]&NX"EJ;*#LMX8U0I):EB<%@W,SM!2.+#CV9Z!O)PX
M6UTP3]FAC8,7R6A2$$$,=;%WZ'M6AUK;N*Q<GF1WS6<_RU;+;2+QPUP#Z00I
MT )!8(;*KXC&Y)5U2.,JH_\);!LOC)W1OSDO, +)22PW8#;JG=T+?7"%@8V5
MF =F(Z8;D8(ND-6!\-E0V?N--&T,T@X%M#-;ER["&4:&TN%R,K:]JI4%3)7(
M:R;-V#83JU:9_.-EK>A53N$Z)#E>((49QVKPO+AVP&].+KO]1F5&RW7C8&+*
MW&AYJ\/M.R(&MQAWS%TF=:V.'S?<.B"0 ,672-<$R3_!X@R_C!2"E;%(LS5!
MK>W/ZSE[BP@/$0QFN(I\\)5PW17J9T<P>ZE9I."M&==1R5-,$8\ 8\0]N(*L
MN)=\1UK/SIM2ZC<Z\_JC775G)XVY<J"1)#!B@AY$LU\VUQEE/(_(^%7B[$AL
MRU"'GR*V^@3(S;P5WKZO+%+D5I9&F?<8#!RS1'#,NH%C%L88FS?^CS%K^[_&
M+/W_,6;M8JW'!.(?UR&[^S;(X24&Z:^W38*%7P)W#V;8%L:_!P\F20F&-;9/
M$LS=X5T3AN'AV&=[))Z>U'];(+[IBY&S<,L-Z4W_>AXJKP6TZB/;+:A-7ZB*
M-[$A_N6WV.Z%67+=CP76PN:W.,2X77H'!BX7S,I_6?P1(& 3QJM82&!W,$.:
MZ@'L+B0/Z5.'>V!J87]%2_/I(2W/"&8A]% _'^;W'=MR=^8V9Z;8OO2T,^S'
MDDT$4BAAJC=#B]7=A86:184CL52NM+]G#O5M;/QUI'K/#RO_)9W91/Y'+\^N
MC!]XP-B8]SB33N!WKD-^<BLGQT@2 I@/6@<X0R/</NO%FSS=H<SB%^1%Q%Z!
MW UAEKEXS:A%:@H=F-_U8ATR8\$YQ^IGEG/WH_(X(6"@1/Y,L.@A^7./E3_=
M:<;BEZY)54RK*2R6>1U45_I=9EEJ_[_#V37%_X*"*XJ,1*XI@.18\Q^VFW,M
M .<>[^G6$MK]2*W6<7-MQ]*+AH-$D7H[Q91[B8DCDG_B.1OW]<BB5?FUI-#A
M;8+Q&Y3^=8@R$._#5FXQ/1OR/%(K^4U3ROCEH//K$),NB;=?^UN$'4A4&B5S
M;C/+&=2"/7!I\]?7)FR0?3=:"T,?APZ9_/EQ77'D\\#.IW&73Q%WM.Z5>J9K
M8/H5QG*&IG9H 1?!7@P!KC2DPK2KZ$+QEFE<WAY:@?[ 0.:;1JC'YV,/KQ'D
M_^<@2[)[E***.C$WIW/'[/BSM!>28A"(I:3PHP5$ZV]F!:N0(P- GZ&C ,*5
MM9I(PV;W[=-V1N;A2R?\B3@;$_FF@R([]?=OA<"%!61*HQA3&H0-:_[CJR1
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MP=;N$%&!I_'L&*/MW\DNFX;W+4@G1ZUU7/+\&($EB[3#Z)1-8&BWX%G0**J
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MI@D><.%8L@L\<#@-),[MAH$:#R+F\5++NJ<^6-N+[-&Z0PMR4LJ_9T2U"%C
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M?R]F^6-]M>4]'6^(7?E_NX?LO]Q)E@.JXP8X&3G31FVAD(>S;GC\?CKR:R
MT;+\._Y*4U?_6@!<GR#6H$%RA%P78WARY7C;^;<P4F?1:L#!)^N0:Q$QYUXZ
M<OT:XHC2UH-P'?NUQRRKO&\__^4PY?]=.L[V3JWAG:=ENW7=R.X=W/^WXM9$
MWE#PP8P 5YERDP.+2INU]RZHJ8 -03M3"5/# BD;E@59C&K1-3P=3Q-+YYF&
M?>@N!W[015.JC=-K#3\7%4;OXEY?P%V3?S.X%W(0(K2*J"<P$FF43ZF<^ 9
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M-MQ6/'IEO/9ZO,>0 N>^S+,PU0<6N/]W#W>#.*HI>8RPO=\#<MQ*2UIC@6!
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M#Y25CQ7JO%I&X5B"]J!Y>-4-9[0T,Q.CA,+W_+V:TF*AF"JR9%XYE%Y4]>)
MS+NH>'>Y2U$<WQ!S?"S>\W2S/<[6H?@F",N]?'XR/)JGV".RQVW-+B<B]LS6
M$S$_>R^O*HXW@UH)O';</[;)$8]W89RC4$"P"KR7V#.6"+T;2S(3;'O94F]5
MAHH.7S0./*C90:<8+W95E;>Z\J/Z(V+O8$J@ 8<PR]@&.(6'RH$$K0HQ Q;"
MX'FJDKFN^R9]C#?PO+5$ _N96%_=<XXR*FF)0Q'IUT0.!BL]"/@C1*ZE&  %
MM!/0,RAH3_ GM?AR_NR)"3/;E3J%AF8#I]N&J4JV_'9'6A<?G<\4\]>^R&X[
M#]^/):WIS>,&$ >K.B499T&]E6WV^1N1&0OSFW][TX=DN6S835I3;WWJOZ,_
MLL[YT6F83R@'ZX-/9(F!$"WE5D!-"$G^,[,#!%J846W*@D+##X1)'G[\P5G<
M3"3MY)NMP9([G.%X(%P^KG@!A2?5/B9-OG*@CYIZ-K>U7^G*O/(JDU!L$U*B
MY:C!T4S[;2CD4%#WE&K+D)79A:EW4G',A,90IEY"9SOH>]=\HP<KY/%YV-,^
MS-0V8VZMX>"Y3*ST'U&6(,2"GR!1 ZP>-Q-63H]E]L80 K#'@JIE#%%_6C8S
MV1"9#&\L3>W(UVJ?;MH/92B942]T^7<I9>;$F4)TX=VT>[.+V+H=AJ@)BX="
M-T"?QZ8LUR\]Y'H?>/W0DY9;J.YH*Z6$FR&7;9Y.2<P3E,UD7=;'&**V>]@K
MIGUC9OTJ(*KU%<AUG"Q<^G8\CU+YE1CQ8E^&0FQ$RH&/=S.Y'#%96((1EI33
MR0&Y)L@-')XEP,7"L:)"4O;79M4N-23!&YA/KG(N?/F]2$OXB&U3YT)STWFP
MPX-P$?R6+Q7[,QMOA0A=!C4WM@A0/OCE8,Z]$ORQN!JL=&ZF6R<^9""DS<>R
M,HL"G\\[[Q]A9_-R?1M1&7P3$\WJ1OZHY^ZMI4NAD8PO57IQ^3+ #@4J2+CA
M8+$]LZA*8;IPLB.P!NO[]5X%=P(I<.9'::Q8B)2SNO<3O1/>4OO\%<;*6!Q8
MPG!!/;*W5HZ(TEO9Z(&+@.Q\?YQ-HR-HJ%IMLDYJ]3%<4&^B\L9^DK\:A\I]
MB+UHL7B? JLLGE7NN'"<+$-GML.Q&!S7%2RH0D6L+[Y*Z5;RJO+HCU09'K;J
M@<U]]=2 1%)&:X"NU:SN=+3S;)C#088CQ S%YMS!^Q>$-3^+/6L;N0%_D_+Z
M*V_8!P5:K2 5UXV0Q$P7 ,%.#]'(%:VH6J/E1)[;50&3PSP9C72!$]_'<]32
M'WLA.5Y)?-VRU%+^I49;8N([15@05VEXFDA16Z'H[B GPJ-/?QRS;1PO27%
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M&QQ(&%GY#=&L$I;;0G'CL@_=8A>F-F)<F;H0N6W:XOVE]CXTRA@=R"Q"!")
M%?^43A&T 35,&&T)I+0E)J!EJH(D,Y6()W4:[[@-3U2TZV7Z/[WPQ?24<%I<
MVHXUU3,%05ILF69-PS-V8?Q?;WOC;PWDT;B;%W[_Q""KHPH8TIN%-R3P]1N]
MH:(CHGSNR_(#P1P9/6;&YQI6@>?J\!-"<W"6P#IXJ1!M2M79"S GN\^A<OI:
M_C8^+FW&K;0W-C<T""M*\@*-9WX:5FM8!%QC5QL9\1_ DY8$0MT !$-,;66V
M:SN>I=DVS9)3?5S^(:OC1=$[NFXIO[%+@=[(NIGSX-%^TD9]2B0<N%@ :CKU
MA1)K5Y[@ 4<<J"90O=006;EH\70%*Q)0^_.;SF#N!/%,C%S]@Z7P(4772P^4
M#H^JS14 IT-!U8)X:+'!]VV,US;Q12,'/ \=N8KJN1HCE-/*]H.B,,@]E'R7
M_(A_ZT,O[-(!B>:I/]^QH))_ MJ6?AUMR:S#DTKP4FC$RACGM_K/GD37SMKP
MTH% E2Q-@MR'TBR? SW-*I>>^3P<XQ#X"0'3X 2P"XM!D-IR\7'X:XMW?EX$
MG4)5RP3?A ='[$BDEB3KWYK(1,]ETH>O^*CD:$E]7GB,*-^%22HS4[&D4B2_
MF1-=W0V-&6<X7M>;^V[FX$M"B!/'POEO+=H:WJ# GPF?>5MNQM&O+X#Q0]V@
M0]$8L"X M5XGTO70O%0*JPE86)$H+:JI++S1?<SOA]YKXYZ[%;7;Y.B/*:\B
M=:>O61UC\RAH:OHS!JTX+BS!=!=&+K+87TM! NTG?YKY W_[TAH$.J*R+HQ?
MS$F_O9/_.?LI=BXP4>U:[7C2S3IK,T?^\<KB-RXV4OQ"YVQO6S8CE#JEH(AQ
MK^@3%#.R6@;<J/HCU)Z35Q@:I25C;4$-*HYK0?MDOPMWXSI>KJ-R(O:->)0Q
M#DBR>%I"R=MQ;7A*/'7')GO5 \PJ=?(ESX5*=6P&2]\ZU>*.^W"H325]$5WJ
M+'CH.E(*;<M,PNQWAZ:*D*$=;YA0C>O**3BPE?SUW$B+;R.M#FE>)#S<]UQ:
M$?=,]=C@*-;*+2+O>DD@$'C\TA/CF>:W5<8S,]2':>I3G!>AE?< !KL%*WR-
MN88EV&-)*0C :1<V/T*3 Q]36\BVW8MG!WH]X1/*!0[M!7V2#24A(5XG3MMK
M7/[CD;#?/&@(3THL !Q"YR9I\\S,W]M)RXTF/9M,=_<Z,#ZRU/TJ$8S]-GUY
MQE1&ZI+Q2:4WIAOIWY7-5M_6?M(#M0<8Q9(K.\QDR%I??=^CX P9B,RI\JW4
MTK5R$UDO#-LX7JTC@5O8KN5$> .2(3I&ENS:A3V\=ZI97A;"%<XGV:$Q_[O]
MDN%]]]8K4BJ'7FQ$F.6#-3TT62@60*R=8,Y"L/J0@AAMM"5XNZKE$=J)1'=?
MO.!<3[7^?&I,R3?/>\G;\W[P0),:0PYBQ*IYP$_6,#1P@B_W+U0O(W=AZNL@
M5.5X<2:RD@L]A(9>+ N@VEG[H1N<MS^A%4FA\C=,EO91^0)_+);^?+#S5V"-
MPE'=7;C_!T'EKM@M+C?QF^H1;LRUVIX"\"C["CP- 5Q"L*$/@EB%CIE@AE%1
MP(6>D$BSR%FW^-ZZ7LOM+Y^[EFD3^-OE7.CG="B!$]PM)%E=<)D. R!KE;L;
M(7)U#LP?UJI$BGV=Z I62OGH]4R_@5M'0GS>$J'U^OCL>Q9D2CA:@&[$V$=%
M4 16'Q,])'N.:^<^'+GQS7,3%G6KWY[7T];'>HCC;MIMY"%H!L)R/8YA"-\Z
M$DY%6$VB*5AR]/P,95Y4EWB?3>Z7]_B)FR]W8;/5: ZZ&]3;SJB6J,?B.0+8
MTEP UBN=G>0F\RM?+0XWMWC]=)1XXITT;"SG6O:SVG?,&3!987=!0%#R&P.U
M; E".'A]8@KBYBY, C1P!_1BT'*8F]_U?J^GV;Y_HNU3Q</CM=8Q;E,,YM'2
M$CI1G1#]>]IY<$A\( EM1)=DV'8">1U?9'KOC/#?$)/UC4U,=<_X\>?]60//
M5BJ<Q7/A]@H65+%X ;$/!G 9[U^*2CX[H;W-]>H8PN_=3.;U\-OK3SD[WJ@&
M7C0^6.AS-/B%$\%" FR"W%@/0<4?K9Y%DNQ%S#\U<P5Z'!M:&[/.3G>HMW4^
MR7;."4Q?_+HEY1W]0_;,ALPCS2/-#RXCKB*\A1:\2?Z492#&X@B:;[HF?\:T
M.+ B\-Y+]O_4RMYB@U4CF5554JY/8TAK!\SO=$)\-E850T36[U <@(5>C!2H
M3#\"8LFVC]!F,[4KP7P]V>=*F_[:J5RIR;ZR:IOS),,N7>),3&N<7^=*H17R
M.5P""BFI6/E=V$TA4(-62;=BS4MW9E6B#V5_"Y\TK(;W7BC]-$E.*7WZ"JG#
MSY:FDC-\\WO@X?G@WW]#D4I8@@N"5/&?':](M"GNY*=K3;,6AS9I*4LR  /W
MC.(]A&SQ"%9X=))=G$U 2^.<I4LX5PWF!N1Q)X0_+AX!G,6"&FK=_^S"KKV*
M>K6I;U7V+8A,C[Y\OS@0-5O+J]11\^-FGF30J:VN-Z'D6TU;!<"=VGX]:=3L
M*K:[=JZL)[<W^V_T[Y?WIIGUQ^;#P\,C:!&O+8__\9)Z!/\U5W F' G8+8.J
MB'Y<,E9J!1(RC[6\T]+2J305TE]-UA&]XO3K>9E"E%M\]X%]ZLDM6P#,F&+3
MK:D0J@[U970MB4&_WJ*5J9U5$8&CY&JN"[<8FH^,7C0HC-4_56.2+6=6L 1(
M&5(.OF%YBP.0).,'\/->8Y<_A0<)B1&*;Q!C9FI4<VEK"PZW!6@>8QGZ[RL+
M%F^>&3Q<'%!;C0W4XV7-0DD7#ZJ4];S SJ_VYAY*:UH--G#LH&Y^RTW)#KHO
M=N[=NY:4 9D4<Z*6N*G-%$%%1"L?@O#+WT&FR#E$=]N9S-J"2*KS4!'.[*DC
MXKSVLN5I''B@]C8D.#*()0M"T6=?+NB_&II$_-V97/S5@CO:W7DJ=-DG@E;O
MH-,]Z%26HY3.93\($[$L=+$X PY _:V8:5A_.'@HYQ%+D>$U_KH9+",OLSE6
MWI#72>YUX92\(AR:-GRT)3DRODSCIE#.^SB.]MO[H*01>S (WV32IP<><NIS
M2L#S,AQDI:<3&K E#./I\.16Y43'W/M'/;H'*[Y(:*@:Z(J1OYA=FTU%WP/_
MT"]!B,#B XV8+Q%^><>W>PJXT:;H',G9V<$1D?Z#%=\DZ4YC6K EZW*SN__\
MT-O,V2JE'V$8,'$6' 'PAIWN^VJ.6B>;-7<ND,:B;VV$S>JG'\OXG&W^H/N!
MN"5L^Q4@N26T"^/ZB=;\9"$'9N^=E2N2U<T<5A:8;J<F%FRADM'==?Y1>G(\
MRDTU*O?RDP+#PVRB7[XTK"X#H5PMU2@XBU>4&D2*A&H!<0_(X8)9IZ;\[)<<
MQZ]&YS@GR&B-Y7SY*:_A(^M]Z^Z\C2D.(E$,<;65%HH+]3025!U@B";,;+NV
M3W\O.$U%/#9T^?-;8LTQ,%C5,FW>,O3X6GI519?P0;^L+2?PD E#U*D;#YS%
MQ=[]9Y88WUF[6BORK,;L>HUEXLCG!W\BTGTXUOI:@5ZN"#\OF.8C/O<;T4[(
M%"0 F7]>;0!1)T2Y0%X&-5JV"#*!S<2<1UYM,ZE5V/;)IFE3QNSYE)Z(5RUQ
M!*SA$>:W)&9>C>WJ+ &>N MKQ!&6A=$"8&E)\B)?;UO0_/*I(^\-AD\_C&NV
M^ZS]:+E[L*P)EH<;V@8U=Q@20E;,BEV8S]Y V"[,]T]9CB=8Z\LYD-KXWCPE
MY_B=QQVO2L@8;Y46NQY9B23#HUI':VL0W@A0N:QK.P&B4D[C="W6)XPD:WH*
M[6M>4T<5<=#ZHQ"E5^R;*>.3JRKPQ9VD0.@Q>0;*7Q?_LP Y[@N#'8RBVM(V
MISN0JZDFE$D& OB<6Y9(?L(A[?GB$<E^WNY/DG;:R#]T]XHDYM="^5SX(SC@
M@0556[9P=$&T+& "U;S^"'9DH.3?Y<=E#5.^;;,A(;WIU:VWV#]L2:[+V1K]
M6MZ""K)]IR 81S!\F>FL@PPD=1?6'>V\Z4&%QQJ..EUN3>Z+'-=NT5\H22.(
MG*O@$[D%8V_=!H^?9#DND!.9:2V(OW;3M):],X/S%,"%-926N@LKN?U),@*A
MA261\_@<J1 N3,GXA/!G9[+OX6(:3=W?30]G)SEZ,@^R'Y/:]T.+ G^$ $)R
M&**X/D^)]G&&'+E6%.5]/EM"(O<][K'_NP"5@>%^T^RP<.X*DH@^!T>LQ?&]
M2(4==N^$8M5<*7F;:8YTH51SW%>FQK'VVU)K5UJ@M8(!1U@\M53)7J&HDD7D
MMYGL9LSUPPN;TK<S\E$<T5.Y^_VTN9<6A%GR6/]-8(,F^2YY=8 ABZQ%GP&C
MU3O&;YKYK[QW=J![MQDWN >U7WPFS!!2>4O:^<F)63VG*G;>FIU7O>C!_^I-
M,X@HD;J2*KC38Z$\0>J<_"UCKQ.Z55,L)-ZKKV&;.@4,#]LI_.;"'V+M[1GS
M8X,+YAU6@W=A_="R+!N@OOXZ^Z4[H.7>PCS2[=1H^U;55K7 &J^EPO"E!$G-
M#R8%L\?5^>88:,"%<6"3Q<M']V+<G.Q4@Y[DB \X^&4B[,<;\Q+IV84FGNKI
M%IF@\%3.]R6A'SWL%9HC1 ?IRBS>O+T=CD3: C/+$!Z+Y#(R-^DY7A:C^ZJ
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M\+IM2AZ5W=&AOSZPO9:!%%A=MN<JE?N0N?"Y*C,^\,2;4]<BLD]L9KS$501
M8)+$,42467SN0<#37=AU4Z<T"RD$]]H48Z+XJE7@V[$-?[@__9J3P4X"&_T]
M@U20VPF\9<99*/XG_U&0-$-F*L/!#QT4531RT\RA\NQ,T-VH2,WDA?K!FO'#
M\:7",!ZDKF*[<GBTMS7;76";M,TXD,7BW:9;H-*PD@PA<)0,Y[W18IPP$VU[
M@IHWW3'&YNLM%=;,'>CK;'OBXCU>NAZ+IY*N D'!M9,',VZ &J'-,E_CR;K
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MT]^R)-N1'[!M&'R'\,(XYW;"?A]KWY]>OOZV)VPN#>T[[&S!!;K252$T[IU
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MA>SD #/?4?,&B(QWIYK^Y>>P%*.A3GHS16R,0AN9I3;4"$I^]7*IZ, UNK[
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M2BVW%+LWSG*B#9K3#PR_??>ZJ3U*,7&?[+5+Q_HB#_NL_MIS[?T4X2N)88.
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M^IWV3@Q#(H'V8<3D-/\(J9U2+.EMMBEHYG,+I#AU$3S42I1 #Q IY\&34)8
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M?][\KB'ACE080W2*["5K M9L-+=M3].3.:368.S\A"G!?8+FX#%(/XI^#Q7
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M=^Y,W1MC$/">D%4/CJA_,9W%XH90B_[YEXIXC2^F(WUTJ20V:,F04]Z'?8R
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M'3R;L?_;-GXI.5^VS[,&<$WO,>ZWK74Z?S1DN*$S7JVR;NG?BJ?XSTT:\W!
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M&W/*,NI]W)0EM[XWX)ZRVX.;6:E)/P4#532MH"&X$F8D]+K.Q#H9O!I*M>K
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MJK1\9B9+&#V.W8LG74+Y#OX,NK>TI1%N^8'<N5;QL[R2=+-/3[?JZ%O>+&7
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MOF!'USH]@XJ\;L;%-H7<B\CQ<QT-N>'K&]J"DH,]$*A;C^8)@99#K_C?RO4
M=AP1 M, F3]@Y9AB8QNX!!>>!Y+7C3IAM4 ?8=9"^4ZYP9)_]AV!8]=I\. -
M)YPHX,74!^!4$DOZ[D_2TOA B6G/H@8P0BVD5PRE164\IJ8P3_W\[G8M92SJ
M%_^#(861IQQZ>H*C"?"7?IOQ ^"CC3WGWGXF^MWN@M('44:3F^%P+[INLO&)
MV\=0GYQJKS8]!JTII8C*AA00H@3->+:E[#UHB_@*H*&O67W_QY5#<Z&>9WR]
MWYW+HCO=^TC>.O3BIE?P__-._5_D[C B9N0?BVL1ZCNH<+;5I=E<K]K=PG#X
MKRR.!=?,^-)-."7&8</5RZ$HQ#0'R8W8[G,[(!G69Z^-'):*Y@YHGQ*5Q#1H
MV0%MATU6T]KQD1CR'/C?@7'YW;WQ.Z IOT>^3Z*9XR-89P)\RR8'N(K.F.4>
MAG9>''%Q$GJ(,_HQQ*KKTVM?5M0DM=TU-MG6[!J5I$=Q6JC431R(RX4K8 @7
M,%^;T.](#+_?./;^9AR2G?D7G -OP:Q-,,V0?] JJ*OT1J)?C4D*K+G&W]?*
MNWN*I]7BAZK?Q7SM,3W-*Z<O9);&Y^;\QQH?CIAK.R"B ?4V2Y[&*MU+VP%E
MN%7[7D1B!J&0PE.MG?=LK^5)_@,G"31_M?C8+V8@M0Q11)D_Y]HRT31:>US0
MJ?2O/[""QIN&]X<5':T6%I^W"K9*?#Z:+?3U/'9^\,/,%$?D"%-[]<Y;P^C;
M87Y:+464/6I4^9G6XW<?V(P<@,TC+H*V3<A#ZUJTAJ4/7)061\&F-[!G:):I
MVA.=S@%Q5VFNX9%/OBNBAN=]PC*3B3==R]$3.R!1&SOFL3!X S3K]:4%9'5?
MN^K%VB81;WQN"'^%35-,]_?<Q&I^KB__O:<[G+Y1\P(]@*>=>P@\JUDT+B'G
M9$.%6W,NM6$*5.+"G#/&9*"'56J2)[Z4>D&;5B!"OW= J<HY+)D,1B:[?:6I
MM8D>-&CM&^35<#G7O"!#Q%7@C7^V8Z%"Z;L>]F1*<S#?XO^H2ZD+A33B>^),
MR';HJ6B,3.,X8*O@ID"BY0YI(B]*S^_A31@8S844[&%SH^G+@M<0[.UZ"DMV
M_@0[AR50@=I#\UI;U4VL19GR$T.F-_Y@&C_4U_Y3_GK"0FFTX=\])*E50B"
MI<?.B1SSX0A/T"&,6\ *TQUU8.)Z%";MUA=DM#>M,-UCU?DCSM7G77N(J2(C
MUS#")FN@)]^F"12[ [K/!=4W\/K*U$[7%\%0C08Z+LD(97NG@"B8:@,GKQ:K
M69[.I2^G;BC*\33T02>RG?F*?N'FJQGKW8 I,YJE#O@&5 .]\WWM48L5MY=J
M3!UI?_JKJS?JLFKDM93E.Z6>*+8[N%3[M[ZK4L4-X3(@+9@>2-*6S^ZW1YA
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M-J9T$_C'32,;*;I*GU=:%"*67^^7V_6VH#PYPNU$3>L2VV.*YG'5_ZUVW>Z
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M.Z\_WR\)S)+!,JZTL'/WL3,T:6.?:4^7QHHVU^W6-V,[8?.9\S=7-D_?;HD
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MOMLCBAMUWSXUWFP]N$>4&7;B'KMLCG:Y37=)\7"L/2>*L8,"Z"32O>9Y'.(
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MB1("?<_S?!1X"4):97SF$GQIGXM&NA_B--!=\8G=!Q.NX_(="<?>@V&ID Z
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MDU"M+*KB0>K,2S7UV>I>'5F+9*]0Z]<3G\!.IUUIKS?#!1TH9KGMG$V<;1W
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M^BSTXC#"CJ?5/TEASJ5]] 8QF3(F_4!H@Z*,.NBK;6 L8SKQ=^IZ.+7W&!H
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MAHIU[^_)R7Z0XW=,\?,^W]&[#'OK#+(9/W2E1+KMV3H*:) 2$D">QH*X0R^
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M6M781P<R"26EE&_D3+S=:7_AO<_KYNN7WQH[84U22OP$!3"(? J1DR00^YS
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M]ZW<36 //I!<TW)60U_16+:.Z>1;[0[.7P=P'@IMOT^H'DJV3&&U2>>U?K6
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M"$W\:@_!F:1&OQ(01D5*SX\Z6V72BXH-RY%>OMA"Q^[&*]-WVY6G+&V]TW6
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MT'>=-(U3'H>.5CJPUNQ+>U4'PC?>B0/Q;73CT%L;53_S1(A/[GVV![:!7]H
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MY]^P\,ZT\?MMVY>[(J?\TWRY++9%%V<A4LE$H0<957%9+/$AH0F"7LKDF2=
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M2@#(1@2SLY/!K.B=JX;!>F ]J6"N/"MW79A_M#!OF ?7YV$V/I69(^;HQ&9
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MM7R?B.K.PN4!5T40\99Y,Q-><R;TC'B'Z(ZSC2F&P3O%\F\*W0\5NGFEZ"3
M+?M5YZ05^'@686.3W@PP1T:])M%1S7HS(/8->\.WK4MAU96U/OY2F;C\=[[@
M(I?61.A)$QVG,(DCJ:1BJ9_2F N8,2%(I-+V/=/Z5L?H3,T4O]E6AN,UH\;U
MJ(["*00B848Q%!Z-(4Z$@&F ,BBW@@0C+Z1(]5?1;W/O LX1&MUOX>0E("O
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M0 ?Y+/-2$H8(!ICZZI@2PL03@=SWL4=X1'',/#/'C%O0AP[[J-/3"_[< ,_
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MHDZ-:(\;=6H#RT'4J=4@ENW>5;KAYVWNC/QTU(<C*<X"'+.8" &C@#*(61+
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M)5Y"$J.*-!HTIZ:@VBZQH.&],O/_X*IYS/-C3L'-0BR+I_ZU9(V_GI)RC.K
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M$%:>7IGD$,DBB7B6IR6W.K@?5LRIV<A:JEM2:@<93 NK.XDA&OI>0BL J=8
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MD8Q"DB0)S+*$YS'.9"25/5ENR+S?G@22Q\GD[*0:;CI]U7T TM%+[^:KG6:
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M3G'"XQ)B'BE;A+,4XBPJ8<324DA)XB2+9@OQI!V\K_8FJ:=+JQF#ZQESTO&
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MBRPO2<(@032%RFO.(.4<PS)+2Q*3),W*PBTFPJ'WR2U&M?!WX*D6WTPU<J"
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M#'.!,V6AHA+2C)0P*=),J$UHQF3B8J$.FY^:'=+2W4)8= 2>G4GQAV1@P^&
MAK-I.*]T( -PU/BHT_R\8L>3^<)3MQ -*7,@NB4#:4(CD:8)3!)<JBT5EY"(
M1$W?G"6T(#$B&7*9N6=[F=H$;OAL-FIUVQ=E=/08SL-I?;Q\&TC#'RMK?(R
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MLHP3(7,!&18Y1"7'L"2H@ F-DERYF(03X>1DNLLP-7/29:XY94C1N8[_M\V
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MI1O[IW7/4_-+]_+I2$IFCK=.*JB!GZH%V*ZYIO($:SV.CHDK]@-CY[(. O?
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M&JNULN2K\8;9C/XF.7@CFH_[/MN]3*ST!9PT,[4N]>4>;-0'C?Z@!\ -Z$$
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M5?\#85=A]0H4!PNMNK0[7KW5*[3>*[MZ33LN2\XNU.5^U66JT=5=Y_S#LLT
M_:45X+-4__ D^!U9+.XKLEP35J?0^"0VG^4]^36C(L]()M0^/F5J+4H+ DDI
M<I@B&J.8H2B6J$N@>V^Z)'D4T&BR[B?6O1\C5J:;G"L)6*V ^L]B 38]%6[
M4FST QORRX8P?0ZOR1(V]FB-M+;MU +W*[!3#&C-X(=EERS]!FP'\[,$C7Y
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MW"54G,[BSC8ZVGG<);7Z9W(7GW4,R^N2Z-77Z#,N4QQ%60P)221$ FG/4%%
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M0/&T#;W0V:C;43/%#[>EAF^YT<H;LA;Z]J%-&)*A*$9,%)!D90Y15I:0R$3
M5,@TBC-6R,@JN^-^\U.C#2V=PVWH 69F3.".1."9OP4A0)66TTI[FMD'C8\Z
MDT\K=CASSSSE.%.?YPL^7SZT7QU-RRQF5, B([K0KBP@5DL]S!E)\SRA0DJK
M4([]YB<W4UOI+"?J/F2&$]49B- 3M14LQ#P]J;.O>;K?^+CS]*1B1_/T]%-.
MAUL_Q6+U5)=%[>JCKIOXH4C@B-"D5'.5(H@*3"%.<P057(07-,T9-LI><:&?
MJ<W<GJ2[:K]KNXBL2] :'2WY "SX@5%XK*P.=7Q@-MI1C1-VM@<OEQ"Y<)QR
M]O4Q#TDNZ7!P]''Q<7\'&I^?-^L-66HNGA5%D9)4466"X@@B'D60\DBJG0E*
M<9%EE$FKK<B%_J;&FX='&JN=J'[/-/J8NQ]J."+Y2J<:/6G#'FN<@"7@N4:_
MMU<_V#BANLG)QJG7KBMEJ2_TUVNA6>M7DZ3[CE35BUQ5?Y**KV?*^,I1CC@D
M/.$0J9T3Q 5FD*6<BC(N,$Z-[A(M^YT:X6B7$U:+:5FGPA1G,W()@%YPJZWE
MF-IIIY;YIOZYS0B_)[?_$I.&0'DN)WFIUU<I'6D(Q;DRD::O^Z.C[M_:+%S]
M!"NW2]ZY(=;$J,^2>/^!N]5Z,TM%RA@I4\BI=BW&2$ J90YQB?(B3N)2""/W
MHY!"3HWH:DDAU:("UI/U>M:[>CC=*7+,07HM/MW^HE7R9C\CD0YRZA1M+3U8
MZ[K_F-8V+ O[&HN E'VUB*_.[[Y -ED,O/7E&'U]D'AWEV]W/T%O%S+,"4(T
M31!4?Z00E;F$99Q3F)09XC+#&>7,9E&P[']J?-]E22';I--J18=KXI!CW75$
MS'@](,[!*?ML@F_9)O@.$>3MAI>OP&_+WL<-!G>#YBA W+&9*])_WS)6/0O>
MJYK832(1E424)8)11G.(B)20)C*&."ZB),%2TEC:)9H8[M!F?HV3:Z+)KTP:
M@<'"M;#D!9S-R,H?=H&YJ0&ME;1?C3, (YF!XC,G]?G.QL])?5'QDSFI+[_E
M< _;<]'\M-HHNGH6"K^L=01($BY+F2*(459"1'4$=)85,"WR+(I0+FAF7GYF
ML*NIV4+?Q'*N:Q7N9 :UT( _"Z#%MKAD',;8X$[6&W*!&>08K;<M6I==,6QA
ML[B>]0;?2#>TYV'T=#MK!,C@!>UP"^/=T1IILG=-:_:&Z\EEW_O]PU(1E5AO
MM&-;G?J4]T)&).4Q$R2!25)[I64,EE@RB 5*<TD)5JQK=QYIVO74F+:3%53:
MM7*U!*SW^2_KSU]'8Q'+>"R',3$]5 R!]!C[SGY\SA9U+?@-:$3W&H#CCI>W
MXSSCCD<^I+,%Y/CHS;H%Y\0,E2XV_E8T__VP?/?XM%B]"/%5+'1//6-T5J9I
MA+BR$[E,%:45*(5E5&20%LJ&S$5"L9G?GDOG4R.U;A?U1%Y4GXOZR+UJI 9M
ME23+O:C54)@Q62B  W-9)S;XK1/\+V"^!)WLH!6^OX/UFA'"&C-_>2+,NQX[
M>X0U*"=R2MBW<66MA\_R_7Q)EFQ.%E]6ZWE]34$5K1*VF0FF&(Q1"B-95X!(
M%9$)'D/.2\1XQE)<YDX5( 8ZG1J+[4HAK"382@TZL<'W3G#7@A%# V#&8;YA
M#<Q='A!UKSIA )'O6A1#7;Y.A0H#$,[6K3!YUU<LQ,?Y4GQ0W:YG*8F03%($
MHQ11G14/04QD"HL$9:S )8IY<5T\Q+:OJ1'0.5]U+3"H);[:V7^'L\%!G#_T
M@N_W1@3NVD@))P!?.5K"!$@/(1-'T-B'3>R:>.70B2-=+H=/'+]R10V1'ZN%
M>F/=E&*>,5S@%!<Q1)DB5(0$AR0N**2\0$DA2E8FA7U*U^..;+[I?\YLKJ?
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M*_0MKE(#[/2X 3U-;L"'_C#5VH#Y$C3ZZ!O?K48>+W@]X.KKWO<:4<:]#O8
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M\N=T_N4_P^P8)RXXA2)ZL*8$4('$Y+W/D+/4/I3HM;G+.=D'.SL1U@.6#@+
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M/<DCU*?0-_$],4+E8+P$GF/MGQ +1!\8:"EY)F<SLW!7><P^:+Z3H!Z<_29
M;"?V#C#TM\4B_S&=S2;&%A909Q!\4SB"AGR&$L!J$60RSK$[.]WL Y?3M7MP
M[YL@8R]A=@""-R3N^9<IQ:M;85!8\NI'FAW7^O,SGG+,+'%;AT[X6C/(JJL0
M&5@C(T/N;62M[<DN=/7@U3<!3W,E= "LER?+UM+T(_P<?IRQ-K%*&"&"A^A,
M &4U.;(B:XC(0E)1E>Q:P^EV:GKP])N J)' .X#.A6#VW6*>3H*6(GU4GM=9
M>H:#TL(2_K4&+U&5F*.5N?6-RXV$C#-=9 AGYF Q=X"5+?UD'*5&JQ%*D(5<
M+U:(:DNQL=:%.ZMMOG-0X?[Y@G%FB QV=_L@07:0&G@[#7$ZVU[HS//F&=W7
MQ8R$OMI>YIP71T=)GCFYY<BD !5UJ%5PY* 3LRX4)KQH[>/N2MNX8?K@E2.#
MJ*@#RW.!KZN9NB"<0^9IXSFE:MV>@F!0@D!M&:>]F%3K[.7MU(Q;$3",]F^'
MV"&JZ !4I]>('\+/>H=XEME/:7E,Q%SC<Z*+<B4@0DR\-LV,&D+*"51"YV-
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MNQ(K960I%(0Z67,<QA)*+(_@>5(Q">2>MWZ/]1A=B2_G"$G6[Y>;9?/&J?B
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M<M.^G\)VE4V+Y&MKGV$U&6M++!F<KZUF2F$0HB749A8<BUJ@:5WU^4 2V\:
M.G%-.U!#++&V^F(,?&$:@G3H C=<\=;\/CP&?(R>"<W1<7=L^!"Y=W!6[M*5
MD-R!Z2+3]VM]/;[$[>]GLHN"O$=/T0S&[$%13 /!$]O2IJPBVLQSZ^*9PZGN
MIMO"X/!\9 UWC.G7BR4Y'?/ME*OT\_,RS%?$7M7Y/&_^--LB(/_OX]6F[_Z9
M?&YJ*+;M&30)S$7%:C?B*#AM>!%(-ZC!6_))F'&HFK] ?%0&1ZY%>V3T[KAY
MQH?2WON,_.VX&'BG_3XG%<SJ.^-_7\RJ^_ZW,)U7E;V??\)TO-PV2EM.5_17
M+^F/\R];'9[UP15UT&KV%H*QD2*+^N(=HP1=1$B<+&'VK5LM#L7+R'5Y?>Z?
M1P5(QT?2)37<81F4C4J)VBA3R%I/9"PX32&P-KSHX(K"TCKM=2#)(]<)]@G[
M(=3=P073#9R>;50GLPY*,J"S2]:.P?41+C>;*]52GYI@4HV1>P<YW?3#&MSM
M;Z63_IN17LP^W=!\MF$J[;;6ML-DTN[CI7TB[8[FN(9[KCA90UL?#RHA)'C/
M#'FJ*I-CJITJ Z;/=AW8=0#WGS=3:7,L)FG& 7T.M,\PU6<%" P#V5\O4VD^
MQ/4R!=VDS1IAX7K7[KWEW8$;=T;]5B+5QB[F=;<^^S%=3:14C-B(8!PC9EBL
MK<0I?+.R""^Q"F>P/7(309U@:0]-WP::@\7> 8:N\/!R<42ASR1HY(PE!\Q[
M4YN/.XA)\=K^QIO,C,JY]3/6&PGI!#.'*_KJU?;!4N\ .A<Z)OV&];YT$J,U
M&(GBXHJNIK@^'"@4+91Z*<^LU':(F:R7B!@7,@T4>WM?JCVDW %,;IEV=L*,
M<RX&KA-(ERFVY,& 2\G35F(V6V$R]X\T=>X!\!DL/]8>/NVDWP.4[I]?=L)8
MDL7:3"++P0HZWRFPK._IP&.2NF9/O&Y]@.U,W+A1_P 0&T0K'<#MZ@BS$RZT
M$*:D2!ZCXKP.D=7@D.*/P!-R(9AEOO4;GILI&??Q:GL@-9!W!ZBYH>_?"2.R
MR.152.0B!D4'M\D00Z+ E06+!DEPI755\JW$C/N2M3UVVDB] _B<!1UO:2ML
MGI---$K/:H:#.5O'<-(&B#PQX$Q915\(W[R:_3H5G92H- S?]Q-P!Q"Y>DGT
M9GX]/?9Q,9N]7BS_",L\28+KP+  ,FY!)8QD0#&#8RC0Q2R#:-UD\8$D=A+G
M[XF(ZX_X!E-/!^A[<5>CY.RX-=I)D'XSD5-;B)D;8%D7Q8T*-K4.Y^ZB9_3&
MG<,!X2'MJQ^BE;T1]FUS@4U[:;EN=!!>&UL8-)&> VU#7BA^0-00O#'@ RIE
M A=&M3\(]YH?.>1#FT?#U($:Z M)VP$!%ZMWMOODU=&WV>(GGCZU_C +\PEG
M2<5L*=BPM;62*Y:"#>M!9BD45XQ9TW[PX<-H'+T?Z..B<"CM=5&W> N'FZD[
M-S$8R+M-S%)$DYVM:10+SI!-]UQF49*));>_V7L0B:.W'AT;G4UTUX&SM]/F
MVXZ+.EZFKR3LRN5J@MXI*;6'XGBAC<@I0-.J@,N9>8Y9R6%.ZH>3.GI+K[&A
MVE27_4+VTHZ\QN6D%&:=E@JXK?O2D9_L92E@75;&,$PYMRX,W(O0T9N'C0W7
MAGH<NW/OG1OR&:D"OY^4/_TVG>%JO9CC1/AD/4\!@F'D@/.D:!]J!]:7S((L
MT5X=%W)+&]\]%A^]W=?@V'L4M8SJ<][%X69KW<S@:B(9TRXP ]+6U_66PK]H
M$H(U(@16.\_NV#]ZC\5';_0U*O":J65L>W?^_&SU>7%+8<+G\./$7:X-^*[<
M$[TO+Q9SV@7K:9R1.N)Z0MM-)EX<E(P.E*]]&*1"D"FR8EP4Z6JD?@LJV],V
M>MNQQP'MR$I].*;]%M-S_%(K%CX_3JBT97%%HKG$[OGKLHD2-6OA&'!C R@9
M''BC!03&@_':NV";MU@_B.+Q.Z6-[8H.H=KN$U+WLXO!&L>#I3/(U^=B]<50
M+@P*8Q:3]_7 >L10JA&0G\0MT>,I=FQ?8[LW/V+"Z7?,FV/G!R[3=(7OR[O%
M&O\=\Q><V) %UD%V(GA=.U-K"$C'C>$V1LX3YJM0O<VIW66Y\7NT/9(?VUSV
MXY_RMS!VXM9<X&NSE\@M+[*^R8681&4.*1ZT-<WKM>!.,RN3V!-8MRPY?E.V
ML<#50@?C ^S&0K;3G .);UFGFZM4)'$#0I9(P9X*]1X_@)8^*FX*?7?0 L++
MY.R&N"=QR]-**9W"["3#L&6H3N_\#==?%WFBC.)1& O:8LW\2P^A" EDN94M
M,:(TK9/BN]"U&_">Q)U-<S6-C\"=LP:G>7UR1\.W;\1QF,TNM#8Z:UTQ05''
MJO$(T;,Z"8LG"JV(_T+^:A#9%>_43H=M2ZIV ^F?^J9F7$V.C^3S-U;WBV!S
M:$22P:;%!A+K]8<^(BEB-5WCR9#D;3A&SLWBRWSS*5M/)B"K31P#<%^K45&3
M)^,U0K&*-GB6#&/KGH9#\[3;]OA37R9U"8^QX_)=A+'CJ$UKA*0(,H$.4H*2
MLH#CGGX1D0=G:LGK;C=2[6C:#=5__INJD;3XIP#O]K?I?VW4_KY\"C-</:\[
M^\*M'4DZ9FT<2*<SJ)@S!"TYV.P3VIR8BZP=='>@:#?@_M]Q6]5<@QT415WN
M"HU1,^D2@Q(Y$1\"A:PZ,F#1)JZ$SU:U[M/P\&[<XDE<'>TO^ Y0<VCCP"A3
MRLI(<+E.L0V601 ^ A=":)F35[+UP[/'Z!,IGL1=T&,JMP,LW_- JHBDT8)4
MG'@IIMY%> G:._J^5D:DUB/J#GZV)O[4%T7-U7+@:Z-7\SS4J[488Y!(SJUE
M)!15O 9G9 919%91%%%4ZY;L^[Y:^U-?#S5205,@/<[(GK#Z^GJV^&-UF84#
M!_6<?>B0XWENIKQ]+]&SA<[:1G)"%W=1@X[1UB(S <&C NV8BIAT] ,\HKJ=
MG@8.?OW,#\O%]RE)[OG/WRE>>3,_&^_^+%$8ONUC?BH![;*0M6-=\KF6V=%&
M"TG7OM+&1R$9$V& *."!5';2&>!0!-T0%@RIK@[\K<N!3RZ(A3E)Y[<)U0 +
M\-YFX+I8;;1&Q5IGL#N:_S2TMN^,.1\B^@YP<RE#4U/=\S2=X266/B\>*DW%
M2I'D,8(.O#9 J$4A1@8@N3"G<Z"_;NV"#<''N*T''AG%HP.A@\WP$FGE--VH
MF+Z>X<E,GV='-3#?)B@GW@9$K2G\YB;69D@*Z%2JLRA+"EESIE3K?G2[T#6N
MR1T?/8N!5=D!/$_'B5^^M9P8K03RG"%A;5 K*7B+LB!0S&8*XSD&V_JPOYF2
M<>UE=Q!LH*ZQ;^!VO%1$68Q)=3!T?;>N;/$0&=:>@M99IU64<;?RVX;7OH/E
M5KK!V5 :ZL#2U8%@JRI)7+V?O_I1A78\77W=AH:;1VO"BI)-"6 Y!8*JYIF<
MCPBE-J"QB7QO(1H;O7N)&K<-2S>X'$:)_=2?;6^O_V,ZIU\)\KA:3YAD,F5&
M^XG5-@B2(WB,-7U.<A,LN'#U_<'!:+Q.Q;BM5;J#WX%JZL *;K/IYR_"7G]_
M-_UX,CGQ=&3BQ'*CHC(6I(NTAU)T$%A4($MQ(B:&3K0.1W:A:]S&*=V!L;DJ
M^S&'+T]6WXKV<_CQZD=U=D_;<$V"\!X+R<GI4(LPB"OG0J%P2[)H(VU"EAL#
M]!Z2QFVLTATV6RJP ZNY*;1X1U(E$6Y9.N%GPF)DL10%(=$F4[S(^G0HD1/,
M,6;T2HG6-S"W$C-NCY7N,-A&:?T8Q>L7\&>2.ZEW/$_:>J&LD1**U &4*06<
M)4]8,AZ+E)J%W+H89G?JQNVJTAU,!U)K!U;S.F?/4EH<D^2W;W\W<P $]UE)
MI,U70LV7L@11((/HR6$)KA3=?,;A+G3UUG:\#2;NA=Z!"CK46 X$NS?S[R3T
MQ;)VP)#<2,,,@O,U5>J3K)QD\)H\888Y9=/Z'O%.@GKK1?Y(0-M7)9TB[,,2
MOX5I/G5[3QR-9_/M.*UGJQ6NZ[A)GC==6!T3#$B8=>0)=R!%=!2(U2G9K=_^
M[T=I;YW)'PF3S94X*E@WJ?RK3$[/9?FV_GG+5)CGM],0I[.-5T.^T,1S$FB0
M")I7#SER2Y%:08A,I&R+"T;NUI1O3P)ZZS[>%(&/IIE.C>6ID_$A_*P>1KU!
M3VEYC!=9G61I="FF $5CLKZ(E>"9#Z S2EN29DJW;D&V'Z6]=1]_9$^QF1*[
M#%A.NU1_Q,UPS(N\N8@HZAMMU*HF_H6O@U<%<)V+RB85IG!P@-Y.7V]=QA\)
MEHT4UB48-V[(J7=RRMG/B6(\:QET[>170(62(<;@0"BCDY>)#H;6+7YVI:VW
M=N./!,(&BNH @+L7BTYXE!YE*J#11E "!=1W_X"6IV08&B9;V\+=J1LWFGG\
MPO$AE+8_'!>TS8:$8TTDK&X1I VVF)@0N' D2*DX"5+5U)6F<T 8@5=[- P%
MRSNH[&0JZR,]CVFEK@[L(WF^IUTHM@W=GGT/TUEUAE\OEK7CQ/G5_*8RB:,2
MI?;#*IK. (7>U-M/!8);J84O6J?6$<T#2>SRB4TSQ%RKY1E.?5T$WB3(A)A7
MM<%JY8="M-_"NK+T\WVYG=E)S!)=<@9D3'0N),G "4X.D1:A8+"1-1\ NR>I
M73ZF&0ROCZ#.'JTJ\4W.R_IGG0VU)J9KV=.F!GF2E(M"9 ^)_E<'\9F:!;.0
M&-/%H_84T0UM4&^EKDNO\]%L:1NE]6%&K_+V_'@UG6,M0=[T6*ER/NLDK"B\
M2ZRV W(4W=&!P<#7ZCOM*<0K.EFC!C_C[Z!OW+3ZV*!LI;BN8$D&_^+)L$D]
MW"#1B9>8A0\"HD5/OGRFKR)),G$;33")/)BAD+DCB>,FTD<"YQ#JZP*?N\N3
MPLQBI,T&2J3@4F&58U0%O$]&,NE+E*T=SMVI&S>/_LBH'$AI_6:/7D_G89YN
M2<,%A8$Q ZA9=9R-@J@E0O%11%I!9RD?!Y9W4#FNF_G8V:-6ZNHASKE@]>LX
M)^*K-E<_[Z4VT8Q\$6<17#&Y,E3GC),078XJI.P5'S0.OY&H+C-$S5!Q1\1]
MN(IZP-RYT_$1OYUW]+_ $4]6)9T"Q6,NUTT;P6ON01M+;K ,/H;6_3[OIZK+
M/,]@J&NKI'[>+US<3E?GA6*.))?(JV=+O]#^H8U$/DS) ;6065]K!-_4UNTS
M]_6Q<S>/8>4.4<O8?24N1E0GNV9UV[22B2QDGDEH8(P(-0OEP2<A0";&G1#)
M^73%M[NEOO$AJW:9?6D-JV%UT8\U(]M\PN3UZ<="%Z,DS^"$)\\W*P=!DB.L
MK/-<J%@?FS6V9G>0TV5>92AKUDHM_0#MHGV^L*\VF:(;I#B1+/"(DD&R9*Y5
MH%^B312%"2<<,I5R;@V^!Y+894KE,8[7UNKK(*3879H3*Q/'.A<&67U()DB>
M(:L(]/W,K50A-G^4NCMUXU8J/C(F!U):!VF^5Z5@6K\OKWZ0TS'_@A_)%K^?
M5V;K?_46\GN8X>:!(\EQFM;5'UG5YE:7OW'A)R?>T^G@A *M:Q[+>@^.S@I
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M^^RH]NKA$ZZ],\@Y1"]#G<F:(::L(:5H7%0QR-SZ$<BNM(T]:^JQ47.M8?8
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M?#Q?FR@U)B;ZM-H79@*'TT$)7Y:X97D?,WWW!S:PRP^@N)$AKD]WI^O3P)B
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M<D)$-+4+4P+/A2LN<RE3\Y*)6V@YU/!^Q.\X/\8ZVN\526TY#[,7QZOUXHC
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M $_/CTF0Y&>>4)^<HM"&?,L@@@;%2#R!>P\8N6/<2)N:MPRY3,&X5V1#X^8
M:8^(E=5R/?D8YE^VCJ'C0JM0.$2FZ_-:Z2$*(\!FI2K[J':[0*%/O0 /^M,Y
M-"XM.,[1-$:DMK^<>P#'":9I0R 6[<D[*W5\3Y909TY#C%X5:ZPM8J=DW2[P
M&-,C/D!95]6]A^1&5OAOT_GTZ/CHA/#"F(^2[& 1AHX\0=3[I H(Y[TRNDZ.
MW.FYVSTJO[3HR$K?1V6+%O(;6_'AQP7"N4LR8'803:X-]2*"%[R T[H$X1,S
M;*<W9/<I_N*BXQP'S12_M_S&SH'L=1:^I:CKS1J/5I.B"RNU]12=A^0U:4S@
M<A"04'(CN&<E7VDUT_).XHR.<<*2,9R)QU;:V/@\:WE&Z%G55RCU>=%W7&T[
M3;Z8A=6*.,;\>?$BK+Y6Q_Y[F-6_(O,;3'#UF6\(#I03%D*QJF)/!YZ4]HGO
M!,V]2?BS74;LB9#%HZNK@P#[UI#R]Q66X]G;:<$)ZEA0.P&2!;9MA!QY+A""
M9!0*AH2\=1^N'<CZLP5>AZ%R*'UU ,&_+1;YC^EL]N;H6Y@N*R^U1<=$>N4=
MCPY<J-.O>=+@:]\#X07]10HEJ]87LS=3\F<[E-L K8%6.L#6[=.G+^R7+(4*
M.G@PNMXE)IU)3#J"DR2DA(DGUQIIN] U3JYQ;-PUUU@'*#S?0]6-N#P$_=6/
M-#NN2=?3#3?!++ADOH!%1\RY%"D 4Q[JG'.-4I406Y<$/(C <9KRC(W+X70X
M=FAR4EY[\NJKBO83^;*KCT@N\'SU8O$=E^$+;I^"3:1&[6U)H'V]XM9109#2
M@U/&.6Y9T+;L%(T\9-5QNNN,&H ,II2QT59[M]3ZQ9/W59]Q>;1Z=USS38OR
M,OQ<3:+ $*J[&KT+H$3]BHD"@L*HS)-%$]A."+MOI7&ZY8R*JJ;"[^!@_7T>
MR=K6QX%;OFA_)*10O&:E"/2>.4>NJ9"Q]AO/Y*E:BH=*3D8J+P6V[B!V!SGC
MM,H9^]!LI9\.H';*PM^GZZ^G+Z'.!AJ\6\S3\;)J8B(+HDK*@0K<DVM:,D07
M"C#C@RY*F>Q:)TMV)&TG"/JG!L$A]#;V&?KLJ+ZVVHISZP*\7BS?S!/Q07'3
MQ<?3FU?3$Z-M\C81,X&150^>@G:E& 15.UZ(X)C>;<[< Q?>+7',G@KD!M=-
M!V;P6=Z,S%N1T$Y:AT^T4C9(+0"-][5$L0X7+0(<F7-I4JTK,XTMWG4J=H/:
MD[FD:*2./_^[R-/6#8M"FZUN,HJ*%N7S8AUF)R%4[?UV\N\NN!_QY^EA\$@/
M*ML1^L@O,0>2<%=/.'D0#HN5X.O,626# A_(%PB611$H"A+8VFD;]0GG!>>H
M:G2Y;;0R7?UC>Z'/!05[)F.-_2R=2>0&>9\4<,S6):NRNIKD:>'#WD#)4WBG
M^1!LW>"\'JJ?#GR&:UQ<>,?%C"W)6 <RU;F"53 ^"@1IHI$^>!YX'!IJ8S^[
M;*GM^P"TI^A[1-&%HG?-4"K#)!3-)?D\A8-3F_<RV3N#3'O;>J+!'>1TAJ)]
M57ZO+=I/_CU Z<0QN<;22>&C92)A41Q,0-IQS 0(1B(4)8T7EBRV:1W1W$-2
M9Y#:5_57(=50#SW ZOK.>X[S])6BP7]LMI^*0FKC$%PJM<VH(5> >PLN:&.U
M0K1L<+_J"DWCOJQ\G!-O?R5T":I3;DXV8"HF9NTEI!#(IB=I2&P6H;8]-$(J
M+>, "><[:>K,6AV$@'OA=8 Z.H#7R:WR)HY_AZ>OCFVV!4,6P#TC)FC;50DQ
MLKXF*H.JA-U>3CRD"^%-A/0&I$-T?;7GZ,&"[P ]U[,^I\^,HPHH>:0HUR H
MB_7M"3D)*H:2N:2_YJT?ZMY&2V<G7$L,-1'_Z$^V_O=B>=9:<F.?!0L:D7G0
MB0M0CCMP43$06BIN!7D"8B?PW/MNZ^K*XW8%:.@,-1#LR+!X%X[P?;G$P\F&
M,8PDXKD%5F??D8G49"*9 HR9>.#.ZMURM?>@XU8"QGO:>:A&%ZW%._8]^"GI
MST[,7E0E"LT"9$M!H[(B@V-% @^8F?21FZMO_V\K';O\P>.IO)&>%HV$UHO"
MGY_0;HKC0M@"(99*N_?@Z7"#K%QT'FN5^&[/-J]\\'BO> =4^#Y"ZT7A+TYH
MUUZ)HF, K@BBBIL /LGJYS#-F,W2Y=W*CZ]\\#@G_\ *WT=HO2C\Y0GM,JBL
MA7/5B56@-$DB!"T!2^3:HP@[5P-?_N!Q'M<,K/!]A-:+PE^='D>RN&SJ^&U#
M.%6Y6'#":\A.),DL<XK?6Y=QTP>/\VIE8(7O([0.T@;7(IVW9\50QA.]2)&P
M0*LIVK$)?,8"IB@A/1:FU97FT.VSF6\?U(YAL&Y?CY$<WT_P/4+HO#B)3T@.
MGH13,Q^)HJ)DJH=##*5D!#-*E2!:MQJ\BY[.LIA[ZOP^*.VK@*=4@_@\K.K/
MY)?3V?$:\SM<;V<(UZ?3))_-=*E'KS=\"%&CU1;N+;FNZ@@+M\%H.L8Y<P3^
MD!C$6#3M+RU],D5*W7IZ4Q=UA/=.W%PN:W>JS9K/?]X\9.WD=),B!%<\%#K*
M0,F<H68@R"XIRU@LC%R=UC=/K8A_"M6*#T'P@^>N#H*"#IR19V34<C5<T^_X
M"5/M'$3&;?LJ''.=H;7M'7XB_U=A.2<C>&;7GO^\^0,V&5X3DE%"D$)$2!0C
MB C.<01>4"2FN7>E=6G;@.R,/"EM'(!>O;7K!"W=;IP:,)]$R-GZ$GTP($QV
MH+QP$#,K8&TIR*R1QK8.!^^C:5P(=P.>G4"]IR9'STDM9O2MQ78 V:908V,&
M?IO25^O%_/2671#E+E#D%)BG\"G&.N?0<S ^"J>8#Q+-?2[] ];K$7C[*G@Q
MK+3'!M!'HGPY313(5.<+EYN1LA0O;P8(_SZ?KD_:\9]=P;F 2,<'"R'4')Z!
MX',$*X,2+EN#;C<@/6S=<2MCA@/4@-+OX,PDWW[SYI/<D)<8U^>B.^W:&Z0Q
MTGLRVY)<$R^1K+B5P+@,EF<1I1H@^7472>.6U0R"LR&4T0&V_EZG;I[-GO&^
M6!M0 ^IL0:G:Q"IQDI.V,B8;R.RV?IMUB8!QT^^#XF9_07> DGN#I]MBI_/,
MLT@RFBS)U43&0.7$P7NEP1<RO\A$YK9U?>CA5(\\:KF+X/61==\!VB^EHB>>
M<9YBO2A!]*!T?9*D2P2>C&&,%>.O#J\]&+B7"!@Y@?+(VE^T4D4'.'HSI\\B
MS_3]_(K30%R]+Y_#CXE.) #+)?"H:5\R+\';6$>_.9UUP&PR-L;6O42-;//&
MQ5M;E76 P4L;Z-F:HJ1XO*YGPN?%AXU"3J[?)AB<1J?JZ ]3_=82R+<A#G-A
MBC8=%\:W?@&[*VWC1A,]6<!6"MP?F+4)3!-@7LM3UNO@2<C>.W02R"U.Y*@H
MLO7*>8AUK(*S0;;O0W(C(>,&(B-#[G#5=&#XKC)QNDU*0.90&TA8DXHR<G!U
M'*9/E@FE,G*N!D;80\Q:\_K$3C&VCWHZ0-G?<?KE:TT[;KLS;SOKGL1KJ_?'
MZ]4ZS&N;\.T62IR[X)(%%"0K$A@#SSE)+6?FM, 80^M'M@\B<)RNVYT@<CA5
M[HU3HB0NF@4C:;F18IB1>(\6\RUCESV*Z_*]D&*8N&QC,L6"YMR"0B1? P.)
M@,7(G68EQM8NXN%4C]/SNQ-,/[+2^S7()\?+M<T\B4Y:X>B D4J35^,HG'.^
MD/^<O+'9>5MDZ^S. TD<IX]X)P >4IW-@J .RI OR*#>8KR\M5YD.K^IWO;;
M6)7*C>D>K9AY2/EW5>]LK*2MG"-YY;FV+M8%:@\YR%ZSE)1&BZTG9W51[WQ=
M^><BB=(&'AP8Q#KY1T;PDD+D4J).QOCH36NO_G9JGD)%\D,P=DN#E$/UU($G
M<W[[=V %X/8*T.?BL8X(REC/0U5G0ZLZLE<I5^3_S]Z;+KF5XVS"5X0([LM/
MU^)NQ^<N.URN[IA?"BZ@K>FTY%=2NLIS]1\HY>9<=20>'6;6&S-3XZWS@,!#
M$#MJS0)K;>BT/<'$Q7"-</5@ ?W)A=P!Q,<L;>6N,'1!@[%!DOW'% 1G#9!O
M7FR*.?CF0_+^!E7TIT?I"4OIAT"FV]MSHUQ)>.U2K>YVVM([6KB (*.$E+1P
M)3#DV#J[_/<MI1\$GJ&E]$,D^<PJH;,**'QBX(AQ-:TDZ)!<0S8H,R;'[@PS
M/5TE]'2E]8,$?D0E]!#N=ZOR]K[ US$I:6QT023(SI/-5F*=NBDB:!=L4D5'
MHUIG 5O1WDM-XG,W!0X#P_._!*^^5$=FEKD4GJ4()B=+[U4J=<&[KQK&6^3D
M9)O6.Z>;$-ZCXAX;<VV!?P  ^IS8\0M^P[/EUVU^:Y'?;3[CZM6G%>ZB2;_5
M>OO*H2-BVL,^T"#X?,2)&D6):YIPOMG%XQ;;+:X$'5S4@,<O\W4Z6Z[/"4&7
MH0_)JJ%+V"VJU(:(NG1.* E<&2E3P<!2\[490P@\RI"](8QK(>R>+8TFHS !
M.).U2J5(\"S0*Y:DRD9'IK7=RVA]^!M3CQ :"P8_6*N-6#RURW.1]US_01=P
M=:.YE61U=:K=\%YO>6:67,/MRME YPF:%RC(I;<"1<#]UK+N^\5I4-14MLNQ
M&?T<T'/A%C*>8S'D!T9G!)G+LD"4:("E8BR64$*.S? S9<1F1&D/Q=,!K)\:
M43_TU]^HU7A#_O\\G%V<^C($$%D*R4O NA%%&9W 8:[Q!G1!L<"$W7.B\H"O
M=HZJ0V3^X("#E@+H%5E7HQLNN7NYW<1($] 9*%$0!\FM("?#12C!".^L11OW
MG,\^[,/3!$DFQU<+,4R\!N+GZISBBAB]^5X#HEL%[[4Q@1D$AKK.LXYT.UR0
MD',.WO$86=RK+_V)#1#W?7M")#6VH)IP=V)T?,"OYZOT.:SQBB.WCW0902]U
MME&V0 J4?)+L"K@Z0U>@$<$IAMGO%=]Z C)[$S3=1HGC9;X<6P!3/VO_QM7\
M[/O;><'?R<5=I*MI'IK7?$N,D#@CQ9EM!&^+ 6MM,));GT7>Z_UZZ O3P6(D
M22Y;L[6#B'M=?OJNW'AGMU<H871Z^UQS0SK8T17RWAI K2*=RQDO6E>8W$O(
M-.VQ8[Q0[?C= 6AN=E&\6N3?EHMP_2<?Z5?KD*J0+N\$^:^9C#$/@OLZT5_3
MG2AT,7A@O@0K<U&M*VL'DCAM2+(!*&[G44:44 < ?-!)N!B"5DS@S'N(B&0!
M&*$@,!U LY"*MYF1$]H\=O\811-G]L8$PYT98LTD,[7E=.\+<)WF5#8(%H0&
MH44=,&IKFM,EL,4IRS*YHS$<GBAY.^W:CM'"W V9VH$>VB:=WZ_F"6>9#+N@
M$X>0@@&E?(1H2%LK,B&=SDX'W?J-N_YZ;[F0 P5ZWWBNX=R=6F\\I +_^$JL
M6VQ>(\[0H&+*!7K0=742<B*%R!38K$S2.1=,>VY^>_);O05YCH/&& SN08_4
M$L8WZ_4YYE_.5[43@]S+Y443Z&_XY_:OUO0P:^F+RH"B9+H%D8%/B92P\%$:
M0V^S:>V6[4=9;WY:(_W37BJ3SDNX>WD^D*"(F,]D%=[@8[U C)2M2SR"0T^&
M&J.GWLE<,Y#H?)%,6'- =N/![_5FY;364FT8/?7+MD/^[D:\J5V0"]PZ#O^9
M;SY__%P/63L>\_V9H9D1S&N^79QE'2AR \ Q9""D"<8DYDW:K[+H*#*F&4TT
M*M).)Y8NQKV\GB_F&WQ+MXI.NZ''OPXR?+5>XV;]CU6=I1ERB$8:I-M45S]$
MGB%*L@7H6F4O1&"BM%Y<]11-TXP?&ON!;"J)J97;^^6&.#,/9Z_/-^<KO!@J
M<VD"5*_W]L-OO1'D\#J@HY KDIR"F%T$K;6TB6>6][3B!W]ZFLD_HRJQ<=G?
M@8W_R&7Y@#4950=L?%FN-A=#!G;&)I\%9VJA:5T50LQ4V@OPQ2?PC/A:(A;F
M6Z] .)#4:<;Y3*CDFLFM&]UWS[5[M]I9%K>O7R3='2VY/4[4D$P,'"*KHRR0
M62ETCD'R8=IO_X_OA33_7)!V$A'TV>?R.LQ7_PYGY_@O#+7N?LO-Z]E#5W_]
MSSFNJO_TO2Q75_-5=I?PB":8AE]OT"$S%B\:M<]<??^Z2^)Z4(C0-B!R"[+4
M39N,,?"6<=",>X/:*.-;1[\?H^?HM_KR9^_82E[[VWF(\[.+;3A;\>1WBP^U
M0VVU'8Q5LVJKR]_6.9H7B1*+2MGL!*0L,WE7B."X]%!D0!Y2<)ZWGOK<C/AI
MLY;-\';G09]$N'U8H#ME\69!;#R_*C20REMOHX>@E*L+S@7]2B 4-#9S3)J%
MT-["O(^43A!W6F#<M3>/EE('8-O6%="7*QM_Q]6W>2(6W1B.=GVZ=2U_6=__
M5Q=E>B$A.D.^G?=(5E70#&+1"%D8SKRTTOKF]6@-Z9\8UBT =;N,;2KI=H#L
M/W[_Q_(;KA:[LM+5UXN(:F7%JXM&TCNK\TRTUBKNP#)50-D8Z8@Q0V)9&FX%
M<;OUBK #R)RX"FXR3"U/*^ .,%R=3%RE;</6UZN1.=QK[[V.P(1A=75?J)E,
M \))%DRAD^36Z]GO)63:.3#=X/!X(76!M-T%NG^E*..1ARCHVG#'Z[4A0ZEH
M 5862:\3RRRUW^_Z"$'3[F/J"'FMA-8! J_,^I^^WXVAO*WAO*TY%+3SA44!
MT=96$.%K.@$#",&+E2:IA,V]H+THFU8;=N(4M9=A3\B\&?&[>[Z+"QV]#5DB
MG0N5W2T B)%,#&VCREA+MIO;D(,([,1Y;XB0AT#87%P]8?'-XNOY9KWE&+]0
M^$[J9()*H*.D\P2&$$V0Y"YRJ9WA+H76N[,?(:<3G+4'P4-P.U(BG8)+7%D3
M1B@M(PC/JSV+#.K6/<C<A6!SEB&UGM[^"#F=/+:3@.L0B70*+GDY@,3Y:++6
M0.K=@\H^D,U!OTU<N9Q0A,!&2[_<)6=:[V):<!TBD9[ =83Y>UT=4&M]I3$>
MLO+DDV6L,XF%!:D9"LNRBF4T'Z/% 3H!<!^NR,D1T<%U^#FL/__Z/^?S;^%L
MVTVZ^3FL5M_I6%N.S)+BQ-9<R+KF=>I/-!"UU& X<5PC7736>O;TXQ1U8BN>
M'BJW SKMY-8!"E]]"_.S>I%?+U>_TXFN(U0_QJMF.>ND?*RCQ\C14T&0W^>T
M ^L-9W3AM67-)T'O25LGAN;DR!Q%EEWT*>QF'&_Y>T\MRPQ]=K8^.B@#6=FF
MMB@69\BC2U;Y'+V/K77EXQ0]_\>]#2(;RJT'7?G@0606/%B&8)FH1A!9XKY(
M 4S'X&RQAC4W1H_#7O/^O_ZPUT9:?:Y_O=?_;#'+?K\?/%:%[DEFUS]:#*G(
M4S=)2TBU^%M))0EP(4&(*1MIF%?1-K[(SZ/X-BE4PCA;5P#IVH,FP*-'\$R2
MQC:!Y>:+\OX.Q;=#\#9>\>T0X7;P#O\3\R<ZP"^XGG]:[.18\U'%(C=21W L
MD%K/Q8./W( Q @/')*-J_0C?3TDG>#LM+);-9=0ETBY"NCS[4K)%LEQU'9V3
M--!%IL.D7$KM%])R?*SUD"MN(><GH7, TSL S^4!,+]:7YSINK3H,OG(#7,Z
M)7#%15 B*W#6)$BJ9*>**8:U7KZY!UF]0>H0^2_'%487^%K-OVW-Y>N3?)BO
M_[N]@,HH8Y(I8#TQC'Y'NEL&#2DK)F5F(>76J>#'Z'G^(;KCG\1F\NH*>W7K
M4S5E:Q7EQ3W5BKM8C('LD,X244&0,H&)3#//DHO-:UP>HV=:;=9.Z@_"Z4@1
M= "GU\L5DGK^]:_TN4Z@H]_^&5;Y0BTGAMHC]V =Z6:EN0/';0%NK//"A\QY
MZU+ZQ^CI!4['2OVV-]E*!#W J6D0TJ/52;BZ<$4R,@OJYAVA!2#C@3EABPRM
M,U__6VG0^.V=#A%3SR.Y=?)= =%U=\1NRVLLTKB,%IBHPZ7JEF_/HP->"M+3
M)(T*^XU?VN=KSS\\<B 2EF.*I0.U>_TV?<35EW?E\H6:\9)-DG156:A=+MDG
M")R\-QF,*T7I$E7KJ/I#M#Q_1^0X\#6555>8^VU9I1C.+NZ.=RHS3190*LG4
MSJJ:6U;TJY!0^H"%SC@:YGZDY?D_P*TQ=X2L.L!<K?[:?+^NIZG#09?GFP\8
M\OSL^R](7_HR7VP+<:YXOSMH$H486.LDM]S37D)P6@'W3D>/LGC5>A/VP<2^
MI#J"8U![&FEW .LW7[[2 6I\XEUYNUQ\VL[IV['_GWB6R2/\8XTSX7.RS!(K
M63V9K5U?VA$KL61A&.<RM6Z=VXNP:881]P?7]E)\WN/NEN5W7,R7*S)PON%J
M4R=.TNN#IYAU]]2G3SCH;A 73E%HXX5FOC@//%?7)H5 NE$Y$"D)>O\M6O/W
M++3A5DI.CA_D;3]%X YBD@A.FI!+4,GXUK6L?X="FR%X&Z_09HAP.[ (:MGX
MK4E741LNE#2 *A104BCP-B%H'4T6]=W@K??!W:6B$YR=%@YWG*FC9-,=NFYL
MDF4^9BN9(2>PUN<:;2$(^D\L/K&D4IVJ-BK&IM['W$K&CT+F0(9/'<^^8\&<
M8Y7F1:)J1R\=(L@@02F7(%CG0(94DM>,!91/F7=/?Z8G5!PJQN4H/.T3'?IR
MLERR.7%?P+C:F^<BA^BD!)M\*<YRJ[PX AVZA[D'IT+'(3SM$QWNLOR+*5.T
MJ9,_7%V"88@WLJX+CD%JJ=%Z[8Y A^MA<,&IT'$(3SLP26K I,;S*IMJ7<7V
MR46M!+=>0LK1@2I9UN*' &@4-Y9YQ4-KC^P^.IY_YNIXH_=H^72(L8L+:)@L
MQAB$4 JG^Q$S1.\1;%!<!9]]O+W2K3G*>C!YCY?P$Y Y@-T=@&87O=LJV O-
MBCH*P[,GGM3A+R+3NYNYV4X6(DE[ZT/KJK@[1/0%E4,D>WM-Z5%L[@ G;?,0
MG">3BO>@;8J@D'%P=6ETMB4$A]);UCI=^;^5;XV?S.D0T<%UN&&<5BUQ7X1X
MYGAPQ3H&C <+REL)D:>ZY%J74)(,Q;2?F_PD6<\_Q'D@:.Z,3VXKP8;C3)JF
M,W\*9V&1\/?/B)N+I%Q8Y.W\C!N#J<MR]67[H>L4W^^?EZM-K>'Z5UC]E_Z'
M\<>Y+P<G.<<EJ$'J\X0<:Y00?;?Z%!87JPT)U^OEV3SOKO0BO[_!A1NSR'^O
MZX:W2=VK3!;W7@M-:%>Y.M(FDTLM,(.7O,Y<0RU<ZW+T)H0?JLO7J\WL4GC;
M.L6,BS7F>[ZT>RR]\<B-PMT2/R5DM00%V7]%,$068[![S:FD[][@#?WNFB\#
M29I6EY\>=9<Z?$S)=6!</+0,B"NO_#;!;"0]=XD5B'4MD# H7?%1%=8Z1=K5
M#K!1Q;[GAJ\A,N@ 2DVW57"7LPFI@(LU6N*T 4\7%B0W:%6T(36? OWR-WP-
M M28&[Z&2+<#9!^R (H9$22+!I@-M=$K"O#9U-6\JOABBD?7NG3_[[WA:Q"F
M&FSX&B+@#C!\__*H.ME8JZ# YDQO5U <@F(:HBN.>\.Y$KXQ2E_ZAJ]C<'B\
MD+I VJ/+H@S+QC %$;DB]C"RP3$+"#I[C\9*YO]WP]<4R&LEM D16(WVQTSU
MG\/7K5J_CNIY1KQA2A)HZA!A4N40N.'@#//)*):Q[)4<>,+/'D34-+KP% [/
MN/+I0/7='E[]XV5Z]66YVLS_'^:?E^O--KP\,Y)A"8;L<-SM+5<0$@K0V6*V
MT5K>O,%S*(W3^=\C0N6)H>--Y=9L^NYHN$SI_,OY69TK]H_5<KW^8['"<%8/
M_ ]Z5G["LESAQ_#7C$?#@G0:2JGN8^WM<HIQ,(6EJ$TRVNO3@G4_PJ=3J-T@
M> 0)]Z]N'SST6_K=]:%MP60=1C#<DR/'8P1?E 6!OC GG<AR[*40!Q$^C>7Z
M/&!]N(2'P]KO8+W 3Y60CZ??:A*+246J"'436]W/Q<%S8<$JP:)R/J?0NL*E
MZ5:3YOWWTV*TB9SZ[%<>F*YN,<S_V$^>/DE_D@4 ;1*BHE:NA%2+6G*M2569
M$,DE<%-$RDYSZUNO0WQ6:7@R[EEBR8+)52U@J3?61^#<:;*(A&-VK_#H_Z;A
M#T7=H6GX(9*;.&+U?K7,YVGS;K4+ .ZJQ8T3*+SRP)461+_'.@6S-IXH*U1V
MAN->1ND3R+OOV\\CX3Y(P,N&W.X#+=<!8[P,_UJ#,G)F0&MOR7FKN:A OY+*
M%6N\2"+LU7RQ'V3N$C =;HZ7Z5V ',G@J;L$/V!",D%6%Z?Y>?GEZW*!5U/B
MK>.8)<?J$9&C+[.'8-!NY^<87J(4MWW>!]H$'__.Y) X5HK+<5CZK'(D=";M
M#=T<IS0Q+!4+'E4 99F+QJ$1?*^PW]\O1W+H&S6>?#H(VOW8O5M+F&?1ZJ"E
M=Q"2D'1U@@%7NVPE2TH'KIEPK9M3[U+Q7/(<@\3]Z/",P;SO #W[!EM^/E]5
MML^B++P> 0+#7(>^"P@J<.".&1E#QFA;EQL,)/&Y9">.P=V84NL E/409&C<
M'K+Y8Y:EAJ1GS)I$UXM!,O5@F27P,18H*#/]/Q2L>1O^WL0]EWS"L0JPO:2F
M-O9?I51GM:YW%FJ]9Z_.SI9_UJ E7;B?B9KYIAZJ;GVO/6?;P:XN:ZM3R*"S
M(L7/&3T!-ANP#IU,0<1\N\7D 1?@D*\_E[S (5@[C4@Z4'MO%M^(:\O5]__0
M+<)?EG\N9D5Y7501H ,R4%$S<%P*X 6MDTYA2*W;1NY2,<T4W=,JLB-YWP%Z
M?D'Z,K&H,F7&33 Q2@11:CV-31QB;88UFEG4G'N6VP^ZO_[^7H@QSQLQ!_.[
M ZQ<OLKO%M5Z?%?>KY9?<;7Y_OXL+#;U,?]:&39+.>D8!0?-6-WP9+ N(O:0
M(U,NH-*^M&X:VH^RO?!EGS>^1I#1L;48G:3!K[NV[UH%4S2W/TS%E!WM>_*F
MJ_RY5B4PEA,D:P0HP0MX8>I:5ZG0!>7:/UN3YL^O_/D[LMK67\UXD,GHNOZ$
MT0U7EOSVB,C!DS.5,3&7>>MVH@=(>0EY\B'HNA-Q:2"A#A[^FT[3+\OSN"GG
M9W>/-A->JRBT!,8*.4ZN<DKJ!)P94U2V5IG6F\SWHVS:OK8.8-A>?AT5:-XY
MR&^XF0E;)PJ[##R4 BI8A.A0D96341OG.2_-RXGO(V3:QK8.H'>T=)HU;O1A
M?%Z%#*:P.>]\?$I3\W%.=&5A*H4UXAS )JQ;Y>H6)2TJ<I%<,AZX3*T3!EU8
MF-<BNIJ1=L63;)TR.7.0=8>SDH:!2R5 (54A3>+:-Y]-\P@Y+\'2'(*R!R.1
M1TJJ VOSZB@?PI__(B:MB%MK>C7>E0_$R=4W7,^\<V*;B@R\C@'D-<B:.0=,
M0G"7E>2\=3[Y::JFA6 S #P$K#;2Z E?_UFN_OMF\7ZU3+B^=22-:*V6#(*+
MJ:X1%=7DJ4%]Q6WBQF)SA;\'6=/Z,:,CK)$\>H(8J?OYF@R>?RR7^=:1LC>V
M!)=JFE&3CL\:?"3G2R4NN31(?SL:Q!XF:UI_972(-9)'3Q"K_E00(481B5B;
MR5XHZ"'L6MR<(7\J8M"M(Z WOS_M?M_103.4PR_,8R4#]FL@>_;B'U]4A^W&
M.4_AQ.Y#SY1^[6!^=>7J"A^CBU:"%@9!H5/@E$?Z;<Y!,N0ZML[>=N'J7DCM
MU[^^UD3M90DD74T10C @O0R@A+40;0C 0BE.>BTE:[VB^EY"7H)[.P19MW7Q
M\=*9NCKPX@17C\KE&9)P3AHR:DLL9-D6\IM";7S7A948E:5W:[\>H <^\!)R
M'X<@IQG3IP;.+Q??K)U.!/XMNVHUQ^Y!N3R1P:!B%AJT81R4IF.%P J4[+!$
M;\@*BGO!:*_/O82LQL&@:B^0+MP),GSJF!:\F1'$E+(17($II&65UQJB0@.8
MBE":J:1L>[_B'D*F=3"F?_Z.ETX'$-M:PS]>$JV(=%4B.(VDAUF(X'U@$!EF
M9NKA=.N9.7>IF*90N1]P'2F7#I#UHW7XZL+Q^O%(S-2JVFC 95F7AAH.7MH"
MH?!40LPJQ]:J; ^RIBEY[@=[K27WXD(ON^K=L&N6VM;N3A-R>9B.:4,M>_*G
MJQ +Y\9%'2,$)04!FAD(2(]W%E;JY'PD&_$EAEBNF_9_J$I_=4-XNX[]%+@(
M411P19!A4^CN>Q0!.(]>1Z>ECJW-@GUI>PF!F"'XN[/6= P9=F%"/'":G[Y?
M[0XV+)F$48",NZ8)!3ZD"%&F+!P/ EWKT.@>9$V+R''P<,=*:"N<GO%V8_VP
M)=/&E"1!LKIQ@D<ZDDP)A,S&:16+U*WKJ?<@:UJ\-8?"OE [4"X=0.TM64<7
MTY%B0)E98A"2<62JYWH=70&E.-/6N.1*Z]GAUU_O%#B'"O;V<OC#N-P!/GXZ
M)\;-%Y\NMXRPQ(MG'*Q+U3K0I:XIYQ"$*":B-5:WKJW[D8)I,Q9CX^0(;G>
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MHH.MH >R9$]FL"2+EO3"11?KEF!GB ^F6E9),F.,0-8ZXC_J@3H-[$UZ.T:
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M_=-R<;[>-GO_8- ;Q05/IDX8K/UX5@8(Q9$5)2TI B><TH."D(]\ZR4$MX?
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M.2BOR0@-48--OD0EM#.V=2WN<ZG!&"+WO6HP!K"Z VOIGG!]T(4S5 (P;%O
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M3CC)&:#-@NZ#L_1 %@]6%<VRCF3SZU80Z*(G=;BP'FA$'L*YKOI1"\LV1E?
M1*)>%>LA%J$A9\],1*=1[?4Z-.]'';T1>9#('MZZ,8!_4PO^APYJU($<=EU
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M&40J""4^\1P_R$W.E 8/WR24A V,,>T#/H4KW&CZMQ%1/)QEST >1T ;RJG
M*.3V[YPHA@QF#'EE KA7-H5(3BR"=9.\C4C=7HQI(+.Q%I^-V< D3+264$22
M"'F.)9@5T2K$HK,2/F'@^I]"ZMI,Y=84P2(L:R>!NQ;'D94T<9]QD5@@SEP
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M7-P"@;,9D%,T2"J,X+Y7@X^75)2R%V-[%:7L0^4&BE(P&%[).(J(8F#8<2Z
M "(@G+SPDD2OMXZA>,9%*7LQJCN<:@UX0OTL? N&?![PHW4N\]4<_#JM$)42
MA^2-C++T\[I2 9QZU8\'7#1#\:1VN/C+]&H>PYL?W\9KVL.LPI\C:H@0S@ &
MGB7$G8 S9S%&V A#A21.F$?OT#;$C_OLUJJ1<B!_NR&)W8"2NFE9D&O3\VC&
M>?8-5M];/3]?5HZ,Z+(M1C (9$+#G6T#TBIB%"53*6B@&2FMJ?K"UJJZ.D[D
M!N50BY+WAYU<77-M,NG^DX='C;1R.-&0$#.Y;;]3&JR%"-<^=0%P2H'YTB,*
M>X#5:HG/0/)V)%\:$+6G&#Q&\M5R"NV[Z2I 2HGE@!I#)( FYX$3I(EQR!+J
MJ1!!V>)C.?:%L=4D6QDA')1C#4CDE^DL^NYB.OY_2XQ6'5[FG[_:Q=^[JTEX
M=_G-^L6;E*+/P6+XE3PL;R2\MTD";L99CKCR$1EO/!+9'K9$)VM+5Z8=!FG=
MR=5#2^<)N%??L5B+XGFW /J/[>0L_/-JOEA68'5/;HP15^",<8*1$F[97RT@
M@X5'-@1B:-)2Q'ZU;D>!47=P]<"NR*G84UL0SX%Z8W#[W^34V!QX=QYGXRXL
M&R?]K9N,@_TY"I1Q:ZA"VEB#..7+1VX46>&2B<P:_-A,W"!N/3:K.Y1Z4*$J
M3>KJHK/<]/I K'3P-48Y :XC!T,A <"(&YD#T Z0$DQI&9B52O03F$U;U!T@
M/:R8%"%K$T98&,\7L[&[6H K;6=Y#/O\0UJ5D7ZZ<O-Q&-O9.,Y'RA('[K5&
MFB; C&>')PB-E,9 .)ZD"J4;\?2'KN[,Z.&-K4&XU'Q=RUV+P"<7N)V&W\;6
MC2?CQ;C\Z.B>VPW5$/$0;$\Q04\Q+VR,R#-+$)>"(VL<")A1AO@DC:##C)P=
MI&[F"9%_G<'IO44V6D )$_"F'36Y1A84N182@8^2!*,4RU1Z-,]VB-JMFME'
M+G:&V@[G0@/7Z1-LMA2U,I)+^R-#7O <JPX!+$@-_C"E'F,@I:>E*T'W *^-
M*1,EI&*7P!5B48O2]VYZ/NM\G,]O7HV=3<.]AV,CR2A.'(XK7D9C,/5@-I \
MQ"B(: V0T@W5N;\OC&U,E3B%')9D5HO"N+8:>S[R FM)O$:6\#P)W8(W+54"
MEQICJS"FEA7OTM@/M#;&1YQ"] JPIE&)>Y0ESN.IX=]K)D[#3<SPTU=@R2]V
M'L/]7WC5S1<C$7+G2L:1-UJ"V^8M,@2N .PQY](K[A[WT3E%SG]O/-H81G$B
M63XITVM'^)X0X.WX1PS7GP*V[X#-TXL<TEP%OGU(TAG,D8S8Y@P,12["H7;"
M2A$=T9@_\FLVQ/WVW+AN.FP "1R<^L]#I69K9?8]9FS/O)]=V<E\^6^\'[$8
M"2\YIRE'RG-? J$T<C1Q1)AGV.9SQ4KW@2\%>]T46EW569ZYS:G+5]WT>YPM
M\AE]'=UBQ*.!<Q@MPGFX#&<V(:VI0LZER%@*(>&=,<5>.]7-HIU,(1Y#W_V%
MQ5P+RS1>V 4 ,9PB7))KA*T%GXQ8%%5^F.P2& I4"A1Y\(%S)FCQ^=WK(:F;
M:SNEDMJ?\ V,$>M34,BML<$[\+8T?. *,_A,:^0=CIP 4& W-%KH.5AB[92"
M=21+&M95[^-B1(WA2E*@#5,!\6 <,LY0Q+$ FU0KKL+@81: HU]8&;\$>=J7
MZFVIJ7OVW=VX*ZR#BI$C;O+CL\AR4Z*$$3%$1HZU",5[5VR'J)%Y&,.EQ([E
M0D/6]CU4=OC('.C&B4A(*? IN* $6:XB$H:D:(55B>T=H>B]>S-YKZ-9O\$J
M'X8/3=Y^]U"]?A[$(I?&2X<49;D&QRV[X#&4J-'4*JEU\4$L6\!I)K552M1*
ML^!8H2HJ3[?:_G[D@^:&>KES6IZUEM6\ 0TO/(K$<FVL9S(.9;.O@Z>9C-50
M$G4T$X[64\.YA/=0RJ9CH$XSK#V2C&$X*+E'GU$*R2 UT3+I0 8O#WD(4B/S
MHX8N0#J"#\]HXO3'Z+NI!SR7B[NX^$^,T\?/=>PTY XF5R#)/_/7I<LLCP)B
MJ.++<I0Y12LS'"T(9_8H5<XG!8(<<Q91SBEGX,$:\HQ:F6V8^OZJFR[&TZOQ
M]&)5J]5-Y[>_^I!==[<-#UPGHQ&6&#QOS2-R(1@4X#,NO0/GN_2SZ7+0MUOJ
MN8^\;9PV>UKN-I!&W8#.!H*<+5:--6XUS-W?YS>4B5O)<T R2 O(,V+!A/8!
M,1:P=\ );08[\R40:$2Z3RR%FP[#R46BW?/P8!;LO;MYY(#*B5J?1[$94#T,
M"!UCRFVS?!*>><M+!Z_W!+&12&23,EV$K;4CF;<&X 8DS^/LTDZ!5]>OO:*D
M&C"0B(?\01"!K',2Y=FSA E*U./*Z@TQS/WV;<1%JR.&0_.I7<5Y6[][6SL^
M"@ZK1*5!5.74I0A\V5\0,0Q(>IJH#Z6[_O8&KFXQ:MO*\DA6MA.'WXG?ZO7J
MB'C#M!(*$:D%XC019 1\IA,1D>(4&2[=:*@O;'5K5I^+H!["R.;E=(74 S/[
M]3C=OOH?61E5DLDB'TU"/ J,3/08T6 B$=XRHDN'_@\$M6X!:]M27)3-[1H(
M[[L<A[SRB^O>)DM&;'G_H(TG#JX5,(-TGK"J--*9T%IC[< TU^YQ#>Q0LKT?
MX'5+:MN6] %%H$'?#([Q0_1?=1/XL^Z:_F<7L[ALR_[[>!+GBVYZCQ+G]N?R
MN67 7C'J&2(QS_6,AH-G@#5B+JH83:#4ID,]N*.AJUONVZB?=UJ>MZOL;]I"
MOID"A9>)S66,T!N%[;*NT1 @M0T)3G3.E%+NB<7!.%WZ"<Y> -:M-&Y;>1=@
MZ7-0TN^FBSB9P*]=V<GYK .*+WY^GMGI/.6IMH1%&G1"E&6,DU3(64M1D(ER
MPW#0H5\+]V,AJ5S#_%RT;S%FMJMIER5M=WTFYR.EO3 B<>2X4F UV1S,5A0\
M8ALDYRQI4;I#?$_0^@GMGS3K=A0?VQ7/FUNCSU,7CP/E>4@#4P1,'QXQLH)*
M)(,V3GFA!#^Q=5#J<1+YDZ;=AN)^2_+^D/"CQ UGF":4$K5@%,%GCA*7!X^X
MX+BES)*AA/@A*/TD\Z5FXDKRZ1G55&[H2%VZ:G+'-D/51>Z#W0DJ'R/E1'$/
MQB/L@SCA 5E-':)>)I^HQ#$-EC8J7_GXR![91.PW/_SD*L#YO1[Y,#\'H]J.
M<SO8S]V;'_9R/+UV#N/B:C:=?^PFD[?7S9Q&2F+.9!X<QS1%^>B"P>W!_B9@
MR4OXG^TWN',/<@V-4R-U9$?*YF.=V90D-'#7;\!_1"UWVHF 4F"Y>,C0W)R,
MY&%XTGDE@?2E:\(V@%)7#MN2EWY30O9BWL$R^&W9D?W3PLX60THB*()9M/.8
M"S:N)KF1Z%M@TJNK6>;>=5=X^.WS;CY>VELC$2F-T6MD?&X!165$&@B,HA1@
M<A.PMVWIY%H9R.O6.#Y'.1]2--I5S:_C.JS/ =O9&IPE2=;D)BXIZ=S)!5Q/
MY[!#*2HNK31YQMIICL-><->MM'R.AV$XL6BGF&@O/; )=4U#+D0%8E.-P7HD
MX'%K9U ,7FA!@^2IZ@5QS(D8K*KS.9Z(X<2BW<MAQ *SVE$XSDFP7/3/D;6
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MHJ?"[9E><2_D&!XA9R_Z(GS8ZW^DDM3:<8N,=P+H8O+$-0%?,DT2QXSKT,S
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M[25743YOH=_P&GWU@_S!V7G\/__K_P-02P,$%     @ T(E(6!*_ M\XJP
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M7Y0ESH:7H/G=D%^'C\WA7X4H9A08$ W>!K.DM':HD:>J6A/]VZUM8)-_AS7
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M=S?/Z*J=YL4=$22MV^CW< 7!*<_0<<"1Q'@NM53);8MO>B_C#S[ ?_*8/J)
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M3]'3DOP=[N]V[U'82*QNC2=ISPBV*J9+T4]6-]N0BW:4-(T#.<1R#)8*M],
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MH@%2: S4:!VE]CXV;Y1(<#"I:0GHY^420Z&[?:0RL,HJLA?21-7XH=XG@'4
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MC!+TB3,JQY,"\_"+&NN-CB25'N?CFKMQ@"J&RP67B*R&?]?@9MG[3IM(6"Z
M?YLX;]$W5+JM9X JA_V=AYW;</B'-L1/6.W677&GS=QEM6##!['&K(< $LU
MN)PSN%;H4.1!1!]([:4I5VG)6E#;TR-Q7&.15%C_C!LP2F1R:P@]9=7.U<[C
M!\A#=\]O"=7$]C1:E6T'6]9-I%B6#W9'$@T8W\0NX I.JB;%=.T[_OP4=B>R
M[<H>2W[YS.K23>9/)ADAO:*^P(Q+E#?'\44LF&:CQ3%D.II,EBY%WT4"S:@:
M!OIBEV_+6._F^+,5"#<4:T)]0RJM!5C4R9#3PGY[G:2*VS+3RE,-$2<;9-);
MTPY36G= \4:4%XV@$OX6S72[*N']S!QM^1F#7^%;86P2/<+JN?YR*^F7XL1[
M&I::86S5PS>WE'FAMLQQYDI,!<G7%.(FX?=*A/[@H$(3YQ_+&F3&1M89H#@D
M\!6*8<T!!;APV:R(V>)OF_LT--V$1P67. :)_T>L[>3.==?/]&<.MK)MD\_H
MD (8!TH*/>!31@[@186M:QA[CFU:5^XC+>OEXGI&*=[,^L*4(\4OPPZUNI?Y
M<K91MI1QI,T/[HQMWHTF$%:PZKT/:/LF:8TZD<8[4M4M1O7@L*=@KZ3!N ;1
M O_9K(VW(\$)PG4*CO7B<>?M;SM(]PA7+K%3^G1P50H<Z5I)'KU94H+93EV)
MV"<=8ZFB?>1*Q T [O&,@[T- &X#@!L( &[5F<@AIIU?#3;MC/1W&&Z[B<;S
M3<YY%7@K6WGS!7%K8#*#?>2F== RJ;-H.DJNZKPN4W+T2F6- %2I2D(W=<EV
MG;:;R;REFIXBSY*Q3;QBPBW4?H\F0XQ1&JB"UN&_N,OR9PX/;;*1_<*1P2E&
M1F#%2G;F8[1G*#Q5.AB]L,\PM,\E$RLI=&H573]C&":J]$S#4MM.,.HB9H\.
MPPQEF91N6BQ!VEN<CF12HAAN/OB(1#@I.!)E<&-.E0$-];J'R]9QK(<X=A']
M:!\3;6 JVI:,@16=)$.)DM4;H:^%_L0=22]!=6)K3_1'F)&1Y1=D=G:=9[KP
M..28$FS$*"DP(5,R-V"2E36ER72!LA%P]%UA/4'*:$SZ,>RNA %'_B(.\_Z>
MCS0.T+>DN18:\PJ2X,$D;0DG-C7>N">Z"!/C5$N>Q0D7 =TA/"%&+J(DI0]B
MW'.!+^'Z1@WWNL_ZQ]P>.\&P2-B;&,&1JA@G)?[Q1I45_K?.^$^T?."?ZL R
MPQ@GT0W\7+/#XY6AX9JAJ:NW81GQ '$HYI1Q6%K.F))(NAPQ[4P_O9,$JB]W
M>"1(+3GX4UQ(TH8"]-%\1P;%P](W0VI^D\OE6)#CDHZ\3K>-F%"KV6<H4-#$
MU8GN-TS"]MX:THTLTR4A<7DD$)@^P$.5)KX"$$?Z'A>(I553B>L&YRI1NI,5
MQ@7 MZ\,<)R GQQ"4&FI*$2I@R&BW\PC+*V8?&D+P[UA.S2PS;HPHC@DUI;A
M*M#].6-KBF.D^!;8LTK8U0,F-Y.'Z\W )U%F.G&;&J7J1E$ZPWX?OXY2T\%E
M)!!:Q H@T+POQJ0ALSJ+$H$^+AU,#:IC'K5H8]XOBNSDF"I"I>LLN(@QRAV&
MGR..C9GPRG4-,H*#RD&5*:SWG<%?6*ANB BLDV:%U]L5:\%0>Z8&2$9)_:.=
M\=@%9?'V9'M+7I[.)3=C<]';O 1+*ZR%T6(+9PMID+",9)DA8(-N3=="$S6P
MT$S32I;P7@_1KPNMEPYB+-I3'66CVXXZ9#OD74DC+6>&XH[#T1+W'<(]Y=G%
M3=TDZE96U8AYS+=QIZ$BJI9AXGQ><6)"/6D?E!2LP^V\"9K).4HYF0R>F=2,
M>S L9FRFD]5>DKV?$$*#TS91Z6#/QWE9A8WC!!^\+9+[G:Q?Z@(%*.S8W$9@
MNF-LG*, 0<.,B45VCB(X4K!7N#$ZWL]?9-P,_IS3H:52G_D8W,#!%1H!_J"?
M_8%A577I ?T(J%(H3>[G7TXV4QC%X Z6.$ .RJK8YHU86/D#_&80 RGIH-VA
MO;7[(RNK_:JD#%J6KTVYX;NE:SW[.?>%K-K3C4)5S06 )2%>-/+L 4*@+R)S
M4&MP,0I]E@@28"9YH;IV>(DY.M%L"WA8D"_>06<OF,(+O1.49U9^>(VUP4MC
MP/J:W+RSE:@W0M$EI#A".01+B_TFJ/UT@MK[FZ#V)J@]D*#V=QFU?CW8J/5'
M5<X0;R&W%IK'E]$7]02)HX97-=5VPT,IF&38"CN+ I? @NJL&9009T;G_-G9
M0T@M!HPIIV^W-:+^7KH(M!WV"RU#)/YZ@JZ/ V&A'PI:G8Q:705JZH&C+\_H
MFL9H0:6F9:#_QIYZOY.'E@I5$*=>R3D;<5L#*NB&D_'LHTSJ#*>XPNKNA&,+
M7"1=LIGH'65V&#$9,E:,!-+<G QL2SE"12ZI+U:/SZO)U;^/OYJ-\X/.\X2]
MO<X(F3EW3ES.P]P@XFB*S =9[MG3%+PN##,"G*Q23KIV&RM$>^GX'[ZB)6M]
MZ*J(J^2<L.$RR0)ELE!^!/UA:'3^7C>Y:_MSR&<1B0_97041>I"<^]9,R*Y0
MX&AF%A0N!DQDQ*4#+]O;MMXWXB.YX#VF>"D_%#8R'\$-83A>RZI $%2A?"2F
M'[&*:T:,*EQU7:CFJ^/V_J*.'E\GZD;JN$A?U@2:BKY(K803C>A@7.^4&7(T
M08+1PU0->'K[!GK\L[\"BMBECG+.(4.#UL4U]_*MV\UL@\?%G%N>BN[M7K@U
M@\[>+%S;#T7"R%'&_*?JAD!VT1>ZTW,69KU*J/VHC*"5RCZS%0VD4*,8%IGP
ML$6!"7,.%1I"B9Q#I\ML+)YA^MJ<3*+6QL E()EZUM!A7VA]F3=PNMV=KM4F
MILQ94V1T#@?O9I0.E"?44J-&[153<,*3!?,:;7NOH[35% MRKCCM*2C?J+SV
M\:=@VCE65\/.[)EI2+7OK==1U%?%1B\^4(^'@<&[%GE]A>PQ-H#*SW1_QQ#[
M7/].Y*25Q]OR&NOX*%"TJ62G(W/)8BA9&P429=L63.[8GSP&%@UOBNW64\]P
M>?7=N! [ND;G_$2![+!$L_W@KL14P;K%'B"%E.7RVI'#]E0'0"D8ZQ90G)OV
MV7VC!O@:"7>^X7ZNX%2'+4)@\G4<J*9?=[YI/BW9,$PPZ)HM3;,047R6ZX3)
M)P//])FQK,7D%N)26Z1#Z4XP+AK8@R84GN+:-R#/6479 @K)6WNDYV8I+=\0
M+F2WC+9,LXDH9UW*$;)](85INNZ J!PT(QDE_3"1((B1?KNO76>'>2;GBPZ8
MNY75+B1S-@)KA3)WZ=PD\IP<'J@P;4ZWM?K:'K1?0.&GZ=R[$F&FS>NN>0E9
MU#LN35M(6CY-\P'W,&ZH<)L-U#OK?^B]MGS:$U0ZA0K6"JNJ;Q*&Z!D$'5-9
MN^I$TH.N?T(ETFER(SK6PGU(5O3%9%HA+;Z:Q,B>1$FJ*Z3%:\8YNC=YAV^V
MC!ANNA8]3OQU]_E@ [#_P/N"FC.^C6Z#/_^X#T;<6[!<ZB?9EVAXZO5R8<V1
MKF6B''^I08AWXGB1JXCVU137Q8Z?SG81@9HTR44ED,P34!:W4=')H">%J1,P
M3DC-PB>=<:WO!4<@"+(M3 \#6F /HZE+V-V@LKU3$  DD6<B/X6UX1.D8]/H
M8Y]F5])T,4:]KB\;IR^J\QP$/-#553J@-'H,O54>)9\*NWYHN_6!G*Q>[Z]:
M-PSR6M@=[+5P-"/WZHO<"&=3ES7U/0GU1[;,*!*RN2F^O=0T.5<I2*OUKX&B
MW<UWAE:OS[.,$7S,Q7$TN0%ZQVXP+I\M/LQ(!UK?+@J6Z_YW@G=YH?(;$R8&
MI4DX7GPA!9,F@C7"KR7$#DSD!W'S!1*(7S2^"56"HW,L.%\F#)K-F,&D3:7H
M.AV&:L!Q2,3_-GU \=F=;_: DP3V@KTP9<S,2>Q@P I"$ D/">.^[$)BL(%K
MV4M3LGW'-;^^-Z[K1V&.JKBA]7<8#I(I.]6D: I'T4A?ZGX1QP!,M@BCWA_N
M6TI,F._SX?LN</7<X% 9T<_]FM%GMOA6PZ?13MZY-0,>>!?=8O 2T0[@Z*Q0
M"6WP=$\(3W>PP=-M\'0;/-T*#?>]P1KNI[;TY(0#D0S%.1J/U:Q"V,.0;77=
MKJS/7%^-C0(7;:A)F1I$S2&Q1DL/0PG\DL5@*.^<@ %3U!!F32H-^NT8W<"1
MMY*BTCN6W]"I&]=Y(+)3[6O][\>N*#AA_&Y".9/41&# ,UP;!I.8QY7SLE)3
MCR.=X5Y<W]#.>E+VV!9RS_L+':VALHE-/XXNVQ^L+KL@YF0!+7$@XC<D]AQT
M ZAAJ;#[!XZ9KEH3#2>25&850( AYY%<URN^D2'-3(T+9)GOZDQAK=%8,;R&
M,MHY0RB0>P!T@G#<$9Z4FJ_8UW"Q&(X+/D+89'C-*-%AD#APGMU971PQ(6R+
M: ])" RIIQ]/66*U3 U;/E/$3\9\^.3*%S7S4ILWZ^P\U[NVPC:Y^02RVE$!
M5J7'!H.>*C\<_4%K[JS:*,S'5I@'@U689](E[5*ZI'V$&[I(I&"=Y/==5'Q6
M57 TPL3UV^AVT)';X:C2#IURIN,O7I,KOTM=X:Z_ V*;\BY$M N8B'/Y SIK
M.859@<MK0>WTUZ-J)N#.?&(#J2P-MSG$F1!?0,FH&Y\$E;)C4@C!<W1+1S7M
MK(\H-X"WR';:&\T9(&%N##L>S4-KH\G;.T%PQ!%"NXCF"Z7.8&)\\*J6QAMR
M@\%]XC!O4U19Q]4L--1YJAM.X]"C'EJC#:$[L>Z6A##H#F'AJ&&[2**!ZFB\
MS1VC0W-!&T1!1]Z=<J:BS[K*1;/XT.\Y&$KW&&P5K/KFLGCLR^)PL)?%>1X<
MQ52H_]$<W,%W+!O.E> &"!)ND669&(C! BO6C"D,"C#**(L5T:*'1)";E V,
MZF?];7#K0;$KQ!23BK+*=3$%%=\ +AY-8\SZ$8X[K%)T_U>K6? 60%"=@9S=
M.CQASOQ0-?D3!-6S[)A!Z4ZH$,%.7FH..[ 6&P7VV ILN!VACRG3195<U# 5
MS-DAJZZG@D/XQ*SV%?4'H#+0(+J)DI1,%O5%36>,#==M3T +&+*Q,/AW#2,W
M7'X&+L]ZQ,GT-BIQ^Y67C_)W>65<Z+ ;F^VVA6>Z<(B1"4B"I"$ S5G@L!OS
M\-2K-1V)ZB2DF@'0^!.%C7?X.A""\U*-:R0$8I"PH3L7V!9A['3N-RCJE)*_
M#9-7WOUIYV('N]GJQZ%./M7/H_8+)44<AE30?'%ZO,H&U8VH#$,FB2@OU2N,
M=1ZC/)[3Q6I$)!]5$J42BQTN?K<7YCA5$7-9FE-PIR1X;X^N%+6"8Z_PCA-D
MWM\\""9IH7/GC<2%FO8 &;J(Q"K?WNDI3^6A,MT1#W3NG@R#3(>=-YTC*HF=
M=9R)L95;7GFBHW(7O&.I_97D@JK*5FS8\M\NV\CCVW+ZP[:4#/G$=98039;W
M(O0PT7*SND7#>!<&$QEO.VV1 @L>Q8-YN$ZCKT)$G1)CH:=!W:IGF>H&%+K8
MX-*/XX$<X,OXB=B1+ZM^>D8_6HU9=J_^URN=2 _ U(1(IIHB^H(R@G4QZ SU
MPZRXW;V6&;?Z^*6/><?JWIEI=_NAR(G7H2Z#LI["R)/_Z,#>-/H=E;6BK?+(
M!W;L0Z.X^1C6@0DW"*:_:7]3IZ,QJ4/-UR1+TR(W>#CB\7'/J)9C.J+,+?(O
M^S_^0?O?)]Q6]-6;0']R99B]#N'MB,&X&F3?+O)BY-P&#OC5Y>VP'PZ(8TSB
MO_V0[!\<J-<JVHOW7TP.7D[&KUX<OHI?'D[4WL'AJY>CPW^]WOWA&V$(.Q:)
M$A3^#?1\9W=)"?I#SVD]S;L9=U_LO.2+\'%!C2^?[QSLOG@(IO'%WL[S%\OA
M^>X%/CS<>;G_56""][Q*>5E^Z-^B/=HA8]"0!.@?]@K"-S=I=G&M3D[_Y_C]
M._ ;SH_[;ZIUF<S>\]U#78RM)+MHNSHCD;T.)'!?>O&IE[ZROB.YZ/?ZUDA*
M6E</36WK^.C\Z.1HNV/;%UL8]]3]&Y3Y!F4^G$C @ ^DB0\\/#PPB-EU:](C
MQD+<-SXP@ ! 1QIG71;]^%K!W7^B2LJE\!8\:M2>1N')\^--OL]9[_MWT/@?
MQCF..9FD CF<CTO;VEZ]M;4V_OSCZY<'![UKSW:6"RVX[^XMNZO!7O"_@WWX
MYP#^V7VYT%U]*HN+U1^,(0V.=5(1J[='-5TX'U2!H8_H2BU8Q#V[9$]\N7[3
M_6(H*X7^$BW=25)B:C?):G_Y2BU4AST"]1W"71Y^0:[*Z+I75> 0I]=]!W[0
MB"]LB_1UQ')C>RTG6>?15'("CTM3#"_GJ<=JG#/PX"?*^..G[F\5#>W?]\@C
MK8ND_(J-%8ZXT]]&8C:2\90VY;O9+# EN"N*X/CFP7F^.<SWE(.[;9(!XT76
MS4 YP5HK:ARROK'&;RW^&T]N/?;<.G+WHD08X.P6Y2$?#*Y[Z<O(0!3FU_+Q
M^J%-PPLN&1H8HF19P.02!HJ*B:E/ &.81PK6R"6=S6"JP7NDF,4?@J^?Y-2B
MW3Z[W7NIU2: J(._C/-I&)QEXYU@"S\QC$(#SF%\^\YB?3LIP B_TX?&2_;@
M[&6E+56AUS1$LWA*%P1LJ5 52E74\ITR#K$BG!S\,DX*V,9TSL3$^ SJOTX-
MLH5!WP>WXX!W7[XI@W$T([F1ANU#VU'"U?],8UO=KM(&-F&L%?4+PAK]2LVD
M;IOI'>%G"'XM0Z\TR; H4265;$JS8;;9%F?>4M&0E+H)15.>'+(G1OQJR7%?
M7U=)JCL+N0^7YD#<W<VOP&I3:"8R,!AZPG4HBCN2$(X76[G/2+'8;@HHMOJZ
M?0%C2O/;KP6:6E*5+T89KO'M\:Y9;&N8P"GO$)5!FF/I4DG,O,BW@XWBKA)B
MYJFYNN_,=KPWS2HT+]DD2:GT":Z.V[M*6CQJKPYMU]%%C@K9L&&7[A$WA67%
MFCY=2^2P]W!CO=(EI^Z5T4X,^2J+7NXTJ/H_P$95Q^]79+BOI ;F7CP\JY[*
M K9&]^#TY%2_347,MY>O+L/]#VC61U6C]F;O[+XGU80?HH+Z!U[4HS*)$ZFD
M/)J@DD1KG)LW<E.RX1E1TFQIA7:QV]8I0BM!)%X:.8T2>([ZG,YM=VB\-NA&
MJW(L\/S7O_[U)_FPUU#0Y1UR7*)M4P=JT<SB\UP25=Q4["^VE*B&TE)0=+>8
M[;+3FISC;>/?#PX]7AB : 'M.GN+YKI[8YY!23.@.QC70WC[I'':%AD'NW\*
MI8]=9+K8P;+L/O_3]C>QZ;ZU ?>H49GS7)=]/?XI_&=>$^U5K,9(3Z^">5X7
M3#Z@[R#W1&+U,!Y6I-,"E^;+,Y /,/%:!^D460N%>4 .$O5]=X(12*2+//VE
M\.*#!X3LBTC\PA7+5&^D.>RG ;5#E4K%/L+8^QET"RZW#;O]*LO9=A^-W?XA
MQ0B;DH1-2<*R0>_A^&>K#DEHE^U>;'@#G%U/X5\?JO,I$!FL<2!,YTSNF4P!
MBW<F/"P.0+?5'/P!QHQF/UA@S5!;*/_-+EW#-))> ^A;"GTK/;>1P0'O)*^Q
M9;%U8:)2FK677[,:X'L/MG;(F#6([^$B2A;&"9LWS>HGOWI!\)$[F4>Z<:4]
M MC(37<QM\U)$S1.55EM,@=?YR)KQ^?/=*]L;*\];38LL>D>^(IN6M>=4GY\
MYW9 D?YUH+<:A'VUV'J\%Q7I &>W="9[G>W%/XJ]'=3]U,SNVQRX@"_X8FI0
MB<)'.'IL<1C<%]KF]]W62<QZS^"-JIF'WPDPM>!V:W5H_;HIZ#%G:H8P$52"
M;A^)(5PW8XIA<L:=*#9,G9BYG#N^I _V#K;&VUK%G^'-BS5!']6-8K\GIJCX
M[NM7+T+J?((4B/"<H>4\<* KS'?X3+&\]2[LPD'E$(EX@@UL;Z\5T3J"(")C
M96B(8L/@*IE4H25^I!;B$^XWPYRZ55+A-T9D+G&#VU&I-!$D=GZ(FBET.\#0
M'2SE  0PT#]P:Q-@3H>D4CP2MXMP0[3VMZ)M:R:#)('A"]*KL@ 3$^4$_!<X
M"+\U("DR+DSH,%$J,8MV/+DQDO;#0VGG,<UO\)3GUG:G0\=KVX9.2=KI.H?%
MRZY@A,T>S;S<\-#0(!W0F/):AE!H7.,='%6"Z^"-:SI_P* :@B2&,S.S&U@/
M+8.0KLLNW+V,FY:R3RCHOK<)NF^"[L,/NJ_:X'UJ'M4?8!$>Q.QZ4NK$OHHW
MV>#[V7SGU0ZD6G^>!XI0I&A;>-4+;CPJ]"B,&]!FM$Z,XP1.C.M>W< =GU51
M <-M!-M#Z<ME6?$1O@4C8/I>;AUF&H.)0Q,&W+V,.M-03\PXF5!\W36T?.[V
M&7ZC<IK=,CG-X>LWP=:(1WZ%DJJ-+]JPGMH++VK<<#QA+GJVW.HWSA6W)D)\
M1Z5H@!19!6.O=CL6F#?J=L+2H+B_E5RK#0=UO\S >ZS(KTD35>.'>I\ 7@RX
MCF@7][^$<AYDJM/Z6"C7+"HK64!P2M'7Q3[,NEVH[R;(5.@)Y<(AW;&^H;1#
M#2T\3.HU_*;0K8 _C3-N;/1#1\&MEA<U5#)-4/2NV^UE..)4NE!C$0F:FC,8
MM\X0H6QC7XO&1^%L4Z\P.G3TPW:) DU3/?XT:0X3;$=CQJ1;)VKV< $ZTKG4
MQQ>?[DR2'0@0H.MDYAYF?FA>&.=I'-6EDME.MMFK<Y6,,V)?H<EWKK;M(5]J
M873[B#N@[:'YH#B5^->;**W9U8]0+V%_1+UD%)ZA(P^V\IB5 T(!J?46#PX;
M;#CX0)G ]0 F,)-\0X9=*%-NGH,'7L4^HA&# U(>@^/"EBCCM,9KD6,B^*PT
MF2;<9RR$S4W'U%I'FKMP.^0,&[85TK.<RA*T%-%?"A7#3")JV0)J %N68+,7
M2>;IHS.+2-! \8WR#$0(_H"%&,_,T;H%GQQ^J/> ^OQ4NA^2T:UX&&' :528
M)V(\2('-$97ZLC(5/M*+R,8,_6.=1B.$_-$-BV_'H%%2INYN)]NZ*,2V<R8M
M$+=40+AZN=#W1%2:'J9&$$)I-PV_R,0 QAF$LM&\"QQPX59^BELX<Q$=MPNB
MV$@WUEO6ZW<^'7+KF&'BS[B(G-#@[1*_0GH@]*T"=]U!$RA#*=9=5$VK;DG4
MX1-@XQ,Z"K1!8PS\PH&?VW7T1M6S.;WCP/6!C6#$*/5SE3^+JN.9R_5.E5V-
M?'8!ZRR+]7D;>PB-TRB9TAG.*%PYE?8WWDG&-T73Z$I)0W!0MJ5T_7$.XQ\U
MH3#/F=+I[WJR?V-L3:2%$<,^@ELP1<M<<9^QV$1M\X*U##8* C'$#+=T2L]@
M'Y)8I-)V(G=>H=OBXOA^KV'&<2*"2^W7Z.[ACXL(N7TS_-&:FUN;,=NAUAN^
MM4H6-46&E]R.I!2MRO89V@[.%\]TJZ0'*R+=P]<_T++1?]C0,*M NXDG?PRZ
MC2HV$&QSWW';UFQZ6=T^3 AIR/!N *G"GEYSIYL;]AHS7:30^4F*0MWD8X(3
ML;.3D7!QIVE8X5J;]'1^HJL(?]Q6R+I&Q;.$O'[R/1HMM.6MU,;>:4IM;6&4
MY<)<ER@V-!Q6-EAAF))R^'JCLIV^[-M8G203;*O:#L%C9[&KG.Y\_VO4OQ Q
M4>R:80^<FNT*DG4Z#NZQH]'"OT<+7%;M&V!_-3P0SB;J5MIR?:)68'$M:^6.
MRO%N<VRI.-8;'0DZ)L['-=_\7ELPO/7!];4VB#9;L9 3_S9QWE**"DZW]0Q0
M8;,/^C"M%ZZMROL:YE)H6J\O8&307LVRUU/#Y;2^BP<_%%5(H, SN._IO-%Z
M']%G0/3DA,6RZ=,.HTYL'J]<BKQ$O^Q6>@JZK03O=>%J&\08M K?"A:V1$>P
MEKR_J#C.F_&,QB5%!\P=OCGQYH7:1L29*[D,)&]:B!N WRL1\82#"DVV;2QK
MD!EK36=BXY"P:2B2-3O,H+Q81<=L>[8-3QK:<0[.";6KO\0Q2!8NXNT5_>6N
M'V\@+N)6MFVRBK;UM-BQ)8X#;TMZP*>,')P+;+4H](!;NVODQ7&K1M1R6OF(
M3_<-SS.O\1X8J"KAW/I2-UBVU!6F+PGX&XY*STJWP#2-8$DP)FF-X3H:U$A5
MMQ@/FTI+T6!<@]""YVE6W=OKX 138@7;=&BXLV"UG8![!/J6D %][KB:$I1%
MK00JTRR%U!TXG<:\+;D;>YNIW_'P;G#K'"Q'>'@:X1T/FTF7(@(?2 <(R*9#
MY1/VQ,A<18^@)JT3T07)MOQ4'HS] C% C-$L51!F'00NKJG+J-<I>:&I8.(#
MYG3XM@/K,OC15B(C</#/ M9 G0&B7)-YC"P0C%QQWPO^KF85&<T?=MAW\'9!
MNXAM[\5*Y:$OZ5_L:?NB%@B7N/0TA%C>W0[B2ZTNMHON62)>3+B#=& </J!E
M1\?\,9L1S<U?9^3GFT!^]X-=-]!^EN[;SB\XUQ?N>>/R)M$PH4=S87?BZV1E
M?,_3-P?T!'%6;!?D?;/JG$;G##:XER>$>]G?X%XVN)?AXUXVP)9[ EM>/4E@
M"S9@P/#Y332>/SU4"_49'MY6]'74UF6C7] 2!),#S$8W"XPF3IU%TU%R5>=U
MF9+-5BKK^:#25A)5K$MVDW48@J(%5)!:Y%DRMC@--,5#,;1GNB]'C&)!=#<.
MN=Y=@10F"-1^*ME5'$J?HFL ZU.RK1FC$T>1T]*Q>L,^;]@^EZSXI- &)UJ4
MQAM&-\+UATOM,,*HBYB#9_##J"R3TLVB)]A)"Z<C$;<HECBZ]=BG40;7]509
M)'0O@&!9!W+-Y+*+4%3'[L@01JHER0E:&4HR%"U9QA'&L#!.<T>R7,I60G@F
MQGFX^P0+,@CO[#K/-%-0R,%)V)%14F#*M62B^R0K:TJO:T8A(^D8$P2'&\2-
MQJ0?PV&@,&!;/.)4Q._Y2-<Y^'$$)B]"XUY2N CN*.'HIB;*Z<DP@N YF9IG
M<<*UIW=($<Q,P5*F]$'T2Q9$4MS(4,/SZ8M](": @XNP2* P8G1.53%.2OSC
MC2HK_&^=\9]H^>K*)#^X3&,2W:"/+?$!O$1T.4IHV+# XTWKDMP^CJSA4,QQ
MX]2)'#8EV1XY:SI(^82/%"C#W*&!(T7E%-K@BH8=X L# V0QG&'79 ,&X6"[
M$YFCE!$C3%JT )*,1C02/E**@M"Y35PMZ7[#Q%[NK3/=7 5=&Y)$0NJOZ0,"
M=13M-:5P1%+K0CFUDBIQX>"$)937DA7!&&=E:N2HP(5#J2HM%26$=+A9-)UY
MA"4REB]MJ9VKG; =(MVVX8$XP:)E7 :Z4F=L:7%&"M\"FU9)#\> Z93EX7HW
M\$F$0DDD"8'A[B!5-XJ2;_;[^'44FRX*:*D50K@1UM3UA?%U;9!.^D6@FDLG
MYH::F8<MBIEWC(+G.0:T4/\Z*RZ"C)*'T:6(TP\FSGQ=@Y3@H'+0:@KSW!AV
M8[&Z4<CMVLF3R ON"K:4BWGF!\A&B?RS[GCLBK* >]*])2]/YY)*M,"3;5Z"
MI7770HRA1<2&-$A81K+6$/-%%ZAKM8DB6&BZ:7U+D-&'J-J%%DT7H3AMJH[]
MTLV79VB?6AK@I)%&-F-Q!^(HBCO&\$<%VL5>WB3J5I;5R'G,-W.GT2+:E@OB
M^,3BQ(3OWCXH*5B-VWD3O)MSZG(V&9HQJ1GE9/B0V78G4[XD)R A/!:'9:/2
MJ;(;YV45-LX3?/"V2.YWM()?Z@)%*.S8W4;VKV-PF"6(4-0PNFSAX:,(#A4*
M#&Z-SJKR-QDGAS_G-$&IU&<^"3=P=H4:AS_HQ_LI4%]Z<&$"IA5*$XK[-Y2-
MXD8QN(LECI 35#I1C9]G<>4/\)M!$*2 E?:'=M?ND*RM=K>2,FC9P;=$CJ/?
M3<B<7-R?^P+?[0%'L:KF N.4=!>:?/8(48 ]R4AQ<.DM?19VX1+W"K-_77N\
MQ"2=U)[%Z"S (:!04?%"H;Q3E&=6A'B5M0%,@\!ZXMR\M 4N,6+1):<X1#D(
M]Q#]#8E'3V1N_9M;ZEC=ZZ5B=>LTW^[HW4=5SA#!*(<3+8'+Z(MZ$BQQZ^W>
M-;R14.KC&1_%)K/@<I!!(VLZ9V+2Z20WF[R((L90&D$\[(Y'U*%<U_RWXR"A
M);K&7T_0 '2P4O1#@?W3Q:Z+_@T!1/3E&:4$T6FJU+0,]-_88>DW=5%5$V5$
MZJ6W^1[;&@:#!T,@8(H?95)G.,5'I?.@(1@ZCX0]+&;%*/F>]$XY6\US0A0P
MY$Q3C!N$!?&?HUWNB]6C,H/3K!Z7@9I>V3@ZY,!,V-KM#!*8,^?$)CR "<+:
MIDASD^6>,4&1O,+0X,"I*N64:[.Y0DBACH'@*UIRU@?ABPRBP@8%[XZ<*A.;
M]\.)#P.U\_>Z^>G;GT/VHDA,Z.ZBC]!#9]VW1$1VA5SGF5E0N"\PJAN7#@AD
M;]LZ'U-8'T:!Q!0SXH?"1N8CN'@,IKZL"L3#%<J'_OH^>UPSJD/AJNMJ/U\5
MM_<7]?/X.E$W4@Q'NK(F_%ST14I#7'>LHWM-I]"0F0TBC/:U:@#*V]?/=W'P
MESK+.4=-T+<R=ZN7AMINU;NY_21RRTK4O=\+M^8;QK('A2C\H.%\C,M+U0W!
M,Z,O=/WG+/MZ35%94IE *Q]X9BL62/]&,6P)8;2+ K..'%HQ5$,YAYJ6$0,\
M\O2U.5E/K6W$2T/RG:S1P[Y@Y#*OX*2E.U^K?4QMN69/ZAP/WN,H3%1.!%IM
MU"A-8Q9>>++@ :-M[W44ZI]BQ<T5YXP$>AZ5USXH&LQ QT)KV*0],PV)<*#U
M.BEZ,GKT@7H_# Q4NLCK*Z06LP$G?J;[NREB)$D2Z'<B**W<QY;7_= '$*/]
M)3L=F4L98V_:B)"0Q#:G"9 LP)T\QF$,I99MJ5C/<'GU7?HPV/&ZJX43!9+&
M\L_6B;MN4P6K''L@ -+$RZM>CHI2.1^%N*W#8=&^[ALUDMR<!^<;[N<*CB0;
M\TL:T^! =6L:YYOFTY)MP/BM+N'2,-B(0E^,2R9O#]SA9\9F%V->J(FY[A._
M3?DD,%T::=YF-0<%#6] ^K.*8[$4\+3F3L^]55KJ.ES);I%N67X34>:Z'CYD
MZT4*U73M#-%M:'I+RJI@F%:R\_UF9;ON#N/XSA>=LH%6XK"0S,0(;"%*C:1S
MDREQDB2@\;2UWKX%GF+J^1>X.M)T[MVN"&!NW)S-Z\R67N"JM>6GY4TU'W /
MJXHJY-DTO@LJP>^U=>J>#-,)5;!6".>_21@R91!-'"+W=(VD9ES7B(K1T^1&
MU+6%79 <Z3O.-+1<?,N)>3^)DE07/XNSCI-TC8(.MW 9$=T@Q]<9.7ZP08YO
MD.,;Y/AWD)_:??Z=)*C^@:9MAA;6V^@V^/./^^"=O@67K/YF'6@W2:I[E'WV
MQX)UZ2_A0$J-6KT3 8ZD>+3EILH]=D*9H50IWIJH ,%T"$<#EL-M5'022DMU
MX@1<+#((L2;1CNN[*]KE-@(3S8)CVC[1YGB 8,WIX2;LK.6,$#/)ZE$K 5A7
M/I@Z[X<AS-/L"DDOF2]G8DQJ03]QDL,\!_$T9*"7#NZ1'D-OE4?)I\*N']K&
M\B!CJV^WLKGJ_OA5M_N=7'5',XIN?9%;[FSJ]C]X3R?J(SN_%+?>W'XKO?V:
M;14H.:?O%(/!O)LL%&,.?C,5S-PB_H*SB(W*#VSLYS:MP(<9P<'8APL 9YZ>
MG2!XEQ<JOS'I0=#FA&''-U)68"((._Q>HGSJ-/<-DH%=-, )\<Q@W%(P[DR,
M-YLQUU2;B-B-^6@"0>7$@R0TJ@\"/;OSS1YDF$".L!F&RH0[CSC8QX("#<+Z
M('A'NY08"&:JG-(PPMQAO#S):)\;X4+@0G%#>^-P*R53#H62@BH<!15PCJ1?
M_C%NGBTJWNC/Z2PE0LRD_7"9D#*.W*"SN=0%RP8XG&E1WX;5JXWH<(MI/$@[
M1BRG,S)>. 4GA'#?L=4RW"O[#AME[TG6=I_:DI$3CF$S>.QHC%0T"-9Y>D;(
MFKMUC8Q$J*GQ&G3P(7'32]]>24^0]C0DCH['QW1>!.B42H1^G:Z;%K/44/*$
M '12F>[4F^M<)EWH]KW^ V)7[)QT4S>1H4GC(W+F&2X.PZW,X\IY6:FIUXJ!
MP9!< -'.\Q->PA: S_O+(5>OM5=]MKX#5W3_.W%%+XAA7G")[([^AF2[3[ ;
MZ-I9X_</J'*_ ,W)G@ADA)4C80V=1W)=M)C0AB$W-9:RI6:M,X5%6F/%6#O"
MJ^0,IT(2!]"60L)*.'1TD9W7<)T=C@L^0C4-\)I1HEWI.'">W5V='3']<XL*
M%ND<#(6O[Y0OL5RF_B^?*>*Y),HW]@:+FCG\S9LU^(;+A5N^?VX^@;RK5+I6
MZ;'!H*42SSS@@[[4LF;O\$U2?IV3\H>;I/PF*;\V2?F7O@[9F(CW-1$/OA,3
M\4SZ?%]*G^^/X%057*50TK7Z+BH^JRHX&B$B[FUT^_"$1;],/HK0/C$;LL.6
M.M/Q2:\)M-_'O7#VUT7R3WF;(]IFS,R[O#.=Y?]"R<.4#&!N]7,83.<+  :-
M\JZX)M VIP<2HIDI&4NL,=T.GE@J1WF.+MF YJ7VR_ ,ZC^RO>A'<X9V&E/9
MCD=WB["IF.T=;EH=''$8W:ZD^5:I<0VF]XJQQTL%UK339(1YA27X;*MDG*>Z
M,6>.SQO:^<ROI'5FU]SQ&9R8\5R/O$-L.+[>KB]M(%,;KW0'ZA ET591>)[W
MJ9R!,:0+A#4C'/V>TP9DR<.FP?H_U%SN4!M_/&A^ERY:\-+-):HOT4,N0WKZ
MM^AY'AS%Q$KST6B</]8@^ ]?EG]<0)_8A>F&U!-N76O)C8@5"@D03(0$KH<H
MH_QX1#L;4ON-I&P4)GW6WRX45ADK+#LCW6VOGL44CWP_NG4&NG:@OZJ%0RE3
M'8UWU"U>DE@N86H);ATB3F>"J*_]&8(^7G;0<!U-J+;5SEXX+#KP91NM/G"-
M=H<.?_$D4Z+'E+(GGH+?\*B 8[-1U4,0/E+5G[A_6$5=V8@')8ANHB3EIBA?
MU'3&%8RZ65^!C5"$=30,_EW#HAAV7U/5R8K/0;8TJ&CZU:U?C.IRR[E5;&[^
MM=NW\;K;D&EM>GHW9X'#;LS#NQ"L%T!D9R&5ML(=-5'8Q)(O,&GX5*IQC;2
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M9C,-%I'AUN%XI6;PS4!;5QP5EVU(.FR'SNI@M/EU>TWKYBU"2BQ'UP48IL_
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M*1B&$R(B)YL6;=-,86H@1UNT9?Y%>:Z^*,>0)2LV4XXE&_#UD]0U/FN^I6>
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M8MJ)C@N8RQRY>Y"J![-F7K;'9M?@*^5L46)_XST@=AX2Y7_\35EO+W??>NN
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MP3:@LTSI[@#>F<,G19/H"CLCH?@&L5@IJ3!P*?B_SB[BM@6X0EUW]L7^ ,4
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MCVM:5M%:>%6!F@C*M7VMRX(((4F;4M\%F$8^H3JQBC'B\_P*"7P92CTVOHS
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MO"G<?G?'V:YY2J%12C! 5.;B-\01!<;9C0J\9SC0&RV!%<J#FSD9SROC1'-
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M1[*(P*%0_A3!J6A&X2&S3LL&31EKC!)6#'S@JQ+^:C\1#V%Y&*(5;KV]L2+
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MC%[?TR?$;546:&FC&R5M+_ FLY),]UUAF]$:^UEX)C?B" .7>>"R/0PZK5]
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M$2#[:@N0+1\-0!9.CX&%PKI*9:"!L;Z#X4Y1LOZP )X G(27VL=VA*#S.!M
MNPNBMCO8ODB:5$9']PZD.6:_+XZ==4:ZUWL(WR6L]M 1M0>)IG5?Y6O%UJ('
M#ZLMD\'%;O2E\;7^$&AOF*W]7G>+L/7(U=>.M_484-OHVQ<>=\,(OVW=]<?J
MKJ_'W+JWNW[X]]^/3R\C\-FCB]\.SX^C]Q_.CWX[O#C^3OSV]SZ\KM73W%77
MNC[J8><_T^I*C S#=4QF&?O9R40G'[G/%8+J$)E;P;'A'97>$WM#U/R[-DL9
M&(B%99B13MA8[=.W>9F7?9*-,J]OL\?.U 8GDF'P@.K_U<$W5O\VQ;Q^Y?_#
MWU (N,FJ5?,X+R-8BP)+LQSLTS3DZ1C$8-,,>CE&F[4<-<%4T\ 6G.B\C]V6
M[;")NH8-<WOYN[NQ+:NGK68;TUN<[BRH^!-6M-KK18]PVE9G"8M.AOWL>V.#
M%HUDLT3C1F%3"7*M83_JHI:J&ZZ55$E2S7N)O4B=UX:2TB>L;%%8]I!3]E)3
MMM3"\!<ZW:R%#J,64OW0[A;0(N <5>5'73U1-4;%O3;6 145E=MZ^[P$IWZ*
MI/ < .D^@QE0"XDN"=&@&!;#7W:]6<N.$][*O@<E5AP_**M!S_EX\^:<]\E4
M-Q.IOA.S&\Z\K$7!ZQFFR,:[D3Y?_[M^X.8_GA/LM7?JN,/*-5>RW:4*J_=Y
MJA! @@61.#5J!'Y#*[$&N@,AVI25(Z!'6H*960W+4UY/I.:^GO*OYX>GEQ?1
MY5ET>G;ZY/CW]^_._GY\'+T].3\^NCP[_T[<Y=.R>&)RUS97S1!2F]OVJ@G)
MH5G,R-(]%+[P,=E![<;2FL-/V,IZS\1 .[YVV#/HP,;VYR#+JI'"X4[&>5:"
M/@&]DI8S[_C]N20V83C#Z0>=<N1(];%7=LOUZ#Z,WG)V_BI8L[Q<3X=MDV&"
M-R-[HW>RN: 0?<H<;$I54?6VJ 4, .!$PFWW#Y[&( &&R6/0P=R#@>0NCVD'
M9'G6+-9"MWK'76./$"."9<'%XOV;&]-J_9)X,RD)2YA38W;<2I5^8OY"8#F<
M8F8?V*WB_-E>?2%JHKLKS/"'+LK#R$O\P;'ZV%1;*Q9K"DBN%Q_L\A1!=B*0
MDI<TSH/].(0C80(B[K!CP)4>3$KUL7J(CO^SE;8[FTD;,)R4PW-)LK9B/&:3
M+=U?;C]VN_7U5LK[(:/&Y?0I4D7941Y7Q'0</H/'P+?.,!"XQ[D<XYY>$S$$
M.7V7Z3DNXI&J)VLY));H<C2E.#/O#1O5+WPW(=>DP(@FV#X*[EHYSP6$_]__
M\OS53W@/K2G!-]:Z[B60$%?;QDKPYC(U8MCTDW:OVI07MHVKMY,0W=@U,JG4
M2IOE67'$/'-W&F>H%;KM'[R7F<%.3*IL=(]FDUM@XQI#$J^WP,;R 8&-W_84
M6,\9<-]@P9\GE[_]=O;N[<GIK]'EX?^L-9D^R,/^V4!<OC^]MN:_:C@8,02Q
MCG/]SPD\'5-7QC*LM*2>Y"S,NBC!Y9$("LD(0,%OXZ0^,?4=T^$Y5.&,29(6
MIB"LFT9%HP+KV,+\5QPY\"-GP>(@!P;FP1A.X(QRIV2S&%(T[^:Q1TQ5S^'Z
M))/^)Z94S7N%#WL7(EACC>F?/$9P([9NS\L$#!QN, W*E6T0^*35N;Y5\U9Y
MX6W\%M. 90(+"G>IYQ6![&#\XC[E^HIB5)A/[.T*-_/AH-+B?N'%D7SGWE%C
M52T"6QR20!>M7%B#[?Z"X&3)![C$ L642+YQZPLM0_B&2T(0U?:LKUZGNZ_)
MT!7I, (.S#?CJ=.ULV,S.QJQ?.84U=U!%LAVP\@P6[6L/IC!N=[>Y:WC.M9C
M'HQ+MI@Y;M$7D&; EZL4(.P0[Q%ZMJ^ F92RMW+8;$$: ^X%?SN5(Q!>9>('
MG[MG:!ZX)1,[=@B&IHX/W7J'7>0,1#5"V%!2+$CD)XX:[O"2 3C^66.&'&!/
M25O24ACGTH![3,^+;CS% G7F,Z-V#=D?*J$Y^,8+H\G<PK,VI$'H/*4!9[MF
M!#)F?[A?-(Y;GH[ON9-=[P;+:!>%9$RG%F96JYR"2/WS9HR'1'J2]A;NZ8PE
M8E*5\ZL)=A(!#[1H\,#FN_O?@<.4*II$^DY5H)RONIXR;;W;HEW=]Y:QZ[2/
M,;W5RLN5N*M/8B#9WJOAG0>5/5T/K=]]':++\\/3BU^.SP]_/GEW<OGWK3MT
MWT4>ACMT";N[1EZ*M?I"]\%AT$'I:;DP%/A\[R!VB@_/5XS1CZB+(:C]6:[3
M*VJY4-<@+/BOR6*&#R/(!KA',A^5YE0S6 2SDB"<8Y/'!06)\50Y93'PCS!$
MU&8,(,?1PNE.NBS5=4*H&; $;(D=C'8O.FEQQ\)M/U*C75,Z)@-!+1^OKC^,
MJ3R\@+O/31])N T9X-%U=EV2,=UH.!WQ:]3Z<&7=\(EOR@C%HW">PPRFR"C:
M0J-#H*H,>PL;YNY4*X2J\WO0'?%<([^FK'9E,JZR<2/_3,LIYJB2B(.F9 U5
MY+>47',IAZ41233H:ALKYAE.0)B4X?56*?<>QF.XKR-Q#Q&MQJL0T ]N&RPX
M4^RU8]%>LDDJ[@Q+L=01+JM_S+.QYFI-S,^B\73H<8\%UA9.U<_]7]K;7<UA
M7!G[]62_P<QAZ!H7$8/.4J)G.90=9TS?W6BY8BN@/?=;5=H)&[:JS4!@+OV&
MNYD=@60,P)CCFD,D-N?)]= B-(;^!1^ZSA^&Y_:SOY_7DA&F:F#/QVG'+T!O
MQWW]!@HU98B24TD4<PHUU ["'$P_'84%HZ@V8.-:IFM0'PD<."#S^6+7-5NW
M-^Z.**NM6LP,-8>V!']+]QO\ I&JL'WHL43 1)FZ.C)@<CPWY#;R<)D@^@@.
M$!!P=N^D<S>*4Z6ORX^:$8D4@/*NJ\T>KW&V JWCTFV8N5N>"[.(Q\)#?U#Y
M-ZD)U&[4S(AS;:-%9Q;H;*DR\@8[J3C1HDMGSJA1."2E\FE4FSX>^'MOKE@"
MO)>/S20BIG\*1P4^:5[0JB'<!>4P_,I5:9AL_/+5M/-']P.!P&9 ]O<]\V!_
M#U<EZ)K"G*9@X: IH.C/);I]4![-BT%X-._/3_XX>7?\Z_%%=/:+D$6?_7EZ
M?'[QV\E[/LX,F?3)V2E<=,H%EMM4T+W%81B^SQ]EPZP0:?16&AJLY3@\#?J^
ML\+E C:'+A?%1?0D-49>,6X$)U2;F,"+7<WAS,L#[%%E<TO=>JC8F&ACB2*:
M*8F.71.*<QY%&$\M5E2F@H%-1NG=1M#.K9BC)WQE7"^>GCR_U]QPSW>A=;0>
ME;L%7G-=-ARWM0!')(HQTN$*B'QGKN8L"_JE>"RL>"QKF4W: X9/\MO+?2SL
M*&-_@DA"VM1ETN,/A;+0-['O]Y&';F@R:CABT>;0=4>2V!KD#E<]/716+!F*
M^'56-:;G#0F8E8A8_JYA S1A_#V98-S4@*A@[F<X_20FB9HA?WZ$'GN"U"WM
MDF(C^"VB$S+H*ID=W\5MS]A6SGPYVZ1Y&,\KE(ZU;;=>%4O:M"B=%B3Y#R6=
M=)_YR-=][;WSH4#4+DJB:%K#1\O^S&VWLR:V*=UEJIY,0._&1B>_T.LX1!^V
M'FUV?/#A,G[@-C6PZ9&WA$=%TVLDAE7*HWMJS[ +*WF*9\7AVIY/R@DYBF5*
ME'FS6/04K'A1,R]BQ<WZ8"1@0)+OX]?"NW=TZ&.:>EVXL*,_+.Z!.FD1'MG;
MQ.;N6H'DNXH"+KSO!![#9EZN7-Y 6CH_6]!) ;;*6&,UW5;A=78Z1S!@5R=9
ME<RGV* 0*]U1ME=(GU=D8@S!$)R.,K&=Y^W!TA:W8H52:\5-UG=BQ)]Y9!!D
M??FN<;>U8X&S),V:?N:)%J[>,V<9@.'810*E.?:/ 1K\LK-@"V/?2!C[FRV,
MO7P\_+PO!I+M.??]1:LBUE+)=,<&JB$\&3EZ* 4$5KK.QW[Y$MKMDLBGWB'*
M>3"5-@QPT8Z*-JD?'HV0"-K-"-?8'T\%S6)=1JI]+!JRK3;?7IZ7-RMS.4LH
M@9$J%9D&T(N3+N[@DNAF$>V\>;H+!][";X$"AU/+@[@;_:2E+K8N3H#<ENFO
M7< TR/G%9 '3&>O)7)L9SHK9M"ST(B"*BZ.N.VA'^][\[CT3BU6M-LFVCRXE
M&CE^-:BDT,M!)(6.CL\O3WXY.3J\_%[X,Q'QXIC).5;I14YO)IH^*BM"3B4:
M1'><"3K*H3?;^?&>B*471#)@)@;\U,A4?44FJV,Q[@MKALV5$+T3%1H3]Y+V
M5^DUPW3\<'YP(\?2TRI?B,+*!;P;)NIAM_B302!M<8.K>8Z^2:6OY@:^Y(\^
M;*M$69?C(_-;G@7]26+"^"DSH,!,_G->-I+?7X#*G3+ RFMUSFLE>(;<$IGA
M[\39H<AX63RA%[-/0=!#5>;L-P7O%,Y1V%C=A>%E*0>E=%X-0ND<7QR=G_W)
M,:OW[X[?_GI,&>EU)YN_H1*Z+"-=P(9+.,E9M6Q4U7_ 2WB@JQI6%+&EFEQ6
MLFH\958[O 4J#7OK\HK5'_>]IVT[*V]TY2E+A[3DK6YTFR4*[L'1.,AAOL"0
M:EG57.$W N7Y,>XI5Z\HL8J0)0MOZ3(18J$%UE3 C1#%4]Y(TI=4;S"I%.+/
MU4S"J]9&2EU_AW!*$S6O,?/*FEI@*J2S*TWYML3:?6UM@G&>7"7,8D\FC#?O
M6-*_"%,03$H35$LP7 :?#Q,WS>H:ZQ$*RLW6S-//R;_QG$&A'C.DH6FVAIFK
MQ5MV:/E5!8P09L"NB$YG<11C?:E$)BQXP/9_EGD:AIH@NUN#!PV=B*B%=3NB
MO\Q"] I[6L4IYCUT>W:V8?!-#<].0(E<KSGOUZ\SF247D1^E,?R\B"0&*6MF
MU[U=DDD;>&*K,$$NJ'FJ0@[]>Y=[I&U<P<3-*U0Z5PIU;$>;+Q5[_!_<I)CC
M2$U*3C;RB@W6MH+=*Q+RL,WQVKVI?R#UX59\O6(U&BD6,J-!NR%&LM&%U3HV
MOV@P[A0D[IC#](">>D,^@3C%V2'"MVJL/7MB6E8ZUW2A*T63MRU8#T<@U@K[
MDV360F_?"O6XRH95C_5Z&#;C_QS]=G@*EN+AZ=OHYP]_/_MPB4;CU^_8N#2:
M5R"S%[L:[YDTV7?#1G-N;T!E*CHUV#2TNK)$^A8;.BY.+1*Q+/[$60*FUH4Q
MS@$(C$0==NJ0).W-("0-_-8/YR>7)\<7T;O#/TG>SBY_.SZ/SH]__?#N\/+L
M_._1T=GO[]^=8,_0[\-?.2S\*B0I*7.(^#G7KWFXBXP[2<-)EV=$;L!'"!;$
MM (1>""8T(,$)4P'+^Q#Y1QW0F.TG'LJ-(LY-B&P11>>D)#N%3:]*JCT"TZE
M,ETXD[\=MGC 6 5!]GH"%B:NR0 .=%RDK5S8F,$V5G,0$8IT8(/MUJ4^JX9X
M:-(J%:&U7<. KR'#M,97H72LC?GV&RA%V3+'"<7J%32'OJ77B*;M<QB^$-LT
MD!5 .6JD(D&"5:3=A)0M6$'T"9/,](P-ZBI,^23';_I#9;9NRP2T;:\/$E;M
M)P- F+A00? ?/'-8]\YO*I?Z:$D7<'-Q-1%J+\2&,2BLQICG<A+TRNG*-V0_
ML_\=+<8K %-:0$RXDOR28EC*6UA326)X:+^QF+9W-.\B-TUQ>WHJV@$<F.QN
M-C,A=+JU]CMO[24[_CZ[-'#QNX+M2"(,XB<KS">X9BK+YUP5FH+A7P[IQ#T8
M1@ONT[/H[.=W)[\>8N$)$I8S6?GW<;2"BI[@]O#5L(F;L^)?QG)D*H(YL<!<
M$M0?$D35?,S.I^^<D6(S:6(N#)Q;F"=35D5(8<G;WE[@3@Y;OCS)9J0$PD-#
MAGX;.18I!F1[$?_XAL],&5H+#W['>Z(?: )[_55H]'JF$6#/ZWAYV4'M\V'T
M[CLZ.W]_=GYX>1P1N\8A%YIMR\ONN];#*"\[!!-Q:K&SYYIBXB94)IP#HP5B
M"]&&*=<0&[0%MDP1V#&WL@!5KN!S4\1")?M,1Q=CXV1K8!L:"<-'U-;9%B#9
M HVG94(I%;9;/'0]CZ?WN>QW%-@\ 3VRIM**\SP] R(M&^%=J>N$D'@(LM.&
MW1R[QK*8(>8:M"NE-E4":#F5!6GU:>GJ>1Q IE.GUS],A_ETSJ7K50=#[9V*
MA]S/WW?KQ\N)-D>^<IY0=Z7:B;B=;-S>.52P9?8V%W\L=K?(W(U$YNX_W4)S
MRZ\%S?V^NY>B1E&>);!:GSB%06DY/$3Q&M8>I&5 N^RN/@VB'>9;0G3LC#P&
M6Z"P:PY--Z+8QD=&&0\(?2;XI#9]8;QC4 J835+760RM%AHFWB!=E?!/\$FD
MT+7F& L%Z3 *2C%$%\3S.#Y*:SUQN /#8CK)I ,D3K)%9RE7@!=:+0$]V/.G
M;PZ=;Y5J]_(J1='%I'T U5A*-/;\X#D<7/Z]AGT(;U)7UTO:"".8EH9*?.ZV
M.4S&]-Y[0O:D=E4]2D+]" '"<8  9,2>:HNPF6]LS%1"DY[]O"-L"ML=XNZU
MPOH9PA;9I'ZXAQ9VT5-?%K2R1CGDGN66Q0X_OHVYM:^F]S.]DPCC^AY-'?X^
MQ+JCB+;Q\&-7#=C!P<?]P^OMRZL[B'W[ _'^VGSHAC+=K]%CEF.J!7!ZHHY;
MT%K#V#NOKC/B#3:L#[)'G?:1=. J6F$O/Y<*HS#G-9P:]&_OUZR'2JO.0.Q4
MU8+)-0'I#'F>-XBMLT=[Z>?;ZVA'RC'41P[6H@^;),1SS&(F60Z;5ZN#N:YW
M<;;OJG,"GGJ!IYAE06@0O->4%T"^3#5S=GJD-ZE$65/*R!%=F1.5FW*>"XN,
MH07Q.HP9M6ZR0>YBKHKAA$K?(#VYO.:&;(B7<4C()2$%]#<MG-+<,BLR64$C
MF8G*$\SN>L@(;%]9I8SA#H#[06D])6-7O*%B+%<A[T=Q(0,"BQF^1?#2F."F
M(X6<+%I5!8X ;R42YJV][!\':+)G9;^.P/G#S/C"<:V'"HZ.7=#_ADU5'D ?
M"R.KJ>GUAF%OB=<:4;:ZQ;*PMM71,E4(9H)4PW/33M9,O;HT(!MJC/3)KT5:
M1#-YRSGE[:56J/>]Z!=FP$5>6MED?*#76@)C2P=%=@/K*R=5'NMN5ZKP%T:2
M/6I5,B.Z:V;N/9  \W+SDQM?<HS/(10)"<XXA#E,%,TBSA&5(/KQ'[NW^^H1
M2^JZ*1%2R8HCBP4:?T)E9>>SW^+U]'X7XB#'%G='CZFO :P0F9!+(K@A$?#M
MST0$^+SF'#PYDJ"Q03;@E&^P/H;BW*QAQ(8W9P W8S G#+7'CD/&^B4#[,-W
MKH)QF&U#.7-5">)%4#H^D7Z[15VKV_<M;598/A ]FVL:,XR!!,492DP'/*;#
M=SZ=!D9(?RP7=2\M?HB8]9&?,!W8<*)M]WF<FQAQ1/>]*@MILNR:37I IE9G
M3<K_&YX8'"0.?L4D+>F=X1V/WK-<9M(R2.M/LZP*823\<-L:UP;W1YKC^_"G
MG#;Y@EE,OWI$?!T9KF&4EA\&<2V7TO(TX1J;PG"[JAX680*14><6IZ!0\DF5
M!;Z\"O<_L1T:K+C<WYA=/<X'%O"@_N2XO /(^S>P>7A42,2,S<TZA-O;Y$9H
M!*SYNOV6F:"X"&,FO4^SYQ*]&#_#AX#1%%A#5!FG+QMCKYN)0O(H,&26J4/)
M@7!LQ#R?9S65FR5D2H^D1YF!!:_&>8B;%KY=Y0=5C2XCX# <QJC+9# "%[:>
MF5GPU*VX&5O@$Z"][+6[]FB1EJ\ /R-<7IPT^Z[HT1%2TQAMYJRBF:('=%*R
M7M41C99:!*A@OOK$TBU$BQ3?KHO3S,R&#._#8+(TVMDD)<.!M'5P)'"PPM3P
M=^KUNXY#?ZQB9:CO8G6HKZ]/7,\A_A"QN>6"1Y8$67N,RE5(PVE<F;;>@06T
M?3&L.L'PJ@D0E))VH-?P;B0^D1%J"9"XP]Z^8SCG%%8(S4RQR]!LJ'0Z3[0_
M_6[.Q8;_EU"=\;OUM%3LO8Y[5H3&ET('71<I>,(+\(Z';H,,HWEW?XMV.>A$
M(-9#ZMQ3DF:=E99_@@V[=5;$%H9X;?;[,NP+7F7\<NFTT7)6;FM?[[DMH;GN
M&-4Z@;$=57OU"[O6WPF:8+9='>?,!%QL0I\@SL[JMBT&]3TH3.)Z;/C[8A(/
MWYZ])]@QUOD0*3ZV03X^CP[?OS\_^^/PW?>!0K[L1:A)&9HI*3=E&2UXKK6J
M_8!YS/'VNG'1_J#Q9!T;XJ/F1N=@<^[L'^PBB1#H#-,U! \?2X(D'$9>0Q*5
MPEGJW'**66T!1IL),-K? HP>$F#T;37Y,%K87QZ?_XXEP>_?'9Y2<=>O9W\<
MGY]B1_MWAW]^'VI<&@D:TFE'<Q)$GHVUU6$"88/':W3$3I[]X*VQEEH132SA
MW]E_NDMV?^T*Z.^HLZ5)1MAMR@V=F@S-,LHD%:4QTEK^$M9;RS>S2E]GY;P&
MI\E\RX>:./I^A O=E@2D*0U*VK(J:"+?VUR/O%H9<$#WU[YTSSM<N8:S8ZOB
M@K#G94]?K@8TT0VZ']+N,&M.SY!MRT7*W#6"2G@+I]L-9C<1CR.5Z1BQQO(@
M>#VRL>F'%)?Y4H#*M]5*P^@C>_C[\>E;^/^7T=EYA"KJY)3+W$13?1]ZR>44
M*6GJL5\Z)8+6WE3[V\K4ADG=P*UM0.GG?JC(P%?:W0M*G\5*XIM"4!*VD/9V
M^(LW&^C]KY%>:/,F8Q,XAEC(398RK*=INT\!OBATJ>)E6T&@'O0\04?5'M-D
MBQUD<_FPHG7S]?=3[+&BZ#V$.>)4U3:!;?,7"&YQ1 ZF9SLJ-S]4K>QQ/ZA3
M=AB]#4_/3H__Y^C=AXN3/TXN_XYGZ^5OQ^()X!;X</K+A].WQV^_HR/WE!.I
MK'G2TJ:IG>#Z-GAL\H.40.R(>'F;PF+LA*@=--.K5L0WN)\%]%FC%KD"$=]@
M0L7N6*^-&\+H(WDLZUG,0N"K=?IA8QY0%[70L%45YO68> +3N8WCTT5NR;OU
M&,>GVC0TAG49<"YUBZ"K1V5!J""'KZ$D4(=5VT:;@W&).R.+=F6ZT?M^2!EX
M)=3< [-/8!HAWP8EW885(1X&1?;)Z<4)!H0OSP_?8C#A_=F[DZ/OA)RBTZD:
MR4J]%L[!@4G<, N/++ $65VT77ZK,#KT?0F>M@3A<YD>BZ3MQ)H=[!QN;+(\
M"$D?PV9 !>5Q_*0V]Q-JK4'MEF%P.Q^^>R>D?-'%AY__^_CH$@E=D"_M\/3O
MT=&[PS]_/L3&PTBG=G3VX3VYQM_3ECITX1_;5:(0[Y.";BR_O4P!2:YN&'U.
M9*$SX\QZ"-J=;->5OC26UH"3D)V'9+6/;T0Z983_Z.)*77&D:5RI><K^,MZ,
M3U<XO:EE-\:XY@F>IG +ANI31I=:4^$^1I# &+S[(LFHPS=Q/#'1@*I[D)5\
MJB]#56()31#'=&1;=YB8?FW$3RRI/@?N;@M.X&NXI4"O[GQW9GL5,\3 QPW-
MS%2G1&-WK;*<L2Z%^&I>6BSN\'FWRW?Z6!,LG9T;G7"*(9,L? YJZU^ZVWF,
M?S\H+3@,MM*WQ[^<G)ZLF][F6VJU.IH+I7O+U)5"4-BW.J_U#8:ZL5R)MKU+
M1/A<(1Q$=QQMX;=3K9 GL"8"P4%#C%YO$)&/]$3:C!Y1EM%K;9VA2,IJ5S)*
M,$"NL\;C-!:+,E_PT6C^BO% %:+"G$Z1.&A#DAF"2#"5IV5A.0V[+&JX<US)
MJ/?XH%;ER*)L:\(*7A7$O,@UL'PU;"8X=NE@$M^2P)F]QZ]7_6%@W45)3)6X
M41F*87",PT;WO=Z@"H/-VGIH$:Q[V[ER_4[PQ!%LN]:\<:?_>\S_ >NNF-?F
MCT.?&^"<N0':/XP^%-+'GAX/5M1[76$6B7*MMW47'8;D;PZN=?,DW^4(U[P'
MEC0<E][BJ*Q-ZX2@U,TK.![IYD;KHG.JM*OF$&"/^PFD7) $R^HF/"($^FX.
MA]?BB8T_@B.#S=(_X77@LI4.+4[8>=N@RR^[-WP\UMDU<'I;O:\XB;O3(KL;
M:5?^C,_1K4#5;M33]F.'#FM7H6 SPW;6I+*7Z*/A*632XNU/F#J@W7S)1J-2
MC1YQ@UTX=^DT7MJ<0HKGA;O5#YBE/;2 RY?"% <-7!FM!\2Q\<J(PA+K/H:]
M^,C8@\\_: AU[0*XGOSFQ@O@$;8_6[L ALUSEQ&(F,:WDB?D!CTKKL=:_<S1
M8BGL\Z/P!]]VXOMGH(#GD5^HT?1=PQ)061R%?>-HFM6NHHXL;3T=Z7_]*[<P
M*A?@5 E_D#"[?YK5D[( \WK!65ZJCR-JC['.2[%%P+R9YZ9@/^-W3IDN K]8
MXF5SK9EG)E"8DSK2P1%-$6I=@%4_648092G),$>LVYEL>2M',CYT%;>>-.OF
MJ[@R7;^& [E#EY/\3R)J.L&(#8KP.9:,S;DZ%45T_\WKEY0V(628W[C2[WF#
M#<GF^17AIAL+*QZZ!*\G]3D "18_9!/$^,B'W#B?*\#K4!U966M1U-)[&3PE
ME<)![_7:&?LQGZ#5J/T4O2SB*3"^%]<XV-YIDL$;N.2O)]TU",D'.:&8W28(
MO\3S&1-V5P=I6Y&XSHK$@VU%8OFU*,_7H2G7TUQR")IR/3Q4H9)\JS^!CHS!
MO$WV+"5S+Y/KT$_L_?7T7!N (!;HTZNUIU88FTH&:)A/Y :*3/R( H3I#(P@
M,$L)!C]C"XUK@5DIC'2']F25YBI/CE@YHDM.[@]>]+=XEB6BW\-AL^Y=0%QM
M23*O0"83RX[;:=Q$Q#6U=&OU\2@RO[R1S*UW# <QAFX)[B*@,*'?JOGW^\]V
MTEV*7^P_QW^5AH98VGD>)LVNE*/S0.5A(UWH<49@TO*F0)9 ]UB#*8.'G<]S
M'>T_2Y\\Z[WS<O0.EG5TZ,S-'L?6W1J;7Q$*K:RDOF.<C1O2)VA81SLOGOZ;
M?9^FQ%:NUR43@U/YBKU)1X>X&O*)+I[X*$^Y@1M9V(4$2:FI\%$JV\9+Z)&3
M'&/Z(0U^BY_1JZ )\?4D&H5&-$1-'8]+03I16I1CMK BGSTMIB)RZ>3[?:>]
MQR[AAQ+VR(!ROX^!ME98^$/E!M)$,\UJXU5U=#S33!EB7Y>ASI<2XJBZUJ9I
M# &,EP]'P;:LKG@0^%V99VF++=?,A)17&,9#:SG%\A%SSRV]'V?2F>U1XNR2
M%.\(6B<T[C,G3!'0+$1[S'\E>7^/T)V9GUGBHQT!H(T6PL1 @7_OEMRC9*2%
M;!L)E6E#(YO\LJ&Y9@,"D OZ#.P^Y$:]?7HJ0UN]:DQ+9Y$!=G2')6MG).G:
MT\.RYAY;-"^P]&'65/*FC 9-['9I_.W":I315K<P)48WC-J]M2+PBCK#S[S]
MD55M7&*KNL>VC;&,4TX_Q;1;*81H]^OM.]*?:VDK$PYSE\#_=D(C.2<,$9VE
M/C%0S=9+DL:E8[0.^K)+C?%4_8-ITN%G4\R=N6F26H?:,(:G43JO#+"MPXEE
M6*E!%'OO<T-A536;E3"U)CE'N" BJ:Q)=X+Q65:U<(H$8\,;]=XW8+8SO4ZD
MF+WO40$[?]_I<[UK&@^9PZ1SD# ,Z+:IC]L"TCK EBS8R.MB9$ZS>YTM2_H/
MD/DA@OI>HMM^F6OP>G@G7&G<F%=5"9N$R7,7A#PBTX9;I >T\R13%+VKI0&)
MZ(DXU!+$*6^Y]ML4S(R/]+I6C.8U<@O6H0XQM#(FBGD;SWY/S1$ASJAQ2Y@"
MMLU*@BK=E@VWLD/*KAQ?PE@T4PNOH"8H<*ZTJLT!NX1*DFMQ>9P!\Z.Y+5?:
M2N.?:]U^G66D_3Q$(MMF7;S@!7<:AA<:^T[C#KI-U9"/&:HG[P;C5DH<!N1;
M#VR)=+80P>:\B3>4?*0.5"&ESJ3V.PL22RVU3<2@/2]ES)*C[&4?1PHD+@W'
M'41)(:P1RV'R8+'FX#6?>PE-O/SD_"*ZFF=,>$2B99_IYSNQ^2P_OC\+VAW-
M0!SN?G?NE@VY3"P=.7#0,%XL09HB.H&\GQ!N>H:5\,N]E@P5$&P.+((+S@;6
M8@6&/!2%4-#*UCZTATXC26*7L/SJ"F\3];5C-D]IF&*@=[2DWK%VT#N%V"3*
M*. B6XC-%^]$Z[Y1JWT5_I9Z,,!PT>9A,]6S XR^QVV9=J&L]MPAT:]8OF4Z
M34(4/2LJ"[VEYMFW&X4MD_WNQ](#XO7>_K9$HW<H!HFY[@"2$HLQ,!@'+W3;
MZH@E0E>K49:#N[!NL6L!^$\NSA"53PX\V@H( %$%GCRI'7*TPK0\.-C1NSO/
M0A?7:[!FGL-NMNGCY-HB^!3X6-VGI&,&)PH,;5<;K#B>Y^0$7./H0C,52;Y
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M7S=XN=]B]/OE7GB]UBWQ_9 1GVK,%<C%<IIPKDB 'HK8TK1I1B/'0:ODY!8
MR9[E=)3;<CS1/)@B(J9O+IV.AO;,!A#&\.A65M/$+.HYODPF%3,VP&E3[SQT
MO+>9F?!&@]^!VQJ#_AWH(2?6O0N[U3(7+B+F#Y3K99X]]^MEMCCLS<1A/]OB
ML,O'A,/>WY:LK%:D[ZL2/-7INI6I0C,%!Q(T/&#+W&+$^L@&*=50,9(5T6="
M4&@:M9@FJF,*--7":T5YCV8Q\T@W*-B49N#9$"J&/]PAR,MT9')#E+TKQ[M"
MT>@!J&R3T!DW),7069<<D9-&F+:15"-WQ!R^P[ M=UBRR_SFJ!M'X@,B:CBK
M*.M'HHN90]IVRK1KQC2VQ7#@A;>TR1V[&PN[3.NQT<7A>>\CZ>:'Y[A-O,:9
M^*D,13;@T/?+P;8JHW<HOZBLBGY7U4?=1'^H?+[^+:-JDP;!$)-T>L61L4_+
M<5&/NQ#)E@BM_N",H*\.OK&<VG;WFR"DF02V_5);5!.S^0A$*R?,1:J9"RQC
MU'J49]2A&K50Q =XB"0WUD',3<AR\)L0<%MY["T&8QA"1$P+B K.\FP&-UUU
M]ZAL<60&XS=CK*CHO#$:#UY&('F51G &IPHW@1'F$E[B3XR47C25AFWZ[47A
MO\LY45(8?#/G0FOXE&-086X%,44XBWF&1Q5!E@>]*4<#W)38#1%!OQ(O%)DO
ME@C]'?8K1>&O=84Y;0G"F^T[RE@)J/JC3GDSUZMW\P VF8C\&IBT/WN310X2
M-,A]EFS6/BLP*6O+X016*8DN(>R/.UT$PD4"V;XJ2W"%%6S#P5O0V^+.WJ$(
M->C:PSF%;>KA-;Q9PFW&NF5FB_EJ?:>>.\&IPW$@RU8:@*KV7_857@Y^!VP!
MJ?T[X/RK-KEX(!XU88D<O!!N :I+JB&*)P8M$&T.1-HFYZ5D&G&4H*KM2/OU
M\WLI%*T>$0OEFOIU;[S@<MAV[9):N)8':$K,3 <K&X:6$+2?+ K._!>#%] M
M]K!W**R,UB^@BZ 8=L?C.@C*N1E\.R]&5?E1%UCME1$ V/MQC970Z,VUJURQ
MRI/0MP;5&_RH_XE8[54+\]^LK&M=4U2DEVV@8CJ"@'6 LYU@N+0),:BE9HZ%
MF[7K-YLQ6-A4M[<I(&JN.L.1XWL/?DMN89'+MJ1!?*]]7WIN).4,O;:PK7KL
MP4OC%B+8+XU>BZ2-Z!]%51881R65:?+:2RV7_:=D:0<?'3RJ+BMKZIHY*,G]
MA1C^ZG7+KD_"QB.*:B)7Z6G3QZWDN?\2IU*LZK5]K&(IDI^6EB+ 4+N5%+S#
MHI(I$2]@]VQ)&"$IVG66SK$(,09+A&(I>*GA3!-[S *U8@Z+._B(;3F%1P2<
M#=*_'AE8#-_(7'JM.1_W+L^/EPV LEB_'AZ^CP@+7SRA?U,W$&:=D+=,VV0E
M7@?>DBNW!,9K6HD@:HRQP RFF57Z"?8R'N59/<%7!B6@&[JM!2;8#HI2W6_E
M[*I4.1B@WL\[R]J![[@!FL[1V!>5"#"0/:7&Y=^B'QYR4[ZORC%(Y\],K7"I
M/FWSV \YO3]G>2Y-? <^JYN4M910]_ G-=V@23W5#>CB1S*Q>H,F]EA5U,C;
M]'9$T"O7UL');+X3;AO+%T@];]0G,E5:U\C'>$4!:V:^CCO%WBK%Q= H9$-?
MS_$&K><96#F*0EC(G#1]!+OE:B-GEV=N]>QN2]K66=+V?%O25GZMDK9OKP4F
M&ZD%9N2@#%_'9ALTNT<E$6_F' IH3379$6A8M+\8_AK\8X/6 ,WM]X]D7C]N
MT+S^6I5U?2?;80@SFV_0S#J=+ UE*6)8=C]5DBU#,TEP](_&L9QNT(*@"GDL
M+DBQ0?-J'?89%B8@'&CX\UMNT/Q>$A[$X\T"]=#,JT>@KF<;-,M2[/I(Y/>?
M&S2SYR2ME$,3MGDVF+TN.(.>ZVJ#YOJRCQZ<,6A8@#?\R:XW:++!=KYI)@2M
M\Y0S%Z5W,\->;3K.WB/('#8;M!9.R7 KH>'/[GPC9S<KKC45#2<*.S_DPY_G
MZPV:YR-$J/V2ES?1CJ.3'%=:&(+'^$W@1-J/Z]U!+\+-IBT"]YFK$5*>+)+'
MP%?P:8.F^!BFMYQFB1R6*DT)J#3P&5YLT R?6*0<BO(8B<6IRX!%V5F4WR.P
MP/^U01-/R0*5-%PW1<[.2"4?\_)J^/.L-@F*=P;Z>:(5\2MPP8M$5)G+S_;%
M'/2,CS8)G7?$K0[8]!C^W":;A-&[:+ CVQ4<B3,DL4_UM<[+&7%V$Y/6=)83
M;EL]#KE.-PG*=S%/$BS/PY9VW\/DZTV"^YU,J3\$37:&W3&KC^,2N8U@4M$
M?PRN_'B3\'A',"7E5(HI$FRM^ @LP*M-PN0A8@N$&HT0BI<4IE-D5A3E]2-1
M(I--PC\=-HW*"M/A ELCJ0J)<T%Y^\H<GJ=!^(O'X/-DFX20\I0XE9J+]%,?
MN^%/]3\V"0CU<UE^?!PE,A\W"0<5:A!7 NE"K5R@ARK%MNN9ZJ;*$EX*_&;0
MRY%O$GCJT++1\1QS&\L,:[AG#,,<F[I--M-KG_NY73FY[?%R#R#XMUOD_1=;
M0'SYM0#Q:^$3V':?Z!V*SR< _\[*M5-A2/6Y=/&MI6_<"A4:$T4=-C#^E&AL
MXX*'X\Z+W6@!IG8=1^F\(N8D*MFCS_P;EU50ZXZ\\"5VES.E][9]*M6Q#YU6
MX]FVJ<2MVX!HX]:]"RPMQI8+9N_9EL=YF= *,_XE4B%C5ZH-D-M%E$RR/(WA
MZ7HF_T0A3N7?,VD9BE^;?]/W]HM9.:]!J^.&1-BV_%EG(R1@ &V?Z025OIY-
M]$T<3<D8!_E\DBOX<ZR"/^NRL/].U1R&[7TYJL+?(@$3]ATPG_A0%Y4BP^2U
M@<^513W)9O6N98T6QROV&J\28C<3$AMS@<4^3O"U$)@7$ .JJ-&%8B95X\SM
MQOAQ!;N1PM"F3TBMY3DU]2#S'[++="M$W4>W??'TW\Q(1[K0V#=5Y;9&'>\_
M+N=%RD2%=WY(4E+U&7T*NA,L3]O)E0"T7-KNZ+LQW-@L[G[_\J;H?P<A'C3C
MKP>OX;8\W<LT7+U.IEGN]TU[B60<5)RTW"'&2C1)T6*<U\QE)8=P+:?PLYUT
MEW; _G/\UR/DEW^V6=3>_/3-D5ZPO=9]'I,1^%9_ F\ICDZ*9"\Z>+K_(CHF
M)#)^@#KYFOO3WZWW\$ D<\O=W2^3AAQ[$[I->NT=V>F>J8P=;J'N5@G(*3KA
M+5[6V&<V[ER[O-,DWOGP?/"RO:7]7E(*4&- GEMJ8&'11E"[^CSUMS'2O[S-
ME6<JR;J>MR("Q VIJGS1+_B#E_@MJ_;=)!X[RFR P-\Q=/7FT4>NMOS;_;#&
MXZ-U2VFW_]*%ZR*)3IOUTRC10!C,P8OCEE2[7QS=RH-3OM&2">-##;G_YMFS
M1^6N;=.S2R23LI3KCH"A8-J,J:K]?F QZ,>BGN>-PMB];1X&_]?;WRQNLZTC
MU:ET#XL]7G7\_' \SO),^O%ZOXG]+HX4B!O/*^D:/,T::2NC:N)G!:^RU@TZ
ME5P/;VT+T_RT357NB.CWHD.O[]E-!A.!F>81][)EXGB*#29:U?PG8@VSU+;N
M,VTI$\4&^4ZV"W.)V.8\RC7\-(X0+8GH3Q@WO+5\"$.#S[-=+W9.WY!1/ZHU
MIBEAW AL]//A.#E[T4GX3+R%:][&;/'FI^V;QH:MG9<=WQ9KJDT*G>:Z^QO,
MN\\(Z+1SN&LFO=+BCL/PO"E^)WF6G9]W0XI;F;D>;GG7I)8;'A71#2K#X@K6
MIY% ;#;5-BIK7Y:Y:"BA7^FK>:XJ.M@Q:Y$5\W)>6Y'N=%5R+0?PT^XK4Q("
M9H9F)9GH=)X'DB1"'LPF; !X)_X]C"/&UDU^9U[78,G!'WJ?0Y(XDF8 ,F4J
M*N;3$;=A2M6B1JX!N).,@V_;N@+^VTE*+5U<!KD5(!(1$H UM,S6TJ?!L-^9
M1@0[DFX%LTR:7U&HO+41>S;<!6S@'/U8FIW.\.P44!V=KIG"(L>B4<F>C>=Y
M_H3$P:JKJD(SCCM+.%'](LEK[1/:(]3, >Z%7<*Q+7F#G2=8WG#5ZWG%']4Y
MM<LRK_*M9_BTC,85=\U%ZB8.2,B>Y<""U2 \#(0SMM13-EZVO7-U4\=.8FEV
M9+]13VI2*6Z]:'.5L#HP?R+T- WF!N:GM00 G3JL0<W/X3RA@\)V[EBFUWB_
M46"0#AO3BLH*%JL*IC0HIZT7CG;XZ3":-./#A49Y4\[SE).:\.J3;(ICH; D
M'00-.[;\6-),_!0;S"0S#[/<YKBH1>)M>=>YUNZ#<SR>R0+<C:,)26<-_^%)
MAM6[RF"]W-1Q162[,8?(K>B%&LQ'VU.DEA>B(\WT1IFHE*[T)LVN2G#BU>85
M6N=[,ZG*^=6DG#>^*BW<XU%NZ;1VKW0#?_%]28K,G;,IGIV\BV8@+)4]_^FN
M>^BRR>[N'OD29HC(V$0%[+#2?I:/0&8*;6]OYE5M='&*UH@;*!W\=<_!#T<A
M'#DPU23K\&._MXIY".7:J2@!\9K<PR\OT3;PGHT[BH-^\$_<]I2HEWAY5ER#
M(2E91N]'[OAN'Q.P(O QZD5SR%01CA,DAY=FJA &P%?S8 @:897D!+37M48[
M#K> BL1))J8AV)*U-._QII=T=&*-1++XTNNLICDTX[03SX(ANEN>6ME]*M,+
M>[F@F5T)"X0Q9;!ATJR&S4!AT.BRU;7&K'N-W7[<A?U]<0+5 ;^KEQM^'$(@
M)3H>"UZ?9*?TL _AIEIZJZ'[=L^WF,-^WX[.WG5'&\0""#TLN]]PKX#(<G#9
MB'3"'S)YFW@8-1<JXY[F8,6*[L_;RH9U5C:\W%8VE(^ILN'Y%AW;KUXY!0PN
M@4XR-K;(@EZWPKU[>NSU8T^//=_"'E>([L]E,5^[>7!W:7WUZ*5UL\".FR.M
M-FB_?F%=^*WE V"]9]WN2M_9>3&JRH_@^5+G>935H"_]2(-04DRH$Q[.QI%Q
MV-D@]G[6>F:NZB88E 3FV@^_*2P=<EG7R/F#P:ALW"Q, X9HY\73?]O%74:8
M>'DVAW:YK2QL3T'&SRC&B+8Y!N!RA.-SU1L] 9]7V#OP@(-WR"1@16,;_+[=
M0D%[AW)948GC(CJGY BM_+IW<.6&@G&0Z3R_4EX?Z3 M;E_@K9ZIJJ'X]M!E
M=0OM[!W*!\/MO!E!$\%Q4@B4XH<8PEQH3EQH"JK"!7Z:6D45WHTY@&8&A UZ
M=JRNRZH5?J%2J#"J@CI:-^7N-JJRF5&55\.*JN!B9NE__9 =O'CVZNGHS?.G
M!_K9\]=/#T;)BY<';\9OQN/T('GU_.#_[#_[82BAF*^DK)=T6,C+$1A>%"D%
MO? +IO&\C'IT?O$A^A5])I=\M1?_J@M=J7SI5OZ"_?4 Q]#;X_\Y.OL]CDY.
MCY9KF_4.\?#WX].WQV^CP].WT?GQQ>7A)?S!A4W_^\/)Y=]Q[,>GER=_'$?O
MWQV>;NA;G)Y=GAP=1V>_T#N<GQSA6UQ<GAW]K^C#Z<EE=/CGX?G;.QHT!\_#
M+;&&U_GU_/#T,CK]\/O/Q^?__I<7K]>FC/^/__^^S"#\IBKE ^<T'3(EU6-R
MZO#LSXK8)H]K^XTXDT&!WPY^LD&VFQ@U:[/9=J-#!LD*I +SU/#'\CK(C9O!
MM1:2[K:KH FU(:70M<57G#*J ([ WJ(4B2)NVLSRJ-<WM]T#]F]_;0A)9:WS
M*M75DP1[_,YJ_:/YQT]I5L]RM?@Q*^CN]*.?0IWV H9RK1%BH')1:Z3A^&NQ
MQMX\W7OQZ@T:9 U884UJ'BRVVA[9:O_9I-WO7KS8>_KRY=*OG^[M+_UNU6V?
M'^R]>O;\3K?]3QHR#QLFI@8U\U\_//O!6:DI HA^/)A]BO9#]9[K<7=NREEH
MP,KOG^#%/\*H7GWC>,"IHGZ@KW^*UGR&+C]/S1*MF/VG./??R8H=IFD%1_B&
M+=IVR6Y?LNA@HQ9MNV2K#$HPV6(. D?_7S;;G(5[@%7[3SK( WM@28QDHUV9
MOY?S:&>#[#P/:;E&0YI,Z)'6A<VF^^0 O79SO5'3>'[Q87VQ]UT/.$]NFA=>
M=YZQ5/@8H+X$UID[P7=4#)A1-8W"4HQVI42TT[\>N]$.N^-<A+%9B^.&OTDN
M3>^YL?^:--]0G)UG+_?>/%W^]><Z.R^?WOFVC_Q0/[7%::AD-N-,?Q KK)6?
MVW_!<G_W^VP-/YN9D%I@RJMLAHALI63CI.0/J8 [DFI;.LU1=#9$8AZYO$3X
MWV>T['<3G6\G&<>N6M;*@UV-VR>E9T,8W- W>[%^";N<M,O+:MTTN:/CS7,Z
M5JW?@28L6]-EDLR1)9\PCD@AEG&[4C-15+V*AO*E5[6(L[<7S-P2L7R^%<N[
M*ZP+*0E_/')Y$7IH/CU'MT*7';/8^7?&10L<F]A\5'/Y)M7>(YXW2<![( )_
M"]=U+ [UTJG]_*C+D-V9Y\^^BCOSXNZW?22[ET>3ZD2PTS^25L6KV@6>=]_(
M@WQ95&)RJCY_]9/?3^/(1F/N<F*\_OHGQO:17^61'25ZK_#TMX)>+X]7DS#7
M#9\ZJHD6Y;SR217*RK 8X(GBMX$@.HAE5$)"(@/7ZVN$ WH<5W#HC0GI"\]&
MAHYLC)0;Z9QW5QPE\,TH(*5 R@4DU4""FYUL3^_%>!,)0BIX23@2;;C4;RM1
M+V5L<1P/]LT+^"7W5^B>S,%A;%Z.CFMF@F#^.ACMW-2HP V#R2HL\4-2:31:
M+5G$;=/<F5MXE>NL:N;:%IH9&$K%RS<S<7^_]&9 Q6C+I54E'XOR)M?IE>8Y
M]JFB).I-5E)($^RF"/X%YCZ"R,HBIZD47A>/<Z7#]>;SNQUYE!XM]@#$_:V0
M^QV\K17!W;V(7BBOR\X>; WXCA%_6+M)C[ :>Y*3 701,;.@OX1P_:PP15 6
M<X?34FGLK ,GV19[OYG8^V%![S<*1?^MP[<*^PY<JV3!Z7O<EJ%+-D!M_/,B
MJF$PJ#9'&OQ-/'E0(8VS:FHM"<[]PEJGMQVIH9;"GRK\3AB?1L3^Q.5P4[H6
MKQC#!<(V-R_4=)1=(;UA3BJ]UHXB'CU0KM".L6D-/TMZAQ%?DL:OJ[+($M3P
M;$"@(1^CIN03E5KR@,F0XFI2<]LZJ;*1 2/?^FZ.PVT54)0"5=$4&:\R;&X<
MDES&1.RD##\HGP'V@$&>7*]SEV?'Z6K7]:2"L<*#R$+ .]38^LM:/7 :P"]H
MU&*,J12V(EPB<3&\2]CSRBV::1FI/\$8:H05PR$,*I[,%'M?XA$T=]5$L&EO
M:L?]> V8[E'?6MZ[K2=Q%XI<QQ'V4R.R,BR;BXG1*R];@AXEX$-CS75+E$?(
M40<WW\-B'FY-PJM6MZW+%8$I8F'\FJ" 6S6LF/_?_AR6VLC.[,)L44R G*0"
M[9QKM+4H/L!;R<P\JB!99;#/Y@VS16+0D)C18EYZ4' :5QHI7P6\1PL"NFLV
M*0L.0(S5)^$[C24R#F8AN H3; DHS>^0DA,#%(87U2B\##<%^&()#\_<AJ<J
MPBF)0>HJ!&9$3'H71U=880 7V>YZZ-ZY=XQ!8'4%%R5L9JL$N^/-0.D@72B-
M^#JK5?B36N5X&WPYOFT3?F]G>*2*CQ0 G<-:F^$V, -D@))F]GZ&7RQY10[O
M@Z) @-T_RE%$U);<TU!J7F&64G$"J ,B&,JYK4.Q^S?5( -Y'>0>2I^_4U@S
MIW(XF1X^J/MU2IYO NN9QH[U-);B6N3^<V6V(#FD0T1QDX!P26UXUOCRYGO"
MAF&PMDK[<U2U]8$?G58FF\T0#AL-6C%1X?'_>WE^^/8X^B4K8+EP3QFLFGSC
M(A$5\TD8[E:BN<@]3G&S# %K-ZKT#K^U$;7Q'",,L;AOF7^ ^U?;D,%G'^?L
MG?:=5D@L-<O@<I)SFBD9.P95&E>>%=(68&?/O-8WZ&'B^.$_9,3A;U'AA84V
M5#9N^6]=W(;.+(]E%D<V$]L:6Y>JVNX'4I7_F%=9G68)\V"2PSUO)F4%\A%N
M7;.JX?Y!4I)LE <O31-!+,4T]6$%^PSV,UR54P L6+-=7I3[;R[B\4YTAA3$
M0I)"9FR,Q+HJ*\)3'B?H%IO6;'EB_WQ8$VUV#Q.-:C=#U,3^M^:>N%/1[S<;
MXS)':[6ON(W"K#$*<S"L*,S="1!>/'_SZL6+U_O/GSU[L0E4"%MR@-LJ>K!L
M/CK\]?SX^/?CT\MHI[>Z_F(WNCR++G\[_DR+;<US'ST4!<( [-)M7?Q7JJ?8
MUL4_>%V\$<!.??S=RTLV;)(WNJ1D -IK6PIWMU*X;?G;K?JF)_N-OB_/&S<]
M6UG]IK<L'9\W\QSV02UN&REM9#%N__3M[WWK3$0KF@$NC\4R+H%*6KCZMU_E
MO2BZ"-#R%*VV;96F*F54E]B4!B,O[?S>/.5N:F''N#!01QO.8'-<$6NGL1NW
M_=N-?E=5,HG #)/]NX!GMAY 'WEW[?8\,IO]EM>#:SGX/B2)/MA\B?X3) :S
MD;@XE^K3.CA+8>7/@R94U".-P\5^K-9+T/7U1C.IUAUGG#Y[OA'G@N#2JG6<
M## %NU&C/NI.BS7N'PF>Z15" 72*5(\Q)0JYLR<C+A%LAMW/U*>>C*27[<[&
MF.>C!M2H35A[!*#-1>2:X9FULHN'R<8J&\U-5ZOVHW9=TL][OO\KRE,N*M ^
M/%CX@S5)85*.L8NKPQ5/3-+QQML![3D*#U/N9(S?SW-247UBN!0)X<LOB3,_
MQ<= [FR,R((J>'(N$W32Z.E:[$F4W3CH/D80(S8?/6!I[7)=",=%-$Z49VJ$
MW1$7#%T&J>B\$F;C.#]6ST!^,KD^7->H#_CA+R5^?&S%^9X8L4!;O[J#6_CD
MF_N%9%R^_.:1^G!JGAWL4>4HPE\Q]SA5'SG)A;!72>$IYUJ8RQ)NH4?&2,E:
MT)TMQ.(.IXZY44<^;H5YX-(S ,S;Q&'3W<X7J<ZS:UV1F F:@$H7E_X O*E:
M_W-.[1)5KKW?J43P <MO8!! E(^<->9P!:%$9$6*_ 5O?L*KMD+[]80V+3UA
MI,.MJ>8)%1ZXB+ LFXC3TA."<LO84YC3\YDTHZ0$;ZCR.N(\Z.C4SQI-E?Y]
M"NX!V2CI7(>G!>%!P Z@7B2T^5-L-]T$S9;!QP#-48]50I9)JRWL$D5/JT@_
M0] 'IN.[TQU%)[?81,$Q8U .]5V?;^P6.MP\1ZX[/SGHN1R;T:H%73&B&8'I
MZK$)[>-*K.D![VO</A#QUP7)GY)^+FSJB)A:_V] @.E^&VA'[:[#ZNE/$?M6
M*K6NQ;DV_1U*UQ6;#PW70ETNF:AK.N>BL<IP,U0?L0N$RD$&=KSFM.)QI=S@
M5HP>-27 'JZO^B0/H^$0HLYO;KL;MG.7'UH<6^NGO5H*C?1!"\UH@X2&U9R8
M/Z:!,*URG^<BVUTZ83,23AI6A4H)L52N[;"T+VZW)MYQK:3Y?BJB3E(.P(HY
MTEWXN)Z/$8JJ+2C4DUON-E]_N5R!.K[T7H'C2G(,D#;7\#?\T&G5Z&:"K^2&
M5-O=YE2_CA!T-9U/:6_XF[0<@5 :$!]WPF:L/74QYZ[4B.Z'G[E+HY'*R;.M
M]%1EZ-/2*L@+VV"8>U74! PFM6$WXP4GBR1?40NV47NI7ZQ/I/&7FY[>I:6*
M.UJ1C&&8_C*HKDP%Q2 F-]^Q&T9HJX.%D-J]0VD@UK("$\2FX!V)+07KZ=\1
M)9B1Q&FKT+&_&%)?:]3$LF\0>VU/6#0VY%%FG('DM[#!(JHF'ONXK,)?YA4J
MDABC3^V>YY4VZ%9J:Y1F8RJ/; *$*<Q><Z.U=^K!E+$-;EPG\ZEL5C*@<'F:
MEOW6&XZXS8S#!DJ(\=2N4H2#3*[JU&!U?6UGE10:88*G7[(U"N["1]75:+8%
M^-I!KSW8G6#4+K'X6V9\>]YI3:Q9TYVVS@*V;W"/1?FBF.$*3Q"'F*@"74N$
MH?L*D$;,U_(!WBI^0R"[3G3*QT6E0.)GD]8)B6]8Z3&6W\'+2=C"4W*!>@NW
MWYAJ*N":J08K<Y+5)/MH"SA5[@H9>DS '@T]I+3/L\U/^YR6G$Y'@<421T+O
MKR7U(Z@YK@EMLIPM'F*.4+:#'96]\\F+/3^#/*$4V7# RQ=##_=4E-BY5%?,
M@C'VG2>XQIT3=G?A<,+?<U\\W HF>$9*H<16IIH-,1KY;5G*+?I[C>CO9\-"
M?V]4#?ZZM>KSS=>J;T4U$"[U6N487ER+4@7/R:DI5)XPWEQ5@J&=J8R" *RJ
M8GLI>MDR;),^K<FVIDHIX\^# DY4/:$VZG2#W=AYIN#]IY(?"<WCIE^OUW=1
MZP@-P1^O&F<ORM6X5F*F\842S.!E(\>(GC$@^^+%YN\$L"\NI<)M+1O@TC_(
MN1P3M*;FZC]BS&%Y,=8SU>-C?>!503%45T$:1S/RZN ?D\4, U=D+<1!& L#
M7^AQ8X.$(4G2R\V7)(_/=3V8NSXN)S$A#8-(UN_6F:IA2XQF>-30LU(U109!
M!FV=>(AX@TO'.O,,4^.9$7@.O4WA"('+I?JVE:G!2"7J3>^^V70*"AJ&DB_<
ML. M#96$NBXS9B>%>Z7E?-3TV=2R:VQ(2]!$"0Q0%[4+U>$=\]*!NLPP8>?,
M,*@U+S(B-6DUS @)X:3FFJ-;X@S""4>GD'89[7HV;^AHH0 <'U4^%S#&A(A$
MN#))DB-&!VCMGQWM,#;YOB;4;>Y+L[KLYC9RI,=C+'J^=C&D]N^&I"I>#4!5
MJ$_$]D9PB61-4,9;@X*5=D0%,.#$&S C.4([R+JDQ&A1&^\O]&*-E1:;RG,R
MJ.#6A;8XRDH[G1%NZ7*>IX;,,%(T*I5>P[%6>1"9/@47)B]PJV;L$Y.@^^\1
MC!UF":M-6@\.:9OL(#A"&A!C2)92)<V<>5LB.)=1&<GO@BDUG#@PAT/:;J\W
M?[L=.NE>&R+^,@RR=\&"+I3+YF"E;26/<%7 KZ[*:TT4D\+AX9C!?/BG5>QT
M(M7MRI5P[W,3!T3>!TK !V*!G,X6_AT"3C5\"D5]D;:'X/86Z2:ZI)WQ2!3&
M:Q'H0?QM>#-D;L7YSE1E*4:RRGL!5@=P>[@_J@@,'B>)GC6UFS.OG@>/21EP
M+ZFEP_:+E<UOA+FH#NP_>&.I 1C0!GVS^1OT"',0U>+)!7/V)F1Z\)IUR:Z_
MU;9=-6#80M]>B]PO(6..;G]3()X IQB/G]6[ NYT. ,;.<T^18==@/E&51&Z
M@:ZQHFV\I-@C8=%&900Z$:-"XH?!8H 4>9.,Q@"X*7/TOG!9K4'P4#5RZTV#
M_EY6&D^O3@[<Y+]K%E'VJ63:XMMEU@,4PN^#IBP8/$'[SJP!42O!Y8MVT*\-
M>7%'M76IO%2K/-$8MQPN[!L:K!V8M;JND74._6DT$VFD&29,4X9'HC.:"[&6
MQ5SBY6.5($J6(6ZZ3;#E'^A#E@OPC_&T$"H];^K1A*BN!69JDUK9E $C)"5!
MN%2,[2"8U@&@!_Y[?+>%SYIOMI(6@25OUHF2P+)QGEVF#-T*HQ[(\Z(W;*CJ
MP",4@W/ C1^W64)CS6K3UP7<IQ)^,B2[9O_IN@V;@[W]_=6&S3'X>K"*5H-S
M&<,QNHB)JQ]=7T[[LE4VML3<]<XFWB_\6BIP.!RCGP<2,VS G#66\I:)LTK
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M-+L-6L$W4AYP9EYBL?;MT>LN8+<I9S\^>;;7TPEU!/X/+[?8*-]^(2T()>Y
M3TAU2,4;:H1$$4>Y9T F+1NXKQW?%NF\F4CGYUND<SE4I//^VJ'.MQ]@YZ:_
M0N2W2UN31\P%QGUY(DYF!]8AI3%"5)MDOO4GU&]9LZI%6?TP/<IP( QGNZ4!
MT?+V96F9S.D\'O%PU;2D-A!^[B8.C]&>;F14NNUWL'J8IF#W2JJV4%,NXME3
MB(<%2Y_?O&F2367:;R7W\59HV\EIV\EI62>G/D%?8V.GKPH@N+6GVQJIMUO
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M(\.>_&!%D.K;5Y4B[3\[:=PT27!EAK$QW,32C#89V%V@<LA"@ +[&I@Y[]T
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M:D)>"KP.S- 17G6% 9MT.!'V-$EN2&L<D98"W>>#\?YBZ744!<A<(8K_HR(
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MMQR,2;/^ZLGSS_[A=7@P)E%#Q.MB16T>?E0>9,,Q%3I<C_(U(404#BTR>_9
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M73Y:OS?6N@1@7U!-Q%>$)-%>.VE,5$&-8]Q0P-EBRV;>U'AQ6\9"5O"59-[
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M^6JI_8C>2,(80O<UA.TUY35T:.&]Y3!,T",'UR R>X=J/&QB!>,&7VNOV%R
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M(#Y+,THV+&#Q[+L<S@+RN6CD4FU\1BD/$:5\N%THY6$!CC=<$C\:OE$]%=-
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M'O61V\=&T,A=A=-0JX\T6KS90XHCTR@J;&3XQP]_H5Z3AS@L+)3#]*=/(<B
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M/*NL3%ZT+)-S 7Q Q_8%1&]CW7'VZEN[)P[QV>V<=U,ND4?EO@M*L23,WDO
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MN,J:H_((7;RO.!%YF^5IY0J/IND!' GJO4O&U[(LZ'1W.C%F%X;BRP4*^!W
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MVU(S0*-&+V"8ZVR+VZ,N$UT=2>4;#S@%DY2;+=P&8>HM%ENV8)SIVV!*J+H
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MN8]=J8_[J'+T$]N:J'#DQVU>9HUZL,7AXWW)$E$]=KL[&0:D: 5=?0!_^FK
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M5,WT7R=MTU<</CBM=%R3QL6</VI;Z@;&]0@*I*K_)%@P];<>2*[8#NM+TZ#
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MA_QUWUP].QCP5\,&C&"&S *>^[J,WC"1+*4O1ME')\0*RG7@G:80QN'D VK
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M.A,UOAYL:KT^= RK-W_:^^)]ZUZ:#Q7 ,9'^-&X$%2JCP6G7LG1.3!S<[;H
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M$>6:N^@>F3.% PT!CCH<QF,7=_8Z%$H2MNS%>D8R#:QP,!/<MFKG#6ETM+$
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MUD?#/_J7W8>C/.Q&'1H@7FW$D B6(J$D<2(0M\,WM<BK*4E)ND0%A.B)!)&
MX2^\.I0]K4(7SY)82Y0YN\ "Z*H;&$.,2EMW< CW+).9<*3&.&DB.#J 60:'
M;\._<'/Q/K_"S+UD_ 3R2B.S+6 .M+)0J8O#-8GOK<C1-,D+B%/<QV+K?L'4
MOMB.BT1L5 E0*+U[<_#$(EJ9/]:77?,7\@:,A(U#=02C0^MA1IB!XZBX"Z(Y
M-D**LW&\G%480#5?[AWN'>[J8U[/S\&L%[9SUFS^T1%&6:6,MU7+U(HHJ_$2
M'=?6G4BQW1@6 =A[[S%:U([=;"*$ TJETJVN9<Q^&75*NC:8#'P!QB>^#&1%
M:J;MH;WD1LD,3U*>!9-JLI'F,9"!)9U;CE:4#"G^$!E=I'P@T#.T*SZJ3./D
M<<6X---6:SK+Z.TAO%"/S2#6"6BD23:1YU;=.L![!>-\HN,++ETL(!K3IJP#
M5M-/_2M/L&]D^/9.L@TD!D>,6J"%*\, Y&./U3R/EBFEOO09SR O4%1CC+28
M),4"D9@A\E<%Y*K, Z@+CV."R?8531>0BU,TSHG0+@,=Q^OI@9-UF%<AOPRZ
MNC;VU0Y%VIWEA !;(8' 0\:^NTWNJQZG%>]J5)A"P L:#B9( QHJ27?#JIJA
M&RD3I81R=3F69,Q3LS @AG-\IX+(XSA9H"GEJ$&ICFIVB>P=>G8R1X,<[\E?
M)P6//G$,*N7='<GQ+2ZRLV&*:TZ*\"TP[D%Z$+$TBG&>C# /Z81^Q:F-H=PT
M1*TO%@ 3;]!TEP@<-)(E0N1F1I,M9*;D?33^<IL#LC+V#!MY<CAGV;"IS+E"
M$/:)35P)25O9(^(%C9V%9Q7&'O6YP+(5C0K)\G0;HD2S7?5RBF7?;&&Q;.L&
M;R=J>.2T#/+^4;)[5HS,L(A]K^2S6: ;,:J3\3@'R_Y*'_'MN#SKH[/6"3?E
M*464(S/R>')LDC5A258,Z7RG^+D./^/A$DH' L]A>4HT1HP)$"N:B05, '.=
M2%B#1J_J!V (05F*HY9S HC/R^>P\BC6/[3[ M&), ",6.VI[/4 S))V^H8O
MLQ+L=SGE IBX1%>5K%9SE'0>Y0 %OE9HC,&C5J(JPS+W^,_E)*%QBHQD"B^.
MDP=5ZDB/*13"<AX]8$/H?Y>=+P('UNS$@<T8Q.TH:.D8O-D["';D2C32[6ZP
M8XP.,2[>>ZTN-[ );_((^EGS+\7N[L^/YK:SM7_[)XW1EJ01'I9%&BMTM*OF
ML.;W&.!"P.TU9Z2.Z6U>KD35X[29-.%BXF0WD&&.1V85U"4Q@*$/L"#9VDJH
MDZ+]VM'Y]L;MVI7Q2P)ME&?-#G0<<9V$<FJ;!C7K($;)40R-HHS]4%2R$,%L
ML]!:Z:M@1X(/PAF#;[>D$@=^<8<1]1@#+.H<Q:N,$T@(WAU/I"$#<28J1N(U
M=?]<Z$2-HW3DAJ@KHEDKYT-?5WLH<'!<#U?:R-2O-7O!##<=89<A3L(-=8PK
MV#F+ITF*]P4 6/F#5\#'@W@A1$ \8-=D\:-@YS(+KM",&6#1O/7U<;!#W\E#
M;%<_[FVPP[G/HOY >PNGG_@#).#38IH#A3_$\:X%\"SSJC@M3TY&K82O,JLD
MQ=0GD"D5+]%/(1X$FH'7M/8I(P*K7?\8RO?H; P$[_13WTB*%KO.>M[":C",
MS*?- !AQ(JZ3YQ-,08*((O11PG\;FR.@O-H,_+)IJU#+C;UZ!\2^@K$UQ5VR
MJ-^0=Z#1K-\<P1YB8=0U#WL E6M>\0JNZ='0!R3AU;*$"='P8K;N,QAQ']2F
MA<%M+PCU(4PKAU).&6P\V!=GO!N%_U>6B&?:F.ARN(6Q3D#K%-S?@(5I7W@$
MAD0MI)Y]W3'LHU7>97__"O>9BJ_,;Y ?GQ,O,BEWA&^!(>U!C,%0N@!83%TD
M5G8A7C461$GC;%FX]L\CU5MKX@,;; ^UD6VR3:&D0CR5.Z#V!Z>[6>:(\F 4
MI5_RY:(<KRA-@)6*S@%@S//0^O<U]!Z92=+A$NP*=\/AX8=<Z4GY95>U/<7@
M<7GZ>XP9"%*AN$/AE#+0U)[69%"$_1":4Q%@K0[,?ZEGQ==#HA-5=#X+[<MO
MEX8N5C$>817C67]X_>FF!["W5^>?.E_#V)'X<%5SM]9((\4$^WMU-QFG2T.*
MA$'%=H&!5VI.D VEV U&DVS$=2G+*![-X,[)MLM\D<>EZNA3%D+HFE1)VCP&
M4_>53J-DMM3PXCV:DBN4VU (<8$S5[* -.I2^&/)7!Q\>DX953I#TUFQI%@=
M93.A0UF-K5[3:YJN5)>I7(@>P8P)>)7Q#ZMWF.QJ(E+:D]#;,<0M;;(P*,;9
M0M!>4B/4DX,5:)S;XHK6GCG7@>KL9;7#W*P66-)TI2*:J7H%-A2Q&Y<^4<$D
M>3]SO<9/:.!2O&M0U7TSFP>P'=# BZ\JU_91UEA V^RA5?%D67XZC?-<)T1.
M[Y)XJIF_<'!=#!R+7"F9NJ'3\F ]A"'EY'':=3/U3XMP[H7,NA#':QESC7,T
M,J32>VP1H7VYHH,JVRCO$)Z/JFUE)Z(9O)%&@WG6=?M4ZT22YU]+<2Q,$CWW
M77!ANFRG28J"$3C@0BAUH>^8G8SJ'[=21YF81\(O YY3/U$LZ 0-=93Q3^/5
M4?ZP5EP5E\43]/'&V3+GB8Y<0C,LN=3I%&9\9'F:1':'%]>(/T0D==P^1>-%
MN+,1)M/DJ+D7LSCB,8NX3G0:5-<]IYNP!LNI[Y$B6O\:EHWNUGF%%/BU5FM#
MAO RN<R+@NX$:HK"&T,>SCY=L%_<@I:L-I1CT%:/]L'>K1(P1+! BU>0T%EO
MO196V\,^=%TG="*[5K'.E%2U@VDC13HJ:/Q=60+^C"&1V@ALMB_EE!Y3E5BG
MCW6>F4U]6;DV"]'<S".TDMV.K4UU>5#2*^$[V-85BK:]I":-MG8!7?1RC]'+
MO>@/3WOGYR>7O:M/PTZ+?4? XG]3<Z/.HX=-Z-:+>/ZP6<NM/%CD?/+@9,LL
M.W'<;:'$A>9A40,^-_05)=8I80\?>6F3.A.72LX?I%:I.?A#53F"MCZ>E7AN
MIE,AS10:GD4/T/>1I.-$'/9KCK"74VK[UI?:_G@ETPE_XT0-<]T$#:-/^%',
M<V;1/1::PJJ<K!E";<*<.& F-6-XE2[#<QTLF/D"P4CU;%NEK^ZS9%)3]>:D
M$6*W,TZ.)W;"5\];9TBO:LS[I8),\1'/1"43AJ9HTJ!C3.F.8)TE-<$8DXA'
M,&T9$K7@'M T3FG<*,I27:CC+0#2&Z#G03-,C.L3>S*/\UM 7!#Z/;^-4IXK
M'-)R2/6%'"'+M<W&"3;V;(2:!S*PUR+(/<+6#.Z[HY(2/B4HA5-4?1G<'7/O
M@$C@UTPI.5F;N!C%%!LT.L?!0.5$-GQ(73!H#-)4]AAQ?>6=X_AI[U!G#QHK
MOWGR:^J%CQ+B0?8PDY1#J*6-4<QG\ARX#)LIQ^+5,L:*I'=R4STUC*Z3[:^<
MEC 0(,0 RF831ATJ$J$>(D'^Z"O-LKU/Z*0'B*!ES+QK;E4MTIE=%FU4B-:(
M@Z,)..EG\/2.!LZ E+^BPZXB:$2^,,()C+-"C]$6KV%Y[O%7 ' LA% U9]>.
M(?R&,>XZM?)$UDQA*1@] .W3<7.[$U[V)7;%M>-20T,Q=>6!,D4L\% B9P*H
M^0*XC> YY5D!ER4,IZUEG-0/="&FZY*VH]C46=JWMOK==-=:L020V43\7C ^
MW1Q&=M/Z2 3$$J"B@7B;%W.?1$$,:*%YEB9C0,K!-QBMI!AA$ D0.@K&#-_!
M$Q^GV\KWPV3/%*L07^V:3=TPPAMC!E1"+@YB:!^%Y<SBLJ1C2=PI51V03%AQ
MP0YK GB$("L4,(5.4"#- F&]EX+FPC=)ON@3#+P?J"[ 5$"A"@SH &%<3#P2
MH&.0/I21D8<LV#FTWH'[N),9FA"LP)V#F(#@"?$WGDB(M,7=JD#,)ZBB0LI&
MDPG2M+@#^+11/,L> EG=12OG*TC%XSAC23QSEV*Q@08$ACX8(;T/CE0B/#P9
M%F':ALR]^HYRL\F'A7"I9&>UV4W/4/<$OI3W):XC+B.LJNJO'V O%%<V*\U-
MTY#0*2OKST.Y2RB#6 [3I#PY/76>3(4K#-()=#H_/VU\[P54P:2WO\SB:?GK
MX>'^WJN?_**'K]\%/:A$^RW'$JM[,[6Q><L="CO]+A@*>^,#U.@ P&L8G)X$
M[X[WW^YO[K)/2D:EI6*JDW2R"DZS-(\FSS$C6G^-'J@0>H7:*0+K"?_3A?@S
M!*@BH2 7J+L9,P"U%$0TP*?5S>BLUG;EZWD!]P+^S0(NJU]/"2!U<]?];(G>
M1+7T8,OYTUYD,RT.*G5YAL4A?]!/Q\W65>L[]/KH>%]XX\+8A^C_62[,P<U=
M+"B?LR2^9<5S>'!XL+F+=13/[_$]Y&FC%?3/B3/N6G 1=B&@Y>Z4.P57-*BD
M4\+^;(VU:8)N6B662=*5%ZBWFQY35!_B]"$9?Q&;=B2V[K/P^H7==+VY@O5V
M_\!(8@;#,H_C<G.7>P&HF@"7_>\D?I 6TW%W%->PC*=1F@7_NTP /S!!?74A
MA".*9\'[/'M(MUM+=2-JW(D.U\]05-A"NQ0$\2HI1ZQP#+!<F>!F>" 5! SE
MD"::6B-.ZK+0-;XJ/,QM@SHXS DJHU^@DHBETLF(D>DT9#ME*A-$@Y?1P_EB
MENAZ#E@> >OG.O'5F!5QCH*(7I>S*!&7[%-7Z1BJ\R.5C()T*-J#94V_@4X#
M5Y9">45^C)N#EI,F]+JIWTD63 )<,8[\)$3],D+W784MC:J7 D]H1#)%X#KU
M6G(&A_, V5] 4=W*]UW/%G5B?,4PQ@E7V$K23E<[L9]*+NLR*P0?%!R&DUFX
M'2@,DAG5"PLF6::J%8:&S[KUO:'5_,?2)WR4$E.NX@<&9&04\ /H]D8)%]X=
M*Q%(8/5245SGD&=- :,=DC?3&7;N8OF#$.2$!C.41E6$:K+BR7T5Z':KSBR'
MI$C:B!$/7]17:RL!G24C"*O,5H:H)B!DF%7+<#;&*M"3==C"J/1.1H5\2_$O
MT-(C&.A0%#"N2(_JT&U*O%'<HF3L%;4M&9/,Z$W@6?K7YF_=AJ>IFC_!^R U
M%5+2I 3SET1EBN,O6!<;03(:X,'4'>K1G/!$H!H963AO/+2H94I=TFNQ)S>R
M4(%Z7982"H7JD&*?.B+CY13YO?-%?C_^L'K=A<-*&#%FJ=Q[K! :)U&>M%3O
MT+/1*=@V-::2R\I[E93''GJJ03/>A?6K[H@W6Y!X1)S=%&]=ZM;MO#9[XD-9
M245'CH*=JRVK@%8^(?TQ3&),>6C$XT/C3? 1W6_8- K8@/1 G=A,M9HJI:9Q
MCY"YMYC#0-?'WGQZ"( I%QG8/)C<BG;EX>*6:H$=2].0JLX%-!_#60(S<R5-
M&,]OI<  FC0XM<B.=X,R^A(;QQ:?#':[K/58.4!*=DR)GV505:/&;86!['^B
M'NPRCZ EM\R$6[.CAW(!"!:<NQ*.H<Q"8QYH6)T0BN9$F8LC5:-Z[H94>HF3
M<7%D70AM+]ETRDU5<"Y0;S,7N4:ZY8KFBF/C)I(.Q[<Z?LGCE:I7Z629Z:/4
MF=FK=,.J%J3= 5R?PV8PWD]AU;:)^^<$PT?/JV\'IY"DNH%:%#<MRX[J#[&"
M&BHD0G=4Z!K_B:Q+/(7= RQ3()EAE,3E Q0R-654<:MHG>*OKCM0;[IP)O6$
MM2R4IMHC+*V], 87;T ]NCF2#S1R[^M=,DK@:,#*:6I50Q 4A#M58[YA."J,
M.0AU.[?XMY[T71D$'IIUOU1Z+ @E!;A0_.OZ0<42*J+B"?]I(.30'%> ]])+
M>.J=]4O#IU?2';,;@? '^ #U.566F=&6:%;&"M]+7#(AJH[OHO26:G<M7)[U
MQ<X80K)1:;!4.X^%CB!GP*IHA(IM583-:@P!*ZD[\?^@=I)R4C5%T"?H0[)Z
M44V!-;2P?*C(+&+F<L%LO+1TD/D&Z!\)3OAE@IM65B>>(15"6>A-58/5RT+;
M)\*%UY!TIVZF.,ZQ$*\0!N9P<0ML@N89R"8JW8M%9>LU4S'Q55:\#BI01<NM
MD8P='R1UO/>V"SIW@$:2T#%WR<)A^4W"SB%YM9=JV,9L1,<% ):K0?(ULT;@
M7A#]%@18Q,@:RKK+<A#R#\L<9!1"M';(RUJ,==])1MWX(3P!K$%E[H,Y:'<I
M6U%>^%HM&?MWYHM9MN)95V PKE3G ^-<:PI8/0@<0V)/9HPA*HW?QH "J16K
MKC/JQ3&5/9!XJGYM\ 9R">Q%$LSG%/PY+^+9/7E<XE82'E$W>U,R0&@[H>&%
M%4_=&>(P6>82))CL70UQ#UI2&92A*@N'GT&F  9F0_M'+!8TK>V.L@)'8E_E
M=-=;B2_F]GVQFT&RR:-CNJY[WG5!]WQ ;_$B^C-N:^0]2Y#KU1BS)N=9&J_J
M90<#PA*J1S,5L)/*C?$0=.F+6-W04S,79SI1M>$$R;DT?"F=V"<VG='5QQ;!
M.%H6I YCL?:[_RZ%>R:,S03TU3BY3V:(()*1M E[%-'#<B&]!?00HF&+W0YA
M,)UEV03EB]JU85D0WA^3FP?YPUR#@7 F"IZ.+6+HPH^C(G86;H :YGHR%\&C
MJ1Y%PU3C_BTFG>/'M@9L9;$R32YM<0*G/D97G!(@#B FP:7.>:F(N2%G4;N:
M$>4"DR4+. 5A8*H<90[<*YSS#*S0 AI2""5<J-J'2(/(%3!M>\?VF$90>B/^
ME\RY59_P++] H(QY MA[LK1G%:+]*?OW:8IX:0X&YQ92?)\GSGP#+D9H\Q('
MF8'AOYSA84]G%:-I,B8!&M%PE+E2[(JO09<%&!;B/*:\3G_:I 2H(T>'S&HU
M +3\@%2#D_+ <2W*A#A[*N-FG$ &G#[&"46%EL<$X%2=C6E;/$A*L%8$42HJ
M$JP5&*=!&3T&0NOZJ7FPWX5C\]0IF3B/'@H,E2 XUV:-?W'FOABQ8&F5KD><
MK=KX&%;7Z#H4T'"J2#@XK@&TZ,#&JU;R"FBF)4 ?8&$@HAG;R4:P3GP7S'1#
M>S"\@.R[+'2W)8<3C)NA[9[$*H:@STOUT:<4 \:(5T)O#L<8H .82=?"QJH/
MZ]XIQ7"HK0R5 HD=Z.X:!!5,W!?8R@F^ ZY%80*P EL'B=(1T>X$OL\I!?OA
MM&W+_;:.'/8K8ZS8II#ZV%ABJ*:3&'7$1MPI2E7E1JB+-.3597:+L!&A9F59
M%P*%4C*BB#9$@C[S^K1]1QBQ$Q@P[Q5@NC!J$<RMG29XP1:5H3>-V5:S J0Z
M"%:F.(]>O]I)=^OUL/':IYDPB'=*/0KVYSL5SFK:1,U5FP -WBK)S)0!TWP&
MQ5I+ I^$T.[*R,E-8"B*DXG?/Y [X+QE<PS0./M +X%? AX#&/D0Z2'58M2U
MH@TPB\>V4VT^D.0.G_J4[H<6*G301K]!#QB*UR8&0@B4Y>@:,W1SH-P\&,W$
M^Q&H(:I/!9^ /Z 1R\7>7U@-7E/)\Q*+JX[V?7'5#U:(_<O@<__FLC<<!I\_
M]@:]JP_M#"71Z@GCY\H\<AWV-)@L"3)4E[ 6["\D 'XT6YFI1S,#S$%U"9;J
MI/;0<.>R5;K*ON(Y1I+80?;BI:!!.>LO8_ ;%D7\J_S'/P#C<1:M?DU2I K^
MZ!_V_5X)$MY#H><XFC'C(,/0U\RU1^^.]U[MTX,%5Y83^61FZCWZ[N_EI/KE
MT='>X:OFK]?^=OV7^Z_W]K_YQ^W<>3.(\7?<Q-S1[P?'M,&0(YX5BRC]___V
M^F].\]>OAXNOP8&M9^ (<UF(N.=OZ_CX[4_61/_N#?KG?P3G_0^]8'C:[UV>
M]H95' 9)/$6"HPH)]H$ ?ZNY])NI568+(E4+].@/>N<GEV>"+A?]F]Y9#36>
MS"U54GT#M_S,@^']"OOMGLT!&_Y:&%FD^"+@QN3Q0RURS/>P>N=H\@*V^G=(
M "91*MS_'$*YPBQY4=)\&<WCYVTRVTU"_?Z*_;Z0%4DF 2SP'QUY:2_?+WCS
M7[K$WR3EC'8]>$G;3I@L5PLLRDUOZS%97I3TOU!&.$,XT:QNY[=7Z"%80EO]
M[+V6 4EWNY_""L\0ENV1JY9H_5RJ_#R"0$Y:V-H'[_ _A_L'>N:&DKJ_8YC-
M".2MB['_[$C>P=&[38SD'3[]SB\R>'76^\_IU448]"]/]^I$<7O5_0MPW/\7
MNJR2-'@_B\9?ID(#O*@-?I&>V\O>\A=JKI/?]B%) :4XFJWQV[9WZ[U%66]1
M'N[_.(NR^;NU*>6?9<VL*V([3VALC^S1;GB[G[,UO(C@8._=(19.'1S\([A6
M4UIZZ7@Y'^6("+<AZSPX/E(+70\BV=;ZCC=[?:^>1[_G2EGC+%A?@$4%6 [Z
M;+<+L%J8]MO[S\?^^_X-JBP$\^X-+OHW-[VSH'=Y^NGB_> $RAZ^KXCPYU=3
M>BG\N5)XZ*7P!TFA.)"[,RK\VV7M9T<QWQWO'>X?_D]S$/-_FD*)AT=[[_:;
MO][?.VC\[D7>ECW11UPS!$UWG:]'?+-'W#/B__I*N;:/GT==54\/3X_OH0>>
M@"^,8#]5TP3PWZ.]-V^>6IR["13RA&F#,$_(YGNI]E*]F<SK">.EVDOUMC&O
M)XR7:B_5V\:\GC#;(TI>]WC=LTDLY0GC+0HOU1M((4\8+]5>JCWS>L)X/\'K
M'J][NB%BGC#>HO!2O37,ZPGCI=I+];8QKR>,EVHOU=O&O)XP7JJ]5&\;\WK"
M>*GV4KUMS.L)XZ7:2_6V,:\GS/:(DM<]7O=L$DMYPGB+PDOU!E+($\9;%-ZB
M\+JG<RSE">,M"B_5&T@A3QAO47B+PNN>SK&4)\S+$26O>[SNV226\H3QWHR7
MZ@VDD">,EVHOU9YY/6&\G^!USX_2/0TCKPS2>"'TI.L>Z9YNMWS_6EZL=JE,
MC9.K>CF#;)SA*YLZR.:??GS*EM[6NQB;8$E[POC @0\<; WS>L)XJ?92O6W,
MZPGCI=I+];8QKR>,EVHOU=O&O)XP7JJ]5&\;\WK">*GV4KUMS.L)LSVBY'6/
MUSV;Q%*>,-ZB\%*]@13RA/%2[:7:,Z\GC)=J+]4OF'D]8;Q4>ZG>-N;UA/%2
M[:5ZVYC7$\9+M9?J;6->3Q@OU5ZJMXUY/6&\5'NIWC;F]83Q4NVE>MN8UQ/&
M2[67ZFUC7D\8+]5>JK>->3UAO%1[J=XVYO6$\5+MI7K;F-<3QDNUE^IM8UY/
M&"_57JJWC7D]8;Q4>ZG>-N;UA/%2[:5ZVYC7$V9[1,GKGK]$]VS7B!J_%L__
M?G2//;KGV(_N\:-[_.B>EV[K><)XU]:[MEO#O)XP7JJ]5&\;\WK">*GV4KUM
MS.L)XZ7:2_6V,:\GC)=J+]7;QKR>,%ZJO51O&_-ZPGBI]E*];<SK">.EVDOU
MMC&O)XR7:B_5V\:\GC!>JK>XR'EKV=N3;H-)YTO(VR@A;ZQE?I'EY:^Z45ZN
M'F)5BA\<UC'D7T3 -[4$[/WG8_]]_R8XV#LX/F[D)WO9A\>M+[M>:'PQ_[;?
M]J>Z45TZ*SP]/#U\_ZH/V'2%I3QA?,#&2_4&4L@3QDNUEVK/O)XP7JJ]5+]@
MYO6$\5+MI7K;F-<3QDNUE^IM8UY/&"_57JJWC7D]8;Q4>ZG>-N;UA/%2[:5Z
MVYC7$\9+M9?J;6->3Q@OU5ZJMXUY/6&\5'NIWC;F]83Q4NVE>MN8UQ/&2[67
MZFUC7D\8+]5>JK>->3UAO%1[J=XVYO6$\5+MI7K;F-<3QDNUE^IM8UY/&"_5
M7JJWC7D]8;Q4>ZG>-N;UA/%2[:5ZVYC7$\9+M9?J;6->3Q@OU7Y\Q$;2T).N
MJZ3SXR/:&!\A5_5R1D2\[L:(B'_ZH05;>EMOO'OC?1,)XXUW[Y)WEGD]8;Q4
M>ZG>-N;UA/%2[:5ZVYC7$\9+M9?J;6->3Q@OU5ZJMXUY/6&\5'NIWC;F]83Q
M4NVE>MN8UQ/&2[67ZFUC7D\8+]5>JK>->3UAO%1[J=XVYO6$\5+MI7K;F-<3
MQDNU;_?:2!IZTG65=+[=JXUVK\:^HT>^>WEM8F^ZT2:F'F)U?!T<UC'K7T3
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MQKFW&,RO_=-QL9[1N)].@OWCIX/7^Q]F_WS(F2RV^HLOEQ?G5]V%A:4Z[[U
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M@XDU2!F[:^FKT](>U+JYMYJV CVM>^=%0R*,93(!8O;1R81R2(8)"&H@2U(
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M178FQ69R(4+)>FR%@IR!&SW4J.')R!\\L^MXDE.-K4%IB4]* +4HXJRG6=V
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MBK 8DM-SXN]J<IN>E9.W(L5/8<[?X9PEERP[,X IWPH.DOR 0;]A.UZ_Y0;
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M?(RCVW"-YEW1 H(16\" O,N;<<^%-;C,?IV*S9OVY[JH"FL)$KVT?E,"?ZI
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M0>V?^Y$WA?^,TG'PZ_\'4$L#!!0    ( -")2%@KOK.O; 0  ,\O   ?
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M\5@WV DF>!UUN6F*[D2H#(U!T!($]?-[ETGQ=Q\S=*2( =)=($U3D4D#I"5
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MED\ T]O+.<S-HU\/+!=YLJ]9<" YR]0\RY(1]ME[.5#?* ;Y_P-02P,$%
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MQX-D^OL0Q[1V/<)M6Y-6@640)*'-V:L*-C40[BK79R90Z=M'#C%*6Z7%TE2
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MN=B3EHO][3?3XTG/O_=Z$X\V]-.FU5C(& V[:C#W_N@C[@8OZ]#2=%90I_>
M6:0^&XCDZ*"N>3#7A6VC1*Z6:5-5L_"#<XCAILUHK;ND60'=?*==Q7'!8 ],
M@2Y):$>.L+W(\<;!^$FN9W%3HTQ,X2M[X-S)W^",;E4'#+@ QK)E7V"S6;#P
M=<8 G+*;C\2TID_M!Z2T1-"A?ORFNQYKH3V5DYXA< [D0%B@\2QKV6-_ATH-
MX(7EF-!2ROJ2:0:6  CHV"U+-*81T/7 +F .P#F4RT+0L6TK%7HE)C/H7N+.
M=5[Y8G(F<_!U,/F_YGT$E-L"8!.$KWL"O:\@]Q&0NVH).+O,G)M9B^#MX%V
M!PF OK#>NK#2:7I&MYVR>Z LK::US4Q$Q3>""'C:+U.^8R#94;<L=?O?SBSC
M%B@CAJF>Y!X/4B[2U?#5>]VUZ8%H-\QAFT&O+TEE_\PLVNG%T+R'J_LEFPS-
M!IE KU*?R8N!N@DUNM6%T8W;LS]S5T/OO<ZN2=J%=[X-<0?:AAY"O]W&2JR3
ML^_"%*'A7.K2Q]A;7B6.S+6:0;"JXHKODG":EA]BNRVE3D/_3(H78A%K"D6
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MC\]]+[6MDYA>A$U$PC#0]O45LK]DR'Z-+?19E=:%-O0O/@/P7H=.I:[OWE'
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M4>PJ7#5&O(*\SZ& )O3K5I(=FL!)API=\H@",8%3BZ$O$S%\#7POR0;H"'/
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M&6EW/>=/*^@7.4F]E'M$8BIG!ZV^'RA[><<NN"FE+$T 5Q*S^TAD_4(05!'
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M# 1Y*1\6#TAT4<8PRJ2: JY.$N5KER\E!0;Q+^D$M177;GS2_.R:=2-?X>@
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M+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( -")2%C'VD%BUC4  #HK @ 5
M          "  0;E P!D>&-M+3(P,C,Q,C,Q7V-A;"YX;6Q02P$"% ,4
M" #0B4A8?[1*LX=W  "W5@4 %0              @ $/&P0 9'AC;2TR,#(S
M,3(S,5]D968N>&UL4$L! A0#%     @ T(E(6(?VU_;3'@$ A+$! !0
M         ( !R9($ &1X8VTM,C R,S$R,S%?9S$N:G!G4$L! A0#%     @
MT(E(6.S$C(PD(P$ O74! !0              ( !SK$% &1X8VTM,C R,S$R
M,S%?9S(N:G!G4$L! A0#%     @ T(E(6.+-)D0-I0( G2\# !0
M     ( !)-4& &1X8VTM,C R,S$R,S%?9S,N:G!G4$L! A0#%     @ T(E(
M6%E* K%!L   2>X  !0              ( !8WH) &1X8VTM,C R,S$R,S%?
M9S0N:G!G4$L! A0#%     @ T(E(6(WNYIF$#@$ 4X,! !0
M ( !UBH* &1X8VTM,C R,S$R,S%?9S4N:G!G4$L! A0#%     @ T(E(6!=C
M[8TY> $ 'Y$/ !4              ( !C#D+ &1X8VTM,C R,S$R,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( -")2%A?!]:H+]\  #9Y"@ 5              "
M ?BQ# !D>&-M+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    " #0B4A8$K\"
MWSBK  #[O 0 '@              @ %:D0T 9'AC;3$R,S$R,#(S97@Q,#$R
M+3(P,35E;7 N:'1M4$L! A0#%     @ T(E(6)U/OEP_!P$ Q)$' !X
M         ( !SCP. &1X8VTQ,C,Q,C R,V5X,3 Q,RUA;65N9&5D+FAT;5!+
M 0(4 Q0    ( -")2%CG:?^O(;T  ,T$!P >              "  4E$#P!D
M>&-M,3(S,3(P,C-E>#$P,30M86UE;F1E9"YH=&U02P$"% ,4    " #0B4A8
M>TN@<(M$  #E/0( '@              @ &F 1  9'AC;3$R,S$R,#(S97@Q
M.3$M<')O8V5D=7(N:'1M4$L! A0#%     @ T(E(6"N^LZ]L!   SR\  !\
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M<V$N:'1M4$L! A0#%     @ T(E(6'XA?8K.!P  124  !L
M ( !XX 0 &1X8VTQ,C,Q,C R,V5X:&EB:70S,3 Q+FAT;5!+ 0(4 Q0    (
M -")2%@%5ZI"S@<  /HC   ;              "  >J($ !D>&-M,3(S,3(P
M,C-E>&AI8FET,S$P,BYH=&U02P$"% ,4    " #0B4A8W8SM>A@$  !9#P
M&P              @ 'QD!  9'AC;3$R,S$R,#(S97AH:6)I=#,R,#$N:'1M
M4$L! A0#%     @ T(E(6(K:>:,>!   H X  !L              ( !0I40
M &1X8VTQ,C,Q,C R,V5X:&EB:70S,C R+FAT;5!+!08     %P 7 %H&  "9
%F1     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>dxcm-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:dxcm="http://www.dexcom.com/20231231"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dxcm-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:MatthewDolanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:MatthewDolanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:PaulFlynnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:PaulFlynnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:GirishNaganathanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:GirishNaganathanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:StevenRPacelliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:StevenRPacelliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:BarryJReganMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:BarryJReganMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:KevinRSayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:KevinRSayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">dxcm:SadieMSternDecember2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">dxcm:SadieMSternDecember2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">dxcm:SadieMStern2023PlanTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">dxcm:SadieMStern2023PlanTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:JeremeMSylvainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:JeremeMSylvainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">dxcm:SadieMSternMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">dxcm:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dxcm:ComputerSoftwareAndHardwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dxcm:ComputerSoftwareAndHardwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:CollaborativeSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:CollaborativeSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:CollaborativeSalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:RestrictedAndPerformanceStockUnitsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:RestrictedAndPerformanceStockUnitsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dxcm:RestrictedAndPerformanceStockUnitsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementInitialPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementInitialPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementInitialPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementInitialPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dxcm:VerilyLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:PaymentsUnderCollaborationAgreementsAxis">dxcm:CollaborativeArrangementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dxcm:ReceiverProductComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dxcm:ReceiverProductComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">dxcm:ReceiverProductComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dxcm:ComputerSoftwareAndHardwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dxcm:ComputerSoftwareAndHardwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dxcm:VerilyIntangibleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dxcm:AcquiredTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dxcm:VerilyIntangibleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">dxcm:AcquiredTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dxcm:ConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dxcm:DebtInstrumentConversionTermAxis">dxcm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dxcm:LondonInterbankOfferedRateLIBOR1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dxcm:LondonInterbankOfferedRateLIBOR1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherForeignMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherForeignMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ResearchDevelopmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ResearchDevelopmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ForeignTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ForeignTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ResearchDevelopmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:ResearchDevelopmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:AMTTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dxcm:AMTTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A401kPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A401kPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A401kPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2022ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2028NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2028NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:A2028NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dxcm:AcceleratedShareRepurchaseASRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dxcm:RestrictedStockUnitsRSUsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dxcm:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001093557</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dxcm:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="trading_day">
        <measure>dxcm:trading_day</measure>
    </unit>
    <unit id="extensionoption">
        <measure>dxcm:extensionOption</measure>
    </unit>
    <unit id="segment">
        <measure>dxcm:segment</measure>
    </unit>
    <unit id="primarymarket">
        <measure>dxcm:primaryMarket</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0001093557</dei:EntityCentralIndexKey>
    <ecd:TrdArrDuration contextRef="c-8" id="f-85">P366D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-20" id="f-86">P366D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-10" id="f-87">P423D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-12" id="f-88">P366D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-14" id="f-89">P366D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-23" id="f-90">P455D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-4" id="f-91">P366D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-6" id="f-92">P366D</ecd:TrdArrDuration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-84" id="f-509">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-86" id="f-511">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-90" id="f-519">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <dxcm:AmortizationPeriodForIncentiveCompensationCosts contextRef="c-93" id="f-535">P1Y</dxcm:AmortizationPeriodForIncentiveCompensationCosts>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-199"
      decimals="7"
      id="f-1023"
      unitRef="number">0.0243476</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-201"
      decimals="7"
      id="f-1024"
      unitRef="number">0.006662</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-203"
      decimals="7"
      id="f-1025"
      unitRef="number">0.0061571</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-24" id="f-1051">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-25" id="f-1058">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-24" id="f-1059">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-1083">http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense</us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-255" id="f-1286">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">000-51222</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">DEXCOM, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">33-0857544</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">6340 Sequence Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">200-0200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.001 Par Value Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">DXCM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-29" unitRef="usd">49400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">385515421</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive proxy statement relating to its 2024 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x201d;) are incorporated by reference in Part&#160;III, Items 10 through 14 of this Annual Report on Form 10-K, as specified in the responses to those item numbers, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-36">42</dei:AuditorFirmId>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-37">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December&#160;31, 2023, the following Section 16 officers and directors adopted or terminated a &#x201c;Rule 10b5-1 trading arrangement&#x201d; (as defined in Item 408 of Regulation S-K of the Exchange Act):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Action&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Action Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate Number of Shares to be Sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expiration Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Matthew Dolan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Vice President, Strategy, Corporate Development and Dexcom Labs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/15/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,326&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/15/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Paul Flynn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Vice President, Global Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/15/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,253&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/15/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Girish Naganathan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Vice President, Chief Technology Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11/20/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,137&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11/20/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Steven R. Pacelli&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Vice President and Managing Director, Dexcom Ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11/27/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,000&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1/23/2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Barry J. Regan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Vice President, Global Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/4/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,430&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/4/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Kevin R. Sayer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chairperson,&#160;President and Chief Executive Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/12/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100,965&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/12/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sadie M. Stern&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Vice President, Chief Human Resources Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/12/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,825&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3/11/2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sadie M. Stern&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Vice President, Chief Human Resources Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12/12/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,708&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3/8/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jereme M. Sylvain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Vice President, Chief Financial Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11/21/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,863&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11/21/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The actual number of shares sold may depend on the net shares vested as a result of tax withholding obligations, the vesting of certain performance-based stock units, the number of shares purchased under employee stock purchase plans, one or more limit orders, as applicable, and therefore, may not be determinable at this time.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the date listed in the table.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 12, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect, under the Exchange Act.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the Rule 10b5-1 trading arrangements that were adopted in the above table are in accordance with our insider trading policy and actual sale transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-4" id="f-38">Matthew Dolan</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-4" id="f-39">Executive Vice President, Strategy, Corporate Development and Dexcom Labs</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-40">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-4" id="f-41">12/15/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-5" decimals="INF" id="f-42" unitRef="shares">15326</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-6" id="f-43">Paul Flynn</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-6" id="f-44">Executive Vice President, Global Revenue</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-6" id="f-45">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-6" id="f-46">12/15/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-7" decimals="INF" id="f-47" unitRef="shares">31253</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-8" id="f-48">Girish Naganathan</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-8" id="f-49">Executive Vice President, Chief Technology Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-8" id="f-50">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-8" id="f-51">11/20/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-9" decimals="INF" id="f-52" unitRef="shares">5137</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-10" id="f-53">Steven R. Pacelli</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-10" id="f-54">Executive Vice President and Managing Director, Dexcom Ventures</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-10" id="f-55">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-10" id="f-56">11/27/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-11" decimals="INF" id="f-57" unitRef="shares">15000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-12" id="f-58">Barry J. Regan</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-12" id="f-59">Executive Vice President, Global Operations</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-12" id="f-60">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-12" id="f-61">12/4/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-13" decimals="INF" id="f-62" unitRef="shares">28430</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-14" id="f-63">Kevin R. Sayer</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-14" id="f-64">Chairperson,&#160;President and Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-14" id="f-65">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-14" id="f-66">12/12/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-15" decimals="INF" id="f-67" unitRef="shares">100965</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-16" id="f-68">Sadie M. Stern</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-16" id="f-69">Executive Vice President, Chief Human Resources Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-16" id="f-70">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-16" id="f-71">12/12/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-17" decimals="INF" id="f-72" unitRef="shares">12825</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-18" id="f-73">Sadie M. Stern</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-18" id="f-74">Executive Vice President, Chief Human Resources Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-18" id="f-75">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrTerminationDate contextRef="c-18" id="f-76">12/12/2023</ecd:TrdArrTerminationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-19" decimals="INF" id="f-77" unitRef="shares">4708</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-20" id="f-78">Jereme M. Sylvain</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-20" id="f-79">Executive Vice President, Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-20" id="f-80">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-20" id="f-81">11/21/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-21" decimals="INF" id="f-82" unitRef="shares">6863</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-22" id="f-83">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-22" id="f-84">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorName contextRef="c-1" id="f-93">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-94">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-24" decimals="-5" id="f-95" unitRef="usd">566300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-25" decimals="-5" id="f-96" unitRef="usd">642300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <dxcm:DebtSecuritiesAvailableForSaleAndEquitySecurities contextRef="c-24" decimals="-5" id="f-97" unitRef="usd">2157800000</dxcm:DebtSecuritiesAvailableForSaleAndEquitySecurities>
    <dxcm:DebtSecuritiesAvailableForSaleAndEquitySecurities contextRef="c-25" decimals="-5" id="f-98" unitRef="usd">1813900000</dxcm:DebtSecuritiesAvailableForSaleAndEquitySecurities>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-24" decimals="-5" id="f-99" unitRef="usd">973900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-25" decimals="-5" id="f-100" unitRef="usd">713300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-24" decimals="-5" id="f-101" unitRef="usd">559600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-25" decimals="-5" id="f-102" unitRef="usd">306700000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-24" decimals="-5" id="f-103" unitRef="usd">168300000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-25" decimals="-5" id="f-104" unitRef="usd">192600000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-24" decimals="-5" id="f-105" unitRef="usd">4425900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-25" decimals="-5" id="f-106" unitRef="usd">3668800000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-24" decimals="-5" id="f-107" unitRef="usd">1113100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-25" decimals="-5" id="f-108" unitRef="usd">1055600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-24" decimals="-5" id="f-109" unitRef="usd">71400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-25" decimals="-5" id="f-110" unitRef="usd">80000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-24" decimals="-5" id="f-111" unitRef="usd">25200000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-25" decimals="-5" id="f-112" unitRef="usd">25700000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-24" decimals="-5" id="f-113" unitRef="usd">134500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-25" decimals="-5" id="f-114" unitRef="usd">173300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-24" decimals="-5" id="f-115" unitRef="usd">419400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-25" decimals="-5" id="f-116" unitRef="usd">341200000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-24" decimals="-5" id="f-117" unitRef="usd">75000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-25" decimals="-5" id="f-118" unitRef="usd">47100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-24" decimals="-5" id="f-119" unitRef="usd">6264500000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-25" decimals="-5" id="f-120" unitRef="usd">5391700000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-24" decimals="-5" id="f-121" unitRef="usd">1345500000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-25" decimals="-5" id="f-122" unitRef="usd">901800000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-24" decimals="-5" id="f-123" unitRef="usd">171000000.0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-25" decimals="-5" id="f-124" unitRef="usd">134300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c-24" decimals="-5" id="f-125" unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c-25" decimals="-5" id="f-126" unitRef="usd">772600000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-24" decimals="-5" id="f-127" unitRef="usd">21100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-25" decimals="-5" id="f-128" unitRef="usd">20500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-24" decimals="-5" id="f-129" unitRef="usd">18400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-25" decimals="-5" id="f-130" unitRef="usd">10100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-24" decimals="-5" id="f-131" unitRef="usd">1556000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-25" decimals="-5" id="f-132" unitRef="usd">1839300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-24" decimals="-5" id="f-133" unitRef="usd">2434200000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-25" decimals="-5" id="f-134" unitRef="usd">1197700000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-24" decimals="-5" id="f-135" unitRef="usd">80100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-25" decimals="-5" id="f-136" unitRef="usd">94600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-24" decimals="-5" id="f-137" unitRef="usd">125600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-25" decimals="-5" id="f-138" unitRef="usd">128300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-24" decimals="-5" id="f-139" unitRef="usd">4195900000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-25" decimals="-5" id="f-140" unitRef="usd">3259900000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-24" id="f-141" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-25" id="f-142" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-25"
      decimals="INF"
      id="f-143"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-24"
      decimals="INF"
      id="f-144"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-24" decimals="-5" id="f-145" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-25" decimals="-5" id="f-146" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-24"
      decimals="INF"
      id="f-147"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-25"
      decimals="INF"
      id="f-148"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-24"
      decimals="INF"
      id="f-149"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-25"
      decimals="INF"
      id="f-150"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding contextRef="c-24" decimals="-5" id="f-151" unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding contextRef="c-25" decimals="-5" id="f-152" unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-24"
      decimals="INF"
      id="f-153"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-25"
      decimals="INF"
      id="f-154"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-24" decimals="-5" id="f-155" unitRef="shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-25" decimals="-5" id="f-156" unitRef="shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-24" decimals="-5" id="f-157" unitRef="shares">407200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-24" decimals="-5" id="f-158" unitRef="shares">385400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-25" decimals="-5" id="f-159" unitRef="shares">393200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-25" decimals="-5" id="f-160" unitRef="shares">386300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-24" decimals="-5" id="f-161" unitRef="usd">400000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-25" decimals="-5" id="f-162" unitRef="usd">400000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-24" decimals="-5" id="f-163" unitRef="usd">3514600000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-25" decimals="-5" id="f-164" unitRef="usd">2258100000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-24" decimals="-5" id="f-165" unitRef="usd">-16700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-25" decimals="-5" id="f-166" unitRef="usd">-11600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-24" decimals="-5" id="f-167" unitRef="usd">1021400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-25" decimals="-5" id="f-168" unitRef="usd">479900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares contextRef="c-24" decimals="-5" id="f-169" unitRef="shares">21800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-25" decimals="-5" id="f-170" unitRef="shares">6900000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-24" decimals="-5" id="f-171" unitRef="usd">2451100000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-25" decimals="-5" id="f-172" unitRef="usd">595000000.0</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-5" id="f-173" unitRef="usd">2068600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-5" id="f-174" unitRef="usd">2131800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-24" decimals="-5" id="f-175" unitRef="usd">6264500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-25" decimals="-5" id="f-176" unitRef="usd">5391700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-177" unitRef="usd">3622300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-5" id="f-178" unitRef="usd">2909800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-27" decimals="-5" id="f-179" unitRef="usd">2448500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-180" unitRef="usd">1333400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-26" decimals="-5" id="f-181" unitRef="usd">1026700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-27" decimals="-5" id="f-182" unitRef="usd">768000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-5" id="f-183" unitRef="usd">2288900000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-26" decimals="-5" id="f-184" unitRef="usd">1883100000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-27" decimals="-5" id="f-185" unitRef="usd">1680500000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-186" unitRef="usd">505800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-26" decimals="-5" id="f-187" unitRef="usd">484200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-27" decimals="-5" id="f-188" unitRef="usd">517100000</us-gaap:ResearchAndDevelopmentExpense>
    <dxcm:CollaborativeResearchAndDevelopmentFee contextRef="c-1" decimals="-5" id="f-189" unitRef="usd">0</dxcm:CollaborativeResearchAndDevelopmentFee>
    <dxcm:CollaborativeResearchAndDevelopmentFee contextRef="c-26" decimals="-5" id="f-190" unitRef="usd">0</dxcm:CollaborativeResearchAndDevelopmentFee>
    <dxcm:CollaborativeResearchAndDevelopmentFee contextRef="c-27" decimals="-5" id="f-191" unitRef="usd">87100000</dxcm:CollaborativeResearchAndDevelopmentFee>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-192" unitRef="usd">1185400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-26" decimals="-5" id="f-193" unitRef="usd">1007700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-27" decimals="-5" id="f-194" unitRef="usd">810500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-5" id="f-195" unitRef="usd">1691200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-26" decimals="-5" id="f-196" unitRef="usd">1491900000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-27" decimals="-5" id="f-197" unitRef="usd">1414700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-5" id="f-198" unitRef="usd">597700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-26" decimals="-5" id="f-199" unitRef="usd">391200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-27" decimals="-5" id="f-200" unitRef="usd">265800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-201" unitRef="usd">112700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-26" decimals="-5" id="f-202" unitRef="usd">-400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-27" decimals="-5" id="f-203" unitRef="usd">-9000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-204" unitRef="usd">710400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-26" decimals="-5" id="f-205" unitRef="usd">390800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-27" decimals="-5" id="f-206" unitRef="usd">256800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-207" unitRef="usd">168900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-208" unitRef="usd">49600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-209" unitRef="usd">39900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-210" unitRef="usd">541500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-5" id="f-211" unitRef="usd">341200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-212" unitRef="usd">216900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-213"
      unitRef="usdPerShare">1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-214"
      unitRef="usdPerShare">0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-215"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-216" unitRef="shares">386000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="-5" id="f-217" unitRef="shares">389400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="-5" id="f-218" unitRef="shares">386900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-219"
      unitRef="usdPerShare">1.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-220"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-221"
      unitRef="usdPerShare">0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-222" unitRef="shares">425500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="-5" id="f-223" unitRef="shares">427500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="-5" id="f-224" unitRef="shares">428800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-225" unitRef="usd">541500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-5" id="f-226" unitRef="usd">341200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-227" unitRef="usd">216900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-228" unitRef="usd">-9200000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-26" decimals="-5" id="f-229" unitRef="usd">-9800000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-5" id="f-230" unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-5" id="f-231" unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-26" decimals="-5" id="f-232" unitRef="usd">-2300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-27" decimals="-5" id="f-233" unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-234" unitRef="usd">-5100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-26" decimals="-5" id="f-235" unitRef="usd">-12100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-5" id="f-236" unitRef="usd">-2700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-237" unitRef="usd">536400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-26" decimals="-5" id="f-238" unitRef="usd">329100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-27" decimals="-5" id="f-239" unitRef="usd">214200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-28" decimals="-5" id="f-240" unitRef="shares">384400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-5" id="f-241" unitRef="usd">400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-5" id="f-242" unitRef="usd">1726500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-5" id="f-243" unitRef="usd">3200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-5" id="f-244" unitRef="usd">-78200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-5" id="f-245" unitRef="usd">-100000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-5" id="f-246" unitRef="usd">1551900000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c-34" decimals="-5" id="f-247" unitRef="shares">2900000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c-27" decimals="-5" id="f-248" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-34" decimals="-5" id="f-249" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-35" decimals="-5" id="f-250" unitRef="usd">20300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-27" decimals="-5" id="f-251" unitRef="usd">20300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt contextRef="c-35" decimals="-5" id="f-252" unitRef="usd">2000000.0</dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt contextRef="c-27" decimals="-5" id="f-253" unitRef="usd">2000000.0</dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-34" decimals="-5" id="f-254" unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-35" decimals="-5" id="f-255" unitRef="usd">32600000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-36" decimals="-5" id="f-256" unitRef="usd">24600000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-27" decimals="-5" id="f-257" unitRef="usd">57200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <dxcm:SharesReceivedFromExerciseOfNoteHedge contextRef="c-34" decimals="-5" id="f-258" unitRef="shares">1000000.0</dxcm:SharesReceivedFromExerciseOfNoteHedge>
    <dxcm:SharesReceivedFromBenefitOfNoteHedgeValue contextRef="c-35" decimals="-5" id="f-259" unitRef="usd">-130800000</dxcm:SharesReceivedFromBenefitOfNoteHedgeValue>
    <dxcm:SharesReceivedFromBenefitOfNoteHedgeValue contextRef="c-36" decimals="-5" id="f-260" unitRef="usd">130800000</dxcm:SharesReceivedFromBenefitOfNoteHedgeValue>
    <dxcm:SharesReceivedFromBenefitOfNoteHedgeValue contextRef="c-27" decimals="-5" id="f-261" unitRef="usd">0</dxcm:SharesReceivedFromBenefitOfNoteHedgeValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-5" id="f-262" unitRef="usd">113400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-5" id="f-263" unitRef="usd">113400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee contextRef="c-35" decimals="-5" id="f-264" unitRef="usd">87100000</dxcm:AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee contextRef="c-27" decimals="-5" id="f-265" unitRef="usd">87100000</dxcm:AdjustmentsToAdditionalPaidInCapitalCollaborativeResearchAndDevelopmentFee>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-5" id="f-266" unitRef="usd">216900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-267" unitRef="usd">216900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-38" decimals="-5" id="f-268" unitRef="usd">-2700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-5" id="f-269" unitRef="usd">-2700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-39" decimals="-5" id="f-270" unitRef="shares">388000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-5" id="f-271" unitRef="usd">400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-5" id="f-272" unitRef="usd">2108700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-5" id="f-273" unitRef="usd">500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-5" id="f-274" unitRef="usd">138700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-5" id="f-275" unitRef="usd">-206200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-5" id="f-276" unitRef="usd">2042100000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c-45" decimals="-5" id="f-277" unitRef="shares">1600000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c-26" decimals="-5" id="f-278" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-45" decimals="-5" id="f-279" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-46" decimals="-5" id="f-280" unitRef="usd">22500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-26" decimals="-5" id="f-281" unitRef="usd">22500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone contextRef="c-45" decimals="-5" id="f-282" unitRef="shares">2900000</dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone>
    <dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones contextRef="c-46" decimals="-5" id="f-283" unitRef="usd">-189300000</dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones>
    <dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones contextRef="c-47" decimals="-5" id="f-284" unitRef="usd">189200000</dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones>
    <dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones contextRef="c-26" decimals="-5" id="f-285" unitRef="usd">-100000</dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-45" decimals="-5" id="f-286" unitRef="shares">6600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-47" decimals="-5" id="f-287" unitRef="usd">557700000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-26" decimals="-5" id="f-288" unitRef="usd">557700000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt contextRef="c-46" decimals="-5" id="f-289" unitRef="usd">400000</dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt contextRef="c-26" decimals="-5" id="f-290" unitRef="usd">400000</dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-45" decimals="-5" id="f-291" unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-46" decimals="-5" id="f-292" unitRef="usd">4200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-47" decimals="-5" id="f-293" unitRef="usd">13200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-26" decimals="-5" id="f-294" unitRef="usd">17400000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <dxcm:SharesReceivedFromExerciseOfNoteHedge contextRef="c-45" decimals="-5" id="f-295" unitRef="shares">300000</dxcm:SharesReceivedFromExerciseOfNoteHedge>
    <dxcm:SharesReceivedFromBenefitOfNoteHedgeValue contextRef="c-46" decimals="-5" id="f-296" unitRef="usd">-33500000</dxcm:SharesReceivedFromBenefitOfNoteHedgeValue>
    <dxcm:SharesReceivedFromBenefitOfNoteHedgeValue contextRef="c-47" decimals="-5" id="f-297" unitRef="usd">33500000</dxcm:SharesReceivedFromBenefitOfNoteHedgeValue>
    <dxcm:SharesReceivedFromBenefitOfNoteHedgeValue contextRef="c-26" decimals="-5" id="f-298" unitRef="usd">0</dxcm:SharesReceivedFromBenefitOfNoteHedgeValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-46" decimals="-5" id="f-299" unitRef="usd">126500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-5" id="f-300" unitRef="usd">126500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones contextRef="c-46" decimals="-5" id="f-301" unitRef="usd">152400000</dxcm:AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones contextRef="c-26" decimals="-5" id="f-302" unitRef="usd">152400000</dxcm:AdjustmentsToAdditionalPaidInCapitalCapitalizationOfSalesBasedMilestones>
    <us-gaap:NetIncomeLoss contextRef="c-48" decimals="-5" id="f-303" unitRef="usd">341200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-5" id="f-304" unitRef="usd">341200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-49" decimals="-5" id="f-305" unitRef="usd">-12100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-26" decimals="-5" id="f-306" unitRef="usd">-12100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-50" decimals="-5" id="f-307" unitRef="shares">386300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-5" id="f-308" unitRef="usd">400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-5" id="f-309" unitRef="usd">2258100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-5" id="f-310" unitRef="usd">-11600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-5" id="f-311" unitRef="usd">479900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-5" id="f-312" unitRef="usd">-595000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-5" id="f-313" unitRef="usd">2131800000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c-55" decimals="-5" id="f-314" unitRef="shares">1400000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c-1" decimals="-5" id="f-315" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-55" decimals="-5" id="f-316" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-56" decimals="-5" id="f-317" unitRef="usd">26600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-5" id="f-318" unitRef="usd">26600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone contextRef="c-55" decimals="-5" id="f-319" unitRef="shares">3700000</dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone>
    <dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones contextRef="c-56" decimals="-5" id="f-320" unitRef="usd">-323400000</dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones>
    <dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones contextRef="c-57" decimals="-5" id="f-321" unitRef="usd">323200000</dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones>
    <dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones contextRef="c-1" decimals="-5" id="f-322" unitRef="usd">-200000</dxcm:StockIssuedDuringPeriodValueAchievementOfMilestones>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-55" decimals="-5" id="f-323" unitRef="shares">6300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-56" decimals="-5" id="f-324" unitRef="usd">200000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-57" decimals="-5" id="f-325" unitRef="usd">689000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-5" id="f-326" unitRef="usd">689200000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt contextRef="c-56" decimals="-5" id="f-327" unitRef="usd">4400000</dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt contextRef="c-1" decimals="-5" id="f-328" unitRef="usd">4400000</dxcm:AdjustmentsToAdditionalPaidInCapitalTaxBenefitFromEquityComponentOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-55" decimals="-5" id="f-329" unitRef="shares">12200000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-56" decimals="-5" id="f-330" unitRef="usd">-13100000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="-5" id="f-331" unitRef="usd">-13100000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <dxcm:SharesReceivedFromExerciseOfNoteHedge contextRef="c-55" decimals="-5" id="f-332" unitRef="shares">12200000</dxcm:SharesReceivedFromExerciseOfNoteHedge>
    <dxcm:SharesReceivedFromBenefitOfNoteHedgeValue contextRef="c-56" decimals="-5" id="f-333" unitRef="usd">-1496500000</dxcm:SharesReceivedFromBenefitOfNoteHedgeValue>
    <dxcm:SharesReceivedFromBenefitOfNoteHedgeValue contextRef="c-57" decimals="-5" id="f-334" unitRef="usd">1490300000</dxcm:SharesReceivedFromBenefitOfNoteHedgeValue>
    <dxcm:SharesReceivedFromBenefitOfNoteHedgeValue contextRef="c-1" decimals="-5" id="f-335" unitRef="usd">-6200000</dxcm:SharesReceivedFromBenefitOfNoteHedgeValue>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax contextRef="c-56" decimals="-5" id="f-336" unitRef="usd">76300000</dxcm:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax>
    <dxcm:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax contextRef="c-1" decimals="-5" id="f-337" unitRef="usd">76300000</dxcm:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCallTransactionsNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-56" decimals="-5" id="f-338" unitRef="usd">150800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-5" id="f-339" unitRef="usd">150800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-58" decimals="-5" id="f-340" unitRef="usd">541500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-341" unitRef="usd">541500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-59" decimals="-5" id="f-342" unitRef="usd">-5100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-343" unitRef="usd">-5100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-60" decimals="-5" id="f-344" unitRef="shares">385400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-5" id="f-345" unitRef="usd">400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-5" id="f-346" unitRef="usd">3514600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-5" id="f-347" unitRef="usd">-16700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-5" id="f-348" unitRef="usd">1021400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-5" id="f-349" unitRef="usd">-2451100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-5" id="f-350" unitRef="usd">2068600000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-351" unitRef="usd">541500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-5" id="f-352" unitRef="usd">341200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-353" unitRef="usd">216900000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-354" unitRef="usd">186000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-26" decimals="-5" id="f-355" unitRef="usd">155900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-27" decimals="-5" id="f-356" unitRef="usd">102000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-357" unitRef="usd">150800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-26" decimals="-5" id="f-358" unitRef="usd">126500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-27" decimals="-5" id="f-359" unitRef="usd">113400000</us-gaap:ShareBasedCompensation>
    <dxcm:CollaborativeResearchAndDevelopmentFee contextRef="c-1" decimals="-5" id="f-360" unitRef="usd">0</dxcm:CollaborativeResearchAndDevelopmentFee>
    <dxcm:CollaborativeResearchAndDevelopmentFee contextRef="c-26" decimals="-5" id="f-361" unitRef="usd">0</dxcm:CollaborativeResearchAndDevelopmentFee>
    <dxcm:CollaborativeResearchAndDevelopmentFee contextRef="c-27" decimals="-5" id="f-362" unitRef="usd">87100000</dxcm:CollaborativeResearchAndDevelopmentFee>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-5" id="f-363" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-26" decimals="-5" id="f-364" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-27" decimals="-5" id="f-365" unitRef="usd">-100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-5" id="f-366" unitRef="usd">7800000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-26" decimals="-5" id="f-367" unitRef="usd">6300000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-27" decimals="-5" id="f-368" unitRef="usd">7200000</us-gaap:PaidInKindInterest>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-1" decimals="-5" id="f-369" unitRef="usd">1900000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-26" decimals="-5" id="f-370" unitRef="usd">200000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-27" decimals="-5" id="f-371" unitRef="usd">11600000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-372" unitRef="usd">-55000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-373" unitRef="usd">-21600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-374" unitRef="usd">15800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-5" id="f-375" unitRef="usd">83900000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-26" decimals="-5" id="f-376" unitRef="usd">-34700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-27" decimals="-5" id="f-377" unitRef="usd">-43600000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-5" id="f-378" unitRef="usd">260100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-26" decimals="-5" id="f-379" unitRef="usd">199900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-27" decimals="-5" id="f-380" unitRef="usd">75500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-5" id="f-381" unitRef="usd">252600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-26" decimals="-5" id="f-382" unitRef="usd">-49300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-27" decimals="-5" id="f-383" unitRef="usd">112200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-5" id="f-384" unitRef="usd">-19300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-26" decimals="-5" id="f-385" unitRef="usd">131600000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-27" decimals="-5" id="f-386" unitRef="usd">21300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <dxcm:IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet contextRef="c-1" decimals="-5" id="f-387" unitRef="usd">4500000</dxcm:IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet>
    <dxcm:IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet contextRef="c-26" decimals="-5" id="f-388" unitRef="usd">5800000</dxcm:IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet>
    <dxcm:IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet contextRef="c-27" decimals="-5" id="f-389" unitRef="usd">100000</dxcm:IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-5" id="f-390" unitRef="usd">466500000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-26" decimals="-5" id="f-391" unitRef="usd">295100000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-27" decimals="-5" id="f-392" unitRef="usd">58000000.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-5" id="f-393" unitRef="usd">37200000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-26" decimals="-5" id="f-394" unitRef="usd">8500000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-27" decimals="-5" id="f-395" unitRef="usd">10400000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="c-1" decimals="-5" id="f-396" unitRef="usd">-2600000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="c-26" decimals="-5" id="f-397" unitRef="usd">11100000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="c-27" decimals="-5" id="f-398" unitRef="usd">8700000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-399" unitRef="usd">748500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-26" decimals="-5" id="f-400" unitRef="usd">669500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-27" decimals="-5" id="f-401" unitRef="usd">442500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-5" id="f-402" unitRef="usd">3200400000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-26" decimals="-5" id="f-403" unitRef="usd">2266300000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-27" decimals="-5" id="f-404" unitRef="usd">2473100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-5" id="f-405" unitRef="usd">2947400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-26" decimals="-5" id="f-406" unitRef="usd">2127800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-27" decimals="-5" id="f-407" unitRef="usd">2666300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-408" unitRef="usd">236600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-26" decimals="-5" id="f-409" unitRef="usd">364800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-27" decimals="-5" id="f-410" unitRef="usd">389200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-5" id="f-411" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-26" decimals="-5" id="f-412" unitRef="usd">3900000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-27" decimals="-5" id="f-413" unitRef="usd">30200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-5" id="f-414" unitRef="usd">17600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-26" decimals="-5" id="f-415" unitRef="usd">14300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-27" decimals="-5" id="f-416" unitRef="usd">-10100000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-417" unitRef="usd">-507200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-26" decimals="-5" id="f-418" unitRef="usd">-521500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-27" decimals="-5" id="f-419" unitRef="usd">-216100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-5" id="f-420" unitRef="usd">26600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-26" decimals="-5" id="f-421" unitRef="usd">22500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-27" decimals="-5" id="f-422" unitRef="usd">20300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-5" id="f-423" unitRef="usd">688700000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-26" decimals="-5" id="f-424" unitRef="usd">557700000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-27" decimals="-5" id="f-425" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-1" decimals="-5" id="f-426" unitRef="usd">1230600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-26" decimals="-5" id="f-427" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-27" decimals="-5" id="f-428" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <dxcm:PaymentsForPurchasesOfCappedCallTransactions contextRef="c-1" decimals="-5" id="f-429" unitRef="usd">101300000</dxcm:PaymentsForPurchasesOfCappedCallTransactions>
    <dxcm:PaymentsForPurchasesOfCappedCallTransactions contextRef="c-26" decimals="-5" id="f-430" unitRef="usd">0</dxcm:PaymentsForPurchasesOfCappedCallTransactions>
    <dxcm:PaymentsForPurchasesOfCappedCallTransactions contextRef="c-27" decimals="-5" id="f-431" unitRef="usd">0</dxcm:PaymentsForPurchasesOfCappedCallTransactions>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-1" decimals="-5" id="f-432" unitRef="usd">787300000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-26" decimals="-5" id="f-433" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-27" decimals="-5" id="f-434" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-5" id="f-435" unitRef="usd">1500000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-26" decimals="-5" id="f-436" unitRef="usd">-17300000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-27" decimals="-5" id="f-437" unitRef="usd">-9900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-438" unitRef="usd">-318600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-26" decimals="-5" id="f-439" unitRef="usd">-552500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-27" decimals="-5" id="f-440" unitRef="usd">10400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-5" id="f-441" unitRef="usd">1500000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-5" id="f-442" unitRef="usd">-5800000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-27" decimals="-5" id="f-443" unitRef="usd">-1400000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-444" unitRef="usd">-75800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-26" decimals="-5" id="f-445" unitRef="usd">-410300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-27" decimals="-5" id="f-446" unitRef="usd">235400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-25" decimals="-5" id="f-447" unitRef="usd">643300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-5" id="f-448" unitRef="usd">1053600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-33" decimals="-5" id="f-449" unitRef="usd">818200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-5" id="f-450" unitRef="usd">567500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-25" decimals="-5" id="f-451" unitRef="usd">643300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-5" id="f-452" unitRef="usd">1053600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-24" decimals="-5" id="f-453" unitRef="usd">566300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-25" decimals="-5" id="f-454" unitRef="usd">642300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-44" decimals="-5" id="f-455" unitRef="usd">1052600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-24" decimals="-5" id="f-456" unitRef="usd">1200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-25" decimals="-5" id="f-457" unitRef="usd">1000000.0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-44" decimals="-5" id="f-458" unitRef="usd">1000000.0</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-5" id="f-459" unitRef="usd">567500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-25" decimals="-5" id="f-460" unitRef="usd">643300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-5" id="f-461" unitRef="usd">1053600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-1" decimals="-5" id="f-462" unitRef="usd">1501900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-26" decimals="-5" id="f-463" unitRef="usd">35900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-27" decimals="-5" id="f-464" unitRef="usd">157700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <dxcm:TreasuryStockValueBenefitReceivedFromNoteHedge contextRef="c-1" decimals="-5" id="f-465" unitRef="usd">1490300000</dxcm:TreasuryStockValueBenefitReceivedFromNoteHedge>
    <dxcm:TreasuryStockValueBenefitReceivedFromNoteHedge contextRef="c-26" decimals="-5" id="f-466" unitRef="usd">33500000</dxcm:TreasuryStockValueBenefitReceivedFromNoteHedge>
    <dxcm:TreasuryStockValueBenefitReceivedFromNoteHedge contextRef="c-27" decimals="-5" id="f-467" unitRef="usd">130800000</dxcm:TreasuryStockValueBenefitReceivedFromNoteHedge>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-1" decimals="-5" id="f-468" unitRef="usd">53200000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-26" decimals="-5" id="f-469" unitRef="usd">25700000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-27" decimals="-5" id="f-470" unitRef="usd">45400000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-5" id="f-471" unitRef="usd">12400000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-26" decimals="-5" id="f-472" unitRef="usd">12200000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-27" decimals="-5" id="f-473" unitRef="usd">11600000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-5" id="f-474" unitRef="usd">212300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-26" decimals="-5" id="f-475" unitRef="usd">114200000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-27" decimals="-5" id="f-476" unitRef="usd">16800000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-477">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;border-bottom:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;1. Organization and Significant Accounting Policies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Business&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DexCom, Inc. is a medical device company that develops and markets continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Unless the context requires otherwise, the terms &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; the &#x201c;company,&#x201d; or &#x201c;Dexcom&#x201d; refer to DexCom, Inc. and its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements include the accounts of DexCom, Inc. and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. We have reclassified certain amounts previously reported in our financial statements to conform to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash. For international subsidiaries whose functional currencies are the local currencies, we translate the financial statements into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. We include translation-related adjustments in comprehensive income and in accumulated other comprehensive loss in the equity section of our consolidated balance sheets. We record gains and losses resulting from transactions with customers and vendors that are denominated in currencies other than the functional currency and from certain intercompany transactions in other income (expense), net in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires us to make certain estimates and assumptions that affect the amounts reported in our consolidated financial statements and the disclosures made in the accompanying notes. Areas requiring significant estimates include rebates, excess or obsolete inventories and the valuation of inventory, accruals for litigation contingencies, and the amount of our worldwide tax provision and the realizability of deferred tax assets. Despite our intention to establish accurate estimates and use reasonable assumptions, actual results may differ from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Uses unadjusted quoted prices that are available in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Uses inputs other than quoted prices included in Level&#160;1 that are observable, either directly or indirectly, through correlation with market data. These include quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Uses unobservable inputs that are supported by little or no market activity and that are significant to the determination of fair value. Level 3 assets and liabilities include those whose fair values are determined using pricing models, discounted cash flow methodologies, or similar valuation techniques and significant judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of most of our cash equivalents using Level 1 inputs. We estimate the fair value of our marketable equity securities using Level 1 inputs and we estimate the fair value of our marketable debt securities using Level 2 inputs. We carry our marketable securities at fair value. We carry our other financial instruments, such as cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities, at cost, which approximates the related fair values due to the short-term maturities of these instruments. See Note 3 &#x201c;Fair Value Measurements&#x201d; to the consolidated financial statements for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider highly liquid investments with a maturity of 90 days or less at the time of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have classified our marketable securities with remaining maturity at purchase of more than three months and remaining maturities of one year or less as short-term marketable securities. We have also classified marketable securities with remaining maturities of greater than one year as short-term marketable securities based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate realized gains or losses on our marketable securities using the specific identification method. We carry our marketable debt securities at fair value with unrealized gains and losses reported as a separate component of stockholders&#x2019; equity in our consolidated balance sheets and included in comprehensive income. Interest income and realized gains and losses on marketable debt securities are included in other income (expense), net in our consolidated statements of operations. We carry our marketable equity securities at fair value with realized and unrealized gains and losses reported in income (loss) from equity investments in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest in various types of debt securities, including debt securities in government-sponsored entities, corporate debt securities, U.S. Treasury securities, supranational securities, and commercial paper. We do not generally intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. See Note 3 &#x201c;Fair Value Measurements&#x201d; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-Term Marketable Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Note 4 &#x201c;Balance Sheet Details and Other Financial Information&#x201d; to the consolidated financial statements for more information on our marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are generally recorded at the invoiced amount, net of prompt pay discounts, for distributors and at net realizable value for direct customers, which is determined using estimates of claim denials and historical reimbursement experience without regard to aging category. Accounts receivable are not interest bearing. We evaluate the creditworthiness of significant customers based on historical trends, the financial condition of our customers, and external market factors. We generally do not require collateral from our customers. We maintain an allowance for doubtful accounts for potential credit losses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a customer account is uncollectible.&#160;Generally, receivable balances that are more than one year past due are deemed uncollectible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Significant Customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term marketable securities, and accounts receivable. We limit our exposure to credit risk by placing our cash and investments with a few major financial institutions. We have also established guidelines regarding diversification of our investments and their maturities that are designed to maintain principal and maximize liquidity. We review these guidelines periodically and modify them to take advantage of trends in yields and interest rates and changes in our operations and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the percentages of total revenue or gross accounts receivable for customers that represent 10% or more of the respective amounts for the periods shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Revenue**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;* Less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;** Total revenue for each customer is net of fees, cash discounts, and rebates directly allocable to that customer. Rebates paid to other entities are excluded; therefore, the combined value may exceed 100%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is valued at the lower of cost or net realizable value on a part-by-part basis that approximates first in, first out. We capitalize inventory produced in preparation for commercial launches when it becomes probable that the product will receive regulatory approval and that the related costs will be recoverable through the commercialization of the product. A number of factors are considered, including the status of the regulatory application approval process, management&#x2019;s judgment of probable future commercial use, and net realizable value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record adjustments to inventory for potential excess or obsolete inventory, as well as inventory that does not pass quality control testing, in order to state inventory at net realizable value. Factors influencing these adjustments include inventories on hand and on order compared to estimated future usage and sales for existing and new products, as well as judgments regarding quality control testing data and assumptions about the likelihood of scrap and obsolescence. Once written down the adjustments are considered permanent and are not reversed until the related inventory is disposed of or sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our products require customized products and components that currently are available from a limited number of sources. We purchase certain components and materials from single sources due to quality considerations, costs or constraints resulting from regulatory requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, our inventory reserves have been adequate to cover our actual losses. However, if actual product life cycles, product quality or market conditions differ from our assumptions, additional inventory adjustments that would increase cost of sales could be required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization. We capitalize additions and improvements and expense maintenance and repairs as incurred. We also capitalize certain costs incurred for the development of enterprise-level business and finance software that we use internally in our operations. Costs incurred in the application development phase are capitalized while costs related to planning and other preliminary project activities and to post-implementation activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate depreciation using the straight-line method over the estimated useful lives of the assets. Estimated useful lives are generally &lt;span style="-sec-ix-hidden:f-509"&gt;three&lt;/span&gt; to five years for computer software and hardware, including internal use software, &lt;span style="-sec-ix-hidden:f-511"&gt;four&lt;/span&gt; to fifteen years for machinery and equipment, and five years for furniture and fixtures. Leasehold and land improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Buildings are amortized over the shorter of the ownership of the building or forty years. We include the amortization of assets that are recorded under finance leases in depreciation expense. On retirement or disposition, the asset cost and related accumulated depreciation are removed from our consolidated balance sheets and any gain or loss is recognized in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the recoverability of the asset by comparing the carrying amount to the future undiscounted cash flows that we expect the asset to generate. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record goodwill when the fair value of consideration transferred in a business combination exceeds the fair value of the identifiable assets acquired and liabilities assumed. Goodwill and other intangible assets that have indefinite useful lives are not amortized, but are tested annually for impairment during the fourth fiscal quarter and whenever events or changes in circumstances indicate that it is more likely than not that the fair value is less than the carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business, and an adverse action or assessment by a regulator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with Dexcom&#x2019;s reporting structure and the availability of discrete financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform the first step of our annual impairment analysis by either comparing a reporting unit&#x2019;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#x2019;s fair value from the last quantitative assessment to determine if there is potential impairment. We may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#x2019;s estimated fair value was significantly in excess of the carrying value of its net assets and we do not believe there have been significant changes in the reporting unit&#x2019;s operations that would significantly decrease its estimated fair value or significantly increase its net assets.&#160;If a quantitative assessment is performed the evaluation includes management estimates of cash flow projections based on internal future projections&#160;and/or use of a market approach by looking at market values of comparable companies. Key assumptions&#160;for these projections include revenue growth, future gross margin and operating margin growth, and weighted cost of capital and terminal growth rates. The revenue and margin growth are based on increased sales of new and existing products as we maintain investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements&#160;to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including the timing and probability of regulatory approvals for our products to be commercialized. We also consider Dexcom&#x2019;s market capitalization as a part of our analysis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the estimated fair value of a reporting unit exceeds the carrying amount of the net assets assigned to that unit, goodwill is not impaired and no further analysis is required. If the carrying value of the net assets assigned to a reporting unit exceeds the estimated fair value of the unit, we perform the second step of the impairment test. In this step we allocate the fair value of the reporting unit calculated in step one to all of the assets and liabilities of that unit, as if we had just acquired the reporting unit in a business combination. The excess of the fair value of the reporting unit over the total amount allocated to the assets and liabilities represents the implied fair value of goodwill. If the carrying amount of a reporting unit&#x2019;s goodwill exceeds its implied fair value, we would record an impairment loss equal to the difference. We recorded no significant goodwill impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in goodwill for the twelve months ended December&#160;31, 2023 and 2022 primarily consisted of translation adjustments on our foreign currency denominated goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are included in intangibles and other assets, net in our consolidated balance sheets. We amortize intangible assets with a finite life, such as the customer relationships, acquired technology and intellectual property, trademarks and trade name, and other intangibles, on a straight-line basis over their estimated useful lives, which range from &lt;span style="-sec-ix-hidden:f-519"&gt;one&lt;/span&gt; to seven years. We review intangible assets that have finite lives and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For transactions other than a business combination, we also capitalize as intangible assets the cost of certain milestones payable by us to collaborative partners and incurred at or after the product has obtained regulatory approval for marketing. The intangible assets associated with these milestones are amortized over the remaining estimated useful life of the underlying asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded no significant intangible asset impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. The effect of a change in tax rate on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under tax law and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file federal and state income tax returns in the United States and income tax returns in various other foreign jurisdictions with varying statutes of limitations. Due to net operating losses incurred, our income tax returns from inception to date are subject to examination by taxing authorities. We recognize interest expense and penalties related to income tax matters, including unrecognized tax benefits, as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income tax expense for basis differences related to global intangible low-taxed income ("GILTI") as a period cost if and when incurred. GILTI is a category of income that is earned abroad by U.S.-controlled foreign corporations (CFCs) and is subject to special treatment under the U.S. tax code.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warranty Accrual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated warranty costs associated with a product are recorded at the time revenue is recognized. We estimate future warranty costs by analyzing historical warranty experience for the timing and amount of returned product, and expectations for future warranty activity based on changes and improvements to the product or process that are in place or will be in place in the future. We evaluate these estimates on at least a quarterly basis to determine the continued appropriateness of our assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to certain legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. We review the status of each significant matter quarterly and assess our potential financial exposure. If the potential loss from a claim or legal proceeding is considered probable and the amount can be reasonably estimated, we record a liability and an expense for the estimated loss and disclose it in our financial statements if it is significant. If we determine that a loss is possible and the range of the loss can be reasonably determined, we do not record a liability or an expense but we disclose the range of the possible loss. We base our judgments on the best information available at the time. As additional information becomes available, we reassess the potential liability related to our pending claims and litigation and may revise our estimates. Any revision of our estimates of potential liability could have a material impact on our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income consists of two elements, net income and other comprehensive loss. We report all components of comprehensive income, including net income, in our financial statements in the period in which they are recognized. Total comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net income and the components of other comprehensive loss, including foreign currency translation adjustments and unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate our revenue from the sale of disposable sensors and our reusable transmitter and receiver, collectively referred to as Reusable Hardware. We also refer to Reusable Hardware and disposable sensors in this section as Components. We generally recognize revenue when control is transferred to our customers in an amount that reflects the net consideration to which we expect to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining how revenue should be recognized, a five-step process is used, which includes identifying performance obligations in the contract, determining whether the performance obligations are separate, allocating the transaction price to each separate performance obligation, estimating the amount of variable consideration to include in the transaction price and determining the timing of revenue recognition for separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contracts and Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider customer purchase orders, which in most cases are governed by agreements with distributors or third-party payors, to be contracts with a customer. For each contract, we consider the obligation to transfer Components to the customer, each of which are distinct, to be separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Transaction Price&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for the Components reflects the net consideration to which we expect to be entitled. Transaction price is typically based on the contracted rates less an estimate of claim denials and historical reimbursement experience by payor, which include current and future expectations regarding reimbursement rates and payor mix. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include an estimate of variable consideration in the calculation of the transaction price at the time of sale, when control of the Components transfers to the customer. Variable consideration includes, but is not limited to: rebates, chargebacks, consideration payable to customers such as specialty distributor and wholesaler fees, product returns provision, prompt payment discounts, and various other promotional or incentive arrangements.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our provisions related to variable consideration as a reduction of accounts receivable when we are not required to make a payment or as a liability when we are required to make a payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review the adequacy of our estimates for transaction price adjustments and variable consideration at each reporting date. If the actual amounts of consideration we receive differ from our estimates, we would adjust our estimates and that would affect reported revenue in the period that such variances become known. If any of these judgments were to change, it could cause a material increase or decrease in the amount of revenue we report in a particular period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to rebates on pricing programs with managed care organizations, such as pharmacy benefit managers, governmental and third-party commercial payors, primarily in the U.S. We estimate provisions for rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or trends and channel inventory data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We participate in chargeback programs, primarily with government entities in the U.S., under which pricing on products below negotiated list prices is provided to participating entities and equal to the difference between their acquisition cost and the lower negotiated price. We estimate provisions for chargebacks primarily based on historical experience on a product and program basis, current contract prices under the chargeback programs and channel inventory data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consideration Payable to the Customer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We pay administrative and service fees to certain of our distributors based on a fixed percentage of the product price. These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price. We accrue for these fees based on actual net sales and contractual fee rates negotiated with the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the terms of their distribution agreements, most distributors do not have rights of return. The distributors typically have a limited time frame to notify us of any missing, damaged, defective or non-conforming products. We generally provide a &#x201c;30-day money back guarantee&#x201d; program whereby first-time end-user customers may return Reusable Hardware. We estimate our product returns provision principally based on historical experience by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Additionally, we consider other specific factors such as estimated shelf life of inventory in the distribution channel and changes to customer terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prompt Payment Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. We estimate prompt payment discount accruals based on actual net sales and contractual discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Various Other Promotional or Incentive Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other promotional or incentive arrangements are periodically offered to customers, including but not limited to co-payment assistance we provide to patients with commercial insurance, promotional programs related to the launch of products or other targeted promotions. We record a provision for the incentive earned based on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenue from sales of Components upon transfer of control of the product to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In cases where our free-of-charge software, mobile applications and updates are deemed to be separate performance obligations, revenue is recognized over time on a ratable basis over the estimated life of the related Reusable Hardware component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our sales of Components include an assurance-type warranty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable and deferred revenue. Payment terms vary by contract type and type of customer and generally range from 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable as of December&#160;31, 2023 included unbilled accounts receivable of $8.0 million. We expect to invoice and collect all unbilled accounts receivable within twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record deferred revenue when we have entered into a contract with a customer and cash payments are received or due prior to transfer of control or satisfaction of the related performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations are generally satisfied within twelve months of the initial contract date. The deferred revenue balances related to performance obligations that will be satisfied after twelve months was $7.4 million as of December&#160;31, 2023 and $19.0 million as of December&#160;31, 2022. These balances are included in other long-term liabilities in our consolidated balance sheets. Revenue recognized in the period from performance obligations satisfied in previous periods was not material for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred cost of sales are associated with transactions for which revenue recognition criteria are not met but product has shipped and released from inventory. Deferred cost of sales are included in prepaid and other current assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive Compensation Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally expense incentive compensation associated with our internal sales force when incurred because the amortization period for such costs, if capitalized, would have been &lt;span style="-sec-ix-hidden:f-535"&gt;one&lt;/span&gt; year or less. We record these costs in selling, general and administrative expense in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Shipment Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record the amounts we charge our customers for the shipping and handling of our products in revenue and we record the related costs as cost of sales in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;We expense costs of research and development as we incur them. Our research and development expenses primarily consists of engineering and research expenses related to our sensing technology, clinical trials, regulatory expenses, quality assurance programs, employee compensation, and business process outsourcers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our technology includes certain software that we develop. We expense software development costs as we incur them until technological feasibility has been established, at which time we capitalize development costs until the product is available for general release to customers. To date, our software has been available for general release concurrent with the establishment of technological feasibility and, accordingly, we have not capitalized any development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into agreements with collaboration partners for the development and commercialization of our products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we account for these agreements, we consider the unique nature, terms and facts and circumstances of each transaction. Below are some example activities and how we account for them:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;Payments to collaboration partners through issuance of common stock as consideration in an asset acquisition are considered share-based payment to non-employees in exchange for goods within the scope of ASC Topic 718, &#x201c;Compensation - Stock Compensation.&#x201d; The amount and the timing of the cost recognition of such milestones in our financial statements is driven by the accounting for the specific type of equity instrument under ASC 718 that aligns with the terms of the agreement, including any performance conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;The value associated with in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) in an asset acquisition incurred prior to regulatory approval is expensed as it does not have an alternative future use and is recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;The value associated with IPR&amp;amp;D in an asset acquisition incurred at or after regulatory approval is usually capitalized as an intangible asset and amortized over the periods in which the related products are expected to contribute to future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense costs to produce advertising as we incur them whereas costs to communicate advertising are expensed when the advertising is first run. Advertising costs are included in selling, general and administrative expenses. Advertising expense was $180.8 million, $160.6 million and $150.1 million for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. Lease right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Lease right-of-use assets and liabilities with terms of more than 12 months are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to determine the present value is our collateralized incremental borrowing rate unless the interest rate implicit in the lease is readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For operating leases, lease expense is recognized on a straight-line basis within operating expenses over the lease term. For finance leases, lease expense is recognized as interest and depreciation; interest using the effective interest method and depreciation on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. Short-term leases with lease terms of 12 months or less are not recorded on the balance sheet and are recognized on a straight line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and lease liabilities are presented separately in our consolidated balance sheets. Finance lease right-of-use assets are included in property and equipment and finance lease liabilities are included in accounts payable and accrued liabilities and in other long-term liabilities in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our lease agreements may contain lease components and non-lease components. For certain asset classes, we have elected to account for both of those components as a single lease component. We use a portfolio approach to account for the right-of-use assets and liabilities associated with certain machinery and equipment leases. Variable lease payments may include payments associated with non-lease components, payments that do not depend on a rate or index, or other costs. Variable lease payments are recognized in the period in which the obligation for those payments are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value time-based restricted stock units or RSUs at the date of grant using the intrinsic value method. Certain RSUs granted to senior management vest based on the achievement of pre-established performance or market goals. We estimate the fair value of these performance/market-based RSUs, or PSUs, at the date of grant using the intrinsic value method and the probability that the specified performance criteria will be met. We update our assessment of the probability that the specified performance criteria will be achieved each quarter and adjust our estimate of the fair value of the PSUs if necessary. The Monte Carlo methodology that we use to estimate the fair value of PSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the PSUs at the date of grant must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If any of the assumptions used change significantly, share-based compensation expense may differ materially from what we have recorded in the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for forfeitures as they occur by reversing any share-based compensation expense related to awards that will not vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Income Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share attributable to common stockholders is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the period and, when dilutive, potential common share equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares consist of shares issuable from RSUs, PSUs, warrants, our senior convertible notes, and collaborative sales-based milestones. Potentially dilutive common shares issuable upon vesting of RSUs, PSUs, and exercise of warrants are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our senior convertible notes are determined using the if-converted method. In periods of net losses, we exclude all potentially dilutive common shares from the computation of the diluted net loss per share for those periods as the effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net income per share for the periods shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;541.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;341.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;554.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;352.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;386.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;386.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive potential common stock outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaborative sales-based milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;425.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;428.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding anti-dilutive securities not included in the diluted net income per share attributable to common stockholders calculations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This guidance is intended improve the accounting for acquired revenue contracts with customers in a business combination. The new guidance requires that the acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The amendments should be applied prospectively to business combinations occurring on or after the adoption date. We adopted ASU 2021-08 in the first quarter of 2023 and there was no impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU expands public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity&#x2019;s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. The ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The ASU should be applied on a prospective basis although retrospective application is permitted. We are currently evaluating the impact of this standard on our consolidated financial disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-479">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements include the accounts of DexCom, Inc. and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. We have reclassified certain amounts previously reported in our financial statements to conform to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash. For international subsidiaries whose functional currencies are the local currencies, we translate the financial statements into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. We include translation-related adjustments in comprehensive income and in accumulated other comprehensive loss in the equity section of our consolidated balance sheets. We record gains and losses resulting from transactions with customers and vendors that are denominated in currencies other than the functional currency and from certain intercompany transactions in other income (expense), net in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-478">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements include the accounts of DexCom, Inc. and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. We have reclassified certain amounts previously reported in our financial statements to conform to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the functional currencies of our international subsidiaries by reviewing the environment where each subsidiary primarily generates and expends cash. For international subsidiaries whose functional currencies are the local currencies, we translate the financial statements into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. We include translation-related adjustments in comprehensive income and in accumulated other comprehensive loss in the equity section of our consolidated balance sheets. We record gains and losses resulting from transactions with customers and vendors that are denominated in currencies other than the functional currency and from certain intercompany transactions in other income (expense), net in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-480">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires us to make certain estimates and assumptions that affect the amounts reported in our consolidated financial statements and the disclosures made in the accompanying notes. Areas requiring significant estimates include rebates, excess or obsolete inventories and the valuation of inventory, accruals for litigation contingencies, and the amount of our worldwide tax provision and the realizability of deferred tax assets. Despite our intention to establish accurate estimates and use reasonable assumptions, actual results may differ from our estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-481">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Uses unadjusted quoted prices that are available in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Uses inputs other than quoted prices included in Level&#160;1 that are observable, either directly or indirectly, through correlation with market data. These include quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Uses unobservable inputs that are supported by little or no market activity and that are significant to the determination of fair value. Level 3 assets and liabilities include those whose fair values are determined using pricing models, discounted cash flow methodologies, or similar valuation techniques and significant judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of most of our cash equivalents using Level 1 inputs. We estimate the fair value of our marketable equity securities using Level 1 inputs and we estimate the fair value of our marketable debt securities using Level 2 inputs. We carry our marketable securities at fair value. We carry our other financial instruments, such as cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities, at cost, which approximates the related fair values due to the short-term maturities of these instruments. See Note 3 &#x201c;Fair Value Measurements&#x201d; to the consolidated financial statements for more information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-482">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider highly liquid investments with a maturity of 90 days or less at the time of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <dxcm:MaturityThresholdOfInvestmentsClassifiedToCashEquivalents contextRef="c-1" id="f-483">P90D</dxcm:MaturityThresholdOfInvestmentsClassifiedToCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-484">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have classified our marketable securities with remaining maturity at purchase of more than three months and remaining maturities of one year or less as short-term marketable securities. We have also classified marketable securities with remaining maturities of greater than one year as short-term marketable securities based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate realized gains or losses on our marketable securities using the specific identification method. We carry our marketable debt securities at fair value with unrealized gains and losses reported as a separate component of stockholders&#x2019; equity in our consolidated balance sheets and included in comprehensive income. Interest income and realized gains and losses on marketable debt securities are included in other income (expense), net in our consolidated statements of operations. We carry our marketable equity securities at fair value with realized and unrealized gains and losses reported in income (loss) from equity investments in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest in various types of debt securities, including debt securities in government-sponsored entities, corporate debt securities, U.S. Treasury securities, supranational securities, and commercial paper. We do not generally intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. See Note 3 &#x201c;Fair Value Measurements&#x201d; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-Term Marketable Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Note 4 &#x201c;Balance Sheet Details and Other Financial Information&#x201d; to the consolidated financial statements for more information on our marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-485">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are generally recorded at the invoiced amount, net of prompt pay discounts, for distributors and at net realizable value for direct customers, which is determined using estimates of claim denials and historical reimbursement experience without regard to aging category. Accounts receivable are not interest bearing. We evaluate the creditworthiness of significant customers based on historical trends, the financial condition of our customers, and external market factors. We generally do not require collateral from our customers. We maintain an allowance for doubtful accounts for potential credit losses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a customer account is uncollectible.&#160;Generally, receivable balances that are more than one year past due are deemed uncollectible.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-486">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Significant Customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term marketable securities, and accounts receivable. We limit our exposure to credit risk by placing our cash and investments with a few major financial institutions. We have also established guidelines regarding diversification of our investments and their maturities that are designed to maintain principal and maximize liquidity. We review these guidelines periodically and modify them to take advantage of trends in yields and interest rates and changes in our operations and financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-487">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the percentages of total revenue or gross accounts receivable for customers that represent 10% or more of the respective amounts for the periods shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Revenue**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;* Less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;** Total revenue for each customer is net of fees, cash discounts, and rebates directly allocable to that customer. Rebates paid to other entities are excluded; therefore, the combined value may exceed 100%.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-65" decimals="2" id="f-488" unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-66" decimals="2" id="f-489" unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-67" decimals="2" id="f-490" unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-68" decimals="2" id="f-491" unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-69" decimals="2" id="f-492" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-70" decimals="2" id="f-493" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-71" decimals="2" id="f-494" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-72" decimals="2" id="f-495" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="2" id="f-496" unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-74" decimals="2" id="f-497" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-498" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-499" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-77" decimals="2" id="f-500" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-78" decimals="2" id="f-501" unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-79" decimals="2" id="f-502" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-80" decimals="2" id="f-503" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-81" decimals="2" id="f-504" unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-82" decimals="2" id="f-505" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-83" decimals="2" id="f-506" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-507">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is valued at the lower of cost or net realizable value on a part-by-part basis that approximates first in, first out. We capitalize inventory produced in preparation for commercial launches when it becomes probable that the product will receive regulatory approval and that the related costs will be recoverable through the commercialization of the product. A number of factors are considered, including the status of the regulatory application approval process, management&#x2019;s judgment of probable future commercial use, and net realizable value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record adjustments to inventory for potential excess or obsolete inventory, as well as inventory that does not pass quality control testing, in order to state inventory at net realizable value. Factors influencing these adjustments include inventories on hand and on order compared to estimated future usage and sales for existing and new products, as well as judgments regarding quality control testing data and assumptions about the likelihood of scrap and obsolescence. Once written down the adjustments are considered permanent and are not reversed until the related inventory is disposed of or sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our products require customized products and components that currently are available from a limited number of sources. We purchase certain components and materials from single sources due to quality considerations, costs or constraints resulting from regulatory requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, our inventory reserves have been adequate to cover our actual losses. However, if actual product life cycles, product quality or market conditions differ from our assumptions, additional inventory adjustments that would increase cost of sales could be required.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-508">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization. We capitalize additions and improvements and expense maintenance and repairs as incurred. We also capitalize certain costs incurred for the development of enterprise-level business and finance software that we use internally in our operations. Costs incurred in the application development phase are capitalized while costs related to planning and other preliminary project activities and to post-implementation activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate depreciation using the straight-line method over the estimated useful lives of the assets. Estimated useful lives are generally &lt;span style="-sec-ix-hidden:f-509"&gt;three&lt;/span&gt; to five years for computer software and hardware, including internal use software, &lt;span style="-sec-ix-hidden:f-511"&gt;four&lt;/span&gt; to fifteen years for machinery and equipment, and five years for furniture and fixtures. Leasehold and land improvements are amortized over the shorter of the estimated useful lives of the assets or the remaining lease term. Buildings are amortized over the shorter of the ownership of the building or forty years. We include the amortization of assets that are recorded under finance leases in depreciation expense. On retirement or disposition, the asset cost and related accumulated depreciation are removed from our consolidated balance sheets and any gain or loss is recognized in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the recoverability of the asset by comparing the carrying amount to the future undiscounted cash flows that we expect the asset to generate. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-85" id="f-510">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-87" id="f-512">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-88" id="f-513">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-89" id="f-514">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-515">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record goodwill when the fair value of consideration transferred in a business combination exceeds the fair value of the identifiable assets acquired and liabilities assumed. Goodwill and other intangible assets that have indefinite useful lives are not amortized, but are tested annually for impairment during the fourth fiscal quarter and whenever events or changes in circumstances indicate that it is more likely than not that the fair value is less than the carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business, and an adverse action or assessment by a regulator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with Dexcom&#x2019;s reporting structure and the availability of discrete financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform the first step of our annual impairment analysis by either comparing a reporting unit&#x2019;s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit&#x2019;s fair value from the last quantitative assessment to determine if there is potential impairment. We may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit&#x2019;s estimated fair value was significantly in excess of the carrying value of its net assets and we do not believe there have been significant changes in the reporting unit&#x2019;s operations that would significantly decrease its estimated fair value or significantly increase its net assets.&#160;If a quantitative assessment is performed the evaluation includes management estimates of cash flow projections based on internal future projections&#160;and/or use of a market approach by looking at market values of comparable companies. Key assumptions&#160;for these projections include revenue growth, future gross margin and operating margin growth, and weighted cost of capital and terminal growth rates. The revenue and margin growth are based on increased sales of new and existing products as we maintain investments in research and development. Additional assumed value creators may include increased efficiencies from capital spending. The resulting cash flows are discounted using a weighted average cost of capital. Operating mechanisms and requirements&#160;to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including the timing and probability of regulatory approvals for our products to be commercialized. We also consider Dexcom&#x2019;s market capitalization as a part of our analysis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the estimated fair value of a reporting unit exceeds the carrying amount of the net assets assigned to that unit, goodwill is not impaired and no further analysis is required. If the carrying value of the net assets assigned to a reporting unit exceeds the estimated fair value of the unit, we perform the second step of the impairment test. In this step we allocate the fair value of the reporting unit calculated in step one to all of the assets and liabilities of that unit, as if we had just acquired the reporting unit in a business combination. The excess of the fair value of the reporting unit over the total amount allocated to the assets and liabilities represents the implied fair value of goodwill. If the carrying amount of a reporting unit&#x2019;s goodwill exceeds its implied fair value, we would record an impairment loss equal to the difference. We recorded no significant goodwill impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in goodwill for the twelve months ended December&#160;31, 2023 and 2022 primarily consisted of translation adjustments on our foreign currency denominated goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are included in intangibles and other assets, net in our consolidated balance sheets. We amortize intangible assets with a finite life, such as the customer relationships, acquired technology and intellectual property, trademarks and trade name, and other intangibles, on a straight-line basis over their estimated useful lives, which range from &lt;span style="-sec-ix-hidden:f-519"&gt;one&lt;/span&gt; to seven years. We review intangible assets that have finite lives and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We estimate the fair value of the asset based on the present value of future cash flows for those assets. If the carrying value of an asset exceeds its estimated fair value, we would record an impairment loss equal to the difference.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For transactions other than a business combination, we also capitalize as intangible assets the cost of certain milestones payable by us to collaborative partners and incurred at or after the product has obtained regulatory approval for marketing. The intangible assets associated with these milestones are amortized over the remaining estimated useful life of the underlying asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded no significant intangible asset impairment charges for the twelve months ended December&#160;31, 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-27" decimals="0" id="f-516" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-26" decimals="0" id="f-517" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="0" id="f-518" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-91" id="f-520">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-27" decimals="0" id="f-521" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="0" id="f-522" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-26" decimals="0" id="f-523" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-524">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. The effect of a change in tax rate on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under tax law and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file federal and state income tax returns in the United States and income tax returns in various other foreign jurisdictions with varying statutes of limitations. Due to net operating losses incurred, our income tax returns from inception to date are subject to examination by taxing authorities. We recognize interest expense and penalties related to income tax matters, including unrecognized tax benefits, as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income tax expense for basis differences related to global intangible low-taxed income ("GILTI") as a period cost if and when incurred. GILTI is a category of income that is earned abroad by U.S.-controlled foreign corporations (CFCs) and is subject to special treatment under the U.S. tax code.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:StandardProductWarrantyPolicy contextRef="c-1" id="f-525">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warranty Accrual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated warranty costs associated with a product are recorded at the time revenue is recognized. We estimate future warranty costs by analyzing historical warranty experience for the timing and amount of returned product, and expectations for future warranty activity based on changes and improvements to the product or process that are in place or will be in place in the future. We evaluate these estimates on at least a quarterly basis to determine the continued appropriateness of our assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:StandardProductWarrantyPolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-526">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to certain legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. We review the status of each significant matter quarterly and assess our potential financial exposure. If the potential loss from a claim or legal proceeding is considered probable and the amount can be reasonably estimated, we record a liability and an expense for the estimated loss and disclose it in our financial statements if it is significant. If we determine that a loss is possible and the range of the loss can be reasonably determined, we do not record a liability or an expense but we disclose the range of the possible loss. We base our judgments on the best information available at the time. As additional information becomes available, we reassess the potential liability related to our pending claims and litigation and may revise our estimates. Any revision of our estimates of potential liability could have a material impact on our financial position and operating results.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-527">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income consists of two elements, net income and other comprehensive loss. We report all components of comprehensive income, including net income, in our financial statements in the period in which they are recognized. Total comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. We report net income and the components of other comprehensive loss, including foreign currency translation adjustments and unrealized gains and losses on marketable securities, net of their related tax effect to arrive at total comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-528">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate our revenue from the sale of disposable sensors and our reusable transmitter and receiver, collectively referred to as Reusable Hardware. We also refer to Reusable Hardware and disposable sensors in this section as Components. We generally recognize revenue when control is transferred to our customers in an amount that reflects the net consideration to which we expect to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining how revenue should be recognized, a five-step process is used, which includes identifying performance obligations in the contract, determining whether the performance obligations are separate, allocating the transaction price to each separate performance obligation, estimating the amount of variable consideration to include in the transaction price and determining the timing of revenue recognition for separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contracts and Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider customer purchase orders, which in most cases are governed by agreements with distributors or third-party payors, to be contracts with a customer. For each contract, we consider the obligation to transfer Components to the customer, each of which are distinct, to be separate performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Transaction Price&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for the Components reflects the net consideration to which we expect to be entitled. Transaction price is typically based on the contracted rates less an estimate of claim denials and historical reimbursement experience by payor, which include current and future expectations regarding reimbursement rates and payor mix. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include an estimate of variable consideration in the calculation of the transaction price at the time of sale, when control of the Components transfers to the customer. Variable consideration includes, but is not limited to: rebates, chargebacks, consideration payable to customers such as specialty distributor and wholesaler fees, product returns provision, prompt payment discounts, and various other promotional or incentive arrangements.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our provisions related to variable consideration as a reduction of accounts receivable when we are not required to make a payment or as a liability when we are required to make a payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review the adequacy of our estimates for transaction price adjustments and variable consideration at each reporting date. If the actual amounts of consideration we receive differ from our estimates, we would adjust our estimates and that would affect reported revenue in the period that such variances become known. If any of these judgments were to change, it could cause a material increase or decrease in the amount of revenue we report in a particular period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to rebates on pricing programs with managed care organizations, such as pharmacy benefit managers, governmental and third-party commercial payors, primarily in the U.S. We estimate provisions for rebates based on contractual arrangements, estimates of products sold subject to rebate, known events or trends and channel inventory data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We participate in chargeback programs, primarily with government entities in the U.S., under which pricing on products below negotiated list prices is provided to participating entities and equal to the difference between their acquisition cost and the lower negotiated price. We estimate provisions for chargebacks primarily based on historical experience on a product and program basis, current contract prices under the chargeback programs and channel inventory data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consideration Payable to the Customer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We pay administrative and service fees to certain of our distributors based on a fixed percentage of the product price. These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price. We accrue for these fees based on actual net sales and contractual fee rates negotiated with the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the terms of their distribution agreements, most distributors do not have rights of return. The distributors typically have a limited time frame to notify us of any missing, damaged, defective or non-conforming products. We generally provide a &#x201c;30-day money back guarantee&#x201d; program whereby first-time end-user customers may return Reusable Hardware. We estimate our product returns provision principally based on historical experience by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Additionally, we consider other specific factors such as estimated shelf life of inventory in the distribution channel and changes to customer terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prompt Payment Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. We estimate prompt payment discount accruals based on actual net sales and contractual discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Various Other Promotional or Incentive Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other promotional or incentive arrangements are periodically offered to customers, including but not limited to co-payment assistance we provide to patients with commercial insurance, promotional programs related to the launch of products or other targeted promotions. We record a provision for the incentive earned based on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenue from sales of Components upon transfer of control of the product to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In cases where our free-of-charge software, mobile applications and updates are deemed to be separate performance obligations, revenue is recognized over time on a ratable basis over the estimated life of the related Reusable Hardware component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our sales of Components include an assurance-type warranty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable and deferred revenue. Payment terms vary by contract type and type of customer and generally range from 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable as of December&#160;31, 2023 included unbilled accounts receivable of $8.0 million. We expect to invoice and collect all unbilled accounts receivable within twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record deferred revenue when we have entered into a contract with a customer and cash payments are received or due prior to transfer of control or satisfaction of the related performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations are generally satisfied within twelve months of the initial contract date. The deferred revenue balances related to performance obligations that will be satisfied after twelve months was $7.4 million as of December&#160;31, 2023 and $19.0 million as of December&#160;31, 2022. These balances are included in other long-term liabilities in our consolidated balance sheets. Revenue recognized in the period from performance obligations satisfied in previous periods was not material for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred cost of sales are associated with transactions for which revenue recognition criteria are not met but product has shipped and released from inventory. Deferred cost of sales are included in prepaid and other current assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive Compensation Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally expense incentive compensation associated with our internal sales force when incurred because the amortization period for such costs, if capitalized, would have been &lt;span style="-sec-ix-hidden:f-535"&gt;one&lt;/span&gt; year or less. We record these costs in selling, general and administrative expense in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <dxcm:RevenueRecognitionSalesReturnsCoveragePeriod contextRef="c-1" id="f-529">P30D</dxcm:RevenueRecognitionSalesReturnsCoveragePeriod>
    <dxcm:ContractPaymentTermsNumberofDays contextRef="c-92" id="f-530">P30D</dxcm:ContractPaymentTermsNumberofDays>
    <dxcm:ContractPaymentTermsNumberofDays contextRef="c-93" id="f-531">P90D</dxcm:ContractPaymentTermsNumberofDays>
    <us-gaap:UnbilledContractsReceivable contextRef="c-24" decimals="-5" id="f-532" unitRef="usd">8000000.0</us-gaap:UnbilledContractsReceivable>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-24" decimals="-5" id="f-533" unitRef="usd">7400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-25" decimals="-5" id="f-534" unitRef="usd">19000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <dxcm:ProductShipmentCostsPolicyTextBlock contextRef="c-1" id="f-536">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Shipment Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record the amounts we charge our customers for the shipping and handling of our products in revenue and we record the related costs as cost of sales in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</dxcm:ProductShipmentCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-537">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;We expense costs of research and development as we incur them. Our research and development expenses primarily consists of engineering and research expenses related to our sensing technology, clinical trials, regulatory expenses, quality assurance programs, employee compensation, and business process outsourcers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our technology includes certain software that we develop. We expense software development costs as we incur them until technological feasibility has been established, at which time we capitalize development costs until the product is available for general release to customers. To date, our software has been available for general release concurrent with the establishment of technological feasibility and, accordingly, we have not capitalized any development costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-538">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into agreements with collaboration partners for the development and commercialization of our products. These arrangements may include payments contingent on the occurrence of certain events such as development, regulatory or sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we account for these agreements, we consider the unique nature, terms and facts and circumstances of each transaction. Below are some example activities and how we account for them:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;Payments to collaboration partners through issuance of common stock as consideration in an asset acquisition are considered share-based payment to non-employees in exchange for goods within the scope of ASC Topic 718, &#x201c;Compensation - Stock Compensation.&#x201d; The amount and the timing of the cost recognition of such milestones in our financial statements is driven by the accounting for the specific type of equity instrument under ASC 718 that aligns with the terms of the agreement, including any performance conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;The value associated with in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) in an asset acquisition incurred prior to regulatory approval is expensed as it does not have an alternative future use and is recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:47.25pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;The value associated with IPR&amp;amp;D in an asset acquisition incurred at or after regulatory approval is usually capitalized as an intangible asset and amortized over the periods in which the related products are expected to contribute to future cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-539">&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We expense costs to produce advertising as we incur them whereas costs to communicate advertising are expensed when the advertising is first run. Advertising costs are included in selling, general and administrative expenses.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-5" id="f-540" unitRef="usd">180800000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-26" decimals="-5" id="f-541" unitRef="usd">160600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-27" decimals="-5" id="f-542" unitRef="usd">150100000</us-gaap:AdvertisingExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-543">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. Lease right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Lease right-of-use assets and liabilities with terms of more than 12 months are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to determine the present value is our collateralized incremental borrowing rate unless the interest rate implicit in the lease is readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For operating leases, lease expense is recognized on a straight-line basis within operating expenses over the lease term. For finance leases, lease expense is recognized as interest and depreciation; interest using the effective interest method and depreciation on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. Short-term leases with lease terms of 12 months or less are not recorded on the balance sheet and are recognized on a straight line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and lease liabilities are presented separately in our consolidated balance sheets. Finance lease right-of-use assets are included in property and equipment and finance lease liabilities are included in accounts payable and accrued liabilities and in other long-term liabilities in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our lease agreements may contain lease components and non-lease components. For certain asset classes, we have elected to account for both of those components as a single lease component. We use a portfolio approach to account for the right-of-use assets and liabilities associated with certain machinery and equipment leases. Variable lease payments may include payments associated with non-lease components, payments that do not depend on a rate or index, or other costs. Variable lease payments are recognized in the period in which the obligation for those payments are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-544">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value time-based restricted stock units or RSUs at the date of grant using the intrinsic value method. Certain RSUs granted to senior management vest based on the achievement of pre-established performance or market goals. We estimate the fair value of these performance/market-based RSUs, or PSUs, at the date of grant using the intrinsic value method and the probability that the specified performance criteria will be met. We update our assessment of the probability that the specified performance criteria will be achieved each quarter and adjust our estimate of the fair value of the PSUs if necessary. The Monte Carlo methodology that we use to estimate the fair value of PSUs at the date of grant incorporates into the valuation the possibility that the market condition may not be satisfied. Provided that the requisite service is rendered, the total fair value of the PSUs at the date of grant must be recognized as compensation expense even if the market condition is not achieved. However, the number of shares that ultimately vest can vary significantly with the performance of the specified market criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If any of the assumptions used change significantly, share-based compensation expense may differ materially from what we have recorded in the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for forfeitures as they occur by reversing any share-based compensation expense related to awards that will not vest.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-545">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Income Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share attributable to common stockholders is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the period and, when dilutive, potential common share equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares consist of shares issuable from RSUs, PSUs, warrants, our senior convertible notes, and collaborative sales-based milestones. Potentially dilutive common shares issuable upon vesting of RSUs, PSUs, and exercise of warrants are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our senior convertible notes are determined using the if-converted method. In periods of net losses, we exclude all potentially dilutive common shares from the computation of the diluted net loss per share for those periods as the effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-546">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net income per share for the periods shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;541.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;341.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Add back interest expense, net of tax attributable to assumed conversion of senior convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;554.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;352.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;386.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;386.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive potential common stock outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaborative sales-based milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;425.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;428.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-547" unitRef="usd">541500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-5" id="f-548" unitRef="usd">341200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-5" id="f-549" unitRef="usd">216900000</us-gaap:NetIncomeLoss>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c-1" decimals="-5" id="f-550" unitRef="usd">12600000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c-26" decimals="-5" id="f-551" unitRef="usd">11000000.0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="c-27" decimals="-5" id="f-552" unitRef="usd">11400000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="c-1" decimals="-5" id="f-553" unitRef="usd">554100000</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="c-26" decimals="-5" id="f-554" unitRef="usd">352200000</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:NetIncomeLossAttributableToParentDiluted contextRef="c-27" decimals="-5" id="f-555" unitRef="usd">228300000</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-557"
      unitRef="usdPerShare">0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-558"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-559"
      unitRef="usdPerShare">1.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-560"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-561"
      unitRef="usdPerShare">0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-562" unitRef="shares">386000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="-5" id="f-563" unitRef="shares">389400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="-5" id="f-564" unitRef="shares">386900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-94" decimals="-5" id="f-565" unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-95" decimals="-5" id="f-566" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-96" decimals="-5" id="f-567" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-97" decimals="-5" id="f-568" unitRef="shares">1100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-98" decimals="-5" id="f-569" unitRef="shares">1000000.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-99" decimals="-5" id="f-570" unitRef="shares">2100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-100"
      decimals="-5"
      id="f-571"
      unitRef="shares">26200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-101"
      decimals="-5"
      id="f-572"
      unitRef="shares">26900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-102"
      decimals="-5"
      id="f-573"
      unitRef="shares">28300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-103"
      decimals="-5"
      id="f-574"
      unitRef="shares">11500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-104"
      decimals="-5"
      id="f-575"
      unitRef="shares">10200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-105"
      decimals="-5"
      id="f-576"
      unitRef="shares">11500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-577" unitRef="shares">425500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="-5" id="f-578" unitRef="shares">427500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="-5" id="f-579" unitRef="shares">428800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-580">&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding anti-dilutive securities not included in the diluted net income per share attributable to common stockholders calculations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units and performance stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-97" decimals="-5" id="f-581" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-98" decimals="-5" id="f-582" unitRef="shares">400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-99" decimals="-5" id="f-583" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-584">&lt;div style="margin-bottom:1pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This guidance is intended improve the accounting for acquired revenue contracts with customers in a business combination. The new guidance requires that the acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective for public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The amendments should be applied prospectively to business combinations occurring on or after the adoption date. We adopted ASU 2021-08 in the first quarter of 2023 and there was no impact to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU expands public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. We are currently evaluating the impact of this standard on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity&#x2019;s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. The ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The ASU should be applied on a prospective basis although retrospective application is permitted. We are currently evaluating the impact of this standard on our consolidated financial disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-585">&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;2. Development and Other Agreements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration with Verily Life Sciences&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 20, 2018, we entered into an Amended and Restated Collaboration and License Agreement with Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited (collectively, &#x201c;Verily&#x201d;), which we refer to as the Restated Collaboration Agreement. This replaced our original Collaboration and License Agreement with Verily dated August 10, 2015, as amended in October 2016, including the royalty obligations provisions under that original agreement. Pursuant to the Restated Collaboration Agreement, we and Verily have agreed to continue to jointly develop a certain next-generation CGM product, and potentially one or more additional CGM products, for which we will have exclusive commercialization rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Restated Collaboration Agreement also provides us with an exclusive license to use intellectual property of Verily resulting from the collaboration, and certain Verily patents, in the development, manufacture and commercialization of blood-based or interstitial glucose monitoring products more generally (subject to certain exclusions, which are outside of the CGM field as it is commonly understood). It also provides us with non-exclusive license rights under Verily&#x2019;s other intellectual property rights to develop, manufacture and commercialize those kinds of glucose monitoring products and certain CGM-product companion software functionalities. The Restated Collaboration Agreement requires us to use commercially reasonable efforts to develop, launch and commercialize the CGM product(s) that are the subject of the collaboration according to certain timing and other objectives, and provides for one executive sponsor from each of Dexcom and Verily to meet periodically and make decisions related to the collaboration (within a limited scope of authority) by consensus.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration of Verily&#x2019;s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we made upfront, incentive, and the product regulatory approval payments, and will make potential payments for contingent sales-based milestones upon the achievement of certain revenue targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the contingent milestones payable in shares of our common stock as equity instruments within the scope of ASC Topic 718. The product regulatory approval and sales-based milestones are accounted for as performance-based awards that vest when the performance conditions have been achieved and are recognized when the achievement of the respective contingent milestone is deemed probable. The value of the contingent milestones is based on our closing stock price on December 28, 2018, which was $29.57 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Upfront and Incentive payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the fourth quarter of 2018, we made an initial payment for an upfront fee of $250.0 million through the issuance of 7.4 million shares of our common stock. We recorded a $217.7 million charge in our consolidated statements of operations during 2018 relating to the issuance of this common stock because this milestone payment did not meet the capitalization criteria. The value of the charge was based on our closing stock price of $29.57 per share on December 28, 2018, the date on which we obtained the necessary regulatory approvals and represents the date the performance- based awards were issued. In 2019, we made a cash incentive payment of $3.2 million due to the completion of certain development obligations and we recorded these payments as research and development expense in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2021, we determined the achievement of the regulatory approval milestone to be probable and recorded an $87.1 million research and development charge in our consolidated statements of operations. This charge is associated with IPR&amp;amp;D obtained in an asset acquisition prior to regulatory approval and therefore does not have an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2022, we received regulatory approval and issued 2.9 million shares of our common stock in connection with our achievement of the related milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2022, we received FDA approval and determined the achievement of the sales-based milestones to be probable. As such, we capitalized the full value of the sales-based milestones, $152.4 million, as an intangible asset. The sales-based milestones are contingent upon the achievement of certain revenue targets. The value of the sales-based milestones is based on: 1) 5.2 million shares of our common stock, as agreed upon in November 2018 and 2) our closing stock price on December 28, 2018 of $29.57 per share. December 28, 2018 is the date on which we obtained the necessary regulatory approvals and represents the date the performance- based awards were issued. The intangible asset will be amortized using the straight-line method over its estimated useful life of 64 months through March 2028. The related amortization expense is recognized in cost of sales in our consolidated statements of operations and disclosed in Note 4 &#x201c;Intangibles, Net&#x201d; to the consolidated financial statements in Part II, Item 8 of this Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2023, we issued 3.7 million shares of our common stock in connection with our achievement of the first sales-based milestone. See the effective tax rate reconciliation in Note 8 &#x201c;Income Taxes&#x201d; to the consolidated financial statements for more information on the tax benefits related to the collaboration agreement milestone share-based payments for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All milestones may be paid in cash or shares of our common stock, at our election. If we elect to make these milestone payments in cash, any such cash payment would be equal to the number of shares that would otherwise be issued for the given milestone payment multiplied by the value of our stock on the date the relevant milestone is achieved, and adjusted to give effect to any stock splits, dividends, or similar events. We intend to pay the remaining sales-based contingent milestone in shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon achievement of the first sales-based milestone event and payment of the corresponding milestone fee by us in December 2023, the term of the Restated Collaboration Agreement was extended from December 31, 2028 to December 31, 2033.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:SharePrice
      contextRef="c-106"
      decimals="INF"
      id="f-586"
      unitRef="usdPerShare">29.57</us-gaap:SharePrice>
    <dxcm:CollaborativeArrangementUpfrontFee contextRef="c-107" decimals="-5" id="f-587" unitRef="usd">250000000.0</dxcm:CollaborativeArrangementUpfrontFee>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-108"
      decimals="-5"
      id="f-588"
      unitRef="shares">7400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <dxcm:CollaborativeResearchAndDevelopmentFee contextRef="c-108" decimals="-5" id="f-589" unitRef="usd">217700000</dxcm:CollaborativeResearchAndDevelopmentFee>
    <us-gaap:SharePrice
      contextRef="c-106"
      decimals="INF"
      id="f-590"
      unitRef="usdPerShare">29.57</us-gaap:SharePrice>
    <dxcm:CollaborativeResearchAndDevelopmentFee contextRef="c-109" decimals="-5" id="f-591" unitRef="usd">3200000</dxcm:CollaborativeResearchAndDevelopmentFee>
    <dxcm:CollaborativeResearchAndDevelopmentFee contextRef="c-110" decimals="-5" id="f-592" unitRef="usd">87100000</dxcm:CollaborativeResearchAndDevelopmentFee>
    <dxcm:SharesIssuedInConnectionWithTheRestatedCollaborationAgreement
      contextRef="c-111"
      decimals="INF"
      id="f-593"
      unitRef="shares">2900000</dxcm:SharesIssuedInConnectionWithTheRestatedCollaborationAgreement>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-112" decimals="-5" id="f-594" unitRef="usd">152400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <dxcm:PotentialFutureCommonStockIssuableSharesNewIssues
      contextRef="c-113"
      decimals="-5"
      id="f-595"
      unitRef="shares">5200000</dxcm:PotentialFutureCommonStockIssuableSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c-106"
      decimals="INF"
      id="f-596"
      unitRef="usdPerShare">29.57</us-gaap:SharePrice>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-114" id="f-597">P64M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <dxcm:PotentialCommonStockIssuableOrIssuedSharesNewIssues
      contextRef="c-115"
      decimals="-5"
      id="f-598"
      unitRef="shares">3700000</dxcm:PotentialCommonStockIssuableOrIssuedSharesNewIssues>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="c-1" id="f-599">&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our Level 1 financial instruments, which are in active markets, using unadjusted quoted market prices for identical instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We obtain the fair values for our Level 2 financial instruments, which are not in active markets, from a primary professional pricing source that uses quoted market prices for identical or comparable instruments, rather than direct observations of quoted prices in active markets. Fair values obtained from this professional pricing source can also be based on pricing models whereby all significant observable inputs, including maturity dates, issue dates, settlement dates, benchmark yields, reported trades, broker-dealer quotes, issue spreads, benchmark securities, bids, offers or other market related data, are observable or can be derived from, or corroborated by, observable market data for substantially the full term of the asset. We validate the quoted market prices provided by our primary pricing service by comparing the fair values of our Level 2 marketable securities portfolio balance provided by our primary pricing service against the fair values provided by our investment managers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2023, classified in accordance with the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;315.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;315.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,612.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,612.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;331.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,488.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2022, classified in accordance with the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;375.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;420.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,813.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,813.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;386.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,858.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,244.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Includes assets which are held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 securities during the twelve months ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Senior Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value, based on trading prices (Level 1 inputs), of our senior convertible notes were as follows as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements Using Level 1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,136.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,262.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,281.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of outstanding senior convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,544.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,451.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For more information on the carrying values of our senior convertible notes, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Convertible Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Note 5 &#x201c;Debt&#x201d; to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency and Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency forward contracts to hedge monetary assets and liabilities denominated in foreign currencies. Our foreign currency forward contracts are not designated as hedging instruments. Therefore, changes in the fair values of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The duration of these contracts is generally one month. The derivative gains and losses are included in other income (expense), net in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of December&#160;31, 2023 and December&#160;31, 2022, the notional amounts of outstanding foreign currency forward contracts were $71.0 million and $62.0 million, respectively. The resulting impact on our consolidated financial statements from currency hedging activities was not significant for the twelve months ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our foreign currency exposures vary but are primarily concentrated in the Australian Dollar, the British Pound, the Canadian Dollar, the Euro, and the Malaysian Ringgit. We monitor the costs and the impact of foreign currency risks upon our financial results as part of our risk management program. We do not use derivative financial instruments for speculation or trading purposes or for activities other than risk management. We do not require and are not required to pledge collateral for these financial instruments and we do not carry any master netting arrangements to mitigate the credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with authoritative guidance, we measure certain non-financial assets and liabilities at fair value on a non-recurring basis. These measurements are usually performed using the discounted cash flow method or cost method and Level 3 inputs. These include items such as non-financial assets and liabilities initially measured at fair value in a business combination and non-financial long-lived assets measured at fair value for an impairment assessment. In general, non-financial assets, including goodwill, intangible assets, and property and equipment, are measured at fair value when there are indicators of impairment and are recorded at fair value only when an impairment is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hold certain other investments that we do not measure at fair value on a recurring basis. The carrying values of these investments are $38.5&#160;million as of December&#160;31, 2023 and $19.0 million as of December&#160;31, 2022. We include them in other assets in our consolidated balance sheets. It is impracticable for us to estimate the fair value of these investments on a recurring basis due to the fact that these entities are privately held and limited information is available. We monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant effect on the fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no significant impairment losses during the twelve months ended December&#160;31, 2023. During the fourth quarter 2022, we vacated a leased building and made it available for sublease, resulting in an impairment of its asset group which consisted primarily of leasehold improvements and right-of-use asset. We recorded $23.0&#160;million in impairment losses during the twelve months ended December&#160;31, 2022. See Note 6 &#x201c;Leases and Other Commitments&#x201d; to the consolidated financial statements for more information. There were no significant impairment losses during the twelve months ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-600">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2023, classified in accordance with the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;315.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;315.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,612.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,612.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;331.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,488.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes financial assets that we measured at fair value on a recurring basis as of December&#160;31, 2022, classified in accordance with the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;375.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;420.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,813.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,813.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;386.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,858.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,244.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Includes assets which are held pursuant to a deferred compensation plan for senior management, which consist mainly of mutual funds.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-116" decimals="-5" id="f-601" unitRef="usd">315900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-117" decimals="-5" id="f-602" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-118" decimals="-5" id="f-603" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-24" decimals="-5" id="f-604" unitRef="usd">315900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-119" decimals="-5" id="f-605" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-120" decimals="-5" id="f-606" unitRef="usd">1612500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-121" decimals="-5" id="f-607" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-122" decimals="-5" id="f-608" unitRef="usd">1612500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-123" decimals="-5" id="f-609" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-124" decimals="-5" id="f-610" unitRef="usd">184700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-125" decimals="-5" id="f-611" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-126" decimals="-5" id="f-612" unitRef="usd">184700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-127" decimals="-5" id="f-613" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-128" decimals="-5" id="f-614" unitRef="usd">360600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-129" decimals="-5" id="f-615" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-130" decimals="-5" id="f-616" unitRef="usd">360600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-116" decimals="-5" id="f-617" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-117" decimals="-5" id="f-618" unitRef="usd">2157800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-118" decimals="-5" id="f-619" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-24" decimals="-5" id="f-620" unitRef="usd">2157800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-116" decimals="-5" id="f-621" unitRef="usd">15200000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-117" decimals="-5" id="f-622" unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-118" decimals="-5" id="f-623" unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-24" decimals="-5" id="f-624" unitRef="usd">15200000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-116" decimals="-5" id="f-625" unitRef="usd">331100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-117" decimals="-5" id="f-626" unitRef="usd">2157800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-118" decimals="-5" id="f-627" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-24" decimals="-5" id="f-628" unitRef="usd">2488900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-131" decimals="-5" id="f-629" unitRef="usd">375900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-132" decimals="-5" id="f-630" unitRef="usd">44800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-133" decimals="-5" id="f-631" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-25" decimals="-5" id="f-632" unitRef="usd">420700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-134" decimals="-5" id="f-633" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-135" decimals="-5" id="f-634" unitRef="usd">1530700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-136" decimals="-5" id="f-635" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-137" decimals="-5" id="f-636" unitRef="usd">1530700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-138" decimals="-5" id="f-637" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-139" decimals="-5" id="f-638" unitRef="usd">119400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-140" decimals="-5" id="f-639" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-141" decimals="-5" id="f-640" unitRef="usd">119400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-142" decimals="-5" id="f-641" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-143" decimals="-5" id="f-642" unitRef="usd">163800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-144" decimals="-5" id="f-643" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-145" decimals="-5" id="f-644" unitRef="usd">163800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-131" decimals="-5" id="f-645" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-132" decimals="-5" id="f-646" unitRef="usd">1813900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-133" decimals="-5" id="f-647" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-25" decimals="-5" id="f-648" unitRef="usd">1813900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-131" decimals="-5" id="f-649" unitRef="usd">10200000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-132" decimals="-5" id="f-650" unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-133" decimals="-5" id="f-651" unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c-25" decimals="-5" id="f-652" unitRef="usd">10200000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-131" decimals="-5" id="f-653" unitRef="usd">386100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-132" decimals="-5" id="f-654" unitRef="usd">1858700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-133" decimals="-5" id="f-655" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-25" decimals="-5" id="f-656" unitRef="usd">2244800000</us-gaap:AssetsFairValueDisclosure>
    <dxcm:FairValueAssetsLevel3TransfersAmount contextRef="c-1" decimals="0" id="f-657" unitRef="usd">0</dxcm:FairValueAssetsLevel3TransfersAmount>
    <dxcm:FairValueAssetsLevel3TransfersAmount contextRef="c-26" decimals="0" id="f-658" unitRef="usd">0</dxcm:FairValueAssetsLevel3TransfersAmount>
    <us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock contextRef="c-1" id="f-659">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value, based on trading prices (Level 1 inputs), of our senior convertible notes were as follows as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements Using Level 1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,136.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,262.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,281.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of outstanding senior convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,544.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,451.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-146" decimals="-5" id="f-660" unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-147" decimals="-5" id="f-661" unitRef="usd">2136200000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-148" decimals="-5" id="f-662" unitRef="usd">1262800000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-149" decimals="-5" id="f-663" unitRef="usd">1314900000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-150" decimals="-5" id="f-664" unitRef="usd">1281800000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-151" decimals="-5" id="f-665" unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-152" decimals="-5" id="f-666" unitRef="usd">2544600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-153" decimals="-5" id="f-667" unitRef="usd">3451100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DerivativeTermOfContract contextRef="c-154" id="f-668">P1M</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeNotionalAmount contextRef="c-155" decimals="-5" id="f-669" unitRef="usd">71000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-156" decimals="-5" id="f-670" unitRef="usd">62000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-24" decimals="-5" id="f-671" unitRef="usd">38500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-25" decimals="-5" id="f-672" unitRef="usd">19000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="0" id="f-673" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-26" decimals="-5" id="f-674" unitRef="usd">23000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-27" decimals="0" id="f-675" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="c-1" id="f-676">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;4. Balance Sheet Details and Other Financial Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #58a618;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term marketable securities, consisting of available-for-sale debt securities, were as follows as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities, available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,611.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,612.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,535.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,819.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,813.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-indent:-7.2pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the estimated market value of our short-term debt securities with contractual maturities up to 12 months was $2.16&#160;billion. As of December 31, 2022, the estimated market value of our short-term debt securities with contractual maturities up to 12 months was $1.81&#160;billion. Gross realized gains and losses on sales of our short-term debt securities for the twelve months ended December&#160;31, 2023, 2022 and 2021 were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review our portfolio of debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For debt securities where the fair value of the investment is less than the amortized cost basis, we have assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities at December&#160;31, 2023 were primarily due to increases in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, we have not recorded an allowance for credit losses. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the twelve months ended December&#160;31, 2023, 2022 and 2021, we had no unrealized gains or losses recognized during the reporting period on equity investments. Realized gains from the sale of an equity investment were not significant for the twelve months ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;983.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;720.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;973.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;713.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserve for prompt payment cash discounts recorded against accounts receivable, excluding allowance for doubtful accounts, was $13.7&#160;million, $8.3&#160;million, $13.7&#160;million as of December&#160;31, 2023, 2022, and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;210.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;306.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the twelve months ended December&#160;31, 2023, 2022 and 2021, we recorded excess and obsolete inventory charges of $16.6 million, $13.9 million and $28.1 million respectively, in cost of sales as a result of our ongoing assessment of sales demand, inventory on hand for each product and the continuous improvement and innovation of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred compensation plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Building&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software and hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;683.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;449.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;264.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;328.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;542.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,622.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,418.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(509.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(363.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,113.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,055.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment for the twelve months ended December&#160;31, 2023, 2022 and 2021 was $147.4 million, $144.1 million and $96.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on disposal of property and equipment during the twelve months ended December&#160;31, 2023, 2022 and 2021 recorded in operating expenses was $0.7 million, $2.2 million and $24.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;Intangibles, Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of gross intangible assets, accumulated amortization, and net intangible asset balances as of December&#160;31, 2023 and December&#160;31, 2022&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Verily intangible asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired technology and intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademarks and trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles, other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Verily intangible&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired technology and intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademarks and trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles, other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note 2 &#x201c;Development and Other Agreements&#x201d; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Excludes Verily intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total amortization expense of finite-lived intangible assets for the twelve months ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.800%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense included in cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents estimated future amortization of the Company&#x2019;s finite-lived intangible assets as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable and Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable trade&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;276.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued tax, audit, and legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued rebates &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;556.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued warranty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred compensation plan liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,345.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;901.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Payroll and Related Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued wages, bonus and taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Warranty&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warranty costs are reflected in our statements of operations as cost of sales. Reconciliations of our accrued warranty costs for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(51.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-Term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue, long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset retirement obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and dividend income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-677">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term marketable securities, consisting of available-for-sale debt securities, were as follows as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities, available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,611.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,612.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Market&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities, available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,535.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;164.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;163.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt securities, available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,819.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;div style="text-align:right"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,813.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;text-indent:-7.2pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Includes debt obligations issued by U.S. government-sponsored enterprises or U.S. government agencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-122" decimals="-5" id="f-678" unitRef="usd">1611800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-122" decimals="-5" id="f-679" unitRef="usd">1200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-122" decimals="-5" id="f-680" unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-122" decimals="-5" id="f-681" unitRef="usd">1612500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-126" decimals="-5" id="f-682" unitRef="usd">184800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-126" decimals="-5" id="f-683" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-126" decimals="-5" id="f-684" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-126" decimals="-5" id="f-685" unitRef="usd">184700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-130" decimals="-5" id="f-686" unitRef="usd">360800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-130" decimals="-5" id="f-687" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-130" decimals="-5" id="f-688" unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-130" decimals="-5" id="f-689" unitRef="usd">360600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-24" decimals="-5" id="f-690" unitRef="usd">2157400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-24" decimals="-5" id="f-691" unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-24" decimals="-5" id="f-692" unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-24" decimals="-5" id="f-693" unitRef="usd">2157800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-137" decimals="-5" id="f-694" unitRef="usd">1535100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-137" decimals="-5" id="f-695" unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-137" decimals="-5" id="f-696" unitRef="usd">4600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-137" decimals="-5" id="f-697" unitRef="usd">1530700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-141" decimals="-5" id="f-698" unitRef="usd">119600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-141" decimals="-5" id="f-699" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-141" decimals="-5" id="f-700" unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-141" decimals="-5" id="f-701" unitRef="usd">119400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-145" decimals="-5" id="f-702" unitRef="usd">164300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-145" decimals="-5" id="f-703" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-145" decimals="-5" id="f-704" unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-145" decimals="-5" id="f-705" unitRef="usd">163800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-25" decimals="-5" id="f-706" unitRef="usd">1819000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-25" decimals="-5" id="f-707" unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-25" decimals="-5" id="f-708" unitRef="usd">5300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-25" decimals="-5" id="f-709" unitRef="usd">1813900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtInstrumentTerm contextRef="c-1" id="f-710">P12M</us-gaap:DebtInstrumentTerm>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-24" decimals="-7" id="f-711" unitRef="usd">2160000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c-26" id="f-712">P12M</us-gaap:DebtInstrumentTerm>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-25" decimals="-7" id="f-713" unitRef="usd">1810000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-27" decimals="INF" id="f-714" unitRef="usd">0</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-26" decimals="INF" id="f-715" unitRef="usd">0</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-1" decimals="INF" id="f-716" unitRef="usd">0</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-717">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;983.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;720.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;973.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;713.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross contextRef="c-24" decimals="-5" id="f-718" unitRef="usd">983200000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-25" decimals="-5" id="f-719" unitRef="usd">720600000</us-gaap:AccountsReceivableGross>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-24" decimals="-5" id="f-720" unitRef="usd">9300000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-25" decimals="-5" id="f-721" unitRef="usd">7300000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet contextRef="c-24" decimals="-5" id="f-722" unitRef="usd">973900000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-25" decimals="-5" id="f-723" unitRef="usd">713300000</us-gaap:AccountsReceivableNet>
    <dxcm:AccountsReceivableAllowanceForCreditLossCashDiscount contextRef="c-24" decimals="-5" id="f-724" unitRef="usd">13700000</dxcm:AccountsReceivableAllowanceForCreditLossCashDiscount>
    <dxcm:AccountsReceivableAllowanceForCreditLossCashDiscount contextRef="c-25" decimals="-5" id="f-725" unitRef="usd">8300000</dxcm:AccountsReceivableAllowanceForCreditLossCashDiscount>
    <dxcm:AccountsReceivableAllowanceForCreditLossCashDiscount contextRef="c-44" decimals="-5" id="f-726" unitRef="usd">13700000</dxcm:AccountsReceivableAllowanceForCreditLossCashDiscount>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-727">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;319.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;210.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;306.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-24" decimals="-5" id="f-728" unitRef="usd">319500000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-25" decimals="-5" id="f-729" unitRef="usd">159000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-24" decimals="-5" id="f-730" unitRef="usd">30000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-25" decimals="-5" id="f-731" unitRef="usd">17200000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-24" decimals="-5" id="f-732" unitRef="usd">210100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-25" decimals="-5" id="f-733" unitRef="usd">130500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-24" decimals="-5" id="f-734" unitRef="usd">559600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-25" decimals="-5" id="f-735" unitRef="usd">306700000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown contextRef="c-157" decimals="-5" id="f-736" unitRef="usd">16600000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-158" decimals="-5" id="f-737" unitRef="usd">13900000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-159" decimals="-5" id="f-738" unitRef="usd">28100000</us-gaap:InventoryWriteDown>
    <dxcm:PrepaidAndOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-739">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred compensation plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</dxcm:PrepaidAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-24" decimals="-5" id="f-740" unitRef="usd">58700000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-25" decimals="-5" id="f-741" unitRef="usd">48900000</us-gaap:PrepaidExpenseCurrent>
    <dxcm:PrepaidInventoryCurrent contextRef="c-24" decimals="-5" id="f-742" unitRef="usd">31500000</dxcm:PrepaidInventoryCurrent>
    <dxcm:PrepaidInventoryCurrent contextRef="c-25" decimals="-5" id="f-743" unitRef="usd">67800000</dxcm:PrepaidInventoryCurrent>
    <dxcm:DeferredCompensationPlanAssetsCurrent contextRef="c-24" decimals="-5" id="f-744" unitRef="usd">15200000</dxcm:DeferredCompensationPlanAssetsCurrent>
    <dxcm:DeferredCompensationPlanAssetsCurrent contextRef="c-25" decimals="-5" id="f-745" unitRef="usd">10200000</dxcm:DeferredCompensationPlanAssetsCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-24" decimals="-5" id="f-746" unitRef="usd">13600000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-25" decimals="-5" id="f-747" unitRef="usd">38900000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsCurrent contextRef="c-24" decimals="-5" id="f-748" unitRef="usd">49300000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-25" decimals="-5" id="f-749" unitRef="usd">26800000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-24" decimals="-5" id="f-750" unitRef="usd">168300000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-25" decimals="-5" id="f-751" unitRef="usd">192600000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-752">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Building&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software and hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;683.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;449.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;264.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;328.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;542.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,622.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,418.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(509.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(363.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,113.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,055.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-160" decimals="-5" id="f-753" unitRef="usd">34500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-161" decimals="-5" id="f-754" unitRef="usd">26900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-162" decimals="-5" id="f-755" unitRef="usd">190500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-163" decimals="-5" id="f-756" unitRef="usd">54300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-88" decimals="-5" id="f-757" unitRef="usd">36900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-164" decimals="-5" id="f-758" unitRef="usd">32600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-165" decimals="-5" id="f-759" unitRef="usd">65800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-166" decimals="-5" id="f-760" unitRef="usd">48800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-167" decimals="-5" id="f-761" unitRef="usd">683300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-168" decimals="-5" id="f-762" unitRef="usd">449200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-169" decimals="-5" id="f-763" unitRef="usd">283400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-170" decimals="-5" id="f-764" unitRef="usd">264400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-171" decimals="-5" id="f-765" unitRef="usd">328100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-172" decimals="-5" id="f-766" unitRef="usd">542600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-24" decimals="-5" id="f-767" unitRef="usd">1622500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-25" decimals="-5" id="f-768" unitRef="usd">1418800000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-24" decimals="-5" id="f-769" unitRef="usd">509400000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-25" decimals="-5" id="f-770" unitRef="usd">363200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-24" decimals="-5" id="f-771" unitRef="usd">1113100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-25" decimals="-5" id="f-772" unitRef="usd">1055600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-773" unitRef="usd">147400000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-26" decimals="-5" id="f-774" unitRef="usd">144100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-27" decimals="-5" id="f-775" unitRef="usd">96300000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-5" id="f-776" unitRef="usd">-700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-26" decimals="-5" id="f-777" unitRef="usd">-2200000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-27" decimals="-5" id="f-778" unitRef="usd">-24500000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-779">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of gross intangible assets, accumulated amortization, and net intangible asset balances as of December&#160;31, 2023 and December&#160;31, 2022&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Verily intangible asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired technology and intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademarks and trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles, other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Verily intangible&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired technology and intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademarks and trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles, other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;See Note 2 &#x201c;Development and Other Agreements&#x201d; to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Excludes Verily intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-173" id="f-780">P4Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-173" decimals="-5" id="f-781" unitRef="usd">152400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-173" decimals="-5" id="f-782" unitRef="usd">31000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-173" decimals="-5" id="f-783" unitRef="usd">121400000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-174" id="f-784">P2Y4M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-174" decimals="-5" id="f-785" unitRef="usd">24100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-174" decimals="-5" id="f-786" unitRef="usd">15000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-174" decimals="-5" id="f-787" unitRef="usd">9100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-175" id="f-788">P0Y9M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-175" decimals="-5" id="f-789" unitRef="usd">14600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-175" decimals="-5" id="f-790" unitRef="usd">12600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-175" decimals="-5" id="f-791" unitRef="usd">2000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-176" id="f-792">P2Y7M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-176" decimals="-5" id="f-793" unitRef="usd">4200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-176" decimals="-5" id="f-794" unitRef="usd">2200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-176" decimals="-5" id="f-795" unitRef="usd">2000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-177" id="f-796">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-177" decimals="-5" id="f-797" unitRef="usd">200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-177" decimals="-5" id="f-798" unitRef="usd">200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-177" decimals="-5" id="f-799" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-24" id="f-800">P4Y1M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-24" decimals="-5" id="f-801" unitRef="usd">195500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-24" decimals="-5" id="f-802" unitRef="usd">61000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-24" decimals="-5" id="f-803" unitRef="usd">134500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-178" id="f-804">P5Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-178" decimals="-5" id="f-805" unitRef="usd">152400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-178" decimals="-5" id="f-806" unitRef="usd">2400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-178" decimals="-5" id="f-807" unitRef="usd">150000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-179" id="f-808">P3Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-179" decimals="-5" id="f-809" unitRef="usd">24100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-179" decimals="-5" id="f-810" unitRef="usd">8700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-179" decimals="-5" id="f-811" unitRef="usd">15400000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-180" id="f-812">P1Y8M12D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-180" decimals="-5" id="f-813" unitRef="usd">14600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-180" decimals="-5" id="f-814" unitRef="usd">9600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-180" decimals="-5" id="f-815" unitRef="usd">5000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-181" id="f-816">P3Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-181" decimals="-5" id="f-817" unitRef="usd">4200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-181" decimals="-5" id="f-818" unitRef="usd">1300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-181" decimals="-5" id="f-819" unitRef="usd">2900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-182" id="f-820">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-182" decimals="-5" id="f-821" unitRef="usd">200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-182" decimals="-5" id="f-822" unitRef="usd">200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-182" decimals="-5" id="f-823" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-25" id="f-824">P4Y10M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-25" decimals="-5" id="f-825" unitRef="usd">195500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-25" decimals="-5" id="f-826" unitRef="usd">22200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-25" decimals="-5" id="f-827" unitRef="usd">173300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c-1" id="f-828">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total amortization expense of finite-lived intangible assets for the twelve months ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.800%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense included in cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales contextRef="c-1" decimals="-5" id="f-829" unitRef="usd">30500000</dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales>
    <dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales contextRef="c-26" decimals="-5" id="f-830" unitRef="usd">4300000</dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales>
    <dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales contextRef="c-27" decimals="-5" id="f-831" unitRef="usd">1900000</dxcm:AmortizationOfIntangibleAssetsIncludedInCostOfSales>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-832" unitRef="usd">8100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-26" decimals="-5" id="f-833" unitRef="usd">7500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-27" decimals="-5" id="f-834" unitRef="usd">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <dxcm:AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses contextRef="c-1" decimals="-5" id="f-835" unitRef="usd">38600000</dxcm:AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses>
    <dxcm:AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses contextRef="c-26" decimals="-5" id="f-836" unitRef="usd">11800000</dxcm:AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses>
    <dxcm:AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses contextRef="c-27" decimals="-5" id="f-837" unitRef="usd">5600000</dxcm:AmortizationOfIntangiblesIncludedInCostOfSalesAndOperatingExpenses>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-838">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents estimated future amortization of the Company&#x2019;s finite-lived intangible assets as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-24" decimals="-5" id="f-839" unitRef="usd">35200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-24" decimals="-5" id="f-840" unitRef="usd">32600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-24" decimals="-5" id="f-841" unitRef="usd">30900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-24" decimals="-5" id="f-842" unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-24" decimals="-5" id="f-843" unitRef="usd">7200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-24" decimals="-5" id="f-844" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-24" decimals="-5" id="f-845" unitRef="usd">134500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="c-1" id="f-846">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:LongTermInvestments contextRef="c-24" decimals="-5" id="f-847" unitRef="usd">38500000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-25" decimals="-5" id="f-848" unitRef="usd">19000000.0</us-gaap:LongTermInvestments>
    <dxcm:LongTermDeposits contextRef="c-24" decimals="-5" id="f-849" unitRef="usd">14400000</dxcm:LongTermDeposits>
    <dxcm:LongTermDeposits contextRef="c-25" decimals="-5" id="f-850" unitRef="usd">16200000</dxcm:LongTermDeposits>
    <dxcm:OtherLongTermAssets contextRef="c-24" decimals="-5" id="f-851" unitRef="usd">22100000</dxcm:OtherLongTermAssets>
    <dxcm:OtherLongTermAssets contextRef="c-25" decimals="-5" id="f-852" unitRef="usd">11900000</dxcm:OtherLongTermAssets>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-24" decimals="-5" id="f-853" unitRef="usd">75000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-25" decimals="-5" id="f-854" unitRef="usd">47100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-855">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable trade&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;276.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued tax, audit, and legal fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued rebates &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;556.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued warranty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred compensation plan liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,345.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;901.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c-24" decimals="-5" id="f-856" unitRef="usd">276400000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c-25" decimals="-5" id="f-857" unitRef="usd">237900000</us-gaap:AccountsPayableTradeCurrent>
    <dxcm:AccruedTaxAuditAndLegalFeesCurrent contextRef="c-24" decimals="-5" id="f-858" unitRef="usd">42600000</dxcm:AccruedTaxAuditAndLegalFeesCurrent>
    <dxcm:AccruedTaxAuditAndLegalFeesCurrent contextRef="c-25" decimals="-5" id="f-859" unitRef="usd">31900000</dxcm:AccruedTaxAuditAndLegalFeesCurrent>
    <dxcm:PharmacyRebatesCurrent contextRef="c-24" decimals="-5" id="f-860" unitRef="usd">950700000</dxcm:PharmacyRebatesCurrent>
    <dxcm:PharmacyRebatesCurrent contextRef="c-25" decimals="-5" id="f-861" unitRef="usd">556400000</dxcm:PharmacyRebatesCurrent>
    <us-gaap:StandardProductWarrantyAccrual contextRef="c-24" decimals="-5" id="f-862" unitRef="usd">12600000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual contextRef="c-25" decimals="-5" id="f-863" unitRef="usd">12800000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-24" decimals="-5" id="f-864" unitRef="usd">7500000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-25" decimals="-5" id="f-865" unitRef="usd">12900000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent contextRef="c-24" decimals="-5" id="f-866" unitRef="usd">15200000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent contextRef="c-25" decimals="-5" id="f-867" unitRef="usd">10200000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-24" decimals="-5" id="f-868" unitRef="usd">40500000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-25" decimals="-5" id="f-869" unitRef="usd">39700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-24" decimals="-5" id="f-870" unitRef="usd">1345500000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-25" decimals="-5" id="f-871" unitRef="usd">901800000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <dxcm:ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock contextRef="c-1" id="f-872">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued wages, bonus and taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</dxcm:ScheduleOfAccruedPayrollAndRelatedExpensesTableTextBlock>
    <dxcm:AccruedWagesBonusesAndTaxesCurrent contextRef="c-24" decimals="-5" id="f-873" unitRef="usd">139800000</dxcm:AccruedWagesBonusesAndTaxesCurrent>
    <dxcm:AccruedWagesBonusesAndTaxesCurrent contextRef="c-25" decimals="-5" id="f-874" unitRef="usd">96800000</dxcm:AccruedWagesBonusesAndTaxesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-24" decimals="-5" id="f-875" unitRef="usd">31200000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-25" decimals="-5" id="f-876" unitRef="usd">37500000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-24" decimals="-5" id="f-877" unitRef="usd">171000000.0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-25" decimals="-5" id="f-878" unitRef="usd">134300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="c-1" id="f-879">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warranty costs are reflected in our statements of operations as cost of sales. Reconciliations of our accrued warranty costs for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(51.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:StandardProductWarrantyAccrual contextRef="c-25" decimals="-5" id="f-880" unitRef="usd">12800000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual contextRef="c-44" decimals="-5" id="f-881" unitRef="usd">12900000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual contextRef="c-33" decimals="-5" id="f-882" unitRef="usd">11700000</us-gaap:StandardProductWarrantyAccrual>
    <dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses contextRef="c-1" decimals="-5" id="f-883" unitRef="usd">51500000</dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses>
    <dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses contextRef="c-26" decimals="-5" id="f-884" unitRef="usd">43000000.0</dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses>
    <dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses contextRef="c-27" decimals="-5" id="f-885" unitRef="usd">41500000</dxcm:StandardProductWarrantyAccrualChargesToCostsAndExpenses>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-1" decimals="-5" id="f-886" unitRef="usd">51700000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-26" decimals="-5" id="f-887" unitRef="usd">43100000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-27" decimals="-5" id="f-888" unitRef="usd">40300000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:StandardProductWarrantyAccrual contextRef="c-24" decimals="-5" id="f-889" unitRef="usd">12600000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual contextRef="c-25" decimals="-5" id="f-890" unitRef="usd">12800000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual contextRef="c-44" decimals="-5" id="f-891" unitRef="usd">12900000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock contextRef="c-1" id="f-892">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue, long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset retirement obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-24" decimals="-5" id="f-893" unitRef="usd">58600000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-25" decimals="-5" id="f-894" unitRef="usd">59600000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-24" decimals="-5" id="f-895" unitRef="usd">7400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-25" decimals="-5" id="f-896" unitRef="usd">19000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AssetRetirementObligation contextRef="c-24" decimals="-5" id="f-897" unitRef="usd">15700000</us-gaap:AssetRetirementObligation>
    <us-gaap:AssetRetirementObligation contextRef="c-25" decimals="-5" id="f-898" unitRef="usd">11100000</us-gaap:AssetRetirementObligation>
    <dxcm:OtherTaxLiabilitiesNoncurrent contextRef="c-24" decimals="-5" id="f-899" unitRef="usd">38700000</dxcm:OtherTaxLiabilitiesNoncurrent>
    <dxcm:OtherTaxLiabilitiesNoncurrent contextRef="c-25" decimals="-5" id="f-900" unitRef="usd">32700000</dxcm:OtherTaxLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-24" decimals="-5" id="f-901" unitRef="usd">5200000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-25" decimals="-5" id="f-902" unitRef="usd">5900000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-24" decimals="-5" id="f-903" unitRef="usd">125600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-25" decimals="-5" id="f-904" unitRef="usd">128300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c-1" id="f-905">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and dividend income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income from equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-1" decimals="-5" id="f-906" unitRef="usd">135000000.0</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-26" decimals="-5" id="f-907" unitRef="usd">23800000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-27" decimals="-5" id="f-908" unitRef="usd">1700000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-909" unitRef="usd">20300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-26" decimals="-5" id="f-910" unitRef="usd">18600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-27" decimals="-5" id="f-911" unitRef="usd">18800000</us-gaap:InterestExpense>
    <us-gaap:DebtAndEquitySecuritiesGainLoss contextRef="c-1" decimals="-5" id="f-912" unitRef="usd">1900000</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <us-gaap:DebtAndEquitySecuritiesGainLoss contextRef="c-26" decimals="-5" id="f-913" unitRef="usd">200000</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <us-gaap:DebtAndEquitySecuritiesGainLoss contextRef="c-27" decimals="-5" id="f-914" unitRef="usd">11600000</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-5" id="f-915" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-26" decimals="-5" id="f-916" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-27" decimals="-5" id="f-917" unitRef="usd">-100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingExpense contextRef="c-1" decimals="-5" id="f-918" unitRef="usd">3900000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c-26" decimals="-5" id="f-919" unitRef="usd">5800000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c-27" decimals="-5" id="f-920" unitRef="usd">3400000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-921" unitRef="usd">112700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-26" decimals="-5" id="f-922" unitRef="usd">-400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-27" decimals="-5" id="f-923" unitRef="usd">-9000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-924">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;5. Debt&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of our senior convertible notes were as follows as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;774.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,207.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,207.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,457.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,982.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount of senior convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,434.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our senior convertible notes for which the if-converted value exceeded the principal amount, the amount in excess of principal was as follows as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,361.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total by which the notes&#x2019; if-converted value exceeds their principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,395.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our senior convertible notes for the periods shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash interest expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual coupon interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total interest expense recognized on senior notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective interest rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:7pt;padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest on the 2023 Notes began accruing upon issuance and is payable semi-annually on June 1 and December 1 of each year. Interest on the 2025 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year. Interest on the 2028 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The effective interest rate presented represents the rate applicable for the period outstanding. The Senior Convertible Notes due 2023 matured on December 1, 2023 and all outstanding principal was settled as described below.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;* Not applicable as no notes were outstanding at this date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Debt Summary&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the key details for our unsecured senior convertible notes due 2023 (the &#x201c;2023 Notes&#x201d;), unsecured senior convertible notes due 2025 (the &#x201c;2025 Notes&#x201d;), and unsecured senior convertible notes due 2028 (the &#x201c;2028 Notes&#x201d;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.260%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Senior Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Offering Completion Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Stated Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Principal Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Proceeds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Initial Conversion Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(per $1,000 principal amount)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Conversion Price&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Settlement Methods&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;November 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$850.0 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$836.6 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24.3476&#160;shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$41.07&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and/or shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;November&#160;15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.21 billion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.19 billion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6620 shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$150.11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and/or shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May&#160;15, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.375%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.25&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.23&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.1571 shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$162.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and/or shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Net proceeds is calculated by deducting the aggregate principal amount from the initial purchasers&#x2019; discounts and estimated costs directly related to the offering.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Subject to adjustments as defined in the indentures.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The senior convertible notes may be settled in cash, stock, or a combination thereof, solely at our discretion. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the if-converted method for assumed conversion of our senior convertible notes to compute the weighted average shares of common stock outstanding for diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No principal payments are due on the senior convertible notes prior to maturity. Other than restrictions relating to certain fundamental changes and consolidations, mergers or asset sales and customary anti-dilution adjustments, the indenture relating to our senior convertible notes include customary terms and covenants, including certain events of default after which the senior convertible notes may be due and payable immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2023 Note Hedge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the offering of the 2023 Notes, in November 2018 we entered into convertible note hedge transactions with two of the initial purchasers of the 2023 Notes (the &#x201c;2023 Counterparties&#x201d;) entitling us to purchase up to&#160;20.7 million&#160;shares of our common stock at an initial price of&#160;$41.07&#160;per share, each of which is subject to adjustment. The cost of the 2023 Note Hedge was&#160;$218.9 million and we accounted for it as an equity instrument by recognizing $218.9 million in&#160;additional paid-in capital&#160;during 2018. The 2023 Note Hedge expired on December&#160;1, 2023. The 2023 Note Hedge is expected to reduce the potential equity dilution upon any conversion of the 2023 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2023 Notes if the daily volume-weighted average price per share of our common stock exceeds the strike price of the 2023 Note Hedge.&#160;The strike price of the 2023 Note Hedge initially corresponds to the conversion price of the 2023 Notes and is subject to certain adjustments under the terms of the 2023 Note Hedge. An assumed exercise of the 2023 Note Hedge by us is considered anti-dilutive since the effect of the inclusion would always be anti-dilutive with respect to the calculation of diluted earnings per share. See below for a description of conversion activity related to the 2023 Notes and shares received as the result of exercising the remaining portion of the 2023 Note Hedge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, we also sold warrants to the 2023 Counterparties to acquire up to&#160;20.7 million shares of our common stock. The 2023 Warrants require net share settlement and a pro rated number of warrants will expire on each of the 60 scheduled trading days starting on March&#160;1, 2024. We received&#160;$183.8 million&#160;in cash proceeds from the sale of the 2023 Warrants, which we recorded in&#160;additional paid-in capital during 2018. The 2023 Warrants could have a dilutive effect on our earnings per share to the extent that the price of our common stock during a given measurement period exceeds the strike price of the 2023 Warrants. The strike price of the 2023 Warrants is initially $49.60 per share and is subject to certain adjustments under the terms of the warrant agreements. We use the treasury share method for assumed conversion of the 2023 Warrants when computing the weighted average common shares outstanding for diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2028 Capped Call Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, in connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions (the &#x201c;2028 Capped Calls&#x201d;) with certain financial institutions. The 2028 Capped Calls will cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2028 Notes, the number of shares of our common stock that will initially underlie the 2028 Notes. The 2028 Capped Calls are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes and/or offset any cash payments that we are required to make in excess of the principal amount of converted 2028 Notes, as the case may be, with such reduction and/or offset subject to a cap. The 2028 Capped Calls have an initial cap price of $212.62 per share, subject to adjustments, which represents a premium of 80% over the closing price of our common stock of $118.12 per share on the Nasdaq Global Select Market on May&#160;2, 2023. The cost to purchase the 2028 Capped Calls of $101.3 million was recorded as a reduction to additional paid-in capital in our consolidated balance sheets as the 2028 Capped Calls met the criteria for classification in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Conversion Activity for Senior Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the 2023 Notes, Circumstance 1 as listed below occurred during the quarters ended December&#160;31, 2022, March&#160;31, 2023, and June&#160;30, 2023. As a result, the 2023 Notes were convertible at the option of the holders from January&#160;1, 2023 through August 31, 2023. Circumstance 5 was applicable to the 2023 Notes beginning September 1, 2023. The 2023 Notes matured on December 1, 2023 and were completely settled. See the following table for the details on the conversion activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Converted Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Principal Amount Converted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares Issued for Settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares Received from Exercise of 2023 Note Hedge&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1/1/2022 - 12/31/2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$17.5 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1/1/2023 - 12/31/2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$774.8&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.2 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.2 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Conversion Rights for Senior Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of our senior convertible notes have the right to require us to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the notes). We will also be required to increase the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or following the delivery by Dexcom of a notice of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table outlines the conversion options related for each of our senior convertible notes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Conversions Rights at the Option of the Holders for the 2023, 2025, and 2028 Notes (&#x201c;Notes&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion Rights at the Option of the Holders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the Notes have the ability to convert all or a portion of their notes in multiples of $1,000 principal amount, at their option prior to 5:00 p.m., New York City time, on the business day immediately preceding September&#160;1, 2023, August&#160;15, 2025, and February&#160;15, 2028 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Circumstance 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During any calendar quarter commencing after the applicable period (and only during such calendar quarter), if the last reported sale price of Dexcom&#x2019;s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable conversion price for the Notes on each applicable trading day&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Circumstance 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of the Notes for each trading day of that five consecutive trading day period was less than 98% of the product of the last reported sale price of Dexcom&#x2019;s common stock and the applicable conversion rate of the Notes on each such trading day&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Circumstance 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we call any or all of the Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date (only with respect to the notes called or deemed called for redemption)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Circumstance 4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of specified corporate events&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Circumstance 5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the 2023 Notes and 2028 Notes, until 5:00 p.m., New York City time, on the second scheduled trading day immediately preceding the maturity date (for the 2025 Notes, it is until the business day immediately preceding the maturity date), holders of the Notes may convert all or a portion of their notes regardless of the foregoing circumstances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Circumstance 1 is available after the calendar quarter ending March&#160;31, 2019, September&#160;30, 2020, and September&#160;30, 2023 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Circumstance 5 is available on or after September&#160;1, 2023, August&#160;15, 2025, and February&#160;15, 2028 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.919%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Conversion Right at Option of the Company for the 2023, 2025, and 2028 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Conversion Right at Our Option&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dexcom may redeem for cash all or part of the Notes, at its option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Dexcom provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Dexcom does not have the right to redeem the Notes prior to December&#160;1, 2021, May&#160;20, 2023, and May&#160;20, 2026 for the 2023 Notes, 2025 Notes, and 2028 Notes, respectively. Dexcom has the right to redeem the notes on or after December&#160;1, 2021 and prior to September&#160;1, 2023 for the 2023 Notes, on or after May&#160;20, 2023 and prior to August&#160;15, 2025 for the 2025 Notes, and on or after May&#160;20, 2026 and prior to February&#160;15, 2028 for the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit Agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Terms of the Revolving Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, we entered into the First Amendment to the Second Amended and Restated Credit Agreement (the "Amended Credit Agreement"), which we had previously entered into in October 2021. The Amended Credit Agreement is a five-year revolving credit facility, that provides for an available principal amount of $200.0 million which can be increased up to $500.0 million at our option subject to customary conditions and approval of our lenders (the &#x201c;Credit Facility&#x201d;). The Amended Credit Agreement will mature on October&#160;13, 2026. Borrowings under the Amended Credit Agreement are available for general corporate purposes, including working capital and capital expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to availability and outstanding borrowings on our Amended Credit Agreement is as follows as of the date indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available principal amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Letters of credit sub-facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding borrowings &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total available balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revolving loans under the Amended Credit Agreement bear interest at our choice of one of three base rates plus a range of applicable rates that are based on our leverage ratio. The minimum and maximum range of applicable rates per annum with respect to any ABR Loan or, Term Benchmark Revolving Loan, RFR Revolving Loan (as defined in the Amended Credit Agreement) under the captions &#x201c;ABR Spread&#x201d;, &#x201c;Term Benchmark/CDOR Spread&#x201d;, &#x201c;RFR Spread&#x201d;, or &#x201c;Unused Commitment Fee Rate&#x201d;, respectively, are outlined in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.879%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.879%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.881%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;ABR Spread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term Benchmark/CDOR Spread and RFR Spread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unused Commitment Fee Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.375%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.375%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.175%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maximum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our obligations under the Amended Credit Agreement are guaranteed by our existing and future wholly-owned domestic subsidiaries, and are secured by a first-priority security interest in substantially all of the assets of Dexcom and the guarantors, including all or a portion of the equity interests of our domestic subsidiaries and first-tier foreign subsidiaries but excluding real property and intellectual property (which is subject to a negative pledge). The Amended Credit Agreement contains covenants that limit certain indebtedness, liens, investments, transactions with affiliates, dividends and other restricted payments, subordinated indebtedness and amendments to subordinated indebtedness documents, and sale and leaseback transactions of Dexcom or any of its domestic subsidiaries. The Amended Credit Agreement also requires us to maintain a maximum leverage ratio and a minimum fixed charge coverage ratio. We were in compliance with these covenants as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, we also have a guarantee facility related to our international operations which is collateralized by a $5.5&#160;million term deposit that is included in non-current &#x201c;Other assets&#x201d; on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-925">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of our senior convertible notes were as follows as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;774.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,207.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,207.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,250.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,457.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,982.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount of senior convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,434.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-146" decimals="-5" id="f-926" unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-147" decimals="-5" id="f-927" unitRef="usd">774800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-148" decimals="-5" id="f-928" unitRef="usd">1207500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-149" decimals="-5" id="f-929" unitRef="usd">1207500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-150" decimals="-5" id="f-930" unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-151" decimals="-5" id="f-931" unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-152" decimals="-5" id="f-932" unitRef="usd">2457500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-153" decimals="-5" id="f-933" unitRef="usd">1982300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-152" decimals="-5" id="f-934" unitRef="usd">23300000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-153" decimals="-5" id="f-935" unitRef="usd">12000000.0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:ConvertibleNotesPayable contextRef="c-152" decimals="-5" id="f-936" unitRef="usd">2434200000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="c-153" decimals="-5" id="f-937" unitRef="usd">1970300000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c-1" id="f-938">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our senior convertible notes for which the if-converted value exceeded the principal amount, the amount in excess of principal was as follows as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,361.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total by which the notes&#x2019; if-converted value exceeds their principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,395.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the key details for our unsecured senior convertible notes due 2023 (the &#x201c;2023 Notes&#x201d;), unsecured senior convertible notes due 2025 (the &#x201c;2025 Notes&#x201d;), and unsecured senior convertible notes due 2028 (the &#x201c;2028 Notes&#x201d;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.260%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Senior Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Offering Completion Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Stated Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Principal Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Proceeds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Initial Conversion Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(per $1,000 principal amount)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Conversion Price&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Settlement Methods&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;November 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$850.0 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$836.6 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24.3476&#160;shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$41.07&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and/or shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;November&#160;15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.21 billion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.19 billion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6620 shares &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$150.11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and/or shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May&#160;15, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.375%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.25&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.23&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.1571 shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$162.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and/or shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Net proceeds is calculated by deducting the aggregate principal amount from the initial purchasers&#x2019; discounts and estimated costs directly related to the offering.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Subject to adjustments as defined in the indentures.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The senior convertible notes may be settled in cash, stock, or a combination thereof, solely at our discretion. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c-183" decimals="-5" id="f-939" unitRef="usd">0</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c-184" decimals="-5" id="f-940" unitRef="usd">1361500000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c-185" decimals="-5" id="f-941" unitRef="usd">56100000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c-186" decimals="-5" id="f-942" unitRef="usd">33600000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c-187" decimals="-5" id="f-943" unitRef="usd">33600000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c-188" decimals="-5" id="f-944" unitRef="usd">0</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c-189" decimals="-5" id="f-945" unitRef="usd">89700000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="c-190" decimals="-5" id="f-946" unitRef="usd">1395100000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c-1" id="f-947">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our senior convertible notes for the periods shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash interest expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual coupon interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total interest expense recognized on senior notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective interest rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Convertible Notes due 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:7pt;padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest on the 2023 Notes began accruing upon issuance and is payable semi-annually on June 1 and December 1 of each year. Interest on the 2025 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year. Interest on the 2028 Notes began accruing upon issuance and is payable semi-annually on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The effective interest rate presented represents the rate applicable for the period outstanding. The Senior Convertible Notes due 2023 matured on December 1, 2023 and all outstanding principal was settled as described below.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;* Not applicable as no notes were outstanding at this date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-1" decimals="-5" id="f-948" unitRef="usd">9100000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-26" decimals="-5" id="f-949" unitRef="usd">8800000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-27" decimals="-5" id="f-950" unitRef="usd">9300000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-5" id="f-951" unitRef="usd">7300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-26" decimals="-5" id="f-952" unitRef="usd">5900000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-27" decimals="-5" id="f-953" unitRef="usd">6000000.0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-5" id="f-954" unitRef="usd">16400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-26" decimals="-5" id="f-955" unitRef="usd">14700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-27" decimals="-5" id="f-956" unitRef="usd">15300000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-191" decimals="3" id="f-957" unitRef="number">0.011</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-192" decimals="3" id="f-958" unitRef="number">0.011</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-193" decimals="3" id="f-959" unitRef="number">0.011</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-194" decimals="3" id="f-960" unitRef="number">0.005</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-195" decimals="3" id="f-961" unitRef="number">0.005</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-196" decimals="3" id="f-962" unitRef="number">0.005</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-197" decimals="3" id="f-963" unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-198"
      decimals="INF"
      id="f-964"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-198" decimals="INF" id="f-965" unitRef="usd">850000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-199" decimals="-5" id="f-966" unitRef="usd">836600000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-198"
      decimals="2"
      id="f-967"
      unitRef="usdPerShare">41.07</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-200"
      decimals="INF"
      id="f-968"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-200" decimals="-7" id="f-969" unitRef="usd">1210000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-201" decimals="-7" id="f-970" unitRef="usd">1190000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-200"
      decimals="2"
      id="f-971"
      unitRef="usdPerShare">150.11</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-202"
      decimals="INF"
      id="f-972"
      unitRef="number">0.00375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-202" decimals="-7" id="f-973" unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-203" decimals="-7" id="f-974" unitRef="usd">1230000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-202"
      decimals="2"
      id="f-975"
      unitRef="usdPerShare">162.41</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <dxcm:DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares
      contextRef="c-204"
      decimals="-5"
      id="f-976"
      unitRef="shares">20700000</dxcm:DebtInstrumentConvertibleAssociatedDerivativeTransactionsNumberOfShares>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-198"
      decimals="2"
      id="f-977"
      unitRef="usdPerShare">41.07</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="c-205" decimals="-5" id="f-978" unitRef="usd">218900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="c-205" decimals="-5" id="f-979" unitRef="usd">218900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c-199"
      decimals="-5"
      id="f-980"
      unitRef="shares">20700000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-199" decimals="INF" id="f-981" unitRef="d">60</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-199" decimals="-5" id="f-982" unitRef="usd">183800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-198"
      decimals="2"
      id="f-983"
      unitRef="usdPerShare">49.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dxcm:DebtInstrumentCapCallTransactionCapPricePerShare
      contextRef="c-206"
      decimals="INF"
      id="f-984"
      unitRef="usdPerShare">212.62</dxcm:DebtInstrumentCapCallTransactionCapPricePerShare>
    <dxcm:DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage
      contextRef="c-206"
      decimals="INF"
      id="f-985"
      unitRef="number">0.80</dxcm:DebtInstrumentConvertibleCappedCallsInitialCapPricePremiumPercentage>
    <us-gaap:SharePrice
      contextRef="c-207"
      decimals="INF"
      id="f-986"
      unitRef="usdPerShare">118.12</us-gaap:SharePrice>
    <dxcm:PaymentsForPurchasesOfCappedCallTransactions contextRef="c-203" decimals="-5" id="f-987" unitRef="usd">101300000</dxcm:PaymentsForPurchasesOfCappedCallTransactions>
    <dxcm:ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock contextRef="c-1" id="f-988">As a result, the 2023 Notes were convertible at the option of the holders from January&#160;1, 2023 through August 31, 2023. Circumstance 5 was applicable to the 2023 Notes beginning September 1, 2023. The 2023 Notes matured on December 1, 2023 and were completely settled. See the following table for the details on the conversion activity:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fiscal Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Converted Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Principal Amount Converted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares Issued for Settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares Received from Exercise of 2023 Note Hedge&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1/1/2022 - 12/31/2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$17.5 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1/1/2023 - 12/31/2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023 Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$774.8&#160;million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.2 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.2 million&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dxcm:ScheduleOfConversionActivityForSeniorConvertibleNotesTableTextBlock>
    <dxcm:DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled contextRef="c-184" decimals="-5" id="f-989" unitRef="usd">17500000</dxcm:DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-208"
      decimals="INF"
      id="f-990"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <dxcm:SharesReceivedFromBenefitOfNoteHedge
      contextRef="c-184"
      decimals="INF"
      id="f-991"
      unitRef="shares">300000</dxcm:SharesReceivedFromBenefitOfNoteHedge>
    <dxcm:DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled contextRef="c-183" decimals="-5" id="f-992" unitRef="usd">774800000</dxcm:DebtInstrumentConvertiblePrincipalAmountExercisedAndSettled>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-209"
      decimals="INF"
      id="f-993"
      unitRef="shares">12200000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <dxcm:SharesReceivedFromBenefitOfNoteHedge
      contextRef="c-183"
      decimals="INF"
      id="f-994"
      unitRef="shares">12200000</dxcm:SharesReceivedFromBenefitOfNoteHedge>
    <dxcm:DebtInstrumentCovenantRepurchasePricePercentage
      contextRef="c-146"
      decimals="INF"
      id="f-995"
      unitRef="number">1</dxcm:DebtInstrumentCovenantRepurchasePricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-210" decimals="INF" id="f-996" unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-211" decimals="INF" id="f-997" unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-210"
      decimals="INF"
      id="f-998"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-212"
      decimals="INF"
      id="f-999"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-213"
      decimals="INF"
      id="f-1000"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-213"
      decimals="INF"
      id="f-1001"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-213"
      decimals="INF"
      id="f-1002"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <dxcm:DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock
      contextRef="c-185"
      decimals="INF"
      id="f-1003"
      unitRef="number">1.30</dxcm:DebtInstrumentRedemptionCovenantPercentOfConversionPriceLastReportedSalePriceOfCommonStock>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-214"
      decimals="INF"
      id="f-1004"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c-215"
      decimals="INF"
      id="f-1005"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-185"
      decimals="INF"
      id="f-1006"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c-216" id="f-1007">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-217" decimals="-5" id="f-1008" unitRef="usd">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <dxcm:LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount contextRef="c-217" decimals="INF" id="f-1009" unitRef="usd">500000000</dxcm:LineOfCreditFacilityMaximumBorrowingCapacityOptionToIncreaseAmount>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="c-1" id="f-1010">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to availability and outstanding borrowings on our Amended Credit Agreement is as follows as of the date indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available principal amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Letters of credit sub-facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding borrowings &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total available balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The minimum and maximum range of applicable rates per annum with respect to any ABR Loan or, Term Benchmark Revolving Loan, RFR Revolving Loan (as defined in the Amended Credit Agreement) under the captions &#x201c;ABR Spread&#x201d;, &#x201c;Term Benchmark/CDOR Spread&#x201d;, &#x201c;RFR Spread&#x201d;, or &#x201c;Unused Commitment Fee Rate&#x201d;, respectively, are outlined in the following table:&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.879%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.879%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.881%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;ABR Spread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term Benchmark/CDOR Spread and RFR Spread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unused Commitment Fee Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.375%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.375%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.175%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maximum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #d9d8d6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-218" decimals="-5" id="f-1011" unitRef="usd">200000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-219" decimals="-5" id="f-1012" unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit contextRef="c-218" decimals="-5" id="f-1013" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-219" decimals="-5" id="f-1014" unitRef="usd">7400000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-24" decimals="-5" id="f-1015" unitRef="usd">192600000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-220"
      decimals="INF"
      id="f-1016"
      unitRef="number">0.00375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-221"
      decimals="INF"
      id="f-1017"
      unitRef="number">0.01375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c-222"
      decimals="INF"
      id="f-1018"
      unitRef="number">0.00175</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-223"
      decimals="INF"
      id="f-1019"
      unitRef="number">0.01000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-224"
      decimals="INF"
      id="f-1020"
      unitRef="number">0.02000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c-225"
      decimals="INF"
      id="f-1021"
      unitRef="number">0.00250</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DepositAssets contextRef="c-24" decimals="-5" id="f-1022" unitRef="usd">5500000</us-gaap:DepositAssets>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1027">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;6. Leases and Other Commitments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have leases for certain machinery and facilities, including office, manufacturing and warehouse space facilities under various domestic and international operating and finance lease arrangements. We also have land leases in Penang, Malaysia that expire through 2082 for the build-out of our international manufacturing facility. Our leases, excluding our land leases in Malaysia, have remaining lease terms of up to seventeen years.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the leases include &#160;&#160;&#160;&#160;one or more options to extend the leases for up to five years per option. Our lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturities of our operating and finance lease liabilities were as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1051"&gt;Less: Current portion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain lease agreements require us to return designated areas of leased space to its original condition upon termination of the lease agreement, for which we record an asset retirement obligation and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, the asset retirement obligation is accreted for the change in its present value and the capitalized asset is depreciated, both over the term of the associated lease agreement. Asset retirement obligations of $15.7&#160;million and $11.1&#160;million as of December&#160;31, 2023 and 2022, respectively, are included in &lt;span style="-sec-ix-hidden:f-1058"&gt;&lt;span style="-sec-ix-hidden:f-1059"&gt;other long-term liabilities&lt;/span&gt;&lt;/span&gt; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use asset impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the result of the Company&#x2019;s transition to a flexible working environment, we vacated a building in San Diego during the fourth quarter of 2022 and made it available for sublease. This resulted in an impairment indicator. We tested the asset group as of November 30, 2022 consisting primarily of the leasehold improvements and right-of-use asset for recoverability by comparing its carrying value to an estimate of future undiscounted cash flows. Based on the results of the recoverability test, we determined that the undiscounted cash flows of the asset group were below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the fair value of the asset group by discounting the estimated future cash flows using level 3 fair value inputs under ASC 820 as described in Note 1. As a result of the impairment test, we recorded a non-cash charge of $23.0&#160;million for the twelve months ended December 31, 2022 in the &#x201c;&lt;span style="-sec-ix-hidden:f-1083"&gt;Selling, general and administrative&lt;/span&gt;&#x201d; caption of our consolidated statements of operations. The fair value of the asset group immediately subsequent to the impairment was $2.5&#160;million and was categorized as Level 3 within the ASC 820, &#x201c;Fair Value Measurements&#x201d; fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to our leases is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of operating lease right-of-use asset included in cash flows from operating activities in our consolidated statements of cash flows was &lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.5 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.4 million, and $18.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We are party to various purchase arrangements related to our operational, manufacturing, and research and development activities. We had approximately $793.0 million as of December&#160;31, 2023 and $442.7 million as of December&#160;31, 2022 of open purchase orders and contractual obligations in the ordinary course of business, the majority of which are due within one year</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-1026">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;6. Leases and Other Commitments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have leases for certain machinery and facilities, including office, manufacturing and warehouse space facilities under various domestic and international operating and finance lease arrangements. We also have land leases in Penang, Malaysia that expire through 2082 for the build-out of our international manufacturing facility. Our leases, excluding our land leases in Malaysia, have remaining lease terms of up to seventeen years.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the leases include &#160;&#160;&#160;&#160;one or more options to extend the leases for up to five years per option. Our lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturities of our operating and finance lease liabilities were as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1051"&gt;Less: Current portion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain lease agreements require us to return designated areas of leased space to its original condition upon termination of the lease agreement, for which we record an asset retirement obligation and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, the asset retirement obligation is accreted for the change in its present value and the capitalized asset is depreciated, both over the term of the associated lease agreement. Asset retirement obligations of $15.7&#160;million and $11.1&#160;million as of December&#160;31, 2023 and 2022, respectively, are included in &lt;span style="-sec-ix-hidden:f-1058"&gt;&lt;span style="-sec-ix-hidden:f-1059"&gt;other long-term liabilities&lt;/span&gt;&lt;/span&gt; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use asset impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the result of the Company&#x2019;s transition to a flexible working environment, we vacated a building in San Diego during the fourth quarter of 2022 and made it available for sublease. This resulted in an impairment indicator. We tested the asset group as of November 30, 2022 consisting primarily of the leasehold improvements and right-of-use asset for recoverability by comparing its carrying value to an estimate of future undiscounted cash flows. Based on the results of the recoverability test, we determined that the undiscounted cash flows of the asset group were below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the fair value of the asset group by discounting the estimated future cash flows using level 3 fair value inputs under ASC 820 as described in Note 1. As a result of the impairment test, we recorded a non-cash charge of $23.0&#160;million for the twelve months ended December 31, 2022 in the &#x201c;&lt;span style="-sec-ix-hidden:f-1083"&gt;Selling, general and administrative&lt;/span&gt;&#x201d; caption of our consolidated statements of operations. The fair value of the asset group immediately subsequent to the impairment was $2.5&#160;million and was categorized as Level 3 within the ASC 820, &#x201c;Fair Value Measurements&#x201d; fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to our leases is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of operating lease right-of-use asset included in cash flows from operating activities in our consolidated statements of cash flows was &lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.5 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.4 million, and $18.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We are party to various purchase arrangements related to our operational, manufacturing, and research and development activities. We had approximately $793.0 million as of December&#160;31, 2023 and $442.7 million as of December&#160;31, 2022 of open purchase orders and contractual obligations in the ordinary course of business, the majority of which are due within one year</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-91" id="f-1028">P17Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <dxcm:LesseeOperatingLeaseNumberOfOptionsToExtend
      contextRef="c-90"
      decimals="INF"
      id="f-1029"
      unitRef="extensionoption">1</dxcm:LesseeOperatingLeaseNumberOfOptionsToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-91" id="f-1030">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1032">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturities of our operating and finance lease liabilities were as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1051"&gt;Less: Current portion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1031">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturities of our operating and finance lease liabilities were as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1051"&gt;Less: Current portion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-24" decimals="-5" id="f-1033" unitRef="usd">26300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-24" decimals="-5" id="f-1034" unitRef="usd">7900000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-24" decimals="-5" id="f-1035" unitRef="usd">24500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-24" decimals="-5" id="f-1036" unitRef="usd">7000000.0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-24" decimals="-5" id="f-1037" unitRef="usd">24400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-24" decimals="-5" id="f-1038" unitRef="usd">6200000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-24" decimals="-5" id="f-1039" unitRef="usd">19200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-24" decimals="-5" id="f-1040" unitRef="usd">5300000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-24" decimals="-5" id="f-1041" unitRef="usd">14200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-24" decimals="-5" id="f-1042" unitRef="usd">5400000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-24" decimals="-5" id="f-1043" unitRef="usd">9300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-24" decimals="-5" id="f-1044" unitRef="usd">60100000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-24" decimals="-5" id="f-1045" unitRef="usd">117900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-24" decimals="-5" id="f-1046" unitRef="usd">91900000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-24" decimals="-5" id="f-1047" unitRef="usd">16700000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-24" decimals="-5" id="f-1048" unitRef="usd">28600000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-24" decimals="-5" id="f-1049" unitRef="usd">101200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-24" decimals="-5" id="f-1050" unitRef="usd">63300000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-24" decimals="-5" id="f-1052" unitRef="usd">21100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-24" decimals="-5" id="f-1053" unitRef="usd">4700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-24" decimals="-5" id="f-1054" unitRef="usd">80100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-24" decimals="-5" id="f-1055" unitRef="usd">58600000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:AssetRetirementObligation contextRef="c-24" decimals="-5" id="f-1056" unitRef="usd">15700000</us-gaap:AssetRetirementObligation>
    <us-gaap:AssetRetirementObligation contextRef="c-25" decimals="-5" id="f-1057" unitRef="usd">11100000</us-gaap:AssetRetirementObligation>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1060">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense for the twelve months ended December&#160;31, 2023, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use asset impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to our leases is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-5" id="f-1061" unitRef="usd">6500000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-26" decimals="-5" id="f-1062" unitRef="usd">5600000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-27" decimals="-5" id="f-1063" unitRef="usd">4100000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-5" id="f-1064" unitRef="usd">3200000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-26" decimals="-5" id="f-1065" unitRef="usd">3300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-27" decimals="-5" id="f-1066" unitRef="usd">3000000.0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-1067" unitRef="usd">22900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-26" decimals="-5" id="f-1068" unitRef="usd">22600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-27" decimals="-5" id="f-1069" unitRef="usd">23300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-1" decimals="-5" id="f-1070" unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-26" decimals="-5" id="f-1071" unitRef="usd">6300000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-27" decimals="-5" id="f-1072" unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-5" id="f-1073" unitRef="usd">2400000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-26" decimals="-5" id="f-1074" unitRef="usd">3500000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-27" decimals="-5" id="f-1075" unitRef="usd">2300000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-5" id="f-1076" unitRef="usd">8300000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-26" decimals="-5" id="f-1077" unitRef="usd">8000000.0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-27" decimals="-5" id="f-1078" unitRef="usd">6000000.0</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-5" id="f-1079" unitRef="usd">43300000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-26" decimals="-5" id="f-1080" unitRef="usd">49300000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-27" decimals="-5" id="f-1081" unitRef="usd">38700000</us-gaap:LeaseCost>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-26" decimals="-5" id="f-1082" unitRef="usd">23000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <dxcm:ImpairedLongLivedAssetsFairValue contextRef="c-24" decimals="-5" id="f-1084" unitRef="usd">2500000</dxcm:ImpairedLongLivedAssetsFairValue>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-1085" unitRef="usd">28100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-26" decimals="-5" id="f-1086" unitRef="usd">26000000.0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-27" decimals="-5" id="f-1087" unitRef="usd">23300000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-5" id="f-1088" unitRef="usd">3200000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-26" decimals="-5" id="f-1089" unitRef="usd">3100000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-27" decimals="-5" id="f-1090" unitRef="usd">1900000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-5" id="f-1091" unitRef="usd">4700000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-26" decimals="-5" id="f-1092" unitRef="usd">15500000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-27" decimals="-5" id="f-1093" unitRef="usd">9900000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-5" id="f-1094" unitRef="usd">7500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-26" decimals="-5" id="f-1095" unitRef="usd">15600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-27" decimals="-5" id="f-1096" unitRef="usd">13100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-5" id="f-1097" unitRef="usd">4200000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-26" decimals="-5" id="f-1098" unitRef="usd">16100000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-27" decimals="-5" id="f-1099" unitRef="usd">6400000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-24" id="f-1100">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-25" id="f-1101">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-44" id="f-1102">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-24" id="f-1103">P14Y1M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-25" id="f-1104">P15Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-44" id="f-1105">P15Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-24" decimals="3" id="f-1106" unitRef="number">0.061</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-25" decimals="3" id="f-1107" unitRef="number">0.060</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-44" decimals="3" id="f-1108" unitRef="number">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-24" decimals="3" id="f-1109" unitRef="number">0.053</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-25" decimals="3" id="f-1110" unitRef="number">0.051</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-44" decimals="3" id="f-1111" unitRef="number">0.051</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <dxcm:LesseeOperatingLeasesLeaseCostAmortization contextRef="c-1" decimals="-5" id="f-1112" unitRef="usd">16500000</dxcm:LesseeOperatingLeasesLeaseCostAmortization>
    <dxcm:LesseeOperatingLeasesLeaseCostAmortization contextRef="c-26" decimals="-5" id="f-1113" unitRef="usd">16400000</dxcm:LesseeOperatingLeasesLeaseCostAmortization>
    <dxcm:LesseeOperatingLeasesLeaseCostAmortization contextRef="c-27" decimals="-5" id="f-1114" unitRef="usd">18000000.0</dxcm:LesseeOperatingLeasesLeaseCostAmortization>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear contextRef="c-24" decimals="-5" id="f-1115" unitRef="usd">793000000</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear contextRef="c-25" decimals="-5" id="f-1116" unitRef="usd">442700000</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <dxcm:RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm contextRef="c-1" id="f-1117">P1Y</dxcm:RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-1118">&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;7. Contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt dotted #32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between June 2021 through the year ended December 31, 2023, we and certain Abbott Diabetes Care, Inc. (&#x201c;Abbott&#x201d;) entities have served patent infringement complaints against each other in multiple jurisdictions against certain continuous glucose monitoring products of each company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to uncertainty surrounding patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time. We intend to protect our intellectual property and defend against Abbott&#x2019;s claims vigorously in all of these actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1119">&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;8. Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes subject to taxes in the following jurisdictions is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;732.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;463.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;318.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside of the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(72.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;710.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;390.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;223.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(93.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant loss and tax credit carryforwards and years of expiration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year of Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other states&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;111.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California AMT Credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of net operating losses and credit carryforwards is subject to an annual limitation due to ownership change limitations provided by Section&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. An ownership change limitation occurred as a result of the stock offering completed in February 2009. The limitation will result in approximately&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.5 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of U.S. research and development tax credits that will expire unused, and is therefore, not reflected in the tax credit carryforwards above. In addition, the related deferred tax assets have been removed from the components of our deferred tax assets as summarized in the table below. The tax benefits related to the remaining federal and state net operating losses and tax credit carryforwards may be further limited or lost if future cumulative changes in ownership exceed 50% within any three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below. Significant judgment is required to evaluate the need for a valuation allowance against deferred tax assets. We review all available positive and negative evidence, including projections of pre-tax book income, earnings history, reliability of forecasting, and reversal of temporary differences. A valuation allowance is established when it is more likely than not that some or all of the deferred tax assets will not be realized. Realization of deferred tax assets is dependent upon future earnings in applicable tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;211.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;741.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(264.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(78.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;406.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets and acquired intangibles assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(69.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;416.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, we completed an intra-entity asset transfer of certain intellectual property between two of our wholly owned foreign subsidiaries to align our structure with the expansion of international business operations. We recorded a $193.2&#160;million deferred tax asset, which represents the difference between the basis of the intellectual property for financial statement and tax purposes, applying the appropriate enacted statutory tax rate. Based on available evidence, management believes it is not more-likely-than-not that the additional foreign deferred tax asset will be realizable, and is therefore, fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a valuation allowance of $264.3 million against our California research and development tax credits, foreign tax credits, and certain foreign intangible assets. During the year ended December&#160;31, 2023, the valuation allowance increased by $185.5 million primarily due to generation of California research and development tax credits, and establishing a valuation allowance against the fair value of certain intellectual property located in Ireland in connection with the intra-entity transfer of this property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between our effective tax rate on income (loss) from continuing operations and the statutory rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock and officers compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration agreement milestone share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(72.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(52.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in statutory tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property transfer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes at effective rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decreases related to prior year tax positions &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the total unrecognized tax benefits at December 31, 2023, 2022, and 2021, $37.0 million, $32.5&#160;million and $29.5&#160;million, respectively, would affect our annual effective tax rate if recognized. Also included in the balance of unrecognized tax benefits at December&#160;31, 2023 is $0.2&#160;million of tax benefits that, if recognized, would result in adjustments to other tax accounts, primarily deferred tax assets. Interest and penalties are classified as a component of income tax expense and were not material for any period presented. Although the timing and outcome of audit settlements are uncertain, it is unlikely there will be a significant reduction of the uncertain tax benefits in the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to our global business activities, we file income tax returns and are subject to routine compliance audits in numerous jurisdictions, including those material jurisdictions listed in the following table. The U.S. net operating losses generated since 1999 and utilized in recent years are open for examination. The years remaining subject to audit, by major jurisdiction, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Jurisdiction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States (Federal and state)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1999 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Malaysia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate under a tax holiday in the Philippines, which is effective through April 30, 2023, and may be extended for another three years if certain additional requirements are satisfied. The tax holiday is conditional upon remaining in good standing, committing no violation of Philippine Economic Zone Authority Rules and Regulations, pertinent circulars and directives. After the expiration of the tax holiday we are still entitled to a preferential rate for a period of 10 years. Therefore from April 30, 2023 through December 31, 2023 we are still subject to a reduced rate of tax. The impact of this tax holiday and preferential rate was immaterial in in 2023, 2022, and 2021. We have been granted an investment tax allowance incentive by the Malaysian Investment Development Authority (MIDA) in Malaysia, which will not be triggered until we meet certain milestones related to the commencement of operations. The tax incentive had no effect on foreign taxes during 2023, 2022, or 2021. As of December 31, 2023 the tax holiday in Malaysia has not yet been triggered, therefore we are subject to the statutory rate and the related tax expense has been included in total tax expense for 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have approximately $36.5&#160;million of undistributed earnings attributable to operations in our controlled foreign corporations as of December 31, 2023. We assert that any foreign earnings will be indefinitely reinvested. Accordingly, we have not recorded a liability for taxes associated with these undistributed earnings. If we determine that all or a portion of such foreign earnings are no longer indefinitely reinvested, we may be subject to additional foreign withholding taxes and U.S. state income taxes. Determination of the amount of unrecognized deferred tax liability on these unremitted earnings is not practicable.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1120">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes subject to taxes in the following jurisdictions is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;732.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;463.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;318.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outside of the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(72.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;710.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;390.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-5" id="f-1121" unitRef="usd">732400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-26" decimals="-5" id="f-1122" unitRef="usd">463500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-27" decimals="-5" id="f-1123" unitRef="usd">318200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-5" id="f-1124" unitRef="usd">-22000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-26" decimals="-5" id="f-1125" unitRef="usd">-72700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-27" decimals="-5" id="f-1126" unitRef="usd">-61400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-1127" unitRef="usd">710400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-26" decimals="-5" id="f-1128" unitRef="usd">390800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-27" decimals="-5" id="f-1129" unitRef="usd">256800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1130">&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the provision for income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;223.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(93.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1131" unitRef="usd">149100000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1132" unitRef="usd">32600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1133" unitRef="usd">5700000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1134" unitRef="usd">18100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1135" unitRef="usd">26100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1136" unitRef="usd">8300000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1137" unitRef="usd">56700000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1138" unitRef="usd">12500000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1139" unitRef="usd">10100000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1140" unitRef="usd">223900000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1141" unitRef="usd">71200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1142" unitRef="usd">24100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1143" unitRef="usd">-93700000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1144" unitRef="usd">-4300000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1145" unitRef="usd">23000000.0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1146" unitRef="usd">14600000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1147" unitRef="usd">-17600000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1148" unitRef="usd">-200000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1149" unitRef="usd">24100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1150" unitRef="usd">300000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1151" unitRef="usd">-7000000.0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1152" unitRef="usd">-55000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1153" unitRef="usd">-21600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1154" unitRef="usd">15800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1155" unitRef="usd">168900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1156" unitRef="usd">49600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1157" unitRef="usd">39900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock contextRef="c-1" id="f-1159">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant loss and tax credit carryforwards and years of expiration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year of Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other states&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;111.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California AMT Credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="c-1" id="f-1158">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant loss and tax credit carryforwards and years of expiration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year of Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;167.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other states&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;111.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California AMT Credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c-226" decimals="-5" id="f-1160" unitRef="usd">20400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-227" decimals="-5" id="f-1161" unitRef="usd">28700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-228" decimals="-5" id="f-1162" unitRef="usd">167700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-229" decimals="-5" id="f-1163" unitRef="usd">185000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-230" decimals="-5" id="f-1164" unitRef="usd">7800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-231" decimals="-5" id="f-1165" unitRef="usd">8500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-232" decimals="-5" id="f-1166" unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-233" decimals="-5" id="f-1167" unitRef="usd">90500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-234" decimals="-5" id="f-1168" unitRef="usd">6000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-235" decimals="-5" id="f-1169" unitRef="usd">9700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-236" decimals="-5" id="f-1170" unitRef="usd">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-237" decimals="-5" id="f-1171" unitRef="usd">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-238" decimals="-5" id="f-1172" unitRef="usd">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-239" decimals="-5" id="f-1173" unitRef="usd">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-240" decimals="-5" id="f-1174" unitRef="usd">111900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-241" decimals="-5" id="f-1175" unitRef="usd">96400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-242" decimals="-5" id="f-1176" unitRef="usd">500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-243" decimals="-5" id="f-1177" unitRef="usd">0</us-gaap:TaxCreditCarryforwardAmount>
    <dxcm:UnusedExpiredFederalIncomeTaxCredits contextRef="c-1" decimals="-5" id="f-1178" unitRef="usd">1500000</dxcm:UnusedExpiredFederalIncomeTaxCredits>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1179">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;211.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;741.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(264.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(78.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;406.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets and acquired intangibles assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(69.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;416.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-24" decimals="-5" id="f-1180" unitRef="usd">18100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-25" decimals="-5" id="f-1181" unitRef="usd">46400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-24" decimals="-5" id="f-1182" unitRef="usd">233400000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-25" decimals="-5" id="f-1183" unitRef="usd">211900000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-24" decimals="-5" id="f-1184" unitRef="usd">71400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-25" decimals="-5" id="f-1185" unitRef="usd">61100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-24" decimals="-5" id="f-1186" unitRef="usd">27000000.0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-25" decimals="-5" id="f-1187" unitRef="usd">16800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <dxcm:DeferredTaxAssetsFixedAssetsAndIntangibleAssets contextRef="c-24" decimals="-5" id="f-1188" unitRef="usd">279800000</dxcm:DeferredTaxAssetsFixedAssetsAndIntangibleAssets>
    <dxcm:DeferredTaxAssetsFixedAssetsAndIntangibleAssets contextRef="c-25" decimals="-5" id="f-1189" unitRef="usd">34400000</dxcm:DeferredTaxAssetsFixedAssetsAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-24" decimals="-5" id="f-1190" unitRef="usd">91000000.0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-25" decimals="-5" id="f-1191" unitRef="usd">105300000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <dxcm:DeferredTaxAssetsConvertibleDebt contextRef="c-24" decimals="-5" id="f-1192" unitRef="usd">-20600000</dxcm:DeferredTaxAssetsConvertibleDebt>
    <dxcm:DeferredTaxAssetsConvertibleDebt contextRef="c-25" decimals="-5" id="f-1193" unitRef="usd">-9300000</dxcm:DeferredTaxAssetsConvertibleDebt>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-24" decimals="-5" id="f-1194" unitRef="usd">741300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-25" decimals="-5" id="f-1195" unitRef="usd">485200000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-24" decimals="-5" id="f-1196" unitRef="usd">264300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-25" decimals="-5" id="f-1197" unitRef="usd">78700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-24" decimals="-5" id="f-1198" unitRef="usd">477000000.0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-25" decimals="-5" id="f-1199" unitRef="usd">406500000</us-gaap:DeferredTaxAssetsNet>
    <dxcm:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets contextRef="c-24" decimals="-5" id="f-1200" unitRef="usd">60400000</dxcm:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <dxcm:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets contextRef="c-25" decimals="-5" id="f-1201" unitRef="usd">69900000</dxcm:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-24" decimals="-5" id="f-1202" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-25" decimals="-5" id="f-1203" unitRef="usd">300000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-24" decimals="-5" id="f-1204" unitRef="usd">60400000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-25" decimals="-5" id="f-1205" unitRef="usd">70200000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-24" decimals="-5" id="f-1206" unitRef="usd">416600000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-25" decimals="-5" id="f-1207" unitRef="usd">336300000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c-244" decimals="-5" id="f-1208" unitRef="usd">193200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-245" decimals="-5" id="f-1209" unitRef="usd">264300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-1210" unitRef="usd">185500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1211">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between our effective tax rate on income (loss) from continuing operations and the statutory rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;149.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock and officers compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration agreement milestone share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(72.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(52.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in statutory tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property transfer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes at effective rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-5" id="f-1212" unitRef="usd">149200000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-26" decimals="-5" id="f-1213" unitRef="usd">82100000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-27" decimals="-5" id="f-1214" unitRef="usd">53900000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-5" id="f-1215" unitRef="usd">7800000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-26" decimals="-5" id="f-1216" unitRef="usd">5400000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-27" decimals="-5" id="f-1217" unitRef="usd">8900000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <dxcm:EffectiveIncomeTaxReconciliationPermanentItems contextRef="c-1" decimals="-5" id="f-1218" unitRef="usd">-2700000</dxcm:EffectiveIncomeTaxReconciliationPermanentItems>
    <dxcm:EffectiveIncomeTaxReconciliationPermanentItems contextRef="c-26" decimals="-5" id="f-1219" unitRef="usd">600000</dxcm:EffectiveIncomeTaxReconciliationPermanentItems>
    <dxcm:EffectiveIncomeTaxReconciliationPermanentItems contextRef="c-27" decimals="-5" id="f-1220" unitRef="usd">5200000</dxcm:EffectiveIncomeTaxReconciliationPermanentItems>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-5" id="f-1221" unitRef="usd">28300000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-26" decimals="-5" id="f-1222" unitRef="usd">23300000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-27" decimals="-5" id="f-1223" unitRef="usd">28900000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-1" decimals="-5" id="f-1224" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-26" decimals="-5" id="f-1225" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-27" decimals="-5" id="f-1226" unitRef="usd">3700000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-5" id="f-1227" unitRef="usd">15800000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-26" decimals="-5" id="f-1228" unitRef="usd">27700000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-27" decimals="-5" id="f-1229" unitRef="usd">20900000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-5" id="f-1230" unitRef="usd">5600000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-26" decimals="-5" id="f-1231" unitRef="usd">-1200000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-27" decimals="-5" id="f-1232" unitRef="usd">-20400000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <dxcm:EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment contextRef="c-1" decimals="-5" id="f-1233" unitRef="usd">-72100000</dxcm:EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment>
    <dxcm:EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment contextRef="c-26" decimals="-5" id="f-1234" unitRef="usd">-52900000</dxcm:EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment>
    <dxcm:EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment contextRef="c-27" decimals="-5" id="f-1235" unitRef="usd">0</dxcm:EffectiveIncomeTaxRateReconciliationCollaborationAgreementMilestoneShareBasedPayment>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-5" id="f-1236" unitRef="usd">19400000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-26" decimals="-5" id="f-1237" unitRef="usd">1000000.0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-27" decimals="-5" id="f-1238" unitRef="usd">-10000000.0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <dxcm:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer contextRef="c-1" decimals="-5" id="f-1239" unitRef="usd">63900000</dxcm:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer>
    <dxcm:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer contextRef="c-26" decimals="-5" id="f-1240" unitRef="usd">0</dxcm:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer>
    <dxcm:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer contextRef="c-27" decimals="-5" id="f-1241" unitRef="usd">0</dxcm:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-5" id="f-1242" unitRef="usd">300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-26" decimals="-5" id="f-1243" unitRef="usd">1300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-27" decimals="-5" id="f-1244" unitRef="usd">-400000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-5" id="f-1245" unitRef="usd">10000000.0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-26" decimals="-5" id="f-1246" unitRef="usd">8900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="-5" id="f-1247" unitRef="usd">14400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-1248" unitRef="usd">168900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-1249" unitRef="usd">49600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-5" id="f-1250" unitRef="usd">39900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="c-1" id="f-1251">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at January&#160;1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decreases related to prior year tax positions &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-33" decimals="-5" id="f-1252" unitRef="usd">36600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-27" decimals="-5" id="f-1253" unitRef="usd">400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-27" decimals="-5" id="f-1254" unitRef="usd">9800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-44" decimals="-5" id="f-1255" unitRef="usd">46800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-26" decimals="-5" id="f-1256" unitRef="usd">900000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-26" decimals="-5" id="f-1257" unitRef="usd">6100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-25" decimals="-5" id="f-1258" unitRef="usd">52000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-5" id="f-1259" unitRef="usd">800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-5" id="f-1260" unitRef="usd">6600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-24" decimals="-5" id="f-1261" unitRef="usd">59400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-24" decimals="-5" id="f-1262" unitRef="usd">37000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-25" decimals="-5" id="f-1263" unitRef="usd">32500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-44" decimals="-5" id="f-1264" unitRef="usd">29500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <dxcm:UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets contextRef="c-24" decimals="-5" id="f-1265" unitRef="usd">200000</dxcm:UnrecognizedTaxBenefitsPotentialAdjustmentToDeferredTaxAssets>
    <us-gaap:SummaryOfIncomeTaxExaminationsTextBlock contextRef="c-1" id="f-1266">The years remaining subject to audit, by major jurisdiction, are as follows:&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.035%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Jurisdiction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States (Federal and state)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1999 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Malaysia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 - 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxExaminationsTextBlock>
    <dxcm:PossibleExtensionPeriodofTaxHoliday contextRef="c-1" id="f-1267">P3Y</dxcm:PossibleExtensionPeriodofTaxHoliday>
    <dxcm:PreferentialTaxRatePeriod contextRef="c-1" id="f-1268">P10Y</dxcm:PreferentialTaxRatePeriod>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="c-24" decimals="-5" id="f-1269" unitRef="usd">36500000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-1270">&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;9. Employee Benefit Plans and Stockholders&#x2019; Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offer various defined contribution plans for U.S. and international employees. The largest defined contribution plan is the 401(k) retirement plan (the 401(k) Plan) covering substantially all employees in the United States that meet certain age requirements. Employees who participate in the 401(k) Plan may contribute up to 90% of their compensation each year, subject to Internal Revenue Service limitations and the terms and conditions of the plan. Under the terms of the 401(k) Plan, we may elect to match a discretionary percentage of contributions. We match 50% of contributions up to 6% of eligible compensation. Total matching contributions under the 401(k) Plan were $14.9 million, $11.1 million and $9.9&#160;million for the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively. Our contributions for other defined contribution plans are not significant for the twelve months ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2015 Employee Stock Purchase Plan (the 2015 ESPP), amended in December 2019, eligible employees may purchase shares of our common stock at semi-annual intervals through periodic payroll deductions during defined Offering Periods. Payroll deductions may not exceed 10% of the participant&#x2019;s cash compensation subject to certain limitations, and the purchase price will be 85% of the lower of the fair market value of the common stock at either the beginning of the applicable Offering Period or the Purchase Date. A total of 6.0 million shares of common stock are reserved for issuance under the 2015 ESPP. The 2015 ESPP shall continue until the earlier to occur of (a) termination of the 2015 ESPP by our Board of Directors, (b) issuance of all of the shares of common stock reserved for issuance under the plan, or (c) May&#160;28, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issued approximately 0.3 million, 0.3 million and 0.3 million shares of common stock under the 2015 ESPP during the twelve months ended December&#160;31, 2023, 2022 and 2021, respectively. As of December&#160;31, 2023, approximately 2.5 million shares remained available for future issuance under the 2015 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2015, we adopted the Amended and Restated 2015 Equity Incentive Plan (the 2015 Plan), which replaced our 2005 Equity Incentive Plan and provides for the grant of incentive and nonstatutory stock options, restricted stock, stock bonuses, stock appreciation rights, RSUs, and PSUs to employees, directors or consultants of the Company. On May 30, 2019, our stockholders approved an increase to the maximum number of shares that may be issued under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are authorized to issue up to&#160;39.2 million&#160;shares of our common stock under the 2015 Plan. As of December&#160;31, 2023, approximately 13.9 million shares remained available for future issuance under the 2015 Plan. We issue new shares of common stock to satisfy RSU and PSU vesting under our employee equity incentive plans.&lt;/span&gt;&lt;/div&gt;RSU awards typically vest in annual installments over &lt;span style="-sec-ix-hidden:f-1286"&gt;three&lt;/span&gt; or four years and vesting is subject to continued service. PSUs are granted to a group of senior officers and the number of shares of our common stock to be received at vesting will range from 0% to 200% of the target award based on the achievement of pre-established performance and market goals. PSUs vest approximately three years from the date of grant, subject to continued employment through that date and certification by the Compensation Committee&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchase Program and Treasury Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Repurchased shares of our common stock are held as treasury shares until they are reissued or retired. When we reissue treasury stock, if the proceeds from the sale are more than the average price we paid to acquire the shares we record an increase in additional paid-in capital. Conversely, if the proceeds from the sale are less than the average price we paid to acquire the shares, we record a decrease in additional paid-in capital to the extent of increases previously recorded for similar transactions and a decrease in retained earnings for any remaining amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our treasury share activity for the periods shown.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.272%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued in connection with 2023 Notes conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares received from Note Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued in connection with the Restated Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares repurchased under the 2022 Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares repurchased under the 2023 Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares repurchased with 2028 Notes proceeds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2022, a duly authorized committee of our Board of Directors authorized and approved a share repurchase program of up to $700.0&#160;million of our outstanding common stock, with a repurchase period that ended on June 30, 2023 (the &#x201c;2022 Share Repurchase Program&#x201d;). Shares of common stock repurchased under the 2022 Share Repurchase Program became treasury shares. We repurchased approximately $557.7 million of our outstanding common stock throughout the duration of the 2022 Share Repurchase Program. The 2022 Share Repurchase Program and the remaining authorization of approximately $142.3&#160;million expired on June 30, 2023. There were no share repurchases under the 2022 Share Repurchase Program in 2023. On August 1, 2022, we entered into an accelerated share repurchase agreement (&#x201c;2022 ASR&#x201d;) with JPMorgan Chase Bank, National Association (&#x201c;JP Morgan&#x201d;) to repurchase up to $700.0&#160;million of our common stock on an accelerated basis through September 29, 2022. On August 3, 2022, we paid $700.0&#160;million to JP Morgan and received an initial delivery of approximately 3.0 million shares of common stock. The final notional amount under the 2022 ASR was $557.7&#160;million or approximately 6.6&#160;million shares of our common stock based on the daily average volume-weighted average price of our common stock during the term of the 2022 ASR for the period from August 1, 2022 to August 31, 2022, less a discount. The 2022 ASR concluded on September 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 24, 2023, our Board of Directors authorized and approved a share repurchase program of up to $500.0&#160;million of our outstanding common stock, with a repurchase period ending no later than October 31, 2024 (the &#x201c;2023 Share Repurchase Program&#x201d;). On October 31, 2023, we entered into an accelerated share repurchase agreement (&#x201c;2023 ASR&#x201d;) with Bank of America, N.A. (&#x201c;BofA&#x201d;) to repurchase $500.0 million of our common stock on an accelerated basis through December 14, 2023. On October 31, 2023, we paid $500.0 million to BofA and received an initial delivery of approximately 4.7 million shares of common stock. The final notional amount under the 2023 ASR was $500.0 million or approximately 4.7 million shares of our common stock based on the daily average volume-weighted average price of our common stock during the term of the 2023 ASR for the period from November 1, 2023 to December 14, 2023, less a discount. The 2023 ASR concluded on December 14, 2023. After completion of the repurchases under the 2023 ASR, no shares remained available for additional repurchases under our 2023 Share Repurchase Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 ASR and 2023 ASR were forward contracts indexed to our own common stock. The forward contracts met all of the applicable criteria for equity classification, so we did not account for them as a derivative instrument. We have reflected the shares delivered to us by the financial institution as treasury shares as of the dates they were delivered to us in computing weighted average shares outstanding for both basic and diluted net income per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, we used a portion of the proceeds of the 2028 Notes to repurchase 1.6 million shares of our common stock for $188.7 million, excluding excise tax due under the Inflation Reduction Act of 2022, for an average per share price of $118.12, via privately negotiated transactions, independent of the 2022 Share Repurchase Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Repurchased shares of our common stock are held as treasury shares until they are reissued or retired. We have not yet determined the ultimate disposition of repurchased shares and consequently we continue to hold them as treasury shares rather than retiring them. Authorization of future stock repurchase programs is subject to the final determination of our Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Award Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU and PSU activity under the 2015 Plan for the twelve months ended December&#160;31, 2023, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt;text-indent:22.5pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nonvested RSU and PSU Activity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions, except weighted average grant date fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares Available for Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&#160;&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;403.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;325.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;361.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total vest-date fair value of RSUs and PSUs that vested during the twelve months ended December&#160;31, 2023, 2022 and 2021 was $157.8 million, $160.1 million and $284.5 million, respectively. As of December&#160;31, 2023, 2.6 million unvested RSUs and 0.3 million unvested PSUs were outstanding under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share-based compensation expense is associated with RSUs, PSUs, and ESPP. The following table summarizes the share-based compensation expense included in our consolidated statements of operations for the periods shown.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total tax benefit related to share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, unrecognized estimated compensation costs related to RSUs and PSUs totaled $199.5 million and are expected to be recognized over a weighted-average period of approximately 1.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value RSUs at the date of grant using the intrinsic value method. We estimate the fair value of PSUs at the date of grant using the intrinsic value method and the probability that the specified performance criteria will be met. We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.20% - 5.47%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.60% - 3.34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.06%&#160;- 0.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility of Dexcom common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34% - 48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45% - 55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36%&#160;- 45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-246"
      decimals="INF"
      id="f-1271"
      unitRef="number">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-246"
      decimals="INF"
      id="f-1272"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-246"
      decimals="INF"
      id="f-1273"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-246" decimals="-5" id="f-1274" unitRef="usd">14900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-247" decimals="-5" id="f-1275" unitRef="usd">11100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-248" decimals="-5" id="f-1276" unitRef="usd">9900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-24"
      decimals="INF"
      id="f-1277"
      unitRef="number">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <dxcm:EmployeePurchasePriceFloorPercentage
      contextRef="c-1"
      decimals="INF"
      id="f-1278"
      unitRef="number">0.85</dxcm:EmployeePurchasePriceFloorPercentage>
    <dxcm:EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized
      contextRef="c-24"
      decimals="INF"
      id="f-1279"
      unitRef="shares">6000000.0</dxcm:EmployeeStockPurchasePlanESPPNumberOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-249"
      decimals="-5"
      id="f-1280"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-250"
      decimals="-5"
      id="f-1281"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-251"
      decimals="-5"
      id="f-1282"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-252"
      decimals="-5"
      id="f-1283"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-253"
      decimals="-5"
      id="f-1284"
      unitRef="shares">39200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-254"
      decimals="-5"
      id="f-1285"
      unitRef="shares">13900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-256" id="f-1287">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-257"
      decimals="INF"
      id="f-1288"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-258"
      decimals="INF"
      id="f-1289"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-259" id="f-1290">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dxcm:ScheduleOfTreasuryShareActivityTableTextBlock contextRef="c-1" id="f-1291">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our treasury share activity for the periods shown.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.272%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued in connection with 2023 Notes conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares received from Note Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued in connection with the Restated Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares repurchased under the 2022 Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares repurchased under the 2023 Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares repurchased with 2028 Notes proceeds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dxcm:ScheduleOfTreasuryShareActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-1" decimals="-5" id="f-1292" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-26"
      decimals="-5"
      id="f-1293"
      unitRef="shares">-400000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-27"
      decimals="-5"
      id="f-1294"
      unitRef="shares">-800000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <dxcm:SharesReceivedFromExerciseOfNoteHedge contextRef="c-1" decimals="-5" id="f-1295" unitRef="shares">12200000</dxcm:SharesReceivedFromExerciseOfNoteHedge>
    <dxcm:SharesReceivedFromExerciseOfNoteHedge
      contextRef="c-26"
      decimals="-5"
      id="f-1296"
      unitRef="shares">300000</dxcm:SharesReceivedFromExerciseOfNoteHedge>
    <dxcm:SharesReceivedFromExerciseOfNoteHedge
      contextRef="c-27"
      decimals="-5"
      id="f-1297"
      unitRef="shares">1000000.0</dxcm:SharesReceivedFromExerciseOfNoteHedge>
    <dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone contextRef="c-1" decimals="-5" id="f-1298" unitRef="shares">3700000</dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone>
    <dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone
      contextRef="c-26"
      decimals="-5"
      id="f-1299"
      unitRef="shares">2900000</dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone>
    <dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone
      contextRef="c-27"
      decimals="-5"
      id="f-1300"
      unitRef="shares">0</dxcm:StockIssuedDuringPeriodSharesAchievementOfMilestone>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-260"
      decimals="-5"
      id="f-1301"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-261"
      decimals="-5"
      id="f-1302"
      unitRef="shares">6600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-262"
      decimals="-5"
      id="f-1303"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-263"
      decimals="-5"
      id="f-1304"
      unitRef="shares">4700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-264"
      decimals="-5"
      id="f-1305"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-265"
      decimals="-5"
      id="f-1306"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-266"
      decimals="-5"
      id="f-1307"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-267"
      decimals="-5"
      id="f-1308"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-268"
      decimals="-5"
      id="f-1309"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-269" decimals="-5" id="f-1310" unitRef="usd">700000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-270" decimals="-5" id="f-1311" unitRef="usd">557700000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-271" decimals="-5" id="f-1312" unitRef="usd">142300000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-272" decimals="0" id="f-1313" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <dxcm:AcceleratedShareRepurchaseAgreementAuthorizedAmount contextRef="c-273" decimals="INF" id="f-1314" unitRef="usd">700000000</dxcm:AcceleratedShareRepurchaseAgreementAuthorizedAmount>
    <us-gaap:PaymentsForRepurchaseOfEquity contextRef="c-274" decimals="-5" id="f-1315" unitRef="usd">700000000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-274"
      decimals="-5"
      id="f-1316"
      unitRef="shares">3000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-270" decimals="-5" id="f-1317" unitRef="usd">557700000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-270"
      decimals="-5"
      id="f-1318"
      unitRef="shares">6600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-275" decimals="-5" id="f-1319" unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <dxcm:AcceleratedShareRepurchaseAgreementAuthorizedAmount contextRef="c-276" decimals="INF" id="f-1320" unitRef="usd">500000000</dxcm:AcceleratedShareRepurchaseAgreementAuthorizedAmount>
    <us-gaap:PaymentsForRepurchaseOfEquity contextRef="c-277" decimals="-5" id="f-1321" unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-277"
      decimals="-5"
      id="f-1322"
      unitRef="shares">4700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-278" decimals="-5" id="f-1323" unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-278"
      decimals="-5"
      id="f-1324"
      unitRef="shares">4700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-279"
      decimals="-5"
      id="f-1325"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-279" decimals="-5" id="f-1326" unitRef="usd">188700000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-279"
      decimals="2"
      id="f-1327"
      unitRef="usdPerShare">118.12</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-1328">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU and PSU activity under the 2015 Plan for the twelve months ended December&#160;31, 2023, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt;text-indent:22.5pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nonvested RSU and PSU Activity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions, except weighted average grant date fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares Available for Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&#160;&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;403.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;325.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;361.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-280"
      decimals="-5"
      id="f-1329"
      unitRef="shares">18000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-281"
      decimals="-5"
      id="f-1330"
      unitRef="shares">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-281"
      decimals="2"
      id="f-1331"
      unitRef="usdPerShare">45.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c-282"
      decimals="-5"
      id="f-1332"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-283"
      decimals="-5"
      id="f-1333"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-283"
      decimals="2"
      id="f-1334"
      unitRef="usdPerShare">87.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <dxcm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested
      contextRef="c-282"
      decimals="-5"
      id="f-1335"
      unitRef="shares">0</dxcm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-283"
      decimals="-5"
      id="f-1336"
      unitRef="shares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-283"
      decimals="2"
      id="f-1337"
      unitRef="usdPerShare">34.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="c-282"
      decimals="-5"
      id="f-1338"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-283"
      decimals="-5"
      id="f-1339"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-283"
      decimals="2"
      id="f-1340"
      unitRef="usdPerShare">69.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-284"
      decimals="-5"
      id="f-1341"
      unitRef="shares">16800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-285"
      decimals="-5"
      id="f-1342"
      unitRef="shares">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-285"
      decimals="2"
      id="f-1343"
      unitRef="usdPerShare">76.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c-285" decimals="-5" id="f-1344" unitRef="usd">403800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c-286"
      decimals="-5"
      id="f-1345"
      unitRef="shares">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-287"
      decimals="-5"
      id="f-1346"
      unitRef="shares">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-287"
      decimals="2"
      id="f-1347"
      unitRef="usdPerShare">96.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <dxcm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested
      contextRef="c-286"
      decimals="-5"
      id="f-1348"
      unitRef="shares">0</dxcm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-287"
      decimals="-5"
      id="f-1349"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-287"
      decimals="2"
      id="f-1350"
      unitRef="usdPerShare">63.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="c-286"
      decimals="-5"
      id="f-1351"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-287"
      decimals="-5"
      id="f-1352"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-287"
      decimals="2"
      id="f-1353"
      unitRef="usdPerShare">92.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-288"
      decimals="-5"
      id="f-1354"
      unitRef="shares">15300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-289"
      decimals="-5"
      id="f-1355"
      unitRef="shares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-289"
      decimals="2"
      id="f-1356"
      unitRef="usdPerShare">94.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c-289" decimals="-5" id="f-1357" unitRef="usd">325600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c-290"
      decimals="-5"
      id="f-1358"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-291"
      decimals="-5"
      id="f-1359"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-291"
      decimals="2"
      id="f-1360"
      unitRef="usdPerShare">112.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <dxcm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested
      contextRef="c-290"
      decimals="-5"
      id="f-1361"
      unitRef="shares">0</dxcm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-291"
      decimals="-5"
      id="f-1362"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-291"
      decimals="2"
      id="f-1363"
      unitRef="usdPerShare">88.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="c-290"
      decimals="-5"
      id="f-1364"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-291"
      decimals="-5"
      id="f-1365"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-291"
      decimals="2"
      id="f-1366"
      unitRef="usdPerShare">106.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-292"
      decimals="-5"
      id="f-1367"
      unitRef="shares">13900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-254"
      decimals="-5"
      id="f-1368"
      unitRef="shares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-254"
      decimals="2"
      id="f-1369"
      unitRef="usdPerShare">105.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c-254" decimals="-5" id="f-1370" unitRef="usd">361200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-293" decimals="-5" id="f-1371" unitRef="usd">157800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-294" decimals="-5" id="f-1372" unitRef="usd">160100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-295" decimals="-5" id="f-1373" unitRef="usd">284500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-296"
      decimals="-5"
      id="f-1374"
      unitRef="shares">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-297"
      decimals="-5"
      id="f-1375"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1376">The following table summarizes the share-based compensation expense included in our consolidated statements of operations for the periods shown.&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total tax benefit related to share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-298" decimals="-5" id="f-1377" unitRef="usd">14600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-299" decimals="-5" id="f-1378" unitRef="usd">11100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-300" decimals="-5" id="f-1379" unitRef="usd">8500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-301" decimals="-5" id="f-1380" unitRef="usd">45500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-302" decimals="-5" id="f-1381" unitRef="usd">42700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-303" decimals="-5" id="f-1382" unitRef="usd">41000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-304" decimals="-5" id="f-1383" unitRef="usd">90700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-305" decimals="-5" id="f-1384" unitRef="usd">72700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-306" decimals="-5" id="f-1385" unitRef="usd">63900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-1386" unitRef="usd">150800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-26" decimals="-5" id="f-1387" unitRef="usd">126500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-27" decimals="-5" id="f-1388" unitRef="usd">113400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-5" id="f-1389" unitRef="usd">40000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-26" decimals="-5" id="f-1390" unitRef="usd">43200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-27" decimals="-5" id="f-1391" unitRef="usd">71100000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-254" decimals="-5" id="f-1392" unitRef="usd">199500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-291" id="f-1393">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1394">We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.20% - 5.47%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.60% - 3.34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.06%&#160;- 0.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility of Dexcom common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34% - 48%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45% - 55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36%&#160;- 45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-307"
      decimals="4"
      id="f-1395"
      unitRef="number">0.0520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-308"
      decimals="4"
      id="f-1396"
      unitRef="number">0.0547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-309"
      decimals="4"
      id="f-1397"
      unitRef="number">0.0060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-310"
      decimals="4"
      id="f-1398"
      unitRef="number">0.0334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-311"
      decimals="4"
      id="f-1399"
      unitRef="number">0.0006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-312"
      decimals="4"
      id="f-1400"
      unitRef="number">0.0007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-313"
      decimals="2"
      id="f-1401"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-314"
      decimals="2"
      id="f-1402"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-315"
      decimals="2"
      id="f-1403"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-307"
      decimals="2"
      id="f-1404"
      unitRef="number">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-308"
      decimals="2"
      id="f-1405"
      unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-309"
      decimals="2"
      id="f-1406"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-310"
      decimals="2"
      id="f-1407"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-311"
      decimals="2"
      id="f-1408"
      unitRef="number">0.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-312"
      decimals="2"
      id="f-1409"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-313" id="f-1410">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-314" id="f-1411">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-315" id="f-1412">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1413">&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;10. Business Segment and Geographic Information&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An operating segment is identified as a component of a business that has discrete financial information available and for which the chief operating decision maker must decide the level of resource allocation. In addition, the guidance for segment reporting indicates certain quantitative materiality thresholds. None of the components of our business meet the definition of an operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently consider our operations to be, and manage our business globally within, one reportable segment, which is consistent with how our President and Chief Executive Officer, who is our chief operating decision maker, reviews our business, makes investment and resource allocation decisions, and assesses operating performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We disaggregate revenue by geographic region and by major sales channel. We have determined that disaggregating revenue into these categories achieves the ASC Topic 606 disclosure objectives of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue by geographic region&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the twelve months ended December&#160;31, 2023, 2022 and 2021, no individual country outside the United States generated revenue that represented more than 10% of our total revenue. The following table sets forth revenue by our two primary geographical markets, the United States and International, based on the geographic location to which we deliver the components, for the periods shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,625.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,142.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,849.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;997.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;767.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;599.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,622.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,909.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue by customer sales channel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our CGM systems through a direct sales organization and through distribution arrangements that allow distributors to sell our products. The following table sets forth revenue by major sales channel for the twelve months ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributor&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,095.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,470.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,024.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;526.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;439.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;424.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,622.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,909.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#32ad10;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our long-lived assets, which consists of property and equipment, net, and operating lease right-of-use assets by geographic region:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;544.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;686.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Malaysia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;515.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;346.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other countries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,184.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1414"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1415">The following table sets forth revenue by our two primary geographical markets, the United States and International, based on the geographic location to which we deliver the components, for the periods shown:&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,625.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,142.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,849.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;997.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;767.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;599.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,622.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,909.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our long-lived assets, which consists of property and equipment, net, and operating lease right-of-use assets by geographic region:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;544.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;686.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Malaysia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;515.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;346.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other countries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,184.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <dxcm:NumberOfPrimaryGeographicMarkets
      contextRef="c-1"
      decimals="INF"
      id="f-1416"
      unitRef="primarymarket">2</dxcm:NumberOfPrimaryGeographicMarkets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-316" decimals="-5" id="f-1417" unitRef="usd">2625300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-316"
      decimals="2"
      id="f-1418"
      unitRef="number">0.72</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-317" decimals="-5" id="f-1419" unitRef="usd">2142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-317"
      decimals="2"
      id="f-1420"
      unitRef="number">0.74</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-318" decimals="-5" id="f-1421" unitRef="usd">1849400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-318"
      decimals="2"
      id="f-1422"
      unitRef="number">0.76</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-319" decimals="-5" id="f-1423" unitRef="usd">997000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-319"
      decimals="2"
      id="f-1424"
      unitRef="number">0.28</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-320" decimals="-5" id="f-1425" unitRef="usd">767800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-320"
      decimals="2"
      id="f-1426"
      unitRef="number">0.26</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-321" decimals="-5" id="f-1427" unitRef="usd">599100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-321"
      decimals="2"
      id="f-1428"
      unitRef="number">0.24</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-1429" unitRef="usd">3622300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage contextRef="c-1" decimals="2" id="f-1430" unitRef="number">1</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-5" id="f-1431" unitRef="usd">2909800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage contextRef="c-26" decimals="2" id="f-1432" unitRef="number">1</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-27" decimals="-5" id="f-1433" unitRef="usd">2448500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage contextRef="c-27" decimals="2" id="f-1434" unitRef="number">1</dxcm:RevenuePercentage>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-1435">The following table sets forth revenue by major sales channel for the twelve months ended December&#160;31, 2023, 2022 and 2021:&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;%&lt;br/&gt;of&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributor&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,095.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,470.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,024.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;526.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;439.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;424.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,622.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,909.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-322" decimals="-5" id="f-1436" unitRef="usd">3095600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-322"
      decimals="2"
      id="f-1437"
      unitRef="number">0.85</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-323" decimals="-5" id="f-1438" unitRef="usd">2470800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-323"
      decimals="2"
      id="f-1439"
      unitRef="number">0.85</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-324" decimals="-5" id="f-1440" unitRef="usd">2024300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-324"
      decimals="2"
      id="f-1441"
      unitRef="number">0.83</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-325" decimals="-5" id="f-1442" unitRef="usd">526700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-325"
      decimals="2"
      id="f-1443"
      unitRef="number">0.15</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-326" decimals="-5" id="f-1444" unitRef="usd">439000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-326"
      decimals="2"
      id="f-1445"
      unitRef="number">0.15</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-327" decimals="-5" id="f-1446" unitRef="usd">424200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage
      contextRef="c-327"
      decimals="2"
      id="f-1447"
      unitRef="number">0.17</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-1448" unitRef="usd">3622300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage contextRef="c-1" decimals="2" id="f-1449" unitRef="number">1</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-5" id="f-1450" unitRef="usd">2909800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage contextRef="c-26" decimals="2" id="f-1451" unitRef="number">1</dxcm:RevenuePercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-27" decimals="-5" id="f-1452" unitRef="usd">2448500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dxcm:RevenuePercentage contextRef="c-27" decimals="2" id="f-1453" unitRef="number">1</dxcm:RevenuePercentage>
    <us-gaap:NoncurrentAssets contextRef="c-328" decimals="-5" id="f-1454" unitRef="usd">544100000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-329" decimals="-5" id="f-1455" unitRef="usd">686100000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-330" decimals="-5" id="f-1456" unitRef="usd">515400000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-331" decimals="-5" id="f-1457" unitRef="usd">346300000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-332" decimals="-5" id="f-1458" unitRef="usd">125000000.0</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-333" decimals="-5" id="f-1459" unitRef="usd">103200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-24" decimals="-5" id="f-1460" unitRef="usd">1184500000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-25" decimals="-5" id="f-1461" unitRef="usd">1135600000</us-gaap:NoncurrentAssets>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c-1" id="f-1462">&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;DexCom, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;SCHEDULE II&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &#x2013; &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#32ad10;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Twelve Months Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning Balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Write-offs and adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bcedaf;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending Balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bcedaf;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bcedaf;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-25" decimals="-5" id="f-1463" unitRef="usd">7300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-44" decimals="-5" id="f-1464" unitRef="usd">5400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-33" decimals="-5" id="f-1465" unitRef="usd">7200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-1" decimals="-5" id="f-1466" unitRef="usd">2000000.0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-26" decimals="-5" id="f-1467" unitRef="usd">2400000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-27" decimals="-5" id="f-1468" unitRef="usd">-1400000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <dxcm:SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments contextRef="c-1" decimals="-5" id="f-1469" unitRef="usd">0</dxcm:SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments>
    <dxcm:SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments contextRef="c-26" decimals="-5" id="f-1470" unitRef="usd">500000</dxcm:SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments>
    <dxcm:SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments contextRef="c-27" decimals="-5" id="f-1471" unitRef="usd">500000</dxcm:SECSchedule1209ValuationAllowancesandReservesDeductionWriteoffsandAdjustments>
    <us-gaap:ValuationAllowancesAndReservesRecoveries contextRef="c-1" decimals="-5" id="f-1472" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesRecoveries>
    <us-gaap:ValuationAllowancesAndReservesRecoveries contextRef="c-26" decimals="-5" id="f-1473" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesRecoveries>
    <us-gaap:ValuationAllowancesAndReservesRecoveries contextRef="c-27" decimals="-5" id="f-1474" unitRef="usd">100000</us-gaap:ValuationAllowancesAndReservesRecoveries>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-24" decimals="-5" id="f-1475" unitRef="usd">9300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-25" decimals="-5" id="f-1476" unitRef="usd">7300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-44" decimals="-5" id="f-1477" unitRef="usd">5400000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
